Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.99.1 - prostaglandin-endoperoxide synthase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
11beta-hydroxysteroid dehydrogenase deficiency
Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney.
Aberrant Crypt Foci
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
A 116-kDa phytoglycoprotein inhibits aberrant crypt foci formation through modulation of manganese superoxide dismutase, inducible nitric oxide synthase, cyclooxygenase-2, nuclear factor-kappa B, activator protein-1, and proliferating cell nuclear antigen in 1,2-dimethylhydrazine/dextran sodium sulfate-treated ICR mice.
A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin.
Administration of Metabiotics Extracted From Probiotic Lactobacillus rhamnosus MD 14 Inhibit Experimental Colorectal Carcinogenesis by Targeting Wnt/?-Catenin Pathway.
Anthocyanin-rich extracts inhibit multiple biomarkers of colon cancer in rats.
Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis.
Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats.
Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis.
Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.
Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways.
Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Coenzyme Q10 attenuated DMH-induced precancerous lesions in SD rats.
COX-2 and iNOS, good targets for chemoprevention of colon cancer.
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis.
Cyclooxygenase-2 is overexpressed in aberrant crypt foci of smokers.
Dietary cardamom inhibits the formation of azoxymethane-induced aberrant crypt foci in mice and reduces COX-2 and iNOS expression in the colon.
Dose-response assessment of the anti-cancer efficacy of soy isoflavones in dimethylhydrazine-treated rats fed 6% fructooligosaccharide.
Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factor beta and cyclooxygenase isoforms in Zucker obese (fa/fa) rats.
Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer.
Evaluation of a selective prostaglandin E receptor EP1 antagonist for potential properties in colon carcinogenesis.
Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.
Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats.
Fructooligosaccharide and soy isoflavone suppress colonic aberrant crypt foci and cyclooxygenase-2 expression in dimethylhydrazine-treated rats.
Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats.
Germinated brown rice (GBR) reduces the incidence of aberrant crypt foci with the involvement of beta-catenin and COX-2 in azoxymethane-induced colon cancer in rats.
Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid.
Indian food ingredients and cancer prevention - an experimental evaluation of anticarcinogenic effects of garlic in rat colon.
Inhibition of azoxymethane-induced aberrant crypt foci in rat by diphenylmethyl selenocyanate through downregulation of COX-2 and modulation of glutathione-S-transferase and lipid peroxidation.
Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats.
Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats.
Is COX-2 a 'collateral' target in cancer prevention?
JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
Light and Moderate Doses of Ethanol in Chemical Carcinogenesis of the Colon in Rats.
Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids.
Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane.
Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.
Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2.
Soy Saponins Meditate the Progression of Colon Cancer in Rats by Inhibiting the Activity of ? -Glucuronidase and the Number of Aberrant Crypt Foci but Not Cyclooxygenase-2 Activity.
Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2.
Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.
Suppression of colonic aberrant crypt foci by soy isoflavones is dose-independent in dimethylhydrazine-treated rats.
Suppressive effect of the herbal medicine Oren-gedoku-to on cyclooxygenase-2 activity and azoxymethane-induced aberrant crypt foci development in rats.
Vitamin E supplementation in chemical colorectal carcinogenesis: a two-edged knife.
[Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis]
Abortion, Habitual
Fragile X-related protein 1 (FXR1) regulates cyclooxygenase-2 (COX-2) expression at the maternal?fetal interface.
Relationship between expression of COX-2, TNF-?, IL-6 and autoimmune-type recurrent miscarriage.
Abortion, Spontaneous
Benefits of ?-lipoic acid in high-risk pregnancies (Review).
Does tumour necrosis factor alpha-induced cyclooxygenase-2 expression lead to spontaneous abortion in Chlamydia trachomatis-infected women.
Hormonal Regulation of Physiology, Innate Immunity and Antibody Response to H1N1 Influenza Virus Infection During Pregnancy.
Proinflammatory cytokines induced altered expression of cyclooxygenase-2 gene results in unreceptive endometrium in women with idiopathic recurrent spontaneous miscarriage.
Prostaglandins in the fetal circulation following maternal ingestion of a prostaglandin synthetase inhibitor during mid-pregnancy.
Relationship between expression of COX-2, TNF-?, IL-6 and autoimmune-type recurrent miscarriage.
Role of cyclooxygenase-2 signaling pathway dysfunction in unexplained recurrent spontaneous abortion.
[Developmental toxicity of the over-the-counter analgetics and antypiretics].
Abscess
Contribution of the prostaglandin E2/EP2 receptor-signaling pathway in abscess formation in rat zymosan-induced pleurisy.
PEP27-2, a Potent Antimicrobial Cell-Penetrating Peptide, Reduces Skin Abscess Formation during Staphylococcus aureus Infections in Mouse When Used in Combination with Antibiotics.
Acidosis
Acidic environment activates inflammatory programs in fibroblasts via a cAMP-MAPK pathway.
Acidosis differently modulates the inflammatory program in monocytes and macrophages.
Cardiopulmonary effects of tumor necrosis factor-alpha in the piglet: influence of cyclooxygenase inhibition.
Enhancement of hypoxic pulmonary vasoconstriction by metabolic acidosis in dogs.
Extracellular Acidosis Regulates the Expression of Inflammatory Mediators in Rat Epithelial Cells.
HIGH-TIDAL VOLUME VENTILATION AGGRAVATES SEPSIS-INDUCED MULTIORGAN DYSFUNCTION IN A DEXAMETHASONE-INHIBITABLE MANNER.
Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
Indomethacin abolishes cerebral blood flow increase in response to acetazolamide-induced extracellular acidosis: a mechanism for its effect on hypercapnia?
Inhibition by free radical scavengers and by cyclooxygenase inhibitors of the effect of acidosis on calcium transport by masseter muscle sarcoplasmic reticulum.
Metabolic acidosis regulates RGS16 and G protein signaling in osteoblasts.
Prolonged hypercapnia-evoked cerebral hyperemia via K(+) channel- and prostaglandin E(2)-dependent endothelial nitric oxide synthase induction.
Regulation of COX-2 mediates acid-induced bone calcium efflux in vitro.
Acidosis, Lactic
A reexamination of the role of oxygen in retrolental fibroplasia.
Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat.
Acidosis, Renal Tubular
Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
Acne Vulgaris
Decreased eicosapentaenoic acid levels in acne vulgaris reveals the presence of a proinflammatory state.
Immunohistochemical Expression of Cyclo-oxygenase 2 and Liver X Receptor-? in Acne Vulgaris.
Induction of inflammatory reactions by lipopolysaccharide in hamster sebaceous glands and pilosebaceous units in vivo and in vitro.
Management of premenstrual acne with Cox-2 inhibitors: a placebo controlled study.
Saponin fraction from Sapindus mukorossi Gaertn as a novel cosmetic additive: Extraction, biological evaluation, analysis of anti-acne mechanism and toxicity prediction.
Acquired Immunodeficiency Syndrome
Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.
Cellular cholesterol modifies flow-mediated gene expression.
Combined Variants in Factor VIII and Prostaglandin Synthase-1 Amplify Hemorrhage Severity Across Three Generations of Descendants.
Cyclooxygenase and lipoxygenase arachidonic acid metabolism by monocytes from human immune deficiency virus-infected drug users.
Cyclooxygenase inhibition and improved oxygenation in patients with pulmonary complications of AIDS.
Essential role of HIV type 1-infected and cyclooxygenase 2-activated macrophages and T cells in HIV type 1 myocarditis.
Human immunodeficiency virus type 1 envelope glycoprotein 120 induces cyclooxygenase-2 expression in neuroblastoma cells through a nuclear factor-kappaB and activating protein-1 mediated mechanism.
Indomethacin enhances the proliferation of mitogen-stimulated T lymphocytes of homosexual males with persistent generalized lymphadenopathy.
Lentiviral infection of rhesus macaques causes long-term injury to cortical and hippocampal projections of prostaglandin-expressing cholinergic basal forebrain neurons.
Pharmacological and non-pharmacological pain relief for office hysteroscopy: an up-to-date review.
Role of 15-deoxy delta(12,14) prostaglandin J2 and Nrf2 pathways in protection against acute lung injury.
Acromegaly
Cyclooxygenase enzyme and PGE2 expression in patients with functional and non-functional pituitary adenomas.
Acute Coronary Syndrome
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
Assessment of platelet function after discontinuation of ticagrelor.
Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome.
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease.
Cyclooxygenase and prostaglandin synthases: roles in plaque stability and instability in humans.
Cyclooxygenase-2 expression and inhibition in atherothrombosis.
Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships.
Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?
Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes.
Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome.
Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
Genetic and Molecular Determinants of Atherosclerotic Plaque Instability.
Greater collagen-induced platelet aggregation following cyclooxygenase 1 inhibition predicts incident acute coronary syndromes.
Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
Novel determinants of plaque instability.
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation.
Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy.
Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes.
Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease.
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.
Vorapaxar in the secondary prevention of atherothrombosis.
[Expression of COX-2 and pregnancy associate plasma protein A in coronary arteries and their relationship with acute coronary syndrome: an autopsy study of 42 cases]
[Protective effect of lornoxicam on development of myocardial infarction in rats under conditions of ischemia and ischemia-reperfusion]
[Role of anti-inflammatory drugs in the treatment of acute coronary syndromes. From athero-inflammation to athero-thrombosis]
[Significance and expression of cyclooxygenase-2 mRNA in peripheral blood monocytes in patients with acute coronary syndrome]
[Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology]
Acute Kidney Injury
Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor.
Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors.
Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid.
Adverse Effects of Oral Nonselective and cyclooxygenase-2-Selective NSAIDs on Hospitalization for Acute Kidney Injury: A Nested Case-Control Cohort Study.
Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex.
COX-2 inhibitor induced anuric renal failure in a previously healthy young woman.
Cyclooxygenase-2 and hypoxia-regulated proteins are modulated by basic fibroblast growth factor in acute renal failure.
Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature.
Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
Effect of Caffeic Acid on Ischemia-Reperfusion-Induced Acute Renal Failure in Rats.
Endothelial prostacyclin protects the kidney from ischemia-reperfusion injury.
Inhibition of glycogen synthase kinase-3? prevents NSAID-induced acute kidney injury.
Modulation of inflammatory response by selective inhibition of cyclooxygenase-1 and cyclooxygenase-2 in acute kidney injury.
Nephrotoxicity related to new therapeutic compounds.
Nephrotoxicity with cyclooxygenase 2 inhibitor use in children.
Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury.
Perioperative COX-2 inhibitors may increase the risk of post-operative acute kidney injury.
Profound urinary protein loss and acute renal failure caused by cyclooxygenase-2 inhibitor.
Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice.
Protective Effect of Taurine on Mice with Doxorubicin-induced Acute Kidney Injury.
Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications.
Renal failure associated with the use of celecoxib and rofecoxib.
Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study.
Thalidomide reduces glycerol-induced acute kidney injury by inhibition of NF-?B, NLRP3 inflammasome, COX-2 and inflammatory cytokines.
[Medication-induced impairment of renal function: what is important?]
Acute Lung Injury
Anti-Inflammatory Effects of Apigenin in Lipopolysaccharide-Induced Inflammatory in Acute Lung Injury by Suppressing COX-2 and NF-kB Pathway.
Bronchial circulation and cyclooxygenase products in acute lung injury.
Components of diesel exhaust particles differentially affect lung expression of cyclooxygenase-2 related to bacterial endotoxin.
Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury.
Cyclooxygenase and lipoxygenase inhibition by BW-755C reduces acrolein smoke-induced acute lung injury.
Cyclooxygenase inhibition prevents PMA-induced increases in lung vascular permeability.
Cyclooxygenase inhibitors prevent ethchlorvynol-induced injury in rat and rabbit lungs.
Cyclooxygenase-2 suppresses polymorphonuclear neutrophil apoptosis after acute lung injury.
Dexamethasone Attenuates LPS-induced Acute Lung Injury through Inhibition of NF-?B, COX-2, and Pro-inflammatory Mediators.
Effect of cyclooxygenase inhibition on ethchlorvynol-induced acute lung injury in dogs.
Effect of eicosanoid inhibition on the development of pulmonary edema after acute lung injury.
Effects of 15-deoxy-delta12,14-prostaglandin J2 on the cyclooxygenase-2 expression in the murine lung in the presence of lipopolysaccharide.
Enhanced microvascular permeability of PMA-induced acute lung injury is not mediated by cyclooxygenase products.
Ginkgo biloba extracts attenuate lipopolysaccharide-induced inflammatory responses in acute lung injury by inhibiting the COX-2 and NF-?B pathways.
Glycyrrhizin treatment is associated with attenuation of lipopolysaccharide-induced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression.
Hydrogen sulfide upregulates cyclooxygenase-2 and prostaglandin E metabolite in sepsis-evoked acute lung injury via transient receptor potential vanilloid type 1 channel activation.
Ibuprofen reduces ethchlorvynol lung injury: possible role of blood flow distribution.
Influence of cyclooxygenase and lipoxygenase inhibitors on oxidative stress-induced lung injury.
Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury.
Matrine Attenuates COX-2 and ICAM-1 Expressions in Human Lung Epithelial Cells and Prevents Acute Lung Injury in LPS-Induced Mice.
Mediators of lung injury in mice following systemic activation of complement.
Medical treatment of pulmonary hypertension in acute lung disease.
Meta-analysis: Methods, strengths, weaknesses, and political uses.
Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation.
Prostaglandins potentiate U-46619-induced pulmonary microvascular dysfunction.
Protective Effect of Isorhamnetin on Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Role of cyclooxygenase-2 in oleic acid-induced acute lung injury.
Shikonin attenuates lipopolysaccharide-induced acute lung injury in mice.
Substance P Upregulates Cyclooxygenase-2 and Prostaglandin E Metabolite by Activating ERK1/2 and NF-{kappa}B in a Mouse Model of Burn-Induced Remote Acute Lung Injury.
The neutrophil respiratory burst and tissue injury in septic acute lung injury: the effect of cyclooxygenase inhibition in swine.
The pulmonary circulation in acute lung injury: a review of some recent advances.
The role of cyclooxygenase-2 in mechanical ventilation-induced lung injury.
[Cyclooxygenase 2 derived lipid mediators play a pivotal role in resolution of acute lung injury]
[Effects of vasoactive cyclooxygenase products on shunt flow and extravascular lung water in acute lung injuries]
[Prostanoids and acute lung injury]
[Protective mechanisms of sevoflurane against one-lung ventilation-induced acute lung injury: role of cyclooxygenase-2 and 5-lipoxygenase pathways].
[The effect of cyclooxygenase-2 inhibitor on acute lung injury]
[The effect of nitric oxide inhalation on the expression of COX-2 and toll-like receptor 4 in rat acute lung injury induced by lipopolysaccharide]
Acute-On-Chronic Liver Failure
[Expression of COX-2 and PPARr in the livers of patients with acute on chronic HBV-related liver failure and their relationship with clinic parameters].
Adenocarcinoma
-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.
11-Oxoeicosatetraenoic acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative eicosanoid.
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
A higher dietary ratio of long-chain omega-3 to total omega-6 fatty acids for prevention of COX-2-dependent adenocarcinomas.
A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation.
A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib.
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway.
A role for cAMP-driven transactivation of EGFR in cancer aggressiveness - therapeutic implications.
Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells.
Acid suppression and chemoprevention in Barrett's oesophagus.
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.
Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Alterations of COX-2, HER-2/neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings.
Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
An investigation of the rate of cyclooxygenase-2 expression on the surface of adenomatous and colorectal adenocarcinoma polyps.
Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus.
Anti-reflux anastomosis following esophagectomy for adenocarcinoma of the esophagogastric junction: impact of duodenogastroesophageal reflux and expression of cyclooxygenase-2 in the remnant esophagus.
Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Antitumor activity in a rat mammary adenocarcinoma: the effect of cyclooxygenase inhibitors and immunization against prostaglandin E2.
Antitumor effect of the selective COX-2 inhibitor celecoxib on endometrial adenocarcinoma in vitro and in vivo.
Apoptotic effects of two COX-2 inhibitors on breast adenocarcinoma cells through COX-2 independent pathway.
Aspirin and non-small cell lung cancer resections: effect on long-term survival.
Association Between COX-2 Expression and Effectiveness of COX-2 Inhibitors in a Phase II Trial in Patients with Metastatic Colorectal Adenocarcinoma.
Barrett esophagus.
Barrett's esophagus: chemoprevention.
Bile acids are multifunctional modulators of the Barrett's carcinogenesis.
Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell lines.
Canonical Wnt Signaling Pathway Plays an Essential Role in N-Methyl-N-Nitrosurea Induced Gastric Tumorigenesis of Mice.
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition.
Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
Cell Intrinsic Role of Cox-2 in Pancreatic Cancer Development.
Characterization of the Prostaglandin E2 path way in a Rat Model of Esophageal Adenocarcinoma.
Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Chemopreventive effect of protein extract of Asterina pectinifera in HT-29 human colon adenocarcinoma cells.
Chicken Skin Mucosa Surrounding Adult Colorectal Adenomas is a Risk Factor for Carcinogenesis.
Clinical and prognosis relevance of COX-2 expression in Tunisian patients with primary gastric adenocarcinoma.
Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma.
Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma.
Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.
Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas.
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma.
Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis.
Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase.
Colorectal cancer and nonsteroidal anti-inflammatory drugs.
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.
Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus.
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
Coordinate up-regulation of low-density lipoprotein receptor and cyclo-oxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies.
Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
Correlation Between Inducible Nitric Oxide Synthase and Cyclooxygenase-2 Expression in Human Colorectal Adenocarcinoma: A Cross-Sectional Study.
Correlation of COX- 2 Expression in Colorectal Carcinoma with Clinicopathological Features.
COX-2 and p53 in human sinonasal cancer: COX-2 expression is associated with adenocarcinoma histology and wood-dust exposure.
COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
COX-2 CA-Haplotype Is a Risk Factor for the Development of Esophageal Adenocarcinoma.
COX-2 expression in canine anal sac adenocarcinomas and in non-neoplastic canine anal sacs.
COX-2 gene expression and methylation profile in Sapajus apella as an experimental model for gastric adenocarcinoma.
Cox-2 in non-small cell lung cancer: A meta-analysis.
COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma.
COX-2 inhibition and lung cancer.
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer.
COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis.
COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention.
COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil.
COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.
COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer.
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
CUGBP2 plays a critical role in apoptosis of breast cancer cells in response to genotoxic injury.
Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.
Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue.
Cyclo-oxygenase-2 expression is associated with mean standardised uptake value on 18F-Fluorodeoxyglucose positron emission tomography in oesophageal adenocarcinoma.
Cyclo-oxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma.
Cyclooxigenase-2 and osteopontin in gastric pre-neoplastic lesions in relation to H-pylori infection and grade of inflammation.
Cyclooxigenase-2 Levels are Increased in the Lung Tissue and Bronchial Tumors of Patients with Chronic Obstructive Pulmonary Disease.
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.
Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Cyclooxygenase 2-mediated apoptotic and inflammatory responses in photodynamic therapy treated breast adenocarcinoma cells and xenografts.
Cyclooxygenase 2: from inflammation to carcinogenesis.
Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis.
Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma.
Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.
Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1.
Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.
Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers.
Cyclooxygenase-2 (COX2) expression in adenocarcinoma surpasses that of squamous cell carcinoma in the uterine cervix.
Cyclooxygenase-2 and B-cell lymphoma-2 expression in cystitis glandularis and primary vesicle adenocarcinoma.
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma.
Cyclooxygenase-2 and prostate carcinogenesis.
Cyclooxygenase-2 expression and cell proliferation are increased in MUC2-positive area of columnar-lined esophagus.
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue.
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.
Cyclooxygenase-2 expression during carcinogenesis in the human stomach.
Cyclooxygenase-2 expression in canine mammary tumors.
Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Cyclooxygenase-2 expression in feline pancreatic adenocarcinomas.
Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.
Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions.
Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A.
Cyclooxygenase-2 expression in human esophageal carcinoma.
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.
Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs.
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.
Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma.
Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.
Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.
Cyclooxygenase-2 in Barrett's esophagus, Barrett's adenocarcinomas, and esophageal SCC: ready for clinical trials.
Cyclooxygenase-2 in human non-small cell lung cancer.
Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.
Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus.
Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
Cyclooxygenase-2 inhibitors in lung cancer.
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR.
Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
Cyclooxygenase-2 up-regulation after FLAP transfection in human adenocarcinoma cell line HT29 cl.19A.
Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer.
Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer.
Cytotoxicity of selected novel chalcone derivatives on human breast, lung and hepatic carcinoma cell lines.
Deoxycholate induces COX-2 expression via Erk1/2-, p38-MAPK and AP-1-dependent mechanisms in esophageal cancer cells.
Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice.
Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid.
Dihydroxy bile acids activate the transcription of cyclooxygenase-2.
Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism.
Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer.
Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines.
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers.
Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma.
Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line.
Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer.
Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model.
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Effects of combined octreotide and aspirin on the growth of gastric cancer.
Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.
Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development.
Efficacy of Dimethylaminoparthenolide and Sulindac in Combination With Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer.
EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival.
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.
Elevated expression of cyclooxygenase-2 in adenocarcinoma of the parotid gland: insights into malignant transformation of pleomorphic adenoma.
Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer.
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Expression and significance of cyclooxygenase 2 gene in lung cancer.
Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype.
Expression of BMP2, TLR3, TLR4 and COX2 in colorectal polyps, adenoma and adenocarcinoma.
Expression of COX-2 and E-cadherin in Tunisian patients with colorectal adenocarcinoma.
Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Expression of COX-2 in stomach cancers and its relation to their biological features.
Expression of COX-2 in Stomach Carcinogenesis.
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.
Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
Expression of cyclooxygenase 2 and vascular endothelial growth factor in gastric carcinoma: Relationship with clinicopathological parameters.
Expression of cyclooxygenase 2 by prostaglandin E(2) in human endometrial adenocarcinoma cell line HEC-1B.
Expression of cyclooxygenase-2 (COX-2) in colorectal adenocarcinoma: an immunohistochemical and histopathological study.
Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma.
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.
Expression of Cyclooxygenase-2 and Tumor Microvessel Density in Colorectal Cancer.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 has no impact on survival in adenocarcinoma of the esophagogastric junction but is associated with favourable clinicopathologic features.
Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth.
Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.
Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression.
Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma.
Expression of cyclooxygenase-2 in endometrial adenocarcinoma.
Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus.
Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.
Expression of cyclooxygenase-2 in human gastric carcinoma.
Expression of cyclooxygenase-2 in human lung carcinoma.
Expression of cyclooxygenase-2 in imprint smears of endometrial carcinoma.
Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation.
Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.
Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.
Expression of Cyclooxygenase-2 Protein in Gastric Carcinogenesis.
Expression of cyclooxygenase-2, Fas and Fas ligand in pulmonary adenocarcinoma and atypical adenomatous hyperplasia.
Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density.
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.
Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer.
Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo.
Expression of PCNA, Ki-67 and COX-2 in breast cancer based on DCE-MRI image information.
Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas.
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.
Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas.
Expression Profile as Predictor of Relapse after Adjuvant Treatment in Gastric Cancer.
Expression profiles of Annexin A1, formylated peptide receptors and cyclooxigenase-2 in gastroesophageal inflammations and neoplasias.
F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells.
Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma.
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures.
Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells.
G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2.
Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Gastroesophageal reflux disease (GERD): current agents and future perspective.
Gastroesophageal reflux disease.
General tolerability and use of nonsteroidal anti-inflammatory drugs.
Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
Guggulsterone, a plant-derived inhibitor of NF-TB, suppresses CDX2 and COX-2 expression and reduces the viability of esophageal adenocarcinoma cells.
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results.
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma.
Helicobacter pylori and non-malignant diseases.
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.
High cyclooxygenase-2 expression in cervical adenocarcinomas.
High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study.
hMLH1, hMSH2 and cyclooxygenase-2 (cox-2) in sporadic colorectal polyps.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth.
Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis.
Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas.
Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.
Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China.
Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
Immunohistochemical Expression of Cyclooxygenase-2 (COX-2) in Feline Endometrial Adenocarcinoma and in Normal and Hyperplastic Endometria.
Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane.
Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression.
Impact of COX-2, IL-1?, TNF-?, IL-4 and IL-10 on the process of carcinogenesisin the large bowel.
Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung.
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
Increased cyclooxygenase-2 expression is correlated with suppressed antitumor immunity in cervical adenocarcinomas.
Increased expression of COX-2 in the development of human lung cancers.
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer.
Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.
Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet.
Increased expression of cyclooxygenase-2 protein in rat lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer.
Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers.
Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.
Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma.
Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer.
Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.
Inflammation-related carcinogenesis and prevention in esophageal adenocarcinoma using rat duodenoesophageal reflux models.
Influence of age and gender on association between -765G > C COX-2 genetic polymorphism and gastric adenocarcinoma risk: a case-control study in Iran.
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.
Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins.
Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model.
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.
Inhibition of the biosynthesis of prostaglandin E2 by low dose aspirin: implications for adenocarcinoma metastasis.
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer.
JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
Lactobacillus acidophilus 74-2 and butyrate induce cyclooxygenase (COX)-1 expression in gastric cancer cells.
Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
Lipoxygenase-5 is overexpressed in prostate adenocarcinoma.
Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia.
Malignant salivary gland tumors and cyclo-oxygenase-2: A histopathological and immunohistochemical analysis with implications on histogenesis.
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Mechanism of P-glycoprotein Expression in the SGC7901 Human Gastric Adenocarcinoma Cell Line Induced by Cyclooxygenase-2.
Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma.
Mitogen-activated protein kinase activation and regulation of cyclooxygenase 2 expression by platelet-activating factor and hCG in human endometrial adenocarcinoma cell line HEC-1B.
Molecular characterization of canine prostaglandin G/H synthase-2 and regulation in prostatic adenocarcinoma cells in vitro.
Molecular Characterization of Canine Prostaglandin G/H Synthase-2 and Regulation in Prostatic Adenocarcinoma Cells in Vitro.
Molecular determinants in targeted therapy for esophageal adenocarcinoma.
NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells.
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line.
Nitric oxide synthase, arginase and cyclooxygenase are involved in muscarinic receptor activation in different murine mammary adenocarcinoma cell lines.
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.
Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation in human colorectal carcinoma tissue.
Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.
Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy.
Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells.
Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs.
Pathologic Features of Colorectal Inflammatory Polyps in Miniature Dachshunds.
PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer.
Phenotype of columnar-lined esophagus in rats with esophagogastroduodenal anastomosis: similarity to human Barrett's esophagus.
Phthalate plasticizer di(2-ethyl-hexyl) phthalate induces cyclooxygenase-2 expression in gastric adenocarcinoma cells.
Picfeltarraenin IA inhibits lipopolysaccharide-induced inflammatory cytokine production by the nuclear factor-?B pathway in human pulmonary epithelial A549 cells.
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: A study from northern India.
Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer.
Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Possible role of PPAR-? and COX-2 receptor modulators in the treatment of Non-Small Cell lung carcinoma.
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas.
Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma.
Preference of Endoscopic Ablation Over Medical Prevention of Esophageal Adenocarcinoma by Patients with Barrett's Esophagus.
Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma.
Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors.
Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions.
Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma.
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma.
Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus.
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma.
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Prostaglandin concentrations and prostaglandin synthetase activity in N-nitrosomethylurea-induced rat mammary adenocarcinoma.
Prostaglandin E(2) and F(2alpha) activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element.
Prostaglandin EP2 receptor expression is increased in Barrett's esophagus and esophageal adenocarcinoma.
Prostaglandin H synthase expression is variable in human colorectal adenocarcinoma cell lines.
Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer.
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
Relationship between cyclooxygenase 8473T>C polymorphism and risk of lung cancer: a case-control study.
Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.
Relationship between HER-2, COX-2, p53 and clinicopathologic features in gastric adenocarcinoma. Do these biomarkers have any prognostic significance?
Reply to Letter to the Editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First).
Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel.
Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against ?? T cell cytotoxicity.
Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A.
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.
Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma.
Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis.
Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma.
Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer.
Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest.
Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin.
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Seminal plasma activates cyclooxygenase-2 and prostaglandin E2 receptor expression and signalling in cervical adenocarcinoma cells.
Seminal plasma enhances cervical adenocarcinoma cell proliferation and tumour growth in vivo.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Signet-ring cell carcinoma of colorectum-current perspectives and molecular biology.
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Sinomenine inhibits proliferation of SGC-7901 gastric adenocarcinoma cells via suppression of cyclooxygenase-2 expression.
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Smoking and COX-2 Functional Polymorphisms Interact to Increase the Risk of Gastric Cardia Adenocarcinoma in Chinese Population.
Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.
Spontaneous adenocarcinoma immunoreactive to cyclooxygenase-2 and transforming growth factor-beta1 in the buccal salivary gland of a Richardson's ground squirrel (Spermophilus richardsonii).
Strategy for prevention of cancers of the esophagus.
Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats.
Suppression by nimesulide of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats.
Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells.
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest.
Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer.
The ?-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor ?B signaling.
The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2.
The Dynamic Changes of Gut Microbiota in Muc2 Deficient Mice.
The effect of prostaglandin modulators on prostate tumor growth and metastasis.
The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma.
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through ?-catenin-dependent and -independent mechanisms.
The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review.
The role of COX-2 in intestinal cancer.
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
The role of cyclooxygenases in inflammation, cancer, and development.
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Tissue microarray-determined expression profiles of cyclooxygenase-2 in colorectal adenocarcinoma: association with clinicopathological parameters.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007)*.
Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site.
Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Upregulation of cyclooxygenase-2 is associated with activation of the alternative nuclear factor kappa B signaling pathway in colonic adenocarcinoma.
[A study on cyclooxygenase-2 protein expression in esophageal carcinoma and premalignant lesions]
[An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
[Chemoprevention of Barrett's esophagus by celecoxib in rats.]
[Construction of recombinant adenovirus vector expressing shRNAs targeting COX-2, AKT1 and PIK3R1 gene and its inhibition effect on proliferation of human gastric adenocarcinoma]
[Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide]
[Cyclooxygenase-2 expression in female pulmonary adenocarcinoma.]
[Different proteome of human lung adenocarcinoma cells treated with NS-398 and cisplation.]
[Expression of COX-2 and its prognostic significance in non-small cell lung cancer.]
[Immunohistochemical markers as prognosticators in gynecologic oncology]
[Influence of selective cyclooxygenase-2 inhibitor on proliferation of human gastric cancer cells]
[Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth]
[Overexpression of COX-2 and a potential clinical application of its inhibitors in lung cancer]
[Overexpression of COX-2 and its clinical significance in non-small cell lung cancer]
[Prognostic significance of cyclooxygenase (COX-1 and COX-2) expression in endometrial carcinoma (clinical and immunohistochemical study)]
[Prognostic significance of cyclooxygenase 2 expression in adenocarcinoma of the esophagus]
[Role of cyclooxygenase-2 in inhibition of human gastric adenocarcinoma cell line SGC-7901 by c9, t11-conjugated linoleic acid]
[Study of COX-2 expression and angiogenesis in non-small cell lung cancer.]
[The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]
[The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma]
[The Expression of COX-2 in Human Lung Cancer and its Relationship with Expression of K-ras and Mcl-1.]
[The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results]
Adenocarcinoma of Lung
Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells.
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma.
Arsenite pretreatment attenuates benzo[a]pyrene cytotoxicity in a human lung adenocarcinoma cell line by decreasing cyclooxygenase-2 levels.
Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis.
Carvacrol encapsulated nanocarrier/ nanoemulsion abrogates angiogenesis by downregulating COX-2, VEGF and CD31 in vitro and in vivo in a lung adenocarcinoma model.
Cinobufocini inhibits NF-?B and COX-2 activation induced by TNF-? in lung adenocarcinoma cells.
Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Cooking oil fumes improve lung adenocarcinoma cell survival through c-IAP2 induction.
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway.
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.
Downregulation of COX-2 and iNOS by amentoflavone and quercetin in A549 human lung adenocarcinoma cell line.
Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
Effects of Feiyanning Decoction, a compound traditional Chinese medicine, on iNOS and COX-2 expressions induced by tumor necrosis factor-? in lung adenocarcinoma cell line.
EGF stimulates cyclooxygenase-2 expression through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells.
Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line.
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Expression of cyclooxygenase-2 in human lung carcinoma.
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.
Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2.
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.
Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma.
Inhibition of the biosynthesis of prostaglandin E2 by low dose aspirin: implications for adenocarcinoma metastasis.
Interferon gamma induces prostaglandin G/H synthase-2 through an autocrine loop via the epidermal growth factor receptor in human bronchial epithelial cells.
Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.
Maximal standardized uptake value on FDG-PET is correlated with cyclooxygenase-2 expression in patients with lung adenocarcinoma.
MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells.
Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
NF-kappaB-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway.
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
Optimized Curcumin, Pomegranate Extract, and Methylsulfonylmethane Reduce Acute, Systemic Inflammatory Response to a Half-marathon Race.
Oral administration of aflatoxin G? induces chronic alveolar inflammation associated with lung tumorigenesis.
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma.
Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3.
Protection by quercetin against cooking oil fumes-induced DNA damage in human lung adenocarcinoma CL-3 cells: role of COX-2.
Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.
Redox Factor-1 Inhibits Cyclooxygenase-2 Expression via Inhibiting of p38 MAPK in the A549 Cells.
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Resveratrol inhibits the proliferation of A549 cells by inhibiting the expression of COX-2.
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.
Study on the Mechanism of Ginseng in the Treatment of Lung Adenocarcinoma Based on Network Pharmacology.
TGF-? Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells.
The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells.
Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells.
Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response element-binding protein.
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
[Cyclooxygenase-2 expression in female pulmonary adenocarcinoma.]
[Effects of RNA interference of COX-2 gene expression on malignant proliferation of A549 cells in vitro]
[Mechanisms of EGF regulation of COX-2 through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells].
[The Effects of Interfering COX-2 Gene Expression on Malignant Proliferation of Human Lung Adenocarcinoma A2 Cell in vitro.]
[The Expression and Clinical Significance of HIF-1?, COX-2 and E-cadherin in Patients with Lung Adenocarcinoma.]
Adenocarcinoma, Bronchiolo-Alveolar
Dietary lipids modulate eicosanoid release and apoptosis of cells of a murine lung alveolar carcinoma.
Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung.
Inhaled indomethacin in bronchorrhea in bronchioloalveolar carcinoma: role of cyclooxygenase.
Adenocarcinoma, Clear Cell
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.
Adenocarcinoma, Mucinous
Increased expression of cyclooxygenase-2 in human salivary gland tumors.
Simultaneous adeno- and squamous cell carcinoma with different phenotypic profiles in a rat model of chronic gastroesophageal reflux.
Adenoma
11?-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis.
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
A molecular/epidemiologic analysis of expression of cyclooxygenases 1 and 2, use of nonsteroidal antiinflammatory drugs, and risk of colorectal adenoma.
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon.
A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma.
Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia.
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.
Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.
Analysis of cyclooxygenase expression in human colorectal adenomas.
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398.
Association between Cyclooxygenase expression and colorectal adenoma characteristics.
Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis.
Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.
Celecoxib for the prevention of sporadic colorectal adenomas.
Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR.
Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.
Chemoprevention in colorectal neoplasias: what is practical and feasible?
Chemoprevention in hereditary colorectal cancer syndromes.
Chemoprevention of Colonic Polyps with Balsalazide: An Exploratory, Double-Blind, Placebo-Controlled Study.
Chemoprevention of colorectal cancer: dietary and pharmacologic approaches.
Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story).
Chemoprevention of colorectal neoplasia: the potential for personalized medicine.
Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2.
Chemopreventive Efficacy and Mechanism of Licofelone in a Mouse Lung Tumor Model via Aspiration.
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.
Chemoprophylaxis in gastrointestinal tumors.
Chicken Skin Mucosa Surrounding Adult Colorectal Adenomas is a Risk Factor for Carcinogenesis.
Co-Expression of Cox-2, C-Met and beta-catenin in Cells Forming Invasive front of Gallbladder Cancer.
Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
Colon polyps and cancer.
Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption.
Colorectal cancer and non-steroidal anti-inflammatory drugs.
Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Colorectal cancer: chemopreventive role of curcumin and resveratrol.
Colorectal polyposis and immune-based therapies.
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.
Comparison of biomarker expression between proximal and distal colorectal adenomas: The Tennessee-Indiana Adenoma Recurrence Study.
Comparison of cyclo-oxygenase 2 expression in colorectal serrated adenomas to expression in tubular adenomas and hyperplastic polyps.
Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells.
Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts.
Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China.
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
Cox-2 and cancer chemoprevention: picking up the pieces.
COX-2 expression in adenoma: an imperfect marker for chemoprevention.
COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics.
COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.
COX-2 inhibition as a tool to treat and prevent colorectal cancer.
COX-2 inhibition in clinical cancer prevention.
COX-2 inhibitors: a potential target for drug therapy in the management of colorectal cancer.
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
Cyclo-oxygenase inhibition in colorectal adenomas and cancer.
Cyclooxygenase 1 and 2 expressions in the human thyroid gland.
Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.
Cyclooxygenase-2 and its role in colorectal cancer development.
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Cyclooxygenase-2 expression and its relationship with proliferation of colorectal adenomas.
Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: Modification by dietary curcumin and implications for clinical trials.
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Cyclooxygenase-2 expression in canine mammary tumors.
Cyclooxygenase-2 expression in colorectal adenomas.
Cyclooxygenase-2 expression in FAP patients carrying germ line MYH mutations.
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.
Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas; correlation with intratumoral microvessel density and apoptotic index.
Cyclooxygenase-2 expression in human pituitary tumors.
Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs.
Cyclooxygenase-2 expression in thyroid neoplasms.
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas.
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers.
Cyclooxygenase-2 immunohistochemical expression in serrated polyps of the colon.
Cyclooxygenase-2 immunoreactivity in depressed-type colorectal adenomas and cancers.
Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland.
Cyclooxygenase-2 in sporadic colorectal polyps: immunohistochemical study and its importance in the early stages of colorectal tumorigenesis.
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Cyclooxygenase-2 is overexpressed in serrated adenoma of the colorectum.
Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta.
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
Decreased Toll-interacting protein and peroxisome proliferator-activated receptor ? are associated with increased expression of Toll-like receptors in colon carcinogenesis.
Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice.
Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps.
Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
Differential stromal and epithelial localization of cyclooxygenase-2 (COX-2) during colorectal tumorigenesis.
Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia.
Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury.
Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence.
Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression.
E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis.
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Effect of prostaglandin E1 on vascular endothelial growth factor production by human macrophages and colon cancer cells.
Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.
Elevated cyclooxygenase-2 levels in Min mouse adenomas.
Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Epithelial-Specific Deletion of 11?-HSD2 Hinders Apcmin/+ Mouse Tumorigenesis.
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin.
Expression of BMP2, TLR3, TLR4 and COX2 in colorectal polyps, adenoma and adenocarcinoma.
Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.
Expression of COX-2, IL-1?, TNF-? and IL-4 in epithelium of serrated adenoma, adenoma and hyperplastic polyp.
Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas.
Expression of Cyclooxygenase-2 and Bcl-2 in human gastric adenomas.
Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 in colonic polyps.
Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.
Expression of Cyclooxygenase-2 Protein in Gastric Carcinogenesis.
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2.
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Gene-specific methylation and subsequent risk of colorectal adenomas among participants of the polyp prevention trial.
Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma.
Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study.
Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps.
Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors.
HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts.
High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors.
High expression of cyclooxygenase-2 in macrophages of human colonic adenoma.
High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma.
hMLH1, hMSH2 and cyclooxygenase-2 (cox-2) in sporadic colorectal polyps.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
Immunoexpression of the COX-2, p53, and caspase-3 proteins in colorectal adenoma and non-neoplastic mucosa.
Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas.
Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.
Immunohistochemical expression of COX-2 in thyroid nodules.
Immunohistochemical expression of cyclooxygenase (COX)-2 in colorectal adenomas.
Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid.
Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Impact of COX-2, IL-1?, TNF-?, IL-4 and IL-10 on the process of carcinogenesisin the large bowel.
Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.
Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Increased cyclooxygenase-2 expression in juvenile polyposis syndrome.
Increased EP4 Receptor Expression in Colorectal Cancer Progression Promotes Cell Growth and Anchorage Independence.
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.
Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet.
Increased expression of cyclooxygenase-2 protein in rat lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine.
Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Increased levels of promutagenic etheno-DNA adducts in colonic polyps of FAP patients.
Indomethacin reduces lung adenoma number in A/J mice.
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Colorectal Adenoma Patients in a Clinical Trial.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.
Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.
Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice.
Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas.
Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis.
Is COX-2 a 'collateral' target in cancer prevention?
Is there a place for practical chemoprevention of colorectal cancer in light of COX-2 heterogeneity?
Lack of anti-tumor activity with the ?-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis.
Linkage Disequilibrium and Haplotype Analysis of COX-2 and Risk of Colorectal Adenoma Development.
Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.
Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.
Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps: a case-control study.
Molecular Pathways and Cellular Metabolism in Colorectal Cancer.
Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma.
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
NSAIDs and colorectal cancer prevention.
NSAIDs and the gastrointestinal tract.
Nuclear factor kappaB is downregulated and correlates with p53 in the Min mouse mucosa during an accelerated tumor growth.
Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc (Min/+) mouse model of intestinal tumorigenesis.
Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells.
Pathologic Features of Colorectal Inflammatory Polyps in Miniature Dachshunds.
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis.
Pharmacological and dietary factors in prevention of colorectal cancer.
Piroxicam-induced regression of intestinal adenomatous polyps in APC(delta474) mice.
Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial.
Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer.
Pomegranate By-Products in Colorectal Cancer Chemoprevention: Effects in Apc-Mutated Pirc Rats and Mechanistic Studies In Vitro and Ex Vivo.
Potential targets for colorectal cancer prevention.
Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade.
Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy.
Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells.
Protective effect of Cox-2 allelic variants on risk of colorectal adenoma development in African Americans.
Protein expression of Fragile Histidine Triad and cyclooxgenase-2 in serrated neoplasia of the colorectum.
Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice.
PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Reduced tumour progression and angiogenesis in 1,2-dimethylhydrazine mice treated with NS-398 is associated with down-regulation of cyclooxygenase-2 and decreased beta-catenin nuclear localisation.
Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis.
Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner.
Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
Relationship between COX-2 expression and clinicopathological features of colorectal cancers.
Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas.
Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer.
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor.
Review article: COX-2, prostanoids and colon cancer.
Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis.
Screening for colon cancer and evaluation of chemoprevention with coxibs.
Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis.
Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Superficially elevated colonic adenoma changed to undetectable configuration on ordinary endoscopy during treatment with preferential cyclooxygenase-2 inhibitor.
Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms.
Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis.
Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis.
Testing for colon neoplasia susceptibility variants at the human COX2 locus.
The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
The clinical potential of cyclooxygenase-2-specific inhibitors.
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
The Dynamic Changes of Gut Microbiota in Muc2 Deficient Mice.
The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas.
The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.
The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas.
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC(Delta474) knockout mice.
The Roles of Dietary PPARgamma Ligands for Metastasis in Colorectal Cancer.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase.
Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth.
[Aspirin in the prevention of colorectal cancer.]
[Chemoprevention of colorectal cancer]
[COX-2 inhibitors in inflammatory bowel disease: friends or foes?]
[Cyclo-oxygenase-2 and p53 immunoreactivity in superficial early colorectal carcinoma]
[Cyclooxygenase-2 expression according to size and location of gastric and colorectal tubular adenomas]
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]
[Expression of cyclooxygenase-2 and relationship with mismatch repaire gene and microsatellite instability in hereditary non-polyposis colorectal cancer]
[Prevention and early diagnosis of colorectal cancer]
[Prophylaxis of colorectal cancer with non steroidal anti-inflammatory drugs- a new reality?]
[Selective cyclooxygenase-2 inhibitors for the prevention of colorectal adenomas: a meta-analysis]
ß-catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy.
Adenoma, Oxyphilic
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Adenoma, Pleomorphic
Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma.
Cyclooxygenase-2 regulates the degree of apoptosis by modulating bcl-2 protein in pleomorphic adenoma and mucoepidermoid carcinoma of the parotid gland.
Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.
Elevated expression of cyclooxygenase-2 in adenocarcinoma of the parotid gland: insights into malignant transformation of pleomorphic adenoma.
Evaluation of VEGF expression correlates with COX-2 expression in pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma.
Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis.
Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors.
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma.
[Expression and clinical significance of Cox-2 and XIAP in malignant tumors of the salivary gland].
[Expression of CD44v6 and COX-2 in pleomorphic adenomas and carcinomas of parotid gland].
Adenoma, Villous
Analysis of cyclooxygenase expression in human colorectal adenomas.
Prostaglandin E2-mediated secretory diarrhea in villous adenoma of rectum: effect of treatment with indomethacin.
[Treatment with indomethacin for the control of the metabolic disorder caused by a villous adenoma of the rectum]
Adenomatous Polyposis Coli
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Adenomatous polyposis coli protein associates with C/EBP beta and increases Bacillus anthracis edema toxin-stimulated gene expression in macrophages.
An increased CD25-positive intestinal regulatory T-lymphocyte population is dependent on Cox-2 activity in the Apc (Min/+) model.
Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
Approach to angiogenesis inhibition based on cyclooxygenase-2.
Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer.
Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.
Celecoxib for the prevention of sporadic colorectal adenomas.
Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
Celecoxib with chemotherapy in colorectal cancer.
Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis.
Chemoprevention in colorectal neoplasias: what is practical and feasible?
Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.
Chemoprevention of colorectal cancer.
Chemoprevention strategies using NSAIDs and COX-2 inhibitors.
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
Colon cancer: a civilization disorder.
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
COX selectivity and animal models for colon cancer.
COX-2 and colon cancer.
COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.
COX-2 inhibition and colorectal cancer.
COX-2 inhibition and prevention of cancer.
COX-2 inhibition in clinical cancer prevention.
COX-2 polymorphisms in patients with familial adenomatous polyposis.
Current application of selective COX-2 inhibitors in cancer prevention and treatment.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclo-oxygenase inhibition in colorectal adenomas and cancer.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
Cyclooxygenase 2: a molecular target for cancer prevention and treatment.
Cyclooxygenase 2: from inflammation to carcinogenesis.
Cyclooxygenase inhibitors in the chemoprevention of colorectal cancer.
Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
Cyclooxygenase-2 and chemoprevention of breast cancer.
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps.
Cyclooxygenase-2 inhibitors in colorectal cancer.
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Cyclooxygenases and colon cancer.
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.
E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression.
Effect of sulindac treatment for attenuated familial adenomatous polyposis with a new germline APC mutation at codon 161: report of a case.
Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro.
Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion.
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin.
Expression of COX-2 and p53 in juvenile polyposis coli and its correlation with adenomatous changes.
Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.
Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large swiss familial adenomatous polyposis kindred.
Hereditary nonpolyposis colorectal cancer: preventive management.
Host Wnt/{beta}-catenin pathway triggered by Helicobacter pylori correlates with regression of gastric intestinal metaplasia after H. pylori eradication.
Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Increased cyclooxygenase-2 expression in juvenile polyposis syndrome.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer.
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Is COX-2 a 'collateral' target in cancer prevention?
Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients.
Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse.
Molecular pathology of cyclooxygenase-2 in neoplasia.
Mucosal prostanoid receptors and synthesis in familial adenomatous polyposis.
Myofibroblasts. II. Intestinal subepithelial myofibroblasts.
Na(+)-stimulated Na+/H+ exchange and an unfavorable Ca2+ homeostasis initiate the cycloxygenase-2 inhibitors-induced apoptotic signals in colonic epithelial cells during the early stage of colon carcinogenesis.
Nimesulide, a selective anti-inflammatory cyclooxygenase-2 inhibitor, does not affect polyp number and mucosal proliferation in familial adenomatous polyposis.
Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality.
Oxidative stress in familial adenomatous polyposis.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model.
Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Protective mechanisms of 6-gingerol in dextran sulfate sodium-induced chronic ulcerative colitis in mice.
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive.
Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis.
Relationship among expression of basic-fibroblast growth factor, MTDH/Astrocyte elevated gene-1, adenomatous polyposis coli, matrix metalloproteinase 9,and COX-2 markers with prognostic factors in prostate carcinomas.
Relationship between Fecal Content of Fatty Acids and Cyclooxygenase mRNA Expression and Fatty Acid Composition in Duodenal Biopsies, Serum Lipoproteins, and Dietary Fat in Colectomized Familial Adenomatous Polyposis Patients.
Retinoic acid inhibits beta-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli.
Role of cyclooxygenase-2 in colorectal cancer.
Screening for colon cancer and evaluation of chemoprevention with coxibs.
Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis.
Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer.
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer.
The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid.
The anti-proliferative potency of celecoxib is not a class effect of coxibs.
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli.
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC(Delta474) knockout mice.
The role of cyclooxygenase-2 and prostaglandins in colon cancer.
Use of NSAIDs for the chemoprevention of colorectal cancer.
[Chemoprevention of colorectal cancer]
[COX and study of cancer therapy]
[COX inhibitor, suppression of polyposis, and chemoprevention]
[Cyclooxygenase 2 inhibitors and adenomatous polyposis coli]
[Cyclooxygenase-2 expression according to size and location of gastric and colorectal tubular adenomas]
[Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis]
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]
Adenomatous Polyps
Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells.
Angiotensin II and epidermal growth factor induce cyclooxygenase-2 expression in intestinal epithelial cells through small GTPases using distinct signaling pathways.
Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden.
Celecoxib as adjunctive therapy for treatment of colorectal cancer.
Celecoxib for the prevention of colorectal adenomatous polyps.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Colorectal Cancer Screening and Prevention.
Colorectal cancer: a summary of the evidence for screening and prevention.
COX-2 and colon cancer: Potential targets for chemoprevention.
COX-2 and colon cancer: potential targets for chemoprevention.
COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics.
COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
Cyclooxygenase-2 expression in colorectal carcinoma, adenomatous polyps and non-tumour bearing margins of resection tissues in a cohort of black Africans.
hMLH1, hMSH2 and cyclooxygenase-2 (cox-2) in sporadic colorectal polyps.
Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB.
Non-Steroidal Anti-inflammatory Drug Use and Risk of Adenomatous and Hyperplastic Polyps.
Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?
Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells.
Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp.
Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray.
The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas.
[Selective cyclooxygenase-2 inhibitors for the prevention of colorectal adenomas: a meta-analysis]
Adenomyosis
Celecoxib reduces inflammation and angiogenesis in mice with adenomyosis.
Celecoxib, a selective COX-2 inhibitor, markedly reduced the severity of tamoxifen-induced adenomyosis in a murine model.
Correlation of LOX?5 and COX?2 expression with inflammatory pathology and clinical features of adenomyosis.
Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.
Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis.
Effect of a hormone-releasing intrauterine system (Mirena(®)) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection.
Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis.
Expression of Cyclooxygenase-2 and Matrix Metalloproteinase-2 in Adenomyosis and Endometrial Polyps and its Correlation With Angiogenesis.
Genetic variation in COX-2 -1195 and the risk of endometriosis and adenomyosis.
Immunohistochemical localization of prostaglandin H synthase in the female reproductive tract and endometriosis.
Leonurine Attenuates Hyperalgesia in Mice with Induced Adenomyosis.
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Suppression of migratory/invasive ability and induction of apoptosis in adenomyosis-derived mesenchymal stem cells by cyclooxygenase-2 inhibitors.
The cancer marker neutrophil gelatinase-associated lipocalin is highly expressed in human endometrial hyperplasia.
The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis.
Adenosarcoma
Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
Adenoviridae Infections
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.
Adrenoleukodystrophy
Arachidonic acid metabolism in fibroblasts from patients with peroxisomal diseases: response to interleukin 1.
Cyclooxygenase pathway in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin.
African Swine Fever
The viral protein A238L inhibits cyclooxygenase-2 expression through a nuclear factor of activated T cell-dependent transactivation pathway.
Aggressive Periodontitis
Effect of a cyclooxygenase-2 inhibitor on interleukin-1beta-stimulated activation of the transcription factor nuclear factor-kappa B in human gingival fibroblasts.
Airway Obstruction
Airway constriction in normal humans produced by inhalation of leukotriene D. Potency, time course, and effect of aspirin therapy.
Analgesic sensitivity in children with asthma.
Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
Eicosanoids modulate hyperpnea-induced late phase airway obstruction and hyperreactivity in dogs.
Intranasal curcumin ameliorates airway inflammation and obstruction by regulating MAPKinase activation (p38, Erk and JNK) and prostaglandin D2 release in murine model of asthma.
The role of cyclooxygenase products in the acute airway obstruction and airway hyperreactivity of ponies with heaves.
[Expressions of cyclooxygenase-2 and matrix metalloproteinase-2 and airflow obstruction in patients with chronic obstructive pulmonary disease]
Albuminuria
A maladaptive role for EP4 receptors in podocytes.
Albumin-induced podocyte injury and protection are associated with regulation of COX-2.
Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria.
Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27).
Influence of the selective COX-2 inhibitor celecoxib on sex differences in blood pressure and albuminuria in spontaneously hypertensive rats.
Interaction of the renin angiotensin and cox systems in the kidney.
Intrarenal Dopamine Inhibits Progression of Diabetic Nephropathy.
PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes.
Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.
Puromycin Induces Reversible Proteinuric Injury in Transgenic Mice Expressing Cyclooxygenase-2 in Podocytes.
Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
RENAL PROTECTIVE EFFECT OF CHRONIC INHIBITION OF COX-2 WITH SC58236 IN STREPTOZOTOCIN-DIABETIC RATS.
Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.
Alkalosis
Different Placebos, Different Mechanisms, Different Outcomes: Lessons for Clinical Trials.
Multiple Ca(2+)-dependent modulators mediate alkalosis-induced vasodilation in newborn piglet lungs.
Alopecia
Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.
Expression of cyclooxygenase isozymes during morphogenesis and cycling of pelage hair follicles in mouse skin: precocious onset of the first catagen phase and alopecia upon cyclooxygenase-2 overexpression.
Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.
Altitude Sickness
Distinct influence of COX-1 and COX-2 on neuroinflammatory response and associated cognitive deficits during high altitude hypoxia.
The effect of naproxen on acute mountain sickness and vascular responses to hypoxia.
Alveolar Bone Loss
Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis.
Comparative evaluation of the efficacy of the cyclooxygenase pathway inhibitor and nitric oxide synthase inhibitor in the reduction of alveolar bone loss in ligature induced periodontitis in rats: An experimental study.
COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats.
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats.
Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss.
Effects of Selective Versus Non-Selective COX-2 Inhibition on Experimental Periodontitis.
Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis.
Exenatide and Sitagliptin Decrease Interleukin 1?, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene Expression But Does Not Reduce Alveolar Bone Loss in Rats With Periodontitis.
Follicle-stimulating hormone enhances alveolar bone resorption via upregulation of cyclooxygenase-2.
Local administration of Tiludronic Acid downregulates important mediators involved in periodontal tissue destruction in experimental periodontitis in rats.
Orthodontic forces add to nicotine-induced loss of periodontal bone : An in vivo and in vitro study.
Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis.
Protective effect of Platymiscium floribundum Vog. in tree extract on periodontitis inflammation in rats.
Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats.
Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.
Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats.
Selective cyclooxygenase-2 inhibition prevents bone resorption.
Alzheimer Disease
?9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling.
A Hypothesis and Evidence That Mercury May be an Etiological Factor in Alzheimer's Disease.
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice.
Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease.
Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: the Hisayama Study.
Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes.
Amyloid-? Induces Cyclooxygenase-2 and PGE2 Release in Human Astrocytes in NF-? B Dependent Manner.
Anti-aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation.
Anti-inflammatory drugs and their mechanism of action.
Anti-inflammatory drugs, cyclooxygenases and other factors.
Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production.
Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese.
Association study of COX-2 (PTGS2) -765 G/C promoter polymorphism by pyrosequencing in Sicilian patients with Alzheimer's disease.
Association study of interferon-?, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease.
Association study of polymorphisms in the cyclooxygenase-2 gene and Alzheimer's disease risk in Chinese.
Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease.
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).
Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
Clinical aspects of COX-2 inhibitors.
Clinical potential of cyclo-oxygenase-2 inhibitors.
COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration.
COX-2 inhibitors as adjunctive therapy in schizophrenia.
COX-2 inhibitors--IBC conference. 12-13 April 1999, Coronado, CA, USA.
Cox-2 Plays a Vital Role in the Impaired Anxiety Like Behavior in Colchicine Induced Rat Model of Alzheimer Disease.
Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.
Cyclooxygenase (COX)-1 Activity Precedes the COX-2 Induction in Abeta-Induced Neuroinflammation.
Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology.
Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity.
Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia.
Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions.
Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease.
Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain.
Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.
Cyclooxygenase inhibitors--current status and future prospects.
Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.
Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology.
Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons.
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.
Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells.
Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.
Cyclooxygenase-2 gene polymorphisms and risk of Alzheimer's disease: A meta-analysis.
Cyclooxygenase-2 Gene Polymorphisms and Risk of Alzheimer's Disease: A Possible Biomoleular Explanation.
Cyclooxygenase-2 in synaptic signaling.
Cyclooxygenase-2 in the hippocampus is up-regulated in Alzheimer's disease but not in variant Alzheimer's disease with cotton wool plaques in humans.
Cyclooxygenase-2 Induced the ?-Amyloid Protein Deposition and Neuronal Apoptosis Via Upregulating the Synthesis of Prostaglandin E2 and 15-Deoxy-?12,14-prostaglandin J2.
Cyclooxygenase-2 is critical for the propagation of ?-amyloid protein and reducing the glycosylation of tau in Alzheimer's disease.
Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.
Cyclooxygenase-2 stimulates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG108-15 cells.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Cyclooxygenase-dependent lipid-modification of brain proteins.
Cyclooxygenases 1 and 2.
Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders.
Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Decreased expression of prostaglandin G/H synthase-2 (PGHS-2) in Alzheimer's disease brain.
Defining the role of COX-2 inhibitors in inflammatory and other diseases.
Deletion of microsomal prostaglandin E synthase-1 protects neuronal cells from cytotoxic effects of ?-amyloid peptide fragment 31-35.
Design, Synthesis and In Vitro Study of 5,6-Diaryl-1,2,4-triazine-3-ylthioacetate Derivatives as COX-2 and ?-Amyloid Aggregation Inhibitors.
Detection of Cyclooxygenase-1 in Activated Microglia During Amyloid Plaque Progression: PET Studies in Alzheimer's Disease Model Mice.
Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats.
Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs.
Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease.
Drp1-dependent mitochondrial fission regulates p62-mediated autophagy in LPS-induced activated microglial cells.
Effect of acetylcholinesterase inhibitors donepezil and rivastigmine on the activity and expression of cyclooxygenases in a model of the inflammatory action of fluoride on macrophages obtained from THP-1 monocytes.
Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders.
ENDOCANNABINOIDS RECEPTORS MEDIATED CENTRAL AND PERIPHERAL EFFECTS (REVIEW).
Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease.
Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(?E9) transgenic mouse models of Alzheimer's disease.
Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors.
From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia.
Glial and neuronal expression of cyclooxygenase-2: relevance to Alzheimer's disease.
Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation.
Induction of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma during nitric oxide-induced apoptotic PC12 cell death.
Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2.
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease.
Influence of four polymorphisms in ABCA1 and PTGS2 genes on risk of Alzheimer's disease: a meta-analysis.
Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease.
Integrated communications between cyclooxygenase-2 and Alzheimer's disease.
Integrated Pathways of COX-2 and mTOR: Roles in Cell Sensing and Alzheimer's Disease.
Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease.
Interleukin-1beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB.
Is cyclooxygenase-1 involved in neuroinflammation?
Is there a Future for Cyclo-Oxygenase Inhibitors in Alzheimer's Disease?
Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease.
Long non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation while Stimulates Neurite Outgrowth and its Correlation with MiR-125b Mediated PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease.
Long noncoding RNA MALAT1 and its target microRNA-125b are potential biomarkers for Alzheimer's disease management via interactions with FOXQ1, PTGS2 and CDK5.
Long-term efficacy and safety of celecoxib in Alzheimer's disease.
Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease.
Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease.
Mechanism of action of antiinflammatory drugs.
Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C.
Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models.
Meta-analysis of cyclooxygenase-2 (COX-2) 765G>C polymorphism and Alzheimer's disease.
Microsomal prostaglandin E synthase-1 is induced in alzheimer's disease and its deletion mitigates alzheimer's disease-like pathology in a mouse model.
Microsomal prostaglandin E synthase-2: Cellular distribution and expression in Alzheimer's disease.
miR-103 Promotes Neurite Outgrowth and Suppresses Cells Apoptosis by Targeting Prostaglandin-Endoperoxide Synthase 2 in Cellular Models of Alzheimer's Disease.
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.
Naringin and Rutin Alleviates Episodic Memory Deficits in Two Differentially Challenged Object Recognition Tasks.
Neuroinflammation in Alzheimer's Disease: Are NSAIDs and Selective COX-2 Inhibitors the Next Line of Therapy?
Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?
Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex.
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease.
Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia.
Neuroprotective Effect of Cyclooxygenase Inhibitors in ICV-STZ Induced Sporadic Alzheimer's Disease in Rats.
New insights into COX-2 biology and inhibition.
Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease.
Nonsteroidal antiinflammatory agents.
Novel insights and therapeutical applications in the field of inhibitors of COX-2.
Novel non-steroidal anti-inflammatory drugs: what we have learned from animal studies.
Oligomers of ?-amyloid protein (A?1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1?, tumour necrosis factor-?, and a nuclear factor ?-B mechanism in the rat brain.
Pain management and beyond: evolving concepts and treatments involving cyclooxygenase inhibition.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
Peripheral inflammatory biomarkers of Alzheimer's disease: the role of platelets.
Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease.
Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors.
Phospholipase A2 is involved in muscarinic receptor-mediated sAPPalpha release independently of cyclooxygenase or lypoxygenase activity in SH-SY5Y cells.
Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH102, a New Synthesized COX2 Inhibitors after I.V. and Oral Administration in Male and Female Rats.
Progress in COX-2 inhibitors: a journey so far.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Prostaglandin A1 Decreases the Phosphorylation of Tau by Activating Protein Phosphatase 2A via a Michael Addition Mechanism at Cysteine 377.
Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease.
Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers.
Prostaglandin I
Prostaglandin I2 Attenuates Prostaglandin E2-Stimulated Expression of Interferon ? in a ?-Amyloid Protein- and NF-?B-Dependent Mechanism.
Prostaglandin I2 upregulates the expression of anterior pharynx-defective-1? and anterior pharynx-defective-1? in amyloid precursor protein/presenilin 1 transgenic mice.
Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.
Prostaglandins and other lipid mediators in Alzheimer's disease.
Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations.
Protective effects of gingerol on streptozotocin-induced sporadic Alzheimer's disease: emphasis on inhibition of ?-amyloid, COX-2, alpha-, beta - secretases and APH1a.
Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders.
Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.
Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme.
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.
Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease.
Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors.
Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
Role of COX-2 in inflammatory and degenerative brain diseases.
Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease.
Role of cyclooxygenase-1 and -2 in health and disease.
Role of Cyclooxygenase-2 and 5-Lipoxygenase Polymorphisms in Alzheimer's Disease in a Population from Northern Italy: Implication for Pharmacogenomics.
Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics.
Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships.
Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential.
Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex.
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression.
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Targeting MicroRNA-125b Promotes Neurite Outgrowth but Represses Cell Apoptosis and Inflammation via Blocking PTGS2 and CDK5 in a FOXQ1-Dependent Way in Alzheimer Disease.
The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
The clinical potential of cyclooxygenase-2-specific inhibitors.
The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease.
The effect of vitamin B12 on synaptic plasticity of hippocampus in Alzheimer's disease model rats.
The potential application of cyclo-oxygenase type 2 inhibitors to Alzheimer's disease.
The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs.
The role of inflammation in CNS injury and disease.
The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo.
Thinking outside the box about COX-1 in Alzheimer's disease.
[Clinical application of cyclooxygenase-2 inhibitors]
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy]
[Effects of Valeriana amurensis on the expressions of iNOS, COX-2 and IkappaCB-alpha in Alzheimer's disease model rat's brain]
[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]
[Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives]
Ameloblastoma
Comparison of fatty acid synthase and cyclooxygenase-2 immunoexpression in embryonal, benign, and malignant odontogenic tissues.
COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma.
Cyclooxygenase-2 protein expression modulates cell proliferation and apoptosis in solid ameloblastoma and odontogenic keratocyst. An immunohistochemical study.
Immunohistochemical analysis of COX-2 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma: A comparative study.
Odontogenic epithelial proliferation is correlated with COX-2 expression in dentigerous cyst and ameloblastoma.
Amnesia
Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT.
Possible glutamatergic and lipid signalling mechanisms in ECT-induced retrograde amnesia: experimental evidence for involvement of COX-2, and review of literature.
The IkappaB kinase inhibitor sulfasalazine impairs long-term memory in the crab Chasmagnathus.
The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
Amnesia, Retrograde
Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT.
Possible glutamatergic and lipid signalling mechanisms in ECT-induced retrograde amnesia: experimental evidence for involvement of COX-2, and review of literature.
Amyloidosis
Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.
Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis.
Induction of cyclooxygenase-2 in human synovial cells by beta 2-microglobulin.
Amyotrophic Lateral Sclerosis
A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
Altered Lipid Metabolism in Brain Injury and Disorders.
Altered lipid metabolism in brain injury and disorders.
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.
Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis.
Function of COX-2 and prostaglandins in neurological disease.
Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia.
Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis.
Induction of cyclooxygenase-2 in reactive glial cells by the CD40 pathway: relevance to amyotrophic lateral sclerosis.
Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis.
Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.
Is prostaglandin E(2) a pathogenic factor in amyotrophic lateral sclerosis?
Nonsteroidal anti-inflammatory drugs differentially affect the heat shock response in cultured spinal cord cells.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Rofecoxib Attenuates the Pathogenesis of Amyotrophic Lateral Sclerosis by Alleviating Cyclooxygenase-2-Mediated Mechanisms.
Trial of celecoxib in amyotrophic lateral sclerosis.
Anaphylaxis
Analgesics, allergy and asthma.
Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs.
Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor.
Anaphylatoxin C3a enhances mucous glycoprotein release from human airways in vitro.
Anti-inflammatory activity of hexane extracts from bones and internal organs of Anguilla japonica suppresses cyclooxygenase-2-dependent prostaglandin D? generation in mast cells and anaphylaxis in mice.
Aspirin and NSAID sensitivity.
Biphasic response of cutaneous blood flow induced by passive cutaneous anaphylaxis in rats.
Bronchial anaphylaxis in actively sensitized Sprague Dawley rats: studies on mediators involved.
Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions.
Ciliary responsiveness in allergic and nonallergic airways.
Cyclooxygenase blockade elevates leukotriene E4 production during acute anaphylaxis in sheep.
Cyclooxygenase metabolites in human lung anaphylaxis: airway vs. parenchyma.
Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from platelets and their in vivo effects on inflammation and anaphylaxis.
Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels.
Effect of pharmacologic agents on antigen-induced decreases in specific lung conductance in sheep.
Effects of 5-lipoxygenase inhibition on cardiac anaphylaxis in isolated guinea pig hearts.
Effects of anaphylaxis mediators on partitioned pulmonary vascular resistance during ragweed shock in dogs.
Effects of exogenous prostaglandins on the release of leukotriene C4-like immunoreactivity and on coronary flow in indomethacin-treated anaphylactic guinea-pig hearts.
Eicosanoid modulation of stress fibers in cultured bovine aortic endothelial cells.
Enhancement of plasma levels of biologically active leukotriene B compounds during anaphylaxis in guinea pigs pretreated by indomethacin or by a fish oil-enriched diet.
Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis.
Idiosyncrasy to pyrazolone drugs.
Involvement of leukotrienes in allergic inflammation in mice.
Leukotrienes, thromboxane A2, and prostaglandins during systemic anaphylaxis in sheep.
Mechanisms of response to antigen in isolated guinea pig trachea after active sensitization.
Meloxicam-associated anaphylactic reaction.
MicroRNA-26a/-26b-COX-2-MIP-2 Loop Regulates Allergic Inflammation and Allergic Inflammation-promoted Enhanced Tumorigenic and Metastatic Potential of Cancer Cells.
Nitric oxide and ?2-adrenoceptor activation attenuate pulmonary vasoconstriction during anaphylactic hypotension in anesthetized BALB/c mice.
Nonsteroidal anti-inflammatory drugs enhance IgE-mediated activation of human basophils in patients with food anaphylaxis dependent and independent of nonsteroidal anti-inflammatory drugs.
On the structure of slow reacting substance of anaphylaxis: evidence of biosynthesis from arachidonic acid.
Ozone-induced bronchial hyperreactivity in guinea pigs is abolished by BW 755C or FPL 55712 but not by indomethacin.
Quantitative analysis of prostanoids in biological fluids by combined capillary column gas chromatography negative ion chemical ionization mass spectrometry.
Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
SRS-A mediated bronchospasm by pharmacologic modification of lung anaphylaxis in vivo.
Total profiling by GC/NICIMS of the major cyclo-oxygenase products from antigen and leukotriene-challenged guinea-pig lung.
[Mastocytosis: an important differential diagnosis in anaphylactoid reaction to Hymenoptera sting. A case report and overview of clinical aspects, diagnosis and current therapy of mastocytosis]
Anaplasia
Association between Degree of Anaplasia and Degree of Inflammation with the Expression of COX-2 in Feline Injection Site Sarcomas.
Anemia
Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract.
Cyclooxygenase-2 haplotypes influence the longitudinal risk of malaria and severe malarial anemia in Kenyan children from a holoendemic transmission region.
Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice.
Effect of Exercise on Cardiac Tissue Oxidative and Inflammatory Mediators in Chronic Kidney Disease.
Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers.
Effects of cyclooxygenase inhibitors on parasite burden, anemia and oxidative stress in murine Trypanosoma cruzi infection.
Impaired systemic production of prostaglandin E2 in children with cerebral malaria.
Non-steroidal anti-inflammatory drugs and the gastrointestinal tract.
Prevention of iron deficiency anemia in IUD users by prostaglandin synthetase inhibitors.
Reduced systemic bicyclo-prostaglandin-E2 and cyclooxygenase-2 gene expression are associated with inefficient erythropoiesis and enhanced uptake of monocytic hemozoin in children with severe malarial anemia.
Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia.
[Expression of COX-1 and COX-2 in the Platelet of Iron Deficiency Anemia Women at Childbearing Age and Its Clinical Significance].
Anemia, Hemolytic
Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.
Anemia, Iron-Deficiency
Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers.
Non-steroidal anti-inflammatory drugs and the gastrointestinal tract.
Prevention of iron deficiency anemia in IUD users by prostaglandin synthetase inhibitors.
[Expression of COX-1 and COX-2 in the Platelet of Iron Deficiency Anemia Women at Childbearing Age and Its Clinical Significance].
Anemia, Sickle Cell
Micro-MRI methods to detect renal cysts in mice.
Modulation of redox pathways in neutrophils from sickle cell disease patients.
Aneurysm
Differential Sex Response to Aspirin in Decreasing Aneurysm Rupture in Humans and Mice.
Disruption of P2X4 purinoceptor and suppression of the inflammation associated with cerebral aneurysm formation.
Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase.
Letter by Wen et al Regarding Article, "Pathophysiology of Intracranial Aneurysms: COX-2 Expression, Iron Deposition in Aneurysm Wall, and Correlation With Magnetic Resonance Imaging".
MF-tricyclic inhibits growth of experimental abdominal aortic aneurysms.
Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.
mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.
Oral Presentations of the 2016 Annual Meeting of the Congress of Neurological Surgeons: San Diego, California: September 24-28, 2016: 100?Differential Sex Response to Aspirin in Decreasing Aneurysm Rupture in Humans and Mice.
Pathophysiology of Intracranial Aneurysms: COX-2 Expression, Iron Deposition in Aneurysm Wall, and Correlation With Magnetic Resonance Imaging.
Protective Effect of Mesenchymal Stem Cells Against the Development of Intracranial Aneurysm Rupture in Mice.
Response by Rodemerk et al to Letter Regarding Article, "Pathophysiology of Intracranial Aneurysms: COX-2 Expression, Iron Deposition in Aneurysm Wall, and Correlation With Magnetic Resonance Imaging".
Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.
Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors.
Angina, Stable
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
[?ptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity].
Angina, Unstable
Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina.
Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease.
Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses.
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.
Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina.
Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
How to get from antiplatelet to antithrombotic treatment.
Identification of differentially expressed genes in coronary atherosclerotic plaques from patients with stable or unstable angina by cDNA array analysis.
Platelet arachidonic acid metabolism in patients with cardiovascular disorders.
Transcellular formation of thromboxane A(2) in mixed incubations of endothelial cells and aspirin-treated platelets strongly depends on the prostaglandin I-synthase activity.
Angioedema
Angioedema associated with aspirin and rofecoxib.
Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs.
Management of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactions.
NSAID-induced urticaria and angioedema: a reappraisal of its clinical management.
Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.
Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Urticaria and angioedema induced by COX-2 inhibitors.
Anhedonia
Sex-Dependent Effects of Neonatal Inflammation on Adult Inflammatory Markers and Behavior.
Anophthalmos
New insights into the obligatory nature of cyclooxygenase-2 and PGE2 during early chick embryogenesis.
Anosmia
Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future.
Anthrax
Rapid induction of inflammatory lipid mediators by the inflammasome in vivo.
Anti-Glomerular Basement Membrane Disease
Hyaluronan-induced cyclooxygenase-2 expression promotes thromboxane A2 production by renal cells.
Anuria
COX-2 inhibitor induced anuric renal failure in a previously healthy young woman.
Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors.
Aortic Aneurysm
Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions.
Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase.
Indomethacin Prevents the Progression of Thoracic Aortic Aneurysm in Marfan Syndrome Mice.
Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.
Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors.
Aortic Aneurysm, Abdominal
Cyclooxygenase-2 expression and its association with increased angiogenesis in human abdominal aortic aneurysms.
Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice.
Defective p27 phosphorylation at serine 10 affects vascular reactivity and increases abdominal aortic aneurysm development via Cox-2 activation.
Effectiveness of Cyclooxygenase-2 Inhibition in Limiting Abdominal Aortic Aneurysm Progression in Mice Correlates with a Differentiated Smooth Muscle Cell Phenotype.
Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice.
Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.
mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.
Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms.
Quercetin Downregulates Cyclooxygenase-2 Expression and HIF-1?/VEGF Signaling-Related Angiogenesis in a Mouse Model of Abdominal Aortic Aneurysm.
Regulatory T cells protected against abdominal aortic aneurysm by suppression of the COX-2 expression.
Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.
The Influence of COX-2 Single Nucleotide Polymorphisms on Abdominal Aortic Aneurysm Development and the Associated Inflammation.
Aortic Coarctation
Increased renal vasoconstriction and gene expression of cyclooxygenase-1 in renovascular hypertension.
Vascular responsiveness to nitric oxide synthesis inhibition in hypertensive rats.
Aortic Valve Disease
Celecoxib Is Associated With Dystrophic Calcification and Aortic Valve Stenosis.
Aortic Valve Stenosis
Induction of aortic valve calcification by celecoxib and its COX-2 independent derivatives is glucocorticoid-dependent.
Apnea
A reexamination of the role of oxygen in retrolental fibroplasia.
Role of TRPA1 and TRPV1 in the ROS-dependent sensory irritation of superior laryngeal capsaicin-sensitive afferents by cigarette smoke in anesthetized rats.
Appendiceal Neoplasms
Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
Arrhythmias, Cardiac
Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
[Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]
Arteriosclerosis
COX-2-derived prostacyclin modulates vascular remodeling.
PKC-delta/c-Src-mediated EGF receptor transactivation regulates thrombin-induced COX-2 expression and PGE(2) production in rat vascular smooth muscle cells.
Sphingosine-1-phosphate induces COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells.
Tissue-specific modulation of cyclooxygenase-2 (Cox-2) expression in the uterus and the v. cava by estrogens and phytoestrogens.
[Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]
Arteritis
Cytokine expression in temporal arteries: comparative analysis between patients with biopsy-positive giant cell arteritis, biopsy-negative giant cell arteritis and biopsy-negative without arteritis.
Arthralgia
A randomized double blind comparison of short-term duodenally administrated whale and seal blubber oils in patients with inflammatory bowel disease and joint pain.
Alteration of gait parameters in a mouse model of surgically induced knee osteoarthritis.
Combatting joint pain and inflammation by dual inhibition of monoacylglycerol lipase and cyclooxygenase-2 in a rat model of osteoarthritis.
Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors.
Cyclooxygenase-2 in synovial tissue and fluid of dysfunctional temporomandibular joints with internal derangement.
Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons.
Expression of microRNAs in the plasma of patients with acute gouty arthritis and the effects of colchicine and etoricoxib on the differential expression of microRNAs.
Immunohistochemical localization of cyclooxygenase-1 and -2 in synovial tissues from patients with internal derangement or osteoarthritis of the temporomandibular joint.
In patients with temporomandibular disorders, do particular interventions influence oral health-related quality of life? A qualitative systematic review of the literature.
Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac.
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice.
Arthritis
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.
A case of acute liver failure due to etodolac.
A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
A deficiency in the prostaglandin D2 receptor CRTH2 exacerbates adjuvant-induced joint inflammation.
A new ditriazine inhibitor of NF-kappaB modulates chronic inflammation and angiogenesis.
A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen.
ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
Accounting for the increase in NSAID expenditure: substitution or leakage?
An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures.
An unusual case of colon perforation with multiple transmural ulcers after use of polmacoxib and everolimus in a metastatic breast cancer patient: A case report.
Andrographolide attenuates complete freund's adjuvant induced arthritis via suppression of inflammatory mediators and pro-inflammatory cytokines.
Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats.
Anti-inflammatory Potential of Alpha-Linolenic Acid Mediated Through Selective COX Inhibition: Computational and Experimental Data.
Anti-rheumatoid arthritis effects in adjuvant-induced arthritis in rats and molecular docking studies of Polygonum orientale L. extracts.
Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity.
Are preferences for cyclooxygenase-2 inhibitors influenced by the certainty effect?
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease.
Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis.
Articular inflammation induced by an enzymatically-inactive Lys49 phospholipase A
Asphodelus tenuifolius extracts arrested inflammation and arthritis through modulation of TNF-?, NF-?B, ILs, and COX-2 activities in in vivo models.
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.
Bacopa monniera (L.) wettst inhibits type ii collagen-induced arthritis in rats.
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.
Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs.
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Cardiovascular effects of the selective cyclooxygenase-2 inhibitors.
Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
Cardiovascular risk and COX-2 inhibition in rheumatological practice.
Cardiovascular risk, hypertension, and NSAIDs.
Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making.
Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Celecoxib Enhances the Anti-inflammatory Effects of Farnesylthiosalicylic Acid on T Cells Independent of Prostaglandin E(2) Production.
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Celecoxib with chemotherapy in colorectal cancer.
Celecoxib-induced erythema multiforme with glyburide cross-reactivity.
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.
Clinical experience with specific COX-2 inhibitors in arthritis.
Clinical implications of selective cyclooxygenase-2 inhibition.
Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis.
Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis.
Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis.
Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments.
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
Complexes of Indomethacin with 4-Carbomethoxy-pyrrolidone PAMAM Dendrimers Show Improved Anti-inflammatory Properties and Temperature-Dependent Binding and Release Profile.
Compositions for treatment of cancer and inflammation.
Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Contrasting Effects of n-3 and n-6 Fatty Acids on Cyclooxygenase-2 in Model Systems for Arthritis.
Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis.
COX-1 and COX-2 tissue expression: implications and predictions.
COX-2 in synovial tissues.
COX-2 inhibition and pain management: a review summary.
COX-2 inhibitors. New medication for arthritis pain.
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?
COX-2 selective NSAID decreases bone ingrowth in vivo.
COX-2 specific inhibitors in the management of arthritis and pain. Introduction.
COX-2-selective inhibitors in the treatment of arthritis.
COX-2: separating myth from reality.
CT20126, a novel immunosuppressant, prevents collagen-induced arthritis through the down-regulation of inflammatory gene expression by inhibiting NF-kappaB activation.
Current state of therapy for pain and inflammation.
Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
Cyclooxygenase-2 and chemoprevention of breast cancer.
Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
Cyclooxygenase-2 in the spinal cord: localization and regulation after a peripheral inflammatory stimulus.
Cyclooxygenase-2 inhibition reverts the decrease in adiponectin levels and attenuates the loss of white adipose tissue during chronic inflammation.
Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
Cyclooxygenase-2 inhibitors in lung cancer.
Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation.
Cyclooxygenase-2 inhibitors: what went wrong?
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Cyclooxygenase-2--10 years later.
Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases.
Detection of Overexpressed COX-2 in Precancerous Lesions of Hamster Pancreas and Lungs by Molecular Imaging: Implications for Early Diagnosis and Prevention.
Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry.
Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis.
Differential expression of COX-2 in osteoarthritis and rheumatoid arthritis.
Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases.
Docking Studies and Molecular Dynamics Simulation of Ipomoea batatas L. Leaves Compounds as Lipoxygenase (LOX) Inhibitor.
Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Effect of selective COX-2 inhibitor, celecoxib on adjuvant-induced arthritis model in irradiated rats.
Effects of anti-arthritis preparations on gene expression and enzyme activity of cyclooxygenase-2 in cultured equine chondrocytes.
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.
Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
Effects of triptolide from Radix Tripterygium wilfordii (Leigongteng) on cartilage cytokines and transcription factor NF-kappaB: a study on induced arthritis in rats.
Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.
Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review.
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
Emerging options with coxib therapy.
Etoricoxib for arthritis and pain management.
Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital.
Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis.
Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis.
Formoterol decreases muscle wasting as well as inflammation in the rat model of rheumatoid arthritis.
Formulary decision-making considerations: COX-2 inhibitors.
Future trends in the development of safer nonsteroidal anti-inflammatory drugs.
G-CSF Receptor Blockade Ameliorates Arthritic Pain and Disease.
Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
Genetics of arthritis severity: A genome-wide and species-wide dissection in HS mice.
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain.
Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression.
Identification and Characterization of Novel Microsomal Prostaglandin E Synthase-1 Inhibitors for Analgesia.
Identification of Active Compounds From Yi Nationality Herbal Formula Wosi Influencing COX-2 and VCAM-1 Signaling.
In Vitro Anti-Inflammatory and In Vivo Antiarthritic Activities of Aqueous and Ethanolic Extracts of Dissotis thollonii Cogn. (Melastomataceae) in Rats.
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
In Vivo Brain Imaging, Biodistribution, and Radiation Dosimetry Estimation of [11C]Celecoxib, a COX-2 PET Ligand, in Nonhuman Primates.
In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.
In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons.
Inflammation and ROS in arthritis: management by Ayurvedic medicinal plants.
Inhibition of cyclooxygenase-2 activity in subchondral bone modifies a subtype of osteoarthritis.
Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it.
Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation.
Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism.
Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis.
Inhibitory effects of JTE-522, a novel prostaglandin H synthase-2 inhibitor, on adjuvant-induced arthritis and bone changes in rats.
Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study.
Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity.
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.
LncRNA H19 regulates macrophage polarization and promotes Freund's complete adjuvant-induced arthritis by upregulating KDM6A.
Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice.
Managing arthritis pain amid evolving science on pain relievers.
Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide.
Melanocortin-4 receptor agonist (RO27-3225) ameliorates soleus but not gastrocnemius atrophy in arthritic rats.
Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.
MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2.
Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model.
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Mitigation of arthritis by high-dose administration of a COX-2 inhibitor in the collagen-induced arthritis model in the mouse.
Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?
Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion.
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis.
Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
Natural products as a gold mine for arthritis treatment.
New COX-2 arthritis drug receives FDA approval.
Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation.
Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection.
Nitric oxide enhances cyclooxygenase activity in articular cartilage.
Nitric oxide synthase and cyclooxygenase interactions in cartilage and meniscus: relationships to joint physiology, arthritis, and tissue repair.
Non-steroidal anti-inflammatory drugs for acute gout.
Novel insights and therapeutical applications in the field of inhibitors of COX-2.
NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
NSAID-induced gastrointestinal and cardiovascular injury.
NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective.
Obesity does not diminish the efficacy of IL-6 signalling blockade in mice with collagen-induced arthritis.
Paederia foetida Linn. inhibits adjuvant induced arthritis by suppression of PGE(2) and COX-2 expression via nuclear factor-?B.
Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility.
Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy.
Pharmacokinetics of Rofecoxib in Children With Sickle Cell Hemoglobinopathy.
Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.
Pinocembrin Reduces Arthritic Symptoms in Mouse Model via Targeting Sox4 Signaling Molecules.
Polystichum braunii extracts inhibit Complete Freund's adjuvant-induced arthritis via upregulation of I-?B, IL-4, and IL-10, downregulation of COX-2, PGE2, IL-1?, IL-6, NF-?B, and TNF-?, and subsiding oxidative stress.
Possible Protective Role of Chloramphenicol in TSST-1 and Coagulase-Positive Staphylococcus aureus-Induced Septic Arthritis with Altered Levels of Inflammatory Mediators.
PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice.
Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis.
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis.
Prostanoid Receptor EP2 as a Therapeutic Target.
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.
Radiosynthesis and evaluation of [18F]FMTP, a COX-2 PET ligand.
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO.
Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis.
Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers.
Resolution of Inflammation in Murine Autoimmune Arthritis Is Disrupted by Cyclooxygenase-2 Inhibition and Restored by Prostaglandin E2-Mediated Lipoxin A4 Production.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
Risk-benefit perspectives in COX-2 blockade.
Role of cyclooxygenases in angiogenesis.
Scientific validation of Anti-arthritic effect of Kashayams - a polyherbal formulation in collagen induced arthritic rats.
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?
Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
Selective Inhibition of COX-2 by a Standardized CO2 Extract of Humulus lupulus in vitro and its Activity in a Mouse Model of Zymosan-Induced Arthritis.
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.
Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis.
Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.
Sex differences in inflammation and inflammatory pain in cyclooxygenase-deficient mice.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
Specific cyclooxygenase-2 (COX-2) inhibitors.
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Structural efficacy of NSAIDs, COX-2 inhibitor and glucocorticoid compared with TNF? blocker: a study in adjuvant-induced arthritis rats.
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Synthesis and quantitative structure-activity relationships of diclofenac analogues.
Terpenes as possible drugs for the mitigation of arthritic symptoms - A systematic review.
The AP-1 Transcription Factor c-Jun Promotes Arthritis by Regulating Cyclooxygenase-2 and Arginase-1 Expression in Macrophages.
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
The COX-2 controversy continues ...but NSAIDs are still in the lead. New studies shed light on risks associated with popular arthritis painkillers.
The double-edged sword of COX-2 selective NSAIDs.
The effects of Celecoxib on inflammation and synovial microcirculation in murine antigen-induced arthritis.
The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat.
The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis.
The impact of nonsteroidal anti-inflammatory drug-induced gastropathy.
The management of pain in arthritis and the use of cyclooxygenase-2 inhibitors: new paradigms and insights.
The melanocortin receptor type 3 agonist d-Trp(8)-?MSH decreases inflammation and muscle wasting in arthritic rats.
The role of COX-2 produced by cartilage in arthritis.
The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis.
The snake venom metalloproteinase BaP1 induces joint hypernociception through TNF-alpha and PGE2-dependent mechanisms.
The unmet anti-inflammatory needs in orthopedics.
The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis.
The usefulness and the limitations of animal models in identifying targets for therapy in arthritis.
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Therapeutic effects of standardized Vitex negundo seeds extract on complete Freund's adjuvant induced arthritis in rats.
Therapeutic potential of COX-2 inhibitors in arthritis.
Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Topical Nano-Vesicular Spanlastics of Celecoxib: Enhanced Anti-Inflammatory Effect and Down-Regulation of TNF-?, NF-?B and COX-2 in Complete Freund's Adjuvant-Induced Arthritis Model in Rats.
Topically Applied Phospho-Sulindac Hydrogel is Efficacious and Safe in the Treatment of Experimental Arthritis in Rats.
Treatments for Inflammatory Arthritis: Potential But Unproven Role of Topical Copaiba.
Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Update on the management of pain in arthritis and the use of cyclooxygenase-2 inhibitors.
Ursolic acid rich Ocimum sanctum L leaf extract loaded nanostructured lipid carriers ameliorate adjuvant induced arthritis in rats by inhibition of COX-1, COX-2, TNF-? and IL-1: Pharmacological and docking studies.
Use of COX-2 specific inhibitors in operative and nonoperative management of patients with arthritis.
Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care setting.
Valdecoxib (Pharmacia).
Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs.
Vision of the future in arthritis care.
Visual disturbance associated with celecoxib.
What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
[Can COX-2 selective inhibitor prevent NSAIDs-related GI toxicity?].
[COX-2 inhibitors: a new treatment in rheumatic diseases]
[Cyclooxygenase-2 (Cox-2) selective inhibitors: socioeconomic and pharmaco-epidemiologic aspects]
[New studies of COX-inhibitors, yet issues remain]
[Novel synthetic method and analgesic activity of tepoxalin].
[Side effects of COX-2 selective inhibitors. Critic related with its administration in patients with rheumatoid arthritis and osteoarthritis]
Arthritis, Experimental
Anti-inflammatory activity of a novel selective cyclooxygenase-2 inhibitor, FR140423, on type II collagen-induced arthritis in Lewis rats.
Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression.
Anti-inflammatory effects of Clematis chinensis Osbeck extract(AR-6) may be associated with NF-?B, TNF-?, and COX-2 in collagen-induced arthritis in rat.
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Antiinflammatory 2,6-di-tert-butyl-4-(2-arylethenyl)phenols.
Antiinflammatory benzimidazole derivative with inhibitory effects on neutrophil function.
Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis.
Changes in prostaglandin E2 (PGE2) levels in paw exudate, stomach and kidney of arthritic rats: effects of flosulide.
Chrysin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis: comparison with celecoxib.
Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis.
Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis.
Effects of the second-generation leukotriene B(4) receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice.
Inhibitory effects of the root extract of Litsea cubeba (Lour.) Pers. on adjuvant arthritis in rats.
Lactobacillus casei reduces the Inflammatory Joint Damage Associated with Collagen-Induced Arthritis (CIA) by Reducing the Pro-Inflammatory Cytokines : Lactobacillus casei: COX-2 inhibitor.
Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.
MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2.
Mitigation of arthritis by high-dose administration of a COX-2 inhibitor in the collagen-induced arthritis model in the mouse.
Nociception and the differential expression of cyclooxygenase-1 (COX-1), the COX-1 variant retaining intron-1 (COX-1v), and COX-2 in mouse dorsal root ganglia (DRG).
Pharmacology of celecoxib in rat brain after kainate administration.
Polymyxin B prevents the development of adjuvant arthritis via modulation of TLR/Cox-2 signaling pathway.
Relations between functional, inflammatory, and degenerative parameters during adjuvant arthritis in rats.
Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice.
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.
Stereoisomeric relationships among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase.
The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis.
The influence of anti-rheumatic drugs on hepatic mRNA levels of acute-phase proteins in rats with adjuvant arthritis.
The usefulness and the limitations of animal models in identifying targets for therapy in arthritis.
Therapeutic effects of the total lignans from Vitex negundo seeds on collagen-induced arthritis in rats.
[Analgesic effects of ionotropic glutamate receptor antagonists MK-801 and NBQX on collagen-induced arthritis rats].
[Antiphlogistic effectiveness of combinations of inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases of the arachidonic acid cascade]
[Simultaneous and sequential inhibition of the arachidonic acid cascade by inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases in carrageenan edema and adjuvant arthritis in the rat]
Arthritis, Gouty
Clinical pharmacology of etoricoxib.
Frontline Science: Reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis.
Soft coral-derived lemnalol alleviates monosodium urate-induced gouty arthritis in rats by inhibiting leukocyte infiltration and iNOS, COX-2 and c-Fos protein expression.
Arthritis, Infectious
Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.
Arthritis, Juvenile
A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen.
Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors.
Arthritis, Psoriatic
A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Nephrotoxicity of selective COX-2 inhibitors.
Single subject pharmacological-MRI (phMRI) study: modulation of brain activity of psoriatic arthritis pain by cyclooxygenase-2 inhibitor.
Arthritis, Reactive
Antiinflammatory effects of etoricoxib alone and combined with NSAIDs in LPS-induced reactive arthritis.
Association between reactive arthritis and antecedent infection with Shigella flexneri carrying a 2-Md plasmid and encoding an HLA-B27 mimetic epitope.
Characterization of the stable maintenance of the Shigella flexneri plasmid pHS-2.
Arthritis, Rheumatoid
(-)-Epiafzelechin: cyclooxygenase-1 inhibitor and anti-inflammatory agent from aerial parts of Celastrus orbiculatus.
4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).
A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis.
A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis.
A glycoprotein from Porphyra yezoensis produces anti-inflammatory effects in liposaccharide-stimulated macrophages via the TLR4 signaling pathway.
A hybrid platform featuring nanomagnetic ligand fishing for discovering COX-2 selective inhibitors from aerial part of Saussurea laniceps Hand.-Mazz.
A mechanistic approach to understanding conjugated linoleic acid's role in inflammation using murine models of rheumatoid arthritis.
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].
A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts.
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model.
A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
A review of the clinical pharmacokinetics of meloxicam.
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
A systematic review on the role of eicosanoid pathways in rheumatoid arthritis.
Activation of inflammation and resolution pathways of lipid mediators in synovial fluid from patients with severe rheumatoid arthritis compared with severe osteoarthritis.
Adiponectin receptor 1 mediates the difference in adiponectin- induced prostaglandin E2 production in rheumatoid arthritis and osteoarthritis synovial fibroblasts.
Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis.
An economic approach to health care.
Anti-arthritogenic effect of Saponin-1 by alteration of Th1/Th2 cytokine paradigm in arthritic mice.
Anti-inflammatory and anti-arthritic effects of the ethanolic extract of Aralia continentalis Kitag. in IL-1?-stimulated human fibroblast-like synoviocytes and rodent models of polyarthritis and nociception.
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner.
Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis.
Apigenin, a nonmutagenic dietary flavonoid suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells.
Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.
Atherosclerotic cardiovascular disease in rheumatoid arthritis.
Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects.
Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.
Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons.
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation.
Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis.
Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Celecoxib: a novel treatment for lung cancer.
Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
Clinical pharmacology of etoricoxib.
Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Clinical pharmacology of selective COX-2 inhibitors.
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells.
Combination of COX-2 inhibitor and metformin attenuates rate of admission in patients with rheumatoid arthritis and diabetes in Taiwan.
Comparative Study of Normal and Rheumatoid Arthritis Fibroblast-Like Synoviocytes Proliferation under Cyclic Mechanical Stretch: Role of Prostaglandin E(2).
Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis.
COX-1 and COX-2 tissue expression: implications and predictions.
COX-2 and colon cancer: Potential targets for chemoprevention.
COX-2 and colon cancer: potential targets for chemoprevention.
Cox-2 gene variants in migraine.
COX-2 inhibitors in rheumatoid arthritis.
COX-2 Inhibitors Modulate IL-12 Signaling Through JAK-STAT Pathway Leading to Th1 Response in Experimental Allergic Encephalomyelitis.
COX-2 inhibitors.
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.
COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?
Current considerations for the management of musculoskeletal pain in Asian countries: a special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs.
Cyclic mechanical stretch downregulates IL-1β-induced COX-2 expression and PGE2 production in rheumatoid arthritis fibroblast-like synoviocytes.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.
Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue.
Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts.
Cyclooxygenase inhibitors--current status and future prospects.
Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.
Cyclooxygenase-1 and -2 isoenzymes.
Cyclooxygenase-2 genotype and rheumatoid arthritis.
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Cyclooxygenase-2 polymorphisms and risk of rheumatoid arthritis in Koreans.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
Defining COX-2 inhibitors.
Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Treatment of Rheumatoid Arthritis.
Development of an HPLC assay to study the effect of endogenous and exogenous substances on heat-induced aggregation of human serum albumin.
Development of Diagnostic Techniques for Early Rheumatoid Arthritis Using Positron Emission Tomography with [(11)C]PK11195 and [(11)C]Ketoprofen Tracers.
Differential expression of COX-2 in osteoarthritis and rheumatoid arthritis.
Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression.
Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
DMARD aurothiomalate inhibits COX-2, MMP-3 and IL-6 expression in chondrocytes by increasing MKP-1 expression and decreasing p38 phosphorylation.
Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib.
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers.
Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells.
Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study.
Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.
Effects of human cyclooxygenase-2 gene silencing on synovial cells of rheumatoid arthritis mediated by lentivirus.
Effects of tenidap on Ca(2+)- and protein kinase C-mediated protein phosphorylation, activation of the arachidonate-mobilizing phospholipase A2 and subsequent eicosanoid formation in macrophages.
Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial.
Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan.
Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen.
Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.
Efficacy of lumiracoxib in osteoarthritis: a review of nine studies.
Enhancement of PLGF production by 15-(S)-HETE via PI3K-Akt, NF-?B and COX-2 pathways in rheumatoid arthritis synovial fibroblast.
Epithelium-specific Ets transcription factor-1 acts as a negative regulator of cyclooxygenase-2 in human rheumatoid arthritis synovial fibroblasts.
Ethyl acetate fraction from Angelica sinensis inhibits IL-1?-induced rheumatoid synovial fibroblast proliferation and COX-2, PGE2, and MMPs production.
Ethyl acetate fraction from Cudrania tricuspidata inhibits IL-1?-induced rheumatoid synovial fibroblast proliferation and MMPs, COX-2 and PGE2 production.
Etodolac: An overview of a selective COX-2 inhibitor.
Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial.
Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
Evening primrose oil and borage oil in rheumatologic conditions.
Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.
Exogenous ATP modulates PGE2 release in macrophages through sustained phosphorylation of CDK9 and p38 MAPK.
Expectations from patients with rheumatoid arthritis regarding COX-2s: cutting to the heart of the matter.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Expression of cyclooxygenase-1 and -2 in rheumatoid arthritis synovium.
Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis.
Fish oil supplementation increases the cyclooxygenase inhibitory activity of paracetamol in rheumatoid arthritis patients.
FK506 augments glucocorticoid-mediated cyclooxygenase-2 down-regulation in human rheumatoid synovial fibroblasts.
FK506 enhances triptolide-induced down-regulation of cyclooxygenase-2, inducible nitric oxide synthase as well as their products PGE2 and NO in TNF-alpha-stimulated synovial fibroblasts from rheumatoid arthritic patients.
Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative.
Folic acid-conjugated glucose and dextran coated iron oxide nanoparticles as MRI contrast agents for diagnosis and treatment response of rheumatoid arthritis.
Formulation and evaluation of mouth dissolving tablets of the Etoricoxib.
Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis.
Global safety of coxibs and NSAIDs.
Glucocorticoid-induced leucine zipper (GILZ) mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 expression.
How to mechanistically explain the CONDOR study data.
Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution.
In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.
In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines.
In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients.
Influence of polymers on the bioavailability of microencapsulated celecoxib.
Inhibition of cyclooxygenase-2 activity in subchondral bone modifies a subtype of osteoarthritis.
Inhibition of human rheumatoid arthritis synovial cell survival by hecogenin and tigogenin is associated with increased apoptosis, p38 mitogen-activated protein kinase activity and upregulation of cyclooxygenase-2.
Iridoid glycosides from the flowers of Gentiana macrophylla Pall. ameliorate collagen-induced arthritis in rats.
Isolation and structural characterization of the photolysis products of etoricoxib.
Kaempferol inhibits IL?1??induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX?2, PGE2 and MMPs.
Low-dose aspirin in the primary prevention of rheumatoid arthritis: the Women's Health Study.
Lumiracoxib (Novartis).
Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Managing the adverse effects of nonsteroidal anti-inflammatory drugs.
MAP kinase subtypes and Akt regulate diosgenin-induced apoptosis of rheumatoid synovial cells in association with COX-2 expression and prostanoid production.
Matching by Propensity Score in Cohort Studies with Three Treatment Groups.
Mechanism of action of aspirin-like drugs.
Mechanism of action of celastrol against rheumatoid arthritis: A network pharmacology analysis.
Mechanism of action of paracetamol.
Mechanisms of action of paracetamol and related analgesics.
Melittin inhibits inflammatory target gene expression and mediator generation via interaction with IkappaB kinase.
Meloxicam in the management of post-operative pain: Narrative review.
Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.
Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis.
Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.
MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2.
Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells.
Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.
Molecular insights into the differences in anti-inflammatory activities of green tea catechins on IL-1? signaling in rheumatoid arthritis synovial fibroblasts.
Molecular targets of dietary polyphenols with anti-inflammatory properties.
Murine mPGES-1 3D structure elucidation and inhibitors binding mode predictions by homology modeling and site-directed mutagenesis.
NCX-4016 (NicOx SA).
Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis.
Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection.
Non steroidal anti-inflammatory and anti-allergy agents.
Non-steroidal anti-inflammatory agent inhibit the synthesis of IgM rheumatoid factor in vitro.
Non-Transcriptional and Translational Function of Canonical NF-?B Signaling in Activating ERK1/2 in IL-1?-Induced COX-2 Expression in Synovial Fibroblasts.
Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Novel therapeutic strategies.
Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis.
Osteoarthritis and rheumatoid arthritis: will new data clarify the risk:benefit ratio of cyclooxygenase-2 inhibitors?
Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism.
Paeoniflorin ameliorates rheumatoid arthritis in rat models through oxidative stress, inflammation and cyclooxygenase 2.
Pain management in osteoarthritis: the role of COX-2 inhibitors.
Pain Relieving Effect of-NSAIDs-CAIs Hybrid Molecules: Systemic and Intra-Articular Treatments against Rheumatoid Arthritis.
Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice.
Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
Persisting eicosanoid pathways in rheumatic diseases.
PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study.
Pharmacoeconomics of coxib therapy.
Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.
Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.
Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors.
Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis.
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.
Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats.
Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes.
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.
Prescriptions for cyclooxygenase-2 inhibitors and other nonsteroidal anti-inflammatory agents in a medicaid managed care population: African Americans versus Caucasians.
Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression.
Prostaglandin synthetase activity from human rheumatoid synovial microsomes. Effect of 'aspirin-like' drug therapy.
Protective effect of taraxasterol against rheumatoid arthritis by the modulation of inflammatory responses in mice.
Quercetin inhibits IL-1?-induced proliferation and production of MMPs, COX-2, and PGE2 by rheumatoid synovial fibroblast.
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Regulation of natural killer cell activity by macrophages in the rheumatoid joint and peripheral blood.
Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO.
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
Resveratrol inhibits BK-induced COX-2 transcription by suppressing acetylation of AP-1 and NF-?B in human rheumatoid arthritis synovial fibroblasts.
Retinoic Acid-Platinum (II) Complex [RT-Pt(II)] Protects Against Rheumatoid Arthritis in Mice via MEK/Nuclear Factor kappa B (NF-?B) Pathway Downregulation.
Retraction: MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2.
Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients.
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Role and regulation of cyclooxygenase-2 during inflammation.
Role of cyclooxygenase-1 and -2 in health and disease.
Role of cyclooxygenases in angiogenesis.
Selective COX-2 inhibitor, NS-398, inhibits the replicative senescence of cultured dermal fibroblasts.
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
Selective inhibition of cyclooxygenase 2-generated prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by taurine chloramine.
Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis.
Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.
Selenium Nanoparticles Dispersed in Phytochemical Exert Anti-Inflammatory Activity by Modulating Catalase, GPx1, and COX-2 Gene Expression in a Rheumatoid Arthritis Rat Model.
Serum COX-2 and FOXO3a in patients with rheumatoid arthritis and correlation with disease activity.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Simultaneous profiling of eicosanoid metabolome in plasma by UPLC-MS/MS method: Application to identify potential makers for rheumatoid arthritis.
Single dose oral celecoxib for postoperative pain.
Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells.
Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma.
Sulforaphane Inhibits IL-1?-Induced Proliferation of Rheumatoid Arthritis Synovial Fibroblasts and the Production of MMPs, COX-2, and PGE2.
Synergistic inhibition of cyclooxygenase-2 expression by vitamin E and aspirin.
Targeted knockout of TNF-? by injection of lentivirus-mediated siRNA into the subacromial bursa for the treatment of subacromial bursitis in rats.
Tetrandrine alleviates symptoms of rheumatoid arthritis in rats by regulating the expression of cyclooxygenase-2 and inflammatory factors.
The cox-2-specific inhibitor celecoxib inhibits adenylyl cyclase.
The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands.
The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors.
The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids.
The neutrophil in rheumatoid arthritis: its role and the inhibition of its activation by nonsteroidal antiinflammatory drugs.
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
The prospective use of COX-2 inhibitors for the treatment of temporomandibular joint inflammatory disorders.
The role of COX-2 in angiogenesis and rheumatoid arthritis.
The transcription factor C/EBPbeta is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts.
Therapeutic effects of standardized Vitex negundo seeds extract on complete Freund's adjuvant induced arthritis in rats.
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.
Traditional Chinese Medicine Aconiti Radix Cocta Improves Rheumatoid Arthritis via Suppressing COX-1 and COX-2.
Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.
Valdecoxib for the management of chronic and acute pain.
Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.
Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
[A critical evaluation of side effect data on COX-2 inhibitors]
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy]
[Effect of sulfasalazine and its metabolites on prostaglandin and leukotriene liberation from human synovial tissue]
[Effect of Triptolide on TNFalpha-induced activation of NF-kappaB and expression of COX-2 and iNOS in human rheumatoid arthritis synovial fibroblasts]
[Effects of RNAi on cyclooxygenase-2 expression and biologic activity of human rheumatoid arthritis synovial fibroblasts]
[Enhancement by FK506 of triptolide-induced inhibition of expression of COX-2 and iNOS in human rheumatoid arthritis synovial fibroblasts]
[New nonsteroidal antiinflammatory drugs in rheumatoid arthritis]
[New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results]
[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]
[Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology]
[Preventing effects of COX-2 inhibitors on rheumatoid joint destruction]
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]
[Selective COX-2 inhibitors for therapy of rheumatoid arthritis]
[Selective cyclooxygenase-2 inhibitors and the digestive tract]
[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review.]
[Side effects of COX-2 selective inhibitors. Critic related with its administration in patients with rheumatoid arthritis and osteoarthritis]
[Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances]
[The medical reason for the prescription of COX-2 selective cyclo oxygenase inhibitor rofecoxib for the treatment of rheumatoid arthritis. A post-marketing surveillance study from Austria]
[The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis]
[Use of meloxicam (movalis) in patients with rheumatic diseases with concomitant coronary heart disease]
Arthus Reaction
Anti-inflammatory action of a novel peptide, SEK-1005, isolated from a Streptomyces.
Ex vivo effects of nonsteroidal antiinflammatory drugs on arachidonic acid metabolism in neutrophils from a reverse passive Arthus reaction.
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
Leukotriene B4 production and pharmacologic regulation of reverse passive Arthus pleurisy: importance of antigen dose.
Release of eicosanoids in rat peritoneal cavity during the Arthus reaction. Effect of the PAF-antagonist BN-52021 and indomethacin.
Asbestosis
COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders.
Expression of cyclooxygenase-2 in human lung carcinoma.
Ascorbic Acid Deficiency
Effects of ascorbic acid deficiency on the in vitro biosynthesis of cyclooxygenase metabolites in guinea pig lungs.
Aspergillosis
12/15-Lipoxygenase Deficiency Impairs Neutrophil Granulopoiesis and Lung Proinflammatory Responses to Aspergillus fumigatus.
Asthenozoospermia
Interleukin-1?, cyclooxygenase-2, and hypoxia-inducible factor-1? in asthenozoospermia.
Asthma
1-[(2,3-Dihydro-1-benzofuran-2-yl) methyl]piperazines as novel anti-inflammatory compounds: Synthesis and evaluation on H3 R/H4 R.
8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro.
A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge.
A functional polymorphism in the promoter region of the cyclooxygenase-2 gene is not associated with asthma and atopy in an Australian population.
A review on herbal antiasthmatics.
A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.
Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease.
Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs.
Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma.
Alteration in the levels of serum lipid peroxide, cyclooxygenase activity and free fatty acids in bronchial asthma.
Alternative splicing of cyclooxygenase-1 gene: altered expression in leucocytes from patients with bronchial asthma and association with aspirin-induced 15-HETE release.
An abnormality of arachidonic acid metabolism is not a generalized phenomenon in patients with aspirin-induced asthma.
An agent that releases basophil and mast cell histamine but blocks cyclooxygenase and lipoxygenase metabolism of arachidonic acid inhibits immunoglobulin E-mediated asthma in rhesus monkeys.
An inhibitor of the lipoxygenase and cyclooxygenase pathways of arachidonic acid, 5, 8, 11, 14-eicosatetraynoic acid, inhibits immunoglobulin E mediated antigen induced monkey asthma and skin reactions.
An intranasal selective antisense oligonucleotide impairs lung cyclooxygenase-2 production and improves inflammation, but worsens airway function, in house dust mite sensitive mice.
An update on the epidemiology of aspirin-exacerbated respiratory disease.
An update on the management of aspirin-exacerbated respiratory disease.
Analgesics and asthma.
Analgesics, allergy and asthma.
Anthocyanins inhibit airway inflammation and hyperresponsiveness in a murine asthma model.
Antipyretic analgesics and the allergic patient.
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.
Aspirin intolerance and nasal polyposis.
Aspirin Intolerance: Experimental Models for Bed-to-Bench.
Aspirin sensitive asthma and arachidonic acid transformation.
Aspirin sensitivity and desensitization for asthma and sinusitis.
Aspirin sensitivity: implications for patients with coronary artery disease.
Aspirin-exacerbated respiratory disease and current treatment modalities.
Aspirin-exacerbated respiratory disease.
Aspirin-exacerbated respiratory disease: A review.
Aspirin-exacerbated respiratory disease: characteristics and management strategies.
Aspirin-induced asthma: a tribute to John Vane as a source of inspiration.
Aspirin-induced asthma: advances in pathogenesis and management.
Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.
Aspirin-induced rhinitis and asthma.
Aspirin-Intolerant Asthma: A Comprehensive Review of Biomarkers and Pathophysiology.
Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma.
Association of prostaglandin-endoperoxide synthase 2 gene polymorphisms with asthma and atopy in Chinese children.
Association of the -14C/G MET and the -765G/C COX-2 Gene Polymorphisms with the Risk of Chronic Rhinosinusitis with Nasal Polyps in a Polish Population.
Asthma in children and ASA intolerance.
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Augmentation of allergic inflammation in the airways of cyclooxygenase-2-deficient mice.
Automated identification of an aspirin-exacerbated respiratory disease cohort.
Beneficial effect of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with asthma during viral infection.
Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.
Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients.
Changes in neurokinin A airway responsiveness with inhaled lysine-acetylsalicylate in asthma.
Clinical and pathologic perspectives on aspirin sensitivity and asthma.
Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.
Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease.
Clinical studies of asthma phenotypes focusing on the role of leukotrienes.
Clinical updates in aspirin-exacerbated respiratory disease.
Computed Tomography Findings in Patients with Samter's Triad: An Observational Study.
Conditional regulation of cyclooxygenase-2 in tracheobronchial epithelial cells modulates pulmonary immunity.
Contribution of histamine and prostanoids to bronchoconstriction provoked by inhaled bradykinin in atopic asthma.
COX-1 sparing drugs in aspirin-sensitive asthma.
COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.
COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma.
COX-2 Inhibits Th9 Differentiation During Allergic Lung Inflammation Via Downregulation of IL-17RB.
COX-2 specific inhibitors in NSAID-intolerant patients.
Cyclooxygenase 2: its regulation, role and impact in airway inflammation.
Cyclooxygenase and lipoxygenase metabolite generation in nasal polyps.
Cyclooxygenase enzymes in allergic inflammation and asthma.
Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy.
Cyclooxygenase-2 and microRNA-155 expression are elevated in asthmatic airway smooth muscle cells.
Cyclooxygenase-2 expression during allergic inflammation in guinea-pig lungs.
Cyclooxygenase-2 gene polymorphisms in an Australian population: association of the -1195G > A promoter polymorphism with mild asthma.
Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma.
Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics.
Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma.
Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis.
Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma.
Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation.
Effect of indomethacin on allergen-induced asthmatic responses.
Effect of inhaled indomethacin in asthmatic patients taking high doses of inhaled corticosteroids.
Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells.
Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics.
Effects of celecoxib on major prostaglandins in asthma.
Effects of inhibition of thromboxane A2 synthesis in aspirin-induced asthma.
Effects of lipid mediator antagonists on predominant mediator-controlled asthmatic reactions in passively sensitized guinea pigs.
Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients.
Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma.
Effects of sulfur dioxide on the expressions of EGF, EGFR, and COX-2 in airway of asthmatic rats.
Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis.
Endogenous cannabinoids may regulate chronic inflammation in aspirin-exacerbated respiratory disease.
Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma.
Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma.
Failure of children with asthma to respond to daily aspirin therapy.
Fine mapping of murine asthma quantitative trait loci and analyses of Ptgs1 and Mrc1 as positional candidate genes.
Flurbiprofen (Ansaid) cross-sensitivity in an aspirin-sensitive asthmatic patient.
Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma.
Functional Role of Fc?RIIB in the Regulation of Mesenchymal Stem Cell Function.
Genetic mechanism of aspirin-induced urticaria/angioedema.
Genetic variants in TNF?, TGFB1, PTGS1 and PTGS2 genes are associated with diisocyanate-induced asthma.
Higher prostaglandin e2 production by dendritic cells from subjects with asthma compared with normal subjects.
Identifying a biomarker network for corticosteroid resistance in asthma from bronchoalveolar lavage samples.
Idiosyncrasy to pyrazolone drugs.
Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease.
Increased excretion of leukotriene E4 during aspirin-induced asthma.
Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment.
Inflammation, allergy and asthma, complex immune origin diseases: mechanisms and therapeutic agents.
Inhaled frusemide and exercise induced asthma: evidence of a role for inhibitory prostanoids.
Inhibition of sodium metabisulphite induced bronchoconstriction by frusemide in asthma: role of cyclooxygenase products.
Inhibitory effect of indomethacin on tachyphylaxis in response to acetaldehyde-induced bronchoconstriction in patients with asthma.
Investigation of the active components and mechanisms of Schisandra chinensis in the treatment of asthma based on a network pharmacology approach and experimental validation.
Leukotriene and prostanoid pathway enzymes in bronchial biopsies of seasonal allergic asthmatics.
Leukotrienes and other eicosanoids as mediators of airway obstruction.
Leukotrienes C and D induce aspirin-sensitive bronchoconstriction in the guinea-pig.
Lipoxygenase inhibitor-provoked acute asthma in a patient with asthma relieved by aspirin.
Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.
Mechanisms of aspirin desensitization.
Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.
MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle.
miR-155 Modulates Cockroach Allergen- and Oxidative Stress-Induced Cyclooxygenase-2 in Asthma.
MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7.
Modulation of arachidonic acid metabolites as potential therapy of asthma.
Myeloid-Derived Suppressor Cells Dampen Airway Inflammation Through Prostaglandin E2 Receptor 4.
New concepts in the pathogenesis of asthma.
Nimesulide does not interfere with airway responsiveness in allergic asthma.
Non steroidal anti-inflammatory and anti-allergy agents.
PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
Polymorphisms in chronic rhinosinusitis with nasal polyps - a systematic review.
Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.
Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics.
Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease.
Prostaglandins in asthma and allergic diseases.
Prostanoids and cough response to capsaicin in asthma and chronic bronchitis.
Protection by two ginkgolides, BN-52020 and BN-52021, against guinea-pig lung anaphylaxis.
Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.
Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects.
Risk of Acute Asthma Attacks Associated With Nonsteroidal Anti-inflammatory Drugs: A Self-Controlled Case Series.
Role of Ca2+ mobilization and Ca2+ sensitization in 8-iso-PGF 2 alpha-induced contraction in airway smooth muscle.
Role of cyclooxygenase 1 and 2 in asthma and rhinitis.
Role of Cyclooxygenase-2 in Exacerbation of Allergen-Induced Airway Remodeling by Multiwalled Carbon Nanotubes.
Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma.
Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.
Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study.
Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
Salsalate cross-sensitivity in aspirin-sensitive patients with asthma.
Saponin-enriched extract of Asparagus cochinchinensis alleviates airway inflammation and remodeling in ovalbumin-induced asthma model.
Selective COX-2 Inhibition Exerts No Negative Effects on Peripheral Blood Lymphocytes in Allergic Asthmatics.
Selective cyclooxygenase-2 inhibitor cross-reactivity in aspirin-exacerbated respiratory disease.
Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13.
Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study.
Signal transduction pathways (MAPKs, NF-?B, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerance.
State of the Art: Medical treatment of aspirin exacerbated respiratory disease (AERD).
Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis.
Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma.
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
The Asian side of asthma and allergy.
The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy.
The cyclooxygenase theory of aspirin-induced asthma.
The DP receptor, allergic inflammation and asthma.
The effects of ML 3000 on antigen-induced responses in sheep.
The importance of COX-2 inhibition for aspirin induced asthma.
The influence of cyclooxygenase inhibition on the loss of bronchoconstrictor response to repeated bradykinin challenge in asthma.
The PGE2-EP2-mast cell axis: An antiasthma mechanism.
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
The protective effects of leukotriene modifiers in aspirininduced asthma.
The Protective Effects of Maresin 1 in the OVA-Induced Asthma Mouse Model.
The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease.
The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors.
The safety of celecoxib in patients with aspirin-sensitive asthma.
Tinospora cordifolia extract modulates COX-2, iNOS, ICAM-1, pro-inflammatory cytokines and redox status in murine model of asthma.
Treatment of patients with respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs.
Treatment practices for aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.
Update on the Management of Aspirin-Exacerbated Respiratory Disease.
[A case of asthma relieved by aspirin--the first case in Japan and investigation of its mechanism]
[A cyclooxygenase-2 selective inhibitor worsens respiratory function and enhances mast cell activity in ovalbumin-sensitized mice.]
[Aspirin-induced asthma as an important type of bronchial asthma]
[Asthma with aspirin intolerance]
[Demonstration of specific platelet function anomaly in asthma induced by aspirin: diagnostic consequences]
[Influence of peroxisome proliferator-activated receptor gamma on airway inflammation of guinea pigs with asthma]
[Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists]
[Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology]
[Thromboxane A2 could be involved in bronchial hyperresponsiveness to methacholine in asthmatic subjects but not in bronchitic subjects]
[Thromboxane A2 receptor antagonist in asthma therapy]
Asthma, Aspirin-Induced
Aspirin intolerance and the cyclooxygenase-leukotriene pathways.
Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients.
COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
Cyclooxygenase-2 inhibitors in aspirin-induced asthma.
Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.
Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis.
Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients.
Low Prostaglandin E(2) and Cyclooxygenase Expression in Nasal Mucosa Fibroblasts of Aspirin-Intolerant Asthmatics.
Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity.
Pathogenesis of nonsteroidal antiinflammatory drug-induced asthma.
Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E(2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients.
Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma.
Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study.
Signal transduction pathways (MAPKs, NF-?B, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerance.
Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma.
The cyclooxygenase theory of aspirin-induced asthma.
The importance of COX-2 inhibition for aspirin induced asthma.
[Asthma with aspirin intolerance]
Asthma, Exercise-Induced
Asthma in children and ASA intolerance.
Inhaled frusemide and exercise induced asthma: evidence of a role for inhibitory prostanoids.
Astrocytoma
A comparative study of arachidonic acid metabolism in rabbit cultured astrocytes and human astrocytoma cells (1321N1).
Amyloid-? Induces Cyclooxygenase-2 and PGE2 Release in Human Astrocytes in NF-? B Dependent Manner.
Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.
Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival.
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Cyclooxygenase-2, Bcl-2, and chromosome 1p analysis in protoplasmic astrocytomas.
Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival.
Expression of prostaglandin H synthase-2 in human brain tumors.
Extracellular HIV-Tat induces cyclooxygenase-2 in glial cells through activation of nuclear factor of activated T cells.
HIV-1 envelope glycoprotein 120 induces cyclooxygenase-2 expression in astrocytoma cells through a nuclear factor-kappaB-dependent mechanism.
Immunohistochemical expression of cycloxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival.
Influence of Caloric Restriction on Constitutive Expression of NF-?B in an Experimental Mouse Astrocytoma.
Microwave-assisted antigen retrieval and incubation with cox-2 antibody of archival paraffin-embedded human oligodendroglioma and astrocytomas.
mRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas.
Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo.
Phospholipase D isozymes mediate epigallocatechin gallate-induced cyclooxygenase-2 expression in astrocyte cells.
Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia.
Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2.
The effect of guggulipid and nimesulide on MPTP-induced mediators of neuroinflammation in rat astrocytoma cells, C6.
Up-regulation of cyclooxygenase-2 by cobalt chloride-induced hypoxia is mediated by phospholipase D isozymes in human astroglioma cells.
Zingansikpoongtang modulates beta-amyloid and IL-1beta-induced cytokine production and cyclooxygenase-2 expression in human astrocytoma cells U373MG.
[Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors]
[Signal transduction of prostaglandin E2 and thromboxane A2]
Ataxia
Molecular mechanisms of low dose ionizing radiation-induced hormesis, adaptive responses, radioresistance, bystander effects, and genomic instability.
Ataxia Telangiectasia
Celecoxib Enhances the Radiosensitizing Effect of 7-Hydroxystaurosporine (UCN-01) in Human Lung Cancer Cell Lines.
Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation.
Implications for breast cancer treatment from increased autotaxin production in adipose tissue after radiotherapy.
Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells.
Atherosclerosis
A Variant in COX-2 Gene Is Associated with Left Main Coronary Artery Disease and Clinical Outcomes of Coronary Artery Bypass Grafting.
Abscisic acid released by human monocytes activates monocytes and vascular smooth muscle cell responses involved in atherogenesis.
Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice.
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition.
Acrolein induces cyclooxygenase-2 and prostaglandin production in human umbilical vein endothelial cells: roles of p38 MAP kinase.
Activation of inflammatory mediators and potential role of ah-receptor ligands in foam cell formation.
Age-related changes in monocyte and platelet cyclooxygenase expression in healthy male humans and rats.
Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits.
Anti-atherogenic effect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice.
Anti-atherogenic effect of San-Huang-Xie-Xin-Tang, a traditional Chinese medicine, in cultured human aortic smooth muscle cells.
Anti-atherosclerotic effects of vitamin E--myth or reality?
Anti-inflammatory drugs and atherosclerosis.
Anti-inflammatory drugs in experimental atherosclerosis. Part 4. Inhibition of atherosclerosis in vivo and thromboxane synthesis and platelet aggregation in vitro.
Anti-inflammatory drugs in experimental atherosclerosis. Part 6. Combination therapy with steroid and non-steroid agents.
Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study.
Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis.
Aspirin inhibits tumor necrosis factor-alpha-stimulated fractalkine expression in human umbilical vein endothelial cells.
Association of COX2 -765G>C promoter polymorphism and coronary artery disease in Korean population.
Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation.
Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study.
Atherosclerosis: the eicosanoid connection.
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.
Cardiovascular complications of non-steroidal anti-inflammatory drugs.
Cardiovascular Consequences of Prostanoid I Receptor Deletion in Microsomal Prostaglandin E Synthase-1-Deficient Hyperlipidemic Mice.
Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo.
Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Celecoxib for the treatment of atherosclerosis.
Cholesterol-3-beta, 5-alpha, 6-beta-triol induced PI(3)K-Akt-eNOS-dependent cyclooxygenase-2 expression in endothelial cells.
Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: A novel model of atherosclerosis associated with chronic inflammation.
Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis.
CLA isomers inhibit TNFalpha-induced eicosanoid release from human vascular smooth muscle cells via a PPARgamma ligand-like action.
Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions.
Complexes of Indomethacin with 4-Carbomethoxy-pyrrolidone PAMAM Dendrimers Show Improved Anti-inflammatory Properties and Temperature-Dependent Binding and Release Profile.
Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques.
Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse.
Could the thromboxane A2 pathway be a therapeutic target for the treatment of obstructive sleep apnea-induced atherosclerosis?
COX-2 and atherosclerosis.
COX-2 and prostaglandins in atherosclerosis.
COX-2 expression in atherosclerosis: the good, the bad or the ugly?
COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study.
COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks.
COX-2-derived prostacyclin modulates vascular remodeling.
Curcumin Attenuates Acrolein-induced COX-2 Expression and Prostaglandin Production in Human Umbilical Vein Endothelial Cells.
Curcumin: from food spice to cancer prevention.
Current oral antiplatelet agents to prevent atherothrombosis.
Cyclo-oxygenase products and atherothrombosis.
Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis.
Cyclooxygenase and atherosclerosis: a smoking area.
Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives.
Cyclooxygenase Inhibitors Repress Vascular Hyaluronan-Synthesis in Murine Atherosclerosis and Neointimal Thickening.
Cyclooxygenase isoforms and atherosclerosis.
Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.
Cyclooxygenase products and atherosclerosis.
Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice.
Cyclooxygenase-2 and atherosclerosis.
Cyclooxygenase-2 and atherosclerosis: friend or foe?
Cyclooxygenase-2 and inflammation in atherosclerosis.
Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein.
Cyclooxygenase-2 genetic polymorphism and stroke subtypes in chinese.
Cyclooxygenase-2 in Endothelial and Vascular Smooth Muscle Cells Restrains Atherogenesis in Hyperlipidemic Mice.
Cyclooxygenase-2 in human pathological disease.
Cyclooxygenase-2 induced by zymosan in human-monocyte-derived dendritic cells shows high stability and its expression is enhanced by atorvastatin.
Cyclooxygenase-2 inhibition and coagulation.
Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia.
Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.
Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk.
Cyclooxygenase-2 inhibitors and atherosclerosis.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages.
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice.
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Differential effects on nitric oxide-mediated vasodilation in mesenteric and uterine arteries from cytomegalovirus-infected mice.
Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein.
Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice.
Distribution profiles of membrane Type-1 matrix metalloproteinase (MT1-MMP), matrix metalloproteinase-2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: comparison with plaque instability analysis.
Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis.
Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease.
Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells.
Effects of aspirin on atherosclerosis and the cyclooxygenase-2 expression in atherosclerotic rabbits.
Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187.
Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.
Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice.
Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients.
Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation.
Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta.
Enhancing and Complementary Mechanisms of Synergistic Action of Acori Tatarinowii Rhizoma and Codonopsis Radix for Alzheimer's Disease Based on Systems Pharmacology.
Exposure to diesel exhaust upregulates COX-2 expression in ApoE knockout mice.
Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling.
Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries.
Functional promoter polymorphism of cyclooxygenase-2 modulates the inflammatory response in stable coronary heart disease.
G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity.
G-765C COX-2 gene promoter polymorphism and risk of atherosclerosis after kidney transplantation.
Hypolipidemic effects of nimesulide and celecoxib in experimentally induced hypercholesterolemia in rabbits.
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study.
Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells.
Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice.
Inhibitors of the Microsomal Prostaglandin E(2) Synthase-1 as Alternative to Non Steroidal Anti-inflammatory Drugs (NSAIDs) - A Critical Review.
Interaction between COX-1 and COX-2 increases susceptibility to ischemic stroke in a Chinese population.
Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function.
Intermittent hypoxia activated cyclooxygenase pathway: role in atherosclerosis.
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.
Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease.
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Mechanisms of aspirin resistance.
Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: A potentially protective mechanism in atherosclerotic vascular disease and cancer.
Methotrexate in atherogenesis and cholesterol metabolism.
Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?
Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?
No association of nineteen COX-2 gene variants to preclinical markers of atherosclerosis The Cardiovascular Risk in Young Finns Study.
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice.
Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis.
Oxidative alterations of cyclooxygenase during atherogenesis.
Oxidized low density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages.
Palmitate Induces Glycosylation of Cyclooxygenase-2 in Primary Human Vascular Smooth Muscle Cells.
Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial.
Pharmacologic inhibition of nitric oxide synthases and cyclooxygenases enhances intimal hyperplasia in balloon-injured rat carotid arteries.
Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors.
Radical acetoacetate oxidation by myeloperoxidase, lactoperoxidase, prostaglandin synthetase, and prostacyclin synthetase: implications for atherosclerosis.
Regulation of cyclooxygenase-2 expression by iloprost in human vascular smooth muscle cells. Role of transcription factors CREB and ICER.
Regulatory mechanisms of the vascular endothelium: an update.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
Role of Cyclooxygenase 2 and Endothelial Nitric Oxide Synthetase in Preclinical Atherosclerosis.
Role of Sandhika: a polyherbal formulation on MC3T3-E1 osteoblast-like cells.
Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin.
Targeted deletions of cyclooxygenase-2 and atherogenesis in mice.
The ARIC Carotid MRI Study of Blood Cellular Markers: An Inverse Association of Monocyte Myeloperoxidase Content With Peripheral Arterial Disease.
The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice.
The involvement of NFAT transcriptional activity suppression in SIRT1-mediated inhibition of COX-2 expression induced by PMA/Ionomycin.
The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway.
The role of cyclooxygenase-2 on endurance exercise training in female LDL-receptor knockout ovariectomized mice.
The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
Two Cu(II) coordination polymers: Heterogeneous catalytic Knoevenagel condensation reaction and treatment activity on atherosclerosis via regulating the expression of the COX-2 in vascular endothelial cells.
Tyrosine nitration in prostaglandin H(2) synthase.
Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis.
Wide Biological Role of Hydroxytyrosol: Possible Therapeutic and Preventive Properties in Cardiovascular Diseases.
WITHDRAWN: Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives.
[Activity of prostaglandin synthetase in human arteries in atherosclerosis (histochemical study)]
[Antiplatelet therapy can unmask an inherited bleeding disorder. Aspirin-like defect of platelets does not protect against atherosclerosis.]
[Controversies regarding the effects of cyclooxygenase inhibitors on the course and complications of arterial atherosclerosis]
[Cyclooxygenase-2 and atherosclerosis: disputation and prospect]
[Cyclooxygenase-2: a new therapeutic target in atherosclerosis?]
[Defects in the prostaglandin system. VII. (Generalized, inherited [?]) cyclooxygenase defect]
[Risk factor assessment of cardiocerebrovascular diseases in patients with rheumatoid arthritis]
[Selenium and the activities of cyclooxygenase and lipoxygenase in cells involved in atherogenesis]
[The role of platelets in atherosclerosis, diabetes mellitus, and chronic kidney disease. An attempt at explaining the TREAT study results].
Atrial Fibrillation
Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use.
Celecoxib-induced change in atrial electrophysiologic substrate in arthritis patients.
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Platelet activation and lipid peroxidation in patients with acute ischemic stroke.
The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia.
Autoimmune Diseases
Anti-inflammatory and immunomodulating effects of the novel agent gamma-(2-aminoethylamino)-2-butyrothienone. 1st communication: inhibitory effects on mouse paw edema.
Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk.
Augmentation of 12-lipoxygenase activity of lymph node and spleen T cells in autoimmune mice MRL/1.
COX-2 Inhibitors Modulate IL-12 Signaling Through JAK-STAT Pathway Leading to Th1 Response in Experimental Allergic Encephalomyelitis.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients.
Non-Transcriptional and Translational Function of Canonical NF-?B Signaling in Activating ERK1/2 in IL-1?-Induced COX-2 Expression in Synovial Fibroblasts.
Risk of preterm birth following late pregnancy exposure to NSAIDs or COX-2 inhibitors.
Role of cyclooxygenase-2 signaling pathway dysfunction in unexplained recurrent spontaneous abortion.
Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells.
Axial Spondyloarthritis
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review.
The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels.
Azotemia
Effect of Exercise on Cardiac Tissue Oxidative and Inflammatory Mediators in Chronic Kidney Disease.
Indomethacin-induced azotaemia and hyperkalaemia: a case study.
NIACIN AMELIORATES OXIDATIVE STRESS, INFLAMMATION, PROTEINURIA, AND HYPERTENSION IN RATS WITH CHRONIC RENAL FAILURE.
Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney.
Bacteremia
Bidirectional effects of hepatic ischemia/reperfusion on E. coli-induced TNF-alpha gene expression.
Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis.
Differential microvascular response to cyclooxygenase blockade in the rat small intestine during acute bacteremia.
Indomethacin, dazoxiben and extravascular lung water after Escherichia coli infusion.
Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia.
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
Bacterial Infections
Accelerated hematopoietic recovery and protective effect of the cyclooxygenase inhibitor indomethacin in bacterial infection of neutropenic mice.
Attenuation of extracellular acidic pH-induced cyclooxygenase-2 expression by nitric oxide.
Beneficial Effects of Exogenous Melatonin in Acute Staphylococcus aureus and Escherichia coli Infection-Induced Inflammation and Associated Behavioral Response in Mice After Exposure to Short Photoperiod.
Chitosomes loaded with cranberry proanthocyanidins attenuate the bacterial lipopolysaccharide-induced expression of iNOS and COX-2 in raw 264.7 macrophages.
Cyclooxygenase-2 Enhances Antimicrobial Peptide Expression and Killing of Staphylococcus aureus.
Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.
Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil.
Escherichia coli-induced inducible nitric oxide synthase and cyclooxygenase expression in the mouse bladder and kidney.
Induction of heme oxygenase-1 attenuates lipopolysaccharide-induced cyclooxygenase-2 expression in mouse brain endothelial cells.
Lipid larceny: channelizing host lipids for establishing successful pathogenesis by bacteria.
Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis.
Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors.
Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models.
Thromboxane synthesis is increased by upregulation of cytosolic phospholipase A2 and cyclooxygenase-2 in peripheral polymorphonuclear leukocytes during bacterial infection in childhood.
Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS.
Barrett Esophagus
Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells.
Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent.
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.
Advances in Barrett's esophagus and esophageal adenocarcinoma.
Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus.
Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus.
Barrett's esophagus.
Barrett's esophagus: chemoprevention.
Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
COX-2 inhibition in upper aerodigestive tract tumors.
COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease.
COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis.
Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma.
Cyclooxygenase-2 and Inflammation Mediators Have a Crucial Role in Reflux-Related Esophageal Histological Changes and Barrett's Esophagus.
Cyclooxygenase-2 expression in Barrett's esophagus.
Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Cyclooxygenase-2 in Barrett's esophagus, Barrett's adenocarcinomas, and esophageal SCC: ready for clinical trials.
Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus.
Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression?
Effect of acid suppression on molecular predictors for esophageal cancer.
Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line.
Effect of celecoxib on cyclooxygenase-2 expression and possible variants in a patient with Barrett's esophagus.
Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking.
Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and cyclooxygenase expressions using chromoendoscopical examination.
Fatty Acid Synthase Expression in Barrett's Esophagus: Implications for Carcinogenesis.
Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Gastroesophageal reflux disease and Barrett's esophagus.
Gastroesophageal reflux disease.
Guggulsterone, a plant-derived inhibitor of NF-TB, suppresses CDX2 and COX-2 expression and reduces the viability of esophageal adenocarcinoma cells.
Helicobacter pylori and non-malignant diseases.
Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Increased Expression of VEGF, COX-2, and Ki-67 in Barrett's Esophagus: Does the Length Matter?
Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Interaction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-? system in experimental rat Barrett's esophagus.
Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
Over-expression of cyclooxygenase-2 in endoscopic biopsies of ectopic gastric mucosa.
Phenotypic differences between esophageal and gastric intestinal metaplasia.
Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy.
Preference of Endoscopic Ablation Over Medical Prevention of Esophageal Adenocarcinoma by Patients with Barrett's Esophagus.
Production of prostaglandinE2 via bile acid is enhanced by trypsin and acid in normal human esophageal epithelial cells.
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.
Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
REG Ialpha protein expression in Barrett's esophagus.
Reply to Letter to the Editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First).
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Strategy for prevention of cancers of the esophagus.
Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats.
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study.
Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression.
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
What is the clinical significance of stromal angiogenesis in Barrett's esophagus?
[A study on cyclooxygenase-2 protein expression in esophageal carcinoma and premalignant lesions]
[Barrett's esophageal adenocarcinoma]
[Chemoprevention of Barrett's esophagus by celecoxib in rats.]
[The clinical, pathological features and expression of Ki-67 and COX-2 in severe reflux esophagitis and Barrett's esophagus]
Bartter Syndrome
Bartter's syndrome: physiological and pharmacological studies.
Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome.
Effect of Sar1-ala8-angiotensin II on blood pressure and renin in Bartter's syndrome, before and after treatment with prostaglandin synthetase inhibitors.
Effect of treatment with prostaglandin synthetase inhibitors on the erythrocyte sodium transport abnormality of Bartter's syndrome.
Effects of Prostaglandin Synthetase Inhibitation on Captopril-Induced Changes in Renal Function in Bartter's Syndrome.
Effects of prostaglandin synthetase inhibition on captopril-induced changes in renal function in Bartter's syndrome.
Growth from birth to adulthood in a patient with the neonatal form of Bartter syndrome.
Induction of microsomal prostaglandin E2 synthase in the macula densa in children with hypokalemic salt-losing tubulopathies.
Long-term use of propranolol, ibuprofen, and spironolactone in the management of Bartter's syndrome.
Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
Plasma "prorenin"-renin in Bartter's syndrome, cystic fibrosis, and chloride deficiency, and the effect of prostaglandin synthetase inhibition.
Prostaglandin synthetase inhibitors in Bartter's syndrome. Effect on immunoreactive prostaglandin E excretion.
Prostaglandins and the kidney.
Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition.
Treatment of Bartter's syndrome in early childhood with prostaglandin synthetase inhibitors.
Treatment of Bartter's syndrome with indomethacin.
[Clinical findings, pathogenesis and treatment of Bartter's syndrome (author's transl)]
Basal Cell Nevus Syndrome
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Bernard-Soulier Syndrome
Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.
Bile Duct Neoplasms
Different expression of cyclooxygenase-2 in biliary epithelia of bile duct cancer with or without pancreaticobiliary maljunction.
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China.
Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases and nuclear factor kappa B.
Resampling-based multiple hypothesis testing procedures for genetic case-control association studies.
Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition.
Bile Reflux
Bile acid induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells.
Elevated cyclooxygenase-2 expression in patients with early gastric cancer in the gastric pylorus.
Laparotomy Attenuates Lipopolysaccharide-Induced Gastric Bleeding in the Rat.
The treatment, management and prevention of oesophageal cancer.
Biliary Atresia
Cyclooxygenase-2 Overexpression is Associated with Clinical Outcome in Biliary Atresia.
Biliary Tract Neoplasms
Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China.
Resampling-based multiple hypothesis testing procedures for genetic case-control association studies.
Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice.
[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]
Blast Crisis
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Blindness
Cytochrome P450 2C8 ?3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization--brief report.
Blister
Blisters in the small intestinal mucosa of coeliac patients contain T cells positive for cyclooxygenase 2.
CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration.
Experimental otitis media with effusion induced by platelet activating factor.
Histopathological and Molecular Changes in the Rabbit Cornea From Arsenical Vesicant Lewisite Exposure.
Indomethacin inhibition of middle ear bone resorption.
Inhibition of HepG2 cell proliferation by ursolic acid and polysaccharides via the downregulation of cyclooxygenase-2.
Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis.
Blood Platelet Disorders
[Genetic defects of prostaglandin and thromboxane synthesis]
Bone Diseases
Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
Bone Diseases, Metabolic
Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction.
Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis.
Chitooligosaccharides prevent osteopenia by promoting bone formation and suppressing bone resorption in ovariectomised rats: possible involvement of COX-2.
Bone Neoplasms
Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and morphine in a mouse model of bone cancer pain.
Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.
Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2.
Bone Resorption
A cat model for the evaluation of mechanisms of bone resorption: induction of bone loss by simulated immune complexes and inhibition by indomethacin.
Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro.
Anti-inflammatory effect of ATB-352, a H2S -releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats.
Bone resorption in experimental otosclerosis in rats.
Bone resorption induced by A23187 is abolished by indomethacin: implications for second messenger utilised by parathyroid hormone.
Capsaicin, a TRPV1 Ligand, Suppresses Bone Resorption by Inhibiting the Prostaglandin E Production of Osteoblasts, and Attenuates the Inflammatory Bone Loss Induced by Lipopolysaccharide.
Celecoxib treatment dampens LPS-induced periapical bone resorption in a mouse model.
Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis.
Chitooligosaccharides prevent osteopenia by promoting bone formation and suppressing bone resorption in ovariectomised rats: possible involvement of COX-2.
Cyclooxygenase inhibitors vary widely in potency for preventing cytokine-induced bone resorption.
Cyclooxygenase products of arachidonic acid metabolism by mouse bone in organ culture.
Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures.
Direct stimulation of bone resorption by epidermal growth factor.
Effect of conjugated linoleic acid on bone formation and rheumatoid arthritis.
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
Effect of streptococcal cell wall components on bone metabolism in vitro.
Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro.
Effects of prostacyclin and prostaglandin E1 (PGE1) on bone resorption in the presence and absence of parathyroid hormone.
Effects of TGF-beta, TNF-alpha, IL-beta and IL-6 alone or in combination, and tyrosine kinase inhibitor on cyclooxygenase expression, prostaglandin E2 production and bone resorption in mouse calvarial bone cells.
Feedback Control of the Arachidonate Cascade in Osteoblastic Cells by 15-deoxy-Delta-Prostaglandin J(2).
Follicle-stimulating hormone enhances alveolar bone resorption via upregulation of cyclooxygenase-2.
Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression.
Humoral hypercalcemia of malignancy. Release of a prostaglandin-stimulating bone-resorbing factor in vitro by human transitional-cell carcinoma cells.
Immuno-localization of COX-1 and COX-2 in the rat molar periodontal tissue after topical application of lipopolysaccharide.
Indomethacin inhibition of middle ear bone resorption.
Inhibition of angiogenesis by humulone, a bitter acid from beer hop.
Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats.
Inhibitory effect of Carthamus tinctorius L. seed extracts on bone resorption mediated by tyrosine kinase, COX-2 (cyclooxygenase) and PG (prostaglandin) E2.
Interleukin-1 alpha induced cyclooxygenase-2 expression in bone-derived endothelial cells.
Interleukin-1beta-induced prostaglandin E2 production by human gingival fibroblasts is upregulated by glycine.
Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures.
Local osteogenic expression of cyclooxygenase-2 and systemic response in porcine models of osteomyelitis.
Metabolic acidosis regulates RGS16 and G protein signaling in osteoblasts.
N-acetyl muramyl dipeptide stimulation of bone resorption in tissue culture.
Omega-3 fatty acid regulates inflammatory cytokine/mediator messenger RNA expression in Porphyromonas gingivalis-induced experimental periodontal disease.
Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis.
Phorbol myristate acetate stimulates osteoclast formation in 1 alpha,25-dihydroxyvitamin D3-primed mouse embryonic calvarial cells by a prostaglandin-dependent mechanism.
Porphyromonas gingivalis induces RANKL in bone marrow stromal cells: involvement of the p38 MAPK.
Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis.
Prostaglandin E2 promotes osteoclast formation in murine hematopoietic cultures through an action on hematopoietic cells.
Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture.
Prostaglandin production by human osteoclasts in culture.
Protective effects of hydroxytyrosol-supplemented refined olive oil in animal models of acute inflammation and rheumatoid arthritis.
Regulation of COX-2 mediates acid-induced bone calcium efflux in vitro.
Regulation of cyclooxygenase-2 expression in human osteoblastic cells by N-acetylcysteine.
Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10.
Retroviral-based gene therapy with cyclooxygenase-2 promotes the union of bony callus tissues and accelerates fracture healing in the rat.
Role of cyclooxygenase-2 in bone resorption.
Selective cyclooxygenase-2 inhibition prevents bone resorption.
Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells.
Sequential expressions of MMP-1, TIMP-1, IL-6, and COX-2 genes in induced periapical lesions in rats.
Short-term supplementation of COX-2 inhibitor suppresses bone turnover in gonad-intact middle-aged male rats.
Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E(2) and selective prostaglandin receptor agonists in murine osteoblastic cells.
Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Stimulation of Fibroblast Growth Factor 23 by Metabolic Acidosis Requires Osteoblastic Intracellular Calcium Signaling and Prostaglandin Synthesis.
Substance P stimulates release of RANKL via COX-2 expression in human dental pulp cells.
Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid.
The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro.
The growth and osteoclastogenic effects of fibroblasts isolated from keratocystic odontogenic tumor.
The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption.
The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivo.
Therapy of malignancy-associated hypercalcemia: 1983.
Topically Applied Phospho-Sulindac Hydrogel is Efficacious and Safe in the Treatment of Experimental Arthritis in Rats.
Transcriptional induction of prostaglandin G/H synthase-2 by basic fibroblast growth factor.
Use of minoxidil to demonstrate that prostacyclin is not the mediator of bone resorption stimulated by growth factors in mouse calvariae.
Vibration enhances PGE2 , IL-6, and IL-8 expression in compressed hPDL cells via cyclooxygenase pathway.
Borna Disease
Upregulation of COX-2 and CGRP expression in resident cells of the Borna disease virus-infected brain is dependent upon inflammation.
Borrelia Infections
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease.
Boutonneuse Fever
Regulation of inducible heme oxygenase and cyclooxygenase isozymes in a mouse model of spotted fever group rickettsiosis.
Bowen's Disease
Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Epithelial to mesenchymal transition in cutaneous squamous cell carcinoma is correlated with COX-2 expression but not with the presence of stromal macrophages or CD10-expressing cells.
Expression of p63 and cyclooxygenase-2 and their correlation in skin tumors.
Immunohistochemical expression of cyclooxygenase-2 in skin cancers.
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Bradycardia
Direct and indirect effects of leukotriene D4 on the lungs of unanesthetized sheep.
Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement.
Brain Concussion
AH6809 decreases production of inflammatory mediators by PGE2 - EP2 - cAMP signaling pathway in an experimentally induced pure cerebral concussion in rats.
Brain Contusion
Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat.
Prior ethanol injection promotes brain edema after traumatic brain injury: evidence for poor prognosis for intoxicated patients.
Brain Damage, Chronic
Hippocampal neuronal cyclooxygenase-2 downstream signaling imbalance in a rat model of chronic aluminium gluconate administration.
Brain Death
Brain death increases COX-1 and COX-2 expression in the renal medulla in a pig model.
Brain Diseases
Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats.
Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression.
Cyclooxygenase in epilepsy: from perception to application.
Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases.
In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons.
Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia.
Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood-brain barrier.
Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity.
Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations.
Role of COX-2 in inflammatory and degenerative brain diseases.
Role of cyclooxygenase isoforms in encephalopathy of cirrhotic rats.
Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide.
The Role of mPGES-1 in Inflammatory Brain Diseases.
The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission.
Brain Edema
Alterations of the eicosanoid synthetic capacity of rat brain microvessels following ischemia: relevance to ischemic brain edema.
Arachidonic acid metabolite production following focal cerebral ischemia: time course and effect of meclofenamate.
Crotalus helleri venom preconditioning reduces postoperative cerebral edema and improves neurological outcomes after surgical brain injury.
Cyclo-oxygenase-2 mediates hyperbaric oxygen preconditioning-induced neuroprotection in the mouse model of surgical brain injury.
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.
Detrimental effects of post-treatment with fatty acids on brain injury in ischemic rats.
Effect of indomethacin on edema following single and repetitive cerebral ischemia in the gerbil.
Effect of KBT-3022, a new cyclooxygenase inhibitor, on experimental brain edema in vitro and in vivo.
Effect of MCI-186 on brain edema in rats.
Effects of cyclooxygenase and lipoxygenase inhibitors on cerebral edema induced by freezing lesions in rats.
Expression of Cyclooxygenase-2 and Its Correlation with Vasogenic Brain Edema in Human Intracranial Meningiomas.
Inducible cyclooxygenase-2 expression after experimental intracerebral hemorrhage.
Induction of brain edema following intracerebral injection of arachidonic acid.
Inhibition of cyclooxygenase 2 by nimesulide decreases prostaglandin E2 formation but does not alter brain edema or clinical recovery after closed head injury in rats.
Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation.
Prior ethanol injection promotes brain edema after traumatic brain injury: evidence for poor prognosis for intoxicated patients.
Progesterone protects blood-brain barrier function and improves neurological outcome following traumatic brain injury in rats.
Receptor for advanced glycation end-product antagonist reduces blood-brain barrier damage after intracerebral hemorrhage.
The neuroprotective effects of cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid hemorrhage.
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]
Brain Infarction
2-Methoxystypandrone ameliorates brain function through preserving BBB integrity and promoting neurogenesis in mice with acute ischemic stroke.
Anti-Inflammatory Effects of Total Isoflavones from Pueraria lobata on Cerebral Ischemia in Rats.
MiRNA-34c-5p protects against cerebral ischemia/reperfusion injury: involvement of anti-apoptotic and anti-inflammatory activities.
Neuroprotective effect of Umbelliferone against Cerebral ischemia/Reperfusion induced neurological deficits: in-vivo and in-silico studies.
The obligatory role of COX-2 expression for induction of HO-1 in ischemic preconditioned rat brain.
Brain Injuries
A dual inhibitor of cyclooxygenase and 5-lipoxygenase protects against kainic acid-induced brain injury.
AH6809 decreases production of inflammatory mediators by PGE2 - EP2 - cAMP signaling pathway in an experimentally induced pure cerebral concussion in rats.
Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia.
Assessment of radioligands for PET imaging of cyclooxygenase-2 in an ischemic neuronal injury model.
Assessment of the effects of the cyclooxygenase-2 inhibitor rofecoxib on visuospatial learning and hippocampal cell death following kainate-induced seizures in the rat.
BK-induced COX-2 expression via PKC-delta-dependent activation of p42/p44 MAPK and NF-kappaB in astrocytes.
Calcium/calcineurin signaling in primary cortical astrocyte cultures: Rcan1-4 and cyclooxygenase-2 as NFAT target genes.
Celecoxib Alleviates Radiation-Induced Brain Injury in Rats by Maintaining the Integrity of Blood-Brain Barrier.
COX-2 is associated with cadmium-induced ICAM-1 expression in cerebrovascular endothelial cells.
COX-2 regulation and TUNEL-positive cell death differ between genders in the secondary inflammatory response following experimental penetrating focal brain injury in rats.
COX2-derived primary and cyclopentenone prostaglandins are increased after asphyxial cardiac arrest.
Cyclooxygenase inhibition as a strategy to ameliorate brain injury.
Cyclooxygenase inhibition in ischemic brain injury.
Cyclooxygenase products of arachidonic acid metabolism in cat cerebral cortex after experimental concussive brain injury.
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.
Cyclooxygenase-2 activity following traumatic brain injury in the developing rat.
Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species.
Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia.
Cyclooxygenase-2 inhibition provides lasting protection against neonatal hypoxic-ischemic brain injury.
Cyclooxygenase-2 Inhibition Provides Lasting Protection Following Germinal Matrix Hemorrhage in Premature Infant Rats.
Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity.
Cyclooxygenase-2 is induced globally in infarcted human brain.
Cyclooxygenase-2-dependent superoxide generation contributes to age-dependent impairment of G protein-mediated cerebrovasodilation.
Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic damage.
Effects of isoflurane on brain inflammation after subarachnoid hemorrhage in mice.
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat.
Effects of the selective cyclooxygenase-2 inhibitor rofecoxib on cell death following traumatic brain injury in the rat.
Ergosta-7,9(11),22-trien-3?-ol Alleviates Intracerebral Hemorrhage-Induced Brain Injury and BV-2 Microglial Activation.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 mRNA in brain damage induced by lipopolysaccharide and intermittent hypoxia-ischemia in neonatal rats.
Function of prostaglandin E2 EP receptors in the acute outcome of rodent hypoxic ischemic encephalopathy.
Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury.
Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice.
Inhibition by free radical scavengers and by cyclooxygenase inhibitors of pial arteriolar abnormalities from concussive brain injury in cats.
Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia.
Intracerebral hemorrhage outcomes following selective blockade or stimulation of the PGE2 EP1 receptor.
Mercaptoethylguanidine inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expressions induced in rats after fluid-percussion brain injury.
MiR-21b-3p protects NS2OY cells against oxygen-glucose deprivation/reperfusion-induced injury by down-regulating cyclooxygenase-2.
Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders.
Neuroinflammatory signaling upregulation in Alzheimer's disease.
Neuronal and nonneuronal COX-2 expression confers neurotoxic and neuroprotective phenotypes in response to excitotoxin challenge.
Nimesulide prevents oxidative stress damage following transient forebrain ischemia in the rat hippocampus.
NMDA and age dependent cerebral hemodynamics after traumatic brain injury.
PGF(2alpha) FP Receptor Contributes to Brain Damage Following Transient Focal Brain Ischemia.
Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats.
Progress in COX-2 inhibitors: a journey so far.
Prostaglandins and other lipid mediators in Alzheimer's disease.
Prostaglandins in physiological and in certain pathological responses of the cerebral circulation.
Protein Disulfide Isomerase as a Novel Target for Cyclopentenone Prostaglandins: Implications for Hypoxic Ischemic Injury.
Purinergic signaling induces cyclooxygenase-1-dependent prostanoid synthesis in microglia: roles in the outcome of excitotoxic brain injury.
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.
Relationship between NOC/oFQ, dynorphin, and COX-2 activation in impaired NMDA cerebrovasodilation after brain injury.
Role of altered cyclooxygenase metabolism in impaired cerebrovasodilation to nociceptin/orphanin FQ following brain injury.
Small molecules targeting cyclooxygenase/prostanoid cascade in experimental brain ischemia: Do they translate?
Spatio-Temporal Distribution of Inflammatory Reaction and Expression of TLR2/4 Signaling Pathway in Rat Brain Following Permanent Focal Cerebral Ischemia.
Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy.
The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene.
The highly selective cyclooxygenase-2 inhibitor DFU is neuroprotective when given several hours after transient cerebral ischemia in gerbils.
The neuroprotective effects of cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid hemorrhage.
Trans-Cinnamaldehyde, An Essential Oil in Cinnamon Powder, Ameliorates Cerebral Ischemia-Induced Brain Injury via Inhibition of Neuroinflammation Through Attenuation of iNOS, COX-2 Expression and NF?-B Signaling Pathway.
Traumatic brain injury induces prolonged accumulation of cyclooxygenase-1 expressing microglia/brain macrophages in rats.
Vasopressin induced cyclooxygenase dependent superoxide generation contributes to K(+) channel function impairment after brain injury.
Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat.
[Brain injury in adenosine A1 receptor knock-out mice after pentetrazole kindling and its correlation with COX-2]
[Mechanism research and effect of ulinastatin in the brain tissue injury of acute hydrogen sulfide intoxicated rats].
[The dynamically changes of COX-2 and the gene expression of COX-2 mRNA after traumatic brain injury in rats]
[The expression of COX-1 and COX-2 following brain injuries]
Brain Injuries, Diffuse
Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability.
Brain Injuries, Traumatic
A single dose of PPAR? agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats.
Activation of cyclo-oxygenase-2 contributes to motor and cognitive dysfunction following diffuse traumatic brain injury in rats.
Cerebral oedema and blood-brain and blood-CSF barriers in experimental brain trauma: effect of indomethacin-A prostaglandin synthetase inhibitor.
COX-1 and COX-2 polymorphisms in susceptibility to cerebral palsy in very preterm infants.
COX-2 Inhibition by Diclofenac Is Associated With Decreased Apoptosis and Lesion Area After Experimental Focal Penetrating Traumatic Brain Injury in Rats.
Curcuminoids in Neurodegenerative Diseases.
Cyclooxygenase-2 activity following traumatic brain injury in the developing rat.
Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat.
Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury.
Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice.
Effects of selective and non-selective cyclooxygenase inhibition against neurological deficit and brain oedema following closed head injury in mice.
Effects of the selective cyclooxygenase-2 inhibitor rofecoxib on cell death following traumatic brain injury in the rat.
Genetic disruption of cyclooxygenase-2 does not improve histological or behavioral outcome after traumatic brain injury in mice.
Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice.
Impact of 5-lipoxygenase inhibitors on the spatiotemporal distribution of inflammatory cells and neuronal COX-2 expression following experimental traumatic brain injury in rats.
Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats.
miR-212-5p attenuates ferroptotic neuronal death after traumatic brain injury by targeting Ptgs2.
Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury.
Possible roles of COX-1 in learning and memory impairment induced by traumatic brain injury in mice.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat.
Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury.
Sequential expression of cyclooxygenase-2, glutamate receptor-2, and platelet activating factor receptor in rat hippocampal neurons after fluid percussion injury.
The Anti-Inflammatory Drug Carprofen Improves Long-Term Outcome and Induces Gliogenesis after Traumatic Brain Injury.
The effects of cyclooxygenase inhibitors on the brain inflammatory response following traumatic brain injury in rats.
The effects of cyclooxygenase inhibitors on the gastric emptying and small intestine transit in the male rats following traumatic brain injury.
Traumatic brain injury induces prolonged accumulation of cyclooxygenase-1 expressing microglia/brain macrophages in rats.
Which is more effective in reducing secondary brain damage resulting from cyclooxygenase expression following traumatic brain injury: calcium channel blockers or cox inhibitors?
[The dynamically changes of COX-2 and the gene expression of COX-2 mRNA after traumatic brain injury in rats]
[The effect of nimesulide on learning and memory function after serve traumatic brain injury in rats].
Brain Ischemia
1alpha,25-Dihydroxyvitamin D(3) treatment does not alter neuronal cyclooxygenase-2 expression in the cerebral cortex after stroke.
A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans.
A cyclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia.
Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats.
Aged Garlic Extract Attenuates Cerebral Damage and Cyclooxygenase-2 Induction after Ischemia and Reperfusion in Rats.
Apobec-1 increases cyclooxygenase-2 and aggravates injury in oxygen-deprived neurogenic cells and middle cerebral artery occlusion rats.
Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia.
Baicalin improved the spatial learning ability of global ischemia/reperfusion rats by reducing hippocampal apoptosis.
Chronic dexamethasone pretreatment aggravates ischemic neuronal necrosis.
Curcumin Protects Neuron against Cerebral Ischemia-Induced Inflammation through Improving PPAR-Gamma Function.
Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage.
Cyclo-oxygenase-2 messenger RNA induction in focal cerebral ischemia.
Cyclooxygenase 2 and intermittent hypoxia-induced spatial deficits in the rat.
Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture.
Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species.
Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia.
Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity.
Cyclooxygenase-2 is induced globally in infarcted human brain.
Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans.
Cyclooxygenase-2 mediates hyperbaric oxygen preconditioning in the rat model of transient global cerebral ischemia.
Cyclooxygenase-2 mediates the development of cortical spreading depression-induced tolerance to transient focal cerebral ischemia in rats.
Cyclooxygenase-2 mRNA expression is associated with c-fos mRNA expression and transient water ADC reduction detected with diffusion MRI during acute focal ischemia in rats.
Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus.
Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice.
Dehydroascorbic acid normalizes several markers of oxidative stress and inflammation in acute hyperglycemic focal cerebral ischemia in the rat.
Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia.
Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils.
Differential cellular distribution and dynamics of HSP70, cyclooxygenase-2, and c-Fos in the rat brain after transient focal ischemia or kainic acid.
Differential regulation of cyclooxygenase-2 in the rat hippocampus after cerebral ischemia and ischemic tolerance.
Divergent effects of prostaglandin receptor signaling on neuronal survival.
Down regulation of COX-2 is involved in hyperbaric oxygen treatment in a rat transient focal cerebral ischemia model.
Down regulation of cyclooxygenase-2 is involved in delayed neuroprotection by ischemic preconditioning in rats.
Effect of cyclooxygenase and lipoxygenase inhibitors on delayed neuronal death in the gerbil hippocampus.
Effect of indomethacin on edema following single and repetitive cerebral ischemia in the gerbil.
Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury.
Effect of selective inhibition of cyclooxygenase 2 on temporary focal cerebral ischemia in rats.
Effects of triflusal and aspirin in a rat model of cerebral ischemia.
Emerging roles of PGE(2) receptors in models of neurological disease.
Flurbiprofen axetil promotes neuroprotection by activation of cerebral peroxisome proliferator-activated receptor gamma after focal cerebral ischemia in rats.
Function of prostaglandin E2 EP receptors in the acute outcome of rodent hypoxic ischemic encephalopathy.
Genetic Deletion or Pharmacological Inhibition of Cyclooxygenase-2 Reduces Blood-Brain Barrier Damage in Experimental Ischemic Stroke.
Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice.
Induced angiogenesis under cerebral ischemia by cyclooxygenase 2 and hypoxia-inducible factor naked DNA in a rat indirect-bypass model.
Induction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage.
Induction of cyclooxygenase-2 messenger RNA after transient and permanent middle cerebral artery occlusion in rats: comparison with c-fos messenger RNA by using in situ hybridization.
Induction of cyclooxygenase-2 mRNA in gerbil hippocampal neurons after transient forebrain ischemia.
Induction of PGH synthase and c-fos mRNA during early reperfusion of ischemic rat brain.
Induction of PGHS-2 mRNA in response to cerebral hypoperfusion in late-gestation fetal sheep.
Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration.
Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia.
Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury?
LncRNA-Malat1 down-regulates miR-211-5p expression to promote neuronal damage from cerebral ischemia reperfusion injury.
Melatonin reduced volume of cerebral infarct induced by photothrombosis in wild-type mice, not in Cyclooxygenase-1 gene knockout mice.
Mesenchymal Stem Cell-Derived Extracellular Vesicles Ameliorates Hippocampal Synaptic Impairment after Transient Global Ischemia.
Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia.
Neuroinflammatory signaling upregulation in Alzheimer's disease.
Neuronal cyclooxygenase-2 activity and prostaglandins PGE2, PGD2, and PGF2 alpha exacerbate hypoxic neuronal injury in neuron-enriched primary culture.
Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway.
Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia.
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia.
Phenidone attenuates oxygen/glucose deprivation-induced neurotoxicity by antioxidant and antiapoptotic action in mouse cortical cultures.
Prostaglandin E receptors as targets for ischemic stroke: Novel evidence and molecular mechanisms of efficacy.
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.
Resveratrol downregulates the TLR4 signaling pathway to reduce brain damage in a rat model of focal cerebral ischemia.
Reversible cerebral vasoconstriction syndrome possibly induced by etoricoxib.
Roles of prostaglandin synthesis in excitotoxic brain diseases.
S-2474, a novel nonsteroidal anti-inflammatory drug, rescues cortical neurons from human group IIA secretory phospholipase A(2)-induced apoptosis.
Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation.
Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2.
Study on cerebroprotective actions of Clerodendron glandulosumleaves extract against long term bilateral common carotid artery occlusion in rats.
Suppression of hyperemia and DNA oxidation by indomethacin in cerebral ischemia.
Temporary focal cerebral ischemia in spontaneously hypertensive rats: the effect of ibuprofen on infarct volume.
Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats.
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy.
The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene.
The dual role of prostaglandin E(2) in excitotoxicity and preconditioning-induced neuroprotection.
The role of prostaglandin e2 in stroke-reperfusion injury.
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemia.
Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat.
Brain Neoplasms
A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas.
Augmentation of chemotherapy-triggered glioma cell apoptosis by blockade of arachidonic acid metabolism-the potential role of ceramide accumulation.
Avoiding glucocorticoid administration in a neurooncological case.
Brain edema in neurooncology: radiological assessment and management.
Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma.
COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation.
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors.
Cyclooxygenase-2 expression in brain metastases.
Cytoplasmic Expression of HuR is Related to Cyclooxygenase-2 Expression in Colon Cancer.
Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma.
Expression of prostaglandin H synthase-2 in human brain tumors.
Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory.
Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme.
Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors.
Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089.
Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.
Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation.
Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib.
Paradoxical effect of aspirin on the growth of C6 rat glioma and on time of development of ENU-induced tumors of the nervous system.
Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.
Plasma circulating cell free messenger RNA as a potential biomarker of melanoma.
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.
The eicosanoid cascade: possible role in gliomas and meningiomas.
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]
[Expression and clinical significance of cyclooxygenase-2 in medulloblastoma]
Breast Diseases
Expression of cyclooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases.
Glucocorticoid receptor changes its cellular location with breast cancer development.
Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease.
Reduced uptake of the proliferation-seeking radiotracer technetium-99m-labelled pentavalent dimercaptosuccinic acid in a 47-year-old woman with severe breast epithelial hyperplasia taking ibuprofen: a case report.
Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer.
Breast Neoplasms
1,25-Dihydroxyvitamin D3 inhibits growth of the breast cancer cell line MCF-7 and downregulates cytochrome P4501B1 through the COX-2/PGE2 pathway.
15-Deoxy-?12,14-prostaglandin J2 induces expression of 15-hydroxyprostaglandin dehydrogenase through Elk-1 activation in human breast cancer MDA-MB-231 cells.
15-Deoxy-?12,14-prostaglandin J2 Upregulates VEGF Expression via NRF2 and Heme Oxygenase-1 in Human Breast Cancer Cells.
15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS.
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.
A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer.
A novel aspirin prodrug inhibits NF?B activity and breast cancer stem cell properties.
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.
A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer.
A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study.
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer.
A window-of-opportunity biomarker study of etodolac in resectable breast cancer.
Aberrant methylation of cyclooxygenase-2 in breast cancer patients.
Activation of HIF-1? by ?-Opioid Receptors Induces COX-2 Expression in Breast Cancer Cells and Leads to Paracrine Activation of Vascular Endothelial Cells.
Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2.
Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro.
Advances in breast oncology: the 2002 ASCO meeting.
American Ginseng Inhibits Induced COX-2 and NFKB Activation in Breast Cancer Cells.
AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin.
Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis.
Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry.
Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway.
Angiotensin-converting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide case-control study.
Anti-inflammatory and anticarcinogenic effect of genistein alone or in combination with capsaicin in TPA-treated rat mammary glands or mammary cancer cell line.
Antibodies as Carrier Molecules: Encapsulating Anti-Inflammatory Drugs inside Herceptine.
Anticarcinogenic activity of quinacrine in the rat mammary gland.
Antimetastatic activity of a cyclooxygenase-2 inhibitor.
Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2.
Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.
Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo.
Antitumor effect of a generation 4 polyamidoamine dendrimer/cyclooxygenase-2 antisense oligodeoxynucleotide complex on breast cancer in vitro and in vivo.
Apoptotic effect of eugenol envolves G2/M phase abrogation accompanied by mitochondrial damage and clastogenic effect on cancer cell in vitro.
Apoptotic effects of two COX-2 inhibitors on breast adenocarcinoma cells through COX-2 independent pathway.
Aromatase and COX-2 expression in human breast cancers.
Aromatase and cyclooxygenases: enzymes in breast cancer.
Aromatic-turmerone attenuates invasion and expression of MMP-9 and COX-2 through inhibition of NF-?B activation in TPA-induced breast cancer cells.
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Aspisol inhibits tumor growth and induces apoptosis in breast cancer.
Association between ABCB1, ABCG2 carrier protein and COX-2 enzyme gene polymorphisms and breast cancer risk in a Turkish population.
Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan.
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.
Association between expression of inflammatory markers in normal breast tissue and mammographic density among premenopausal and postmenopausal women.
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer.
Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.
Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers.
Association of the three common SNPs of cyclooxygenase-2 gene (rs20417, rs689466, and rs5275) with the susceptibility of breast cancer: an updated meta-analysis involving 34,590 subjects.
Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines.
Beta-ionone-inhibited proliferation of breast cancer cells by inhibited COX-2 activity.
Bisphenol A induces COX-2 through the mitogen-activated protein kinase pathway and is associated with levels of inflammation-related markers in elderly populations.
Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts.
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Breast cancer--new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?
Butein downregulates phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in cancerous and non-cancerous breast cells.
Calcium metabolism in breast cancer.
Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer?
Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.
Cannabidiolic acid dampens the expression of cyclooxygenase-2 in MDA-MB-231 breast cancer cells: Possible implication of the peroxisome proliferator-activated receptor ?/? abrogation.
Cannabidiolic Acid-Mediated Interference with AP-1 Transcriptional Activity in MDA-MB-231 Breast Cancer Cells.
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.
Carotenoid isolates of Spondias mombin demonstrate anticancer effects in DMBA-induced breast cancer in Wistar rats through X-linked inhibitor of apoptosis protein (XIAP) antagonism and anti-inflammation.
Caveolin-1-mediated suppression of cyclooxygenase-2 via a {beta}-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression.
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.
Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-?B pathway.
Celecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell Lines.
Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial.
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen.
Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Chemoprevention of cancer--focusing on clinical trials.
Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.
Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.
Cigarette Smoke Regulates Calcium-Independent Phospholipase A2 Metabolic Pathways in Breast Cancer.
Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate.
Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue.
Clinical value of cyclooxygenase-2 expression in human breast carcinoma.
Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.
Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model.
Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.
Coagulation factor VIIa-mediated protease-activated receptor 2 activation leads to ?-catenin accumulation via the AKT/GSK3? pathway and contributes to breast cancer progression.
Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Combination of EGFR and COX-2 inhibitors in breast cancer patient.
Combined Treatment of Breast Cancer Cell Lines with Vitamin D and COX-2 Inhibitors.
Combining flavopiridol with various signal transduction inhibitors.
Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.
Comparative Evaluation of Nimesulide-Loaded Nanoparticles for Anticancer Activity Against Breast Cancer Cells.
Comparative pharmacokinetics study of anastrozole after single administration and combination with celecoxib.
Comparison of stearidonic acid and alpha-linolenic acid on PGE2 production and COX-2 protein levels in MDA-MB-231 breast cancer cell cultures.
Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells.
Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.
Conjugated Linoleic Acid Attenuates Cyclooxygenase-2 Transcriptional Activity via an Anti-AP-1 Mechanism in MCF-7 Breast Cancer Cells.
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.
Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells.
Correction: MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer.
Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer.
Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.
Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.
Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival.
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer.
Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer.
COX-2 and PGE2-dependent immunomodulation in breast cancer.
COX-2 and prostanoid receptors: good targets for chemoprevention.
COX-2 dependent regulation of mechanotransduction in human breast cancer cells.
COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation.
COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
COX-2 expression does not correlate with microvessel density in breast cancer.
COX-2 Expression in Breast Carcinoma with Correlation to Clinicopathological Parameters
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome.
COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification.
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
Cox-2 expression on tissue microarray of breast cancer.
COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin.
COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis.
COX-2 induces IL-11 production in human breast cancer cells.
COX-2 induces oncogenic micro RNA miR655 in human breast cancer.
COX-2 induction by heparanase in the progression of breast cancer.
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.
COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer.
COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.
COX-2 inhibitors and breast cancer.
COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.
COX-2 inhibitors for the prevention of breast cancer.
COX-2 inhibitors: a novel strategy in the management of breast cancer.
COX-2 involvement in breast cancer metastasis to bone.
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
COX-2 localization within plasma membrane caveolae-like structures in human lobular intraepithelial neoplasia of the breast.
COX-2 modulates mammary tumor progression in response to collagen density.
COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer.
COX-2 overexpression increases malignant potential of human glioma cells through Id1.
COX-2 overexpression increases motility and invasion of breast cancer cells.
COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness.
COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro.
COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.
Cross-talk between SIM2s and NF?B regulates cyclooxygenase 2 expression in breast cancer.
Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
CUGBP2 plays a critical role in apoptosis of breast cancer cells in response to genotoxic injury.
Curcumin as an Adjuvant to Breast Cancer Treatment.
Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Current concepts in cyclooxygenase inhibition in breast cancer.
Current directions for COX-2 inhibition in breast cancer.
Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis.
CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2.
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.
Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB.
Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer.
Cyclo-oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer.
Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer.
Cyclooxygenase 2 polymorphism (Val511Ala), nonsteroidal anti-inflammatory drug use and breast cancer in African American women.
Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.
Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle.
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.
Cyclooxygenase-1 and -2 isoenzymes.
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
Cyclooxygenase-2 169C>G and 8473T>C gene polymorphisms and prostaglandin E2 level in breast cancer: A case-control study.
Cyclooxygenase-2 and chemoprevention of breast cancer.
Cyclooxygenase-2 and the inflammogenesis of breast cancer.
Cyclooxygenase-2 as a target for anticancer drug development.
Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.
Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts.
Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Cyclooxygenase-2 enzyme induces the expression of the ?-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer.
Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy.
Cyclooxygenase-2 expression during immortalization and breast cancer progression.
Cyclooxygenase-2 Expression in Animal Cancers.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Cyclooxygenase-2 expression in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression.
Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients.
Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines.
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.
Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes.
Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells.
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast.
Cyclooxygenase-2 gene expression in human breast cancer.
Cyclooxygenase-2 immunoexpression in breast cancer: Progesterone receptor influence.
Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells.
Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway.
Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.
Cyclooxygenase-2 induces the expression of the alpha 2,3 sialyltransferase-3 (ST3Gal-I) in breast cancer.
Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model.
Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.
Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells.
Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.
Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer.
Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation.
Cyclooxygenase-2 Polymorphisms and Breast Cancer Associated Risk in Pakistani Patients.
Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
Cyclooxygenase-2 promoter activation by the aromatic hydrocarbon receptor in breast cancer mcf-7 cells: repressive effects of conjugated linoleic acid.
Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells.
Cyclooxygenase-2 regulates TGF?-induced cancer stemness in triple-negative breast cancer.
Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells.
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells.
Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.
Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.
Cyclooxygenase-2: a potential target in breast cancer.
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Cytoplasmic PPAR? is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers.
Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.
Deciphering of Key Pharmacological Pathways of Poria Cocos Intervention in Breast Cancer Based on Integrated Pharmacological Method.
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density.
Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.
Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia.
Design, Synthesis and Biological Evaluation of4-(Imidazolylmethyl)-2-(4-methylsulfonyl phenyl)-Quinoline Derivatives as Selective COX-2 Inhibitors and In-vitro Anti-breast Cancer Agents.
Detection of COX-2 in liquid biopsy in patients with breast cancer.
Dietary fat and breast cancer metastasis by human tumor xenografts.
Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor.
Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer.
Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.
Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines.
Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients.
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.
Discovery, synthesis and molecular corroborations of medicinally important novel pyrazoles; drug efficacy determinations through in silico, in vitro and cytotoxicity validations.
Do early premalignant changes in normal breast epithelial cells predict cancer development?
Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer.
Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells.
Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion.
Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis.
Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.
Effect of Hispolon from Phellinus lonicerinus (Agaricomycetes) on Estrogen Receptors, Aromatase, and Cyclooxygenase II in MCF-7 Breast Cancer Cells.
Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands.
Effect of lysine antifibrinolytics and cyclooxygenase inhibitors on the proteolytic profile of breast cancer cells interacting with macrophages or endothelial cells.
Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
Effects and mechanism of downregulation of COX?2 expression by RNA interference on proliferation and apoptosis of human breast cancer MCF?7 cells.
Effects of anesthetic interventions on breast cancer behavior, cancer-related patient outcomes, and postoperative recovery.
Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.
Effects of dietary menhaden oil, soy, and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice.
Effects of eicosanoid synthesis inhibitors on the in vitro growth and prostaglandin E and leukotriene B secretion of a human breast cancer cell line.
Effects of enriched environment on COX-2, leptin and eicosanoids in a mouse model of breast cancer.
Effects of high and low dietary fat and indomethacin on tumour growth, hormone receptor status and growth factor expression in DMBA-induced rat breast cancer.
Effects of linoleic acid and eicosanoid synthesis inhibitors on the growth and c-myc oncogene expression of human breast cancer cells.
Effects of Six Weeks Endurance Training and Aloe Vera Supplementation on COX-2 and VEGF Levels in Mice with Breast Cancer
Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.
Elevated cyclooxygenase-2 expression is associated with histological grade in invasive ductal breast carcinoma.
Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.
Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.
Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells.
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.
EpCAM and COX?2 expression are positively correlated in human breast cancer.
Epigenetic change in E-Cardherin and COX-2 to predict chronic periodontitis.
Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study.
Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer.
Evaluation of Antioxidant Intakes in Relation to Inflammatory Markers Expression Within the Normal Breast Tissue of Breast Cancer Patients.
Evaluation of potential Stat3-regulated genes in human breast cancer.
Evaluation of the contribution of cyclooxygenase 2 genotypes to breast cancer in Taiwan.
Evidence of an autocrine role for leptin and leptin receptor in human breast cancer.
Expression of COX-2 and steroid converting enzymes in breast cancer.
Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness.
Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer.
Expression of cyclooxygenase-1 and -2 in human breast cancer.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.
Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors.
Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
Expression of cyclooxygenase-2 and Bcl-2 in breast cancer and their relationship with triple-negative disease.
Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis.
Expression of cyclooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases.
Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors.
Expression of Cyclooxygenase-2 in Human Breast Carcinoma: Relevance to Tumor Angiogenesis and Expression of Estrogen Receptor.
Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact.
Expression of cyclooxygenase-2 in malignant and benign breast tumors.
Expression of integrin ?3?1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer.
Expression of PCNA, Ki-67 and COX-2 in breast cancer based on DCE-MRI image information.
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma.
Expression of VEGF, COX-2 and MMP-9 in breast cancer and their relationship with ultrasound findings.
Expressions of ER, PR, HER-2, COX-2, and VEGF in Primary and Relapsed/Metastatic Breast Cancers.
Failure of indomethacin to reduce hypercalcemia in patients with breast cancer.
Five COX-2 gene polymorphisms and risk of breast cancer: an updated meta-analysis based on 19 case-control studies.
Fluorinated 2'-hydroxychalcones as garcinol analogs with enhanced antioxidant and anticancer activities.
Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells.
Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population.
Functional promoter -765 G?>?C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women.
Gancochlearols E - I, meroterpenoids from Ganoderma cochlear against COX-2 and triple negative breast cancer cells and the absolute configuration assignment of ganomycin K.
Genes controlling spread of breast cancer to lung "gang of 4".
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk.
Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study.
Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase.
Glucocorticoid receptor changes its cellular location with breast cancer development.
Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells.
Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression.
Growth inhibitory and anti-metastatic activity of epithelial cell adhesion molecule targeted three-way junctional delta-5-desaturase siRNA nanoparticle for breast cancer therapy.
Heparanase and COX-2 expression as predictors of lymph node metastasis in large, high-grade breast tumors.
HER-2/neu-Positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications.
Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program.
Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2.
HPV16 E6 Promotes Breast Cancer Proliferation via Upregulation of COX-2 Expression.
HPV16 E7 increases COX-2 expression and promotes the proliferation of breast cancer.
Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood-brain barrier.
Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.
Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.
Identification of genes and miRNAs in paclitaxel treatment for breast cancer.
Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas.
Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
IL-1 does not reverse the anti-proliferative effect of aspirin in breast cancer cells.
Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA.
Iminodibenzyl induced redirected COX-2 activity inhibits breast cancer progression.
Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: A pilot study.
Immunohistochemical expression of cyclooxygenase-2 in skin cancers.
Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer.
Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine.
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors.
IMP1 suppresses breast tumor growth and metastasis through the regulation of its target mRNAs.
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.
Impact of cyclooxygenase-2 in breast cancer.
Impact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients.
Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system.
In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells.
In vitro capacity of various cyclooxygenase inhibitors to revert immune suppression caused by radiation therapy for breast cancer.
In vitro effects of eicosanoid synthesis inhibitors in the presence of linoleic acid on MDA-MB-231 human breast cancer cells.
In vitro growth inhibition by indomethacin on human oral squamous cell carcinoma lines synergistically suppressed by all-trans retinoic acid correlating to apoptosis.
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.
Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density.
Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer.
Increased expression of ZNF 703 in breast cancer tissue: An opportunity for RNAi-NSAID combinatorial therapy.
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047.
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.
Inflammation and IGF-I activate the Akt pathway in breast cancer.
Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy.
Inflammatory lymphangiogenesis in postpartum breast tissue remodeling.
Influence of calcitriol on prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cell lines.
Influence of coenzyme A-independent transacylase and cyclooxygenase inhibitors on the proliferation of breast cancer cells.
Influence of VEGF, COX-2, and MMP-9 expression on the molybdenum-targeted X-ray in breast cancer.
Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum.
Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B.
Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells.
Inhibition of cyclooxygenase-2 and induction of apoptosis in estrogen-nonresponsive breast cancer cells by Antrodia camphorata.
Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression.
Inhibition of PKC-induced COX-2 and IL-8 Expression in Human Breast Cancer Cells by Glucosamine.
Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.
Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer.
Integrin ?3?1 controls mRNA splicing that determines Cox-2 mRNA stability in breast cancer cells.
Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.
Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2.
Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.
Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
Jaceosidin, a pharmacologically active flavone derived from Artemisia argyi, inhibits phorbol-ester-induced upregulation of COX-2 and MMP-9 by blocking phosphorylation of ERK-1 and -2 in cultured human mammary epithelial cells.
Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth.
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Lack of association between COX-2 8473T>C polymorphism and breast cancer risk: a meta-analysis.
Lack of association between cyclooxygenase 2-765G/C gene polymorphism and breast cancer risk in Ahvaz, west-south Iran.
Lack of association of the cyclooxygenase-2 gene 8473T>C polymorphism with breast cancer risk: a meta-analysis.
Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at increased risk of breast cancer.
Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up.
Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer.
Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Leptin induces CREB-dependent aromatase activation through COX-2 expression in breast cancer cells.
Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression.
Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer.
Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis.
Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium.
Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Low-dose aspirin, non-steroidal anti-inflammatory drugs, selective COX-2 inhibitors and breast cancer recurrence.
Macrophages induce COX-2 expression in breast cancer cells: Role of IL-1{beta} auto-amplification.
Madhuca indica Inhibits Breast Cancer Cell Proliferation by Modulating COX-2 Expression.
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Markers of the uPA system and common prognostic factors in breast cancer.
MCF-7 breast cancer cell line grown in agarose culture for study of COX-2 inhibitors in three-dimensional growth system.
Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ER? status.
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.
Metastatic potential in MDA-MB-231 human breast cancer cells is inhibited by proton beam irradiation via the Akt/nuclear factor-?B signaling pathway.
Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2.
Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients.
Methylation status and overexpression of COX-2 in Tunisian patients with ductal invasive breast carcinoma.
MicroRNA and cyclooxygenase-2 in breast cancer.
Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy.
Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells.
miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-?B/COX-2 activation.
Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer.
MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer.
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.
Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4.
Modulation of tumorigenesis and oestrogen receptor-alpha expression by cell culture conditions in a stem cell-derived breast epithelial cell line.
Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy Against Breast Cancer Cell Models.
Molecular Characterization of Feline COX-2 and Expression in Feline Mammary Carcinomas.
Molecular markers of therapeutic resistance in breast cancer.
Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents.
MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1.
Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.
MYLK and PTGS1 Genetic Variations Associated with Osteoporosis and Benign Breast Tumors in Korean Women.
NDRG2 controls COX-2/PGE?-mediated breast cancer cell migration and invasion.
Neoadjuvant Therapy with Celecoxib to Women with Early Stage Breast Cancer.
Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer.
New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.
Nexrutine inhibits survival and induces g1 cell cycle arrest, which is associated with apoptosis or autophagy depending on the breast cancer cell line.
NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2.
Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms.
Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer.
Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling.
Non-steroidal anti-inflammatory drugs target the pro-tumorigenic extracellular matrix of the postpartum mammary gland.
Nonaspirin NSAIDs and contralateral breast cancer risk.
Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study.
Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease.
Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.
Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer.
Novel augmentation by bufalin of protein kinase C-induced cyclooxygenase-2 and IL-8 production in human breast cancer cells.
Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer.
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.
NSAIDs and breast cancer: a possible prevention and treatment strategy.
Nuclear co-localization and functional interaction of COX-2 and HIF-1? characterize bone metastasis of human breast carcinoma.
Obacunone exhibits anti-proliferative and anti-aromatase activity in vitro by inhibiting the p38 MAPK signaling pathway in MCF-7 human breast adenocarcinoma cells.
Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production.
Opposing roles for mammary epithelial-specific PPAR? signaling and activation during breast tumour progression.
Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.
Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways.
Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma.
Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors.
Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line.
p-TSA.H2O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer.
p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.
Perioperative COX-2 and ?-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.
PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors.
pH and redox dual-responsive nanoparticles based on disulfide-containing poly(?-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Phorbol Ester TPA Modulates Chemoresistance in the Drug Sensitive Breast Cancer Cell Line MCF-7 by Inducing Expression of Drug Efflux Transporter ABCG2.
Phosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1, interleukin-1beta and cyclooxygenase-2 mRNA in human breast cancer cell lines.
Physiological COX-2 Expression in Breast Epithelium Associates with COX-2 Levels in Ductal Carcinoma in Situ and Invasive Breast Cancer in Young Women.
Pifithrin-?, an inhibitor of p53 transactivation, up-regulates COX-2 expression through an MAPK-dependent pathway.
Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features.
Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.
Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study.
Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice.
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.
Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system.
Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.
Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.
Presenilin 1/gamma-secretase is associated with cadmium-induced E-cadherin cleavage and COX-2 gene expression in T47D breast cancer cells.
Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.
Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2.
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Prognostic factors in Hungarian breast cancer patients.
Prognostic impact of cyclooxygenase-2 in breast cancer.
Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
Prognostic Significance of Cyclooxygenase-2 and Response to Chemotherapy in Invasive Ductal Breast Carcinoma Patients by Real Time Surface Plasmon Resonance Analysis.
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy.
Prognostic Significance of Prostaglandin-Endoperoxide Synthase-2 Expressions in Human Breast Carcinoma: A Multiomic Approach.
Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression.
Proliferative responses of normal human mammary and MCF-7 breast cancer cells to linoleic acid, conjugated linoleic acid and eicosanoid synthesis inhibitors in culture.
Promoter methylation regulates cyclooxygenase expression in breast cancer.
Prostaglandin E Receptor EP1 Suppresses Breast Cancer Metastasis and Is Linked to Survival Differences and Cancer Disparities.
Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis.
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.
Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4.
Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients.
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
Prostaglandin E2 induces CYP1B1 expression via ligand-independent activation of the ERalpha pathway in human breast cancer cells.
Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis.
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Prostaglandin metabolising enzymes and PGE2 are inversely correlated with vitamin D receptor and 25(OH)2D3 in breast cancer.
Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines.
Prostaglandin synthetase and prostaglandin E2 levels in human breast carcinoma.
Prostaglandins in human breast cancer. Identification of a cytosolic prostaglandin-9-keto-reductase activity.
Protective effects of dendrosomal curcumin on an animal metastatic breast tumor.
Proteomic profiling of cancer stem cells derived from primary tumors of HER2/Neu transgenic mice.
PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer.
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
Quercetin Suppresses Cyclooxygenase-2 Expression and Angiogenesis through Inactivation of P300 Signaling.
Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor.
Reduced expression of cyclooxygenase-2 in primary breast cancer.
Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors.
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer.
Reduced uptake of the proliferation-seeking radiotracer technetium-99m-labelled pentavalent dimercaptosuccinic acid in a 47-year-old woman with severe breast epithelial hyperplasia taking ibuprofen: a case report.
Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors.
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis.
Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.
Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches.
Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer.
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance.
Relationship of the suppression of macrophage mediated tumor cytotoxicity in conjunction with secretion of prostaglandin from the macrophages of breast cancer patients.
Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells.
RhoGDI deficiency induces constitutive activation of Rho GTPases and COX-2 pathways in association with breast cancer progression.
Role of Aspirin in Breast Cancer Survival.
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.
Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell Line.
Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer.
Role of cyclooxygenase-2 in breast cancer.
Role of cyclooxygenase-2 in colorectal cancer.
Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells.
Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.
Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast.
Roles of ERK and p38 mitogen-activated protein kinases in phorbol ester-induced NF-kappaB activation and COX-2 expression in human breast epithelial cells.
Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer.
Roles of the cyclooxygenase 2-matrix metalloproteinase 1 pathway in brain metastasis of breast cancer.
Rottlerin enhances IL-1?-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cells.
Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression.
Selective association of peroxiredoxin 1 with genomic DNA and COX-2 upstream promoter elements in estrogen receptor negative breast cancer cells.
Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer.
Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk.
Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer.
Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy.
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Silencing of COX-2 by RNAi modulates epithelial-mesenchymal transition in breast cancer cells partially dependent on the PGE2 cascade.
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells.
Silibinin and Paclitaxel Cotreatment Significantly Suppress the Activity and Lung Metastasis of Triple Negative 4T1 Mammary Tumor Cell in Mice.
Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells.
Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells.
Soya isoflavones suppress phorbol 12-myristate 13-acetate-induced COX-2 expression in MCF-7 cells.
ST3Gal III modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules.
Stable transfection of estrogen receptor-alpha suppresses expression of cyclooxygenase-2 and vascular endothelial growth factor-C in MDA-MB-231 breast cancer cells.
Starfish polysaccharides downregulate metastatic activity through the MAPK signaling pathway in MCF-7 human breast cancer cells.
Stephania delavayi Diels. inhibits breast carcinoma proliferation through the p38 MAPK/NF-?B/COX-2 pathway.
Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients.
Structure Based Design and Synthesis of Peptide Inhibitor of Human LOX-12: In Vitro and In Vivo Analysis of a Novel Therapeutic Agent for Breast Cancer.
Studies of postpartum mammary gland involution reveal novel pro-metastatic mechanisms.
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Study on cow ghee versus soybean oil on 7,12-dimethylbenz(a)-anthracene induced mammary carcinogenesis & expression of cyclooxygenase-2 & peroxisome proliferators activated receptor-? in rats.
Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy.
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9.
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition.
Suppression of inflammatory cascade is implicated in methyl amooranin-mediated inhibition of experimental mammary carcinogenesis.
Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Survival effects of cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast cancer.
Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
Suspension state promotes metastasis of breast cancer cells by up-regulating cyclooxygenase-2.
Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
Synergistic Antiproliferative Effects of Combined ? -Tocotrienol and PPAR ? Antagonist Treatment Are Mediated through PPAR ? -Independent Mechanisms in Breast Cancer Cells.
Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
Synthesis of Hybrids of Dihydropyrimidine and Pyridazinone as potential anti-Breast Cancer agents.
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer.
Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells.
Targeting of COX-2 expression by recombinant adenovirus shRNA attenuates the malignant biological behavior of breast cancer cells.
Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population.
Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferation.
The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines.
The Cyclooxygenase-2 (PTGS2) 8473T>C Polymorphism is Associated with Breast Cancer Risk.
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
The direct inhibition of prostaglandin synthetase of human breast cancer tumor tissue by tamoxifen.
The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines.
The effect of NSAIDs exposure on breast cancer risk in female patients with autoimmune diseases.
The expression of inflammatory markers and their potential influence on efflux transporters in drug-resistant mesial temporal lobe epilepsy tissue.
The importance of COX-2 expression as prognostic factor in early breast cancer.
The Inhibitory Effect of Roasted Licorice Extract on Human Metastatic Breast Cancer Cell-Induced Bone Destruction.
The Licorice Flavonoid Isoliquiritigenin Suppresses Phorbol Ester-induced Cyclooxygenase-2 Expression in the Non-tumorigenic MCF-10A Breast Cell Line.
The malignant phenotype of breast cancer cells is reduced by COX-2 silencing.
The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.
The potential role of cyclooxygenase-2 (COX-2) during early breast cancer therapy.
The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients.
The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia.
The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
The role of COX-2 inhibition in breast cancer treatment and prevention.
The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition.
The role of cyclooxygenase-2 in breast cancer: review.
The role of cyclooxygenase-2-dependent signaling via cyclic AMP response element activation on aromatase up-regulation by o,p'-DDT in human breast cancer cells.
The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer.
The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.
Thromboxane production by platelets during tumor cell-induced platelet activation.
Tpl-2/cot and cox-2 in breast cancer.
Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
Tristetraprolin: a novel mediator of the anticancer properties of resveratrol.
Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
Two Novel tri-aryl Derivatives Attenuate the Invasion- Promoting Effects of Stromal Mesenchymal Stem Cells on Breast Cancer.
Understanding the tumour microenvironment communication network from a NOS2/COX2 perspective.
Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.
Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation.
Urinary prostaglandin E2 metabolite and breast cancer risk.
Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Postmenopausal Breast Cancer Incidence.
Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study.
Valuing Bioactive Lipids from Green, Red and Brown Macroalgae from Aquaculture, to Foster Functionality and Biotechnological Applications.
Virtual screening of the multi-gene regulatory molecular mechanism of Si-Wu-tang against non-triple-negative breast cancer based on network pharmacology combined with experimental validation.
Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice.
Vitamin E and breast cancer.
[Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism]
[Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats]
[Clinicopathologic significance of cyclooxygenase-2 mRNA expression in human breast carcinoma]
[COX and study of cancer therapy]
[Cox-2 and CD105 expression in breast cancer and disease-free survival.]
[Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials]
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]
[Effect of lupeol on migration and invasion of human breast cancer MDA-MB-231 cells and its mechanism].
[Expression of the cyclooxygenase-2 gene in human breast carcinoma]
[Flow cytometric quantitative analysis of multiple tumor suppressor gene 1 (MTS1) and cyclooxygenase-2 (COX-2) gene expressions in invasive breast cancers and their clinical significance]
[Inhibitory effects of Aspisol on growth of transplanted breast cancer in C3H mice]
[Neoplastic effect of indomethacin in N-methyl-N-nitrosourea induced mammary carcinogenesis in female rats].
[Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues]
[The clinical significance of expression of cyclooxygenase-2 gene in breast cancer]
[The connection of miR-21 and miR-155 with regulation of 15-HPGDH mRNA in human breast cancer cells].
[The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer]
[The effect of selective cyclooxygenase-2 inhibitor nimesulide on breast cancer induced by dimethylbenzoic acid in rats]
[The effects of celecoxib on mammary tumorigenesis and aging in HER2/neu transgenic mice]
[The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer]
Breast Neoplasms, Male
Survivin and COX-2 expression in male breast carcinoma.
Bronchial Hyperreactivity
New antiasthmatic drugs from traditional medicine?
Bronchial Spasm
Arachidonic acid metabolism and inhibition of cyclooxygenase in platelets from asthmatic subjects with aspirin intolerance.
Aspirin-exacerbated respiratory disease: evaluation and management.
Differential effects of thiopental on methacholine- and serotonin-induced bronchoconstriction in dogs.
Increased excretion of leukotriene E4 during aspirin-induced asthma.
Labetalol protects against the potentiation by propranolol of the bronchospasm to norepinephrine in guinea-pigs.
Mechanisms of aspirin sensitivity.
Near-fatal bronchospasm in an asthmatic patient following ingestion of flurbiprofen. A case report.
Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease.
Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease.
Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach.
Severe bronchospasm after parenteral parecoxib: cyclooxygenase-2 inhibitors: not the answer yet.
SRS-A mediated bronchospasm by pharmacologic modification of lung anaphylaxis in vivo.
The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation.
The influence of misoprostol (synthetic analogue of prostaglandin E1) on aspirin-induced bronchoconstriction in aspirin-sensitive asthma.
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
[COX-2 Inhibitors for the management of postoperative pain]
[Iatrogenic drug-induced bronchospasm, cough, and bronchiolitis. Etiologic and physiopathologic aspects]
[Role of arachidonic acid (ETE) and its metabolites in the pathogenesis of bronchial spasm. I. Metabolites formed under the effect of cyclooxygenase]
[The influence of misoprostol on post-aspirin bronchoconstriction in patients with aspirin sensitive asthma]
Bronchiectasis
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Bronchiolitis
Cyclooxygenase-2 expression in experimental post-transplant obliterative bronchiolitis.
Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology.
Bronchitis, Chronic
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Involvement of mitogen-activated protein kinase activation in cyclooxygenase-2 and transforming growth factor-? production in alveolar macrophage from chronic bronchitis rats.
Prostanoids and cough response to capsaicin in asthma and chronic bronchitis.
[Effects of mangiferin on cytokines in rats with chronic bronchitis and expression of macrophage COX-2 in mice].
[Thromboxane A2 could be involved in bronchial hyperresponsiveness to methacholine in asthmatic subjects but not in bronchitic subjects]
Bronchopneumonia
5-lipoxygenase and cyclooxygenase-2 in porcine parasitic bronchopneumonia: immunohistochemical and biochemical investigations.
Bronchopulmonary Dysplasia
Cyclooxygenase-2 in human perinatal lung.
Cyclooxygenase-2 in newborn hyperoxic lung injury.
Cyclooxygenase-2 inhibition partially protects against 60% O2 -mediated lung injury in neonatal rats.
Iloprost attenuates hyperoxia-mediated impairment of lung development in newborn mice.
Brucellosis
COX-2 Inhibition Reduces Brucella Bacterial Burden in Draining Lymph Nodes.
Prostaglandin I2 (PGI2) inhibits Brucella abortus internalization in macrophages via PGI2 receptor signaling, and its analogue affects immune response and disease outcome in mice.
Burkitt Lymphoma
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells.
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
Bursitis
Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder.
Inflammatory cytokines are overexpressed in the subacromial bursa of frozen shoulder.
Stromal cell-derived factor 1 (SDF-1, CXCL12) is increased in subacromial bursitis and downregulated by steroid and nonsteroidal anti-inflammatory agents.
Candidemia
TNF-alpha and cyclooxygenase metabolites do not modulate C. albicans septic shock with disseminated candidiasis.
Candidiasis
TNF-alpha and cyclooxygenase metabolites do not modulate C. albicans septic shock with disseminated candidiasis.
Capsule Opacification
Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.
Carcinogenesis
15-Deoxy-?12,14-prostaglandin J2 Induces Epithelial-to-mesenchymal Transition in Human Breast Cancer Cells and Promotes Fibroblast Activation.
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
3,5-Disubstituted Isoxazole Derivatives: Potential Inhibitors of Inflammation and Cancer.
5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis.
5-deoxykaempferol plays a potential therapeutic role by targeting multiple signaling pathways in skin cancer.
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
5-methoxyindole metabolites of L-tryptophan: control of COX-2 expression, inflammation and tumorigenesis.
6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1.
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population.
A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid.
A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats.
A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression.
A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters.
A Genetic Variant in 3'-Untranslated Region of Cyclooxygenases-2 Gene Is Associated with Risk of Gastric Cancer in a Chinese Population.
A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice.
A Mechanism by which Ergosterol Inhibits the Promotion of Bladder Carcinogenesis in Rats.
A mechanistic study of cigarette smoke and cyclooxygenase-2 on proliferation of gastric cancer cells.
A new cyclo-oxygenase-2 gene variant in the Han Chinese population is associated with an increased risk of gastric carcinoma.
A newly synthesized compound, 4'-geranyloxyferulic acid-N(omega)-nitro-l-arginine methyl ester suppresses inflammation-associated colorectal carcinogenesis in male mice.
A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer.
A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection.
A positive feedback loop between STAT3 and cyclooxygenase-2 gene may contribute to Helicobacter pylori-associated human gastric tumorigenesis.
A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway.
A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2.
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis.
A role for cyclooxygenase-2 in ultraviolet light-induced skin carcinogenesis.
A selective cyclooxygenase-2 inhibitor (Etodolac) prevents spontaneous biliary tumorigenesis in a hamster bilioenterostomy model.
A selective cyclooxygenase-2 inhibitor prevents inflammation-related squamous cell carcinogenesis of the forestomach via duodenogastric reflux in rats.
Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia.
Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas.
Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice.
Acetyl-11-keto-?-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/ cyclooxygenase-2 signaling pathway.
Actinic cheilitis: Epithelial expression of COX-2 and its association with mast cell tryptase and PAR-2.
Activating protein 1-mediated cyclooxygenase-2 expression is independent of N-terminal phosphorylation of c-Jun.
Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis.
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.
Activation of platelet-activating factor receptor in SZ95 sebocytes results in inflammatory cytokine and prostaglandin E production.
Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells.
Administration of Metabiotics Extracted From Probiotic Lactobacillus rhamnosus MD 14 Inhibit Experimental Colorectal Carcinogenesis by Targeting Wnt/?-Catenin Pathway.
Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate.
Ajoene, a natural product with non-steroidal anti-inflammatory drug (NSAID)-like properties?
Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis.
Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.
Altered prostanoid signaling contributes to increased skin tumorigenesis in tpl2 knockout mice.
An immunohistochemical study of cyclooxygenase (COX)-2 expression in endocrine tumors of the pancreas.
An increased CD25-positive intestinal regulatory T-lymphocyte population is dependent on Cox-2 activity in the Apc (Min/+) model.
An inflammatory mediator, prostaglandin E2, in colorectal cancer.
An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
Analysis of Cox-2 expression in Wilms' tumor.
Analysis of cyclooxygenase expression in human colorectal adenomas.
Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells.
Angiotensin II bi-directionally regulates cyclooxygenase-2 expression in intestinal epithelial cells.
Anisomycin induces COX-2 mRNA expression through p38(MAPK) and CREB independent of small GTPases in intestinal epithelial cells.
Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase.
Anti-cancer and anti-hepatitis C virus NS5B polymerase activity of etodolac 1,2,4-triazoles.
Anti-carcinogenic properties of curcumin on colorectal cancer.
Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis.
Anti-Inflammatory Mechanism Involved in Pomegranate-Mediated Prevention of Breast Cancer: the Role of NF-?B and Nrf2 Signaling Pathways.
Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis.
Anti-metastatic Action of Non-steroidal Anti-inflammatory Drugs.
Anti-Proliferative and Apoptotic Effects of Etoricoxib, a Selective COX-2 Inhibitor, on 1,2-Dimethylhydrazine Dihydrochloride-Induced Colon Carcinogenesis.
Anti-Tumor Mechanisms of Novel 3-(4-Substituted Benzyl)-5-Isopropil-5- Phenylhydantoin Derivatives in Human Colon Cancer Cell Line.
Antidepressants, eicosanoids and the prevention and treatment of cancer. A review.
Antidepressants, prostaglandins and the prevention and treatment of cancer.
Antineoplastic effect of a novel chemopreventive agent, neokestose, on the Caco-2 cell line via inhibition of expression of nuclear factor-?B and cyclooxygenase-2.
Antiproliferative activity of guava leaf extract via inhibition of prostaglandin endoperoxide H synthase isoforms.
Antiproliferative and anti-inflammatory properties of diindolylmethane and lupeol against N-butyl-N-(4-hydroxybutyl) nitrosamine induced bladder carcinogenesis in experimental rats.
Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2.
Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Antitumor Activities of Ethyl Acetate Extracts from Selaginella doederleinii Hieron In Vitro and In Vivo and Its Possible Mechanism.
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Antitumor effect of a generation 4 polyamidoamine dendrimer/cyclooxygenase-2 antisense oligodeoxynucleotide complex on breast cancer in vitro and in vivo.
Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Antitumor promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin.
Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.
Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice.
Apigenin prevents UVB-induced cyclooxygenase 2 expression: coupled mRNA stabilization and translational inhibition.
Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells.
Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer.
Aspirin may modify tumor microenvironment via antiplatelet effect.
Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).
Assessment of cyclooxygenase-1 and 2 gene expression levels in chronic autoimmune thyroiditis, papillary thyroid carcinoma and nontoxic nodular goitre.
Association Between COX-2 Expression and Effectiveness of COX-2 Inhibitors in a Phase II Trial in Patients with Metastatic Colorectal Adenocarcinoma.
Association between Cyclooxygenase expression and colorectal adenoma characteristics.
Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.
Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis.
Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation.
Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population.
Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer.
Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2.
Avenanthramides inhibit proliferation of human colon cancer cell lines in vitro.
Azoxymethane protects intestinal stem cells and reduces crypt epithelial mitosis through a COX-1-dependent mechanism.
Barrett's Esophagus.
Barrett's esophagus: chemoprevention.
BCL?3 promotes cyclooxygenase?2/prostaglandin E2 signalling in colorectal cancer.
Benzo[a]pyrene diol-epoxide (B[a]PDE) upregulates COX-2 expression through MAPKs/AP-1 and IKKbeta/NF-kappaB in mouse epidermal Cl41 cells.
Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells.
beta-Carotene downregulates the steady-state and heregulin-alpha-induced COX-2 pathways in colon cancer cells.
Beta-Catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3'-UTR.
Beta-ionone-inhibited proliferation of breast cancer cells by inhibited COX-2 activity.
Beyond the scalpel: targeting hedgehog in skin cancer prevention.
Bile acid induces cyclo-oxygenase-2 expression in cultured human pharyngeal cells: a possible mechanism of carcinogenesis in the upper aerodigestive tract by laryngopharyngeal reflux.
Bile acid promotes the proliferation of squamous cell carcinoma of the esophagus, independent of its inducing COX-2 expression.
Bile acids are multifunctional modulators of the Barrett's carcinogenesis.
Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.
Bile duct cyst as precursor to biliary tract cancer.
Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.
Biological effects of selective COX-2 inhibitor NS398 on human glioblastoma cell lines.
Bisphenol A-induced epithelial to mesenchymal transition is mediated by cyclooxygenase-2 up-regulation in human endometrial carcinoma cells.
Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice.
Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro.
Bovine milk-derived ?-lactalbumin inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sodium sulfate-treated mice.
Breast cancer--new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?
Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition.
c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells.
C/EBPbeta is over-expressed in gastric carcinogenesis and is associated with COX-2 expression.
Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression.
Caffeine promotes ultraviolet B-induced apoptosis in human keratinocytes without complete DNA repair.
Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer?
Cancer chemoprevention drug targets.
Cancer chemoprevention through interruption of multistage carcinogenesis. The lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer.
Cancer morphogenesis: role of mitochondrial failure.
Cancer prevention: a new era beyond cyclooxygenase-2.
Cancer preventive phytochemicals as speed breakers in inflammatory signaling involved in aberrant COX-2 expression.
Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.
Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer.
Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway.
Carcinogenetic process in gallbladder mucosa with pancreaticobiliary maljunction (Review).
Carcinogenic Potential of Biliary Epithelium of Congenital Choledochal Cyst Model in Rats: A Special Reference to HDAC Expression.
Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis).
Caveolin-1 facilitates cyclooxygenase-2 protein degradation.
CD24 Expression Is Increased in 5-Fluorouracil-Treated Esophageal Adenocarcinoma Cells.
Celecoxib alleviates zinc deficiency-promoted colon tumorigenesis through suppressing inflammation.
Celecoxib and melatonin in prevention of female rat mammary carcinogenesis.
Celecoxib and radiation therapy in non-small-cell lung cancer.
Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro.
Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway.
Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro.
Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Celecoxib Loaded In-Situ Provesicular Powder and Its In-Vitro Cytotoxic Effect for Cancer Therapy: Fabrication, Characterization, Optimization and Pharmacokinetic Evaluation.
Celecoxib mitigates cigarette smoke induced oxidative stress in mice.
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
Cell cycle regulation and apoptotic cell death in experimental colon carcinogenesis: intervening with cyclooxygenase-2 inhibitors.
Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
Cell-type-specific roles for COX-2 in UVB-induced skin cancer.
Cellular density-dependent down-regulation of EP4 prostanoid receptors via the up-regulation of hypoxia-inducible factor-1? in HCA-7 human colon cancer cells.
Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity.
Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity.
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.
Characterization of the Prostaglandin E2 path way in a Rat Model of Esophageal Adenocarcinoma.
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.
Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats.
Chemoprevention in colorectal neoplasias: what is practical and feasible?
Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention.
Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors.
Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2.
Chemoprevention of colon cancer by Korean food plant components.
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells.
Chemoprevention of colon carcinogenesis by phenylethyl-3-methylcaffeate.
Chemoprevention of colonic tumorigenesis by dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice.
Chemoprevention of colorectal cancer by non-steroidal anti-inflammatory drugs.
Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back.
Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro.
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Chemoprevention of gastric cancer by celecoxib in rats.
Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor.
Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study.
Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible?
Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers.
Chemoprevention of lung cancer.
Chemoprevention of mammary carcinogenesis in female rats by rofecoxib.
Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor.
Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Chemopreventive activity of grape juice concentrate (G8000TM) on rat colon carcinogenesis induced by azoxymethane.
Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death.
Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours.
Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis.
Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane.
Chemopreventive effect of saikosaponin-d on diethylinitrosamine-induced hepatocarcinogenesis: involvement of CCAAT/enhancer binding protein ? and cyclooxygenase-2.
Chemopreventive effect of Toona sinensis leaf extract on 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch squamous cell carcinogenesis.
Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.
Chemopreventive Effects of Eryngium foetidum L. Leaves on COX-2 Reduction in Mice Induced Colorectal Carcinogenesis.
Chemopreventive Effects of Licorice and Its Components.
Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, against PhIP-induced mammary carcinogenesis.
Chemopreventive effects of nonsteroidal anti-inflammatory drugs on 1,2-dimethylhydrazine-induced colon carcinogenesis in rats.
Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2.
Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis.
Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways.
Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun.
Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer.
cis-9,trans-11-conjugated linoleic acid down-regulates phorbol ester-induced NF-kappaB activation and subsequent COX-2 expression in hairless mouse skin by targeting IkappaB kinase and PI3K-Akt.
Clinical and prognosis relevance of COX-2 expression in Tunisian patients with primary gastric adenocarcinoma.
Clinical evidence of the relationship between aspirin and breast cancer risk (review).
Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours.
Clinical potential of cyclo-oxygenase-2 inhibitors.
Clinicopathologic significance of expression of cyclooxygenase-2 in human esophageal squamous cell carcinoma.
Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma.
Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.
Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas.
Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.
Coenzyme Q10 attenuated DMH-induced precancerous lesions in SD rats.
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma.
Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
Colon Macrophages Polarized by Commensal Bacteria Cause Colitis and Cancer through the Bystander Effect.
Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation.
Combination between Taxol-Encapsulated Liposomes and Eruca sativa Seed Extract Suppresses Mammary Tumors in Female Rats Induced by 7,12 Dimethylbenz(?)anthracene.
Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells.
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement.
Combined COX-2/PPAR? Expression as Independent Negative Prognosticator for Vulvar Cancer Patients.
Combined effect of genetic polymorphisms in phase I and II biotransformation enzymes on head and neck cancer risk.
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Comparative effects of piroxicam and esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene in rats on high- and low-fat diets.
Comparative effects of prostaglandin H synthase-catalyzed binding of two 5-nitrofuran urinary bladder carcinogens.
Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome.
Conjugated Linoleic Acid Attenuates Cyclooxygenase-2 Transcriptional Activity via an Anti-AP-1 Mechanism in MCF-7 Breast Cancer Cells.
Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.
Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.
Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan.
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.
Coordinated Increased Expression of Cyclooxygenase2 and Nuclear Factor ?B Is a Steady Feature of Urinary Bladder Carcinogenesis.
Coordinated upregulation of COX-2 and NF-kappaB is a steady feature of laryngeal carcinogenesis.
Cordycepin inhibits lipopolysaccharide-induced cell migration and invasion in human colorectal carcinoma HCT-116 cells through down-regulation of prostaglandin E2 receptor EP4.
Correlation of 15-prostagladin dehydrogenase expression with clinicopathological factors and survival rate in gastric adenocarcinoma.
Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome.
Correlative expression of cyclooxygenase-1 (cox-1) and human epidermal growth factor receptor type-2 (her-2) in endometrial cancer.
COX selectivity and animal models for colon cancer.
COX-2 - a target for preventing hepatic carcinoma?
COX-2 and colon cancer.
COX-2 and colorectal cancer.
Cox-2 and IL-10 polymorphisms and association with squamous cell carcinoma of the head and neck in a Korean sample.
COX-2 and iNOS, good targets for chemoprevention of colon cancer.
COX-2 and p53 in human sinonasal cancer: COX-2 expression is associated with adenocarcinoma histology and wood-dust exposure.
COX-2 and prostanoid receptors: good targets for chemoprevention.
COX-2 correlates with F-box protein, Skp2 expression and prognosis in human gastric carcinoma.
COX-2 expression and effects of COX-2 inhibition in colorectal carcinomas and their liver metastases.
COX-2 expression and tumor angiogenesis in colorectal cancer.
COX-2 expression does not correlate with microvessel density in breast cancer.
COX-2 expression during early lung squamous cell carcinoma oncogenesis.
COX-2 Expression in Breast Carcinoma with Correlation to Clinicopathological Parameters
COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers.
COX-2 expression in canine normal and neoplastic mammary gland.
COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray.
COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification.
Cox-2 expression in ovarian malignancies: a review of the clinical aspects.
COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome.
Cox-2 expression in retinoblastoma.
COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics.
COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.
COX-2 Forms Regulatory Loop with YAP to Promote Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells.
COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma.
COX-2 inhibition as a tool to treat and prevent colorectal cancer.
COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
COX-2 Inhibitors and Gastric Cancer.
COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.
COX-2 inhibitors and their role in gynecology.
COX-2 inhibitors for the prevention of breast cancer.
COX-2 inhibitors in cancer treatment and prevention, a recent development.
COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer.
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
COX-2 localization within plasma membrane caveolae-like structures in human lobular intraepithelial neoplasia of the breast.
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID.
COX-2 overexpression as a biomarker of early cervical carcinogenesis: A pilot study.
COX-2 overexpression in canine tumors: potential therapeutic targets in oncology.
COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis.
COX-2 Polymorphism, Use of Nonsteroidal Anti-Inflammatory Drugs, and Risk of Colon Cancer in African Americans (United States).
COX-2 polymorphisms -765G?C and -1195A?G and hepatocellular carcinoma risk.
COX-2 polymorphisms and the risk for head and neck cancer in white patients.
COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men.
COX-2 promotes mammary adipose tissue inflammation, local estrogen biosynthesis, and carcinogenesis in high-sugar/fat diet treated mice.
COX-2 rs5275 and rs689466 polymorphism and risk of lung cancer: A PRISMA-compliant meta-analysis.
COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents.
COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates.
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation.
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
COX-2, TFF1, and Src define better prognosis in young patients with gastric cancer.
COX-2, VEGF and tumour angiogenesis.
COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF).
COX-2-PGE2-EPs in gynecological cancers.
COX-2: a molecular target for colorectal cancer prevention.
COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.
COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma.
Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis.
Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Curcumin and resveratrol synergistically stimulate p21 and regulate cox-2 by maintaining adequate zinc levels during lung carcinogenesis.
Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation.
Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer.
Current application of selective COX-2 inhibitors in cancer prevention and treatment.
Cyclo-oxygenase 2 expression in laryngeal squamous cell carcinoma and its clinical correlates.
Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance.
Cyclo-oxygenase inhibition in colorectal adenomas and cancer.
Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance.
Cyclo-oxygenase-2 expression in oral squamous cell carcinoma.
Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis.
Cyclooxigenase-2 and osteopontin in gastric pre-neoplastic lesions in relation to H-pylori infection and grade of inflammation.
Cyclooxygeanse-2 promotes metastasis in osteosarcoma.
Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians.
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.
Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications.
Cyclooxygenase 2 expression in pterygium.
Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives.
Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice.
Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells.
Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention.
Cyclooxygenase 2: a molecular target for cancer prevention and treatment.
Cyclooxygenase 2: from inflammation to carcinogenesis.
Cyclooxygenase 2: understanding the pathophysiological role through genetically altered mouse models.
Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?
Cyclooxygenase as a target in chemoprevention by probiotics during 1,2-dimethylhydrazine induced colon carcinogenesis in rats.
Cyclooxygenase expression in the gallbladder.
Cyclooxygenase inhibition in cancer prevention and treatment.
Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts.
Cyclooxygenase inhibitors in the chemoprevention of colorectal cancer.
Cyclooxygenase isozymes in oral squamous cell carcinoma:a real-time RT-PCR study with clinic pathological correlations.
Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available?
Cyclooxygenase, cancer stem cells and DNA methylation play important roles in colorectal carcinogenesis.
Cyclooxygenase- and lipoxygenase-mediated DNA damage.
Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature.
Cyclooxygenase-1 and -2 expression in urothelial carcinomas of the urinary bladder in cows.
Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.
Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1.
Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2'-Des-methyl-sulindac Sulfide Scaffold.
Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.
Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.
Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis.
Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse.
Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas.
Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.
Cyclooxygenase-2 (COX-2) gene polymorphism in patients with differentiated thyroid carcinomas in the Turkish population
Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers.
Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
Cyclooxygenase-2 (COX-2) mediates arsenite inhibition of UVB-induced cellular apoptosis in mouse epidermal Cl41 cells.
Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers.
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer.
Cyclooxygenase-2 - An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma- An Immunohistochemical Study.
Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis.
Cyclooxygenase-2 and Bcl-2 expression in the stomach mucosa of Wistar rats exposed to Helicobacter pylori, N'-methyl- N'-nitro- N-nitrosoguanidine and bile.
Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays.
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Cyclooxygenase-2 and carcinogenesis.
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.
Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma.
Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Cyclooxygenase-2 and prostate carcinogenesis.
Cyclooxygenase-2 and skin carcinogenesis.
Cyclooxygenase-2 and the inflammogenesis of breast cancer.
Cyclooxygenase-2 and tumor biology.
Cyclooxygenase-2 downregulates inducible nitric oxide synthase in rat intestinal epithelial cells.
Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases.
Cyclooxygenase-2 expression and clinical parameters in laryngeal squamous cell carcinoma, vocal fold nodule, and laryngeal atypical hyperplasia.
Cyclooxygenase-2 expression and connection with tumor recurrence and histopathologic parameters in gastrointestinal stromal tumors.
Cyclooxygenase-2 expression and its association with thyroid lesions.
Cyclooxygenase-2 expression and its relationship with proliferation of colorectal adenomas.
Cyclooxygenase-2 expression and prostanoid biogenesis reflect clinical phenotype in human colorectal fibroblast strains.
Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma.
Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer.
Cyclooxygenase-2 expression correlates with membrane-type-1 matrix metalloproteinase expression in colorectal cancer tissue.
Cyclooxygenase-2 expression correlates with nuclear p53 accumulation in gastric carcinoma.
Cyclooxygenase-2 expression determines neo-angiogenesis in gallbladder carcinomas.
Cyclooxygenase-2 expression during carcinogenesis in the human stomach.
Cyclooxygenase-2 Expression in Animal Cancers.
Cyclooxygenase-2 expression in borderline ovarian tumors.
Cyclooxygenase-2 expression in canine appendicular osteosarcomas.
Cyclooxygenase-2 expression in canine mammary tumors.
Cyclooxygenase-2 expression in central giant cell lesion of the jaws: an immunohistochemical study.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia.
Cyclooxygenase-2 expression in chondrosarcoma.
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study .
Cyclooxygenase-2 expression in clear cell renal cell carcinoma.
Cyclooxygenase-2 expression in colorectal adenomas.
Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps.
Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection.
Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.
Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions.
Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.
Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas; correlation with intratumoral microvessel density and apoptotic index.
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.
Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis.
Cyclooxygenase-2 expression in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression.
Cyclooxygenase-2 expression in medullary thyroid carcinoma.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines.
Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms.
Cyclooxygenase-2 expression in oral tongue squamous cell carcinoma.
Cyclooxygenase-2 expression in primary Merkel cell carcinoma.
Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs.
Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression in the endometrium at the end of 2 years' continuous combined hormone replacement therapy.
Cyclooxygenase-2 expression in the gallbladder of patients with anomalous arrangement of the pancreaticobiliary duct.
Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients.
Cyclooxygenase-2 expression in thyroid neoplasms.
Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation.
Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.
Cyclooxygenase-2 expression is associated with elevated aspartate aminotransferase level in hepatocellular carcinoma.
Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas.
Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis.
Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis.
Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis.
Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia.
Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer.
Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.
Cyclooxygenase-2 Expression Is Up-regulated by 2-Aminobiphenyl in a ROS and MAPK-Dependent Signaling Pathway in a Bladder Cancer Cell Line.
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.
Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure.
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast.
Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.
Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma?
Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53.
Cyclooxygenase-2 Generates the Endogenous Mutagen trans-4-Hydroxy-2-nonenal in Enterococcus faecalis-Infected Macrophages.
Cyclooxygenase-2 in cancer: A review.
Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract.
Cyclooxygenase-2 in lung carcinogenesis and chemoprevention: Roger S. Mitchell lecture.
Cyclooxygenase-2 in oncogenesis.
Cyclooxygenase-2 in sporadic colorectal polyps: immunohistochemical study and its importance in the early stages of colorectal tumorigenesis.
Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An update on the molecular mechanisms.
Cyclooxygenase-2 induces neoplastic transformation by inhibiting p53-dependent oncogene-induced senescence.
Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells.
Cyclooxygenase-2 induction requires activation of nuclear factor of activated T-cells in Beas-2B cells after vanadium exposure and plays an anti-apoptotic role.
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression.
Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.
Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids.
Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.
Cyclooxygenase-2 inhibitors in colorectal cancer.
Cyclooxygenase-2 inhibitors in glioma therapy.
Cyclooxygenase-2 inhibitors in tumorigenesis (part I).
Cyclooxygenase-2 inhibitors in tumorigenesis (Part II).
Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway.
Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis.
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR.
Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
Cyclooxygenase-2 knockdown by RNA interference in colon cancer.
Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells.
Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines.
Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.
Cyclooxygenase-2 over-expression inhibits liver apoptosis induced by hyperglycemia.
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer.
Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.
Cyclooxygenase-2 overexpression in colorectal cancer is associated with non-polypoid growth.
Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis.
Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation.
Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
Cyclooxygenase-2 Polymorphisms and Breast Cancer Associated Risk in Pakistani Patients.
Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis.
Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents.
Cyclooxygenase-2 prevents fas-induced liver injury through up-regulation of epidermal growth factor receptor.
Cyclooxygenase-2 promoter polymorphism -899G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province.
Cyclooxygenase-2 promotes prostate cancer progression.
Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.
Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma.
Cyclooxygenase-2 protein expression modulates cell proliferation and apoptosis in solid ameloblastoma and odontogenic keratocyst. An immunohistochemical study.
Cyclooxygenase-2 regulates the degree of apoptosis by modulating bcl-2 protein in pleomorphic adenoma and mucoepidermoid carcinoma of the parotid gland.
Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors.
Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis.
Cyclooxygenase-2, a Potential Therapeutic Target, Is Regulated by miR-101 in Esophageal Squamous Cell Carcinoma.
Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas.
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.
Cyclooxygenase-2: a novel target for cancer chemotherapy?
Cyclooxygenase-2: a potential target in breast cancer.
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Cyclooxygenases and colon cancer.
Cyclooxygenases in hepatocellular carcinoma.
Cyclooxygenases: Mediators of UV-Induced Skin Cancer and Potential Targets for Prevention.
Cyclooxygenases: structural and functional insights.
Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2.
Cytoplasmic PPAR? is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers.
Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas.
Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis.
Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells.
Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.
Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.
Deletion of macrophage migration inhibitory factor inhibits murine oral carcinogenesis: Potential role for chronic pro-inflammatory immune mediators.
Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MKK4 and PI-3 kinase.
Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition.
Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids.
Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Detouring the Undesired Route of Helicobacter pylori-Induced Gastric Carcinogenesis.
Development of invasive follicular cell carcinomas in a rat thyroid carcinogenesis model: biological impact of capsular inflammation and reduced cyclooxygenase-2 expression.
Development of PET Radioligands Targeting COX-2 for Colorectal Cancer Staging, a Review of in vitro and Preclinical Imaging Studies.
Diallyl trisulfide inhibits phorbol ester-induced tumor promotion, activation of AP-1, and expression of COX-2 in mouse skin by blocking JNK and Akt signaling.
Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.
Diclofenac, a selective COX-2 inhibitor, inhibits DMH-induced colon tumorigenesis through suppression of MCP-1, MIP-1? and VEGF.
Diet and cancer prevention studies in p53-deficient mice.
Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis.
Dietary Fat, Fatty Acids and Breast Cancer.
Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats.
Dietary Mixed Cereal Grains Ameliorate the Azoxymethane and Dextran Sodium Sulfate-Induced Colonic Carcinogenesis in C57BL/6J Mice.
Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk.
Dietary prevention of Helicobacter pylori-associated gastric cancer with kimchi.
Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention.
Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma.
Differential combined effect of COX inhibitors on cell survival suppressed by sorafenib in the HepG2 cell line.
Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines.
Differential effects of theaflavin monogallates on cell growth, apoptosis, and Cox-2 gene expression in cancerous versus normal cells.
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis.
Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma.
Differential Inhibitory Effects of the Polyphenol Ellagic Acid on Inflammatory Mediators NF-kappaB, iNOS, COX-2, TNF-alpha, and IL-6 in 1,2-Dimethylhydrazine-Induced Rat Colon Carcinogenesis.
Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam.
Differential protein expression in the epidermis of wild-type and COX-2 transgenic mice.
Differential stromal and epithelial localization of cyclooxygenase-2 (COX-2) during colorectal tumorigenesis.
Differential targeting of protein kinase B in cell death induced by sulindac and its metabolite sulindac sulfide.
Dihydroxystilbenes prevent azoxymethane/dextran sulfate sodium-induced colon cancer by inhibiting colon cytokines, a chemokine, and programmed cell death-1 in C57BL/6J mice.
Direct Sequencing of Cyclooxygenase-2 (COX-2) Revealed an Intronic Variant rs201231411 in Iranian Patients with Pancreatic Cancer.
Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia.
Discovery of lesser known flavones as inhibitors of NF-?B signaling in MDA-MB-231 breast cancer cells--A SAR study.
Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells.
DNA adducts formed by ring-oxidation of the carcinogen 2-naphthylamine with prostaglandin H synthase in vitro and in the dog urothelium in vivo.
DNA repair Ku proteins in gastric cancer cells and pancreatic acinar cells.
DNA-hypomethylating agent, 5'-azacytidine, induces cyclooxygenase-2 expression via the PI3-kinase/Akt and extracellular signal-regulated kinase-1/2 pathways in human HT1080 fibrosarcoma cells.
Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?
Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Docosahexaenoic acid inhibits insulin-induced activation of sterol regulatory-element binding protein 1 and cyclooxygenase-2 expression through upregulation of SIRT1 in human colon epithelial cells.
Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR.
Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-?B and an inflammatory protein, iNOS.
Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.
Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer.
Down-regulation of COX-2 activity by 1?,25(OH)2D3 is VDR dependent in endothelial cells transformed by Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.
Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth.
Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer.
Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer.
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids.
Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth.
Dysregulated post-transcriptional control of COX-2 gene expression in cancer.
Dysregulation of cellular signaling in gastric cancer.
E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis.
Early upregulation of cyclooxygenase-2 in human papillomavirus type 16 and telomerase-induced immortalization of human esophageal epithelial cells.
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers.
Effect of azoxymethane and curcumin on transcriptional levels of cyclooxygenase-1 and -2 during initiation of colon carcinogenesis.
Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer.
Effect of cyclooxygenase-2 antisense oligodeoxyribonucleotides in A-549 lung cancer cells.
Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model.
Effect of flurbiprofen and 16,16-dimethyl prostaglandin E2 on gastrointestinal tumorigenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats: glandular epithelium of stomach and duodenum.
Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer.
Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis.
Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands.
Effect of LY293111 in combination with gemcitabine in colonic cancer.
Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells.
Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial.
Effect of pertussis toxin and herbimycin A on proteinase-activated receptor 2-mediated cyclooxygenase 2 expression in Helicobacter pylori-infected gastric epithelial AGS cells.
Effect of prostaglandin E1 on vascular endothelial growth factor production by human macrophages and colon cancer cells.
Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat.
Effect of sphingosine kinase 1 inhibition on blood pressure.
Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat.
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Effective suppression of azoxymethane-induced aberrant crypt foci formation in mice with citrus peel flavonoids.
Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells.
Effects of adlay on azoxymethane-induced colon carcinogenesis in rats.
Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis.
Effects of C-Phycocyanin on the representative genes of tumor development in mouse skin exposed to 12-O-tetradecanoyl-phorbol-13-acetate.
Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.
Effects of cyclooxygenase-2 antisense vector on proliferation of human cholangiocarcinoma cells.
Effects of cyclooxygenase-2 gene silencing on the biological behavior of SKOV3 ovarian cancer cells.
Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.
Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane.
Effects of Genetic and Pharmacologic Inhibition of COX-2 on Colitis-associated Carcinogenesis in Mice.
Effects of IL-1? on the proliferation and apoptosis of gastric epithelial cells and acid secretion from isolated rabbit parietal cells.
Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial.
Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors.
Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.
Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells.
Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells.
Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells.
Effects of rich-in-fat diets and highly selective COX-2 inhibitors on 7,12-dimethylbenz-(A)-anthracene-induced tumor growth.
Effects of selective estrogen receptor modulators and genistein on the expression of ERalpha/beta and COX-1/2 in ovarectomized mouse uteri.
Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines.
Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet.
EGFR Signaling Is Required for TGF-beta1 Mediated COX-2 Induction in Human Bronchial Epithelial Cells.
EGFR, HER-2 and COX-2 levels in colorectal cancer.
Eicosanoid profiling in colon cancer: Emergence of a pattern.
Eicosanoid signaling in carcinogenesis of colorectal cancer.
Eicosanoids and HB-EGF/EGFR in cancer.
EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and ?-catenin activation.
Elevated cyclooxygenase-2 expression in patients with early gastric cancer in the gastric pylorus.
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.
Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for COX-2 induction by areca quid ingredients in oral keratinocytes.
Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ?mplications for cholangiocarcinogenesis.
Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors.
Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase.
Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Enhancement of experimental colon cancer by genistein.
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells.
EP4 upregulation of Ras signaling and feedback regulation of Ras in human colon tissues and cancer cells.
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.
Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma.
Epithelial-Specific Deletion of 11?-HSD2 Hinders Apcmin/+ Mouse Tumorigenesis.
Essential role of c-Jun induction and coactivator p300 in epidermal growth factor-induced gene expression of cyclooxygenase-2 in human epidermoid carcinoma A431 cells.
Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
Ethanol extracts of Allium sp. regulate cyclooxygenase-2 and E-cadherin expression in gastric cancer MKN74 cell line and enhance doxorubicin toxicity.
Ethyl acetate fraction of adlay bran ethanolic extract inhibits oncogene expression and suppresses DMH-induced preneoplastic lesions of the colon in F344 rats through an anti-inflammatory pathway.
Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells.
Evaluation of chemopreventive response of two cycloxygenase-2 inhibitors, etoricoxib and diclofenac in rat colon cancer using FTIR and NMR spectroscopic techniques.
Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.
Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line.
Evaluation of the contribution of cyclooxygenase 2 genotypes to breast cancer in Taiwan.
Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence.
Exogenous hydrogen sulfide promotes hepatocellular carcinoma cell growth by activating the STAT3-COX-2 signaling pathway.
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Experimental models of gene-environment interaction for cancer chemoprevention studies.
Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy.
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers.
Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas.
Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors.
Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: a retrospective study.
Expression and regulation of cyclooxygenase-2 in normal and neoplastic canine keratinocytes.
Expression and significance of cyclooxygenase 2 gene in lung cancer.
Expression of 15-PGDH is downregulated by COX-2 in gastric cancer.
Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.
Expression of COX-2 and p53 in juvenile polyposis coli and its correlation with adenomatous changes.
Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma.
Expression of COX-2 in stomach cancers and its relation to their biological features.
Expression of COX-2 in Stomach Carcinogenesis.
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.
Expression of COX-2 is increased with age in papillary thyroid cancer.
Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis.
Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer.
Expression of cyclooxygenase-1 and -2 and clinicopathologic features of colorectal cancer in northern Thailand.
Expression of cyclooxygenase-1 and -2 in canine nasal carcinomas.
Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma.
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.
Expression of cyclooxygenase-2 (COX-2) in colorectal adenocarcinoma: an immunohistochemical and histopathological study.
Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial lesions.
Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas.
Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa.
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?
Expression of cyclooxygenase-2 and nitrotyrosine in human gastric mucosa before and after Helicobacter pylori eradication.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in primary central nervous system lymphomas.
Expression of cyclooxygenase-2 has no impact on survival in adenocarcinoma of the esophagogastric junction but is associated with favourable clinicopathologic features.
Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion.
Expression of cyclooxygenase-2 in colonic polyps.
Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma.
Expression of cyclooxygenase-2 in endometrial adenocarcinoma.
Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis.
Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation.
Expression of cyclooxygenase-2 in human hyperplastic gastric polyps.
Expression of cyclooxygenase-2 in malignant and benign breast tumors.
Expression of Cyclooxygenase-2 in naturally occurring bovine cutaneous fibropapillomas.
Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation.
Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression.
Expression of cyclooxygenase-2 in prostate carcinoma.
Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression.
Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells.
Expression of cyclooxygenase-2 protein in colorectal carcinomas.
Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.
Expression of Cyclooxygenase-2 Protein in Gastric Carcinogenesis.
Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma.
Expression of cysteinylLT1 receptor in human testicular cancer and growth reduction by its antagonist through apoptosis.
Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas.
Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Expression of inducible microsomal prostaglandin E synthase in local lesions of endometriosis patients.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Expression of inflammation related enzymes during experimental rat lung carcinogenesis.
Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco.
Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray.
Expression of p53, p16 and cyclooxygenase-2 in esophageal cancer with tissue microarray.
Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in Oral Squamous Cell Carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation.
Expression of prostaglandin H synthase-2 in human brain tumors.
Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells.
Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac.
Expression Patterns of Cancer Stem Cell Markers During Specific Celecoxib Therapy in Multistep Rat Colon Carcinogenesis Bioassays.
Expression Profile as Predictor of Relapse after Adjuvant Treatment in Gastric Cancer.
Expression profiles of Annexin A1, formylated peptide receptors and cyclooxigenase-2 in gastroesophageal inflammations and neoplasias.
Expression profiles of proliferative and antiapoptotic genes in sporadic and colitis-related mouse colon cancer models.
Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma.
Feedback control of cyclooxygenase-2 expression through PPARgamma.
Fermented Ganjangs (Soy Sauce and Sesame Sauce) Attenuates Colonic Carcinogenesis in Azoxymethane/Dextran Sodium Sulfate-Treated C57BL/6J Mice.
Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention.
Fluorination as tool to improve bioanalytical sensitivity and COX-2-selective antitumor activity of cobalt alkyne complexes.
Free radical scavenging and COX-2 inhibition by simple colon metabolites of polyphenols: A theoretical approach.
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.
Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer.
Functional characterization of cyclooxygenase-2 polymorphisms.
Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population.
Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma.
Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma.
Functional polymorphisms of the cyclooxygenase-2 gene and prognosis of hepatocellular carcinoma - a cohort study in Chinese people.
Functionalized magnetic nanoparticles coupled with mass spectrometry for screening and identification of cyclooxygenase-1 inhibitors from natural products.
Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha.
Gastric cancer: basic aspects.
Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells.
Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy.
Gene expression patterns of COX-1, COX-2 and iNOS in H. Pylori infected histopathological conditions.
Gene expression profiling signatures for the diagnosis and prevention of oral cavity carcinogenesis-genome-wide analysis using RNA-seq technology.
Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents.
Genetic and microenvironmental implications in prostate cancer progression and metastasis.
Genetic Deficiency of the Histamine H4-Receptor Reduces Experimental Colorectal Carcinogenesis in Mice.
Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice.
Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.
Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma.
Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study.
Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility.
Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study.
Genetic variation in the COX-2 gene and the association with prostate cancer risk.
Genetic Variations in Prostaglandin E2 Pathway Identified as Susceptibility Biomarkers for Gastric Cancer in an Intermediate Risk European Country.
Genetic-deletion of Cyclooxygenase-2 Downstream Prostacyclin Synthase Suppresses Inflammatory Reactions but Facilitates Carcinogenesis, unlike Deletion of Microsomal Prostaglandin E Synthase-1.
Genistein inhibits phorbol ester-induced NF-?B transcriptional activity and COX-2 expression by blocking the phosphorylation of p65/Rel in human mammary epithelial cells.
Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer.
Geraniol inhibits murine skin tumorigenesis by modulating COX-2 expression, Ras-ERK1/2 signaling pathway and apoptosis.
Gq protein mediates UVB-induced cyclooxygenase-2 expression by stimulating HB-EGF secretion from HaCaT human keratinocytes.
Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis.
Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention.
H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis.
Harmine combined with paclitaxel inhibits tumor proliferation and induces apoptosis through down-regulation of cyclooxygenase-2 expression in gastric cancer.
Harmine induces apoptosis and inhibits tumor cell proliferation, migration and invasion through down-regulation of cyclooxygenase-2 expression in gastric cancer.
HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells.
Helicobacter pylori eradication to prevent gastric cancer: Underlying molecular and cellular mechanisms.
Helicobacter pylori extract induces nuclear factor-kappa B, activator protein-1, and cyclooxygenase-2 in esophageal epithelial cells.
Helicobacter pylori infection in gastric cancerogenesis.
Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis.
Helicobacter pylori promotes apoptosis, activates cyclooxygenase (COX)-2 and inhibits heat shock protein HSP70 in gastric cancer epithelial cells.
Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro.
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells.
Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.
Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma.
HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.
High COX-2 expression in canine mast cell tumours is associated with proliferation, angiogenesis and decreased overall survival.
High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: a multivariate survival study.
High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer.
High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy.
High Expression of COX-2 Associated with the Depth of Invasion on Acral Melanoma by Increasing TGF-?1.
High expression of cyclooxygenase-2 in macrophages of human colonic adenoma.
High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement.
High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma.
Histopathology and expression of Ki-67 and cyclooxygenase-2 in childhood Helicobacter pylori gastritis.
HNE as an inducer of COX-2.
hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.
Homeodomain protein CDX2 regulates COX-2 expression in colorectal cancer.
Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.
Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.
Host cyclooxygenase-2 modulates carcinoma growth.
HT-29 colorectal cancer cells undergoing apoptosis overexpress COX-2 to delay ursolic acid-induced cell death.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.
Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-kappaB and AP-1: IkappaB kinase and c-Jun-N-terminal kinase as respective potential upstream targets.
Hyperbaric oxygen therapy reduces COX-2 expression in a dimethylhydrazine-induced rat model of colorectal carcinogenesis.
Hypermethylation of RAR?2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma.
Hypermethylation of tumor-related genes in tunisian patients with gastric carcinoma: Clinical and biological significance.
Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice.
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2?/COX-2.
Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
IL1?-mediated Stromal COX-2 signaling mediates proliferation and invasiveness of colonic epithelial cancer cells.
Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions.
Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation.
Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.
Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma.
Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma.
Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.
Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features.
Immunohistochemical assessment of p16, COX-2 and EGFR in HPV-positive cervical squamous intraepithelial lesions.
Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: A pilot study.
Immunohistochemical detectability of cyclooxygenase-2 expression in cells of human melanocytic skin lesions: A methodological review.
Immunohistochemical Detection of COX-2 in Feline and Canine Actinic Keratoses and Cutaneous Squamous Cell Carcinoma.
Immunohistochemical detection of Ki-67 is not associated with tumor-infiltrating macrophages and cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical evaluation of cyclooxygenase expression in corneal squamous cell carcinoma in horses.
Immunohistochemical expression of COX-2 in thyroid nodules.
Immunohistochemical Expression of Cyclooxygenase-2 (COX-2) in Feline Endometrial Adenocarcinoma and in Normal and Hyperplastic Endometria.
Immunohistochemical expression of cyclooxygenase-2 in canine ovarian carcinomas.
Immunohistochemical expression of cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival.
Immunohistochemical markers of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer.
Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line.
Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.
Impact of group IVA cytosolic phospholipase A ( 2 ) gene polymorphisms on phenotypic features of patients with familial adenomatous polyposis.
Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.
Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: Current state-of-the science.
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development.
Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
In utero and lactational exposure of DEHP increases the susceptibility of prostate carcinogenesis in male offspring through PSCA hypomethylation.
In vitro evidence of the role of COX-2 in attenuating gastric inflammation and promoting gastric carcinogenesis.
Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung.
Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer.
Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs.
Increased cyclooxygenase-2 expression in juvenile polyposis syndrome.
Increased cyclooxygenase-2 expression in large flat colorectal tumors (laterally spreading tumors).
Increased expression of COX-2 in the development of human lung cancers.
Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib.
Increased expression of cyclooxygenase-2 in first-degree relatives of gastric cancer patients.
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.
Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet.
Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.
Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer.
Increased expression of TLR-2, COX-2, and SOD-2 genes in the peripheral blood leukocytes of opisthorchiasis patients induced by Opisthorchis viverrini antigen.
Increased level of serum prostaglandin-2 in early stage of esophageal squamous cell carcinoma.
Increased oxidative stress with gene alteration in urinary bladder urothelium after the Chernobyl accident.
Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth.
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer.
Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Induction of cyclooxygenase-2 and invasiveness by transforming growth factor-beta(1) in immortalized mouse colonocytes expressing oncogenic Ras.
Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression.
Induction of cyclooxygenase-2 by bovine type I collagen in macrophages via C/EBP and CREB activation by multiple cell signaling pathways.
Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells.
Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells.
Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to G?i and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells.
Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation.
Induction of lung lesions in Wistar rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by aspirin and phenethyl isothiocyanate.
Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells.
Induction of pulmonary carcinogenesis in Wistar rats by a single dose of 9, 10 Dimethylbenz(a)anthracene (DMBA) and the chemopreventive role of Diclofenac.
Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells.
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.
Inflammation and Oral Cancer: An Update Review on Targeted Therapies.
Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale.
Inflammation as cause for scar cancers of the lung.
Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Colorectal Adenoma Patients in a Clinical Trial.
Inflammatory markers in cancer: Potential resources.
Inflammatory myofibroblastic tumor in the head and neck-a neoplasm with both tumor features and inflammation.
Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib.
Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors.
Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.
Influence of glutathione S-transferase pi and p53 expression on tumor frequency and spectrum in mice.
Influence of seasonal variation on Thymus longicaulis C. Presl chemical composition and its antioxidant and anti-inflammatory properties.
Influences of Helicobacter pylori on cyclooxygenase-2 expression and prostaglandinE2 synthesis in rat gastric epithelial cells in vitro.
Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats.
Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells.
Inhibition of 11?-Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression as Well as the ERK and mTOR Signaling Pathways.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Inhibition of azoxymethane-induced aberrant crypt foci in rat by diphenylmethyl selenocyanate through downregulation of COX-2 and modulation of glutathione-S-transferase and lipid peroxidation.
Inhibition of azoxymethane-induced colon carcinogenesis in rats due to JTE-522, a selective cyclooxygenase-2 inhibitor.
Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).
Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis.
Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53.
Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex.
Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells.
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.
Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer.
Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract.
Inhibition of cyclooxygenase: a novel approach to cancer prevention.
Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.
Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522.
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Inhibition of hypoxia-induced cyclooxygenase-2 by Korean Red Ginseng is dependent on peroxisome proliferator-activated receptor gamma.
Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 activity by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose in murine macrophage cells.
Inhibition of NF-?B, Bcl-2 and COX-2 Gene Expression by an Extract of Eruca sativa Seeds during Rat Mammary Gland Carcinogenesis.
Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells.
Inhibition of phorbol ester-induced COX-2 expression by some edible African plants.
Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells.
Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Inhibition of TPA-induced cyclooxygenase-2 (COX-2) expression by apigenin through downregulation of Akt signal transduction in human keratinocytes.
Inhibitors of the Microsomal Prostaglandin E(2) Synthase-1 as Alternative to Non Steroidal Anti-inflammatory Drugs (NSAIDs) - A Critical Review.
Inhibitory effect of citrus 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone on 12-O-tetradecanoylphorbol 13-acetate-induced skin inflammation and tumor promotion in mice.
Inhibitory effect of Coptidis Rhizoma and Scutellariae Radix on azoxymethane-induced aberrant crypt foci formation in rat colon.
Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.
Inhibitory effect of magnolol on TPA-induced skin inflammation and tumor promotion in mice.
Inhibitory effect of meloxicam, a cyclooxygenase-2 inhibitor, on N-nitrosobis (2-oxopropyl) amine induced biliary carcinogenesis in Syrian hamsters.
Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats.
Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line.
Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells.
Inhibitory Effects of a Rice Hull Constituent on Tumor Necrosis Factor {alpha}, Prostaglandin E2, and Cyclooxygenase-2 Production in Lipopolysaccharide-Activated Mouse Macrophages.
Inhibitory effects of epigallocatechin-3-gallate on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in F344 rats.
Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats.
Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis.
Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats.
Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets.
Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in rats initiated with 4-nitroquinoline 1-oxide.
Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium.
Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide.
Interaction between cyclooxygenase-2 and inducible nitric oxide synthase in gastric cancer.
Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.
Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer.
Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis.
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas.
Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis.
Intracellular unesterified arachidonic acid signals apoptosis.
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.
Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis.
Involvement of ERK AND p38 MAP kinase in AAPH-induced COX-2 expression in HaCaT cells.
Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents.
Involvement of NADPH oxidases in suppression of cyclooxygenase-2 promoter-dependent transcriptional activities by sesamol.
Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein.
Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis.
Involvement of prostaglandin E2 in bile acid-caused promotion of colon carcinogenesis and anti-promotion by the cyclooxygenase inhibitor indomethacin.
Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors.
Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis.
Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Is COX-2 inhibition a panacea for cancer prevention?
Is cyclooxygenase-2 important in skin carcinogenesis?
JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats.
JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
K-Ras and cyclooxygenase-2 coactivation augments intraductal papillary mucinous neoplasm and Notch1 mimicking human pancreas lesions.
K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse.
Ketoconazole suppresses prostaglandin E(2)-induced cyclooxygenase-2 expression in human epidermoid carcinoma A-431 cells.
KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi's sarcoma.
Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells.
Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse.
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
Leukotrienes induce cell-survival signaling in intestinal epithelial cells.
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.
Levuglandin Forms Adducts with Histone H4 in a Cyclooxygenase-2-Dependent Manner, Altering Its Interaction with DNA.
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
Ligand Activation of Peroxisome Proliferator-Activated Receptor-{beta}/{delta} (PPAR{beta}/{delta}) and Inhibition of Cyclooxygenase 2 (COX2) Enhances Inhibition of Skin Tumorigenesis.
Lipopolysaccharide initiates a positive feedback of epidermal growth factor receptor signaling by prostaglandin E2 in human biliary carcinoma cells.
Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer.
Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention.
Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE?.
LKB1/PEA3/?Np63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure.
Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.
Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma.
Loss of p53 in stromal fibroblasts enhances tumor cell proliferation through nitric-oxide-mediated cyclooxygenase 2 activation.
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer.
Lung cancer and cyclooxygenase-2.
Lung cancer chemoprevention with celecoxib in former smokers.
Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2.
Luteolin, a Novel Natural Inhibitor of Tumor Progression Locus 2 Serine/Threonine Kinase, Inhibits Tumor Necrosis Factor-{alpha}-Induced Cyclooxygenase-2 Expression in JB6 Mouse Epidermis Cells.
Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes.
Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts.
Many actions of cyclooxygenase-2 in cellular dynamics and in cancer.
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity.
Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia.
Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer.
Meloxicam inhibits the growth of colorectal cancer cells.
Meloxicam inhibits the growth of non-small cell lung cancer.
Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs.
Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma.
Metachronous Carcinomas of the Biliary Tract in a Patient Treated Three Times with Curative Surgery.
Methanol extracts of Stewartia koreana inhibit cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) gene expression by blocking NF-kappaB transactivation in LPS-activated RAW 264.7 cells.
Methanolic extract of adlay seed suppresses COX-2 expression of human lung cancer cells via inhibition of gene transcription.
Methyl syringate, a TRPA1 agonist represses hypoxia-induced cyclooxygenase-2 in lung cancer cells.
Micromolar concentrations of sodium arsenite induce cyclooxygenase-2 expression and stimulate p42/44 mitogen-activated protein kinase phosphorylation in normal human epidermal keratinocytes.
MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.
MicroRNA-146a as a Prognostic Biomarker for Esophageal Squamous Cell Carcinoma.
MicroRNAs in the anticancer effects of celecoxib: A systematic review.
Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression.
Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention.
MiR-1297 regulates the growth, migration and invasion of colorectal cancer cells by targeting cyclo-oxygenase-2.
miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway.
MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.
Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis.
MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells.
Modifying effect of tuna orbital oil rich in docosahexaenoic acid and vitamin D3 on azoxymethane-induced colonic aberrant crypt foci in rats.
Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats.
Modulation by aspirin and naproxen of nucleotide alterations and tumors in the lung of mice exposed to environmental cigarette smoke since birth.
Modulation by Licofelone and Celecoxib of Experimentally Induced Cancer and Preneoplastic Lesions in Mice Exposed to Cigarette Smoke.
Modulation of COX-2 expression in peripheral blood cells by increased intake of fruit and vegetables?
Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids.
Modulation of tumorigenesis and oestrogen receptor-alpha expression by cell culture conditions in a stem cell-derived breast epithelial cell line.
Modulatory effect of hesperidin on benzo(a)pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9.
Modulatory influence of garlic and tomato on cyclooxygenase-2 activity, cell proliferation and apoptosis during azoxymethane induced colon carcinogenesis in rat.
Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane.
Molecular Characterization of Feline COX-2 and Expression in Feline Mammary Carcinomas.
Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8.
Molecular Insights into the Interaction of RONS and Thieno[3,2-c]pyran Analogs with SIRT6/COX-2: A Molecular Dynamics Study.
Molecular Mechanisms Behind the Chemopreventive Effects of Anthocyanidins.
Molecular Mechanisms Underlying Chemopreventive Activities of Glycyrrhizic Acid against UVB-Radiation-Induced Carcinogenesis in SKH-1 Hairless Mouse Epidermis.
Molecular pathology of cyclooxygenase-2 in neoplasia.
Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?
Molecular profile of colorectal cancer in Indonesia: is there another pathway?
Molecularly targeted approaches to the chemoprevention of lung cancer.
Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma.
More than structural cells, fibroblasts create and orchestrate the tumor microenvironment.
Morin regulates the expression of NF-kappaB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma.
Mucin-depleted foci show strong activation of inflammatory markers in 1,2-dimethylhydrazine-induced carcinogenesis and are promoted by the inflammatory agent sodium dextran sulfate.
Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling.
Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.
Myeloid Differentiation Factor 88 Signaling in Bone Marrow-Derived Cells Promotes Gastric Tumorigenesis by Generation of Inflammatory Microenvironment.
N-3 fatty acids and lipid peroxidation in breast cancer inhibition.
N-methylnitrosourea aggravates gastrointestinal polyposis in Lkb1+/- mice.
Natural COX-2 inhibitors as promising anti-inflammatory agents: an update.
New insights into the functions of Cox-2 in skin and esophageal malignancies.
New NSAID Targets and Derivatives for Colorectal Cancer Chemoprevention.
New targets for the modulation of radiation response--selective inhibition of the enzyme cyclooxygenase 2.
NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins.
NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure.
Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Nimesulide and indomethacin induce apoptosis in head and neck cancer cells.
Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats.
Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines.
Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality.
Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer.
Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract.
Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects.
Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: A population-based case-control study.
Nonsteroidal anti-inflammatory drugs may prevent colon cancer through suppression of hepatocyte growth factor expression.
Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells.
NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2.
NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines.
Nuclear factor ?B and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma.
Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation in human colorectal carcinoma tissue.
Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer.
Nucleobindin co-localizes and associates with cyclooxygenase (COX)-2 in human neutrophils.
Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer.
o,p'-DDT induces cyclooxygenase-2 gene expression in murine macrophages: Role of AP-1 and CRE promoter elements and PI3-kinase/Akt/MAPK signaling pathways.
Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis.
Olive Leaf Extract and Its Main Component Oleuropein Prevent Chronic Ultraviolet B Radiation-Induced Skin Damage and Carcinogenesis in Hairless Mice.
omega-3 Fatty Acids, Genetic Variants in COX-2 and Prostate Cancer.
Opposing roles for mammary epithelial-specific PPAR? signaling and activation during breast tumour progression.
Oral administration of aflatoxin G? induces chronic alveolar inflammation associated with lung tumorigenesis.
Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis.
Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx.
Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes.
Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer.
Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma.
Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract.
Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis.
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder.
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.
Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability.
Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies.
Oxidative stress mediated idiosyncratic drug toxicity.
Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis.
p-Phenylenediamine induced DNA damage in SV-40 immortalized human uroepithelial cells and expression of mutant p53 and COX-2 proteins.
p38 MAP kinase plays a functional role in UVB-Induced mouse skin carcinogenesis.
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.
Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc (Min/+) mouse model of intestinal tumorigenesis.
Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells.
Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche.
Paradoxical effects of resveratrol on the two prostaglandin H synthases.
Participation of cyclooxygenase-2 in lip carcinogenesis.
Pathogenesis of Helicobacter pylori Infection.
Pattern of expression of cyclooxygenase-2 in malignant transformation of sinonasal inverted papilloma.
Pectin-encrusted gold nanocomposites containing phytic acid and jacalin: 1,2-dimethylhydrazine-induced colon carcinogenesis in Wistar rats, PI3K/Akt, COX-2, and serum metabolomics as potential targets.
Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines.
Peroxisome proliferator-activated receptor delta and gastric cancer (Review).
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells.
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis.
PGE2 production in oral cancer cell lines is COX-2-dependent.
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.
Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice.
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells.
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Phenolcarboxylic acids from medicinal herbs exert anticancer effects through disruption of COX-2 activity.
Phloretin Inhibits Phorbol Ester-Induced Tumor Promotion and Expression of Cyclooxygenase-2 in Mouse Skin: Extracellular Signal-Regulated Kinase and Nuclear Factor-?B as Potential Targets.
Photoprotective Activity of Topsentin, A Bis(Indole) Alkaloid from the Marine Sponge Spongosorites genitrix, by Regulation of COX-2 and Mir-4485 Expression in UVB-Irradiated Human Keratinocyte Cells.
Photoprotective effects of sulindac against ultraviolet B-induced phototoxicity in the skin of SKH-1 hairless mice.
Piceatannol inhibits phorbol ester-induced NF-kappa B activation and COX-2 expression in cultured human mammary epithelial cells.
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Pilot study: duodenal MDR1 and COX2 gene expression in cats with inflammatory bowel disease and low-grade alimentary lymphoma.
Pin1 is required for ultraviolet A-stimulated cyclooxygenase-2 induction in mouse epidermal cells.
Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus.
Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms.
Pleurotus ostreatus inhibits colitis-related colon carcinogenesis in mice.
Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.
Polymorphisms in arachidonic acid metabolism-related genes and the risk and prognosis of colorectal cancer.
Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort.
Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.
Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies.
Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region.
Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Posttranscriptional Regulation of Cyclooxygenase 2 Expression in Colorectal Cancer.
Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells.
Potential Benefits of Omega-3 Fatty Acids in Non-Melanoma Skin Cancer.
Potential molecular targets in chemopreventative action of celecoxib: a proteomics analysis of J774.A1 macrophage-like cell line.
Potential of butein, a tetrahydroxychalcone to obliterate cancer.
Potential relevance of cyclooxygenase-2 expression in keratocystic odontogenic tumours - an immunohistochemical study.
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis.
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
Potential role of selective COX-2 inhibitors in cancer management.
Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy.
Potentiation of tumor formation by topical administration of 15-deoxy-delta12,14-prostaglandin J2 in a model of skin carcinogenesis.
PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells.
PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.
Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma.
Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats.
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Prevention of human cancer by modulation of chronic inflammatory processes.
Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.
Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor.
Preventive effect of Juzen-taiho-to on endometrial carcinogenesis in mice is based on Shimotsu-to constituent.
Preventive effect of ortho dimer of butylated hydroxyanisole on activator protein-1 activation and cyclooxygenase-2 expression in macrophages stimulated by fimbriae of Porphyromonas gingivalis, an oral anaerobe.
Pro/antioxidant status in murine skin following topical exposure to cumene hydroperoxide throughout the ontogeny of skin cancer.
Proapoptotic, Anti-Cell Proliferative, Anti-Inflammatory and Anti-Angiogenic Potential of Carnosic Acid during 7,12 Dimethylbenz[a]Anthracene-Induced Hamster Buccal Pouch Carcinogenesis.
Probiotic Lactobacillus salivarius Ren prevent dimethylhydrazine-induced colorectal cancer through protein kinase B inhibition.
Probiotics (Lactobacillus acidophilus and Lactobacillus rhamnosus GG) in Conjunction with Celecoxib (selective COX-2 inhibitor) Modulated DMH-Induced Early Experimental Colon Carcinogenesis.
Probiotics regulate the expression of COX-2 in intestinal epithelial cells.
Production of prostaglandinE2 via bile acid is enhanced by trypsin and acid in normal human esophageal epithelial cells.
Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions.
Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis.
Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer.
Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma.
Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma.
Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis.
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.
Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer.
Progression of liver oncogenesis in the double transgenic mice c-myc/TGF ? is not enhanced by cyclooxygenase-2 expression.
Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.
Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells.
Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk.
Prospects in NSAID-derived chemoprevention of colorectal cancer.
Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells.
Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.
Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumor--a single institution series.
Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
Prostaglandin E2 receptor EP1 phosphorylate CREB and mediates MMP2 expression in human cholangiocarcinoma cells.
PROSTAGLANDIN E2 stimulates cancer-related phenotypes in prostate cancer PC3 cells through cyclooxygenase-2.
Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin.
Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells.
Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells.
Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer.
Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?
Prostaglandin EP1 receptor down-regulates expression of cyclooxygenase-2 by facilitating its proteasomal degradation.
Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect.
Prostaglandin inhibitors and the chemoprevention of noncolonic malignancy.
Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.
Prostaglandin synthases influence thyroid follicular cell proliferation but not carcinogenesis in rats initiated with N-bis(2-hydroxypropyl)nitrosamine.
Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis.
Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin.
Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.
Prostanoid receptor EP1 expression in breast cancer.
Protective effect of berberine on expression pattern of apoptotic, cell proliferative, inflammatory and angiogenic markers during 7,12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis.
Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype.
Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters.
Protein expression of Fragile Histidine Triad and cyclooxgenase-2 in serrated neoplasia of the colorectum.
Protein expression profiles in the epidermis of cyclooxygenase-2 transgenic mice by 2-dimensional gel electrophoresis and mass spectrometry.
Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.
Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein.
Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells.
PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3? signaling pathway in DMH induced early colon carcinogenesis in rat.
Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice.
PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice.
Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts.
Quantitative analysis of COX-2 promoter methylation in gastric carcinoma.
Quantitative trait locus mapping of susceptibilities to butylated hydroxytoluene-induced lung tumor promotion and pulmonary inflammation in CXB mice.
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
Quercetin Suppresses Early Colon Carcinogenesis Partly through Inhibition of Inflammatory Mediators.
R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis.
Ras up-regulation of cyclooxygenase-2.
Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors.
Recent advances in chemoprevention of cancer.
Red ginseng represses hypoxia-induced cyclooxygenase-2 through sirtuin1 activation.
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.
Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive.
Regular exercise reduces colon tumorigenesis associated with suppression of iNOS.
Regulation of COX-2 transcription in a colon cancer cell line by Pontin52/TIP49a.
Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1.
Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.
Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Regulation of inflammation and COX-2 gene expression in benzo (a) pyrene induced lung carcinogenesis in mice by all trans retinoic acid (ATRA).
Regulation of p53, nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin.
Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis.
Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells.
Relationship between cysteinyl-leukotriene-1 receptor and human transitional cell carcinoma in bladder.
Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic makeup.
Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against ?? T cell cytotoxicity.
Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Resveratrol directly targets COX-2 to inhibit carcinogenesis.
Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets.
Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets.
Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells.
Review article: COX-2, prostanoids and colon cancer.
RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor.
RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.
ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences.
Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer.
Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis.
Role of COX-2 specific inhibitors in oncogenesis.
Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis.
Role of cyclooxygenase inhibitors for the prevention of colorectal cancer.
Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis.
Role of cyclooxygenase-2 in breast cancer.
Role of Cyclooxygenase-2 in colorectal cancer patients.
Role of cyclooxygenase-2 in colorectal cancer.
Role of cyclooxygenase-2 in gastric cancer development and progression.
Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.
Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma.
Role of Modulator of Inflammation Cyclooxygenase-2 in Gammaherpesvirus Mediated Tumorigenesis.
Role of nitric oxide in cancer biology.
Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes.
Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.
Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis.
Role of the Slug Transcription Factor in Chemically-Induced Skin Cancer.
Roles of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression and beta-catenin activation in gastric carcinogenesis in N-methyl-N-nitrosourea-treated K19-C2mE transgenic mice.
Roles of ERK and p38 mitogen-activated protein kinases in phorbol ester-induced NF-kappaB activation and COX-2 expression in human breast epithelial cells.
Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis.
Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention.
Saturated Fatty Acids Up-regulate COX-2 Expression in Prostate Epithelial Cells via Toll-like Receptor 4/NF-?B Signaling.
Screening and isolation of cyclooxygenase-2 inhibitors from the stem bark of Phellodendron amurense Ruprecht by ultrafiltration with liquid chromatography and tandem mass spectrometry, and complex chromatography.
Screening and isolation of cyclooxygenase-2 inhibitors from Trifolium pratense L. via ultrafiltration, enzyme-immobilized magnetic beads, semi-preparative high-performance liquid chromatography and high-speed counter-current chromatography.
Select Dietary Phytochemicals Function as Inhibitors of COX-1 but Not COX-2.
Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer.
Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.
Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.
Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.
Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest.
Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog.
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Sequential expression of inducible nitric oxide synthase and cyclooxygenase-2 during DMBA-induced hamster buccal pouch carcinogenesis.
Sesamol suppresses cyclooxygenase-2 transcriptional activity in colon cancer cells and modifies intestinal polyp development in Apc (Min/+) mice.
Short-term Celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Significance of COX-2 expression in human esophageal squamous cell carcinoma.
Significance of COX-2 expression in human renal cell carcinoma cell lines.
Significance of COX-2 expression in human renal cell carcinoma.
Significance of Cyclooxygenase-2 in Oncogenesis.
Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.
Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus.
Significance of immunohistochemical overexpression of cyclooxygenase-2 in overall and disease-free survival of oral squamous cell carcinoma patients.
Silibinin inhibits tumor promotional triggers and tumorigenesis against chemically induced two-stage skin carcinogenesis in Swiss albino mice: possible role of oxidative stress and inflammation.
Silibinin Suppresses Spontaneous Tumorigenesis in APC (min/+) Mouse Model by Modulating Beta-Catenin Pathway.
Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.
Some perspectives on dietary inhibition of carcinogenesis: studies with curcumin and tea.
Soya isoflavones suppress phorbol 12-myristate 13-acetate-induced COX-2 expression in MCF-7 cells.
Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells.
Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production.
Sphingosine Kinase 1 expression in peritoneal macrophages is required for colon carcinogenesis.
Sphingosine kinase 1 is up-regulated in colon carcinogenesis.
Strategies for colon cancer prevention: combination of chemopreventive agents.
Stromal COX-2 signaling activated by deoxycholic acid mediates proliferation and invasiveness of colorectal epithelial cancer cells.
Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells.
Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Study of the effects of cyclooxygenase-2 inhibitor on the promotion of hepatic tumorigenesis in rats fed a high fat diet.
Study on cow ghee versus soybean oil on 7,12-dimethylbenz(a)-anthracene induced mammary carcinogenesis & expression of cyclooxygenase-2 & peroxisome proliferators activated receptor-? in rats.
Study to elucidate molecular mechanism behind zinc chemo-preventive role during lung carcinogenesis.
Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.
Suppression by flavonoids of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells: structure-activity relationship.
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9.
Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2.
Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure.
Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages.
Suppression of inflammatory cascade is implicated in methyl amooranin-mediated inhibition of experimental mammary carcinogenesis.
Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor.
Suppression of promoter-dependent transcriptional activity of inducible nitric oxide synthase by sodium butyrate in colon cancer cells.
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer.
Suppression of the Inflammatory Cascade is Implicated in Resveratrol Chemoprevention of Experimental Hepatocarcinogenesis.
Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice.
Suppressive effects of the kahweol and cafestol on cyclooxygenase-2 expression in macrophages.
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.
Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells.
Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors.
Synthesis of Resveratrol Derivatives and In Vitro Screening for Potential Cancer Chemopreventive Activities.
Synthesis, characterization, and cellular investigations of porphyrin- and chlorin-indomethacin conjugates for photodynamic therapy of cancer.
Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest.
Syphacia muris infection in rats attenuates colorectal carcinogenesis through oxidative stress and gene expression alterations. Implications for modulatory effects by Bryostatin-1.
Syringic acid modulates molecular marker-involved cell proliferation, survival, apoptosis, inflammation, and angiogenesis in DMBA-induced oral squamous cell carcinoma in Syrian hamsters.
Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer.
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
Targeting COX-2 abrogates mammary tumorigenesis: Breaking cancer-associated suppression of immunosurveillance.
Targeting COX-2 expression by natural compounds: A promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy.
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer.
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
Targeting NOX, INOS and COX-2 in inflammatory cells: Chemoprevention using food phytochemicals.
Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells.
Targeting PRPK and TOPK for skin cancer prevention and therapy.
Targeting the inflammatory pathways to enhance chemotherapy of cancer.
Techniques used to study regulation of cyclooxygenase-2 promoter sites.
Terminalia Chebula Attenuates DMBA/Croton Oil-Induced Oxidative Stress and Inflammation in Swiss albino Mouse Skin.
The -1195G allele increases the transcriptional activity of cyclooxygenase-2 gene (COX-2) in colon cancer cell lines.
The ?-3 polyunsaturated fatty acids prevented colitis-associated carcinogenesis through blocking dissociation of ?-catenin complex, inhibiting COX-2 through repressing NF-?B, and inducing 15-prostaglandin dehydrogenase.
The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid.
The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
The association between cyclooxygenase-2 1195 G/A polymorphism and hepatocellular carcinoma: evidence from a meta-analysis.
The Bitter Barricading of Prostaglandin Biosynthesis Pathway: Understanding the Molecular Mechanism of Selective Cyclooxygenase-2 Inhibition by Amarogentin, a Secoiridoid Glycoside from Swertia chirayita.
The Co-regulatory Role of 5-Lipoxygenase and Cyclooxygenase-2 in the Carcinogenesis and their Promotion by Cigarette Smoking in Colons.
The contributions of cyclooxygenase-2 to tumor angiogenesis.
The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis.
The COX-2 -765 G>C polymorphism is associated with increased risk of gastric carcinogenesis in the Chinese Hui ethnic population.
The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers.
The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK.
The Cyclooxygenase-2 (PTGS2) 8473T>C Polymorphism is Associated with Breast Cancer Risk.
The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model.
The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway.
The cysteinylLT1 receptor in human renal cell carcinoma.
The dark side of "the force" - lipid nanoparticles enhance the oncogenesis of diethylnitrosamine and result in liver cancer in mice.
The dietary phytochemical 3,3'-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-?B, MAPK, and p53 signaling.
The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers.
The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma.
The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent.
The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines.
The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer cells.
The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis.
The effects of radix curcumae extract on expressions of VEGF, COX-2 and PCNA in gastric mucosa of rats fed with MNNG.
The establishment of supramolecular immunobead real-time PCR and the identification of Cox-2 as a metastasis-related marker in colorectal carcinoma.
The evolution of predictive oncology and molecular-based therapy for oral cancer prevention.
The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.
The future of targeted therapy: combining novel agents.
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.
The importance of cyclooxygenase in carcinogenesis: is it a therapeutic target?
The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models.
The inhibitory effect of vitamin E on arachidonic acid metabolism during the process of urethane-induced lung tumorigenesis in mice.
The Licorice Flavonoid Isoliquiritigenin Suppresses Phorbol Ester-induced Cyclooxygenase-2 Expression in the Non-tumorigenic MCF-10A Breast Cell Line.
The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis.
The molecular basis of colorectal carcinogenesis.
The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.
The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.
The Novel Nutraceutical KJS018A Prevents Hepatocarcinogenesis Promoted by Inflammation.
The potential and rationale for COX-2 inhibitors in lung cancer.
The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells.
The relationship between cyclooxygenase-2 expression and colorectal cancer.
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells.
The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in ApcMin mice.
The RNA-binding protein HuR regulates the expression of cyclooxygenase-2.
The role of COX-2 in oral cancer development, and chemoprevention/ treatment of oral cancer by selective COX-2 inhibitors.
The Role of Cyclooxygenase-2 in Colorectal Carcinogenesis.
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma.
The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma.
The role of inflammation in inflammatory breast cancer.
The role of inflammation in skin cancer.
The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac.
The role of PGE2-associated inflammatory responses in gastric cancer development.
The Role of Proinflammatory Pathways in the Pathogenesis of Colitis-Associated Colorectal Cancer.
The role of selective COX-2 inhibitors in reactive oxygen species formation in osteosarcoma cells after X-ray irradiation.
the selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma.
The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers.
The value of MG7-Ag and COX-2 for predicting malignancy in gastric precancerous lesions.
Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis.
Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
Time-selective chemoprevention of vitamin E and selenium on esophageal carcinogenesis in rats: The possible role of nuclear factor kappaB signaling pathway.
To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor.
Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression.
Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression.
Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.
Tpl2 is a key mediator of arsenite-induced signal transduction.
Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells.
Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs.
Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues.
Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells.
Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice.
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.
Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression.
Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.
Transitional Cell Carcinoma in Fishing Cats (Prionailurus viverrinus): Pathology and Expression of Cyclooxygenase-1, -2, and p53.
Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.
Trianthema portulacastrum Linn. Displays Anti-Inflammatory Responses during Chemically Induced Rat Mammary Tumorigenesis through Simultaneous and Differential Regulation of NF-?B and Nrf2 Signaling Pathways.
Tristetraprolin downregulates the expression of both VEGF and COX-2 in human colon cancer.
Triticum aestivum Sprouts Extract Inhibits Azoymethane (AOM)/Dextran Sodium Sulfate (DSS)-Induced Colon Carcinogenesis in Mice.
Troglitazone induction of COX-2 expression is dependent on ERK activation in keratinocytes.
Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.
Tumor promotion as a target of cancer prevention.
Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression.
Types and amount of dietary fat and colon cancer risk: Prevention by omega-3 fatty acid-rich diets.
Up-regulation of cyclooxygenase 2 and matrix metalloproteinases-2 and -9 in cutaneous squamous cell carcinoma: active role of inflammation and tissue remodeling in carcinogenesis.
Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.
Up-regulation of cyclooxygenase-2 by interleukin-1beta in colon carcinoma cells.
Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase.
Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus.
Up-regulation of p53 and mitochondrial signaling pathway in apoptosis by a combination of COX-2 inhibitor, celecoxib and dolastatin 15, a marine mollusk linear peptide in experimental colon carcinogenesis.
Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease.
Update on SAR Studies Toward New COX-1 Selective Inhibitors.
Ursodeoxycholic acid and chemoprevention of colorectal cancer.
UVB radiation-induced ?-catenin signaling is enhanced by COX-2 expression in keratinocytes.
Vietnamese coriander inhibits cell proliferation, survival and migration via suppression of Akt/mTOR pathway in oral squamous cell carcinoma.
Vitamin E supplementation in chemical colorectal carcinogenesis: a two-edged knife.
What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?
Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor-kappa B.
XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers.
Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression.
Zinc supplementation suppresses 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis.
Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model.
[A relationship between cyclooxygenase-2 expression and tumor angiogenesis in experimental rat liver carcinogenesis.]
[A study on cyclooxygenase-2 protein expression and vasculature during experimental rat lung carcinogenesis]
[Antisense inhibition of cyclooxygenase-2 reduces malignant phenotype of gastric cancer cells]
[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
[Aspirin in the prevention of colorectal cancer.]
[Clinicopathologic significance of cyclooxygenase-2 mRNA expression in human breast carcinoma]
[Combination therapies using cyclooxygenase-2 inhibitors and angiotensin-converting enzyme inhibitors in colon carcinogenesis]
[COX and study of cancer therapy]
[COX inhibitor, suppression of polyposis, and chemoprevention]
[COX-2 expression in the H. pylori infected gastric mucosal epithelia and its significance]
[COX-2 inhibitor and colon cancer]
[COX-2 inhibitors in inflammatory bowel disease: friends or foes?]
[COX-2 inhibitors: a novel way to prevent and treat the carcinogenesis of oral mucosa]
[Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide]
[Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials]
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]
[Cyclooxygenase 2 and carcinogenesis]
[Cyclooxygenase 2 inhibitors and lung carcinoma]
[Cyclooxygenase-2 expression according to size and location of gastric and colorectal tubular adenomas]
[Cyclooxygenase-2 expression in female pulmonary adenocarcinoma.]
[Cyclooxygenase-2, inducible nitric oxide synthase protein expression and vasculature during experimental rat lung carcinogenesis.]
[Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications]
[Cyclooxygenases in the skin]
[Ease-2 and inducible nitric oxide synthase in tongue hyperplasia and tongue squamous cell carcinoma]
[Effect of selective cyclooxygenase-2 inhibitor celebrex on expression of vascular endothelial growth factor (VEGF) in pancreatic carcinoma]
[Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis]
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]
[Effects of selective cyclooxygenase-2 inhibitor on proliferation and apoptosis of human bladder cancer cell line T24]
[Erb-2 overexpression in breast cancer]
[Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma]
[Expression and clinical significance of cyclooxygenase-2 in nasal and paranasal sinus carcinoma]
[Expression and clinical significance of hypoxia-inducible factor-1alpha and cyclooxygenase-2 in laryngeal squamous cell carcinoma]
[Expression and prognostic significance of cyclooxygenase-2 in supraglottic laryngeal squamous cell carcinomas]
[Expression and significance of COX-2 and S-100 positive dendritic cell in laryngeal carcinoma]
[Expression and significance of interleukin-8 cyclooxygenase-2 and trefoil family factor 1 in the remnant stomach mucosa]
[Expression of COX-2 and VEGF-C in squamous cell carcinoma of the tongue and its correlation to lymph node metastasis]
[Expression of cyclooxygenase-2 in esophageal squamous cell carcinogenesis]
[Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas]
[Expression of cyclooxygenase-2, hMLH1 and hMSH2 proteins, and their relationship with microsatellite instability in gastric carcinoma]
[Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation.]
[Expression of NF-kappaB and COX-2 in tongue squamous cell carcinoma]
[Expression of the cyclooxygenase-2 gene in human breast carcinoma]
[Expression of tissue microarray p53, p16 and cyclooxygenase-2 in gastric cancer]
[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]
[Expressions and significance of COX-2 and P-gp in human hepatocellular cacinoma tissues].
[Expressions of cyclooxygenase-2 and cholecystokinin-B receptor mRNA in human colorectal cancer and their significances]
[Flow cytometric quantitative analysis of multiple tumor suppressor gene 1 (MTS1) and cyclooxygenase-2 (COX-2) gene expressions in invasive breast cancers and their clinical significance]
[Genetic polymorphisms in the promoter region of cyclooxygenase-2 and their association with risk of gastric cancer]
[Inhibitory effects of Aspisol on growth of transplanted breast cancer in C3H mice]
[Mechanisms of EGF regulation of COX-2 through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells].
[Neoplastic effect of indomethacin in N-methyl-N-nitrosourea induced mammary carcinogenesis in female rats].
[Overexpression of COX-2 and a potential clinical application of its inhibitors in lung cancer]
[Relation between COX-2 protein expression and biologic behavior of ovarian carcinoma]
[Role of COX-2 and PPAR in gastric carcinogenesis]
[Role of cyclooxygenase-2 (COX-2) and peroxisome proliferator-activated receptor (PPAR) in gastric cancer]
[Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases]
[Roles of cyclooxygenase-2 and caspase-3 expression in pathogenesis of lung carcinoma: an experiment with rats]
[Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma]
[Study on the effect of COX-2's selective inhibitor on human colorectal adenoma cells proliferation]
[The change of cyclooxygenase-2 and inducible nitric oxide synthase in the gastric mucosa one year after eradication of Helicobacter pylori]
[The clinical significance of expression of cyclooxygenase-2 gene in breast cancer]
[The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]
[The expressiong of cyclooxygenase-2 in laryngeal squamous cell carcinoma and its relationship with MVD]
[The expressions of cyclooxygenase-2 (Cox-2),VEGF in oral squamous cell carcinoma and precancerous lesions and their significances]
[The significance of the expression of cyclooxygenase-2 in bladder transitional cell carcinoma tissues]
Carcinoid Tumor
An evaluation of cyclooxygenase-2 as a prognostic biomarker in mid-gut carcinoid tumours.
Expression of cyclo-oxygenase-2 in gastrointestinal carcinoid tumors.
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
Carcinoma
15-Lipoxygenase-2 is differentially expressed in normal and neoplastic ovary.
5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats.
7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma.
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
?-Conotoxins Enhance both the In Vivo Suppression of Ehrlich carcinoma Growth and In Vitro Reduction in Cell Viability Elicited by Cyclooxygenase and Lipoxygenase Inhibitors.
?-linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-? activation and COX-2 inhibition.
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder.
A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.
A new cyclooxygenase-2 inhibitor, (1E,4E)-1,5-bis(2-bromophenyl)penta-1,4-dien-3-one (GL63) suppresses cyclooxygenase-2 gene expression in human lung epithelial cancer cells: coupled mRNA stabilization and posttranscriptional inhibition.
A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma.
A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment.
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
A replication-selective adenoviral vector for head and neck cancers.
A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation.
A selective cyclooxygenase-2 inhibitor prevents inflammation-related squamous cell carcinogenesis of the forestomach via duodenogastric reflux in rats.
A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells.
A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells.
A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas.
A study on expression pattern of cyclooxygenase-2 in carcinoma of cervix.
A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer.
Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma.
Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas.
Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin.
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.
Adaptor protein p62 promotes skin tumor growth and metastasis and is induced by UVA radiation.
Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro.
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.
Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck.
Advances that are changing the diagnosis and treatment of malignant bone tumors.
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.
Alterations in lipid mediated signaling and Wnt/ ? -catenin signaling in DMH induced colon cancer on supplementation of fish oil.
Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma.
Altered 1-14C arachidonic acid metabolism in arterial wall from patients with renal cell carcinoma.
Amphiregulin as a tumor promoter for oral squamous cell carcinoma: involvement of cyclooxygenase 2.
An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies.
An apple oligogalactan suppresses endotoxin-induced cyclooxygenase-2 expression by inhibition of LPS pathways.
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer.
Analysis by high performance liquid chromatography of cyclooxygenase products of arachidonic acid metabolism in plasma of rabbits bearing the VX2 carcinoma.
Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.
Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability.
Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
Anaplastic Mammary Carcinoma in Cat.
Androgen receptor promotes the migration and invasion of upper urinary tract urothelial carcinoma cells through the upregulation of MMP-9 and COX-2.
Anti-angiogenesis therapy in pancreatic carcinoma.
Anti-Cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma (ESCC) through Down-Regulation of COX-2 mRNA and PGE2.
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells.
Antiproliferative activity of guava leaf extract via inhibition of prostaglandin endoperoxide H synthase isoforms.
Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target.
Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.
Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.
Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398.
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Application of epidermal growth factor receptor, vascular endothelial growth factor and cyclooxygenase-2 in prognosis of esophageal carcinomas.
Apurinic/apyrimidinic endonuclease-1 is associated with angiogenesis and VEGF production via upregulation of COX-2 expression in esophageal cancer tissues.
Arachidonic acid metabolism and cell proliferation in rat mammary carcinoma cells treated with indomethacin.
Arachidonic acid metabolites in saliva of patients with squamous cell carcinoma of the head and neck.
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.
Arsenite pretreatment attenuates benzo[a]pyrene cytotoxicity in a human lung adenocarcinoma cell line by decreasing cyclooxygenase-2 levels.
Aspirin, platelets, and cancer: The point of view of the internist.
Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk.
Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.
Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.
Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer.
Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas.
Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation.
Association of Single Nucleotide Polymorphisms in the Prostaglandin-endoperoxide Synthase 2 (PTGS2) and Phospholipase A2 Group IIA (PLA2G2A) Genes with Susceptibility to Esophageal Squamous Cell Carcinoma.
Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients With Cervical Cancer.
Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas.
Beta-Catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3'-UTR.
Bile acid promotes the proliferation of squamous cell carcinoma of the esophagus, independent of its inducing COX-2 expression.
Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers.
Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells.
Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy.
Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis.
c-Jun N-terminal kinase negatively regulates epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines.
Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer?
Cantharidin-induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line.
CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma.
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.
Celecoxib Enhances the Chemotherapeutic Response of Cisplatin and TNF-? in SiHa Cells through Reactive Oxygen Species-Mediated Mitochondrial Pathway.
Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.
Celecoxib Inhibits Helicobacter pylori-induced Invasion of Gastric Cancer Cells Through an Adenine Nucleotide Translocator-Dependent Mechanism.
Celecoxib inhibits proliferation and induces apoptosis via cyclooxygenase-2 pathway in human pancreatic carcinoma cells.
Cell density influences the effect of celecoxib in two carcinoma cell lines.
Cell-type-specific roles for COX-2 in UVB-induced skin cancer.
CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.
Characterization of the effects of antiangiogenic agents on tumor pathophysiology.
Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats.
Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor.
Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study.
Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible?
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Chemopreventive activity of Tualang honey against oral squamous cell carcinoma-in vivo.
Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours.
Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.
Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells.
Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent.
Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining.
Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam.
Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours.
Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.
Clinicopathologic implications of the epidermal growth factor receptor, cyclooxygenase 2 expression, and human papillomavirus status in squamous cell carcinoma of the uterine cervix in the elderly.
Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma.
Clinicopathologic significance of expression of cyclooxygenase-2 in human esophageal squamous cell carcinoma.
Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma.
Clinicopathological significance of cyclooxygenase-2 expression in hypopharyngeal squamous cell carcinoma.
Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma.
Co-Expression of Cox-2, C-Met and beta-catenin in Cells Forming Invasive front of Gallbladder Cancer.
Coexpression of COX-2 and iNOS in Angiogenesis of Superficial Esophageal Squamous Cell Carcinoma.
Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma.
Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
Colonic luminal contents induce cyclooxygenase 2 transcription in human colon carcinoma cells.
Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
Combination of celecoxib and PD184161 exerts synergistic inhibitory effects on gallbladder cancer cell proliferation.
Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
COMBINATION OF RADIATION THERAPY AND FIROCOXIB FOR THE TREATMENT OF CANINE NASAL CARCINOMA.
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma.
Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.
Combined Targeted Proteomics and Oxylipin Metabolomics for Monitoring of the COX-2 Pathway.
Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.
Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer.
Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo.
Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Comparison of COX2 expression between oral squamous cell carcinoma, leukoplakia and normal mucosa.
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus.
Comparison of fatty acid synthase and cyclooxygenase-2 immunoexpression in embryonal, benign, and malignant odontogenic tissues.
Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk.
Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma.
Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome.
Constitutive expression of the cyclooxygenase-2 gene in T-cell lines infected with human T cell leukemia virus type I.
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
Coordinate up-regulation of low-density lipoprotein receptor and cyclo-oxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies.
Coordinated Increased Expression of Cyclooxygenase2 and Nuclear Factor ?B Is a Steady Feature of Urinary Bladder Carcinogenesis.
Coordinated upregulation of COX-2 and NF-kappaB is a steady feature of laryngeal carcinogenesis.
Correlation among 16 biological factors [p53, p21(waf1), MIB-1 (Ki-67), p16(INK4A), cyclin D1, E-cadherin, Bcl-2, TNF-?, NF-?B, TGF-?, MMP-7, COX-2, EGFR, HER2/neu, ER, and HIF-1?] and clinical outcomes following curative chemoradiation therapy in 10 patients with esophageal squamous cell carcinoma.
Correlation analysis of c-myc, p21(WAF/CIP1), p53, C-erbB-2 and COX-2 proteins in esophageal squamous cell carcinoma.
Correlation and expression of COX-2 and P53 protein in basal cell carcinoma of eyelid.
Correlation Between Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression in Canine and Feline Squamous Cell Carcinomas.
Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.
Correlation between cyclooxygenase-2, proliferative activity, and mucin phenotype in human advanced gastric cancer.
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas.
Correlation of BRAF Variant V595E, Breed, Histological Grade and Cyclooxygenase-2 Expression in Canine Transitional Cell Carcinomas.
Correlation of COX- 2 Expression in Colorectal Carcinoma with Clinicopathological Features.
Correlation of COX-2 expression in stromal cells with high stage, high grade, and poor prognosis in urothelial carcinoma of upper urinary tracts.
Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma.
Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome.
Correspondence re: M. Kondo et al., Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res., 5: 4005-4012, 1999.
COX-1 and COX-2 Expression in Feline Oral Squamous Cell Carcinoma.
COX-1 and COX-2 expression in stage I and II invasive cervical carcinoma: relationship to disease relapse and long-term survival.
COX-1 is coupled with mPGES-1 and ABCC4 in human cervix cancer cells.
COX-2 (PTGS2) gene methylation in epithelial, subepithelial lymphocyte and stromal tissue compartments in a spectrum of esophageal squamous neoplasia.
COX-2 - a target for preventing hepatic carcinoma?
Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Cox-2 and IL-10 polymorphisms and association with squamous cell carcinoma of the head and neck in a Korean sample.
COX-2 and p53 in human sinonasal cancer: COX-2 expression is associated with adenocarcinoma histology and wood-dust exposure.
COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ.
COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.
COX-2 correlates with F-box protein, Skp2 expression and prognosis in human gastric carcinoma.
COX-2 Docking Structural Analysis with Phytochemical Extracts of Rosemary: A Possible Cytotoxicity on Head and Neck Squamous Cell Carcinoma Cell Line (HEp-2).
COX-2 expression and effects of COX-2 inhibition in colorectal carcinomas and their liver metastases.
COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy.
COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma.
COX-2 expression during early lung squamous cell carcinoma oncogenesis.
COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables.
COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic for molecular markers.
COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers.
COX-2 expression in canine mammary carcinomas: correlation with angiogenesis (or microvessel density) and overall survival.
COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome.
COX-2 expression in oral lichen planus.
Cox-2 expression in ovarian malignancies: a review of the clinical aspects.
COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome.
COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis.
COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer.
COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters.
COX-2 expression pattern is related to ovarian cancer differentiation and prognosis, but is not consistent with new model of pathogenesis.
COX-2 Gene increases tongue cancer cell proliferation and invasion through VEGF-C pathway.
Cox-2 gene overexpression in ureteral stump urothelial carcinoma following nephrectomy for renal cell carcinoma: a case report.
Cox-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity.
COX-2 inhibition and lung cancer.
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
COX-2 inhibition in clinical cancer prevention.
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
COX-2 inhibitor, NS398, enhances Fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines.
COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites.
COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals.
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67.
Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID.
COX-2 overexpression Induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin.
COX-2 polymorphisms and the risk for head and neck cancer in white patients.
COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data.
COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells.
COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates.
COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma.
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
CXCR-4 and COX-2 Expression in Basal Cell Carcinomas and Well-Differentiated Squamous Cell Carcinomas of the Skin; Their Relationship with Tumor Invasiveness and Histological Subtype.
Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer.
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.
Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.
Cyclo-oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer.
Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.
Cyclo-oxygenase-2 expression in oral squamous cell carcinoma.
Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue.
Cyclo-oxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Cyclooxygenase 1 and 2 expressions in the human thyroid gland.
Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas.
Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications.
Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy.
Cyclooxygenase 2 expression in serous tumors of the ovary.
Cyclooxygenase 2 expression in soft tissue leiomyosarcoma.
Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice.
Cyclooxygenase 2 in gastric carcinoma is expressed in doublecortin- and CaM kinase-like-1-positive tuft cells.
Cyclooxygenase 2 promoter-based replication-selective adenoviral vector for hypopharyngeal cancer.
Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.
Cyclooxygenase and CD147 expression in oral squamous cell carcinoma patient samples and cell lines.
Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Cyclooxygenase regulates angiogenesis induced by colon cancer cells.
Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?
Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature.
Cyclooxygenase-1 and -2 expression in urothelial carcinomas of the urinary bladder in cows.
Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer.
Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1.
Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2'-Des-methyl-sulindac Sulfide Scaffold.
Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions.
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer.
Cyclooxygenase-2 (COX2) expression in adenocarcinoma surpasses that of squamous cell carcinoma in the uterine cervix.
Cyclooxygenase-2 -765 G/C polymorphisms and susceptibility to hepatitis B-related liver cancer in Han Chinese population.
Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.
Cyclooxygenase-2 and Bcl-2 expression in the stomach mucosa of Wistar rats exposed to Helicobacter pylori, N'-methyl- N'-nitro- N-nitrosoguanidine and bile.
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
Cyclooxygenase-2 and gastric cancer.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.
Cyclooxygenase-2 and its role in colorectal cancer development.
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Cyclooxygenase-2 and prostate carcinogenesis.
Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density.
Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases.
Cyclooxygenase-2 expression and association with skin cancer: A meta-analysis based on Chinese patients.
Cyclooxygenase-2 expression and clinical parameters in laryngeal squamous cell carcinoma, vocal fold nodule, and laryngeal atypical hyperplasia.
Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma.
Cyclooxygenase-2 Expression and Its Correlation with Primary Tumor Size and Lymph Node Involvement in Nasopharyngeal Carcinoma.
Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma.
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma.
Cyclooxygenase-2 expression correlates with nuclear p53 accumulation in gastric carcinoma.
Cyclooxygenase-2 expression determines neo-angiogenesis in gallbladder carcinomas.
Cyclooxygenase-2 expression during carcinogenesis in the human stomach.
Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix.
Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis.
Cyclooxygenase-2 expression in borderline ovarian tumors.
Cyclooxygenase-2 expression in brain metastases.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables.
Cyclooxygenase-2 Expression in Cervical Squamous Cell Carcinoma: the Significance of Expression in Neoplastic Cells within the Lymphovascular Space.
Cyclooxygenase-2 expression in chondrosarcoma.
Cyclooxygenase-2 expression in chronic gastritis and gastric carcinoma, correlation with prognostic parameters.
Cyclooxygenase-2 expression in clear cell renal cell carcinoma.
Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome.
Cyclooxygenase-2 expression in equine tumors.
Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Cyclooxygenase-2 expression in FAP patients carrying germ line MYH mutations.
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Cyclooxygenase-2 expression in human esophageal carcinoma.
Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas; correlation with intratumoral microvessel density and apoptotic index.
Cyclooxygenase-2 expression in human pituitary tumors.
Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentation.
Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis.
Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Cyclooxygenase-2 expression in oral squamous cell carcinoma.
Cyclooxygenase-2 expression in oral tongue squamous cell carcinoma.
Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma.
Cyclooxygenase-2 expression in primary Merkel cell carcinoma.
Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome.
Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis.
Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression in the endometrium at the end of 2 years' continuous combined hormone replacement therapy.
Cyclooxygenase-2 expression in thyroid neoplasms.
Cyclooxygenase-2 expression in thyroid nodules.
Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics.
Cyclooxygenase-2 expression in uterine leiomyosarcomas.
Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation.
Cyclooxygenase-2 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma.
Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.
Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients.
Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis.
Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma.
Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma.
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.
Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma?
Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells.
Cyclooxygenase-2 gene and epithelial ovarian carcinoma risk.
Cyclooxygenase-2 gene and lung carcinoma risk.
Cyclooxygenase-2 Gly587Arg variant is associated with differential enzymatic activity and risk of esophageal squamous-cell carcinoma.
Cyclooxygenase-2 immunoreactivity in equine ocular squamous-cell carcinoma.
Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis.
Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland.
Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells.
Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma.
Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells.
Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.
Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.
Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.
Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study.
Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma.
Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: an immunohistochemical study.
Cyclooxygenase-2 is overexpressed in human cervical cancer.
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma.
Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma.
Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta.
Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma.
Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis.
Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients.
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
Cyclooxygenase-2 overexpression is related to polypoid growth and K-ras gene mutation in T1 colorectal carcinomas.
Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma.
Cyclooxygenase-2 polymorphisms and susceptibility to gastric carcinoma: a meta-analysis.
Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma.
Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma.
Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence.
Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma.
Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
Cyclooxygenase-2, a Potential Therapeutic Target, Is Regulated by miR-101 in Esophageal Squamous Cell Carcinoma.
Cyclooxygenase-2, angiogenesis, tumor cell proliferation, P-glycoprotein in advanced ovarian serous carcinoma.
Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas.
Cyclooxygenase-2-1195G>A Polymorphism and Head and Neck Squamous Cell Carcinoma Susceptibility: A Meta-Analysis of 1564 Cases and 2346 Controls.
Cyclooxygenase-2-765G>C functional promoter polymorphism and its association with oral squamous cell carcinoma.
Cyclooxygenase-2/prostaglandin E(2) pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells.
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.
Cyclooxygenase-2: a novel target in human solid tumors.
Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer.
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells.
Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation.
Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2.
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.
Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma.
Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.
Cytoplasmic HuR over-expression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Cytotoxicity of selected novel chalcone derivatives on human breast, lung and hepatic carcinoma cell lines.
Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells.
Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas.
Decreased gene expression of human beta-defensin-1 in the development of squamous cell carcinoma of the oral cavity.
Decreased polyunsaturated Fatty Acid content contributes to increased survival in human colon cancer.
Decreased Toll-interacting protein and peroxisome proliferator-activated receptor ? are associated with increased expression of Toll-like receptors in colon carcinogenesis.
DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target.
Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma.
Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor.
Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression.
Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
Development of invasive follicular cell carcinomas in a rat thyroid carcinogenesis model: biological impact of capsular inflammation and reduced cyclooxygenase-2 expression.
Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.
Different Chemical Structures and Physiological/Pathological Roles of Cyclooxygenases.
Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines.
Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.
Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells.
Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer.
Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis.
Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma.
Differential protein expression in the epidermis of wild-type and COX-2 transgenic mice.
Differential stromal and epithelial localization of cyclooxygenase-2 (COX-2) during colorectal tumorigenesis.
Differentiation of normal and cancer cells induced by sulfhydryl reduction: biochemical and molecular mechanisms.
Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins.
Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers.
Dioscorea japonica extract down-regulates prostaglandin E2 synthetic pathway and induces apoptosis in lung cancer cells.
Diosgenin suppresses COX-2 and mPGES-1 via GR and improves LPS-induced liver injury in mouse.
Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia.
Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates.
Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer.
Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury.
DNA polymorphisms and tissue cyclooxygenase-2 expression in oral lichen planus: a case-control study.
Do early premalignant changes in normal breast epithelial cells predict cancer development?
Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer.
Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells.
Down-regulation of cyclooxygenase-2 expression but up-regulation of cyclooxygenase-1 in renal carcinomas of the Eker (TSC2 gene mutant) rat model.
Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma.
Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines.
Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines.
Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.
Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma.
Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas.
E series of prostaglandin receptor 2-mediated activation of extracellular signal-regulated kinase/activator protein-1 signaling is required for the mitogenic action of prostaglandin E2 in esophageal squamous-cell carcinoma.
E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis.
Early upregulation of cyclooxygenase-2 in human papillomavirus type 16 and telomerase-induced immortalization of human esophageal epithelial cells.
Effect of cyclooxygenase-2 antisense oligodeoxyribonucleotides in A-549 lung cancer cells.
Effect of Ferula persica plant methanol extract on the level of Cox-2 in induced squamous cell carcinoma (SCC) in rat tongue.
Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells.
Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells.
Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.
Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor.
Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice.
Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.
Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts.
Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin d1 and ki-67 in a xenograft model of ovarian carcinoma.
Effects of cyclooxygenase-2 non-selective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells.
Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma.
Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.
Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.
Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells.
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Effects of the Inhibition of Cyclooxygenase-2 on Human Esophageal Cancer Cells: Inhibition of Cell Proliferation and Induction of Apoptosis.
Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet.
Efficacy comparison of lyophilised black raspberries and combination of celecoxib and PBIT in prevention of carcinogen-induced oesophageal cancer in rats.
EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma.
EGFR, HER-2 and COX-2 levels in colorectal cancer.
Eicosanoid regulation of angiogenesis in tumors.
Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA.
Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control.
Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy.
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.
Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for COX-2 induction by areca quid ingredients in oral keratinocytes.
Elevated Levels of Urinary Prostaglandin E Metabolite Indicate a Poor Prognosis in Ever Smoker Head and Neck Squamous Cell Carcinoma Patients.
Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
Ellagitannins from Punica granatum leaves suppress microsomal prostaglandin E synthase-1 expression and induce lung cancer cells to undergo apoptosis.
Endoplasmic Reticulum Stress Response as a Possible Mechanism of Cyclooxygenase-2-independent Anticancer Effect of Celecoxib.
Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor.
Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.
Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression.
Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas.
Enhancement of 5-Fluorouracil Efficacy on High COX-2 Expressing HCA-7 Cells by Low Dose Indomethacin and NS-398 but not on Low COX-2 Expressing HT-29 Cells.
Enhancement of chemotherapeutic drug-induced apoptosis by a cyclooxygenase-2 inhibitor in hypopharyngeal carcinoma cells.
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Enhancement of the sensitivity of renal cell carcinoma cells to fas-mediated cytotoxicity and apoptosis by the selective cyclooxygenase-2 inhibitor JTE-522.
EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways.
Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma.
Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4.
Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation.
Epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines is mediated through extracellular signal-regulated kinase 1/2 and p38 but is Src and nuclear factor-kappa B independent.
Epithelial to mesenchymal transition in cutaneous squamous cell carcinoma is correlated with COX-2 expression but not with the presence of stromal macrophages or CD10-expressing cells.
Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.
Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer.
Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma.
Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line.
Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma.
Evaluation of HPV and EBV in OSCC and the expression of p53, p16, E-cadherin, COX-2, MYC, and MLH1.
Evaluation of P53, E-cadherin, Cox-2, and EGFR protein imunnoexpression on prognostic of resected gallbladder carcinoma.
Evaluation of VEGF expression correlates with COX-2 expression in pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma.
Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression.
Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment.
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Expression analysis of cyclooxygenase-2 in patients suffering from esophageal squamous cell carcinoma.
Expression and clinical implication of cyclooxygenase-2 and e-cadherin in oral squamous cell carcinomas.
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma.
Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors.
Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2.
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma.
Expression characteristics of heparanase in colon carcinoma and its close relationship with cyclooxygenase-2 and angiogenesis.
Expression of 15-hydroxyprostaglandin dehydrogenase, a COX-2 antagonist and tumour suppressor, is not altered in gastric carcinomas.
Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis.
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin.
Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients.
Expression of Cox-1 and Cox-2 in canine mammary tumours.
Expression of COX-1, COX-2 and mPGES-1 in penile and preputial papillomas and squamous cell carcinomas in the horse.
Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features.
Expression of COX-2 and HER-2/neu and estrogen and progesterone receptor in primary squamous cell carcinomas of the endometrium.
Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma.
Expression of COX-2 in stomach cancers and its relation to their biological features.
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.
Expression of COX-2 proteins in gastric mucosal lesions.
Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Expression of COX-2, CD44v6 and CD147 and Relationship with Invasion and Lymph Node Metastasis in Hypopharyngeal Squamous Cell Carcinoma.
Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis.
Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions.
Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs.
Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas.
Expression of cyclooxygenase 2 and vascular endothelial growth factor in gastric carcinoma: Relationship with clinicopathological parameters.
Expression of cyclooxygenase 2 in human malignant melanoma.
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.
Expression of cyclooxygenase-1 and -2 in canine nasal carcinomas.
Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.
Expression of cyclooxygenase-1 and -2 in naturally occurring squamous cell carcinomas in horses.
Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma.
Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in normal and pathological human oral mucosa.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate.
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.
Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.
Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma.
Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa.
Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?
Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis.
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.
Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions.
Expression of cyclooxygenase-2 by equine ocular and adnexal squamous cell carcinomas.
Expression of cyclooxygenase-2 has no impact on survival in adenocarcinoma of the esophagogastric junction but is associated with favourable clinicopathologic features.
Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Expression of cyclooxygenase-2 in canine nasal carcinomas.
Expression of cyclooxygenase-2 in canine renal cell carcinoma.
Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.
Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma.
Expression of cyclooxygenase-2 in endometrial adenocarcinoma.
Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression.
Expression of Cyclooxygenase-2 in Human Epithelial Skin Lesions: A Systematic Review of Immunohistochemical Studies.
Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas.
Expression of cyclooxygenase-2 in human gastric carcinoma.
Expression of cyclooxygenase-2 in human lung carcinoma.
Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey.
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation.
Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival.
Expression of cyclooxygenase-2 in patients with bladder carcinoma.
Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression.
Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Expression of cyclooxygenase-2 in prostate carcinoma.
Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival.
Expression of Cyclooxygenase-2 in Squamous Cell Carcinoma and Keratoacanthoma and its Clinical Significance.
Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder.
Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs.
Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression.
Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.
Expression of cyclooxygenase-2 protein in colorectal carcinomas.
Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.
Expression of Cyclooxygenase-2 Protein in Gastric Carcinogenesis.
Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma.
Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis.
Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma.
Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-?B in oral squamous cell carcinoma.
Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas.
Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma.
Expression of Human epidermal growth factor receptor 2, Survivin, Enhancer of zeste homolog -2, Cyclooxygenase-2, p53 and p16 molecular markers in Gall bladder carcinoma.
Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma.
Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Expression of indolamine-2,3-dioxygenase and cyclooxygenase-2 in different disease stages of cutaneous squamous cell carcinoma.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density.
Expression of inflammation related enzymes during experimental rat lung carcinogenesis.
Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma.
Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?
Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs.
Expression of miR-143 Reduces Growth and Migration of Human Bladder Carcinoma Cells by Targeting Cyclooxygenase-2.
Expression of p27, COX-2, MLH1, and MSH2 in young patients with colon carcinoma and correlation with morphologic findings.
Expression of p63 and cyclooxygenase-2 and their correlation in skin tumors.
Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers.
Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in Oral Squamous Cell Carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation.
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.
Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance.
Expression of VEGF and Cox-2 in Patients with Esophageal Squamous Cell Carcinoma
Expression of VEGF, VEGFR, EGFR, COX-2 and MVD in cervical carcinoma, in relation with the response to radio-chemotherapy.
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH(2))D(3)) and prostaglandin E(2) (PGE(2)) serum level in ovarian cancer patients.
Expression profiles of Annexin A1, formylated peptide receptors and cyclooxigenase-2 in gastroesophageal inflammations and neoplasias.
Expression-targeted gene therapy for the treatment of transitional cell carcinoma.
Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression.
Extracellular matrix fibronectin increases prostaglandin E2 receptor subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2.
Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases.
Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression.
Flaxseed enriched diet-mediated reduction in ovarian cancer severity is correlated to the reduction of prostaglandin E2 in laying hen ovaries.
Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.
Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma.
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Functional variants of COX-2 and risk of tobacco-related oral squamous cell carcinoma in high-risk Asian Indians.
Gene expression patterns of COX-1, COX-2 and iNOS in H. Pylori infected histopathological conditions.
Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells.
Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells.
Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells.
Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa.
Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis.
Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer.
Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder.
Heparanase and cyclooxygenase-2 gene and protein expressions during progression of oral epithelial dysplasia to carcinoma.
Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression.
HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival.
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.
Heterogeneous distribution of COX-2 over-expression in human colon carcinoma cells.
HIF-1? and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma.
High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors.
High cyclooxygenase-2 expression in cervical adenocarcinomas.
High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma.
High expression of cyclooxygenase 2 is an indicator of prognosis for patients with esophageal squamous cell carcinoma after Ivor Lewis esophagectomy.
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas.
High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma.
Hippocampal dysfunctions in tumor-bearing mice.
Histologic correlation of VEGF and COX-2 expression with tumor size in squamous cell carcinoma of the larynx and hypopharynx.
Histopathological and Immunohistochemical Characteristics of Thyroid Carcinoma in the Dog.
Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB.
Host cyclooxygenase-2 modulates carcinoma growth.
Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
Hyperthermia Suppresses Post - In Vitro Proliferation and Tumor Growth in Murine Malignant Melanoma and Colon Carcinoma.
Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas.
Identification and absolute configuration of dihydroxy-arachidonic acids formed by oxygenation of 5S-hydroxyeicosatetraenoic acid by native and aspirin-acetylated cyclooxygenase-2.
Identification of a new broad-spectrum CD8+ T cell epitope from over-expressed antigen COX-2 in esophageal carcinoma.
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer.
Identification of key genes and long non?coding RNAs in celecoxib?treated lung squamous cell carcinoma cell line by RNA?sequencing.
Identification of novel target proteins in sebaceous gland carcinoma.
IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells.
IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2.
Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.
Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.
Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma.
Immunoexpression of cyclooxygenase-2 in primary gastric carcinomas and lymph node metastases.
Immunoexpression of p53 and COX-2 in basal cell carcinoma.
Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective.
Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.
Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China.
Immunohistochemical Demonstration of Membrane-bound Prostaglandin E(2) Synthase-1 in Papillary Thyroid Carcinoma.
Immunohistochemical Detection of COX-2 in Feline and Canine Actinic Keratoses and Cutaneous Squamous Cell Carcinoma.
Immunohistochemical detection of Ki-67 is not associated with tumor-infiltrating macrophages and cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical evaluation of COX-2 expression in HPV-positive cervical squamous intraepithelial lesions.
Immunohistochemical evaluation of cyclooxygenase expression in corneal squamous cell carcinoma in horses.
Immunohistochemical expression of COX-2 in thyroid nodules.
Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid.
Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
Immunohistochemical expression of cyclooxygenase-2 in canine ovarian carcinomas.
Immunohistochemical expression of cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical expression of cyclooxygenase-2 in skin cancers.
Immunohistochemical Expression of Matrix Metalloproteinase-1 and Cyclooxygenase-2 in Cutaneous Squamous Cell and Basal Cell Carcinoma.
Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival.
Immunohistochemical markers of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer.
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor.
Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line.
Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
In vitro evidence of the role of COX-2 in attenuating gastric inflammation and promoting gastric carcinogenesis.
In vitro susceptibility to anticancer agents of the human KB carcinoma cell line transfected with COX-2 cDNA.
Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis.
Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival.
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.
Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer.
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs.
Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.
Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: a pilot study.
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.
Increased expression of cyclooxygenase-2 in human salivary gland tumors.
Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.
Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer.
Increased level of serum prostaglandin-2 in early stage of esophageal squamous cell carcinoma.
Increased levels of promutagenic etheno-DNA adducts in colonic polyps of FAP patients.
Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1.
Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor.
Induction of COX-2 protein expression by vanadate in A549 human lung carcinoma cell line through EGF receptor and p38 MAPK-mediated pathway.
Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference.
Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.
Inhibition of 11?-Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression as Well as the ERK and mTOR Signaling Pathways.
Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis.
Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer.
Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44.
Inhibition of Cyclooxygenase-2 Suppresses Lymph Node Metastasis via Reduction of Lymphangiogenesis.
Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation.
Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib.
Inhibition of growth of a murine squamous cell carcinoma by a cyclooxygenase inhibitor increases leukotriene B4 production.
Inhibition of ovarian cancer proliferation and invasion by pachymic acid.
Inhibition of TPA-induced cyclooxygenase-2 (COX-2) expression by apigenin through downregulation of Akt signal transduction in human keratinocytes.
Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21.
Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells.
Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer.
Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A(2) and peroxisome proliferator-activated receptor gamma.
Inhibitory effect of HuR gene small interfering RNA segment on laryngeal carcinoma Hep-2 cell growth.
Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line.
Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2 in vitro.
Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets.
Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in rats initiated with 4-nitroquinoline 1-oxide.
Interaction between cyclooxygenase-2 and inducible nitric oxide synthase in gastric cancer.
Interaction of Cyclooxygenase-2 with Helicobacter pylori Induces Gastric Chronic Nonresolving Inflammation and the Formation of Syndrome of Internal Block of Static Blood in Helicobacter pylori-Related Gastric Diseases.
Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro.
Interplay between oncoproteins and antioxidant enzymes in esophageal carcinoma treated without and with chemoradiotherapy: a prospective study.
Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma.
Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
Involvement of cyclooxygenase-2 in the tumor site-dependent production of parathyroid hormone-related protein in colon 26 carcinoma.
Is cyclooxygenase-2 important in skin carcinogenesis?
JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse.
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.
KRAS, EGFR, PDGFR-?, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE).
Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation.
Lipopolysaccharide initiates a positive feedback of epidermal growth factor receptor signaling by prostaglandin E2 in human biliary carcinoma cells.
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.
Lipoxygenase-5 is overexpressed in prostate adenocarcinoma.
Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma.
Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2.
Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.
Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma.
Lower expression of cyclooxygenase-2: is it associated with the development of borderline ovarian tumors?
Malignant salivary gland tumors and cyclo-oxygenase-2: A histopathological and immunohistochemical analysis with implications on histogenesis.
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells.
Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma.
MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival.
MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells.
Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study.
Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma.
Minor salivary gland carcinoma: a review of 35 cases.
MiR-124-3p Suppresses Prostatic Carcinoma by Targeting PTGS2 Through the AKT/NF-?B Pathway.
miR-203 is involved in the laryngeal carcinoma pathogenesis via targeting VEGFA and Cox-2.
MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.
miR-26b is downregulated in human tongue squamous cell carcinoma and regulates cell proliferation and metastasis through a COX-2-dependent mechanism.
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells.
MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells.
Mixed-Generation PAMAM G3-G0 Megamer as a Drug Delivery System for Nimesulide: Antitumor Activity of the Conjugate Against Human Squamous Carcinoma and Glioblastoma Cells.
Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and gamma-rays regulating expression of the BCL-2 family proteins, COX-2 and p21.
Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer.
Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice.
Molecular carcinogenesis in equine penile cancer: A potential animal model for human penile cancer.
Molecular Characterization of Feline COX-2 and Expression in Feline Mammary Carcinomas.
Molecular Imaging of Cyclooxygenase-2 in Canine Transitional Cell Carcinomas In Vitro and In Vivo.
Molecular pathology of cyclooxygenase-2 in neoplasia.
Molecular typing of epithelial ovarian carcinomas using inflammatory markers.
Multicenter Phase II Trial of Combination Therapy with Meloxicam, a COX-2 Inhibitor, and Natural Interferon-{alpha} for Metastatic Renal Cell Carcinoma.
Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.
New insights into the functions of Cox-2 in skin and esophageal malignancies.
NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer.
NFAT2 overexpression suppresses the malignancy of hepatocellular carcinoma through inducing Egr2 expression.
Nicotine, lung and cancer.
Nimesulide and indomethacin induce apoptosis in head and neck cancer cells.
Nimesulide inhibited the growth of hypopharyngeal carcinoma cells via suppressing Survivin expression.
Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line.
Nine-year follow-up of a patient with attenuated familial adenomatous polyposis treated with cyclo-oxygenase-2 inhibitors.
Nitric Oxide (NO) and Cyclooxygenase-2 (COX-2) Cross-Talk in Co-Cultures of Tumor Spheroids with Normal Cells.
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.
Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model.
Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma.
Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma.
Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-induced expression of COX-2.
NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation.
Nuclear factor ?B and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma.
Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.
Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression.
Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A.
Oncolytic adenoviral therapy in gallbladder carcinoma.
Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2.
Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation.
Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis.
Overexpression of COX-2 in oral squamous cell carcinoma patients undergoing chemoradiotherapy.
Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx.
Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma.
Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes.
Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma.
Overexpression of cyclooxygenase-2 in carcinoma of the pancreas.
Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract.
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
Overexpression of cyclooxygenase-2 in NCI-H292 human alveolar epithelial carcinoma cells: Roles of p38 MAPK, ERK-1/2, and PI3K/PKB signaling proteins.
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder.
Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1alpha expression, and tumor angiogenesis.
Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy.
Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients.
Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma.
Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy.
Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies.
Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
Overexpression of lipocalins and pro-inflammatory chemokines and altered methylation of PTGS2 and APC2 in oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide.
Overexpression of phospholipase A2 Group IIA in esophageal squamous cell carcinoma and association with cyclooxygenase-2 expression.
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
P21, COX-2, and E-cadherin are potential prognostic factors for esophageal squamous cell carcinoma.
P53, COX-2, iNOS protein expression changes and their relationship with anti-oxidant enzymes in surgically and multi-modality treated esophageal carcinoma patients.
Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells.
Pattern of expression of cyclooxygenase-2 in malignant transformation of sinonasal inverted papilloma.
PDLIM4 Repression by Hypermethylation as a Potential Biomarker for Prostate Cancer.
Peroxisome proliferator-activated receptor {gamma} in human breast carcinoma: a modulator of estrogenic actions.
PGE2 production in oral cancer cell lines is COX-2-dependent.
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells.
Phase-II trial of combination treatment of interferon-?, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma.
PHGPx overexpression induces an increase in COX-2 activity in colon carcinoma cells.
PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro.
Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms.
Polarization and Distribution of Tumor-Associated Macrophages and COX-2 Expression in Basal Cell Carcinoma of the Ocular Adnexae.
Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study.
Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes.
Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population.
Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk.
Positive and negative regulation of prostaglandin E2 biosynthesis in human colorectal carcinoma cells by cancer chemopreventive agents.
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Possible role of PPAR-? and COX-2 receptor modulators in the treatment of Non-Small Cell lung carcinoma.
Postoperative efficacy of low-temperature plasma radiofrequency ablation in elderly patients with laryngeal carcinoma and its influences on tumor markers and COX-2 and VEGF expressions in laryngeal carcinoma tissues.
Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Potential targets for colorectal cancer prevention.
PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.
Prediction of lymphovascular space invasion using a combination of tenascin-C, cox-2, and PET/CT radiomics in patients with early-stage cervical squamous cell carcinoma.
Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.
Preferential expression of cyclooxygenase-2 in colonic-phenotype of gastric intestinal metaplasia: association with helicobacter pylori and gastric carcinoma.
Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice.
Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.
Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model.
Production of prostaglandinE2 via bile acid is enhanced by trypsin and acid in normal human esophageal epithelial cells.
Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors.
Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy.
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.
Prognostic evaluation of COX-2 expression in renal cell carcinoma.
Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma.
Prognostic implications of cimetidine on advanced serous ovarian carcinoma related to cyclooxygenase-2 expression.
Prognostic importance of COX-2 expression in patients with colorectal cancer.
Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma.
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens.
Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma.
Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma.
Prognostic significance of cyclooxygenase-2 in cervical cancer: A meta-analysis.
Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma.
Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma.
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.
Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.
Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
Prognostic value of COX-2, P53, and EZH-2 evaluated by quantitative image analysis in premalignant and malignant breast lesions.
Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder.
Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma.
Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.
Promoter methylation regulates cigarette smoke-stimulated cyclooxygenase-2 expression in esophageal squamous cell carcinoma.
Promoter methylation status of the tumor suppressor genes p16 and cadherin 1 in cervical intraepithelial neoplasia.
Promotion of cell differentiation, and suppression of cell growth and cyclooxygenase-2 expression by differentiation-inducing agents in human oral squamous carcinoma SCC25 cells.
Promotion of hematogenous metastatic potentials in human KB carcinoma cells with overexpression of cyclooxygenase-2.
Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth.
Prostaglandin E(2) Drives Cyclooxygenase-2 Expression via Cyclic AMP Response Element Activation in Human Pancreatic Cancer Cells.
Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells.
Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin.
Prostaglandins in human breast cancer. Identification of a cytosolic prostaglandin-9-keto-reductase activity.
Prostaglandins in the stomach: an update.
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression.
Prostanoid induces premetastatic niche in regional lymph nodes.
Protein kinase C delta overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2.
Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer.
Quantitative analysis of COX-2 promoter methylation in gastric carcinoma.
R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway.
Radiation quality effects alteration in COX-2 pathway to trigger radiation-induced bystander response in A549 lung carcinoma cells.
Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2.
Radioiodinated indomethacin amide for molecular imaging of cyclooxygenase-2 expressing tumors.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder.
Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors.
Re: cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.
Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines.
Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells.
Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation.
Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.
Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder.
Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.
Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
Relationship among expression of basic-fibroblast growth factor, MTDH/Astrocyte elevated gene-1, adenomatous polyposis coli, matrix metalloproteinase 9,and COX-2 markers with prognostic factors in prostate carcinomas.
Relationship between arachidonic acid pathway and human renal cell carcinoma.
Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma.
Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.
Relationship of CD95 and COX-2 in renal cell carcinomas with survival and other prognostic parameters: A tissue microarray study.
Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma.
Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.
Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells.
Retraction Note to: Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells.
Retraction.
Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy.
Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer.
Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.
RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility.
Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.
Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Role of cyclooxygenase-2, ezrin and matrix metalloproteinase-9 as predictive markers for recurrence of basal cell carcinoma.
Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.
Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways.
Scutellaria baicalensis alleviates cantharidin-induced rat hemorrhagic cystitis through inhibition of cyclooxygenase-2 overexpression.
Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma.
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.
Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma.
Seminal plasma activates cyclooxygenase-2 and prostaglandin E2 receptor expression and signalling in cervical adenocarcinoma cells.
Sequential expression of inducible nitric oxide synthase and cyclooxygenase-2 during DMBA-induced hamster buccal pouch carcinogenesis.
Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase.
shRNA-targeted Cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells.
Significance of COX-2 expression in human esophageal squamous cell carcinoma.
Significance of COX-2 expression in human renal cell carcinoma cell lines.
Significance of COX-2 expression in human renal cell carcinoma.
Significance of Cyclooxygenase 2, EZH-2 Polycomb Group and p53 Expression in Actinic Keratosis and Squamous Cell Carcinomas of the Skin.
Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.
Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus.
Significance of immunohistochemical overexpression of cyclooxygenase-2 in overall and disease-free survival of oral squamous cell carcinoma patients.
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo.
Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas.
SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells.
Sodium arsenite-induced abnormalities in expressions of Caveolin-1, eNOS, IKK?, and COX-2 in SV-40 immortalized human uroepithelial cells and in urothelial carcinomas.
Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.
Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production.
Streptococcus gallolyticus conspires myeloid cells to promote tumorigenesis of inflammatory bowel disease.
Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma.
Studies on the Contribution of Cox-2 Expression in the Progression of Oral Squamous Cell Carcinoma and H-Ras Activation.
Study of cyclooxygenase-2 in renal cell carcinoma.
Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment.
Study on the association of COX-2 genetic polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu province in China.
Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells.
Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model.
Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth.
Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms.
Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
Survivin and Cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes.
Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival.
Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro.
T-oligo treatment decreases constitutive and UVB-induced COX-2 levels through p53- and NFkappaB-dependent repression of the COX-2 promoter.
Tangeretin suppresses IL-1beta-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells.
Targeted expression of ornithine decarboxylase antizyme prevents upper aerodigestive tract carcinogenesis in p53-deficient mice.
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Targeting PRPK and TOPK for skin cancer prevention and therapy.
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor.
The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid.
The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade.
The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy.
The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.
The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway.
The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines.
The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
The Cyclooxygenase-2 Inhibitor Nimesulide, a Nonsteroidal Analgesic, Decreases the Effect of Radiation Therapy in Head-and-Neck Cancer Cells.
The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis.
The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma.
The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines.
The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo.
The effects of cyclooxygenase-2 inhibition on apoptosis and cell cycle distribution using two in vitro models of nasal squamous cell carcinoma.
The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells.
The expression of cyclooxygenase in transitional cell carcinoma cell lines: its correlation with tumor differentiation, invasiveness and prostanoids production.
The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma.
The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases.
The function of COX-2 in human ovarian carcinoma.
The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1.
The impact of cyclooxygenase-2 and vascular endothelial growth factor C immunoexpression on the prognosis of penile carcinoma.
The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines.
The inhibitory effect of Gleditsia sinensis on cyclooxygenase-2 expression in human esophageal squamous cell carcinoma.
The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.
The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?
The prognostic roles of cyclooxygenase-2 for patients with basal cell carcinoma.
The prognostic significance of COX-2 and survivin expression in ovarian cancer.
The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma.
The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma.
The relationship between cyclooxygenase-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma.
The relationship between HPV16 and expression of cyclooxygenase-2, P53 and their prognostic roles in esophageal squamous cell carcinoma.
The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer.
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder.
The role of angiogenesis and COX-2 expression in the evolution of vulvar lichen sclerosus to squamous cell carcinoma of the vulva.
The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.
The role of COX-2 inhibitors in lung cancer.
The role of COX-2/PGE(2) in gossypol-induced apoptosis of colorectal carcinoma cells.
The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma.
The role of functional polymorphisms of cyclooxygenase 2 in renal cell carcinoma.
The role of Ki-67, p16, CD34, Bcl-2, cyclooxygenase-2 in the pathogenesis of proliferative verrucous leukoplakia.
The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
The therapeutic activity of curcumin through its anti-cancer potential on oral squamous cell carcinoma: A study on Sprague Dawley rat.
The transcription factor Snail expressed in cutaneous squamous cell carcinoma induces epithelial-mesenchymal transition and down-regulates COX-2.
Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice.
Thromboxane production by platelets during tumor cell-induced platelet activation.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues.
Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells.
Transitional Cell Carcinoma in Fishing Cats (Prionailurus viverrinus): Pathology and Expression of Cyclooxygenase-1, -2, and p53.
Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.
Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma.
Translational approach utilizing COX-2, p53, and MDM2 expressions in malignant transformation of oral submucous fibrosis.
Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer.
Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction.
Tumor cells induce COX-2 and mPGES-1 expression in microvascular endothelial cells mainly by means of IL-1 receptor activation.
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: mechanisms of enhancement using prostaglandin synthetase inhibitors.
Tumor-Associated Macrophage-Induced Invasion and Angiogenesis of Human Basal Cell Carcinoma Cells by Cyclooxygenase-2 Induction.
Up-regulation of cyclooxygenase 2 and matrix metalloproteinases-2 and -9 in cutaneous squamous cell carcinoma: active role of inflammation and tissue remodeling in carcinogenesis.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Up-regulation of cyclooxygenase-2 by interleukin-1beta in colon carcinoma cells.
Up-regulation of cyclooxygenase-2 by product-prostaglandin E2.
Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase.
Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus.
Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2 -1195G>a polymorphism reveal risk of oral cancer.
USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer.
Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.
VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma.
VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value.
VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro.
Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression.
Zinc deficiency potentiates induction and progression of lingual and esophageal tumors in p53-deficient mice.
Zinc supplementation suppresses 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis.
[A case of favorable response after combination treatment with interferon-? and cyclooxygenase-2 inhibitor against metastatic renal cell carcinoma].
[A relationship between cyclooxygenase-2 expression and tumor angiogenesis in experimental rat liver carcinogenesis.]
[A study on cyclooxygenase-2 protein expression and vasculature during experimental rat lung carcinogenesis]
[A study on cyclooxygenase-2 protein expression in esophageal carcinoma and premalignant lesions]
[Analysis of HIF-1? and COX-2 expression in tumor stroma and correlation with the degree of neoplasm invasiveness in laryngeal cancer--preliminary study].
[Anti-cancer treatment with prostaglandin synthetase inhibitor in animal models]
[Association between Helicobacter pylori cagA strain infection and expression of cyclooxygenase 2 in gastric carcinoma]
[Association of abnormal cyclooxygenase-2 gene expression with colorectal carcinoma metastasis]
[Clinical significance and relationship between HIF-1alpha, COX-2, VEGF and microvessel density expression in laryngeal carcinoma].
[Correlation of cyclooxygenase 2 expression with microlymphatic density and its clinical significance]
[Correlation of Helicobacter pylori infection with the expression of COX-2 and EGFR and VEGF in human gastric carcinoma]
[COX and study of cancer therapy]
[COX-2 associated loss of apoptosis activity in intestinal neoplams in Apc gene knock-out mice]
[COX-2 inhibitors in inflammatory bowel disease: friends or foes?]
[Cyclo-oxygenase-2 and p53 immunoreactivity in superficial early colorectal carcinoma]
[Cyclooxygenase 2 inhibitors and lung carcinoma]
[Cyclooxygenase inhibitors in chemoprevention and treatment of esophageal squamous cell carcinoma]
[Cyclooxygenase-2, inducible nitric oxide synthase protein expression and vasculature during experimental rat lung carcinogenesis.]
[Cyclooxygenases in the skin]
[Cyclooxygenases]
[Development of new treatment modalities for advanced head and neck carcinomas]
[Ease-2 and inducible nitric oxide synthase in tongue hyperplasia and tongue squamous cell carcinoma]
[Effect of cyclooxygenase-2 inhibitor on expression of matrix metalloproteinase-2 and invasion of tongue squamous cell carcinoma cell line Tca8113].
[Effect of GPX4 on proliferation and metastasis of renal clear cell carcinoma and its relationship with expression of IGF-1R and COX-2].
[Effect of Kanglaite injection oncyclooxygenase activity in lung carcinoma A549 cell]
[Effect of selective cyclooxygenase-2 inhibitor celebrex on expression of vascular endothelial growth factor (VEGF) in pancreatic carcinoma]
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]
[Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]
[Effects of tea polyphenols on the expression of NF-?B, COX-2 and survivin in Lewis lung carcinoma xenografts in C57BL/6 mice].
[Epidermal growth factor stimulates the proliferation of human esophageal squamous cell carcinoma HKESC-1 cells by increasing COX-2 expression].
[Expression and clinical significance of COX-2 and BCL-2 in distal transitional mucosa adjacent to rectal carcinoma].
[Expression and clinical significance of Cox-2 and XIAP in malignant tumors of the salivary gland].
[Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma]
[Expression and clinical significance of cyclooxygenase-2 in nasal and paranasal sinus carcinoma]
[Expression and clinical significance of hypoxia-inducible factor-1alpha and cyclooxygenase-2 in laryngeal squamous cell carcinoma]
[Expression and implication of cyclooxygenase-2 mRNA in prostate cancer]
[Expression and prognostic significance of cyclooxygenase-2 in supraglottic laryngeal squamous cell carcinomas]
[Expression and significance of COX-2 and S-100 positive dendritic cell in laryngeal carcinoma]
[Expression and significance of cyclooxygenase-2 in human pancreatic carcinomas]
[Expression of CD44v6 and COX-2 in pleomorphic adenomas and carcinomas of parotid gland].
[Expression of COX-2 and its prognostic significance in non-small cell lung cancer.]
[Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance]
[Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]
[Expression of COX-2 and VEGF-C in squamous cell carcinoma of the tongue and its correlation to lymph node metastasis]
[Expression of cyclooxygenase in bladder transitional cell carcinoma]
[Expression of cyclooxygenase-2 and p53 and their correlation in carcinoma of larynx]
[Expression of cyclooxygenase-2 and relationship with mismatch repaire gene and microsatellite instability in hereditary non-polyposis colorectal cancer]
[Expression of cyclooxygenase-2 and urokinase plasminogen activator in gastric carcinoma and the clinical significance thereof]
[Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof]
[Expression of cyclooxygenase-2 in esophageal squamous cell carcinogenesis]
[Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas]
[Expression of cyclooxygenase-2 in ovarian carcinoma and its significance]
[Expression of cyclooxygenase-2, hMLH1 and hMSH2 proteins, and their relationship with microsatellite instability in gastric carcinoma]
[Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation.]
[Expression of NF-kappaB and COX-2 in tongue squamous cell carcinoma]
[Expression of p53, p21, PCNA and COX-2 and its relationship with recurrence in the early-stage laryngeal cancer with negative surgical margin].
[Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance.]
[Expressions of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma and their correlation]
[Gastric carcinoma and chronic gastritis: epigenetic regulation of CDH1 (E-Cadherin), CDKN2A (p16INK4A), PTGS2 (COX-2) and EGFR genes through methylation]
[Influence of selective cyclooxygenase-2 inhibitor on proliferation of human gastric cancer cells]
[Inhibition of angiogenesis in pancreatic carcinoma by cyclooxygenase-2 antisense oligodeoxynucleotides]
[Inhibition of the growth of a murine transplantable tumor, colon 26, by the prostaglandin synthetase inhibitor, indomethacin]
[Inhibitory effects of COX-2 inhibitor on migration of human tongue squamous cell carcinoma Tca8113 cells]
[Mechanism and effect of selective cyclooxygenase-2 inhibitor NS-398 on human cervical carcinoma cells]
[Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors]
[NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]
[Nimesulide induced apoptosis and inhibited metastasis of hypopharyngeal carcinoma cells].
[Nuclear factor kappaB/p65 and cyclooxygenase-2 expression and clinic significance in human laryngeal squamous cell carcinoma]
[Overexpression of COX-2 and its clinical significance in non-small cell lung cancer]
[p53, p16 E COX-2 expression in esophageal squamous cell carcinoma and histopathological association]
[Prognostic role and regulation of cyclooxygenase-2 (COX-2) in ovarian carcinoma]
[Prostate carcinoma: higher COX-2 contents in advanced tumors]
[Relation between COX-2 protein expression and biologic behavior of ovarian carcinoma]
[Relationship between cyclooxygenase (COX)-2 and malignant tumors]
[Relationship between cyclooxygenase-2 in nasopharyngeal carcinoma and cervical lymph node metastasis].
[Relationship between cyclooxygenase-2 protein expression, prostaglandins levels and biologic behavior in ovarian carcinoma tissue]
[Relationship between the expression of cyclooxygenase-2 and microvessel density in oral squamnous cell carcinoma]
[Relationship of cyclooxygenase 2 expression and chemotherapy response and prognosis in human ovarian carcinoma]
[Relationship of cyclooxygenase-2 and multidrug resistance associated factors to chemosensitivities in gastrointestinal carcinomas]
[Roles of cyclooxygenase-2 and caspase-3 expression in pathogenesis of lung carcinoma: an experiment with rats]
[Short-term preoperative treatment of celecoxib, a selective cyclooxygenase-2 inhibitor, on E-cadherin expression in gastric carcinoma tissues.]
[Study of COX-2 expression and angiogenesis in non-small cell lung cancer.]
[Study on inhibitory effects of c9, t11-conjugated linoleic acid on migration of human gastric carcinoma cell line via cyclooxygenase-2 pathway]
[The antimicrobial effects of chitosans on oral pathogenic microbes in vitro.]
[The characteristics of prostaglandin E synthesis in epithelial ovarian tumors]
[The expression and significance of HIF-1alpha and COX-2 in laryngeal squamous cell carcinoma]
[The expression of COX-2 mRNA and protein in human laryngeal squamous cell carcinoma]
[The expressiong of cyclooxygenase-2 in laryngeal squamous cell carcinoma and its relationship with MVD]
[The expressions of cyclooxygenase-2 (Cox-2),VEGF in oral squamous cell carcinoma and precancerous lesions and their significances]
[The IL-6 and COX-2 expression related to sensitivity of chemoradiotherapy and prognosis in esophageal carcinoma]
[The influence of COX-2 depressant in angiogenesis of oral squamous cell carcinoma].
[The significance of the expression of cyclooxygenase-2 in bladder transitional cell carcinoma tissues]
Carcinoma in Situ
Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma.
Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy.
Coexpression of COX-2 and iNOS in Angiogenesis of Superficial Esophageal Squamous Cell Carcinoma.
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix.
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer.
Expression analysis of cyclooxygenase-2 in patients suffering from esophageal squamous cell carcinoma.
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.
Expression of cyclooxygenase-2 by equine ocular and adnexal squamous cell carcinomas.
Expression of inflammation related enzymes during experimental rat lung carcinogenesis.
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice.
Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer.
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Significance of COX-2 expression in human esophageal squamous cell carcinoma.
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Targeted expression of ornithine decarboxylase antizyme prevents upper aerodigestive tract carcinogenesis in p53-deficient mice.
Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus.
[A study on cyclooxygenase-2 protein expression and vasculature during experimental rat lung carcinogenesis]
[A study on cyclooxygenase-2 protein expression in esophageal carcinoma and premalignant lesions]
[Cyclooxygenase-2, inducible nitric oxide synthase protein expression and vasculature during experimental rat lung carcinogenesis.]
Carcinoma, Acinar Cell
Increased expression of cyclooxygenase-2 in human salivary gland tumors.
Carcinoma, Adenoid Cystic
Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix.
Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.
Evaluation of VEGF expression correlates with COX-2 expression in pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma.
[Expression and clinical significance of Cox-2 and XIAP in malignant tumors of the salivary gland].
Carcinoma, Adenosquamous
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
Carcinoma, Basal Cell
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk.
Correlation and expression of COX-2 and P53 protein in basal cell carcinoma of eyelid.
CXCR-4 and COX-2 Expression in Basal Cell Carcinomas and Well-Differentiated Squamous Cell Carcinomas of the Skin; Their Relationship with Tumor Invasiveness and Histological Subtype.
Cyclooxygenase-2 expression and association with skin cancer: A meta-analysis based on Chinese patients.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis.
Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation.
Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer.
Expression of Cyclooxygenase-2 in Human Epithelial Skin Lesions: A Systematic Review of Immunohistochemical Studies.
Immunoexpression of p53 and COX-2 in basal cell carcinoma.
Immunohistochemical expression of cyclooxygenase-2 in skin cancers.
Immunohistochemical Expression of Matrix Metalloproteinase-1 and Cyclooxygenase-2 in Cutaneous Squamous Cell and Basal Cell Carcinoma.
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: a pilot study.
Polarization and Distribution of Tumor-Associated Macrophages and COX-2 Expression in Basal Cell Carcinoma of the Ocular Adnexae.
Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes.
Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.
Role of cyclooxygenase-2, ezrin and matrix metalloproteinase-9 as predictive markers for recurrence of basal cell carcinoma.
The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases.
The prognostic roles of cyclooxygenase-2 for patients with basal cell carcinoma.
Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma.
Tumor-Associated Macrophage-Induced Invasion and Angiogenesis of Human Basal Cell Carcinoma Cells by Cyclooxygenase-2 Induction.
Carcinoma, Bronchogenic
Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.
Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas.
Immunohistochemical markers of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer.
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment.
Carcinoma, Ductal
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.
A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer.
Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer?
Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer.
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
COX-2 Expression in Breast Carcinoma with Correlation to Clinicopathological Parameters
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts.
Cyclooxygenase-2 expression during immortalization and breast cancer progression.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast.
Cyclooxygenase-2 immunoexpression in breast cancer: Progesterone receptor influence.
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Cyclooxygenase-2: a potential target in breast cancer.
DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.
Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors.
Expression of cyclooxygenase-2 and its relation to histological grade, inducible nitric oxide synthase, matrix metalloproteinase-2, CD-34, Caspase-3, and CD8 in invasive ductal carcinoma of the breast.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Expression of cyclooxygenase-2 in malignant and benign breast tumors.
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.
High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer.
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.
Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer.
Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium.
Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors.
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.
Physiological COX-2 Expression in Breast Epithelium Associates with COX-2 Levels in Ductal Carcinoma in Situ and Invasive Breast Cancer in Young Women.
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Prognostic Significance of Cyclooxygenase-2 and Response to Chemotherapy in Invasive Ductal Breast Carcinoma Patients by Real Time Surface Plasmon Resonance Analysis.
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.
The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Carcinoma, Endometrioid
Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.
Carcinoma, Hepatocellular
A New Ligustrazine Derivative-Selective Cytotoxicity by Suppression of NF-?B/p65 and COX-2 Expression on Human Hepatoma Cells. Part 3.
A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery.
A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment.
Absence of nuclear factor kappaB inhibition by NSAIDs in hepatocytes.
Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Altered expression of COX-2 and TNF-? in patients with hepatocellular carcinoma.
Anti-tumorigenic efficacy of Tangeretin in Liver Cancer - An in-silico approach.
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis.
Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-?, and Vascular Endothelial Growth Factor-A Genes, and Susceptibility to Hepatocellular Carcinoma.
Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in taiwan.
Associations between Cox-2 rs20417 and rs5275 polymorphisms and the risk of hepatocellular carcinoma: a meta analysis.
C-Phycocyanin inhibits MDR1 through reactive oxygen species and cyclooxygenase-2 mediated pathways in human hepatocellular carcinoma cell line.
Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line.
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Chebulagic Acid Synergizes the Cytotoxicity of Doxorubicin in Human Hepatocellular Carcinoma Through COX-2 Dependant Modulation of MDR-1.
Chemoprevention of cancer--focusing on clinical trials.
Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor.
Chemopreventive effect of saikosaponin-d on diethylinitrosamine-induced hepatocarcinogenesis: involvement of CCAAT/enhancer binding protein ? and cyclooxygenase-2.
Chitosan nanoparticles loaded with aspirin and 5-fluororacil enable synergistic antitumour activity through the modulation of NF-?B/COX-2 signalling pathway.
Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest.
Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC).
Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases.
Combination of cyclooxygenase-2 inhibitor and doxorubicin increases the growth inhibition and apoptosis in human hepatocellular carcinoma cells.
Common Variants of the Prostaglandin-Endoperoxide Synthase 2 Gene and Hepatocellular Carcinoma Susceptibility.
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis.
Correlation of microRNA-16, microRNA-21 and microRNA-101 expression with cyclooxygenase-2 expression and angiogenic factors in cirrhotic and noncirrhotic human hepatocellular carcinoma.
Correspondence re: M. Kondo et al., Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res., 5: 4005-4012, 1999.
COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival.
COX-2 Forms Regulatory Loop with YAP to Promote Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells.
COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1?/PKM2 pathway.
COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis.
COX-2 polymorphisms -765G?C and -1195A?G and hepatocellular carcinoma risk.
COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclooxygenase inhibition is associated with downregulation of apolipoprotein AI promoter activity in cultured hepatoma cell line HepG2.
Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells.
Cyclooxygenase-2 -1195G>A (rs689466) polymorphism and cancer susceptibility: an updated meta-analysis involving 50,672 subjects.
Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma.
Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization.
Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment.
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study .
Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States.
Cyclooxygenase-2 expression in hepatocellular carcinoma.
Cyclooxygenase-2 expression is associated with elevated aspartate aminotransferase level in hepatocellular carcinoma.
Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival.
Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents.
Cyclooxygenase-2 gene polymorphisms and susceptibility to hepatocellular carcinoma: A meta-analysis based on 10 case-control studies.
Cyclooxygenase-2 in hepatocellular carcinoma.
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids.
Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice.
Cyclooxygenase-2 is a target of microRNA-16 in human hepatoma cells.
Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma.
Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Cyclooxygenase-2 promoter polymorphism -899G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province.
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Cyclooxygenase-2 single-nucleotide polymorphisms and hepatocellular carcinoma in Egypt.
Cyclooxygenases in hepatocellular carcinoma.
Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma.
Detection of membrane-bound enzymes in cells using immunoassay and Raman microspectroscopy.
Dietary alpha-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells.
Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis.
Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?
Dose-dependent effect of dietary conjugated linoleic acid on the growth of rat hepatoma dRLh-84 cells in vivo.
Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2.
Effect of Ginkgo biloba extract on the expressions of Cox-2 and GST-Pi in rats with hepatocellular carcinoma risk.
Effect of heptitis C virus core protein on cellular gene expression: specific inhibition of cyclooxygenase 2.
Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells.
Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial.
Effects of adenovirus-mediated human cyclooxygenase-2 antisense RNA on the growth of hepatocellular carcinoma.
Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice.
Effects of the Geiji-Bokryung-Hwan on carrageenan-induced inflammation in mice and cyclooxygenase-2 in hepatoma cells of HepG2 and Hep3B.
Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase.
Endoplasmic Reticulum Stress-Induced Resistance to Doxorubicin Is Reversed by Mulberry Leaf Polyphenol Extract in Hepatocellular Carcinoma through Inhibition of COX-2.
Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.
Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line.
Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma.
Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma.
Exogenous hydrogen sulfide exerts proliferation/anti-apoptosis/angiogenesis/migration effects via amplifying the activation of NF-?B pathway in PLC/PRF/5 hepatoma cells.
Exogenous hydrogen sulfide promotes hepatocellular carcinoma cell growth by activating the STAT3-COX-2 signaling pathway.
Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy.
Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation.
Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2.
Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma.
Functional polymorphisms of the cyclooxygenase-2 gene and prognosis of hepatocellular carcinoma - a cohort study in Chinese people.
Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation.
Guggulsterone sensitized drug-resistant human hepatocarcinoma cells to doxorubicin through a Cox-2/P-gp dependent pathway.
Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice.
Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-?B signal cascade.
Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication.
Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features.
In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
In Vitro and In Vivo Protective Effects of Flavonoid-Enriched Lotus Seedpod Extract on Lipopolysaccharide-Induced Hepatic Inflammation.
In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.
Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.
Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma.
Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors.
Induction of cyclooxygenase-2 by tumor promoters in transformed and cytochrome P450 2E1-expressing hepatocytes.
Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
Inhibition of HepG2 cell proliferation by ursolic acid and polysaccharides via the downregulation of cyclooxygenase-2.
Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.
Inhibitory effects of inhibitors of arachidonic acid metabolism on the evolution of rat liver preneoplastic foci into nodules and hepatocellular carcinomas with or without phenobarbital exposure.
Interferon-? and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.
Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines.
Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
Knockdown of cyclooxygenase-2 leads to growth inhibition and cell cycle arrest in hepatocellular carcinoma cells.
Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival.
lncRNA HULC promotes the growth of hepatocellular carcinoma cells via stabilizing COX-2 protein.
Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization.
Loss of endogenous TGF-beta effect induces mouse hepatoma malignancy by correlation with cyclooxygenase-2 and VEGF.
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Mechanism-based in vitro screening of potential cancer chemopreventive agents.
Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.
Melatonin and (-)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer.
Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis.
Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation.
Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways.
Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1? Signaling in Hepatocellular Carcinoma.
Microalgal extract from thermotolerant Coelastrella sp. F50 retards the liver tumor progression by targeting hepatic cancer stem cells.
MicroRNA-30a-3p acts as a tumor suppressor in MHCC-97H hepatocellular carcinoma cells by targeting COX-2.
Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/?-catenin signaling axis.
MiR-136 inhibits malignant progression of hepatocellular carcinoma cells by targeting cyclooxygenase 2.
Morin regulates the expression of NF-kappaB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma.
Nimesulide inhibits the proliferation of HepG2 by up-regulation of Smad4.
Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma.
Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.
NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines.
NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways.
NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspase-independent apoptosis.
Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.
Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis.
Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.
P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Pattern of Apoptosis by NS398, a Selective COX-2 Inhibitor, in Hepatocellular Carcinoma Cell Lines.
Potent antitumor activity in experimental hepatocellular carcinoma by adenovirus-mediated coexpression of TRAIL and shRNA against COX-2.
Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis.
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells.
Proapoptotic activity of NAG-1 is cell type specific and not related to COX-2 expression.
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis.
Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways.
Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells.
Prostaglandin E(2) receptor EP(1) transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells.
Quercetin attenuates TNF-induced inflammation in hepatic cells by inhibiting the NF-?B pathway.
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Radiosynthesis and evaluation of 11C-labeled diaryl-substituted imidazole and indole derivatives for mapping cyclooxygenase-2.
Radiosynthesis and in vivo evaluation of 11C-labeled 1,5-diarylpyrazole derivatives for mapping cyclooxygenases.
Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors.
Regression of hepatocellular carcinoma due to cyclooxygenase (COX)-2 inhibitor.
Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1? is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
Regulation of cyclooxygenase 2 expression in hepatocytes by CCAAT/enhancer-binding proteins.
Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.
Regulatory regions of growth-related genes can activate an exogenous gene of the alpha-fetoprotein promoter to a comparable degree in human hepatocellular carcinoma cells.
Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.
RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells.
Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis.
Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest.
Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma.
Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma.
Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells.
Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.
Study of the effects of cyclooxygenase-2 inhibitor on the promotion of hepatic tumorigenesis in rats fed a high fat diet.
Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2.
Sustained increase in intracellular free calcium and activation of cyclooxygenase-2 expression in mouse hepatoma cells treated with dioxin.
Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.
Synergistic Effects of Curcumin and 5-Fluorouracil on the Hepatocellular Carcinoma In vivo and vitro through regulating the expression of COX-2 and NF-?B.
Targeted nano-delivery of novel omega-3 conjugate against hepatocellular carcinoma: Regulating COX-2/bcl-2 expression in an animal model.
The association between cyclooxygenase-2 1195 G/A polymorphism and hepatocellular carcinoma: evidence from a meta-analysis.
The Association between Three Cyclooxygenase-2 Polymorphisms and Hepatocellular Carcinoma Risk: A Meta-Analysis.
The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis.
The cyclooxygenase-2 inhibitor celecoxib attenuates hepatocellular carcinoma growth and c-Met expression in an orthotopic mouse model.
The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression.
The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line.
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.
The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma.
Therapeutic effect of coenzyme Q10 against experimentally-induced hepatocellular carcinoma in rats.
Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.
Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma.
Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.
[A Case of Complete Regression of Hepatocellular Carcinoma during Administration of COX-2 Inhibitor.]
[Diclofenac suppresses hepatoma cell proliferation and promotes cyclooxygenase-2 mRNA expression]
[Down-regulation of survivin in growth inhibition of hepatoma cells induced by a selective cyclooxygenase-2 inhibitor]
[Effect of saikosaponins-d on cyclooxygenase-2 expression of human hepatocellular carcinoma cell line SMMC-7721.]
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellar carcinoma].
[Effects of COX-2 gene silencing by shRNA on biological characteristics of human hepatocellular carcinoma cell line HepG2]
[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma]
[Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells.]
[Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases]
[Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma]
[The effects of adenovirus-mediated human COX-2 antisense RNA on the growth of hepatocellular carcinoma]
[The expression of hepatitis B virus X protein and cyclooxygenase-2 in hepatitis B virus-related hepatocellular carcinoma: correlation with microangiogenesis and metastasis, and what is the possible mechanism].
[The Expressions of Somatostatin and Cycloxygenase-2 in Chronic Hepatitis, Hepatic Cirrhosis, Precancerous Lesion and Hepatocellular Carcinoma].
Carcinoma, Intraductal, Noninfiltrating
A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer.
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.
Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes.
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.
Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ.
COX-2 Expression in Breast Carcinoma with Correlation to Clinicopathological Parameters
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
COX-2 induction by heparanase in the progression of breast cancer.
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.
Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
Cyclooxygenase-2 expression during immortalization and breast cancer progression.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast.
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.
Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer.
Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors.
Expression of cyclooxygenase-2 in malignant and benign breast tumors.
Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.
Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: A pilot study.
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.
Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors.
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.
Physiological COX-2 Expression in Breast Epithelium Associates with COX-2 Levels in Ductal Carcinoma in Situ and Invasive Breast Cancer in Young Women.
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy.
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.
Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
Carcinoma, Large Cell
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Carcinoma, Lewis Lung
Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo.
COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.
Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer.
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A(2) and peroxisome proliferator-activated receptor gamma.
Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression.
Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth.
Prostanoid induces premetastatic niche in regional lymph nodes.
Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.
Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction.
Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.
[Anti-cancer treatment with prostaglandin synthetase inhibitor in animal models]
[Effects of tea polyphenols on the expression of NF-?B, COX-2 and survivin in Lewis lung carcinoma xenografts in C57BL/6 mice].
Carcinoma, Lobular
Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer.
The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Carcinoma, Medullary
An immunohistochemical survey of nine cases of medullary carcinoma of thyroid including reactivity for Cox-1 and Cox-2 enzymes.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.
Immunohistochemical expression of COX-2 in thyroid nodules.
Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression.
Carcinoma, Merkel Cell
Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma.
Cyclooxygenase-2 expression in primary Merkel cell carcinoma.
Carcinoma, Mucoepidermoid
Cyclooxygenase-2 regulates the degree of apoptosis by modulating bcl-2 protein in pleomorphic adenoma and mucoepidermoid carcinoma of the parotid gland.
Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.
Evaluation of VEGF expression correlates with COX-2 expression in pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma.
Increased expression of cyclooxygenase-2 in human salivary gland tumors.
Malignant salivary gland tumors and cyclo-oxygenase-2: A histopathological and immunohistochemical analysis with implications on histogenesis.
Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma.
Predictive value of cyclooxygenase 2 and Bcl-2 for cervical lymph node metastasis in mucoepidermoid carcinoma.
[Expression and clinical significance of Cox-2 and XIAP in malignant tumors of the salivary gland].
Carcinoma, Neuroendocrine
Cyclooxygenase-2 expression in primary Merkel cell carcinoma.
Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
Carcinoma, Non-Small-Cell Lung
A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.
Adenoid cystic carcinoma of the trachea and bronchus--a clinicopathologic study with DNA flow cytometric analysis and oncogene expression.
Association between COX-2 polymorphisms and non-small cell lung cancer susceptibility.
Association between cyclooxygenase and epidermal growth factor receptor pathways in non-small cell lung cancer.
Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer.
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion.
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Camptothecin-induced apoptosis in non-small cell lung cancer is independent of cyclooxygenase expression.
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.
Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers.
Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines.
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer.
Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis.
Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.
Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer.
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Correction: EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features.
Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.
Correlation of cyclooxygenase-2 expression with hypoxia in non-small cell lung cancer.
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
Cox-2 in non-small cell lung cancer: A meta-analysis.
COX-2 inhibition and lung cancer.
COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites.
COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals.
COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.
COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells.
Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Cyclooxygenase 2 inhibition in patients with non-small cell lung cancer: Is this still a valid target for therapy?
Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.
Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.
Cyclooxygenase as a target in lung cancer.
Cyclooxygenase-2 Expression in Non-Small Cell Lung Cancer Correlates With Hypertrophic Osteoarthropathy.
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
Cyclooxygenase-2 genetic variants influence intratumoral infiltration of Foxp3-positive regulatory T cells in non-small cell lung cancer.
Cyclooxygenase-2 in human non-small cell lung cancer.
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.
Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis.
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.
Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer.
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.
Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
Dioscorea japonica extract down-regulates prostaglandin E2 synthetic pathway and induces apoptosis in lung cancer cells.
Diosgenin suppresses COX-2 and mPGES-1 via GR and improves LPS-induced liver injury in mouse.
Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer.
Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.
EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features.
EGFR Signaling Is Required for TGF-beta1 Mediated COX-2 Induction in Human Bronchial Epithelial Cells.
Ellagitannins from Punica granatum leaves suppress microsomal prostaglandin E synthase-1 expression and induce lung cancer cells to undergo apoptosis.
Emerging drugs for non-small cell lung cancer.
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.
Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: Correlations with angiogenesis and prognosis.
Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance.
Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients.
Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.
Extracellular matrix fibronectin increases prostaglandin E2 receptor subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2.
Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer.
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.
Hierarchical clustering of lung cancer cell lines using DNA methylation markers.
Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2.
IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF.
IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression.
IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer.
Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1, DeltaE3 recombinant adenovirus vectors.
Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells.
Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells.
Lentivirus-mediated shRNA interference targeting cyclooxygenase-2 inhibits growth of human non-small cell lung cancer.
Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/?-catenin signalling pathway.
Meloxicam inhibits the growth of non-small cell lung cancer.
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.
Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway.
Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44.
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
Overexpression of cyclooxygenase-2 in non-small cell lung cancer.
PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells.
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.
Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.
Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer.
Possible role of PPAR-? and COX-2 receptor modulators in the treatment of Non-Small Cell lung carcinoma.
Proanthocyanidins inhibit in vitro and in vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin E(2) and prostaglandin E(2) receptors.
Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.
Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer.
Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer.
Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer.
Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Retraction.
Revisiting the role of COX-2 inhibitor for non-small cell lung cancer.
Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.
Structural Probing, Screening and Structure-Based Drug Repositioning Insights into the Identification of Potential Cox-2 Inhibitors from Selective Coxibs.
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
Targeting COX-2/PG-E2 with a COX-2 inhibitor in combination with chemotherapy for non-small cell lung cancer: are we ready for phase III?
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).
The potential and rationale for COX-2 inhibitors in lung cancer.
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer.
The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer.
Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer.
Urinary levels of prostaglandin E2 are positively correlated with intratumoral infiltration of Foxp3(+) regulatory T cells in non-small cell lung cancer.
USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer.
[A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment.]
[Effect of NF-kappaB on inhibition of non-small cell lung cancer cell cyclooxygenase-2 by brucine].
[Effects of cyclooxygenase-2 antisense vector on proliferation and sensitivity to cisplatin of H1299 cells.]
[Expression and clinical significance of CD3, CD4 and COX-2 in non-small cell lung cancer].
[Expression and significance of COX-2 and its transcription factors NFAT3 and c-Jun in non-small cell lung cancer].
[Expression of COX-2 and its prognostic significance in non-small cell lung cancer.]
[Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance.]
[Overexpression of COX-2 and its clinical significance in non-small cell lung cancer]
[Prognostic value of survivin and cyclooxygenase-2 expression in non-small cell lung cancer: a tissue microarray analysis.]
[Study of COX-2 expression and angiogenesis in non-small cell lung cancer.]
[Suppression of COX-2 protein to cell apoptosis in non-small cell lung cancer.]
[The Expression of COX-2 in Human Lung Cancer and its Relationship with Expression of K-ras and Mcl-1.]
Carcinoma, Ovarian Epithelial
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Blueberries inhibit cyclooxygenase-1 and cyclooxygenase-2 activity in human epithelial ovarian cancer.
CD24, COX-2, and p53 in epithelial ovarian cancer and its clinical significance.
Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours.
COX-1 Inhibitors: Beyond Structure Toward Therapy.
Cox-2 expression in ovarian malignancies: a review of the clinical aspects.
Cox-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity.
COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.
COX-2: a protein with an active role in gynecological cancers.
Cyclooxygenase Inhibitors in Epithelial Ovarian Cancer Treatment.
Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium.
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.
Cyclooxygenase-2 gene and epithelial ovarian carcinoma risk.
Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.
Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells.
Expression of Cyclooxygenase-1 and 2 in Epithelial Ovarian Cancer: A Clinicopathologic Study.
Expression of cyclooxygenase-1 in epithelial ovarian cancer: a clinicopathological study.
Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.
Lower expression of cyclooxygenase-2: is it associated with the development of borderline ovarian tumors?
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
PET radiotracer [¹?F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation.
Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: A meta-analysis of observational studies.
The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer.
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer.
[The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis]
Carcinoma, Papillary
Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters.
Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.
Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.
COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness.
Cyclooxygenase 1 and 2 expressions in the human thyroid gland.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.
Cyclooxygenase-2 expression in thyroid neoplasms.
Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland.
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma.
Immunohistochemical expression of COX-2 in thyroid nodules.
Papillary Carcinoma of the Thyroid: High Expression of COX-2 and Low Expression of KAI-1/CD82 Are Associated with Increased Tumor Invasiveness.
Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth.
The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid.
Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase.
Carcinoma, Renal Cell
?-linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-? activation and COX-2 inhibition.
Altered 1-14C arachidonic acid metabolism in arterial wall from patients with renal cell carcinoma.
Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining.
Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.
Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis.
Cox-2 gene overexpression in ureteral stump urothelial carcinoma following nephrectomy for renal cell carcinoma: a case report.
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma.
Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma.
Cyclooxygenase-2 expression in brain metastases.
Cyclooxygenase-2 expression in clear cell renal cell carcinoma.
Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma?
Down-regulation of cyclooxygenase-2 expression but up-regulation of cyclooxygenase-1 in renal carcinomas of the Eker (TSC2 gene mutant) rat model.
Enhancement of the sensitivity of renal cell carcinoma cells to fas-mediated cytotoxicity and apoptosis by the selective cyclooxygenase-2 inhibitor JTE-522.
Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients.
Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma.
Expression of cyclooxygenase-2 in canine renal cell carcinoma.
Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival.
Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases.
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line.
Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor.
Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma.
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Multicenter Phase II Trial of Combination Therapy with Meloxicam, a COX-2 Inhibitor, and Natural Interferon-{alpha} for Metastatic Renal Cell Carcinoma.
Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma.
Phase-II trial of combination treatment of interferon-?, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma.
Prognostic evaluation of COX-2 expression in renal cell carcinoma.
Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Re: cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Relationship between arachidonic acid pathway and human renal cell carcinoma.
Relationship of CD95 and COX-2 in renal cell carcinomas with survival and other prognostic parameters: A tissue microarray study.
Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism.
Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy.
Significance of COX-2 expression in human renal cell carcinoma cell lines.
Significance of COX-2 expression in human renal cell carcinoma.
Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.
Study of cyclooxygenase-2 in renal cell carcinoma.
The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy.
The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma.
The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer.
The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.
The role of functional polymorphisms of cyclooxygenase 2 in renal cell carcinoma.
The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy.
VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value.
[A case of favorable response after combination treatment with interferon-? and cyclooxygenase-2 inhibitor against metastatic renal cell carcinoma].
[Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]
[Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation.]
Carcinoma, Signet Ring Cell
Expression of COX-2 in stomach cancers and its relation to their biological features.
Carcinoma, Squamous Cell
7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma.
A replication-selective adenoviral vector for head and neck cancers.
A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation.
A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells.
A soft coral natural product, 11-episinulariolide acetate, inhibits gene expression of cyclooxygenase-2 and interleukin-8 through attenuation of calcium signaling.
Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin.
Adaptor protein p62 promotes skin tumor growth and metastasis and is induced by UVA radiation.
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.
Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck.
An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies.
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Arachidonic acid metabolites in saliva of patients with squamous cell carcinoma of the head and neck.
Aspirin and non-small cell lung cancer resections: effect on long-term survival.
Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT.
Aspirin inhibits the proliferation of tobacco-related esophageal squamous carcinomas cell lines through cyclooxygenase 2 pathway.
Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk.
Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients With Cervical Cancer.
Bile acid promotes the proliferation of squamous cell carcinoma of the esophagus, independent of its inducing COX-2 expression.
Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers.
Biosynthesis of prostaglandins and hydroxy fatty acids in primary squamous carcinomas of head and neck in humans.
Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy.
c-Jun N-terminal kinase negatively regulates epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines.
Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.
Cell-type-specific roles for COX-2 in UVB-induced skin cancer.
Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study.
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Clinicopathologic implications of the epidermal growth factor receptor, cyclooxygenase 2 expression, and human papillomavirus status in squamous cell carcinoma of the uterine cervix in the elderly.
Clinicopathological significance of cyclooxygenase-2 expression in hypopharyngeal squamous cell carcinoma.
Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Correlation Between Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression in Canine and Feline Squamous Cell Carcinomas.
Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma.
Cox-2 and IL-10 polymorphisms and association with squamous cell carcinoma of the head and neck in a Korean sample.
COX-2 and p53 in human sinonasal cancer: COX-2 expression is associated with adenocarcinoma histology and wood-dust exposure.
COX-2 Docking Structural Analysis with Phytochemical Extracts of Rosemary: A Possible Cytotoxicity on Head and Neck Squamous Cell Carcinoma Cell Line (HEp-2).
COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma.
COX-2 expression during early lung squamous cell carcinoma oncogenesis.
COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer.
COX-2 inhibition and lung cancer.
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data.
CXCR-4 and COX-2 Expression in Basal Cell Carcinomas and Well-Differentiated Squamous Cell Carcinomas of the Skin; Their Relationship with Tumor Invasiveness and Histological Subtype.
Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue.
Cyclo-oxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma.
Cyclooxigenase-2 Levels are Increased in the Lung Tissue and Bronchial Tumors of Patients with Chronic Obstructive Pulmonary Disease.
Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1.
Cyclooxygenase-2 (COX2) expression in adenocarcinoma surpasses that of squamous cell carcinoma in the uterine cervix.
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence.
Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases.
Cyclooxygenase-2 expression and association with skin cancer: A meta-analysis based on Chinese patients.
Cyclooxygenase-2 Expression and Its Correlation with Primary Tumor Size and Lymph Node Involvement in Nasopharyngeal Carcinoma.
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables.
Cyclooxygenase-2 Expression in Cervical Squamous Cell Carcinoma: the Significance of Expression in Neoplastic Cells within the Lymphovascular Space.
Cyclooxygenase-2 expression in human esophageal carcinoma.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Cyclooxygenase-2 expression in oral squamous cell carcinoma.
Cyclooxygenase-2 expression in oral tongue squamous cell carcinoma.
Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome.
Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis.
Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma.
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.
Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis.
Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion.
Cyclooxygenase-2 inhibitor enhances whereas prostaglandin E2 inhibits the production of interferon-induced protein of 10 kDa in epidermoid carcinoma A431.
Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.
Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma.
Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma.
Cyclooxygenase-2-1195G>A Polymorphism and Head and Neck Squamous Cell Carcinoma Susceptibility: A Meta-Analysis of 1564 Cases and 2346 Controls.
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.
Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer.
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation.
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.
Cytoplasmic HuR over-expression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas.
DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target.
Depletion of phospholipid hydroperoxide glutathione peroxidase up-regulates arachidonate metabolism by 12S-lipoxygenase and cyclooxygenase 1 in human epidermoid carcinoma A431 cells.
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.
Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines.
Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.
Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer.
Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma.
Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer.
Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma.
Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.
Effect of Ferula persica plant methanol extract on the level of Cox-2 in induced squamous cell carcinoma (SCC) in rat tongue.
Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Effects of cyclooxygenase-2 non-selective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells.
Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma.
Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.
Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA.
Elevated Levels of Urinary Prostaglandin E Metabolite Indicate a Poor Prognosis in Ever Smoker Head and Neck Squamous Cell Carcinoma Patients.
Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
Endoplasmic Reticulum Stress Response as a Possible Mechanism of Cyclooxygenase-2-independent Anticancer Effect of Celecoxib.
Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression.
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Enhancement of prostaglandin E2 production by epidermal growth factor requires the coordinate activation of cytosolic phospholipase A2 and cyclooxygenase 2 in human squamous carcinoma A431 cells.
EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways.
Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma.
Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4.
Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation.
Epithelial to mesenchymal transition in cutaneous squamous cell carcinoma is correlated with COX-2 expression but not with the presence of stromal macrophages or CD10-expressing cells.
Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Essential role of c-Jun induction and coactivator p300 in epidermal growth factor-induced gene expression of cyclooxygenase-2 in human epidermoid carcinoma A431 cells.
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Expression and significance of cyclooxygenase 2 gene in lung cancer.
Expression of Cox-1 and Cox-2 in canine mammary tumours.
Expression of COX-1, COX-2 and mPGES-1 in penile and preputial papillomas and squamous cell carcinomas in the horse.
Expression of COX-2 and HER-2/neu and estrogen and progesterone receptor in primary squamous cell carcinomas of the endometrium.
Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions.
Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs.
Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas.
Expression of cyclooxygenase-1 and -2 in naturally occurring squamous cell carcinomas in horses.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma.
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.
Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa.
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.
Expression of cyclooxygenase-2 by equine ocular and adnexal squamous cell carcinomas.
Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.
Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas.
Expression of cyclooxygenase-2 in human lung carcinoma.
Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey.
Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation.
Expression of Cyclooxygenase-2 in Squamous Cell Carcinoma and Keratoacanthoma and its Clinical Significance.
Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression.
Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma.
Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas.
Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Expression of indolamine-2,3-dioxygenase and cyclooxygenase-2 in different disease stages of cutaneous squamous cell carcinoma.
Expression of inflammation related enzymes during experimental rat lung carcinogenesis.
Expression of p63 and cyclooxygenase-2 and their correlation in skin tumors.
Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers.
Function of DNA methyltransferase 3a in lead (Pb(2+) )-Induced Cyclooxygenase-2 gene.
Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression.
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.
High cyclooxygenase-2 expression in cervical adenocarcinomas.
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
Histologic correlation of VEGF and COX-2 expression with tumor size in squamous cell carcinoma of the larynx and hypopharynx.
Identification of key genes and long non?coding RNAs in celecoxib?treated lung squamous cell carcinoma cell line by RNA?sequencing.
Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.
Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective.
Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China.
Immunohistochemical Detection of COX-2 in Feline and Canine Actinic Keratoses and Cutaneous Squamous Cell Carcinoma.
Immunohistochemical evaluation of cyclooxygenase expression in corneal squamous cell carcinoma in horses.
Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
Immunohistochemical expression of cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical expression of cyclooxygenase-2 in skin cancers.
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor.
Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs.
Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.
Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways.
Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis.
Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer.
Inhibition of growth of a murine squamous cell carcinoma by a cyclooxygenase inhibitor increases leukotriene B4 production.
Inhibition of TPA-induced cyclooxygenase-2 (COX-2) expression by apigenin through downregulation of Akt signal transduction in human keratinocytes.
Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression.
Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21.
Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line.
Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells.
Isodesacetyluvaricin, an Annonaceous acetogenin, specifically inhibits gene expression of cyclooxygenase-2.
Ketoconazole suppresses prostaglandin E(2)-induced cyclooxygenase-2 expression in human epidermoid carcinoma A-431 cells.
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression.
Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2.
Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes.
miR-26b is downregulated in human tongue squamous cell carcinoma and regulates cell proliferation and metastasis through a COX-2-dependent mechanism.
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells.
Mixed-Generation PAMAM G3-G0 Megamer as a Drug Delivery System for Nimesulide: Antitumor Activity of the Conjugate Against Human Squamous Carcinoma and Glioblastoma Cells.
Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and gamma-rays regulating expression of the BCL-2 family proteins, COX-2 and p21.
Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer.
Molecular carcinogenesis in equine penile cancer: A potential animal model for human penile cancer.
Molecular pathology of cyclooxygenase-2 in neoplasia.
New insights into the functions of Cox-2 in skin and esophageal malignancies.
Nimesulide and indomethacin induce apoptosis in head and neck cancer cells.
Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway.
Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma.
NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-induced expression of COX-2.
Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation.
Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx.
Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder.
Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy.
Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy.
Pattern of expression of cyclooxygenase-2 in malignant transformation of sinonasal inverted papilloma.
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Prediction of lymphovascular space invasion using a combination of tenascin-C, cox-2, and PET/CT radiomics in patients with early-stage cervical squamous cell carcinoma.
Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.
Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma.
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
Prognostic significance of cyclooxygenase-2 in cervical cancer: A meta-analysis.
Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma.
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder.
Promotion of cell differentiation, and suppression of cell growth and cyclooxygenase-2 expression by differentiation-inducing agents in human oral squamous carcinoma SCC25 cells.
Protein kinase C delta overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2.
Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases.
Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.
Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells.
Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells.
Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways.
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.
Sequential expression of inducible nitric oxide synthase and cyclooxygenase-2 during DMBA-induced hamster buccal pouch carcinogenesis.
Significance of Cyclooxygenase 2, EZH-2 Polycomb Group and p53 Expression in Actinic Keratosis and Squamous Cell Carcinomas of the Skin.
Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus.
Simultaneous adeno- and squamous cell carcinoma with different phenotypic profiles in a rat model of chronic gastroesophageal reflux.
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production.
Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model.
Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival.
T-oligo treatment decreases constitutive and UVB-induced COX-2 levels through p53- and NFkappaB-dependent repression of the COX-2 promoter.
Targeted expression of ornithine decarboxylase antizyme prevents upper aerodigestive tract carcinogenesis in p53-deficient mice.
Targeting PRPK and TOPK for skin cancer prevention and therapy.
The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor.
The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines.
The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
The effect of betel nut extract on cell growth and prostaglandin endoperoxide synthase in human epidermoid carcinoma cells.
The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines.
The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo.
The effects of cyclooxygenase-2 inhibition on apoptosis and cell cycle distribution using two in vitro models of nasal squamous cell carcinoma.
The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells.
The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases.
The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1.
The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines.
The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma.
The role of angiogenesis and COX-2 expression in the evolution of vulvar lichen sclerosus to squamous cell carcinoma of the vulva.
The role of Ki-67, p16, CD34, Bcl-2, cyclooxygenase-2 in the pathogenesis of proliferative verrucous leukoplakia.
The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
The transcription factor Snail expressed in cutaneous squamous cell carcinoma induces epithelial-mesenchymal transition and down-regulates COX-2.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: mechanisms of enhancement using prostaglandin synthetase inhibitors.
Up-regulation of cyclooxygenase 2 and matrix metalloproteinases-2 and -9 in cutaneous squamous cell carcinoma: active role of inflammation and tissue remodeling in carcinogenesis.
Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus.
[A study on cyclooxygenase-2 protein expression and vasculature during experimental rat lung carcinogenesis]
[Analysis of HIF-1? and COX-2 expression in tumor stroma and correlation with the degree of neoplasm invasiveness in laryngeal cancer--preliminary study].
[Cyclooxygenase inhibitors in chemoprevention and treatment of esophageal squamous cell carcinoma]
[Cyclooxygenase-2, inducible nitric oxide synthase protein expression and vasculature during experimental rat lung carcinogenesis.]
[Cyclooxygenases in the skin]
[Ease-2 and inducible nitric oxide synthase in tongue hyperplasia and tongue squamous cell carcinoma]
[Effect of cyclooxygenase-2 inhibitor on expression of matrix metalloproteinase-2 and invasion of tongue squamous cell carcinoma cell line Tca8113].
[Expression and prognostic significance of cyclooxygenase-2 in supraglottic laryngeal squamous cell carcinomas]
[Expression of COX-2 and its prognostic significance in non-small cell lung cancer.]
[Expression of COX-2 and VEGF-C in squamous cell carcinoma of the tongue and its correlation to lymph node metastasis]
[Expression of cyclooxygenase-2 and p53 and their correlation in carcinoma of larynx]
[Expression of cyclooxygenase-2 in esophageal squamous cell carcinogenesis]
[Expression of NF-kappaB and COX-2 in tongue squamous cell carcinoma]
[Inhibitory effects of COX-2 inhibitor on migration of human tongue squamous cell carcinoma Tca8113 cells]
[Overexpression of COX-2 and its clinical significance in non-small cell lung cancer]
[Relationship between cyclooxygenase-2 in nasopharyngeal carcinoma and cervical lymph node metastasis].
[Roles of cyclooxygenase-2 and caspase-3 expression in pathogenesis of lung carcinoma: an experiment with rats]
[Study of COX-2 expression and angiogenesis in non-small cell lung cancer.]
[The antimicrobial effects of chitosans on oral pathogenic microbes in vitro.]
[The expression and significance of HIF-1alpha and COX-2 in laryngeal squamous cell carcinoma]
Carcinoma, Transitional Cell
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.
Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.
Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam.
Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.
Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
Correlation of BRAF Variant V595E, Breed, Histological Grade and Cyclooxygenase-2 Expression in Canine Transitional Cell Carcinomas.
Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue.
Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics.
Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.
Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells.
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma.
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells.
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.
Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs.
Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma.
Expression of miR-143 Reduces Growth and Migration of Human Bladder Carcinoma Cells by Targeting Cyclooxygenase-2.
Expression-targeted gene therapy for the treatment of transitional cell carcinoma.
Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Molecular Imaging of Cyclooxygenase-2 in Canine Transitional Cell Carcinomas In Vitro and In Vivo.
Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract.
Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder.
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder.
Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.
Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder.
Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.
Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells.
The expression of cyclooxygenase in transitional cell carcinoma cell lines: its correlation with tumor differentiation, invasiveness and prostanoids production.
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder.
Transitional Cell Carcinoma in Fishing Cats (Prionailurus viverrinus): Pathology and Expression of Cyclooxygenase-1, -2, and p53.
[Expression of cyclooxygenase in bladder transitional cell carcinoma]
[Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof]
[Expressions of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma and their correlation]
[The significance of the expression of cyclooxygenase-2 in bladder transitional cell carcinoma tissues]
Carcinosarcoma
COX-2 expression in uterine carcinosarcoma.
COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
Cyclooxygenase-2 expression in uterine leiomyosarcomas.
Cyclooxygenase-2 Is an Independent Predictor of Poor Prognosis in Uterine Leiomyosarcomas.
Expression of Cox-1 and Cox-2 in canine mammary tumours.
Response of Walker 256 carcinosarcoma cells to 12-O-tetradecanoylphorbol 13-acetate: possible regulation by endogenous cyclooxygenase metabolites.
The Effect of Cyclooxygenase-2 Expression in Uterine Carcinosarcoma on Survival: A Reassessment Based on Mature Data.
Cardiomegaly
Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release.
c-Src/Pyk2/EGFR/PI3K/Akt/CREB-activated pathway contributes to human cardiomyocyte hypertrophy: Role of COX-2 induction.
Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27).
Celecoxib alleviates pathological cardiac hypertrophy and fibrosis via M1-like macrophage infiltration in neonatal mice.
Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice.
COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats.
MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.
Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction.
Regulation of the membrane-localized prostaglandin E synthases mPGES-1 and mPGES-2 in cardiac myocytes and fibroblasts.
Roles of cyclooxygenase-2 and phosphorylated Akt (Thr308) in cardiac hypertrophy regression mediated by left-ventricular unloading.
Cardiomyopathies
Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?
Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure.
Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy.
Increased release of arachidonic acid and eicosanoids in iron-overloaded cardiomyocytes.
Myocardial Redox Hormesis Protects the Heart of Female Mice in Sepsis.
Cardiomyopathy, Dilated
2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation.
2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.
Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited DCM mouse model.
Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.
Cardiotoxicity
A hybrid platform featuring nanomagnetic ligand fishing for discovering COX-2 selective inhibitors from aerial part of Saussurea laniceps Hand.-Mazz.
Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin.
An open prospective study on postmarketing evaluation of the efficacy and tolerability of diacerein in osteo-arthritis of the knee (DOK).
Cardiovascular effects of cyclooxygenase-2 inhibitors.
Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.
Chemoprevention of colorectal neoplasia.
Chemoprotective role of an extract of the heart of the Phoenix dactylifera tree on adriamycin-induced cardiotoxicity and nephrotoxicity by regulating apoptosis, oxidative stress and PD-1 suppression.
Chitosan and Curcumin Nanoformulations against Potential Cardiac Risks Associated with Hydroxyapatite Nanoparticles in Wistar Male Rats.
Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement.
COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors.
Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin.
Do selective cyclo-oxygenase-2 inhibitors have a future?
Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats.
Effects of cyclooxygenase and lipoxygenase inhibitors on digoxin-induced arrhythmias and haemodynamics in guinea-pigs.
Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion.
Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice.
Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug.
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.
Nonaspirin Nonsteroidal Antiinflammatory Drug Use in the Nordic Countries from a Cardiovascular Risk Perspective, 2000-2016: A Drug Utilization Study.
NSAIDs and breast cancer: a possible prevention and treatment strategy.
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review.
TCDD-induced chick cardiotoxicity is abolished by a selective cyclooxygenase-2 (COX-2) inhibitor NS398.
The COX-2/prostanoid signaling cascades in seizure disorders.
The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities.
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Cardiovascular Diseases
2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin promotes endothelial cell apoptosis through activation of EP3/p38MAPK/Bcl-2 pathway.
A case of takotsubo cardiomyopathy precipitated by lumiracoxib, a selective COX-2 inhibitor.
A polymorphism in the cyclooxygenase 1 gene is associated with decreased inflammatory prostaglandin F2alpha formation and lower risk of cardiovascular disease.
A polymorphism in the cyclooxygenase 2 gene in type 1 diabetic patients with nephropathy.
A Review on the Relationship between Aspirin and Bone Health.
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition.
Age and rising rates of cyclooxygenase-2 inhibitor use. Results from a national survey.
Amelioration of Cholesterol Induced Atherosclerosis by Normalizing Gene Expression, Cholesterol Profile and Antioxidant Enzymes by Vigna unguiculata.
An ion channel hypothesis to explain divergent cardiovascular safety of COX-2 inhibitors: the answer to a hotly-debated puzzle? (Relates to article by Brueggemann, et al., Fast Forward 15 July 2009).
Anti-inflammatory drugs in the 21st century.
Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2.
Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity.
Aspirin induces platelet receptor shedding via ADAM17 (TACE).
Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.
Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia.
Association of cyclooxygenase-2 genetic variant with cardiovascular disease.
Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study.
Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction.
Benefits and Risks of Nonsteroidal Anti-inflammatory Drugs: Methodologic Limitations Lead to Clinical Uncertainties.
Biochemistry of protein tyrosine nitration in cardiovascular pathology.
c-Src/Pyk2/EGFR/PI3K/Akt/CREB-activated pathway contributes to human cardiomyocyte hypertrophy: Role of COX-2 induction.
Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?
Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective.
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Cardiovascular risk and COX-2 inhibition in rheumatological practice.
Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making.
Celecoxib aggravates atherogenesis and upregulates leukotrienes in ApoE-/- mice and lipopolysaccharide-stimulated RAW264.7 macrophages.
Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation.
Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib.
Characterization of aspirin esterase activity in health and disease: In vitro and ex vivo studies.
Cigarette smoking, cyclooxygenase-2 pathway and cancer.
Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse.
COX-2 in cardiovascular disease.
Cox-2 inhibitors and cardiovascular disease: considerable heat, but not much light.
COX-2 inhibitors in the treatment of cardiovascular disease.
COX-2 inhibitors--IBC conference. 12-13 April 1999, Coronado, CA, USA.
Cox-2 polymorphisms and cardiovascular disease: Elucidating the hidden side of the disease.
COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
COX-2-derived prostacyclin confers atheroprotection on female mice.
COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice.
Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis.
Cyclooxygenase inhibition and atherothrombosis.
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.
Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke.
Cyclooxygenase-1 haplotype modulates platelet response to aspirin.
Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.
Cyclooxygenase-2 and kidney failure.
Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein.
Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation.
Cyclooxygenase-2 inhibitors.
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin.
Detection of Overexpressed COX-2 in Precancerous Lesions of Hamster Pancreas and Lungs by Molecular Imaging: Implications for Early Diagnosis and Prevention.
Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.
Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Distinctive Under-Expression Profile of Inflammatory and Redox Genes in the Blood of Elderly Patients with Cardiovascular Disease.
Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes.
Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy.
Does the timing of aspirin administration influence its antiplatelet effect - review of literature on chronotherapy.
Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits.
Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription.
Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2.
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke.
eNOS, COX-2, and prostacyclin production are impaired in endothelial cells from diabetics.
Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries.
Extended-Release Tramadol (ULTRAM(R)ER): A Pharmacotherapeutic, Pharmacokinetic, and Pharmacodynamic Focus on Effectiveness and Safety in Patients with Chronic/Persistent Pain.
Factors associated with celecoxib and rofecoxib utilization.
Formononetin protects against ox-LDL-induced endothelial dysfunction by activating PPAR-? signaling based on network pharmacology and experimental validation.
Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly chinese patients with cardiovascular disease.
Fulvic acid attenuates homocysteine-induced cyclooxygenase-2 expression in human monocytes.
Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness.
Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis.
Interplay Between Oxidative Stress, Cyclooxygenases, and Prostanoids in Cardiovascular Diseases.
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.
Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease.
Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease.
Mechanisms of adiponectin-mediated COX-2 induction and protection against iron injury in mouse hepatocytes.
Mechanisms of aspirin resistance.
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events.
Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.
Mitogenic effects of cytokines on smooth muscle are critically dependent on protein kinase A and are unmasked by steroids and cyclooxygenase inhibitors.
Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
Natural products and their derivatives as cyclooxygenase-2 inhibitors.
Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug.
Nitric oxide pathway-mediated relaxant effect of aqueous sesame leaves extract (Sesamum radiatum Schum. & Thonn.) in the guinea-pig isolated aorta smooth muscle.
Non-steroidal Anti-inflammatory Drug Use and Risk of Age-Related Macular Degeneration in the California Teachers Study.
Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?
Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomics.
NSAIDs-dependent adaption of the mitochondria-proteasome system in immortalized human cardiomyocytes.
Oxidative enzymopathies and vascular disease.
PAR1-dependent COX-2/PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes.
Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease.
Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach.
Precaution, cyclooxygenase inhibition, and cardiovascular risk.
Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors.
Regulator of calcineurin 1 modulates vascular contractility and stiffness through the upregulation of COX-2-derived prostanoids.
Release of tumor necrosis factor-alpha and prostanoids in whole blood cultures after in vivo exposure to low-dose aspirin.
Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents.
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Selective COX-2 inhibition improves endothelial function in coronary artery disease.
Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups.
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.
Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation.
The basis for the chemopreventive action of resveratrol.
The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin.
The Influence of COX-2 Single Nucleotide Polymorphisms on Abdominal Aortic Aneurysm Development and the Associated Inflammation.
The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction.
Transcriptional Control of COX-2 via C/EBPbeta.
Transgenic mouse for conditional, tissue-specific Cox-2 overexpression.
Untargeted Metabolomics to Go beyond the Canonical Effect of Acetylsalicylic Acid.
Update on SAR Studies Toward New COX-1 Selective Inhibitors.
Upregulation of cyclooxygenase-2 by motorcycle exhaust particulate-induced reactive oxygen species enhances rat vascular smooth muscle cell proliferation.
Use of cox-2 inhibitors in patients with retinal venous occlusive disease.
Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction.
What is the harm-benefit ratio of Cox-2 inhibitors?
When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis?
Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2.
[Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?]
[Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists]
[Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases].
[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
[VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases]
Carotid Artery Diseases
Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB.
Carotid Artery Thrombosis
Arterial Thrombosis Is Accompanied by Elevated Mitogen-Activated Protein Kinase (MAPK) and Cyclooxygenase-2 (COX-2) Expression via Toll-Like Receptor 4 (TLR-4) Activation by S100A8/A9.
Carotid Stenosis
Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition.
Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB.
Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis.
Carpal Tunnel Syndrome
COX-2 up-regulation in idiopathic carpal tunnel syndrome.
Catalepsy
CNB-001, a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson's disease mice.
Cyclooxygenase inhibitor modulation of dopamine-related behaviours.
Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy.
Effect of prostaglandin synthetase inhibitors on non-analgesic actions of morphine.
Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.
Participation of prostaglandins in the action of kinins on the central dopaminergic system in the rat. I. The action of kinins on the central dopaminergic system after pretreatment with indomethacin.
Cataract
Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients.
Comparison of topically applied flurbiprofen or bromfenac ophthalmic solution on post-operative ocular hypertension in canine patients following cataract surgery.
Correlations between optical coherence tomography measurement of macular thickness and visual acuity after cataract extraction.
Cyanidin-3-O-glucoside Protects Lens Epithelial Cells against High Glucose-Induced Apoptosis and Prevents Cataract Formation via Suppressing NF-?B Activation and Cox-2 Expression.
Cyclooxygenase-2 inhibitors: a new therapeutic option in the treatment of macular edema after cataract surgery.
Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal.
Fatty acids modulate the efficacy of lutein in cataract prevention: Assessment of oxidative and inflammatory parameters in rats.
Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.
Regulated over-expression of DNA polymerase beta mediates early onset cataract in mice.
Role of interleukin 6 in the inflammatory response after cataract surgery. An experimental and clinical study.
Successful treatment of cystoid macular edema with valdecoxib.
The role of prostaglandins E2 and F2 alpha in ultraviolet radiation-induced cortical cataracts in vivo.
Topical flurbiprofen in extracapsular cataract surgery: effect on pupillary diameter and iris fluorescein leakage.
Topical flurbiprofen in intraocular surgery on diabetic and nondiabetic patients.
Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives.
Catatonia
Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats.
Selective cyclooxygenase-2 inhibitor compound 11b improves haloperidol-induced catatonia by enhancing the striatum dopaminergic neurotransmission.
The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission.
Celiac Disease
A Peptide from Kiwifruit Exerts Anti-Inflammatory Effects in Celiac Disease Mucosa.
Cell Transformation, Neoplastic
Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K.
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.
Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.
Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression.
Central Nervous System Diseases
Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death.
Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.
Upregulation of COX-2 and CGRP expression in resident cells of the Borna disease virus-infected brain is dependent upon inflammation.
Cerebral Cortical Thinning
COX-2 gene dosage dependent defects in kidney development.
Cerebral Hemorrhage
A Promoter polymorphism (rs17222919, -1316T/G) of ALOX5AP is associated with intracerebral hemorrhage in Korean population.
Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death.
Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage.
History of Nonsteroidal Anti-inflammatory Drug Use and Functional Outcomes After Spontaneous Intracerebral Hemorrhage.
Inducible cyclooxygenase-2 expression after experimental intracerebral hemorrhage.
Cerebral Infarction
Alpinia oxyphylla Miq extract reduces cerebral infarction by downregulating JNK-mediated TLR4/T3JAM- and ASK1-related inflammatory signaling in the acute phase of transient focal cerebral ischemia in rats.
Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction.
Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans.
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat.
Improvement in neurogenic detrusor overactivity by peripheral C fiber's suppression with cyclooxygenase inhibitors.
Melatonin reduced volume of cerebral infarct induced by photothrombosis in wild-type mice, not in Cyclooxygenase-1 gene knockout mice.
Modulation of stretch evoked adenosine triphosphate release from bladder epithelium by prostaglandin E?.
Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction.
Overactive bladder--experimental aspects.
Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
Role of cyclooxygenase-2 in the development of bladder overactivity after cerebral infarction in the rat.
Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia.
SO2 inhalation contributes to the development and progression of ischemic stroke in the brain.
Splenic Immune Cells In Experimental Neonatal Hypoxia-Ischemia.
Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat.
Cerebral Palsy
COX-1 and COX-2 polymorphisms in susceptibility to cerebral palsy in very preterm infants.
Cerebral Small Vessel Diseases
A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model.
Cyclooxygenase 2 genetic polymorphism may increase the risk of developing leukoaraiosis in chinese.
Cerebrovascular Disorders
-New aspects in antithrombotic therapy--platelet inhibitors-.
A cyclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia.
A study of hemostasis in ischemic cerebrovascular disease. II. Abnormalities in platelet ADP release, platelet cyclooxygenase regeneration time and platelet factor 3 availability.
COX-2 inhibitor for the treatment of idiopathic stabbing headache secondary to cerebrovascular diseases.
COX-2 rs20417 Polymorphism Is Associated with Stroke and White Matter Disease.
Cyclo-oxygenase-2 -765G > C promoter variants are associated with lower carotid plaque echogenicity in Japanese.
Cyclooxygenase and prostaglandin synthases: roles in plaque stability and instability in humans.
Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans.
Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy.
Misoprostol reverse hippocampal neuron cyclooxygenase-2 downstream signaling imbalance in aluminum-overload rats.
Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction.
The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia.
[Risk factor assessment of cardiocerebrovascular diseases in patients with rheumatoid arthritis]
Cervical Intraepithelial Neoplasia
Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients With Cervical Cancer.
Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer.
Cox-2, EGFR, and ERBB-2 Expression in Cervical Intraepithelial Neoplasia and Cervical Cancer Using an Automated Imaging System.
Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer.
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia.
Cyclooxygenase-2 in cervical neoplasia: a review.
Cyclooxygenase-2 is overexpressed in human cervical cancer.
Increased serum progesterone and estradiol correlate to increased COX-2 tissue expression in cervical intraepithelial neoplasia.
Promoter methylation status of the tumor suppressor genes p16 and cadherin 1 in cervical intraepithelial neoplasia.
The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial.
The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
Chagas Disease
Circulating levels of cyclooxygenase metabolites in experimental Trypanosoma cruzi infections.
Correction: Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.
COX-2 rs20417 Polymorphism Is Associated with Stroke and White Matter Disease.
Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.
Depletion of immature B cells during Trypanosoma cruzi infection: involvement of myeloid cells and the cyclooxygenase pathway.
Effects of cyclooxygenase inhibitors on parasite burden, anemia and oxidative stress in murine Trypanosoma cruzi infection.
Inducible cyclooxygenase released prostaglandin mediates immunosuppression in acute phase of experimental Trypanosoma cruzi infection.
Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.
Protection of vascular endothelium by aspirin in a murine model of chronic Chagas' disease.
Trypanosoma cruzi: The role of PGE2 in immune response during the acute phase of experimental infection.
Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages.
Cheilitis
Actinic cheilitis: Epithelial expression of COX-2 and its association with mast cell tryptase and PAR-2.
Increased fibroblast density in actinic cheilitis: association with tryptase-positive mast cells, actinic elastosis and epithelial p53 and COX-2 expression.
Chemical and Drug Induced Liver Injury
A protective role for cyclooxygenase-2 in drug-induced liver injury in mice.
Prolonged cholestasis associated with short-term use of celecoxib.
Chlamydia Infections
Chlamydia infection causes loss of pacemaker cells and inhibits oocyte transport in the mouse oviduct.
Cholangiocarcinoma
A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth.
Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma.
Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.
Akt expression may predict favorable prognosis in cholangiocarcinoma.
Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.
Bile from a patient with anomalous pancreaticobiliary ductal union promotes the proliferation of human cholangiocarcinoma cells via COX-2 pathway.
Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines.
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation.
Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.
Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas.
COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells.
Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets.
Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha.
Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest.
Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids.
Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.
Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement.
Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma.
Effects of Aspirin and Non-Steroidal Anti-Inflammatory Drugs on the Risk of Cholangiocarcinoma: A Meta-Analysis.
Effects of cyclooxygenase-2 antisense vector on proliferation of human cholangiocarcinoma cells.
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma.
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.
Expression of COX-2 and VEGF-C in cholangiocarcinomas at different clinical and pathological stages.
Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.
Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis.
High promoter activity of cytokeratin-19 gene in cholangiocarcinoma.
Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma.
Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells.
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF).
MiR-21 Targets 15-PGDH and Promotes Cholangiocarcinoma Growth.
Oxidative stress-mediated mouse liver lesions caused by Clonorchis sinensis infection.
Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis.
PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells.
Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma.
Proliferative activity of bile from congenital choledochal cyst patients.
Resistance of cholangiocarcinoma cells to parthenolide-induced apoptosis by the excretory-secretory products of Clonorchis sinensis.
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
Synthesis and characterization of boron fenbufen and its F-18 labeled homolog for boron neutron capture therapy of COX-2 overexpressed cholangiocarcinoma.
Synthesis and evaluation of ortho-[18F] fluorocelecoxib for COX-2 cholangiocarcinoma imaging.
Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line.
The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells.
[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma]
[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]
[Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases]
Cholangitis
Prostaglandin E receptors in bile ducts of hepatolithiasis patients and the pathobiological significance for cholangitis.
Cholangitis, Sclerosing
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ?mplications for cholangiocarcinogenesis.
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
Metachronous Carcinomas of the Biliary Tract in a Patient Treated Three Times with Curative Surgery.
Cholecystitis
Arachidonic acid metabolites in hepatobiliary physiology and disease.
Cyclooxygenase expression in the gallbladder.
Effect of oral ibuprofen on formation of prostaglandins E and F by human gallbladder muscle and mucosa.
Evaluation of prostacyclin production by human gallbladder.
Indomethacin intravenously--a new way for effective relief of biliary pain: a double-blind study in man.
Role of cyclooxygenase-2 for fluid secretion by the inflamed gallbladder mucosa.
Cholecystitis, Acute
Treatment of biliary colic and acute cholecystitis with prostaglandin synthetase inhibitors.
Choledochal Cyst
Carcinogenic Potential of Biliary Epithelium of Congenital Choledochal Cyst Model in Rats: A Special Reference to HDAC Expression.
Cyclooxygenase-2 Overexpression is Associated with Clinical Outcome in Biliary Atresia.
Proliferative activity of bile from congenital choledochal cyst patients.
Cholera
Cholera toxin induces a shift from inactive to active cyclooxygenase 2 in alveolar macrophages activated by Mycobacterium bovis BCG.
Cholera toxin induces prostaglandin synthesis via post-transcriptional activation of cyclooxygenase-2 in the rat jejunum.
Differential effects of prostaglandin synthetase inhibitors on prostaglandin E2 binding and on prostaglandin- or cholera toxin-induced cyclic AMP accumulation in the rabbit uterus.
Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinase production by human monocytes.
Effects of indomethacin on intestinal secretion, prostaglandin E and cyclic AMP: evidence against a role for prostaglandins in cholera toxin-induced secretion.
Effects of indomethacin on Salmonella typhimurium- and cholera toxin-induced fluid accumulation in the porcine small intestine.
Involvement of Rho and p38 MAPK in endothelin-1-induced expression of PGHS-2 mRNA in osteoblast-like cells.
Mechanisms of cholera toxin-induced diarrhea.
Pathophysiological mechanisms of diarrhea caused by the Vibrio cholerae O1 El Tor variant: an in vivo study in mice.
PDGF-stimulated cyclic AMP formation in airway smooth muscle: assessment of the roles of MAP kinase, cytosolic phospholipase A2, and arachidonate metabolites.
Prostaglandin E(2) upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Role of cyclooxygenase enzymes in a murine model of experimental cholera.
Role of mast cells and pro-inflammatory mediators on the intestinal secretion induced by cholera toxin.
Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA.
Cholestasis
Effect of selective cyclooxygenase-2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts.
Chondroblastoma
Expression of cyclooxygenase-2 in chondroblastoma: immunohistochemical analysis with special emphasis on local inflammatory reaction.
Intracortical chondroblastoma mimicking intra-articular osteoid osteoma.
Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.
Chondroma
Cyclooxygenase-2 expression in chondrosarcoma.
Chondrosarcoma
COX-2 expression in chondrosarcoma: a role for celecoxib treatment?
Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.
Cyclooxygenase-2 expression in chondrosarcoma.
Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma.
Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas.
Endothelin-1 enhances cell migration through COX-2 up-regulation in human chondrosarcoma.
Expression of molecular markers in low-grade chondrosarcomas and cartilaginous tumors with uncertain differentiation.
Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.
Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis.
Chordoma
Expression of Ezrin, Mmp-9 and Cox-2 in 50 Chordoma Specimens: A Clinical and Immunohistochemical Analysis.
Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.
Steroid hormone receptor and COX-2 expression in chordoma.
Chorioamnionitis
Differential expression and regulation of microsomal prostaglandin E(2) synthase in human fetal membranes and placenta with infection and in cultured trophoblast cells.
Effects of 4-hydroxy-2-nonenal, a marker of oxidative stress, on the cyclooxygenase-2 of human placenta in chorioamnionitis.
Evidence for interleukin-10-mediated inhibition of cyclo- oxygenase-2 expression and prostaglandin production in preterm human placenta.
In utero exposure to phthalates and fetal development.
Placental expression of enzymes regulating prostaglandin synthesis and degradation.
Choroidal Neovascularization
Cyclooxygenase inhibitor improved an exudative lesion of choroidal neovascularization in age-related macular degeneration.
Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization.
Reduced Choroidal Neovascular Membrane Formation in Cyclooxygenase-2 Null Mice.
Topical Diclofenac-Loaded Liposomes Ameliorate Laser-Induced Choroidal Neovascularization in Mice and Non-Human Primates.
Chronic Periodontitis
A novel hypothesis concerning the mechanisms of activation, and of control, of periodontal bone loss.
Alteration of PTGS2 promoter methylation in chronic periodontitis.
Association of matrix metalloproteinase (MMP)-1, 3, 9, interleukin (IL)-2, 8 and cyclooxygenase (COX)-2 gene polymorphisms with chronic periodontitis in a Chinese population.
Association of matrix metalloproteinase (MMP-1, MMP-3 and MMP-9) and cyclooxygenase-2 gene polymorphisms and their proteins with chronic periodontitis.
Common single nucleotide polymorphisms in cyclooxygenase-2 and risk of severe chronic periodontitis in a Chinese population.
Cox-2 Expression in Gingival Biopsies From Periodontal Patients is Correlated With Connective Tissue Loss.
COX-2 gene polymorphisms and risk of chronic periodontitis: a case-control study and meta-analysis.
Cyclooxygenase 2 gene polymorphisms and chronic periodontitis in a North Indian population: a pilot study.
Cyclooxygenase-2 and matrix metalloproteinase-9 expressions correlate with tissue inflammation degree in periodontal disease.
Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and prostaglandin F2alpha and clinical parameters of chronic periodontitis.
Elevated levels of cyclooxygenase 1 and 2 in human cyclosporine induced gingival overgrowth.
Epigenetic change in E-Cardherin and COX-2 to predict chronic periodontitis.
Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy.
The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis.
The effect of low-level diode laser on COX-2 gene expression in chronic periodontitis patients.
The overexpression of cyclo-oxygenase-2 in chronic periodontitis.
Chronic Urticaria
A possible role for cyclooxygenase 2 inhibitors in the treatment of chronic urticaria.
Analgesics.
Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years.
Management of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactions.
Mechanism of chronic urticaria exacerbation by aspirin.
Prevention and treatment of reactions to NSAIDs.
Restoration of aspirin tolerance following omalizumab treatment in a patient with chronic spontaneous urticaria.
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression of COX-1 and COX-2 enzymes in patients suffering from chronic autoimmune urticaria - a pilot study.
The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria.
Cleft Palate
Biochemical mechanism of glucocorticoid-and phenytoin-induced cleft palate.
Palatal development and the arachidonic acid cascade.
Clonorchiasis
Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis.
Coinfection
Establishment of a Cell Culture Model Permissive for Infection by Hepatitis B and C Viruses.
Expression of immune response genes in rainbow trout skin induced by Gyrodactylus derjavini infections.
Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia.
The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels.
The role of annexin A1 in Candida albicans and Candida auris infections in murine neutrophils.
Colic
A double-blind, placebo controlled comparison of the morphine sparing effect of oral rofecoxib and diclofenac for acute renal colic.
Comparison of a narcotic (oxicone) and a non-narcotic anti-inflammatory analgesic (indoprofen) in the treatment of renal colic.
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo.
Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter.
Diclofenac sodium and spasmolytic drugs in the treatment of ureteral colic: a comparative study.
Diclofenac sodium in ureteral colic: a double-blind comparison trial with placebo.
Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial.
Eicosanoid synthesis in the isolated human renal pelvis, ureter and bladder.
Indomethacin as prophylaxis against ureteral colic following extracorporeal shock wave lithotripsy.
Ketorolac effectively inhibits ureteral contractility in vitro.
NS-398 (a Selective Cyclooxygenase-2 Inhibitor) Decreases Agonist-Induced Contraction of the Human Ureter via Calcium Channel Inhibition.
Prostaglandin synthetase inhibition of renal pelvic smooth muscle in the rabbit.
Real-time PCR analysis of RNA extracted from formalin-fixed and paraffin-embeded tissues: effects of the fixation on outcome reliability.
Selective cyclooxygenase-2 inhibitors reduce ureteral contraction in vitro: a better alternative for renal colic?
Sparing the gut: COX-2 inhibitors herald a new era for treatment of horses with surgical colic.
The role of cyclooxygenase inhibitors in repair of ischaemic-injured jejunal mucosa in the horse.
The role of prostanoids in the complications of extracorporeal shock wave lithotripsy (ESWL) in children.
Treatment of biliary colic and acute cholecystitis with prostaglandin synthetase inhibitors.
Treatment of renal colic by desmopressin intranasal spray and diclofenac sodium.
Treatment of renal colic by prostaglandin synthetase inhibitors and avafortan (analgesic antispasmodic).
Use of diclofenac in analgesia.
Colitis
15-Deoxy-?12,14-Prostaglandin J2 Promotes Resolution of Experimentally Induced Colitis.
A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model.
A novel toll-like receptor 4 (TLR4) antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis.
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis.
Acetic acid-derived prostaglandin-dependent colonic adaptive cytoprotection is preserved in chronic colitis: role of cyclo-oxygenase.
Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.
Amentoflavone inhibits iNOS, COX-2 expression and modulates cytokine profile, NF-?B signal transduction pathways in rats with ulcerative colitis.
An ?-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF-?B in rats with TNBS-induced colitis.
Andrographolide derivative AL-1 ameliorates TNBS-induced colitis in mice: involvement of NF-?B and PPAR-? signaling pathways.
Anti-inflammatory effects and changes in prostaglandin patterns induced by 7beta-hydroxy-epiandrosterone in rats with colitis.
Anti-inflammatory effects of an ethanol extract of Aster glehni via inhibition of NF-?B activation in mice with DSS-induced colitis.
Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice.
Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines.
Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.
Antisense inhibition of cyclooxygenase-2 causes a selective suppression of the Na+-H+ exchanger isoform 3 in rat kidney in experimental colitis.
AphaMax®, an Aphanizomenon Flos-Aquae Aqueous Extract, Exerts Intestinal Protective Effects in Experimental Colitis in Rats.
Apigenin supplementation protects the development of dextran sulfate sodium-induced murine experimental colitis by inhibiting canonical and non-canonical inflammasome signaling pathways.
Apple polyphenols extract (APE) improves colon damage in a rat model of colitis.
Aqueous extract of Bruguiera gymnorrhiza leaves protects against dextran sulfate sodium induced ulcerative colitis in mice via suppressing NF-?B activation and modulating intestinal microbiota.
Beneficial effects of THSG on acetic acid-induced experimental colitis: involvement of upregulation of PPAR-? and inhibition of the Nf-?b inflammatory pathway.
Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis.
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.
Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.
Chemopreventive Activity of Red Ginseng Oil in a Mouse Model of Azoxymethane/Dextran Sulfate Sodium-Induced Inflammation-Associated Colon Carcinogenesis.
Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice.
Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK.
Combined Therapy with Rheum tanguticum Polysaccharide and Low-dose 5-ASA Ameliorates TNBS-Induced Colitis in Rats by Suppression of NF-?B.
Combined Treatment with Hyaluronic Acid and Mesalamine Protects Rats from Inflammatory Bowel Disease Induced by Intracolonic Administration of Trinitrobenzenesulfonic Acid.
Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice.
Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model.
Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors.
Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis.
Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis.
Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2.
Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats.
Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.
Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction.
Cyclooxygenase-2 contributes to dysmotility and enhanced excitability of myenteric AH neurones in the inflamed guinea pig distal colon.
Cyclooxygenase-2 inhibition and experimental colitis: beneficial effects of phosphorothioated antisense oligonucleotide and meloxicam.
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo.
Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.
Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis.
Cynanchum wilfordii Polysaccharides Suppress Dextran Sulfate Sodium-Induced Acute Colitis in Mice and the Production of Inflammatory Mediators from Macrophages.
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
Dextran-5-(4-ethoxycarbonylphenylazo)salicylic acid ester, a polymeric colon-specific prodrug releasing 5-aminosalicylic acid and benzocaine, ameliorates TNBS-induced rat colitis.
Dietary Crocin Inhibits Colitis and Colitis-Associated Colorectal Carcinogenesis in Male ICR Mice.
Dietary fatty acids modulate chronic colitis, colitis-associated colon neoplasia and COX-2 expression in IL-10 knockout mice.
Dietary Geraniol by Oral or Enema Administration Strongly Reduces Dysbiosis and Systemic Inflammation in Dextran Sulfate Sodium-Treated Mice.
Differential role of cyclooxygenase 1 and 2 isoforms in the modulation of colonic neuromuscular function in experimental inflammation.
Dilodendron bipinnatum Radlk. extract alleviates ulcerative colitis induced by TNBS in rats by reducing inflammatory cell infiltration, TNF-? and IL-1? concentrations, IL-17 and COX-2 expressions, supporting mucus production and promotes an antioxidant effect.
Dimethyl Fumarate Alleviates Dextran Sulfate Sodium-Induced Colitis, through the Activation of Nrf2-Mediated Antioxidant and Anti-inflammatory Pathways.
Dipotassium Glycyrrhizate Improves Intestinal Mucosal Healing by Modulating Extracellular Matrix Remodeling Genes and Restoring Epithelial Barrier Functions.
Dipotassium glycyrrhizate via HMGB1 or AMPK signaling suppresses oxidative stress during intestinal inflammation.
Distinct roles for hematopoietic and extra-hematopoietic sphingosine kinase-1 in inflammatory bowel disease.
Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis.
Dyospiros kaki phenolics inhibit colitis and colon cancer cell proliferation, but not gelatinase activities.
Eclipta prostrata Improves DSS-Induced Colitis through Regulation of Inflammatory Response in Intestinal Epithelial Cells.
Effect of COX-2 inhibitor after TNBS-induced colitis in Wistar rats.
Effect of COX-2 inhibitor lumiracoxib and the TNF-? antagonist etanercept on TNBS-induced colitis in Wistar rats.
Effect of dehydroleucodine in experimental colitis in rats and mice.
Effect of Forced Physical Activity on the Severity of Experimental Colitis in Normal Weight and Obese Mice. Involvement of Oxidative Stress and Proinflammatory Biomarkers.
Effect of nimesulide on acetic acid- and leukotriene-induced inflammatory bowel disease in rats.
Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid.
Effects of 17?-estradiol on colorectal cancer development after azoxymethane/dextran sulfate sodium treatment of ovariectomized mice.
Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut.
Effects of cyclooxygenase and lipoxygenase inhibition on eicosanoids and healing of acetic acid colitis in rats.
Effects of Lactobacillus rhamnosus GG and Lactobacillus reuteri R2LC on acetic acid-induced colitis in rats.
Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis.
Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors.
Effects of pro-inflammatory cytokines, lipopolysaccharide and COX-2 mediators on human colonic neuromuscular function and epithelial permeability.
Effects of Prunus mume Sieb. et Zucc extract and its biopolymer encapsulation on a mouse model of colitis.
Effects of Vitamin D Supplementation on Inflammation, Colonic Cell Kinetics, and Microbiota in Colitis: A Review.
Enteropathogenic e.coli sustains iodoacetamide-induced ulcerative colitis-like colitis in rats: modulation of IL-1?, IL-6, TNF-?, COX-2, and apoptosisi.
Evaluation of the immunoexpression of COX-1, COX-2 and p53 in Crohn's disease.
Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.
Fatty acid synthase inhibitor C75 ameliorates experimental colitis.
Ferulic acid ameliorates TNBS-induced ulcerative colitis through modulation of cytokines, oxidative stress, iNOs, COX-2, and apoptosis in laboratory rats.
Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study.
Fresh Saengshik Showed a Positive Effect on Mitigating Dextran Sulfate Sodium-Induced Experimental Colitis in Mice.
Gastroprotective effects of the nonsaponin fraction of Korean Red Ginseng through cyclooxygenase-1 upregulation.
Gaudichaudione H Inhibits Inflammatory Responses in Macrophages and Dextran Sodium Sulfate-Induced Colitis in Mice.
Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves.
Glycoprotein isolated from Ulmus davidiana Nakai modulates inflammatory related factors in mouse colonic tissues.
Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats.
High Red Meat Intake Exacerbates Dextran Sulfate-Induced Colitis by Altering Gut Microbiota in Mice.
Host nuclear factor erythroid 2-related factor-2 defense system determines the outcome of dextran sulfate sodium-induced colitis in mice.
Hyaluronic acid as a rescue therapy for trinitrobenzene sulfonic acid-induced colitis through Cox-2 and PGE2 in a Toll-like receptor 4-dependent way.
Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.
Indomethacin worsens and a leukotriene biosynthesis inhibitor accelerates mucosal healing in rat colitis.
Inflammatory alterations in excluded colon in rats: a comparison with chemically induced colitis.
Influence of extra virgin olive oil diet enriched with hydroxytyrosol in a chronic DSS colitis model.
Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats.
Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
Inhibitory effect of ?-sitosterol on TNBS-induced colitis in mice.
Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice.
Interleukin-1 in the pathogenesis of and protection from inflammatory bowel disease.
Interleukin-17 induces an atypical M2-like macrophage subpopulation that regulates intestinal inflammation.
Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis.
Limonin ameliorates dextran sulfate sodium-induced chronic colitis in mice by inhibiting PERK-ATF4-CHOP pathway of ER stress and NF-?B signaling.
Local administration of 4-Thiouridine, a novel molecule with potent anti-inflammatory properties, protects against experimental colitis and arthritis.
Managing colonic inflammation associated gut derangements by systematically optimised and targeted ginger extract-Lactobacillus acidophilus loaded pharmacobiotic alginate beads.
Mast cells and the cyclooxygenase pathway mediate colonic afferent nerve sensitization in a murine colitis model.
MC-12, an Annexin A1-Based Peptide, Is Effective in the Treatment of Experimental Colitis.
Mechanism underlying the reversal of contractility dysfunction in experimental colitis by cyclooxygenase-2 inhibition.
Mesalazine activates adenosine monophosphate-activated protein kinase: Implication in the anti-inflammatory activity of this anti-colitic drug.
Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease.
Microalgae aqueous extracts exert intestinal protective effects in Caco-2 cells and dextran sodium sulphate-induced mouse colitis.
Modulating effect of Biophytum sensitivum extract on rats with acetic acid-induced ulcerative colitis.
MyD88 signaling promotes both mucosal homeostatic and fibrotic responses during Salmonella-induced colitis.
Nadroparin Sodium Activates Nrf2/HO-1 Pathway in Acetic Acid-Induced Colitis in Rats.
Neurogenic contraction of mouse rectum via the cyclooxygenase pathway: Changes of PGE(2)-induced contraction with dextran sulfate sodium-induced colitis.
Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease.
Oleuropein ameliorates acute colitis in mice.
On the suppression of food intake in experimental models of colitis in the rat.
Participation of the intestinal microbiota in the mechanism of beneficial effect of treatment with synbiotic Syngut on experimental colitis under stress conditions.
Peptide Hp(2-20) accelerates healing of TNBS-induced colitis in the rat.
Pharmabiotic beads with improved encapsulation and gut survival for management of colonic inflammation associated gut derangements.
Pharmacologycal activity of peperina (Minthostachys verticillata) on gastrointestinal tract.
Piperine, a functional food alkaloid, exhibits inhibitory potential against TNBS-induced colitis via the inhibition of I?B-?/NF-?B and induces tight junction protein (claudin-1, occludin, and ZO-1) signaling pathway in experimental mice.
Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer.
Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice.
Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2.
Prevent Effects of Lactobacillus Fermentum HY01 on Dextran Sulfate Sodium-Induced Colitis in Mice.
Prevention of colitis-associated colorectal cancer with 8-hydroxydeoxyguanosine.
Preventive and therapeutic effects of blueberry (Vaccinium corymbosum) extract against DSS-induced ulcerative colitis by regulation of antioxidant and inflammatory mediators.
Preventive effect of bergenin against the development of TNBS-induced acute colitis in rats is associated with inflammatory mediators inhibition and NLRP3/ASC inflammasome signaling pathways.
Prostaglandin ethanolamides attenuate damage in a human explant colitis model.
Prostaglandins and epithelial response to injury.
Protease-activated receptor-2 activation: a major actor in intestinal inflammation.
Protective effect of gentiopicroside against dextran sodium sulfate induced colitis in mice.
Protective effect of isoquercitrin against acute dextran sulfate sodium-induced rat colitis depends on the severity of tissue damage.
Protective effect of marine mangrove Rhizophora apiculata on acetic acid induced experimental colitis by regulating anti-oxidant enzymes, inflammatory mediators and nuclear factor-kappa B subunits.
Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice.
Protective effects of Pogostemon cablin Bentham water extract on inflammatory cytokine expression in TNBS-induced colitis in rats.
Protective Effects of Polysaccharide Extracted from Portulacae oleracea L. on Colitis Induced by Dextran Sulfate Sodium.
Protective Effects of Tyrosol Against DSS-Induced Ulcerative Colitis in Rats.
Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats.
Quercus ilex Extract Ameliorates Acute TNBS-Induced Colitis in Rats.
Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis.
Regulation of Colonic Epithelial Repair in Mice by Toll-like Receptors and Hyaluronic Acid.
Repeated predictable stress causes resilience against colitis-induced behavioral changes in mice.
Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model.
Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-?B and STAT3 activation.
Selective COX-2 Inhibition Reduces Leukocyte Sticking and Improves the Microcirculation in TNBS Colitis.
Standardized Fraction of Turbinaria ornata Alleviates Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice via Upregulation of FOXP3+ Regulatory T Cells.
Substance P Stimulates Cyclooxygenase-2 and Prostaglandin E2 Expression through JAK-STAT Activation in Human Colonic Epithelial Cells.
The anti-inflammatory effects of a high-frequency oligodeoxynucleotide from the genomic DNA of Lactobacillus casei.
The Anti-Inflammatory Potential of Mimosa caesalpiniifolia Following Experimental Colitis: Role of COX-2 and TNF-Alpha Expression.
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.
The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice.
The Dynamic Changes of Gut Microbiota in Muc2 Deficient Mice.
The effect of alpha-melanocyte stimulating hormone on colonic inflammation in the rat.
The effect of essential fatty acid deficiency on eicosanoid production in the inflamed rat colonic mucosa.
The effect of trinitrobenzene sulfonic acid (TNB) on colonocyte arachidonic acid metabolism.
The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats.
The GPR55 antagonist CID16020046 protects against intestinal inflammation.
The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor.
The preventive effect and underlying mechanism of Rhus chinensis Mill. fruits on dextran sulphate sodium-induced ulcerative colitis in mice.
The profiling of bioactives in Akebia trifoliata pericarp and metabolites, bioavailability and in vivo anti-inflammatory activities in DSS-induced colitis mice.
The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis.
Therapeutic action and underlying mechanisms of a combination of two pentacyclic triterpenes, alpha- and beta-amyrin, in a mouse model of colitis.
Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis.
Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis.
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.
Vascular contribution of adrenomedullin to microcirculatory improvement in experimental colitis.
[Acute colitis closely following the beginning of celecoxib treatment]
[Mechanism of exacerbation of colonic damage in experimental colitis treated with celecoxib]
[null].
[PPARgamma-gene therapy using an adenovirus vector for inflammatory bowel disease]
[Protective effect of epigallocatechin-3-gallate on inflammatory bowel disease: experiment with rat models of induced colitis]
[Selective COX-2 inhibitor-associated colitis: two case reports]
Colitis, Collagenous
Cyclooxygenase-2 immunoreactivity in collagenous colitis.
Colitis, Ischemic
Polydeoxyribonucleotide Exerts Therapeutic Effect by Increasing VEGF and Inhibiting Inflammatory Cytokines in Ischemic Colitis Rats.
Colitis, Ulcerative
Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats.
Amentoflavone inhibits iNOS, COX-2 expression and modulates cytokine profile, NF-?B signal transduction pathways in rats with ulcerative colitis.
Analysis of the pharmacological mechanism of Banxia Xiexin decoction in treating depression and ulcerative colitis based on a biological network module.
Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases.
Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer.
COX-2 and Ki-67 immunohistochemical markers in the assessment of long-standing ulcerative colitis associated dysplasia.
Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer.
Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice.
Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.
Cyclooxygenase-2 immunoreactivity in collagenous colitis.
Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.
D-limonene exhibits anti-inflammatory and antioxidant properties in an ulcerative colitis rat model via regulation of iNOS, COX-2, PGE2 and ERK signaling pathways.
Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease.
Dilodendron bipinnatum Radlk. extract alleviates ulcerative colitis induced by TNBS in rats by reducing inflammatory cell infiltration, TNF-? and IL-1? concentrations, IL-17 and COX-2 expressions, supporting mucus production and promotes an antioxidant effect.
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?
Expression of cyclooxygenase-2 and nitric oxide synthase 2 in swine ulcerative colitis caused by Salmonella typhimurium.
Ferulic acid ameliorates TNBS-induced ulcerative colitis through modulation of cytokines, oxidative stress, iNOs, COX-2, and apoptosis in laboratory rats.
Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves.
Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis.
Immunohistochemical expression of proinflammatory enzyme COX-2 and p53 in ulcerative colitis and its associated dysplasia and colorectal carcinoma.
In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis.
Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats.
Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis.
Modulation of human colonic arachidonic acid metabolism by sulfasalazine.
Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease.
Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis.
Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients.
Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis.
Promoter polymorphism of cyclooxygenase-1 (COX1) is not associated with ulcerative colitis in the Japanese population.
Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone.
Protective Effect of D-Carvone against Dextran Sulfate Sodium Induced Ulcerative Colitis in Balb/c Mice and LPS Induced RAW Cells via the Inhibition of COX-2 and TNF-?.
Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice.
Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis.
Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis.
Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.
Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
Ulcerative colitis-induced hepatic damage in mice: studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression.
Unravelling the Phytochemical Composition and the Pharmacological Properties of an Optimized Extract from the Fruit from Prunus mahaleb L.: From Traditional Liqueur Market to the Pharmacy Shelf.
[Synthesis of eicosanoids in the colonic mucosa in patients with ulcerative colitis]
Colitis-Associated Neoplasms
Angiogenin regulates PKD activation and COX-2 expression induced by TNF-? and bradykinin in the colonic myofibroblast.
Bufalin, a Traditional Chinese Medicine Compound, Prevents Tumor Formation in Two Murine Models of Colorectal Cancer.
Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer.
Endomicroscopic Imaging of COX-2 Activity in Murine Sporadic and Colitis-Associated Colorectal Cancer.
Inflammation and colorectal cancer.
Inflammation in sporadic colorectal cancer.
Influence of myeloperoxidase on colon tumor occurrence in inflamed versus non-inflamed colons of Apc(Min/+) mice.
Proteases and their receptors as mediators of inflammation-associated colon cancer.
The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor.
TNF-alpha and LPA promote synergistic expression of COX-2 in human colonic myofibroblasts: role of LPA-mediated transactivation of upregulated EGFR.
Toll-like receptor 4 signaling integrates intestinal inflammation with tumorigenesis: lessons from the murine model of colitis-associated cancer.
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.
Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression.
Colonic Diseases
Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.
Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease.
Colonic Neoplasms
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
17beta-Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells.
6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1.
?-Catenin recognizes a specific RNA motif in the cyclooxygenase-2 mRNA 3'-UTR and interacts with HuR in colon cancer cells.
A celecoxib derivative potently inhibits proliferation of colon adenocarcinoma cells by induction of apoptosis.
A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation.
A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
A New Model to Study the Role of Arachidonic Acid in Colon Cancer Pathophysiology.
A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells.
A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth.
A novel NSAID derivative, phospho-ibuprofen, prevents AOM-induced colon cancer in rats.
A review of the anti-tumor effect of the combined administration of a cyclooxygenase-2 selective inhibitor and a non-specific immunostimulant protein-bound polysaccharide on an advanced colon cancer model using colon cancer cell lines.
A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer.
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers.
Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells.
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.
Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells.
Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice.
Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells.
Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells.
alpha2beta1 integrin signalling enhances cyclooxygenase-2 expression in intestinal epithelial cells.
Altered eicosanoid levels in human colon cancer.
Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.
AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin.
An upstream CRE-E-box element is essential for gastrin-dependent activation of the cyclooxygenase-2 gene in human colon cancer cells.
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
Anti-inflammatory drugs and their mechanism of action.
Anti-inflammatory effect and inhibition of nitric oxide production by targeting COXs and iNOS enzymes with the 1,2-diphenylbenzimidazole pharmacophore.
Anti-tumor activity of the novel hexahydrocannabinol analog LYR-8 in Human colorectal tumor xenograft is mediated through the inhibition of Akt and hypoxia-inducible factor-1? activation.
Anticancer effect of COX-2 inhibitor DuP-697 alone and in combination with tyrosine kinase inhibitor (E7080) on colon cancer cell lines.
Antioxidant activities of extracts from five anti-viral medicinal plants.
Antiproliferative activity of New Zealand propolis and phenolic compounds vs human colorectal adenocarcinoma cells.
Antiproliferative crude soy saponin extract modulates the expression of IkappaBalpha, protein kinase C, and cyclooxygenase-2 in human colon cancer cells.
Antiproliferative effect of a novel nitro-oxy derivative of celecoxib in human colon cancer cells: role of COX-2 and nitric oxide.
Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats.
Apoptosis inducing effect of plumbagin on colonic cancer cells depends on expression of COX-2.
Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway.
Apoptotic effect of eugenol envolves G2/M phase abrogation accompanied by mitochondrial damage and clastogenic effect on cancer cell in vitro.
Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk.
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression.
Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-?B to the COX-2 promoter.
Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats.
Aspirin-like molecules that covalently inactivate cyclooxygenase-2.
Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas.
Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis.
Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells.
Avenanthramides inhibit proliferation of human colon cancer cell lines in vitro.
Azoxymethane protects intestinal stem cells and reduces crypt epithelial mitosis through a COX-1-dependent mechanism.
beta-Carotene downregulates the steady-state and heregulin-alpha-induced COX-2 pathways in colon cancer cells.
Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.
Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro.
Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells.
Briarane Diterpenes Diminish COX-2 Expression in Human Colon Adenocarcinoma Cells.
Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition.
Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue.
C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy through inhibition of COX-2 expression.
Cadmium Induces Migration of Colon Cancer Cells: Roles of Reactive Oxygen Species, P38 and Cyclooxygenase-2.
Can licorice lick colon cancer?
Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis).
Caveolin-1 facilitates cyclooxygenase-2 protein degradation.
Caveolin-1-mediated suppression of cyclooxygenase-2 via a {beta}-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression.
CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration.
CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.
Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/?-catenin signaling pathway.
Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29).
Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells.
Celecoxib increases retinoid sensitivity in human colon cancer cell lines.
Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.
Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR.
Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression.
Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression.
Celecoxib treatment alters the gene expression profile of normal colonic mucosa.
Cellular density-dependent down-regulation of EP4 prostanoid receptors via the up-regulation of hypoxia-inducible factor-1? in HCA-7 human colon cancer cells.
Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems.
Chemical composition of volatile oil from Citrus limettioides and their inhibition of colon cancer cell proliferation
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.
Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.
Chemoprevention of Colon Cancer by iNOS-Selective Inhibitors.
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
Chemoprevention of DMH-induced rat colon carcinoma initiation by combination administration of piroxicam and C-phycocyanin.
Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Chemopreventive effect of chitosan oligosaccharide against colon carcinogenesis.
Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis.
Chemopreventive effects of a low-side-effect antibiotic drug, erythromycin, on mouse intestinal tumors.
Chemopreventive effects of nonsteroidal anti-inflammatory drugs in the membrane lipid composition and fluidity parameters of the 1,2-dimethylhydrazine-induced colon carcinogenesis in rats.
Chemopreventive effects of nonsteroidal anti-inflammatory drugs on 1,2-dimethylhydrazine-induced colon carcinogenesis in rats.
Chemopreventive effects of polysaccharides extract from Asterina pectinifera on HT-29 human colon adenocarcinoma cells.
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Chemopreventive efficacy of green tea drinking against 1,2-dimethyl hydrazine-induced rat colon carcinogenesis.
Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways.
Chemopreventive response of diclofenac, a non-steroidal anti-inflammatory drug in experimental carcinogenesis.
Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells.
Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer.
Clinical aspects of COX-2 inhibitors.
Co-Expression of Cox-2, C-Met and beta-catenin in Cells Forming Invasive front of Gallbladder Cancer.
Colocalization of BAX with BID and VDAC-1 in nimesulide-induced apoptosis of human colon adenocarcinoma COLO 205 cells.
Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor.
Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
Colon cancer: genomics and apoptotic events.
Colonic luminal contents induce cyclooxygenase 2 transcription in human colon carcinoma cells.
Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways.
Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats.
Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer.
Comparison of protein expression by isotope-coded affinity tag labeling.
Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells.
Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models.
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
Coprocytobiology: on the nature of cellular elements from stools in the pathophysiology of colonic disease.
Correlation between COX-2 and APC expression in left versus right-sided human colon cancer.
Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells.
Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003;63:5239-42.
Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.
COX-1 and COX-2 tissue expression: implications and predictions.
COX-2 and colon cancer.
COX-2 and colon cancer: Potential targets for chemoprevention.
COX-2 and colon cancer: potential targets for chemoprevention.
COX-2 and iNOS, good targets for chemoprevention of colon cancer.
COX-2 expression during early lung squamous cell carcinoma oncogenesis.
COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status.
COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.
COX-2 inhibitors--IBC conference. 12-13 April 1999, Coronado, CA, USA.
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells.
COX-2 Polymorphism, Use of Nonsteroidal Anti-Inflammatory Drugs, and Risk of Colon Cancer in African Americans (United States).
COX-2- and endoplasmic reticulum stress-independent induction of ULBP-1 and enhancement of sensitivity to NK cell-mediated cytotoxicity by celecoxib in colon cancer cells.
COX-2: a target for colon cancer prevention.
Cranberry extract and quercetin modulate the expression of cyclooxygenase-2 (COX-2) and I?B? in human colon cancer cells
Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B /p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions.
Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells.
Cyclooxygenase 2 inhibitors and colon cancer.
Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells.
Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.
Cyclooxygenase as a target in chemoprevention by probiotics during 1,2-dimethylhydrazine induced colon carcinogenesis in rats.
Cyclooxygenase Inhibitors Induce Colon Cancer Cell Apoptosis Via PPARdelta --> 14-3-3epsilon Pathway.
Cyclooxygenase inhibitors--current status and future prospects.
Cyclooxygenase regulates angiogenesis induced by colon cancer cells.
Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.
Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.
Cyclooxygenase-2 and 5-lipoxygenase pathways in diosgenin-induced apoptosis in HT-29 and HCT-116 colon cancer cells.
Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection.
Cyclooxygenase-2 expression in early gastric cancer, intestinal metaplasia and Helicobacter pylori infection.
Cyclooxygenase-2 expression in hepatocellular carcinoma.
Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A.
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.
Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy.
Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers.
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.
Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15.
Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract.
Cyclooxygenase-2 in Dukes B colon cancer.
Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer.
Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer.
Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins.
Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways.
Cyclooxygenase-2 knockdown by RNA interference in colon cancer.
Cyclooxygenase-2 knockdown using retinoic acid chalcone (RAC), a promising therapeutic strategy for colon cancer.
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells.
Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Cyclooxygenase-2 plays a suppressive role for induction of apoptosis in isoliquiritigenin-treated mouse colon cancer cells.
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells.
Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors.
Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Cyclooxygenase-2/Carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells.
Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer.
Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells.
Cyclooxygenases 1 and 2.
Cyclooxygenases and colon cancer.
Cytoplasmic Expression of HuR is Related to Cyclooxygenase-2 Expression in Colon Cancer.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis.
DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis.
Depressed-type early invasive colon cancer in a patient treated with cyclooxygenase-2 inhibitor.
Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway.
Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.
Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice.
Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis.
Dietary non-nutritive factors in targeting of regulatory molecules in colorectal cancer: an update.
Differential cytotoxic activity of Quercetin on colonic cancer cells depends on ROS generation through COX-2 expression.
Differential modulation of cyclooxygenase-mediated prostaglandin production by the putative cancer chemopreventive flavonoids tricin, apigenin and quercetin.
Dihomo-?-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase.
Discovery of Novel 2-Amino-5-(Substituted)-1,3,4-Thiadiazole Derivatives: New Utilities for Colon Cancer Treatment.
Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation.
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model.
Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription.
Effect of indomethacin on Bfl-1, WISP-1 and proliferating cell nuclear antigen in colon cancer cell line HCT116 cells.
Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model.
Effect of NS-398 on colon cancer cells.
Effect of Rumex Abyssinicus on preneoplastic lesions in dimethylhydrazine induced colon carcinogenesis in rats.
Effect of TGF-?1 on Apoptosis of Colon Cancer Cells Via the ERK Signaling Pathway.
Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells.
Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro.
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Effects of cotreatment of 12-O-tetradecanoylphorbol-13-acetate and H2O2 on apoptotic regulation via AMP-activated protein kinase-cyclooxygenase-2 signals.
Effects of Cyclooxygenase and Lipoxygenase Inhibitors on the Proliferation of Colon Cancer Cells and Their Production of Eicosanoids.
Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane.
Effects of purified green and black tea polyphenols on cyclooxygenase- and lipoxygenase-dependent metabolism of arachidonic acid in human colon mucosa and colon tumor tissues.
Effects of the black tea polyphenol theaflavin-2 on apoptotic and inflammatory pathways in vitro and in vivo.
EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells.
EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF.
EP4 receptor as a novel promising therapeutic target in colon cancer.
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.
Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells.
Epithelial cyclooxygenase-2 expression: a model for pathogenesis of colon cancer.
Ethanolic Extract of Bark from Salix aegyptiaca Ameliorates 1,2-dimethylhydrazine-induced Colon Carcinogenesis in Mice by Reducing Oxidative Stress.
Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells.
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Experimental models of gene-environment interaction for cancer chemoprevention studies.
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Expression of Cyclooxygenase-2 and Tumor Microvessel Density in Colorectal Cancer.
Expression of cyclooxygenase-2 in human hyperplastic gastric polyps.
Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.
Expression of HLA Class I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon Cancer.
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.
Expression of prostaglandin H synthase-2 in human brain tumors.
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.
Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas.
Expression Patterns of Cancer Stem Cell Markers During Specific Celecoxib Therapy in Multistep Rat Colon Carcinogenesis Bioassays.
Expressions of TIMP-1, COX-2 and MMP-7 in Colon Polyp and Colon Cancer.
Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma.
Fenretinide inhibits phorbol ester-induced cyclooxygenase-2 expression in human colon adenocarcinoma cells.
Fish oil enhances targeted apoptosis during colon tumor initiation in part by downregulating Bcl-2.
Flavanols from Japanese quince (Chaenomeles japonica) fruit suppress expression of cyclooxygenase-2, metalloproteinase-9, and nuclear factor-kappaB in human colon cancer cells.
Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies.
Free radical scavenging and COX-2 inhibition by simple colon metabolites of polyphenols: A theoretical approach.
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.
Gamma-herpesvirus neoplasia: a growing role for COX-2.
Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production.
Germinated brown rice (GBR) reduces the incidence of aberrant crypt foci with the involvement of beta-catenin and COX-2 in azoxymethane-induced colon cancer in rats.
GPx2 counteracts PGE2 production by dampening COX-2 and mPGES-1 expression in human colon cancer cells.
Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2.
Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content.
Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention.
Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer.
Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells.
HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling.
High expression of cyclooxygenase-2 in macrophages of human colonic adenoma.
Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB.
Human fecal water inhibits COX-2 in colonic HT-29 cells: role of phenolic compounds.
Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.
Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells.
Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer.
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.
Hypertonic environment elicits cyclooxygenase-2-driven prostaglandin E2 generation by colon cancer cells: role of cytosolic phospholipase A2-alpha and kinase signaling pathways.
Hypoxia-inducible factor-2? is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer.
Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells.
Immunohistochemical expression of cyclooxygenase-2 in oral squamous cell carcinoma.
Impact of celecoxib on soluble intercellular adhesion molecule-1 and soluble e-cadherin concentrations in human colon cancer cell line cultures exposed to phytic acid and TNF-alpha.
In vitro effects on polydextrose by colonic bacteria and caco-2 cell cyclooxygenase gene expression.
Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer.
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.
Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers.
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Indomethacin antagonizes EP(2) prostanoid receptor activation in LS174T human colon cancer cells.
Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: A novel cyclooxygenase-inhibition-independent effect.
Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines.
Induction of apoptosis by Panduratin A isolated from Kaempferia pandurata in human colon cancer HT-29 cells.
Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway.
Induction of apoptosis in colon cancer cells by nonsteroidal anti-inflammatory drugs.
Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to G?i and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells.
Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells.
Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades.
Influence of myeloperoxidase on colon tumor occurrence in inflamed versus non-inflamed colons of Apc(Min/+) mice.
Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells.
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Inhibition of arachidonic acid metabolism decreases tumor cell invasion and matrix metalloproteinase expression.
Inhibition of COX-2 Impairs Colon Cancer Liver Metastasis through Reduced Stromal Cell Reaction.
Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53.
Inhibition of COX-2 in Colon Cancer Modulates Tumor Growth and MDR-1 Expression to Enhance Tumor Regression in Therapy-Refractory Cancers In Vivo.
Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy.
Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells.
Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522.
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment.
Inhibition of PGE2/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress.
Inhibition of the biosynthesis of prostaglandin E2 by low dose aspirin: implications for adenocarcinoma metastasis.
Inhibition of TNFalpha-induced iNOS expression in HSV-tk transduced 9L glioblastoma cell lines by Marasmius oreades substances through NF-kappaB- and MAPK-dependent mechanisms.
Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer.
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study.
Intracellular colon cancer-associated Escherichia coli promote protumoral activities of human macrophages by inducing sustained COX-2 expression.
Intracellular unesterified arachidonic acid signals apoptosis.
Intron 1 retaining cyclooxygenase 1 splice variant is induced by osmotic stress in human intestinal epithelial cells.
Involvement of NADPH oxidases in suppression of cyclooxygenase-2 promoter-dependent transcriptional activities by sesamol.
Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer.
JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats.
Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ?-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.
Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-?-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2.
Lactate promotes PGE2 synthesis and gluconeogenesis in monocytes to benefit the growth of inflammation-associated colorectal tumor.
Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.
Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression.
Levamisole modulates prostaglandin E2 production and cyclooxygenase II gene expression in human colonic cancer cells.
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.
Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells.
Light and Moderate Doses of Ethanol in Chemical Carcinogenesis of the Colon in Rats.
Linkage Disequilibrium and Haplotype Analysis of COX-2 and Risk of Colorectal Adenoma Development.
Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells.
Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells.
Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer.
Mechanism of action of antiinflammatory drugs.
Mechanisms involved in the antiproliferative and proapoptotic effects of unsaponifiable fraction of extra virgin olive oil on HT-29 cancer cells.
Mechanisms of colon cancer prevention with and beyond COX-2 inhibition.
Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480.
Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways.
Meloxicam inhibits the growth of colorectal cancer cells.
MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival.
Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer.
MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells.
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment.
Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells.
Modulation of transcription by the peroxisome proliferator-activated receptor delta--binding RNA aptamer in colon cancer cells.
Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression.
Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling.
Myofibroblasts. II. Intestinal subepithelial myofibroblasts.
n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved.
n-6 Linoleic Acid Induces Epigenetics Alterations Associated with Colonic Inflammation and Cancer.
NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression.
Nicotine increases colon cancer cell migration and invasion through epithelial to mesenchymal transition (EMT): COX-2 involvement.
Nitric Oxide (NO) and Cyclooxygenase-2 (COX-2) Cross-Talk in Co-Cultures of Tumor Spheroids with Normal Cells.
Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines.
Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer.
No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk.
NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?
Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy.
Nonsteroidal anti-inflammatory drugs stimulate spermidine/spermine acetyltransferase and deplete polyamine content in colon cancer cells.
Nonsteroidal antiinflammatory agents.
Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer.
Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.
Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.
Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
NSAIDs activate PTEN and other phosphatases in human colon cancer cells: novel mechanism for chemopreventive action of NSAIDs.
NSAIDs and the colon.
Nutritional targeting of cyclooxygenase-2 for colon cancer prevention.
Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway.
Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2.
p-HPEA-EDA, a phenolic compound of virgin olive oil, activates AMP-activated protein kinase to inhibit carcinogenesis.
Pain management and beyond: evolving concepts and treatments involving cyclooxygenase inhibition.
PCR differential display-based identification of regulator of G protein signaling 10 as the target gene in human colon cancer cells induced by black tea polyphenol theaflavin monogallate.
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis.
PHGPx overexpression induces an increase in COX-2 activity in colon carcinoma cells.
Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.
PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac.
Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis.
Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer.
Polysaccharide-Rich Fractions from Rosa rugosa Thunb.-Composition and Chemopreventive Potential.
Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region.
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis.
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas.
Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
Primary and secondary prevention of colorectal cancer.
Probiotics (Lactobacillus acidophilus and Lactobacillus rhamnosus GG) in Conjunction with Celecoxib (selective COX-2 inhibitor) Modulated DMH-Induced Early Experimental Colon Carcinogenesis.
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer.
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.
Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.
Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells.
Prostaglandin E2-stimulated prostanoid EP4 receptors induce prolonged de novo prostaglandin E2 synthesis through biphasic phosphorylation of extracellular signal-regulated kinases mediated by activation of protein kinase A in HCA-7 human colon cancer cells.
Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect.
Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia.
Prostaglandin H synthase expression is variable in human colorectal adenocarcinoma cell lines.
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression.
Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors.
Protective Effect of Nerium Oleander Distillate and Tarantula Cubensis Alcoholic Extract on Cancer Biomarkers on Colon and Liver Tissues of Rats with Experimental Colon Cancer.
Protein kinase A-mediated 14-3-3 association impedes human Dapper1 to promote dishevelled degradation.
PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer.
PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts.
Pyrimidine-based fluorescent COX-2 inhibitors: synthesis and biological evaluation.
Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis.
Quercetin Suppresses Early Colon Carcinogenesis Partly through Inhibition of Inflammatory Mediators.
Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels.
Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors.
RE: Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer.
Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2.
Reduced tumour progression and angiogenesis in 1,2-dimethylhydrazine mice treated with NS-398 is associated with down-regulation of cyclooxygenase-2 and decreased beta-catenin nuclear localisation.
Reduction of intracellular pH inhibits constitutive expression of cyclooxygenase-2 in human colon cancer cells.
Regression of follicular lymphoma with Devil's Claw: coincidence or causation?
Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells.
Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction.
Regulation of COX-2 transcription in a colon cancer cell line by Pontin52/TIP49a.
Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1.
Regulation of leukotriene-dependent induction of cyclooxygenase-2 and Bcl-2.
Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells.
Research on the inhibiting effect of tanshinone IIA on colon cancer cell growth via COX-2-Wnt/?-catenin signaling pathway.
Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment.
Resveratrol directly targets COX-2 to inhibit carcinogenesis.
Resveratrol Treatment Inhibits Proliferation of and Induces Apoptosis in Human Colon Cancer Cells.
Retinoic acid inhibits beta-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli.
Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer.
Review article: COX-2, prostanoids and colon cancer.
Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.
RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells.
RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.
Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis.
Role of cyclooxygenase-1 and -2 in health and disease.
Role of cyclooxygenase-2 in breast cancer.
Role of cyclooxygenase-2 in colorectal cancer.
Role of GSK-3? in Regulation of Canonical Wnt/?-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer.
Roles of COX-1 and COX-2 in gastrointestinal pathophysiology.
Rosmarinic Acid antagonizes activator protein-1-dependent activation of cyclooxygenase-2 expression in human cancer and nonmalignant cell lines.
Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells.
Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential.
Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.
Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin.
Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells.
Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells.
Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines.
Selenomethionine regulates cyclooxygenase-2 (COX-2) expression through nuclear factor-kappa B (NF-kappaB) in colon cancer cells.
Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells.
Sesamol suppresses cyclooxygenase-2 transcriptional activity in colon cancer cells and modifies intestinal polyp development in Apc (Min/+) mice.
Short chain fatty acid butyrate uptake reduces expressions of prostanoid EP4 receptors and their mediation of cyclooxygenase-2 induction in HCA-7 human colon cancer cells.
Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.
Smad3 mutant mice develop colon cancer with overexpression of COX-2.
Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation.
Soy Saponins Meditate the Progression of Colon Cancer in Rats by Inhibiting the Activity of ? -Glucuronidase and the Number of Aberrant Crypt Foci but Not Cyclooxygenase-2 Activity.
Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells.
Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production.
Sphingosine kinase 1 expression enhances colon tumor growth.
Sphingosine kinase 1 is up-regulated in colon carcinogenesis.
STAT1-independent inhibition of cyclooxygenase-2 expression by IFNgamma; a common pathway of IFNgamma-mediated gene repression but not gene activation.
Staurosporine synergistically potentiates the deoxycholate-mediated induction of COX-2 expression.
Stromal COX-2 signaling activated by deoxycholic acid mediates proliferation and invasiveness of colorectal epithelial cancer cells.
Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer.
Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Sulforaphane, a Chemopreventive Compound, Inhibits Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Expression in Human HT-29 Colon Cancer Cells.
Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells.
Suppression by flavonoids of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells: structure-activity relationship.
Suppression of ?-catenin and Cyclooxygenase-2 Expression and Cell Proliferation in Azoxymethane-Induced Colonic Cancer in Rats by Rice Bran Phytic Acid (PA).
Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure.
Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib.
Suppression of promoter-dependent transcriptional activity of inducible nitric oxide synthase by sodium butyrate in colon cancer cells.
Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray.
Survivin and Cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes.
Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention.
Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway.
Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29.
Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines.
Synthesis, characterisation and biological evaluation of copper and silver complexes based on acetylsalicylic acid.
Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.
Targeting angiogenic pathway for chemoprevention of experimental colon cancer using C-phycocyanin as cyclooxygenase-2 inhibitor.
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer.
Targeting Heterogeneous Tumors Using a Multifunctional Molecular Prodrug.
Tart cherry anthocyanins inhibit tumor development in Apc(Min) mice and reduce proliferation of human colon cancer cells.
The -1195G allele increases the transcriptional activity of cyclooxygenase-2 gene (COX-2) in colon cancer cell lines.
The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid.
The anti-proliferative potency of celecoxib is not a class effect of coxibs.
The CCK-2/gastrin splice variant receptor retaining intron 4 transactivates the COX-2 promoter in vitro.
The clinical potential of cyclooxygenase-2-specific inhibitors.
The Co-regulatory Role of 5-Lipoxygenase and Cyclooxygenase-2 in the Carcinogenesis and their Promotion by Cigarette Smoking in Colons.
The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells.
The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats.
The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway.
The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model.
The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells.
The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells.
The flavouring phytochemical 2-pentanone reduces prostaglandin production and COX-2 expression in colon cancer cells.
The Impact of Dietary Polyphenols on COX-2 Expression in Colorectal Cancer.
The involvement of nuclear factor-kappa B in cyclooxygenase-2 overexpression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene.
The modulating role of nuclear factor-kappaB in the action of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone.
The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.
The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor.
The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
The retinoid fenretinide inhibits proliferation and downregulates cyclooxygenase-2 gene expression in human colon adenocarcinoma cell lines.
The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death.
The role of cyclooxygenase-2 and prostaglandins in colon cancer.
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
The role of cyclooxygenase-2 in the pathogenesis of skin cancer.
The role of cyclooxygenases in inflammation, cancer, and development.
The treatment of advanced colorectal cancer: where are we now and where do we go?
Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation.
TNF?-activated stromal COX-2 signalling promotes proliferative and invasive potential of colon cancer epithelial cells.
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
Transcriptional regulation of the COX-2 expression by nitric oxide in colon cancer cell lines.
Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe.
Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer.
Triptolide inhibits cyclooxygenase-2 and inducible nitric oxide synthase expression in human colon cancer and leukemia cells.
Tristetraprolin downregulates the expression of both VEGF and COX-2 in human colon cancer.
Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression.
Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.
Tumour-suppressive effect of oestrogen receptor ? in colorectal cancer patients, colon cancer cells, and a zebrafish model.
Two distinct pathways for cyclooxygenase-2 protein degradation.
Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways.
Two Pathways for Cyclooxygenase-2 Protein Degradation In Vivo.
Up-regulation of cyclooxygenase-2-derived prostaglandin E(2) in colon cancer cells resistant to 5-fluorouracil.
Upregulation of C-C chemokine receptor type 7 expression by membrane-associated prostaglandin E synthase-1/prostaglandin E2 requires glycogen synthase kinase 3?-mediated signal transduction in colon cancer cells.
Upregulation of Prostaglandin E2 by Inducible Microsomal Prostaglandin E Synthase-1 in Colon Cancer.
Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis.
Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer.
Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.
Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells.
UVB radiation-induced ?-catenin signaling is enhanced by COX-2 expression in keratinocytes.
Valdecoxib Recovers the Lipid Composition, Order and Dynamics in Colon Cancer Cell Lines Independent of COX-2 Expression: An ATR-FTIR Spectroscopy Study.
Vitamin E metabolite 13'-carboxychromanols inhibit pro-inflammatory enzymes, induce apoptosis and autophagy in human cancer cells by modulating sphingolipids and suppress colon tumor development in mice.
Why is cyclooxygenase-2 expressed in neuroendocrine cells of the human alimentary tract?
XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers.
[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
[Celecoxib increased cellular ATRA sensitivity of human colon cancer cell lines through COX-2-independent mechanisms].
[Characteristics of colon cancer diagnosed in patients taking aspirin or warfarin]
[CHL prevent colon neoplasms in mice and its selective inhibition on COX-2]
[Colon cancer and COX-2]
[Colon cancer and cyclooxygenase]
[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer]
[COX and study of cancer therapy]
[COX-2 inhibitor and colon cancer]
[Effect of COX-2 inhibitor on the expression of BCL-3 and cyclin D1 in human colon cancer cell line SW480]
[Effect of indomethacin on human colorectal cancer cells HCT116 and SW480]
[Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis]
[Effects of selective and non-selective cyclooxygenase-2 inhibitor on the growth of colon cancer cells]
[Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: an experimental study]
[Induction of NAG-1 gene expression in colon cancer cells by non-steroidal anti-inflammatory drugs]
[Molecular mechanism of cyclooxygenase-2 inhibitor in inhibition of proliferation of colon cancer cells by modulating Stat5 signal transduction pathway]
[Neoplastic effect of indomethacin in N-methyl-N-nitrosourea induced mammary carcinogenesis in female rats].
[Preventive effects of berberine on experimental colon cancer and relationship with cyclooxygenase-2 expression].
[Study on inhibitory effect of matrine on cyclooxygenase-2 expression in colon cancer HT-29 cell line]
[The role of TLR4 receptor in development of inflammation and carcinogenesis in ulcerative colitis and pharmacotherapy of this disorder].
Colorectal Neoplasms
"Letter to editor" in lieu of article published in Mol Biol Rep. 2012 May; 39(5):5219-24. PTGS2 (COX2) -765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population.
15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice.
15-lipoxygenase-1 in colorectal cancer: a review.
15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis.
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1.
?-catenin negatively regulates expression of the prostaglandin transporter PGT in the normal intestinal epithelium and colorectal tumour cells: a role in the chemopreventive efficacy of aspirin?
?-Catenin Regulation in Sporadic Colorectal Carcinogenesis: Not as Simple as APC.
A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
A molecular/epidemiologic analysis of expression of cyclooxygenases 1 and 2, use of nonsteroidal antiinflammatory drugs, and risk of colorectal adenoma.
A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth.
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways.
A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis.
A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer.
A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells.
Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia.
Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors.
Acetylsalicylic Acid and its Potential for Chemoprevention of Colorectal Carcinoma.
Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells.
Acute changes in colonic PGE2 levels as a biomarker of efficacy after treatment of the Pirc (F344/NTac-Apc am1137) rat with celecoxib.
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer.
Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice.
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.
An apple oligogalactan potentiates the growth inhibitory effect of celecoxib on colorectal cancer.
An association between the PTGS2 rs5275 polymorphism and colorectal cancer risk in families with inherited non-syndromic predisposition.
An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
An upstream CRE-E-box element is essential for gastrin-dependent activation of the cyclooxygenase-2 gene in human colon cancer cells.
Angiotensin II and epidermal growth factor induce cyclooxygenase-2 expression in intestinal epithelial cells through small GTPases using distinct signaling pathways.
ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression.
Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells.
Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases.
Antineoplastic effect of a novel chemopreventive agent, neokestose, on the Caco-2 cell line via inhibition of expression of nuclear factor-?B and cyclooxygenase-2.
Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells.
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines.
Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398.
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Arachidonic acid and colorectal carcinogenesis.
Aspirin alone and combined with a statin suppresses eicosanoid formation in human colon tissue.
Aspirin and colorectal cancer: back to the future.
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.
Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD).
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
Aspirin use and survival after diagnosis of colorectal cancer.
Aspirin, COX-2, and the risk of colorectal cancer.
Aspirin, cyclooxygenase inhibition and colorectal cancer.
Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway.
Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer.
Association Between COX-2 Expression and Effectiveness of COX-2 Inhibitors in a Phase II Trial in Patients with Metastatic Colorectal Adenocarcinoma.
Association between cyclooxygenase-2-expressing macrophages, ulceration and microvessel density in colorectal cancer.
Association between Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer: A Population-Based Case-Control Study.
Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas.
Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis.
Association of folate intake, dietary habits, smoking and COX-2 promotor -765G>C polymorphism with K-ras mutation in patients with colorectal cancer.
Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population.
Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer.
Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer.
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.
Beta-Catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3'-UTR.
Beta-catenin--a linchpin in colorectal carcinogenesis?
Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer.
Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells.
c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells.
c-Myb and its Effector COX-2 as an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer.
Cancer and cyclooxygenase-2 (COX-2) inhibition.
Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective.
Cardiovascular Risk Markers and Mechanisms in Targeting the COX Pathway for Colorectal Cancer Prevention.
CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro.
Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.
Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo.
Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer.
Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
Cell adhesion property affected by cyclooxygenase and lipoxygenase: Opto-electric approach.
CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.
Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity.
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems.
Chemoprevention of arylamine-induced colorectal aberrant crypts.
Chemoprevention of cancer--focusing on clinical trials.
Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors.
Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2.
Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back.
Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.
Chemoprevention of colorectal cancer.
Chemoprevention of colorectal cancer: dietary and pharmacologic approaches.
Chemopreventive effects of Khaya senegalensis bark extract on human colorectal cancer.
Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2.
Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer.
Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.
Chemotherapy in colorectal cancer: new options and new challenges.
Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents.
Clinical value of detecting IQGAP3, B7-H4 and cyclooxygenase-2 in the diagnosis and prognostic evaluation of colorectal cancer.
Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer.
Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis.
Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation.
Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.
Colorectal cancer and nonsteroidal anti-inflammatory drugs.
Colorectal cancer chemoprevention: aspirin, other NSAID and COX-2 inhibitors.
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.
Colorectal Cancer Screening and Prevention.
Colorectal cancer: a summary of the evidence for screening and prevention.
Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Comparing the Effects of COX and Non-COX-inhibiting NSAIDs on Enhancement of Apoptosis and Inhibition of Aberrant Crypt Foci Formation in a Rat Colorectal Cancer Model.
Comparison of cyclo-oxygenase 2 expression in colorectal serrated adenomas to expression in tubular adenomas and hyperplastic polyps.
Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis.
Comparison of protein expression by isotope-coded affinity tag labeling.
Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading.
Connecting COX-2 and Wnt in cancer.
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
Coordinate up-regulation of low-density lipoprotein receptor and cyclo-oxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies.
Cordycepin inhibits lipopolysaccharide-induced cell migration and invasion in human colorectal carcinoma HCT-116 cells through down-regulation of prostaglandin E2 receptor EP4.
Correction to: Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega?3 polyunsaturated fatty acid eicosapentaenoic acid.
Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.
Correlation of COX- 2 Expression in Colorectal Carcinoma with Clinicopathological Features.
Correlation of cyclooxygenase 2 expression and inflammatory cells infiltration in colorectal cancer.
Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.
COX-2 Active Agents in the Chemoprevention of Colorectal Cancer.
Cox-2 and cancer chemoprevention: picking up the pieces.
COX-2 and colorectal cancer.
COX-2 Contributes to P-glycoprotein-Mediated Multidrug Resistance via phosphorylation of c-Jun at Ser63/73 in Colorectal Cancer.
COX-2 expression and effects of COX-2 inhibition in colorectal carcinomas and their liver metastases.
COX-2 expression and tumor angiogenesis in colorectal cancer.
Cox-2 expression in retinoblastoma.
COX-2 expression is unexpectedly high in viable colorectal mucosal cells: is there life for chemoprophylaxis after VICTOR?
COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status.
COX-2 gene rs689466 polymorphism is associated with increased risk of colorectal cancer among Caucasians: a meta-analysis.
COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.
COX-2 inhibition and colorectal cancer.
COX-2 inhibition and prevention of cancer.
COX-2 inhibition as a tool to treat and prevent colorectal cancer.
COX-2 inhibition in clinical cancer prevention.
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
COX-2 inhibitors for colorectal cancer.
COX-2 inhibitors for the prevention of breast cancer.
COX-2 inhibitors: a potential target for drug therapy in the management of colorectal cancer.
COX-2 overexpression in canine tumors: potential therapeutic targets in oncology.
COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk.
COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention.
COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer.
COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
COX-2: a molecular target for colorectal cancer prevention.
COX2 Inhibitor NS398 Reduces HT-29 Cell Invasiveness by Modulating Signaling Pathways Mediated by EGFR and HIF1-?.
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials.
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors.
Cyclo-oxygenase 2 inhibition in colorectal cancer therapy.
Cyclo-oxygenase inhibition in colorectal adenomas and cancer.
Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer.
Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency.
Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice.
Cyclooxygenase 2 polymorphism and colorectal cancer: -765G>C variant modifies risk associated with smoking and body mass index.
Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?
Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention.
Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention.
Cyclooxygenase inhibitors in the chemoprevention of colorectal cancer.
Cyclooxygenase, NSAIDs, and colorectal cancer.
Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.
Cyclooxygenase-2 (COX2) gene polymorphisms and the risk of sporadic colorectal cancer and polyps among Jordanian population.
Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer.
Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays.
Cyclooxygenase-2 and chemoprevention of breast cancer.
Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection.
Cyclooxygenase-2 and colorectal cancer.
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis.
Cyclooxygenase-2 and its role in colorectal cancer development.
Cyclooxygenase-2 and tumor biology.
Cyclooxygenase-2 as a target for prevention of colorectal cancer.
Cyclooxygenase-2 expression and angiogenesis in colorectal cancer.
Cyclooxygenase-2 expression and angiogenesis in gastric hyperplastic polyp--association with polyp size.
Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer.
Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma.
Cyclooxygenase-2 expression correlates with membrane-type-1 matrix metalloproteinase expression in colorectal cancer tissue.
Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients.
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Cyclooxygenase-2 Expression in Animal Cancers.
Cyclooxygenase-2 expression in colorectal cancer liver metastases.
Cyclooxygenase-2 expression in colorectal carcinoma, adenomatous polyps and non-tumour bearing margins of resection tissues in a cohort of black Africans.
Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A.
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.
Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.
Cyclooxygenase-2 expression in polyps from a patient with juvenile polyposis syndrome with mutant BMPR1A.
Cyclooxygenase-2 expression in primary human colorectal cancers and bone marrow micrometastases.
Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy.
Cyclooxygenase-2 expression in the hereditary mixed polyposis syndrome.
Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients.
Cyclooxygenase-2 Expression Is a Predictive Marker for Late Recurrence in Colorectal Cancer.
Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.
Cyclooxygenase-2 gene polymorphisms and susceptibility to colorectal cancer in a Brazilian population.
Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study.
Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract.
Cyclooxygenase-2 in sporadic colorectal polyps: immunohistochemical study and its importance in the early stages of colorectal tumorigenesis.
Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Cyclooxygenase-2 inhibition prevents colorectal cancer: from the bench to the bed side.
Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression.
Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.
Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint.
Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.
Cyclooxygenase-2 inhibitors in colorectal cancer.
Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways.
Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer.
Cyclooxygenase-2 overexpression in colorectal cancer is associated with non-polypoid growth.
Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells.
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
Cyclooxygenase-2 overexpression is related to polypoid growth and K-ras gene mutation in T1 colorectal carcinomas.
Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Cyclooxygenase-2 polymorphisms and susceptibility to colorectal cancer: a meta-analysis.
Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.
Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB.
Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells.
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid.
Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines.
Cyclooxygenase-2/Carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells.
Cyclooxygenase-2: a novel target for cancer chemotherapy?
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma.
Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
Cytoplasmic Expression of HuR is Related to Cyclooxygenase-2 Expression in Colon Cancer.
Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells.
Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice.
Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps.
Development of Colorectal-Targeted Dietary Supplement Tablets Containing Natural Purple Rice Bran Oil as a Colorectal Chemopreventive.
Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.
Development of PET Radioligands Targeting COX-2 for Colorectal Cancer Staging, a Review of in vitro and Preclinical Imaging Studies.
Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.
Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
Differential expression of cyclo-oxygenase-2 and nuclear beta-catenin in colorectal cancer tissue.
Differential expression of cyclooxygenase 2 in human colorectal cancer.
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
Differential stromal and epithelial localization of cyclooxygenase-2 (COX-2) during colorectal tumorigenesis.
Digital analysis of the expression levels of multiple colorectal cancer-related genes by multiplexed digital-PCR coupled with hydrogel bead-array.
Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia.
Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.
Does miRNA-155 Promote Cyclooxygenase-2 Expression in Cancer?
Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells.
Dual Blockade of the EGFR and COX-2 Pathways: A Phase II Trial of Cetuximab and Celecoxib in Patients With Chemotherapy Refractory Metastatic Colorectal Cancer.
Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.
Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis.
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Effect of ginger root on cyclooxygenase-1 and 15-hydroxyprostaglandin dehydrogenase expression in colonic mucosa of humans at normal and increased risk for colorectal cancer.
Effect of indomethacin on Bfl-1, WISP-1 and proliferating cell nuclear antigen in colon cancer cell line HCT116 cells.
Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells.
Effect of silibinin in human colorectal cancer cells: Targeting the activation of NF-?B signaling.
Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells.
Effects of cotreatment of 12-O-tetradecanoylphorbol-13-acetate and H2O2 on apoptotic regulation via AMP-activated protein kinase-cyclooxygenase-2 signals.
Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.
Effects of Jianpi Jiedu Recipe () on reversion of P-glycoprotein-mediated multidrug resistance through COX-2 pathway in colorectal cancer.
Effects of moderate alcohol consumption on gene expression related to colonic inflammation and antioxidant enzymes in rats.
Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors.
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells.
EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells.
EGF receptor and COX-1/COX-2 enzyme proteins as related to corresponding mRNAs in human per-operative biopsies of colorectal cancer.
EGFR, HER-2 and COX-2 levels in colorectal cancer.
Endogenous lipid hydroperoxide-mediated DNA-adduct formation in min mice.
Endomicroscopic Imaging of COX-2 Activity in Murine Sporadic and Colitis-Associated Colorectal Cancer.
Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer.
Enhancement of T lymphocyte proliferative response to mitogens by indomethacin in breast and colorectal cancer patients.
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.
Epigenetic silencing of miR-137 contributes to early colorectal carcinogenesis by impaired Aurora-A inhibition.
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.
Epithelial cyclooxygenase-2 expression: a model for pathogenesis of colon cancer.
Ethanol enhances arsenic-induced cyclooxygenase-2 expression via both NFAT and NF-?B signalings in colorectal cancer cells.
Ethyl acetate extract from Glycosmis parva leaf induces apoptosis and cell-cycle arrest by decreasing expression of COX-2 and altering BCL-2 family gene expression in human colorectal cancer HT-29 cells.
Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer.
Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer.
Evaluation of Glycosylated PTGS2 in Colorectal Cancer for NSAIDS-Based Adjuvant Therapy.
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Expression and association of carbonic anhydrase IX and cyclooxygenase-2 in colorectal cancer.
Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation.
Expression of 15-lipoxygenase-1 in human colorectal cancer.
Expression of beta-catenin, COX-2 and iNOS in colorectal cancer: relevance of COX-2 adn iNOS inhibitors for treatment in Malaysia.
Expression of COX-2 and HER-2 in colorectal cancer and their correlation.
Expression of COX-2, MMP-2 and VEGF in stage II and III colorectal cancer and the clinical significance.
Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue.
Expression of cyclooxygenase-1 and -2 and clinicopathologic features of colorectal cancer in northern Thailand.
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Expression of cyclooxygenase-2 (COX-2) in colorectal adenocarcinoma: an immunohistochemical and histopathological study.
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in colorectal cancers.
Expression of cyclooxygenase-2 and its relationship with mismatch repair and microsatellite instability in hereditary nonpolyposis colorectal cancer.
Expression of cyclooxygenase-2 and mucin 1 in colorectal cancer.
Expression of Cyclooxygenase-2 and Tumor Microvessel Density in Colorectal Cancer.
Expression of cyclooxygenase-2 in colonic polyps.
Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression.
Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance.
Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.
Expression of cyclooxygenase-2 in patients with bladder carcinoma.
Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer.
Expression of cyclooxygenase-2 protein in colorectal carcinomas.
Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.
Expression of cytosolic and group X secretory phospholipase A(2) genes in human colorectal adenocarcinomas.
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Expression of NF-kB and COX-2 in Young Versus Older Patients with Sporadic Colorectal Cancer.
Expression of p27, COX-2, MLH1, and MSH2 in young patients with colon carcinoma and correlation with morphologic findings.
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.
Expression profiles of proliferative and antiapoptotic genes in sporadic and colitis-related mouse colon cancer models.
Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer.
Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression.
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer.
FosB transcription factor regulates COX-2 expression in colorectal cancer cells without affecting PGE2 expression.
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
Gellan gum macrobeads loaded with naproxen: The impact of various naturally derived polymers on pH-dependent behavior.
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells.
Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis.
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
Glucocorticoids promote the development of azoxymethane and dextran sulfate sodium-induced colorectal carcinoma in mice.
Graphene Oxide-Based Suppression of Nonspecificity in Loop-Mediated Isothermal Amplification Enabling the Sensitive Detection of Cyclooxygenase-2 mRNA in Colorectal Cancer.
Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis.
Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells.
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
Hedgehog-glioma-associated oncogene homolog-1 signaling in colon cancer cells and its role in the celecoxib-mediated anti-cancer effect.
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma.
Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer.
Hereditary nonpolyposis colorectal cancer: preventive management.
Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: Correlation with tumor angiogenesis.
Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition.
HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts.
HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.
High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer.
Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in ApcMin/+ mice.
Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB.
Homeodomain protein CDX2 regulates COX-2 expression in colorectal cancer.
Host cyclooxygenase-2 modulates carcinoma growth.
HSP90 Inhibition Suppresses PGE2 Production via Modulating COX-2 and 15-PGDH Expression in HT-29 Colorectal Cancer Cells.
HT-29 colorectal cancer cells undergoing apoptosis overexpress COX-2 to delay ursolic acid-induced cell death.
Hypermethylation of RAR?2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma.
Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway.
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}.
Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b.
Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.
Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells.
Immunohistochemical expression of proinflammatory enzyme COX-2 and p53 in ulcerative colitis and its associated dysplasia and colorectal carcinoma.
Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue.
Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.
Impact of structural alterations on the radiopharmacological profile of 18F-labeled pyrimidines as cyclooxygenase-2 (COX-2) imaging agents.
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Implications of low COX-2 expression in colorectal neoplasms with defective DNA mismatch repair.
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer.
Increased cyclooxygenase-2 expression in large flat colorectal tumors (laterally spreading tumors).
Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.
Increased EP4 Receptor Expression in Colorectal Cancer Progression Promotes Cell Growth and Anchorage Independence.
Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Indomethacin antagonizes EP(2) prostanoid receptor activation in LS174T human colon cancer cells.
Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells.
Indomethacin enhancement of lymphocyte responses to phytohemagglutinin in breast, stomach and colorectal cancer patients.
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to G?i and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells.
Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells.
Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma.
Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer.
Inflammatory mediators and nuclear receptor signaling in colorectal cancer.
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.
Inhibition of COX-2 in Colon Cancer Modulates Tumor Growth and MDR-1 Expression to Enhance Tumor Regression in Therapy-Refractory Cancers In Vivo.
Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy.
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522.
Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.
Inhibitory Effects of Culinary Herbs and Spices on the Growth of HCA-7 Colorectal Cancer Cells and Their COX-2 Expression.
Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study.
Interplay between post-translational cyclooxygenase-2 modifications and the metabolic and proteomic profile in a colorectal cancer cohort.
Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis.
Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level.
Investigating the Connection Between Endogenous Heme Accumulation and COX2 Activity in Cancer Cells.
Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion.
Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice.
In vitro antiproliferative activity of 2,3-dihydroxy-9,10-anthraquinone induced apoptosis against COLO320 cells through cytochrome c release caspase mediated pathway with PI3K/AKT and COX-2 inhibition.
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Is there a place for practical chemoprevention of colorectal cancer in light of COX-2 heterogeneity?
Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer.
JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats.
JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study.
Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients.
Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells.
Levamisole modulates prostaglandin E2 production and cyclooxygenase II gene expression in human colonic cancer cells.
LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs.
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention.
Localization of cyclo-oxygenase-2 in human recurrent colorectal cancer.
Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.
Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer.
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer.
Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study.
Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells.
Many actions of cyclooxygenase-2 in cellular dynamics and in cancer.
Mechanism of action of aspirin-like drugs.
Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480.
Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia.
Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer.
Meloxicam inhibits the growth of non-small cell lung cancer.
Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis.
Meta-analysis of the association between COX-2 polymorphisms and risk of colorectal cancer based on case-control studies.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
MF tricyclic and sulindac retard tumor formation in an animal model.
MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival.
Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis.
MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells.
MiR-1297 regulates the growth, migration and invasion of colorectal cancer cells by targeting cyclo-oxygenase-2.
MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting COX-2 and ALOX5.
Modulation of cyclooxygenase-2 expression by APC in HT-29 human colorectal carcinoma cells.
Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2.
Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention.
Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8.
Molecular determinants of cetuximab efficacy.
Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines.
Molecular profiling analysis for colorectal cancer patients with Pi-Xu or Shi-Re syndrome.
mTOR Signaling is Involved in Indomethacin and Nimesulide Suppression of Colorectal Cancer Cell Growth via a COX-2 Independent Pathway.
Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.
Multi-omics Analysis Reveals Adipose-tumor Crosstalk in Patients with Colorectal Cancer.
n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties.
New perspectives on APC control of cell fate and proliferation in colorectal cancer.
New strategies for colorectal cancer prevention and treatment.
New targeted therapies in gastrointestinal cancers.
NF-kappaB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors.
Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation.
Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer.
Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer.
Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.
Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and colorectal cancer prevention.
Novel 1,4-benzothazines obliterate COX-2 mediated JAK-2/STAT-3 signals with potential regulation of oxidative and metabolic stress during colorectal cancer.
Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.
Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line.
NSAIDs and colorectal cancer prevention.
Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation in human colorectal carcinoma tissue.
Nutritional targeting of cyclooxygenase-2 for colon cancer prevention.
Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2.
Over-expression of COX-2 mRNA in colorectal cancer.
Over-Expression of Cyclooxygenase-2 in Colorectal Cancer Patients.
Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer.
Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomas.
Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism.
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Oxylipin patterns in human colon adenomas.
Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE? synthesis and COX-2 expression.
Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells.
Parecoxib: an enhancer of radiation therapy for colorectal cancer.
Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2.
PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2.
Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines.
Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
Peroxisome-proliferator-activated receptors gamma and beta/delta mediate vascular endothelial growth factor production in colorectal tumor cells.
PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model.
pH-Dependent Behavior of Novel Gellan Beads Loaded with Naproxen.
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro.
Physical Activity and Cancer Outcomes: A Precision Medicine Approach.
Physical Activity, Tumor PTGS2 Expression, and Colorectal Cancer Survival: A Molecular Pathological Epidemiology (MPE) Approach.
Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.
Phytochemical Investigations of Three Rhodocodon (Hyacinthaceae Sensu APG II) Species.
Pifithrin-?, an inhibitor of p53 transactivation, up-regulates COX-2 expression through an MAPK-dependent pathway.
Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer.
Platelet activation in patients with colorectal cancer.
Poly-?-glutamic acid induces apoptosis via reduction of COX-2 expression in TPA-induced HT-29 human colorectal cancer cells.
Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors.
POLYMORPHISM OF THE COX-2 GENE AND SUSCEPTIBILITY TO COLON AND RECTAL CANCER.
Polymorphisms in arachidonic acid metabolism-related genes and the risk and prognosis of colorectal cancer.
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer.
Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.
Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells.
Poor prognosis of colorectal cancer in patients over 80 years old is associated with down-regulation of tumor suppressor genes.
Population-based case-control study: chemoprotection of colorectal cancer with non-aspirin nonsteroidal anti-inflammatory drugs and other drugs for pain control.
Positive and negative regulation of prostaglandin E2 biosynthesis in human colorectal carcinoma cells by cancer chemopreventive agents.
Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer: An update.
Posttranscriptional Regulation of Cyclooxygenase 2 Expression in Colorectal Cancer.
Potential cost-effectiveness of colorectal cancer chemoprevention with nonsteroidal anti-inflammatory drugs.
Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis.
Potential targets for colorectal cancer prevention.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening.
Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs.
Predictive utility of cyclo-oxygenase-2 expression by colon and rectal cancer.
Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies.
Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Prevention of colorectal cancer: tumor progression, chemoprevention, and COX-2 inhibition.
Preventive inositol hexaphosphate extracted from rice bran inhibits colorectal cancer through involvement of Wnt/?-catenin and COX-2 pathways.
Probiotics (Lactobacillus acidophilus and Lactobacillus rhamnosus GG) in Conjunction with Celecoxib (selective COX-2 inhibitor) Modulated DMH-Induced Early Experimental Colon Carcinogenesis.
Progastrin and cyclooxygenase-2 in colorectal cancer.
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression.
Prognostic importance of COX-2 expression in patients with colorectal cancer.
Prognostic importance of increased cyclooxygenase-2 levels in colorectal carcinomas: a 5-year single-institution study.
Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Prognostic Significance of COX-2 Immunohistochemical Expression in Colorectal Cancer: A Meta-Analysis of the Literature.
Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer.
Prognostic significance of cytosolic phospholipase A2 expression in patients with colorectal cancer.
Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population.
Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer.
Progressive Increase of Regulatory T Cells and Decrease of CD8+ T Cells and CD8+ T Cells/Regulatory T Cells Ratio during Colorectal Cancer Development.
Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers.
Promising new agents for treatment of patients with colorectal cancer.
Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma.
Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells.
Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer.
Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk.
Prospects in NSAID-derived chemoprevention of colorectal cancer.
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.
Prostaglandin E
Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells.
Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade.
Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer.
Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin.
Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells.
Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells.
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy.
Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression.
Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype.
Protein abundance alterations in matched sets of macroscopically normal colon mucosa and colorectal carcinoma.
Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells.
PTGS2 (COX2) -765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population.
PTGS2 (Cyclooxygenase-2) Expression and Survival among Colorectal Cancer Patients: A Systematic Review.
PTGS2 Over-Expression: A Colorectal Carcinoma Initiator not an Invasive Factor.
Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels.
Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome.
Reduced COX-2 protein in colorectal cancer with defective mismatch repair.
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Reducing the risk of colorectal cancer by intervening in the process of carcinogenesis: a status report.
Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive.
Regular exercise reduces colon tumorigenesis associated with suppression of iNOS.
Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines.
Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells.
Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer.
Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner.
Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
Relationship between COX-2 expression and clinicopathological features of colorectal cancers.
Relative Expression of Vitamin D Hydroxylases, CYP27B1 and CYP24A1, and of Cyclooxygenase-2 and Heterogeneity of Human Colorectal Cancer in Relation to Age, Gender, Tumor Location, and Malignancy: Results from Factor and Cluster Analysis.
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor.
Review article: cyclooxygenase--a target for colon cancer prevention.
Review article: the prevention of colorectal cancer.
Review: NSAIDs and COX-2 inhibitors may prevent colorectal cancer but increase gastrointestinal and cardiovascular harm.
RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility.
Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study.
Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: a meta-analysis.
RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.
Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer.
Rofecoxib has different effects on chemokine production in colorectal cancer cells and tumor immune splenocytes.
Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis.
Role of cyclooxygenase inhibitors for the prevention of colorectal cancer.
Role of Cyclooxygenase-2 in colorectal cancer patients.
Role of cyclooxygenase-2 in colorectal cancer.
Role of cyclooxygenase-2 in pathogenesis and prevention of colorectal cancer.
Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer.
Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study.
Role of microsomal prostaglandin E synthase-1 (mPGES-1)-derived prostaglandin E2 in colon carcinogenesis.
Role of retinoids in the prevention and treatment of colorectal cancer.
Role of vitamin and mineral supplementation and aspirin use in cancer survivors.
Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line.
Screening for novel protein targets of indomethacin in HCT116 human colon cancer cells using proteomics.
Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.
Selective PGE2 Suppression Inhibits Colon Carcinogenesis and Modifies Local Mucosal Immunity.
Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells.
Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.
SerpinB3 upregulates the Cyclooxygenase-2 / ?-Catenin positive loop in colorectal cancer.
Short chain fatty acid butyrate uptake reduces expressions of prostanoid EP4 receptors and their mediation of cyclooxygenase-2 induction in HCA-7 human colon cancer cells.
Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells.
Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.
Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo.
Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas.
Smoking and Colorectal Cancer Risk by Tumor Genetic and Epigenetic Subtypes: A Molecular Pathological Epidemiology (MPE) Study.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
STAT1-independent inhibition of cyclooxygenase-2 expression by IFNgamma; a common pathway of IFNgamma-mediated gene repression but not gene activation.
Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.
STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression.
Stromal COX-2 signaling are correlated with colorectal cancer: A review.
Study of cyclooxygenase-2 in renal cell carcinoma.
Study of the polymorphisms of cyclooxygenase-2 (-765G>C) and 5-lipoxygenase (1708G>A) in patients with colorectal cancer.
Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522.
Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis.
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.
Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention.
Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29.
Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines.
Tanshinone II--a inhibits angiogenesis through down regulation of COX-2 in human colorectal cancer.
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer.
TEMPORARY REMOVAL: Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K/AKT pathway.
TGF-? acts as a dual regulator of COX-2/PGE2 tumor promotion depending of its cross-interaction with H-Ras and Wnt/?-catenin pathways in colorectal cancer cells.
The -765C allele of the cyclooxygenase-2 gene as a potential risk factor of colorectal cancer: a meta-analysis.
The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-?- catenin signaling axis.
The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid.
The Clinical Significance of Promoter Methylation of Fluoropyrimidine Metabolizing and Cyclooxygenase Genes in Colorectal Cancer.
The Co-regulatory Role of 5-Lipoxygenase and Cyclooxygenase-2 in the Carcinogenesis and their Promotion by Cigarette Smoking in Colons.
The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway.
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.
The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer.
The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers.
The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-?B genes expression.
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
The effect of meloxicam, a selective COX-2 inhibitor, on the microvasculature of small metastatic liver tumors in rats.
The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action.
The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.
The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer.
The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells.
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2.
The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells.
The establishment of supramolecular immunobead real-time PCR and the identification of Cox-2 as a metastasis-related marker in colorectal carcinoma.
The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas.
The Expression of Both Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 in Tissues Is Associated with Poor Prognosis in Colorectal Cancer Patients.
The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67.
The Impact of Dietary Polyphenols on COX-2 Expression in Colorectal Cancer.
The inhibitory effect of resveratrol on COX-2 expression in human colorectal cancer: a promising therapeutic strategy.
The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells.
The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2.
The nonsteroidal anti-inflammatory drug indomethacin activates the eIF2alpha kinase PKR, causing a translational block in human colorectal cancer cells.
The P2Y2/Src/p38/COX-2 pathway is involved in the resistance to ursolic acid-induced apoptosis in colorectal and prostate cancer cells.
The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells.
The prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/ COX2) rs5277 polymorphism does not influence risk of colorectal cancer in an Iranian population.
The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas.
The relationship between cyclooxygenase-2 expression and colorectal cancer.
The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study.
The role of COX-2 in intestinal cancer.
The role of COX-2 in intestinal inflammation and colorectal cancer.
The role of COX-2/PGE(2) in gossypol-induced apoptosis of colorectal carcinoma cells.
The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer.
The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines.
The Role of Cyclooxygenase-2 in Colorectal Cancer.
The Role of Cyclooxygenase-2 in Colorectal Carcinogenesis.
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland.
The role of NF-?B and PPAR? in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors.
The Roles of Dietary PPARgamma Ligands for Metastasis in Colorectal Cancer.
The Simultaneous Expression of Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 May Enhance Angiogenesis and Tumor Venous Invasion in Tissues of Colorectal Cancers.
The specialty of colon and rectal surgery: its impact on patient care and role in academic medicine.
Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis.
Three-dimensional growth as multicellular spheroid activates the proangiogenic phenotype of colorectal carcinoma cells via LFA-1-dependent VEGF: implications on hepatic micrometastasis.
Tissue microarray-determined expression profiles of cyclooxygenase-2 in colorectal adenocarcinoma: association with clinicopathological parameters.
Tissue-specific modulation of cyclooxygenase-2 (Cox-2) expression in the uterus and the v. cava by estrogens and phytoestrogens.
Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression.
Tomato powder impedes the development of azoxymethane-induced colorectal cancer in rats through suppression of COX-2 expression via NF-?B and regulating Nrf2/HO-1 pathway.
Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer.
Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features.
Uncoupling of oxidative phosphorylation and Smac/DIABLO release are not sufficient to account for induction of apoptosis by sulindac sulfide in human colorectal cancer cells.
Understanding the Interplay between COX-2 and hTERT in Colorectal Cancer Using a Multi-Omics Analysis.
Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review.
Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells.
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2.
Urinary prostaglandin E2 metabolite and risk for colorectal adenoma.
Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia.
Use of NSAIDs for the chemoprevention of colorectal cancer.
Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer.
Variation in cyclooxygenase expression levels within the colorectum.
Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
Vitamin D, linoleic acid, arachidonic acid and COX-2 in colorectal cancer patients in relation to disease stage, tumour localisation and disease progression.
WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth.
YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer.
[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
[Aspirin in the prevention of colorectal cancer.]
[Association of abnormal cyclooxygenase-2 gene expression with colorectal carcinoma metastasis]
[Chemo-preventive effect of Angelica sinensis' supercritical extracts on AOM/DSS-induced mouse colorectal carcinoma associated with inflammation].
[CHL prevent colon neoplasms in mice and its selective inhibition on COX-2]
[Clinical application of cyclooxygenase-2 inhibitors]
[Colorectal cancer and inhibition of cyclooxygenase-2]
[Correlation between Stat3 signal transduction pathway and expression of cyclooxygenase-2 in colorectal cancer cells]
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]
[Cyclooxygenase 2 and colorectal cancer: therapeutic implications]
[Cyclooxygenase 2 inhibitors and colorectal cancer]
[Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma]
[Cyclooxygenase-2 -765G>C polymorphism and susceptibility to colorectal cancer: a meta-analysis].
[Cyclooxygenase-2 expression according to size and location of gastric and colorectal tubular adenomas]
[Cyclooxygenase-2 expression as a prognostic factor in sporadic colorectal cancer]
[Detection of fecal peroxisome proliferator-activated receptor delta and cyclooxygenase 2 mRNA in screening of colorectal cancer].
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]
[Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors]
[Evaluation of cyclooxygenase-2 in the prediction of liver metastasis of colorectal carcinoma]
[Expression of COX-2 protein in colorectal carcinoma and the clinical implication]
[Expression of cyclooxygenase-2 and relationship with mismatch repaire gene and microsatellite instability in hereditary non-polyposis colorectal cancer]
[Expressions of cyclooxygenase-2 and cholecystokinin-B receptor mRNA in human colorectal cancer and their significances]
[Molecular epidemiologic analysis of the levels of metalloproteases and cyclooxygenase-2 in colorectal cancer]
[Molecular mechanism of cyclooxygenase-2 inhibitor in inhibition of proliferation of colon cancer cells by modulating Stat5 signal transduction pathway]
[Prophylaxis of colorectal cancer with non steroidal anti-inflammatory drugs- a new reality?]
[Rationale and prospects for the use of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer]
[Relationship between carcinoembryonic antigen and cyclooxygenase 2 expression and colorectal cancer]
[Relationship between multi-gene proteins in colorectal carcinoma complicated with chronic schistosomiasis: an immunohistochemical study by using tis- sue microarray techniques].
[Relationship between multi-gene proteins in colorectal carcinoma complicated with chronic schistosomiasis: an immunohistochemical study by using tissue microarray techniques].
[Selective cyclooxygenase-2 inhibitors for the prevention of colorectal adenomas: a meta-analysis]
[Study on the effect of COX-2's selective inhibitor on human colorectal adenoma cells proliferation]
Colorectal Neoplasms, Hereditary Nonpolyposis
Celecoxib treatment alters the gene expression profile of normal colonic mucosa.
COX-2 inhibition in clinical cancer prevention.
Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency.
Expression of cyclooxygenase-2 and its relationship with mismatch repair and microsatellite instability in hereditary nonpolyposis colorectal cancer.
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Coma
Thinking outside the box about COX-1 in Alzheimer's disease.
Common Variable Immunodeficiency
A novel arachidonic acid metabolite with stimulatory effect on PHA-induced mitogenesis of lymphocytes.
Improved in vitro antigen-specific antibody synthesis in two patients with common variable immunodeficiency taking an oral cyclooxygenase and lipoxygenase inhibitor (ketoprofen).
Communicable Diseases
C. albicans activates cyclooxygenase but not its product prostaglandin E? in HPV 16-stabilized cells.
Confusion
Areca nut procyanidins prevent ultraviolet light B-induced photoaging via suppression of cyclooxygenase-2 and matrix metalloproteinases in mouse skin.
Cardiovascular risks of cyclooxygenase inhibition.
Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy.
Congenital Abnormalities
COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues.
Embryonic expression of cyclooxygenase-2 causes malformations in axial skeleton.
Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism.
High-grade slippage of the lumbar spine in a rat model of spondylolisthesis: effects of cyclooxygenase-2 inhibitor on its deformity.
Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation.
Conjunctivitis
Involvement of cyclooxygenase-2 in rat models of conjunctivitis.
Ocular adverse effects associated with systemic medications : recognition and management.
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
Conjunctivitis, Allergic
Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching.
The DP receptor, allergic inflammation and asthma.
The pruritogenic and inflammatory effects of prostanoids in the conjunctiva.
Connective Tissue Diseases
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.
Contracture
Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum.
Bacterial toxin N-formyl-methionyl-leucyl-phenylalanine acutely contracts human and rabbit detrusor through the release of eicosanoids.
Cyclooxygenase-2 inhibitor celecoxib attenuates joint contracture following immobilization in rat knees.
Different levels of COX-1 and COX-2 enzymes in synoviocytes and chondrocytes during joint contracture formation.
Inhibition of COX-2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture.
Interactions of calcium, prostaglandins and indomethacin on the smooth muscle of the bladder.
Corneal Edema
Antagonists and inhibitors of lipid mediators in experimental inflammation of the cornea.
Intracamerally injected platelet activating factor (PAF) induces marked intraocular inflammatory reactions.
Modulation of immunogenic keratitis in rabbits by topical administration of inhibitors of lipoxygenase and cyclooxygenase.
Corneal Injuries
Acute corneal injury in rabbits following nitrogen mustard ocular exposure.
Corneal Neovascularization
Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization.
Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat.
Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis.
The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat.
Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.
Use of flurbiprofen to inhibit corneal neovascularization.
Corneal Opacity
Subconjunctival injection of tumor necrosis factor-? pre-stimulated bone marrow-derived mesenchymal stem cells enhances anti-inflammation and anti-fibrosis in ocular alkali burns.
Coronary Artery Disease
A common promoter variant of the gene encoding cyclooxygenase-1 (PTGS1) is related to decreased incidence of myocardial infarction in patients with coronary artery disease.
A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors.
A randomized, double-blind, placebo-controlled trial of a COX-2 inhibitor (Rofecoxib) in patients undergoing coronary artery bypass surgery.
A Variant in COX-2 Gene Is Associated with Left Main Coronary Artery Disease and Clinical Outcomes of Coronary Artery Bypass Grafting.
Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism.
Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift. Analysis of the effects of a combination of aspirin and n-3 fatty acids on the eicosanoid profile.
Association of COX-2 -765G>C genetic polymorphism with coronary artery disease: a meta-analysis.
Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Atherosclerosis: the eicosanoid connection.
Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents.
Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease.
Cox-2 gene polymorphism and IL-6 levels in coronary artery disease.
COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study.
Crossreacting drugs and chemicals.
Cyclooxygenase inhibition in patients with coronary artery disease.
Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: A meta-analysis.
Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation.
Cyclooxygenase-2 inhibitors dilemma in cardiovascular medicine: are all family members bad players?
Effect of aspirin on coronary collateral blood flow.
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease.
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
I have coronary artery disease and osteoarthritis. What can you tell me about COX-2 inhibitors and their possible effects on my heart?
Interaction between COX-2 G-765C and smoking in relation to coronary artery disease in a Chinese Uighur population.
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease.
MicroRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2.
Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.
P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events?
Persistent Incisional Pain after Noncardiac Surgery: An International Prospective Cohort Study.
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.
Predicting significance of COX-2 expression of peripheral blood monocyte in patients with coronary artery disease.
PTGS2 gene polymorphism -765G>C is associated with coronary artery disease: a meta-analysis.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Selective COX-2 inhibition endothelial function in coronary artery disease. Chenevard R, Hurlimann D, Bechir M et al Circulation 2003; 107: 405-09.
Selective COX-2 inhibition improves endothelial function in coronary artery disease.
Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease.
Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.
The COX-2 rs20417 Polymorphism and Risk of Coronary Artery Disease: Evidence from 17,621 Subjects.
The Cyclooxygenase-1 C50T Polymorphism Is Not Associated with Aspirin Responsiveness Status in Stable Coronary Artery Disease Tunisian Patients.
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
[Selective COX-2 inhibition improves endothelial function in coronary artery disease]
Coronary Disease
-New aspects in antithrombotic therapy--platelet inhibitors-.
Acute coronary disease Athero-Inflammation: Therapeutic approach.
Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?
Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone.
Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort.
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
Cyclooxygenase inhibition is associated with downregulation of apolipoprotein AI promoter activity in cultured hepatoma cell line HepG2.
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.
Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages.
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?
Effect of in vitro incorporation of prostanoid precursors, superoxide radical and hydrogen peroxide on platelet function.
Feverfew for migraine prophylaxis: a systematic review.
Functional promoter polymorphism of cyclooxygenase-2 modulates the inflammatory response in stable coronary heart disease.
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study.
Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.
No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography.
Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
The effect of hydroxy safflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-?.
The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data.
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
[Risk factor assessment of cardiocerebrovascular diseases in patients with rheumatoid arthritis]
[Use of meloxicam (movalis) in patients with rheumatic diseases with concomitant coronary heart disease]
Coronary Occlusion
Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors.
Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo.
Inducible cardiac-specific overexpression of cyclooxygenase-2 (COX-2) confers resistance to ischemia/reperfusion injury.
Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat.
Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
Coronavirus Infections
Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.
Cough
Antitussive effect of NS-398, a selective cyclooxygenase-2 inhibitor, in guinea pigs.
Bradykinin sensitizes the cough reflex via a B2 receptor dependent activation of TRPV1 and TRPA1 channels through metabolites of cyclooxygenase and 12-lipoxygenase.
Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil.
COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma.
Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics.
Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.
Pharmacological studies of allergic cough in the guinea pig.
Pharmacology of bradykinin evoked coughing in guinea pigs.
Prostanoids and cough response to capsaicin in asthma and chronic bronchitis.
Protease-activated receptor-2 activation exaggerates TRPV1-mediated cough in guinea pigs.
Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors.
Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome.
Tachyphylaxis to capsaicin-induced cough and its reversal by indomethacin, in patients with the sinobronchial syndrome.
The effect of sulindac on the abnormal cough reflex associated with dry cough.
COVID-19
Anti-coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin.
Bioinformatic analyses hinted at augmented T helper 17 cell differentiation and cytokine response as the central mechanism of COVID-19-associated Guillain-Barré syndrome.
Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study.
Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19).
Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication.
Cyclooxygenase inhibitor use is associated with increased COVID-19 severity.
Etoricoxib may inhibit cytokine storm to treat COVID-19.
Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.
Morphoproteomics and Etiopathogenic Features of Pulmonary COVID-19 with Therapeutic Implications: A Case Study.
Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.
Potential mechanisms of Chinese Herbal Medicine that implicated in the treatment of COVID-19 related renal injury.
Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.
Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).
Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019.
Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?
Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.
Upregulation of FOXP3 is associated with severity of hypoxia and poor outcomes in COVID-19 patients.
What about COVID-19 and arachidonic acid pathway?
Cowpox
Poxvirus-induced alteration of arachidonate metabolism.
Craniocerebral Trauma
Beneficial effects of acute intravenous ibuprofen on neurologic recovery of head-injured mice: comparison of cyclooxygenase inhibition with inhibition of thromboxane A2 synthetase or 5-lipoxygenase.
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy.
Use of indomethacin in brain-injured patients with cerebral perfusion pressure impairment: preliminary report.
Craniopharyngioma
Expression of prostaglandin H synthase-2 in human brain tumors.
Creutzfeldt-Jakob Syndrome
Cyclooxygenase-1 and -2 in brains of patients who died with sporadic Creutzfeldt-Jakob disease.
Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease.
Role of COX-2 in inflammatory and degenerative brain diseases.
Crohn Disease
Cellular localization of cyclo-oxygenase isozymes in Crohn's disease and colorectal cancer.
Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer.
Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.
Cyclooxygenase-2 expression and role of vasoconstrictor prostanoids in small mesenteric arteries from patients with Crohn's disease.
Cyclooxygenase-2 immunoreactivity in collagenous colitis.
Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.
Evaluation of the immunoexpression of COX-1, COX-2 and p53 in Crohn's disease.
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?
Expression of protease-activated receptor-1 and -2 in orofacial granulomatosis.
Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis.
Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives.
Novel Anti-inflammatory Functions For Endothelial and Myeloid Cyclooxygenase-2 in a New Mouse Model of Crohn's Disease.
Regulated spatial distribution of cyclooxygenases and lipoxygenases in Crohn's ulcer.
Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis.
Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.
The functional -765G?C polymorphism of the COX-2 gene may reduce the risk of developing crohn's disease.
Cryptorchidism
Cryptorchidism-induced CFTR down-regulation results in disruption of testicular tight junctions through up-regulation of NF-?B/COX-2/PGE2.
Cyclooxygenase-2 Protects Germ Cells Against Spermatogenesis Disturbance in Experimental Cryptorchidism Model Mice.
Cystadenocarcinoma, Serous
Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.
FSH-regulated gene expression profiles in ovarian tumours and normal ovaries.
Cystadenoma
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.
Cystadenoma, Serous
Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice.
Cystic Fibrosis
Aquagenic wrinkling of the palms in patients with cystic fibrosis homozygous for the delta F508 CFTR mutation.
Aquagenic wrinkling of the palms is due to vasoconstriction of palmar skin vasculature.
Atypical form of transient reactive papulotranslucent acrokeratoderma in a cystic fibrosis carrier.
Bradykinin increases IL-8 generation in airway epithelial cells via COX-2-derived prostanoids.
Cyclooxygenase 2 and lipoxin A? in nasal polyps in cystic fibrosis.
Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis.
Expression of cyclooxygenase and lipoxygenase enzymes in sinonasal mucosa of patients with cystic fibrosis.
In vivo lipid peroxidation and platelet activation in cystic fibrosis.
Increased ?5- and ?6-desaturase, cyclooxygenase-2, and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic fibrosis.
Lipopolysaccharide induction of cyclooxygenase-2 in long-term nasal epithelial cultures in Cystic Fibrosis.
Plasma "prorenin"-renin in Bartter's syndrome, cystic fibrosis, and chloride deficiency, and the effect of prostaglandin synthetase inhibition.
Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients.
Renal Medullary Interstitial COX-2 (Cyclooxygenase-2) Is Essential in Preventing Salt-Sensitive Hypertension and Maintaining Renal Inner Medulla/Papilla Structural Integrity.
Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis.
Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis.
Cystitis
C-Phycocyanin Alleviates Bladder Inflammation and Dysfunction in Cyclophosphamide-Induced Cystitis in a Mouse Model by Inhibiting COX-2 and EP4.
COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat.
Cyclooxygenase-2 and B-cell lymphoma-2 expression in cystitis glandularis and primary vesicle adenocarcinoma.
Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder.
Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats.
Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Cyclophosphamide induced cystitis: role of nitric oxide synthase, cyclooxygenase-1 and 2, and NK(1) receptors.
Dual involvements of cyclooxygenase and nitric oxide synthase expressions in ketamine-induced ulcerative cystitis in rat bladder.
Editorial Comment on: Intravesical Botulinum Toxin A Administration Inhibits COX-2 and EP4 Expression and Suppresses Bladder Hyperactivity in Cyclophosphamide-Induced Cystitis in Rats.
Editorial Comment to Novel strategy for cystitis glandularis: Oral treatment with cyclooxygenase-2 inhibitor.
Epigenetic regulation of COX?2 expression by DNA hypomethylation via NF??B activation in ketamine?induced ulcerative cystitis.
Expression of cyclooxygenase-2 in dogs with cystitis.
Expression of cyclooxygenase-2 in patients with bladder carcinoma.
Expression of cyclooxygenase-2 in urinary bladder in rats with cyclophosphamide-induced cystitis.
Hydrochloric acid induced changes in macrophage migration inhibitory factor in the bladder, peripheral and central nervous system of the rat.
Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist.
Induction of COX-2 expression by acrolein in the rat model of hemorrhagic cystitis.
Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis.
Intravesical Botulinum Toxin A Administration Inhibits COX-2 and EP4 Expression and Suppresses Bladder Hyperactivity in Cyclophosphamide-Induced Cystitis in Rats.
Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma.
Novel strategy for cystitis glandularis: Oral treatment with cyclooxygenase-2 inhibitor.
Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer.
ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis.
Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report.
Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following experimental cystitis in rats.
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Scutellaria baicalensis alleviates cantharidin-induced rat hemorrhagic cystitis through inhibition of cyclooxygenase-2 overexpression.
Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation.
Spectral heart rate variability in rats with cyclophosphamide-induced hemorrhagic cystitis treated with cyclooxygenase inhibitors.
The influence of piroxicam, a non-selective cyclooxygenase inhibitor, on autonomic nervous system activity in experimental cyclophosphamide-induced hemorrhagic cystitis and bladder outlet obstruction in rats.
Translocation of NF-?B and expression of cyclooxygenase-2 are enhanced by ketamine-induced ulcerative cystitis in rat bladder.
[Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas]
[TYPICAL TYPE CYSTITIS GLANDULARIS PRESENTING URINARY RETENTION IN A YOUNG MAN: ADJUVANT THERAPY USING ORAL CYCLOOXYGENASE-2 INHIBITOR: A CASE REPORT].
Cystitis, Interstitial
Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis.
Cysts
Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters.
Calcifying odontogenic cyst: A 26-year retrospective clinicopathological analysis and immunohistochemical study.
Cyclooxygenase (COX)-2 Inhibitors Reduce Toxoplasma gondii Infection and Upregulate the Pro-inflammatory Immune Response in Calomys callosus Rodents and Human Monocyte Cell Line.
Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium.
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis.
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in ovarian endometriotic cysts and their relationship with angiogenesis.
Immunohistochemical analysis of COX-2 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma: A comparative study.
Lithium induces microcysts and polyuria in adolescent rat kidney independent of cyclooxygenase-2.
Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis.
Micro-MRI methods to detect renal cysts in mice.
Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.
PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes.
Regression of experimentally induced endometriosis with a new selective cyclooxygenase-2 enzyme inhibitor.
[Expression of cylooxygenase-2 in endometriosis]
[Molecular characterization of Echinococcus granulosus isolates obtained from different hosts].
Cytochrome-c Oxidase Deficiency
Cyclooxygenase knockout mice: models for elucidating isoform-specific functions.
Cytomegalovirus Infections
Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.
Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication.
Darier Disease
Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERCA2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease.
Dehydration
15-Deoxy-?¹²,¹?-prostaglandin J? as an electrophilic mediator.
15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes.
15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis.
15-Deoxy-Delta(12,14)-prostaglandin J2: an electrophilic trigger of cellular responses.
Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus.
An endogenous electrophile that modulates the regulatory mechanism of protein turnover: inhibitory effects of 15-deoxy-Delta 12,14-prostaglandin J2 on proteasome.
Chronic COX-2 inhibition reduces medullary HSP70 expression and induces papillary apoptosis in dehydrated rats.
COX2 in a euryhaline teleost, Fundulus heteroclitus: primary sequence, distribution, localization, and potential function in gills during salinity acclimation.
Cyclooxygenase-2 mediates induction of the renal stanniocalcin-1 gene by arginine vasopressin.
Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat.
Cyclooxygenase-2-dependent phosphorylation of the pro-apoptotic protein Bad inhibits tonicity-induced apoptosis in renal medullary cells.
Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells.
Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2.
Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet.
Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.
Nonenzymatic Free Radical-catalyzed Generation of 15-Deoxy-{Delta}12,14-Prostaglandin J2-like Compounds (Deoxy-J2-Isoprostanes) in Vivo.
Physiological regulation of the renal vasopressin receptor-effector pathway in dogs.
Prostaglandin J2 series induces the gene expression of monocyte chemoattractant protein-1 during the maturation phase of cultured adipocytes.
Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro.
Regulation of cyclooxygenase-2 in renal medulla.
Regulation of Nrf2-dependent gene expression by 15-deoxy-Delta(12,14)-prostaglandin J(2).
Thioredoxin as a molecular target of cyclopentenone prostaglandins.
Delirium
Delirium From the COX-2 inhibitor refecoxib.
Risk factors for postoperative delirium in patients undergoing lower extremity joint arthroplasty: a retrospective population-based cohort study.
Deltaretrovirus Infections
Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus.
Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.
Dementia
Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: the Hisayama Study.
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).
Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia.
COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia.
Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease.
Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia.
From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia.
Human immunodeficiency virus type 1 envelope glycoprotein 120 induces cyclooxygenase-2 expression in neuroblastoma cells through a nuclear factor-kappaB and activating protein-1 mediated mechanism.
Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia.
Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease.
Integrated Pathways of COX-2 and mTOR: Roles in Cell Sensing and Alzheimer's Disease.
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease.
Relevance of COX-2 gene expression in dementia with lewy bodies associated with Alzheimer pathology.
Supportive care of elderly patients with cancer.
Demyelinating Diseases
Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: Role of cyclooxygenase-2.
Celecoxib Exerts a Therapeutic Effect Against Demyelination by Improving the Immune and Inflammatory Microenvironments.
Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death.
Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.
Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion.
Sildenafil (Viagra®) down regulates cytokines and prevents demyelination in a cuprizone-induced MS mouse model.
The cyclooxygenase-2 pathway via the PGE(2) EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination.
The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis.
Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination.
Up-regulation of cyclooxygenase-2 in inflammatory demyelinating neuropathy.
Dengue
Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents.
Dengue Virus Induced COX-2 Signaling Is Regulated Through Nutrient Sensor GCN2.
Differential effects of triptolide and tetrandrine on activation of COX-2, NF-kappaB, and AP-1 and virus production in dengue virus-infected human lung cells.
Dental Calculus
Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis.
Dental Plaque
Myricetin Inhibition of Peptidoglycan-Induced COX-2 Expression in H9c2 Cardiomyocytes.
Dentigerous Cyst
Immunohistochemical analysis of COX-2 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma: A comparative study.
Odontogenic epithelial proliferation is correlated with COX-2 expression in dentigerous cyst and ameloblastoma.
Dermatitis
A sesquiterpenol extract potently suppresses inflammation in macrophages and mice skin and prevents chronic liver damage in mice through JNK-dependent HO-1 expression.
Anti-inflammatory effect of Astaxanthin in phthalic anhydride-induced atopic dermatitis animal model.
Anti-inflammatory effect of Centella asiatica phytosome in a mouse model of phthalic anhydride-induced atopic dermatitis.
Anti-Inflammatory Effect of Titrated Extract of Centella asiatica in Phthalic Anhydride-Induced Allergic Dermatitis Animal Model.
Conjugated linoleic acid attenuates 2,4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-?B signaling.
Deficiency of n-6 polyunsaturated fatty acids is mainly responsible for atopic dermatitis-like pruritic skin inflammation in special diet-fed hairless mice.
Knockdown of sodium channel Nax reduces dermatitis symptoms in rabbit skin.
Modulation of HMGB1 translocation and RAGE/NF?B cascade by quercetin treatment mitigates atopic dermatitis in NC/Nga transgenic mice.
Pharmacological studies on dithranol-induced irritative dermatitis in mice.
Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice.
Salidroside suppresses solar ultraviolet-induced skin inflammation by targeting cyclooxygenase-2.
The metabolic transformations of columbinic acid and the effect of topical application of the major metabolites on rat skin.
Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice.
Dermatitis, Atopic
COX-1 inhibition enhances scratching behaviour in NC/Nga mice with atopic dermatitis.
Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA.
Reduced lipoxygenase and cyclooxygenase mediated signaling in PBMC of atopic dermatitis patients.
The Asian side of asthma and allergy.
The DP receptor, allergic inflammation and asthma.
Topical hypochlorous acid (HOCl) blocks inflammatory gene expression and tumorigenic progression in UV-exposed SKH-1 high risk mouse skin.
Dermatitis, Contact
17beta-Estradiol enhances expression of inflammatory cytokines and inducible nitric oxide synthase in mouse contact hypersensitivity.
A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene- but not dimethylbenz(a)anthracene-treated mice.
Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities.
Effect of chunghyuldan in chronic oxazolone-induced mouse dermatitis.
Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis.
Fibroblasts support migration of monocyte-derived dendritic cells by secretion of PGE2 and MMP-1.
Phytochemical and biological studies of bryophytes.
Repeated low-dose ultraviolet (UV) B exposures of humans induce limited photoprotection against the immune effects of erythemal UVB radiation.
Suppression of the cutaneous immune response following topical application of the prostaglandin PGE2.
Dermatitis, Irritant
[Cyclooxygenases in the skin]
Dermatofibrosarcoma
Cyclooxygenase-2 expression in dermatofibroma and dermatofibrosarcoma protuberans.
Expression of retinoic acid receptor beta in dermatofibrosarcoma protuberans.
Dermatomyositis
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis.
The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis.
Diabetes Complications
Altered endothelium-dependent and -independent hyperpolarization and endothelium-dependent relaxation in carotid arteries isolated from streptozotocin-induced diabetic rats.
Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes.
Diabetes Insipidus
Desamino-D-Arginine vasopressin induces fatty acid cyclooxygenase activity in the renal medulla of diabetes insipidus rats.
Diabetes Insipidus, Nephrogenic
Dysregulation of Renal Cyclooxygenase-2 in Rats with Lithium-induced Nephrogenic Diabetes Insipidus.
Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus.
Prostaglandin synthetase inhibitors in the treatment of nephrogenic diabetes insipidus.
Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2.
Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor.
Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors.
Diabetes Insipidus, Neurogenic
Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus.
Diabetes Mellitus
Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia.
Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians.
Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside?
Celecoxib-induced nephrotoxicity in a renal transplant recipient.
Chitosan-microcapsulated insulin alleviates mesenteric microcirculation dysfunction via modulating COX-2 and VCAM-1 expression in rats with diabetes mellitus.
COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice.
Cyclooxygenase 2 expression in chronic pancreatitis: correlation with stage of the disease and diabetes mellitus.
Depression of cyclooxygenase-2 induction in aortas of rats with type 1 and type 2 diabetes mellitus.
Diabetes Upregulation of Cyclooxygenase 2 Contributes to Altered Coronary Reactivity After Cardiac Surgery.
Effect of prostaglandin synthetase inhibitors on platelet aggregation and thromboxane production in diabetes mellitus.
Effects of Supervised Structured Aerobic Exercise Training Program on Interleukin-6, Nitric Oxide Synthase-1, and Cyclooxygenase-2 in Type 2 Diabetes Mellitus.
Evaluation of the effects of glimepiride (Amaryl) and repaglinide (novoNorm) on atherosclerosis progression in high cholesterol-fed male rabbits.
Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats.
Glucocorticoids use in kidney transplant setting.
Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes.
Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus.
Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus.
Mechanism of impaired responses of cerebral arterioles during diabetes mellitus.
NSAID Use in Individuals at Risk of Renal Adverse Events: An Observational Study to Investigate Trends in Australian Veterans.
Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus.
Reactive oxygen species and cyclooxygenase 2-derived thromboxane A2 reduce angiotensin II type 2 receptor vasorelaxation in diabetic rat resistance arteries.
Reduction of lipopolysaccharide-induced cyclooxygenase-2 expression in diabetic arteries.
Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study.
Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus.
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys.
Up-regulation of vascular cyclooxygenase-2 in diabetes mellitus.
Diabetes Mellitus, Experimental
Effect of experimental diabetes on glomerular filtration rate and glomerular prostanoid production in the rat.
Diabetes Mellitus, Type 1
Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus.
Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes.
Carvedilol prevents pancreatic ?-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-?B, COX-2, iNOS and oxidative stress.
Cellular distribution and contribution of cyclooxygenase COX-2 to diabetogenesis in NOD mouse.
COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice.
Direct administration of interleukin-1 and interferon-gamma to rat pancreas leads to the in vivo production of nitric oxide and expression of inducible nitric oxide synthase and inducible cyclooxygenase.
Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients.
Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature.
Expression of cyclooxygenase-2 in intestinal goblet cells of pre-diabetic NOD mice.
Free radicals and the pathogenesis of type 1 diabetes: beta-cell cytokine-mediated free radical generation via cyclooxygenase-2.
Glycaemic variability in paediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI): a cross-sectional cohort study.
Macrophage Cyclooxygenase-2 Protects Against Development of Diabetic Nephropathy.
Nigella Sativa and Thymoquinone Suppress Cyclooxygenase-2 and Oxidative Stress in Pancreatic Tissue of Streptozotocin-Induced Diabetic Rats.
Peripheral macro- and microcirculation in short-term insulin-dependent diabetes mellitus: the role of prostaglandins in early haemodynamic changes.
Persistent STAT5 phosphorylation and epigenetic dysregulation of GM-CSF and PGS2/COX2 expression in Type 1 diabetic human monocytes.
PTGS-2-PTGER2/4 signaling pathway partially protects from diabetogenic toxicity of streptozotocin in mice.
Renal cyclooxygenase-2 in obese Zucker (fatty) rats.
Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus.
Renal hemodynamics and urinary excretion of 6-keto-prostaglandin F1 alpha and thromboxane B2 in newly diagnosed type I diabetic patients.
Renal Hyperfiltration is a Determinant of Endothelial Function Responses to Cyclooxygenase 2 Inhibition in Type 1 Diabetes.
The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes.
Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation.
Diabetes Mellitus, Type 2
Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria.
Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia.
Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians.
Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population.
Cyclooxygenase 2, toll-like receptor 4 and interleukin 1? mRNA expression in atherosclerotic plaques of type 2 diabetic patients.
Depression of cyclooxygenase-2 induction in aortas of rats with type 1 and type 2 diabetes mellitus.
Effects of Supervised Structured Aerobic Exercise Training Program on Interleukin-6, Nitric Oxide Synthase-1, and Cyclooxygenase-2 in Type 2 Diabetes Mellitus.
Eicosanoids, ?-cell function, and diabetes.
Evaluation of cyclooxygenase oxylipins as potential biomarker for obesity-associated adipose tissue inflammation and type 2 diabetes using targeted multiple reaction monitoring mass spectrometry.
Immunohistochemical examination of cyclooxygenase-2 and renin in a KK-A(y) mouse model of diabetic nephropathy.
Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus.
In vitro and in silico elucidation of antidiabetic and anti-inflammatory activities of bioactive compounds from Momordica charantia L.
Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus.
Inhibitory potential of ginger extracts against enzymes linked to type 2 diabetes, inflammation and induced oxidative stress.
Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus.
Potential associations between variants of genes encoding regulators of inflammation, and mediators of inflammation in type 2 diabetes and insulin resistance.
Prostanoid release and constrictor responses to noradrenaline in the rat mesenteric vascular bed in non-insulin-dependent diabetes mellitus.
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer.
Diabetes, Gestational
Elevated Expression of Vascular Adhesion Molecule-1, Plasminogen Activator Inhibitor-1, Cyclooxygenase-2, and Thrombomodulin in Human Umbilical Vein Endothelial Cells from Hospitalized Gestational Diabetes Mellitus Patients.
Diabetic Angiopathies
15-Hydroxy-5,8,11,13-eicosatetraenoic acid inhibits human vascular cyclooxygenase. Potential role in diabetic vascular disease.
Altered platelet function in diabetes mellitus.
Aspirin resistance and platelet turnover: A 25-year old issue.
Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update.
Lipid inflammatory mediators in diabetic vascular disease.
Peroxynitrite-induced nitration of cyclooxygenase-2 and inducible nitric oxide synthase promotes their binding in diabetic angiopathy.
Diabetic Cardiomyopathies
Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy.
Diabetic Foot
[Effects of San-huang-sheng-fu oil on peripheral circulatory disorders and foot ulcers in diabetic rats and the mechanisms].
Diabetic Ketoacidosis
Plasma prostaglandin levels and circulating fuel levels in rats with diabetic ketoacidosis: effects of cyclooxygenase inhibitors and of alpha and beta adrenergic blockade.
Diabetic Nephropathies
7-Ketocholesterol induces ROS-mediated mRNA expression of 12-lipoxygenase, cyclooxygenase-2 and pro-inflammatory cytokines in human mesangial cells: Potential role in diabetic nephropathy.
A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension.
Effect of losartan on cyclooxygenase-2 expression in normal human mesangial cells and kidneys of rats with diabetic nephropathy.
Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy.
Expression pattern of genes in peripheral blood mononuclear cells in diabetic nephropathy.
HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose.
Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes.
Immunohistochemical examination of cyclooxygenase-2 and renin in a KK-A(y) mouse model of diabetic nephropathy.
Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications.
Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: put the blame on the (pro)renin receptor?
Interaction of the renin angiotensin and cox systems in the kidney.
Macrophage Cyclooxygenase-2 Protects Against Development of Diabetic Nephropathy.
Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats.
Neuronal Nitric Oxide Synthase and Cyclooxygenase-2 in Diabetic Nephropathy of Type 2 Diabetic OLETF Rats.
Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.
Podocyte-specific knockout of cyclooxygenase 2 exacerbates diabetic kidney disease.
Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy.
Relationship between 12/15-lipoxygenase and COX-2 in mesangial cells: potential role in diabetic nephropathy.
Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications.
Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment.
Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: involvement of SIRT1 and TGF-?1 pathway.
The thromboxane receptor antagonist s18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein e-deficient mice.
[Mechanism and effect of cyclooxygenase-2 inhibitor meloxicam on the protection of diabetic nephropathy in rats]
Diabetic Neuropathies
Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway.
Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration.
Effect of dipyrone and thalidomide alone and in combination on STZ-induced diabetic neuropathic pain.
Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes.
Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats.
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets.
NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy.
Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress.
Quercetin protects rat dorsal root ganglion neurons against high glucose-induced injury in vitro through Nrf-2/HO-1 activation and NF-?B inhibition.
SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: An insight into its mechanism for neuroprotection.
Targeting inflammation in diabetes: Newer therapeutic options.
Diabetic Retinopathy
Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy.
CYCLO-OXYGENASE-2 EXPRESSION IN HUMAN IDIOPATHIC EPIRETINAL MEMBRANE.
Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy.
Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas.
Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats.
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression.
diacylglycerol kinase (atp) deficiency
Epileptogenesis in diacylglycerol kinase epsilon deficiency up-regulates COX-2 and tyrosine hydroxylase in hippocampus.
Digestive System Neoplasms
Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis.
The -765G>C polymorphism in the cyclooxygenase-2 gene and digestive system cancer: a meta-analysis.
Diverticular Diseases
Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease.
Down Syndrome
Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells.
Early increased density of cyclooxygenase-2 (COX-2) immunoreactive neurons in Down syndrome.
Enhancement of lipopolysaccharide-stimulated cyclooxygenase-2 mRNA expression and prostaglandin E2 production in gingival fibroblasts from individuals with Down syndrome.
Integrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cells.
Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1.
Drug Eruptions
Multifocal Fixed Drug Eruption with COX-2 Inhibitor-Celecoxib.
Drug Hypersensitivity
Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE.
Meloxicam-associated anaphylactic reaction.
Drug Resistant Epilepsy
[Effects of cyclooxygenase-2 selective inhibitor celecoxib on the expression of major vault protein in rats with status epilepticus].
Drug-Related Side Effects and Adverse Reactions
A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
Adverse Drug Events Involving COX-2 Inhibitors.
Adverse drug reactions in hospitals: a narrative review.
Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital.
Cholestatic hepatitis with small duct injury associated with celecoxib.
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
Cyclo-oxygenase 2 function is essential for bone fracture healing.
Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPAR?/?-Dependent Vasodilator Pathway.
Deep sequencing of prostaglandin-endoperoxide synthase (PTGE) genes reveals genetic susceptibility for cross-reactive hypersensitivity to NSAID.
Gene Variants and Haplotypes Modifying Transcription Factor Binding Sites in the Human Cyclooxygenase 1 and 2 (PTGS1 and PTGS2) Genes.
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
Interaction of rofecoxib and celecoxib with warfarin.
Palliative care pharmacotherapy literature summaries and analyses.
Pattern recognition analysis for the prediction of adverse effects by nonsteroidal anti-inflammatory drugs using 1H NMR-based metabolomics in rats.
[Cyclooxygenase inhibitors: adverse drug reactions are unavoidable, but only a few are (acutely) dangerous]
[First spontaneous reports of adverse drug reactions to the new selective COX-2 non-steroid anti-inflammatory drugs]
[First spontaneous reports of adverse drug reactions to the new selective COX-2 non-steroideal anti-inflammatory drugs]
[Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity]
Dry Eye Syndromes
Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits.
Dry eye-induced CCR7+CD11b+ cell lymph node homing is induced by COX-2 activities.
Dry Socket
The cyclooxygenase-2 inhibitor celecoxib and alveolar osteitis (Journal of the Irish Dental Association 2011; 57 (1): 50-53).
The cyclooxygenase-2 inhibitor celecoxib and alveolar osteitis.
Ductus Arteriosus, Patent
A high ductal flow velocity is associated with successful pharmacological closure of patent ductus arteriosus in infants 22-27 weeks gestational age.
A reexamination of the role of oxygen in retrolental fibroplasia.
Adverse effects of drugs on the immature kidney.
Attenuated cyclooxygenase-2 expression contributes to patent ductus arteriosus in preterm mice.
Biphasic response of the ductus arteriosus to combined administration of indomethacin and L-NAME in fetal rats.
Chronic in utero cyclooxygenase inhibition alters PGE2-regulated ductus arteriosus contractile pathways and prevents postnatal closure.
Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.
Common clinical and practical questions on the use of intravenous Ibuprofen lysine for the treatment of patent ductus arteriosus.
Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial.
Cyclooxygenase Inhibitors in Preterm Infants With Patent Ductus Arteriosus: Effects on Cardiac and Vascular Indices.
Does Treatment of Patent Ductus Arteriosus With Cyclooxygenase Inhibitors Affect Neonatal Regional Tissue Oxygenation?
Drug Closure of a Patent Ductus Arteriosus in An Extremely Low Birth Weight Premature Newborn. A Case Report.
Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment.
Effects of ibuprofen and hypoxia on neutrophil apoptosis in neonates.
Evidence-based use of acetaminophen for hemodynamically significant ductus arteriosus in preterm infants.
Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats.
Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants.
Neurodevelopmental outcome after COX inhibitor treatment for patent ductus arteriosus.
Outcome following patent ductus arteriosus ligation in premature infants: a retrospective cohort analysis.
Patent Ductus Arteriosus, Low Platelets, Cyclooxygenase Inhibitors, and Intraventricular Hemorrhage in Very Low Birth Weight Preterm Infants.
Pharmacoeconomics of Surgical Interventions vs. Cyclooxygenase Inhibitors for the Treatment of Patent Ductus Arteriosus.
Post-insult ibuprofen treatment attenuates damage to the serotonergic system after hypoxia-ischemia in the immature rat brain.
Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.
Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem.
Renal and Cardiovascular Characterization of COX-2 Knockdown Mice.
Studies of pulmonary prostaglandin biosynthetic and catabolic enzymes as factors in ductus arteriosus patency and closure. Evidence for a shift in products with gestational age.
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.
The promise of prostaglandins: have they fulfilled their potential as therapeutic targets for the delay of preterm birth?
Thromboxane A(2) receptor stimulation promotes closure of the rat ductus arteriosus through enhancing neointima formation.
Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants.
Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants.
[Paracetamol (acetaminophen) use in neonatology: a (re)appreciation of an old drug].
Dumping Syndrome
Comprehensive investigations of quality of life after esophagectomy with special reference to the route of reconstruction.
Duodenal Ulcer
Cyclooxygenase (COX)-1 and COX-2 both play an important role in the protection of the duodenal mucosa in cats.
Cyclooxygenase-2 inhibitor-associated minimal-change disease.
Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats.
Prostaglandins and vagal stimulation of gastric secretion in duodenal ulcer patients.
Role of prostanoids in experimental duodenal ulcer in rat.
Therapy of rheumatoid arthritis: new developments and trends.
Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis?
[Characteristics of prostanoid synthesis in patients with duodenal ulcer complicated by a history of hemorrhage]
[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]
[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
Duodenogastric Reflux
A selective cyclooxygenase-2 inhibitor prevents inflammation-related squamous cell carcinogenesis of the forestomach via duodenogastric reflux in rats.
Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor.
Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids.
Gastroesophageal reflux disease.
Late administration of a specific COX-2 inhibitor does not treat and/or prevent progression of gastric tumors in rats submitted to duodenogastric reflux procedure.
Dyskinesias
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.
Ibuprofen or piroxicam protects nigral neurons and delays the development of L-dopa induced dyskinesia in rats with experimental Parkinsonism: influence on angiogenesis.
Dyslipidemias
Aging associated with mild dyslipidemia reveals that COX-2 preserves dilation despite endothelial dysfunction.
Effects of Anthocyanins on Vascular Health.
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
Dyspareunia
COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain.
Dyspnea
Analgesics.
Effect of endotoxin on ventilation and breath variability: role of cyclooxygenase pathway.
Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.
The influence of misoprostol (synthetic analogue of prostaglandin E1) on aspirin-induced bronchoconstriction in aspirin-sensitive asthma.
Dystocia
Do uterine PTGS2, PGFS, and PTGFR expression play a role in canine uterine inertia?
Earache
Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors.
Eclampsia
Correlation analysis between COX-2 gene polymorphism and eclampsia.
Influence of serum HMW adiponectin level in patients with pregnancy-induced hypertension syndrome on the occurrence of eclampsia in secondary pregnancy.
Ectromelia
New insights into the obligatory nature of cyclooxygenase-2 and PGE2 during early chick embryogenesis.
Edema, Cardiac
Beneficial actions of a free radical scavenger in traumatic shock and myocardial ischemia.
Embolism
A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats.
Massive pulmonary embolus without hypoxemia.
The role of endothelin-1 as a mediator of the pressure response after air embolism in blood perfused lungs.
Embolism, Air
Mechanisms of stimulation of vagal pulmonary C fibers by pulmonary air embolism in dogs.
Encephalitis
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus.
An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk.
Benzo[a]pyrene diol epoxide up-regulates COX-2 expression through NF-kappaB in rat astrocytes.
Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats.
Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide.
Chronic Brain Inflammation: The Neurochemical Basis for Drugs to Reduce Inflammation.
Cyclooxygenase-2 in epilepsy.
Cyclooxygenase-2 is involved in HIV-1 Tat-induced inflammatory responses in the brain.
Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury.
Divergence of brain prostaglandin H synthase activity and oxidative damage in mice with encephalitis.
Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors.
In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines.
Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.
Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia.
Lentiviral infection of rhesus macaques causes long-term injury to cortical and hippocampal projections of prostaglandin-expressing cholinergic basal forebrain neurons.
Neonatal Systemic Exposure to Lipopolysaccharide Enhances Susceptibility of Nigrostriatal Dopaminergic Neurons to Rotenone Neurotoxicity in Later Life.
Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions.
NSAID treatment suppresses VSV propagation in mouse CNS.
Oxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependence.
Radiosynthesis and evaluation of [18F]FMTP, a COX-2 PET ligand.
Role of redox signaling in neuroinflammation and neurodegenerative diseases.
Systems Pharmacology-Based Approach to Comparatively Study the Independent and Synergistic Mechanisms of Danhong Injection and Naoxintong Capsule in Ischemic Stroke Treatment.
The COX-2-derived PGE2 autocrine contributes to bradykinin-induced matrix metalloproteinase-9 expression and astrocytic migration via STAT3 signaling.
The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo.
Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
TNFalpha-induced cyclooxygenase 2 not only increases the vasopermeability of blood-brain barrier but also enhances the neutrophil survival in Escherichia coli-induced brain inflammation.
Upregulation of COX-2 and CGRP expression in resident cells of the Borna disease virus-infected brain is dependent upon inflammation.
Upregulation of COX-2/PGE2 by ET-1 Mediated Through Ca(2+)-Dependent Signals in Mouse Brain Microvascular Endothelial Cells.
Encephalomalacia
Lipoxygenase and other enzymes of arachidonic acid metabolism in the brain of chicks affected by nutritional encephalomalacia.
Encephalomyelitis
COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression.
Cyclooxygenase expression and prostaglandin levels in central nervous system tissues during the course of chronic relapsing experimental autoimmune encephalomyelitis (EAE).
Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death.
Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma.
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells.
Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes.
Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway.
The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression.
COX-2 Inhibitors Modulate IL-12 Signaling Through JAK-STAT Pathway Leading to Th1 Response in Experimental Allergic Encephalomyelitis.
Cyclooxygenase expression and prostaglandin levels in central nervous system tissues during the course of chronic relapsing experimental autoimmune encephalomyelitis (EAE).
Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma.
Glia-T cell dialogue.
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells.
Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes.
Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway.
End Stage Liver Disease
Role of cyclooxygenase isoforms in encephalopathy of cirrhotic rats.
Endocarditis
Cellular immunity in Q fever: modulation of responsiveness by a suppressor T cell-monocyte circuit.
Myricetin Inhibition of Peptidoglycan-Induced COX-2 Expression in H9c2 Cardiomyocytes.
Endometrial Hyperplasia
COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.
Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase.
Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome.
Cyclooxygenase-2 expression in the endometrium at the end of 2 years' continuous combined hormone replacement therapy.
Does Uterine Prolapse Alter Endometrial Cyclooxygenase 2 Expression and Promote the Development of Premalignant Lesions?
Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
NF-?B and COX-2 expression in nonmalignant endometrial lesions and cancer.
Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
The cancer marker neutrophil gelatinase-associated lipocalin is highly expressed in human endometrial hyperplasia.
Endometrial Neoplasms
Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology.
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Bisphenol A-induced epithelial to mesenchymal transition is mediated by cyclooxygenase-2 up-regulation in human endometrial carcinoma cells.
Cell cycle regulators and apoptosis-associated proteins in relation to proliferative activity and degree of apoptosis in HNPCC versus sporadic endometrial carcinoma.
Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers.
Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues.
Clinicopathologic and prognostic significance of cyclooxygenase-2 expression in endometrial carcinoma.
Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Correlative expression of cyclooxygenase-1 (cox-1) and human epidermal growth factor receptor type-2 (her-2) in endometrial cancer.
Corrigendum: Cyclooxygenase-2 and ?-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer.
COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
COX-2-PGE2-EPs in gynecological cancers.
Cyclooxyenase-2 expression in endometrium carcinoma.
Cyclooxygenase inhibitors may be more effective in hormone-dependent endometrial cancers: interaction between cyclooxygenase and aromatase.
Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.
Cyclooxygenase-2 and ?-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer.
Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Cyclooxygenase-2 expression correlates with apoptosis and angiogenesis in endometrial cancer tissue.
Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase.
Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome.
Cyclooxygenase-2 in Cancer and Angiogenesis.
Effect of lentivirus mediated cyclooxygenase-2 gene shorthairpinRNA on invasiveness of endometrial carcinoma.
Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers.
Elevation of ?-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production.
Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma.
Expression of cyclooxygenase-2 in endometrial adenocarcinoma.
Expression of cyclooxygenase-2 in imprint smears of endometrial carcinoma.
Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma.
Expression of metalloproteinases 2 and 9 and cyclooxygenase 2 in endometrial carcinoma.
Expression of mTOR protein and its clinical significance in endometrial cancer.
Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis.
Expressions and clinical significance of COX-2, VEGF-C, and EFGR in endometrial carcinoma.
Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells.
Immunohistochemical Expression of Cyclooxygenase-2 (COX-2) in Feline Endometrial Adenocarcinoma and in Normal and Hyperplastic Endometria.
Immunohistochemical expression of MMP-2, MMP-9 and COX-2 in Stage IA malignant polyps of the endometrium.
Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.
Integrated eicosanoid lipidomics and gene expression reveal decreased prostaglandin catabolism and increased 5-lipoxygenase expression in aggressive subtypes of endometrial cancer.
Intratumoral CD8+ Lymphocyte Infiltration as a Prognostic Factor and Its Relationship With Cyclooxygenase 2 Expression and Microsatellite Instability in Endometrial Cancer.
JTE-522, a selective COX-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL95-2 cells.
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer.
MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.
Multiple roles of cyclooxygenase-2 in endometrial cancer.
NF-?B and COX-2 expression in nonmalignant endometrial lesions and cancer.
Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells.
Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.
Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma.
Oxytocin Increases Invasive Properties of Endometrial Cancer Cells Through Phosphatidylinositol 3-Kinase/AKT-Dependent Up-Regulation of Cyclooxygenase-1, -2 and X-Linked Inhibitor of Apoptosis Protein.
Polymorphisms in cyclooxygenase-2 gene in endometrial cancer patients.
Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis.
Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome.
Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells.
Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway.
Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells.
Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma.
Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells.
Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126.
The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture.
The effects of the selective cyclooxygenase-2 inhibitor on endometrial cytological findings in uterine endometrial cancer patients.
The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma.
The relationship of COX-2 expression with estrogen receptor, progesterone receptor and prognostic parameters in endometrial carcinomas.
To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor.
Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
Variances in the level of of COX-2 and iNOS in different grades of endometrial cancer.
[Disturbance of gene expression in endometrial cancer as therapy aim].
[Expression and function of cyclooxygenase-2 in endometrial carcinoma]
[Prognostic significance of cyclooxygenase (COX-1 and COX-2) expression in endometrial carcinoma (clinical and immunohistochemical study)]
Endometriosis
-1195 A/G promoter variants of the cyclooxygenase-2 gene increases the risk of pain occurrence in endometriotic women.
6-Shogaol reduces progression of experimental endometriosis in vivo and in vitro via regulation of VGEF and inhibition of COX-2 and PGE2-mediated inflammatory responses.
A functional promoter polymorphism in interleukin-10 gene influences susceptibility to endometriosis.
A Review of the Epigenetic Contributions to Endometriosis.
A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model.
A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice.
Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters.
Anastrozole and celecoxib for endometriosis treatment, good to keep them apart?
Angiotensin II activates the calcineurin/NFAT signaling pathway and induces cyclooxygenase-2 expression in rat endometrial stromal cells.
Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions--old answers?
B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.
Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions.
Comparing The Effects of Glycyrrhiza glabra Root Extract, A Cyclooxygenase-2 Inhibitor (Celecoxib) and A Gonadotropin-Releasing Hormone Analog (Diphereline) in A Rat Model of Endometriosis.
COX-2 gene promoter DNA methylation status in eutopic and ectopic endometrium of Egyptian women with endometriosis.
COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain.
Cyclooxygenase-2 ( COX -2) Gene-765G/C Polymorphism and Advanced-Stage Endometriosis in Korean Women.
Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium.
Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis.
Cyclooxygenase-2 expression, Ki-67 labeling index, and perifocal neovascularization in endometriotic lesions.
Cyclooxygenase-2 in Endometriosis.
Cyclooxygenase-2 overexpression in ovarian endometriomas is associated with higher risk of recurrence.
Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms.
Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats.
Cytokines, Angiogenesis, and Extracellular Matrix Degradation are Augmented by Oxidative Stress in Endometriosis.
Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis.
Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells.
Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis.
DNA hypomethylation of the COX-2 gene promoter is associated with up-regulation of its mRNA expression in eutopic endometrium of endometriosis.
Effect of Yikun Neiyi Wan on the expression of aromatase P450, COX-2, and ER related receptor in endometrial cells in vitro from patients with endometriosis.
Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.
Effects of Yiweining recipe on expressions of metalloproteinase-2 and cyclooxygenase-2 mRNAs in ectopic endometrium of rats with endometriosis.
Enhanced cyclooxygenase-2 expression levels and metalloproteinase 2 and 9 activation by Hexachlorobenzene in human endometrial stromal cells.
EP2 receptor antagonism reduces peripheral and central hyperalgesia in a preclinical mouse model of endometriosis.
Evaluation of the frequency of G-765C polymorphism in the promoter region of the COX-2 gene and its correlation with the expression of this gene in the endometrium of women with endometriosis.
Expression and possible role of non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) in the human endometrium and endometriosis.
Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2? biosynthesis and action in ovarian endometriosis tissue and in model cell lines.
Expression of COX-2 in intestinal endometriosis to: Tokyol C, et al. Int J Gynecol Pathol 2009;28:148-56.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in ovarian endometriotic cysts and their relationship with angiogenesis.
Expression of cyclooxygenase-2 in eutopic endometrium and ovarian endometriotic tissue in women with severe endometriosis.
Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis.
Expression of glycodelin and cyclooxygenase-2 in human endometrial tissue following three-dimensional culture.
Expression of inducible microsomal prostaglandin E synthase in local lesions of endometriosis patients.
Genetic variation in COX-2 -1195 and the risk of endometriosis and adenomyosis.
GnRH II as a possible cytostatic regulator in the development of endometriosis.
Gonadotropin-Releasing Hormone Agonist Reduces Aromatase Cytochrome P450 and Cyclooxygenase-2 in Ovarian Endometrioma and Eutopic Endometrium of Patients with Endometriosis.
Hormonal therapy deregulates prostaglandin-endoperoxidase synthase 2 (PTGS2) expression in endometriotic tissues.
Hypoxia induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human endometrial cells.
Identification of common mechanisms between endometriosis and ovarian cancer.
Identification of differentially expressed proteins associated with recurrence in ovarian endometriotic cysts.
Identification of endometriosis-related genes by representational difference analysis of cDNA.
Immunohistochemical analysis of an ectopic endometriosis in the uterine round ligament.
Immunohistochemical localization of prostaglandin H synthase in the female reproductive tract and endometriosis.
Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis?
Implication of the RAGE-EN-RAGE axis in endometriosis.
Increased cyclooxygenase-2 expression is associated with better clinical outcome in patients submitted to complete ablation for severe endometriosis.
Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients.
Induction of peritoneal endometriosis in nude mice with use of human immortalized endometriosis epithelial and stromal cells: a potential experimental tool to study molecular pathogenesis of endometriosis in humans.
Inflammatory status influences aromatase and steroid receptor expression in endometriosis.
Inhibition of IDO1 suppresses cyclooxygenase-2 and matrix metalloproteinase-9 expression and decreases proliferation, adhesion and invasion of endometrial stromal cells.
Interleukin-17F increases the secretion of interleukin-8 and the expression of cyclooxygenase 2 in endometriosis.
Interleukin-1? induces cyclooxygenase-2 expression and promotes the invasive ability of human mesenchymal stem cells derived from ovarian endometrioma.
Leptin on peritoneal macrophages of patients with endometriosis.
Leukotrienes in gynaecology: the hypothetical value of anti-leukotriene therapy in dysmenorrhoea and endometriosis.
Lipopolysaccharide promoted proliferation and invasion of endometriotic stromal cells via induction of cyclooxygenase-2 expression.
Lipoxin A4 Suppresses IL-1?-Induced Cyclooxygenase-2 Expression Through Inhibition of p38 MAPK Activation in Endometriosis.
MAPK/ERK signal pathway involved expression of COX-2 and VEGF by IL-1? induced in human endometriosis stromal cells in vitro.
Menstrual blood-derived stromal stem cells from women with and without endometriosis reveal different phenotypic and functional characteristics.
Nerve Growth Factor Is Associated With Sexual Pain in Women With Endometriosis.
Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis.
Non-steroidal targets in the diagnosis and treatment of endometriosis.
Ovarian cancers arising from endometriosis: A microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2.
Peritoneal fluid eicosanoids in chronic pelvic pain.
Peritoneal fluid of patients with endometriosis promotes proliferation of endometrial stromal cells and induces COX-2 expression.
Providing new insights into the endometriosisassociated cancer arising in episiotomy scars.
PTGS2 down-regulation in cumulus cells of infertile women with endometriosis.
Regression of endometrial explants in a rat model of endometriosis treated with melatonin.
Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib.
Regression of experimentally induced endometriosis with a new selective cyclooxygenase-2 enzyme inhibitor.
Regulation of Matrix Metalloproteinase-2 Activity by COX-2-PGE2-pAKT Axis Promotes Angiogenesis in Endometriosis.
Relationship between Toll-like receptor-4 and mPGES-1 gene expression in local lesions of endometriosis patients.
Role of IL-18 in pathogenesis of endometriosis.
Role of inflammation and aromatase expression in the eutopic endometrium and its relationship with the development of endometriosis.
Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis.
Selective estrogen-receptor modulators and aromatase inhibitors: promising new medical therapies for endometriosis?
Stretch magnitude- and frequency-dependent cyclooxygenase 2 and prostaglandin E2 up-regulation in human endometrial stromal cells: possible implications in endometriosis.
Suppression of COUP-TFII by proinflammatory cytokines contributes to the pathogenesis of endometriosis.
Suppression of IL-1beta-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells.
Suppressive Effects of Ursolic Acid on Human Endometriotic Stromal Cells Survival.
The -1195A>G polymorphism in Ciclooxygenase-2 gene is associated with lower risk of endometriosis.
The Anti-Inflammatory Effect of Octyl Gallate Through Inhibition of Nuclear Factor-?B (NF-?B) Pathway in Rat Endometriosis Model.
The effects of ulipristal on Bax/Bcl-2, cytochrome C, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis.
The expression of Cox-2, NF-?B, and VEGF in ectopic endometrial tissues within fallopian tubes suggests different etiologies.
The inducible prostaglandin E synthase mPGES-1 regulates growth of endometrial tissues and angiogenesis in a mouse implantation model.
The pro-inflammatory and anti-inflammatory role of hyaluronic acid in endometriosis.
The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis.
Therapeutic potential of andrographolide for treating endometriosis.
Tumor necrosis factor-alpha-induced cyclooxygenase-2 overexpression in eutopic endometrium of women with endometriosis by stromal cell culture through nuclear factor-kappaB activation.
Up-regulation of cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic cells by macrophage migration inhibitory factor: involvement of novel kinase signaling pathways.
[COX-2-expression in extragenital endometriosis lesions as a novel therapeutical approach?]
[Expression of cylooxygenase-2 in endometriosis]
[Inhibitory effects of Sanlengwan on aromatase and cyclooxygenase-2 in rats of endometriosis]
[Targeted interruption of COX-2 gene by siRNA inhibits the expression of VEGF, MMP-9, the activity of COX-2 and stimulates the apoptosis in eutopic, ectopic endometrial stromal cells of women with endometriosis].
Endometritis
Cyclooxyenase-2 expression in endometrium carcinoma.
Destination of corpus luteum in postpartum clinical endometritis cows and factors affecting self-recovery.
Endometrial mRNA expression of prostaglandin synthase enzymes PTGS 2, PTGFS and mPTGES 1 in repeat-breeding cows with cytologically determined endometritis.
Endometritis in the bitch: Immunohistochemical localization of cyclooxygenase 2.
Eucalyptus robusta leaves methanolic extract suppresses inflammatory mediators by specifically targeting TLR4/TLR9, MPO, COX2, iNOS and inflammatory cytokines in experimentally-induced endometritis in rats.
Evidence for Increased Content of PGF2?, PGE2, and 6-keto-PGF1? in Endometrial Tissue Cultures From Heavy Draft Mares in Anestrus With Endometritis.
Expression of Cyclooxygenase-2 in the Endometrium of Gilts with Different Stages of Endometritis.
Expression of cyclooxygenase-2 in the inflammatory changed porcine uterus.
Uterine clinical findings, fertility rate, leucocyte migration, and COX-2 protein levels in the endometrial tissue of susceptible mares treated with platelet-rich plasma before and after AI.
[The role of prostaglandins and Cyclooxygenase in pathogenesis of chronic endometritis].
Endotoxemia
?-Solanine Isolated from Solanum tuberosum L. cv Jayoung Abrogates LPS-Induced Inflammatory Responses via NF-?B Inactivation in RAW 264.7 Macrophages and Endotoxin-Induced Shock Model in Mice.
A novel isoquinoline derivative exhibits anti-inflammatory properties and improves the outcomes of endotoxemia.
Activation of type II alveolar epithelial cells during acute endotoxemia.
Age-dependent changes in the regulation of cyclooxygenases in the gastrointestinal tract after gram-negative endotoxemia.
Alpha-melanocyte-stimulating hormone through melanocortin-4 receptor inhibits nitric oxide synthase and cyclooxygenase expression in the hypothalamus of male rats.
Alteration in heme oxygenase-1 and nitric oxide synthase-2 gene expression during endotoxemia in cyclooxygenase-2-deficient mice.
An assessment of the participatory role of prostaglandins and serotonin in the pathophysiology of endotoxic shock.
An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia.
Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway.
Berberine ameliorates COX-2 expression in rat small intestinal mucosa partially through PPAR? pathway during acute endotoxemia.
Berberine hydrochloride attenuates cyclooxygenase-2 expression in rat small intestinal mucosa during acute endotoxemia.
Biflorin, Isolated from the Flower Buds of Syzygium aromaticum L., Suppresses LPS-Induced Inflammatory Mediators via STAT1 Inactivation in Macrophages and Protects Mice from Endotoxin Shock.
Brain expression of inducible cyclooxygenase 2 messenger RNA in rats undergoing cardiopulmonary bypass.
BW755C modifies endotoxin-induced respiratory failure in pigs.
Changes in DNA integrity and gene expression in ovarian follicular cells of lipopolysaccharide-treated female mice.
COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex.
Cyclooxygenase-1 suppresses lipopolysaccharide-induced changes in rat gastric inducible nitric oxide synthase.
Cyclooxygenase-1-dependent prostaglandin synthesis modulates tumor necrosis factor-alpha secretion in lipopolysaccharide-challenged murine resident peritoneal macrophages.
Cyclooxygenase-2-deficient mice are resistant to endotoxin-induced inflammation and death.
Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis.
Dexamethasone and indomethacin modify endotoxin-induced respiratory failure in pigs.
Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat.
Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration.
Disruption of COX-2 and eNOS does not confer protection from cardiovascular failure in lipopolysaccharide-treated conscious mice and isolated vascular rings.
Effect of endotoxin on ventilation and breath variability: role of cyclooxygenase pathway.
Effect of ibuprofen upon denervated skeletal muscle resistance and compliance vessels during endotoxemia.
Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxemia in sheep.
Effect of NG-nitro-L-arginine-methyl-ester on cardiopulmonary function and biosynthesis of cyclooxygenase products during porcine endotoxemia.
Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice.
Effectiveness of dual cyclooxygense and leukotriene blockade with ibuprofen and LY203647 during canine endotoxic shock.
Effects of cyclooxygenase inhibitors on pulmonary vascular responses to endotoxin in unanesthetized sheep.
Effects of cyclooxygenase inhibitors on the alterations in lung mechanics caused by endotoxemia in the unanesthetized sheep.
Effects of flunixin meglumine on cardiopulmonary responses to endotoxin in ponies.
Effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on cardiovascular alterations in endotoxemia.
Endotoxin and lung injury.
Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages.
Endotoxin-induced eicosanoid production by equine vascular endothelial cells and neutrophils.
EP2 Receptor Blockade Attenuates COX-2 Upregulation During Intestinal Inflammation.
Ethanol Extract of Potentilla supina Linne Suppresses LPS-induced Inflammatory Responses through NF-?B and AP-1 Inactivation in Macrophages and in Endotoxic mice.
Ibuprofen attenuates cardiopulmonary dysfunction by modifying vascular tone in endotoxemia.
In vivo study on cross talk between inducible nitric-oxide synthase and cyclooxygenase in rat gastric mucosa: effect of cyclooxygenase activity on nitric oxide production.
Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia: role in resistance to damage.
Inhibition of endothelin-1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis.
Investigation of mRNA expression of tumor necrosis factor-alpha, interleukin-1beta, and cyclooxygenase-2 in cultured equine digital artery smooth muscle cells after exposure to endotoxin.
Ketamine attenuates liver injury attributed to endotoxemia: role of cyclooxygenase-2.
Metabolites of arachidonic acid in experimental lung vascular injury.
Microdialysis-evaluated myocardial cyclooxygenase-mediated inflammation and early circulatory depression in porcine endotoxemia.
Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor.
Novel Combination of COX-2 Inhibitor and Antioxidant Therapy for Modulating Oxidative Stress Associated with Intestinal Ischemic Reperfusion Injury and Endotoxemia.
Oxidative injury and survival during endotoxemia.
Perinatal Endotoxemia Induces Sustained Hepatic COX-2 Expression through an NFx03BA;B-Dependent Mechanism.
Phospholipase Cgamma1 signalling regulates lipopolysaccharide-induced cyclooxygenase-2 expression in cardiomyocytes.
Pulmonary dysfunction caused by diffuse lung inflammation. Roles of metabolites of arachidonic acid.
Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule.
Regulation of cyclooxygenase-2 by nitric oxide in activated hepatic macrophages during acute endotoxemia.
Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice.
Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis.
Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat.
The role of cyclooxygenase in regulation of vasomotor tone during endotoxemia.
The role of p38 mitogen-activated kinase (MAPK) in the mechanism regulating cyclooxygenase gene expression in equine leukocytes.
Entamoebiasis
Entamoeba histolytica: induction of cyclooxygenase-2 expression during amoebic liver abscess formation in hamsters (Mesocricetus auratus).
Enteritis
Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel injury in rats.
Microbial metabolite deoxycholic acid controls Clostridium perfringens-induced chicken necrotic enteritis through attenuating inflammatory cyclooxygenase signaling.
Radiotherapy: long-term effects on gastrointestinal function.
Enterocolitis
Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism.
MyD88 signaling promotes both mucosal homeostatic and fibrotic responses during Salmonella-induced colitis.
Salmonella enterica serovar Enteritidis enterocolitis during late stages of gestation induces an adverse pregnancy outcome in the murine model.
Enterocolitis, Necrotizing
Amniotic Fluid Stem Cells Prevent Development of Ascites in a Neonatal Rat Model of Necrotizing Enterocolitis.
Low-dose cyclooxygenase-2 (COX-2) inhibitor celecoxib plays a protective role in the rat model of neonatal necrotizing enterocolitis.
Molecular signaling in necrotizing enterocolitis: regulation of intestinal COX-2 expression.
Mucosal loss with increased expression of IL-6, IL-8, and COX-2 in a formula-feeding only neonatal rat model of necrotizing enterocolitis.
The promise of prostaglandins: have they fulfilled their potential as therapeutic targets for the delay of preterm birth?
[Protective effects of curcumin on neonatal rats with necrotizing enterocolitis]
Enzootic Bovine Leukosis
Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus.
Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.
Eosinophilia
Anthocyanins inhibit airway inflammation and hyperresponsiveness in a murine asthma model.
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Contribution of leukotriene B4 to airway inflammation and the effect of antagonists.
Cyclooxygenase inhibition augments allergic inflammation through CD4-dependent, STAT6-independent mechanisms.
Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice.
Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia.
Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation.
Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Increased prostaglandin E2 concentrations and cyclooxygenase-2 expression in asthmatic subjects with sputum eosinophilia.
Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells.
Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody.
Peucedanum japonicum extract attenuates allergic airway inflammation by inhibiting Th2 cell activation and production of pro-inflammatory mediators.
Pharmacological modulation of the late eosinophilia induced by antigen in actively sensitized rats.
Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.
Ependymoma
Cyclooxygenase-2 (cox-2) expression and angiogenesis in intracranial ependymomas.
Cyclooxygenase-2 expression in ependymoma of the spinal cord.
Expression of cyclo-oxygenase-2 in ependymal tumors.
Expression of prostaglandin H synthase-2 in human brain tumors.
Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro.
Epidermolysis Bullosa Dystrophica
ATP-induced cell contraction with epidermolysis bullosa dystrophica recessive and normal dermal fibroblasts.
Epilepsy
A possible role of cyclooxygenase-2 in the relationship between sleep and sudden unexpected death in epilepsy.
Acute effects of aceclofenac, COX-2 inhibitor, on penicillin-induced epileptiform activity.
An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders.
Anticonvulsant Effects of Dingxian Pill in Pentylenetetrazol-Kindled Rats.
Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy.
Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.
Chemotactic and mitogenic stimuli of neuronal apoptosis in patients with medically intractable temporal lobe epilepsy.
Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy.
COX-2-PGE2 signaling pathway contributes to hippocampal neuronal injury and cognitive impairment in PTZ-kindled epilepsy mice.
Cyclooxygenase in epilepsy: from perception to application.
Cyclooxygenase system contributes to the maintenance of post convulsive period of epileptic phenomena in the genetically epileptic El mice.
Cyclooxygenase-1 as a Potential Therapeutic Target for Seizure Suppression: Evidences from Zebrafish Pentylenetetrazole-Seizure Model.
Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management.
Cyclooxygenase-2 expression in the hippocampus of genetically epilepsy susceptible El mice was increased after seizure.
Cyclooxygenase-2 in epilepsy.
Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus.
Differential effect of prostaglandin synthetase inhibitor pretreatment on pentylenetetrazol-induced seizures in rat.
Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy.
Effect of cyclooxygenase inhibitors on pentylenetetrazol (PTZ)-induced convulsions: Possible mechanism of action.
Effect of cyclooxygenase-2 (COX-2) inhibitors in various animal models (bicuculline, picrotoxin, maximal electroshock-induced convulsions) of epilepsy with possible mechanism of action.
Effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, on various biochemical parameters of brain associated with pentylenetetrazol-induced chemical kindling in mice.
Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy.
Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3? signaling pathway.
Ibuprofen Exerts Antiepileptic and Neuroprotective Effects in the Rat Model of Pentylenetetrazol-Induced Epilepsy via the COX-2/NLRP3/IL-18 Pathway.
Impact of a selective cyclooxygenase-2 inhibitor, celecoxib, on cortical excitability and electrophysiological properties of the brain in healthy volunteers: A randomized, double-blind, placebo-controlled study.
Indomethacin treatment prior to pentylenetetrazole-induced seizures downregulates the expression of il1b and cox2 and decreases seizure-like behavior in zebrafish larvae.
Induction of astrocytic cyclooxygenase-2 in epileptic patients with hippocampal sclerosis.
Inhibitor effect of dexketoprofen in rat model of pentylenetetrazol-induced seizures.
Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors.
Linked activation of nitric oxide synthase and cyclooxygenase in peripheral monocytes of asymptomatic migraine without aura patients.
LncRNA NEAT1 affects inflammatory response by targeting miR-129-5p and regulating Notch signaling pathway in epilepsy.
Managing epilepsy-associated depression: Serotonin enhancers or serotonin producers?
Neuroinflammatory signaling upregulation in Alzheimer's disease.
Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.
Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches.
Postictal behavioural impairments are due to a severe prolonged hypoperfusion/hypoxia event that is COX-2 dependent.
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Prophylactic, prandial rofecoxib treatment lacks efficacy against acute PTZ-induced seizure generation and kindling acquisition.
Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations.
Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies.
Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy?
Staged anticonvulsant screening for chronic epilepsy.
Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection.
Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice.
Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy.
Temporal profile of serum mitochondrial DNA (mtDNA) in patients with aneurysmal subarachnoid hemorrhage (aSAH).
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy.
The expression of inflammatory markers and their potential influence on efflux transporters in drug-resistant mesial temporal lobe epilepsy tissue.
Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it.
Epilepsy, Absence
Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats.
Epilepsy, Temporal Lobe
Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.
Chemotactic and mitogenic stimuli of neuronal apoptosis in patients with medically intractable temporal lobe epilepsy.
Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy.
Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy.
Induction of astrocytic cyclooxygenase-2 in epileptic patients with hippocampal sclerosis.
Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice.
Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy.
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy.
Epiretinal Membrane
CYCLO-OXYGENASE-2 EXPRESSION IN HUMAN IDIOPATHIC EPIRETINAL MEMBRANE.
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Epistaxis
The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
Epstein-Barr Virus Infections
Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.
Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma.
Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1.
[Expression and prognostic value of COX- 2, p16(INK4A) and p53 in patients with classical Hodgkin lymphoma].
Erectile Dysfunction
New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (COX) blockers in erectile dysfunction.
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.
Erythema
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Effects of several agents on UVB- and UVA plus systemic fluoroquinolone-induced erythema of guinea pig skin evaluated by reflectance colorimetry.
Eicosanoids in skin UV inflammation.
Fucoxanthin-Containing Cream Prevents Epidermal Hyperplasia and UVB-Induced Skin Erythema in Mice.
Increased cyclooxygenase expression and thymine dimer formation after repeated exposures of humans to low doses of solar simulated radiation.
Inhibition of erythema induced by pro-inflammatory esters of 12-deoxyphorbol.
Local gene expression changes after UV-irradiation of human skin.
Nitric oxide and human skin blood flow responses to acetylcholine and ultraviolet light.
Photoprotection by honeybush extracts, hesperidin and mangiferin against UVB-induced skin damage in SKH-1 mice.
Protective effects of grape stem extract against UVB-induced damage in C57BL mice skin.
Risk assessment of excess drug and sunscreen absorption via skin with ablative fractional laser resurfacing : Optimization of the applied dose for postoperative care.
Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance.
Selective cyclooxygenase-2 inhibition produces heterogeneous erythema response to ultraviolet irradiation.
The anti-inflammatory and pharmacological effects of topically applied flurbiprofen on human skin 24 hours after ultraviolet B irradiation.
The effect of topically applied agents on ultraviolet erythema in guinea pigs.
The eicosanoid response to high dose UVR exposure of individuals prone and resistant to sunburn.
The pattern and kinetics in human skin of erythema and mediators during the acute and late-phase response (LPR).
The sunburn response in human skin is characterized by sequential eicosanoid profiles that may mediate its early and late phases.
Topical delivery of l-theanine ameliorates TPA-induced acute skin inflammation via downregulating endothelial PECAM-1 and neutrophil infiltration and activation.
UVB-induced DNA damage, generation of reactive oxygen species, and inflammation are effectively attenuated by the flavonoid luteolin in vitro and in vivo.
[Cyclooxygenases in the skin]
Erythema Multiforme
COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
Erythromelalgia
Aspirin Responsive Thrombotic Complications in Thrombocythemia Vera. A Novel Platelet-Mediated Arterial Thrombophilia.
Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
Prostaglandin cyclooxygenase products but not thromboxane A(2) are involved in the pathogenesis of ewthromelalgia in thrombocythaemia.
Escherichia coli Infections
Cyclooxygenase-2 Inhibition Reduces Autophagy of Macrophages Enhancing Extraintestinal Pathogenic Escherichia coli Infection.
Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.
Esophageal Neoplasms
A cyclooxygase-2 inhibitor NS-398-enhanced apoptosis of esophageal carcinoma cell EC9706 by adjusting expression of survivin and caspase-3.
Amiloride and guggulsterone suppression of esophageal cancer cell growth in vitro and in nude mouse xenografts.
Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer.
Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Antitumor effect of retinoic acid receptor-beta2 associated with suppression of cyclooxygenase-2.
Apurinic/apyrimidinic endonuclease-1 is associated with angiogenesis and VEGF production via upregulation of COX-2 expression in esophageal cancer tissues.
Association of Single Nucleotide Polymorphisms in the Prostaglandin-endoperoxide Synthase 2 (PTGS2) and Phospholipase A2 Group IIA (PLA2G2A) Genes with Susceptibility to Esophageal Squamous Cell Carcinoma.
Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation.
Celecoxib antagonizes the cytotoxicity of oxaliplatin in human esophageal cancer cells by impairing the drug influx.
Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer.
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Coexpression of COX-2 and iNOS in Angiogenesis of Superficial Esophageal Squamous Cell Carcinoma.
COX-2 (PTGS2) gene methylation in epithelial, subepithelial lymphocyte and stromal tissue compartments in a spectrum of esophageal squamous neoplasia.
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
COX-2: a target for prevention and treatment of esophageal cancer.
Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence.
Cyclooxygenase-2 expression in human esophageal carcinoma.
Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis.
Cyclooxygenase-2 inhibitors.
Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis.
Deoxycholate induces COX-2 expression via Erk1/2-, p38-MAPK and AP-1-dependent mechanisms in esophageal cancer cells.
Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells.
Effects of the Inhibition of Cyclooxygenase-2 on Human Esophageal Cancer Cells: Inhibition of Cell Proliferation and Induction of Apoptosis.
Evaluating the expression of cyclooxygenase-2 enzyme by immunohistochemistry in normal and tumoral tissue before and after neoadjuvant chemoradiotherapy in patients with esophageal cancer in Khorasan Province.
Expression characteristics of heparanase in colon carcinoma and its close relationship with cyclooxygenase-2 and angiogenesis.
Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas.
Expression of p53, p16 and cyclooxygenase-2 in esophageal cancer with tissue microarray.
Gastroesophageal reflux disease and Barrett's esophagus.
Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2.
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer.
Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China.
Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects.
Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression.
Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells.
Inflammation-related carcinogenesis and prevention in esophageal adenocarcinoma using rat duodenoesophageal reflux models.
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
New insights into the functions of Cox-2 in skin and esophageal malignancies.
NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2.
NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action.
Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398.
Rhizoma Paridis Saponins Suppresses Tumor Growth in a Rat Model of N-Nitrosomethylbenzylamine-Induced Esophageal Cancer by Inhibiting Cyclooxygenases-2 Pathway.
Strategy for prevention of cancers of the esophagus.
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor.
The close correlation between heparanase and COX-2 expression in lymphangiogenesis of cervical cancer.
The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.
The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma.
The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo.
The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis.
The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells.
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
[Correlation of cyclooxygenase 2 expression with microlymphatic density and its clinical significance]
[Cyclooxygenase-2 expression in esophageal cancer cells and induction by mitomycin C]
[Genetic polymorphisms in STK15 and MMP-2 associated susceptibility to esophageal cancer in Mongolian population]
[Small interfering RNA in silencing cox-2 expression enhances radiosensitivity of esophageal cancer EC9706 cell].
Esophageal Squamous Cell Carcinoma
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells.
Anti-Cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma (ESCC) through Down-Regulation of COX-2 mRNA and PGE2.
Apurinic/apyrimidinic endonuclease-1 is associated with angiogenesis and VEGF production via upregulation of COX-2 expression in esophageal cancer tissues.
Association of Single Nucleotide Polymorphisms in the Prostaglandin-endoperoxide Synthase 2 (PTGS2) and Phospholipase A2 Group IIA (PLA2G2A) Genes with Susceptibility to Esophageal Squamous Cell Carcinoma.
Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma.
Clinicopathologic significance of expression of cyclooxygenase-2 in human esophageal squamous cell carcinoma.
Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma.
Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma.
Coexpression of COX-2 and iNOS in Angiogenesis of Superficial Esophageal Squamous Cell Carcinoma.
Correlation among 16 biological factors [p53, p21(waf1), MIB-1 (Ki-67), p16(INK4A), cyclin D1, E-cadherin, Bcl-2, TNF-?, NF-?B, TGF-?, MMP-7, COX-2, EGFR, HER2/neu, ER, and HIF-1?] and clinical outcomes following curative chemoradiation therapy in 10 patients with esophageal squamous cell carcinoma.
Correlation analysis of c-myc, p21(WAF/CIP1), p53, C-erbB-2 and COX-2 proteins in esophageal squamous cell carcinoma.
COX-2 (PTGS2) gene methylation in epithelial, subepithelial lymphocyte and stromal tissue compartments in a spectrum of esophageal squamous neoplasia.
COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID.
COX-2 overexpression Induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin.
Cyclo-oxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma.
Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma.
Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: an immunohistochemical study.
Cyclooxygenase-2, a Potential Therapeutic Target, Is Regulated by miR-101 in Esophageal Squamous Cell Carcinoma.
Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma.
E series of prostaglandin receptor 2-mediated activation of extracellular signal-regulated kinase/activator protein-1 signaling is required for the mitogenic action of prostaglandin E2 in esophageal squamous-cell carcinoma.
Early upregulation of cyclooxygenase-2 in human papillomavirus type 16 and telomerase-induced immortalization of human esophageal epithelial cells.
Effects of cyclooxygenase-2 non-selective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells.
Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma.
Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells.
Effects of the Inhibition of Cyclooxygenase-2 on Human Esophageal Cancer Cells: Inhibition of Cell Proliferation and Induction of Apoptosis.
Efficacy comparison of lyophilised black raspberries and combination of celecoxib and PBIT in prevention of carcinogen-induced oesophageal cancer in rats.
Expression analysis of cyclooxygenase-2 in patients suffering from esophageal squamous cell carcinoma.
Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas.
Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression.
Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs.
Expression of VEGF and Cox-2 in Patients with Esophageal Squamous Cell Carcinoma
Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma.
High expression of cyclooxygenase 2 is an indicator of prognosis for patients with esophageal squamous cell carcinoma after Ivor Lewis esophagectomy.
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer.
Increased level of serum prostaglandin-2 in early stage of esophageal squamous cell carcinoma.
JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma.
MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.
Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A.
Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients.
Overexpression of phospholipase A2 Group IIA in esophageal squamous cell carcinoma and association with cyclooxygenase-2 expression.
P21, COX-2, and E-cadherin are potential prognostic factors for esophageal squamous cell carcinoma.
Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms.
Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study.
Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.
Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy.
Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma.
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma.
Promoter methylation regulates cigarette smoke-stimulated cyclooxygenase-2 expression in esophageal squamous cell carcinoma.
Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells.
Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma.
Significance of COX-2 expression in human esophageal squamous cell carcinoma.
Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus.
The inhibitory effect of Gleditsia sinensis on cyclooxygenase-2 expression in human esophageal squamous cell carcinoma.
The relationship between cyclooxygenase-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma.
The relationship between HPV16 and expression of cyclooxygenase-2, P53 and their prognostic roles in esophageal squamous cell carcinoma.
VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma.
[Correlation of cyclooxygenase 2 expression with microlymphatic density and its clinical significance]
[Cyclooxygenase inhibitors in chemoprevention and treatment of esophageal squamous cell carcinoma]
[Epidermal growth factor stimulates the proliferation of human esophageal squamous cell carcinoma HKESC-1 cells by increasing COX-2 expression].
[Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma]
[Expression of cyclooxygenase-2 in esophageal squamous cell carcinogenesis]
[p53, p16 E COX-2 expression in esophageal squamous cell carcinoma and histopathological association]
Esophagitis
Animal model of Acid-reflux esophagitis: pathogenic roles of acid/pepsin, prostaglandins, and amino acids.
Anti-Oxidative and Anti-Inflammatory Effects of QGC in Cultured Feline Esophageal Epithelial Cells.
Anti-reflux anastomosis following esophagectomy for adenocarcinoma of the esophagogastric junction: impact of duodenogastroesophageal reflux and expression of cyclooxygenase-2 in the remnant esophagus.
Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus.
Beneficial effect of indomethacin on acid-induced esophagitis in cats.
Biphasic effect of prostaglandin E2 in a rat model of esophagitis mediated by EP1 receptors: relation to pepsin secretion.
Celecoxib associated esophagitis: review of gastrointestinal side effects from cox-2 inhibitors.
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids.
Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line.
Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.
Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus.
Interaction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-? system in experimental rat Barrett's esophagus.
Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Protection by indomethacin against acute radiation esophagitis.
Selective COX-2 inhibition is associated with decreased mucosal damage induced by acid and pepsin in rabbit esophagitis.
[Chemoprevention in adenocarcinoma of the esophagus]
[Evaluation of the activity of prostaglandin synthetase in biopsies of the cardio-esophageal region. Relation between sliding hiatal hernia and reflux esophagitis]
[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
Esophagitis, Peptic
Acid-induced COX-2 expression and prostaglandin E2 production via activation of ERK1/2 and p38 MAPK in cultured feline esophageal smooth muscle cells.
Anti-reflux anastomosis following esophagectomy for adenocarcinoma of the esophagogastric junction: impact of duodenogastroesophageal reflux and expression of cyclooxygenase-2 in the remnant esophagus.
Comprehensive investigations of quality of life after esophagectomy with special reference to the route of reconstruction.
COX-2 CA-Haplotype Is a Risk Factor for the Development of Esophageal Adenocarcinoma.
Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma.
Is the etiology of eosinophilic esophagitis in adults a response to allergy or reflux injury? Study of cellular proliferation markers.
Molecular Pathways: Pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett's esophagus.
Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
What is the clinical significance of stromal angiogenesis in Barrett's esophagus?
[Evaluation of the activity of prostaglandin synthetase in biopsies of the cardio-esophageal region. Relation between sliding hiatal hernia and reflux esophagitis]
[The clinical, pathological features and expression of Ki-67 and COX-2 in severe reflux esophagitis and Barrett's esophagus]
Essential Hypertension
Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man.
Antihypertensive effect of enalapril in essential hypertension: role of prostacyclin.
Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension.
Endothelial nitric oxide synthase, cyclooxygenase-2, and essential hypertension: is there an interaction?
Enhanced blood pressure response to cyclooxygenase inhibition in salt-sensitive human essential hypertension.
Reduction of the antihypertensive effect of captopril induced by prostaglandin synthetase inhibition.
Renal prostaglandins in borderline and sustained essential hypertension.
Response to Endothelial nitric oxide synthase, cyclooxygenase-2, and essential hypertension: is there an interaction?
Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension.
Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension.
Exanthema
A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial.
Dermatosis in magnesium-deficient hairless rats: effects of steroidal and non-steroidal anti-inflammatory drugs.
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Exfoliation Syndrome
Immunohistochemical Profiles of LOXL-1, FBN1, TGF-?1, and COX-2 in Pseudoexfoliation Syndrome.
Extranodal Extension
Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer.
Eye Diseases
Cyclooxygenase-2 expression in the cornea of dogs with keratitis.
New aspects of mast cell biology.
Fabry Disease
Differential involvement of COX1 and COX2 in the vasculopathy associated with the {alpha}-galactosidase A-knockout mouse.
Facial Paralysis
Activation of NF-?B signaling pathway in HSV-1-induced mouse facial palsy: Possible relation to therapeutic effect of glucocorticoids.
Familial Mediterranean Fever
Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.
Familial Primary Pulmonary Hypertension
The use of low dose aspirin in pregnancy.
Fasciitis
Expression of HuR and Cyclooxygenase-2 in Nodular Fasciitis and Low-Grade Sarcoma: An Immunohistochemical Study.
Fatty Liver
Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats.
Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor.
Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats.
Constitutive activation of AMPK ?1 in vascular endothelium promotes high-fat diet-induced fatty liver injury: role of COX-2 induction.
Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease.
COX-2 in liver fibrosis.
COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator.
COX-2-mediated Inflammation in Fat Is Crucial for Obesity-linked Insulin Resistance and Fatty Liver.
Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice.
Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes.
Cyclooxygenase inhibition upregulates liver carnitine palmitoyltransferase 1A (CPT1A) expression and improves fatty liver.
Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
Dietary arachidonic acid protects mice against the fatty liver induced by a high fat diet and by ethanol.
Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis.
Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C.
Suppressing Cyclooxygenase-2 Prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt/p53 signal pathway.
The Dualistic Effect of COX-2-Mediated Signaling in Obesity and Insulin Resistance.
Thromboxane Inhibitors Attenuate Inflammatory and Fibrotic Changes in Rat Liver Despite Continued Ethanol Administrations.
Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats.
Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).
[An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis]
[Effect of total flavones of hawthorn leafonon expression of COX-2/Nrf2 in liver of rats with nonalcoholic steatohepatitis].
[Effects of ellagic acid on inflammation and oxidative stress induced by AKT gene transfection in mice with fatty liver disease].
Fetal Death
Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide.
Genetic analysis of fetal development and parturition control in the mouse.
Fetal Diseases
Developmental damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic environment.
Effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in mice.
UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin.
Fetal Growth Retardation
Celecoxib restores angiogenic factor expression at the maternal-fetal interface in the BPH/5 mouse model of preeclampsia.
Cyclooxygenase inhibitors affect bone mineralization in rat fetuses.
Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development.
Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors.
Thromboxane A(2) limits differentiation and enhances apoptosis of cultured human trophoblasts.
[Developmental toxicity of the over-the-counter analgetics and antypiretics].
Fibroadenoma
Expression of cyclooxygenase-1 and -2 in human breast cancer.
Expression of cyclooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases.
Expression of cyclooxygenase-2 in malignant and benign breast tumors.
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
[Expression of the cyclooxygenase-2 gene in human breast carcinoma]
Fibroma
Comparison of fatty acid synthase and cyclooxygenase-2 immunoexpression in embryonal, benign, and malignant odontogenic tissues.
Immunohistochemical staining with non-phospho ?-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.
Fibromatosis, Aggressive
A comparison of methods for the analysis of low abundance proteins in desmoid tumor cells.
Complete remission of pancreatic head desmoid tumor treated by COX-2 inhibitor-a case report.
CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor).
Desmoid tumor-associated pain is dependent on mast cell expression of cyclooxygenase-2.
Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.
Nuclear expression of ?-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.
Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors.
Successful treatment of a recurrent chest wall desmoid tumor with cyclooxygenase-2 inhibitors.
Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study.
Fibrosarcoma
A Transcriptional Regulatory Role for the Membrane Type-1 Matrix Metalloproteinase in Carcinogen-Induced Inflammasome Gene Expression.
Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities.
Comparison of fatty acid synthase and cyclooxygenase-2 immunoexpression in embryonal, benign, and malignant odontogenic tissues.
Cyclooxygenase-2 expression induced by photofrin photodynamic therapy involves the p38 MAPK pathway.
Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.
Dietary menhaden oil lowers plasma prostaglandins and calcium in mice bearing the prostaglandin-producing HSDM1 fibrosarcoma.
DNA-hypomethylating agent, 5'-azacytidine, induces cyclooxygenase-2 expression via the PI3-kinase/Akt and extracellular signal-regulated kinase-1/2 pathways in human HT1080 fibrosarcoma cells.
DTD, an anti-inflammatory ditriazine, inhibits angiogenesis in vitro and in vivo.
Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells.
Induction of prostaglandin endoperoxide synthase-2 by serine-threonine phosphatase inhibition.
Modulation of tumor cell motility by prostaglandins and inhibitors of prostaglandin synthesis.
Pifithrin-?, an inhibitor of p53 transactivation, up-regulates COX-2 expression through an MAPK-dependent pathway.
The effect of nonsteroidal antiinflammatory drugs ibuprofen, flurbiprofen, and diclofenac on in vitro and in vivo growth of mouse fibrosarcoma.
Tumour necrosis factor-alpha-dependent regulation of prostaglandin endoperoxide synthase-2.
Tyrosine phosphatase-dependent/tyrosine kinase-independent induction of nuclear factor-kappa B by tumor necrosis factor-alpha: effects on prostaglandin endoperoxide synthase-2 mRNA accumulation.
Follicular Cyst
Licorice ethanol extract improves symptoms of polycytic ovary syndrome in Letrozole-induced female rats.
Folliculitis
Induction of inflammatory reactions by lipopolysaccharide in hamster sebaceous glands and pilosebaceous units in vivo and in vitro.
Foot Ulcer
[Effects of San-huang-sheng-fu oil on peripheral circulatory disorders and foot ulcers in diabetic rats and the mechanisms].
Friedreich Ataxia
Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia.
Gallbladder Diseases
Arachidonic acid metabolites in hepatobiliary physiology and disease.
Effect of oral ibuprofen on formation of prostaglandins E and F by human gallbladder muscle and mucosa.
Synthetic pathways of gallbladder mucosal prostanoids: the role of cyclooxygenase-1 and 2.
Gallbladder Neoplasms
Co-Expression of Cox-2, C-Met and beta-catenin in Cells Forming Invasive front of Gallbladder Cancer.
Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.
Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population.
Inhibitory effect of meloxicam, a cyclooxygenase-2 inhibitor, on N-nitrosobis (2-oxopropyl) amine induced biliary carcinogenesis in Syrian hamsters.
Oncolytic adenoviral therapy in gallbladder carcinoma.
Role of ErbB2 mediated AKT and MAPK pathway in gall bladder cell proliferation induced by argemone oil and butter yellow : Argemone oil and butter yellow induced gall bladder cell proliferation.
Synthetic pathways of gallbladder mucosal prostanoids: the role of cyclooxygenase-1 and 2.
The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells.
Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice.
Gallstones
Arachidonic acid metabolites in hepatobiliary physiology and disease.
Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.
Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population.
Indomethacin decreases viscosity of gallbladder bile in patients with cholesterol gallstone disease.
Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China.
[The impact of selective cycloxygenase-2 inhibitor celexibo on the formation of cholesterol gallstone]
Ganglion Cysts
Neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) against peripheral nerve transection-induced apoptosis.
The effect of a peripheral block on inflammation-induced prostaglandin E2 and cyclooxygenase expression in rats.
Gastric Outlet Obstruction
[Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions]
Gastrinoma
An immunohistochemical study of cyclooxygenase (COX)-2 expression in endocrine tumors of the pancreas.
Gastritis
4-Vinyl-2,6-dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori-infected carcinogen-treated Mongolian gerbils.
A positive feedback loop between STAT3 and cyclooxygenase-2 gene may contribute to Helicobacter pylori-associated human gastric tumorigenesis.
Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.
Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2.
Anti-Inflammatory Effects of Licania macrocarpa Cuatrec Methanol Extract Target Src- and TAK1-Mediated Pathways.
Assessment of COX-2 expression presence and severity by immunohistochemical method in patients with chronic active gastritis and intestinal metaplasia.
Asymptomatic and symptomatic gastroduodenal patients affected by rheumatic disease treated with non-steroidal anti-inflammatory drugs.
Baicalin protects against ethanol-induced chronic gastritis in rats by inhibiting Akt/NF-?B pathway.
Bile acid induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells.
COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications.
Cross-talk between inducible nitric oxide synthase and cyclooxygenase in Helicobacter-pylori-induced gastritis.
Cutting edge: cyclooxygenase-2 activation suppresses Th1 polarization in response to Helicobacter pylori.
Cyclooxigenase-2 and osteopontin in gastric pre-neoplastic lesions in relation to H-pylori infection and grade of inflammation.
Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa.
Cyclooxygenase-2 expression in chronic gastritis and gastric carcinoma, correlation with prognostic parameters.
Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection.
Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions.
Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.
Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention.
Effect of H. pylori on COX-2 expression in gastric remnant after distal gastrectomy.
Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer.
Effects of cyclooxygenase-2 inhibitor on gastric acid secretion in Helicobacter pylori-infected C57BL/6 mice.
Effects of selective cyclooxygenase-2 inhibitor and non-selective NSAIDs on Helicobacter pylori-induced gastritis in Mongolian gerbils.
Evaluation of specific biochemical indicators of Helicobacter pylori-associated gastric cancer in Egypt.
Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis.
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma.
Expression of COX-2 in Stomach Carcinogenesis.
Expression of cyclooxygenase-2 in gastritis and gastric premalignant lesions.
Gastroprotective effects of the nonsaponin fraction of Korean Red Ginseng through cyclooxygenase-1 upregulation.
Histopathology and expression of Ki-67 and cyclooxygenase-2 in childhood Helicobacter pylori gastritis.
Impact of Cyclooxygenase-2 1195 G-Carrier Genotype Associated with Intestinal Metaplasia and Endoscopic Findings Based on Kyoto Classification.
Implications of corpus gastritis, atrophy and cyclooxygenase in the development of gastric erosions after curing Helicobacter pylori infection.
In vitro evidence of the role of COX-2 in attenuating gastric inflammation and promoting gastric carcinogenesis.
Increase in gastric acid-induced afferent input to the brainstem in mice with gastritis.
Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis.
Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis.
Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.
Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection.
Investigation of anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients.
Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice.
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans.
Methylation status of COX-2 in blood leukocyte DNA and risk of gastric cancer in a high-risk Chinese population.
Monocyte chemoattractant protein 1 (MCP-1) released from Helicobacter pylori stimulated gastric epithelial cells induces cyclooxygenase 2 expression and activation in T cells.
Mucosal expression of cyclooxygenase isoforms 1 and 2 is increased with worsening damage to the gastric mucosa.
Nonsteroidal anti-inflammatory drug-induced acute gastric injury in Helicobacter pylori gastritis in Mongolian gerbils.
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells.
Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model.
Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.
Remnant gastritis should be evaluated histologically rather than endoscopically.
Role of cyclooxygenase-2 functional gene polymorphisms in Helicobacter pylori induced gastritis and gastric atrophy.
Role of cyclooxygenase-2 in Helicobacter pylori- induced gastritis in Mongolian gerbils.
Role of cyclooxygenase-2 in modulating gastric acid secretion in the normal and inflamed rat stomach.
Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Supportive care of elderly patients with cancer.
Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor gamma activation.
The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis.
The role of cyclooxygenase in gastric mucosal protection.
Uncovering the Mechanisms and Molecular Targets of Weibing Formula 1 against Gastritis: Coupling Network Pharmacology with GEO Database.
When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations.
[COX-2 expression in the H. pylori infected gastric mucosal epithelia and its significance]
[Cyclooxygenase activity in chronic gastritis]
[Exploration of the correlation between Chinese medicine syndrome types of verrucous gastritis and the pressions of gastric mucosal hypoxia-inducible factor-1alpha as well as downstream molecules].
[Expression of peroxisome proliferators-activated receptor-gamma and cyclooxygenase-2 in Helicobacter pylori infection-associated diseases and significance thereof]
[Gastric carcinoma and chronic gastritis: epigenetic regulation of CDH1 (E-Cadherin), CDKN2A (p16INK4A), PTGS2 (COX-2) and EGFR genes through methylation]
[Quantification of cyclooxygenase-2 methylation in gastric mucosa by denaturing high performance liquid chromatography assay]
[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
[The change of cyclooxygenase-2 and inducible nitric oxide synthase in the gastric mucosa one year after eradication of Helicobacter pylori]
[The choice of selective COX-2 inhibitors]
Gastritis, Atrophic
Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy.
Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population.
H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis.
In vitro evidence of the role of COX-2 in attenuating gastric inflammation and promoting gastric carcinogenesis.
Methylation status of COX-2 in blood leukocyte DNA and risk of gastric cancer in a high-risk Chinese population.
Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.
Pathogenesis of Helicobacter pylori Infection.
The value of MG7-Ag and COX-2 for predicting malignancy in gastric precancerous lesions.
[Association between promoter methylation of cyclooxygenase-2 and expression, and precancerous gastric lesions in a high-risk population]
[COX-2 expression in the H. pylori infected gastric mucosal epithelia and its significance]
[Expression of peroxisome proliferators-activated receptor-gamma and cyclooxygenase-2 in Helicobacter pylori infection-associated diseases and significance thereof]
Gastroesophageal Reflux
A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients.
Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus.
COX-2 CA-Haplotype Is a Risk Factor for the Development of Esophageal Adenocarcinoma.
COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease.
Esophagoprotective activity of angiotensin-(1-7) in experimental model of acute reflux esophagitis. Evidence for the role of nitric oxide, sensory nerves, hypoxia-inducible factor-1alpha and proinflammatory cytokines.
Gastroesophageal reflux disease (GERD): current agents and future perspective.
Gastroesophageal reflux disease.
Helicobacter pylori and non-malignant diseases.
Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects.
Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus.
Induction of prostaglandin E synthase by gastroesophageal reflux contents in normal esophageal epithelial cells and esophageal cancer cells.
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis.
What is the clinical significance of stromal angiogenesis in Barrett's esophagus?
Gastrointestinal Diseases
Chromatin and DNA methylation dynamics of Helicobacter pylori-induced COX-2 activation.
Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
Digestive Disease Week 2001. COX-2 and gastrointestinal disease. 20-23 May 2001, Atlanta, GA, USA.
Genetic Variants in PTGS1 and NOS3 Genes Increase the Risk of Upper Gastrointestinal Bleeding: A Case-Control Study.
Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.
Nicotine and Gastrointestinal Disorders: Its Role in Ulceration and Cancer Development.
Prostaglandin potentiates 5-HT responses in stomach and ileum innervating visceral afferent sensory neurons.
The iatrogenic costs of NSAID therapy: a population study.
[Expression of COX-1 and COX-2 and gastrointestinal diseases]
[Recent development of selective cyclooxygenase-2 inhibitors]
Gastrointestinal Hemorrhage
Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario.
Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Gastrointestinal Neoplasms
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
A polymorphism in the 3'-utr of cyclooxygenase-2 and the risk of gastric cancer.
Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer.
Association between COX-2 -1195G>A polymorphism and gastrointestinal cancer risk: A meta-analysis.
Association of COX-2 Promoter Polymorphism with Gastrointestinal Tract Cancer in Iran.
Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers.
Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells.
Correlation between cyclooxygenase-2, proliferative activity, and mucin phenotype in human advanced gastric cancer.
Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells.
COX-2 (PTGS2) gene methylation in epithelial, subepithelial lymphocyte and stromal tissue compartments in a spectrum of esophageal squamous neoplasia.
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers.
Cyclooxygenase-2 and gastrointestinal cancer.
Cyclooxygenase-2 expression in human thyroid disease.
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.
Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An update on the molecular mechanisms.
Dietary supplementation with carbonate increases expression of ornithine decarboxylase and proliferation in gastric mucosa in a rat model of gastric cancer.
Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer.
Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines.
Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines.
Expression of cycloxygenase-2 in human bladder and renal cell carcinoma.
Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa.
Immunohistochemical expression of cyclooxygenase-2 in skin cancers.
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
In vitro evidence of the role of COX-2 in attenuating gastric inflammation and promoting gastric carcinogenesis.
Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden.
Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines.
Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells.
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells.
Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.
Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis.
The role of prostaglandins and other eicosanoids in the gastrointestinal tract.
Translational Research in Pancreatic Cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
[Expression and significance of cyclooxygenase-2 in human pancreatic carcinomas]
Gastrointestinal Stromal Tumors
Coexpression of cyclooxygenase-2 and vascular endothelial growth factor in gastrointestinal stromal tumor: possible relations to pathological parameters and clinical behavior.
Cyclooxygenase-2 expression and clinical outcome in gastrointestinal stromal tumors.
Cyclooxygenase-2 expression and connection with tumor recurrence and histopathologic parameters in gastrointestinal stromal tumors.
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.
Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters.
Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors.
Expressions of cyclooxygenase 2 in gastrointestinal stromal tumors.
Gastroparesis
Effects of cyclooxygenase-2 inhibitor on glucagon-induced delayed gastric emptying and gastric dysrhythmia in dogs.
Effects of ketamine/xylazine on expression of tumor necrosis factor-alpha, inducible nitric oxide synthase, and cyclo-oxygenase-2 in rat gastric mucosa during endotoxemia.
Effects of lipopolysaccharide on gastric stasis: role of cyclooxygenase.
Gastroschisis
Celosomy is associated with prenatal exposure to cyclooxygenase inhibitors.
New insights into the obligatory nature of cyclooxygenase-2 and PGE2 during early chick embryogenesis.
Genetic Diseases, Inborn
Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.
Giant Cell Tumor of Bone
[Survivin and COX-2 expressions in giant cell tumor of bone and their relation to the prognosis]
Giant Cell Tumors
[Survivin and COX-2 expressions in giant cell tumor of bone and their relation to the prognosis]
Gingival Overgrowth
Elevated levels of cyclooxygenase 1 and 2 in human cyclosporine induced gingival overgrowth.
Gingivitis
Cox-2 Expression in Gingival Biopsies From Periodontal Patients is Correlated With Connective Tissue Loss.
Cyclooxygenase-2 and matrix metalloproteinase-9 expressions correlate with tissue inflammation degree in periodontal disease.
Flurbiprofen in the prevention and treatment of experimental gingivitis.
Preterm birth and/or low birth weight are associated with periodontal disease and the increased placental immunohistochemical expression of inflammatory markers.
The effect of age on prostaglandin-synthesizing enzymes in the development of gingivitis.
Glaucoma
Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients.
Betalain exerts a protective effect against glaucoma is majorly through the association of inflammatory cytokines.
Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body.
Corneal toxicity from topical ocular and systemic medications.
Cyclooxygenase-1 and cyclooxygenase-2 in the human optic nerve head.
Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.
Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells.
Enhanced expression of cyclooxygenase-2 in glaucomatous dog eyes.
Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes.
Induction of rabbit cyclooxygenase 2 in the anterior uvea following glaucoma filtration surgery.
Pathophysiology of cyclooxygenase inhibition in animal models.
The function of the selective inhibitors of cyclooxygenase 2.
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
Glaucoma, Angle-Closure
Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes.
Glaucoma, Open-Angle
Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body.
Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients.
Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism.
Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinases.
Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure.
R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells.
Glioblastoma
A drug combination targeting hypoxia induced chemoresistance and stemness in glioma cells.
A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells.
Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma.
Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1? and A? between glial and neuron cells.
An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk.
Biological effects of selective COX-2 inhibitor NS398 on human glioblastoma cell lines.
Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines.
Biphasic effects of luteolin on interleukin-1?-induced cyclooxygenase-2 expression in glioblastoma cells.
Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
COX-2 overexpression increases malignant potential of human glioma cells through Id1.
Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro.
Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression.
Cyclooxygenase Inhibition Alters Proliferative, Migratory, and Invasive Properties of Human Glioblastoma Cells In Vitro.
Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma.
Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Cyclooxygenase-2 in glioblastoma multiforme.
Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance.
Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma.
Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines.
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.
Effect of Paracetamol in the Proliferation of Glioblastoma Cell Line: The Role of Apoptosis, COX-2 and Cyclin B Expressions.
Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.
Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.
Expression of prostaglandin H synthase-2 in human brain tumors.
Gemcitabine, vinorelbine and cyclooxygenase inhibitors in the treatment of glioblastoma. Ultrastructural analyses in C6 glioma in vitro.
Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme.
Inducible cyclooxygenase (COX-2) in glioblastoma--clinical and immunohistochemical (COX-2-VEGF) correlations.
Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma.
Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.
Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398.
Methylation of hypoxia-inducible factor (HIF)-1? by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration.
miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2.
Mixed-Generation PAMAM G3-G0 Megamer as a Drug Delivery System for Nimesulide: Antitumor Activity of the Conjugate Against Human Squamous Carcinoma and Glioblastoma Cells.
mRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas.
NFATc1 activation promotes the invasion of U251 human glioblastoma multiforme cells through COX-2.
Olive oil compounds inhibit the paracrine regulation of TNF-?-induced endothelial cell migration through reduced glioblastoma cell cyclooxygenase-2 expression.
Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo.
Permeability of Hypogymnia physodes Extract Component-Physodic Acid through the Blood-Brain Barrier as an Important Argument for Its Anticancer and Neuroprotective Activity within the Central Nervous System.
Prostaglandin E2 Signaling: Alternative Target for Glioblastoma?
Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents.
S1P d20:1, an endogenous modulator of S1P d18:1/S1P2 -dependent signaling.
The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells.
The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells.
The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPAR? Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway.
Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma.
Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation.
Ultrastructural evidence for differentiation in a human glioblastoma cell line treated with inhibitors of eicosanoid metabolism.
[Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors]
Glioma
?-Conotoxins and ?-Cobratoxin Promote, while Lipoxygenase and Cyclooxygenase Inhibitors Suppress the Proliferation of Glioma C6 Cells.
A drug combination targeting hypoxia induced chemoresistance and stemness in glioma cells.
A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells.
Activation of PTGS2/NF-?B signaling pathway enhances radiation resistance of glioma.
Adenosine rescues glioma cells from cytokine-induced death by interfering with the signaling network involved in nitric oxide production.
Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.
Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy.
Aspirin Induced Glioma Apoptosis through Noxa Upregulation.
Association between genetic polymorphisms of PTGS2 and glioma in a Chinese population.
Bee venom suppresses LPS-mediated NO/iNOS induction through inhibition of PKC-alpha expression.
Biological effects of selective COX-2 inhibitor NS398 on human glioblastoma cell lines.
Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells.
Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.
Celecoxib increased expression of 14-3-3sigma and induced apoptosis of glioma cells.
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
COX-2 and c-kit expression in canine gliomas.
COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells.
COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.
COX-2 overexpression increases malignant potential of human glioma cells through Id1.
COX-2 regulates the proliferation of glioma stem like cells.
Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells.
Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro.
Cyclooxygenase in the treatment of glioma: its complex role in signal transduction.
Cyclooxygenase inhibitor induces the upregulation of connexin-43 expression in C6 glioma cells.
Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme.
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.
Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival.
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Cyclooxygenase-2 Induction by Amino Acid Deprivation Requires p38 Mitogen-Activated Protein Kinase in Human Glioma Cells.
Cyclooxygenase-2 inhibitor prevents radiation-enhanced infiltration of F98 glioma cells in brain of Fischer rat.
Cyclooxygenase-2 inhibitors in glioma therapy.
Cyclooxygenase-2 stimulates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG108-15 cells.
Cytosolic and calcium-independent phospholipase A(2) mediate glioma-enhanced proangiogenic activity of brain endothelial cells.
Data supporting the inability of indomethacin to induce autophagy in U251 glioma cells.
Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma.
Differential effects of interferon-gamma on the expression of cyclooxygenase-2 in high-grade human gliomas versus primary astrocytes.
EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.
Elevated cellular PpIX potentiates sonodynamic therapy in a mouse glioma stem cell-bearing glioma model by downregulating the Akt/NF-?B/MDR1 pathway.
Endothelial PKC?-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?
Engineering of clinical glioma treatment: prediction of pro-invasive molecular events in treated gliomas.
Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Ephedorae herba decreases lipopolysaccharide-induced cyclooxgenase-2 protein expression and NF-kappaB-dependent transcription in C6 rat glioma cells.
Epidermal growth factor-dependent cyclooxygenase-2 induction in gliomas requires protein kinase C-delta.
Ethanol extract of Lycopodium serratum Thunb. Attenuates lipopolysaccharide-induced C6 glioma cells migration via matrix metalloproteinase-9 expression.
Evaluation of human glioma using in-vivo proton magnetic resonance spectroscopy combined with expression of cyclooxygenase-2: a preliminary clinical trial.
Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy.
Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas.
Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo.
Expression of prostaglandin H synthase-2 in human brain tumors.
Expression of RhoA and COX-2 and their roles in the occurrence and progression of brain glioma.
gamma-Mangostin inhibits inhibitor-kappaB kinase activity and decreases lipopolysaccharide-induced cyclooxygenase-2 gene expression in C6 rat glioma cells.
Garcinone B reduces prostaglandin E2 release and NF-kappaB-mediated transcription in C6 rat glioma cells.
Gemcitabine, vinorelbine and cyclooxygenase inhibitors in the treatment of glioblastoma. Ultrastructural analyses in C6 glioma in vitro.
Glioma growth inhibition by selective COX-2 inhibitors via cyclooxygenase independent pathways: implications for therapy.
Glioma-secreted soluble factors stimulate microglial activation: The role of interleukin-1? and tumor necrosis factor-?.
HGF/MET signaling promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production.
In vitro effects of anandamide and prostamide e2 on normal and transformed nerve cells.
Indomethacin based new triazolothiadiazine derivatives: Synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies.
Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma.
Induction of cyclooxygenase-2 expression by interleukin-1beta in human glioma cell line, U87MG.
Induction of macrophagic prostaglandin E2 synthesis by glioma cells.
Induction of prostaglandin E2 synthesis and microsomal prostaglandin E synthase-1 expression in murine microglia by glioma-derived soluble factors. Laboratory investigation.
Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1.
Inhibition of cyclooxygenase and prostaglandin E2 synthesis by gamma-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells.
Inhibition of Glioblastoma Cell Growth In Vitro and In Vivo by Brucine, a Component of Chinese Medicine.
Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089.
Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Integration of epidemiology, immunobiology, and translational research for brain tumors.
Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib.
Isoalantolactone inhibits IKK? kinase activity to interrupt the NF-?B/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin in glioblastoma.
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Mechanisms of immune evasion by gliomas.
Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation.
MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression.
MicroRNA-128 inhibits proliferation and invasion of glioma cells by targeting COX-2.
Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A.
Midkine promoter-based conditionally replicative adenovirus for malignant glioma therapy.
miR-101 inhibits glioma cell invasion via the downregulation of COX-2.
miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2.
MiR-26b Mimic Inhibits Glioma Proliferation In Vitro and In Vivo Suppressing COX-2 Expression.
mRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas.
Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells.
Overexpression of S100A9 in human glioma and in-vitro inhibition by aspirin.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo.
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Plausible role of naringenin against cerebrally implanted C6 glioma cells in rats.
Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
Production of soluble autocrine inhibitory factors by human glioma cell lines.
Protective effect of verbascoside in activated C6 glioma cells: possible molecular mechanisms.
Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration.
Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells.
Resveratrol inhibits glioma cell growth via targeting oncogenic microRNAs and multiple signaling pathways.
Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells.
Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP.
Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.
Snail and Cox-2 expressions are associated with WHO tumor grade and survival rate of patients with gliomas.
Taurine chloramine inhibits production of nitric oxide and prostaglandin E2 in activated C6 glioma cells by suppressing inducible nitric oxide synthase and cyclooxygenase-2 expression.
The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells.
The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPAR? Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
The eicosanoid cascade: possible role in gliomas and meningiomas.
The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway.
The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas.
Transcription Factor Interactions Mediate EGF-Dependent COX-2 Expression.
Transcriptional and translational regulation of COX-2 expression by cadmium in C6 glioma cells.
Transcriptional regulation of cyclooxygenase-1 by histone deacetylase inhibitors in normal human astrocyte cells.
Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4.
Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells.
Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma.
[Inhibiting cerebral glioma growth with continuous low-dose chemotherapy and cyclooxygenase-2 inhibitor in nude mice]
[MiR-26b inhibits proliferation, invasion, and migration of glioma by targeting cyclooxygenase-2].
Glioma, Subependymal
Expression of cyclo-oxygenase-2 in ependymal tumors.
Gliosarcoma
A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas.
Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma.
Glomerulonephritis
CCAAT/enhancer-binding protein-delta is induced in mesangial area during the early stages of anti-Thy1.1 glomerulonephritis and regulates cell proliferation and inflammatory gene expression in cultured rat mesangial cells.
COX-2 dependent PGE(2) downregulates alpha(v) integrin expression via the EP(3) receptor in cultured mesangial cells.
Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis.
Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury.
Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis.
Paradoxical exacerbation of leukocyte-mediated glomerulonephritis with cyclooxygenase inhibition.
Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis.
Regulatory effects of inducible nitric oxide synthase on cyclooxygenase-2 and heme oxygenase-1 expression in experimental glomerulonephritis.
Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis.
Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.
The effect of renal administration of a selective cyclooxygenase-2 inhibitor or stable prostaglandin I(2) analog on the progression of sclerotic glomerulonephritis in rats.
Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis.
Glomerulonephritis, IGA
Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study.
Role of cyclooxygenase-2 in deoxynivalenol-induced immunoglobulin a nephropathy.
Small bowel cyclooxygenase 2 (COX-2) expression in patients with IgA nephropathy.
Glomerulonephritis, Membranous
Analysis of renal immunoexpression of cyclooxygenase-1 and cyclooxygenase-2 in lupus and nonlupus membranous glomerulopathy.
Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis.
Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat.
Enhanced glomerular prostaglandin formation in experimental membranous nephropathy.
Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib.
Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.
Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.
Glomerulosclerosis, Focal Segmental
Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum.
Osthole improves an accelerated focal segmental glomerulosclerosis model in the early stage by activating the Nrf2 antioxidant pathway and subsequently inhibiting NF-?B-mediated COX-2 expression and apoptosis.
Glomus Tumor
Immunohistochemical demonstration of cyclooxygenase-2 in glomus tumors.
Glucose Intolerance
Glucocorticoids use in kidney transplant setting.
Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
Metabolic syndrome exacerbates amyloid pathology in a comorbid Alzheimer's mouse model.
Goiter
Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis.
Goiter, Nodular
Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma.
Gout
A survey on the management of gout in Malaysia.
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Decrystallization of Crystals Using Gold "Nano-Bullets" and the Metal-Assisted and Microwave-Accelerated Decrystallization Technique.
Dosing of Antirheumatic Drugs in Renal Disease and Dialysis.
Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-? and COX-2.
Formulation and evaluation of mouth dissolving tablets of the Etoricoxib.
Indomethacin-induced azotaemia and hyperkalaemia: a case study.
Nonsteroidal anti-inflammatory drugs for treatment of acute gout.
Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch.
Significance of Serum Markers and Urinary Microalbumin in the Diagnosis of Early Renal Damage in Patients with Gout.
Virtual and In vitro bioassay screening of phytochemical inhibitors from flavonoids and isoflavones against Xanthine oxidase and Cyclooxygenase-2 for gout treatment.
Virtual and In Vitro Bioassay Screening of Phytochemical Inhibitors from Flavonoids and Isoflavones Against Xanthine Oxidase and Cyclooxygenase-2 for Gout Treatment.
[Inhibiting cyclooxygenase and 5-lipoxygenase activities is an anti-inflammatory mechanism of Huzhang Gout Granule.]
Granuloma
Absence of circulating aldosterone attenuates foreign body reaction around surgical sutures.
Anti-inflammatory and antioxidant activities of the methanol extract of Gynura segetum leaf.
Aryl/heteroaryl substituted celecoxib derivatives as COX-2 inhibitors: Synthesis, anti-inflammatory activity and molecular docking studies.
Assessment of clinicopathological characteristics and immunoexpression of COX-2 and IL-10 in oral pyogenic granuloma.
Bis basic substituted diaminobenzobisthiazoles as potential antiarthritic agents.
Curcumin potentiates the anti-inflammatory activity of cyclooxygenase inhibitors in the cotton pellet granuloma pouch model.
Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants.
Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidine derivatives bearing thiazolidinone moiety as anti-inflammatory agents.
Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation.
Evaluation of anti-inflammatory, analgesic activities, and side effects of some pyrazole derivatives.
Focal accumulation of cyclooxygenase-1 (COX-1) and COX-2 expressing cells in cerebral malaria.
Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis.
Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation.
Pharmacological properties of the antiinflammatory agent 10-methylamine-11-H-indeno-[1,2-b]quinolin-11-one (MB432).
Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis.
Role of lipoxygenase products in murine pulmonary granuloma formation.
Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants.
The flavonoid-enriched extract from the root of Smilax china L. inhibits inflammatory responses via the TLR-4-mediated signaling pathway.
[Comparison of the pharmacologic effect of diacerein and a selective COX-2 inhibitor in the mouse induced-granuloma model]
[Endogenous prostaglandins and angiogenesis]
[Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors]
Granulomatous Disease, Chronic
Toxoplasma gondii alters eicosanoid release by human mononuclear phagocytes: role of leukotrienes in interferon gamma-induced antitoxoplasma activity.
Granulosa Cell Tumor
COX-2 expression in nonepithelial ovarian malignancies.
Graves Disease
Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on Ophthalmopathy and Antibody Concentrations.
Immunohistochemical expression of COX-2 in thyroid nodules.
Graves Ophthalmopathy
Celecoxib and Pioglitazone as Potential Therapeutics for Regulating TGF-?-Induced Hyaluronan in Dysthyroid Myopathy.
Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy.
Hyaluronic acid induces COX-2 expression via CD44 in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.
Improvement of thyroid eye disease following treatment with the cyclooxygenase-2 selective inhibitor celecoxib.
Pirfenidone attenuates IL-1?-induced COX-2 and PGE2 production in orbital fibroblasts through suppression of NF-?B activity.
Guillain-Barre Syndrome
New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis.
Gynecomastia
Possible involvement of aromatase overexpression induced by cyclo-oxygenase-2 in the pathogenesis of idiopathic gynecomastia.
Hamartoma
Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas.
Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.
Molecular insights into Peutz-Jeghers syndrome: two probands with a germline mutation of LKB1.
Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers syndrome.
Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas.
Hand-Foot Syndrome
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Hashimoto Disease
Assessment of cyclooxygenase-1 and 2 gene expression levels in chronic autoimmune thyroiditis, papillary thyroid carcinoma and nontoxic nodular goitre.
Head and Neck Neoplasms
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis.
COX-2 expression in dysplasia of the head and neck: correlation with elF4E.
COX-2 polymorphisms and the risk for head and neck cancer in white patients.
Cyclooxygenase isozymes in oral squamous cell carcinoma:a real-time RT-PCR study with clinic pathological correlations.
Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma.
Cyclooxygenase-2 inhibitor and cisplatin combination as a radiosensitizer in the treatment of head and neck cancer patients.
Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.
Emerging drugs for head and neck cancer.
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.
Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study.
Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco.
Genetic polymorphisms in the prostaglandin pathway genes and risk of head and neck cancer.
Head and neck cancer recurrence and mortality in nonselective cyclooxygenase inhibitor users.
Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.
Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.
In vitro growth inhibition by indomethacin on human oral squamous cell carcinoma lines synergistically suppressed by all-trans retinoic acid correlating to apoptosis.
Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein.
Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer.
Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.
Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer.
Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer.
Low COX2 in tumor and upregulation in stroma mark laryngeal squamous cell carcinoma progression.
Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer.
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis.
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
Prognostic significance of cyclooxygenase-2 overexpression in glottic cancer.
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Prostaglandins in carcinomas of the head and neck.
Recurrent respiratory papillomatosis: update 2008.
Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: A pilot randomized trial in head and neck cancer.
Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer.
The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers.
The effect of nimesulide, a selective cyclooxygenase-2 inhibitor, on Ets-1 and Ets-2 expression in head and neck cancer cell lines.
The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines.
The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
Wnt signaling controls radiosensitivity via cyclooxygenase-2-mediated Ku expression in head and neck cancer.
Head Injuries, Closed
Effects of selective and non-selective cyclooxygenase inhibition against neurological deficit and brain oedema following closed head injury in mice.
Inhibition of cyclooxygenase 2 by nimesulide decreases prostaglandin E2 formation but does not alter brain edema or clinical recovery after closed head injury in rats.
Headache Disorders
Low concentrations of lithium and cyclooxygenase inhibitors enhance endothelin-1 (ET-1)-induced contractions in human temporal artery, but not in porcine ophthalmic artery.
Headache Disorders, Primary
COX-2 inhibitor for the treatment of idiopathic stabbing headache secondary to cerebrovascular diseases.
Primary stabbing headache can be responsive to etoricoxib, a selective COX-2 inhibitor.
Hearing Loss
Assessment of the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 inhibitor, in rats.
Cyclo-oxygenase enzyme in the perilymph of human inner ear.
Influence of Ginkgo Biloba extract (EGb 761) on expression of IL-1 Beta, IL-6, TNF-alfa, HSP-70, HSF-1 and COX-2 after noise exposure in the rat cochlea.
Salicylate, mefenamate, meclofenamate, and quinine on cochlear potentials.
The effect of celecoxib, a cyclooxygenase-2 inhibitor on noise- induced hearing loss.
Hearing Loss, Noise-Induced
Inhibition of cyclooxygenase-2 by NS398 attenuates noise-induced hearing loss in mice.
Resveratrol Decreases Noise-Induced Cyclooxygenase-2 Expression in the Rat Cochlea.
Heart Arrest
Cyclooxygenase inhibition prior to ventricular fibrillation induced ischemia reperfusion injury impairs survival and outcomes.
Vascular changes after cardiopulmonary bypass and ischemic cardiac arrest: roles of nitric oxide synthase and cyclooxygenase.
Heart Defects, Congenital
Ductus-dependent fetal cardiac defects contraindicate indomethacin tocolysis.
Heart Diseases
By the way, doctor. I'm confused. I've read your articles about heart disease being caused by inflammation. If the COX-2 drugs are anti-inflammatory, why do they seem to make heart disease worse, not better?
Clinical pharmacology of etoricoxib.
Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
Cyclooxygenase-2 in Endothelial and Vascular Smooth Muscle Cells Restrains Atherogenesis in Hyperlipidemic Mice.
Cyclooxygenase-2 in human pathological disease.
Effect of dietary n-3 fatty acids on cerebral microcirculation.
gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells.
Getting to the heart of COX-2 inhibition.
Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease.
Medicine. Estrogen's ties to COX-2 may explain heart disease gender gap.
Prostacyclin in the cardiovascular system: new aspects and open questions.
The role of COX-2 in heart pathology.
Thromboxane A2 Generation, in the Absence of Platelet COX-1 Activity, in Patients With and Without Atherothrombotic Myocardial Infarction.
[Risk factor assessment of cardiocerebrovascular diseases in patients with rheumatoid arthritis]
[Safe use of non-steroidal anti-inflammatory drugs]
Heart Failure
2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation.
A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems.
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function.
Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Cardiovascular risk, hypertension, and NSAIDs.
Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use.
Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice.
Coronary and cardiac sensitivity to the vasoselective benzothiazepine-like calcium antagonist, clentiazem, in experimental heart failure.
Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients?
COX-2 inhibitors and risk of heart failure.
COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
Cyclooxygenase products sensitize muscle mechanoreceptors in humans with heart failure.
Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor.
Cyclooxygenase-2 and nuclear factor-kappaB in myocardium of end stage human heart failure.
Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome.
Cyclooxygenase-2 induction in congestive heart failure: friend or foe?
Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure.
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?
Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure.
Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with Enalapril. Ifetroban Study Group.
Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
Eicosanoid profiling in effluent of isolated perfused heart of Tg?q*44 mice with advanced heart failure.
Emotion recollected in tranquility: lessons learned from the COX-2 saga.
Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy.
GEO Data Sets Analysis Identifies COX-2 and Its Related Micro RNAs as Biomarkers for Non-Ischemic Heart Failure.
Heart failure induced by non-cardiac drugs.
Impaired coronary sensitivity to diltiazem in experimental heart failure: involvement of the cyclooxygenase but not the nitric oxide-synthase pathway.
Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: role of nuclear factor kappaB.
Indomethacin-induced azotaemia and hyperkalaemia: a case study.
Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.
Induction of HO-1 by carbon monoxide releasing molecule-2 attenuates thrombin-induced COX-2 expression and hypertrophy in primary human cardiomyocytes.
Inhibition of cyclooxygenase-2 reduces hypothalamic excitation in rats with adriamycin-induced heart failure.
Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice.
Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure.
Mechanism of QSYQ on anti-apoptosis mediated by different subtypes of cyclooxygenase in AMI induced heart failure rats.
Metabo and mechanoreceptor expression in human heart failure: relationships with the locomotor muscle afferent influence on exercise responses.
Molecular basis for the improvement in muscle metaboreflex and mechanoreflex control in exercise-trained humans with chronic heart failure.
Myocardial reactive hyperemia in experimental chronic heart failure: evidence for the role of K+ adenosine triphosphate-dependent channels and cyclooxygenase activity.
Nimesulide: some pharmaceutical and pharmacological aspects--an update.
No effect of endoperoxide 4 or thromboxane A2 receptor blockade on static mechanoreflex activation in rats with heart failure.
Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials.
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Nonsteroidal anti-inflammatory drugs and heart failure.
Nonsteroidal Anti-Inflammatory Drugs and Risk of First Hospitalization for Heart Failure in Patients with No History of Heart Failure: A Population-Based Case-Crossover Study.
Pharmacotherapy in congestive heart failure: COX-2 inhibition: a cautionary note in congestive heart failure.
Prescription painkillers linked to greater risk of heart failure.
Raging the War Against Inflammation With Natural Products.
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure.
Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications.
Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
Roles of cyclooxygenase-2 and phosphorylated Akt (Thr308) in cardiac hypertrophy regression mediated by left-ventricular unloading.
Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.
TCDD-induced chick cardiotoxicity is abolished by a selective cyclooxygenase-2 (COX-2) inhibitor NS398.
The contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failure.
The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury.
The translational therapeutics of prostaglandin inhibition in atherothrombosis.
The use of NSAIDs in rheumatic disorders 2005: a global perspective.
Three-dimensional structure of human cyclooxygenase (hCOX)-1.
Update on guidelines for the treatment of chronic musculoskeletal pain.
Upregulation of COX-2 and PGE2 Induced by TNF-? Mediated Through TNFR1/MitoROS/PKC?/P38 MAPK, JNK1/2/FoxO1 Cascade in Human Cardiac Fibroblasts.
Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.
Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
Worsening heart failure associated with COX-2 inhibitors.
[Association between non-steroid antiinflammatory drugs intake and decompensation of heart failure]
[Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]
[Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects]
[Renin, aldosterone and prostaglandins in heart failure]
[Research advances of prostaglandin E2 synthases and receptors in cardiovascular diseases].
[Risk factor assessment of cardiocerebrovascular diseases in patients with rheumatoid arthritis]
[Role of prostaglandins in regulation of kidney function in heart failure]
Heart Neoplasms
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus.
Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia.
Heart Septal Defects, Ventricular
Combined treatment potentiates the developmental toxicity of ibuprofen and acetazolamide in rats.
Congenital ventricular septal defects and prenatal exposure to cyclooxygenase inhibitors.
Heart Valve Diseases
Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.
Helicobacter Infections
Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-alpha-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice.
Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model.
Hemangioma
Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma.
Hemangioma, Capillary
CD105 expression in oral capillary hemangiomas and cavernous hemangiomas.
Hemangioma, Cavernous
CD105 expression in oral capillary hemangiomas and cavernous hemangiomas.
Hemangiosarcoma
Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor.
Hematologic Neoplasms
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.
Cyclooxygenase-2 in oncogenesis.
Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents.
Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma.
Leukemic cells modulate induction of COX-2 in human stromal fibroblasts.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.
The cyclooxygenase-2/prostaglandin E2 pathway and its role in the pathogenesis of human and dog hematological malignancies.
The emerging role of angiogenesis inhibitors in hematologic malignancies.
The influence of Cox-2 and bioactive lipids on hematological cancers.
The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.
[Effect of As(2)O(3) on Expressions of COX-2 and Matrix Metalloproteinases in SGC7901 and K562 Cells.]
Hematoma, Subdural, Chronic
Possible role of cyclooxygenase-2 in developing chronic subdural hematoma.
Hematuria
Association of renal papillary necrosis and ankylosing spondylitis.
Cyclooxygenase-1 and -2 expression in urothelial carcinomas of the urinary bladder in cows.
Scutellaria baicalensis alleviates cantharidin-induced rat hemorrhagic cystitis through inhibition of cyclooxygenase-2 overexpression.
Small bowel cyclooxygenase 2 (COX-2) expression in patients with IgA nephropathy.
Hemophilia A
Is the cardiovascular toxicity of NSAIDS and COX-2 selective inhibitors underestimated in patients with haemophilia?
Pain management in people with hemophilia in childhood and young adulthood.
Rofecoxib as adjunctive therapy for haemophilic arthropathy.
Hemorrhagic Stroke
Pharmacological brain cooling with indomethacin in acute hemorrhagic stroke: antiinflammatory cytokines and antioxidative effects.
Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study.
Significance of cyclooxygenase-2 elevation in middle cerebral artery for patients with hemorrhagic moyamoya disease.
Hepatic Encephalopathy
Lack of detrimental or therapeutic effects of cyclooxygenase inhibition in bile duct-ligated rats with hepatic encephalopathy.
Selective cyclooxygenase inhibition improves hepatic encephalopathy in fulminant hepatic failure of rat.
Hepatic Insufficiency
Pharmacokinetics of etoricoxib in patients with hepatic impairment.
Hepatitis
A Network Pharmacology Study of the Molecular Mechanisms of Hypericum japonicum in the Treatment of Cholestatic Hepatitis with Validation in an Alpha-Naphthylisothiocyanate (ANIT) Hepatotoxicity Rat Model.
A novel biologically active seleno-organic compound--VI. Protection by ebselen (PZ 51) against galactosamine/endotoxin-induced hepatitis in mice.
Acute cholestatic hepatitis associated with celecoxib.
Chronic exposure of nanomolar MC-LR caused oxidative stress and inflammatory responses in HepG2 cells.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclooxygenase activity is important for efficient replication of mouse hepatitis virus at an early stage of infection.
Cyclooxygenase-2 -765 G/C polymorphisms and susceptibility to hepatitis B-related liver cancer in Han Chinese population.
Cyclooxygenase-2 and inducible nitric oxide synthase in omental arteries harvested from patients with severe liver diseases: immuno-localization and influence on vascular tone.
Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma.
Cyclooxygenase-2 promoter polymorphism -899G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province.
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Effect of dietary alpha-linolenate/linoleate balance on endotoxin-induced hepatitis in mice.
Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice.
Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis.
Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.
Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis.
Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence.
Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients.
Theoretical basis of a beneficial role for vitamin D in viral hepatitis.
Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.
[Cholestatic hepatitis associated with nimesulide--a case report]
[Relationship between cyclooxysenase 2 and serious hepatitis].
[Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases]
Hepatitis B
COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis.
Cyclooxygenase-2 -765 G/C polymorphisms and susceptibility to hepatitis B-related liver cancer in Han Chinese population.
Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Endoplasmic Reticulum stress induced by Hepatitis B virus X protein enhances cyclooxygenase 2 expression via activating transcription factor-4.
Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase.
Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy.
Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2.
HBx targeting to mitochondria and ROS generation are necessary but insufficient for HBV-induced cyclooxygenase-2 expression.
Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2.
Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma.
Induction of Cyclooxygenase-2 Expression by Hepatitis B Virus Depends on Demethylation-associated Recruitment of Transcription Factors to the Promoter.
Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival.
Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.
Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkappaB pathway in a human monocytic cell line, THP-1.
The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression.
[COX-2 as an early diagnostic marker of virus-associated human malignant neoplasms].
[Expression of COX-2 and PPARr in the livers of patients with acute on chronic HBV-related liver failure and their relationship with clinic parameters].
[The expression of hepatitis B virus X protein and cyclooxygenase-2 in hepatitis B virus-related hepatocellular carcinoma: correlation with microangiogenesis and metastasis, and what is the possible mechanism].
Hepatitis B, Chronic
Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance.
Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment.
Cyclooxygenase-2 promoter polymorphism -899G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province.
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy.
Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2.
Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis.
Hepatitis C
Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways.
Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560.
Aqueous Extract of the Edible Gracilaria tenuistipitata Inhibits Hepatitis C Viral Replication via Cyclooxygenase-2 Suppression and Reduces Virus-Induced Inflammation.
Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases.
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment.
Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents.
Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression.
Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.
Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-?B signal cascade.
Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication.
Hepatotoxicity associated with non-steroidal anti-inflammatory drugs.
Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.
Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.
Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins.
Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival.
Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression.
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
New 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides inhibit hepatitis C virus replication via suppression of cyclooxygenase-2.
NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways.
Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma.
Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients.
Plasmon-waveguide resonance spectroscopy applied to three potential drug targets: cyclooxygenase-2, hepatitis C virus RNA polymerase and integrin alpha V beta 3.
San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression.
[The effect of HCV core protein on the expression of cyclooxygenase 2 (COX-2) in HepG2 cells]
Hepatitis C, Chronic
Cyclo-oxygenase 2 expression impairs serum-withdrawal-induced apoptosis in liver cells.
Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment.
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.
Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins.
Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study.
Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C.
[Treatment of chronic virus hepatitis with acetylsalicylic acid]
Hepatitis, Alcoholic
Role of Kupffer cells in alcoholic hepatitis.
Hepatitis, Chronic
COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis.
Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study .
Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States.
Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma.
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Expression of cyclooxygenase 2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis.
Expression of cyclooxygenase mRNA in the livers of mice with interferon-gamma chronic hepatitis.
Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.
Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis.
The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis.
[The Expressions of Somatostatin and Cycloxygenase-2 in Chronic Hepatitis, Hepatic Cirrhosis, Precancerous Lesion and Hepatocellular Carcinoma].
Hepatopulmonary Syndrome
Cyclooxygenase-2 promotes pulmonary intravascular macrophage accumulation by exacerbating BMP signaling in rat experimental hepatopulmonary syndrome.
Roles of cyclooxygenase 2 and hepatic venous flow in patients with HHT or hepatopulmonary syndrome.
Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.
Hepatorenal Syndrome
Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome.
Herpes Genitalis
Failure of ibuprofen in treatment of herpes genitalis.
Herpes Simplex
Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer.
Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus.
Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells.
Immunomodulation of cellular cytotoxicity to herpes simplex virus infection in pregnancy by inhibition of eicosanoid metabolism.
Indomethacin enhancement of human natural killer cytotoxicity to herpes simplex virus infected cells in vitro and in vivo.
Induction of cellular functions in spontaneously immortalized rat-2 cells transfected with cloned herpes simplex virus type 2 (HSV-2) DNA.
Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex virus type 1 reactivation.
Inhibition of TNFalpha-induced iNOS expression in HSV-tk transduced 9L glioblastoma cell lines by Marasmius oreades substances through NF-kappaB- and MAPK-dependent mechanisms.
Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma.
Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking.
Studies of phospholipase and cyclooxygenase activities in herpes simplex virus type 2-transformed rat cells.
Suppression of herpes simplex virus 1 reactivation in a mouse eye model by cyclooxygenase inhibitor, heat shock protein inhibitor, and adenosine monophosphate.
The involvement of nuclear factor-kappa B in cyclooxygenase-2 overexpression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene.
The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections.
[Experimental study of suppression of reactivation of herpes simplex virus type 1 by cyclooxygenase 2 inhibitor with acyclovir]
Herpes Zoster
Characterization and application of Raman labels for confocal Raman microspectroscopic detection of cellular proteins in single cells.
Role of arachidonic acid metabolism in ACTH-stimulated cortisol secretion by bovine adrenocortical cells.
Trace amounts of antibiotic exacerbated diarrhea and systemic inflammation of weaned pigs infected with a pathogenic Escherichia coli.
Vanillin protects the blood-milk barrier and inhibits the inflammatory response in LPS-induced mastitis in mice.
Herpesviridae Infections
Biological interactions between herpesviruses and cyclooxygenase enzymes.
Evidence of COX-1 and COX-2 expression in Kaposi's sarcoma tissues.
Gamma-herpesvirus neoplasia: a growing role for COX-2.
Histiocytic Sarcoma
Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor.
Histiocytoma, Benign Fibrous
Cyclooxygenase-2 expression in dermatofibroma and dermatofibrosarcoma protuberans.
Histiocytoma, Malignant Fibrous
A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line.
Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase.
HIV Infections
A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.
An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.
ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV.
Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
Induction of cyclooxygenase-2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions.
Hodgkin Disease
Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark.
Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma.
Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma.
Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: a retrospective study.
Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD.
Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis.
Expression of prostaglandin H synthase (cyclooxygenase) in Hodgkin's mononuclear and Reed-Sternberg cells. Functional resemblance between H-RS cells and histiocytes or interdigitating reticulum cells.
Normalization of monocyte candidacidal deficiency by cyclooxygenase inhibitors in Hodgkin's disease.
Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma.
Radiation Therapy Overcomes Adverse Prognostic Role of Cyclooxygenase-2 Expression on Reed-Sternberg Cells in Early Hodgkin Lymphoma.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
[Expression and prognostic value of COX- 2, p16(INK4A) and p53 in patients with classical Hodgkin lymphoma].
Huntington Disease
Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms.
Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.
Hydrocephalus
Cyclooxygenase-2 Inhibition Provides Lasting Protection Following Germinal Matrix Hemorrhage in Premature Infant Rats.
Temporal profile of serum mitochondrial DNA (mtDNA) in patients with aneurysmal subarachnoid hemorrhage (aSAH).
Hydronephrosis
A mouse strain less responsive to dioxin-induced prostaglandin e2 synthesis is resistant to the onset of neonatal hydronephrosis.
Analyses of renal medullary lipid droplets from normal, hydronephrotic, and indomethacin treated rabbits.
Critical role of cyclooxygenase-2 activation in pathogenesis of hydronephrosis caused by lactational exposure of mice to dioxin.
Eicosanoid synthesis by rabbit hydronephrotic cortical interstitial cells in culture.
Predominant role of cytosolic phospholipase A2? in dioxin-induced neonatal hydronephrosis in mice.
Renal cortical drug and xenobiotic metabolism following urinary tract obstruction.
Severe toxicity and cyclooxygenase (COX)-2 mRNA increase by lithium in the neonatal mouse kidney.
TCDD-induced cyclooxygenase-2 expression is mediated by the nongenomic pathway in mouse MMDD1 macula densa cells and kidneys.
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Hydrops Fetalis
Doppler echocardiography in the human fetus.
Ductus-dependent fetal cardiac defects contraindicate indomethacin tocolysis.
Hyperaldosteronism
Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
[Treatment of congenital chloride diarrhea with prostaglandin synthetase inhibitor (author's transl)]
Hyperalgesia
5-HT acts on nociceptive primary afferents through an indirect mechanism to induce hyperalgesia in the subcutaneous tissue.
Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products.
An opioid receptor-independent mechanism underlies motility dysfunction and visceral hyperalgesia in opioid-induced bowel dysfunction.
Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
Analysis of interaction between etoricoxib and tramadol against mechanical hyperalgesia of spinal cord injury in rats.
Analysis of prostaglandin G/H synthase-2 inhibition using peroxidase-induced luminol luminescence.
Anti-allodynic effects of oral COX-2 selective inhibitor on postoperative pain in the rat.
Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.
Anti-inflammatory effect of licofelone against various inflammatory challenges.
Antinociceptive effect of resveratrol in carrageenan-evoked hyperalgesia in rats: prolonged effect related to COX-2 expression impairment.
Antinociceptive Effect of Tetrandrine on LPS-Induced Hyperalgesia via the Inhibition of IKK? Phosphorylation and the COX-2/PGE2 Pathway in Mice.
Articular inflammation induced by an enzymatically-inactive Lys49 phospholipase A
BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
Beta-estradiol induced catecholamine-sensitive hyperalgesia: a contribution to pain in Raynaud's phenomenon.
Bradykinin and interleukin-1? synergistically increase the expression of cyclooxygenase-2 through the RNA-binding protein HuR in rat dorsal root ganglion cells.
Bradykinin into amygdala induces thermal hyperalgesia in rats.
Bradykinin receptor antagonists and cyclooxygenase inhibitors in vincristine- and streptozotocin-induced hyperalgesia.
Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia.
Capnellene, a natural marine compound derived from soft coral, attenuates chronic constriction injury-induced neuropathic pain in rats.
Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord.
Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1.
Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1/2 signaling.
Central cyclooxygenase inhibitors reduced IL-1beta-induced hyperalgesia in temporomandibular joint of freely moving rats.
Central cyclooxygenase-2 participates in interleukin-1 beta-induced hyperalgesia in the orofacial formalin test of freely moving rats.
Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2.
Co-induction of cyclooxyenase-2 and early growth response gene (Egr-1) in spinal cord in a clinical model of persistent inflammation and hyperalgesia.
Consequences of altered eicosanoid patterns for nociceptive processing in mPGES-1-deficient mice.
Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia.
Contribution of large-sized primary sensory neuronal sensitization to mechanical allodynia by upregulation of hyperpolarization-activated cyclic nucleotide gated channels via cyclooxygenase 1 cascade.
Corrigendum to 'Role of spinal cyclooxygenase-2 and prostaglandin E2 in fentanyl-induced hyperalgesia in rats' (Br J Anaesth 2018; 120: 827-35).
COX-1-dependent prostaglandin D2 in microglia contributes to neuropathic pain via DP2 receptor in spinal neurons.
COX-2 contributed to the remifentanil-induced hyperalgesia related to ephrinB/EphB signaling.
COX-2 expression and function in the hyperalgesic response to paw inflammation in mice.
COX-2 inhibitor prevents the development of hyperalgesia induced by intrathecal NMDA or AMPA.
COX-2 is required for the modulation of spinal nociceptive information related to ephrinB/EphB signalling.
Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain.
Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury.
Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.
Cyclooxygenase inhibitors and thalidomide ameliorate vincristine-induced hyperalgesia in rats.
Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats.
Cyclooxygenase Isoform Exchange Blocks Brain-Mediated Inflammatory Symptoms.
Cyclooxygenase-1 in the spinal cord plays an important role in postoperative pain.
Cyclooxygenase-2 inhibition potentiates morphine antinociception at the spinal level in a postoperative pain model.
Cyclooxygenase-2 inhibitor SC-236 attenuates mechanical allodynia following nerve root injury in rats.
Cyclooxygenase-2 is induced in the endothelial cells throughout the central nervous system during carrageenan-induced hind paw inflammation; its possible role in hyperalgesia.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity.
Cyclooxygenases in the skin: pharmacological and toxicological implications.
Development of an Experimental Animal Model for Lower Back Pain by Percutaneous Injury-Induced Lumbar Facet Joint Osteoarthritis.
Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.
Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil.
Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation.
Dragon's blood inhibits chronic inflammatory and neuropathic pain responses by blocking the synthesis and release of substance P in rats.
Dragon's Blood Inhibits Chronic Inflammatory and Neuropathic Pain Responses by Blocking the Synthesis and Release of Substance P in Rats.
Effect of colchicine on nerve growth factor-induced leukocyte accumulation and thermal hyperalgesia in the rat.
Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats.
Effect of cyclooxygenase and nitric oxide synthase inhibitors on streptozotocin-induced hyperalgesia in rats.
Effect of cyclooxygenase and nitric oxide synthase inhibitors on vincristine induced hyperalgesia in rats.
Effect of endotoxin treatment on the expression and localization of spinal cyclooxygenase, prostaglandin synthases, and PGD2 receptors.
Effect of selective inhibition of cyclooxygenase-2 on lipopolysaccharide-induced hyperalgesia.
Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: a randomized controlled trial in healthy volunteers [ISRCTN05282752,NCT00260325].
Effect of zileuton in radicular pain induced by herniated nucleus pulposus in rats.
Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans.
Effects of Extract of Arrabidaea chica Verlot on an Experimental Model of Osteoarthritis.
Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail.
Electroacupuncture inhibits inflammatory edema and hyperalgesia through regulation of cyclooxygenase synthesis in both peripheral and central nociceptive sites.
Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats.
Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan.
EP2 receptor plays pivotal roles in generating mechanical hyperalgesia after lengthening contractions.
Epidural injection of cyclooxygenase-2 inhibitor attenuates pain-related behavior following application of nucleus pulposus to the nerve root in the rat.
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.
Etodolac Blocks the Allyl Isothiocyanate-Induced Response in Mouse Sensory Neurons by Selective TRPA1 Activation.
Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.
Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat.
Failure of intrathecal ketorolac to reduce remifentanil-induced postinfusion hyperalgesia in humans.
Four PGE2 EP receptors are up-regulated in injured nerve following partial sciatic nerve ligation.
Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial.
GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.
Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition.
Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors.
Hyperalgesic and edematogenic effects of Secapin-2, a peptide isolated from Africanized honeybee (Apis mellifera) venom.
Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice.
Hypothalamic mechanisms of pain modulatory actions of cytokines and prostaglandin E2.
Ibuprofen blocks changes in Na v 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant-induced inflammation in rat.
Impaired acute and inflammatory nociception in mice lacking the p50 subunit of NF-kappaB.
Indomethacin attenuates mechanical allodynia during the organization but not the maintenance of the peripheral neuropathic pain induced by nervus ischiadicus chronic constriction injury.
Inflammatory mediators in the pronociceptive effects induced by Bothrops leucurus snake venom: The role of biogenic amines, nitric oxide, and eicosanoids.
Influence of high-dose intraoperative remifentanil with intravenous ibuprofen on postoperative morphine consumption in patients undergoing pancreaticoduodenectomy: a randomized trial.
Inhibition of COX-2 alleviates lumbar spinal stenosis-induced chronic mechanical allodynia in rats.
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production.
Inhibition of peripheral interleukin-1 beta-induced hyperalgesia by the intracerebroventricular administration of diclofenac and alpha-melanocyte-stimulating hormone.
Inhibition of spinal 15-LOX-1 attenuates TLR4-dependent, nonsteroidal anti-inflammatory drug-unresponsive hyperalgesia in male rats.
Inhibition of spinal prostaglandin synthesis early after L5/L6 nerve ligation prevents the development of prostaglandin-dependent and prostaglandin-independent allodynia in the rat.
Interleukin-1 receptor antagonist ameliorates the pain hypersensitivity, spinal inflammation and oxidative stress induced by systemic lipopolysaccharide in neonatal rats.
Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity.
Interleukin-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E(2).
Interleukin-6 is a candidate molecule that transmits inflammatory information to the CNS.
Interleukin-8 as a mediator of sympathetic pain.
Intracerebroventricular injection of tumor necrosis factor-alpha induces thermal hyperalgesia in rats.
Intracisternal administration of chemokines facilitated formalin-induced behavioral responses in the orofacial area of freely moving rats.
Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats.
Intraplantar injection of a cyclooxygenase inhibitor ketorolac reduces immunoreactivities of substance P, calcitonin gene-related peptide, and dynorphin in the dorsal horn of rats with nerve injury or inflammation.
Intraplantar-injected ceramide in rats induces hyperalgesia through an NF-{kappa}B- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E2 pathway.
Intrathecal protease-activated receptor stimulation produces thermal hyperalgesia through spinal cyclooxygenase activity.
Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats.
Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom.
L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats.
Laser-photobiomodulation on experimental cancer pain model in Walker Tumor-256.
Leonurine Attenuates Hyperalgesia in Mice with Induced Adenomyosis.
Low-level laser therapy (LLLT) reduces the COX-2 mRNA expression in both subplantar and total brain tissues in the model of peripheral inflammation induced by administration of carrageenan.
Manganese Oxide Nanozymes Ameliorate Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve-Transection Induced Neuropathic Pain.
Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis.
Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
Mechanical hyperalgesia in streptozotocin-diabetic rats.
Mechanism of aspirin-induced inhibition on the secondary hyperalgesia in osteoarthritis model rats.
Mechanisms underlying transient receptor potential ankyrin 1 (TRPA1)-mediated hyperalgesia and edema.
Mediation of primary afferent peripheral hyperalgesia by the cAMP second messenger system.
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy.
Migraine, allodynia, and implications for treatment.
Modification of rat model of sciatica induced by lumber disc herniation and the anti-inflammatory effect of osthole given by epidural catheterization.
Modification of the lead molecule: Tryptophan and piperidine appended triazines reversing inflammation and hyeperalgesia in rats.
Modulatory effect of cyclooxygenase inhibitors on sildenafil-induced antinociception.
Muscle hyperalgesia induced by peripheral P2X3 receptors is modulated by inflammatory mediators.
N-methyl D-aspartate induced mechanical allodynia is blocked by nitric oxide synthase and cyclooxygenase-2 inhibitors.
Neonatal immune challenge alters nociception in the adult rat.
Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
Nitric oxide reverses endotoxin-induced inflammatory hyperalgesia via inhibition of prostacyclin production in mice.
Nocebo and the contribution of psychosocial factors to the generation of pain.
Nociception and the differential expression of cyclooxygenase-1 (COX-1), the COX-1 variant retaining intron-1 (COX-1v), and COX-2 in mouse dorsal root ganglia (DRG).
Nociception in cyclooxygenase isozyme-deficient mice.
Nonopioid actions of intrathecal dynorphin evoke spinal excitatory amino acid and prostaglandin E2 release mediated by cyclooxygenase-1 and -2.
Nonsteroidal anti-inflammatory drugs and acetaminophen ameliorate muscular mechanical hyperalgesia developed after lengthening contractions via cyclooxygenase-2 independent mechanisms in rats.
Nutmeg oil alleviates chronic inflammatory pain through inhibition of COX-2 expression and substance P release in vivo.
ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis.
Osthole ameliorates neurogenic and inflammatory hyperalgesia by modulation of iNOS, COX-2, and inflammatory cytokines in mice.
Overexpressed transient receptor potential vanilloid 3 ion channels in skin keratinocytes modulate pain sensitivity via prostaglandin E2.
P2X3 and P2X2/3 receptors activation induces articular hyperalgesia by an indirect sensitization of the primary afferent nociceptor in the rats' knee joint.
Participation of cyclooxygenases in cutaneous thermal nociception under non-inflamed and inflamed conditions.
Pathogenesis of spinally mediated hyperalgesia in diabetes.
Pathway to carrageenan-induced inflammation in the hind limb of the rat.
Paulistine-The Functional Duality of a Wasp Venom Peptide Toxin.
Peri-sciatic administration of indomethacin early after nerve injury can attenuate the development of tactile allodynia in a rat model of L5 single spinal nerve injury.
Periganglionic inflammation elicits a distally radiating pain hypersensitivity by promoting COX-2 induction in the dorsal root ganglion.
Peripheral formalin injection induces long-lasting increases in cyclooxygenase 1 expression by microglia in the spinal cord.
Peripheral inflammatory hyperalgesia depends on the COX increase in the dorsal root ganglion.
Peripheral P2X7 receptor-induced mechanical hyperalgesia is mediated by bradykinin.
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Pharmacological and histopathological characterization of a hyperalgesia model induced by freeze lesion.
Pharmacological characterisation of a rat model of incisional pain.
Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain.
Pharmacological characterization of carrageenan induced heat muscle hyperalgesia in rats using non-selective, preferential and selective COX-2 inhibitors.
Pharmacological characterization of the algesic response to the subplantar injection of serotonin in the rat.
Pharmacological characterization of the chronic constriction injury model of neuropathic pain.
Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following experimental cystitis in rats.
Pharmacological modulation of eicosanoid levels and hyperalgesia in yeast-induced inflammation.
Postoperative administration of the analgesic tramadol, but not the selective cyclooxygenase-2 inhibitor parecoxib, abolishes postoperative hyperalgesia in a new model of postoperative pain in rats.
Preoperative but Not Postoperative Flurbiprofen Axetil Alleviates Remifentanil Induced Hyperalgesia after Laparoscopic Gynecological Surgery: A Prospective, Randomized, Double-blinded, Trial.
Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats.
Probable role of spinal purinoceptors in the analgesic effect of Trigonella foenum (TFG) leaves extract.
Progesterone reduces the expression of spinal cyclooxygenase-2 and inducible nitric oxide synthase and prevents allodynia in a rat model of central neuropathic pain.
Prostaglandin E(2) glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity.
Prostaglandin E2 release evoked by intrathecal dynorphin is dependent on spinal p38 mitogen activated protein kinase.
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
Prostanoids in the preoptic hypothalamus mediate systemic lipopolysaccharide-induced hyperalgesia in rats.
Protective Effect of Antioxidants in Nitric Oxide/COX-2 Interaction during Inflammatory Pain: The Role of Nitration.
Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway.
R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models.
Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics.
Resveratrol attenuates inflammation-induced hyperexcitability of trigeminal spinal nucleus caudalis neurons associated with hyperalgesia in rats.
Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw.
Reversal of LPS-induced central and peripheral hyperalgesia by green tea extract.
Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model.
Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury.
Role of central endothelin-1 in hyperalgesia, anhedonia, and hypolocomotion induced by endotoxin in male rats.
Role of cyclooxygenase-2 in lipopolysaccharide-induced hyperalgesia in formalin test.
Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice.
Role of kinin and prostaglandin in cutaneous thermal nociception.
Role of spinal cyclooxygenase (COX)-2 on thermal hyperalgesia evoked by carageenan injection in the rat.
Role of spinal cyclooxygenase-2 and prostaglandin E2 in fentanyl-induced hyperalgesia in rats.
Role of spinal p38alpha and beta MAPK in inflammatory hyperalgesia and spinal COX-2 expression.
Secondary hyperalgesia in the rat first degree burn model is independent of spinal cyclooxygenase and nitric oxide synthase.
Selective cyclooxygenase inhibition: its role in pain and anaesthesia.
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.
Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2.
Sensitization of meningeal nociceptors: inhibition by naproxen.
Sensitization of nociceptors by prostaglandin E2-glycerol contributes to hyperalgesia in mice with sickle cell disease.
Serotonin is a directly-acting hyperalgesic agent in the rat.
Sex differences in inflammation and inflammatory pain in cyclooxygenase-deficient mice.
Spinal actions of NSAIDS in blocking spinally mediated hyperalgesia: the role of cyclooxygenase products.
Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide-induced hyperalgesia in rats.
Spinal cyclooxygenase-2 is involved in development of allodynia after nerve injury in rats.
Spinal nerve ligation-induced activation of nuclear factor kappaB is facilitated by prostaglandins in the affected spinal cord and is a critical step in the development of mechanical allodynia.
Spinal neural cyclooxygenase-2 mediates pain caused in a rat model of lumbar disk herniation.
Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2.
Spinal prostaglandins facilitate exaggerated A- and C-fiber-mediated reflex responses and are critical to the development of allodynia early after L5-L6 spinal nerve ligation.
Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice.
Suppression of hyperexcitability of trigeminal nociceptive neurons associated with inflammatory hyperalgesia following systemic administration of lutein via inhibition of cyclooxygenase-2 cascade signaling.
Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord.
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
Systemic Lipopolysaccharide-Induced Pain Sensitivity and Spinal Inflammation Were Reduced by Minocycline in Neonatal Rats.
Systemic meloxicam reduces tactile allodynia development after L5 single spinal nerve injury in rats.
Tempol, a Superoxide Dismutase Mimetic Agent, Inhibits Superoxide Anion-Induced Inflammatory Pain in Mice.
The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1.
The anti-inflammatory effects of 2 Hz electroacupuncture with different intensities on acute carrageenan-induced inflammation in the rat paw.
The attenuation of pain behaviour and serum interleukin-6 concentration by nimesulide in a rat model of neuropathic pain.
The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans.
The effect of a peripheral block on inflammation-induced prostaglandin E2 and cyclooxygenase expression in rats.
The ehrlich tumor induces pain-like behavior in mice: a novel model of cancer pain for pathophysiological studies and pharmacological screening.
The long-term exposure of rat cultured dorsal root ganglion cells to bradykinin induced the release of prostaglandin E2 by the activation of cyclooxygenase-2.
The molecular link between C-C-chemokine ligand 2-induced leukocyte recruitment and hyperalgesia.
The neuropathic phenotype of the K/BxN transgenic mouse with spontaneous arthritis: pain, nerve sprouting and joint remodeling.
The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia.
The pre-emptive analgesic effect of a cyclooxygenase-2 inhibitor in a rat model of acute postoperative pain.
The role of the spinal opioid receptor like1 receptor, the NK-1 receptor, and cyclooxygenase-2 in maintaining postoperative pain in the rat.
The spinal biology in humans and animals of pain states generated by persistent small afferent input.
The superoxide anion donor, potassium superoxide, induces pain and inflammation in mice through production of reactive oxygen species and cyclooxygenase-2.
The VGF-derived peptide TLQP-21 contributes to inflammatory and nerve injury-induced hypersensitivity.
Therapeutic potential of andrographolide for treating endometriosis.
Thymulin induces c-fos expression in the spinal cord of rats which is reversed by meloxicam and morphine.
Topical bicuculline to the rat spinal cord induces highly localized allodynia that is mediated by spinal prostaglandins.
Transient up-regulation of spinal cyclooxygenase-2 and neuronal nitric oxide synthase following surgical inflammation.
TRPV1 and TRPV4 play pivotal roles in delayed onset muscle soreness.
TRPV1, Targeted by miR-338-3p, Induces Neuropathic Pain by Interacting with NECAB2.
Tumour necrosis factor alpha mediates transient receptor potential vanilloid 1-dependent bilateral thermal hyperalgesia with distinct peripheral roles of interleukin-1beta, protein kinase C and cyclooxygenase-2 signalling.
Upregulated glial cell line-derived neurotrophic factor through cyclooxygenase-2 activation in the muscle is required for mechanical hyperalgesia after exercise in rats.
Upregulation of dorsal horn microglial cyclooxygenase-1 and neuronal cyclooxygenase-2 after thoracic deep muscle incisions in the rat.
[Changes of COX-2 expression in the dorsal horn of the spinal cord during formalin-induced inflammatory pain and hyperalgesia in rats].
[Ketorolac for prevention of acute postoperative pain]
[Modulation of cortical pain processing by cyclooxygenase inhibition : A functional MRI study.]
Hypercalcemia
Humoral hypercalcemia of malignancy. Release of a prostaglandin-stimulating bone-resorbing factor in vitro by human transitional-cell carcinoma cells.
Hypercalcemia in association with a Leydig cell tumor in the rat: a model for tumor-induced hypercalcemia in man.
Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors.
Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.
The eicosanoid factor: a determinant of individuality of nephron segments.
Tumor necrosis factor-alpha induces renal cyclooxygenase-2 expression in response to hypercalcemia.
Hypercholesterolemia
Altered mechanisms of endothelium-dependent dilation in skeletal muscle arterioles with genetic hypercholesterolemia.
Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits.
Aspirin resistance.
Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats.
Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia.
Effect of gestational hypercholesterolemia and maternal immunization on offspring plasma eicosanoids.
Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta.
Gene Transfer of COX-1 Improves Lumen Size and Blood Flow in Carotid Bypass Grafts.
Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition.
Hypolipidemic effects of nimesulide and celecoxib in experimentally induced hypercholesterolemia in rabbits.
In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets.
Mechanisms of ischemia-induced cavernosal smooth muscle relaxation impairment in a rabbit model of vasculogenic erectile dysfunction.
Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction.
Hyperemia
Antioxidant CR-6 protects against reperfusion injury after a transient episode of focal brain ischemia in rats.
Astrocyte-mediated control of cerebral blood flow.
Bradykinin-induced renal hemodynamic alterations: renin and prostaglandin relationships.
Contribution of nitric oxide and prostaglandins to reactive hyperemia in human forearm.
Coronary and systemic hemodynamic effects of sustained inhibition of nitric oxide synthesis in conscious dogs. Evidence for cross talk between nitric oxide and cyclooxygenase in coronary vessels.
Coupling of neural activity to blood flow in olfactory glomeruli is mediated by astrocytic pathways.
Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans.
Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases.
Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex.
Differential effect of cyclooxygenase inhibitors on absorptive hyperemia.
Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut.
Effects of antiaggregant and antiinflammatory doses of aspirin on coronary hemodynamics and myocardial reactive hyperemia in conscious dogs.
Endogenous prostaglandins and afferent sensory nerves in gastroprotective effect of hydrogen sulfide against stress-induced gastric lesions.
Endotoxin augments cerebral hyperemic response to halothane by inducing nitric oxide synthase and cyclooxygenase.
Evidence for sensory nerve involvement in cutaneous reactive hyperemia in humans.
Exogenous and Endogenous Hydrogen Sulfide Protects Gastric Mucosa against the Formation and Time-Dependent Development of Ischemia/Reperfusion-Induced Acute Lesions Progressing into Deeper Ulcerations.
Functional hyperemia of skeletal muscle: role of endothelium.
Indomethacin attenuates early postischemic vasogenic edema and cerebral injury.
Inhibitory effect of quinacrine on myocardial reactive hyperemia in the dog.
Local heating of human skin causes hyperemia without mediation by muscarinic cholinergic receptors or prostanoids.
Mechanism of aggravation of mucosal injury by intravenous nicotine in rat stomach.
Myocardial reactive hyperemia in experimental chronic heart failure: evidence for the role of K+ adenosine triphosphate-dependent channels and cyclooxygenase activity.
Nitric oxide and prostanoids contribute to isoflurane-induced cerebral hyperemia in pigs.
Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat.
Prostaglandin synthesis inhibition and postprandial intestinal hyperemia.
Pyrogenic renal hyperemia: the role of prostaglandins.
Regulation of postocclusive hyperemia by endogenously synthesized prostaglandins in the dog heart.
Relationship between opioids and prostaglandins in hypoxia-induced vasodilation of pial arteries in the newborn pig.
Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia.
The Effect of Aging and Indomethacin on Forearm Reactive Hyperemia in Healthy Adults.
Types of potassium channels involved in coronary reactive hyperemia depend on duration of preceding ischemia in rat hearts.
[The participation of humoral factors released by the endothelium in the development of reactive hyperemia]
Hyperglycemia
Activation of phosphoinositide 3-kinase in response to high glucose leads to regulation of reactive oxygen species-related nuclear factor-kappaB activation and cyclooxygenase-2 expression in mesangial cells.
Atorvastatin reduces the plasma lipids and oxidative stress but did not reverse the inhibition of prostacyclin generation by aortas in streptozotocin diabetic rats.
Benzylamine and methylamine, substrates of semicarbazide-sensitive amine oxidase, attenuate inflammatory response induced by lipopolysaccharide.
Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6.
Cyclooxygenase-2 over-expression inhibits liver apoptosis induced by hyperglycemia.
Dehydroascorbic acid normalizes several markers of oxidative stress and inflammation in acute hyperglycemic focal cerebral ischemia in the rat.
Developmental damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic environment.
Drug intervention can correct subnormal retinal oxygenation response in experimental diabetic retinopathy.
Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice.
Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes.
Elevated glucose blocks angiotensin-(1-7) and bradykinin interaction: the role of cyclooxygenase products.
Gene expression in peripheral blood mononuclear cells from children with diabetes.
Glucose-induced regulation of COX-2 expression in human islets of Langerhans.
Hyperfiltration in ubiquitin C-terminal hydrolase L1-deleted mice.
HYPERGLYCEMIA-INDUCED PLATELET ACTIVATION IN TYPE 2 DIABETES MELLITUS IS RESISTANT TO ASPIRIN BUT NOT TO A NITRIC OXIDE-DONATING AGENT.
Indomethacin inhibits thymic involution in mice with streptozotocin-induced diabetes.
Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats.
Mechanisms of Burn-induced Impairment in Gastric Slow Waves and Emptying in Rats.
Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis.
Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.
Protective effect of sun ginseng against diabetic renal damage.
Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes.
Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy.
Spreading depression-induced gene expression is regulated by plasma glucose.
Streptozotocin-Induced Maternal Hyperglycemia Increases the Expression of Antioxidant Enzymes and Mast Cell Number in Offspring Rat Ventral Prostate.
Hyperhidrosis
Atypical form of transient reactive papulotranslucent acrokeratoderma in a cystic fibrosis carrier.
Hyperhomocysteinemia
Cyclooxygenase-2 derived thromboxane A(2) and reactive oxygen species mediate flow-induced constrictions of venules in hyperhomocysteinemia.
Homocysteine causes dysfunction of chondrocytes and oxidative stress through repression of SIRT1/AMPK pathway: A possible link between hyperhomocysteinemia and osteoarthritis.
Induction of hepatic cyclooxygenase-2 by hyperhomocysteinemia via nuclear factor-kappaB activation.
Hyperinsulinism
Androgens are necessary for the development of fructose-induced hypertension.
Central interleukin 1-elicited hyperinsulinemia is mediated by prostaglandins but not autonomics.
Fructose-induced inflammation, insulin resistance and oxidative stress: A liver pathological triad effectively disrupted by lipoic acid.
Indomethacin reverses interleukin-1-induced hyperinsulinemia in conscious and freely moving rats.
Renal cyclooxygenase-2 in obese Zucker (fatty) rats.
Hyperkalemia
Adenosine instead of supranormal potassium in cardioplegic solution preserves endothelium-derived hyperpolarization factor-dependent vasodilation.
COX-2 and the kidneys.
Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study.
Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet.
Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet.
Hyperkalemia exposure impairs EDHF-mediated endothelial function in the human coronary artery.
Risk of hyperkalemia associated with selective COX-2 inhibitors.
Hyperlipidemias
Downregulation of miR-146a, cyclooxygenase-2 and advanced glycation end-products in simvastatin-treated older patients with hyperlipidemia.
Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma.
The role of platelet hyperfunction in thrombus formation in hyperlipidemia.
Hyperlipoproteinemia Type II
Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia.
Hyperostosis, Cortical, Congenital
Prostaglandin synthetase inhibitor in Caffey disease.
Hyperoxaluria
An animal model of calcium oxalate urolithiasis based on a cyclooxygenase 2 selective inhibitor.
Hyperparathyroidism, Primary
Do cyclooxygenase-2 knockout mice have primary hyperparathyroidism?
Hyperparathyroidism, Secondary
Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.
Hyperpigmentation
Mimosine Dipeptide Enantiomsers: Improved Inhibitors against Melanogenesis and Cyclooxygenase.
siRNA-mediated knock-down of COX-2 in melanocytes suppresses melanogenesis.
Hypersensitivity
A novel concept of immunological and allergy interactions in autism spectrum disorders: Molecular, anti-inflammatory effect of osthole.
An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk.
An opioid receptor-independent mechanism underlies motility dysfunction and visceral hyperalgesia in opioid-induced bowel dysfunction.
An update on the epidemiology of aspirin-exacerbated respiratory disease.
Analgesics.
Anti-allergic effect of a chloroform-soluble extract of Cinnamomum cambodianum in bone marrow-derived mast cells.
Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Aspirin induces IL-4 production: augmented IL-4 production in aspirin-exacerbated respiratory disease.
Aspirin resistance: an evaluation of current evidence and measurement methods.
Aspirin sensitivity and desensitization for asthma and sinusitis.
Aspirin-exacerbated respiratory disease: evaluation and management.
Association of the -14C/G MET and the -765G/C COX-2 Gene Polymorphisms with the Risk of Chronic Rhinosinusitis with Nasal Polyps in a Polish Population.
Avoidance of nonsteroidal anti-inflammatory drugs after negative provocation tests in urticaria/angioedema reactions: Real-world experience.
Behind the scene: Paracetamol hypersensitivity in children.
Celecoxib reverts oxaliplatin-induced neuropathic pain through inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion.
Citreorosein, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, attenuates cyclooxygenase-2-dependent prostaglandin D(2) generation by blocking Akt and JNK pathways in mouse bone marrow-derived mast cells.
Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years.
Combination treatment using the COX-2 inhibitor meloxicam and an anti-allergic in pollinosis.
Comparison of expression profiles induced by dust mite in airway epithelia reveals a common pathway.
Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity.
COX-2 induces T cell accumulation and IFN-? production during the development of chromium allergy.
Cross-reactivity among drugs: clinical problems.
Cutaneous hypersensitivity to multiple NSAIDs: never take tolerance to selective COX-2 inhibitors (COXIBs) for granted!
CXCL5 mediates UVB irradiation-induced pain.
Cyclooxygenase in rat pleural hypersensitivity reactions.
Cytokine-induced neutrophil chemoattractant 1 (CINC-1) mediates the sympathetic component of inflammatory mechanical hypersensitivitiy in rats.
Deep sequencing of prostaglandin-endoperoxide synthase (PTGE) genes reveals genetic susceptibility for cross-reactive hypersensitivity to NSAID.
Dermal exposure to jet fuel suppresses delayed-type hypersensitivity: a critical role for aromatic hydrocarbons.
Development of an in vivo bioassay method for allergy-preventive substances using hen-egg white lysozyme (HEL)-induced blood flow decrease.
Developmental Differences in Spinal Cyclooxygenase 1 Expression after Surgical Incision.
Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats.
Downregulation of spinal astrocytic connexin43 leads to upregulation of interleukin-6 and cyclooxygenase-2 and mechanical hypersensitivity in mice.
Effect of dipyrone and thalidomide alone and in combination on STZ-induced diabetic neuropathic pain.
Effect of flurbiprofen, a cyclooxygenase inhibiting drug, on induced allergic rhinitis.
Effects of intrathecal ketorolac on human experimental pain.
Electroacupuncture inhibits cyclooxygenase-2 up-regulation in rat spinal cord after spinal nerve ligation.
Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta.
Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs.
Expression of Arachidonate Metabolism Enzymes and Receptors in Nasal Polyps of Aspirin-Hypersensitive Asthmatics.
Failure of intrathecal ketorolac to reduce remifentanil-induced postinfusion hyperalgesia in humans.
GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
High Expression of IL-1RI and EP? Receptors in the IL-1?/COX-2 Pathway, and a New Alternative to Non-Steroidal Drugs-Osthole in Inhibition COX-2.
Hypersensitivity to antipyretics: pathogenesis, diagnosis, and management.
Hypersensitivity to cyclooxygenase inhibitory drugs in children: a study of 164 cases.
Identification of cis-acting elements and signaling components of high affinity IgE receptor that regulate the expression of cyclooxygenase-2.
Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database.
Idiosyncrasy to pyrazolone drugs.
Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease.
Induction of cyclooxygenase-2 expression by allergens in lymphocytes from allergic patients.
Inflammation, allergy and asthma, complex immune origin diseases: mechanisms and therapeutic agents.
Inhibition of histidine decarboxylase and tumour promoter-induced arachidonic acid release by lecanoric acid analogues.
Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity.
Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
Intrathecal administration of a cylcooxygenase-1, but not a cyclooxygenase-2 inhibitor, reverses the effects of laparotomy on exploratory activity in rats.
Intrathecal ketorolac does not improve acute or chronic pain after hip arthroplasty: a randomized controlled trial.
Intrathecal morphine and ketorolac analgesia after surgery: comparison of spontaneous and elicited responses in rats.
Mechanisms underlying the nociceptive responses induced by platelet-activating factor (PAF) in the rat paw.
Method development and validation for ultra-high pressure liquid chromatography/tandem mass spectrometry determination of multiple prostanoids in biological samples.
MicroRNA-26a/-26b-COX-2-MIP-2 Loop Regulates Allergic Inflammation and Allergic Inflammation-promoted Enhanced Tumorigenic and Metastatic Potential of Cancer Cells.
Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans.
Mucosal exfoliation as a selective reaction to etoricoxib.
N-Caffeoyl serotonin as selective COX-2 inhibitor.
Neonatal immune challenge alters nociception in the adult rat.
New concepts in the pathogenesis of asthma.
Nonsteroidal anti-inflammatory drug hypersensitivity in preschool children.
Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Oxidative stress and COX cause hyper-responsiveness in vascular smooth muscle of the femoral artery from diabetic rats.
Paracetamol allergy in clinical practice.
Parecoxib as an alternative in COX-2 hypersensitivity.
Periganglionic inflammation elicits a distally radiating pain hypersensitivity by promoting COX-2 induction in the dorsal root ganglion.
Pharmacologic modulation of delayed-type hypersensitivity in mice.
Physicians' communication of risks from non-steroidal anti-inflammatory drugs and attitude towards providing adverse drug reaction information to patients.
Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.
Possible link between history of hypersensitivity to a specific non-steroidal anti-inflammatory drug (NSAID) and positive results following challenge test to alternative NSAIDS.
Practical approach to the treatment of NSAID hypersensitivity.
Preemptive effects of intrathecal cyclooxygenase inhibitor or nitric oxide synthase inhibitor on thermal hypersensitivity following peripheral nerve injury.
Products of arachidonic acid metabolism and the effects of cyclooxygenase inhibition on ongoing cutaneous allergic reactions in human beings.
Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
Prostaglandin E2 contributes to the synthesis of brain-derived neurotrophic factor in primary sensory neuron in ganglion explant cultures and in a neuropathic pain model.
Prostaglandin E2, Produced by Mast Cells in Colon Tissues from Patients with Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice.
Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics.
Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
Restricted cyclooxygenase-2 expression in the central nervous system following acute and delayed-type hypersensitivity responses to bacillus Calmette-Guérin.
Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury.
Role of lipoxygenase products in murine pulmonary granuloma formation.
Safe full-dose one-step nabumetone challenge in patients with nonsteroidal anti-inflammatory drug hypersensitivity.
Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach.
Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.
Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study.
Sex differences in vascular reactivity of coronary artery bypass graft conduits.
Sex Differences Revealed in a Mouse CFA Inflammation Model with Macrophage Targeted Nanotheranostics.
Significance of CYCLOOXYGENASE-2(COX-2), PERIOSTIN (POSTN) and INTERLEUKIN-4(IL-4) gene expression in the pathogenesis of chronic rhinosinusitis with nasal polyps.
Spinal cord dynorphin expression increases, but does not drive microglial prostaglandin production or mechanical hypersensitivity after incisional surgery in rats.
Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity.
State of the Art: Medical treatment of aspirin exacerbated respiratory disease (AERD).
The broken balance in aspirin hypersensitivity.
Tolerability to paracetamol and preferential COX-2 inhibitors in patients with cross-reactive nonsteroidal anti-inflammatory drugs hypersensitivity.
Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients.
Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs.
Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
Tolerance to etoricoxib in children with nonsteroidal anti-inflammatory drug hypersensitivity.
Treatment of refractory mesenteric traction syndrome without cyclooxygenase inhibitors.
[Allergy and intolerance to nonsteroidal anti-inflammatory drugs in children].
[Effect of tolmetin on responsiveness of isolated guinea pig tracheal smooth muscles]
[Management of Adverse Effects Associated with Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitor].
[Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists]
[«Sulfonamide allergy» - which drugs must patients avoid?].
Hypersensitivity, Delayed
Effects of cyclooxygenase and lipoxygenase inhibitors on inflammation associated with oxazolone-induced delayed hypersensitivity.
Inhibition of contact dermatitis in animal models and suppression of proinflammatory gene expression by topically applied flavonoid, wogonin.
Selective cyclooxygenase-2 (COX-2) inhibitors reduce anti-Mycobacterium antibodies in adjuvant arthritic rats.
Hypersensitivity, Immediate
Human respiratory mucus.
Release of calcitonin gene-related peptide in cardiac anaphylaxis.
[Immediate hypersenstivity reactions to nonsteroidal anti-inflammatory drugs: allergy or pseudo-allergy?]
Hypertension
A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels.
A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
Abnormal Pressure Stress Reduces Interleukin-1?-Induced Cyclooxygenase-2 Expression in Cultured Rat Vascular Smooth Muscle Cells.
Acute effects of cyclooxygenase-2 inhibition on renal function in heterozygous ren-2-transgenic rats on normal or low sodium intake.
Adverse effects of COX-2 inhibitors.
Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
Adverse interactions of rofecoxib with lisinopril in spontaneously hypertensive rats.
Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria.
Analysis of angiotensin II mediated COX-2 downregulation in angiotensin II- or aldosterone-infused hypertensive rat.
Analysis of Vascular Cell Response to Hypertension Induced by Pressure Loading and Its Application as a Tool for Exploring Pharmacological Modes of Action.
Androgens are necessary for the development of fructose-induced hypertension.
Angiotensin II induces cyclooxygenase 2 expression in rat astrocytes via the angiotensin type 1 receptor.
Angiotensin II-Dependent Hypertension Requires Cyclooxygenase 1-Derived Prostaglandin E2 and EP1 Receptor Signaling in the Subfornical Organ of the Brain.
Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2.
Aspirin lowers blood pressure in patients with renovascular hypertension.
Aspirin suppresses cardiac fibroblast proliferation and collagen formation through downregulation of angiotensin type 1 receptor transcription.
Association of candidate gene polymorphisms with chronic kidney disease in Japanese individuals with hypertension.
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
Association of plasma cyclooxygenase-2 levels and genetic polymorphisms with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults.
Association of the genetic variants of APOA5 and PRKCH with hypertension in community-dwelling Japanese individuals.
Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release.
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase-2 upregulation: implications on hypertension.
Brain-targeted Angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation.
Cadmium exposure activates NADPH oxidase, renin-angiotensin system and cyclooxygenase 2 pathways in arteries, inducing hypertension and vascular damage.
Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms.
Calcitriol inhibits COX-1 and COX-2 expressions of renal vasculature in hypertension: Reactive oxygen species involved?
Cardiovascular events in early rheumatoid arthritis (RA) are a result of inflammatory burden and traditional risk factors: a five year prospective study.
Cardiovascular risk and COX-2 inhibition in rheumatological practice.
Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Cardiovascular risk, hypertension, and NSAIDs.
Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use.
Cause for concern in the use of non-steroidal anti-inflammatory medications in the community -a population-based study.
Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
Celecoxib restores angiogenic factor expression at the maternal-fetal interface in the BPH/5 mouse model of preeclampsia.
Celecoxib use and circulating oxylipins in a colon polyp prevention trial.
Celecoxib-induced nephrotoxicity in a renal transplant recipient.
Chronic cyclooxygenase-2 inhibition prevents the worsening of hypertension and endothelial dysfunction induced by ouabain in resistance arteries of spontaneously hypertensive rats.
Chronic inhibition of NOS-2 ameliorates renal injury, as well as COX-2 and TGF-beta 1 overexpression in 5/6 nephrectomized rats.
Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
Coronary action of endothelin-1 and vasopressin during acute hypertension in anesthetized goats. Role of nitric oxide and prostanoids.
Correction of endothelial dysfunction in patients with arterial hypertension.
COX-2 and angiotensin II-induced hypertension and oxidative stress.
COX-2 and the kidney.
COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
COX-2 inhibitors and hypertension.
COX-2 inhibitors and the kidney.
COX-2 inhibitors in rheumatoid arthritis.
COX-2 mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla.
COX-2-derived prostacyclin modulates vascular remodeling.
COX-2-Independent Activation of Renal (Pro)Renin Receptor Contributes to DOCA-Salt Hypertension in Rats.
Crosstalk between (Pro)renin receptor and COX-2 in the renal medulla during angiotensin II-induced hypertension.
Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
Cyclo-oxygenase-2, endothelium and aortic reactivity during deoxycorticosterone acetate salt-induced hypertension.
Cyclooxygenase inhibition reduces blood pressure elevation and vascular reactivity dysfunction caused by inhibition of nitric oxide synthase in rats.
Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats.
Cyclooxygenase pathway is involved in the vascular reactivity and inhibition of the Na+, K+-ATPase activity in the tail artery from L-NAME-treated rats.
Cyclooxygenase pathway mediates lung injury induced by phorbol and platelets.
Cyclooxygenase-1 inhibition attenuates angiotensin II-salt hypertension and neurogenic pressor activity in the rat.
Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney.
Cyclooxygenase-2 and kidney failure.
Cyclooxygenase-2 expression in lung in patients with congenital heart malformations and pulmonary arterial hypertension.
Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension.
Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension.
Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events?
Cyclooxygenase-2--specific inhibitors: are they safe?
Cyclosporin A and pressor responsiveness in sheep.
Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition.
Demethoxycurcumin Preserves Renovascular Function by Downregulating COX-2 Expression in Hypertension.
Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Differential role of cyclooxygenase-1 and -2 on renal vasoconstriction to ?1-adrenoceptor stimulation in normotensive and hypertensive rats.
Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy.
Do COX-2 inhibitors worsen renal function?
Does cyclooxygenase-2 affect blood pressure?
Early co-expression of cyclooxygenase-2 and renin in the rat kidney cortex contributes to the development of N(G)-nitro-l-arginine methyl ester induced hypertension.
Effect of apocynin treatment on renal expression of COX-2, NOS1, and renin in Wistar-Kyoto and spontaneously hypertensive rats.
Effect of cyclooxygenase-2 inhibitors on blood pressure.
Effect of Exercise on Cardiac Tissue Oxidative and Inflammatory Mediators in Chronic Kidney Disease.
Effect of sphingosine kinase 1 inhibition on blood pressure.
Effect of the NADPH oxidase inhibitor apocynin on ischemia-reperfusion lung injury.
Effects of chronic treatment with cyclooxygenase inhibitor, indomethacin on oral contraceptive-induced high blood pressure in female rats.
Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors.
Effects of low-dose aspirin on maternal blood pressure and vascular function in an experimental model of gestational hypertension.
Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema.
Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats.
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Eicosanoids and tumor necrosis factor-alpha in the kidney.
Endothelial COX-2 inhibition: possible relevance for hypertension and cardiovascular risk?
Endothelial Dysfunction in Diabetes and Hypertension: Cross Talk in RAS, BMP4, and ROS-dependent COX-2-derived Prostanoids.
Endothelium-dependent contractions and endothelial dysfunction in human hypertension.
Endothelium-derived contracting factors mediate the Ang II-induced endothelial dysfunction in the rat aorta: preventive effect of red wine polyphenols.
Enhanced vasorelaxant effects of the endocannabinoid-like mediator, oleamide, in hypertension.
Ethyl Acetate Fraction of Lannea microcarpa Engl. and K. Krause (Anacardiaceae) Trunk Barks Corrects Angiotensin II-Induced Hypertension and Endothelial Dysfunction in Mice.
Etoricoxib Attenuates Effect of Antihypertensives in a Rodent Model of DOCA-Salt Induced Hypertension.
Examination of the expression of cyclooxygenase-2 in placenta villi from sufferers of pregnancy induced hypertension.
Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy.
Free radicals in retinal and choroidal blood flow autoregulation in the piglet: interaction with prostaglandins.
Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension.
Genetic analysis of 22 candidate genes for hypertension in the Japanese population.
George E. Brown memorial lecture. Oxygen radicals in cerebral vascular injury.
Glomerular prostaglandin formation in two-kidney, one-clip hypertensive rats.
H2S inhibition of chemical hypoxia-induced proliferation of HPASMCs is mediated by the upregulation of COX-2/PGI2.
Hypertension alters role of iNOS, COX-2, and oxidative stress in bradykinin relaxation impairment after LPS in rat cerebral arteries.
Hypertension and cyclooxygenase-2 inhibitors: target: the renal medulla.
Hypertension and sex differences in the age-related renal changes when cyclooxygenase-2 activity is reduced during nephrogenesis.
Hypertension increases the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in phenylephrine responses.
Hypertension: Haematopoietic COX-2 in salt-sensitive hypertension.
Identification of differential gene expression profile from peripheral blood cells of military pilots with hypertension by RNA sequencing analysis.
Increase in heme oxygenase-1 levels ameliorates renovascular hypertension.
Increased renal vasoconstriction and gene expression of cyclooxygenase-1 in renovascular hypertension.
Indomethacin and LY171883 modify porcine cardiopulmonary responses to leukotrienes.
Indomethacin, dazoxiben and extravascular lung water after Escherichia coli infusion.
Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice.
Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats.
Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertension.
Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension.
Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney.
Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice.
Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction.
Intracamerally injected platelet activating factor (PAF) induces marked intraocular inflammatory reactions.
Intrarenal Dopamine Attenuates Deoxycorticosterone Acetate/High Salt-Induced Blood Pressure Elevation in Part Through Activation of a Medullary Cyclooxygenase 2 Pathway.
Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice.
Long-term Mercury Exposure Accelerates the Development of Hypertension in Prehypertensive Spontaneously Hypertensive Rats Inducing Endothelial Dysfunction: the Role of Oxidative Stress and Cyclooxygenase-2.
Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats.
Low-Dose Aspirin Treatment Attenuates Male Rat Salt-Sensitive Hypertension via Platelet Cyclooxygenase 1 and Complement Cascade Pathway.
Lung oedema induced by Tityus serrulatus scorpion venom in the rat.
MAPK pathway activation by chronic lead-exposure increases vascular reactivity through oxidative stress/cyclooxygenase-2-dependent pathways.
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Mechanism of cerebral arteriolar abnormalities after acute hypertension.
Mechanisms of augmented vasoconstriction induced by 5-hydroxytryptamine in aortic rings from spontaneously hypertensive rats.
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.
Natural Antioxidants and Hypertension: Promise and Challenges.
Nephrotoxicity related to new therapeutic compounds.
New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study.
NIACIN AMELIORATES OXIDATIVE STRESS, INFLAMMATION, PROTEINURIA, AND HYPERTENSION IN RATS WITH CHRONIC RENAL FAILURE.
Nimesulide: some pharmaceutical and pharmacological aspects--an update.
Nitric oxide synthase-inhibition hypertension is associated with altered endothelial cyclooxygenase function.
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Nonsteroidal Anti-Inflammatory Drugs and the Kidney.
Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders.
Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis.
Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney.
Opposite Modulatory Effects of Selective and Non-Selective Cyclooxygenase Inhibition on Cardiovascular and Autonomic Consequences of Cyclosporine in Female Rats.
Oxidative stress induced by tert-butyl hydroperoxide causes vasoconstriction in the aorta from hypertensive and aged rats: role of cyclooxygenase-2 isoform.
Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension.
Parecoxib Increases Blood Pressure Through Inhibition of Cyclooxygenase-2 Messenger RNA in an Experimental Model.
Perinatal lead exposure affects nitric oxide and cyclooxygenase pathways in aorta of weaned rats.
Peroxisome Proliferator Activated Receptor-? Agonist Slows the Progression of Hypertension, Attenuates Plasma Interleukin-6 Levels and Renal Inflammatory Markers in Angiotensin II Infused Mice.
Peroxisome Proliferator-Activated Receptor-? Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension.
Peroxisome proliferator-activated receptor-? activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress.
Pioglitazone reduces angiotensin II-induced COX-2 expression through the inhibition of ROS production and ET-1 transcription in vascular cells from SHR rats.
Possible role for brain prostanoid pathways in the development of angiotensin II-salt hypertension in rats.
Post-ischemic rupture of the anterior papillary muscle of the right ventricle associated with persistent pulmonary hypertension of the newborn: a case report.
Potassium Intake Prevents the Induction of the Renin-Angiotensin System and Increases Medullary ACE2 and COX-2 in the Kidneys of Angiotensin II-Dependent Hypertensive Rats.
Prenatal Undernutrition Changes Renovascular Responses of Nimesulide in Rat Kidneys.
Prostacyclin protects against elevated blood pressure and cardiac fibrosis.
Prostacyclin therapy for pulmonary arterial hypertension.
Prostaglandin synthetase activity in kidney medulla during the development of experimental hypertension in the rat.
Prostaglandins in action indispensable roles of cyclooxygenase-1 and -2 in endothelium-dependent contractions.
Psoriasis and hypertension: a case-control study.
Pulmonary and cardiorenal cyclooxygenase-1 (COX-1), -2 (COX-2), and microsomal prostaglandin E synthase-1 (mPGES-1) and -2 (mPGES-2) expression in a hypertension model.
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Reciprocal Relationship Between Reactive Oxygen Species and Cyclooxygenase-2 and Vascular Dysfunction in Hypertension.
Regulation and function of renal medullary cyclooxygenase-2 during high salt loading.
Regulation of YAP by Mammalian Target of Rapamycin Complex 1 in Endothelial Cells Controls Blood Pressure Through COX-2/mPGES-1/PGE2 Cascade.
Relationship between COX-2 specific inhibitors and hypertension.
Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study.
Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications.
Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors.
Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
Renal medullary cyclooxygenase-2 and (pro)renin receptor expression during angiotensin II-dependent hypertension.
Renal Medullary Interstitial COX-2 (Cyclooxygenase-2) Is Essential in Preventing Salt-Sensitive Hypertension and Maintaining Renal Inner Medulla/Papilla Structural Integrity.
Renal molecular mechanisms underlying altered Na+ handling and genesis of hypertension during adulthood in prenatally undernourished rats.
RENAL PROTECTIVE EFFECT OF CHRONIC INHIBITION OF COX-2 WITH SC58236 IN STREPTOZOTOCIN-DIABETIC RATS.
Risk factors for hypertension in rheumatoid arthritis patients-A systematic review.
Rofecoxib.
Role for thromboxane receptors in angiotensin-II-induced hypertension.
Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation.
Role of macula densa cyclooxygenase-2 in renovascular hypertension.
Role of NADPHox/Rho-kinase signaling in the cyclosporine-NSAIDs interactions on blood pressure and baroreflexes in female rats.
Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension.
Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats.
Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?
Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.
Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).
Tempol, an antioxidant, restores endothelium-derived hyperpolarizing factor-mediated vasodilation during hypertension.
The Cardiovascular Pharmacology of COX-2 Inhibition.
The effect of indomethacin and prostacyclin agonists on blood pressure in a rat model of preeclampsia.
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
The impact of ethnicity and cardiovascular risk on the pharmacologic management of osteoarthritis: a US perspective.
The Obligatory Role of the Acetylcholine-Induced Endothelium-Dependent Contraction in Hypertension: Can Arachidonic Acid Resolve this Inflammation?
The prescription patterns and safety profiles of oral non-steroidal anti-inflammatory drugs in China: an 8-year real-life analysis.
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
The role of dermcidin isoform 2: a two-faceted atherosclerotic risk factor for coronary artery disease and the effect of acetyl salicylic Acid on it.
The translational therapeutics of prostaglandin inhibition in atherothrombosis.
The use of NSAIDs in rheumatic disorders 2005: a global perspective.
Treatment strategies for osteoarthritis patients with pain and hypertension.
Tubuloglomerular feedback is decreased in COX-1 knockout mice after chronic angiotensin II infusion.
Update on guidelines for the treatment of chronic musculoskeletal pain.
Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species.
Use of cox-2 inhibitors in patients with retinal venous occlusive disease.
Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
Uteroplacental insufficiency alters nephrogenesis and downregulates cyclooxygenase-2 expression in a model of IUGR with adult-onset hypertension.
Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives.
Vascular and Macrophage Heme Oxygenase-1 in Hypertension: A Mini-Review.
Vascular COX-2 modulates blood pressure and thrombosis in mice.
Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene.
Vascular smooth muscle, endothelial regulation and effects of aspirin in hypertension.
Vascular Smooth Muscle-Specific EP4 Receptor Deletion in Mice Exacerbates Angiotensin II-Induced Renal Injury.
Vasoconstrictor role of cyclooxygenase-1-mediated prostacyclin synthesis in non-insulin-dependent diabetic mice induced by high-fat diet and streptozotocin.
Vasomotor Reaction to Cyclooxygenase-1-Mediated Prostacyclin Synthesis in Carotid Arteries from Two-Kidney-One-Clip Hypertensive Mice.
Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2.
[Association and interaction of AGT, AGTR1, ACE, ADRB2, DRD1, ADD1, ADD2, ATP2B1, TBXA2R and PTGS2 genes on the risk of hypertension in Antioquian population].
[Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]
[Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects]
[Research advances of prostaglandin E2 synthases and receptors in cardiovascular diseases].
Hypertension, Malignant
Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension.
Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension.
Hypertension, Portal
A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury.
Amelioration of cirrhotic portal hypertension by targeted cyclooxygenase-1 siRNA delivery to liver sinusoidal endothelium with polyethylenimine grafted hyaluronic acid.
Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury.
Arachidonic acid metabolites and endothelial dysfunction of portal hypertension.
Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.
Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats.
Cyclooxygenase expression in splanchnic hyposensitivity to glypressin of bleeding portal hypertensive rats.
Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension.
Effects of Ultra-Low-Dose Aspirin in Thrombosis and Haemorrhage.
Endothelial COX-1 and -2 differentially affect reactivity of MVB in portal hypertensive rats.
Influence of nitric oxide synthase and cyclooxygenase blockade on expression of cyclooxygenase and hemodynamics in rats with portal hypertension.
Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension.
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
PGE
Role of cyclooxygenase isoforms in prostacyclin biosynthesis and murine prehepatic portal hypertension.
Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension.
Selective cyclooxygenase (COX) inhibition causes damage to portal hypertensive gastric mucosa: roles of nitric oxide and NF-kappaB.
The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction.
[Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases]
[The Expressions of Somatostatin and Cycloxygenase-2 in Chronic Hepatitis, Hepatic Cirrhosis, Precancerous Lesion and Hepatocellular Carcinoma].
Hypertension, Pregnancy-Induced
Control of prostacyclin synthesis in pregnancy-induced hypertension.
Cyclooxygenase gene expression in human endometrium and decidua.
Examination of the expression of cyclooxygenase-2 in placenta villi from sufferers of pregnancy induced hypertension.
Increased placental production of leukotriene B4 in gestational hypertension.
Vascular smooth muscle, endothelial regulation and effects of aspirin in hypertension.
Hypertension, Pulmonary
Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells.
Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension.
Arachidonate raises vascular resistance but not permeability in lungs of awake sheep.
Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs.
Attenuation of chronic hypoxic pulmonary hypertension in rats by cyclooxygenase products and by nitric oxide.
Autocrine function of inducible nitric oxide synthase and cyclooxygenase-2 in proliferation of human and rat pulmonary artery smooth-muscle cells: species variation.
Bacterial lipopolysaccharide induction of the prostaglandin G/H synthase 2 gene causes thromboxane-dependent pulmonary hypertension in rabbits.
Blunted hypoxic vasoconstriction in oleic acid lung injury: effect of cyclooxygenase inhibitors.
Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Chronic bronchitis: reflex on the pulmonary circulation.
Circulatory responses to endothelin-1 and nitric oxide with special reference to endotoxin shock and nitric oxide inhalation.
Cyclooxygenase and lipoxygenase inhibition by BW-755C reduces acrolein smoke-induced acute lung injury.
Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary embolism.
Cyclooxygenase inhibition during phorbol-induced granulocyte stimulation in awake sheep.
Cyclooxygenase products contribute to endothelin-induced pulmonary hypertension and altered lung mechanics in sheep.
Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension.
Cyclooxygenase-2 and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn pigs.
Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility.
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis.
Effect of blood and albumin on pulmonary hypertension and edema in perfused rabbit lungs.
Effects of cyclooxygenase inhibitors on pulmonary vascular responses to endotoxin in unanesthetized sheep.
Effects of indomethacin in utero on the pulmonary vasculature of the newborn guinea pig.
Enhanced microvascular permeability of PMA-induced acute lung injury is not mediated by cyclooxygenase products.
Gene therapy for acute lung injury.
Impact of prostaglandin and thromboxane synthesis blockade on disposition of group B streptococcus in lung and liver of intact piglet.
In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase.
Indomethacin, dazoxiben and extravascular lung water after Escherichia coli infusion.
Influence of prostaglandin D2 on hemodynamic effects of group B streptococcus in neonatal lambs.
Intratracheal administration of cyclooxygenase-1-transduced adipose tissue-derived stem cells ameliorates monocrotaline-induced pulmonary hypertension in rats.
Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2.
Intrinsic microbicidal activity and pulmonary hypertension in isolated newborn piglet lungs.
Isolated small bowel perforation following intrauterine treatment with indomethacin.
Leukotrienes, thromboxane A2, and prostaglandins during systemic anaphylaxis in sheep.
Lipoxygenase and cyclooxygenase blockade by BW755C does not prevent the secondary phase of septic pulmonary hypertension.
Medical treatment of pulmonary hypertension in acute lung disease.
Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis.
Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors.
Prostaglandin synthetase inhibitors and pulmonary hypertension.
Pulmonary dysfunction caused by diffuse lung inflammation. Roles of metabolites of arachidonic acid.
Pulmonary hypertensive response to foreign body microemboli.
Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline.
Pulmonary vascular pressures of strenuously exercising thoroughbreds after administration of phenylbutazone.
Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation.
rs2910164 Polymorphism Confers a Decreased Risk for Pulmonary Hypertension by Compromising the Processing of microRNA-146a.
Successful treatment of adult respiratory distress syndrome by histamine and prostaglandin blockade in a porcine Pseudomonas model.
Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2.
The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs.
The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock.
The promise of prostaglandins: have they fulfilled their potential as therapeutic targets for the delay of preterm birth?
The pulmonary hypertension of sclerosing agents is prevented by cyclooxygenase inhibitors.
[Developmental toxicity of the over-the-counter analgetics and antypiretics].
[Transient right ventricular hypertrophy in a newborn infant exposed in utero to nimesulide]
Hypertension, Renal
Regulation of ANP secretion from isolated atria by prostaglandins and cyclooxygenase-2.
Hypertension, Renovascular
Aspirin lowers blood pressure in patients with renovascular hypertension.
Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release.
Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension.
Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension.
Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension.
Cyclooxygenase-2 up-regulation in reflux nephropathy.
Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP.
Exaggerated renal thromboxane and prostaglandin release by angiotensin II in suprarenal aortic coarctation hypertension.
Increase in heme oxygenase-1 levels ameliorates renovascular hypertension.
Increased renal vasoconstriction and gene expression of cyclooxygenase-1 in renovascular hypertension.
Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Renal cortical regulation of COX-1 and functionally related products in early renovascular hypertension (rat).
Role of macula densa cyclooxygenase-2 in renovascular hypertension.
Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension.
Hyperthyroidism
Effects of Hypo- and Hyperthyroidism on Proliferation, Angiogenesis, Apoptosis and Expression of COX-2 in the Corpus Luteum of Female Rats.
Luteal activity of pregnant rats with hypo-and hyperthyroidism.
Hypertriglyceridemia
Fructose-induced inflammation, insulin resistance and oxidative stress: A liver pathological triad effectively disrupted by lipoic acid.
NIACIN AMELIORATES OXIDATIVE STRESS, INFLAMMATION, PROTEINURIA, AND HYPERTENSION IN RATS WITH CHRONIC RENAL FAILURE.
Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke.
Hypertrophy, Left Ventricular
2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation.
[The use of nebivolol for the treatment of hypertension in patients with osteoarthrosis]
Hypertrophy, Right Ventricular
Chronic Normobaric Hypoxia Induces Pulmonary Hypertension in Rats: Role of NF-?B.
Thromboxane does not mediate pulmonary vascular response to monocrotaline pyrrole.
[Transient right ventricular hypertrophy in a newborn infant exposed in utero to nimesulide]
Hyperventilation
Cerebral metabolic response to low blood flow: possible role of cytochrome oxidase inhibition.
Corticospinal excitability is associated with hypocapnia but not changes in cerebral blood flow.
Effect of indomethacin on the regulation of cerebral blood flow during respiratory alkalosis in newborn piglets.
Hyperventilation induces release of cytokines from perfused mouse lung.
Modulation of arachidonic acid-evoked cardiorespiratory effects by the central lipoxygenase pathway.
The relative contributions of histamine and prostanoids to bronchoconstriction provoked by isocapnic hyperventilation in asthma.
Use of indomethacin in brain-injured patients with cerebral perfusion pressure impairment: preliminary report.
Hypoalbuminemia
The influence of albumin and calcium on human platelet arachidonic acid metabolism.
Hypoaldosteronism
Hyperkalaemia with cyclooxygenase-2 inhibition and hypoaldosteronism.
Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
Paracrine regulation of the renin-aldosterone system.
Hypoglycemia
Benzylamine and methylamine, substrates of semicarbazide-sensitive amine oxidase, attenuate inflammatory response induced by lipopolysaccharide.
Hypokalemia
[Expert consensus for the diagnosis and treatment of patients with Gitelman syndrome].
Hypoparathyroidism
[Mechanisms of thrombocyte aggregation in experimental hypoparathyroidism]
Hypopharyngeal Neoplasms
Cyclooxygenase 2 promoter-based replication-selective adenoviral vector for hypopharyngeal cancer.
Enhancement of chemotherapeutic drug-induced apoptosis by a cyclooxygenase-2 inhibitor in hypopharyngeal carcinoma cells.
Histologic correlation of VEGF and COX-2 expression with tumor size in squamous cell carcinoma of the larynx and hypopharynx.
Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer.
Hypoprothrombinemias
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Hypotension
Activation of mTOR/I?B-?/NF-?B pathway contributes to LPS-induced hypotension and inflammation in rats.
Aspirin-exacerbated respiratory disease: evaluation and management.
Beagle puppy model of intraventricular hemorrhage: randomized indomethacin prevention trial.
Beneficial effect of indomethacin on acid-induced esophagitis in cats.
Blockade of PGHS-2 Inhibits the Hypothalamus-Pituitary-Adrenal Axis Response to Cerebral Hypoperfusion in the Sheep Fetus.
Bovine lactoferrin has a nitric oxide-dependent hypotensive effect in rats.
C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes.
Cardiopulmonary effects of tumor necrosis factor-alpha in the piglet: influence of cyclooxygenase inhibition.
Cardiovascular effects of leukotriene C4 and D4 in the anesthetized and conscious domestic hen.
Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.
Circulatory responses to endothelin-1 and nitric oxide with special reference to endotoxin shock and nitric oxide inhalation.
Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Contribution of Vasoactive Eicosanoids and Nitric Oxide Production to the Effect of Selective Cyclooxygenase-2 Inhibitor, NS-398, on Endotoxin-Induced Hypotension in Rats.
Contribution of vasoactive eicosanoids and nitric oxide production to the effect of selective cyclooxygenase-2 inhibitor, NS-398, on endotoxin-induced hypotension in rats.
Coronary effects of endothelin-1 and vasopressin during acute hypotension in anesthetized goats.
Cyclooxygenase-1 or -2--which one mediates lipopolysaccharide-induced hypothermia?
Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.
Effect of preischemia cyclooxygenase inhibition by zomepirac sodium on reflow, cerebral autoregulation, and EEG recovery in the cat after global ischemia.
Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone.
Haemodynamic and haematologic effects of Acanthaster planci venom in dogs.
HIGH-TIDAL VOLUME VENTILATION AGGRAVATES SEPSIS-INDUCED MULTIORGAN DYSFUNCTION IN A DEXAMETHASONE-INHIBITABLE MANNER.
Hypotensive effect of endothelin-1 in nitric oxide-deprived, hypertensive pregnant rats.
Increased survival of endotoxin-injected dogs treated with methylprednisolone, naloxone, and ibuprofen.
Induction of PGHS-2 mRNA in response to cerebral hypoperfusion in late-gestation fetal sheep.
Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.
Intracamerally injected platelet activating factor (PAF) induces marked intraocular inflammatory reactions.
Involvement of COX and NOS induction in the sympatho-activation during sepsis.
Lipoxygenase and cyclooxygenase blockade by BW755C prevents endotoxin-induced hypotension but not changes in glucose metabolism.
Mast cell disease.
Nitric oxide and ?2-adrenoceptor activation attenuate pulmonary vasoconstriction during anaphylactic hypotension in anesthetized BALB/c mice.
Opioids and the prostanoid system in the control of cerebral blood flow in hypotensive piglets.
Phospholipase A2-induced hypotension in the rat and its pharmacological modulation.
Piroxicam Reverses Endotoxin-Induced Hypotension in Rats: Contribution of Vasoactive Eicosanoids and Nitric Oxide.
Platelet activation in carotid sinuses triggers reflex sympathoinhibition and hypotension.
Prostaglandins inhibit cytochrome P450 4A activity and contribute to endotoxin-induced hypotension in rats via nitric oxide production.
Pulmonary vasoregulation by cyclooxygenase metabolites and angiotensin II after hypoperfusion in conscious, pentobarbital-anesthetized, and halothane-anesthetized dogs.
Role of platelet-activating factor and prostanoids in hemodynamic changes in rat experimental endotoxic shock.
San-Huang-Xie-Xin-Tang reduces lipopolysaccharides-induced hypotension and inflammatory mediators.
The action of sevoflurane on vascular smooth muscle of isolated mesenteric resistance arteries (part 1): role of endothelium.
The role of Syk/I?B-?/NF-?B pathway activation in the reversal effect of BAY 61-3606, a selective Syk inhibitor, on hypotension and inflammation in a rat model of zymosan-induced non-septic shock.
TNF-alpha and cyclooxygenase metabolites do not modulate C. albicans septic shock with disseminated candidiasis.
Treatment of refractory mesenteric traction syndrome without cyclooxygenase inhibitors.
Ventilation-induced lung injury in rats is associated with organ injury and systemic inflammation that is attenuated by dexamethasone.
Hypotension, Orthostatic
The treatment of idiopathic orthostatic hypotension: a combined fludrocortisone and flurbiprofen regime.
[The treatment of orthostatic hypotension with metoclopramide]
Hypothyroidism
Effects of Hypo- and Hyperthyroidism on Proliferation, Angiogenesis, Apoptosis and Expression of COX-2 in the Corpus Luteum of Female Rats.
Hypothyroidism increases cyclooxygenase-2 levels and pro-inflammatory response and decreases cell proliferation and neuroblast differentiation in the hippocampus.
Hypoventilation
Hypoventilation and elevation of end-expiratory pressure release a substance which relaxes isolated arteries and disaggregates platelets in the presence of cyclooxygenase inhibitors.
Hypoxia, Brain
Effect of cyclooxygenase inhibition on brain cell membrane lipid peroxidation during hypoxia in newborn piglets.
Protective effect of KBT-3022, a new cyclooxygenase inhibitor, in cerebral hypoxia and ischemia.
Hypoxia-Ischemia, Brain
Cyclooxygenase-2 inhibition provides lasting protection against neonatal hypoxic-ischemic brain injury.
Molecular hydrogen alleviates asphyxia-induced neuronal cyclooxygenase-2 expression in newborn pigs.
The effects of indomethacin on caspases, glutathione level and lipid peroxidation in the newborn rats with hypoxic-ischemic cerebral injury.
Idiopathic Pulmonary Fibrosis
A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.
A haplotype of cyclooxygenase-2 gene is associated with idiopathic pulmonary fibrosis.
Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2.
Cyclooxygenase and cytokine regulation in lung fibroblasts activated with viral versus bacterial pathogen associated molecular patterns.
Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis.
Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis.
Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis.
Evaluation of cyclooxygenase-2 fluctuation via a near-infrared fluorescent probe in idiopathic pulmonary fibrosis cell and mice models.
Immunohistochemical and morphometric evaluation of COX 1 and COX-2 in the remodeled lung in idiopathic pulmonary fibrosis and systemic sclerosis.
MELATONIN ALLEVIATES BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN MICE.
Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis.
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.
ikappab kinase deficiency
Activation of both nuclear factor of activated T cells and inhibitor of nuclear factor-kappa B kinase beta-subunit-/nuclear factor-kappa B is critical for cyclooxygenase-2 induction by benzo[a]pyrene in human bronchial epithelial cells.
Ileitis
Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.
Unique Regulation of Intestinal Villus Epithelial Cl-/HCO3- Exchange by Cyclooxygenase Pathway Metabolites of Arachidonic Acid in a Mouse Model of Spontaneous Ileitis.
Ileus
Alvimopan and COX-2 inhibition reverse opioid and inflammatory components of postoperative ileus.
Clinical Trial: The impact of cyclooxygenase inhibitors on gastrointestinal recovery after major surgery: a randomised double blind controlled trial of Celecoxib or Diclofenac versus placebo.
COX-2 dependent inflammation increases spinal Fos expression during rodent postoperative ileus.
COX-2 inhibitors and postoperative ileus.
Differential salutary effects of nonselective and selective COX-2 inhibitors in postoperative ileus in rats.
Differential sensitization of afferent neuronal pathways during postoperative ileus in the mouse jejunum.
Effect of cyclooxygenase inhibitors in postoperative ileus: an experimental study.
Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans.
Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions.
Gastric and small bowel ileus after severe burn in rats: The effect of cyclooxygenase-2 inhibitors.
Mentation on the immunological modulation of gastrointestinal motility.
PPAR{gamma} Activation Alleviates Postoperative Ileus in Mice by Inhibition of Egr-1 Expression and Its Downstream Target Genes.
Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility.
Products of cyclooxygenase-2 depress duodenal function in rats subjected to abdominal surgery.
Prostanoid production via COX-2 as a causative mechanism of rodent postoperative ileus.
The impact of cyclooxygenase inhibition on duodenal motility and mucosal alkaline secretion in anaesthetised rats.
The role and interactions of nitric oxide (NO), carbon monoxide (CO), and prostanoids in the pathogenesis of postoperative ileus in rats.
The selective cyclooxygenase-2 inhibitor parecoxib markedly improves the ability of the duodenum to regulate luminal hypertonicity in anaesthetized rats.
Immune System Diseases
Anti-inflammation action of xanthones from Swertia chirayita by regulating COX-2/NF-?B/MAPKs/Akt signaling pathways in RAW 264.7 macrophage cells.
Cyclooxygenase-2 blockade inhibits accumulation and function of myeloid-derived suppressor cells and restores T cell response after traumatic stress.
Prevention of spontaneous polyarthritis in NZB/KN mice by treatment with a novel thiazole derivative, SM-8849.
Infarction, Middle Cerebral Artery
Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats.
Anti-Inflammatory Effects of Total Isoflavones from Pueraria lobata on Cerebral Ischemia in Rats.
Apobec-1 increases cyclooxygenase-2 and aggravates injury in oxygen-deprived neurogenic cells and middle cerebral artery occlusion rats.
Arachidonic acid metabolite production following focal cerebral ischemia: time course and effect of meclofenamate.
Celecoxib-Dependent Neuroprotection in a Rat Model of Transient Middle Cerebral Artery Occlusion (tMCAO) Involves Modifications in Unfolded Protein Response (UPR) and Proteasome.
Cyclo-oxygenase-2 messenger RNA induction in focal cerebral ischemia.
Cyclooxygenase-1 gene knockout does not alter middle cerebral artery occlusion in a mouse stroke model.
Cyclooxygenase-2 activity contributes to neuronal expression of cyclin D1 after anoxia/ischemia in vitro and in vivo.
Cyclooxygenase-2 and Prostaglandin E2 are Associated with Middle Cerebral Artery Occlusion and Hemorrhage in Patients with Moyamoya Disease.
Cyclooxygenase-2 mediates the development of cortical spreading depression-induced tolerance to transient focal cerebral ischemia in rats.
Effect of indomethacin and a free radical scavenger on cerebral blood flow and edema after cerebral artery occlusion in cats.
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat.
Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat.
Genetic Deletion or Pharmacological Inhibition of Cyclooxygenase-2 Reduces Blood-Brain Barrier Damage in Experimental Ischemic Stroke.
Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice.
Induction of cyclooxygenase-2 messenger RNA after transient and permanent middle cerebral artery occlusion in rats: comparison with c-fos messenger RNA by using in situ hybridization.
Inhibition of Acyl-CoA Synthetase Long-Chain Family Member 4 Facilitates Neurological Recovery After Stroke by Regulation Ferroptosis.
Metabolic changes of arachidonic acid after cerebral ischemia-reperfusion in diabetic rats.
Microglia and cyclooxygenase-2: Possible therapeutic targets of progesterone for stroke.
Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction.
Parecoxib is neuroprotective in spontaneously hypertensive rats after transient middle cerebral artery occlusion: a divided treatment response?
Perillyl alcohol improves functional and histological outcomes against ischemia-reperfusion injury by attenuation of oxidative stress and repression of COX-2, NOS-2 and NF-?B in middle cerebral artery occlusion rats.
Piperine suppresses cerebral ischemia-reperfusion-induced inflammation through the repression of COX-2, NOS-2, and NF-?B in middle cerebral artery occlusion rat model.
Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity.
Protective effect of Etoricoxib against middle cerebral artery occlusion induced transient focal cerebral ischemia in rats.
Resveratrol attenuates brain damage in permanent focal cerebral ischemia via activation of PI3K/Akt signaling pathway in rats.
Temporary focal cerebral ischemia in spontaneously hypertensive rats: the effect of ibuprofen on infarct volume.
The cyclooxygenase site, but not the peroxidase site of cyclooxygenase-2 is required for neurotoxicity in hypoxic and ischemic injury.
Infections
-
5-LOX inhibitor modulates the inflammatory responses provoked by Helicobacter pylori infection.
A cyclooxygenase-2 homologue encoded by rhesus cytomegalovirus is a determinant for endothelial cell tropism.
A Novel Virulence Strategy for Pseudomonas aeruginosa Mediated by an Autotransporter with Arginine-Specific Aminopeptidase Activity.
A reexamination of the role of oxygen in retrolental fibroplasia.
Activation of COX-2/PGE2 Promotes Sapovirus Replication via the Inhibition of Nitric Oxide Production.
Activation of monocyte cyclooxygenase-2 gene expression by human herpesvirus 6. Role for cyclic AMP-responsive element-binding protein and activator protein-1.
Adenovirus type 5 exerts multiple effects on the expression and activity of cytosolic phospholipase A2, cyclooxygenase-2, and prostaglandin synthesis.
Amebic infection in the human colon induces cyclooxygenase-2.
An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.
Analysis of chicken mucosal immune response to Eimeria tenella and Eimeria maxima infection by quantitative reverse transcription-PCR.
Analysis of proinflammatory gene expression by RBIV infection in rock bream, Oplegnathus faciatus.
Anti-biofilm effect by the combined action of fluconazole and acetylsalicylic acid against species of Candida parapsilosis complex.
Anti-inflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: a novel mechanism.
Anti-inflammatory and anti-oxidative effect of Korean propolis on Helicobacter pylori-induced gastric damage in vitro.
Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2.
Antibacterial and COX-1 Inhibitory Effect of Medicinal Plants from the Pamir Mountains, Afghanistan.
Antiviral activity of a selective COX-2 inhibitor NS-398 on avian influenza H5N1 infection.
Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro.
Aqueous Extract of the Edible Gracilaria tenuistipitata Inhibits Hepatitis C Viral Replication via Cyclooxygenase-2 Suppression and Reduces Virus-Induced Inflammation.
Arachidonic Acid Derived Lipid Mediators Influence Kaposi's Sarcoma-Associated Herpesvirus Infection and Pathogenesis.
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease.
ASC-dependent RIP2 Kinase Regulates Reduced PGE2 Production in Chronic Periodontitis.
Aspirin inhibits Chlamydia pneumoniae-induced NF-kappa B activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth.
Aspirin modulates innate inflammatory response and inhibits the entry of Trypanosoma cruzi in mouse peritoneal macrophages.
Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan.
Association between reactive arthritis and antecedent infection with Shigella flexneri carrying a 2-Md plasmid and encoding an HLA-B27 mimetic epitope.
Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer.
Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2.
Besnoitia besnoiti infections activate primary bovine endothelial cells and promote PMN adhesion and NET formation under physiological flow condition.
Bioactive lipids in Trypanosoma cruzi infection.
Biogenically Synthesized Polysaccharides-Capped Silver Nanoparticles: Immunomodulatory and Antibacterial Potentialities Against Resistant Pseudomonas aeruginosa.
Blood COX-2 and PGES gene transcription during the peripartum period of dairy cows with normal puerperium or with uterine infection.
Bluetongue virus-induced activation of primary bovine lung microvascular endothelial cells.
Bordetella pertussis adenylate cyclase toxin (ACT) induces cyclooxygenase-2 (COX-2) in murine macrophages and is facilitated by ACT interaction with CD11b/CD18 (Mac-1).
Bovine herpesvirus 4 is tropic for bovine endometrial cells and modulates endocrine function.
Burn injury with infection alters prostaglandin E2 synthesis and metabolism.
BVDV alters uterine prostaglandin production during pregnancy recognition in cows.
Cancerogenesis in Helicobacter pylori infected stomach--role of growth factors, apoptosis and cyclooxygenases.
Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells.
Cardioprotective actions of curcumin on the pathogenic NFAT/COX-2/prostaglandin E2 pathway induced during Trypanosoma cruzi infection.
Cascade of fever production in mice infected with influenza virus.
CCR5-Dependent Activation of mTORC1 Regulates Translation of Inducible NO Synthase and COX-2 during Encephalomyocarditis Virus Infection.
Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils.
Cellular signals involved in cyclooxygenase-2 expression induced by human cytomegalovirus.
Characterization of the stable maintenance of the Shigella flexneri plasmid pHS-2.
Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible?
Chromatin and DNA methylation dynamics of Helicobacter pylori-induced COX-2 activation.
Chronic infection during placental malaria is associated with up-regulation of cycloxygenase-2.
Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection.
Circulating levels of cyclooxygenase metabolites in experimental Trypanosoma cruzi infections.
Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma.
Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK.
Club cell 10-kDa protein (CC10) inhibits cPLA2/COX2 pathway to alleviate RSV-induced airway inflammation and AHR.
Combination of EPA with Carotenoids and Polyphenol Synergistically Attenuated the Transformation of Microglia to M1 Phenotype Via Inhibition of NF-?B.
Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma.
Concurrent Control of KSHV Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: A New Prospect to the Therapeutic Potential of Lipoxin A4.
Conditional knockout mouse for tissue-specific disruption of the cyclooxygenase-2 (Cox-2) gene.
Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection.
Control of salivary secretion by nitric oxide and its role in neuroimmunomodulation.
Correction: Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.
Correlations among Helicobacter pylori infection and the expression of cyclooxygenase-2 and vascular endothelial growth factor in gastric mucosa with intestinal metaplasia or dysplasia.
COX-1 and COX-2 polymorphisms in susceptibility to cerebral palsy in very preterm infants.
COX-1 and COX-3 inhibitors.
COX-2 Gene Promoter Methylation in Patients Infected with Helicobacter Pylori.
COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression.
Cox-2 inhibition abrogates Chlamydia pneumoniae-induced PGE2 and MMP-1 expression.
COX-2 inhibition affects growth rate of Chlamydia muridarum within epithelial cells.
COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production.
COX-2 Inhibition Reduces Brucella Bacterial Burden in Draining Lymph Nodes.
COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications.
Cross-talk between inducible nitric oxide synthase and cyclooxygenase in Helicobacter-pylori-induced gastritis.
Cutting edge: cyclooxygenase-2 activation suppresses Th1 polarization in response to Helicobacter pylori.
Cyclo-oxygenase 2 expression impairs serum-withdrawal-induced apoptosis in liver cells.
Cyclooxigenase-2 and osteopontin in gastric pre-neoplastic lesions in relation to H-pylori infection and grade of inflammation.
Cyclooxygenase (COX)-2 Inhibitors Reduce Toxoplasma gondii Infection and Upregulate the Pro-inflammatory Immune Response in Calomys callosus Rodents and Human Monocyte Cell Line.
Cyclooxygenase (COX)-2 modulates Toxoplasma gondii infection, immune response and lipid droplets formation in human trophoblast cells and villous explants.
Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression.
Cyclooxygenase activity is important for efficient replication of mouse hepatitis virus at an early stage of infection.
Cyclooxygenase expression during Helicobacter pylori infection in Mongolian gerbils.
Cyclooxygenase inhibitor use is associated with increased COVID-19 severity.
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice.
Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus.
Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17.
Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.
Cyclooxygenase-2 blockade inhibits accumulation and function of myeloid-derived suppressor cells and restores T cell response after traumatic stress.
Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma.
Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment.
Cyclooxygenase-2 expression in early gastric cancer, intestinal metaplasia and Helicobacter pylori infection.
Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection.
Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents.
Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression.
Cyclooxygenase-2 Generates the Endogenous Mutagen trans-4-Hydroxy-2-nonenal in Enterococcus faecalis-Infected Macrophages.
Cyclooxygenase-2 haplotypes influence the longitudinal risk of malaria and severe malarial anemia in Kenyan children from a holoendemic transmission region.
Cyclooxygenase-2 Inhibition Enhances Activation of T Helper Type 1 Responses During Salmonella Infection.
Cyclooxygenase-2 Inhibition Reduces Autophagy of Macrophages Enhancing Extraintestinal Pathogenic Escherichia coli Infection.
Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection.
Cyclooxygenase-2 inhibits tumor necrosis factor alpha-mediated apoptosis in renal glomerular mesangial cells.
Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Cyclooxygenase-2/Carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells.
Cytokine-mediated regulation of monocyte/macrophage cytotoxicity in human immunodeficiency virus-1 infection.
Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.
Depletion of immature B cells during Trypanosoma cruzi infection: involvement of myeloid cells and the cyclooxygenase pathway.
Deregulation of cyclooxygenase and nitric oxide synthase gene expression in the inflammatory cascade triggered by experimental group B streptococcal meningitis in the newborn brain and cerebral microvessels.
Design, synthesis and preliminary evaluation of the anti-inflammatory of the specific selective targeting druggable enzymome cyclooxygenase-2 (COX-2) small molecule.
Designing of CD8+ and CD8+-overlapped CD4+ epitope vaccine by targeting late and early proteins of human papillomavirus.
Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies.
Diminished COX-2/PGE2-Mediated Antiviral Response Due to Impaired NOX/MAPK Signaling in G6PD-Knockdown Lung Epithelial Cells.
Disease resistance and response against Vibrio anguillarum intestinal infection in European seabass (Dicentrarchus labrax) fed low fish meal and fish oil diets.
Dynamics of transcription of immunomodulatory genes in endothelial cells infected with different coccidian parasites.
Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention.
Effect of experimental genital mycoplasmosis on gene expression in the fetal brain.
Effect of H. pylori infection on the expression of cyclooxygenase-2 in human gastric mucosa.
Effect of H. pylori on COX-2 expression in gastric remnant after distal gastrectomy.
Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer.
Effect of heptitis C virus core protein on cellular gene expression: specific inhibition of cyclooxygenase 2.
Effect of Probiotics and Triple Eradication Therapy on the Cyclooxygenase (COX)-2 Expression, Apoptosis, and Functional Gastric Mucosal Impairment in Helicobacter pylori-Infected Mongolian Gerbils.
Effects of cyclooxygenase inhibitors on parasite burden, anemia and oxidative stress in murine Trypanosoma cruzi infection.
Effects of Cyclooxygenase-1 and -2 Gene Disruption on Helicobacter pylori-Induced Gastric Inflammation.
Effects of cyclooxygenase-2 inhibitor on gastric acid secretion in Helicobacter pylori-infected C57BL/6 mice.
Effects of dietary arachidonic acid in European sea bass (Dicentrarchus labrax) distal intestine lipid classes and gut health.
Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E do not depend on Helicobacter pylori infection.
Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity.
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
Effects of selective cyclooxygenase-2 inhibitor and non-selective NSAIDs on Helicobacter pylori-induced gastritis in Mongolian gerbils.
Effects of treatments with cyclooxygenase inhibitors on chickens infected with Eimeria acervulina.
Eicosanoid pathway on host resistance and inflammation during Mycobacterium tuberculosis infection is comprised by LTB4 reduction but not PGE2 increment.
Enhanced activation of cyclooxygenase-2 downregulates Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa.
Entamoeba histolytica Cyclooxygenase-Like Protein Regulates Cysteine Protease Expression and Virulence.
Entamoeba histolytica: induction of cyclooxygenase-2 expression during amoebic liver abscess formation in hamsters (Mesocricetus auratus).
Enteroinvasive bacteria alter barrier and transport properties of human intestinal epithelium: role of iNOS and COX-2.
Enterovirus 71 antagonizes the antiviral activity of host STAT3 and IL-6R with partial dependence on virus-induced miR-124.
EP2/4 Receptors Promote the Synthesis of PGE2 Increasing Tissue Damage in Bovine Endometrial Explants Induced by Escherichia coli.
Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment.
ESAT-6 induced COX-2 expression involves coordinated interplay between PI3K and MAPK signaling.
Escherichia coli-induced inducible nitric oxide synthase and cyclooxygenase expression in the mouse bladder and kidney.
Ethyl acetate fraction of flavonoids from Polygonum hydropiper L. modulates pseudorabies virus-induced inflammation in RAW264.7 cells via the NF-?B and MAPK pathways.
Evidence for tumor necrosis factor alpha as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis.
Experimental murine schistosomiasis: reduced hepatic morbidity after pre- and/or post-infection treatment with ibuprofen or diclofenac sodium.
Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis.
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma.
Expression of COX-1, COX-2, and inducible nitric oxide synthase protein in human gastric antrum with Helicobacter pylori infection.
Expression of COX-1, COX-2, and PPAR-gamma in the gastric mucosa of children with Helicobacter pylori infection.
Expression of COX-2 proteins in gastric mucosal lesions.
Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis.
Expression of cyclooxygenase 2 and vascular endothelial growth factor in gastric carcinoma: Relationship with clinicopathological parameters.
Expression of cyclooxygenase-2 and nitric oxide synthase 2 in swine ulcerative colitis caused by Salmonella typhimurium.
Expression of cyclooxygenase-2 and nitrotyrosine in human gastric mucosa before and after Helicobacter pylori eradication.
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis.
Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression.
Expression of cyclooxygenase-2 in the mammary gland tissue of goats affected with caprine contagious agalactia.
Expression of cyclooxygenase-2, alpha 1-acid-glycoprotein and inducible nitric oxide synthase in the developing lesions of murine leprosy.
Expression of cyclooxygenases in Helicobacter pylori gastritis and residual gastritis after distal gastrectomy.
Expression of immune response genes in rainbow trout skin induced by Gyrodactylus derjavini infections.
Expression of immune-related genes of Nile tilapia Oreochromis niloticus after Gyrodactylus cichlidarum and Cichlidogyrus sclerosus infections demonstrating immunosupression in coinfection.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Expression of nitric oxide synthase 2 and cyclooxygenase-2 in swine experimentally infected with Actinobacillus pleuropneumoniae.
Extracellular HIV-Tat induces cyclooxygenase-2 in glial cells through activation of nuclear factor of activated T cells.
Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet.
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Gastric cancer and Helicobacter pylori infection.
Gastric MALT-lymphoma, gastrin and cyclooxygenases.
Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy.
Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor.
Gene expression profiling in human neutrophils after infection with Acinetobacter baumannii in vitro.
Genetic polymorphisms of cyclooxygenase-1 (COX-1) are associated with functional dyspepsia in Japanese women.
Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population.
Gonococcal porin IB activates NF-kappaB in human urethral epithelium and increases the expression of host antiapoptotic factors.
H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis.
H1N1 influenza virus infection results in adverse pregnancy outcomes by disrupting tissue-specific hormonal regulation.
HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway.
Helicobacter and gastric malignancies.
Helicobacter pylori and non-malignant diseases.
Helicobacter pylori eradication therapy on histologic change in the distal esophagus.
Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies.
Helicobacter pylori infection in gastric cancerogenesis.
Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa.
Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis.
Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer.
Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway.
Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.
Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors.
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer.
Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer.
Helicobacter pylori-induced expression of interleukin-8 and cyclooxygenase-2 in AGS gastric epithelial cells: mediation by nuclear factor-kappaB.
Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2.
High Expression of IL-36? in Influenza Patients Regulates Interferon Signaling Pathway and Causes Programmed Cell Death During Influenza Virus Infection.
Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients.
Highly pathogenic porcine reproductive and respiratory syndrome virus induces prostaglandin E2 production through cyclooxygenase 1, which is dependent on the ERK1/2-p-C/EBP-? pathway.
Histochemical investigations of the biochemical defence mechanism in experimental trichinellosis: II. prostaglandin synthase activity.
Histopathology and expression of Ki-67 and cyclooxygenase-2 in childhood Helicobacter pylori gastritis.
Hormonal Regulation of Physiology, Innate Immunity and Antibody Response to H1N1 Influenza Virus Infection During Pregnancy.
Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.
Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages.
Host single nucleotide polymorphisms of MMP-9 -1562/TIMP-1 372 have gender differences in the risk of gastric intestinal metaplasia after Helicobacter pylori infection.
Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.
Human cytomegalovirus circumvents NF-kappa B dependence in retinal pigment epithelial cells.
Human cytomegalovirus induced cyclooxygenase-2 in human retinal pigment epithelial cells augments viral replication through a prostaglandin pathway.
Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.
Human follicular dendritic cells promote germinal center B cell survival by providing prostaglandins.
Human intestinal epithelial cells respond to Cryptosporidium parvum infection with increased prostaglandin H synthase 2 expression and prostaglandin E2 and F2alpha production.
Hypoxia Induces Macrophage tnfa Expression via Cyclooxygenase and Prostaglandin E2 in vivo.
Identification by DNA microarray of genes involved in Candida albicans-treated gingival epithelial cells.
Identification of novel cyclooxygenase-2-dependent genes in Helicobacter pylori infection in vivo.
IDO, COX and iNOS have an important role in the proliferation of Neospora caninum in neuron/glia co-cultures.
IL-10 suppresses bactericidal response of macrophages against Salmonella Typhimurium.
IL-1beta treatment does not co-ordinately up-regulate mPGES-1 and COX-2 mRNA expression, but results in higher degree of cellular and intracellular co-localization of their immunoreactive proteins in human placenta trophoblast cells.
Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei.
Immune-related genes expression profile in orange-spotted grouper during exposure to Cryptocaryon irritans.
Immunohistochemical assessment of p16, COX-2 and EGFR in HPV-positive cervical squamous intraepithelial lesions.
Immunohistochemical evaluation of interleukin-23 and cyclooxygenase-2 in the muscles of mice infected with Trichinella spiralis.
Immunohistochemical Labelling of Cyclooxygenase-2 in Lung Lesions of Calves Infected with Mycoplasma bovis.
Immunomodulation of cellular cytotoxicity to herpes simplex virus infection in pregnancy by inhibition of eicosanoid metabolism.
Immunopathogenesis of cerebral malaria.
Immunoprotective effects of cyclooxygenase inhibition in patients with major surgical trauma.
Impact of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on gastric ulcerogenesis in experimental animals and in humans.
Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration.
Implications of corpus gastritis, atrophy and cyclooxygenase in the development of gastric erosions after curing Helicobacter pylori infection.
Inactivation of COX-2, HMLH1 and CDKN2A Gene by Promoter Methylation in Gastric Cancer: Relationship with Histological Subtype, Tumor Location and Helicobacter pylori Genotype.
Increased COX-2 Expression in Human Vaginal Epithelial Cells Exposed to Nonoxynol-9, a Vaginal Contraceptive Microbicide that Failed to Protect Women from HIV-1 Infection.
Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis.
Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins.
Indomethacin enhances the proliferation of mitogen-stimulated T lymphocytes of homosexual males with persistent generalized lymphadenopathy.
Inducible cyclooxygenase released prostaglandin E2 modulates the severity of infection caused by Streptococcus pyogenes.
Inducible cyclooxygenase released prostaglandin mediates immunosuppression in acute phase of experimental Trypanosoma cruzi infection.
Induction of cyclo-oxygenase-2 by acute liver allograft rejection and cytomegalovirus infection in the rat.
Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1, DeltaE3 recombinant adenovirus vectors.
Induction of Cyclooxygenase (COX)-2 in Human Vaginal Epithelial Cells in Response to TLR ligands and TNF-?
Induction of Cyclooxygenase 2 by Streptococcus pyogenes Is Mediated by Cytolysins.
Induction of cyclooxygenase-2 by human monocytes exposed to group B streptococci.
Induction of cyclooxygenase-2 by overexpression of the human catalase gene in cerebral microvascular endothelial cells.
Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades.
Infection and activation of airway epithelial cells by Chlamydia pneumoniae.
Infection of human endothelial cells with spotted Fever group rickettsiae stimulates cyclooxygenase 2 expression and release of vasoactive prostaglandins.
Infection of human urethral epithelium with Neisseria gonorrhoeae elicits an upregulation of host anti-apoptotic factors and protects cells from staurosporine-induced apoptosis.
Infectious bursal disease virus infection induces macrophage activation via p38 MAPK and NF-kappaB pathways.
Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.
Influence of COX-2 and local cytokine expressions in gastric ulcer mucosa by H. pylori and NSAID.
Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.
Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection.
Influences of Helicobacter pylori on cyclooxygenase-2 expression and prostaglandinE2 synthesis in rat gastric epithelial cells in vitro.
Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs.
Influenza A viruses suppress cyclooxygenase-2 expression by affecting its mRNA stability.
Infrequent COX-2 expression due to promoter hypermethylation in gastric cancers in Dalian, China.
Inhibition of attaching and effacing lesion formation following enteropathogenic Escherichia coli and Shiga toxin-producing E. coli infection.
Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication.
Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.
Inhibition of rotavirus ECwt infection in ICR suckling mice by N-acetylcysteine, peroxisome proliferator-activated receptor gamma agonists and cyclooxygenase-2 inhibitors.
Inhibition of salivary secretion by lipopolysaccharide: possible role of prostaglandins.
Inhibition of TNF-alpha-induced cyclooxygenase-2 expression by Mycobacterium bovis BCG in human alveolar epithelial A549 cells.
Inhibitory effect of polysaccharide of Sargassum weizhouense on PCV2 induced inflammation in mice by suppressing histone acetylation.
Interaction of Cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer.
Interaction of Cyclooxygenase-2 with Helicobacter pylori Induces Gastric Chronic Nonresolving Inflammation and the Formation of Syndrome of Internal Block of Static Blood in Helicobacter pylori-Related Gastric Diseases.
Interaction of Helicobacter pylori (Hp) and nonsteroidal anti-inflammatory drugs (NSAID) on gastric mucosa and risk of ulcerations.
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
Intracellular colon cancer-associated Escherichia coli promote protumoral activities of human macrophages by inducing sustained COX-2 expression.
Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria.
Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice.
Involvement of p38 MAPK-dependent activator protein (AP-1) activation in modulation of gastric mucosal inflammatory responses to Helicobacter pylori by ghrelin.
Involvement of prostaglandins in the immunosuppression occurring during experimental infection by Paracoccidioides brasiliensis.
Involvement of TLR4 signaling regulated-COX2/PGE2 axis in liver fibrosis induced by Schistosoma japonicum infection.
Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion.
Kaposi's Sarcoma-Associated Herpesvirus Induces Nrf2 Activation in Latently Infected Endothelial Cells through SQSTM1 Phosphorylation and Interaction with Polyubiquitinated Keap1.
KH-type splicing regulatory protein is regulated by nuclear factor-?B signaling to mediate innate immunity in Caco-2 cells infected by Salmonella enteritidis.
Leishmania donovani-induced macrophages cyclooxygenase-2 and prostaglandin E2 synthesis.
Local immune system in oviduct physiology and pathophysiology: attack or tolerance?
Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans.
Localization of prostaglandin H synthase, prostaglandin dehydrogenase, corticotropin releasing hormone and glucocorticoid receptor in rhesus monkey fetal membranes with labor and in the presence of infection.
LPS promotes a monocyte phenotype permissive for human cytomegalovirus immediate-early gene expression upon infection but not reactivation from latency.
M. bovis BCG induced expression of COX-2 involves nitric oxide-dependent and -independent signaling pathways.
Macrophage activation associated with chronic murine cytomegalovirus infection results in more severe experimental choroidal neovascularization.
Matrix metalloproteinase secretion by gastric epithelial cells is regulated by E prostaglandins and MAPKs.
Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction.
Melatonin antagonizes lipopolysaccharide-induced pulpal fibroblast responses.
Microcirculatory alteration in low-grade gastric mucosa-associated lymphoma by Helicobacter heilmannii infection: its relation to vascular endothelial growth factor and cyclooxygenase-2.
Microglial activation induces neuronal death in Chandipura virus infection.
MicroRNA-29b modulates Japanese encephalitis virus-induced microglia activation by targeting tumor necrosis factor alpha-induced protein 3.
MicroRNA-381 protects myocardial cell function in children and mice with viral myocarditis via targeting cyclooxygenase-2 expression.
Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2.
Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking.
Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors.
Morphoproteomics and Etiopathogenic Features of Pulmonary COVID-19 with Therapeutic Implications: A Case Study.
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.
Muramyl dipeptide potentiates staphylococcal lipoteichoic acid induction of cyclooxygenase-2 expression in macrophages.
Mycobacterial 3-hydroxyacyl-l-thioester dehydratase Y derived from Mycobacterium tuberculosis induces COX-2 expression in mouse macrophages through MAPK-NF-?B pathway.
Mycobacterium bovis Bacillus Calmette-Guerin Induces TLR2-Mediated Formation of Lipid Bodies: Intracellular Domains for Eicosanoid Synthesis In Vivo.
Mycobacterium indicus pranii downregulates MMP-9 and iNOS through COX-2 dependent and TNF-? independent pathway in mouse peritoneal macrophages in vitro.
Natural COX-2 inhibitors as promising anti-inflammatory agents: an update.
Neonatal bacterial infection alters fever to live and simulated infections in adulthood.
Neuron-Derived ADAM10 Production Stimulates Peripheral Nerve Injury-Induced Neuropathic Pain by Cleavage of E-Cadherin in Satellite Glial Cells.
Neuronal cyclooxygenase-2 activity and prostaglandins PGE2, PGD2, and PGF2 alpha exacerbate hypoxic neuronal injury in neuron-enriched primary culture.
NFAT AND CREB REGULATE KAPOSI'S SARCOMA ASSOCIATED HERPES VIRUS (KSHV) INDUCED CYCLOOXYGENASE-2 (COX-2).
Nonsteroidal anti-inflammatory drug-induced acute gastric injury in Helicobacter pylori gastritis in Mongolian gerbils.
Nontypeable Haemophilus influenzae induces COX-2 and PGE2 expression in lung epithelial cells via activation of p38 MAPK and NF-kappa B.
Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome.
Novel Function of Cyclooxygenase-2: Suppressing Mycobacteria by Promoting Autophagy via the Protein Kinase B/Mammalian Target of Rapamycin Pathway.
NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways.
NSP2 Is Important for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus to Trigger High Fever-Related COX-2-PGE2 Pathway in Pigs.
Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer.
OmpA is the critical component for Escherichia coli invasion-induced astrocyte activation.
Over-expression of cyclooxygenase-2 in endoscopic biopsies of ectopic gastric mucosa.
Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients.
Overexpression of human catalase inhibits proliferation and promotes apoptosis in vascular smooth muscle cells.
Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells.
Peptidases from latex of Carica candamarcensis upregulate COX-2 and IL-1 mRNA transcripts against Salmonella enterica ser. Typhimurium-mediated inflammation.
Persistent increase in myofibroblasts in Helicobacter heilmannii-infected mice but not in Helicobacter pylori-infected Mongolian gerbils: colocalization of COX-2 and bFGF immunoreactivity.
Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study.
Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: A study from northern India.
Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei.
Potential mechanisms of Chinese Herbal Medicine that implicated in the treatment of COVID-19 related renal injury.
Potential roles for regulatory oxygenases in rickettsial pathogenesis.
Poxvirus-induced alteration of arachidonate metabolism.
Preferential expression of cyclooxygenase-2 in colonic-phenotype of gastric intestinal metaplasia: association with helicobacter pylori and gastric carcinoma.
Preterm birth and/or low birth weight are associated with periodontal disease and the increased placental immunohistochemical expression of inflammatory markers.
Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria.
Production of prostaglandin E2 in monocytes stimulated in vitro by Chlamydia trachomatis, Chlamydophila pneumoniae, and Mycoplasma fermentans.
Production of prostaglandin E? in response to infection with modified vaccinia Ankara virus.
Progastrin and cyclooxygenase-2 in colorectal cancer.
Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis.
Prostacyclin and hormone levels in patients with symptoms of miscarriage and infection.
Prostaglandin E 2 /Leukotriene B 4 balance induced by Lutzomyia longipalpis saliva favors Leishmania infantum infection.
Prostaglandin E2 induction during mouse adenovirus type 1 respiratory infection regulates inflammatory mediator generation but does not affect viral pathogenesis.
Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer.
Prostaglandin synthetase inhibitors in primary herpes infections.
Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.
Protective Effects of Silibinin on Helicobacter pylori-induced Gastritis: NF-?B and STAT3 as Potential Targets.
Proteomics Investigation of the Time Course Responses of RAW264.7 Macrophages to Infections With the Wild-Type and Twin-Arginine Translocation Mutant Strains of Brucella melitensis.
Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection.
Radiosynthesis and evaluation of [18F]FMTP, a COX-2 PET ligand.
Raging the War Against Inflammation With Natural Products.
Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkappaB pathway in a human monocytic cell line, THP-1.
Recombinant OmpA protein fragments mediate interleukin-17 regulation to prevent Escherichia coli meningitis.
Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells.
Regulation of cyclooxygenase-2 expression by macrophages in response to double-stranded RNA and viral infection.
Regulation of inducible heme oxygenase and cyclooxygenase isozymes in a mouse model of spotted fever group rickettsiosis.
Replication of Marek's Disease Virus Is Dependent on Synthesis of De Novo Fatty Acid and Prostaglandin E2.
Resistance mesenteric arteries display hypercontractility in the resolution time of Strongyloides venezuelensis infection.
Resolvin D1 Dampens Pulmonary Inflammation and Promotes Clearance of Nontypeable Haemophilus influenzae.
Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy.
Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling.
Reversible restriction of vesicular stomatitis virus in permissive cells treated with inhibitors of prostaglandin biosynthesis.
Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from nonatopic subjects.
Rickettsia rickettsii infection of human macrovascular and microvascular endothelial cells reveals activation of both common and cell type-specific host response mechanisms.
Rickettsia rickettsii infection of human pulmonary microvascular endothelial cells: modulation of cyclooxygenase-2 expression.
Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study.
RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells.
Role of cyclooxygenase-2 in gastric cancer development and progression.
Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice.
Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis.
Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production.
Role of MAPK in the regulation of double-stranded RNA- and encephalomyocarditis virus-induced cyclooxygenase-2 expression by macrophages.
Role of mitogen-activated protein kinases in influenza virus induction of prostaglandin E2 from arachidonic acid in bronchial epithelial cells.
Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology.
Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis.
ROS induced by spring viraemia of carp virus activate the inflammatory response via the MAPK/AP-1 and PI3K signaling pathways.
RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication.
Salmonella enterica serovar Typhimurium infection induces cyclooxygenase 2 expression in macrophages: involvement of Salmonella pathogenicity island 2.
Salmonella infection induces a hypersecretory phenotype in human intestinal xenografts by inducing cyclooxygenase 2.
Salmonella pathogenicity island 2-dependent expression of suppressor of cytokine signaling 3 in macrophages.
Selective COX-2 Inhibitor (Meloxicam) and Tooth-Supporting Bone Quality. A Histomorphometric Study in Rats.
Selective cyclooxygenase inhibitors prevent the growth of Chlamydia pneumoniae in HL cells.
Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.
Selective inhibition of COX-2 is beneficial to mice infected intranasally with VSV.
Selective inhibition of inhibitory kappa B kinase-beta abrogates induction of nitric oxide synthase in lipopolysaccharide-stimulated rat aortic smooth muscle cells.
Serologic and histopathologic study of Chlamydia pneumoniae infection in atherosclerosis: a possible pathogenetic mechanism of atherosclerosis induced by Chlamydia pneumoniae.
Sex differences in mucosal response to Helicobacter pylori infection in the stomach and variations in interleukin-8, COX-2 and trefoil factor family 1 gene expression.
Sex Differences Revealed in a Mouse CFA Inflammation Model with Macrophage Targeted Nanotheranostics.
Short-term/low-dose aspirin-induced duodenal erosions are not dependent on Helicobacter pylori infection, cyclooxygenase expression and prostaglandin E2 levels.
Sinensetin suppresses influenza a virus-triggered inflammation through inhibition of NF-?B and MAPKs signalings.
Staphylococcus aureus induces expression of receptor activator of NF-kappaB ligand and prostaglandin E2 in infected murine osteoblasts.
Streptococcus suis Induces Expression of Cyclooxygenase-2 in Porcine Lung Tissue.
Study on the association of COX-2 genetic polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu province in China.
Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia.
Suppression of Heme Oxygenase-1 by Prostaglandin E2-Protein Kinase A-A-Kinase Anchoring Protein Signaling Is Central for Augmented Cyclooxygenase-2 Expression in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages.
Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways.
Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
Synergistic upregulation of inducible nitric oxide synthase and cyclooxygenase-2 in gastric mucosa of Mongolian gerbils by a high-salt diet and Helicobacter pylori infection.
Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.
Temporal profile of serum mitochondrial DNA (mtDNA) in patients with aneurysmal subarachnoid hemorrhage (aSAH).
The ameliorative effect of hemp seed hexane extracts on the Propionibacterium acnes-induced inflammation and lipogenesis in sebocytes.
The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
The characteristics of the expression of heat shock proteins and COX-2 in the liver of hamsters infected with Clonorchis sinensis, and the change of endocrine hormones and cytokines.
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.
The cyclooxygenase site, but not the peroxidase site of cyclooxygenase-2 is required for neurotoxicity in hypoxic and ischemic injury.
The Effect of Helicobacter pylori on Epidermal Growth Factor Receptor-Induced Signal Transduction and the Preventive Effect of Celecoxib in Gastric Cancer Cells.
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels.
The effect of indomethacin on muscle and liver protein synthesis and on whole-body protein degradation during abdominal sepsis in the rat.
The Effects of Oral and Enteric Campylobacter concisus Strains on Expression of TLR4, MD-2, TLR2, TLR5 and COX-2 in HT-29 Cells.
The expression of cyclooxygenase and the production of prostaglandin E2 in neutrophils after burn injury and infection.
The inflammatory effect of infection with Hymenolepis diminuta via the increased expression and activity of COX-1 and COX-2 in the rat jejunum and colon.
The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer.
The non-steroidal anti-inflammatory drug carprofen negatively impacts new bone formation and antibiotic efficacy in a rat model of orthopaedic-device-related infection.
The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis.
The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections.
The Prostaglandin E2-EP3 Receptor Axis Regulates Anaplasma phagocytophilum-Mediated NLRC4 Inflammasome Activation.
The Pseudomonas autoinducer N-(3-oxododecanoyl) homoserine lactone induces cyclooxygenase-2 and prostaglandin E2 production in human lung fibroblasts: implications for inflammation.
The relationship between HPV16 and expression of cyclooxygenase-2, P53 and their prognostic roles in esophageal squamous cell carcinoma.
The role and regulation of COX-2 during viral infection.
The role of endothelial cell-derived inflammatory and vasoactive mediators in the pathogenesis of bluetongue.
The role of n-3 fatty acids in gestation and parturition.
the selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE(2) release in murine brain-derived endothelial cells following Theiler's virus infection.
The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2.
Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10.
Transcriptional regulation of cyclo-oxygenase expression: three pillars of control.
Transcriptome Profiling of Bovine Macrophages Infected by Mycobacterium avium spp. paratuberculosis Depicts Foam Cell and Innate Immune Tolerance Phenotypes.
Transgenic mouse for conditional, tissue-specific Cox-2 overexpression.
Treating Influenza Infection, From Now and Into the Future.
Triggering of DC migration by dengue virus stimulation of COX-2-dependent signaling cascades in vitro highlights the significance of these cascades beyond inflammation.
Triptolide Modulates the Expression of Inflammation-Associated lncRNA-PACER and lincRNA-p21 in Mycobacterium tuberculosis-Infected Monocyte-Derived Macrophages.
Trypanosoma cruzi infection and endothelin-1 cooperatively activate pathogenic inflammatory pathways in cardiomyocytes.
Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: Correlation with minocycline administration as a therapeutic agent.
Up-regulation of astrocyte cyclooxygenase-2, CCAAT/enhancer-binding protein-homology protein, glucose-related protein 78, eukaryotic initiation factor 2 alpha, and c-Jun N-terminal kinase by a neurovirulent murine retrovirus.
Upregulated cyclooxygenase-2 inhibits apoptosis of human gastric epithelial cells infected with Helicobacter pylori.
Upregulation of Cytokines and Differentiation of Th17 and Treg by Dendritic Cells: Central Role of Prostaglandin E2 Induced by Mycobacterium bovis.
Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-? by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection.
Weighted Gene Co-Expression Network Analysis Identifies Key Modules and Hub Genes Associated with Mycobacterial Infection of Human Macrophages.
[Are COX-2 inhibitors truly able to prevent NSAIDs-associated ulcer?]
[Association between Helicobacter pylori cagA strain infection and expression of cyclooxygenase 2 in gastric carcinoma]
[Association between promoter methylation of cyclooxygenase-2 and expression, and precancerous gastric lesions in a high-risk population]
[Chinese herbal medicine Jianpi Jiedu Formula down-regulates the expression of vascular endothelial growth factor in human gastric cell line MKN45 induced by Helicobacter pylori by inhibiting cyclooxygenase-2.]
[Correlation of Helicobacter pylori infection with the expression of COX-2 and EGFR and VEGF in human gastric carcinoma]
[Effect of Helicobacter pylori infection on proliferation and apoptosis in stomach antrum in smoking patients].
[Effect of jianpi jiedu recipe on microvessel density and cyclooxygenm-2 expression in Heliobacter pylori induced gastric cancer].
[EXPERIMENTAL STUDY ON LENTIVIRUS-MEDIATED MULTI-GENES CO-TRANSFECTION IN BONE MARROW MESENCHYMAL STEM CELLS FOR TREATMENT OF KNEE OSTEOARTHRITIS IN CYNOMOLGUS MONKEY].
[Expression of peroxisome proliferators-activated receptor-gamma and cyclooxygenase-2 in Helicobacter pylori infection-associated diseases and significance thereof]
[Intra-cellular signal pathway and synthesis of prostaglandin E2 during invasion of macrophage by Toxoplasma gondii]
[Protein expression and clinical significance of cyclooxygenase 2 and nuclear factor kappa B in gastric mucosa-associated lymphoid tissue lymphoma.]
[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
[Research on relationships of gastric cancer with serum trace elements, Helicobacter pylori and COX-2 in gastric tissue]
[Silencing of COX-2 in nasopharyngeal carcinoma cells with a shRNAmir lentivirus vector]
[The change of cyclooxygenase-2 and inducible nitric oxide synthase in the gastric mucosa one year after eradication of Helicobacter pylori]
Infertility
A new case of NSAID-induced infertility.
A prostaglandin D2 system in the human testis.
An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.
Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters.
COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain.
Cyclooxygenase-2 in Endometriosis.
Endometrial mRNA expression of selected pro-inflammatory factors and mucins in repeat breeder cows with and without subclinical endometritis.
Endometriosis.
Evidence for an adaptation in ROS scavenging systems in human testicular peritubular cells from infertility patients.
Fragile X-related protein 1 (FXR1) regulates cyclooxygenase-2 (COX-2) expression at the maternal?fetal interface.
Non-steroidal anti-inflammatory drugs (NSAIDs) and ovulation: lessons from morphology.
PTGS2 down-regulation in cumulus cells of infertile women with endometriosis.
Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy.
The Role of Arachidonic and Linoleic Acid Derivatives in Pathological Pregnancies and the Human Reproduction Process.
[Reversible infertility from nonsteroidal anti-inflammatory drugs]
Infertility, Female
Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic makeup.
Infertility, Male
Expression of cyclooxygenase-1 (COX-1) and COX-2 in human male gametes from normal patients, and those with varicocele and diabetes: a potential molecular marker for diagnosing male infertility disorders.
[The effects of prostaglandin synthetase inhibitor on male infertility]
Inflammatory Bowel Diseases
?-Catenin Regulation in Sporadic Colorectal Carcinogenesis: Not as Simple as APC.
A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study.
A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease.
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis.
Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats.
CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration.
Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract.
Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: A potential pharmacologic mechanism and therapeutic advantages.
Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer.
Coprocytobiology: on the nature of cellular elements from stools in the pathophysiology of colonic disease.
COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats.
Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.
Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study.
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis.
Cyclooxygenase-2 immunoexpression in intestinal epithelium and lamina propria of cats with inflammatory bowel disease and low grade alimentary lymphoma.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
Cyclooxygenase-2 inhibitors in colorectal cancer.
Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.
Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.
Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis.
Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut.
Elucidation of colon-protective efficacy of diosgenin in experimental TNBS-induced colitis: inhibition of NF-?B/IkB-? and Bax/Caspase-1 signaling pathways.
Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions.
Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction?
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?
Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease.
Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study.
Flavonoids exert distinct modulatory actions on cyclooxygenase 2 and NF-kappaB in an intestinal epithelial cell line (IEC18).
Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease.
Hepatocyte growth factor expression in dextran sodium sulfate-induced colitis in rats.
HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts.
Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis.
Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.
Interleukin-1 in the pathogenesis of and protection from inflammatory bowel disease.
Isoliquiritigenin suppresses tumor necrosis factor-?-induced inflammation via peroxisome proliferator-activated receptor-? in intestinal epithelial cells.
Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis.
Mechanism underlying the reversal of contractility dysfunction in experimental colitis by cyclooxygenase-2 inhibition.
Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease.
New aspects of mast cell biology.
Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives.
Novel Anti-inflammatory Functions For Endothelial and Myeloid Cyclooxygenase-2 in a New Mouse Model of Crohn's Disease.
NSAIDs and the colon.
Possible mode of action of 5-aminosalicylic acid.
Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug-Induced Clinical Relapse in Patients With Inflammatory Bowel Disease.
Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats.
Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells.
Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis.
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
Selective COX-2 inhibitors and gastrointestinal mucosal injury: pharmacological and therapeutic considerations.
Selective COX-2 inhibitors and human inflammatory bowel disease.
Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease.
The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats.
The endogenous bioactive lipid prostaglandin D2-glycerol ester reduces murine colitis via DP1 and PPAR? receptors.
The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
The role of COX-2 in intestinal inflammation and colorectal cancer.
The specialty of colon and rectal surgery: its impact on patient care and role in academic medicine.
The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease.
The transcription factor C/EBPbeta is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts.
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum.
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
[Clinical and genetic characteristics of patients with chronic enteropathy associated with SLCO2A1 gene].
[COX-2 inhibitors in inflammatory bowel disease: friends or foes?]
[COX-2 inhibitors to patients with inflammatory bowel disease]
[Gastrointestinal complications related to NSAIDs]
[Inflammatory bowel diseases]
[Protective effect of epigallocatechin-3-gallate on inflammatory bowel disease: experiment with rat models of induced colitis]
Inflammatory Breast Neoplasms
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.
Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell Line.
Influenza in Birds
Antiviral activity of a selective COX-2 inhibitor NS-398 on avian influenza H5N1 infection.
Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor.
Influenza, Human
Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection.
Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection.
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Dissection of the potential anti-influenza materials and mechanism of Lonicerae japonicae flos based on in vivo substances profiling and network pharmacology.
High Expression of IL-36? in Influenza Patients Regulates Interferon Signaling Pathway and Causes Programmed Cell Death During Influenza Virus Infection.
High-throughput screen of protein expression levels induced by cyclooxygenase-2 during influenza a virus infection.
Immunomodulatory therapy for severe influenza.
Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs.
Influenza A virus induces Interleukin-27 through cyclooxygenase-2 and protein kinase A signaling.
Influenza A viruses suppress cyclooxygenase-2 expression by affecting its mRNA stability.
Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice.
The cytokine storm of severe influenza and development of immunomodulatory therapy.
Insulin Resistance
A Network Pharmacology-Based Strategy for Unveiling the Mechanisms of Tripterygium Wilfordii Hook F against Diabetic Kidney Disease.
A new paradigm for diabetes and obesity: the hepatic insulin sensitizing substance (HISS) hypothesis.
A proposed new paradigm for insulin resistance.
Ablation of TRPV1 Abolishes Salicylate-Induced Sympathetic Activity Suppression and Exacerbates Salicylate-Induced Renal Dysfunction in Diet-Induced Obesity.
Aggravation by prostaglandin E2 of interleukin-6-dependent insulin resistance in hepatocytes.
Androgens are necessary for the development of fructose-induced hypertension.
Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians.
Candesartan Neuroprotection in Rat Primary Neurons Negatively Correlates with Aging and Senescence: a Transcriptomic Analysis.
Comment on Francés et al. Hepatic Cyclooxygenase-2 Expression Protects Against Diet-Induced Steatosis, Obesity, and Insulin Resistance. Diabetes 2015;64:1522-1531.
Comparative Proteomic Study of Fatty Acid-treated Myoblasts Reveals Role of Cox-2 in Palmitate-induced Insulin Resistance.
Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptom score of patients with benign prostatic hyperplasia.
COX-2-mediated Inflammation in Fat Is Crucial for Obesity-linked Insulin Resistance and Fatty Liver.
Critical illness myopathy: what is happening?
Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cells.
Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKalpha-independent manner.
Different Impacts of Saturated and Unsaturated Free Fatty Acids on COX-2 Expression in C2C12 Myotubes.
Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects.
Effects of diabetes and insulin resistance in pregnant rats on ex vivo vascular reaction to magnesium.
Effects of insulin resistance and testosterone on the participation of cyclooxygenase isoforms in vascular reactivity.
Flavonoids from Camellia sinensis (L.) O. Kuntze seed ameliorates TNF-? induced insulin resistance in HepG2 cells.
Fucoxanthin regulates adipocytokine mRNA expression in white adipose tissue of diabetic/obese KK-Ay mice.
Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A2 Pathway.
Hepatic cyclooxygenase-2 expression protects against diet-induced steatosis, obesity and insulin resistance.
Hypolipidemic and hypoglycemic activities of a oleanolic acid derivative from Malva parviflora on streptozotocin-induced diabetic mice.
Importance of adipocyte cyclooxygenase-2 and prostaglandin E2-prostaglandin E receptor 3 signaling in the development of obesity-induced adipose tissue inflammation and insulin resistance.
Importance of cyclooxygenase 2-mediated low-grade inflammation in the development of fructose-induced insulin resistance in rats.
Indomethacin activates peroxisome proliferator-activated receptor ? to improve insulin resistance in cotton pellet granuloma model.
Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice.
Influence of annexin A7 on insulin sensitivity of cellular glucose uptake.
Influence of serum HMW adiponectin level in patients with pregnancy-induced hypertension syndrome on the occurrence of eclampsia in secondary pregnancy.
Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects.
Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
Metabolic syndrome exacerbates amyloid pathology in a comorbid Alzheimer's mouse model.
Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention.
Network Pharmacology-Based Strategy to Investigate the Pharmacological Mechanisms of Ginkgo biloba Extract for Aging.
Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor ?.
Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer.
Pharmaceutical reversal of insulin resistance.
Polyphenol-rich grape powder extract (GPE) attenuates inflammation in human macrophages and in human adipocytes exposed to macrophage-conditioned media.
Potential associations between variants of genes encoding regulators of inflammation, and mediators of inflammation in type 2 diabetes and insulin resistance.
Regulation of MicroRNA 183 by Cyclooxygenase 2 in Liver Is DEAD-Box Helicase p68 (DDX5) Dependent: Role in Insulin Signaling.
Response to Comment on Francés et al. Hepatic Cyclooxygenase-2 Expression Protects Against Diet-Induced Steatosis, Obesity, and Insulin Resistance. Diabetes 2015;64:1522-1531.
Selective COX2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats.
Serum adipocyte fatty acid-binding protein in the critically ill.
The Dualistic Effect of COX-2-Mediated Signaling in Obesity and Insulin Resistance.
The importance of cyclooxygenase 2-mediated oxidative stress in obesity-induced muscular insulin resistance in high-fat-fed rats.
Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis.
Uterine anomalies in cell proliferation, energy homeostasis and oxidative stress in PCOS hamsters, M. auratus: Therapeutic potentials of melatonin.
Insulinoma
An immunohistochemical study of cyclooxygenase (COX)-2 expression in endocrine tumors of the pancreas.
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
The gene encoding cyclooxygenase-2 is regulated by IL-1? and prostaglandins in 832/13 rat insulinoma cells.
Intermittent Claudication
Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication.
Intervertebral Disc Displacement
Analysis and prevalence of inflammatory cells in subtypes of lumbar disc herniations under cyclooxygenase-2 inhibitor therapy.
Epidural injection of cyclooxygenase-2 inhibitor attenuates pain-related behavior following application of nucleus pulposus to the nerve root in the rat.
Role of the tumor necrosis factor-alpha, cyclooxygenase-2, prostaglandin E2, and effect of low-intensity pulsed ultrasound in an in vitro herniated disc resorption model.
Spinal neural cyclooxygenase-2 mediates pain caused in a rat model of lumbar disk herniation.
The role of cyclooxygenase-2 in lumbar disc herniation.
YKL-40 in human lumbar herniated disc and its relationships with nitric oxide and cyclooxygenase-2.
Intestinal Diseases
Prevalence and molecular diversity of pHS-2 plasmids, marker for arthritogenicity, among clinical Escherichia coli Shigella isolates.
Intestinal Neoplasms
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Prostaglandin E2 and Krüppel-like transcription factors synergistically induce the expression of decay-accelerating factor in intestinal epithelial cells.
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
The role of COX-2 in intestinal cancer.
[A new drug approach approved in the USA. Cox-2 inhibitor in intestinal cancer]
Intestinal Polyposis
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.
Chemoprevention of intestinal polyposis by COX-2 inhibition: from mouse to man.
Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Clinical potential of cyclo-oxygenase-2 inhibitors.
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
Endogenous conversion of ?-6 to ?-3 polyunsaturated fatty acids in fat-1 mice attenuated intestinal polyposis by either inhibiting COX-2/?-catenin signaling or activating 15-PGDH/IL-18.
In search of a better aspirin: suppression of intestinal polyposis by targeted inhibition of cyclooxygenase 2.
Suppression of intestinal polyposis by inhibition of COX-2 in Apc knockout mice.
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Intestinal Pseudo-Obstruction
Efficacy and safety of low-dose celecoxib in reducing post-operative paralytic ileus after major abdominal surgery.
Intracranial Aneurysm
Differential Sex Response to Aspirin in Decreasing Aneurysm Rupture in Humans and Mice.
Letter by Wen et al Regarding Article, "Pathophysiology of Intracranial Aneurysms: COX-2 Expression, Iron Deposition in Aneurysm Wall, and Correlation With Magnetic Resonance Imaging".
Pathophysiology of Intracranial Aneurysms: COX-2 Expression, Iron Deposition in Aneurysm Wall, and Correlation With Magnetic Resonance Imaging.
PGE(2) -EP(2) receptor signaling in endothelium is activated by hemodynamic stress and induces cerebral aneurysm through an amplifying loop via NF-?B.
Potential role of aspirin in the prevention of aneurysmal subarachnoid hemorrhage.
Response by Rodemerk et al to Letter Regarding Article, "Pathophysiology of Intracranial Aneurysms: COX-2 Expression, Iron Deposition in Aneurysm Wall, and Correlation With Magnetic Resonance Imaging".
Upregulation of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) in wall of ruptured human cerebral aneurysms: preliminary results.
Intracranial Hemorrhages
12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics.
Cyclooxygenase-2 Inhibition Provides Lasting Protection Following Germinal Matrix Hemorrhage in Premature Infant Rats.
Intussusception
Association of tumor necrosis factor, interleukin-6 and cyclooxygenase pathway with lipopolysaccharide-induced intussusception.
Role of nitric oxide and cyclooxygenase pathway in lipopolysaccharide-induced intussusception.
Iritis
COX-2 inhibitors prolong trauma-induced elevations of iris hyaluronan.
Iron Overload
Increased release of arachidonic acid and eicosanoids in iron-overloaded cardiomyocytes.
Iron Overload Protects from Obesity by Ferroptosis.
Specific roles for Group V secretory PLA? in retinal iron-induced oxidative stress. Implications for age-related macular degeneration.
Irritable Bowel Syndrome
?-Catenin Regulation in Sporadic Colorectal Carcinogenesis: Not as Simple as APC.
Ischemic Attack, Transient
Development of cyclooxygenase and lipoxygenase metabolites of arachidonic acid after transient cerebral ischemia.
Inhibition of Acyl-CoA Synthetase Long-Chain Family Member 4 Facilitates Neurological Recovery After Stroke by Regulation Ferroptosis.
The highly selective cyclooxygenase-2 inhibitor DFU is neuroprotective when given several hours after transient cerebral ischemia in gerbils.
Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus.
Ischemic Stroke
A Promoter polymorphism (rs17222919, -1316T/G) of ALOX5AP is associated with intracerebral hemorrhage in Korean population.
An interactive association of common sequence variants in the neuropeptide Y gene with susceptibility to ischemic stroke.
Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production.
Association of COX-2 rs20417 with aspirin resistance.
Association of GPIa and COX-2 gene polymorphism with aspirin resistance.
Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use.
Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.
COX-2 rs20417 Polymorphism Is Associated with Stroke and White Matter Disease.
Cyclooxygenase and prostaglandin synthases: roles in plaque stability and instability in humans.
Cyclooxygenase Inhibition Limits Blood-Brain Barrier Disruption following Intracerebral Injection of Tumor Necrosis Factor-{alpha} in the Rat.
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.
Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: A meta-analysis.
Cyclooxygenase-2 expression and inhibition in atherothrombosis.
Cyclooxygenase-2 genetic polymorphism and stroke subtypes in chinese.
Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Enhanced in vivo platelet activation in subtypes of ischemic stroke.
Environmental nitrogen dioxide (NO(2)) exposure influences development and progression of ischemic stroke.
Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke.
Genetic and Molecular Determinants of Atherosclerotic Plaque Instability.
Genetic Deletion or Pharmacological Inhibition of Cyclooxygenase-2 Reduces Blood-Brain Barrier Damage in Experimental Ischemic Stroke.
Genetic variants of PTGS2, TXA2R and TXAS1 are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients.
Genetic Variation of Inflammatory Genes to Ischemic Stroke Risk in a Chinese Han Population.
Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding.
Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin.
Influence of the Cyclooxygenase-2 Gene -765G/C and -1195G/A Polymorphisms on Development of Ischemic Stroke.
Inhibition of cyclooxygenase-1 does not reduce mortality in post-ischemic stroke rats.
Interaction between COX-1 and COX-2 increases susceptibility to ischemic stroke in a Chinese population.
Intravenous implanted neural stem cells migrate to injury site, reduce infarct volume, and improve behavior after cerebral ischemia.
Mass spectrometry-based urinary metabolomics for the investigation on the mechanism of action of Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. leaves against ischemic stroke in rats.
Microglia and cyclooxygenase-2: Possible therapeutic targets of progesterone for stroke.
Molecular pathology of cerebral ischemia: delayed gene expression and strategies for neuroprotection.
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke.
Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia.
New drugs and new targets.
Novel determinants of plaque instability.
Platelet activation and lipid peroxidation in patients with acute ischemic stroke.
Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach.
Prostaglandin E(2) EP1 receptors: downstream effectors of COX-2 neurotoxicity.
Pyrazolopyridine derivative acts as a novel cyclooxygenase inhibitor: antiplatelet effect in aged patients with ischemic stroke.
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.
Reversible cerebral vasoconstriction syndrome possibly induced by etoricoxib.
Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.
Smoking and drinking influence the advancing of ischemic stroke disease by targeting PTGS2 and TNFAIP3.
The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets.
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
Trans-Cinnamaldehyde, An Essential Oil in Cinnamon Powder, Ameliorates Cerebral Ischemia-Induced Brain Injury via Inhibition of Neuroinflammation Through Attenuation of iNOS, COX-2 Expression and NF?-B Signaling Pathway.
Upregulated expression of Toll-like receptor 4 in peripheral blood of ischaemic stroke patients correlates with cyclooxygenase 2 expression.
Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population.
Variants in COX-2, PTGIS, and TBXAS1 Are Associated with Carotid Artery or Intracranial Arterial Stenosis and Neurologic Deterioration in Ischemic Stroke Patients.
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Jaw Cysts
Ca2+ stimulates COX-2 expression through calcium-sensing receptor in fibroblasts.
Joint Diseases
An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model.
Arthropathy in art and the history of pain management--through the centuries to cyclooxygenase-2 inhibitors.
Choosing and using non-steroidal anti-inflammatory drugs in haemophilia.
COX-1, COX-2 and articular joint disease: a role for chondroprotective agents.
Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases.
Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital.
Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis.
Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy.
Non-steroidal anti-inflammatory drug gastropathy: causes and treatment.
Pain management in people with hemophilia in childhood and young adulthood.
Reactive oxygen species induce Cox-2 expression via TAK1 activation in synovial fibroblast cells.
Regulation of cyclooxygenase-2 expression in human osteoblastic cells by N-acetylcysteine.
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
Therapeutic potential of COX-2 inhibitors in arthritis.
[Comparison of the pharmacologic effect of diacerein and a selective COX-2 inhibitor in the mouse induced-granuloma model]
[Levels of different metabolites of arachidonic acid in synovial fluid of patients with arthrosis or rheumatoid arthritis]
Keloid
Adipose-derived stem cells inhibit dermal fibroblast growth and induce apoptosis in keloids through the arachidonic acid-derived cyclooxygenase-2/prostaglandin E2 cascade by paracrine.
Differential effects of hexoses and sucrose, and platelet-derived growth factor isoforms on cyclooxygenase-1 and -2 mRNA expression in keloid, hypertrophic scar and granulation tissue fibroblasts.
Growth Differentiation Factor-9 Promotes Fibroblast Proliferation and Migration in Keloids through the Smad2/3 Pathway.
Immunohistochemical Evaluation of COX-1 and COX-2 Expression in Keloid and Hypertrophic Scar.
Immunohistochemical Expression of Cyclooxygenases in Hypertrophic Scars and Keloids.
Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis.
Keratitis
Cyclooxygenase-2 expression in the cornea of dogs with keratitis.
Effects of COX-2 inhibitor NS-398 on IL-10 expression in rat fungal keratitis.
Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice.
Modulation of immunogenic keratitis in rabbits by topical administration of inhibitors of lipoxygenase and cyclooxygenase.
Pathophysiology of cyclooxygenase inhibition in animal models.
Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis.
Keratoacanthoma
Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers.
Expression of Cyclooxygenase-2 in Squamous Cell Carcinoma and Keratoacanthoma and its Clinical Significance.
Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin.
Keratoconus
Modification of prostaglandin E2 and collagen synthesis in keratoconus fibroblasts, associated with an increase of interleukin 1 alpha receptor number.
Keratosis
Expression of p63 and cyclooxygenase-2 and their correlation in skin tumors.
Keratosis, Actinic
Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation.
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Clinical outcome and cyclo-oxygenase-2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib.
Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis.
Cyclooxygenase-2 expression in actinic keratosis.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Epithelial to mesenchymal transition in cutaneous squamous cell carcinoma is correlated with COX-2 expression but not with the presence of stromal macrophages or CD10-expressing cells.
Expression of p63 and cyclooxygenase-2 and their correlation in skin tumors.
Field treatment of actinic keratoses - focus on COX-2-inhibitors.
Genetically determined susceptibility to COX-2 inhibitors: a report of exaggerated responders to diclofenac 3% gel in the treatment of actinic keratoses.
Immunohistochemical Detection of COX-2 in Feline and Canine Actinic Keratoses and Cutaneous Squamous Cell Carcinoma.
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
LONG-TERM USE OF A NEW TOPICAL FORMULATION CONTAINING PIROXICAM 0.8% AND SUNSCREEN: EFFICACY AND TOLERABILITY ON ACTINIC KERATOSIS. A PROOF OF CONCEPT STUDY.
Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma.
Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin.
Significance of Cyclooxygenase 2, EZH-2 Polycomb Group and p53 Expression in Actinic Keratosis and Squamous Cell Carcinomas of the Skin.
The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases.
Treatment of actinic keratosis through inhibition of cyclooxygenase-2: Potential mechanism of action of diclofenac sodium 3% in hyaluronic acid 2.5.
[Cyclooxygenases in the skin]
Keratosis, Seborrheic
Overexpression of linker for activated T cells, cyclooxygenase-2, CD1a, CD68 and myeloid/histiocyte antigen in an inflamed seborrheic keratosis.
Kidney Diseases
Autoimmune kidney disease in MRL/lpr mice inhibited by OK-432; II. Effect of indomethacin.
Cause for concern in the use of non-steroidal anti-inflammatory medications in the community -a population-based study.
Glucocorticoids use in kidney transplant setting.
Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease.
The Antioxidative Role of Natural Compounds from a Green Coconut Mesocarp Undeniably Contributes to Control Diabetic Complications as Evidenced by the Associated Genes and Biochemical Indexes.
[NSAID--COX-2-inhibitors, where is the difference? Focus on the modes of action]
Kidney Diseases, Cystic
Alterations in renal cytosolic phospholipase A2 and cyclooxygenases in polycystic kidney disease.
COX-2 expression in cystic kidneys is dependent on dietary n-3 fatty acid composition.
Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2WS25/- mouse model of autosomal dominant polycystic kidney disease.
Distinct oxylipin alterations in diverse models of cystic kidney diseases.
Kidney Failure, Chronic
Adverse interactions of rofecoxib with lisinopril in spontaneously hypertensive rats.
Analgesic use and the risk for progression of chronic kidney disease.
Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure.
Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia.
Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.
Cyclooxygenase inhibition improves endothelium-dependent vasodilatation in patients with chronic renal failure.
Effects of No.2 Renal Failure Recipe on expressions of cyclooxygenase-2 and -1 mRNAs in rats with chronic renal failure.
Microsomal Prostaglandin E Synthase-1-Derived PGE2 Inhibits Vascular Smooth Muscle Cell Calcification.
Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic.
Pharmacokinetics of etoricoxib in patients with renal impairment.
Prostaglandin E2 receptor EP2 mediates the effect of cyclooxygenase 2 on secondary parathyroid hyperplasia in end-stage renal disease.
Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study.
The effect of platelet number and haematocrit on whole blood thromboxane synthesis.
Kidney Neoplasms
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2?/COX-2.
Novel glycoside from Wedelia calendulacea inhibits diethyl nitrosamine-induced renal cancer via downregulating the COX-2 and PEG
Laryngeal Neoplasms
Bile acid induces cyclo-oxygenase-2 expression in cultured human pharyngeal cells: a possible mechanism of carcinogenesis in the upper aerodigestive tract by laryngopharyngeal reflux.
Cannabis smoke can be a major risk factor for early-age laryngeal cancer-a molecular signaling-based approach.
Combined effect of genetic polymorphisms in phase I and II biotransformation enzymes on head and neck cancer risk.
Cyclooxygenase-2 Inhibition Enhances Proliferation of NKT Cells Derived from Patients with Laryngeal Cancer.
Expression of Cox-2 protein in radioresistant laryngeal cancer.
Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation.
Low COX2 in tumor and upregulation in stroma mark laryngeal squamous cell carcinoma progression.
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Tissue microarray analysis reveals prognostic significance of COX-2 expression for local relapse in T1-2N0 larynx cancer treated with primary radiation therapy.
[Analysis of HIF-1? and COX-2 expression in tumor stroma and correlation with the degree of neoplasm invasiveness in laryngeal cancer--preliminary study].
[Effects of rosiglitazone on the Hep-2 cell proliferation, cell cycle and COX-2 expression]
[Expression of p53, p21, PCNA and COX-2 and its relationship with recurrence in the early-stage laryngeal cancer with negative surgical margin].
[Tissue microarray technique and its uses in study of relation between expression of cyclooxygenase in laryngeal neoplasms]
Laryngismus
Aspirin-exacerbated respiratory disease: evaluation and management.
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
Laryngitis
A new model of laryngitis: neuropeptide, cyclooxygenase, and cytokine profile.
The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.
Laryngopharyngeal Reflux
Bile acid induces cyclo-oxygenase-2 expression in cultured human pharyngeal cells: a possible mechanism of carcinogenesis in the upper aerodigestive tract by laryngopharyngeal reflux.
Latent Infection
Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion.
The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection.
Leg Ulcer
Expression of cyclooxygenase isoforms in normal human skin and chronic venous ulcers.
Leiomyoma
A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.
Analysis of the in vitro effects of di-(2-ethylhexyl) phthalate exposure on human uterine leiomyoma cells.
Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1.
Comparative expression of thioredoxin-1 in uterine leiomyomas and myometrium.
Cyclooxygenase-2 inhibitor, celecoxib, inhibits leiomyoma cell proliferation through the nuclear factor ?B pathway.
Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
High expression of cyclooxygenase-2 in uterine fibroids and its correlation with cell proliferation.
Indomethacin for the treatment of symptomatic leiomyoma uteri during pregnancy.
Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice.
The effect of a prostaglandin synthetase inhibitor, indomethacin, on excessive uterine bleeding.
The endothelin axis in uterine leiomyomas: new insights.
Tumour angiogenesis in Epstein-Barr virus-associated post-transplant smooth muscle tumours.
Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling.
Leiomyosarcoma
Cyclooxygenase 2 expression in soft tissue leiomyosarcoma.
Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts.
Cyclooxygenase-2 expression in uterine leiomyosarcomas.
Cyclooxygenase-2 Is an Independent Predictor of Poor Prognosis in Uterine Leiomyosarcomas.
Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.
Leishmaniasis
Arachidonic acid metabolism in murine leishmaniasis (Donovani): ex-vivo evidence for increased cyclooxygenase and 5-lipoxygenase activity in spleen cells.
Prostaglandin E 2 /Leukotriene B 4 balance induced by Lutzomyia longipalpis saliva favors Leishmania infantum infection.
Role of Prostaglandin F2? Production in Lipid Bodies From Leishmania infantum chagasi: Insights on Virulence.
Lentigo
siRNA-mediated knock-down of COX-2 in melanocytes suppresses melanogenesis.
Leprosy
Cyclooxygenase 2 and vascular endothelial growth factor-potential targets to manage lepra reactions: A case-control study.
Cyclooxygenase 2 expression in vessels and nerves in reversal reaction leprosy.
Expression of cyclooxygenase type 2 in lepromatous and tuberculoid leprosy lesions.
Expression of cyclooxygenase-2, alpha 1-acid-glycoprotein and inducible nitric oxide synthase in the developing lesions of murine leprosy.
Leprosy, Lepromatous
TLR6-Driven Lipid Droplets in Mycobacterium leprae-Infected Schwann Cells: Immunoinflammatory Platforms Associated with Bacterial Persistence.
Leprosy, Tuberculoid
Expression of cyclooxygenase type 2 in lepromatous and tuberculoid leprosy lesions.
Leukemia
?-Sitosterol Ameliorates Endometrium Receptivity in PCOS-Like Mice: The Mediation of Gut Microbiota.
A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.
Adaptive configuring of radial basis function network by hybrid particle swarm algorithm for QSAR studies of organic compounds.
Adipose tissue-derived stromal cells retain immunosuppressive and angiogenic activity after coculture with cord blood hematopoietic precursors.
AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/?-catenin signaling pathway.
AMP-activated protein kinase mediates T cell activation-induced expression of FasL and COX-2 via protein kinase C theta-dependent pathway in human Jurkat T leukemia cells.
Anti-inflammatory action of phenolic compounds from Gastrodia elata root.
Anti-inflammatory activity of myricetin-3-O-beta-D-glucuronide and related compounds.
Anti-inflammatory activity of pectolinarigenin and pectolinarin isolated from Cirsium chanroenicum.
Anti-inflammatory, Anti-estrogenic, and Anti-implantation Activity of Bergia suffruticosa (Delile) Fenzl.
Anti-leukemic effects of gallic acid on human leukemia K562 cells: Downregulation of COX-2, inhibition of BCR/ABL kinase and NF-?B inactivation.
Antileukemic effects of piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro.
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
Association study of cyclooxygenase 2 single nucleotide polymorphisms and childhood acute lymphoblastic leukemia in Taiwan.
Autocrine prostaglandin E2 signaling promotes promonocytic leukemia cell survival via COX-2 expression and MAPK pathway.
Bioactive constituents of the seeds of Brucea javanica.
Bioactive Potential of Several Actinobacteria Isolated from Microbiologically Barely Explored Desert Habitat, Saudi Arabia.
Butyric acid enhances cyclooxygenase activity in rat basophilic leukemia 2H3 cells.
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.
Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model.
Combination of Celecoxib and Doxorubicin Increases the Growth Inhibition and Apoptosis in Acute Myeloid Leukemia Cells.
Constitutive expression of the cyclooxygenase-2 gene in T-cell lines infected with human T cell leukemia virus type I.
Corrigendum to "AMP-activated protein kinase mediates T cell activation-induced expression of FasL and COX-2 via protein kinase C theta-dependent pathway in human Jurkat T leukemia cells" [Cell. Signal. 24 (2012) 1195-1207].
COX-2 expression in fibroblast aggregates as a functional indicator for the anti-inflammatory activity of leukemia patients' bone marrow-derived hematopoietic cells.
Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells.
Critical evaluation of human endometrial explants as an ex vivo model system: a molecular approach.
Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.
Cyclooxygenase-1, but not -2, in blast cells of patients with acute leukemia.
Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation.
Cyclooxygenase-2 (Cox-2) and blast cells of patients with acute leukemia.
Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin M.
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes.
Cyclopamine and jervine induce COX-2 overexpression in human erythroleukemia cells but only cyclopamine has a pro-apoptoticeffect.
Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia.
Detection of a novel cyclooxygenase metabolite produced by human promyelocytic leukemia (HL-60) cells.
Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro.
Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation.
Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human endometrial cell culture model.
Effect of natsudaidain isolated from Citrus plants on TNF-alpha and cyclooxygenase-2 expression in RBL-2H3 cells.
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Endometrial and conceptus expression of HoxA10, transforming growth factor beta1, leukemia inhibitory factor, and prostaglandin H synthase-2 in early pregnant pigs with gonadotropin-induced estrus.
Enzymatic formation of prostaglandin D2 by rat basophilic leukemia cells and normal rat mast cells.
EPAC2-mediated calreticulin regulates LIF and COX2 expression in human endometrial glandular cells.
Evaluation of selected lichens from iceland for cancer chemopreventive and cytotoxic activity.
Ex Vivo Induced Regulatory Human/Murine Mesenchymal Stem Cells as Immune Modulators.
Fractions of Boswellia serrata suppress LTA4, LTC4, Cyclooxygenase-2 activities and mRNA in HL-60 Cells and reduce lung inflammation in BALB/c mice.
Functional Genetic Variations of Cyclooxygenase-2 and Susceptibility to Acute Myeloid Leukemia in a Chinese Population.
Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation.
Human pericytes for ischemic heart repair.
Identification of novel target proteins in sebaceous gland carcinoma.
Immunostimulatory effect of laminarin on RAW 264.7 mouse macrophages.
Implantation: molecular basis of embryo-uterine dialogue.
Induction of apoptosis and inhibition of cyclooxygenase-2 expression by N-methyl-N'-nitro-N-nitrosoguanidine in human leukemia cells.
Inhibition of cyclooxygenase-2 and telomerase activities in human leukemia cells by dideoxypetrosynol A, a polyacetylene from the marine sponge Petrosia sp.
Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells.
Interferon-resistant cell line lacks fatty acid cyclooxygenase activity.
Leukemic cells modulate induction of COX-2 in human stromal fibroblasts.
Licarin A is a candidate compound for the treatment of immediate hypersensitivity via inhibition of rat mast cell line RBL-2H3 cells.
Lipoxin A4 blocks embryo implantation by controlling estrogen receptor ? activity.
Marrow Stromal Cell-Based Cyclooxygenase 2 Ex Vivo Gene-Transfer Strategy Surprisingly Lacks Bone-Regeneration Effects and Suppresses the Bone-Regeneration Action of Bone Morphogenetic Protein 4 in a Mouse Critical-Sized Calvarial Defect Model.
Mechanical instability and titanium particles induce similar transcriptomic changes in a rat model for periprosthetic osteolysis and aseptic loosening.
Metabolism of cyclooxygenase and lipoxygenase products by 15-prostaglandin dehydrogenase from human HL-60 leukemia cells.
Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model.
Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors.
Pharmacological Activity, Pharmacokinetics, and Toxicity of Timosaponin AIII, a Natural Product Isolated From Anemarrhena asphodeloides Bunge: A Review.
Pharmacological properties of a new anti-inflammatory compound, alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolacto ne (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase.
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells.
Prokineticin 1 signaling and gene regulation in early human pregnancy.
Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells.
Selective inhibition of the lipoxygenase metabolic pathway of arachidonic acid by the SRS-A antagonist, FPL 55712.
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
sn-1,2-Diacylglycerols and phorbol diesters stimulate thromboxane synthesis by de novo synthesis of prostaglandin H synthase in human promyelocytic leukemia cells.
Studies on lipoxygenase inhibitors. I. MY3-469 (3-methoxytropolone), a potent and selective inhibitor of 12-lipoxygenase, produced by Streptoverticillium hadanonense KY11449.
Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase and cyclooxygenase inhibitors.
Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity.
Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
The cyclooxygenase-2/prostaglandin E2 pathway and its role in the pathogenesis of human and dog hematological malignancies.
The pharmacologic effects of 5-[3,5-bis(1,1-dimethylethyl)-4- hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione, choline salt (CI-986), a novel inhibitor of arachidonic acid metabolism in models of inflammation, analgesia and gastric irritation.
The role of AMP-activated protein kinase in quercetin-induced apoptosis of HL-60 cells.
The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis.
Triptolide inhibits cyclooxygenase-2 and inducible nitric oxide synthase expression in human colon cancer and leukemia cells.
Vascular endothelial growth factor-c (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
[Apoptosis in P388 leukemia cells induced by specific inhibitors of 5- and 12-lipoxygenase and the product of cyclooxygenase, prostaglandin E2]
[Effects of COX-2 inhibitor celecoxib on expressions of VEGF, b-FGF and TGF-? mRNA in acute leukemia cells].
[Expression of cyclooxygenase-2 in bone marrow cells of chronic leukemia and its significance.]
[Expression of cyclooxygenase-2 in bone marrow cells of leukemia patients and its association with angiogenesis.]
Leukemia, Erythroblastic, Acute
Berberis libanotica extract targets NF-?B/COX-2, PI3K/Akt and mitochondrial/caspase signalling to induce human erythroleukemia cell apoptosis.
Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents.
Cyclopamine and jervine induce COX-2 overexpression in human erythroleukemia cells but only cyclopamine has a pro-apoptoticeffect.
Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells.
Induction of cyclooxygenase and suppression of 12-lipoxygenase in human erythroleukemia cells upon phorbol ester-induced differentiation.
Induction of thromboxane synthase and prostaglandin endoperoxide synthase mRNAs in human erythroleukemia cells by phorbol ester.
Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-?B and FHC pathways.
[Effect of IFN-?2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
Leukemia, Feline
Feline injection site sarcoma: immunohistochemical characteristics.
Investigating the Connection Between Endogenous Heme Accumulation and COX2 Activity in Cancer Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Apoptosis induced by molecular targeting therapy in hematological malignancies.
Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells.
COX-2 inhibitory treatment in chronic lymphocytic leukemia: a preliminary clinical study.
Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
[Expression of cyclooxygenase-2 in bone marrow cells of chronic leukemia and its significance.]
Leukemia, Lymphoid
Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
[Expression of cyclooxygenase-2 in bone marrow cells of chronic leukemia and its significance.]
Leukemia, Myeloid
Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling.
TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia.
Leukemia, Myeloid, Acute
Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
Cyclooxygenase-2, prostaglandin E2 and acute myeloid leukemia.
Functional Genetic Variations of Cyclooxygenase-2 and Susceptibility to Acute Myeloid Leukemia in a Chinese Population.
IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia.
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
Vascular endothelial growth factor-c (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
[Effect of COX-2 inhibitor celecoxib on proliferation, apoptosis of HL-60 cells and its mechanism].
Leukemia, Promyelocytic, Acute
Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation.
Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia.
Leukemia, T-Cell
Constitutive expression of the cyclooxygenase-2 gene in T-cell lines infected with human T cell leukemia virus type I.
Leukocytosis
Microalgae aqueous extracts exert intestinal protective effects in Caco-2 cells and dextran sodium sulphate-induced mouse colitis.
Nonsteroidal anti-inflammatory agents in the therapy for experimental pneumococcal meningitis.
Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation.
Leukoencephalopathies
COX-2 rs20417 Polymorphism Is Associated with Stroke and White Matter Disease.
Leukomalacia, Periventricular
COX-1 and COX-2 polymorphisms in susceptibility to cerebral palsy in very preterm infants.
Leukopenia
Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis.
Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil.
Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis.
Elucidation of the molecular mechanism of Sanguisorba Officinalis L. against leukopenia based on network pharmacology.
Expression of the cyclooxygenase isoforms in the prodromal stage of black walnut-induced laminitis in horses.
Haemodynamic and haematologic effects of Acanthaster planci venom in dogs.
Prevention of the toxic action of tumor necrosis factor by cyclooxygenase inhibitor and leukopenia.
Leukoplakia
Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias.
NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res., 10: 1565-1573, 2004.
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.
The role of Ki-67, p16, CD34, Bcl-2, cyclooxygenase-2 in the pathogenesis of proliferative verrucous leukoplakia.
Leukoplakia, Oral
Antitumor effect of retinoic acid receptor-beta2 associated with suppression of cyclooxygenase-2.
Comparison of COX2 expression between oral squamous cell carcinoma, leukoplakia and normal mucosa.
COX-2 inhibition in upper aerodigestive tract tumors.
Cyclooxygenase-2 and Ki67 Expression in Oral Leukoplakia: a Clinicopathological Study.
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.
Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.
Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias.
Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions.
[The expressions of cyclooxygenase-2 (Cox-2),VEGF in oral squamous cell carcinoma and precancerous lesions and their significances]
Leukostasis
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.
Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function.
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.
Leydig Cell Tumor
COX-2 gene polymorphisms and protein expression in renomedullary interstitial cell tumors.
Renal interstitial cell tumor in a dog: clinicopathologic, imaging, and histologic features.
Lichen Planus
DNA polymorphisms and tissue cyclooxygenase-2 expression in oral lichen planus: a case-control study.
Expression of Ki-67, p53, ?-SMA and COX-2 in lichen planus and related lesions: A pilot study.
Immunohistochemical evaluation of the effect of acitretin and systemic steroid treatments on Ki-67, Bcl-2, and COX-2 levels in cutaneous lichen planus patients.
The role of cyclooxygenase-2 and prostaglandin E2 in the pathogenesis of cutaneous lichen planus.
Lichen Planus, Oral
COX-2 expression in oral lichen planus.
COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma.
DNA content, Cyclooxygenase-2 expression and loss of E-cadherin expression do not predict risk of malignant transformation in oral lichen planus.
DNA polymorphisms and tissue cyclooxygenase-2 expression in oral lichen planus: a case-control study.
Elucidating the role of Cyclooxygenase-2 in the pathogenesis of oral lichen planus - an immunohistochemical study with supportive histochemical analysis.
Expression of COX-2 and bcl-2 in oral lichen planus lesions and lichenoid reactions.
Increased cyclooxygenase 2 expression in association with oral lichen planus severity.
Increased levels of COX-2 and oral lichen planus.
Increased levels of COX-2 in oral lichen planus supports an autoimmune cause of the disease.
Reply to increased levels of COX-2 and oral lichen planus by P.D. Pigatto, F. Spaderi, G.P. Bombeccari, G. Guzzi by Danielsson et al.
Lichen Sclerosus et Atrophicus
Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial lesions.
linoleate 13s-lipoxygenase deficiency
Acquired von Willebrand disease and storage pool disease in chronic myelocytic leukemia.
Deficiency of platelet lipoxygenase activity in myeloproliferative disorders.
Lipomatosis
Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report.
Liposarcoma
Relationship of endothelial area with VEGF-A, COX-2, maspin, c-KIT, and DOG-1 immunoreactivity in liposarcomas versus non-lipomatous soft tissue tumors.
Liver Abscess, Amebic
Entamoeba histolytica induces cyclooxygenase-2 expression in macrophages during amebic liver abscess formation.
Entamoeba histolytica: induction of cyclooxygenase-2 expression during amoebic liver abscess formation in hamsters (Mesocricetus auratus).
Entamoeba histolytica: inflammatory process during amoebic liver abscess formation involves cyclooxygenase-2 expression in macrophages and trophozoites.
Liver Cirrhosis
Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury.
Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat.
Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-?, and Vascular Endothelial Growth Factor-A Genes, and Susceptibility to Hepatocellular Carcinoma.
Beneficial effects of Chinese prescription Kangen-karyu on diabetes associated with hyperlipidemia, advanced glycation endproducts, and oxidative stress in streptozotocin-induced diabetic rats.
Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats.
Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum.
Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats.
Corn oil enhancing hepatic lipid peroxidation induced by CCl4 does not aggravate liver fibrosis in rats.
COX-2 in liver fibrosis.
Curc-mPEG454, a PEGylated Curcumin Derivative, Improves Anti-inflammatory and Antioxidant Activities: a Comparative Study.
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study .
Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
Cyclooxygenase-2 promoter polymorphism -899G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province.
Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression.
Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis.
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Effect of renal prostaglandins on survival in patients with liver cirrhosis.
Effect of selective cyclooxygenase-2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts.
Eicosanoid production by density-defined human peritoneal macrophages during inflammation.
Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice.
Expression of cyclooxygenase 2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis.
Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachloride.
Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma.
Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats.
Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing ?-catenin signalling pathway in experimental liver fibrosis.
Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398.
Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches.
Interaction between prostanoids and nitric oxide in the control of tubular function in rats with chronic bile duct ligation.
Investigation of the hepatoprotective effect of Corydalis saxicola Bunting on carbon tetrachloride-induced liver fibrosis in rats by 1H-NMR-based metabonomics and network pharmacology approaches.
Involvement of TLR4 signaling regulated-COX2/PGE2 axis in liver fibrosis induced by Schistosoma japonicum infection.
JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1.
Microglia activation in hepatic encephalopathy.
Preventive effect of ethanol extract from Chinese sumac fruits against tetrachloromethane-induced liver fibrosis in mice.
Protective effect of ethyl acetate fraction of Drynaria quercifolia against CCl
Sulfasalazine prevents the increase in TGF-?, COX-2, nuclear NF?B translocation and fibrosis in CCl4-induced liver cirrhosis in the rat.
Suppression of oxidative stress and improvement of liver functions in mice by ursolic acid via LKB1-AMP-activated protein kinase signaling.
The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.
[Role of cyclooxygenase 2 and its inhibitor valdecoxib in liver fibrosis].
[The Expressions of Somatostatin and Cycloxygenase-2 in Chronic Hepatitis, Hepatic Cirrhosis, Precancerous Lesion and Hepatocellular Carcinoma].
Liver Cirrhosis, Biliary
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
Liver Diseases
A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice.
A molecular-logic gate for COX-2 and NAT based on conformational and structural changes: visualizing the progression of liver disease.
A Network Pharmacology Study of the Molecular Mechanisms of Hypericum japonicum in the Treatment of Cholestatic Hepatitis with Validation in an Alpha-Naphthylisothiocyanate (ANIT) Hepatotoxicity Rat Model.
Apocynin reduced doxycycline-induced acute liver injury in ovariectomized mice.
Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells.
Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats.
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease.
COX-2 in liver fibrosis.
COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator.
Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases.
Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives.
Cyclooxygenase-1 serves a vital hepato-protective function in chemically induced acute liver injury.
Cyclooxygenase-2 and inducible nitric oxide synthase in omental arteries harvested from patients with severe liver diseases: immuno-localization and influence on vascular tone.
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study .
Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression.
Cyclooxygenase-2 Inhibitor Reduces Hepatic Stiffness in Pediatric Chronic Liver Disease Patients Following Kasai Portoenterostomy.
Cyclooxygenase-2 Overexpression is Associated with Clinical Outcome in Biliary Atresia.
Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat.
Effect of selective cyclooxygenase-2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts.
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2.
Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.
Hepatotoxicity associated with non-steroidal anti-inflammatory drugs.
Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence.
Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins.
Pharmaceutical reversal of insulin resistance.
Protective role of hepatocyte cyclooxygenase-2 expression against liver ischemia-reperfusion injury in mice.
Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis.
Renal effects of selective cyclooxygenase inhibition in experimental liver disease.
Renal eicosanoids as determinants of renal function in liver disease.
Renal prostaglandins and the control of renal function in liver disease.
Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.
[An experimental study on the expression and pathogenic effects of cyclooxygenase-2 in nonalcoholic fatty liver disease]
[Effects of ellagic acid on inflammation and oxidative stress induced by AKT gene transfection in mice with fatty liver disease].
[Relationship between single nucleotide polymorphisms in the promoter of COX-2 gene and hereditariness to NAFLD].
[Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases]
[Study on the mechanism of preventing alcholic liver disease by selective cyclooxygenase 2 inhibitor]
[The roles of cyclooxygenase-2 and 5-lipoxygenase in liver disease]
Liver Diseases, Alcoholic
Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease.
Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat.
[The activation of nuclear factor kappa B and the expression of cyclooxygenase-2 in alcoholic liver disease in rats]
[The role of cyclooxygenase-2 in the pathogenesis of alcoholic liver diseases]
Liver Failure
Cyclooxygenase-2 prevents fas-induced liver injury through up-regulation of epidermal growth factor receptor.
Nimesulide-induced hepatotoxicity and fatal hepatic failure.
[A study on the role of cyclooxygenase-2 in lipopolysaccharide mediated fulminate hepatic failure]
[Expression of COX-2 and PPARr in the livers of patients with acute on chronic HBV-related liver failure and their relationship with clinic parameters].
Liver Failure, Acute
COX-2 inhibitor (nimesulide) induced acute liver failure.
Cyclooxygenase-2 and inducible nitric oxide synthase in omental arteries harvested from patients with severe liver diseases: immuno-localization and influence on vascular tone.
Hepatic encephalopathy: effects of liver failure on brain function.
N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
Role of cyclooxygenase isoforms in encephalopathy of cirrhotic rats.
Selective cyclooxygenase inhibition improves hepatic encephalopathy in fulminant hepatic failure of rat.
The Modulating Effect of Ursodeoxycholic Acid on Liver Tissue Cyclooxygenase-2 Expression Following Extended Hepatectomy.
Transgenic expression of cyclooxygenase-2 in hepatocytes accelerates endotoxin-induced acute liver failure.
[Cholestatic hepatitis associated with nimesulide--a case report]
Liver Neoplasms
A novel anti-tumorigenic mechanism by herbal extract saikosaponin-d through p-STAT3/C/EBP? signaling suppression of COX-2 in liver cancer.
Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2.
Bioactive cembranoids from the soft coral Sinularia crassa.
Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest.
Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
Cyclo-oxygenase 2 expression impairs serum-withdrawal-induced apoptosis in liver cells.
Cyclooxygenase-2 -765 G/C polymorphisms and susceptibility to hepatitis B-related liver cancer in Han Chinese population.
Cyclooxygenase-2 expression in hepatocellular carcinoma.
Cyclooxygenase-2 promoter polymorphism -899G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province.
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Cyclooxygenases in hepatocellular carcinoma.
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
Effects of adenovirus-mediated human cyclooxygenase-2 antisense RNA on the growth of hepatocellular carcinoma.
Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.
Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation.
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1? is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2.
Synthesis and characterization of boron fenbufen and its F-18 labeled homolog for boron neutron capture therapy of COX-2 overexpressed cholangiocarcinoma.
The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line.
[Inhibitory Effects of Cyclooxygenase-2 Inhibitor Celecoxib on Growth and Angiogenesis of Human Liver Cancer HepG2 Cell Xenografts in Small Nude Mice.]
[The effects of adenovirus-mediated human COX-2 antisense RNA on the growth of hepatocellular carcinoma]
Lordosis
Cytokines inhibit sexual behavior in female rats: II. Prostaglandins mediate the suppressive effects of interleukin-1beta.
Lung Diseases
AdipoR-increased intracellular ROS promotes cPLA2 and COX-2 expressions via activation of PKC and p300 in adiponectin-stimulated human alveolar type II cells.
Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications.
Cyclooxygenase and cytokine regulation in lung fibroblasts activated with viral versus bacterial pathogen associated molecular patterns.
Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility.
Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis.
Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants.
Inhibition of TNFalpha-induced cyclooxygenase-2 expression by amentoflavone through suppression of NF-kappaB activation in A549 cells.
Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases.
Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients.
Role of cyclooxygenase inhibition and hyperoxia in regulating pulmonary perfusion in dogs.
The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts.
The association between the use of non-steroidal anti-inflammatory drugs and atrial fibrillation: A nationwide case-control study.
The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension.
Thrombin induces cyclooxygenase-2 expression via the ERK and NF-kappaB pathways in human lung fibroblasts.
Lung Injury
Acanthopanax trifoliatus inhibits lipopolysaccharide-induced inflammatory response in vitro and in vivo.
Acute cigarette smoke exposure causes lung injury in rabbits treated with ibuprofen.
Altered expression of cyclooxygenase-2, 12-lipoxygenase, inducible nitric oxide synthase-2 and surfactant protein D in lungs of patients with pulmonary injury caused by sulfur mustard.
Amelioration of meconium-induced acute lung injury by parecoxib in a rabbit model.
Arachidonate cyclooxygenase metabolites as mediators of complement-initiated lung injury.
Bacterial lipopolysaccharide induction of the prostaglandin G/H synthase 2 gene causes thromboxane-dependent pulmonary hypertension in rabbits.
Beneficial effects of ibuprofen in oleic acid induced lung injury.
Bile acids increase alveolar epithelial permeability via MAP kinase, cytosolic phospholipase A2 , cyclooxygenase-2, PGE2 and junctional proteins.
Blunted hypoxic vasoconstriction in oleic acid lung injury: effect of cyclooxygenase inhibitors.
Cecal ligation and puncture is associated with pulmonary injury in the rat: role of cyclooxygenase pathway products.
Control of shunt pathway perfusion in diffuse granulomatous lung disease.
COX-2 inhibition attenuates lung injury induced by skeletal muscle ischemia reperfusion in rats.
COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders.
Cyclooxygenase metabolites possibly produced by endothelial cells mediate the lung injury caused by mechanically stimulated leukocytes.
Cyclooxygenase pathway mediates lung injury induced by phorbol and platelets.
Cyclooxygenase-2 gene disruption attenuates the severity of acute pancreatitis and pancreatitis-associated lung injury.
Cyclooxygenase-2 in newborn hyperoxic lung injury.
Cyclooxygenase-2 inhibition partially protects against 60% O2 -mediated lung injury in neonatal rats.
Cyclooxygenase-2 plays a central role in the genesis of pancreatitis and associated lung injury.
Cycloxygenase Inhibition Enhances the Effects of Surfactant Therapy in Endotoxin-Induced Rat Model of ARDS.
Diseases caused by silica: mechanisms of injury and disease development.
Effect of cyclooxygenase inhibition on amphotericin B-induced lung injury in awake sheep.
Effect of cyclooxygenase-2 inhibitor pretreatment on gas exchange after hydrochloric acid aspiration in rats.
Effects of acute and chronic hypoxia on rat lung cyclooxygenase.
Effects of COX-2 inhibitor on ventilator-induced lung injury in rats.
Eicosanoids are involved in the permeability changes but not the pulmonary hypertension after systemic activation of complement.
Endotoxin-induced lung injury in rats: role of eicosanoids.
Estrogen receptor antagonist fulvestrant (ICI 182,780) inhibits the anti-inflammatory effect of glucocorticoids.
Evidence for peroxidase-mediated metabolism of cyclophosphamide.
Functional and inflammatory alterations in the lung following exposure of rats to nitrogen mustard.
Ginsenoside Rh2 Ameliorates Lipopolysaccharide-Induced Acute Lung Injury by Regulating the TLR4/PI3K/Akt/mTOR, Raf-1/MEK/ERK, and Keap1/Nrf2/HO-1 Signaling Pathways in Mice.
Granulocyte-macrophage colony-stimulating factor amplifies lipopolysaccharide-induced bronchoconstriction by a neutrophil- and cyclooxygenase 2-dependent mechanism.
GYY4137 attenuates LPS-induced acute lung injury via heme oxygenase-1 modulation.
Hypercapnic acidosis in ventilator-induced lung injury.
Ibuprofen prevents synthetic smoke-induced pulmonary edema.
Immunohistochemical analysis of the COX-2 marker in acute pulmonary injury in rats.
Increased expression of cyclooxygenase 2 mediates oil fly ash-induced lung injury.
Influence of cyclooxygenase and lipoxygenase inhibitors on oxidative stress-induced lung injury.
Inhibition of COX-2 Aggravates Neutrophil Migration and Pneumocyte Apoptosis in Surfactant-Depleted Rat Lungs.
Inhibition of cyclooxygenase and nitric oxide synthase in hypoxic vasoconstriction and oleic acid-induced lung injury.
Inhibition of cyclooxygenase metabolite production attenuates ischemia-reperfusion lung injury.
Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury.
Inhibition of eicosanoids does not prevent neutrophil injury from phorbol in isolated rabbit lung.
Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice.
Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
Leukotriene B4 induces lung injury in the rabbit: role of neutrophils and effect of indomethacin.
Macrophage cyclooxygenase expression, immunosuppression, and cardiopulmonary dysfunction after blunt chest trauma.
Mechanisms of increased pulmonary microvascular permeability induced by FMLP in isolated rabbit lungs.
MELATONIN ALLEVIATES BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN MICE.
MMP19 is a Key Regulator of Lung Fibrosis in Mice and Humans.
Neutrophil-associated lung injury after the infusion of activated plasma.
Oleic acid induces pulmonary injury independent of eicosanoids in the isolated, perfused rabbit lung.
Parecoxib reduced ventilation induced lung injury in acute respiratory distress syndrome.
Pharmacologic reduction in tumor necrosis factor activity of pulmonary alveolar macrophages.
Phospholipase A2-induced lung edema and its mechanism in isolated perfused guinea pig lung.
Potential therapeutic effects of avenanthramide-C against lung toxicity caused by silver nanoparticles injection in rats.
Prostaglandin E1 infusion fails to prevent hyperoxic lung injury in adult rabbits.
Protective effect of Arbutus unedo aqueous extract in carrageenan-induced lung inflammation in mice.
Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat.
Protective Role of Cyclooxygenase (COX)-2 in Experimental Lung Injury: Evidence of a Lipoxin A(4)-Mediated Effect.
Pulmonary delivery of tea tree oil-?-cyclodextrin inclusion complexes for the treatment of fungal and bacterial pneumonia.
Rat pulmonary cyclooxygenase-2 expression in response to endotoxin challenge: differential regulation in the various types of cells in the lung.
Reactive oxygen species and molecular mechanism of silica-induced lung injury.
S-nitroso human serum albumin given after LPS challenge reduces acute lung injury and prolongs survival in a rat model of endotoxemia.
S-nitroso-human-albumin: a new therapeutic approach in endotoxic shock.
Scutellaria baicalensis Ameliorates Acute Lung Injury by Suppressing Inflammation In Vitro and In Vivo.
Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production.
Site of pulmonary vasodilation by inhaled nitric oxide in microembolic lung injury.
Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat.
Systemic and lung physiological changes in rats after intravascular activation of complement.
The role of cyclooxygenase and lipoxygenase mediators in oxidant-induced lung injury.
The role of cyclooxygenase products in lung injury induced by tumor necrosis factor in sheep.
The role of cyclooxygenase-2 in mechanical ventilation-induced lung injury.
Lung Neoplasms
2D Nanomaterial, Ti3C2 MXene-Based Sensor to Guide Lung Cancer Therapy and Management.
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population.
A genetic polymorphism in prostaglandin synthase 2 (8473, T-->C) and the risk of lung cancer.
A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy.
A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
A phase II study of carboplatin and paclitacel with meloxicam.
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study.
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.
Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis.
Adenoid cystic carcinoma of the trachea and bronchus--a clinicopathologic study with DNA flow cytometric analysis and oncogene expression.
Adenovirus-uteroglobin suppresses COX-2 expression via inhibition of NF-kappaB activity in lung cancer cells.
Alpha-tocopheryl succinate, in contrast to alpha-tocopherol and alpha-tocopheryl acetate, inhibits prostaglandin E2 production in human lung epithelial cells.
Amaryllidaceae alkaloids from Crinum latifolium with cytotoxic, antimicrobial, antioxidant, and anti-inflammatory activities.
Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer.
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model.
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.
Apoptosis Activation in Human Lung Cancer Cell Lines by a Novel Synthetic Peptide Derived from Conus californicus Venom.
Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer.
Association Between COX-2 Polymorphisms and Lung Cancer Risk.
Association between COX-2 polymorphisms and non-small cell lung cancer susceptibility.
Association between cyclooxygenase and epidermal growth factor receptor pathways in non-small cell lung cancer.
Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer.
Association of COX-2 8473T>C Gene Polymorphism with Lung Cancer Risk.
Association of the 8473T>C Cyclooxygenase-2 (COX-2) Gene Polymorphism with Lung Cancer Risk in Asians.
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion.
Avenanthramide C suppresses hypoxia-induced cyclooxygenase-2 expression through sirtuin1 activation in non-small-cell lung cancer cells.
Bee venom induces apoptosis and inhibits expression of cyclooxygenase-2 mRNA in human lung cancer cell line NCI-H1299.
Bellidifolin Inhibits Proliferation of A549 Cells by Regulating STAT3/COX-2 Expression and Protein Activity.
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Bisphenol A induces COX-2 through the mitogen-activated protein kinase pathway and is associated with levels of inflammation-related markers in elderly populations.
Black tea polyphenols restrict benzopyrene-induced mouse lung cancer progression through inhibition of Cox-2 and induction of caspase-3 expression.
BPTF cooperates with p50 NF-?B to promote COX-2 expression and tumor cell growth in lung cancer.
Butein induces cell apoptosis and inhibition of cyclooxygenase?2 expression in A549 lung cancer cells.
Camptothecin-induced apoptosis in non-small cell lung cancer is independent of cyclooxygenase expression.
Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway.
Celecoxib and radiation therapy in non-small-cell lung cancer.
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Celecoxib decreases Ki-67 proliferative index in active smokers.
Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression.
Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress.
Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers.
Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells.
Celecoxib upregulates ULBP-1 expression in lung cancer cells via the JNK/PI3K signaling pathway and increases susceptibility to natural killer cell cytotoxicity.
Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell.
Celecoxib: a novel treatment for lung cancer.
Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.
Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines.
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.
Chemopreventive action of diclofenac in dimethybenzanthracene induced lung cancer in female Wistar rat.
Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis.
Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer.
Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: How hot is the link?
Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
Cleavage and polyadenylation specific factor 4 targets NF-?B/cyclooxygenase-2 signaling to promote lung cancer growth and progression.
Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis.
Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.
Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.
Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer.
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway.
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Combined treatment with the Cox-2 inhibitor niflumic acid and PPAR? ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells.
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Correction: EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features.
Correction: Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression.
Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.
Correlation of cyclooxygenase-2 expression with hypoxia in non-small cell lung cancer.
COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer.
COX-2 and PPAR-? confer cannabidiol-induced apoptosis of human lung cancer cells.
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
COX-2 expression during early lung squamous cell carcinoma oncogenesis.
COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.
Cox-2 in non-small cell lung cancer: A meta-analysis.
COX-2 inhibition and lung cancer.
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
COX-2 inhibitor, celecoxib, may prevent lung cancer.
COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites.
COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals.
COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.
COX-2 overexpression in canine tumors: potential therapeutic targets in oncology.
COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
COX-2 rs5275 and rs689466 polymorphism and risk of lung cancer: A PRISMA-compliant meta-analysis.
COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
COX-2-dependent stabilization of survivin in non-small cell lung cancer.
COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2.
Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells.
Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?
Cyclooxigenase-2 Levels are Increased in the Lung Tissue and Bronchial Tumors of Patients with Chronic Obstructive Pulmonary Disease.
Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways.
Cyclooxygenase 2 inhibition in patients with non-small cell lung cancer: Is this still a valid target for therapy?
Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.
Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.
Cyclooxygenase 2-dependent regulation of antitumor immunity in lung cancer.
Cyclooxygenase as a target in lung cancer.
Cyclooxygenase inhibitors combined with deuterium-enriched water augment cytotoxicity in A549 lung cancer cell line via activation of apoptosis and MAPK pathways.
Cyclooxygenase inhibitors not inhibit resting lung cancer A549 cell proliferation.
Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.
Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers.
Cyclooxygenase-2 expression in lung cancer cells evaluated by immunocytochemistry.
Cyclooxygenase-2 Expression in Non-Small Cell Lung Cancer Correlates With Hypertrophic Osteoarthropathy.
Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation.
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes.
Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer.
Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
Cyclooxygenase-2 genetic variants influence intratumoral infiltration of Foxp3-positive regulatory T cells in non-small cell lung cancer.
Cyclooxygenase-2 in human non-small cell lung cancer.
Cyclooxygenase-2 in lung cancer.
Cyclooxygenase-2 induced ?1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway.
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.
Cyclooxygenase-2 inhibitor NS-398 suppresses cell growth and constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells.
Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Cyclooxygenase-2 inhibitors as chemopreventive agents in lung cancer.
Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.
Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed.
Cyclooxygenase-2 inhibitors in lung cancer.
Cyclooxygenase-2 is associated with malignant phenotypes in human lung cancer.
Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells.
Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis.
Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.
Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation.
Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer.
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
Cyclooxygenase-2: a target for chemoprevention and treatment of non-small-cell lung cancer.
Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells.
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Decreased expression level and DNA-binding activity of specificity protein 1 via cyclooxygenase-2 inhibition antagonizes radiation resistance, cell migration and invasion in radiation-resistant lung cancer cells.
Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells.
Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.
Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
DMNQ S-64 induces apoptosis via caspase activation and cyclooxygenase-2 inhibition in human nonsmall lung cancer cells.
Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Downregulation of NF-?B and PCNA in the regulatory pathways of apoptosis by cyclooxygenase-2 inhibitors in experimental lung cancer.
Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
Dysregulation of FURIN by prostaglandin-endoperoxide synthase 2 in lung epithelial NCI-H292 cells.
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer.
Effect of cyclooxygenase-2 antisense oligodeoxyribonucleotides in A-549 lung cancer cells.
Effect of molecular targeted therapy combined with radiotherapy on the expression and prognostic value of COX-2 and VEGF in bone metastasis of lung cancer.
Effects of aspirin on small-cell lung cancer mortality and metastatic presentation.
Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.
Effects of Eicosapentaenoic and Docosahexaenoic n-3 Fatty Acids From Fish Oil and Preferential Cox-2 Inhibition on Systemic Syndromes in Patients With Advanced Lung Cancer.
Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2.
Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis.
EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features.
EGFR Signaling Is Required for TGF-beta1 Mediated COX-2 Induction in Human Bronchial Epithelial Cells.
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Elevation of Prostaglandin E2 in Lung Cancer Patients with Digital Clubbing.
Emerging drugs for non-small cell lung cancer.
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.
Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.
Erratum: Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis.
Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line.
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Expression and significance of cyclooxygenase 2 gene in lung cancer.
Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: Correlations with angiogenesis and prognosis.
Expression of cyclooxygenase-2 in human lung carcinoma.
Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance.
Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients.
Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.
Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications.
Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines.
Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer.
Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2.
Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKK?/NF-?B signaling pathway in lung cancer cells.
Green tea inhibits cycolooxygenase-2 in non-small cell lung cancer cells through the induction of Annexin-1.
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results.
Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer.
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.
HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway.
Hierarchical clustering of lung cancer cell lines using DNA methylation markers.
Histamine regulates cyclooxygenase 2 gene activation through Orai1-mediated NF?B activation in lung cancer cells.
hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.
Identification of key genes involved in nasopharyngeal carcinoma.
IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF.
IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression.
IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer.
Iminodibenzyl redirected cyclooxygenase-2 catalyzed dihomo-?-linolenic acid peroxidation pattern in lung cancer.
Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non- small-cell lung cancer.
Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.
Increase of carcinogenic risk via enhancement of cyclooxygenase-2 expression and hydroxyestradiol accumulation in human lung cells as a result of interaction between BaP and 17-beta estradiol.
Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.
Increased expression of COX-2 in the development of human lung cancers.
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: A novel cyclooxygenase-inhibition-independent effect.
INDUCTION BUT NOT INHIBITION OF COX-2 CONFERS HUMAN LUNG CANCER CELL APOPTOSIS BY CELECOXIB.
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1, DeltaE3 recombinant adenovirus vectors.
Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells.
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment.
Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.
Inhibition of 11?-Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression as Well as the ERK and mTOR Signaling Pathways.
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis.
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.
Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells.
Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma.
Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.
Inhibitory effects of scutellarein on proliferation of human lung cancer A549 cells through ERK and NF?B mediated by the EGFR pathway.
Insulin-like growth factor binding protein-4 inhibits cell growth, migration and invasion, and downregulates COX-2 expression in A549 lung cancer cells.
Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients.
Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells.
Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Knockdown of 14-kDa phosphohistidine phosphatase expression suppresses lung cancer cell growth in vivo possibly through inhibition of NF-?B signaling pathway.
Knockdown of end-binding protein 1 induces apoptosis in radioresistant A549 lung cancer cells via p38 kinase-dependent COX-2 upregulation.
Korean Red Ginseng suppresses bisphenol A-induced expression of cyclooxygenase-2 and cellular migration of A549 human lung cancer cell through inhibition of reactive oxygen species.
Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.
Lack of association of the cyclooxygenase 8473 T>C polymorphism with lung cancer: evidence from 9841 subjects.
Lentivirus-mediated shRNA interference targeting cyclooxygenase-2 inhibits growth of human non-small cell lung cancer.
LKB1/PEA3/?Np63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure.
LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer.
Localization of cyclooxygenase-2 protein expression in lung cancer specimens by immunohistochemical analysis.
Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR?-dependent pathway.
Lung cancer and cyclooxygenase-2.
Lung cancer chemoprevention with celecoxib in former smokers.
Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/?-catenin signalling pathway.
Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway.
Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer.
MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
Meloxicam inhibits the growth of non-small cell lung cancer.
Methanandamide increases COX-2 expression and tumor growth in murine lung cancer.
Methanolic extract of adlay seed suppresses COX-2 expression of human lung cancer cells via inhibition of gene transcription.
Methyl syringate, a TRPA1 agonist represses hypoxia-induced cyclooxygenase-2 in lung cancer cells.
Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2.
miR-146a suppresses 5-lipoxygenase activating protein (FLAP) expression and Leukotriene B4 production in lung cancer cells.
MiR-26b suppresses tumor cell proliferation, migration and invasion by directly targeting COX-2 in lung cancer.
miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells.
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells.
Mitigation and Treatment of Radiation-Induced Thoracic Injury With a Cyclooxygenase-2 Inhibitor, Celecoxib.
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.
Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide.
Modulatory effect of hesperidin on benzo(a)pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9.
Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis.
Multifaceted roles of cyclooxygenase-2 in lung cancer.
Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells.
Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer.
NF-{kappa}B mediates a protective response in cancer cells treated with inhibitors of fatty acid synthase.
Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3.
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.
Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway.
Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44.
Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.
Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells.
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
Overexpression of cyclooxygenase-2 in NCI-H292 human alveolar epithelial carcinoma cells: Roles of p38 MAPK, ERK-1/2, and PI3K/PKB signaling proteins.
Overexpression of cyclooxygenase-2 in non-small cell lung cancer.
Pachymic acid inhibits cell growth and modulates arachidonic acid metabolism in nonsmall cell lung cancer A549 cells.
PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells.
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth.
Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.
Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213.
Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.
Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo.
Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.
Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH102, a New Synthesized COX2 Inhibitors after I.V. and Oral Administration in Male and Female Rats.
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.
Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study.
Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers.
Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer.
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
PPAR? ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.
Proanthocyanidins inhibit in vitro and in vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin E(2) and prostaglandin E(2) receptors.
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.
Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer.
Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer.
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer.
Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.
Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix.
Protection by quercetin against cooking oil fumes-induced DNA damage in human lung adenocarcinoma CL-3 cells: role of COX-2.
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer.
Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Randomized, double-blind, placebo-controlled, multicenter phase ii study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Reactive oxygen species and lung tumorigenesis by mutant K-ras: a working hypothesis.
Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer.
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Regulation of COX-2 expression by miR-146a in lung cancer cells.
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Relationship between cyclooxygenase 8473T>C polymorphism and risk of lung cancer: a case-control study.
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Retraction.
Revisiting the role of COX-2 inhibitor for non-small cell lung cancer.
Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer.
Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer.
Role of cytokines in experimentally induced lung cancer and chemoprevention by COX-2 selective inhibitor, etoricoxib.
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.
Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
rs2910164 Polymorphism Confers a Decreased Risk for Pulmonary Hypertension by Compromising the Processing of microRNA-146a.
Screening method for nonsteroidal antiinflammatory drugs based on the cyclooxygenase 2 pathway activated by serum-free stimulation in A549 cells.
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.
Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism.
Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection.
Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.
Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.
Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents.
Silibinin modulates TNF-? and IFN-? mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells.
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors.
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.
Structural Probing, Screening and Structure-Based Drug Repositioning Insights into the Identification of Potential Cox-2 Inhibitors from Selective Coxibs.
Suppression of cyclooxygenase 2 increases chemosensitivity to sesamin through the Akt?PI3K signaling pathway in lung cancer cells.
Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition.
Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2.
Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
Synergistic association of PTGS2 and CYP2E1 genetic polymorphisms with lung cancer risk in northeastern Chinese.
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells.
Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer.
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
Targeting COX-2/PG-E2 with a COX-2 inhibitor in combination with chemotherapy for non-small cell lung cancer: are we ready for phase III?
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Targeting the eicosanoid pathway in non-small-cell lung cancer.
TGF-? Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells.
TGF-?1 Downregulates COX-2 Expression Leading to Decrease of PGE2 Production in Human Lung Cancer A549 Cells, Which Is Involved in Fibrotic Response to TGF-?1.
The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
The effects of nimesulide combined with cisplatin on lung cancer.
The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).
The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer.
The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
The NF-?B family member RelB regulates microRNA miR-146a to suppress cigarette smoke-induced COX-2 protein expression in lung fibroblasts.
The potential and rationale for COX-2 inhibitors in lung cancer.
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
The rigid steroid 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) is a dissociated glucocorticoid receptor modulator potentially useful as a novel coadjuvant in breast cancer chemotherapy.
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
The role of COX-2 inhibitors in lung cancer.
The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer.
The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer.
The transcription factor c-Fos coordinates with histone lysine-specific demethylase 2A to activate the expression of cyclooxygenase-2.
The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer.
Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response element-binding protein.
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.
Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-?-treated A549 cells.
Tubeimoside-1 inhibits proliferation and induces apoptosis by increasing the Bax to Bcl-2 ratio and decreasing COX-2 expression in lung cancer A549 cells.
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer.
Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
Upregulation of COX-2 in the lung cancer promotes overexpression of multidrug resistance protein 4 (MRP4) via PGE2-dependent pathway.
Upregulation of intrinsic apoptotic pathway in NSAIDs mediated chemoprevention of experimental lung carcinogenesis.
Urinary levels of prostaglandin E2 are positively correlated with intratumoral infiltration of Foxp3(+) regulatory T cells in non-small cell lung cancer.
USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer.
Wikyungtang inhibits proliferation of A549 human lung cancer cells via inducing apoptosis and suppressing cyclooxygenase-2 activity.
Yin Yang 1 enhances cyclooxygenase-2 gene expression in macrophages.
[A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment.]
[Correlation of time-density curve of CT enhancement with angiogenesis in lung cancer.]
[COX and study of cancer therapy]
[Cyclooxygenase 2 genetic variant interacting with tobacco smoking and the risk of lung cancer].
[Detection of EGFR and COX-2 expression by immunohistochemical method on a tissue microarray section in lung cancer and biological significance]
[Effect of cyclooxygenase-2 inhibitor, nimesulide, combined with cisplatin on lung cancer.]
[Effect of cyclooxygenase-2,and matrix metalloproteinase-2 expression on prognosis of lung cancer]
[Effect of NF-kappaB on inhibition of non-small cell lung cancer cell cyclooxygenase-2 by brucine].
[Effects of cyclooxygenase-2 antisense vector on proliferation and sensitivity to cisplatin of H1299 cells.]
[Effects of tea polyphenols on the expression of NF-?B, COX-2 and survivin in Lewis lung carcinoma xenografts in C57BL/6 mice].
[Expression and clinical significance of CD3, CD4 and COX-2 in non-small cell lung cancer].
[Expression and significance of COX-2 and its transcription factors NFAT3 and c-Jun in non-small cell lung cancer].
[Expression of COX-2 and its prognostic significance in non-small cell lung cancer.]
[Expressions of cyclooxygenase-2 and vascular endothelial growth factor in human lung cancer tissue.]
[Inhibitory effect of nimesulide and oxaliplatin on tumor growth and lymphatic metastasis of transplanted human lung cancer in nude mice].
[Mechanisms of EGF regulation of COX-2 through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells].
[Overexpression of COX-2 and a potential clinical application of its inhibitors in lung cancer]
[Overexpression of COX-2 and its clinical significance in non-small cell lung cancer]
[Prognostic value of survivin and cyclooxygenase-2 expression in non-small cell lung cancer: a tissue microarray analysis.]
[Roles of cyclooxygenase-2 and caspase-3 expression in pathogenesis of lung carcinoma: an experiment with rats]
[Study of COX-2 expression and angiogenesis in non-small cell lung cancer.]
[Suppression of COX-2 protein to cell apoptosis in non-small cell lung cancer.]
[Suppressive efffects of clarithromycin and cyclooxygenase-2 inhibitor, etodolac on N-nitrosobis(2-hydroxypropyl)amine(BHP)- induced experimental lung neoplasm in rats]
[The Expression of COX-2 in Human Lung Cancer and its Relationship with Expression of K-ras and Mcl-1.]
[The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results]
Lupus Erythematosus, Systemic
Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: molecular mechanisms and therapeutic potential.
Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE.
Cyclooxygenase-2 polymorphisms and risk of systemic lupus erythematosus in Koreans.
Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus.
Renal prostaglandins in systemic lupus erythematosus.
[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
Lupus Nephritis
Activation of Cyclooxygenase-2 by ATF4 During Endoplasmic Reticulum Stress Regulates Kidney Podocyte Autophagy Induced by Lupus Nephritis.
Analysis of renal immunoexpression of cyclooxygenase-1 and cyclooxygenase-2 in lupus and nonlupus membranous glomerulopathy.
Eicosanoid synthesis in peripheral blood monocytes: a marker of disease activity in lupus nephritis.
Hyaluronan-induced cyclooxygenase-2 expression promotes thromboxane A2 production by renal cells.
Increased renal thromboxane production in murine lupus nephritis.
Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
Selective Cyclooxygenase-2 Inhibitor Suppresses Renal Thromboxane Production but Not Proliferative Lesions in the MRL/lpr Murine Model of Lupus Nephritis.
Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis.
Lyme Disease
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease.
Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.
Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17.
Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis.
Lymphatic Metastasis
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer.
Aberrant expression of ?-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer.
Aberrant methylation of cyclooxygenase-2 in breast cancer patients.
Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression.
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Assessment of promising protein markers for vulva cancer.
Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.
Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer?
Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent.
Clinical relevance of cyclo-oxygenase 2 and peroxisome proliferator activated receptor ? in eyelid sebaceous gland carcinoma.
Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues.
Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.
Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma.
Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma.
Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.
Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis.
Clinicopathological significance of cyclooxygenase-2 expression in hypopharyngeal squamous cell carcinoma.
Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma.
Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer.
Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis.
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome.
Concurrent Expression of Cyclo-oxygenase-2 and Epidermal Growth Factor Receptor in Canine Malignant Mammary Tumours.
Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer.
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
Correlation between Spiral CT Preoperative Staging of Pancreatic Cancer and PTEN and COX-2 Expression.
Correlation of COX- 2 Expression in Colorectal Carcinoma with Clinicopathological Features.
Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma.
COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome.
COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness.
COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.
Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.
Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables.
Cyclooxygenase-2 Expression in Cervical Squamous Cell Carcinoma: the Significance of Expression in Neoplastic Cells within the Lymphovascular Space.
Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 expression in lymph node metastasis of cervical and vulvar cancer.
Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients.
Cyclooxygenase-2 expression in oral squamous cell carcinoma.
Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma.
Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis.
Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer.
Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-c and lymph node metastasis in human oral tongue cancer.
Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients.
Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma.
Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.
Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study.
Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland.
Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.
Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.
Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma.
Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells.
Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma.
Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis.
Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Evaluation of VEGF expression correlates with COX-2 expression in pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma.
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma.
Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma.
Expression of 15-PGDH is downregulated by COX-2 in gastric cancer.
Expression of COX-2 in stomach cancers and its relation to their biological features.
Expression of COX-2 proteins in gastric mucosal lesions.
Expression of COX-2, CD44v6 and CD147 and Relationship with Invasion and Lymph Node Metastasis in Hypopharyngeal Squamous Cell Carcinoma.
Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma.
Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis.
Expression of cyclooxygenase-1 and -2 and clinicopathologic features of colorectal cancer in northern Thailand.
Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.
Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma.
Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer.
Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance.
Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors.
Expression of cyclooxygenase-2 protein in colorectal carcinomas.
Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients.
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma.
Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in Oral Squamous Cell Carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation.
Expressions and clinical significance of COX-2, VEGF-C, and EFGR in endometrial carcinoma.
Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.
Heparanase and COX-2 expression as predictors of lymph node metastasis in large, high-grade breast tumors.
HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival.
Heterogeneity of COX-2 and multidrug resistance between primary tumors and regional lymph node metastases of gastric cancer.
High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
Identification of potential prognostic markers for vulvar cancer using immunohistochemical staining of tissue microarrays.
Immunoexpression of cyclooxygenase-2 in primary gastric carcinomas and lymph node metastases.
Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.
Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer.
Increased expression of COX-2 in the development of human lung cancers.
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention.
Influence of VEGF, COX-2, and MMP-9 expression on the molybdenum-targeted X-ray in breast cancer.
Inhibition of Cyclooxygenase-2 Suppresses Lymph Node Metastasis via Reduction of Lymphangiogenesis.
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion.
Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2.
MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells.
Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.
Overexpression of cyclooxygenase-2 in gastric cancer correlates with the high abundance of vascular endothelial growth factor-C and lymphatic metastasis.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis.
Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors.
Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability.
Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma.
PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.
Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Predictive value of cyclooxygenase 2 and Bcl-2 for cervical lymph node metastasis in mucoepidermoid carcinoma.
Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma.
Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis.
Prognostic impact of cyclooxygenase-2 in breast cancer.
Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma.
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma.
Prognostic significance of expression of cysteine-rich 61 and cyclooxygenase-2 in gastric cancer.
Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer.
Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
Protein predictive signatures for lymph node metastasis of gastric cancer.
PTGS2 (COX-2) -765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma.
Quantitative analysis of COX-2 promoter methylation in gastric carcinoma.
Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.
Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer.
Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.
Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer.
Role of cyclooxygenase-2 in gastric cancer development and progression.
Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer.
Significance of Cox-2 expression in rectal cancers with or without preoperative radiotherapy.
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray.
The association between COX-2 gene rs5275 polymorphism and Nasopharyngeal carcinoma risk.
The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.
The Cyclooxygenase-2 (PTGS2) 8473T>C Polymorphism is Associated with Breast Cancer Risk.
The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis.
The relationship between cyclooxygenase-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma.
The relationship between HPV16 and expression of cyclooxygenase-2, P53 and their prognostic roles in esophageal squamous cell carcinoma.
The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
The role of COX-2 inhibition in breast cancer treatment and prevention.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
[Association of abnormal cyclooxygenase-2 gene expression with colorectal carcinoma metastasis]
[Clinicopathologic significance of cyclooxygenase-2 mRNA expression in human breast carcinoma]
[Correlation between Stat3 signal transduction pathway and expression of cyclooxygenase-2 in colorectal cancer cells]
[Correlation of cyclooxygenase 2 expression with microlymphatic density and its clinical significance]
[Correlation of time-density curve of CT enhancement with angiogenesis in lung cancer.]
[COX- 2 expression in gastric cancer and its relationship with lymphangiogenesis and lymph node metastasis]
[Detection of EGFR and COX-2 expression by immunohistochemical method on a tissue microarray section in lung cancer and biological significance]
[Evaluation of cyclooxygenase-2 in the prediction of liver metastasis of colorectal carcinoma]
[Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma]
[Expression and function of cyclooxygenase-2 in endometrial carcinoma]
[Expression of COX-2 and its prognostic significance in non-small cell lung cancer.]
[Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance]
[Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]
[Expression of COX-2 and VEGF-C in squamous cell carcinoma of the tongue and its correlation to lymph node metastasis]
[Expression of cyclooxygenase-2 in esophageal squamous cell carcinogenesis]
[Expression of NF-kappaB and COX-2 in tongue squamous cell carcinoma]
[Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance.]
[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]
[Expressions of COX-2 and MMP-2 in nasopharyngeal carcinoma and the their relationship with lymph node metastasis]
[Flow cytometric quantitative analysis of multiple tumor suppressor gene 1 (MTS1) and cyclooxygenase-2 (COX-2) gene expressions in invasive breast cancers and their clinical significance]
[Inhibitory effect of nimesulide and oxaliplatin on tumor growth and lymphatic metastasis of transplanted human lung cancer in nude mice].
[Prognostic value of survivin and cyclooxygenase-2 expression in non-small cell lung cancer: a tissue microarray analysis.]
[Relation between COX-2 protein expression and biologic behavior of ovarian carcinoma]
[Relationship between cyclooxygenase- 2 expression and angiogenesis in patients with gastric cancer]
[Relationship between cyclooxygenase-2 in nasopharyngeal carcinoma and cervical lymph node metastasis].
[Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior]
[Suppression of COX-2 protein to cell apoptosis in non-small cell lung cancer.]
[The Expression and Clinical Significance of HIF-1?, COX-2 and E-cadherin in Patients with Lung Adenocarcinoma.]
[The expressiong of cyclooxygenase-2 in laryngeal squamous cell carcinoma and its relationship with MVD]
[The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer]
[The role of cyclooxygenase-2 and vascular endothelial growth factor-C in lymphatic metastasis of gastric cancer]
Lymphedema
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Leukotriene B4 antagonism ameliorates experimental lymphedema.
Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema.
Lymphocytosis
Reduced COX-2 protein in colorectal cancer with defective mismatch repair.
Lymphoma
A functional (pro)renin receptor is expressed in human lymphocytes and monocytes.
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
Angiogenesis in nodal B cell lymphomas: a high throughput study.
Anti-neuroinflammatory and neuroprotective effects of the Lindera neesiana fruit in vitro.
Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines.
Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type.
COX-2 independent effects of Celecoxib sensitize Lymphoma B cells to TRAIL-mediated apoptosis.
Cyclooxygenase-2 (Cox-2) expression in lymphomas.
Cyclooxygenase-2 expression in lymphoma in north-west of iran.
Cyclooxygenase-2 expression in non-Hodgkin's lymphomas.
Cyclooxygenase-2 immunoexpression in intestinal epithelium and lamina propria of cats with inflammatory bowel disease and low grade alimentary lymphoma.
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma.
Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: a retrospective study.
Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in primary central nervous system lymphomas.
Expression of prostaglandin H synthase-2 in human brain tumors.
Glucocorticoid-induced lymphoma cell growth inhibition: the role of leukotriene B4.
Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.
Immunohistochemical expression of cyclooxygenase-2 in normal, hyperplastic and neoplastic canine lymphoid tissues.
Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.
Inflammatory myofibroblastic tumor in the head and neck-a neoplasm with both tumor features and inflammation.
Korean Red Ginseng Extract Enhances the Anticancer Effects of Imatinib Mesylate Through Abrogation p38 and STAT5 Activation in KBM-5 Cells.
Microcirculatory alteration in low-grade gastric mucosa-associated lymphoma by Helicobacter heilmannii infection: its relation to vascular endothelial growth factor and cyclooxygenase-2.
Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases.
Mutagenic response of mouse lymphoma cells after activation of benzidine and 2-aminofluorene with purified prostaglandin H synthase.
Nano hydroxyapatite induces glioma cell apoptosis by suppressing NF-?B signaling pathway.
Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression.
Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas.
Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.
Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells.
Regression of follicular lymphoma with Devil's Claw: coincidence or causation?
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
The cyclooxygenase-2/prostaglandin E2 pathway and its role in the pathogenesis of human and dog hematological malignancies.
[Association of abnormal cyclooxygenase-2 gene expression with colorectal carcinoma metastasis]
[Protein expression and clinical significance of cyclooxygenase 2 and nuclear factor kappa B in gastric mucosa-associated lymphoid tissue lymphoma.]
[The expression of COX-2 mRNA and protein in human laryngeal squamous cell carcinoma]
Lymphoma, B-Cell
Açaí Berries Inhibit Colon Tumorigenesis in Azoxymethane/Dextran Sulfate Sodium-Treated Mice.
Ameliorative effects of silymarin on HCl-induced acute lung injury in rats; role of the Nrf-2/HO-1 pathway.
Anti-neuroinflammatory and neuroprotective effects of the Lindera neesiana fruit in vitro.
Avicularin Relieves Depressive-Like Behaviors Induced by Chronic Unpredictable Mild Stress in Mice.
Cicadidae Periostracum, the Cast-Off Skin of Cicada, Protects Dopaminergic Neurons in a Model of Parkinson's Disease.
Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein.
Combination of celecoxib (Celebrex(®)) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.
Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells.
Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.
Effects of a nutrient mixture on immunohistochemical localization of cancer markers in human cervical cancer HeLa cell tumor xenografts in female nude mice.
Eugenol Exerts Apoptotic Effect and Modulates the Sensitivity of HeLa Cells to Cisplatin and Radiation.
Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells.
Exercise Training Prevents Dexamethasone-induced Rarefaction.
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma.
Hazelnut and neuroprotection: Improved memory and hindered anxiety in response to intra-hippocampal A? injection.
Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.
Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma?
Investigation of the anti-cataractogenic mechanisms of curcumin through in vivo and in vitro studies.
Isoform-Specific Role of Akt in Oral Squamous Cell Carcinoma.
Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.
Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis.
Microcirculatory alteration in low-grade gastric mucosa-associated lymphoma by Helicobacter heilmannii infection: its relation to vascular endothelial growth factor and cyclooxygenase-2.
Nano hydroxyapatite induces glioma cell apoptosis by suppressing NF-?B signaling pathway.
Phyllanthin Averts Oxidative Stress and Neuroinflammation in Cerebral Ischemic-Reperfusion Injury through Modulation of the NF-?B and AMPK/Nrf2 Pathways.
Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.
Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.
Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
Syringic acid modulates molecular marker-involved cell proliferation, survival, apoptosis, inflammation, and angiogenesis in DMBA-induced oral squamous cell carcinoma in Syrian hamsters.
The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis.
Lymphoma, B-Cell, Marginal Zone
Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma.
Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies.
Microcirculatory alteration in low-grade gastric mucosa-associated lymphoma by Helicobacter heilmannii infection: its relation to vascular endothelial growth factor and cyclooxygenase-2.
[Protein expression and clinical significance of cyclooxygenase 2 and nuclear factor kappa B in gastric mucosa-associated lymphoid tissue lymphoma.]
Lymphoma, Large B-Cell, Diffuse
Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.
Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
Lymphoma, Non-Hodgkin
Concurrent targeting of EP1/EP4 receptors and COX-2 induces synergistic apoptosis in KSHV and EBV associated non-Hodgkin lymphoma cell lines.
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Lymphangiogenesis in non-Hodgkin's lymphoma and its correlation with cyclooxygenase-2 and vascular endothelial growth factor-C.
Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
[Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma]
Lymphoma, Primary Effusion
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
Lymphoma, T-Cell
Cyclooxygenase-2 is not expressed by canine cutaneous epitheliotropic T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF).
Lymphoma, T-Cell, Peripheral
Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-?B pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Lymphopenia
The COX-2 gene promoter polymorphism -765 delays CD4 T-cell reconstitution after lymphocyte depletion with antithymocyte globulins.
Macular Degeneration
Cyclooxygenase inhibitor improved an exudative lesion of choroidal neovascularization in age-related macular degeneration.
Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients.
Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model.
Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD.
Macular Edema
Cyclooxygenase-2 inhibitors: a new therapeutic option in the treatment of macular edema after cataract surgery.
Successful treatment of cystoid macular edema with valdecoxib.
The opinion of the Expert Group of the Polish Society of Ophthalmology on using nepafenac in the prevention of postoperative macular edema after cataract surgery in diabetic patients.
Magnesium Deficiency
Alteration of prostanoid metabolism in rats with magnesium deficiency.
Malaria
Activities of Andrographis paniculata (AS201-01) Tablet on Cox-2 and Prostaglandin Expression of Placental of Plasmodium berghei Infected Mice.
Chronic infection during placental malaria is associated with up-regulation of cycloxygenase-2.
Cyclooxygenase-2 haplotypes influence the longitudinal risk of malaria and severe malarial anemia in Kenyan children from a holoendemic transmission region.
Cyclooxygenase-2 in the pathogenesis of murine cerebral malaria.
Immunopathogenesis of cerebral malaria.
Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria.
Reduced peripheral PGE2 biosynthesis in Plasmodium falciparum malaria occurs through hemozoin-induced suppression of blood mononuclear cell cyclooxygenase-2 gene expression via an interleukin-10-independent mechanism.
Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia.
Suppression of in-vitro lymphoproliferative responses in acute malaria patients can be partially reversed by indomethacin.
Suppression of Prostaglandin E2 by Malaria Parasite Products and Antipyretics Promotes Overproduction of Tumor Necrosis Factor- alpha : Association with the Pathogenesis of Childhood Malarial Anemia.
Malaria, Cerebral
Cyclooxygenase-2 in the pathogenesis of murine cerebral malaria.
Differences in the modulation of reactive species, lipid bodies, cyclooxygenase-2, 5-lipoxygenase and PPAR-? in cerebral malaria-susceptible and resistant mice.
Focal accumulation of cyclooxygenase-1 (COX-1) and COX-2 expressing cells in cerebral malaria.
Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia.
Malaria, Falciparum
Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria.
Reduced peripheral PGE2 biosynthesis in Plasmodium falciparum malaria occurs through hemozoin-induced suppression of blood mononuclear cell cyclooxygenase-2 gene expression via an interleukin-10-independent mechanism.
Malnutrition
Effect of periconceptional undernutrition in sheep on late gestation expression of mRNA and protein from genes involved in fetal adrenal steroidogenesis and placental prostaglandin production.
Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management.
NADPH oxidase and enhanced superoxide generation in intrauterine undernourished rats: involvement of the renin-angiotensin system.
Mania
Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?
Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches.
Mood-stabilizers target the brain arachidonic acid cascade.
Mastitis
Activity of cyclooxygenase-2 and nitric oxide in milk leucocytes following intramammary inoculation of a bio-response modifier during bovine Staphylococcus aureus subclinical mastitis.
Dietary Selenium Deficiency Exacerbates Lipopolysaccharide-Induced Inflammatory Response in Mouse Mastitis Models.
Effect of prostaglandin synthetase inhibitors on endotoxin-induced mastitis.
Effect of prostaglandin synthetase inhibitors on mammary blood flow during experimentally induced mastitis in lactating goats.
Expression of cyclooxygenase-2 in the mammary gland tissue of goats affected with caprine contagious agalactia.
Flunixin Meglumine Reduces Milk Isoprostane Concentrations in Holstein Dairy Cattle Suffering from Acute Coliform Mastitis.
The combined use of lipoxygenase and cyclooxygenase inhibitors in Klebsiella pneumoniae-induced bovine mastitis.
Mastocytoma
Identification of mRNA for prostaglandin endoperoxide synthetase from mouse mastocytoma P-815 cells.
Identification of the mRNA and polypeptide subunit for prostaglandin endoperoxide synthase from mouse mastocytoma P-815 cells.
Mast cells and cell-to-cell interactions in airways.
Mitogen-inducible prostaglandin G/H synthase is expressed in canine mastocytoma cells.
Sodium n-butyrate induces prostaglandin synthetase activity in mastocytoma P-815 cells.
Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase.
Mastocytosis
Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis.
Mast cell disease.
Protective Effect of Cashew Gum (Anacardium occidentale L.) on 5-Fluorouracil-Induced Intestinal Mucositis.
Role of Rutin in 5-Fluorouracil-Induced Intestinal Mucositis: Prevention of Histological Damage and Reduction of Inflammation and Oxidative Stress.
Troxerutin Prevents 5-Fluorouracil Induced Morphological Changes in the Intestinal Mucosa: Role of Cyclooxygenase-2 Pathway.
Mastocytosis, Systemic
Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition.
Meconium Aspiration Syndrome
Meconium aspiration stimulates cyclooxygenase-2 and nitric oxide synthase-2 expression in rat lungs.
Meconium stimulates cyclooxygenase-2 expression in rat lungs.
Medulloblastoma
Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.
Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation.
Expression of prostaglandin H synthase-2 in human brain tumors.
MT1-MMP expression level status dictates the in vitro action of lupeol on inflammatory biomarkers MMP-9 and COX-2 in medulloblastoma cells.
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.
[Expression and clinical significance of cyclooxygenase-2 in medulloblastoma]
Megacolon
[Mechanism of exacerbation of colonic damage in experimental colitis treated with celecoxib]
Melanoma
ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output.
Amfenac increases the radiosensitivity of uveal melanoma cell lines.
Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression.
Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma.
Anticancer activity of anandamide in human cutaneous melanoma cells.
Antiproliferative Diarylpyrazole Derivatives as Dual Inhibitors of the ERK Pathway and COX-2.
Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.
Apoptotic effect of eugenol envolves G2/M phase abrogation accompanied by mitochondrial damage and clastogenic effect on cancer cell in vitro.
Aspirin Suppresses PGE2 and Activates AMP Kinase to Inhibit Melanoma Cell Motility, Pigmentation, and Selective Tumor Growth In Vivo.
Association of promoter polymorphism -765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts.
ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo.
Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E2 and prostaglandin E2 receptors.
Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.
Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism.
Chemoprevention of skin melanoma: facts and myths.
Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor.
Combination therapy of PKC? and COX-2 inhibitors synergistically suppress melanoma metastasis.
Comparative expression of cyclooxygenase 2 and Ki67 in amelanotic and conventional oral melanomas.
Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results.
Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor.
Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Correction to: Combination therapy of PKC? and COX-2 inhibitors synergistically suppress melanoma metastasis.
COX-1 and COX-2 Expression in Canine Cutaneous, Oral and Ocular Melanocytic Tumours.
COX-2 as a potential biomarker and therapeutic target in melanoma.
COX-2 expression in malignant melanoma: a novel prognostic marker?
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
COX-2 Silencing in Canine Malignant Melanoma Inhibits Malignant Behaviour.
Cyclo-oxygenase-2 expression in photon-radiated and non-radiated uveal melanomas.
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma.
Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice.
Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Cyclooxygenase-2 expression in brain metastases.
Cyclooxygenase-2 expression in equine tumors.
Cyclooxygenase-2 expression in human irradiated uveal melanomas.
Cyclooxygenase-2 expression in the eyes of cats with and without uveitis.
Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours.
Cyclooxygenase-2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas.
Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms.
Cyclooxygenase-2 Facilitates Newcastle Disease Virus Proliferation and Is as a Target for Canthin-6-One Antiviral Activity.
Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies.
Cyclooxygenase-2 inhibition and regression of metastatic melanoma.
Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells.
Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma.
Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma.
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells.
DHA induces apoptosis and differentiation in human melanoma cells in vitro: involvement of HuR-mediated COX-2 mRNA stabilization and ?-catenin nuclear translocation.
Different detectability of cyclooxygenase-2 (COX-2) protein in standard paraffin sections and tissue microarrays of human melanomas and naevi - Comparative study.
Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.
Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells.
Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.
Endogenous PGE(2) induces MCP-1 expression via EP4/p38 MAPK signaling in melanoma.
Enhanced expression of cyclooxygenase-2 related multi-drug resistance gene in melanoma and osteosarcoma cell lines by TSG-6 secreted from canine adipose-derived mesenchymal stem/stromal cells.
Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.
Evaluation of Cyclooxygenase-2 Expression in Association with Clinical-Pathological Factors in Malignant Melanoma.
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
Evaluation of tumor-specific promoter activities in melanoma.
Expression and significance of factors related to angiogenesis in choroidal melanoma.
Expression of Ca(2+)-independent and Ca(2+)-dependent phospholipases A(2) and cyclooxygenases in human melanocytes and malignant melanoma cell lines.
Expression of COX-2 and prognostic outcome in uveal melanoma.
Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
Expression of cyclooxygenase 2 in human malignant melanoma.
Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression.
Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
Expression of cyclooxygenase-2 in canine uveal melanocytic neoplasms.
Expression of the CD117, COX-2 and HSP90 antigens and cell proliferation in fine-needle-aspirated cells from metastatic melanomas.
Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma.
Gene transfer of pro-opiomelanocortin prohormone suppressed the growth and metastasis of melanoma: involvement of alpha-melanocyte-stimulating hormone-mediated inhibition of the nuclear factor kappaB/cyclooxygenase-2 pathway.
Grape seed proanthocyanidins inhibit melanoma cell invasiveness by reduction of PGE2 synthesis and reversal of epithelial-to-mesenchymal transition.
Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition.
High Expression of COX-2 Associated with the Depth of Invasion on Acral Melanoma by Increasing TGF-?1.
Hyperthermia Suppresses Post - In Vitro Proliferation and Tumor Growth in Murine Malignant Melanoma and Colon Carcinoma.
Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells.
Immunohistochemical detectability of cyclooxygenase-2 expression in cells of human melanocytic skin lesions: A methodological review.
Immunohistochemical expression of COX-2 and c-kit in metastatic uveal melanoma.
Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions.
Immunohistochemical expression of cyclooxygenase-2 (COX-2) in oral nevi and melanoma.
Impact of Human Adipose Tissue-Derived Stem Cells on Malignant Melanoma Cells in An In Vitro Co-culture Model.
In Vitro Effects of Selective COX and LOX Inhibitors and Their Combinations with Antineoplastic Drugs in the Mouse Melanoma Cell Line B16F10.
In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin.
Indomethacin enhancement of immunocompetence in melanoma patients.
Influence of morphology and malignancy of three new human melanoma cell lines on the cyclooxygenase pathway.
Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.
Investigating associations of cyclooxygenase-2 expression with angiogenesis, proliferation, macrophage and T-lymphocyte infiltration in canine melanocytic tumours.
Ipobscurine, an indole alkaloid from Ipomoea obscura, inhibits tumor cell invasion and experimental metastasis by inducing apoptosis.
Karyopherin ? 2 promotes proliferation, migration and invasion through activating NF-?B/p65 signaling pathways in melanoma cells.
Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment.
Leukotriene B4 creates a favorable microenvironment for murine melanoma growth.
Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
MicroRNA-143-3p inhibits growth and invasiveness of melanoma cells by targeting cyclooxygenase-2 and inversely correlates with malignant melanoma progression.
Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.
NF-?B p65 and p105 implicate in interleukin 1?-mediated COX-2 expression in melanoma cells.
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
Optical imaging of COX-2: Studies on an autofluorescent 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitor.
Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via ?9?1 integrin.
pH-Responsive nanoparticles based on ibuprofen prodrug as drug carriers for inhibition of primary tumor growth and metastasis.
PKCalpha-MAPK/ERK-phospholipase A(2) signaling is required for human melanoma-enhanced brain endothelial cell proliferation and motility.
Plasma circulating cell free messenger RNA as a potential biomarker of melanoma.
Polysaccharide from Inonotus obliquus inhibits migration and invasion in B16-F10 cells by suppressing MMP?2 and MMP?9 via downregulation of NF-?B signaling pathway.
Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma.
Prognostic Significance of CD200 Protein Expression and its Correlation with COX-2 in Cutaneous Melanoma.
Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.
Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II.
Prostaglandin D production in FM55 melanoma cells is regulated by alpha-melanocyte-stimulating hormone and is not related to melanin production.
Prostaglandin production by melanocytic cells and the effect of alpha-melanocyte stimulating hormone.
Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin.
Quantitative measurement of iNOS expression in melanoma, nasopharyngeal, colorectal, and breast tumors of Tunisian patients: comparative study and clinical significance.
Radiation therapy generates platelet-activating factor agonists.
Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival.
Reduction of COX-2 through modulating miR-124/SPHK1 axis contributes to the antimetastatic effect of alpinumisoflavone in melanoma.
Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy.
Resveratrol-mediated inhibition of cyclooxygenase-2 in melanocytes suppresses melanogenesis through extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/Akt signalling.
Retraction: Green Tea Catechins Reduce Invasive Potential of Human Melanoma Cells by Targeting COX-2, PGE2 Receptors and Epithelial-to-Mesenchymal Transition.
Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma.
Sarcophine-diol inhibits expression of COX-2, inhibits activity of cPLA?, enhances degradation of PLA? and PLC(?)1 and Inhibits cell membrane permeability in mouse melanoma B??F?? cells.
Similar antineoplastic effects of nimesulide, a selective COX-2 inhibitor, and prostaglandin E1 on B16-F10 murine melanoma cells.
Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.
Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.
Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis.
Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
The association between nonsteroidal anti-inflammatory drugs and skin cancer: Different responses in American and European populations.
The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production.
The metastatic microenvironment: Brain-residing melanoma metastasis and dormant micrometastasis.
The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.
The role of immunohistochemistry expression of COX-2 in differentiating pigmented benign and malignant skin neoplasms.
The role of lipid signaling in the progression of malignant melanoma.
The tumor-promoting role of TRIP4 in melanoma progression and its involvement in response to BRAF-targeted therapy.
The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma.
The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
Therapeutic intervention of proanthocyanidins on the migration capacity of melanoma cells is mediated through PGE2 receptors and ?-catenin signaling molecules.
Timosaponin AIII inhibits melanoma cell migration by suppressing COX-2 and in vivo tumor metastasis.
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition.
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients.
Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.
Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts.
Visualization of cyclooxygenase-2 using a 2,3-diarylsubstituted indole-based inhibitor and confocal laser induced cryofluorescence microscopy at 20K in melanoma cells in vitro.
Vitamin C suppresses proliferation of the human melanoma cell SK-MEL-2 through the inhibition of cyclooxygenase-2 (COX-2) expression and the modulation of insulin-like growth factor II (IGF-II) production.
[Evaluation of COX-2 protein expression in melanocytic nevi in children].
Melanoma, Experimental
Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma.
Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma.
Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.
Melanosis
CD4, IL-17, and COX-2 Are Associated With Subclinical Inflammation in Malar Melasma.
siRNA-mediated knock-down of COX-2 in melanocytes suppresses melanogenesis.
Melioidosis
Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei.
Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei.
Melkersson-Rosenthal Syndrome
Expression of protease-activated receptor-1 and -2 in orofacial granulomatosis.
Memory Disorders
Celecoxib Alleviates Memory Deficits by Downregulation of COX-2 Expression and Upregulation of the BDNF-TrkB Signaling Pathway in a Diabetic Rat Model.
Chronic acrylamide exposure induced glia cell activation, NLRP3 infl-ammasome upregulation and cognitive impairment.
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.
Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice.
Luteolin alleviates cognitive impairment in Alzheimer's disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation.
Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer's disease model in mice: involvement of Na(+), K(+)-ATPase.
Protective effect of flavonoids against aging- and lipopolysaccharide-induced cognitive impairment in mice.
Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice.
Systemic and developmental exposure to lead causes spatial memory deficits and a reduction in COX-2 immunoreactivity in the hippocampus of male rats.
The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease.
Meningioma
A study on the biological behavior of human brain tumors. Part I. Arachidonic acid metabolism and DNA content.
An observational study on the expression of cyclooxygenase-2 in meningioma.
Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma.
Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Comparative morphological and immunohistochemical study of human meningioma after intracranial transplantation into nude mice.
Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas.
Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade.
Cyclooxygenase-2 (COX-2) overexpression in meningiomas: real time PCR and immunohistochemistry.
Effect of systemic celecoxib on human meningioma after intracranial transplantation into nude mice.
Erratum to: Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma.
Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
Expression of Cyclooxygenase-2 and Its Correlation with Vasogenic Brain Edema in Human Intracranial Meningiomas.
Expression of prostaglandin H synthase-2 in human brain tumors.
Identification of a Transcription Factor-microRNA-Gene Coregulation Network in Meningioma through a Bioinformatic Analysis.
Immunohistochemical analysis of cyclooxygenase-2 and brain fatty acid binding protein expression in grades I-II meningiomas: Correlation with tumor grade and clinical outcome after radiotherapy.
Immunohistochemical expression of cyclooxygenase-2 (COX-2) is not associated with tumor grade in feline meningiomas.
Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors.
Meningioma: an update.
Recurrence/Regrowth in Grade I Meningioma: How to Predict?
Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas.
The eicosanoid cascade: possible role in gliomas and meningiomas.
Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.
Meningitis
Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor.
Deregulation of cyclooxygenase and nitric oxide synthase gene expression in the inflammatory cascade triggered by experimental group B streptococcal meningitis in the newborn brain and cerebral microvessels.
Neuroinflammatory role of prostaglandins during experimental meningitis: evidence suggestive of an in vivo relationship between nitric oxide and prostaglandins.
Meningitis, Bacterial
Cyclooxygenase Inhibition Limits Blood-Brain Barrier Disruption following Intracerebral Injection of Tumor Necrosis Factor-{alpha} in the Rat.
Superoxide dismutase inhibits brain oedema formation in experimental pneumococcal meningitis.
Menorrhagia
Assessment of medical treatments for menorrhagia.
Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid.
Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies.
Endometrial prostaglandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo.
Management of cyclical menorrhagia with prostaglandin synthetase inhibitor.
Medical therapies for chronic menorrhagia.
Prostaglandins and menorrhagia.
Reduction of menstrual blood loss by naproxen in intrauterine contraceptive device users.
The effect of a prostaglandin synthetase inhibitor, indomethacin, on excessive uterine bleeding.
The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis.
The levonorgestrel-releasing intrauterine system as an alternative to hysterectomy in peri-menopausal women.
Treatment of IUD related menorrhagia by indomethacin.
Mesothelioma
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
COX-2 overexpression in canine tumors: potential therapeutic targets in oncology.
COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort.
Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis.
Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.
Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.
Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.
Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans.
The Value of COX-2, NF-?B, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma.
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
Mesothelioma, Malignant
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort.
Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.
Metabolic Diseases
Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia.
Prostaglandins in action indispensable roles of cyclooxygenase-1 and -2 in endothelium-dependent contractions.
Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase.
The emerging role of COX-2, 15-LOX, and PPAR? in metabolic diseases and cancer: An introduction to novel multi-target directed ligands (MTDLs).
Metabolic Syndrome
ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
Dietary trans-10, cis-12 conjugated linoleic acid reduces early glomerular enlargement and elevated renal cyclooxygenase-2 levels in young obese fa/fa zucker rats.
Effect of glycine on the cyclooxygenase pathway of the kidney arachidonic acid metabolism in a rat model of metabolic syndrome.
High fat diet-induced metabolically obese and normal weight rabbit model shows early vascular dysfunction: mechanisms involved.
Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.
Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism.
Role of cox-2 in vascular inflammation: an experimental model of metabolic syndrome.
Selective COX2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats.
Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.
The protective role of Kangen-karyu against fructose-induced metabolic syndrome in a rat model.
[Disturbed synthesis of eicosanoids in patients with metabolic syndrome]
Metrorrhagia
Activation of NF-kappaB and COX-2 expression is associated with breakthrough bleeding in patients using oral contraceptives in extended regimens.
The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium.
Migraine Disorders
A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine.
A review on the management of migraine in the Avicenna's Canon of Medicine.
A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: effects of nitroglycerin.
Association of COX-2 Promoter Polymorphisms -765G/C and -1195A/G with Migraine.
Association of the cyclooxygenase-2 1759A allele with migraine in Chinese Han individuals.
Celecoxib reduces cortical spreading depression-induced macrophage activation and dilatation of dural but not pial arteries in rodents: implications for mechanism of action in terminating migraine attacks.
Cox-2 gene variants in migraine.
Differential effects of corticosteroids on the expression of cyclooxygenase-2, tumour necrosis factor-alpha and matrix metalloproteinase-9 in an animal model of migraine.
Effects of Parecoxib on Plasma Protein Extravasation and c-Fos Expression in the Rat.
Exercise suppresses COX-2 pro-inflammatory pathway in vestibular migraine.
Genomic abnormalities in patients with migraine and chronic migraine: preliminary blood gene expression suggests platelet abnormalities.
Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei.
Linked activation of nitric oxide synthase and cyclooxygenase in peripheral monocytes of asymptomatic migraine without aura patients.
Localization of COX-1 and COX-2 in the intracranial dura mater of the rat.
NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data.
Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers.
Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches.
Potential effect and mechanism of action of topical chamomile (Matricaria chammomila L.) oil on migraine headache: A medical hypothesis.
Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine.
Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine.
Rofecoxib in migraine.
Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine.
Sensitization of meningeal nociceptors: inhibition by naproxen.
Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine.
Systems pharmacology to decipher the combinational anti-migraine effects of Tianshu formula.
Tuling Wendan Decoction combined with flunarizine in the treatment of migraine patients and the effect of intervention on serum cyclooxygenase-2, endothelin-1 and nitric oxide.
Valdecoxib for the management of chronic and acute pain.
Migraine without Aura
Linked activation of nitric oxide synthase and cyclooxygenase in peripheral monocytes of asymptomatic migraine without aura patients.
Miosis
The putative role of prostaglandins in surgical miosis.
Topical flurbiprofen in extracapsular cataract surgery: effect on pupillary diameter and iris fluorescein leakage.
Mitochondrial Diseases
Small intestinal injury caused by NSAIDs/aspirin: finding new from old.
mitogen-activated protein kinase kinase kinase deficiency
MAP3K8 Regulates Cox-2-Mediated Prostaglandin E2 Production in the Lung and Suppresses Pulmonary Inflammation and Fibrosis.
Motor Neuron Disease
Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia.
Nonsteroidal anti-inflammatory drugs differentially affect the heat shock response in cultured spinal cord cells.
Mouth Neoplasms
Actinic cheilitis: Epithelial expression of COX-2 and its association with mast cell tryptase and PAR-2.
Antitumor Activity of Ficus deltoidea Extract on Oral Cancer: An In Vivo Study.
Areca nut components affect COX-2, cyclin B1/cdc25C and keratin expression, PGE2 production in keratinocyte is related to reactive oxygen species, CYP1A1, Src, EGFR and Ras signaling.
Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes.
Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.
Butyrate inhibits oral cancer cell proliferation and regulates expression of secretory phospholipase A2-X and COX-2.
Caffeic Acid phenethyl ester is a potential therapeutic agent for oral cancer.
Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer.
Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent.
Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis.
Correlation of epigenetic change and identification of risk factors for oral submucous fibrosis.
COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma.
CTGF inhibits cell motility and COX-2 expression in oral cancer cells.
Cyclooxygenase isozymes in oral squamous cell carcinoma:a real-time RT-PCR study with clinic pathological correlations.
Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions.
Cyclooxygenase-2 expression in oral squamous cell carcinoma.
Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms.
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions.
Deregulated cyclooxygenase-2 expression in oral premalignant tissues.
Deregulation of lysophosphatidic acid metabolism in oral cancer promotes cell migration via the up-regulation of COX-2.
Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA.
Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas.
Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco.
Functional Polymorphisms in COX-2 Gene Are Correlated with the Risk of Oral Cancer.
Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-?B inhibition in oral cancer.
Helioxanthin suppresses the cross talk of COX-2/PGE2 and EGFR/ERK pathway to inhibit Arecoline-induced Oral Cancer Cell (T28) proliferation and blocks tumor growth in xenografted nude mice.
Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma.
Impact of combined treatment with nimesulide and cisplatin on oral carcinoma cells.
Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1.
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression.
Lactobacillus salivarius REN inhibits rat oral cancer induced by 4-nitroquioline 1-oxide.
Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer.
Modulation of apoptosis by berberine through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells.
NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins.
NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res., 10: 1565-1573, 2004.
Operculina turpethum extract inhibits growth and proliferation by inhibiting NF-?B, COX-2 and cyclin D1 and induces apoptosis by up regulating P53 in oral cancer cells.
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation.
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Overexpression of lipocalins and pro-inflammatory chemokines and altered methylation of PTGS2 and APC2 in oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide.
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma.
Promotion of hematogenous metastatic potentials in human KB carcinoma cells with overexpression of cyclooxygenase-2.
Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells.
Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines.
Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma.
Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production.
Staphylococcus aureus induces COX-2-dependent proliferation and malignant transformation in oral keratinocytes.
Synthesis of new selective cytotoxic ricinine analogues against oral squamous cell carcinoma.
The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function.
The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
The dietary phytochemical 3,3'-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-?B, MAPK, and p53 signaling.
The effect of betel nut extract on cell growth and prostaglandin endoperoxide synthase in human epidermoid carcinoma cells.
The role of COX-2 in oral cancer development, and chemoprevention/ treatment of oral cancer by selective COX-2 inhibitors.
Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2 -1195G>a polymorphism reveal risk of oral cancer.
Which putatively pre-malignant oral lesions become oral cancers? Clinical relevance of early targeting of high-risk individuals.
[High-performance liquid chromatography for determining celecoxib concentration in hamster tongue tissue after oral local application.]
[In vitro investigation on the mechanism of cyclooxygenase-2 upregulation induced by spleen tyrosine kinase-nuclear factor ?B signaling in cancer pain caused by oral cancer-associated macrophage].
[Oral cancer. Cyclooxygenase inhibitors for prevention: beneficial or risky]
Moyamoya Disease
Cyclooxygenase-2 and Prostaglandin E2 are Associated with Middle Cerebral Artery Occlusion and Hemorrhage in Patients with Moyamoya Disease.
Increase in prostaglandin E(2) production by interleukin-1beta in arterial smooth muscle cells derived from patients with moyamoya disease.
Significance of cyclooxygenase-2 elevation in middle cerebral artery for patients with hemorrhagic moyamoya disease.
Mucocutaneous Lymph Node Syndrome
The Relationship of COX-2 Gene Polymorphisms and Susceptibility to Kawasaki Disease in Chinese Population.
Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease.
Mucositis
A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2.
Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis.
Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice.
Correction: olmesartan decreased levels of IL-1? and TNF-?, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model.
Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols.
Hangeshashinto (TJ-14) prevents radiation-induced mucositis by suppressing cyclooxygenase-2 expression and chemotaxis of inflammatory cells.
Histological evaluation of peri-implant mucosal and gingival tissues in peri-implantitis, peri-implant mucositis and periodontitis patients: a cross-sectional clinical study.
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy.
Olmesartan decreased levels of IL-1? and TNF-?, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model.
Radiation therapy-induced mucositis: relationships between fractionated radiation, NF-kappaB, COX-1, and COX-2.
Role of Rutin in 5-Fluorouracil-Induced Intestinal Mucositis: Prevention of Histological Damage and Reduction of Inflammation and Oxidative Stress.
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study.
The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis.
Troxerutin Prevents 5-Fluorouracil Induced Morphological Changes in the Intestinal Mucosa: Role of Cyclooxygenase-2 Pathway.
Multiple Myeloma
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma.
Cyclooxygenase-2 (COX-2) in multiple myeloma: prognostic factor or therapeutic target?
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.
Cytotoxicity of apigenin toward multiple myeloma cell lines and suppression of iNOS and COX-2 expression in STAT1-transfected HEK293 cells.
Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma.
Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival.
Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study.
Small interfering RNA of cyclooxygenase-2 induces growth inhibition and apoptosis independently of Bcl-2 in human myeloma RPMI8226 cells.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
The association between COX-2 expression and survival in myeloma patients.
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
[Expressions of vascular endothelial growth factor and cyclooxygenase-2 in patients with multiple myeloma and its significance.]
Multiple Sclerosis
A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis.
A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation.
Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: Role of cyclooxygenase-2.
COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression.
COX-2 promoter region polymorphisms in multiple sclerosis: lack of association of -765G>C with disease risk.
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.
Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death.
Cyclooxygenase-2 in synaptic signaling.
Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion.
Ketogenic diets attenuate cyclooxygenase and lipoxygenase gene expression in multiple sclerosis.
Measles virus-induced mononuclear leukocyte adherence inhibition: effect of some drugs influencing arachidonic acid metabolic pathways.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.
The cyclooxygenase-2 pathway via the PGE(2) EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination.
The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis.
Mumps
The Acidic Fraction of Isatidis Radix Regulates Inflammatory Response in LPS-Stimulated RAW264.7 Macrophages through MAPKs and NF-?B Pathway.
Muscle Cramp
Prostanoid Receptor EP2 as a Therapeutic Target.
Muscle Neoplasms
Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
Muscle Spasticity
Effects of Toll-Like Receptor 4 Antagonists Against Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage in Mice.
Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit.
Muscular Atrophy
Mechanical stimulation of skeletal muscle cells mitigates glucocorticoid-induced decreases in prostaglandin production and prostaglandin synthase activity.
Silencing COX-2 blocks PDK1/TRAF4-induced AKT activation to inhibit fibrogenesis during skeletal muscle atrophy.
Muscular Diseases
Characterization of a myopathy caused by prostaglandin dysfunction.
Critical illness myopathy: what is happening?
Human septic myopathy: induction of cyclooxygenase, heme oxygenase and activation of the ubiquitin proteolytic pathway.
Inhibition of prostaglandin synthesis produces a muscular dystrophy-like myopathy.
Muscular Dystrophies
A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.
Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy.
The early induction of cyclooxygenase 2 associated with neurofibrillary degeneration in brains of patients with Fukuyama-type congenital muscular dystrophy.
Muscular Dystrophy, Duchenne
Cyclooxygenase-2 expression in skeletal muscle of knockout mice suffering Duchenne muscular dystrophy.
Erratum to: Cyclooxygenase-2 expression in skeletal muscle of knockout mice suffering Duchenne muscular dystrophy.
Musculoskeletal Diseases
A case of acute liver failure due to etodolac.
Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population.
Musculoskeletal Pain
A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?
Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making.
Celecoxib, NSAIDs and the skeleton.
Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department: a randomized controlled trial.
Current considerations for the management of musculoskeletal pain in Asian countries: a special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs.
Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
Efficacy and safety of short-term use of COX-2 inhibitors in patients after an acute stroke with musculoskeletal pain.
Pain management in people with hemophilia in childhood and young adulthood.
Pharmacotherapy for regional musculoskeletal pain.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
The role of tramadol in current treatment strategies for musculoskeletal pain.
[Pain therapy with antipyretic analgesics]
Myalgia
A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise.
Celecoxib use and circulating oxylipins in a colon polyp prevention trial.
Does preoperatively administered parecoxib prevent succinylcholine-associated myalgia? A randomized, placebo-controlled trial.
Effects of intracerebroventricular injection of vitamin B12 on formalin-induced muscle pain in rats: Role of cyclooxygenase pathway and opioid receptors.
EP2 receptor plays pivotal roles in generating mechanical hyperalgesia after lengthening contractions.
IL-6, cyclooxygenase in muscle pain.
Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice.
Mycoplasma Infections
Mycoplasma MALP-2 induces HO-1 expression via MAPKs and Nrf2 pathways to modulate COX-2 expression in human monocytes.
Mycoses
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
ROS-induced Oxidative Injury involved in Pathogenesis of Fungal Keratitis via p38 MAPK Activation.
Sonic hedgehog-responsive lipoxygenases and cyclooxygenase-2 modulate Dectin-1-induced inflammatory cytokines.
Mycosis Fungoides
COX-2 is a novel target in therapy of mycosis fungoides.
COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF).
Cyclooxygenase-2 Gene Polymorphisms - 765G>C and -1195A>G and Mycosis Fungoides.
Cyclooxygenase-2 Gene Polymorphisms -765G>C and -1195A>G and Mycosis Fungoides Risk.
Myelitis
EFFECT OF 17beta-ESTRADIOL ON SIGNAL TRANSDUCTION PATHWAYS AND SECONDARY DAMAGE IN EXPERIMENTAL SPINAL CORD TRAUMA.
Effects of zileuton and montelukast in mouse experimental spinal cord injury.
Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma.
Immunomodulatory effects of etanercept in an experimental model of spinal cord injury.
Interleukin-1 receptor antagonist ameliorates the pain hypersensitivity, spinal inflammation and oxidative stress induced by systemic lipopolysaccharide in neonatal rats.
Myocardial Infarction
-New aspects in antithrombotic therapy--platelet inhibitors-.
5-methoxytryptophan is a potential marker for post-myocardial infarction heart failure - a preliminary approach to clinical utility.
A Case of Acute Myocardial Infarction Induced by Selective Cyclooxygenase-2 Inhibitor.
A common promoter variant of the gene encoding cyclooxygenase-1 (PTGS1) is related to decreased incidence of myocardial infarction in patients with coronary artery disease.
A pathogenetic mechanism for COX-2 inhibitor-induced cardiovascular events proposed to be useful in structuring medical testimony in rofecoxib trials.
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.
A proposed fairer method for conducting rofecoxib trials.
Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
Anti-platelet effects of nimesulide in isoproterenol-induced myocardial ischaemia and infarction in rabbits.
Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib.
Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?
Ascorbic acid prevents acute myocardial infarction induced by isoproterenol in rats: role of inducible nitric oxide synthase production.
Aspirin resistance: A fact or a myth?
Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses.
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation.
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction.
Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome.
Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and modulates the early inflammatory response.
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?
Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.
Cardiovascular Biology of Prostanoids and Drug Discovery.
Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
Cardiovascular hazard and non-steroidal anti-inflammatory drugs.
Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Cardiovascular risk, hypertension, and NSAIDs.
Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use.
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals.
Celecoxib after the onset of reperfusion reduces apoptosis in the amygdala.
Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
Chitosan and Curcumin Nanoformulations against Potential Cardiac Risks Associated with Hydroxyapatite Nanoparticles in Wistar Male Rats.
Chronic pretreatment with celecoxib reduces infarct size.
Chronic treatment with rofecoxib but not ischemic preconditioning of the myocardium ameliorates early intestinal damage following cardiac ischemia/reperfusion injury in rats.
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice.
Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice.
Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
COX-2 chronology.
COX-2 inhibitors and metabolism of essential fatty acids.
COX-2 Selective Nonsteroidal Anti-inflammatory Drugs and Risk of Gastrointestinal Tract Complications and Myocardial Infarction: An Instrumental Variable Analysis.
COX-2 signaling and cancer: new players in old arena.
COX-2-derived prostacyclin modulates vascular remodeling.
COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.
Current drug therapy for rheumatoid arthritis.
Current oral antiplatelet agents to prevent atherothrombosis.
Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Cyclooxygenase inhibition prior to ventricular fibrillation induced ischemia reperfusion injury impairs survival and outcomes.
Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy.
Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in rabbit. Cyclooxygenase pathway's involvement in preconditioning.
Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor.
Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction.
Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
Cyclooxygenase-2 inhibitors and myocardial infarction.
Cyclooxygenase-2 inhibitors.
Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.
Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner.
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function.
Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.
Direct and indirect effects of aldosterone on cyclooxygenase-2 and interleukin-6 expression in rat cardiac cells in culture and after myocardial infarction.
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.
Does rofecoxib increase TNF-alpha levels?
Drug-induced thrombosis--experimental, clinical, and mechanistic considerations.
Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
Emotion recollected in tranquility: lessons learned from the COX-2 saga.
Estrogen stimulation of COX-2-derived PGI2 confers atheroprotection.
Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women.
Expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and its significance.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in the normal human heart and in myocardial infarction.
Factors associated with celecoxib and rofecoxib utilization.
FCER1G and PTGS2 Serve as Potential Diagnostic Biomarkers of Acute Myocardial Infarction Based on Integrated Bioinformatics Analyses.
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
Hepatic ischemia and reperfusion injury in the absence of myeloid cell-derived COX-2 in mice.
Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations.
Ibuprofen arginate retains eNOS substrate activity and reverses endothelial dysfunction: implications for the COX-2/ADMA axis.
In Vivo Delivery of Nucleic Acids via Glycopolymer Vehicles Affords Therapeutic Infarct Size Reduction In Vivo.
Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.
Inducible cardiac-specific overexpression of cyclooxygenase-2 (COX-2) confers resistance to ischemia/reperfusion injury.
Influence of cardioprotective cyclooxygenase and lipoxygenase inhibitors on peroxidative injury to myocardial-membrane phospholipid.
Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse.
Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction.
International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction.
Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial.
MicroRNA-26b relieves inflammatory response and myocardial remodeling of mice with myocardial infarction by suppression of MAPK pathway through binding to PTGS2.
Microsomal Prostaglandin E Synthase-1-Derived PGE2 Inhibits Vascular Smooth Muscle Cell Calcification.
Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction.
Muscle cyclo-oxygenase-2 pathway contributes to the exaggerated muscle mechanoreflex in rats with congestive heart failure.
New aspects of cyclooxygenase-2 inhibition in myocardial infarction and ischaemia.
Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.
Nitric oxide donors.
Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders.
NSAID prescribing precautions.
NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective.
Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs.
PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-?-independent manner.
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.
PKA, Rap1, ERK1/2, and p90RSK mediate PGE2 and EP4 signaling in neonatal ventricular myocytes.
Platelet Activity in the Early Stage of Acute Myocardial Infarction: Relation to Time of Presentation, Treatment with Either Tissue Plasminogen Activator or Streptokinase and Cyclooxygenase Inhibition.
Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach.
Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study.
Prostanoids in the pathophysiology of human coronary artery.
Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.
Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo.
Rat paw oedema modeling and NSAIDs: Timing of effects.
Relationship between cyclooxygenase-2 inhibition and thrombogenesis.
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.
Response to "No Obvious Extra Cardiovascular Risk Associated With Low-Dose NSAIDs," "Do NSAIDs Actually Protect Against Myocardial Infarction and Death?," and "Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?"
Reversible cerebral vasoconstriction syndrome possibly induced by etoricoxib.
Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project.
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain.
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Role of cyclooxygenase-2 in myocardial infarction and ischaemia.
Roles of Cyclooxygenase 2 in Sevoflurane- and Olprinone-Induced Early Phase of Preconditioning and Postconditioning Against Myocardial Infarction in Rat Hearts.
Rosiglitazone: a disappointing DREAM.
Selective COX-2 inhibitors and risk of myocardial infarction.
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?
Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction.
Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia.
Selective cyclooxygenase-2 inhibitor NS-398 attenuates myocardial fibrosis in mice after myocardial infarction via Snail signaling pathway.
Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction.
Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review.
Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).
Summaries for patients. Cyclooxygenase-2 inhibitors and heart attacks: varying effects?
Targeting apoptosis pathways by Celecoxib in cancer.
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
The Cardiovascular Pharmacology of COX-2 Inhibition.
The disputed role of COX-2 in myocardial infarction, is the jury still out?
The EP4 antagonist, L-161,982, induces apoptosis, cell cycle arrest and inhibits prostaglandin E2 induced proliferation in oral squamous carcinoma Tca8113 cells.
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
The risk for myocardial infarction with cyclooxygenase-2 inhibitors.
The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults.
The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.
The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.
The Role of Cyclooxygenase-1 and -2 in Sevoflurane-Induced Postconditioning Against Myocardial Infarction.
The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.
The translational therapeutics of prostaglandin inhibition in atherothrombosis.
The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada.
Thromboxane A2 Generation, in the Absence of Platelet COX-1 Activity, in Patients With and Without Atherothrombotic Myocardial Infarction.
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.
Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction.
Variants of the Coagulation and Inflammation Genes Are Replicably Associated with Myocardial Infarction and Epistatically Interact in Russians.
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Vioxx(R): What should we tell our patients?
[Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes in patients with acute myocardial infarction and modulates the early inflammatory response]
[Clinical pharmacology of acetylsalicylic acid]
[Critical reevaluation of cyclooxygenase two inhibitors in perioperative pain therapy]
[Effects of propyl gallate on serum inflammatory factors and protein expression of COX-2 and ICAM-1 in ischemic myocardium of rats with acute myocardial infarction]
[Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects]
[Protective effect of lornoxicam on development of myocardial infarction in rats under conditions of ischemia and ischemia-reperfusion]
[Recent development of selective cyclooxygenase-2 inhibitors]
[Research advances of prostaglandin E2 synthases and receptors in cardiovascular diseases].
[Specific cyclooxygenase-2 inhibitor analgesics: therapeutic advances.]
[Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction].
[Study on the association of cyclooxygenase-2 -765g>C and prostacyclin synthase C1117A polymorphisms and the risk of myocardial infarction in Uigur population of Xinjiang, China]
Myocardial Ischemia
Adverse interactions of rofecoxib with lisinopril in spontaneously hypertensive rats.
Anti-myocardial ischemia effect of Syringa pinnatifolia Hemsl. by inhibiting expression of cyclooxygenase-1 and -2 in myocardial tissues of mice.
Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside?
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Cyclooxygenase-2 in myocardial ischemia: is it really a friend?
Effect of platelet depletion and inhibition of platelet cyclooxygenase on C5a-mediated myocardial ischemia.
Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.
Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF.
Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.
Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2.
Mediation of cardiac ischemia by thromboxanes released from human platelets.
Modulation of coronary flow rate and cardiac contractility by the divalent cation ionophore A23187 and inhibitors of the cyclooxygenase and 5-lipoxygenase pathways: development of heterogeneous patterns of myocardial ischemia.
Parecoxib inhibits apoptosis in acute myocardial infarction due to permanent coronary ligation but not due to ischemia-reperfusion.
Platelet-mediated cardiac ischemia.
Post-ischemic rupture of the anterior papillary muscle of the right ventricle associated with persistent pulmonary hypertension of the newborn: a case report.
Serotonin-induced human coronary microvascular contraction during acute myocardial ischemia is blocked by COX-2 inhibition.
The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist.
Thromboxane A2-induced arrhythmias in the anesthetized rabbit.
Thromboxane is produced in response to intracoronary infusions of complement C5a in pigs. Cyclooxygenase blockade does not reduce the myocardial ischemia and leukocyte accumulation.
Uncovering the Protective Mechanism of the Volatile Oil of Acorus tatarinowii against Acute Myocardial Ischemia Injury Using Network Pharmacology and Experimental Validation.
Myocardial Reperfusion Injury
Effects of supplementation with iloprost on the cardioprotection by BW755C (a dual inhibitor of cyclooxygenase and lipoxygenase enzymes) in myocardial reperfusion injury.
Myocardial Stunning
Aspirin does not prevent the attenuation of myocardial stunning by the ACE inhibitor ramiprilat.
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.
Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits.
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.
Effect of cyclooxygenase blockade on the beneficial actions of nicorandil in the stunned myocardium of dogs.
Effects of nicorandil on coronary circulation and myocardial ischemia.
Myocarditis
A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats.
Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart.
Correction: Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.
Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.
Essential role of HIV type 1-infected and cyclooxygenase 2-activated macrophages and T cells in HIV type 1 myocarditis.
IL-1? reduces cardiac lymphatic muscle contraction via COX-2 and PGE2 induction: Potential role in myocarditis.
Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis.
MicroRNA-381 protects myocardial cell function in children and mice with viral myocarditis via targeting cyclooxygenase-2 expression.
Myoepithelioma
Increased expression of cyclooxygenase-2 in human salivary gland tumors.
Myofascial Pain Syndromes
Nonsteroidal anti-inflammatory drugs and acetaminophen ameliorate muscular mechanical hyperalgesia developed after lengthening contractions via cyclooxygenase-2 independent mechanisms in rats.
Myoma
Bisphenol A at environmentally relevant doses induces cyclooxygenase-2 expression and promotes invasion of human mesenchymal stem cells derived from uterine myoma tissue.
Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies.
Immunohistochemical localization of selected pro-inflammatory factors in uterine myomas and myometrium in women of various ages.
Resveratrol inhibits human leiomyoma cell proliferation via crosstalk between integrin ?v?3 and IGF-1R.
Myositis
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis.
The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis.
Nasal Obstruction
Expression and localization of COX-2 in human airways and cultured airway epithelial cells.
Mechanisms of aspirin sensitivity.
Nasal Polyps
Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease.
Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future.
Association of the -14C/G MET and the -765G/C COX-2 Gene Polymorphisms with the Risk of Chronic Rhinosinusitis with Nasal Polyps in a Polish Population.
Autophagy is deficient and inversely correlated with COX-2 expression in nasal polyps: a novel insight into the inflammation mechanism.
Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.
Clinical updates in aspirin-exacerbated respiratory disease.
Computed Tomography Findings in Patients with Samter's Triad: An Observational Study.
COX-2 Overexpression in Schneiderian Papillomas.
Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps.
Cyclooxygenase 2 and lipoxin A? in nasal polyps in cystic fibrosis.
Cyclooxygenase and lipoxygenase metabolite generation in nasal polyps.
Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics.
Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma.
Expression and localization of cyclooxigenases (Cox-1 and Cox-2) in nasal respiratory mucosa. Does Cox-2 play a key role in the immunology of nasal polyps?
Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma.
Expression of Arachidonate Metabolism Enzymes and Receptors in Nasal Polyps of Aspirin-Hypersensitive Asthmatics.
Expression of COX-1, COX-2, 5-LOX and CysLT 2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease.
Expression of cyclo-oxygenase 1 and 2 proteins in upper respiratory mucosa.
Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients.
Expression of cyclooxygenase in nasal polyps from atopic and nonatopic subjects.
Expression of cyclooxygenase-2 and 5-lipoxygenase in nasal polyps associated with interleukin-4 promoter polymorphism -590.
Expression of glucocorticoid receptors and cyclooxygenase-2 in nasal polyps from nonallergic patients.
Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic Rhinosinusitis with Nasal Polyps.
Expression, localization, and significance of vascular permeability/vascular endothelial growth factor in nasal polyps.
Glucocorticoid therapy increases COX-2 gene expression in nasal polyps in vivo.
Increased expression of L-plastin in nasal polyp of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.
Inducible cyclooxygenase and interleukin 6 gene expressions in nasal polyp fibroblasts: possible implication in the pathogenesis of nasal polyposis.
Lipopolysaccharide induction of cyclooxygenase-2 in long-term nasal epithelial cultures in Cystic Fibrosis.
Low Prostaglandin E(2) and Cyclooxygenase Expression in Nasal Mucosa Fibroblasts of Aspirin-Intolerant Asthmatics.
Mechanisms of aspirin desensitization.
Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.
Mucin 5AC is significantly upregulated in exosomes from the nasal lavage fluid and may promote the expression of COX-2, VEGF and MMP-9: an implication in nasal polyp pathogenesis.
New immunohistologic findings on the differential role of cyclooxygenase 1 and cyclooxygenase 2 in nasal polyposis.
Nuclear factor-kappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmatics.
Polymorphisms in chronic rhinosinusitis with nasal polyps - a systematic review.
Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis.
Release of cyclooxygenase-2 and lipoxin A4 from blood leukocytes in aspirin-exacerbated respiratory disease.
Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study.
Significance of CYCLOOXYGENASE-2(COX-2), PERIOSTIN (POSTN) and INTERLEUKIN-4(IL-4) gene expression in the pathogenesis of chronic rhinosinusitis with nasal polyps.
State of the Art: Medical treatment of aspirin exacerbated respiratory disease (AERD).
Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis.
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
The effect of corticosteroid therapy on cyclooxygenase 2, vascular endothelial growth factor, and inducible nitric oxide synthase expression levels in nasal polyposis.
The influence of anti-inflammatory drugs on the proliferation of fibroblast derived from nasal polyps.
Topical glucocorticoids downregulate COX-1 positive cells in nasal polyps.
Update on the Management of Aspirin-Exacerbated Respiratory Disease.
Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis.
[Effect of clarithromycin on the expressions of cyclooxygenase-2 and nuclear factor-kappa B in nasal polyps in vitro]
[Expressions of EOS and COX-2 in nasal polyps in patients with aspirin triad syndrome and its significance].
[Significances of COX-2, p21, Ki-67 expression and HPV infection in nasal inverted papilloma].
Nasopharyngeal Carcinoma
Aberrant expression of ?-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer.
Activating enhancer-binding protein-2? induces cyclooxygenase-2 thus promoting nasopharyngeal carcinoma growth.
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein.
Association between 8473T>C polymorphism in the cyclooxygenase-2 gene and the risk of nasopharyngeal carcinoma.
Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression.
Clinical significance of circulating tumor cells and their expression of cyclooxygenase-2 in patients with nasopharyngeal carcinoma.
Correlation between COX-2 gene polymorphism and susceptibility to nasopharyngeal carcinoma.
Correlations between expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, cyclooxygenase-2 and clinicopathological variables and treatment outcomes in nasopharyngeal carcinomas.
COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.
Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications.
Cyclooxygenase-2 Expression and Its Correlation with Primary Tumor Size and Lymph Node Involvement in Nasopharyngeal Carcinoma.
Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma.
Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity.
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1.
Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells.
Effusanin E suppresses nasopharyngeal carcinoma cell growth by inhibiting NF-?B and COX-2 signaling.
High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma.
High COX-2 expression in cancer-associated fibiroblasts contributes to poor survival and promotes migration and invasiveness in nasopharyngeal carcinoma.
Identification of key genes involved in nasopharyngeal carcinoma.
Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: no significant correlations with clinicopathological variables and treatment outcomes.
Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells.
lncRNA HOTAIR upregulates COX-2 expression to promote invasion and migration of nasopharyngeal carcinoma by interacting with miR-101.
Overexpression of COX-2 and LMP1 are correlated with lymph node in Tunisian NPC patients.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis.
Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma.
Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-?B/COX-2 pathway.
Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma.
Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma.
Prognostic significance of expression of vegf and cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR.
PTGS2 (COX-2) -765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma.
Quantitative measurement of iNOS expression in melanoma, nasopharyngeal, colorectal, and breast tumors of Tunisian patients: comparative study and clinical significance.
Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Relationship between cyclooxygenase-2 (COX-2) content and prognosis in nasopharyngeal carcinoma before and after radiochemotherapy.
Retraction to "Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis" [Oral Oncol. 41 (2005) 903-908].
Study on the Drug Targets and Molecular Mechanisms of Rhizoma Curcumae in the Treatment of Nasopharyngeal Carcinoma Based on Network Pharmacology.
The association between COX-2 gene rs5275 polymorphism and Nasopharyngeal carcinoma risk.
The CC-genotype of the cyclooxygenase-2 gene associates with decreased risk of nasopharyngeal carcinoma in a Tunisian population.
The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma.
The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
Three concerns with regards to the utilization of COX-2 inhibitor (celecoxib) in combination with standard chemoradiotherapy for nasopharyngeal carcinoma.
Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01).
[Effect of shRNAmir lentiviral vector-mediated COX-2 silencing on the radiosensitivity of nasopharyngeal carcinoma cells].
[Expression and correlation of cyclooxygenase-2 and vascular endothelial growth factor in nasopharyngeal carcinoma-].
[Expression and relationship of EBV LMP1, COX-2 and VEGF-C in nasopharyngeal carcinoma]
[Expressions of COX-2 and MMP-2 in nasopharyngeal carcinoma and the their relationship with lymph node metastasis]
[Expressions of cyclooxygenase-2 and basic fibroblast growth factor in nasopharyngeal carcinoma and their association with radiotherapy sensitivity].
[Influence of celecoxib on invasiveness of human high-metastatic nasopharyngeal carcinoma cell line CNE-2Z].
[Relationship between cyclooxygenase-2 in nasopharyngeal carcinoma and cervical lymph node metastasis].
[Silencing of COX-2 in nasopharyngeal carcinoma cells with a shRNAmir lentivirus vector]
[The expression and relationship of cyclooxygenase-2 and latent membrane protein-1 in nasopharyngeal carcinoma]
[The value of cyclooxygenase-2 to predict the effect of radiotherapy in nasopharyngeal carcinoma]
Nasopharyngeal Neoplasms
Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal Cancer.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression.
Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies.
Nematode Infections
Lung fibroblasts produce IL-33 in response to stimulation with retinoblastoma-binding protein 9 via production of prostaglandin E2.
Neonatal Sepsis
T-cell proliferative responses following sepsis in neonatal rats.
Neoplasm Invasiveness
[Analysis of HIF-1? and COX-2 expression in tumor stroma and correlation with the degree of neoplasm invasiveness in laryngeal cancer--preliminary study].
Neoplasm Metastasis
(-)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer.
11?-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis.
15-Lipoxygenase-2 is differentially expressed in normal and neoplastic ovary.
17beta-Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells.
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy.
A functional role for hemostasis in early cancer development.
A novel aspirin prodrug inhibits NF?B activity and breast cancer stem cell properties.
A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death.
A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer.
A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis.
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
A review of the anti-tumor effect of the combined administration of a cyclooxygenase-2 selective inhibitor and a non-specific immunostimulant protein-bound polysaccharide on an advanced colon cancer model using colon cancer cell lines.
A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
Abalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity.
Aberrant expression of ?-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer.
Aberrant methylation of cyclooxygenase-2 in breast cancer patients.
Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas.
Adaptor protein p62 promotes skin tumor growth and metastasis and is induced by UVA radiation.
Advances in cancer pain management.
An Investigation on the Therapeutic Potential of Butein, A Tretrahydroxychalcone Against Human Oral Squamous Cell Carcinoma.
Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression.
Anesthetic drug propofol inhibits the expression of interleukin-6, interleukin-8 and cyclooxygenase-2, a potential mechanism for propofol in suppressing tumor development and metastasis.
Anesthetic Techniques and Cancer Recurrence after Surgery.
Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase.
Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.
Anti-metastatic Action of Non-steroidal Anti-inflammatory Drugs.
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model.
Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases.
Anticancer potential of silymarin: from bench to bed side.
Antidepressants, eicosanoids and the prevention and treatment of cancer. A review.
Antidepressants, prostaglandins and the prevention and treatment of cancer.
Antimetastatic activity of a cyclooxygenase-2 inhibitor.
Antimetastatic role of Smad4 signaling in colorectal cancer.
Antitumor Activity of Ficus deltoidea Extract on Oral Cancer: An In Vivo Study.
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.
Approach to angiogenesis inhibition based on cyclooxygenase-2.
Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.
Aspirin and non-small cell lung cancer resections: effect on long-term survival.
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2.
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.
Aspirin reduces lung cancer metastasis to regional lymph nodes.
Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).
Assessment of promising protein markers for vulva cancer.
Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.
Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.
Association of promoter polymorphism -765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts.
Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer.
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E2 and prostaglandin E2 receptors.
Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts.
Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer?
Can licorice lick colon cancer?
CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression.
Celecoxib and radiation therapy in non-small-cell lung cancer.
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.
Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro.
Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer.
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.
Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2.
Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent.
Clinical and prognosis relevance of COX-2 expression in Tunisian patients with primary gastric adenocarcinoma.
Clinical relevance of cyclo-oxygenase 2 and peroxisome proliferator activated receptor ? in eyelid sebaceous gland carcinoma.
Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues.
Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.
Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma.
Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma.
Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma.
Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.
Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis.
Clinicopathological significance of cyclooxygenase-2 expression in hypopharyngeal squamous cell carcinoma.
Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma.
Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer.
Coexpression of cyclooxygenase-2 and vascular endothelial growth factor in gastrointestinal stromal tumor: possible relations to pathological parameters and clinical behavior.
Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis.
Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids.
Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice.
Combination therapy of PKC? and COX-2 inhibitors synergistically suppress melanoma metastasis.
Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor.
Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome.
Concomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: A pharmacodynamics perspective.
Concurrent Expression of Cyclo-oxygenase-2 and Epidermal Growth Factor Receptor in Canine Malignant Mammary Tumours.
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.
Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche.
Correction to: Combination therapy of PKC? and COX-2 inhibitors synergistically suppress melanoma metastasis.
Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer.
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
Correlation between Spiral CT Preoperative Staging of Pancreatic Cancer and PTEN and COX-2 Expression.
Correlation of 15-prostagladin dehydrogenase expression with clinicopathological factors and survival rate in gastric adenocarcinoma.
Correlation of COX- 2 Expression in Colorectal Carcinoma with Clinicopathological Features.
Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness.
Coumarin sulfonamides derivatives as potent and selective COX-2 inhibitors with efficacy in suppressing cancer proliferation and metastasis.
Cox-2 and Her2/neu co-expression in invasive bladder cancer.
COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
COX-2 expression and effects of COX-2 inhibition in colorectal carcinomas and their liver metastases.
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma.
COX-2 expression in canine normal and neoplastic mammary gland.
COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray.
COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome.
COX-2 expression in malignant melanoma: a novel prognostic marker?
COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome.
COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
COX-2 Gene increases tongue cancer cell proliferation and invasion through VEGF-C pathway.
COX-2 gene promoter haplotypes and prostate cancer risk.
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms.
COX-2 induces IL-11 production in human breast cancer cells.
COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.
COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.
COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer.
COX-2 involvement in breast cancer metastasis to bone.
COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness.
COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67.
Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
COX-2 overexpression increases motility and invasion of breast cancer cells.
Cox-2 promotes mesenchymal stem cells differentiation into cardiocytes by activating JNK and ERK pathway.
COX-2 promotes metastasis and predicts prognosis on gastric cancer via regulating mTOR.
COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.
COX-2 regulates E-cadherin expression through the NF-?B/Snail signaling pathway in gastric cancer.
COX-2 signaling and cancer: new players in old arena.
COX-2 Signaling in the Tumor Microenvironment.
COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.
COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib.
Cross-talk between SIM2s and NF?B regulates cyclooxygenase 2 expression in breast cancer.
CTGF inhibits cell motility and COX-2 expression in oral cancer cells.
Curcumin and cancer: an "old-age" disease with an "age-old" solution.
Curcumin as an Adjuvant to Breast Cancer Treatment.
Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer.
Cutaneous and intra-abdominal abscess formation in rats following radio frequency [corrected] ablation of liver tumors in combination with celecoxib treatment.
CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2.
Cyclo-oxygenase 2 expression in laryngeal squamous cell carcinoma and its clinical correlates.
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.
Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.
Cyclo-oxygenase-2 expression in photon-radiated and non-radiated uveal melanomas.
Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygeanse-2 promotes metastasis in osteosarcoma.
Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians.
Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.
Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?
Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle.
Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.
Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.
Cyclooxygenase-2 (COX-2) overexpression in meningiomas: real time PCR and immunohistochemistry.
Cyclooxygenase-2 - An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma- An Immunohistochemical Study.
Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Cyclooxygenase-2 and the inflammogenesis of breast cancer.
Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.
Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.
Cyclooxygenase-2 expression and angiogenesis in colorectal cancer.
Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer.
Cyclooxygenase-2 expression as a predictor of para-aortic lymph node recurrence in uterine cervical cancer.
Cyclooxygenase-2 expression correlates with development, progression, metastasis, and prognosis of osteosarcoma: a meta-analysis and trial sequential analysis.
Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: evidence for a Bcl-2-dependent mechanism.
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Cyclooxygenase-2 expression in brain metastases.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables.
Cyclooxygenase-2 Expression in Cervical Squamous Cell Carcinoma: the Significance of Expression in Neoplastic Cells within the Lymphovascular Space.
Cyclooxygenase-2 expression in chronic gastritis and gastric carcinoma, correlation with prognostic parameters.
Cyclooxygenase-2 expression in colorectal cancer liver metastases.
Cyclooxygenase-2 expression in human thyroid disease.
Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 expression in lymph node metastasis of cervical and vulvar cancer.
Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients.
Cyclooxygenase-2 Expression in Non-Small Cell Lung Cancer Correlates With Hypertrophic Osteoarthropathy.
Cyclooxygenase-2 expression in oral squamous cell carcinoma.
Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma.
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.
Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy.
Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis.
Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer.
Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-c and lymph node metastasis in human oral tongue cancer.
Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients.
Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis.
Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma.
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers.
Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms.
Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.
Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study.
Cyclooxygenase-2 immunoexpression in breast cancer: Progesterone receptor influence.
Cyclooxygenase-2 in cancer: A review.
Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland.
Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance.
Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.
Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model.
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.
Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression.
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.
Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.
Cyclooxygenase-2 inhibitors in colorectal cancer.
Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway.
Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.
Cyclooxygenase-2 Is an Independent Predictor of Poor Prognosis in Uterine Leiomyosarcomas.
Cyclooxygenase-2 is associated with malignant phenotypes in human lung cancer.
Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines.
Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer.
Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma.
Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis.
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Cyclooxygenase-2 Overexpression Predicts Poor Survival in Patients with High-grade Extremity Osteosarcoma: A Pilot Study.
Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.
Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma.
Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells.
Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygenase-2 protein expression modulates cell proliferation and apoptosis in solid ameloblastoma and odontogenic keratocyst. An immunohistochemical study.
Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.
Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells.
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells.
Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription.
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.
Cyclooxygenases and colon cancer.
Cyclooxygenases, prostanoids, and tumor progression.
Cycloxygenase-2 is Essential for the Survival and Proliferation of Gastric Cancer Cells.
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Design and construction of COX-2 specific fluorescent probes.
Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.
Dietary Fat, Fatty Acids and Breast Cancer.
Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor.
Dietary phytochemicals alter epigenetic events and signaling pathways for inhibition of metastasis cascade : Phytoblockers of metastasis cascade.
Different matrix micro-environments in colon cancer and diverticular disease.
Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma.
Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Dihydropyrazole Derivatives Containing Benzo Oxygen Heterocycle and Sulfonamide Moieties Selectively and Potently Inhibit COX-2: Design, Synthesis, and Anti-Colon Cancer Activity Evaluation.
Disruption of tumour-host communication by downregulation of LFA-1 reduces COX-2 and e-NOS expression and inhibits brain metastasis growth.
Docosahexaenoic acid inhibits lipopolysaccharide-induced metastatic activities by decreasing inflammation on prostate cancer cell.
Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells.
Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion.
Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: A pilot study.
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Ductal adenocarcinoma of the pancreas usually retained SMAD4 and p53 protein status as well as expression of epithelial-to-mesenchymal transition markers and cell cycle regulators at the stage of liver metastasis.
Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis.
Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer.
Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.
Effect of molecular targeted therapy combined with radiotherapy on the expression and prognostic value of COX-2 and VEGF in bone metastasis of lung cancer.
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.
Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor.
Effects of dietary menhaden oil, soy, and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice.
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF.
Eicosanoids in Cancer: New Roles in Immunoregulation.
Eicosanoids in inflammation and cancer: the role of COX-2.
Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer.
Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.
Elevated dietary linoleic acid increases gastric carcinoma cell invasion and metastasis in mice.
Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways.
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.
EpCAM and COX?2 expression are positively correlated in human breast cancer.
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4.
Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation.
Epithelial to mesenchymal transition in cutaneous squamous cell carcinoma is correlated with COX-2 expression but not with the presence of stromal macrophages or CD10-expressing cells.
Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Evaluation of Cyclooxygenase-2 Expression in Association with Clinical-Pathological Factors in Malignant Melanoma.
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line.
Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms.
Evaluation of VEGF expression correlates with COX-2 expression in pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma.
Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.
Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression.
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma.
Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma.
Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor.
Expression of 15-PGDH is downregulated by COX-2 in gastric cancer.
Expression of angiogenic factors is increased in metastasised renal cell carcinomas.
Expression of COX-2 and HER-2 in colorectal cancer and their correlation.
Expression of COX-2 proteins in gastric mucosal lesions.
Expression of COX-2, CD44v6 and CD147 and Relationship with Invasion and Lymph Node Metastasis in Hypopharyngeal Squamous Cell Carcinoma.
Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma.
Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis.
Expression of cyclo-oxygenase-2 in gastrointestinal carcinoid tumors.
Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal Cancer.
Expression of cyclooxygenase-1 and -2 and clinicopathologic features of colorectal cancer in northern Thailand.
Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.
Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.
Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis.
Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer.
Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis.
Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance.
Expression of cyclooxygenase-2 in gastric cancer and its relation to liver metastasis and long-term prognosis.
Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors.
Expression of Cyclooxygenase-2 in Human Breast Carcinoma: Relevance to Tumor Angiogenesis and Expression of Estrogen Receptor.
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Expression of cyclooxygenase-2 in patients with bladder carcinoma.
Expression of cyclooxygenase-2 in prostate carcinoma.
Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival.
Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder.
Expression of cyclooxygenase-2 protein in colorectal carcinomas.
Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
Expression of embryonic lethal abnormal vision (ELAV)-like protein HuR and cyclooxygenase-2 (COX-2) in Ewing sarcoma.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density.
Expression of inflammation related enzymes during experimental rat lung carcinogenesis.
Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors.
Expression of metastases-associated genes in cervical cancers resected in the proliferative and secretory phases of the menstrual cycle.
Expression of molecular markers in low-grade chondrosarcomas and cartilaginous tumors with uncertain differentiation.
Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients.
Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer.
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma.
Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in Oral Squamous Cell Carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation.
Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.
Expression of the CD117, COX-2 and HSP90 antigens and cell proliferation in fine-needle-aspirated cells from metastatic melanomas.
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance.
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
Expressions and clinical significance of COX-2, VEGF-C, and EFGR in endometrial carcinoma.
Expressions of TIMP-1, COX-2 and MMP-7 in Colon Polyp and Colon Cancer.
Flavonoids of the Genus Iris (Iridaceae).
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.
Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.
Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer.
Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma.
Future Aspects for Cannabinoids in Breast Cancer Therapy.
Genes controlling spread of breast cancer to lung "gang of 4".
Glucose-regulated protein 78 mediates hormone-independent prostate cancer progression and metastasis through maspin and COX-2 expression.
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Downregulates the Expression of Protumor Factors Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in a GM-CSF Receptor-Independent Manner in Cervical Cancer Cells.
Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition.
Guggulsterone for Chemoprevention of Cancer.
Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis.
Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.
Heparanase and COX-2 expression as predictors of lymph node metastasis in large, high-grade breast tumors.
HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival.
Heterogeneity of COX-2 and multidrug resistance between primary tumors and regional lymph node metastases of gastric cancer.
High COX-2 expression in cancer-associated fibiroblasts contributes to poor survival and promotes migration and invasiveness in nasopharyngeal carcinoma.
High COX-2 expression in canine mast cell tumours is associated with proliferation, angiogenesis and decreased overall survival.
High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion.
High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy.
High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement.
Histologic correlation of VEGF and COX-2 expression with tumor size in squamous cell carcinoma of the larynx and hypopharynx.
Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2.
Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
Hypertonic environment elicits cyclooxygenase-2-driven prostaglandin E2 generation by colon cancer cells: role of cytosolic phospholipase A2-alpha and kinase signaling pathways.
Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases.
Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
Identification of potential prognostic markers for vulvar cancer using immunohistochemical staining of tissue microarrays.
IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis.
Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation.
Iminodibenzyl redirected cyclooxygenase-2 catalyzed dihomo-?-linolenic acid peroxidation pattern in lung cancer.
Immunoexpression of cyclooxygenase-2 in primary gastric carcinomas and lymph node metastases.
Immunohistochemical detectability of cyclooxygenase-2 expression in cells of human melanocytic skin lesions: A methodological review.
Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer.
Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival.
Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue.
Impact of celecoxib on soluble intercellular adhesion molecule-1 and soluble e-cadherin concentrations in human colon cancer cell line cultures exposed to phytic acid and TNF-alpha.
Impact of cyclooxygenase-2 and prostaglandin-E2 expression on clinical outcome after pulmonary metastasectomy.
Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.
Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor.
In vivo preclinical evaluation of the new 68Ga-labeled beta-cyclodextrin in prostaglandin E2 (PGE2) positive tumor model using positron emission tomography.
Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer.
Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis.
Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: a pilot study.
Increased expression of COX-2 in the development of human lung cancers.
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Inducible cyclooxygenase (COX-2) in glioblastoma--clinical and immunohistochemical (COX-2-VEGF) correlations.
Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines.
Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention.
Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2.
Inflammatory lymphangiogenesis in postpartum breast tissue remodeling.
Influence of dietary linoleic acid on experimental human breast cancer cell metastasis in athymic nude mice.
Influence of VEGF, COX-2, and MMP-9 expression on the molybdenum-targeted X-ray in breast cancer.
Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
Inhibition of cancer cell epithelial mesenchymal transition by normal fibroblasts via production of 5-methoxytryptophan.
Inhibition of COX-2 Impairs Colon Cancer Liver Metastasis through Reduced Stromal Cell Reaction.
Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy.
Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression.
Inhibition of Cyclooxygenase-2 Suppresses Lymph Node Metastasis via Reduction of Lymphangiogenesis.
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.
Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522.
Inhibition of human malignant neuroblastoma cell DNA synthesis by lipoxygenase metabolites of arachidonic acid.
Inhibition of invasion and experimental metastasis of murine melanoma cells by Ipomoea obscura (L.) is mediated through the down-regulation of inflammatory mediators and matrix-metalloproteinases.
Inhibition of the biosynthesis of prostaglandin E2 by low dose aspirin: implications for adenocarcinoma metastasis.
Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression.
Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer.
Inhibitory Effect of IFN-beta, on the Antitumor Activity of Celecoxib in U87 Glioma Model.
INPP4B suppresses prostate cancer cell invasion.
Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer.
Intracellular AGR2 transduces PGE2 stimuli to promote epithelial-mesenchymal transition and metastasis of colorectal cancer.
Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.
Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion.
Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells.
JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats.
JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study.
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment.
Licoricidin, an Active Compound in the Hexane/Ethanol Extract of Glycyrrhiza uralensis, Inhibits Lung Metastasis of 4T1 Murine Mammary Carcinoma Cells.
Linoleic acid metabolism in metastatic and nonmetastatic murine mammary tumor cells.
Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis.
Lipoxygenase-5 is overexpressed in prostate adenocarcinoma.
Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization.
Loss of retinal cadherin facilitates mammary tumor progression and metastasis.
Lung cancer and cyclooxygenase-2.
Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
Massive T-lymphocyte infiltration into the host stroma is essential for fibroblast growth factor-2-promoted growth and metastasis of mammary tumors via neovascular stability.
MBP-1 Suppresses Growth and Metastasis of Gastric Cancer Cells through COX-2.
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo.
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.
Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the ?-catenin signaling pathway.
Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis.
Metastatic potential in MDA-MB-231 human breast cancer cells is inhibited by proton beam irradiation via the Akt/nuclear factor-?B signaling pathway.
Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2.
Methylation status and overexpression of COX-2 in Tunisian patients with ductal invasive breast carcinoma.
MicroRNA and cyclooxygenase-2 in breast cancer.
MicroRNA-708 activation by glucocorticoid receptor agonists regulate breast cancer tumorigenesis and metastasis via downregulation of NF-?B signaling.
MicroRNAs in the anticancer effects of celecoxib: A systematic review.
Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b+Gr1+MDSCs from bone marrow.
Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer.
miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells.
MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.
miR-26b is downregulated in human tongue squamous cell carcinoma and regulates cell proliferation and metastasis through a COX-2-dependent mechanism.
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.
MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells.
Molecular basis of traditional Chinese medicine in cancer chemoprevention.
Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer.
Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases.
Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyll, and selected oxidative metabolites with 5-lipoxygenase.
Molecular signature of nitric oxide on major cancer hallmarks of colorectal carcinoma.
More than structural cells, fibroblasts create and orchestrate the tumor microenvironment.
Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: prognostic value and effects of preoperative radio (chemo) therapy.
Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis.
Multicenter Phase II Trial of Combination Therapy with Meloxicam, a COX-2 Inhibitor, and Natural Interferon-{alpha} for Metastatic Renal Cell Carcinoma.
Multifaceted link between cancer and inflammation.
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.
Multiple roles of cyclooxygenase-2 in endometrial cancer.
Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves ?v?5 integrin, ILK and AP-1-dependent pathways.
Nephroblastoma overexpressed gene (NOV) enhances RCC cell motility through upregulation of ICAM-1 and COX-2 expression via Akt pathway.
New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.
New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
Nitric oxide signaling in colon cancer chemoprevention.
Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.
Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression.
Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Nuclear co-localization and functional interaction of COX-2 and HIF-1? characterize bone metastasis of human breast carcinoma.
Oncogenic action of phospholipase A2 in prostate cancer.
Oncogenic action of secreted phospholipase A2 in prostate cancer.
Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2.
Overexpression of COX-2 and LMP1 are correlated with lymph node in Tunisian NPC patients.
Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation.
Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.
Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer.
Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomas.
Overexpression of cyclooxygenase-2 in gastric cancer correlates with the high abundance of vascular endothelial growth factor-C and lymphatic metastasis.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis.
Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy.
Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors.
Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability.
Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma.
P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene.
Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression.
Papillary Carcinoma of the Thyroid: High Expression of COX-2 and Low Expression of KAI-1/CD82 Are Associated with Increased Tumor Invasiveness.
Participation of macrophages in the mechanism mediating the enhancement of metastasis formation after tumour resection.
Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1.
Perioperative COX-2 and ?-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis.
Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.
pH-Responsive nanoparticles based on ibuprofen prodrug as drug carriers for inhibition of primary tumor growth and metastasis.
Phyto-sesquiterpene lactone deoxyelephantopin and cisplatin synergistically suppress lung metastasis of B16 melanoma in mice with reduced nephrotoxicity.
Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis.
Pitfalls in the use of arachidonic acid oxidation products to assign lipoxygenase activity in cancer cells.
Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Possible role of PPAR-? and COX-2 receptor modulators in the treatment of Non-Small Cell lung carcinoma.
Potent anti-cancer effects of citrus peel flavonoids in human prostate xenograft tumors.
Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy.
PPAR? ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.
Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases.
Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies.
Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients.
Predictive value of cyclooxygenase 2 and Bcl-2 for cervical lymph node metastasis in mucoepidermoid carcinoma.
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer.
Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma.
Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2.
Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis.
Prognostic evaluation of COX-2 expression in renal cell carcinoma.
Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma.
Prognostic impact of cyclooxygenase-2 in breast cancer.
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Prognostic importance of COX-2 expression in patients with colorectal cancer.
Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer.
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
Prognostic Significance of COX-2 Immunohistochemical Expression in Colorectal Cancer: A Meta-Analysis of the Literature.
Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma.
Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma.
Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis.
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma.
Prognostic significance of expression of cysteine-rich 61 and cyclooxygenase-2 in gastric cancer.
Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer.
Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression.
Promotion of hematogenous metastatic potentials in human KB carcinoma cells with overexpression of cyclooxygenase-2.
Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer.
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer.
Prostaglandin E2 stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells.
Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells.
Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells.
Prostanoid induces premetastatic niche in regional lymph nodes.
Protein kinase CK2 promotes cancer cell viability via up-regulation of cyclooxygenase-2 expression and enhanced prostaglandin E2 production.
Protein predictive signatures for lymph node metastasis of gastric cancer.
PTGS2 (COX-2) -765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma.
PTGS2 Over-Expression: A Colorectal Carcinoma Initiator not an Invasive Factor.
Pyruvate Kinase M2 Promotes Prostate Cancer Metastasis Through Regulating ERK1/2-COX-2 Signaling.
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Quantitative analysis of COX-2 promoter methylation in gastric carcinoma.
Quantitative measurement of iNOS expression in melanoma, nasopharyngeal, colorectal, and breast tumors of Tunisian patients: comparative study and clinical significance.
Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.
Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors.
Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.
Reduction of COX-2 through modulating miR-124/SPHK1 axis contributes to the antimetastatic effect of alpinumisoflavone in melanoma.
Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs.
Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis.
Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1? is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.
Regulation of transforming growth factor-{beta}-dependent cyclooxygenase-2 expression in fibroblasts.
Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.
Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.
Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against ?? T cell cytotoxicity.
Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy.
Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell Line.
Role of COX-2 selective inhibitors for prevention and treatment of cancer.
Role of COX-2 specific inhibitors in oncogenesis.
Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer.
Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer.
Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer.
Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer.
Role of retinoids in the prevention and treatment of colorectal cancer.
Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Roles of the cyclooxygenase 2-matrix metalloproteinase 1 pathway in brain metastasis of breast cancer.
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer.
Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest.
Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin.
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo.
Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer.
Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
shRNA-targeted Cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells.
Significance of Cox-2 expression in rectal cancers with or without preoperative radiotherapy.
Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells.
Silibinin and Paclitaxel Cotreatment Significantly Suppress the Activity and Lung Metastasis of Triple Negative 4T1 Mammary Tumor Cell in Mice.
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas.
Smoking-induced changes in cancer-related factors in patients with upper tract urothelial cancer.
Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.
Starfish polysaccharides downregulate metastatic activity through the MAPK signaling pathway in MCF-7 human breast cancer cells.
STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression.
Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma.
Studies of postpartum mammary gland involution reveal novel pro-metastatic mechanisms.
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3.
Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2.
Suppression by nimesulide of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process.
Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray.
Survival effects of cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast cancer.
Suspension state promotes metastasis of breast cancer cells by up-regulating cyclooxygenase-2.
Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.
Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer.
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Targeting ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer.
TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.
The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer.
The Cyclooxygenase-2 (PTGS2) 8473T>C Polymorphism is Associated with Breast Cancer Risk.
The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
The cyclooxygenase-2/prostaglandin E2 pathway and its role in the pathogenesis of human and dog hematological malignancies.
The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.
The establishment of supramolecular immunobead real-time PCR and the identification of Cox-2 as a metastasis-related marker in colorectal carcinoma.
The Expression of Both Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 in Tissues Is Associated with Poor Prognosis in Colorectal Cancer Patients.
The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression.
The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
The impact of COX-2 on invasion of osteosarcoma cell and its mechanism of regulation.
The impact of cyclooxygenase-2 and vascular endothelial growth factor C immunoexpression on the prognosis of penile carcinoma.
The Licorice Flavonoid Isoliquiritigenin Suppresses Phorbol Ester-induced Cyclooxygenase-2 Expression in the Non-tumorigenic MCF-10A Breast Cell Line.
The malignant phenotype of breast cancer cells is reduced by COX-2 silencing.
The metastatic microenvironment: Brain-residing melanoma metastasis and dormant micrometastasis.
The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis.
The rationale for a role for diet and nutrition in the prevention and treatment of cancer.
The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer.
The relationship between cyclooxygenase-2 expression and colorectal cancer.
The relationship between cyclooxygenase-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma.
The relationship between HPV16 and expression of cyclooxygenase-2, P53 and their prognostic roles in esophageal squamous cell carcinoma.
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells.
The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer.
The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
The role of COX-2 inhibition in breast cancer treatment and prevention.
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.
The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.
The therapeutic effect of miR-125b is enhanced by the prostaglandin endoperoxide synthase 2/cyclooxygenase 2 blockade and hampers ETS1 in the context of the microenvironment of bone metastasis.
Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis.
Thyroid Cancer and Nonsteroidal Anti-Inflammatory Drug Use: A Pooled Analysis of Patients Older Than 40 Years of Age.
Timosaponin AIII inhibits melanoma cell migration by suppressing COX-2 and in vivo tumor metastasis.
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells.
Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors.
Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of "tumor-phlegm microenvironment".
Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.
Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer.
Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis.
Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.
Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition.
Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2.
Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.
VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro.
Vitamin E and breast cancer.
[A study on cyclooxygenase-2 protein expression and vasculature during experimental rat lung carcinogenesis]
[Association of abnormal cyclooxygenase-2 gene expression with colorectal carcinoma metastasis]
[Clinicopathologic significance of cyclooxygenase-2 mRNA expression in human breast carcinoma]
[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer]
[Correlation between Stat3 signal transduction pathway and expression of cyclooxygenase-2 in colorectal cancer cells]
[Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma]
[Correlation of time-density curve of CT enhancement with angiogenesis in lung cancer.]
[COX and study of cancer therapy]
[COX- 2 expression in gastric cancer and its relationship with lymphangiogenesis and lymph node metastasis]
[Cox-2 and CD105 expression in breast cancer and disease-free survival.]
[Coxibs for postoperative analgesia].
[Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma]
[Cyclooxygenase-2 expression as a prognostic factor in sporadic colorectal cancer]
[Cyclooxygenase-2 expression in female pulmonary adenocarcinoma.]
[Cyclooxygenase-2, inducible nitric oxide synthase protein expression and vasculature during experimental rat lung carcinogenesis.]
[Detection of EGFR and COX-2 expression by immunohistochemical method on a tissue microarray section in lung cancer and biological significance]
[Effect of cyclooxygenase-2,and matrix metalloproteinase-2 expression on prognosis of lung cancer]
[Effect of GPX4 on proliferation and metastasis of renal clear cell carcinoma and its relationship with expression of IGF-1R and COX-2].
[Effects of cyclooxygenase-2 antisense vector on proliferation and sensitivity to cisplatin of H1299 cells.]
[Evaluation of cyclooxygenase-2 in the prediction of liver metastasis of colorectal carcinoma]
[Expression and clinical significance of Cox-2 and XIAP in malignant tumors of the salivary gland].
[Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma]
[Expression and function of cyclooxygenase-2 in endometrial carcinoma]
[Expression of COX-2 and its prognostic significance in non-small cell lung cancer.]
[Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance]
[Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]
[Expression of COX-2 and VEGF-C in papillary thyroid carcinoma and their relationship to cervical lymph metastases]
[Expression of COX-2 and VEGF-C in squamous cell carcinoma of the tongue and its correlation to lymph node metastasis]
[Expression of COX-2 protein in colorectal carcinoma and the clinical implication]
[Expression of cyclooxygenase-2 in esophageal squamous cell carcinogenesis]
[Expression of NF-kappaB and COX-2 in tongue squamous cell carcinoma]
[Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance.]
[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]
[Expressions of COX-2 and MMP-2 in nasopharyngeal carcinoma and the their relationship with lymph node metastasis]
[Expressions of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma and their correlation]
[Flow cytometric quantitative analysis of multiple tumor suppressor gene 1 (MTS1) and cyclooxygenase-2 (COX-2) gene expressions in invasive breast cancers and their clinical significance]
[Overexpression of COX-2 and a potential clinical application of its inhibitors in lung cancer]
[Prognostic value of survivin and cyclooxygenase-2 expression in non-small cell lung cancer: a tissue microarray analysis.]
[Relationship between cyclooxygenase- 2 expression and angiogenesis in patients with gastric cancer]
[Relationship between cyclooxygenase-2 in nasopharyngeal carcinoma and cervical lymph node metastasis].
[Relationship between the expression of cyclooxygenase-2 and microvessel density in oral squamnous cell carcinoma]
[Relationship of cyclooxygenase 2 expression and chemotherapy response and prognosis in human ovarian carcinoma]
[Roles of cyclooxygenase-2 and caspase-3 expression in pathogenesis of lung carcinoma: an experiment with rats]
[Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior]
[Suppression of COX-2 protein to cell apoptosis in non-small cell lung cancer.]
[The connection of miR-21 and miR-155 with regulation of 15-HPGDH mRNA in human breast cancer cells].
[The expression and significance of HIF-1alpha and COX-2 in laryngeal squamous cell carcinoma]
[The Expression of COX-2 in Human Lung Cancer and its Relationship with Expression of K-ras and Mcl-1.]
[The expression of COX-2 mRNA and protein in human laryngeal squamous cell carcinoma]
[The expression of hepatitis B virus X protein and cyclooxygenase-2 in hepatitis B virus-related hepatocellular carcinoma: correlation with microangiogenesis and metastasis, and what is the possible mechanism].
[The expressiong of cyclooxygenase-2 in laryngeal squamous cell carcinoma and its relationship with MVD]
[The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo]
Neoplasm Micrometastasis
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
Cyclooxygenase-2 expression in primary human colorectal cancers and bone marrow micrometastases.
The metastatic microenvironment: Brain-residing melanoma metastasis and dormant micrometastasis.
Neoplasm, Residual
Concurrent Aspirin Use Is Associated with Improved Outcome in Rectal Cancer Patients Who Undergo Chemoradiation Therapy.
Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma.
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.
NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins.
Neoplasms
-
"Letter to editor" in lieu of article published in Mol Biol Rep. 2012 May; 39(5):5219-24. PTGS2 (COX2) -765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population.
(-)-Myrtenol accelerates healing of acetic acid-induced gastric ulcers in rats and in human gastric adenocarcinoma cells.
(1?3)-?-d-Glucan stimulates nitric oxide generation and cytokine mRNA expression in macrophages.
(7R,8S)-Dehydrodiconiferyl Alcohol Suppresses Lipopolysaccharide-Induced Inflammatory Responses in BV2 Microglia by Inhibiting MAPK Signaling.
(±) Gancochlearols A and B: cytotoxic and COX-2 inhibitory meroterpenoids from Ganoderma cochlear.
-765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies.
1,10-Seco-Eudesmane sesquiterpenoids as a new type of anti-neuroinflammatory agents by suppressing TLR4/NF-?B/MAPK pathways.
1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity.
1,2,4-Triazole-conjugated 1,3,4-thiadiazole hybrid scaffolds: A potent ameliorant of carrageenan-induced inflammation by lessening proinflammatory mediators.
1,25-Dihydroxyvitamin D3 inhibits growth of the breast cancer cell line MCF-7 and downregulates cytochrome P4501B1 through the COX-2/PGE2 pathway.
1-(5-bromo-2-hydroxy-4-methoxyphenyl)ethanone [SE1] suppresses pro-inflammatory responses by blocking NF-?B and MAPK signaling pathways in activated microglia.
11?-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis.
15-Deoxy-?12,14-prostaglandin J2 Upregulates VEGF Expression via NRF2 and Heme Oxygenase-1 in Human Breast Cancer Cells.
15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism.
15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS.
15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.
15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy.
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice.
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
17-Beta estradiol and hydroxyestradiols interact via the NF-kappa B pathway to elevate cyclooxygenase 2 expression and prostaglandin E2 secretion in human bronchial epithelial cells.
17?-estradiol aggravated temporomandibular joint inflammation through NF-?B pathway in ovariectomized rats.
17beta-Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells.
18?-Glycyrrhetinic acid inhibits IL-1?-induced inflammatory response in mouse chondrocytes and prevents osteoarthritic progression by activating Nrf2.
18?-glycyrrhetinic acid suppresses gastric cancer by activation of miR-149-3p-Wnt-1 signaling.
18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models.
2, 3-Diaryl-5-ethylsulfanylmethyltetrahydrofurans as a new class of COX-2 inhibitors and cytotoxic agents.
2,5-Dimethyl-celecoxib inhibits cell cycle progression and induces apoptosis in human leukemia cells.
2-(4-{2-[(phenylthio)acetyl]carbonohydrazonoyl}phenoxy)acetamide as a new lead compound for management of allergic rhinitis.
2-Hydroxyethyl methacrylate inflammatory effects in human gingival fibroblasts.
20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-kappaB in RAW 264.7 macrophages stimulated with lipopolysaccharide.
3-Deazaadenosine, an S-adenosylhomocysteine hydrolase inhibitor, attenuates lipopolysaccharide-induced inflammatory responses via inhibition of AP-1 and NF-?B signaling.
3?-Angeloyloxy-8?,10?-dihydroxyeremophila-7(11)-en-12,8?-lactone Inhibits Lipopolysaccharide-Induced Nitric Oxide Production in RAW264.7 Cells.
4'-Methoxyresveratrol Alleviated AGE-Induced Inflammation via RAGE-Mediated NF-?B and NLRP3 Inflammasome Pathway.
4,5-Diaryl 3(2H)Furanones: Anti-Inflammatory Activity and Influence on Cancer Growth.
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone promoted gastric cancer growth through prostaglandin E receptor (EP2 and EP4) in vivo and in vitro.
4-nitrophenol exposure in T24 human bladder cancer cells promotes proliferation, motilities, and epithelial-to-mesenchymal transition.
4-O-Methylgallic acid suppresses inflammation-associated gene expression by inhibition of redox-based NF-kappaB activation.
4-Vinyl-2,6-dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori-infected carcinogen-treated Mongolian gerbils.
5,7-dihydroxy-2-(3-hydroxy-4, 5-dimethoxy-phenyl)-chromen-4-one-a flavone from Bruguiera gymnorrhiza displaying anti-inflammatory properties.
5-Lipoxygenase and Cyclooxygenase inhibitory Dammarane triterpenoid 1 from Borassus flabellifer seed coat, inhibits Tumor Necrosis Factor-? secretion in LPS induced THP-1 human monocytes and induces apoptosis in MIA PaCa-2 Pancreatic cancer cells.
5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
5-methoxyindole metabolites of L-tryptophan: control of COX-2 expression, inflammation and tumorigenesis.
5-Methoxytryptophan-dependent inhibition of oral squamous cell carcinoma metastasis.
5-Methoxytryptophan-dependent protection of cardiomyocytes from heart ischemia reperfusion injury.
6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1.
6-Dehydrogingerdione restrains lipopolysaccharide-induced inflammatory responses in RAW 264.7 macrophages.
6-Gingerol abates benzo[a]pyrene-induced colonic injury via suppression of oxido-inflammatory stress responses in BALB/c mice.
6-Shogaol, a ginger product, modulates neuroinflammation: a new approach to neuroprotection.
7-Deoxy-trans-dihydronarciclasine Isolated from Lycoris chejuensis Inhibits Neuroinflammation in Experimental Models.
7-methoxyflavanone alleviates neuroinflammation in lipopolysaccharide-stimulated microglial cells by inhibiting TLR4/MyD88/MAPK signalling and activating the Nrf2/NQO-1 pathway.
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
?-3 Polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer.
?-Alanine supplementation reduces anxiety and increases neurotrophin expression in both young and older rats.
?-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPAR? pathway.
?-Catenin recognizes a specific RNA motif in the cyclooxygenase-2 mRNA 3'-UTR and interacts with HuR in colon cancer cells.
?-Chaconine isolated from a Solanum tuberosum L. cv Jayoung suppresses lipopolysaccharide-induced pro-inflammatory mediators via AP-1 inactivation in RAW 264.7 macrophages and protects mice from endotoxin shock.
?-Cyperone (CYP) down-regulates NF-?B and MAPKs signaling, attenuating inflammation and extracellular matrix degradation in chondrocytes, to ameliorate osteoarthritis in mice.
?-Ecdysone suppresses inflammatory responses via the Nrf2 pathway in lipopolysaccharide-stimulated RAW 264.7 cells.
?-Elemene inhibits 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate-induced skin tumorigenesis through suppression of NF-?B-associated signaling events in the mouse skin model.
?-glutamylcysteine exhibits anti-inflammatory effects by increasing cellular glutathione level.
?-Linolenic acid (ALA) is an anti-inflammatory agent in inflammatory bowel disease.
?-Linolenic Fatty Acid Supplementation Decreases Tumor Growth and Cachexia Parameters in Walker 256 Tumor-Bearing Rats.
?-Sitosterol-loaded solid lipid nanoparticles ameliorate complete Freund's adjuvant-induced arthritis in rats: involvement of NF-?B and HO-1/Nrf-2 pathway.
?-sitosteryl-3-O-?-glucopyranoside isolated from the bark of Sorbus commixta ameliorates pro-inflammatory mediators in RAW 264.7 macrophages.
?-Solanine Isolated from Solanum tuberosum L. cv Jayoung Abrogates LPS-Induced Inflammatory Responses via NF-?B Inactivation in RAW 264.7 Macrophages and Endotoxin-Induced Shock Model in Mice.
?-Tocotrienol inhibits lipopolysaccharide-induced interlukin-6 and granulocyte colony-stimulating factor by suppressing C/EBP? and NF-?B in macrophages.
?2-AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells.
A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis.
A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns.
A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy.
A causal relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism.
A chondroprotective effect of moracin on IL-1?-induced primary rat chondrocytes and an osteoarthritis rat model through Nrf2/HO-1 and NF-?B axes.
A cohort study of p27 localization in colon cancer, body mass index, and patient survival.
A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes.
A combination of selective COX-2 inhibitors and hydrogen peroxide increase the reactive oxygen species formation in osteosarcoma cells after X-ray irradiation.
A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation.
A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs.
A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis.
A comparative study on chemical compositions and biological activities of four essential oils: Cymbopogon citratus (DC.) Stapf, Cinnamomum cassia (L.) Presl, Salvia japonica Thunb. and Rosa rugosa Thunb.
A comparative study: Difference in omega-6/omega-3 balance and saturated fat in diets for Atlantic salmon (Salmo salar) affect immune-, fat metabolism-, oxidative and apoptotic-gene expression, and eicosanoid secretion in head kidney leukocytes.
A comparative study: the prospective influence of nanovectors in leveraging the chemopreventive potential of COX-2 inhibitors against skin cancer.
A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
A comparison on expression of selected biomarkers between primary lung cancers and matched metastases.
A competent synthesis and efficient anti-inflammatory responses of isatinimino acridinedione moiety via suppression of in vivo NF-?B, COX-2 and iNOS signaling.
A computational view of COX-2 inhibition.
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.
A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression.
A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
A cross-talk between NFAT and NF-?B Pathways is Crucial for Nickel-Induced COX-2 expression in Beas-2B cells.
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters.
A dual role for ?1 integrin in an in vitro Streptococcus mitis/human gingival fibroblasts co-culture model in response to TEGDMA.
A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line.
A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
A functional progesterone receptor is required for immunomodulation, reduction of reactive gliosis and survival of oligodendrocyte precursors in the injured spinal cord.
A functional role for hemostasis in early cancer development.
A galactomannoglucan derived from Agaricus brasiliensis: Purification, characterization and macrophage activation via MAPK and I?B/NF?B pathways.
A Genetic Variant in 3'-Untranslated Region of Cyclooxygenases-2 Gene Is Associated with Risk of Gastric Cancer in a Chinese Population.
A glucogalactomanan polysaccharide isolated from Agaricus bisporus causes an inflammatory response via the ERK/MAPK and I?B/NF?B pathways in macrophages.
A high-fat diet increases angiogenesis, solid tumor growth, and lung metastasis of CT26 colon cancer cells in obesity-resistant BALB/c mice.
A higher dietary ratio of long-chain omega-3 to total omega-6 fatty acids for prevention of COX-2-dependent adenocarcinomas.
A journey of celecoxib from pain to cancer.
A Lipid Anchor Improves the Protective Effect of Ectoine in Inflammation.
A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.
A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers.
A mechanistic study of cigarette smoke and cyclooxygenase-2 on proliferation of gastric cancer cells.
A Meta-Analysis of PTGS1 and PTGS2 Polymorphisms and NSAID Intake on the Risk of Developing Cancer.
A model of intrauterine infection and preterm delivery in mice.
A multi-targeted approach to suppress tumor-promoting inflammation.
A multiplex tissue immunoblotting assay for proteomic profiling: a pilot study of the normal to tumor transition of esophageal squamous cell carcinoma.
A Network Pharmacology Approach to Explore the Mechanisms of Shugan Jianpi Formula in Liver Fibrosis.
A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins.
A new cyclooxygenase-2 inhibitor, (1E,4E)-1,5-bis(2-bromophenyl)penta-1,4-dien-3-one (GL63) suppresses cyclooxygenase-2 gene expression in human lung epithelial cancer cells: coupled mRNA stabilization and posttranscriptional inhibition.
A new ditriazine inhibitor of NF-kappaB modulates chronic inflammation and angiogenesis.
A New Formyl Peptide Receptor-1 Antagonist Conjugated Fullerene Nanoparticle for Targeted Treatment of Degenerative Disc Diseases.
A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-small Cell Lung and Colorectal Cancers: Design, Synthesis, In Silico and In Vitro Studies Providing Mechanistic Insight into Their Anticancer Potencies.
A new steroidal saponin, furotrilliumoside from Trillium tschonoskii inhibits lipopolysaccharide-induced inflammation in Raw264.7 cells by targeting PI3K/Akt, MARK and Nrf2/HO-1 pathways.
A newly synthesized compound, 4'-geranyloxyferulic acid-N(omega)-nitro-l-arginine methyl ester suppresses inflammation-associated colorectal carcinogenesis in male mice.
A Nile blue based infrared fluorescent probe: imaging tumors that over-express cyclooxygenase-2.
A Novel and Selective p38 Mitogen-Activated Protein Kinase Inhibitor Attenuates LPS-Induced Neuroinflammation in BV2 Microglia and a Mouse Model.
A novel anti-pancreatic cancer agent, LY293111.
A novel caffeoyl triterpene attenuates cerebral ischemic injury with potent anti-inflammatory and hypothermic effects.
A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
A Novel Cytotoxic T lymphocyte Epitope Analogue with Enhanced Activity Derived From Cyclooxygenase-2.
A novel embedment-free immunoelectron microscopy technique reveals association of apoptosis-regulating proteins with subcellular structures.
A novel glucosamine derivative exerts anti-inflammatory actions via inhibition of nuclear factor-kappaB.
A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-?B in HCT116 human colon cancer cells.
A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death.
A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate.
A novel integrative network approach to understand the interplay between cardiovascular disease and other complex disorders.
A novel isoquinoline derivative exhibits anti-inflammatory properties and improves the outcomes of endotoxemia.
A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
A novel near-infrared fluorescent probe for monitoring cyclooxygenase-2 in inflammation and tumor.
A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model.
A Novel Protein Fraction from Sesbania grandiflora Shows Potential Anticancer and Chemopreventive Efficacy, in vitro and in vivo.
A novel rat model of seminal vesiculitis.
A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo.
A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer.
A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy.
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and ?-catenin transcriptional activity.
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.
A nuclear factor kappa B-derived inhibitor tripeptide inhibits UVB-induced photoaging process.
A p38 MAPK-mediated alteration of COX-2/PGE2 regulates immunomodulatory properties in human mesenchymal stem cell aging.
A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection.
A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
A Phase 1/2 Study of Flavocoxid, an Oral NF-?B Inhibitor, in Duchenne Muscular Dystrophy.
A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients.
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
A phase II study of carboplatin and paclitacel with meloxicam.
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
A pinusolide derivative, 15-methoxypinusolidic acid from Biota orientalis inhibits inducible nitric oxide synthase in microglial cells: Implication for a potential anti-inflammatory effect.
A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells.
A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study.
A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.
A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells.
A potential role for aspirin in the prevention and treatment of cholangiocarcinoma.
A potential role of PUFAs and COXIBs in cancer chemoprevention.
A Prospective Cohort Study Shows Unique Epigenetic, Genetic, and Prognostic Features of Synchronous Colorectal Cancers.
A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment.
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis.
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
A reactive oxygen species-generating, cyclooxygenase-2 inhibiting, cancer stem cell-potent tetranuclear copper(ii) cluster.
A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2.
A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.
A replication-selective adenoviral vector for head and neck cancers.
A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.
A review on chemistry, source and therapeutic potential of lambertianic acid.
A review on pain-relieving activity of berberine.
A Review on the Relationship between Aspirin and Bone Health.
A role for cAMP-driven transactivation of EGFR in cancer aggressiveness - therapeutic implications.
A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation.
A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer.
A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness.
A selective CB2 agonist protects against the inflammatory response and joint destruction in collagen-induced arthritis mice.
A selective cyclooxygenase-2 inhibitor (Etodolac) prevents spontaneous biliary tumorigenesis in a hamster bilioenterostomy model.
A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells.
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line.
A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells.
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
A single dose of PPAR? agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats.
A soft coral natural product, 11-episinulariolide acetate, inhibits gene expression of cyclooxygenase-2 and interleukin-8 through attenuation of calcium signaling.
A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male Apc(Min/+) mice.
A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas.
A study of the mechanisms underlying the anti-inflammatory effect of ellagic acid in carrageenan-induced paw edema in rats.
A study on expression pattern of cyclooxygenase-2 in carcinoma of cervix.
A Sulfated Polysaccharide from Saccharina japonica Suppresses LPS-Induced Inflammation Both in a Macrophage Cell Model via Blocking MAPK/NF-?B Signal Pathways In Vitro and a Zebrafish Model of Embryos and Larvae In Vivo.
A synbiotic combination of Lactobacillus gasseri 505 and Cudrania tricuspidata leaf extract prevents hepatic toxicity induced by colorectal cancer in mice.
A synthetic cationic antimicrobial peptide inhibits inflammatory response and the NLRP3 inflammasome by neutralizing LPS and ATP.
A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.
A tetramethoxychalcone from Chloranthus henryi suppresses lipopolysaccharide-induced inflammatory responses in BV2 microglia.
A transparent artificial dura mater made of silk fibroin as an inhibitor of inflammation in craniotomized rats.
A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression.
A unique preovulatory expression pattern plays a key role in the physiological functions of BMP-15 in the mouse.
A voluntary oral ethanol-feeding rat model associated with necroinflammatory liver injury.
A wholly nutritional 'multifocal angiostatic therapy' for control of disseminated cancer.
A window-of-opportunity biomarker study of etodolac in resectable breast cancer.
a-Tocopherol modifies the expression of genes related to oxidative stress and apoptosis during invitro maturation and enhances the developmental competence of rabbit oocytes.
Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative.
Abalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity.
Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model.
Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.
Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer.
Aberrant methylation of cyclooxygenase-2 in breast cancer patients.
Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas.
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.
Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma.
Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism.
Ablation of PKM2 ameliorated ER stress-induced apoptosis and associated inflammation response in IL-1?-treated chondrocytes via blocking Rspo2-mediated Wnt/?-catenin signaling.
Ablation of the Transcription Factor Nrf2 Promotes Ischemia-Induced Neovascularization by Enhancing the Inflammatory Response.
Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin.
Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.
Absence of circulating aldosterone attenuates foreign body reaction around surgical sutures.
Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy.
Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice.
Acacia ferruginea inhibits tumor progression by regulating inflammatory mediators-(TNF-a, iNOS, COX-2, IL-1?, IL-6, IFN-?, IL-2, GM-CSF) and pro-angiogenic growth factor- VEGF.
Accelerative effect of a selective cyclooxygenase-2 inhibitor on Fas-mediated apoptosis in human neutrophils.
Accessible Method for the Development of Novel Sterol Analogues with Dipeptide-like Side Chains That Act as Neuroinflammation Inhibitors.
Acetaldehyde prevents nuclear factor-kappa B activation and hepatic inflammation in ethanol-fed rats.
Acetyl Eburicoic Acid from Laetiporus sulphureus var. miniatus Suppresses Inflammation in Murine Macrophage RAW 264.7 Cells.
Acetylsalicylic acid induces programmed cell death in Arabidopsis cell cultures.
Achillea millefolium L. Essential Oil Inhibits LPS-Induced Oxidative Stress and Nitric Oxide Production in RAW 264.7 Macrophages.
Acid suppression and chemoprevention in Barrett's oesophagus.
Acridocarpus Smeathmannii (DC.) Guill. & Perr. Root enhanced reproductive behavior and sexual function in male wistar rats: Biochemical and pharmacological mechanisms.
Actinic cheilitis: Epithelial expression of COX-2 and its association with mast cell tryptase and PAR-2.
Activating enhancer-binding protein-2? induces cyclooxygenase-2 thus promoting nasopharyngeal carcinoma growth.
Activation of 2-aminofluorene by prostaglandin endoperoxide H synthase-2.
Activation of adherent vascular neutrophils in the lung during acute endotoxemia.
Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae.
Activation of both nuclear factor of activated T cells and inhibitor of nuclear factor-kappa B kinase beta-subunit-/nuclear factor-kappa B is critical for cyclooxygenase-2 induction by benzo[a]pyrene in human bronchial epithelial cells.
Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers.
Activation of central PPAR-? attenuates angiotensin II-induced hypertension.
Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats.
Activation of inflammatory mediators and potential role of ah-receptor ligands in foam cell formation.
Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats.
Activation of microglial cells by ceruloplasmin.
Activation of mTOR/I?B-?/NF-?B pathway contributes to LPS-induced hypotension and inflammation in rats.
Activation of NF-?B signaling pathway in HSV-1-induced mouse facial palsy: Possible relation to therapeutic effect of glucocorticoids.
Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammation-induced cell death.
Activation of Poly(ADP-Ribose) Polymerase-1 Delays Wound Healing by Regulating Keratinocyte Migration and Production of Inflammatory Mediators.
Activation of PTGS2/NF-?B signaling pathway enhances radiation resistance of glioma.
Activation of the arachidonic acid metabolic pathway and induction of sleep disturbance by sacral osteoblastoma: A case report.
Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells.
Acupuncture Can Regulate the Peripheral Immune Cell Spectrum and Inflammatory Environment of the Vascular Dementia Rat, and Improve the Cognitive Dysfunction of the Rats.
Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut.
Acute exposure to lead acetate activates microglia and induces subsequent bystander neuronal death via caspase-3 activation.
Acute gastric changes after intracerebral hemorrhage in rats.
Acylpolyamine Mygalin as a TLR4 Antagonist Based on Molecular Docking and In Vitro Analyses.
ADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation.
Adaptor protein p62 promotes skin tumor growth and metastasis and is induced by UVA radiation.
Addendum: Gamma-tocopherol, cox-2, and cancer risk.
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.
Additive Effects of Zinc Chloride on the Suppression of Hepatitis A Virus Replication by Interferon in Human Hepatoma Huh7 Cells.
Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of inflammatory bowel disease.
Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Adenoid cystic carcinoma of the trachea and bronchus--a clinicopathologic study with DNA flow cytometric analysis and oncogene expression.
Adenomatous polyposis coli protein associates with C/EBP beta and increases Bacillus anthracis edema toxin-stimulated gene expression in macrophages.
Adenosine A1 Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea.
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.
Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer.
Adenovirus-uteroglobin suppresses COX-2 expression via inhibition of NF-kappaB activity in lung cancer cells.
Adipocyte-derived lipids increase angiotensin-converting enzyme (ACE) expression and modulate macrophage phenotype.
Adiponectin inhibits lipoplysaccharide-induced inflammation and promotes osteogenesis in hPDLCs.
Adipose tissue contributes to hepatic pro-inflammatory response when dietary fish oil is replaced by vegetable oil in large yellow croaker (Larimichthys crocea): An ex vivo study.
Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study.
Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities.
Administration of Metabiotics Extracted From Probiotic Lactobacillus rhamnosus MD 14 Inhibit Experimental Colorectal Carcinogenesis by Targeting Wnt/?-Catenin Pathway.
Administration of red ginseng ameliorates memory decline in aged mice.
Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult.
Adrenomedullin 2 attenuates LPS-induced inflammation in microglia cells by receptor-mediated cAMP-PKA pathway.
Advances in cancer pain management.
Advances in the medical treatment of juvenile rheumatoid arthritis.
Advances that are changing the diagnosis and treatment of malignant bone tumors.
Aerobic Training and Green Tea Extract Protect against N-methyl-N-nitrosourea-induced Prostate Cancer.
Aerobic Training and Green Tea Extract Protect against NMU-induced Prostate Cancer.
African swine fever virus blocks the host cell antiviral inflammatory response through a direct inhibition of PKC-theta-mediated p300 transactivation.
Age dependent increase in prostaglandin pathway coincides with onset of ovarian cancer in laying hens.
Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate.
AGEs exacerbates coronary microvascular dysfunction in NoCAD by activating endoplasmic reticulum stress-mediated PERK signaling pathway.
Aggressive Mammary Cancers Lacking Lymphocytic Infiltration Arise in Irradiated Mice and Can Be Prevented by Dietary Intervention.
Agrocybe chaxingu polysaccharide prevent inflammation through the inhibition of COX-2 and NO production.
AH6809 decreases production of inflammatory mediators by PGE2 - EP2 - cAMP signaling pathway in an experimentally induced pure cerebral concussion in rats.
Ajoene, a natural product with non-steroidal anti-inflammatory drug (NSAID)-like properties?
Akebia Saponin D attenuates amyloid ?-induced cognitive deficits and inflammatory response in rats: Involvement of Akt/NF-?B pathway.
Akebia trifoliata pericarp extract ameliorates inflammation through NF-?B/MAPK signaling pathways and modifies gut microbiota.
Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor.
Akt expression may predict favorable prognosis in cholangiocarcinoma.
Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
AKT-targeted anti-inflammatory activity of Panax ginseng calyx ethanolic extract.
Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-?B, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells.
Albumin-encapsulated Nanoparticles of Naproxen Platinum(IV) Complexes with Inflammation Inhibitory Competence Displaying Effective Antitumor Activities in vitro and in vivo.
Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation.
ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output.
Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages.
Alkali treated antioxidative crude polysaccharide from Russula alatoreticula potentiates murine macrophages by tunning TLR/NF-?B pathway.
Alkaloids as Cyclooxygenase Inhibitors in Anticancer Drug Discovery.
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.
Alleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory Drugs.
Alleviation effects of natural volatile organic compounds from Pinus densiflora and Chamaecyparis obtusa on systemic and pulmonary inflammation.
Alleviative effect of selenium on inflammatory damage caused by lead via inhibiting inflammatory factors and heat shock proteins in chicken testes.
Allogenic Pure Platelet-Rich Plasma Therapy for Adhesive Capsulitis: A Bed-to-Bench Study With Propensity Score Matching Using a Corticosteroid Control Group.
Allopurinol ameliorates thioacetamide-induced acute liver failure by regulating cellular redox-sensitive transcription factors in rats.
Aloperine suppresses allergic airway inflammation through NF-?B, MAPK, and Nrf2/HO-1 signaling pathways in mice.
Alpha lipoic acid exerts antioxidant effect via Nrf2/HO-1 pathway activation and suppresses hepatic stellate cells activation induced by methotrexate in rats.
Alpha lipoic acid prevents doxorubicin-induced nephrotoxicity by mitigation of oxidative stress, inflammation, and apoptosis in rats.
Alpha-lipoic acid promotes the growth of rat hepatic pre-neoplastic lesions in the choline-deficient model.
Alpha-Pinene Exhibits Anti-Inflammatory Activity Through the Suppression of MAPKs and the NF-?B Pathway in Mouse Peritoneal Macrophages.
Alpinia oxyphylla Miq extract reduces cerebral infarction by downregulating JNK-mediated TLR4/T3JAM- and ASK1-related inflammatory signaling in the acute phase of transient focal cerebral ischemia in rats.
Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (?) anthracene-induced mammary carcinogenesis.
Alterations in lipid mediated signaling and Wnt/ ? -catenin signaling in DMH induced colon cancer on supplementation of fish oil.
Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma.
Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
Alterations in trace element levels and mRNA expression of Hsps and inflammatory cytokines in livers of duck exposed to molybdenum or/and cadmium.
Alterations of COX-2, HER-2/neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings.
Alterations of metabolic activity in human osteoarthritic osteoblasts by lipid peroxidation end product 4-hydroxynonenal.
Altered Biological Potential and Radioresponse of Murine Tumors in Different Microenvironments.
Altered eicosanoid levels in human colon cancer.
Altered expression of COX-2 and TNF-? in patients with hepatocellular carcinoma.
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.
Altered Expression of {beta}-catenin, E-cadherin, Cycloxygenase-2, and p53 Protein by Ovine Intestinal Adenocarcinoma Cells.
Altered mRNA Expression of Genes Involved in Endocannabinoid Signalling in Squamous Cell Carcinoma of the Oral Tongue.
Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression.
Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha.
Amaryllidaceae alkaloids from the bulbs of Lycoris radiata with cytotoxic and anti-inflammatory activities.
Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation.
Amelioration of experimental autoimmune encephalomyelitis by Ishige okamurae.
Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture.
Amelioration of the Protein Expression of Cox2, NF?B, and STAT-3 by Some Antioxidants in the Liver of Sodium Fluoride-Intoxicated Rats.
Ameliorative effect of Alnus japonica ethanol extract on colitis through the inhibition of inflammatory responses and attenuation of intestinal barrier disruption in vivo and in vitro.
Ameliorative effect of selenium nanoparticles and fish oil on cisplatin and gamma irradiation-induced nephrotoxicity in male albino rats.
Ameliorative effects of Diammonium Glycyrrhizinate on inflammation in focal cerebral ischemic-reperfusion injury.
Ameliorative effects of indomethacin at different concentrations on endothelial insulin resistance through two distinct pathways.
Ameliorative effects of Trichosanthes dioica Extract in suppressing inflammatory mediators and attenuating oxidative stress.
Amentoflavone inhibits iNOS, COX-2 expression and modulates cytokine profile, NF-?B signal transduction pathways in rats with ulcerative colitis.
AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/?-catenin signaling pathway.
Ammonia inhalation-induced inflammation and structural impairment in the bursa of fabricius and thymus of broilers through NF-?B signaling pathway.
AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin.
Amphiregulin as a tumor promoter for oral squamous cell carcinoma: involvement of cyclooxygenase 2.
AMPK Activation Inhibits Expression of Proinflammatory Mediators Through Downregulation of PI3K/p38 MAPK and NF-?B Signaling in Murine Macrophages.
Amplification of Lipopolysaccharide-Induced Cytokine Synthesis in Non-Small Cell Lung Cancer/Neutrophil Cocultures.
Amygdalin attenuates acute liver injury induced by D-galactosamine and lipopolysaccharide by regulating the NLRP3, NF-?B and Nrf2/NQO1 signalling pathways.
An ?-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF-?B in rats with TNBS-induced colitis.
An Activity-Based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells.
An Algal Metabolite-Based PPAR-? Agonist Displayed Anti-Inflammatory Effect via Inhibition of the NF-?B Pathway.
An alpha-lipoic acid-decursinol hybrid compound attenuates lipopolysaccharide-mediated inflammation in BV2 and RAW264.7 cells.
An analysis on the suppression of NO and PGE2 by diphenylheptane A and its effect on glycerophospholipids of lipopolysaccharide-induced RAW264.7 cells with UPLC/ESI-QTOF-MS.
An aqueous extract of Platycodi radix inhibits LPS-induced NF-kappaB nuclear translocation in human cultured airway epithelial cells.
An ARC-regulated IL1?/Cox-2/PGE2/?-catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML.
An Ethanolic Extract of Allium hookeri Root Alleviates Reflux Esophagitis and Modulates NF-?B Signaling.
An evaluation of cyclooxygenase-2 as a prognostic biomarker in mid-gut carcinoid tumours.
An extract of the medicinal plant Artemisia annua modulates production of inflammatory markers in activated neutrophils.
An immunohistochemical study of cyclooxygenase (COX)-2 expression in endocrine tumors of the pancreas.
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
An immunohistochemical survey of nine cases of medullary carcinoma of thyroid including reactivity for Cox-1 and Cox-2 enzymes.
An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures.
An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation.
An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer.
An investigation of the immunotoxicity of oil sands processed water and leachates in trout leukocytes.
An investigation of the rate of cyclooxygenase-2 expression on the surface of adenomatous and colorectal adenocarcinoma polyps.
An observational study on the expression of cyclooxygenase-2 in meningioma.
An off-on COX-2-specific fluorescent probe: targeting the Golgi apparatus of cancer cells.
An overview on the expression of cyclooxygenase-2 in tumors of the head and neck.
An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.
An updated review of protective effects of rosemary and its active constituents against natural and chemical toxicities.
Analgesic and Anti-Inflammatory Activities of Rosa taiwanensis Nakai in Mice.
Analgesic and Anti-Inflammatory Activities of the Methanol Extract from Pogostemon cablin.
Analgesic and anti-inflammatory effects and molecular mechanisms of Kadsura heteroclita stems, an anti-arthritic Chinese Tujia ethnomedicinal herb.
Analgesic and anti-inflammatory effects of the amphibian neurotoxin, anntoxin.
Analgesic Effect of Toll-like Receptor 4 Antagonistic Peptide 2 on Mechanical Allodynia Induced with Spinal Nerve Ligation in Rats.
Analgesic usage for low back pain: impact on health care costs and service use.
Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation.
Analysis of Cox-2 expression in Wilms' tumor.
Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression.
Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis.
Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry.
Analysis of K-ras mutations and expression of cyclooxygenase-2 and gastrin protein in laterally spreading tumors.
Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability.
Ancient Chinese Formula Qiong-Yu-Gao Protects Against Cisplatin-Induced Nephrotoxicity Without Reducing Anti-tumor Activity.
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway.
Anesthetic drug propofol inhibits the expression of interleukin-6, interleukin-8 and cyclooxygenase-2, a potential mechanism for propofol in suppressing tumor development and metastasis.
Anesthetic Techniques and Cancer Recurrence after Surgery.
Angelica Dahurica Regulated the Polarization of Macrophages and Accelerated Wound Healing in Diabetes: A Network Pharmacology Study and In Vivo Experimental Validation.
Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study.
Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study.
Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells.
Angiopoietin-Like Protein 7 Promotes an Inflammatory Phenotype in RAW264.7 Macrophages Through the P38 MAPK Signaling Pathway.
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
Antagonism of GPR4 with NE 52-QQ57 and the Suppression of AGE-Induced Degradation of Type II Collagen in Human Chondrocytes.
Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.
Anthocyanin content, antioxidant, anti-inflammatory and anticancer properties of blackberry and raspberry fruits
Anthocyanin-rich açai (Euterpe oleracea Mart.) fruit pulp fractions attenuate inflammatory stress signaling in mouse brain BV-2 microglial cells.
Anthocyanins from Lycium ruthenicum Murr. Ameliorated d-Galactose-Induced Memory Impairment, Oxidative Stress, and Neuroinflammation in Adult Rats.
Anthocyanins in Cornus alternifolia, Cornus controversa, Cornus kousa and Cornus florida fruits with health benefits.
Anti-aggregatory effect of boswellic acid in high-fat fed rats: involvement of redox and inflammatory cascades.
Anti-Amnesic Effect of Walnut via the Regulation of BBB Function and Neuro-Inflammation in A?1-42-Induced Mice.
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Anti-angiogenic therapy in breast cancer.
Anti-Apoptotic and Anti-Inflammatory Activities of Edible Fresh Water Algae Prasiola japonica in UVB-Irradiated Skin Keratinocytes.
Anti-arthritic effects of Ephedra sinica STAPF herb-acupuncture: inhibition of lipopolysaccharide-induced inflammation and adjuvant-induced polyarthritis.
Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase.
Anti-cancer and anti-hepatitis C virus NS5B polymerase activity of etodolac 1,2,4-triazoles.
Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma.
Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.
Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice.
Anti-carcinogenic properties of curcumin on colorectal cancer.
Anti-Colitic Effects of Ethanol Extract of Persea americana Mill. through Suppression of Pro-Inflammatory Mediators via NF-?B/STAT3 Inactivation in Dextran Sulfate Sodium-Induced Colitis Mice.
Anti-colitic effects of kanjangs (fermented soy sauce and sesame sauce) in dextran sulfate sodium-induced colitis in mice.
Anti-coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin.
Anti-fibrotic potential of a
Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
Anti-glycative and anti-inflammatory effects of protocatechuic acid in brain of mice treated by d-galactose.
Anti-inflammation and Anti-Cancer Activity of Ethanol Extract of Antarctic Freshwater Microalga, Micractinium sp.
Anti-inflammation Effects of Cordyceps sinensis Mycelium in Focal Cerebral Ischemic Injury Rats.
Anti-inflammatory action of herbal medicine comprised of Scutellaria baicalensis and Chrysanthemum morifolium.
Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages.
Anti-inflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: a novel mechanism.
Anti-Inflammatory Activities and Liver Protection of Alisol F and 25-Anhydroalisol F through the Inhibition of MAPK, STAT3, and NF-?B Activation In Vitro and In Vivo.
Anti-inflammatory activities of amber extract in lipopolysaccharide-induced RAW 264.7 macrophages.
Anti-Inflammatory Activities of Licorice Extract and Its Active Compounds, Glycyrrhizic Acid, Liquiritin and Liquiritigenin, in BV2 Cells and Mice Liver.
Anti-inflammatory activities of Maillard reaction products from whey protein isolate fermented by Lactobacillus gasseri 4M13 in lipopolysaccharide-stimulated RAW264.7 cells.
Anti-Inflammatory Activity and Bioactive Constituents of Cultivated Fruiting Bodies of Xylaria nigripes (Ascomycetes), a Chinese Medicinal Fungus.
Anti-inflammatory activity of 21(alpha, beta)-methylmelianodiols, novel compounds from Poncirus trifoliata Rafinesque.
Anti-inflammatory Activity of ?-Carotene, Lycopene and Tri-
Anti-inflammatory activity of ?-patchoulene isolated from patchouli oil in mice.
Anti-Inflammatory activity of chrysophanol through the suppression of NF-kappaB/caspase-1 activation in vitro and in vivo.
Anti-Inflammatory Activity of Citric Acid-Treated Wheat Germ Extract in Lipopolysaccharide-Stimulated Macrophages.
Anti-inflammatory activity of four Bolivian Baccharis species (Compositae).
Anti-Inflammatory Activity of Haskap Cultivars is Polyphenols-Dependent.
Anti-Inflammatory Activity of Heterocarpin from the Salt Marsh Plant Corydalis heterocarpa in LPS-Induced RAW 264.7 Macrophage Cells.
Anti-inflammatory activity of horseradish (Armoracia rusticana) root extracts in LPS-stimulated macrophages.
Anti-inflammatory activity of lansais from endophytic Streptomyces sp. SUC1 in LPS-induced RAW 264.7 cells
Anti-inflammatory activity of methylene chloride fraction from Glehnia littoralis extract via suppression of NF-kappaB and mitogen-activated protein kinase activity.
Anti-inflammatory activity of monogalactosyldiacylglycerol in human articular cartilage in vitro: activation of an anti-inflammatory cyclooxygenase-2 (COX-2) pathway.
Anti-inflammatory activity of N-(3-florophenyl)ethylcaffeamide in mice.
Anti-inflammatory activity of Nerium indicum by inhibition of prostaglandin E2 in murine splenic lymphocytes.
Anti-inflammatory activity of omphalocarpin isolated from Radix Toddaliae Asiaticae.
Anti-inflammatory activity of ortho-trifluoromethoxy-substituted 4-piperidione-containing mono-carbonyl curcumin derivatives in vitro and in vivo.
Anti-inflammatory activity of polyphenolics from açai (Euterpe oleracea Martius) in intestinal myofibroblasts CCD-18Co cells.
Anti-inflammatory activity of selected plants from Saudi Arabia.
Anti-Inflammatory Activity of Some Characteristic Constituents from the Vine Stems of Spatholobus suberectus.
Anti-inflammatory activity of the artificial antioxidants 2-tert-butyl-4-methoxyphenol (BHA), 2,6-di-tert-butyl-4-methylphenol (BHT) and 2,4,6-tri-tert-butylphenol (TBP), and their various combinations.
Anti-inflammatory activity of traditional Chinese medicinal herbs.
Anti-Inflammatory Activity of Water-Soluble Polysaccharide of Agaricus blazei Murill on Ovariectomized Osteopenic Rats.
Anti-inflammatory and analgesic activities of indigo through regulating the IKK?/I?B/NF-?B pathway in mice.
Anti-inflammatory and analgesic effects of human placenta extract.
Anti-inflammatory and analgesic potential of Tamarindus indica Linn. (Fabaceae): a narrative review.
Anti-Inflammatory and Anti-Allergic Effects of Saponarin and Its Impact on Signaling Pathways of RAW 264.7, RBL-2H3, and HaCaT Cells.
Anti-inflammatory and anti-granuloma activity of Berberis aristata DC. in experimental models of inflammation.
Anti-Inflammatory and Anti-Hyperuricemic Functions of Two Synthetic Hybrid Drugs with Dual Biological Active Sites.
Anti-inflammatory and anti-infectious effects of Evodia rutaecarpa (Wuzhuyu) and its major bioactive components.
Anti-inflammatory and anti-oxidant effect of Calea urticifolia lyophilized aqueous extract on lipopolysaccharide-stimulated RAW 264.7 macrophages.
Anti-inflammatory and anti-oxidative effect of Korean propolis on Helicobacter pylori-induced gastric damage in vitro.
Anti-Inflammatory and Anti-Oxidative Effects of luteolin-7-O-glucuronide in LPS-Stimulated Murine Macrophages through TAK1 Inhibition and Nrf2 Activation.
Anti-inflammatory and antinociceptive activities of bufalin in rodents.
Anti-inflammatory and antinociceptive effects of racemic goniothalamin, a styryl lactone.
Anti-Inflammatory and Antioxidant Actions of N-Arachidonoyl Serotonin in RAW264.7 Cells.
Anti-inflammatory and antioxidant effect of Kerabala: a value-added ayurvedic formulation from virgin coconut oil inhibits pathogenesis in adjuvant-induced arthritis.
Anti-Inflammatory and Antioxidant Effects of Anthocyanins of Trifolium pratense (Red Clover) in Lipopolysaccharide-Stimulated RAW-267.4 Macrophages.
Anti-Inflammatory and Antiproliferative Activities of Trifolirhizin, a Flavonoid from Sophora flavescens Roots.
Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model.
Anti-inflammatory and heme oxygenase-1 inducing activities of lanostane triterpenes isolated from mushroom Ganoderma lucidum in RAW264.7 cells.
Anti-inflammatory and immunomodulatory effects of Critonia aromatisans leaves: Downregulation of pro-inflammatory cytokines.
Anti-Inflammatory and Photoaging-Protective Effects of Olea europaea through Inhibition of AP-1 and NF-[Formula: see text] B Pathways.
Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis.
Anti-inflammatory and side effects of cyclooxygenase inhibitors.
Anti-inflammatory constituents of Sappan Lignum.
Anti-inflammatory drugs suppress ultrasound-mediated mesenchymal stromal cell tropism to kidneys.
Anti-inflammatory drugs, cyclooxygenases and other factors.
Anti-inflammatory effect of alpha-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-kappaB and mitogen-activated protein kinase pathways.
Anti-inflammatory effect of Apo-9'-fucoxanthinone via inhibition of MAPKs and NF-kB signaling pathway in LPS-stimulated RAW 264.7 macrophages and zebrafish model.
Anti-inflammatory effect of birsonimadiol from seeds of Byrsonima crassifolia.
Anti-inflammatory effect of citrus unshiu peel in LPS-stimulated RAW 264.7 macrophage cells.
Anti-inflammatory effect of Columbianetin on activated human mast cells.
Anti-inflammatory effect of Cortex Eucommiae via modulation of the toll-like receptor 4 pathway in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Anti-inflammatory effect of coumarins isolated from Corydalis heterocarpa in HT-29 human colon carcinoma cells.
Anti-inflammatory effect of delphinidin on intramedullary spinal pressure in a spinal cord injury rat model.
Anti-inflammatory effect of Ganluyin, a Chinese classic prescription, in chronic pharyngitis rat model.
Anti-inflammatory effect of geranium nanoemulsion macrophages induced with soluble protein of Candida albicans.
Anti-Inflammatory Effect of Local Anaesthetic Ropivacaine in Lipopolysaccharide-Stimulated RAW264.7 Macrophages.
Anti-inflammatory effect of Lycium Fruit water extract in lipopolysaccharide-stimulated RAW 264.7 macrophage cells.
Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells.
Anti-inflammatory effect of methoxyflavonoids from Chiliadenus montanus (Jasonia Montana) growing in Egypt.
Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-?B inactivation.
Anti-inflammatory effect of prunetin via the suppression of NF-?B pathway.
Anti-inflammatory effect of remifentanil in lipopolysaccharide-stimulated amniotic epithelial cells.
Anti-inflammatory effect of selenium on lead-induced testicular inflammation by inhibiting NLRP3 inflammasome activation in chickens.
Anti-inflammatory effect of supercritical extract and its constituents from Ishige okamurae.
Anti-inflammatory effect of Tauroursodeoxycholic acid in RAW 264.7 macrophages, Bone marrow-derived macrophages, BV2 microglial cells, and spinal cord injury.
Anti-inflammatory effect of the water fraction from hawthorn fruit on LPS-stimulated RAW 264.7 cells.
Anti-inflammatory effects and antioxidant activity of dihydroasparagusic acid in lipopolysaccharide-activated microglial cells.
Anti-Inflammatory Effects of 5?,8?-Epidioxycholest-6-en-3?-ol, a Steroidal Endoperoxide Isolated from Aplysia depilans, Based on Bioguided Fractionation and NMR Analysis.
Anti-inflammatory effects of 6'-O-acetyl mangiferin from Iris rossii Baker via NF-?b signal blocking in lipopolysaccharide-stimulated RAW 264.7 cells.
Anti-inflammatory effects of a traditional Korean medicine: Ojayeonjonghwan.
Anti-inflammatory effects of a triple-bond resveratrol analog: structure and function relationship.
Anti-inflammatory effects of Amomum compactum on RAW 264.7 cells via induction of heme oxygenase-1.
Anti-inflammatory effects of an optimized PPAR-? agonist via NF-?B pathway inhibition.
Anti-inflammatory effects of carvacrol: evidence for a key role of interleukin-10.
Anti-inflammatory effects of chemical components from Ginkgo biloba L. male flowers on lipopolysaccharide-stimulated RAW264.7 macrophages.
Anti-inflammatory effects of dexmedetomidine on human amnion-derived WISH cells.
Anti-inflammatory effects of egg white combined with chalcanthite in lipopolysaccharide-stimulated BV2 microglia through the inhibition of NF-?B, MAPK and PI3K/Akt signaling pathways.
Anti-Inflammatory Effects of Fermented Bark of Acanthopanax sessiliflorus and Its Isolated Compounds on Lipopolysaccharide-Treated RAW 264.7 Macrophage Cells.
Anti-inflammatory effects of fucoidan through inhibition of NF-?B, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells.
Anti-Inflammatory Effects of Ginsenoside-Rh2 Inhibits LPS-Induced Activation of Microglia and Overproduction of Inflammatory Mediators Via Modulation of TGF-?1/Smad Pathway.
Anti-inflammatory effects of glaucocalyxin B in microglia cells.
Anti-inflammatory Effects of KOTMIN13: A Mixed Herbal Medicine in LPS-stimulated RAW 264.7 Cells and Mouse Edema Models.
Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy.
Anti-inflammatory effects of low-level light emitting diode therapy on Achilles tendinitis in rats.
Anti-inflammatory effects of luteolin on experimental autoimmune thyroiditis in mice.
Anti-inflammatory effects of methanol extracts from the Antarctic lichen, Amandinea sp. in LPS-stimulated raw 264.7 macrophages and zebrafish.
Anti-inflammatory effects of Nelumbo leaf extracts and identification of their metabolites.
Anti-inflammatory Effects of Novel Polysaccharide Sacran Extracted from Cyanobacterium Aphanothece sacrum in Various Inflammatory Animal Models.
Anti-inflammatory effects of olive-derived hydroxytyrosol on lipopolysaccharide-induced inflammation in RAW264.7 cells.
Anti-inflammatory Effects of Oxymatrine Through Inhibition of Nuclear Factor-kappa B and Mitogen-activated Protein Kinase Activation in Lipopolysaccharide-induced BV2 Microglia Cells.
Anti-inflammatory effects of Polygala tenuifolia root through inhibition of NF-?B activation in lipopolysaccharide-induced BV2 microglial cells.
Anti-inflammatory effects of proanthocyanidin-rich red rice extract via suppression of MAPK, AP-1 and NF-?B pathways in Raw 264.7 macrophages.
Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia.
Anti-inflammatory effects of prostaglandin E2 in the central nervous system in response to brain injury and circulating lipopolysaccharide.
Anti-inflammatory Effects of Sanhuang-Siwu-Tang in Lipopolysaccharide-Stimulated RAW264.7 Macrophages and BV2 Microglial Cells.
Anti-inflammatory effects of Scoparia dulcis L. and betulinic acid.
Anti-inflammatory effects of shikonin in human periodontal ligament cells.
Anti-Inflammatory Effects of Step Electrical Stimulation on Complete Freund's Adjuvant (CFA) Induced Rheumatoid Arthritis Rats.
Anti-Inflammatory Effects of Supercritical Carbon Dioxide Extract and Its Isolated Carnosic Acid from Rosmarinus officinalis Leaves.
Anti-inflammatory effects of the willow bark extract STW 33-I (Proaktiv((R))) in LPS-activated human monocytes and differentiated macrophages.
Anti-inflammatory effects of total alkaloids from Rubus aleaefolius Poir. on non-alcoholic fatty liver disease through regulation of the NF-?B pathway.
Anti-inflammatory effects of vina-ginsenoside R2 and majonoside R2 isolated from Panax vietnamensis and their metabolites in lipopolysaccharide-stimulated macrophages.
Anti-Inflammatory Functions of Alverine via Targeting Src in the NF-?B Pathway.
Anti-inflammatory functions of the CDC25 phosphatase inhibitor BN82002 via targeting AKT2.
Anti-inflammatory Limonoids From Cortex Dictamni.
Anti-inflammatory mechanism of total glycosides of Acanthopanax Giraldii.
Anti-inflammatory mechanisms of phenanthroindolizidine alkaloids.
Anti-inflammatory phomalichenones from an endolichenic fungus Phoma sp.
Anti-inflammatory Potential of Petiveria alliacea on Activated RAW264.7 Murine Macrophages.
Anti-inflammatory Potential of Quercetin-3-O-?-D-("2"-galloyl)-glucopyranoside and Quercetin Isolated from Diospyros kaki calyx via Suppression of MAP Signaling Molecules in LPS-induced RAW 264.7 Macrophages.
Anti-inflammatory potential of Trifolium pratense L. leaf extract in LPS-stimulated RAW264.7 cells and in a rat model of carrageenan-induced inflammation.
Anti-inflammatory role of curcumin in retinal disorders (Review).
Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation.
Anti-inflammatory role of tempol (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl) in nephroprotection.
Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside.
Anti-inflammatory, Anti-estrogenic, and Anti-implantation Activity of Bergia suffruticosa (Delile) Fenzl.
Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis.
Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis.
Anti-metastatic Action of Non-steroidal Anti-inflammatory Drugs.
Anti-neuroinflammatory activity of 6,7-dihydroxy-2,4-dimethoxy phenanthrene isolated from Dioscorea batatas Decne partly through suppressing the p38 MAPK/NF-?B pathway in BV2 microglial cells.
Anti-neuroinflammatory activity of a novel cannabinoid derivative by inhibiting the NF-?B signaling pathway in lipopolysaccharide-induced BV-2 microglial cells.
Anti-neuroinflammatory effect of aurantiamide acetate from the marine fungus Aspergillus sp. SF-5921: inhibition of NF-?B and MAPK pathways in lipopolysaccharide-induced mouse BV2 microglial cells.
Anti-neuroinflammatory Effects of 12-Dehydrogingerdione in LPS-Activated Microglia through Inhibiting Akt/IKK/NF-?B Pathway and Activating Nrf-2/HO-1 Pathway.
Anti-neuroinflammatory effects of 20C from Gastrodia elata via regulating autophagy in LPS-activated BV-2 cells through MAPKs and TLR4/Akt/mTOR signaling pathways.
Anti-neuroinflammatory effects of citreohybridonol involving TLR4-MyD88-mediated inhibition of NF-?B and MAPK signaling pathways in lipopolysaccharide-stimulated BV2 cells.
Anti-neuroinflammatory effects of ethanolic extract of black chokeberry (
Anti-Neuroinflammatory Effects of Fucoxanthin via Inhibition of Akt/NF-?B and MAPKs/AP-1 Pathways and Activation of PKA/CREB Pathway in Lipopolysaccharide-Activated BV-2 Microglial Cells.
Anti-Neuroinflammatory ent-Kaurane Diterpenoids from Pteris multifida Roots.
Anti-nociceptive and anti-inflammatory effects of the ethanol extract of Arenga pinnata (Wurmb) Merr. fruit.
Anti-oxidative and anti-inflammatory effects of Lobelia chinensis in vitro and in vivo.
Anti-photoaging effect of aaptamine in UVB-irradiated human dermal fibroblasts and epidermal keratinocytes.
Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells.
Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs.
Anti-tumor activity of the novel hexahydrocannabinol analog LYR-8 in Human colorectal tumor xenograft is mediated through the inhibition of Akt and hypoxia-inducible factor-1? activation.
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model.
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.
Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators.
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats.
Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
Antiarthritic Potential of Comprehensively Standardized Extract of Alternanthera bettzickiana: In Vitro and In Vivo Studies.
Antibacterial and Anti-inflammatory Activity of Traditional Chinese Herb Pairs, Angelica sinensis and Sophora flavescens.
Antibodies as Carrier Molecules: Encapsulating Anti-Inflammatory Drugs inside Herceptine.
Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-kappaB and crosstalk between the extrinsic and intrinsic apoptotic pathways.
Anticancer activity of fish oils against human lung cancer is associated with changes in formation of PGE(2) and PGE(3) and Alteration of Akt Phosphorylation.
Anticancer activity of Scutellaria baicalensis and its potential mechanism.
Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana.
Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives.
Anticancer effects of licofelone (ML-3000) in prostate cancer cells.
Anticancer potential of silymarin: from bench to bed side.
Anticoagulant from Taraxacum platycarpum.
Antidepressant-like Effects of p-Coumaric Acid on LPS-induced Depressive and Inflammatory Changes in Rats.
Antidepressants, prostaglandins and the prevention and treatment of cancer.
Antihypertensive potential of selected pyrimidine derivatives: Explanation of underlying mechanistic pathways.
Antiinflammatory and Analgesic Activities of Ethanol Extract and Isolated Compounds from Millettia pulchra.
Antiinflammatory and antihyperalgesic activity of C-phycocyanin.
Antiinflammatory effect of lactic acid bacteria: inhibition of cyclooxygenase-2 by suppressing nuclear factor-kappaB in Raw264.7 macrophage cells.
Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1.
Antimetastatic activity of a cyclooxygenase-2 inhibitor.
Antimetastatic activity of pinosylvin, a natural stilbenoid, is associated with the suppression of matrix metalloproteinases.
Antimetastatic role of Smad4 signaling in colorectal cancer.
Antineoplastic effect of a novel chemopreventive agent, neokestose, on the Caco-2 cell line via inhibition of expression of nuclear factor-?B and cyclooxygenase-2.
Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells.
Antinociceptive and anti-inflammatory activities of a triterpene-rich fraction from Himatanthus drasticus.
Antinociceptive and anti-inflammatory effects of electroacupuncture on experimental arthritis of the rat temporomandibular joint.
Antinociceptive and anti-inflammatory effects of essential oil extracted from Chamaecyparis obtusa in mice.
Antinociceptive effects of dezocine on complete Freund's adjuvant-induced inflammatory pain in rats.
Antiobesity and anti-inflammation effects of Hakka stir-fried tea of different storage years on high-fat diet-induced obese mice model via activating the AMPK/ACC/CPT1 pathway.
Antioxidant and anti-inflammatory activities of N-acetyldopamine dimers from Periostracum Cicadae.
Antioxidant and Anti-Inflammatory Effects of Crocin Ameliorate Doxorubicin-Induced Nephrotoxicity in Rats.
Antioxidant and anti-inflammatory effects of intravenously injected adipose derived mesenchymal stem cells in dogs with acute spinal cord injury.
Antioxidant and Anti-inflammatory Effects of Yam (Dioscorea batatas Decne.) on Azoxymethane-induced Colonic Aberrant Crypt Foci in F344 Rats.
Antioxidant and anti-inflammatory properties of curcumin.
Antioxidant effect of acetyl-l-carnitine against cisplatin-induced cardiotoxicity.
Antioxidant, anti-inflammatory and anti-fibrotic effects of Boswellia serrate gum resin in CCl4-induced hepatotoxicity.
Antioxidant, Anti-Inflammatory and Anticancer Activities of Methanolic Extract of Thottea siliquosa: An In Vitro and In Silico Study.
Antioxidant, anti-proliferative and cyclooxygenase-2 inhibitory activities of ethanolic extracts from lemon balm (Melissa officinalis L.) leaves
Antioxidant, antinociceptive, and anti-inflammatory activities of Xanthii Fructus extract.
Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells.
Antioxidative and anti-inflammatory effect of Phellinus igniarius on RAW 264.7 macrophage cells.
Antiproliferative activity of New Zealand propolis and phenolic compounds vs human colorectal adenocarcinoma cells.
Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen †.
Antiproliferative and anti-inflammatory properties of diindolylmethane and lupeol against N-butyl-N-(4-hydroxybutyl) nitrosamine induced bladder carcinogenesis in experimental rats.
Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2.
Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines.
Antiproliferative effect of indomethacin on CML cells is related to the suppression of STATs/Bcl-XL signal pathway.
Antipyretic and Anti-inflammatory Effects of Asiaticoside in Lipopolysaccharide-treated Rat through Up-regulation of Heme Oxygenase-1.
Antipyretic and antioxidant activities of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles in rats.
Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.
Antitumor Activity of Ficus deltoidea Extract on Oral Cancer: An In Vivo Study.
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Antitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice.
Antitumor and antimetastatic effects of licochalcone A in mouse models.
Antitumor effect of a generation 4 polyamidoamine dendrimer/cyclooxygenase-2 antisense oligodeoxynucleotide complex on breast cancer in vitro and in vivo.
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model.
Antitumor effect of retinoic acid receptor-beta2 associated with suppression of cyclooxygenase-2.
Antitumor effect of the selective COX-2 inhibitor celecoxib on endometrial adenocarcinoma in vitro and in vivo.
Antitumor effects of a cyclooxygenase-2 inhibitor, meloxicam, alone and in combination with radiation and/or 5-fluorouracil in cultured tumor cells.
Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Antitumor effects of inhibitors of arachidonic acid cascade on experimentally induced intestinal tumors.
Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.
Antitumor immunostimulatory activity of polysaccharides from Salvia chinensis Benth.
Antitumor promoting potential of selected phytochemicals derived from spices: a review.
Antitumor promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin.
Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy.
Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.
Antitumorigenic Effects of ZAK?, an Alternative Splicing Isoform of ZAK.
AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata.
Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.
Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice.
Apigenin inhibits tumor necrosis factor alpha plus high glucose induced-LOX-1 expression in human endothelial cells.
Apigenin, a nonmutagenic dietary flavonoid suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells.
Apocynin protects against ethanol-induced gastric ulcer in rats by attenuating the upregulation of NADPH oxidases 1 and 4.
Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398.
Apoptosis induction and inhibition of colon-26 tumour growth and angiogenesis: findings on COX-1 and COX-2 inhibitors in vitro & in vivo and topical diclofenac in hyaluronan.
Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway.
Apoptotic Effect of Tolfenamic Acid in KB Human Oral Cancer Cells: Possible Involvement of the p38 MAPK Pathway.
Application of a Validated QSTR Model for Repurposing COX-2 Inhibitor Coumarin Derivatives as Potential Antitumor Agents.
Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid.
Approach to angiogenesis inhibition based on cyclooxygenase-2.
Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.
Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer.
Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer.
Aqueous and Ethanol Extracts of Daylily Flower (Hemerocallis fulva L.) Protect HUVE Cells Against High Glucose.
Aqueous Extract of the Edible Gracilaria tenuistipitata Inhibits Hepatitis C Viral Replication via Cyclooxygenase-2 Suppression and Reduces Virus-Induced Inflammation.
Aqueous Terminalia arjuna extract modulates expression of key atherosclerosis-related proteins in a hypercholesterolemic rabbit: A proteomic-based study.
Arachidonic acid and colorectal carcinogenesis.
Arachidonic acid metabolic profiles in human meningiomas and gliomas.
Arachidonic acid metabolism in growth control of A549 human lung adenocarcinoma cells.
Arachidonic acid metabolites in saliva of patients with squamous cell carcinoma of the head and neck.
Arachidonoyl ethanolamide (AEA)-induced apoptosis is mediated by J-series prostaglandins and is enhanced by fatty acid amide hydrolase (FAAH) blockade.
Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: Role of cyclooxygenase-2 and novel J-series prostamides.
Arctigenin prevents the progression of osteoarthritis by targeting PI3K/Akt/NF-?B axis: In vitro and in vivo studies.
Are cytokines possible mediators of cancer cachexia?
Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
Areca nut extracts increased the expression of cyclooxygenase-2, prostaglandin E2 and interleukin-1? in human immune cells via oxidative stress.
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.
Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration.
Aromatase and COX-2 expression in human breast cancers.
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Aromatic side-chain conformational switch on the surface of the RNA Recognition Motif enables RNA discrimination.
Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells.
Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
Arsenic-induced testicular toxicity in Gallus gallus: Expressions of inflammatory cytokines and heat shock proteins.
Artemisiae Iwayomogii Herba inhibits lipopolysaccharide-induced neuroinflammation by regulating NF-?B and MAPK signaling pathways.
Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression.
Artesunate Protects Against Sepsis-Induced Lung Injury Via Heme Oxygenase-1 Modulation.
Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis.
Artocarpin attenuates ultraviolet B-induced skin damage in hairless mice by antioxidant and anti-inflammatory effect.
Arvelexin isolated from the Brassica rapa abolishes inducible NF-?B activation by inhibiting IKK activation, thereby suppressing NF-?B-regulated pro-inflammatory gene expression.
Aryl Hydrocarbon Receptor Role in Co-Ordinating SARS-CoV-2 Entry and Symptomatology: Linking Cytotoxicity Changes in COVID-19 and Cancers; Modulation by Racial Discrimination Stress.
Arylbenzofuran isolated from Dalbergia odorifera suppresses lipopolysaccharide-induced mouse BV2 microglial cell activation, which protects mouse hippocampal HT22 cells death from neuroinflammation-mediated toxicity.
Arylidene analogues as selective COX-2 inhibitors: synthesis, characterization, in silico and in vitro studies.
Asiasari sieboldii suppresses inflammatory mediators through the induction of hemeoxygenase-1 expression in RAW264.7 cells.
Asiatic acid from Potentilla chinensis attenuate ethanol-induced hepatic injury via suppression of oxidative stress and Kupffer cell activation.
Aspartate alleviates liver injury and regulates mRNA expressions of TLR4 and NOD signaling-related genes in weaned pigs after lipopolysaccharide challenge.
Asperuloside and Asperulosidic Acid Exert an Anti-Inflammatory Effect via Suppression of the NF-?B and MAPK Signaling Pathways in LPS-Induced RAW 264.7 Macrophages.
Aspirin acts in esophageal cancer: a brief review.
Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
Aspirin and colorectal cancer: back to the future.
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer.
Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression.
Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD).
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2.
Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study.
Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-?B to the COX-2 promoter.
Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2.
Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT.
Aspirin inhibits prostaglandins to prevents colon tumor formation via down-regulating Wnt production.
Aspirin may modify tumor microenvironment via antiplatelet effect.
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.
Aspirin reduces lung cancer metastasis to regional lymph nodes.
Aspirin triggers formation of anti-inflammatory mediators: New mechanism for an old drug.
Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
Aspirin use and survival after diagnosis of colorectal cancer.
Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).
Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha.
Aspirin-induced inhibition of adipogenesis was p53-dependent and associated with inactivation of pentose phosphate pathway.
Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation.
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness.
Assessment of angiogenesis: implications for ultrasound imaging.
Assessment of cyclooxygenase-1 and 2 gene expression levels in chronic autoimmune thyroiditis, papillary thyroid carcinoma and nontoxic nodular goitre.
Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor.
Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex.
Assessment of promising protein markers for vulva cancer.
Association between a functional variant at PTGS2 gene 3'UTR and its mRNA expression in lymphoblastoid cell lines.
Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer.
Association between areca-stimulated vimentin expression and the progression of head and neck cancers.
Association Between COX-2 Expression and Effectiveness of COX-2 Inhibitors in a Phase II Trial in Patients with Metastatic Colorectal Adenocarcinoma.
Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer.
Association between Cyclooxygenase expression and colorectal adenoma characteristics.
Association between cyclooxygenase-2 (COX-2) 8473 T?>?C polymorphism and cancer risk: a meta-analysis and trial sequential analysis.
Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan.
Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.
Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk.
Association between cyclooxygenase-2-expressing macrophages, ulceration and microvessel density in colorectal cancer.
Association between Degree of Anaplasia and Degree of Inflammation with the Expression of COX-2 in Feline Injection Site Sarcomas.
Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.
Association between expression of inflammatory markers in normal breast tissue and mammographic density among premenopausal and postmenopausal women.
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer.
Association between overexpression of cyclooxygenase-2 and suppression of apoptosis in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion.
Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality.
Association between serum concentrations of perfluoroalkyl substances (PFAS) and expression of serum microRNAs in a cohort highly exposed to PFAS from drinking water.
Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-?, and Vascular Endothelial Growth Factor-A Genes, and Susceptibility to Hepatocellular Carcinoma.
Association of Activation of Induced COX-2, iNOS and Cytokines with NF-kappa B Depression by Taiwan Wild Grape Ethanolic Extract in Mice.
Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer.
Association of COX-2 Promoter Polymorphism with Gastrointestinal Tract Cancer in Iran.
Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in taiwan.
Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.
Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer.
Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas.
Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis.
Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation.
Association of organochlorine pesticides with the mRNA expression of tumour necrosis factor-alpha (
Association of tumor necrosis factor, interleukin-6 and cyclooxygenase pathway with lipopolysaccharide-induced intussusception.
Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome.
Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population.
Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer.
Associations of Biomarkers of Inflammation and Breast Cancer in the Breast Adipose Tissue of Women with Combined Measures of Adiposity.
Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation.
Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2.
Astaxanthin Suppresses PM2.5-Induced Neuroinflammation by Regulating Akt Phosphorylation in BV-2 Microglial Cells.
Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages.
Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation.
Astilbin ameliorates deoxynivalenol-induced oxidative stress and apoptosis in intestinal porcine epithelial cells (IPEC-J2).
Astilbin prevents osteoarthritis development through the TLR4/MD-2 pathway.
Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony.
ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo.
Atherosclerotic cardiovascular disease in rheumatoid arthritis.
ATP-Binding Pocket-Targeted Suppression of Src and Syk by Luteolin Contributes to Its Anti-Inflammatory Action.
Atractylone, an active constituent of KMP6, attenuates allergic inflammation on allergic rhinitis in vitro and in vivo models.
Atsttrin reduces lipopolysaccharide-induced neuroinflammation by inhibiting the nuclear factor kappa B signaling pathway.
Attenuation of Aluminum Chloride-Induced Neuroinflammation and Caspase Activation Through the AKT/GSK-3? Pathway by Hesperidin in Wistar Rats.
Attenuation of atherosclerotic complications by modulating inflammatory responses in hypercholesterolemic rats with dietary Njavara rice bran oil.
Attenuation of inflammation and cartilage degradation by sulfasalazine-containing hyaluronic acid on osteoarthritis rat model.
Attenuation of inflammatory responses by (+)-syringaresinol via MAP-Kinase-mediated suppression of NF-?B signaling in vitro and in vivo.
Attenuation of macrophage apoptosis by the cAMP-signaling system.
Attenuation of NDEA-induced hepatocarcinogenesis by naringenin in rats.
Attenuation of the cardiac inflammatory changes and lipid anomalies by (-)-epigallocatechin-gallate in cigarette smoke-exposed rats.
Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients With Cervical Cancer.
Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin.
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.
Autocrine prostaglandin E2 signaling promotes promonocytic leukemia cell survival via COX-2 expression and MAPK pathway.
Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion.
Automatic evaluation of cyclooxygenase 2 inhibition induced by metal-based anticancer compounds.
Autophagic flux regulates microglial phenotype according to the time of oxygen-glucose deprivation/reperfusion.
Autophagy upregulates inflammatory cytokines in gingival tissue of patients with periodontitis and lipopolysaccharide-stimulated human gingival fibroblasts.
Avenanthramides inhibit proliferation of human colon cancer cell lines in vitro.
Avian Papilloma and Squamous Cell Carcinoma: a Histopathological, Immunohistochemical and Virological study.
Avocado soybean unsaponifiables (ASU) suppress TNF-alpha, IL-1beta, COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages.
Ba-Wei-Die-Huang-Wan (Hachimi-jio-gan) can ameliorate ketamine-induced cystitis by modulating neuroreceptors, inflammatory mediators, and fibrogenesis in a rat model.
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
Bacterial porins stimulate bone resorption.
Baicalin Ameliorates Collagen-Induced Arthritis Through the Suppression of Janus Kinase 1 (JAK1)/Signal Transducer and Activator of Transcription 3 (STAT3) Signaling in Mice.
Baicalin protects against zearalenone-induced chicks liver and kidney injury by inhibiting expression of oxidative stress, inflammatory cytokines and caspase signaling pathway.
Bamboo vinegar decreases inflammatory mediator expression and NLRP3 inflammasome activation by inhibiting reactive oxygen species generation and protein kinase C-?/? activation.
Barrett's esophagus.
Barrett's esophagus: chemoprevention.
Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease.
Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia.
Beneficial Effects of Exogenous Melatonin in Acute Staphylococcus aureus and Escherichia coli Infection-Induced Inflammation and Associated Behavioral Response in Mice After Exposure to Short Photoperiod.
Beneficial Effects of Poplar Buds on Hyperglycemia, Dyslipidemia, Oxidative Stress, and Inflammation in Streptozotocin-Induced Type-2 Diabetes.
Benfotiamine Attenuates Inflammatory Response in LPS Stimulated BV-2 Microglia.
Benzimidazole Containing Acetamide Derivatives Attenuate Neuroinflammation and Oxidative Stress in Ethanol-Induced Neurodegeneration.
Benzo(a)pyrene induces oxidative stress, pro-inflammatory cytokines, expression of nuclear factor-kappa B and deregulation of wnt/beta-catenin signaling in colons of BALB/c mice.
Benzoxathiole derivative blocks lipopolysaccharide-induced nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene transcription through inactivating inhibitory kappaB kinase beta.
Benzo[a]pyrene diol epoxide up-regulates COX-2 expression through NF-kappaB in rat astrocytes.
Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-kappaB.
Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells.
Berberine alleviates amyloid ?25-35-induced inflammatory response in human neuroblastoma cells by inhibiting proinflammatory factors.
Berberine exerts nephroprotective effect against cisplatin-induced kidney damage through inhibition of oxidative/nitrosative stress, inflammation, autophagy and apoptosis.
Berberine reduces neuroglia activation and inflammation in streptozotocin-induced diabetic mice.
Berberine suppresses growth and metastasis of endometrial cancer cells via miR-101/COX-2.
Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E2 and prostaglandin E2 receptors.
Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.
Bergapten alleviates osteoarthritis by regulating the ANP32A/ATM signaling pathway.
Bergaptol from blossoms of Citrus aurantium L. var. amara Engl inhibits LPS-induced inflammatory responses and ox-LDL-induced lipid deposition.
Berry Phenolic and Volatile Extracts Inhibit Pro-Inflammatory Cytokine Secretion in LPS-Stimulated RAW264.7 Cells through Suppression of NF-?B Signaling Pathway.
Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines.
Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas.
beta-catenin-mediated signaling: A novel molecular target for chemoprevention with anti-inflammatory substances.
Beta-ionone-inhibited proliferation of breast cancer cells by inhibited COX-2 activity.
Beta-naphthoflavone inhibits LPS-induced inflammation in BV-2 cells via AKT/Nrf-2/HO-1-NF-?B signaling axis.
Beyond the scalpel: targeting hedgehog in skin cancer prevention.
Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid.
Bidirectional effects of hepatic ischemia/reperfusion on E. coli-induced TNF-alpha gene expression.
Bidirectional Regulation of COX-2 Expression Between Cancer Cells and Macrophages.
Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma.
Bile acid induced gene expression in LT97 colonic adenoma cells.
Bile acids are multifunctional modulators of the Barrett's carcinogenesis.
Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression.
Biliverdin Protects the Isolated Rat Lungs from Ischemia-reperfusion Injury via Antioxidative, Anti-inflammatory and Anti-apoptotic Effects.
BIO alleviates inflammation through inhibition of GSK-3? in a rat model of intracerebral hemorrhage.
Bioactive acylphloroglucinols from Hypericum densiflorum.
Bioactive peptide from Pyropia yezoensis and its anti-inflammatory activities.
Bioactive Potential of Several Actinobacteria Isolated from Microbiologically Barely Explored Desert Habitat, Saudi Arabia.
Bioactivity-Guided Extract Optimization of Osmanthus fragrans var. aurantiacus Leaves and Anti-Inflammatory Activities of Phillyrin.
Bioassay-guided isolation of an alkaloid with antiangiogenic and antitumor activities from the extract of Fissistigma cavaleriei root.
Biochemical evaluation and molecular docking assessment of the anti-inflammatory potential of Phyllanthus nivosus leaf against ulcerative colitis.
Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.
Biogenic Polyphosphate Nanoparticles from a Marine Cyanobacterium Synechococcus sp. PCC 7002: Production, Characterization, and Anti-Inflammatory Properties In Vitro.
Bioinformatics and experimental findings reveal the therapeutic actions and targets of pachymic acid against cystitis glandularis.
Bioinformatics Based Therapeutic Effects of Sinomenium Acutum.
Biologic response modifiers in genitourinary neoplasia.
Biological pathways involved in the aggressive behavior of the keratocystic odontogenic tumor and possible implications for molecular oriented treatment - an overview.
Biology of Cox-2: An Application in Cancer Therapeutics.
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Biomarkers associated with idiopathic frozen shoulder: a systematic review.
Biomarkers of pituitary neoplasms.
Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines.
Bis(ethylmaltolato)oxidovanadium (IV) attenuates amyloid-beta-mediated neuroinflammation by inhibiting NF-?B signaling pathway via a PPAR?-dependent mechanism.
Bisphenol A-induced epithelial to mesenchymal transition is mediated by cyclooxygenase-2 up-regulation in human endometrial carcinoma cells.
Black rice anthocyanin-rich extract and rosmarinic acid, alone and in combination, protect against DSS-induced colitis in mice.
Black tea polyphenols restrict benzopyrene-induced mouse lung cancer progression through inhibition of Cox-2 and induction of caspase-3 expression.
Black Tea: Phytochemicals, Cancer Chemoprevention and Clinical Studies.
Blockade NF-kappaB activation prohibits TNF-alpha-induced cyclooxygenase-2 gene expression in ED27 trophoblast-like cells.
Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice.
Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage.
Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Blockade of NEAT1 represses inflammation response and lipid uptake via modulating miR-342-3p in human macrophages THP-1 cells.
Blockade of prostaglandin products augments macrophage and neutrophil tumor necrosis factor synthesis in burn injury.
Blocking autophagy enhances meloxicam lethality to hepatocellular carcinoma by promotion of endoplasmic reticulum stress.
Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma.
Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis.
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.
Blocking tumor cell eicosanoid synthesis by GPx4 impedes tumor growth and malignancy.
Blood-borne interleukin-1? acts on the subfornical organ to upregulate the sympathoexcitatory milieu of the hypothalamic paraventricular nucleus.
BML-111 Protected LPS/D-GalN-Induced Acute Liver Injury in Rats.
Boeravinone B Protects Brain against Cerebral Ichemia Reperfusion Injury in Rats: Possible Role of Anti-inflammatory and Antioxidant.
Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells.
Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.
Bortezomib attenuates murine collagen-induced arthritis.
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.
Boschniakia rossica prevents the carbon tetrachloride-induced hepatotoxicity in rat.
Both stromal cell and colonocyte epidermal growth factor receptors control HCT116 colon cancer cell growth in tumor xenografts.
Bovine milk-derived ?-lactalbumin inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sodium sulfate-treated mice.
BPTF cooperates with p50 NF-?B to promote COX-2 expression and tumor cell growth in lung cancer.
Bracteanolide A abrogates oxidative stress-induced cellular damage and protects against hepatic ischemia and reperfusion injury in rats.
Brain Fatty Acid Composition and Inflammation in Mice Fed with High-Carbohydrate Diet or High-Fat Diet.
Brazilian berry extract (Myrciaria jaboticaba): A promising therapy to minimize prostatic inflammation and oxidative stress.
Breaking the cycle: the role of omega-3 polyunsaturated fatty acids in inflammation-driven cancers.
Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts.
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Breast cancer--new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?
Breast tumor tissue inflammation but not lobular involution is associated with survival among breast cancer patients in the Multiethnic Cohort.
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin.
Brevicompanine E reduces lipopolysaccharide-induced production of proinflammatory cytokines and enzymes in microglia by inhibiting activation of activator protein-1 and nuclear factor-kappaB.
Bridelia ferruginea Produces Antineuroinflammatory Activity through Inhibition of Nuclear Factor-kappa B and p38 MAPK Signalling.
Brilliant blue G attenuates neuro-inflammation via regulating MAPKs and NF-?B signaling pathways in lipopolysaccharide-induced BV2 microglia cells.
Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia.
Bromelain Enhances the Anti-tumor Effects of Cisplatin on 4T1 Breast Tumor Model In Vivo.
Bufalin, a Traditional Chinese Medicine Compound, Prevents Tumor Formation in Two Murine Models of Colorectal Cancer.
Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue.
Byakangelicin inhibits IL-1?-induced mouse chondrocyte inflammation in vitro and ameliorates murine osteoarthritis in vivo.
c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells.
c-Myb and its Effector COX-2 as an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer.
c-myc amplification is frequent in esophageal adenocarcinoma and correlated with the upregulation of VEGF-A expression.
C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages.
C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy through inhibition of COX-2 expression.
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Cadherins: The Superfamily Critically Involved in Breast Cancer.
Cadmium induced inflammation and apoptosis of porcine epididymis via activating RAF1/MEK/ERK and NF-?B pathways.
Cadmium-induced calcium release and prostaglandin E2 production in neonatal mouse calvaria are dependent on cox-2 induction and protein kinase C activation.
Cadmium-induced endoplasmic reticulum stress in chicken neutrophils is alleviated by selenium.
Caffeic acid attenuates 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced NF-?B and COX-2 expression in mouse skin: abrogation of oxidative stress, inflammatory responses and proinflammatory cytokine production.
Caffeoyloxy-5,6-dihydro-4-methyl-(2H)-pyran-2-one isolated from the leaves of Olinia usambarensis attenuates LPS-induced inflammatory mediators by inactivating AP-1 and NF-?B.
Calcium-independent phospholipase A2 through arachidonic acid mobilization is involved in Caco-2 cell growth.
Calcium-sensing receptor signaling pathways in medullary thick ascending limb cells mediate COX-2-derived PGE2 production: functional significance.
Calpeptin attenuated apoptosis and intracellular inflammatory changes in muscle cells.
Camptothecin-induced apoptosis in non-small cell lung cancer is independent of cyclooxygenase expression.
Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis?
Can aprepitant used for nausea and vomiting be good gastrointestinal complaints?
Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer?
Can intravesical application of paracetamol benefit the chemotherapy treatment of bladder cancer?
Can licorice lick colon cancer?
Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?
Cancer and cyclooxygenase-2 (COX-2) inhibition.
Cancer and thrombosis in women - molecular mechanisms.
Cancer Associated Fibroblasts express pro-inflammatory factors in human breast and ovarian tumors.
Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models.
Cancer chemoprevention through interruption of multistage carcinogenesis. The lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer.
Cancer Chemopreventive Activity of Maslinic Acid: Suppression of COX-2 Expression and Inhibition of NF-kappaB and AP-1 Activation in Raji Cells.
Cancer chemopreventive activity of resveratrol.
Cancer prevention: a new era beyond cyclooxygenase-2.
Cancer preventive phytochemicals as speed breakers in inflammatory signaling involved in aberrant COX-2 expression.
Cancer-induced anorexia in tumor-bearing mice is dependent on cyclooxygenase-1.
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.
Cancerogenesis in Helicobacter pylori infected stomach--role of growth factors, apoptosis and cyclooxygenases.
Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxygenase inhibitors.
Canine mammary tumors as a model for human disease.
Cannabidiolic acid dampens the expression of cyclooxygenase-2 in MDA-MB-231 breast cancer cells: Possible implication of the peroxisome proliferator-activated receptor ?/? abrogation.
Cannabidiolic acid-mediated selective down-regulation of c-fos in highly aggressive breast cancer MDA-MB-231 cells: possible involvement of its down-regulation in the abrogation of aggressiveness.
Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-?B pathways.
Cannabinoid receptor agonist WIN55212-2 reduces unpredictable mild stress-induced depressive behavior of rats.
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.
Cannabis smoke can be a major risk factor for early-age laryngeal cancer-a molecular signaling-based approach.
Canolol inhibits gastric tumors initiation and progression through COX-2/PGE2 pathway in K19-C2mE transgenic mice.
Capsaicin inhibits benzo(a)pyrene-induced lung carcinogenesis in an in vivo mouse model.
Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs.
Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer.
Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway.
Carcinogenic Effects of Whole Life Exposure to Inorganic Arsenic in CD1 Mice.
Cardamonin protects nucleus pulposus cells against IL-1?-induced inflammation and catabolism via Nrf2/NF-?B axis.
Cardioprotective effect of zingerone against oxidative stress, inflammation, and apoptosis induced by cisplatin or gamma radiation in rats.
Cardiopulmonary effects of tumor necrosis factor-alpha in the piglet: influence of cyclooxygenase inhibition.
Cardiospermum halicacabum ethanol extract inhibits LPS induced COX-2, TNF-alpha and iNOS expression, which is mediated by NF-kappaB regulation, in RAW264.7 cells.
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
Cardiovascular Risk Markers and Mechanisms in Targeting the COX Pathway for Colorectal Cancer Prevention.
Carica papaya leaf extract inhibits prostatitis-associated prostatic hyperplasia via the TRAF6/TAK1/MEK/NF-?B pathway.
Carnosic Acid Induces Anti-Inflammatory Effects in Paraquat-Treated SH-SY5Y Cells Through a Mechanism Involving a Crosstalk Between the Nrf2/HO-1 Axis and NF-?B.
Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats.
Carveol Attenuates Seizure Severity and Neuroinflammation in Pentylenetetrazole-Kindled Epileptic Rats by Regulating the Nrf2 Signaling Pathway.
Cassia sieberiana DC. leaves modulate LPS-induced inflammatory response in THP-1 cells and inhibit eicosanoid-metabolizing enzymes.
Catechin-7-O-?-D-glucopyranoside isolated from the seed of Phaseolus calcaratus Roxburgh ameliorates experimental colitis in rats.
Caveolin-1 facilitates cyclooxygenase-2 protein degradation.
Caveolin-1-mediated suppression of cyclooxygenase-2 via a {beta}-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression.
CCL20 Stimulates Proinflammatory Mediator Synthesis in Human Fibroblast-like Synoviocytes Through a MAP Kinase-dependent Process with Transcriptional and Posttranscriptional Control.
CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma.
CD200Fc attenuates inflammatory responses and maintains barrier function by suppressing NF-?B pathway in cigarette smoke extract induced endothelial cells.
CD200Fc Attenuates Retinal Glial Responses and RGCs Apoptosis After Optic Nerve Crush by Modulating CD200/CD200R1 Interaction.
CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.
CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease.
CD44(+) gastric cancer cells with stemness properties are chemoradioresistant and highly invasive.
CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.
Celastrol Ameliorates Ulcerative Colitis-Related Colorectal Cancer in Mice via Suppressing Inflammatory Responses and Epithelial-Mesenchymal Transition.
Celecoxib activates a novel mitochondrial apoptosis signaling pathway.
Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib.
Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP.
Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.
Celecoxib and melatonin in prevention of female rat mammary carcinogenesis.
Celecoxib and radiation therapy in non-small-cell lung cancer.
Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor.
Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.
Celecoxib can prevent tumor growth and distant metastasis in postoperative setting.
Celecoxib Conjugated Fluorescent Probe for Identification and Discrimination of Cyclooxygenase-2 Enzyme in Cancer Cells.
Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction.
Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway.
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.
Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production.
Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro.
Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP.
Celecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome function.
Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
Celecoxib for the prevention of colorectal adenomatous polyps.
Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study.
Celecoxib for the prevention of sporadic colorectal adenomas.
Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Celecoxib in Cancer Therapy and Prevention - Review.
Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells.
Celecoxib increased expression of 14-3-3sigma and induced apoptosis of glioma cells.
Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line.
Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression.
Celecoxib induces regression of putative preneoplastic lesions in rat liver.
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.
Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines.
Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer.
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Celecoxib inhibits ureteral contractility and prostanoid release.
Celecoxib Loaded In-Situ Provesicular Powder and Its In-Vitro Cytotoxic Effect for Cancer Therapy: Fabrication, Characterization, Optimization and Pharmacokinetic Evaluation.
Celecoxib mitigates cigarette smoke induced oxidative stress in mice.
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice.
Celecoxib plays a multiple role to peripheral blood lymphocytes and allografts in acute rejection in rats after cardiac transplantation.
Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation.
Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism.
Celecoxib promotes degranulation of CD8(+) T cells in HPV-induced lesions of K14-HPV16 transgenic mice.
Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression.
Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice.
Celecoxib reduces skin damage after radiation: selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor.
Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies.
Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism.
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells.
Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells.
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells.
Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defects.
Celecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell Lines.
Celecoxib upregulates ULBP-1 expression in lung cancer cells via the JNK/PI3K signaling pathway and increases susceptibility to natural killer cell cytotoxicity.
Celecoxib with chemotherapy in colorectal cancer.
Celecoxib, a COX-2 Selective Inhibitor, Induces Cell Cycle Arrest at the G2/M Phase in HeLa Cervical Cancer Cells.
Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells.
Celecoxib-Induced Self-Assembly of Smart Albumin-Doxorubicin Conjugate for Enhanced Cancer Therapy.
Celecoxib: a novel treatment for lung cancer.
Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
Cell cycle regulators and apoptosis-associated proteins in relation to proliferative activity and degree of apoptosis in HNPCC versus sporadic endometrial carcinoma.
Cell Intrinsic Role of Cox-2 in Pancreatic Cancer Development.
Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
Cell-cell contacts trigger programmed necrosis and induce cyclooxygenase-2 expression.
Cell-type-specific roles for COX-2 in UVB-induced skin cancer.
Cellular and molecular biology of prostacyclin synthase.
Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen.
Cellular localization of cyclo-oxygenase isozymes in Crohn's disease and colorectal cancer.
Cembranoid diterpenes from the soft coral Lobophytum crassum and their anti-inflammatory activities.
Centella asiatica Leaf Extract Protects Against Indomethacin-Induced Gastric Mucosal Injury in Rats.
Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogen-activated protein kinase signaling.
Cepharanthine mitigates pro-inflammatory cytokine response in lung injury induced by hemorrhagic shock/resuscitation in rats.
Ceramide-induced enhancement of secretory phospholipase A2 expression via generation of reactive oxygen species in tumor necrosis factor-alpha-stimulated mesangial cells.
Cerbera manghas methanol extract exerts anti-inflammatory activity by targeting c-Jun N-terminal kinase in the AP-1 pathway.
Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer.
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.
Changes in gene expression contribute to cancer prevention by COX inhibitors.
CHARACTERIZATION OF COVALENT ADDUCTS OF NUCLEOSIDES AND DNA FORMED BY REACTION WITH LEVUGLANDIN.
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.
Characterization of microsomal prostaglandin E synthase 1 inhibitors.
Characterization of prostaglandin endoperoxide synthase from a human cell line.
Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture.
Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers.
Characterization of the effects of antiangiogenic agents on tumor pathophysiology.
Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.
Chemical Composition of Pterospermum heterophyllum Root and its Anti-Arthritis Effect on Adjuvant-Induced Arthritis in Rats via Modulation of Inflammatory Responses.
Chemical Constituents Identified from Fruit Body of Cordyceps bassiana and Their Anti-Inflammatory Activity.
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.
Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats.
Chemoprevention in hereditary colorectal cancer syndromes.
Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Chemoprevention of cancer--focusing on clinical trials.
Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors.
Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis(methylene)selenocyanate, a novel organoselenium compound with low toxicity.
Chemoprevention of Colon Cancer by iNOS-Selective Inhibitors.
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells.
Chemoprevention of colon carcinogenesis by phenylethyl-3-methylcaffeate.
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.
Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor.
Chemoprevention of Colonic Polyps with Balsalazide: An Exploratory, Double-Blind, Placebo-Controlled Study.
Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back.
Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro.
Chemoprevention of colorectal cancer: dietary and pharmacologic approaches.
Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story).
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Chemoprevention of Esophageal Squamous Cell Carcinoma with Berries.
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Chemoprevention of gastric cancer by celecoxib in rats.
Chemoprevention of mammary carcinogenesis in female rats by rofecoxib.
Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Chemopreventive action of diclofenac in dimethybenzanthracene induced lung cancer in female Wistar rat.
Chemopreventive action of non-steroidal anti-inflammatory drugs on the inflammatory pathways in colon cancer.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Chemopreventive Activity of Red Ginseng Oil in a Mouse Model of Azoxymethane/Dextran Sulfate Sodium-Induced Inflammation-Associated Colon Carcinogenesis.
Chemopreventive activity of Tualang honey against oral squamous cell carcinoma-in vivo.
Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death.
Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells.
Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours.
Chemopreventive effect of celecoxib in gastric cancer.
Chemopreventive effect of farnesol on DMBA/TPA-induced skin tumorigenesis: involvement of inflammation, Ras-ERK pathway and apoptosis.
Chemopreventive effect of saikosaponin-d on diethylinitrosamine-induced hepatocarcinogenesis: involvement of CCAAT/enhancer binding protein ? and cyclooxygenase-2.
Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.
Chemopreventive effects of aloin against 1,2-dimethylhydrazine-induced preneoplastic lesions in the colon of Wistar rats.
Chemopreventive effects of aspirin at a glance.
Chemopreventive effects of dietary canola oil on colon cancer development.
Chemopreventive effects of dietary flaxseed on colon tumor development.
Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis.
Chemopreventive effects of resveratrol and resveratrol derivatives.
Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.
Chemopreventive effects of the standardized extract (DA-9601) of Artemisia asiatica on azoxymethane-initiated and dextran sulfate sodium-promoted mouse colon carcinogenesis.
Chemopreventive efficacy of green tea drinking against 1,2-dimethyl hydrazine-induced rat colon carcinogenesis.
Chemopreventive efficacy of juniper berry oil (Juniperus communis L.) on azoxymethane-induced colon carcinogenesis in rat.
Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.
Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun.
Chemoradiotherapy: emerging treatment improvement strategies.
Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.
Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor.
Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.
Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model.
Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer.
Chitooligosaccharides Prevents the Development of Colitis-Associated Colorectal Cancer by Modulating the Intestinal Microbiota and Mycobiota.
Chitosan and Curcumin Nanoformulations against Potential Cardiac Risks Associated with Hydroxyapatite Nanoparticles in Wistar Male Rats.
Chitosan inhibits prostaglandin E2 formation and cyclooxygenase-2 induction in lipopolysaccharide-treated RAW 264.7 macrophages.
Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice.
Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases.
Chlorinated cobalt alkyne complexes derived from acetylsalicylic acid as new specific antitumor agents.
Chlorinated Flavonoids Modulate the Inflammatory Process in Human Blood.
Cholesterol supplementation prevents necrosis and inflammation but enhances fibrosis in alcoholic liver disease in the rat.
Choline phospholipid metabolites of human vascular endothelial cells altered by cyclooxygenase inhibition, growth factor depletion, and paracrine factors secreted by cancer cells.
Chondrocyte-derived extracellular matrix suppresses pathogenesis of human pterygium epithelial cells by blocking the NF-?B signaling pathways.
Chondroitin sulfate inhibits lipopolysaccharide-induced inflammation in rat astrocytes by preventing nuclear factor kappa B activation.
Chromene suppresses the activation of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 cells.
Chronic Arsenic Exposure and Angiogenesis in Human Bronchial Epithelial Cells via the ROS/miR-199a-5p/HIF-1?/COX-2 Pathway.
Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis.
Chronic depletion of gonadal testosterone leads to blood-brain barrier dysfunction and inflammation in male mice.
Chronic Exposure of Renal Stem Cells to Inorganic Arsenic Induces a Cancer Phenotype.
Chronic inflammation and pathogenesis of GI and pancreatic cancers.
Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.
Chronic obstructive pulmonary disease: effects beyond the lungs.
Chronic psychosocial stress increases the risk for inflammation-related colon carcinogenesis in male mice.
Chronic unpredictable stress-induced reproductive deficits were prevented by probiotics.
Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.
Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis.
Chrysoeriol ameliorates TPA-induced acute skin inflammation in mice and inhibits NF-?B and STAT3 pathways.
Chrysophyllum albidum fruit peel attenuates nociceptive pain and inflammatory response in rodents by inhibition of pro-inflammatory cytokines and COX-2 expression through suppression of NF-?B activation.
Chunghyuldan attenuates brain microglial inflammatory response.
Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: How hot is the link?
Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer.
Cigarette smoking, cyclooxygenase-2 pathway and cancer.
Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
Ciliary neurotrophic factor and interleukin-6 differentially activate microglia.
Cinnamaldehyde derivatives inhibit degranulation and inflammatory mediator production in rat basophilic leukemia cells.
Cinnamon Extract and Probiotic Supplementation Alleviate Copper-Induced Nephrotoxicity via Modulating Oxidative Stress, Inflammation, and Apoptosis in Broiler Chickens.
Cinobufocini inhibits NF-?B and COX-2 activation induced by TNF-? in lung adenocarcinoma cells.
circRNA_0084043 contributes to the progression of diabetic retinopathy via sponging miR-140-3p and inducing TGFA gene expression in retinal pigment epithelial cells.
Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent.
Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma.
cis-9,trans-11-conjugated linoleic acid down-regulates phorbol ester-induced NF-kappaB activation and subsequent COX-2 expression in hairless mouse skin by targeting IkappaB kinase and PI3K-Akt.
Citrus aurantium L. and Its Flavonoids Regulate TNBS-Induced Inflammatory Bowel Disease through Anti-Inflammation and Suppressing Isolated Jejunum Contraction.
Clarithromycin Attenuates Radiation-Induced Lung Injury in Mice.
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression.
Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
Cleavage and polyadenylation specific factor 4 targets NF-?B/cyclooxygenase-2 signaling to promote lung cancer growth and progression.
Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining.
Clinical and prognosis relevance of COX-2 expression in Tunisian patients with primary gastric adenocarcinoma.
Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents.
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.
Clinical evaluations of a new ovarian cancer marker, COX-1.
Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours.
Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer.
Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers.
Clinical relevance of cyclo-oxygenase 2 and peroxisome proliferator activated receptor ? in eyelid sebaceous gland carcinoma.
Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue.
Clinical significance of circulating tumor cells and their expression of cyclooxygenase-2 in patients with nasopharyngeal carcinoma.
Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues.
Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC).
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma.
Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.
Clinical significance of prostaglandin E synthase expression in gastric cancer tissue.
Clinical significance of the tumor microenvironment in non-small cell lung cancer.
Clinical significance of vasculogenic mimicry in human gliomas.
Clinical significance of VEGFR-2 and (18)F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Clinical value of cyclooxygenase-2 expression in human breast carcinoma.
Clinical value of detecting IQGAP3, B7-H4 and cyclooxygenase-2 in the diagnosis and prognostic evaluation of colorectal cancer.
Clinical value of intratumoral metabolic heterogeneity in [18F]FDG PET/CT for prediction of recurrence in patients with locally advanced colorectal cancer.
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma.
Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma.
Clinicopathologic significance of expression of cyclooxygenase-2 in human esophageal squamous cell carcinoma.
Clinicopathological and biological features of DNA tetraploid colorectal cancers.
Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings.
Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.
Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis.
Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma.
Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma.
Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma.
Clinicopathological significance of cyclooxygenase-2 expression in hypopharyngeal squamous cell carcinoma.
Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma.
Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer.
Cloning and expression of TNF-alpha, IL-1beta and COX-2 in an anadromous and landlocked strain of Atlantic salmon (Salmo salar L.) during the smolting period.
Cloning of Mongolian gerbil cDNAs encoding inflammatory proteins, and their expression in glandular stomach during H. pylori infection.
Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice.
Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model.
Co-administration of 5FU and propolis on AOM/DSS induced colorectal cancer in BALB-c mice.
Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.
Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas.
Co-Expression of Cox-2, C-Met and beta-catenin in Cells Forming Invasive front of Gallbladder Cancer.
Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.
Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts.
Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer.
Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.
Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition.
Cocarcinogenic effect of capsaicin involves activation of EGFR signaling but not TRPV1.
Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase kinase.
Coenzyme Q10 attenuated DMH-induced precancerous lesions in SD rats.
Coexpression of COX-2 and iNOS in Angiogenesis of Superficial Esophageal Squamous Cell Carcinoma.
Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Coexpression of cyclooxygenase-2 and vascular endothelial growth factor in gastrointestinal stromal tumor: possible relations to pathological parameters and clinical behavior.
Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases.
Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis.
Coffee, but Neither Decaffeinated Coffee nor Caffeine, Elicits Chemoprotection Against a Direct Carcinogen in the Colon of Wistar Rats.
Coix Seed Extract, a Commonly Used Treatment for Cancer in China, Inhibits NFkappaB and Protein Kinase C Signaling.
Coixol Suppresses NF-?B, MAPK Pathways and NLRP3 Inflammasome Activation in Lipopolysaccharide-Induced RAW 264.7 Cells.
Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor.
Colon cancer chemoprevention with ginseng and other botanicals.
Colon cancer proliferating desulfosinigrin in wasabi (Wasabia japonica).
Colon cancer: a civilization disorder.
Colon cancer: genomics and apoptotic events.
Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice.
Colon Macrophages Polarized by Commensal Bacteria Cause Colitis and Cancer through the Bystander Effect.
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation.
Colonic luminal contents induce cyclooxygenase 2 transcription in human colon carcinoma cells.
Color Doppler velocimetry and three-dimensional color power angiography of cervical carcinoma.
Colorectal cancer and non-steroidal anti-inflammatory drugs.
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.
Colostrum supplementation with n-3 fatty acids does not alter calf outcome on a healthy commercial farm.
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo.
Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein.
Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways.
Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
Combination of celecoxib (Celebrex(®)) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.
Combination of Celecoxib and Doxorubicin Increases the Growth Inhibition and Apoptosis in Acute Myeloid Leukemia Cells.
Combination of celecoxib and PD184161 exerts synergistic inhibitory effects on gallbladder cancer cell proliferation.
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Combination of cyclooxygenase-2 inhibitor and doxorubicin increases the growth inhibition and apoptosis in human hepatocellular carcinoma cells.
Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Combination of magnetic targeting with synergistic inhibition of NF-?B and glutathione via micellar drug nanomedicine enhances its anti-tumor efficacy.
Combination of Pan-HDAC Inhibitor and COX-2 Inhibitor Produces Synergistic Anticancer Effects in Human Salivary Adenoid Cystic Cancer Cells.
Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Combination of selenium and green tea improves the efficacy of chemoprevention in a rat colorectal cancer model by modulating genetic and epigenetic biomarkers.
Combination of the anthocyanidins malvidin and peonidin attenuates lipopolysaccharide-mediated inflammatory gene expression in primary human adipocytes.
Combination of white tea and peppermint demonstrated synergistic antibacterial and anti-inflammatory activities.
Combination therapy of chitosan, gynostemma, and motherwort alleviates the progression of experimental rat chronic renal failure by inhibiting STAT1 activation.
Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway.
Combinational Treatment Effect of Tetrahydrocurcumin and Celecoxib on Cervical Cancer Cell-Induced Tumor Growth and Tumor Angiogenesis in Nude Mice.
Combined activity of COX-1 and COX-2 is increased in non-neoplastic colonic mucosa from colorectal neoplasia patients.
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma.
Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement.
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.
Combined Therapy with Rheum tanguticum Polysaccharide and Low-dose 5-ASA Ameliorates TNBS-Induced Colitis in Rats by Suppression of NF-?B.
Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.
Combined Treatment with Hyaluronic Acid and Mesalamine Protects Rats from Inflammatory Bowel Disease Induced by Intracolonic Administration of Trinitrobenzenesulfonic Acid.
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.
Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice.
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Commentary: targeting colorectal cancer through molecular biology.
Communication between human macrophages and epithelial cancer cell lines dictates lipid mediator biosynthesis.
Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.
Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Comparative Analysis of Peritoneum and Tumor Eicosanoids and Pathways in Advanced Ovarian Cancer.
Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations.
Comparative effect of horse gram and black gram on inflammatory mediators and antioxidant status.
Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver.
Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer.
Comparative study of cytotoxicity, tumor necrosis factor, and prostaglandin release after stimulation of rat Kupffer cells, murine Kupffer cells, and murine inflammatory liver macrophages.
Comparative study on hepatoprotection of pine nut (Pinus koraiensis Sieb. et Zucc.) polysaccharide against different types of chemical-induced liver injury models in vivo.
Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results.
Comparison of anti-inflammatory effects of berberine, and its natural oxidative and reduced derivatives from Rhizoma Coptidis in vitro and in vivo.
Comparison of caspase genes for the induction of apoptosis following gene delivery.
Comparison of cyclo-oxygenase 2 expression in colorectal serrated adenomas to expression in tubular adenomas and hyperplastic polyps.
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus.
Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis.
Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue.
Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.
Comparison of Photoacoustically Derived Hemoglobin and Oxygenation Measurements with Contrast-Enhanced Ultrasound Estimated Vascularity and Immunohistochemical Staining in a Breast Cancer Model.
Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.
Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells.
Comparison on the anti-inflammatory effect of Cortex Phellodendri Chinensis and Cortex Phellodendri Amurensis in 12-O-tetradecanoyl-phorbol-13-acetate-induced ear edema in mice.
Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells.
Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells.
Complete remission of pancreatic head desmoid tumor treated by COX-2 inhibitor-a case report.
Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma.
Complexity of COX-2 gene regulation.
Composition and Mechanism of Antitumor Effects of Hericium erinaceus Mushroom Extracts in Tumor-Bearing Mice.
Compositions for treatment of cancer and inflammation.
Computational and pharmacological investigation of novel 1,5-diaryl-1,4-pentadien-3-one derivatives for analgesic, anti-inflammatory and anticancer potential.
Computational and Preclinical Evidence of Anti-ischemic Properties of L-Carnitine-Rich Supplement via Stimulation of Anti-inflammatory and Antioxidant Events in Testicular Torsed Rats.
Computational pharmacology and bioinformatics to explore the potential mechanism of Schisandra against atherosclerosis.
Concanavalin-A triggers inflammatory response through JAK/STAT3 signalling and modulates MT1-MMP regulation of COX-2 in mesenchymal stromal cells.
Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models.
Concomitant consumption of lycopene and fish oil inhibits tumor growth and progression in a mouse xenograft model of colon cancer.
Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome.
Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility.
Concomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: A pharmacodynamics perspective.
Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.
Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading.
Concurrent Expression of Cyclo-oxygenase-2 and Epidermal Growth Factor Receptor in Canine Malignant Mammary Tumours.
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice.
Conditioned media from adipose-tissue-derived mesenchymal stem cells downregulate degradative mediators induced by interleukin-1? in osteoarthritic chondrocytes.
Conditioned medium from human gingival mesenchymal stem cells protects motor-neuron-like NSC-34 cells against scratch-injury-induced cell death.
Conjugated linoleic acid (CLA) modulates prostaglandin E2 (PGE2) signaling in canine mammary cells.
Conjugated linoleic acid attenuates 2,4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-?B signaling.
Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPAR gamma-dependent mechanism.
Conjugated polyhydroxybenzene derivatives block tumor necrosis factor-alpha-mediated nuclear factor-kappaB activation and cyclooxygenase-2 gene transcription by targeting IkappaB kinase activity.
Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.
Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.
Connecting COX-2 and Wnt in cancer.
Connexin 43 plays an important role in the transformation of cholangiocytes with Clonochis sinensis excretory-secretory protein and N-nitrosodimethylamine.
Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts.
Constituents of Asparagus officinalis evaluated for inhibitory activity against cyclooxygenase-2.
Constituents of the stems of Macrococculus pomiferus and their inhibitory activities against cyclooxygenases-1 and -2.
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Constitutive TLR4 signalling in intestinal epithelium reduces tumor load by increasing apoptosis in APC(Min/+) mice.
Contribution of membrane-associated prostaglandin E2 synthase to bone resorption.
Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan.
Convergence of genetic, nutritional and inflammatory factors in gastrointestinal cancers.
Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche.
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.
Cooperative Enhancement of Radiosensitivity After Combined Treatment of 17-(Allylamino)-17-Demethoxygeldanamycin and Celecoxib in Human Lung and Colon Cancer Cell Lines.
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
Coordinate up-regulation of low-density lipoprotein receptor and cyclo-oxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies.
Coordinated upregulation of COX-2 and NF-kappaB is a steady feature of laryngeal carcinogenesis.
Copper conjugates of nimesulide Schiff bases targeting VEGF, COX and Bcl-2 in pancreatic cancer cells.
Cordycepin inhibits lipopolysaccharide-induced cell migration and invasion in human colorectal carcinoma HCT-116 cells through down-regulation of prostaglandin E2 receptor EP4.
Cordyceps militaris Improves Chronic Kidney Disease by Affecting TLR4/NF-?B Redox Signaling Pathway.
Core-Shell Distinct Nanodrug Showing On-Demand Sequential Drug Release To Act on Multiple Cell Types for Synergistic Anticancer Therapy.
Coriandrum sativum attenuates microglia mediated neuroinflammation and MPTP-induced behavioral and oxidative changes in Parkinson's disease mouse model.
Correction to: Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors.
Correlation among 16 biological factors [p53, p21(waf1), MIB-1 (Ki-67), p16(INK4A), cyclin D1, E-cadherin, Bcl-2, TNF-?, NF-?B, TGF-?, MMP-7, COX-2, EGFR, HER2/neu, ER, and HIF-1?] and clinical outcomes following curative chemoradiation therapy in 10 patients with esophageal squamous cell carcinoma.
Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer.
Correlation analysis of c-myc, p21(WAF/CIP1), p53, C-erbB-2 and COX-2 proteins in esophageal squamous cell carcinoma.
Correlation between angiogenic/inflammatory mediators in Wister rat model of liver dysplasia.
Correlation Between Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression in Canine and Feline Squamous Cell Carcinomas.
Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.
Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.
Correlation between cyclooxygenase-2, proliferative activity, and mucin phenotype in human advanced gastric cancer.
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis.
Correlation Between Inducible Nitric Oxide Synthase and Cyclooxygenase-2 Expression in Human Colorectal Adenocarcinoma: A Cross-Sectional Study.
Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas.
Correlation between Spiral CT Preoperative Staging of Pancreatic Cancer and PTEN and COX-2 Expression.
Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma.
Correlation of 15-prostagladin dehydrogenase expression with clinicopathological factors and survival rate in gastric adenocarcinoma.
Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.
Correlation of BRAF Variant V595E, Breed, Histological Grade and Cyclooxygenase-2 Expression in Canine Transitional Cell Carcinomas.
Correlation of COX- 2 Expression in Colorectal Carcinoma with Clinicopathological Features.
Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival.
Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis.
Correlation of COX-2 expression in stromal cells with high stage, high grade, and poor prognosis in urothelial carcinoma of upper urinary tracts.
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells.
Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
Correlative expression of cyclooxygenase-1 (cox-1) and human epidermal growth factor receptor type-2 (her-2) in endometrial cancer.
Correspondence re: M. Kondo et al., Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res., 5: 4005-4012, 1999.
Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003;63:5239-42.
Cortisol inhibits NF-?B and MAPK pathways in LPS activated bovine endometrial epithelial cells.
Corynoline Isolated from Corydalis bungeana Turcz. Exhibits Anti-Inflammatory Effects via Modulation of Nfr2 and MAPKs.
Costunolide inhibits proinflammatory cytokines and iNOS in activated murine BV2 microglia.
Coumarin sulfonamides derivatives as potent and selective COX-2 inhibitors with efficacy in suppressing cancer proliferation and metastasis.
Coumarins from Angelica decursiva inhibit lipopolysaccharide-induced nitrite oxide production in RAW 264.7 cells.
Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2.
Coupling of COX-1 to mPGES1 for prostaglandin E2 biosynthesis in the murine mammary gland.
COX and LOX eicosanoids modulate platelet activation and procoagulation induced by two murine cancer cells.
COX inhibitors Indomethacin and Sulindac derivatives as antiproliferative agents: Synthesis, biological evaluation, and mechanism investigation.
COX inhibitors: a patent review (2011 - 2014).
COX selectivity and animal models for colon cancer.
COX-1 and -2 expressions in sex-related organs of neonatally estrogen-treated rats and in activated and nonactivated macrophage RAW264.7 cells with phytoestrogen.
COX-1 and COX-2 Expression in Canine Cutaneous, Oral and Ocular Melanocytic Tumours.
COX-1 and COX-2 expression in osteoid osteomas.
COX-1 and COX-2 expression in stage I and II invasive cervical carcinoma: relationship to disease relapse and long-term survival.
COX-1 and COX-2 tissue expression: implications and predictions.
COX-1 Inhibitors: Beyond Structure Toward Therapy.
COX-2 (PTGS2) gene methylation in epithelial, subepithelial lymphocyte and stromal tissue compartments in a spectrum of esophageal squamous neoplasia.
COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer.
COX-2 and advanced digestive cancer phenotypes.
COX-2 and c-kit expression in canine gliomas.
Cox-2 and cancer chemoprevention: picking up the pieces.
COX-2 and cancer: a new approach to an old problem.
COX-2 and colon cancer.
COX-2 and colon cancer: Potential targets for chemoprevention.
COX-2 and colon cancer: potential targets for chemoprevention.
COX-2 and gastric cancer: More on inflammation and neoplasia.
Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer.
COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer.
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
COX-2 and p53 in human sinonasal cancer: COX-2 expression is associated with adenocarcinoma histology and wood-dust exposure.
COX-2 and PGE2-dependent immunomodulation in breast cancer.
COX-2 and PPAR-? confer cannabidiol-induced apoptosis of human lung cancer cells.
COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.
COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line.
COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma.
COX-2 as a target for cancer chemotherapy.
COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells.
COX-2 correlates with F-box protein, Skp2 expression and prognosis in human gastric carcinoma.
COX-2 dependent regulation of mechanotransduction in human breast cancer cells.
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
COX-2 expression and inflammatory effects by diesel exhaust particles in vitro and in vivo.
COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy.
COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128.
COX-2 expression and tumor angiogenesis in colorectal cancer.
COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study.
COX-2 expression correlates with microvessel density in non-melanoma skin cancer from renal transplant recipients and immunocompetent individuals.
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma.
COX-2 expression does not correlate with microvessel density in breast cancer.
COX-2 expression during early lung squamous cell carcinoma oncogenesis.
COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables.
COX-2 expression in B lymphocytes: Links to vaccines, inflammation and malignancy.
COX-2 Expression in Breast Carcinoma with Correlation to Clinicopathological Parameters
COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers.
COX-2 expression in canine mammary carcinomas: correlation with angiogenesis (or microvessel density) and overall survival.
COX-2 expression in canine normal and neoplastic mammary gland.
COX-2 expression in chondrosarcoma: a role for celecoxib treatment?
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
COX-2 expression in dysplasia of the head and neck: correlation with elF4E.
COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival.
COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?
COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome.
COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification.
COX-2 expression in malignant melanoma: a novel prognostic marker?
COX-2 expression in nonepithelial ovarian malignancies.
Cox-2 expression in ovarian malignancies: a review of the clinical aspects.
COX-2 expression in pseudomyxoma peritonei.
COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome.
COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis.
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.
COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer.
Cox-2 expression on tissue microarray of breast cancer.
COX-2 expression pattern is related to ovarian cancer differentiation and prognosis, but is not consistent with new model of pathogenesis.
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin.
COX-2 Forms Regulatory Loop with YAP to Promote Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells.
Cox-2 gene expression in chemically induced skin papillomas cannot predict subsequent tumor fate.
COX-2 gene polymorphisms and protein expression in renomedullary interstitial cell tumors.
COX-2 gene promoter haplotypes and prostate cancer risk.
Cox-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity.
COX-2 in cancer: Gordian knot or Achilles heel?
COX-2 in large bowel cancer: a one-sided story.
COX-2 in murine intestinal tumors.
Cox-2 in non-small cell lung cancer: A meta-analysis.
COX-2 in Radiotherapy; a potential target for radioprotection and radiosensitization.
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms.
COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
COX-2 induces IL-11 production in human breast cancer cells.
COX-2 induces lytic reactivation of EBV through PGE2 by modulating the EP receptor signaling pathway.
COX-2 induction by heparanase in the progression of breast cancer.
COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator.
COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.
COX-2 inhibition and cancer: experimental findings and clinical correlates.
COX-2 inhibition and lung cancer.
COX-2 inhibition and prevention of cancer.
COX-2 inhibition as a tool to treat and prevent colorectal cancer.
COX-2 inhibition attenuates lung injury induced by skeletal muscle ischemia reperfusion in rats.
COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.
COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.
COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
COX-2 Inhibition Improves Immune System Homeostasis and Decreases Liver Damage in Septic Rats.
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?
COX-2 inhibition in clinical cancer prevention.
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
COX-2 inhibition in upper aerodigestive tract tumors.
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro.
COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models.
COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.
COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer.
COX-2 inhibitor NS-398 suppresses doxorubicin-induced p53 accumulation through inhibition of ROS-mediated Jnk activation.
COX-2 inhibitor prevents tumor induced down regulation of classical DC lineage specific transcription factor Zbtb46 resulting in immunocompetent DC and decreased tumor burden.
COX-2 inhibitor, NS398, enhances Fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines.
COX-2 inhibitors act as radiosensitizer in tumor treatment.
COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy: reports from a symposium held in conjunction with the Radiation Therapy Oncology Group June 2001 Meeting.
COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.
COX-2 inhibitors and their role in gynecology.
COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins.
COX-2 inhibitors as cancer treatment: will they be the new warfarin or trastuzumab?
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
COX-2 inhibitors as radiosensitizing agents for cancer therapy.
COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells.
COX-2 inhibitors for the prevention of breast cancer.
COX-2 inhibitors in cancer treatment and prevention, a recent development.
Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells.
COX-2 Inhibitors Modulate IL-12 Signaling Through JAK-STAT Pathway Leading to Th1 Response in Experimental Allergic Encephalomyelitis.
COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
COX-2 inhibitors still eyed for cancer prevention.
COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites.
COX-2 inhibitors. A new class of antiangiogenic agents.
COX-2 inhibitors: cancer prevention or cardiovascular risk?
COX-2 inhibitors: cancer trials test new uses for pain drug.
COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells.
COX-2 involvement in breast cancer metastasis to bone.
COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer.
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness.
COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67.
Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
COX-2 Limits Prostanoid Production in Activated HUVECs and Is a Source of PGH2 for Transcellular Metabolism to PGE2 by Tumor Cells.
COX-2 localization within plasma membrane caveolae-like structures in human lobular intraepithelial neoplasia of the breast.
COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer.
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
COX-2 modulates mammary tumor progression in response to collagen density.
COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID.
COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease.
COX-2 mRNA is increased in oesophageal mucosal cells by a proton pump inhibitor.
COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer.
COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.
COX-2 overexpression as a biomarker of early cervical carcinogenesis: A pilot study.
COX-2 overexpression in canine tumors: potential therapeutic targets in oncology.
COX-2 Overexpression in Schneiderian Papillomas.
COX-2 overexpression increases malignant potential of human glioma cells through Id1.
COX-2 overexpression increases motility and invasion of breast cancer cells.
COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention.
COX-2 polymorphisms and the risk for head and neck cancer in white patients.
COX-2 polymorphisms in patients with familial adenomatous polyposis.
COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men.
Cox-2 promotes chromogranin A expression and bioactivity: evidence for a prostaglandin E2-dependent mechanism and the involvement of a proximal cyclic adenosine 5'-monophosphate-responsive element.
COX-2 promotes mammary adipose tissue inflammation, local estrogen biosynthesis, and carcinogenesis in high-sugar/fat diet treated mice.
Cox-2 promotes mesenchymal stem cells differentiation into cardiocytes by activating JNK and ERK pathway.
COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.
COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells.
COX-2 regulates E-cadherin expression through the NF-?B/Snail signaling pathway in gastric cancer.
COX-2 signaling and cancer: new players in old arena.
COX-2 Signaling in the Tumor Microenvironment.
COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro.
COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells.
COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates.
COX-2 targeting in cancer: a new beginning?
COX-2 upregulation in thymomas and thymic carcinomas.
COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Cox-2, EGFR, and ERBB-2 Expression in Cervical Intraepithelial Neoplasia and Cervical Cancer Using an Automated Imaging System.
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review).
COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil.
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
COX-2, VEGF and tumour angiogenesis.
COX-2-765G>C Polymorphism Increases the Risk of Cancer: A Meta-Analysis.
COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF).
COX-2-dependent stabilization of survivin in non-small cell lung cancer.
COX-2-mediated Inflammation in Fat Is Crucial for Obesity-linked Insulin Resistance and Fatty Liver.
COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.
COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.
COX-2-PGE2-EPs in gynecological cancers.
COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy.
COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.
COX-2: a molecular target for colorectal cancer prevention.
COX-2: a protein with an active role in gynecological cancers.
COX-2: a target for colon cancer prevention.
COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention.
COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin down-regulation.
COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib.
COX2 expression is associated with preoperative tumor volume but not with volumetric tumor growth in vestibular schwannoma.
COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake.
COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma.
COX2 regulation of breast cancer bone metastasis.
CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer.
Crocetin downregulates the proinflammatory cytokines in methylcholanthrene-induced rodent tumor model and inhibits COX-2 expression in cervical cancer cells.
Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells.
Cross-talk between SIM2s and NF?B regulates cyclooxygenase 2 expression in breast cancer.
Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis.
Crosstalk between possible cytostatic and antiinflammatory potential of ketoprofen in the treatment of culture of colon and cervix cancer cell lines.
Crosstalk with Inflammatory Macrophages Shapes the Regulatory Properties of Multipotent Adult Progenitor Cells.
Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression.
Cryptotanshinone protects dextran sulfate sodium-induced experimental ulcerative colitis in mice by inhibiting intestinal inflammation.
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
CT20126, a novel immunosuppressant, prevents collagen-induced arthritis through the down-regulation of inflammatory gene expression by inhibiting NF-kappaB activation.
CTB glycoprotein (75kDa) inhibits IgE releasing, TNF-? and IL-6 expressed by bisphenol A in vivo and in vitro.
CTGF inhibits cell motility and COX-2 expression in oral cancer cells.
CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Cudratricusxanthone A Inhibits Lipid Accumulation and Expression of Inducible Nitric Oxide Synthase in 3T3-L1 Preadipocytes.
Curative effects of hydrogen sulfide against acetaminophen-induced hepatotoxicity in mice.
Curcuma longa and Curcuma mangga leaves exhibit functional food property.
Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats.
Curcumin attenuates radiation-induced inflammation and fibrosis in rat lungs.
Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines.
Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1.
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells.
Curcumin exerts antidifferentiation effect through AMPKalpha-PPAR-gamma in 3T3-L1 adipocytes and antiproliferatory effect through AMPKalpha-COX-2 in cancer cells.
Curcumin impairs tumor suppressor p53 function in colon cancer cells.
Curcumin improves prostanoid ratio in diabetic mesenteric arteries associated with cyclooxygenase-2 and NF-?B suppression.
Curcumin induces apoptosis and inhibits growth of orthotopic human non-small cell lung cancer xenografts.
Curcumin inhibits APOE4-induced injury by activating peroxisome proliferator-activated receptor-? (PPAR?) in SH-SY5Y cells.
Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in MCF10A human breast epithelial cells.
Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues.
Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition.
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.
Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.
Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer.
Curcumin-induced cell cycle arrest and apoptosis in human acute promyelocytic leukemia HL-60 cells via MMP changes and caspase-3 activation.
Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.
Curcumin: from food spice to cancer prevention.
Current application of selective COX-2 inhibitors in cancer prevention and treatment.
Current directions for COX-2 inhibition in breast cancer.
Current status of COX-2 inhibitors.
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases.
CXCR-4 and COX-2 Expression in Basal Cell Carcinomas and Well-Differentiated Squamous Cell Carcinomas of the Skin; Their Relationship with Tumor Invasiveness and Histological Subtype.
CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development.
Cyanidin-3-glucoside inhibits UVB-induced oxidative damage and inflammation by regulating MAP kinase and NF-?B signaling pathways in SKH-1 hairless mice skin.
Cyanidin-3-glucoside suppresses B[a]PDE-induced cyclooxygenase-2 expression by directly inhibiting Fyn kinase activity.
Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity.
Cyanidin-3-O-glucoside attenuates acute lung injury in sepsis rats.
Cyclic compressive loading on 3D tissue of human synovial fibroblasts upregulates prostaglandin E2 via COX-2 production without IL-1? and TNF-?.
Cycling hypoxia induces a specific amplified inflammatory phenotype in endothelial cells and enhances tumor-promoting inflammation in vivo.
Cyclo-oxygenase 2 expression in laryngeal squamous cell carcinoma and its clinical correlates.
Cyclo-oxygenase 2 inhibition in colorectal cancer therapy.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance.
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.
Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells.
Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.
Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance.
Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer.
Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?
Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.
Cyclo-oxygenase-2 expression in oral squamous cell carcinoma.
Cyclo-oxygenase-2 expression in photon-radiated and non-radiated uveal melanomas.
Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue.
Cyclo-oxygenase-2 expression is associated with mean standardised uptake value on 18F-Fluorodeoxyglucose positron emission tomography in oesophageal adenocarcinoma.
Cyclo-oxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma.
Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis.
Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis.
Cyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions-in vitro study.
Cyclooxigenase-2 Levels are Increased in the Lung Tissue and Bronchial Tumors of Patients with Chronic Obstructive Pulmonary Disease.
Cyclooxygeanse-2 promotes metastasis in osteosarcoma.
Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro.
Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways.
Cyclooxygenase (COX)-1 Activity Precedes the COX-2 Induction in Abeta-Induced Neuroinflammation.
Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression.
Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice.
Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer.
Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer.
Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians.
Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer.
Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency.
Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications.
Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging.
Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy.
Cyclooxygenase 2 expression in serous tumors of the ovary.
Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice.
Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.
Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice.
Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells.
Cyclooxygenase 2 promoter-based replication-selective adenoviral vector for hypopharyngeal cancer.
Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-?B Pathway.
Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity.
Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.
Cyclooxygenase 2-mediated apoptotic and inflammatory responses in photodynamic therapy treated breast adenocarcinoma cells and xenografts.
Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.
Cyclooxygenase 2: a molecular target for cancer prevention and treatment.
Cyclooxygenase 2: from inflammation to carcinogenesis.
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Cyclooxygenase and CD147 expression in oral squamous cell carcinoma patient samples and cell lines.
Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.
Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Cyclooxygenase and lipoxygenase inhibitors in cancer therapy.
Cyclooxygenase and nitric oxide synthase pathways mediate the respiratory effects of TNF-? in rats.
Cyclooxygenase and prostaglandin in cancer.
Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?
Cyclooxygenase as a target in lung cancer.
Cyclooxygenase enzyme and PGE2 expression in patients with functional and non-functional pituitary adenomas.
Cyclooxygenase expression in the gallbladder.
Cyclooxygenase expression is not required for release of arachidonic acid from cells by some nonsteroidal anti-inflammatory drugs and cancer preventive agents.
Cyclooxygenase in biology and disease.
Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis.
Cyclooxygenase in the treatment of glioma: its complex role in signal transduction.
Cyclooxygenase inhibition as a target for prevention of tobacco-related cancers.
Cyclooxygenase inhibition attenuates brain angiogenesis and independently decreases mouse survival under hypoxia.
Cyclooxygenase inhibition in cancer prevention and treatment.
Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice.
Cyclooxygenase inhibition in human monocytes increases endotoxin-induced TNF alpha without affecting cyclooxygenase-2 expression.
Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.
Cyclooxygenase Inhibition Limits Blood-Brain Barrier Disruption following Intracerebral Injection of Tumor Necrosis Factor-{alpha} in the Rat.
Cyclooxygenase inhibition with ibuprofen: effect on biodistribution of perflubron emulsions in mice with mammary tumor.
Cyclooxygenase inhibitor ketorolac or mast cell stabilizers: immunologic challenges in cancer therapy.
Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation.
Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle.
Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.
Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma.
Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock.
Cyclooxygenase Inhibitors in Epithelial Ovarian Cancer Treatment.
Cyclooxygenase inhibitors induce apoptosis in oral cavity cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene.
Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene.
Cyclooxygenase Inhibitors Induce Colon Cancer Cell Apoptosis Via PPARdelta --> 14-3-3epsilon Pathway.
Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein.
Cyclooxygenase inhibitors modulate NK activities that control metastatic disease.
Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.
Cyclooxygenase inhibitors prevent the induction of tolerance to the toxic effects of tumor necrosis factor.
Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.
Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Cyclooxygenase inhibitors: drugs for cancer prevention.
Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy.
Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma.
Cyclooxygenase isozymes in oral squamous cell carcinoma:a real-time RT-PCR study with clinic pathological correlations.
Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.
Cyclooxygenase knockout mice: models for elucidating isoform-specific functions.
Cyclooxygenase, cancer stem cells and DNA methylation play important roles in colorectal carcinogenesis.
Cyclooxygenase, lipoxygenase and tumor angiogenesis.
Cyclooxygenase- and lipoxygenase-mediated DNA damage.
Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature.
Cyclooxygenase-1 and -2 expression in urothelial carcinomas of the urinary bladder in cows.
Cyclooxygenase-1 and -2 isoenzymes.
Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.
Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium.
Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.
Cyclooxygenase-1 deletion enhances apoptosis but does not protect against ultraviolet light-induced tumors.
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.
Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer.
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.
Cyclooxygenase-1-dependent prostaglandin synthesis modulates tumor necrosis factor-alpha secretion in lipopolysaccharide-challenged murine resident peritoneal macrophages.
Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2'-Des-methyl-sulindac Sulfide Scaffold.
Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.
Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.
Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.
Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis.
Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse.
Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma.
Cyclooxygenase-2 (cox-2) expression and angiogenesis in intracranial ependymomas.
Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme.
Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas.
Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions.
Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.
Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade.
Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery.
Cyclooxygenase-2 (Cox-2) expression in lymphomas.
Cyclooxygenase-2 (COX-2) expression in solid pseudopapillary tumor of the pancreas: a pilot study.
Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.
Cyclooxygenase-2 (COX-2) immunostaining does not correlate with the degree of vulvar neoplasia.
Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells.
Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.
Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer.
Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers.
Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors.
Cyclooxygenase-2 (COX-2) overexpression in meningiomas: real time PCR and immunohistochemistry.
Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer.
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Cyclooxygenase-2 (COX-2)--a therapeutic target in liver cancer?
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer.
Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
Cyclooxygenase-2 (COX2) expression in adenocarcinoma surpasses that of squamous cell carcinoma in the uterine cervix.
Cyclooxygenase-2 - An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma- An Immunohistochemical Study.
Cyclooxygenase-2 -1195G>A (rs689466) polymorphism and cancer susceptibility: an updated meta-analysis involving 50,672 subjects.
Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer.
Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.
Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis.
Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy.
Cyclooxygenase-2 and Angiogenesis in Prostate Cancer.
Cyclooxygenase-2 and B-cell lymphoma-2 expression in cystitis glandularis and primary vesicle adenocarcinoma.
Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays.
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.
Cyclooxygenase-2 and carcinogenesis.
Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection.
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.
Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets.
Cyclooxygenase-2 and gastric cancer.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and gastrointestinal cancer.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.
Cyclooxygenase-2 and its role in colorectal cancer development.
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
Cyclooxygenase-2 and prostaglandins in articular tissues.
Cyclooxygenase-2 and prostate carcinogenesis.
Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density.
Cyclooxygenase-2 and the inflammogenesis of breast cancer.
Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.
Cyclooxygenase-2 and tumor biology.
Cyclooxygenase-2 as a Biomarker with Diagnostic, Therapeutic, Prognostic, and Predictive Relevance in Small Animal Oncology.
Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review.
Cyclooxygenase-2 as a target for anticancer drug development.
Cyclooxygenase-2 biology.
Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.
Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells.
Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.
Cyclooxygenase-2 enzyme induces the expression of the ?-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer.
Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence.
Cyclooxygenase-2 expression and angiogenesis in colorectal cancer.
Cyclooxygenase-2 expression and angiogenesis in gastric hyperplastic polyp--association with polyp size.
Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases.
Cyclooxygenase-2 expression and clinical outcome in gastrointestinal stromal tumors.
Cyclooxygenase-2 expression and connection with tumor recurrence and histopathologic parameters in gastrointestinal stromal tumors.
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma.
Cyclooxygenase-2 expression and its association with thyroid lesions.
Cyclooxygenase-2 Expression and Its Correlation with Primary Tumor Size and Lymph Node Involvement in Nasopharyngeal Carcinoma.
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Cyclooxygenase-2 expression and prostanoid biogenesis reflect clinical phenotype in human colorectal fibroblast strains.
Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma.
Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer.
Cyclooxygenase-2 expression as a predictor of para-aortic lymph node recurrence in uterine cervical cancer.
Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma.
Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer.
Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue.
Cyclooxygenase-2 expression correlates with apoptosis and angiogenesis in endometrial cancer tissue.
Cyclooxygenase-2 expression correlates with development, progression, metastasis, and prognosis of osteosarcoma: a meta-analysis and trial sequential analysis.
Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy.
Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer.
Cyclooxygenase-2 expression correlates with membrane-type-1 matrix metalloproteinase expression in colorectal cancer tissue.
Cyclooxygenase-2 expression correlates with nuclear p53 accumulation in gastric carcinoma.
Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: evidence for a Bcl-2-dependent mechanism.
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.
Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients.
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Cyclooxygenase-2 expression determines neo-angiogenesis in gallbladder carcinomas.
Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.
Cyclooxygenase-2 expression during carcinogenesis in the human stomach.
Cyclooxygenase-2 expression during immortalization and breast cancer progression.
Cyclooxygenase-2 expression in actinic keratosis.
Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor.
Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix.
Cyclooxygenase-2 Expression in Animal Cancers.
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.
Cyclooxygenase-2 expression in borderline ovarian tumors.
Cyclooxygenase-2 expression in brain metastases.
Cyclooxygenase-2 expression in canine appendicular osteosarcomas.
Cyclooxygenase-2 expression in canine mammary tumors.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables.
Cyclooxygenase-2 expression in cervical intraepithelial neoplasia.
Cyclooxygenase-2 Expression in Cervical Squamous Cell Carcinoma: the Significance of Expression in Neoplastic Cells within the Lymphovascular Space.
Cyclooxygenase-2 expression in chondrosarcoma.
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study .
Cyclooxygenase-2 expression in clear cell renal cell carcinoma.
Cyclooxygenase-2 expression in colorectal cancer liver metastases.
Cyclooxygenase-2 expression in colorectal carcinoma, adenomatous polyps and non-tumour bearing margins of resection tissues in a cohort of black Africans.
Cyclooxygenase-2 expression in dermatofibroma and dermatofibrosarcoma protuberans.
Cyclooxygenase-2 expression in early gastric cancer, intestinal metaplasia and Helicobacter pylori infection.
Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase.
Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome.
Cyclooxygenase-2 expression in ependymoma of the spinal cord.
Cyclooxygenase-2 expression in equine tumors.
Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps.
Cyclooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors.
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.
Cyclooxygenase-2 expression in hepatocellular carcinoma.
Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.
Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.
Cyclooxygenase-2 expression in human esophageal carcinoma.
Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas; correlation with intratumoral microvessel density and apoptotic index.
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Cyclooxygenase-2 expression in human irradiated uveal melanomas.
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.
Cyclooxygenase-2 expression in human pituitary tumors.
Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentation.
Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis.
Cyclooxygenase-2 expression in human thyroid disease.
Cyclooxygenase-2 expression in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression.
Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 expression in lymph node metastasis of cervical and vulvar cancer.
Cyclooxygenase-2 expression in lymphoma in north-west of iran.
Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
Cyclooxygenase-2 expression in medullary thyroid carcinoma.
Cyclooxygenase-2 expression in non-Hodgkin's lymphomas.
Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients.
Cyclooxygenase-2 Expression in Non-Small Cell Lung Cancer Correlates With Hypertrophic Osteoarthropathy.
Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines.
Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms.
Cyclooxygenase-2 expression in oral squamous cell carcinoma.
Cyclooxygenase-2 expression in oral tongue squamous cell carcinoma.
Cyclooxygenase-2 expression in pediatric sarcomas.
Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer.
Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma.
Cyclooxygenase-2 expression in primary and recurrent pterygium.
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.
Cyclooxygenase-2 expression in primary human colorectal cancers and bone marrow micrometastases.
Cyclooxygenase-2 expression in primary Merkel cell carcinoma.
Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes.
Cyclooxygenase-2 expression in retinoblastoma: an immunohistochemical analysis.
Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy.
Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs.
Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome.
Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis.
Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.
Cyclooxygenase-2 expression in stromal tumors of the gastrointestinal tract.
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Cyclooxygenase-2 expression in the endometrium at the end of 2 years' continuous combined hormone replacement therapy.
Cyclooxygenase-2 expression in the normal human eye and its expression pattern in selected eye tumours.
Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients.
Cyclooxygenase-2 expression in thyroid neoplasms.
Cyclooxygenase-2 expression in thyroid nodules.
Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics.
Cyclooxygenase-2 expression in uterine leiomyosarcomas.
Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours.
Cyclooxygenase-2 expression in Warthin's tumour.
Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells.
Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation.
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
Cyclooxygenase-2 Expression Is a Predictive Marker for Late Recurrence in Colorectal Cancer.
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.
Cyclooxygenase-2 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma.
Cyclooxygenase-2 expression is associated with elevated aspartate aminotransferase level in hepatocellular carcinoma.
Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.
Cyclooxygenase-2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas.
Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival.
Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer.
Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients.
Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis.
Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis.
Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia.
Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer.
Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma.
Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma.
Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers.
Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms.
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.
Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure.
Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast.
Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.
Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53.
Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells.
Cyclooxygenase-2 gene expression in human breast cancer.
Cyclooxygenase-2 Gene Polymorphisms -765G>C and -1195A>G and Mycosis Fungoides Risk.
Cyclooxygenase-2 gene polymorphisms and risk of cervical cancer in a North Indian population.
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions.
Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
Cyclooxygenase-2 immunoexpression in breast cancer: Progesterone receptor influence.
Cyclooxygenase-2 immunoreactivity in depressed-type colorectal adenomas and cancers.
Cyclooxygenase-2 immunoreactivity in equine ocular squamous-cell carcinoma.
Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis.
Cyclooxygenase-2 in Cancer and Angiogenesis.
Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract.
Cyclooxygenase-2 in cancer: A review.
Cyclooxygenase-2 in cervical neoplasia: a review.
Cyclooxygenase-2 in epilepsy.
Cyclooxygenase-2 in gastrointestinal malignancies.
Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.
Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase.
Cyclooxygenase-2 in human non-small cell lung cancer.
Cyclooxygenase-2 in human pathological disease.
Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland.
Cyclooxygenase-2 in oligodendroglial neoplasms.
Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance.
Cyclooxygenase-2 in oncogenesis.
Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells.
Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An update on the molecular mechanisms.
Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells.
Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma.
Cyclooxygenase-2 induced ?1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway.
Cyclooxygenase-2 Induced the ?-Amyloid Protein Deposition and Neuronal Apoptosis Via Upregulating the Synthesis of Prostaglandin E2 and 15-Deoxy-?12,14-prostaglandin J2.
Cyclooxygenase-2 induces the expression of the alpha 2,3 sialyltransferase-3 (ST3Gal-I) in breast cancer.
Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells.
Cyclooxygenase-2 induction in rat spinal cord injury mediated by proinflammatory tumor necrosis factor-alpha and interleukin-1.
Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.
Cyclooxygenase-2 inhibition and coagulation.
Cyclooxygenase-2 inhibition and gastric cancer.
Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.
Cyclooxygenase-2 inhibition attenuates hypoxic cancer cells induced m2-polarization of macrophages.
Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer.
Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model.
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells.
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.
Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma.
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer.
Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.
Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer.
Cyclooxygenase-2 inhibition prevents colorectal cancer: from the bench to the bed side.
Cyclooxygenase-2 inhibition promotes enhancement of antitumor responses by transcutaneous vaccination with cytosine-phosphate-guanosine-oligodeoxynucleotides and model tumor antigen.
Cyclooxygenase-2 inhibition reverts the decrease in adiponectin levels and attenuates the loss of white adipose tissue during chronic inflammation.
Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity.
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.
Cyclooxygenase-2 inhibitor enhances whereas prostaglandin E2 inhibits the production of interferon-induced protein of 10 kDa in epidermoid carcinoma A431.
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids.
Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.
Cyclooxygenase-2 inhibitor NS-398 suppresses cell growth and constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells.
Cyclooxygenase-2 inhibitor SC-236 [4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1-pyrazol-1-l] benzenesulfonamide] suppresses nuclear factor-kappaB activation and phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and c-Jun N-terminal kinase in human mast cell line cells.
Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.
Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.
Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer.
Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia.
Cyclooxygenase-2 inhibitors and cancer.
Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
Cyclooxygenase-2 inhibitors differentially attenuate pentylenetetrazol-induced seizures and increase of pro- and anti-inflammatory cytokine levels in the cerebral cortex and hippocampus of mice.
Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.
Cyclooxygenase-2 inhibitors in cancer prevention and treatment.
Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.
Cyclooxygenase-2 inhibitors in colorectal cancer.
Cyclooxygenase-2 inhibitors in glioma therapy.
Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed.
Cyclooxygenase-2 inhibitors in lung cancer.
Cyclooxygenase-2 inhibitors in tumorigenesis (Part II).
Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway.
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism.
Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts.
Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice.
Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice.
Cyclooxygenase-2 inhibits tumor necrosis factor alpha-mediated apoptosis in renal glomerular mesangial cells.
Cyclooxygenase-2 interacts with MMP and FGF pathways to promote epimorphic regeneration in lizard Hemidactylus flaviviridis.
Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis.
Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells.
Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.
Cyclooxygenase-2 is a target of microRNA-16 in human hepatoma cells.
Cyclooxygenase-2 Is an Independent Predictor of Poor Prognosis in Uterine Leiomyosarcomas.
Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.
Cyclooxygenase-2 is associated with malignant phenotypes in human lung cancer.
Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Cyclooxygenase-2 is induced in brain blood vessels during fever evoked by peripheral or central administration of tumor necrosis factor.
Cyclooxygenase-2 is involved in HIV-1 Tat-induced inflammatory responses in the brain.
Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma.
Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha.
Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: an immunohistochemical study.
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.
Cyclooxygenase-2 is overexpressed in human cervical cancer.
Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells.
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways.
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
Cyclooxygenase-2 knockdown using retinoic acid chalcone (RAC), a promising therapeutic strategy for colon cancer.
Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells.
Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis.
Cyclooxygenase-2 mediates the sensitizing effects of systemic IL-1-beta on excitotoxic brain lesions in newborn mice.
Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.
Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.
Cyclooxygenase-2 or Tumor Necrosis Factor-? Inhibitors Attenuate the Mechanotransductive Effects of Pulsed Focused Ultrasound to Suppress Mesenchymal Stromal Cell Homing to Healthy and Dystrophic Muscle.
Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta.
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas.
Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer.
Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.
Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma.
Cyclooxygenase-2 overexpression in colorectal cancer is associated with non-polypoid growth.
Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis.
Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.
Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells.
Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1.
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients.
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
Cyclooxygenase-2 overexpression is related to polypoid growth and K-ras gene mutation in T1 colorectal carcinomas.
Cyclooxygenase-2 Overexpression Predicts Poor Survival in Patients with High-grade Extremity Osteosarcoma: A Pilot Study.
Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma.
Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.
Cyclooxygenase-2 Polymorphisms and Pancreatic Cancer Susceptibility.
Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis.
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents.
Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
Cyclooxygenase-2 promoter 765C increase of digestive tract cancer risk in the Chinese population: a meta-analysis.
Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma.
Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma.
Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence.
Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells.
Cyclooxygenase-2 Promotes Hepatocellular Apoptosis by Interacting with TNF-? and IL-6 in the Pathogenesis of Nonalcoholic Steatohepatitis in Rats.
Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition.
Cyclooxygenase-2 promotes prostate cancer progression.
Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.
Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma.
Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells.
Cyclooxygenase-2 regulates TGF?-induced cancer stemness in triple-negative breast cancer.
Cyclooxygenase-2 regulates the degree of apoptosis by modulating bcl-2 protein in pleomorphic adenoma and mucoepidermoid carcinoma of the parotid gland.
Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors.
Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.
Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPAR?/?-Dependent Vasodilator Pathway.
Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas.
Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line.
Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme.
Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation.
Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells.
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells.
Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis.
Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Cyclooxygenase-2, angiogenesis, tumor cell proliferation, P-glycoprotein in advanced ovarian serous carcinoma.
Cyclooxygenase-2, Bcl-2, and chromosome 1p analysis in protoplasmic astrocytomas.
Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?
Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas.
Cyclooxygenase-2-765G>C functional promoter polymorphism and its association with oral squamous cell carcinoma.
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.
Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription.
Cyclooxygenase-2-Mediated Up-Regulation of Mitochondrial Transcription Factor A Mitigates the Radio-Sensitivity of Cancer Cells.
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Cyclooxygenase-2: a molecular target for chemoprevention of epithelial tumors of skin and colon.
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.
Cyclooxygenase-2: a novel target for cancer chemotherapy?
Cyclooxygenase-2: a novel target in human solid tumors.
Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer.
Cyclooxygenase-2: a potential target in breast cancer.
Cyclooxygenase-2: a potential target in human cancer.
Cyclooxygenase-2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy.
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Cyclooxygenase-2: a target for the prevention and treatment of cancers of the upper digestive tract.
Cyclooxygenase-2: a therapeutic target for prostate cancer.
Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?
Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype.
Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells.
Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitors.
Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor).
Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
Cyclooxygenases and colon cancer.
Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus).
Cyclooxygenases in cancer: chemoprevention and sensitization to conventional therapies.
Cyclooxygenases in cancer: progress and perspective.
Cyclooxygenases in hepatocellular carcinoma.
Cyclooxygenases in the skin: pharmacological and toxicological implications.
Cyclooxygenases, prostanoids, and tumor progression.
Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma.
Cyclooxygenases: Mediators of UV-Induced Skin Cancer and Potential Targets for Prevention.
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
Cyclopamine and jervine induce COX-2 overexpression in human erythroleukemia cells but only cyclopamine has a pro-apoptoticeffect.
Cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells.
Cyclosporin-A inhibits the expression of cyclooxygenase-2 in gingiva.
Cycloxygenase-2 (COX-2)--a potential target for screening of small molecules as radiation countermeasure agents: an in silico study.
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine.
Cynanchum wilfordii Polysaccharides Suppress Dextran Sulfate Sodium-Induced Acute Colitis in Mice and the Production of Inflammatory Mediators from Macrophages.
Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway.
Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2.
Cytochalasin B modulates macrophage-mediated inflammatory responses.
Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis.
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.
Cytokine and cyclooxygenase-2 protein in brain areas of tumor-bearing mice with prostanoid-related anorexia.
Cytokine modulation of immune activation associated suppression of macrophage cyclooxygenase activity in vivo.
Cytokine networks involved in the regulation of haemopoietic stem cell proliferation and differentiation.
Cytokine production by infrapatellar fat pad can be stimulated by interleukin 1? and inhibited by peroxisome proliferator activated receptor ? agonist.
Cytokine release from mononuclear cells in patients irradiated for breast cancer.
Cytokine responses of intestinal epithelial-like caco-2 cells to non-pathogenic and opportunistic pathogenic yeasts in the presence of butyric Acid.
Cytokine-induced bronchoconstriction in precision-cut lung slices is dependent upon cyclooxygenase-2 and thromboxane receptor activation.
Cytokines present in smokers' serum interact with smoke components to enhance endothelial dysfunction.
Cytokines, Angiogenesis, and Extracellular Matrix Degradation are Augmented by Oxidative Stress in Endometriosis.
Cytokines, Chaperones and Neuroinflammatory Responses in Heroin-Related Death: What Can We Learn from Different Patterns of Cellular Expression?
Cytokines, growth factors and prostaglandin synthesis in the uterus of pregnant and non-pregnant bitches: the features of placental sites.
Cytoplasmic Expression of HuR is Related to Cyclooxygenase-2 Expression in Colon Cancer.
Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma.
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.
Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment.
Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer.
Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis.
Cytoplasmic PPAR? is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers.
Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407).
Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts.
Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours.
Cytotoxic and anti-inflammatory tirucallane triterpenoids from Dysoxylum binectariferum.
Cytotoxic and apoptotic functions of licofelone on rat glioma cells.
Cytotoxic, anti-inflammatory and hemostatic spirostane-steroidal saponins from the ethanol extract of the roots of Bletilla striata.
Cytotoxicity and Pro-Apoptotic, Antioxidant and Anti-Inflammatory Activities of Geopropolis Produced by the Stingless Bee Melipona fasciculata Smith.
Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes.
d-Limonene protects PC12 cells against corticosterone-induced neurotoxicity by activating the AMPK pathway.
Danhong Injection Attenuates Cerebral Ischemia-Reperfusion Injury in Rats Through the Suppression of the Neuroinflammation.
Daphnetin alleviates lipopolysaccharide/d-galactosamine-induced acute liver failure via the inhibition of NLRP3, MAPK and NF-?B, and the induction of autophagy.
Data Mining, Network Pharmacology, and Molecular Docking Explore the Effects of Core Traditional Chinese Medicine Prescriptions in Patients with Rectal Cancer and Qi and Blood Deficiency Syndrome.
Date syrup-derived polyphenols attenuate angiogenic responses and exhibits anti-inflammatory activity mediated by vascular endothelial growth factor and cyclooxygenase-2 expression in endothelial cells.
Dauricine negatively regulates lipopolysaccharide- or cecal ligation and puncture-induced inflammatory response via NF-?B inactivation.
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Death-associated protein kinase 3 mediates vascular inflammation and development of hypertension in spontaneously hypertensive rats.
Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells.
Decrease in expression or activity of cytosolic phospholipase A(2)alpha increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells.
Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic damage.
Decreased expression level and DNA-binding activity of specificity protein 1 via cyclooxygenase-2 inhibition antagonizes radiation resistance, cell migration and invasion in radiation-resistant lung cancer cells.
Decreased expression of tumor necrosis factor-alpha-stimulated gene 6 in cumulus cells of the cyclooxygenase-2 and EP2 null mice.
Decreased gene expression of human beta-defensin-1 in the development of squamous cell carcinoma of the oral cavity.
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2.
Decreased systemic IGF-1 in response to calorie restriction modulates murine tumor cell growth, nuclear factor-?B activation, and inflammation-related gene expression.
Decreased Toll-interacting protein and peroxisome proliferator-activated receptor ? are associated with increased expression of Toll-like receptors in colon carcinogenesis.
Decreased tumor growth in Walker 256 tumor-bearing rats chronically supplemented with fish oil involves COX-2 and PGE2 reduction associated with apoptosis and increased peroxidation.
Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer.
Decursin alleviates the aggravation of osteoarthritis via inhibiting PI3K-Akt and NF-kB signal pathway.
Defective Arachidonate Release and PGE2 Production in Gialpha2-Deficient Intestinal and Colonic Subepithelial Myofibroblasts.
Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis.
Defining the role of COX-2 inhibitors in inflammatory and other diseases.
Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth.
Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells.
Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K.
Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor.
Delayed treatment of propofol inhibits lipopolysaccharide-induced inflammation in microglia through the PI3K/PKB pathway.
Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.
Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.
Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis.
Deletion of macrophage migration inhibitory factor inhibits murine oral carcinogenesis: Potential role for chronic pro-inflammatory immune mediators.
Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2).
Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling.
Demethylzeylasteral ameliorates inflammation in a rat model of unilateral ureteral obstruction through inhibiting activation of the NF??B pathway.
Dendropanax dentiger (Harms) Merr. root and its major constituents exert therapeutic effect on adjuvant-induced arthritis in rats.
Deoxynivalenol induces oxidative stress, inflammatory response and apoptosis in bovine mammary epithelial cells.
Depletion of cellular cholesterol enhances macrophage MAPK activation by chitin microparticles but not by heat-killed Mycobacterium bovis BCG.
Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma.
Deregulated cyclooxygenase-2 expression in oral premalignant tissues.
Deregulation of cyclooxygenase and nitric oxide synthase gene expression in the inflammatory cascade triggered by experimental group B streptococcal meningitis in the newborn brain and cerebral microvessels.
Deregulation of lysophosphatidic acid metabolism in oral cancer promotes cell migration via the up-regulation of COX-2.
Dermal Fibroblasts Promote Alternative Macrophage Activation Improving Impaired Wound Healing.
Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway.
Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition.
Design and construction of COX-2 specific fluorescent probes.
Design and Synthesis of a Novel NIR Celecoxib-Based Fluorescent Probe for Cyclooxygenase-2 Targeted Bioimaging in Tumor Cells.
Design and synthesis of pyrazole-pyrazoline hybrids as cancer-associated selective COX-2 inhibitors.
Design of a 3D BMP-2-Delivering Tannylated PCL Scaffold and Its Anti-Oxidant, Anti-Inflammatory, and Osteogenic Effects In Vitro.
Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.
Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents.
Design, Synthesis and Biological Evaluation of New 1,3-diphenyl-3- (phenylamino)propan-1-ones as Selective Cyclooxygenase (COX-2) Inhibitors.
Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents.
Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy.
Design, Synthesis and Biological Evaluation of4-(Imidazolylmethyl)-2-(4-methylsulfonyl phenyl)-Quinoline Derivatives as Selective COX-2 Inhibitors and In-vitro Anti-breast Cancer Agents.
Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors.
Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.
Design, synthesis, and SAR study of novel 4,5-dihydropyrazole-Thiazole derivatives with anti-inflammatory activities for the treatment of sepsis.
Design, Synthesis, and Structure-Activity Relationship Studies of Fluorescent Inhibitors of Cycloxygenase-2 as Targeted Optical Imaging Agents.
Designing a clinical trial of non-steroidal anti-inflammatory drugs for cancer pain: a survey of UK palliative care physicians.
Desmethylanhydroicaritin inhibits NF-kappaB-regulated inflammatory gene expression by modulating the redox-sensitive PI3K/PTEN/Akt pathway.
Desmethylbellidifolin From Gentianella acuta Ameliorate TNBS-Induced Ulcerative Colitis Through Antispasmodic Effect and Anti-Inflammation.
Desmoid tumor-associated pain is dependent on mast cell expression of cyclooxygenase-2.
Details of hyperplastic polyps of the stomach shrinking after anti-Helicobacter pylori therapy.
Detection of carcinogen-induced bladder cancer by fluorocoxib A.
Detection of circulating tumor necrosis factor after endotoxin administration.
Detection of COX-2 in liquid biopsy in patients with breast cancer.
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.
Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps.
Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.
Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis.
Detection of Non-Melanoma Skin Cancer by in vivo Fluorescence Imaging with Fluorocoxib A.
Detection of Overexpressed COX-2 in Precancerous Lesions of Hamster Pancreas and Lungs by Molecular Imaging: Implications for Early Diagnosis and Prevention.
Detection of pain-related molecules in the subchondral bone of osteoarthritic knees.
Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression.
Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A.
Development and In Vitro Evaluation of 2-Methoxyestradiol Loaded Polymeric Micelles for Enhancing Anticancer Activities in Prostate Cancer.
Development and pharmacological evaluation of vancomycin loaded chitosan films.
Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription.
Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
Development of a series of 4-hydroxycoumarin platinum(IV) hybrids as antitumor agents: Synthesis, biological evaluation and action mechanism investigation.
Development of An Oral Treatment with the PPAR-?-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease.
Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review.
Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells.
Development of Postoperative Pain in Patients with End-Stage Knee Osteoarthritis Is Associated with Upregulation of Genes Related to Extracellular Matrix Degradation, Inflammation, and Apoptosis Measured in the Peripheral Blood before Knee Surgery.
Development of Rofecoxib-Based Fluorescent Probes and Investigations on Their Solvatochromism, AIE Activity, Mechanochromism, and COX-2-Targeted Bioimaging.
Dexmedetomidine inhibits apoptosis and expression of COX-2 induced by lipopolysaccharide in primary human alveolar epithelial type 2?cells.
DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice.
DHA at nutritional doses restores insulin sensitivity in skeletal muscle by preventing lipotoxicity and inflammation.
Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.
Diagnostic potential of differentially regulated microRNAs among endometriosis, endometrioid ovarian cancer, and endometrial cancer.
Diallyl Disulfide Prevents Cyclophosphamide-Induced Hemorrhagic Cystitis in Rats through the Inhibition of Oxidative Damage, MAPKs, and NF-?B Pathways.
Diallyl Disulfide Suppresses Inflammatory and Oxidative Machineries following Carrageenan Injection-Induced Paw Edema in Mice.
Diallyl trisulfide inhibits phorbol ester-induced tumor promotion, activation of AP-1, and expression of COX-2 in mouse skin by blocking JNK and Akt signaling.
Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.
Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity.
Dieckol isolated from a brown alga, Eisenia nipponica, suppresses ear swelling from allergic inflammation in mouse.
Dietary administration of scallion extract effectively inhibits colorectal tumor growth: cellular and molecular mechanisms in mice.
Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice.
Dietary canolol induces apoptosis in human cervical carcinoma HeLa cells through ROS-MAPK mediated mitochondrial signaling pathway: In vitro and in vivo.
Dietary Crocin Inhibits Colitis and Colitis-Associated Colorectal Carcinogenesis in Male ICR Mice.
Dietary exposure to bisphenol A affects memory function and neuroimmune biomarkers in allergic asthmatic mice.
Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis.
Dietary Fat, Fatty Acids and Breast Cancer.
Dietary fatty acids modulate chronic colitis, colitis-associated colon neoplasia and COX-2 expression in IL-10 knockout mice.
Dietary grape seed proanthocyanidins inhibit 12-O-tetradecanoyl phorbol-13-acetate-caused skin tumor promotion in 7,12-dimethylbenz[a]anthracene-initiated mouse skin, which is associated with the inhibition of inflammatory responses.
Dietary Grape Seed Proanthocyanidins Inhibit UVB-Induced Cyclooxygenase-2 Expression and Other Inflammatory Mediators in UVB-Exposed Skin and Skin Tumors of SKH-1 Hairless Mice.
Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor.
Dietary Mixed Cereal Grains Ameliorate the Azoxymethane and Dextran Sodium Sulfate-Induced Colonic Carcinogenesis in C57BL/6J Mice.
Dietary Polyacetylenic Oxylipins Falcarinol and Falcarindiol Prevent Inflammation and Colorectal Neoplastic Transformation: A Mechanistic and Dose-Response Study in A Rat Model.
Dietary prevention of Helicobacter pylori-associated gastric cancer with kimchi.
Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice.
Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression.
Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat.
Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration.
Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response.
Dietary supplementation with Allium hirtifolium and/or Astragalus hamosus improved ?memory and reduced neuro-inflammation in the rat model of Alzheimer's disease.
Dietary supplementation with omega-3 polyunsaturated fatty acid-rich oils protects against visible-light-induced retinal damage in vivo.
Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Diethylcarbamazine attenuates the development of carrageenan-induced lung injury in mice.
Differences in Expression of Uroplakin III, Cytokeratin 7, and Cyclooxygenase-2 in Canine Proliferative Urothelial Lesions of the Urinary Bladder.
Different cell cycle modulation by celecoxib at different concentrations.
Different detectability of cyclooxygenase-2 (COX-2) protein in standard paraffin sections and tissue microarrays of human melanomas and naevi - Comparative study.
Different expression of cyclooxygenase-2 (COX-2) in selected nonmelanocytic human cutaneous lesions.
Different expression of cyclooxygenase-2 in biliary epithelia of bile duct cancer with or without pancreaticobiliary maljunction.
Different matrix micro-environments in colon cancer and diverticular disease.
Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer.
Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma.
Different Solvent Fractions of Acanthopanax senticosus Harms Exert Antioxidant and Anti-Inflammatory Activities and Inhibit the Human Kv1.3 Channel.
Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines.
Differential cyclooxygenase-2 transcriptional control in proliferating versus quiescent fibroblasts.
Differential cytotoxic activity of Quercetin on colonic cancer cells depends on ROS generation through COX-2 expression.
Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines.
Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood-brain barrier damage.
Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on Celecoxib-induced apoptosis.
Differential effects of corticosteroids on the expression of cyclooxygenase-2, tumour necrosis factor-alpha and matrix metalloproteinase-9 in an animal model of migraine.
Differential effects of WEB 2086 and SRI 63-441 on TNF-alpha-induced alterations in cardiopulmonary function.
Differential expression of cyclo-oxygenase-2 and nuclear beta-catenin in colorectal cancer tissue.
Differential expression of cyclooxygenase 2 in human colorectal cancer.
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.
Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells.
Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis.
Differential expression of tumor necrosis factor ?, interleukin 1?, nuclear factor ?B in nasal mucosa among chronic rhinosinusitis patients with and without polyps.
Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma.
Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid.
Differential hepatoprotective mechanisms of rutin and quercetin in CCl(4)-intoxicated BALB/cN mice.
Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids.
DIFFERENTIAL INHIBITION OF TUMOUR CELL-INDUCED PLATELET AGGREGATION BY NICOTINATE ASPIRIN PRODRUG (ST0702) AND ASPIRIN.
Differential modulation of AMPK signaling pathways by low or high levels of exogenous reactive oxygen species in colon cancer cells.
Differential modulatory effects of Annexin 1 on nitric oxide synthase induction by lipopolysaccharide in macrophages.
Differential protein expression between esophageal squamous cell carcinoma and dysplasia, and prognostic significance of protein markers.
Differential protein expression in the epidermis of wild-type and COX-2 transgenic mice.
Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors.
Differential regulation in human amnion epithelial and fibroblast cells of prostaglandin E(2) production and prostaglandin H synthase-2 mRNA expression by dexamethasone but not tumour necrosis factor-alpha.
Differential regulation of COX-2 transcription by Ras- and Rho-family of GTPases.
Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages.
Dihomo-?-linolenic acid inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA.
Dihomo-?-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase.
Dihomo-gamma-linolenic acid inhibits tumour necrosis factor-alpha production by human leucocytes independently of cyclooxygenase activity.
Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators.
Dihydromyricetin Attenuates Inflammation through TLR4/NF-kappaB Pathway.
Dihydropyrazole Derivatives Containing Benzo Oxygen Heterocycle and Sulfonamide Moieties Selectively and Potently Inhibit COX-2: Design, Synthesis, and Anti-Colon Cancer Activity Evaluation.
Dihydrotanshinone exhibits an anti-inflammatory effect in vitro and in vivo through blocking TLR4 dimerization.
Dihydroxystilbenes prevent azoxymethane/dextran sulfate sodium-induced colon cancer by inhibiting colon cytokines, a chemokine, and programmed cell death-1 in C57BL/6J mice.
Dimethyl cardamonin inhibits lipopolysaccharide-induced inflammatory factors through blocking NF-kappaB p65 activation.
Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
Dimethyl fumarate attenuates neuroinflammation and neurobehavioral deficits induced by experimental traumatic brain injury.
Dimethyl Sulfoxide Attenuates Acute Lung Injury Induced by Hemorrhagic Shock/Resuscitation in Rats.
Dioscin attenuates hepatic ischemia-reperfusion injury in rats through inhibition of oxidative-nitrative stress, inflammation and apoptosis.
Dioscorea japonica extract down-regulates prostaglandin E2 synthetic pathway and induces apoptosis in lung cancer cells.
Diosgenin induces cell cycle arrest and apoptosis in HEL cells with increase in intracellular calcium level, activation of cPLA2 and COX-2 overexpression.
Diosmin suppresses the proinflammatory mediators in lipopolysaccharide-induced RAW264.7 macrophages via NF-?B and MAPKs signal pathways.
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia.
Disarming suppressor cells to improve immunotherapy.
Discovering pH triggered charge rebound surface modulated topical nanotherapy against aggressive skin papilloma.
Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents.
Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases.
Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma.
Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: Design, synthesis, and structure-activity relationship.
Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.
Discovery of novel aminophosphonate derivatives containing pyrazole moiety as potential selective COX-2 inhibitors.
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates.
Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
Discovery of the possible mechanisms in kouyanqing granule for treatment of oral ulcers based on network pharmacology.
Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer.
Disruption of Chromosomal Architecture of cox2 Locus Sensitizes Lung Cancer Cells to Radiotherapy.
Disruption of P2X4 purinoceptor and suppression of the inflammation associated with cerebral aneurysm formation.
Disruption of tumour-host communication by downregulation of LFA-1 reduces COX-2 and e-NOS expression and inhibits brain metastasis growth.
Dissection of the role of paeoniflorin in the traditional Chinese medicinal formula Si-Ni-San against contact dermatitis in mice.
Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis.
Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.
Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells.
Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy.
Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis.
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Diversity and similarity in signaling events leading to rapid Cox-2 induction by tumor necrosis factor-alpha and phorbol ester in human endothelial cells.
DJ-1 mutation decreases astroglial release of inflammatory mediators.
DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.
DNA methylation and environmental exposures in human hepatocellular carcinoma.
DNA oxidation induced by cyclooxygenase-2.
DNA Sequence Variants in the Five Prime Untranslated Region of the Cyclooxygenase-2 Gene Are Commonly Found in Healthy Dogs and Gray Wolves.
DNA-hypomethylating agent, 5'-azacytidine, induces cyclooxygenase-2 expression via the PI3-kinase/Akt and extracellular signal-regulated kinase-1/2 pathways in human HT1080 fibrosarcoma cells.
Do COX-2 inhibitors reduce metachronous cancer development?
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Docking Studies and Molecular Dynamics Simulation of Ipomoea batatas L. Leaves Compounds as Lipoxygenase (LOX) Inhibitor.
Docosahexaenoic acid ester of phloridzin inhibit lipopolysaccharide-induced inflammation in THP-1 differentiated macrophages.
Docosahexaenoic acid inhibits insulin-induced activation of sterol regulatory-element binding protein 1 and cyclooxygenase-2 expression through upregulation of SIRT1 in human colon epithelial cells.
Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR.
Does miRNA-155 Promote Cyclooxygenase-2 Expression in Cancer?
Does the release of arachidonic acid from cells play a role in cancer chemoprevention?
Does tumour necrosis factor alpha-induced cyclooxygenase-2 expression lead to spontaneous abortion in Chlamydia trachomatis-infected women.
Dose-dependent effect of dietary conjugated linoleic acid on the growth of rat hepatoma dRLh-84 cells in vivo.
Dose-dependent study of effects of 532-nm continuous wave laser on rat skin: A mechanistic insight.
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
Down-regulation of COX-2 activity by 1?,25(OH)2D3 is VDR dependent in endothelial cells transformed by Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.
Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells.
Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.
Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Down-regulation of microsomal prostaglandin E2 synthase-1 in the infrapatellar fat pad of osteoarthritis patients with hypercholesterolemia.
Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma.
Downregulating PI3K/Akt/NF-?B signaling with allicin for ameliorating the progression of osteoarthritis: in vitro and vivo studies.
Downregulation of microglial activation by achillolide a.
Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth.
Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture.
Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model.
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
Downregulation of XIST ameliorates acute kidney injury by sponging miR-142-5p and targeting PDCD4.
Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: A pilot study.
Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells.
Dual acting anti-inflammatory drugs.
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer.
Dual effects of acetylsalicylic acid on mast cell degranulation, expression of cyclooxygenase-2 and release of pro-inflammatory cytokines.
Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal.
Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation.
Dual Human Carbonic Anhydrase/Cyclooxygenase-2 Inhibitors: A Promising Approach for Cancer Treatment.
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells.
DuCLOX-2/5 Inhibition Attenuates Inflammatory Response and Induces Mitochondrial Apoptosis for Mammary Gland Chemoprevention.
DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention.
Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.
DXXK exerts anti-inflammatory effects by inhibiting the lipopolysaccharide-induced NF-?B/COX-2 signalling pathway and the expression of inflammatory mediators.
Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer.
Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth.
Dysregulated post-transcriptional control of COX-2 gene expression in cancer.
E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion.
Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy.
Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis.
Early laminar events involving endothelial activation in horses with black walnut- induced laminitis.
Early methyl donor deficiency produces severe gastritis in mothers and offspring through N-homocysteinylation of cytoskeleton proteins, cellular stress, and inflammation.
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers.
EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer.
Eclipta prostrata Improves DSS-Induced Colitis through Regulation of Inflammatory Response in Intestinal Epithelial Cells.
Ectopic hepatocellular carcinoma arising from pancreas: a case report and review of the literature.
Effect of 17-alpha hydroxyprogesterone caproate on the production of tumor necrosis factor-alpha and the expression of cyclooxygenase-2 in lipopolysaccharide-treated gravid human myometrial explants.
Effect of ?-3 and ?-9 fatty acid rich oils on lipoxygenases and cyclooxygenases enzymes and on the growth of a mammary adenocarcinoma model.
Effect of a nonprotein bioactive agent on the reduction of cyclooxygenase-2 and tumor necrosis factor-alpha in human intervertebral disc cells in vitro.
Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma.
Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain.
Effect of alpha-tocopherol on the expression of hepatic vascular stress genes in response to sepsis.
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.
Effect of ascorbic acid on hepatic vasoregulatory gene expression during polymicrobial sepsis.
Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats.
Effect of beta- and alpha-glucans on immune modulating factors expression in enterocyte-like Caco-2 and goblet-like LS 174T cells.
Effect of body-weight loading onto the articular cartilage on the occurrence of quinolone-induced chondrotoxicity in juvenile rats.
Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer.
Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancer.
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Effect of celecoxib on inhibiting tumor repopulation during radiotherapy in human FaDu squamous cell carcinoma.
Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer.
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Effect of citronellol on NF-kB inflammatory signaling molecules in chemical carcinogen-induced mammary cancer in the rat model.
Effect of cold plasma on periodontal wound healing-an in vitro study.
Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.
Effect of Combined Treatment with Ursolic Acid and Resveratrol on Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate.
Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.
Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours.
Effect of cyclooxygenase inhibitors in the adhesion of tumor cells to endothelial cells.
Effect of cyclooxygenase-2 antisense oligodeoxyribonucleotides in A-549 lung cancer cells.
Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention.
Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.
Effect of cytosolic phospholipase A2 on proinflammatory cytokine-induced bone resorptive genes including receptor activator of nuclear factor kappa B ligand in human dental pulp cells.
Effect of digital hypothermia on lamellar inflammatory signaling in the euglycemic hyperinsulinemic clamp laminitis model.
Effect of doxycycline and meloxicam on cytokines, brain-derived neurotrophic factor, matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-3 and cyclooxygenase-2 in brain.
Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription.
Effect of Fucoxanthin Alone and in Combination with D-glucosamine Hydrochloride on Carrageenan/kaolin-induced Experimental Arthritis in Rats.
Effect of functional oils on the immune response of broilers challenged with Eimeria spp.
Effect of GCSB-5, a Herbal Formulation, on Monosodium Iodoacetate-Induced Osteoarthritis in Rats.
Effect of heat-killed Enterococcus faecalis EF-2001 on ethanol-induced acute gastric injury in mice: Protective effect of EF-2001 on acute gastric ulcer.
Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer.
Effect of hesperidin and neohesperidin from bittersweet orange (Citrus aurantium var. bigaradia) peel on indomethacin-induced peptic ulcers in rats.
Effect of indomethacin on Bfl-1, WISP-1 and proliferating cell nuclear antigen in colon cancer cell line HCT116 cells.
Effect of indomethacin on the kinetics of tumour necrosis factor alpha release and tumour necrosis factor alpha gene expression by human blood monocytes.
Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells.
Effect of Lactobacillus rhamnosus GR-1 supernatant and fetal sex on lipopolysaccharide-induced cytokine and prostaglandin-regulating enzymes in human placental trophoblast cells: implications for treatment of bacterial vaginosis and prevention of preterm labor.
Effect of lindane and phenobarbital on cyclooxygenase-2 expression and prostanoid synthesis by Kupffer cells.
Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model.
Effect of lipoteichoic acid on dermal vascular permeability in mice.
Effect of mechanical compression on the lumbar nerve root: localization and changes of intraradicular inflammatory cytokines, nitric oxide, and cyclooxygenase.
Effect of natsudaidain isolated from Citrus plants on TNF-alpha and cyclooxygenase-2 expression in RBL-2H3 cells.
Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells.
Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury.
Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells.
Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort.
Effect of NSAIDs on the aminopeptidase activity of cultured human osteoblasts.
Effect of Orally Administered Atractylodes macrocephala Koidz Water Extract on Macrophage and T Cell Inflammatory Response in Mice.
Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells.
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.
Effect of pyrrolidine dithiocarbamate on hepatic vascular stress gene expression during ischemia and reperfusion.
Effect of red clover isoflavones on cox-2 activity in murine and human monocyte/macrophage cells.
Effect of retinoids on LPS-induced COX-2 expression and COX-2 associated PGE(2) release from mouse peritoneal macrophages and TNF-alpha release from rat peripheral blood mononuclear cells.
Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat.
Effect of saccharin on inflammation in 3T3-L1 adipocytes and the related mechanism.
Effect of selective COX-2 inhibitor, celecoxib on adjuvant-induced arthritis model in irradiated rats.
Effect of Selenium Against Lead-Induced Damage on the Gene Expression of Heat Shock Proteins and Inflammatory Cytokines in Peripheral Blood Lymphocytes of Chickens.
Effect of silibinin on the growth and progression of primary lung tumors in mice.
Effect of silk fibroin peptide derived from silkworm Bombyx mori on the anti-inflammatory effect of Tat-SOD in a mice edema model.
Effect of sphingosine kinase 1 inhibition on blood pressure.
Effect of Tempol, a Membrane-Permeable Free Radical Scavenger, on In Vitro Model of Eye Inflammation on Rabbit Corneal Cells.
Effect of TGF-?1 on Apoptosis of Colon Cancer Cells Via the ERK Signaling Pathway.
Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
Effect of the protein kinase inhibitors, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 on Lewis lung carcinoma tumor progression.
Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model.
Effect of Trolox on altered vasoregulatory gene expression in hepatic ischemia/reperfusion.
Effect of vitamin C on azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated early colon cancer in mice.
Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis.
Effects of (-)-epicatechin on neuroinflammation and hyperphosphorylation of tau in the hippocampus of aged mice.
Effects of ?-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro.
Effects of a nutrient mixture on immunohistochemical localization of cancer markers in human cervical cancer HeLa cell tumor xenografts in female nude mice.
Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice.
Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro.
Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro.
Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.
Effects of adlay on azoxymethane-induced colon carcinogenesis in rats.
Effects of an oral hydro-ethanolic purple coneflower extract on performance, clinical health and immune parameters in calves.
Effects of Angelica gigas Nakai as an Anti-Inflammatory Agent in In Vitro and In Vivo Atopic Dermatitis Models.
Effects of anti-inflammatory cytokine agent (FR167653) and serine protease inhibitor on warm ischemia-reperfusion injury of the liver graft.
Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway.
Effects of arachidonic acid metabolites in a murine model of squamous cell carcinoma.
Effects of Aspirin, Nonsteroidal Anti-inflammatory Drugs, Statin and COX2 Inhibitor on the Developments of Urological Malignancies: A Population-Based Study with 10-Year Follow-up Data in Korea.
Effects of Berberine chloride on the liver of streptozotocin-induced diabetes in albino Wistar rats.
Effects of C-phycocyanin and Spirulina on Salicylate-Induced Tinnitus, Expression of NMDA Receptor and Inflammatory Genes.
Effects of caffeine on sperm characteristics after thawing and inflammatory response in the uterus after artificial insemination with frozen-thawed boar semen.
Effects of caffeoylquinic acid derivatives and C-flavonoid from Lychnophora ericoides on in vitro inflammatory mediator production.
Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells.
Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Effects of chronic celecoxib on testicular function in normal and lipopolysaccharide-treated rats.
Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice.
Effects of Cigarette Smoking and Restraint Stress on Human Colon Tumor Growth in Mice.
Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.
Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice.
Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice.
Effects of Cyclooxygenase on the Urothelium of the Urinary Bladder of Mice Exposed to Pelvic Radiation.
Effects of cyclooxygenase-2 gene silencing on the biological behavior of SKOV3 ovarian cancer cells.
Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.
Effects of Dexmedetomidine on Regulating Endotoxin-Induced Up-Regulation of Inflammatory Molecules in Murine Macrophages.
Effects of dietary flaxseed on intestinal tumorigenesis in Apc(Min) mouse.
Effects of dietary menhaden oil, soy, and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice.
Effects of docosahexaenoic supplementation and in vitro vitamin C on the oxidative and inflammatory neutrophil response to activation.
Effects of eccentric treadmill exercise on inflammatory gene expression in human skeletal muscle.
Effects of enriched environment on COX-2, leptin and eicosanoids in a mouse model of breast cancer.
Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines.
Effects of Excess Manganese on the Oxidative Status, and the Expression of Inflammatory Factors and Heat Shock Proteins in Cock Kidneys.
Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-? and COX-2.
Effects of Feiyanning Decoction, a compound traditional Chinese medicine, on iNOS and COX-2 expressions induced by tumor necrosis factor-? in lung adenocarcinoma cell line.
Effects of fish oil supplementation on prostaglandins in normal and tumor colon tissue: modulation by the lipogenic phenotype of colon tumors.
Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo.
Effects of Gastrodin against Lead-Induced Brain Injury in Mice Associated with the Wnt/Nrf2 Pathway.
Effects of Genetic and Pharmacologic Inhibition of COX-2 on Colitis-associated Carcinogenesis in Mice.
Effects of glycyrrhizin on lipopolysaccharide-induced acute lung injury in a mouse model.
Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2.
Effects of high and low dietary fat and indomethacin on tumour growth, hormone receptor status and growth factor expression in DMBA-induced rat breast cancer.
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis.
Effects of inflammatory responses, apoptosis, and STAT3/NF-?B- and Nrf2-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet.
Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat.
Effects of Lithium on Inflammation.
Effects of low-frequency ultrasound and microbubbles on angiogenesis-associated proteins in subcutaneous tumors of nude mice.
Effects of loxoprofen on the apical root resorption during orthodontic tooth movement in rats.
Effects of Molybdenum or/and Cadmium on mRNA Expression Levels of Inflammatory Cytokines and HSPs in Duck Spleens.
Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors.
Effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on cardiovascular alterations in endotoxemia.
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development.
Effects of oral and vaginal administration of levonorgestrel emergency contraception on markers of endometrial receptivity.
Effects of oral meloxicam administration to beef cattle receiving lipopolysaccharide administration or vaccination against respiratory pathogens.
Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.
Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas.
Effects of pergolide mesylate on transduction efficiency of PEP-1-catalase protein.
Effects of phenidone (DuCLOX-2/5 inhibitor) against N-methyl-N-nitrosourea induced mammary gland carcinoma in albino rats.
Effects of phorbol ester tumor promoters in platelet aggregation and platelet production of cyclooxygenase products.
Effects of photobiomodulation therapy and topical non-steroidal anti-inflammatory drug on skeletal muscle injury induced by contusion in rats-part 2: biochemical aspects.
Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells.
Effects of polyphenol extract from olive pomace on anoxia-induced endothelial dysfunction.
Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells.
Effects of remifentanil preconditioning on factors related to uterine contraction in WISH cells.
Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin.
Effects of rich-in-fat diets and highly selective COX-2 inhibitors on 7,12-dimethylbenz-(A)-anthracene-induced tumor growth.
Effects of RU486 and indomethacin on meiotic maturation, formation of extracellular matrix, and progesterone production by porcine oocyte-cumulus complexes.
Effects of Salvia miltiorrhiza Polysaccharides on Lipopolysaccharide-Induced Inflammatory Factor Release in RAW264.7 Cells.
Effects of sappanchalcone on the cytoprotection and anti-inflammation via heme oxygenase-1 in human pulp and periodontal ligament cells.
Effects of selective cyclooxygenase enzyme inhibitors on lipopolysaccharide-induced dual thermoregulatory changes in rats.
Effects of selenium-enriched Agaricus blazei Murill on liver metabolic dysfunction in mice, a comparison with selenium-deficient Agaricus blazei Murill and sodium selenite.
Effects of silencing cyclooxygenase-2 expression via RNA interference on the tumorigenicity of the SMMC-7721 human hepatocarcinoma cell line.
Effects of Six Weeks Endurance Training and Aloe Vera Supplementation on COX-2 and VEGF Levels in Mice with Breast Cancer
Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: a review.
Effects of TGF-beta, TNF-alpha, IL-beta and IL-6 alone or in combination, and tyrosine kinase inhibitor on cyclooxygenase expression, prostaglandin E2 production and bone resorption in mouse calvarial bone cells.
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Effects of the Inhibition of Cyclooxygenase-2 on Human Esophageal Cancer Cells: Inhibition of Cell Proliferation and Induction of Apoptosis.
Effects of the novel non-steroidal anti-inflammatory compound [N-(2-thiolethyl)-2- {2- [N'- (2,6- dichlorophenyl) amino] phenyl}acetamide on cytokines and apoptosis in ischaemic rat brain.
Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet.
Effects of TNF-alpha on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs.
Effects of Tribulus terrestris on monosodium iodoacetate?induced osteoarthritis pain in rats.
Effects of volatile oils of Angelica sinensis on an acute inflammation rat model.
Effects of wogonin, a plant flavone from Scutellaria radix, on skin inflammation: in vivo regulation of inflammation-associated gene expression.
Effects of yakuchinone A and yakuchinone B on the phorbol ester-induced expression of COX-2 and iNOS and activation of NF-kappaB in mouse skin.
Effects of zileuton and montelukast in mouse experimental spinal cord injury.
Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials.
Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema.
Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome.
Efficacy of hyaluronic acid on intervertebral disc inflammation: An in vitro study using notochordal cell lines and human disc cells.
Efficacy of meloxicam in combination with preoperative chemotherapy for breast cancer - Japan Breast Cancer Research Network (JBCRN) 02-1 trial.
Effusanin E suppresses nasopharyngeal carcinoma cell growth by inhibiting NF-?B and COX-2 signaling.
EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
EGFR Signaling Is Required for TGF-beta1 Mediated COX-2 Induction in Human Bronchial Epithelial Cells.
EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer.
EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival.
EGFR, HER-2 and COX-2 levels in colorectal cancer.
Eicosanoid profile in cultured human pulmonary artery smooth muscle cells treated with IL-1 beta and TNF alpha.
Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment.
Eicosanoid regulation of angiogenesis in tumors.
Eicosanoid synthesis by alveolar macrophages in rats with malignant mammary tumors: differences in rats treated with and without carrageenan implants.
Eicosanoids and HB-EGF/EGFR in cancer.
Eicosanoids and linoleate-enhanced growth of mouse mammary tumor cells.
Eicosanoids in Cancer: New Roles in Immunoregulation.
Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy.
Eicosanoids in inflammation and cancer: the role of COX-2.
Eicosapentaenoic acid modulates CyA-induced proinflammatory cytokine over-expression in osteoblastic cells in vitro.
Eicosapentaenoic acid reduces the invasive and metastatic activities of malignant tumor cells.
Electromagnetic Field Devices and Their Effects on Nociception and Peripheral Inflammatory Pain Mechanisms.
Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA.
Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control.
Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer.
Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy.
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.
Elevated cyclooxygenase-2 expression is associated with histological grade in invasive ductal breast carcinoma.
Elevated cyclooxygenase-2 levels in Min mouse adenomas.
Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for COX-2 induction by areca quid ingredients in oral keratinocytes.
Elevated expression of cyclooxygenase-2 in adenocarcinoma of the parotid gland: insights into malignant transformation of pleomorphic adenoma.
Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma.
Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner.
Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.
Elevated levels of the Steroidogenic Factor-1 are associated with over-expression of CYP19 in an Estrogen producing testicular Leydig cell tumour.
Elevated Levels of Urinary PGE-M Are Found in Tobacco Users and Indicate a Poor Prognosis for Oral Squamous Cell Carcinoma Patients.
Elevated Levels of Urinary Prostaglandin E Metabolite Indicate a Poor Prognosis in Ever Smoker Head and Neck Squamous Cell Carcinoma Patients.
Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
Ellagic acid ameliorates lung damage in rats via modulating antioxidant activities, inhibitory effects on inflammatory mediators and apoptosis-inducing activities.
Ellagic acid prevents kidney injury and oxidative damage via regulation of Nrf-2/NF-?B signaling in carbon tetrachloride induced rats.
Ellagic acid restored lead-induced nephrotoxicity by anti-inflammatory, anti-apoptotic and free radical scavenging activities.
Ellagitannins from Punica granatum leaves suppress microsomal prostaglandin E synthase-1 expression and induce lung cancer cells to undergo apoptosis.
Elucidating the mechanisms of action of parecoxib in the MG-63 osteosarcoma cell line.
Elucidation of anti-inflammatory potencies of Eucommia ulmoides bark and Plantago asiatica seeds.
Elucidation of colon-protective efficacy of diosgenin in experimental TNBS-induced colitis: inhibition of NF-?B/IkB-? and Bax/Caspase-1 signaling pathways.
Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis.
Elucidation of the molecular mechanism underlying the anti-inflammatory activity of an effective and safe bipyrazole-based compound.
Emodin Inhibits Inflammation, Carcinogenesis, and Cancer Progression in the AOM/DSS Model of Colitis-Associated Intestinal Tumorigenesis.
Emodin inhibits LPS-induced inflammatory response by activating PPAR-? in mouse mammary epithelial cells.
Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.
Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury.
Endogenous BMP-4/ROS/COX-2 Mediated IPC and Resveratrol Alleviated Brain Damage.
Endomicroscopic Imaging of COX-2 Activity in Murine Sporadic and Colitis-Associated Colorectal Cancer.
Endoplasmic reticulum stress increases brain MAPK signaling, inflammation and renin-angiotensin system activity and sympathetic nerve activity in heart failure.
Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Endothelial PKC?-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?
Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor.
Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.
Endotoxic shock. Part II: A review of treatment.
Endotoxin priming of thromboxane-related vasoconstrictor responses in perfused rabbit lungs.
Endotoxin tolerance: a review.
Endotoxin tolerance: A review.
Enforced Expression of miR-101 inhibits prostate cancer cell growth by modulating cyclooxygenase-2 pathway in vivo.
Engineering of a novel hybrid enzyme: an anti-inflammatory drug target with triple catalytic activities directly converting arachidonic acid into the inflammatory prostaglandin E2.
Enhanced conditioning of adverse memories in the mouse modified swim test is associated with neuroinflammatory changes - Effects that are susceptible to antidepressants.
Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat.
Enhanced Death Ligand-Induced Apoptosis in Cutaneous SCC Cells by Treatment with Diclofenac/Hyaluronic Acid Correlates with Downregulation of c-FLIP.
Enhanced endothelial cell retraction mediated by 12(S)-HETE: a proposed mechanism for the role of platelets in tumor cell metastasis.
Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression.
Enhanced expression of cyclooxygenase-2 related multi-drug resistance gene in melanoma and osteosarcoma cell lines by TSG-6 secreted from canine adipose-derived mesenchymal stem/stromal cells.
Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation.
Enhanced expression of pro-inflammatory mediators and liver X receptor-regulated lipogenic genes in nonalcoholic fatty liver disease and hepatitits C.
Enhanced expression of proproliferative and antiapoptotic genes in ulcerative colitis-associated neoplasia.
Enhanced Immune Response Improves Resistance to Cadmium Stress in Triploid Crucian Carp.
Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.
Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination.
Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.
Enhanced liver tumor promotion but not liver initiation activity in rats subjected to combined administration of omeprazole and ?-naphthoflavone.
Enhanced release of prostaglandin E2 from macrophages of rats with silicosis.
Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522.
Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.
Enhancement of anti-inflammatory activity of PEP-1-FK506 binding protein by silk fibroin peptide.
Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Enhancement of carcinogen-induced malignant cell transformation by prostaglandin F(2 alpha).
Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and SC236 via inhibiting P-glycoprotein activity.
Enhancement of experimental colon cancer by genistein.
Enhancement of experimental colon carcinogenesis by dietary 6-phenylhexyl isothiocyanate.
Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Enhancement of slow-wave sleep by tumor necrosis factor-alpha is mediated by cyclooxygenase-2 in rats.
Enhancement of the Anti-Inflammatory Effect of Mustard Kimchi on RAW 264.7 Macrophages by the Lactobacillus plantarum Fermentation-Mediated Generation of Phenolic Compound Derivatives.
Enhancement of the sensitivity of renal cell carcinoma cells to fas-mediated cytotoxicity and apoptosis by the selective cyclooxygenase-2 inhibitor JTE-522.
Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Enhancing the tumor cell selectivity of a rhodamine-decorated iridium(III) complex by conjugating with indomethacin for COX-2 targeted photodynamic therapy.
Enriched environment housing improved the laying hen's resistance to transport stress via modulating the heat shock protective response and inflammation.
EOP, a newly synthesized ethyl pyruvate derivative, attenuates the production of inflammatory mediators via p38, ERK and NF-?B pathways in lipopolysaccharide-activated BV-2 microglial cells.
EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality.
EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways.
EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival.
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.
Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks.
Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition in photoprotection.
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2.
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells.
Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma.
Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4.
Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation.
Epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines is mediated through extracellular signal-regulated kinase 1/2 and p38 but is Src and nuclear factor-kappa B independent.
Epigallocatechin gallate inhibits phorbol ester-induced activation of NF-kappa B and CREB in mouse skin: role of p38 MAPK.
Epigallocatechin-3-gallate attenuates cerebral cortex damage and promotes brain regeneration in acrylamide-treated rats.
Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties.
Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas.
Epigenetic deregulation of the COX pathway in cancer.
Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.
Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis.
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer.
Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer.
Epigenetics, an early event in the modulation of gene expression by inositol hexaphosphate in ethylnitrosourea exposed mouse lungs.
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.
Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues.
Epithelial to mesenchymal transition in cutaneous squamous cell carcinoma is correlated with COX-2 expression but not with the presence of stromal macrophages or CD10-expressing cells.
Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.
Epithelial-Specific Deletion of 11?-HSD2 Hinders Apcmin/+ Mouse Tumorigenesis.
Epoxyeicosatrienoic acid (EET)-stimulated angiogenesis is mediated by epoxy hydroxyeicosatrienoic acids (EHETs) formed from COX-2.
Epstein-Barr virus induces invasion and metastasis factors.
Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1.
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer.
ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.
ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.
Eriobotrya japonica leaf and its triterpenes inhibited lipopolysaccharide-induced cytokines and inducible enzyme production via the nuclear factor-kappaB signaling pathway in lung epithelial cells.
Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner.
Erratum to "Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells" [Redox Biol. 11 (2017) 653-662].
Erucin exerts anti-inflammatory properties in murine macrophages and mouse skin: possible mediation through the inhibition of NF?B signaling.
Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study.
Escin attenuates cerebral edema induced by acute omethoate poisoning.
Esculentoside A ameliorates cecal ligation and puncture-induced acute kidney injury in rats.
Esculentoside A exerts anti-inflammatory activity in microglial cells.
Esophageal squamous cell carcinoma cell proliferation induced by exposure to low concentration of cigarette smoke extract is mediated via targeting miR-101-3p/COX-2 pathway.
ESR studies on reactivity of protein-derived tyrosyl radicals formed by prostaglandin H synthase and ribonucleotide reductase.
Essential oil from leaves of Liquidambar formosana ameliorates inflammatory response in lipopolysaccharide-activated mouse macrophages.
Essential oil from the heartwood of Taiwan fir ameliorates LPS-induced inflammatory response by inhibiting the activation of mitogen-activated protein kinase.
Essential role of NF-kappa B activation in silica-induced inflammatory mediator production in macrophages.
Essential roles of Toll-like receptor-4 signaling in arthritis induced by type II collagen antibody and LPS.
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.
Establishment and characterization of mouse bone marrow-derived mast cell hybridomas.
Establishment and characterization of novel xenograft models of human biliary tract carcinomas.
Establishment of inflammatory model induced by Pseudorabies virus infection in mice.
Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes.
Estradiol-potentiated cadherin-11 in synovial membrane involves in temporomandibular joint inflammation in rats.
Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
Estrogen or Estrogen Receptor Agonist Inhibits Lipopolysaccharide Induced Microglial Activation and Death.
Estrogen receptor antagonist fulvestrant (ICI 182,780) inhibits the anti-inflammatory effect of glucocorticoids.
Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-?B nuclear translocation and the activation of the PI3K/Akt signaling pathway.
Ethanol Extract of Lilium Bulbs Plays an Anti-Inflammatory Role by Targeting the IKK[Formula: see text]/[Formula: see text]-Mediated NF-[Formula: see text]B Pathway in Macrophages.
Ethanol extract of Synurus deltoides (Aiton) Nakai suppresses in vitro LPS-induced cytokine production in RAW 264.7 macrophages and in vivo acute inflammatory symptoms.
Ethanol via Regulation of NF-?B/p53 Signaling Pathway Increases Manganese-Induced Inflammation and Apoptosis in Hypothalamus of Rats.
Ethanolic extract of Pyrus pashia buch ham ex. D. Don (Kainth): A bioaccessible source of polyphenols with anti-inflammatory activity in vitro and in vivo.
Ethyl acetate extract from Angelica Dahuricae Radix inhibits lipopolysaccharide-induced production of nitric oxide, prostaglandin E2 and tumor necrosis factor-alphavia mitogen-activated protein kinases and nuclear factor-kappaB in macrophages.
Ethyl acetate fraction of Terminalia bellirica (Gaertn.) Roxb. fruits inhibits proinflammatory mediators via down regulating nuclear factor-?B in LPS stimulated Raw 264.7 cells.
Ethyl pyruvate ameliorates 3-nitropropionic acid-induced striatal toxicity through anti-neuronal cell death and anti-inflammatory mechanisms.
Ethyl pyruvate ameliorates liver injury secondary to severe acute pancreatitis.
Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock.
Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells.
Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Eucalyptus robusta leaves methanolic extract suppresses inflammatory mediators by specifically targeting TLR4/TLR9, MPO, COX2, iNOS and inflammatory cytokines in experimentally-induced endometritis in rats.
Eugenol precludes cutaneous chemical carcinogenesis in mouse by preventing oxidative stress and inflammation and by inducing apoptosis.
Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells.
Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer.
Evaluating the expression of cyclooxygenase-2 enzyme by immunohistochemistry in normal and tumoral tissue before and after neoadjuvant chemoradiotherapy in patients with esophageal cancer in Khorasan Province.
Evaluation of Anti-Inflammatory Properties of Isoorientin Isolated from Tubers of Pueraria tuberosa.
Evaluation of Antioxidant Intakes in Relation to Inflammatory Markers Expression Within the Normal Breast Tissue of Breast Cancer Patients.
Evaluation of Brazilian plants on cancer chemoprevention targets in vitro.
Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma.
Evaluation of Cyclooxygenase-2 Expression in Association with Clinical-Pathological Factors in Malignant Melanoma.
Evaluation of Cyclooxygenase-2 Expression in Canine Mast Cell Tumours.
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.
Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line.
Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options.
Evaluation of expression of apoptosis-related proteins and their correlation with HPV, telomerase activity, and apoptotic index in cervical cancer.
Evaluation of Glycosylated PTGS2 in Colorectal Cancer for NSAIDS-Based Adjuvant Therapy.
Evaluation of human glioma using in-vivo proton magnetic resonance spectroscopy combined with expression of cyclooxygenase-2: a preliminary clinical trial.
Evaluation of immunohistochemical expression of P-glycoprotein in neoplasms of the mammary gland in bitches.
Evaluation of inflammation-related genes polymorphisms in Mexican with Alzheimer's disease: a pilot study.
Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours.
Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.
Evaluation of natural products on inhibition of inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) in cultured mouse macrophage cells.
Evaluation of pentacyclic triterpenes found in Perilla frutescens for inhibition of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Evaluation of potential Stat3-regulated genes in human breast cancer.
Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms.
Evaluation of protective effects of costunolide and dehydrocostuslactone on ethanol-induced gastric ulcer in mice based on multi-pathway regulation.
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Evaluation of selected lichens from iceland for cancer chemopreventive and cytotoxic activity.
Evaluation of targeted arterial delivery of the branched chain fatty acid 12-methyltetradecanoic acid as a novel therapy for solid tumors.
Evaluation of the contribution of cyclooxygenase 2 genotypes to breast cancer in Taiwan.
Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study.
Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(?)anthracene-induced mammary carcinogenesis.
Evaluation of VEGF expression correlates with COX-2 expression in pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma.
Evaluation of wound healing properties of bioactive aqueous fraction from Moringa oleifera Lam on experimentally induced diabetic animal model.
Evidence for tumor necrosis factor alpha as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis.
Evidence of COX-1 and COX-2 expression in Kaposi's sarcoma tissues.
Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines.
Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma.
Ex Vivo Study on the Antioxidant Activity of a Winemaking By-Product Polyphenolic Extract (Taurisolo®) on Human Neutrophils.
Exacerbation of alcoholic liver injury by enteral endotoxin in rats.
Examination of the effect of combined use of Er:YAG laser irradiation and mechanical force loading on bone metabolism using primary human gingival fibroblasts.
Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology.
Excessive reactive oxygen species are therapeutic targets for intervertebral disc degeneration.
Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence.
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.
Exogenous heat shock cognate protein 70 pretreatment attenuates cardiac and hepatic dysfunction with associated anti-inflammatory responses in experimental septic shock.
Exopolysaccharide Isolated from Lactobacillus plantarum L-14 Has Anti-Inflammatory Effects via the Toll-Like Receptor 4 Pathway in LPS-Induced RAW 264.7 Cells.
Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases.
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Experimental and theoretical investigations of cyclometalated ruthenium(ii) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities in various cancer cell lines.
Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.
Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy.
Exploring the Role of IL-32 in HIV-Related Kaposi Sarcoma.
Exposure of Wistar rats to 24-h psycho-social stress alters gene expression in the inferior colliculus.
Exposure to chewing tobacco promotes primary oral squamous cell carcinoma and regional lymph node metastasis by alterations of SDF1?/CXCR4 axis.
Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies.
Exposure to Perfluorooctanoic Acid Induces Cognitive Deficits via Altering Gut Microbiota Composition, Impairing Intestinal Barrier Integrity, and Causing Inflammation in Gut and Brain.
Expression analysis of cyclooxygenase-2 in patients suffering from esophageal squamous cell carcinoma.
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers.
Expression and association of carbonic anhydrase IX and cyclooxygenase-2 in colorectal cancer.
Expression and clinical implication of cyclooxygenase-2 and e-cadherin in oral squamous cell carcinomas.
Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas.
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma.
Expression and clinical significance of cyclooxygenase-2 and microRNA-143 in osteosarcoma.
Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors.
Expression and localization of COX-2 in human airways and cultured airway epithelial cells.
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: a retrospective study.
Expression and regulation of cyclooxygenase-2 in normal and neoplastic canine keratinocytes.
Expression and regulation of cyclooxygenase-2 in rat microglia.
Expression and significance of cyclooxygenase 2 gene in lung cancer.
Expression levels of cyclooxygenase-2, tumor necrosis factor-? and inducible NO synthase in placental tissue of normal and preeclamptic pregnancies.
Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor.
Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: Correlations with angiogenesis and prognosis.
Expression of 15-hydroxyprostaglandin dehydrogenase, a COX-2 antagonist and tumour suppressor, is not altered in gastric carcinomas.
Expression of 15-lipoxygenase-1 in human colorectal cancer.
Expression of 15-PGDH is downregulated by COX-2 in gastric cancer.
Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis.
Expression of antiapoptotic and proapoptotic molecules in diabetic retinas.
Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis.
Expression of beta-catenin, COX-2 and iNOS in colorectal cancer: relevance of COX-2 adn iNOS inhibitors for treatment in Malaysia.
Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.
Expression of Ca(2+)-independent and Ca(2+)-dependent phospholipases A(2) and cyclooxygenases in human melanocytes and malignant melanoma cell lines.
Expression of Cox-1 and Cox-2 in canine mammary tumours.
Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features.
Expression of COX-2 and HER-2 in colorectal cancer and their correlation.
Expression of COX-2 and prognostic outcome in uveal melanoma.
Expression of COX-2 and steroid converting enzymes in breast cancer.
Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness.
Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma.
Expression of COX-2 in stomach cancers and its relation to their biological features.
Expression of COX-2 in Stomach Carcinogenesis.
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.
Expression of COX-2 is increased with age in papillary thyroid cancer.
Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD.
Expression of Cox-2 protein in radioresistant laryngeal cancer.
Expression of COX-2 proteins in gastric mucosal lesions.
Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Expression of COX-2, CD44v6 and CD147 and Relationship with Invasion and Lymph Node Metastasis in Hypopharyngeal Squamous Cell Carcinoma.
Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis.
Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue.
Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters.
Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis.
Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
Expression of cyclo-oxygenase-2 in ependymal tumors.
Expression of cyclo-oxygenase-2 in gastrointestinal carcinoid tumors.
Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions.
Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs.
Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas.
Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Expression of cyclooxygenase 2 and vascular endothelial growth factor in gastric carcinoma: Relationship with clinicopathological parameters.
Expression of cyclooxygenase 2 in human malignant melanoma.
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.
Expression of cyclooxygenase-1 and -2 and clinicopathologic features of colorectal cancer in northern Thailand.
Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.
Expression of cyclooxygenase-1 and -2 in canine nasal carcinomas.
Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.
Expression of cyclooxygenase-1 and -2 in human breast cancer.
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Expression of cyclooxygenase-1 and -2 in naturally occurring squamous cell carcinomas in horses.
Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells.
Expression of Cyclooxygenase-1 and 2 in Epithelial Ovarian Cancer: A Clinicopathologic Study.
Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.
Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in normal and pathological human oral mucosa.
Expression of cyclooxygenase-1 and cyclooxygenase-2, syndecan-1 and connective tissue growth factor in benign and malignant breast tissue from premenopausal women.
Expression of cyclooxygenase-1/-2, microsomal prostaglandin-E synthase-1 and E-prostanoid receptor 2 and regulation of inflammatory mediators by PGE(2) in the amoeboid microglia in hypoxic postnatal rats and murine BV-2 cells.
Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors.
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.
Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial lesions.
Expression of cyclooxygenase-2 (COX-2) in pituitary tumours.
Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications.
Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma.
Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa.
Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.
Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.
Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma.
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?
Expression of cyclooxygenase-2 and its correlation with clinicopathologic factors of ampulla of vater cancer.
Expression of Cyclooxygenase-2 and Its Correlation with Vasogenic Brain Edema in Human Intracranial Meningiomas.
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in colorectal cancers.
Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis.
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.
Expression of cyclooxygenase-2 and microsomal prostaglandin-E synthase in amoeboid microglial cells in the developing brain and effects of cyclooxygenase-2 neutralization on BV-2 microglial cells.
Expression of cyclooxygenase-2 and mucin 1 in colorectal cancer.
Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression.
Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis.
Expression of cyclooxygenase-2 and pro-inflammatory cytokines induced by 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) in human mast cells requires NF-kappa B activation.
Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions.
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
Expression of Cyclooxygenase-2 and Tumor Microvessel Density in Colorectal Cancer.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in primary central nervous system lymphomas.
Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer.
Expression of cyclooxygenase-2 by equine ocular and adnexal squamous cell carcinomas.
Expression of cyclooxygenase-2 has no impact on survival in adenocarcinoma of the esophagogastric junction but is associated with favourable clinicopathologic features.
Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth.
Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
Expression of cyclooxygenase-2 in canine epithelial nasal tumors.
Expression of cyclooxygenase-2 in canine uveal melanocytic neoplasms.
Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion.
Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.
Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis.
Expression of cyclooxygenase-2 in chondroblastoma: immunohistochemical analysis with special emphasis on local inflammatory reaction.
Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression.
Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance.
Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma.
Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression.
Expression of cyclooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases.
Expression of cyclooxygenase-2 in foetal rat hepatocytes stimulated with lipopolysaccharide and pro-inflammatory cytokines.
Expression of cyclooxygenase-2 in gastric cancer and its relation to liver metastasis and long-term prognosis.
Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus.
Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors.
Expression of Cyclooxygenase-2 in Human Breast Carcinoma: Relevance to Tumor Angiogenesis and Expression of Estrogen Receptor.
Expression of Cyclooxygenase-2 in Human Epithelial Skin Lesions: A Systematic Review of Immunohistochemical Studies.
Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas.
Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.
Expression of cyclooxygenase-2 in human gastric carcinoma.
Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation.
Expression of cyclooxygenase-2 in human lung carcinoma.
Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey.
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.
Expression of cyclooxygenase-2 in imprint smears of endometrial carcinoma.
Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact.
Expression of cyclooxygenase-2 in malignant and benign breast tumors.
Expression of Cyclooxygenase-2 in naturally occurring bovine cutaneous fibropapillomas.
Expression of cyclooxygenase-2 in neoplasms of the mammary gland in bitches.
Expression of cyclooxygenase-2 in osteosarcoma of bone.
Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation.
Expression of cyclooxygenase-2 in patients with bladder carcinoma.
Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression.
Expression of cyclooxygenase-2 in prostate carcinoma.
Expression of cyclooxygenase-2 in rat testis.
Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival.
Expression of Cyclooxygenase-2 in Squamous Cell Carcinoma and Keratoacanthoma and its Clinical Significance.
Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder.
Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs.
Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.
Expression of cyclooxygenase-2 in Wilms tumor: immunohistochemical study using tissue microarray methodology.
Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression.
Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells.
Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study.
Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer.
Expression of cyclooxygenase-2 protein in colorectal carcinomas.
Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.
Expression of Cyclooxygenase-2 Protein in Gastric Carcinogenesis.
Expression of cyclooxygenase-2 related to angiogenesis in uterine cervical cancers.
Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis.
Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
Expression of cyclooxygenase-2, Fas and Fas ligand in pulmonary adenocarcinoma and atypical adenomatous hyperplasia.
Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer.
Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
Expression of cytokine-induced neutrophil chemoattractant suppresses tumor necrosis factor alpha expression and thereby prevents the follicles from undergoing atresia and apoptosis.
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
Expression of embryonic lethal abnormal vision (ELAV)-like protein HuR and cyclooxygenase-2 (COX-2) in Ewing sarcoma.
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy.
Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma.
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Expression of Ezrin, Mmp-9 and Cox-2 in 50 Chordoma Specimens: A Clinical and Immunohistochemical Analysis.
Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma.
Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma.
Expression of genes in the canine pre-implantation uterus and embryo: implications for an active role of the embryo before and during invasion.
Expression of hepatic vascular stress genes following ischemia/reperfusion and subsequent endotoxemia.
Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
Expression of HLA Class I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon Cancer.
Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density.
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.
Expression of iNOS, COX-2 and VEGF in canine mammary tumours and non-neoplastic mammary glands: Association with clinicopathological features and tumour grade.
Expression of Ki67, BCL-2, and COX-2 in Canine Cutaneous Mast Cell Tumors: Association With Grading and Prognosis.
Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?
Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors.
Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors.
Expression of long non-coding RNA CCHE1 in colorectal carcinoma: correlations with clinicopathological features and ERK/COX-2 pathway.
Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors.
Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance.
Expression of methylation-modulated tumor-related genes in endoscopically resected early esophageal squamous neoplasia.
Expression of miR-143 Reduces Growth and Migration of Human Bladder Carcinoma Cells by Targeting Cyclooxygenase-2.
Expression of molecular markers in low-grade chondrosarcomas and cartilaginous tumors with uncertain differentiation.
Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.
Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients.
Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco.
Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer.
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma.
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo.
Expression of p63 and cyclooxygenase-2 and their correlation in skin tumors.
Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers.
Expression of PCNA, Ki-67 and COX-2 in breast cancer based on DCE-MRI image information.
Expression of Phospholipase D in Periodontitis and Its Role in the Inflammatory and Osteoclastic Response by Nicotine- and Lipopolysaccharide-Stimulated Human Periodontal Ligament Cells.
Expression of prostaglandin e synthases in periodontitis immunolocalization and cellular regulation.
Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas.
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.
Expression of prostaglandin H synthase-2 in human brain tumors.
Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells.
Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis.
Expression of sFRP-4 and beta-catenin in human colorectal carcinoma.
Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.
Expression of the aryl hydrocarbon receptor pathway and cyclooxygenase-2 in dog tumors.
Expression of the CD117, COX-2 and HSP90 antigens and cell proliferation in fine-needle-aspirated cells from metastatic melanomas.
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma.
Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis.
Expression of the genes for peroxisome proliferator-activated receptor-?, cyclooxygenase-2, and proinflammatory cytokines in granulosa cells from women with polycystic ovary syndrome.
Expression of the p73 protein in rectal cancers with or without preoperative radiotherapy.
Expression of the prostaglandin F synthase AKR1B1 and the prostaglandin transporter SLCO2A1 in human fetal membranes in relation to spontaneous term and preterm labor.
Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis.
Expression of tumor necrosis factor-alpha and cyclooxygenase-2 mRNA in porcine split-thickness wounds treated with epidermal growth factor by quantitative real-time PCR.
Expression of type V secretory phospholipase A in myocardial remodelling after infarction.
Expression of VEGF and Cox-2 in Patients with Esophageal Squamous Cell Carcinoma
Expression of VEGF, VEGFR, EGFR, COX-2 and MVD in cervical carcinoma, in relation with the response to radio-chemotherapy.
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH(2))D(3)) and prostaglandin E(2) (PGE(2)) serum level in ovarian cancer patients.
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
Expression pattern of cyclooxygenase-2 in normal rat epidermis and pilosebaceous unit during hair cycle.
Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
Expression profile analysis of colon cancer cells in response to sulindac or aspirin.
Expression profile of NF-?B regulated genes in sporadic colorectal cancer patients.
Expression profiles of Annexin A1, formylated peptide receptors and cyclooxigenase-2 in gastroesophageal inflammations and neoplasias.
Expression profiles of proliferative and antiapoptotic genes in sporadic and colitis-related mouse colon cancer models.
Expression-targeted gene therapy for the treatment of transitional cell carcinoma.
Expressions and clinical significance of COX-2, VEGF-C, and EFGR in endometrial carcinoma.
Expressions of cyclooxygenase 2 in gastrointestinal stromal tumors.
Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression.
Expressions of ER, PR, HER-2, COX-2, and VEGF in Primary and Relapsed/Metastatic Breast Cancers.
Expressions of Ras Homolog Gene Family, Member A (RhoA) and Cyclooxygenase-2 (COX-2) Proteins in Early Gastric Cancer and Their Role in the Development of Gastric Cancer.
Expressions of TIMP-1, COX-2 and MMP-7 in Colon Polyp and Colon Cancer.
Extracellular ATP enhances radiation-induced brain injury through microglial activation and paracrine signaling via P2X7 receptor.
Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase 2.
Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer.
Extracellular Vesicles Derived from Bone Marrow Mesenchymal Stem Cells Protect against Experimental Colitis via Attenuating Colon Inflammation, Oxidative Stress and Apoptosis.
Extracellular Vesicles from Bovine Follicular Fluid Support Cumulus Expansion.
Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review.
Extraction Process, Component Analysis, and In Vitro Antioxidant, Antibacterial, and Anti-Inflammatory Activities of Total Flavonoid Extracts from Abutilon theophrasti Medic. Leaves.
FA15, a hydrophobic derivative of ferulic acid, suppresses inflammatory responses and skin tumor promotion: comparison with ferulic acid.
Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer.
Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines.
Failure of indomethacin to inhibit growth of the R3230AC mammary tumor in rats.
Farrerol ameliorate adjuvant-induced ankle injury via alteration of PPAR-? signal pathway.
Farrerol attenuates MPP+ -induced inflammatory response by TLR4 signaling in a microglia cell line.
Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-?B signaling pathways.
Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
Fatty acid metabolites in rapidly proliferating breast cancer.
Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells.
Features of bilirubin-induced reactive microglia: from phagocytosis to inflammation.
Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model.
Fermentation by Lactobacillus enhances anti-inflammatory effect of Oyaksungisan on LPS-stimulated RAW 264.7 mouse macrophage cells.
Fermentation improves anti-inflammatory effect of sipjeondaebotang on LPS-stimulated RAW 264.7 cells.
Fermented Ganjangs (Soy Sauce and Sesame Sauce) Attenuates Colonic Carcinogenesis in Azoxymethane/Dextran Sodium Sulfate-Treated C57BL/6J Mice.
Fernblock (Polypodium leucotomos Extract): Molecular Mechanisms and Pleiotropic Effects in Light-Related Skin Conditions, Photoaging and Skin Cancers, a Review.
FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression.
Fibroblast-like synovial cells derived from synovial fluid.
Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma.
First Evidence for the Anti-inflammatory Activity of Fucoxanthin in High-Fat-Diet-Induced Obesity in Mice and the Antioxidant Functions in PC12 Cells.
Fisetin inhibits the generation of inflammatory mediators in interleukin-1?-induced human lung epithelial cells by suppressing the NF-?B and ERK1/2 pathways.
Fisetin Suppresses Macrophage-Mediated Inflammatory Responses by Blockade of Src and Syk.
Fisetin, a dietary flavonoid, ameliorates experimental colitis in mice: Relevance of NF-?B signaling.
Fish Oil Alleviates Activation of Hypothalamic-Pituitary-Adrenal Axis Associated with Inhibition of TLR4 and NOD Signaling Pathways in Weaned Piglets after a Lipopolysaccharide Challenge.
Fish oil augments celecoxib mediated alteration in apoptotic pathway in the initiation phase of 7,12-dimethylbenz(?)anthracene-induced mammary carcinogenesis.
Fish oil increases muscle protein mass and modulates Akt/FOXO, TLR4, and NOD signaling in weanling piglets after lipopolysaccharide challenge.
Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression.
Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention.
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone.
Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis.
Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.
Flavonoids from Boldoa purpurascens inhibit proinflammatory cytokines (TNF-? and IL-6) and the expression of COX-2.
Flavonoids Identified from Korean Scutellaria baicalensis Georgi Inhibit Inflammatory Signaling by Suppressing Activation of NF- ? B and MAPK in RAW 264.7 Cells.
Flavonoids Isolated from Flowers of Lonicera japonica Thunb. Inhibit Inflammatory Responses in BV2 Microglial Cells by Suppressing TNF-? and IL-? Through PI3K/Akt/NF-kb Signaling Pathways.
Flavonoids of the Genus Iris (Iridaceae).
FlexPro MD®, a Combination of Krill Oil, Astaxanthin and Hyaluronic Acid, Reduces Pain Behavior and Inhibits Inflammatory Response in Monosodium Iodoacetate-Induced Osteoarthritis in Rats.
Fluence-dependent effects of low-level laser therapy in myofascial trigger spots on modulation of biochemicals associated with pain in a rabbit model.
Fluorescence discrimination of cancer from inflammation by molecular response to COX-2 enzymes.
Fluorescence tumor imaging by i.v. administered indocyanine green in a mouse model of colitis-associated colon cancer.
Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site.
Fluoride-elicited developmental testicular toxicity in rats: Roles of endoplasmic reticulum stress and inflammatory response.
Fluorinated 2'-hydroxychalcones as garcinol analogs with enhanced antioxidant and anticancer activities.
Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.
Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer.
Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies.
FLZ attenuates learning and memory deficits via suppressing neuroinflammation induced by LPS in mice.
Follistatin-like protein 1 (FSTL1) promotes chondrocyte expression of matrix metalloproteinase and inflammatory factors via the NF-?B pathway.
Food Polyphenols Fail to Cause a Biologically Relevant Reduction of COX-2 Activity.
Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells.
Formosanin C attenuates lipopolysaccharide-induced inflammation through nuclear factor-?B inhibition in macrophages.
Forsythiaside attenuates lipopolysaccharide-induced inflammatory responses in the bursa of Fabricius of chickens by downregulating the NF-?B signaling pathway.
Forsythoside A Alleviates High Glucose-Induced Oxidative Stress and Inflammation in Podocytes by Inactivating MAPK Signaling via MMP12 Inhibition.
FOXP3 inhibits cancer stem cell self-renewal via transcriptional repression of COX2 in colorectal cancer cells.
FPS-ZM1 inhibits LPS-induced microglial inflammation by suppressing JAK/STAT signaling pathway.
Fragile X-related protein 1 (FXR1) regulates cyclooxygenase-2 (COX-2) expression at the maternal?fetal interface.
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.
From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.
Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.
Fruits extracts of Hovenia dulcis Thunb. suppresses lipopolysaccharide-stimulated inflammatory responses through nuclear factor-kappaB pathway in Raw 264.7 cells.
FSH-regulated gene expression profiles in ovarian tumours and normal ovaries.
Fucoidan Isolated from Saccharina japonica Inhibits LPS-Induced Inflammation in Macrophages via Blocking NF-?B, MAPK and JAK-STAT Pathways.
Fucoxanthinol from the Diatom Nitzschia Laevis Ameliorates Neuroinflammatory Responses in Lipopolysaccharide-Stimulated BV-2 Microglia.
Fullerene C?? Derivatives Attenuated Microglia-Mediated Prion Peptide Neurotoxicity.
Function of DNA methyltransferase 3a in lead (Pb(2+) )-Induced Cyclooxygenase-2 gene.
Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer.
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
Functional Food Quality of Curcuma caesia, Curcuma zedoaria and Curcuma aeruginosa Endemic to Northeastern India.
Functional Genetic Variations of Cyclooxygenase-2 and Susceptibility to Acute Myeloid Leukemia in a Chinese Population.
Functional loss of p53 cooperates with the in vivo microenvironment to promote malignant progression of gastric cancers.
Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population.
Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma.
Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India.
Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma.
Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population.
Functional polymorphisms of the cyclooxygenase-2 gene and prognosis of hepatocellular carcinoma - a cohort study in Chinese people.
Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses.
Further evaluation of a novel nano-scale gene vector for in vivo transfection of siRNA.
Future Aspects for Cannabinoids in Breast Cancer Therapy.
Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha.
G protein-coupled estrogen receptor is involved in the anti-inflammatory effects of genistein in microglia.
G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1.
G?13/PDZ-RhoGEF/RhoA signaling is essential for gastrin-releasing peptide receptor-mediated colon cancer cell migration.
Gabapentin attenuates intestinal inflammation: Role of PPAR-gamma receptor.
GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells.
Galangin Activates Nrf2 Signaling and Attenuates Oxidative Damage, Inflammation, and Apoptosis in a Rat Model of Cyclophosphamide-Induced Hepatotoxicity.
Galangin protects human rheumatoid arthritis fibroblast?like synoviocytes via suppression of the NF??B/NLRP3 pathway.
Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model of Parkinson's Disease in Rats.
Galangin Suppresses Renal Inflammation via the Inhibition of NF-?B, PI3K/AKT and NLRP3 in Uric Acid Treated NRK-52E Tubular Epithelial Cells.
Galanin modulates the neural niche to favour perineural invasion in head and neck cancer.
Galectin-1 attenuates neurodegeneration in Parkinson's disease model by modulating microglial MAPK/I?B/NF?B axis through its carbohydrate-recognition domain.
Galectin-1 exhibits a protective effect against hepatotoxicity induced by dextran sulfate sodium in mice.
Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2.
Gallbladder cancer: Clinical and pathological approach.
Galpha(13) stimulates Rho-dependent activation of the cyclooxygenase-2 promoter.
Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKK?/NF-?B signaling pathway in lung cancer cells.
Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines.
Gamma-herpesvirus neoplasia: a growing role for COX-2.
gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells.
Gangliosides activate cultured rat brain microglia.
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Gastric cancer and Helicobacter pylori infection.
Gastric cancer: an infectious disease.
Gastric MALT-lymphoma, gastrin and cyclooxygenases.
Gastrodin attenuation of the inflammatory response in H9c2 cardiomyocytes involves inhibition of NF-?B and MAPKs activation via the phosphatidylinositol 3-kinase signaling.
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat.
Gastroprotective Effects of Fermented Lotus Root against Ethanol/HCl-Induced Gastric Mucosal Acute Toxicity in Rats.
Gastroprotective effects of Hwanglyeonhaedok-tang against Helicobacter pylori-induced gastric cell injury.
Gastroprotective Effects of PMK-S005 against Ethanol-Induced Acute Gastric Damage in Rats.
Gaudichaudione H Inhibits Inflammatory Responses in Macrophages and Dextran Sodium Sulfate-Induced Colitis in Mice.
Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study.
Gellan gum macrobeads loaded with naproxen: The impact of various naturally derived polymers on pH-dependent behavior.
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.
Gemfibrozil Pretreatment Affecting Antioxidant Defense System and Inflammatory, but not Nrf-2 Signaling Pathways Resulted in Female Neuroprotection and Male Neurotoxicity in the Rat Models of Global Cerebral Ischemia-Reperfusion.
Gene activity associated with cancers treated by surgical oncologists.
Gene expression alterations of human peripheral blood monocytes induced by medium-term treatment with the TH2-cytokines interleukin-4 and -13.
Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Gene expression changes in peripheral blood mononuclear cells during measles virus infection.
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Gene expression of factors related to the immune reaction in response to intramammary Escherichia coli lipopolysaccharide challenge.
Gene expression of immunologically important factors in blood cells, milk cells, and mammary tissue of cows.
Gene expression of isoformic enzymes in arachidonate cyclooxygenase pathway and the regulation by tumor necrosis factor alpha during life cycle of adipocytes.
Gene expression of oncogenes, antimicrobial peptides, and cytokines in the development of oral leukoplakia.
Gene expression of prostaglandin EP4 receptor in three canine carcinomas.
Gene Microarray Analyses of Daboia russelli russelli Daboiatoxin Treatment of THP-1 Human Macrophages Infected with Burkholderia pseudomallei.
Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells.
Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents.
Gene transfer of pro-opiomelanocortin prohormone suppressed the growth and metastasis of melanoma: involvement of alpha-melanocyte-stimulating hormone-mediated inhibition of the nuclear factor kappaB/cyclooxygenase-2 pathway.
Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth.
Genes for prostaglandin synthesis, transport and inactivation are differentially expressed in human uterine tissues, and the prostaglandin F synthase AKR1B1 is induced in myometrial cells by inflammatory cytokines.
Genes that mediate breast cancer metastasis to the brain.
Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation.
Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis.
Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3.
Genetic and microenvironmental implications in prostate cancer progression and metastasis.
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
Genetic polymorphisms as non-modifiable susceptibility factors to laryngeal cancer.
Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility.
Genetic-deletion of Cyclooxygenase-2 Downstream Prostacyclin Synthase Suppresses Inflammatory Reactions but Facilitates Carcinogenesis, unlike Deletion of Microsomal Prostaglandin E Synthase-1.
Geniposide suppresses LPS-induced nitric oxide, PGE2 and inflammatory cytokine by downregulating NF-?B, MAPK and AP-1 signaling pathways in macrophages.
Genistein-attenuated Gastric Injury on Indomethacin-induced Gastropathy in Rats.
Gentiopicroside protects neurons from astrocyte-mediated inflammatory injuries by inhibition of nuclear factor-?B and mitogen-activated protein kinase signaling pathways.
Geraniol attenuates 4NQO-induced tongue carcinogenesis through downregulating the activation of NF-?B in rats.
Ghrelin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus.
Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis.
Ginkgolic Acid is a Multi-Target Inhibitor of Key Enzymes in Pro-Inflammatory Lipid Mediator Biosynthesis.
Ginsenoside Rb1, A Major Saponin from Panax ginseng, Exerts Protective Effects Against Acetaminophen-Induced Hepatotoxicity in Mice.
Ginsenoside Rd inhibits IL-1?-induced inflammation and degradation of intervertebral disc chondrocytes by increasing IL1RAP ubiquitination.
Ginsenoside Rg1 Attenuates Lipopolysaccharide-Induced Inflammatory Responses Via the Phospholipase C-?1 Signaling Pathway in Murine BV-2 Microglial Cells.
Ginsenoside Rg1 Exerts Anti-inflammatory Effects via G Protein-Coupled Estrogen Receptor in Lipopolysaccharide-Induced Microglia Activation.
Ginsenoside rg3 alleviates lipopolysaccharide-induced learning and memory impairments by anti-inflammatory activity in rats.
Ginsenoside Rg3 Sensitizes Colorectal Cancer to Radiotherapy through Downregulation of Proliferative and Angiogenic Biomarkers.
Ginsenoside Rg5 Ameliorates Cisplatin-Induced Nephrotoxicity in Mice through Inhibition of Inflammation, Oxidative Stress, and Apoptosis.
Glioma-secreted soluble factors stimulate microglial activation: The role of interleukin-1? and tumor necrosis factor-?.
Global and region-specific post-transcriptional and post-translational modifications of bisphenol A in human prostate cancer cells.
Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation.
Global Tumor RNA Expression in Early Establishment of Experimental Tumor Growth and Related Angiogenesis following Cox-Inhibition Evaluated by Microarray Analysis.
Glottic versus supraglottic tumors: differential molecular profile.
Glucagon induces airway smooth muscle relaxation by nitric oxide and prostaglandin E?.
Glucocorticoid availability in colonic inflammation of rat.
Glucocorticoids use in kidney transplant setting.
Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner.
Glucose degradation products increase apoptosis of human mesothelial cells.
Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice.
Glutathione peroxidases in different stages of carcinogenesis.
Glycine inhibits ethanol-induced oxidative stress, neuroinflammation and apoptotic neurodegeneration in postnatal rat brain.
Glycine- and proline-rich glycoprotein regulates the balance between cell proliferation and apoptosis for ACF formation in 1,2-dimethylhydrazine-treated A/J mice.
Glycomacropeptide Prevents Iron/Ascorbate-Induced Oxidative Stress, Inflammation and Insulin Sensitivity with an Impact on Lipoprotein Production in Intestinal Caco-2/15 Cells.
Glycyrrhiza glabra L. Extract Inhibits LPS-Induced Inflammation in RAW Macrophages.
Glycyrrhizin ameliorates metabolic syndrome-induced liver damage in experimental rat model.
Glycyrrhizin inhibits osteoarthritis development through suppressing the PI3K/AKT/NF-?B signaling pathway in vivo and in vitro.
Gomisin N ameliorates lipopolysaccharide-induced depressive-like behaviors by attenuating inflammation in the hypothalamic paraventricular nucleus and central nucleus of the amygdala in mice.
Gonadotropins Induce Tumor Cell Migration and Invasion by Increasing Cyclooxygenases Expression and Prostaglandin E2 Production in Human Ovarian Cancer Cells.
GPER and IGF-1R mediate the anti-inflammatory effect of genistein against lipopolysaccharide (LPS)-induced nigrostriatal injury in rats.
Gram-negative bacterial lipopolysaccharide impairs hyaluronan clearance in vivo and its uptake by the isolated, perfused rat liver.
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Downregulates the Expression of Protumor Factors Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in a GM-CSF Receptor-Independent Manner in Cervical Cancer Cells.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is released by female mouse bladder urothelial cells and expressed by the urothelium as an early response to lipopolysaccharides (LPS).
Granulocyte-macrophage colony-stimulating factor amplifies lipopolysaccharide-induced bronchoconstriction by a neutrophil- and cyclooxygenase 2-dependent mechanism.
Grape and wine polyphenols down-regulate the expression of signal transduction genes and inhibit the growth of estrogen receptor-negative MDA-MB231 tumors in nu/nu mouse xenografts.
Grape-seed proanthocyanidins inhibit the lipopolysaccharide-induced inflammatory mediator expression in RAW264.7 macrophages by suppressing MAPK and NF-?b signal pathways.
Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells.
Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation.
Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.
Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene.
Green tea polyphenols in the prevention of colon cancer.
Green tea polyphenols mitigate bone loss of female rats in a chronic inflammation-induced bone loss model.
Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content.
GROWTH FACTORS AND COX2 IN WOUND HEALING: AN EXPERIMENTAL STUDY WITH EHRLICH TUMORS.
Growth hormone releasing hormone induces the expression of nitric oxide synthase.
Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis.
Growth inhibition and eicosanoid metabolism in the R3230AC mammary adenocarcinoma by interferon.
Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Growth inhibition and prostaglandin metabolism in the R3230AC mammary adenocarcinoma by reduced glutathione.
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes.
Growth inhibitory effects of PC-NSAIDs on human breast cancer subtypes in cell culture.
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.
Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1.
Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro.
Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-{kappa}B and STAT3 pathways in head and neck cancer cells.
Guggulsterone Attenuated Lipopolysaccharide-Induced Inflammatory Responses in Mouse Inner Medullary Collecting Duct-3 Cells.
Guggulsterone for Chemoprevention of Cancer.
Guggulsterone suppresses LPS induced inflammation of human middle ear epithelial cells (HMEEC).
Guttiferone K Exerts the Anti-inflammatory Effect on Mycobacterium Tuberculosis- (H37Ra-) Infected Macrophages by Targeting the TLR/IRAK-1 Mediated Akt and NF-?B Pathway.
Gyeji-tang water extract exerts anti-inflammatory activity through inhibition of ERK and NF-?B pathways in lipopolysaccharide-stimulated RAW 264.7 cells.
Gypenoside IX Suppresses p38 MAPK/Akt/NF?B Signaling Pathway Activation and Inflammatory Responses in Astrocytes Stimulated by Proinflammatory Mediators.
H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis.
Halo-Substituted Chalcones and Azachalcones-Inhibited, Lipopolysaccharited-Stimulated, Pro-Inflammatory Responses through the TLR4-Mediated Pathway.
Hand Ground Nanoscale Zn(II)-Coordination Polymers Derived from NSAIDs: Cell Migration Inhibition of Human Breast Cancer Cells.
Harmine combined with paclitaxel inhibits tumor proliferation and induces apoptosis through down-regulation of cyclooxygenase-2 expression in gastric cancer.
Harmine induces apoptosis and inhibits tumor cell proliferation, migration and invasion through down-regulation of cyclooxygenase-2 expression in gastric cancer.
Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
Hawthorn Herbal Preparation from Crataegus oxyacantha Attenuates In Vivo Carbon Tetrachloride -Induced Hepatic Fibrosis via Modulating Oxidative Stress and Inflammation.
Hazelnut and neuroprotection: Improved memory and hindered anxiety in response to intra-hippocampal A? injection.
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
He-Jie-Shen-Shi Decoction as an Adjuvant Therapy on Severe Coronavirus Disease 2019: A Retrospective Cohort and Potential Mechanistic Study.
Health Potential of Aloe vera against Oxidative Stress Induced Corneal Damage: An "In Vitro" Study.
Heat shock protein 70 suppresses neuroinflammation induced by ?-synuclein in astrocytes.
Heat stress-induced memory impairment is associated with neuroinflammation in mice.
Heat-killed whole-cell products of the probiotic Pseudomonas aeruginosa VSG2 strain affect in vitro cytokine expression in head kidney macrophages of Labeo rohita.
Heat-Processed Scutellariae Radix Protects Hepatic Inflammation through the Amelioration of Oxidative Stress in Lipopolysaccharide-Induced Mice.
Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro.
Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies.
Helicobacter pylori infection in gastric cancerogenesis.
Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa.
Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer.
Helicobacter pylori lipopolysaccharide activates Rac1 and transcription of NADPH oxidase Nox1 and its organizer NOXO1 in guinea pig gastric mucosal cells.
Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.
Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer.
Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer.
Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation.
HEMA-induced cytotoxicity: oxidative stress, genotoxicity and apoptosis.
Heme oxygenase-1 expression is associated with tumor aggressiveness and outcomes in patients with bladder cancer: a correlation with smoking intensity.
Heme Oxygenase-1 Induction and Anti-inflammatory Actions of Atractylodes macrocephala and Taraxacum herba Extracts Prevented Colitis and Was More Effective than Sulfasalazine in Preventing Relapse.
Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder.
Heparanase and COX-2 expression as predictors of lymph node metastasis in large, high-grade breast tumors.
Heparanase and cyclooxygenase-2 gene and protein expressions during progression of oral epithelial dysplasia to carcinoma.
Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2.
Heparanase promotes angiogenesis through Cox-2 and HIF1alpha.
Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.
Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition.
Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-?B signal cascade.
Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors.
Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression.
Hepatoprotective activity of berberine is mediated by inhibition of TNF-?, COX-2, and iNOS expression in CCl(4)-intoxicated mice.
Hepatoprotective effect of pinoresinol on carbon tetrachloride-induced hepatic damage in mice.
Hepatoprotective effect of polysaccharides from Boschniakia rossica on carbon tetrachloride-induced toxicity in mice.
Hepatoprotective effect of Spirulina platensis against carbon tetrachloride-induced liver injury in male rats.
Hepatoprotective effect of the flavonoid fraction isolated from the flower of Inula britannica against D-Galactosamine-induced hepatic injury.
Hepatoprotective Effect of Ugonin M, A Helminthostachyszeylanica Constituent, on Acetaminophen-Induced Acute Liver Injury in Mice.
Hepatoprotective effects of Mimic of Manganese superoxide dismutase against carbon tetrachloride-induced hepatic injury.
Hepatoprotective Effects of the Polysaccharide Isolated from Tarphochlamys affinis (Acanthaceae) against CCl(4)-Induced Hepatic Injury.
Hepatoprotective effects of total saponins isolated from Taraphochlamys affinis against carbon tetrachloride induced liver injury in rats.
Hepatoprotective effects of zingerone on carbon tetrachloride- and dimethylnitrosamine-induced liver injuries in rats.
Hepatoprotective, antioxidant and, anti-inflammatory potentials of gallic acid in carbon tetrachloride-induced hepatic damage in Wistar rats.
Hepatotoxicity Induced by Isoniazid-Lipopolysaccharide through Endoplasmic Reticulum Stress, Autophagy, and Apoptosis Pathways in Zebrafish.
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.
Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression.
Herbal medicine, cancer prevention and cyclooxygenase 2 inhibition.
Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells.
Hesperetin Suppresses Inflammatory Responses in Lipopolysaccharide-Induced RAW 264.7 Cells via the Inhibition of NF-?B and Activation of Nrf2/HO-1 Pathways.
Hesperidin protects against stress induced gastric ulcer through regulation of peroxisome proliferator activator receptor gamma in diabetic rats.
Heterogeneity of COX-2 and multidrug resistance between primary tumors and regional lymph node metastases of gastric cancer.
Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: Correlation with tumor angiogenesis.
HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling.
Higenamine inhibits IL-1?-induced inflammation in human nucleus pulposus cells.
High COX-2 expression in cancer-associated fibiroblasts contributes to poor survival and promotes migration and invasiveness in nasopharyngeal carcinoma.
High COX-2 expression in canine mast cell tumours is associated with proliferation, angiogenesis and decreased overall survival.
High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: a multivariate survival study.
High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors.
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
High cyclooxygenase-2 expression in cervical adenocarcinomas.
High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion.
High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy.
High expression of cyclooxygenase-2 in macrophages of human colonic adenoma.
High Expression of HuR in Cytoplasm, but Not Nuclei, Is Associated with Malignant Aggressiveness and Prognosis in Bladder Cancer.
High glucose induces a priming effect in macrophages and exacerbates the production of pro-inflammatory cytokines after a challenge.
High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement.
High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas.
High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo.
High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time.
High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma.
High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study.
High-fat diet exacerbates inflammation and cell survival signals in the skin of ultraviolet B-irradiated C57BL/6 mice.
High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.
Highly sensitive naphthalene-based two-photon fluorescent probe for in situ real-time bioimaging of ultratrace cyclooxygenase-2 in living biosystems.
Hippocampal dysfunctions in tumor-bearing mice.
Hirsutenone inhibits phorbol ester-induced upregulation of COX-2 and MMP-9 in cultured human mammary epithelial cells: NF-kappaB as a potential molecular target.
Hispidin analogue davallialactone attenuates carbon tetrachloride-induced hepatotoxicity in mice.
Hispolon Protects against Acute Liver Damage in the Rat by Inhibiting Lipid Peroxidation, Proinflammatory Cytokine, and Oxidative Stress and Downregulating the Expressions of iNOS, COX-2, and MMP-9.
Histamine receptor antagonists, cyclooxygenase blockade, and tumor necrosis factor during acute septic insult.
Histologic correlation of VEGF and COX-2 expression with tumor size in squamous cell carcinoma of the larynx and hypopharynx.
Histone acetyltransferase p300 is induced by p38MAPK after photodynamic therapy: the therapeutic response is increased by the p300HAT inhibitor anacardic acid.
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells.
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
HMG-CoA Reductase Inhibitors Attenuate Neuronal Damage by Suppressing Oxygen Glucose Deprivation-Induced Activated Microglial Cells.
hMLH1, hMSH2 and cyclooxygenase-2 (cox-2) in sporadic colorectal polyps.
hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.
Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.
Honokiol protects rats against eccentric exercise-induced skeletal muscle damage by inhibiting NF-kappaB induced oxidative stress and inflammation.
Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation.
Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.
Host cyclooxygenase-2 modulates carcinoma growth.
Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.
Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth.
Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis.
HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio.
HSPA12B: a novel facilitator of lung tumor growth.
Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
Human fecal water inhibits COX-2 in colonic HT-29 cells: role of phenolic compounds.
Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Human Interferon Inducible Transmembrane Protein 3 (IFITM3) Inhibits Influenza Virus A Replication and Inflammation by Interacting with ABHD16A.
Human lupus T cells resist inactivation and escape death by upregulating COX-2.
Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms.
Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.
Human umbilical cord blood-stem cells direct macrophage polarization and block inflammasome activation to alleviate rheumatoid arthritis.
Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2.
Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-kappaB and AP-1: IkappaB kinase and c-Jun-N-terminal kinase as respective potential upstream targets.
HuR expression is a marker of poor prognosis in renal cell carcinoma.
HuR in pheochromocytomas and paragangliomas - overexpression in verified malignant tumors.
HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium.
HuR knockdown changes the oncogenic potential of oral cancer cells.
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs.
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.
Hydrogen sulfide-releasing anti-inflammatory drugs for chemoprevention and treatment of cancer.
Hydrogen tunneling steps in cyclooxygenase-2 catalysis.
Hydroxysafflor yellow A (HSYA) targets the NF-?B and MAPK pathways and ameliorates the development of osteoarthritis.
Hydroxysafflor yellow A suppresses angiogenesis of hepatocellular carcinoma through inhibition of p38 MAPK phosphorylation.
Hydroxytyrosol Exerts Anti-Inflammatory and Anti-Oxidant Activities in a Mouse Model of Systemic Inflammation.
Hyperglycemic Condition Causes Pro-Inflammatory and Permeability Alterations Associated with Monocyte Recruitment and Deregulated NF?B/PPAR? Pathways on Cerebral Endothelial Cells: Evidence for Polyphenols Uptake and Protective Effect.
Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection.
Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Hypermethylation of RAR?2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma.
Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-alpha-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice.
Hyperthermia Suppresses Post - In Vitro Proliferation and Tumor Growth in Murine Malignant Melanoma and Colon Carcinoma.
Hyperventilation induces release of cytokines from perfused mouse lung.
Hypothermia followed by rapid rewarming exacerbates ischemia-induced brain injury and augments inflammatory response in rats.
Hypothermia suppresses inducible nitric oxide synthase and stimulates cyclooxygenase-2 in lipopolysaccharide stimulated BV-2 cells.
Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis.
Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth.
Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway.
Hypoxia Induces Macrophage tnfa Expression via Cyclooxygenase and Prostaglandin E2 in vivo.
Hypoxia induces pivotal tumor angiogenesis control factors including p53, vascular endothelial growth factor and the NFkappaB-dependent inducible nitric oxide synthase and cyclooxygenase-2.
Hypoxia potentiates tumor necrosis factor-? induced expression of inducible nitric oxide synthase and cyclooxygenase-2 in white and brown adipocytes.
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2?/COX-2.
Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells.
Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness.
IB05204, a dichloropyridodithienotriazine, inhibits angiogenesis in vitro and in vivo.
Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.
Ibuprofen causes reduced toxic effects of interleukin 2 administration in patients with metastatic cancer.
Ibuprofen inhibits neuroinflammation and attenuates white matter damage following hypoxia-ischemia in the immature rodent brain.
Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas.
Ibuprofen-loaded porous microspheres suppressed the progression of monosodium iodoacetate-induced osteoarthritis in a rat model.
Icariin derivative inhibits inflammation through suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways.
Icariside II attenuates lipopolysaccharide-induced neuroinflammation through inhibiting TLR4/MyD88/NF-?B pathway in rats.
Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK/I?B/NF-?B/BACE1 signaling pathway.
Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats.
Identification and characterization of cysteinyl-leukotriene formation in tissue slices from human intracranial tumors: evidence for their biosynthesis under in vivo conditions.
Identification and functional outcome of mRNAs associated with RNA-binding protein TIA-1.
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases.
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer.
Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells.
Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
Identification of narciclasine from Lycoris radiata (L'Her.) Herb. and its inhibitory effect on LPS-induced inflammatory responses in macrophages.
Identification of novel cellular targets in biliary tract cancers using global gene expression technology.
Identification of novel cyclooxygenase-2-dependent genes in Helicobacter pylori infection in vivo.
Identification of potential candidate genes for lip and oral cavity cancer using network analysis.
Identification of potential markers of oocyte competence expressed in bovine cumulus cells matured with follicle-stimulating hormone and/or phorbol myristate acetate in vitro.
Identification of potential prognostic markers for vulvar cancer using immunohistochemical staining of tissue microarrays.
IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2.
IL-12-deficiency suppresses 12-O-tetradecanoylphorbol-13-acetate-induced skin tumor development in 7, 12-dimethylbenz(a)anthracene-initiated mouse skin through inhibition of inflammation.
IL-17F deficiency inhibits small intestinal tumorigenesis in ApcMin/+ mice.
IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia.
IL-1? and IL-1? as alternative biomarkers for risk assessment and the prediction of skin sensitization potency.
IL-1? reduces cardiac lymphatic muscle contraction via COX-2 and PGE2 induction: Potential role in myocarditis.
IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis.
IL-21 Enhances the Degradation of Cartilage Through the JAK-STAT Signaling Pathway During Osteonecrosis of Femoral Head Cartilage.
IL-33/ST2 signaling contributes to radicular pain by modulating MAPK and NF-?B activation and inflammatory mediator expression in the spinal cord in rat models of noncompressive lumber disk herniation.
IL1?-mediated Stromal COX-2 signaling mediates proliferation and invasiveness of colonic epithelial cancer cells.
Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions.
Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA.
Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation.
Iminodibenzyl redirected cyclooxygenase-2 catalyzed dihomo-?-linolenic acid peroxidation pattern in lung cancer.
Immediate inflammatory response and scar formation in wounded vocal folds.
Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography.
Immune regulatory functions of human beta-defensin-2 in odontoblast-like cells.
Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.
Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.
Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory.
Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis.
Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma.
Immunoexpression of p53 and COX-2 in basal cell carcinoma.
Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective.
Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas.
Immunohistochemical analysis of COX-2 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma: A comparative study.
Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation.
Immunohistochemical analysis of cyclooxygenase-2 and brain fatty acid binding protein expression in grades I-II meningiomas: Correlation with tumor grade and clinical outcome after radiotherapy.
Immunohistochemical Analysis of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha in Periapical Lesions.
Immunohistochemical analysis of cyclooxygenase-2 and vascular endothelial growth factor in pancreaticobiliary maljunction.
Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.
Immunohistochemical Analysis of Cyclooxygenase-2 in Non-Melanocytic Skin Cancer: Correlation With Morphological Subtype and Histologic Grade.
Immunohistochemical assessment of p16, COX-2 and EGFR in HPV-positive cervical squamous intraepithelial lesions.
Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: A pilot study.
Immunohistochemical Demonstration of Membrane-bound Prostaglandin E(2) Synthase-1 in Papillary Thyroid Carcinoma.
Immunohistochemical detectability of cyclooxygenase-2 expression in cells of human melanocytic skin lesions: A methodological review.
Immunohistochemical detection of Ki-67 is not associated with tumor-infiltrating macrophages and cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical evaluation of COX-2 expression in HPV-positive cervical squamous intraepithelial lesions.
Immunohistochemical evaluation of cyclooxygenase expression in corneal squamous cell carcinoma in horses.
Immunohistochemical evaluation of expression of heat shock proteins HSP70 and HSP90 in mammary gland neoplasms in bitches.
Immunohistochemical expression of COX-2 in thyroid nodules.
Immunohistochemical Expression of COX-2, mPGES and EP2 Receptor in Normal and Reactive Canine Bone and in Canine Osteosarcoma.
Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions.
Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid.
Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
Immunohistochemical Expression of Cyclooxygenase-2 (COX-2) in Feline Endometrial Adenocarcinoma and in Normal and Hyperplastic Endometria.
Immunohistochemical expression of cyclooxygenase-2 (COX-2) in oral nevi and melanoma.
Immunohistochemical expression of cyclooxygenase-2 (COX-2) is not associated with tumor grade in feline meningiomas.
Immunohistochemical expression of cyclooxygenase-2 in normal, hyperplastic and neoplastic canine lymphoid tissues.
Immunohistochemical expression of cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation.
Immunohistochemical expression of cyclooxygenase-2 in skin cancers.
Immunohistochemical expression of cycloxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival.
Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer.
Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.
Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival.
Immunohistochemical features and staging of early gastric cancer.
Immunohistochemical localization of selected pro-inflammatory factors in uterine myomas and myometrium in women of various ages.
Immunohistochemical markers of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer.
Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine.
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor.
Immunohistochemical Vascular Factor Expression in Canine Inflammatory Mammary Carcinoma.
Immunohistochemical visualization of pro-inflammatory cytokines and enzymes in ovarian tumors.
Immunomodulation of Parkinson's disease using Mucuna pruriens (Mp).
Immunomodulatory and anti-inflammatory effects of total flavonoids of Astragalus by regulating NF-?B and MAPK signalling pathways in RAW 264.7 macrophages.
Immunomodulatory effects of inhaled carbon monoxide on rat syngeneic small bowel graft motility.
Immunomodulatory effects of xanthan gum in LPS-stimulated RAW 264.7 macrophages.
Immunosensors for quantifying cyclooxygenase 2 pain biomarkers.
Immunostimulatory activity of isoflavone-glycosides and ethanol extract from a fermented soybean product in human primary immune cells.
Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation, cyclooxygenase enzyme, and lipid peroxidation.
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial.
Impact of COX-2, IL-1?, TNF-?, IL-4 and IL-10 on the process of carcinogenesisin the large bowel.
Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.
Impact of Cyclooxygenase-2 1195 G-Carrier Genotype Associated with Intestinal Metaplasia and Endoscopic Findings Based on Kyoto Classification.
Impact of cyclooxygenase-2 and prostaglandin-E2 expression on clinical outcome after pulmonary metastasectomy.
Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line.
Impact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients.
Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.
Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.
Impact of local injection of brain-derived neurotrophic factor-expressing mesenchymal stromal cells (MSCs) combined with intravenous MSC delivery in a canine model of chronic spinal cord injury.
Impact of polyphenols in phagocyte functions.
Impact of structural alterations on the radiopharmacological profile of 18F-labeled pyrimidines as cyclooxygenase-2 (COX-2) imaging agents.
Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Impaired gastric ulcer healing in diabetic rats: role of heat shock protein, growth factors, prostaglandins and proinflammatory cytokines.
Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis.
Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor.
Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system.
Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice.
Implications of low COX-2 expression in colorectal neoplasms with defective DNA mismatch repair.
Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2.
Improvement of hyperlipidemia by indomethacin in Min mice.
Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.
In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression.
In regard to Ishikawa et al.: Cyclooxygenase-2 impairs treatment effect of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis (Int J Radiat Oncol Biol Phys 2006;66:1347-1355).
In silico database screening of potential targets and pathways of compounds contained in plants used for psoriasis vulgaris.
In Silico Screening for Anti-Inflammatory Bioactive Molecules from Ayurvedic Decoction, Balaguluchyadi Kashayam.
In situ click chemistry generation of cyclooxygenase-2 inhibitors.
In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.
In vitro and in vivo anti-inflammatory activity of digested peptides derived from salmon myofibrillar protein conjugated with a small quantity of alginate oligosaccharide.
In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines.
In Vitro and In Vivo Protective Effects of Flavonoid-Enriched Lotus Seedpod Extract on Lipopolysaccharide-Induced Hepatic Inflammation.
In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin.
In vitro anti-inflammatory effects of different solution fractions of ethanol extract from Melilotus suaveolens Ledeb.
In vitro anti-inflammatory properties of fermented pepino (Solanum muricatum) milk by ?-aminobutyric acid-producing Lactobacillus brevis and an in vivo animal model for evaluating its effects on hypertension.
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
In vitro cyclooxygenase-2 protein expression and enzymatic activity in neoplastic cells.
In Vitro Cytotoxic Effects of Celecoxib, Mefenamic Acid, Aspirin and Indometacin on Several Cells Lines.
In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines.
In Vitro Effects of Calcium Fructoborate upon Production of Inflammatory Mediators by LPS-stimulated RAW 264.7 Macrophages.
In vitro effects of meloxicam on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis.
In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells.
In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations.
In vitro evaluation of the synergistic antioxidant and anti-inflammatory activities of the combined extracts from Malaysian Ganoderma lucidum and Egyptian Chlorella vulgaris.
In vitro prostaglandin H synthase- and monooxygenase-mediated binding of aflatoxin B1 to DNA in guinea-pig tissue microsomes.
In vitro study of biofunctional indicators after exposure to asbestos-like fluoro-edenite fibres.
In vitro susceptibility to anticancer agents of the human KB carcinoma cell line transfected with COX-2 cDNA.
In vivo and In vitro Anti-Inflammatory Activity of Indazole and Its Derivatives.
In vivo and in vitro anti-inflammatory effects of Zao-Jiao-Ci (the spine of Gleditsia sinensis Lam.) aqueous extract and its mechanisms of action.
In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell.
In vivo and in vitro Approach to Anti-arthritic and Anti-inflammatory Effect of Crocetin by Alteration of Nuclear Factor-E2-Related Factor 2/hem Oxygenase (HO)-1 and NF-?B Expression.
In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons.
In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines.
In vivo optical molecular imaging of matrix metalloproteinase activity following celecoxib therapy for colorectal cancer.
In vivo preclinical evaluation of the new 68Ga-labeled beta-cyclodextrin in prostaglandin E2 (PGE2) positive tumor model using positron emission tomography.
In Vivo, Proteomic, and In Silico Investigation of Sapodilla for Therapeutic Potential in Gastrointestinal Disorders.
In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease.
Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells.
Inactivation of COX-2, HMLH1 and CDKN2A Gene by Promoter Methylation in Gastric Cancer: Relationship with Histological Subtype, Tumor Location and Helicobacter pylori Genotype.
Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme.
Increase of carcinogenic risk via enhancement of cyclooxygenase-2 expression and hydroxyestradiol accumulation in human lung cells as a result of interaction between BaP and 17-beta estradiol.
Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer.
Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer.
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.
Increased central and peripheral inflammation and inflammatory hyperalgesia in Zucker rat model of leptin receptor deficiency and genetic obesity.
Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis.
Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival.
Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer.
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.
Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.
Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer.
Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs.
Increased cyclooxygenase-2 expression in large flat colorectal tumors (laterally spreading tumors).
Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.
Increased cyclooxygenase-2 expression is correlated with suppressed antitumor immunity in cervical adenocarcinomas.
Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.
Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: a pilot study.
Increased expression of COX-2 in the development of human lung cancers.
Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib.
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma.
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer.
Increased expression of cyclooxygenase-2 in first-degree relatives of gastric cancer patients.
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.
Increased expression of cyclooxygenase-2 in human salivary gland tumors.
Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet.
Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide.
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.
Increased expression of cyclooxygenase-2 protein in rat lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine.
Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer.
Increased expression of interleukin-1alpha and cyclooxygenase-2 in human gastric cancer: a possible role in tumor progression.
Increased Expression of Thioredoxin-1 Binding Protein-2 in Placentas in Preeclampsia.
Increased inflammatory biomarkers and changes in biological rhythms in bipolar disorder: A case-control study.
Increased levels of COX-2 in oral lichen planus supports an autoimmune cause of the disease.
Increased levels of luminol-enhanced chemiluminescence by rectal mucosa of patients with colonic neoplasia: a possible marker for colonic neoplasia.
Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats.
Increased PGE2 levels in nonmalignant mucosa adjacent to squamous cell carcinoma of the head and neck.
Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers.
Increased serum progesterone and estradiol correlate to increased COX-2 tissue expression in cervical intraepithelial neoplasia.
Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines.
Increased survival rate by local release of diclofenac in a murine model of recurrent oral carcinoma.
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
Indicaxanthin from cactus pear fruit exerts anti-inflammatory effects in carrageenin-induced rat pleurisy.
Indometacin ameliorates high glucose-induced proliferation and invasion via modulation of e-cadherin in pancreatic cancer cells.
Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model.
Indomethacin and telomerase activity in tumor growth retardation.
Indomethacin derivatives as tubulin stabilizers to inhibit cancer cell proliferation.
Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: A novel cyclooxygenase-inhibition-independent effect.
Indomethacin inhibits the accumulation of tumor cells in mouse lungs and subsequent growth of lung metastases.
Indomethacin sensitizes resistant transformed cells to macrophage cytotoxicity.
Indoxyl Sulfate Affects Glial Function Increasing Oxidative Stress and Neuroinflammation in Chronic Kidney Disease: Interaction between Astrocytes and Microglia.
Induced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-?1/Smad-Mediated Epithelial to Mesenchymal Transition.
Inducible cyclooxygenase (COX-2) in glioblastoma--clinical and immunohistochemical (COX-2-VEGF) correlations.
Inducible cyclooxygenase and interleukin 6 gene expressions in nasal polyp fibroblasts: possible implication in the pathogenesis of nasal polyposis.
Inducible GBP5 Mediates the Antiviral Response via Interferon-Related Pathways during Influenza A Virus Infection.
Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer.
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
Inducible Nitric Oxide Synthase (NOS2) in the Carcinogenesis of Gastrointestinal Cancers.
Inducible nitric oxide synthase-vascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents.
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer.
INDUCTION BUT NOT INHIBITION OF COX-2 CONFERS HUMAN LUNG CANCER CELL APOPTOSIS BY CELECOXIB.
Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma.
Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1.
Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines.
Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines.
Induction of apoptosis by R-flurbiprofen in human colon carcinoma cells: involvement of p53.
Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway.
Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047.
Induction of COX-2 by acrolein in rat lung epithelial cells.
Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type.
Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells.
Induction of cyclooxygenase and prostaglandin E2 production by the bovine pre-embryo.
Induction of cyclooxygenase expression and enhancement of malignant cell transformation by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3.
Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells.
Induction of cyclooxygenase-2 by staurosporine through the activation of nuclear factor for IL-6 (NF-IL6) and activator protein 2 (AP2) in an osteoblast-like cell line.
Induction of cyclooxygenase-2 by tumor promoters in transformed and cytochrome P450 2E1-expressing hepatocytes.
Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells.
Induction of cyclooxygenase-2 in alveolar macrophages after acid aspiration: selective cyclooxygenase-2 blockade reduces interleukin-6 production.
Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells.
Induction of cyclooxygenase-2 in Ras-transformed human mammary epithelial cells undergoing apoptosis.
Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference.
Induction of lung lesions in Wistar rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by aspirin and phenethyl isothiocyanate.
Induction of macrophagic prostaglandin E2 synthesis by glioma cells.
Induction of microsomal prostaglandin E synthase-1 in human gingival fibroblasts.
Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells.
Induction of proinflammatory cytokines and C-reactive protein in human macrophage cell line U937 exposed to air pollution particulates.
Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.
Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma.
Induction of prostaglandin H synthase-2 and tumor necrosis factor-alpha in human amnionic WISH cells by various stimuli occurs through distinct intracellular mechanisms.
Induction of prostaglandin I(2) receptor by tumor necrosis factor alpha in osteoblastic MC3T3-E1 cells.
Induction of prosurvival molecules during treatment: rethinking therapy options for photodynamic therapy.
Induction of Retinoid X Receptor Activity and Consequent Upregulation of p21WAF1/CIP1 by Indenoisoquinolines in MCF7 Cells.
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth.
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.
Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences.
Inflammation and cancer: an epidemiological perspective.
Inflammation and cancer: how friendly is the relationship for cancer patients?
Inflammation and cancer: tumor initiation, progression and metastasis, and Chinese botanical medicines.
Inflammation and colorectal cancer.
Inflammation and IGF-I activate the Akt pathway in breast cancer.
Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer.
Inflammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: link between cholesterol homeostasis and self-tolerance?
Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale.
Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways.
Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy.
Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases.
Inflammation, autotoxicity and Alzheimer disease.
Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2.
Inflammation, cancer, and targets of ginseng.
Inflammation, COX-2 inhibitors, and cancer.
Inflammation, macrophage in cancer progression and chinese herbal treatment.
Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.
Inflammation-related factors predicting prognosis of gastric cancer.
Inflammation: gearing the journey to cancer.
Inflammatory and cytotoxic effects of bifenthrin in primary microglia and organotypic hippocampal slice cultures.
Inflammatory and oxidative mechanisms potentiate bifenthrin-induced neurological alterations and anxiety-like behavior in adult rats.
Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer.
Inflammatory cytokines are overexpressed in the subacromial bursa of frozen shoulder.
Inflammatory effects of inhaled sulfur mustard in rat lung.
Inflammatory factor profiles one hour following vocal fold injury.
Inflammatory gene mRNA expression in human peripheral blood and its association with colorectal cancer.
Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.
Inflammatory lymphangiogenesis in postpartum breast tissue remodeling.
Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.
Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease.
Inflammatory myofibroblastic tumor in the head and neck-a neoplasm with both tumor features and inflammation.
Inflammatory Process and Molecular Targets for Antiinflammatory Nutraceuticals.
Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib.
Inflammatory repercussions in female steroid responsive glands after perinatal exposure to bisphenol A and 17-? estradiol.
Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO2 , NO2 , and PM2.5.
Inflammatory responses in embryonal cardiomyocytes exposed to LPS challenge: an in vitro model of deciphering the effects of LPS on the heart.
Inflammatory responses of RAW 264.7 macrophages upon exposure to nanoparticles: Role of ROS-NF?B signaling pathway.
Influence of an n-3 long-chain polyunsaturated fatty acid-enriched diet on experimentally induced synovitis in horses.
Influence of Caloric Restriction on Constitutive Expression of NF-?B in an Experimental Mouse Astrocytoma.
Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer.
Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.
Influence of dietary linoleic acid on experimental human breast cancer cell metastasis in athymic nude mice.
Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells.
Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection.
Influence of light on aryl hydrocarbon receptor signaling and consequences in drug metabolism, physiology and disease.
Influence of morphology and malignancy of three new human melanoma cell lines on the cyclooxygenase pathway.
Influence of myeloperoxidase on colon tumor occurrence in inflamed versus non-inflamed colons of Apc(Min/+) mice.
Influence of omega-3 and omega-6 fatty acid sources on prostaglandin levels in mice.
Influence of seasonal variation on Thymus longicaulis C. Presl chemical composition and its antioxidant and anti-inflammatory properties.
Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats.
Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo.
Influences of Helicobacter pylori on cyclooxygenase-2 expression and prostaglandinE2 synthesis in rat gastric epithelial cells in vitro.
Influencing COX-2 activity by COX related pathways in inflammation and cancer.
Infrequent COX-2 expression due to promoter hypermethylation in gastric cancers in Dalian, China.
Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.
Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells.
Inhibition by dietary menhaden oil of cyclooxygenase-1 and -2 in N-nitrosomethylurea-induced rat mammary tumors.
Inhibition by indomethacin and 5,8,11,14-eicosatetraynoic acid of the induction of rat hepatic ornithine decarboxylase by the tumor promoters phenobarbital and 12-O-tetradecanoylphorbol-13-acetate in vivo.
Inhibition of 11?-Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression as Well as the ERK and mTOR Signaling Pathways.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-caused tumor promotion in 7,12-dimethylbenz[a]anthracene-initiated SENCAR mouse skin by a polyphenolic fraction isolated from green tea.
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
Inhibition of Acute Phase Inflammation by Laminaria japonica through Regulation of iNOS-NF- ? B Pathway.
Inhibition of Akt/PKB by a COX-2 inhibitor induces apoptosis in gastric cancer cells.
Inhibition of angiogenesis by humulone, a bitter acid from beer hop.
Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.
Inhibition of arachidonic acid metabolism decreases tumor cell invasion and matrix metalloproteinase expression.
Inhibition of bacterial MDR by celecoxib, a cyclooxygenase-2 inhibitor.
Inhibition of bcl-2 and cox-2 Protein Expression after Local Application of a New Carmustine-Loaded Clinoptilolite-Based Delivery System in a Chemically Induced Skin Cancer Model in Mice.
Inhibition of Brain Mitogen-Activated Protein Kinase Signaling Reduces Central Endoplasmic Reticulum Stress and Inflammation and Sympathetic Nerve Activity in Heart Failure Rats.
Inhibition of breast cancer cell motility with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGF?/miR-21 signaling.
Inhibition of cancer cell epithelial mesenchymal transition by normal fibroblasts via production of 5-methoxytryptophan.
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Inhibition of CCAAT/enhancer binding protein ? expression by chrysin in microglial cells results in anti-inflammatory and neuroprotective effects.
Inhibition of CD44 induces apoptosis, inflammation, and matrix metalloproteinase expression in tendinopathy.
Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages.
Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B.
Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway.
Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3.
Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis.
Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model.
Inhibition of COX-2 Impairs Colon Cancer Liver Metastasis through Reduced Stromal Cell Reaction.
Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53.
Inhibition of COX-2 in Colon Cancer Modulates Tumor Growth and MDR-1 Expression to Enhance Tumor Regression in Therapy-Refractory Cancers In Vivo.
Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex.
Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.
Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation.
Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Inhibition of cyclooxygenase-2 activity in subchondral bone modifies a subtype of osteoarthritis.
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.
Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN, Eljuga L, Shawber CJ, Feirt N, Mansukhani M, Stempak D, Baruchel S, Bender JG, Kandel JJ, Yamashiro DJ, Department of Pediatrics, College of Physicians and Surgeons of Columbia University, New York, NY.
Inhibition of Cyclooxygenase-2 Disrupts Tumor Vascular Mural Cell Recruitment and Survival Signaling.
Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells.
Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors.
Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis.
Inhibition of cyclooxygenase-2 expression and restoration of gap junction intercellular communication in H-ras-transformed rat liver epithelial cells by caffeic acid phenethyl ester.
Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer.
Inhibition of cyclooxygenase-2 gene expression by p53.
Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice.
Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis.
Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44.
Inhibition of Cyclooxygenase-2 Suppresses Lymph Node Metastasis via Reduction of Lymphangiogenesis.
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation.
Inhibition of cyclooxygenase-2 with NS-398 and the prevention of radiation-induced transformation, micronuclei formation and clonogenic cell death in C3H 10T1/2 cells.
Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma?
Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract.
Inhibition of cyclooxygenase: a novel approach to cancer prevention.
Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.
Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib.
Inhibition of fatty acid amide hydrolase by PF-3845 alleviates the nitrergic and proinflammatory response in rat hippocampus following acute stress.
Inhibition of Glioblastoma Cell Growth In Vitro and In Vivo by Brucine, a Component of Chinese Medicine.
Inhibition of HIF-1?/EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells.
Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen.
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Inhibition of human malignant neuroblastoma cell DNA synthesis by lipoxygenase metabolites of arachidonic acid.
Inhibition of human neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor nimesulide.
Inhibition of inducible prostaglandin E2 production and cyclooxygenase-2 expression by curdione from Curcuma zedoaria.
Inhibition of inflammation and oxidative stress by Angelica dahuricae radix extract decreases apoptotic cell death and improves functional recovery after spinal cord injury.
Inhibition of invasion and experimental metastasis of murine melanoma cells by Ipomoea obscura (L.) is mediated through the down-regulation of inflammatory mediators and matrix-metalloproteinases.
Inhibition of Lipid Accumulation and Cyclooxygenase-2 Expression in Differentiating 3T3-L1 Preadipocytes by Pazopanib, a Multikinase Inhibitor.
Inhibition of lipid peroxidation, cyclooxygenase enzyme and human tumor cell proliferation by compounds in herbal water.
Inhibition of Lipopolysaccharide-Induced Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Expression by 4-[(2'-O-acetyl-?-L-Rhamnosyloxy)Benzyl]Isothiocyanate from Moringa oleifera.
Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195.
Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase by butein in RAW 264.7 cells.
Inhibition of lipopolysaccharide-inducible nitric oxide synthase, TNF-alpha and COX-2 expression by sauchinone effects on I-kappaBalpha phosphorylation, C/EBP and AP-1 activation.
Inhibition of LPS-induced inflammatory responses by Satureja hortensis extracts in J774.1 macrophages.
Inhibition of LPS-induced iNOS, COX-2 and cytokines expression by poncirin through the NF-kappaB inactivation in RAW 264.7 macrophage cells.
Inhibition of lung cancer in diethylnitrosamine-induced mice by Rhizoma paridis saponins.
Inhibition of Macrophage Migration Inhibitory Factor (MIF) tautomerase activity suppresses Microglia-mediated inflmmatory responses.
Inhibition of MAP kinases and down regulation of TNF-alpha, IL-beta and COX-2 genes by the crude extracts from marine bacteria.
Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells.
Inhibition of Neuroinflammation by Synthetic Androstene Derivatives Incorporating Amino Acid Methyl Esters on Activated BV-2 Microglia.
Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes.
Inhibition of NK1R attenuates LPS-induced microglial inflammation and consequent death of PC12 cells.
Inhibition of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model.
Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.
Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.
Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells.
Inhibition of Phorbol Ester-induced Mouse Skin Tumor Promotion and COX-2 Expression by Celecoxib: C/EBP as a Potential Molecular Target.
Inhibition of photodynamic therapy induced-immunosuppression with aminolevulinic acid leads to enhanced outcomes of tumors and pre-cancerous lesions.
Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma.
Inhibition of PI3K/Akt/NF-?B signaling with leonurine for ameliorating the progression of osteoarthritis: In vitro and in vivo studies.
Inhibition of PKC-induced COX-2 and IL-8 Expression in Human Breast Cancer Cells by Glucosamine.
Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes.
Inhibition of precancerous lesions development in kidneys by chrysin via regulating hyperproliferation, inflammation and apoptosis at pre clinical stage.
Inhibition of Pro-inflammatory Mediators and Cytokines by Chlorella Vulgaris Extracts.
Inhibition of proliferation of human cancer cells and cyclooxygenase enzymes by anthocyanidins and catechins.
Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Inhibition of Signal Transducer and Activator of Transcription 3 and Cyclooxygenase-2 Is Involved in Radiosensitization of Cepharanthine in HeLa Cells.
Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs.
Inhibition of soybean lipoxygenase and mouse skin tumor promotion by onion and garlic components.
Inhibition of the biosynthesis of prostaglandin E2 by low dose aspirin: implications for adenocarcinoma metastasis.
Inhibition of the development of N-nitrosomethylbenzylamine-induced esophageal tumors in rats by strawberries and aspirin, alone and in combination.
Inhibition of the interactions between metastatic human breast cancer cells and platelets by ?-nitrostyrene derivatives.
Inhibition of TNF-alpha-induced cyclooxygenase-2 expression by Mycobacterium bovis BCG in human alveolar epithelial A549 cells.
Inhibition of TPA and 12(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects.
Inhibition of TPA-induced cyclooxygenase-2 (COX-2) expression by apigenin through downregulation of Akt signal transduction in human keratinocytes.
Inhibition of tubulogenesis and of carcinogen-mediated signaling in brain endothelial cells highlight the antiangiogenic properties of a mumbaistatin analog.
Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives.
Inhibition of tumor angiogenesis by oral etoposide.
Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome.
Inhibition of UVB-Induced Inflammation by Laminaria japonica Extract via Regulation of nc886-PKR Pathway.
Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression.
Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21.
Inhibitor of growth-4 mediates chromatin modification and has a suppressive effect on tumorigenesis and innate immunity.
Inhibitors of COX activity preserve muscle mass in mice bearing the Lewis lung carcinoma, but not the B16 melanoma.
Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines.
Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents.
Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.
Inhibitory action of nitric oxide on circulating tumor necrosis factor-induced NF-kappaB activity and COX-2 transcription in the endothelium of the brain capillaries.
Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation.
Inhibitory effect of 30-kDa phytoglycoprotein on expression of TNF-alpha and COX-2 via activation of PKCalpha and ERK 1/2 in LPS-stimulated RAW 264.7 cells.
Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models.
Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer.
Inhibitory effect of brazilin on osteoclast differentiation and its mechanism of action.
Inhibitory effect of carvacrol on lipopolysaccharide-induced memory impairment in rats.
Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin.
Inhibitory effect of Gardenblue blueberry (Vaccinium ashei Reade) anthocyanin extracts on lipopolysaccharide-stimulated inflammatory response in RAW 264.7 cells.
Inhibitory effect of ginsenoside Rg5 and its metabolite ginsenoside Rh3 in an oxazolone-induced mouse chronic dermatitis model.
Inhibitory effect of heat-killed Lactobacillus strain on immunoglobulin E-mediated degranulation and late-phase immune reactions of mouse bone marrow-derived mast cells.
Inhibitory Effect of IFN-beta, on the Antitumor Activity of Celecoxib in U87 Glioma Model.
Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.
Inhibitory effect of isomorellin on cholangiocarcinoma cells via suppression of NF-?B translocation, the phosphorylated p38 MAPK pathway and MMP-2 and uPA expression.
Inhibitory effect of Jangkanghwan (Korean traditional food) on experimental ulcerative colitis in mice.
Inhibitory Effect of Litchi (Litchi chinensis Sonn.) Flower on Lipopolysaccharide-Induced Expression of Proinflammatory Mediators in RAW264.7 Cells through NF-?B, ERK, and JAK2/STAT3 Inactivation.
Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes.
Inhibitory effect of MIL glycoprotein on expression of pro-inflammatory mediators in carbon tetrachloride-induced mice liver damage.
Inhibitory effect of oxycoumarins isolated from the Thai medicinal plant Clausena guillauminii on the inflammation mediators, iNOS, TNF-alpha, and COX-2 expression in mouse macrophage RAW 264.7.
Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.
Inhibitory effect of Physalis alkekengi L. var. franchetii extract and its chloroform fraction on LPS or LPS/IFN-?-stimulated inflammatory response in peritoneal macrophages.
Inhibitory Effect of Phytoglycoprotein (115 kDa) on the Expression of TNF-alpha and Interleukin-1beta via Inhibition of MAP Kinase in Primary Cultured Mouse Thymocytes.
Inhibitory effect of the branches of Hovenia dulcis Thunb. and its constituent pinosylvin on the activities of IgE-mediated mast cells and passive cutaneous anaphylaxis in mice.
Inhibitory Effects of 4-Hydroxyderricin and Xanthoangelol on Lipopolysaccharide-Induced Inflammatory Responses in RAW264 Macrophages.
Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells.
Inhibitory effects of a new iridoid, patridoid II and its isomers, on nitric oxide and TNF-alpha production in cultured murine macrophages.
Inhibitory Effects of a Rice Hull Constituent on Tumor Necrosis Factor {alpha}, Prostaglandin E2, and Cyclooxygenase-2 Production in Lipopolysaccharide-Activated Mouse Macrophages.
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Inhibitory effects of Akebia quinata ethanol extract on TNF-?-mediated vascular inflammation in human aortic smooth muscle cells.
Inhibitory effects of asiatic acid on 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol 13-acetate-induced tumor promotion in mice.
Inhibitory Effects of Aucklandia lappa Decne. Extract on Inflammatory and Oxidative Responses in LPS-Treated Macrophages.
Inhibitory effects of black pepper (Piper nigrum) extracts and compounds on human tumor cell proliferation, cyclooxygenase enzymes, lipid peroxidation and nuclear transcription factor-kappa-B.
Inhibitory effects of Chikusetsusaponin IVa on lipopolysaccharide-induced pro-inflammatory responses in THP-1 cells.
Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis.
Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats.
Inhibitory Effects of Glycoprotein Isolated from Laminaria japonica on Lipopolysaccharide-Induced Pro-Inflammatory Mediators in BV2 Microglial Cells.
Inhibitory effects of Humulus japonicus extract against hepatic injury in a diabetic rat model.
Inhibitory effects of Korean red ginseng and its genuine constituents ginsenosides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis reaction and contact dermatitis models.
Inhibitory Effects of Myricetin on Lipopolysaccharide-Induced Neuroinflammation.
Inhibitory effects of nardostachin on nitric oxide, prostaglandin E2, and tumor necrosis factor-alpha production in lipopolysaccharide activated macrophages.
Inhibitory Effects of Nobiletin on Hepatocellular Carcinoma In Vitro and In Vivo.
Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets.
Inhibitory Effects of Panduratin A on Allergy-Related Mediator Production in Rat Basophilic Leukemia Mast Cells.
Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma.
Inhibitory effects of sigma-2 receptor agonists on T lymphocyte activation.
Inhibitory effects of silk protein, sericin on UVB-induced acute damage and tumor promotion by reducing oxidative stress in the skin of hairless mouse.
Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors.
Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium.
Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion.
Inhibitory effects of tocopherols on expression of the cyclooxygenase-2 gene in RAW264.7 cells stimulated by lipopolysaccharide, tumor necrosis factor-? or Porphyromonas gingivalis fimbriae.
Inhibitory effects of traditional herbal formula pyungwi-san on inflammatory response in vitro and in vivo.
Inhibitory Potencies of Several Iridoids on Cyclooxygenase-1, Cyclooxygnase-2 Enzymes Activities, Tumor Necrosis factor-{alpha} and Nitric Oxide Production In Vitro.
Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy.
iNOS signaling interacts with COX-2 pathway in colonic fibroblasts.
Insights into cyclooxygenase-2 inhibition by isolated bioactive compounds 3-caffeoyl-4-dihydrocaffeoyl quinic acid and isorhamnetin 3-O-?-D-glucopyranoside from Salicornia herbacea.
Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta.
Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats.
Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells.
Intake of grape-derived polyphenols reduces C26 tumor growth by inhibiting angiogenesis and inducing apoptosis.
Intake of high-fat diet stimulates the risk of ultraviolet radiation-induced skin tumors and malignant progression of papillomas to carcinoma in SKH-1 hairless mice.
Integrated Pathways of COX-2 and mTOR: Roles in Cell Sensing and Alzheimer's Disease.
Integrating surgery into treatment paradigms for organ preservation: tailoring treatment to biology improves outcomes.
Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer.
Integrin ?3?1 controls mRNA splicing that determines Cox-2 mRNA stability in breast cancer cells.
Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation.
Interaction between adipose tissue stromal cells and gastric cancer cells in vitro.
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2.
Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice.
Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients.
Interaction of Cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer.
Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin.
Interactions between cytokines and eicosanoids: a study using human peritoneal macrophages.
Interactions of the aryl hydrocarbon receptor with inflammatory mediators: beyond CYP1A regulation.
Interferon gamma antagonizes interleukin-1beta-induced cyclooxygenase-2 expression and prostaglandin E(2) production in human myometrial cells.
Interferon-? plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways.
Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro.
Interferon-gamma suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbeta binding.
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
Interleukin-1 and the effects of cyclooxygenase inhibitors on its biological activities.
Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures.
Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
Interleukin-10 modifies the effects of interleukin-1beta and tumor necrosis factor-alpha on the activity and expression of prostaglandin H synthase-2 and the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase in cultured term human villous trophoblast and chorion trophoblast cells.
Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells.
Interleukin-18-induced inflammatory responses in synoviocytes and chondrocytes from osteoarthritic patients.
Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease.
Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling.
Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures.
Interleukin-4 Modulates the Inflammatory Response in Ifosfamide-Induced Hemorrhagic Cystitis.
Interleukin-4-inhibited mRNA expression in mixed rat glial and in isolated microglial cultures.
Interleukin-8 producing malignant fibrous histiocytoma with prolonged Fever.
Interplay between oncoproteins and antioxidant enzymes in esophageal carcinoma treated without and with chemoradiotherapy: a prospective study.
Interplay between post-translational cyclooxygenase-2 modifications and the metabolic and proteomic profile in a colorectal cancer cohort.
Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma.
Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma.
Intervention of Acidophilus-casei dahi and Wheat bran against molecular alteration in colon carcinogenesis.
Intervention with the crude polysaccharides of Physalis pubescens L. mitigates colitis by preventing oxidative damage, aberrant immune responses, and dysbacteriosis.
Intestinal anti-inflammatory activity of combined quercitrin and dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, in rats with DSS-induced colitis.
Intestinal Anti-Inflammatory Effects of Selenized Ulva pertusa Polysaccharides in a Dextran Sulfate Sodium-Induced Inflammatory Bowel Disease Model.
Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis.
Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma.
Intestinal-type sinonasal adenocarcinomas. Immunohistochemical profile of 66 cases.
Intra-abdominal activation of a local inflammatory response within the human muscularis externa during laparotomy.
Intra-hippocampal injection of lipopolysaccharide inhibits kindled seizures and retards kindling rate in adult rats.
Intraarticular osteoid osteoma associated with synovitis: a possible role of cyclooxygenase-2 expression by osteoblasts in the nidus.
Intracellular Ca2+ mediates lipoxygenase-induced proliferation of U-373 MG human astrocytoma cells.
Intracellular colon cancer-associated Escherichia coli promote protumoral activities of human macrophages by inducing sustained COX-2 expression.
Intracellular unesterified arachidonic acid signals apoptosis.
Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-?B-dependent inflammation process in a mouse model of Parkinson's disease.
Intratumoral CD8+ Lymphocyte Infiltration as a Prognostic Factor and Its Relationship With Cyclooxygenase 2 Expression and Microsatellite Instability in Endometrial Cancer.
Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.
Intravenous injection of l-BMAA induces a rat model with comprehensive characteristics of amyotrophic lateral sclerosis/Parkinson-dementia complex.
Introduction to eicosanoids and the gastroenteric tract.
Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer.
Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis.
Inverse expression of dihydrodiol dehydrogenase and glutathione-S-transferase in patients with esophageal squamous cell carcinoma.
Investigating associations of cyclooxygenase-2 expression with angiogenesis, proliferation, macrophage and T-lymphocyte infiltration in canine melanocytic tumours.
Investigating the anti-inflammatory effects of high molecular weight secretions from Limosilactobacillus reuteri PTCC 1655 on LPS-stimulated PMA-differentiated THP-1 cells.
Investigating the Connection Between Endogenous Heme Accumulation and COX2 Activity in Cancer Cells.
Investigating the Multitarget Pharmacological Mechanism of Ursolic Acid Acting on Colon Cancer: A Network Pharmacology Approach.
Investigation of anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients.
Investigation of constituents from Cinnamomum camphora (L.) J. Presl and evaluation of their anti-inflammatory properties in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Investigation of Dracocephalum kotschyi Plant Extract on the Effective Inflammatory Transcription Factors and Mediators in Activated Macrophages.
Investigation of Modulatory Effect of Pinolenic Acid (PNA) on Inflammatory Responses in Human THP-1 Macrophage-Like Cell and Mouse Models.
Investigation of mRNA expression of tumor necrosis factor-alpha, interleukin-1beta, and cyclooxygenase-2 in cultured equine digital artery smooth muscle cells after exposure to endotoxin.
Investigation of the effects of short-term inhalation of carbon nanoparticles on brains and lungs of c57bl/6j and p47(phox-/-) mice.
Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells.
Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.
Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion.
Involvement of cyclooxygenase-2 in serum-induced prostaglandin production by human oral gingival epithelial cells.
Involvement of cyclooxygenase-2 in the tumor site-dependent production of parathyroid hormone-related protein in colon 26 carcinoma.
Involvement of EGF receptor activation in the induction of cyclooxygenase-2 in HaCaT keratinocytes after UVB.
Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
Involvement of inflammatory mediators in macrophage antitumor activity.
Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein.
Involvement of Nrf2/HO-1 antioxidant signaling and NF-?B inflammatory response in the potential protective effects of vincamine against methotrexate-induced nephrotoxicity in rats: cross talk between nephrotoxicity and neurotoxicity.
Involvement of Platelets in Cancers.
Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.
Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide.
Involvement of Rho-kinase/I?B-?/NF-?B activation in IL-1?-induced inflammatory response and oxidative stress in human chondrocytes.
Involvement of STAT3, NF-?B and associated downstream molecules before and after the onset of urethane induced lung tumors in mouse.
Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells.
Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors.
In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer.
Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis.
Ionizing radiation induces astrocyte gliosis through microglia activation.
Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation.
IRAK1/4-targeted anti-inflammatory action of caffeic acid.
Iridoid glycosides from the flowers of Gentiana macrophylla Pall. ameliorate collagen-induced arthritis in rats.
Irisin Protects Against Motor Dysfunction of Rats with Spinal Cord Injury via Adenosine 5'-Monophosphate (AMP)-Activated Protein Kinase-Nuclear Factor Kappa-B Pathway.
Is antibody therapy of tumor compromised by infusion-related reactions? A case for inhibiting the activity of cyclooxygenase-2.
Is COX-2 a 'collateral' target in cancer prevention?
Is COX-2 inhibition a panacea for cancer prevention?
Is Curcumin a Possibility to Treat Inflammatory Bowel Diseases?
Is cyclooxygenase-2 important in skin carcinogenesis?
Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer.
Is there a place for practical chemoprevention of colorectal cancer in light of COX-2 heterogeneity?
Isatins inhibit cyclooxygenase-2 and inducible nitric oxide synthase in a mouse macrophage cell line.
Isoalantolactone inhibits IKK? kinase activity to interrupt the NF-?B/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin in glioblastoma.
Isoflavone-rich extracts from wooly glycine Glycine tomentella inhibits LPS-induced TNF-alpha expression in a macrophage cell line of Atlantic salmon (Salmo salar L.).
Isoform-Specific Role of Akt in Oral Squamous Cell Carcinoma.
Isofraxidin attenuates IL-1?-induced inflammatory response in human nucleus pulposus cells.
Isoginkgetin treatment attenuated lipopolysaccharide-induced monoamine neurotransmitter deficiency and depression-like behaviors through downregulating p38/NF-?B signaling pathway and suppressing microglia-induced apoptosis.
Isolation and characterization of anti-inflammatory peptides derived from whey protein.
Isolation and characterization of phellodendronoside A, a new isoquinoline alkaloid glycoside with anti-inflammatory activity from Phellodendron chinense Schneid.
Isolation and Characterization of Two Flavonoids, Engeletin and Astilbin, from the Leaves of Engelhardia roxburghiana, and Their Potential Anti-inflammatory Properties.
Isolation of Novel Sesquiterpeniods and Anti-neuroinflammatory Metabolites from Nardostachys jatamansi.
Isoleucilactucin Ameliorates Coal Fly Ash-Induced Inflammation through the NF-?B and MAPK Pathways in MH-S Cells.
Isoliquiritigenin suppresses tumor necrosis factor-?-induced inflammation via peroxisome proliferator-activated receptor-? in intestinal epithelial cells.
Isoorientin attenuates lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-related MAPK/NF-?B signaling pathway in BV-2 microglia.
Isoprenylcysteine carboxyl methyltransferase inhibitors exerts anti-inflammatory activity.
Isorhamnetin Suppresses Skin Cancer through Direct Inhibition of MEK1 and PI3-K.
Isotrifoliol inhibits pro-inflammatory mediators by suppression of TLR/NF-?B and TLR/MAPK signaling in LPS-induced RAW264.7 cells.
ISSLS PRIZE IN BASIC SCIENCE 2018: Growth differentiation factor-6 attenuated pro-inflammatory molecular changes in the rabbit anular-puncture model and degenerated disc-induced pain generation in the rat xenograft radiculopathy model.
Jaceosidin, a pharmacologically active flavone derived from Artemisia argyi, inhibits phorbol-ester-induced upregulation of COX-2 and MMP-9 by blocking phosphorylation of ERK-1 and -2 in cultured human mammary epithelial cells.
JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors.
JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
JAK2-targeted anti-inflammatory effect of a resveratrol derivative 2,4-dihydroxy-N-(4-hydroxyphenyl)benzamide.
JAK2/STAT3 pathway mediating inflammatory responses in heatstroke-induced rats.
Japanese quince (Chaenomeles japonica) leaf phenol extract as modulator of the inflammatory response in lipopolysaccharide-triggered murine macrophage RAW 264.7 cells.
JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats.
JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study.
Juglanin ameliorates LPS-induced neuroinflammation in animal models of Parkinson's disease and cell culture via inactivating TLR4/NF-?B pathway.
JWH133 inhibits MPP+-induced inflammatory response and iron influx in astrocytes.
K-Ras and cyclooxygenase-2 coactivation augments intraductal papillary mucinous neoplasm and Notch1 mimicking human pancreas lesions.
Kaempferia parviflora Extract as a Potential Anti-Acne Agent with Anti-Inflammatory, Sebostatic and Anti-Propionibacterium acnes Activity.
Kaempferol acts through mitogen-activated protein kinases and protein kinase B/Akt to elicit protection in a model of neuroinflammation in BV2 microglial cells.
Kaempferol Attenuates LPS-Induced Striatum Injury in Mice Involving Anti-Neuroinflammation, Maintaining BBB Integrity, and Down-Regulating the HMGB1/TLR4 Pathway.
Kalopanaxsaponin A Exerts Anti-Inflammatory Effects in Lipopolysaccharide-Stimulated Microglia via Inhibition of JNK and NF-?B/AP-1 Pathways.
Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells.
Ketoconazole attenuates radiation-induction of tumor necrosis factor.
Ketoprofen affects the mammary immune response in dairy cows in vivo and in vitro.
Key role for constitutive cyclooxygenase-2 of MDCK cells in basal signaling and response to released ATP.
Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth.
KG-135 inhibits COX-2 expression by blocking the activation of JNK and AP-1 in phorbol ester-stimulated human breast epithelial cells.
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ?-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.
Knockdown of 14-kDa phosphohistidine phosphatase expression suppresses lung cancer cell growth in vivo possibly through inhibition of NF-?B signaling pathway.
Knockdown of cyclooxygenase-2 leads to growth inhibition and cell cycle arrest in hepatocellular carcinoma cells.
Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-?-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2.
Knockdown of NEAT1 exerts suppressive effects on diabetic retinopathy progression via inactivating TGF-?1 and VEGF signaling pathways.
Knockdown of NFAT3 blocked TPA-induced COX-2 and iNOS expression, and enhanced cell transformation in Cl41 cells.
Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment.
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression.
Krüppel-like factor 4 regulates amyloid-? (A?)-induced neuroinflammation in Alzheimer's disease.
KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi's sarcoma.
Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.
Kudzu Leaf Extract Suppresses the Production of Inducible Nitric Oxide Synthase, Cyclooxygenase-2, Tumor Necrosis Factor-Alpha, and Interleukin-6 via Inhibition of JNK, TBK1 and STAT1 in Inflammatory Macrophages.
L-F001, a novel multifunctional ROCK inhibitor, suppresses neuroinflammation in vitro and in vivo: Involvement of NF-?B inhibition and Nrf2 pathway activation.
Labdane diterpenes in Curcuma mangga rhizomes inhibit lipid peroxidation, cyclooxygenase enzymes and human tumour cell proliferation
Lack of Alpha-Synuclein Modulates Microglial Phenotype In Vitro.
Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Lack of association between cyclooxygenase 2-765G/C gene polymorphism and breast cancer risk in Ahvaz, west-south Iran.
Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population.
Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells.
Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice.
Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival.
Lack of RNase L attenuates macrophage functions.
Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis.
Lactobacillus acidophilus 74-2 and butyrate induce cyclooxygenase (COX)-1 expression in gastric cancer cells.
Lactobacillus plantarum CAU1055 ameliorates inflammation in lipopolysaccharide-induced RAW264.7 cells and a dextran sulfate sodium-induced colitis animal model.
Lactoferrin-dual drug nanoconjugate: Synergistic anti-tumor efficacy of docetaxel and the NF-?B inhibitor celastrol.
Lapatinib inhibits meiotic maturation of porcine oocyte-cumulus complexes cultured in vitro in gonadotropin-supplemented medium.
Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.
Laser photobiomodulation of pro-inflammatory mediators on Walker Tumor 256 induced rats.
Late administration of a specific COX-2 inhibitor does not treat and/or prevent progression of gastric tumors in rats submitted to duodenogastric reflux procedure.
LCB 03-0110, a Novel Pan-Discoidin Domain Receptor/c-Src Family Tyrosine Kinase Inhibitor, Suppresses Scar Formation by Inhibiting Fibroblast and Macrophage Activation.
Leaky brain in neurological and psychiatric disorders: Drivers and consequences.
Lentivirus-mediated shRNA interference targeting cyclooxygenase-2 inhibits growth of human non-small cell lung cancer.
Leonurine attenuates lipopolysaccharide-induced inflammatory responses in human endothelial cells: Involvement of reactive oxygen species and NF-?B pathways.
Leonurine exerts anti-inflammatory effect by regulating inflammatory signaling pathways and cytokines in LPS-induced mouse mastitis.
Leptin deficiency-induced obesity exacerbates ultraviolet B radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet B-irradiated mouse skin.
Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression.
Leukemic cells modulate induction of COX-2 in human stromal fibroblasts.
Leukocyte populations and mRNA expression of inflammatory factors in quarter milk fractions at different somatic cell score levels in dairy cows.
Leukotriene A4 hydrolase as a target for cancer prevention and therapy.
Leukotriene B4 creates a favorable microenvironment for murine melanoma growth.
Leukotriene D4-induced Caco-2 cell proliferation is mediated by prostaglandin E2 synthesis.
Levels of Cyclooxygenase 2, Interleukin-6, and Tumour Necrosis Factor-? in Fibroblast Cell Culture Models after Photobiomodulation at 660?nm.
Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands.
Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer.
Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.
Levosulpiride, (S)-(-)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl) methyl]-2-methoxybenzamide, enhances the transduction efficiency of PEP-1-ribosomal protein S3 in vitro and in vivo.
Levuglandin Forms Adducts with Histone H4 in a Cyclooxygenase-2-Dependent Manner, Altering Its Interaction with DNA.
LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs.
Licarin A is a candidate compound for the treatment of immediate hypersensitivity via inhibition of rat mast cell line RBL-2H3 cells.
Licochalcone E present in licorice suppresses lung metastasis in the 4T1 mammary orthotopic cancer model.
Licofelone abolishes survival of carcinogenic fibroblasts by inducing apoptosis.
Licoricidin, an Active Compound in the Hexane/Ethanol Extract of Glycyrrhiza uralensis, Inhibits Lung Metastasis of 4T1 Murine Mammary Carcinoma Cells.
Lignans from Saururus chinensis exhibit anti-inflammatory activity by influencing the Nrf2/HO-1 activation pathway.
Limited Proteolysis of Cyclooxygenase-2 Enhances Cell Proliferation.
Limonoids isolated from Toona sinensis and their radical scavenging, anti-inflammatory and cytotoxic activities.
LINC00461 Promoted Endometrial Carcinoma Growth and Migration by Targeting MicroRNA-219-5p/Cyclooxygenase-2 Signaling Axis.
LINC00657 expedites neuropathic pain development by modulating miR-136/ZEB1 axis in a rat model.
Linkage Disequilibrium and Haplotype Analysis of COX-2 and Risk of Colorectal Adenoma Development.
Linoleic acid metabolism in metastatic and nonmetastatic murine mammary tumor cells.
Lipid a radiosensitizes hypoxic EMT-6 tumor cells: role of the NF-kappaB signaling pathway.
Lipid mediators of tumor necrosis factor-alpha-induced uveitis.
Lipid peroxidation, cyclooxygenase enzyme and tumor cell proliferation inhibitory compounds in Cornus kousa fruits.
Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells.
Lipopolysaccharide activates the kallikrein-kinin system in mouse choroid plexus cell line ECPC4.
Lipopolysaccharide Delays Closure of the Rat Ductus Arteriosus by Induction of Inducible Nitric Oxide Synthase But Not Prostaglandin E2.
Lipopolysaccharide initiates a bypass feedback loop of epidermal growth factor receptor signaling by HPS70-induced COX-2 in H22 hepatocarcinoma cells.
Lipopolysaccharide initiates a positive feedback of epidermal growth factor receptor signaling by prostaglandin E2 in human biliary carcinoma cells.
Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus.
Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis.
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.
Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention.
Lipoxygenase inhibitors for cancer prevention: promises and risks.
Lipoxygenase-5 is overexpressed in prostate adenocarcinoma.
Liquiritin suppresses UVB?induced skin injury through prevention of inflammation, oxidative stress and apoptosis through the TLR4/MyD88/NF??B and MAPK/caspase signaling pathways.
Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE?.
Liver Injury Induced by Carbon Tetrachloride in Mice Is Prevented by the Antioxidant Capacity of Anji White Tea Polyphenols.
LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma.
lncRNA HOTAIR upregulates COX-2 expression to promote invasion and migration of nasopharyngeal carcinoma by interacting with miR-101.
lncRNA-PACER upregulates COX-2 and PGE2 through the NF-?B pathway to promote the proliferation and invasion of colorectal-cancer cells.
Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation.
Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium.
Localization of cyclo-oxygenase-2 in human recurrent colorectal cancer.
Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.
Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2.
Loganin prevents BV-2 microglia cells from A?1-42 -induced inflammation via regulating TLR4/TRAF6/NF-?B axis.
Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization.
Long non-coding RNA small nucleolar RNA host gene 1 alleviates the progression of epilepsy by regulating the miR-181a/BCL-2 axis in vitro.
Lonicera caerulea L. Polyphenols Alleviate Oxidative Stress-Induced Intestinal Environment Imbalance and Lipopolysaccharide-Induced Liver Injury in HFD-Fed Rats by Regulating the Nrf2/HO-1/NQO1 and MAPK Pathways.
Loss of 15-Hydroxyprostaglandin Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumors.
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Loss of endogenous TGF-beta effect induces mouse hepatoma malignancy by correlation with cyclooxygenase-2 and VEGF.
Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Loss of INK4a/Arf gene enhances ultraviolet radiation-induced cutaneous tumor development.
Loss of miR-101-3p Promotes Transmigration of Metastatic Breast Cancer Cells through the Brain Endothelium by Inducing COX-2/MMP1 Signaling.
Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis.
Loss of p53 in stromal fibroblasts enhances tumor cell proliferation through nitric-oxide-mediated cyclooxygenase 2 activation.
Loss of PPAR? expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment.
Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells.
Low COX2 in tumor and upregulation in stroma mark laryngeal squamous cell carcinoma progression.
Low molecular weight heparin prevents lipopolysaccharide induced-hippocampus-dependent cognitive impairments in mice.
Low-cytotoxic synthetic bromorutaecarpine exhibits anti-inflammation and activation of transient receptor potential vanilloid type 1 activities.
Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.
Low-grade inflammation in symptomatic knee osteoarthritis: prognostic value of inflammatory plasma lipids and peripheral blood leukocyte biomarkers.
Low-level laser therapy and sodium diclofenac in acute inflammatory response induced by skeletal muscle trauma: Effects in muscle morphology and mRNA gene expression of inflammatory markers.
Lower expression of cyclooxygenase-2: is it associated with the development of borderline ovarian tumors?
Lumbar ligamentum flavum hypertrophy is due to accumulation of inflammation-related scar tissue.
Luminescent iridium(iii) complexes as COX-2-specific imaging agents in cancer cells.
Lung cancer and cyclooxygenase-2.
Lung-derived soluble mediators are pathogenic in ventilator-induced lung injury.
Lutein suppresses inflammatory responses through Nrf2 activation and NF-?B inactivation in lipopolysaccharide-stimulated BV-2 microglia.
Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney.
Luteolin Inhibits Fibrillary ?-Amyloid1-40-Induced Inflammation in a Human Blood-Brain Barrier Model by Suppressing the p38 MAPK-Mediated NF-?B Signaling Pathways.
Luteolin inhibits microglial inflammation and improves neuron survival against inflammation.
Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer.
Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages.
Luteolin Suppresses Inflammatory Mediator Expression by Blocking the Akt/NF?B Pathway in Acute Lung Injury Induced by Lipopolysaccharide in Mice.
Luteolin, a Novel Natural Inhibitor of Tumor Progression Locus 2 Serine/Threonine Kinase, Inhibits Tumor Necrosis Factor-{alpha}-Induced Cyclooxygenase-2 Expression in JB6 Mouse Epidermis Cells.
Luteoloside attenuates neuroinflammation in focal cerebral ischemia in rats via regulation of the PPAR?/Nrf2/NF-?B signaling pathway.
Luteoloside Inhibits IL-1?-Induced Apoptosis and Catabolism in Nucleus Pulposus Cells and Ameliorates Intervertebral Disk Degeneration.
Lutonarin from Barley Seedlings Inhibits the Lipopolysacchride-Stimulated Inflammatory Response of RAW 264.7 Macrophages by Suppressing Nuclear Factor-?B Signaling.
LXW7 attenuates inflammation via suppressing Akt/nuclear factor kappa B and mitogen-activated protein kinases signaling pathways in lipopolysaccharide-stimulated BV2 microglial cells.
Lychee Seed Fraction Inhibits A?(1-42)-Induced Neuroinflammation in BV-2 Cells via NF-?B Signaling Pathway.
Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma.
Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix.
Lymphocyte responses exacerbate angiotensin II-dependent hypertension.
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.
Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques.
Lysozyme-Antimicrobial Peptide Fusion Protein Promotes the Diabetic Wound Size Reduction in Streptozotocin (STZ)-Induced Diabetic Rats.
Macelignan inhibits histamine release and inflammatory mediator production in activated rat basophilic leukemia mast cells.
Macrophage-mediated tumor cell killing: lack of dependence on the cyclooxygenase pathway of prostaglandin synthesis.
Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth.
Macrophages induce COX-2 expression in breast cancer cells: Role of IL-1{beta} auto-amplification.
Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/?-catenin signalling pathway.
Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2.
Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice.
Madecassoside prevents A?25-35-induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway.
Magnesium chenoursodeoxycholic acid ameliorates carbon tetrachloride-induced liver fibrosis in rats.
Magnetic ligand fishing combination with high-performance liquid chromatography-diode array detector-mass spectrometry to screen and characterize cyclooxygenase-2 inhibitors from green tea.
Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells.
Major constituents of Boswellia carteri resin exhibit cyclooxygenase enzyme inhibition and antiproliferative activity.
Malignant salivary gland tumors and cyclo-oxygenase-2: A histopathological and immunohistochemical analysis with implications on histogenesis.
Malonic Acid Isolated from Pinus densiflora Inhibits UVB-Induced Oxidative Stress and Inflammation in HaCaT Keratinocytes.
Maltol inhibits the progression of osteoarthritis via the nuclear factor-erythroid 2-related factor-2/heme oxygenase-1 signal pathway in vitro and in vivo.
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Mammographic density and breast tissue expression of inflammatory markers, growth factors, and vimentin.
Management of Barrett's esophagus with and without dysplasia.
Mangiferin decreases inflammation and oxidative damage in rat brain after stress.
Mangiferin: A xanthonoid with multipotent anti-inflammatory potential.
Mannan-binding lectin suppresses growth of hepatocellular carcinoma by regulating hepatic stellate cell activation via the ERK/COX-2/PGE2 pathway.
Many actions of cyclooxygenase-2 in cellular dynamics and in cancer.
MAPK (ERK2) kinase--a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth.
Mapping of the proinflammatory domains of MspTL of Treponema lecithinolyticum.
Maresin 1, a Proresolving Lipid Mediator, Mitigates Carbon Tetrachloride-Induced Liver Injury in Mice.
Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.
Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines.
Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway.
Maslinic acid prevents IL-1?-induced inflammatory response in osteoarthritis via PI3K/AKT/NF-?B pathways.
Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
Massive T-lymphocyte infiltration into the host stroma is essential for fibroblast growth factor-2-promoted growth and metastasis of mammary tumors via neovascular stability.
Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis.
Maternal and fetal roles in bacterially induced preterm labor in the mouse.
Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer.
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Maximal standardized uptake value on FDG-PET is correlated with cyclooxygenase-2 expression in patients with lung adenocarcinoma.
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
MBP-1 Suppresses Growth and Metastasis of Gastric Cancer Cells through COX-2.
Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
McN-A-343, a muscarinic agonist, reduces inflammation and oxidative stress in an experimental model of ulcerative colitis.
Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry.
Measurement of prostaglandin E2 in rectal mucosa in human subjects: a method study.
Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: importance of monocyte chemoattractant protein-1 modulation.
Mechanism of action of antiinflammatory drugs.
Mechanism of action of key enzymes associated with cancer propagation and their inhibition by various chemotherapeutic agents.
Mechanism of anti-inflammatory activity of umbelliferone 6-carboxylic acid isolated from Angelica decursiva.
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo.
Mechanisms by which licochalcone e exhibits potent anti-inflammatory properties: studies with phorbol ester-treated mouse skin and lipopolysaccharide-stimulated murine macrophages.
Mechanisms involved in the attenuation of intestinal toxicity induced by (S)-(+)-ketoprofen in re-fed rats.
Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity.
Mechanisms of action of nonpeptide hormones on resveratrol-induced antiproliferation of cancer cells.
Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.
Mechanisms of disease: Carcinogenesis in Barrett's esophagus.
Mechanisms of disease: Inflammatory mediators and cancer prevention.
Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention.
Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer.
Mechanisms of quinolone phototoxicity.
Mechanisms of Thymoquinone Hepatorenal Protection in Methotrexate-Induced Toxicity in Rats.
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia.
Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis.
Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer.
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.
MEDICAL BASIS OF DIABETIC NEUROPATHY FORMATION (REVIEW).
Medicinal Chemistry and Pharmacology Focused on Cannabidiol, a Major Component of the Fiber-Type Cannabis.
Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae).
Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective.
Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: A potentially protective mechanism in atherosclerotic vascular disease and cancer.
Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.
Melatonin Modulates the Antioxidant Defenses and the Expression of Proinflammatory Mediators in Pancreatic Stellate Cells Subjected to Hypoxia.
Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting Survivin and XIAP.
Melatonin protects against lipopolysaccharide-induced epididymitis in sheep epididymal epithelial cells in vitro.
Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells.
Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways.
Meloxicam increases intracellular accumulation of doxorubicin via downregulation of multidrug resistance-associated protein 1 (MRP1) in A549 cells.
Meloxicam inhibits fipronil-induced apoptosis via modulation of the oxidative stress and inflammatory response in SH-SY5Y cells.
Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
Meloxicam inhibits the growth of colorectal cancer cells.
Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the ?-catenin signaling pathway.
Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1? Signaling in Hepatocellular Carcinoma.
Meningioma: an update.
Meroterpenoid dimers from Ganoderma cochlear and their cytotoxic and COX-2 inhibitory activities.
Meroterpenoids from the Brown Alga Cystoseira usneoides as Potential Anti-Inflammatory and Lung Anticancer Agents.
Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis.
Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma.
Meta-analysis of the association between COX-2 polymorphisms and risk of colorectal cancer based on case-control studies.
Metabolic and molecular relative percentage coreduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism.
Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes.
Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta and down-regulation of proinflammatory mediators.
Metastasis-Associated 1 (MTA1) Gene Expression Promotes Angiogenesis in Mouse Xenografts from Human Non-Small Cell Lung Cancer (NSCLC) Cells.
Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer.
Metastatic potential in MDA-MB-231 human breast cancer cells is inhibited by proton beam irradiation via the Akt/nuclear factor-?B signaling pathway.
Metformin and silymarin afford protection in cyclosporine A induced hepatorenal toxicity in rat by modulating redox status and inflammation.
Metformin Inhibits Lipoteichoic Acid-Induced Oxidative Stress and Inflammation Through AMPK/NRF2/NF-?B Signaling Pathway in Bovine Mammary Epithelial Cells.
Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression.
Methanandamide increases COX-2 expression and tumor growth in murine lung cancer.
Methanol Extract of Artemisia apiacea Hance Attenuates the Expression of Inflammatory Mediators via NF- ? B Inactivation.
Methanolic extract of adlay seed suppresses COX-2 expression of human lung cancer cells via inhibition of gene transcription.
Method development and validation for ultra-high pressure liquid chromatography/tandem mass spectrometry determination of multiple prostanoids in biological samples.
Methyl syringate, a TRPA1 agonist represses hypoxia-induced cyclooxygenase-2 in lung cancer cells.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients.
Methylation status and overexpression of COX-2 in Tunisian patients with ductal invasive breast carcinoma.
Methylation Status of Genes in Non-Neoplastic Mucosa From Patients With Ulcerative Colitis-Associated Colorectal Cancer.
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma.
MF tricyclic and sulindac retard tumor formation in an animal model.
Micheliolide suppresses LPS-induced neuroinflammatory responses.
Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2.
Microalgae aqueous extracts exert intestinal protective effects in Caco-2 cells and dextran sodium sulphate-induced mouse colitis.
MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival.
MicroRNA and cyclooxygenase-2 in breast cancer.
MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.
MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2.
MicroRNA-183-5p protects human derived cell line SH-SY5Y cells from mepivacaine-induced injury.
MicroRNA-26a/-26b-COX-2-MIP-2 Loop Regulates Allergic Inflammation and Allergic Inflammation-promoted Enhanced Tumorigenic and Metastatic Potential of Cancer Cells.
MicroRNA-30a-3p acts as a tumor suppressor in MHCC-97H hepatocellular carcinoma cells by targeting COX-2.
MicroRNA-708 activation by glucocorticoid receptor agonists regulate breast cancer tumorigenesis and metastasis via downregulation of NF-?B signaling.
MicroRNAs as Biomarkers of Pain Intensity in Patients With Chronic Fatigue Syndrome.
MicroRNAs in the anticancer effects of celecoxib: A systematic review.
Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.
Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients.
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression.
Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis.
Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/?-catenin signaling axis.
Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy.
Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.
Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study.
Microvessel density is a prognostic marker of human gastric cancer.
Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer.
Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma.
Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention.
Minor salivary gland carcinoma: a review of 35 cases.
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF).
MiR-1297 regulates the growth, migration and invasion of colorectal cancer cells by targeting cyclo-oxygenase-2.
miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway.
miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells.
MiR-144-5p limits experimental abdominal aortic aneurysm formation by mitigating M1 macrophage-associated inflammation: Suppression of TLR2 and OLR1.
MiR-150 alleviates neuropathic pain via inhibiting toll-like receptor 5.
miR-203 is involved in the laryngeal carcinoma pathogenesis via targeting VEGFA and Cox-2.
MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting COX-2 and ALOX5.
miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-?B/COX-2 activation.
MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.
miR-26b is downregulated in human tongue squamous cell carcinoma and regulates cell proliferation and metastasis through a COX-2-dependent mechanism.
MiR-26b suppresses tumor cell proliferation, migration and invasion by directly targeting COX-2 in lung cancer.
miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models.
miR-370-3p Alleviates Ulcerative Colitis-Related Colorectal Cancer in Mice Through Inhibiting the Inflammatory Response and Epithelial-Mesenchymal Transition.
miR-573 is a negative regulator in the pathogenesis of rheumatoid arthritis.
miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells.
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells.
Mitigation of cisplatin induced nephrotoxicity by casticin in male albino rats.
Mitochondria of a human multidrug-resistant hepatocellular carcinoma cell line constitutively express inducible nitric oxide synthase in the inner membrane.
Mitochondria protection with ginkgolide B-loaded polymeric nanocapsules prevents diethylnitrosamine-induced hepatocarcinoma in rats.
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.
Mitochondrial targeting of TR3 is involved in TPA induced apoptosis in breast cancer cells.
Mitofusin 2 Deficiency Causes Pro-Inflammatory Effects in Human Primary Macrophages.
Mitogen-activated protein kinase phosphatase-1 prevents lipopolysaccharide-induced apoptosis in immature rat intestinal epithelial cells.
Mitogenic effects of cytokines on smooth muscle are critically dependent on protein kinase A and are unmasked by steroids and cyclooxygenase inhibitors.
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity.
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.
MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells.
Mode of action of aspirin as a chemopreventive agent.
Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus.
Modification of palm oil for anti-inflammatory nutraceutical properties.
Modified Shenlingbaizhu decoction reduces intestinal adenoma formation in adenomatous polyposis coli multiple intestinal neoplasia mice by suppression of hypoxia-inducible factor 1?-induced CD4+CD25+forkhead box P3 regulatory T cells.
Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats.
Modulating effect of Biophytum sensitivum extract on rats with acetic acid-induced ulcerative colitis.
Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases.
Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer.
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Modulation of COX-2, INF-?, glutamatergic and opioid systems contributes to antinociceptive, anti-inflammatory and anti-hyperalgesic effects of bis(3-amino-2-pyridine) diselenide.
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger.
Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids.
Modulation of genomic and epigenetic end-points by celecoxib.
Modulation of HMGB1 translocation and RAGE/NF?B cascade by quercetin treatment mitigates atopic dermatitis in NC/Nga transgenic mice.
Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4.
Modulation of humoral immune responses and inhibition of proinflammatory cytokines and nitric oxide production by 10-methoxycanthin-6-one.
Modulation of hyperglycemia and TNF?-mediated inflammation by helichrysum and grapefruit extracts in diabetic db/db mice.
Modulation of inflammatory cytokines by omega-3 Fatty acids.
Modulation of inflammatory responses by diterpene acids from Helianthus annuus L.
Modulation of lipopolysaccharide-stimulated macrophage tumor necrosis factor-alpha production by omega-3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10.
Modulation of Macrophage Polarization and HMGB1-TLR2/TLR4 Cascade Plays a Crucial Role for Cardiac Remodeling in Senescence-Accelerated Prone Mice.
Modulation of oxidative/nitrosative stress and inflammatory response by rapamycin in target and distant organs in rats exposed to hindlimb ischemia/reperfusion: The role of mTOR.
Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway.
Modulation of the prostaglandin-endoperoxide synthase 2 gene expression by variant haplotypes: influence of the 3'-untranslated region.
Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain.
Modulation of tumor cell motility by prostaglandins and inhibitors of prostaglandin synthesis.
Modulative effect of a new hydrazide derivative on wheat-induced pulmonary inflammation in rats.
Modulatory effect of cadmium on the expression of phospholipase A2 and proinflammatory genes in rat testis.
Mogroside V Alleviates Lipopolysaccharide-Induced Neuroinflammation via Inhibition of TLR4-MyD88 and Activation of AKT/AMPK-Nrf2 Signaling Pathway.
Molecular analysis of primary gastric cancer, corresponding xenografts, and 2 novel gastric carcinoma cell lines reveals novel alterations in gastric carcinogenesis.
Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy Against Breast Cancer Cell Models.
Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2.
Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition.
Molecular basis of therapeutic approaches to gastric cancer.
Molecular basis of traditional Chinese medicine in cancer chemoprevention.
Molecular Changes in Sub-lesional Muscle Following Acute Phase of Spinal Cord Injury.
Molecular Characterization of Feline COX-2 and Expression in Feline Mammary Carcinomas.
Molecular characterization of the grape seeds extract's effect against chemically induced liver cancer: In vivo and in vitro analyses.
Molecular chemoprevention by morin - A plant flavonoid that targets nuclear factor kappa B in experimental colon cancer.
Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data.
Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8.
Molecular determinants in targeted therapy for esophageal adenocarcinoma.
Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer.
Molecular docking and fluorescence characterization of benzothieno[3,2-d]pyrimidin-4-one sulphonamide thio-derivatives, a novel class of selective cyclooxygenase-2 inhibitors.
Molecular Imaging of Cyclooxygenase-2 in Canine Transitional Cell Carcinomas In Vitro and In Vivo.
Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.
Molecular Insights into the Interaction of RONS and Thieno[3,2-c]pyran Analogs with SIRT6/COX-2: A Molecular Dynamics Study.
Molecular investigation of the direct anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines.
Molecular Link Mechanisms between Inflammation and Cancer.
Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy.
Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases.
Molecular Mechanisms Behind the Chemopreventive Effects of Anthocyanidins.
Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units.
Molecular mechanisms involved in chemoprevention of black raspberry extracts: from transcription factors to their target genes.
Molecular Mechanisms of Curcumin in Neuroinflammatory Disorders: A Mini Review of Current Evidences.
Molecular mechanisms of low dose ionizing radiation-induced hormesis, adaptive responses, radioresistance, bystander effects, and genomic instability.
Molecular mechanisms of topical anti-inflammatory effects of lipoxin A(4) in endotoxin-induced uveitis.
Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation.
Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyll, and selected oxidative metabolites with 5-lipoxygenase.
Molecular pathology of cyclooxygenase-2 in neoplasia.
Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer.
Molecular signature of nitric oxide on major cancer hallmarks of colorectal carcinoma.
Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking.
Molecular typing of epithelial ovarian carcinomas using inflammatory markers.
Mono-, di-, and triaryl substituted tetrahydropyrans as cyclooxygenase-2 and tumor growth inhibitors. Synthesis and biological evaluation.
Monocyte chemoattractant protein 1 and CD40 ligation have a synergistic effect on vascular endothelial growth factor production through cyclooxygenase 2 upregulation in gastric cancer.
Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2.
Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state.
Monoterpenoid indole alkaloids from Alstonia rupestris with cytotoxic, anti-inflammatory and antifungal activities.
Monotropein isolated from the roots of Morinda officinalis ameliorates proinflammatory mediators in RAW 264.7 macrophages and dextran sulfate sodium (DSS)-induced colitis via NF-?B inactivation.
Montelukast, a CysLT1 receptor antagonist, reduces colon cancer stemness and tumor burden in a mouse xenograft model of human colon cancer.
Moracin C, A Phenolic Compound Isolated from Artocarpus heterophyllus, Suppresses Lipopolysaccharide-Activated Inflammatory Responses in Murine Raw264.7 Macrophages.
More than structural cells, fibroblasts create and orchestrate the tumor microenvironment.
Morin protects against acrylamide-induced neurotoxicity in rats: an investigation into different signal pathways.
Morinda citrifolia edible leaf extract enhanced immune response against lung cancer.
Moringa oleifera Alkaloids Inhibited PC3 Cells Growth and Migration Through the COX-2 Mediated Wnt/?-Catenin Signaling Pathway.
Moringa oleifera Flower Extract Suppresses the Activation of Inflammatory Mediators in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages via NF-?B Pathway.
Moringa oleifera from Cambodia Ameliorates Oxidative Stress, Hyperglycemia, and Kidney Dysfunction in Type 2 Diabetic Mice.
Morphoproteomic confirmation of an activated nuclear factor-?Bp65 pathway in follicular thyroid carcinoma.
Morphoproteomic-Guided Treatment of Chemotherapy Resistant Colon Cancer using Natural Based Therapies: A Case Study.
Mouse brain plasmalogens are targets for hypochlorous acid-mediated modification in vitro and in vivo.
Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs.
mPGES-1 and ALOX5/-15 in tumor-associated macrophages.
mPGES-1 as a target for cancer suppression A comprehensive invited review "Phospholipase A(2) and lipid mediators"
mRNA induction and cytokine release of inflammatory mediators during in vitro exposure of human nasal respiratory epithelia to acetaldehyde.
mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.
Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.
Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy.
Mulberry leaves extract ameliorates alcohol-induced liver damages through reduction of acetaldehyde toxicity and inhibition of apoptosis caused by oxidative stress signals.
Multi-targeted therapy by curcumin: how spicy is it?
Multifaceted link between cancer and inflammation.
Multifaceted roles of cyclooxygenase-2 in lung cancer.
Multifocal angiostatic therapy: an update.
Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398.
Multilevel pharmacological manipulation of adenosine-prostaglandin E?/cAMP nexus in the tumor microenvironment: a 'two hit' therapeutic opportunity.
Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.
Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.
Multiple roles of cyclooxygenase-2 in endometrial cancer.
Muscone Protects Vertebral End-plate Degeneration by Antiinflammatory Property.
Mutagenesis and carcinogenesis induced by dibenzo[a,l]pyrene in the mouse oral cavity: A potential new model for oral cancer.
Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1.
Mycobacterium indicus pranii downregulates MMP-9 and iNOS through COX-2 dependent and TNF-? independent pathway in mouse peritoneal macrophages in vitro.
Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.
Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: tumor necrosis factor-alpha receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling.
Myeloperoxidase is increased in human cerebral aneurysms and increases formation and rupture of cerebral aneurysms in mice.
Myofibroblasts. II. Intestinal subepithelial myofibroblasts.
Myricetin down-regulates phorbol ester-induced cyclooxygenase-2 expression in mouse epidermal cells by blocking activation of nuclear factor kappa B.
Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis.
Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice.
n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation.
n-3 polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionising radiation with inhibition of tumour angiogenesis.
n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
n-6 Linoleic Acid Induces Epigenetics Alterations Associated with Colonic Inflammation and Cancer.
N-Acetylcysteine Reduces miR-146a and NF-?B p65 Inflammatory Signaling Following Cadmium Hepatotoxicity in Rats.
N-Palmitoylethanolamine-oxazoline (PEA-OXA) as a new therapeutic strategy to control neuroinflammation: neuroprotective effects in experimental models of spinal cord and brain injury.
N-trans-feruloyltyramine inhibits LPS-induced NO and PGE2 production in RAW 264.7 macrophages: Involvement of AP-1 and MAP kinase signalling pathways.
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
NADPH Oxidase as a Target for Modulation of Radiation Response; Implications to Carcinogenesis and Radiotherapy.
Nadroparin Sodium Activates Nrf2/HO-1 Pathway in Acetic Acid-Induced Colitis in Rats.
Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis.
Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers.
Nano-gold displayed anti-inflammatory property via NF-kB pathways by suppressing COX-2 activity.
Nanoscale photosensitizer with tumor-selective turn-on fluorescence and activatable photodynamic therapy treatment for COX-2 overexpressed cancer cells.
Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo.
Naringenin ameliorates learning and memory impairment following systemic lipopolysaccharide challenge in the rat.
Naringenin attenuates CCl4 induced hepatic inflammation by the activation of Nrf2 mediated pathway in rats.
Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway.
Naringin protects against cyclophosphamide-induced hepatotoxicity and nephrotoxicity through modulation of oxidative stress, inflammation, apoptosis, autophagy, and DNA damage.
Natural and synthetic avenanthramides activate caspases 2, 8, 3 and downregulate hTERT, MDR1 and COX-2 genes in CaCo-2 and Hep3B cancer cells.
Natural Dietary Supplement, Carvacrol, Alleviates LPS-Induced Oxidative Stress, Neurodegeneration, and Depressive-Like Behaviors via the Nrf2/HO-1 Pathway.
Natural inhibitors of carcinogenesis.
Natural Phenolic Acid, Product of the Honey Bee, for the Control of Oxidative Stress, Peritoneal Angiogenesis, and Tumor Growth in Mice.
Natural product inhibitors of cyclooxygenase (COX) enzyme: A Review on Current status and future perspectives.
Natural products and their derivatives as cyclooxygenase-2 inhibitors.
Natural products as a gold mine for arthritis treatment.
Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease.
Necrosis in DU145 prostate cancer spheroids induces COX-2/mPGES-1-derived PGE2 to promote tumor growth and to inhibit T cell activation.
Necrostatin-1 attenuates lipopolysaccharide-induced acute lung injury in mice.
Neferine, a Bisbenzylisoquinoline Alkaloid, Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis.
Negative feedback regulation of phosphatidylinositol 3-kinase/Akt pathway by over-expressed cyclooxygenase-2 in human epidermal cancer cells.
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
Neoadjuvant Treatment With Cyclooxygenase-2 Inhibitor and Prednisolone Allows Conservative Surgery for Inflammatory Myofibroblastic Tumor of the Bladder.
Neonatal bacterial infection alters fever to live and simulated infections in adulthood.
Neonatal exposure to estradiol-17? modulates tumour necrosis factor alpha and cyclooxygenase-2 expression in brain and also in ovaries of adult female rats.
Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer.
Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves ?v?5 integrin, ILK and AP-1-dependent pathways.
Nephroblastoma overexpressed gene (NOV) enhances RCC cell motility through upregulation of ICAM-1 and COX-2 expression via Akt pathway.
Nephroprotective Effects of Polydatin against Ischemia/Reperfusion Injury: A Role for the PI3K/Akt Signal Pathway.
Nephrotoxic effect of subchronic exposure to S-(1,2-dichlorovinyl)-L-cysteine in mice.
Network analysis of inflammatory genes and their transcriptional regulators in coronary artery disease.
Network Pharmacology Analysis of Traditional Chinese Medicine Formula Shuang Di Shou Zhen Tablets Treating Nonexudative Age-Related Macular Degeneration.
Network Pharmacology of Yougui Pill Combined with Buzhong Yiqi Decoction for the Treatment of Sexual Dysfunction.
Neurobiological basis of fever.
Neurogenesis and neuroprotection in the adult brain. A putative role for 5-lipoxygenase?
Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition.
Neuroprotection of Dexmedetomidine against Cerebral Ischemia-Reperfusion Injury in Rats: Involved in Inhibition of NF-?B and Inflammation Response.
Neuroprotective and Anti-Inflammatory Activities of Allyl Isothiocyanate through Attenuation of JNK/NF-?B/TNF-? Signaling.
Neuroprotective Effect of Fisetin Against the Cerebral Ischemia-Reperfusion Damage via Suppression of Oxidative Stress and Inflammatory Parameters.
Neuroprotective Effect of Optimized Yinxieling Formula in 6-OHDA-Induced Chronic Model of Parkinson's Disease through the Inflammation Pathway.
Neuroprotective effect of Scutellaria baicalensis on spinal cord injury in rats.
Neuroprotective effects of glyceryl nonivamide against microglia-like cells and 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells.
Neuroprotective effects of Kaempferide-7-O-(4?-O-acetylrhamnosyl)-3-O-rutinoside on cerebral ischemia-reperfusion injury in rats.
Neuroprotective Effects of Platonin, a Therapeutic Immunomodulating Medicine, on Traumatic Brain Injury in Mice after Controlled Cortical Impact.
Neuroprotective role of Asiatic acid in aluminium chloride induced rat model of Alzheimer's disease.
Neuroprotective role of kolaviron in striatal redo-inflammation associated with rotenone model of Parkinson's disease.
Neurotoxicity and neuroinflammatory effects of bisphenol A in male rats: the neuroprotective role of grape seed proanthocyanidins.
Neutralizing tumor-promoting inflammation with polypeptide-dexamethasone conjugate for microenvironment modulation and colorectal cancer therapy.
Neutrophils from pregnant women produce thromboxane and tumor necrosis factor-alpha in response to linoleic acid and oxidative stress.
New 12,23-Epoxydammarane Type Saponins Obtained from Panax notoginseng Leaves and Their Anti-Inflammatory Activity.
New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation.
New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways.
New approaches to the treatment of inflammatory disease : focus on small-molecule inhibitors of signal transduction pathways.
New aspects of mast cell biology.
New celecoxib multiparticulate systems to improve glioblastoma treatment.
New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.
New diagnostic markers in salivary gland tumors.
New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly.
New ferrocene compounds as selective cyclooxygenase (COX-2) inhibitors: design, synthesis, cytotoxicity and enzyme-inhibitory activity.
New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy.
New insights into COX-2 biology and inhibition.
New insights into the functions of Cox-2 in skin and esophageal malignancies.
New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.
New NSAID Targets and Derivatives for Colorectal Cancer Chemoprevention.
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
New Pharmaceutical Treatment of Gastric MALT Lymphoma: Anti-angiogenesis Treatment using VEGF Receptor Antibodies and Celecoxib.
New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.
New pyrimidines and triazolopyrimidines as antiproliferative and antioxidants with cyclooxygenase-1/2 inhibitory potential.
New targeted therapies in gastrointestinal cancers.
New targets for the modulation of radiation response--selective inhibition of the enzyme cyclooxygenase 2.
NF-?B activation mediates LPS-or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock.
NF-?B and COX-2 expression in nonmalignant endometrial lesions and cancer.
NF-?B p65 and p105 implicate in interleukin 1?-mediated COX-2 expression in melanoma cells.
NF-?B pathway took part in the development of apoptosis mediated by miR-15a and oxidative stress via mitochondrial pathway in ammonia-treated chicken splenic lymphocytes.
NF-?B signaling modulates radiation?induced microglial activation.
NF-?B targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors.
NF-?B-targeted anti-inflammatory activity of Prunella vulgaris var. lilacina in macrophages RAW 264.7.
NF-?B/p53-activated inflammatory response involves in diquat-induced mitochondrial dysfunction and apoptosis.
NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins.
NF-kappaB blockade upregulates Bax, TSP-1, and TSP-2 expression in rat granulation tissue.
NF-kappaB induces PGE(2)-synthesizing enzymes in neurons.
NF-kappaBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes.
NFAT3 is Required for EGF-Induced COX-2 Transcription, but Neither iNOS Transcription Nor Cell Transformation in Cl 41 Cells.
Nickel and Oxidative stress: Cell Signaling Mechanisms and Protective Role of Vitamin C.
Nickel chloride (NiCl2)-caused inflammatory responses via activation of NF-?B pathway and reduction of anti-inflammatory mediator expression in the kidney.
Nickel-refining dust regulates the expression of inflammatory factors in NIH/3T3 cells.
Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways.
Nicotine and gastric cancer.
Nicotine and Gastrointestinal Disorders: Its Role in Ulceration and Cancer Development.
Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation.
Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2.
Nicotine, lung and cancer.
Nicotine-induced cellular stresses and autophagy in human cancer colon cells: A supportive effect on cell homeostasis via up-regulation of Cox-2 and PGE(2) production.
Nifedipine inhibits oxidative stress and ameliorates osteoarthritis by activating the nuclear factor erythroid-2-related factor 2 pathway.
Nimesulide inhibits tumor growth in mice implanted hepatoma: overexpression of Bax over Bcl-2.
Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice.
Nitric Oxide (NO) and Cyclooxygenase-2 (COX-2) Cross-Talk in Co-Cultures of Tumor Spheroids with Normal Cells.
Nitric oxide and hepatocellular cancer.
Nitric oxide enhances cyclooxygenase activity in articular cartilage.
Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-kappaB.
Nitric oxide signaling in colon cancer chemoprevention.
Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis.
Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines.
Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer.
Nitric-oxide-donating NSAIDs as agents for cancer prevention.
Nitro-imidazole-based ruthenium complexes with antioxidant and anti-inflammatory activities.
Nitrogen Dioxide and Ultrafine Particles Dominate the Biological Effects of Inhaled Diesel Exhaust Treated by a Catalyzed Diesel Particulate Filter.
Nitrogen mustard exposure of murine skin induces DNA damage, oxidative stress and activation of MAPK/Akt-AP1 pathway leading to induction of inflammatory and proteolytic mediators.
No significant effects of Poly(I:C) on human umbilical cord-derived mesenchymal stem cells in the treatment of B6.MRL-Fas(lpr) mice.
Nobiletin Inhibits Helicobacterium pylori Infection-Induced Gastric Carcinogenic Signaling by Blocking Inflammation, Apoptosis, and Mitogen-Activated Protein Kinase Events in Gastric Epithelial-1 Cells.
Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition.
Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality.
Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44.
Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.
Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs.
Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer.
Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention.
Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract.
Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells.
Non-steroidal anti-inflammatory drugs target the pro-tumorigenic extracellular matrix of the postpartum mammary gland.
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic.
Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation.
Non-steroidal targets in the diagnosis and treatment of endometriosis.
Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.
Noninvasive of adenovirus tumor retargeting in living subjects by a soluble adenovirus receptor-epidermal growth factor (sCAR-EGF) fusion protein.
Nonocular Melanocytic Neoplasia in Cats: Characterization and Proposal of a Histologic Classification Scheme to More Accurately Predict Clinical Outcome.
Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation.
Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study.
Nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of colorectal cancer.
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.
Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence.
Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.
Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: A population-based case-control study.
Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression.
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression.
Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer.
Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase.
Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.
Notch2-induced COX-2 expression enhancing gastric cancer progression.
Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.
Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Novel agents that potentially inhibit irinotecan-induced diarrhea.
Novel anti-inflammatory function of NSC95397 by the suppression of multiple kinases.
Novel antineoplastic isochalcones inhibit the expression of cyclooxygenase 1,2 and EGF in human prostate cancer cell line LNCaP.
Novel Antitumor Platinum(II) Conjugates Containing the Nonsteroidal Anti-inflammatory Agent Diclofenac: Synthesis and Dual Mechanisms of Antiproliferative Effects.
Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression.
Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.
Novel Dual Inhibitors Of Nuclear Factor-Kappa B (NF-?b) And Cyclooxygenase-2 (COX-2): Synthesis, In Vitro Anticancer Activity And Stability Studies Of Lantadene-Non Steroidal Anti-Inflammatory Drug (NSAID) Conjugates.
Novel dual-targeting anti-proliferative dihydrotriazine-chalcone derivatives display suppression of cancer cell invasion and inflammation by inhibiting the NF-?B signaling pathway.
Novel ent-Kaurane Diterpenoid from Rubus corchorifolius L. f. Inhibits Human Colon Cancer Cell Growth via Inducing Cell Cycle Arrest and Apoptosis.
Novel Function of Cyclooxygenase-2: Suppressing Mycobacteria by Promoting Autophagy via the Protein Kinase B/Mammalian Target of Rapamycin Pathway.
Novel insights into the mechanism of action of intravesical immunomodulators.
Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk.
Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells.
Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells.
Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention.
Novel non-steroidal anti-inflammatory drugs: what we have learned from animal studies.
Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.
Novel sampling procedure to characterize bovine subclinical endometritis by uterine secretions and tissue.
Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line.
Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.
Novel synthetic gluco-disaccharide RSCL-0409--a lipopolysaccharide-induced Toll-like receptor-mediated signalling antagonist.
Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
Nrf2 and NF-?B modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes.
Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis.
NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2.
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation.
NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells.
NS398 induces apoptosis in non-small cell lung cancer cells.
NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspase-independent apoptosis.
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
NSAIDs and breast cancer recurrence in a prospective cohort study.
NSAIDs and cancer prevention: targets downstream of COX-2.
NSAIDs and the colon.
NSAIDs as Cancer Preventive Agents.
NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res., 10: 1565-1573, 2004.
NSAIDs in neuroblastoma therapy.
NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
NSAIDs: Old Drugs Reveal New Anticancer Targets.
Nuclear expression of ?-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.
Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation in human colorectal carcinoma tissue.
Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins.
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy.
Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer.
Nuclear monomeric integrin ?v in cancer cells is a coactivator regulated by thyroid hormone.
Nuclear receptor retinoid-related orphan receptor ?1 modulates the metabolic activity of human osteoblasts.
Nucleoside and N-acetyldopamine derivatives from the insect Aspongopus chinensis.
Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression.
Nucling interacts with nuclear factor-kappaB, regulating its cellular distribution.
Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background.
Nutritional and botanical modulation of the inflammatory cascade--eicosanoids, cyclooxygenases, and lipoxygenases--as an adjunct in cancer therapy.
Nutritional targeting of cyclooxygenase-2 for colon cancer prevention.
o,p'-DDT induces cyclooxygenase-2 gene expression in murine macrophages: Role of AP-1 and CRE promoter elements and PI3-kinase/Akt/MAPK signaling pathways.
Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.
Ochratoxin A-induced cell proliferation and tumor promotion in mouse skin by activating the expression of cyclin-D1 and cyclooxygenase-2 through nuclear factor-kappa B and activator protein-1.
Odontoblastic Differentiation, Inflammatory Response, and Angiogenic Potential of 4 Calcium Silicate-based Cements: Micromega MTA, ProRoot MTA, RetroMTA, and Experimental Calcium Silicate Cement.
Odontogenic epithelial proliferation is correlated with COX-2 expression in dentigerous cyst and ameloblastoma.
Oenanthe Javanica Extract Protects Mouse Skin from UVB Radiation via Attenuating Collagen Disruption and Inflammation.
Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A.
Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis.
Oldhamianoside II, a new triterpenoid saponin, prevents tumor growth via inducing cell apoptosis and inhibiting angiogenesis.
Oleanolic acid oxime derivatives and their conjugates with aspirin modulate the NF-?B-mediated transcription in HepG2 hepatoma cells.
Oligomers of ?-amyloid protein (A?1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1?, tumour necrosis factor-?, and a nuclear factor ?-B mechanism in the rat brain.
Oligonol Inhibits Dextran Sulfate Sodium-induced Colitis and Colonic Adenoma Formation in Mice.
Oligonol, a low-molecular-weight polyphenol derived from lychee peel, attenuates diabetes-induced pancreatic damage by inhibiting inflammatory responses via oxidative stress-dependent mitogen-activated protein kinase/nuclear factor-kappa B signaling.
Olive Leaf Extract and Its Main Component Oleuropein Prevent Chronic Ultraviolet B Radiation-Induced Skin Damage and Carcinogenesis in Hairless Mice.
Olive oil compounds inhibit the paracrine regulation of TNF-?-induced endothelial cell migration through reduced glioblastoma cell cyclooxygenase-2 expression.
Olive-Derived Hydroxytyrosol Shows Anti-inflammatory Effect without Gastric Damage in Rats.
Olmesartan decreases IL-1? and TNF-? levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis.
Olmesartan Prevented Intra-articular Inflammation Induced by Zymosan in Rats.
Omega-3 fatty acids to augment cancer therapy.
Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer.
Omentin-1 protects against bleomycin-induced acute lung injury.
Oncogenic action of phospholipase A2 in prostate cancer.
Oncogenic action of secreted phospholipase A2 in prostate cancer.
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma.
Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2.
Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety.
Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharide.
One-Pot Synthesis of Coumarin-Indomethacin Hybrids as COX-2 Targeting Probes for Cancer Imaging.
Opioids induce renal abnormalities in tumor-bearing mice.
Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency.
Oral administration of oleuropein attenuates cisplatin-induced acute renal injury in mice through inhibition of ERK signaling.
Oral carcinogenesis induced by 4-nitroquinoline 1-oxide in lecithin:retinol acyltransferase gene knockout mice.
Oral Supplementation of Tocotrienol-Rich Fraction Alleviates Severity of Ulcerative Colitis in Mice.
Orally Administrated Lactobacillus pentosus var. plantarum C29 Ameliorates Age-Dependent Colitis by Inhibiting the Nuclear Factor-Kappa B Signaling Pathway via the Regulation of Lipopolysaccharide Production by Gut Microbiota.
Organochlorine pesticides induce inflammation, ROS production, and DNA damage in human epithelial ovary cells: An in vitro study.
Oriental Medicine Samhwangsasim-tang Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Th1 Cell Responses and Upregulating Treg Cell Responses.
Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2.
Oryza sativa (Rice) Hull Extract Inhibits Lipopolysaccharide-Induced Inflammatory Response in RAW264.7 Macrophages by Suppressing Extracellular Signal-regulated Kinase, c-Jun N-terminal Kinase, and Nuclear Factor-?B Activation.
Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via ?9?1 integrin.
OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma Progression in vitro and in vivo.
OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
Over-Expression of Cyclooxygenase-2 in Colorectal Cancer Patients.
Over-expression of cyclooxygenase-2 in endoscopic biopsies of ectopic gastric mucosa.
Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.
Over-expression of nuclear factor-?B family genes and inflammatory molecules is related to chronic obstructive pulmonary disease.
Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.
Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.
Overexpression of COX-2 and LMP1 are correlated with lymph node in Tunisian NPC patients.
Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation.
Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.
Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx.
Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways.
Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma.
Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer.
Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer.
Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomas.
Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma.
Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma.
Overexpression of cyclooxygenase-2 in carcinoma of the pancreas.
Overexpression of cyclooxygenase-2 in gastric cancer correlates with the high abundance of vascular endothelial growth factor-C and lymphatic metastasis.
Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract.
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells.
Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression.
Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis.
Overexpression of cyclooxygenase-2 in NCI-H292 human alveolar epithelial carcinoma cells: Roles of p38 MAPK, ERK-1/2, and PI3K/PKB signaling proteins.
Overexpression of cyclooxygenase-2 in non-small cell lung cancer.
Overexpression of cyclooxygenase-2 in rabbit basilar artery endothelial cells after subarachnoid hemorrhage.
Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder.
Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1alpha expression, and tumor angiogenesis.
Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma.
Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy.
Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors.
Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients.
Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma.
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.
Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy.
Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability.
Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies.
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis.
Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-alpha expression but not tumor promotion.
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma.
Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development.
Oxidative signalling and inflammatory pathways in Alzheimer's disease.
Oxygenation by COX-2 (cyclo-oxygenase-2) of 3-HETE (3-hydroxyeicosatetraenoic acid), a fungal mimetic of arachidonic acid, produces a cascade of novel bioactive 3-hydroxyeicosanoids.
Oxymatrine exhibits anti-neuroinflammatory effects on A?1-42-induced primary microglia cells by inhibiting NF-?B and MAPK signaling pathways.
Oxyresveratrol ameliorates ethanol-induced gastric ulcer via downregulation of IL-6, TNF-?, NF-?B, and COX-2 levels, and upregulation of TFF-2 levels.
Oxysophocarpine Ameliorates Carrageenan-induced Inflammatory Pain via Inhibiting Expressions of Prostaglandin E2 and Cytokines in Mice.
Oxysophocarpine reduces oxygen-glucose deprivation-induced microglial activation and injury.
Ozonated water improves lipopolysaccharide-induced responses of an odontoblast-like cell line.
p-HPEA-EDA, a phenolic compound of virgin olive oil, activates AMP-activated protein kinase to inhibit carcinogenesis.
p-TSA.H2O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer.
p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.
p16(INK4A) Represses the paracrine tumor-promoting effects of breast stromal fibroblasts.
P2X7 receptor activation contributes to an initial upstream mechanism of lipopolysaccharide-induced vascular dysfunction.
p38 MAP kinase plays a functional role in UVB-Induced mouse skin carcinogenesis.
p38 MAPK and NF-kappaB mediate COX-2 expression in human airway myocytes.
p38 MAPK plays a distinct role in sulforaphane-induced up-regulation of ARE-dependent enzymes and down-regulation of COX-2 in human bladder cancer cells.
p38 mediates mechanical allodynia in a mouse model of type 2 diabetes.
p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes.
p38 Mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation.
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.
p50-associated COX-2 extragenic RNA (PACER) activates COX-2 gene expression by occluding repressive NF-?B complexes.
P53, COX-2, iNOS protein expression changes and their relationship with anti-oxidant enzymes in surgically and multi-modality treated esophageal carcinoma patients.
Pachymic acid inhibits cell growth and modulates arachidonic acid metabolism in nonsmall cell lung cancer A549 cells.
Paeonia japonica, Houttuynia cordata, and Aster scaber water extracts induce nitric oxide and cytokine production by lipopolysaccharide-activated macrophages.
Paeoniflorin ameliorates rheumatoid arthritis in rat models through oxidative stress, inflammation and cyclooxygenase 2.
Paeoniflorin Prevents Intestinal Barrier Disruption and Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in Caco-2 Cell Monolayers.
Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE? synthesis and COX-2 expression.
Palmitate induces nitric oxide production and inflammatory cytokine expression in zebrafish.
Pan-cancer analysis of the metabolic reaction network.
Panax ginseng Fruit Has Anti-Inflammatory Effect and Induces Osteogenic Differentiation by Regulating Nrf2/HO-1 Signaling Pathway in In Vitro and In Vivo Models of Periodontitis.
Panax ginseng modulates oxidative stress, DNA damage, apoptosis, and inflammations induced by silicon dioxide nanoparticles in rats.
Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells.
Pancreatic cancer: from molecular signature to target therapy.
Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs.
Papillary Carcinoma of the Thyroid: High Expression of COX-2 and Low Expression of KAI-1/CD82 Are Associated with Increased Tumor Invasiveness.
Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc (Min/+) mouse model of intestinal tumorigenesis.
Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells.
Paracrine effect of canine allogenic umbilical cord blood-derived mesenchymal stromal cells mixed with beta-tricalcium phosphate on bone regeneration in ectopic implantations.
Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche.
Paradoxical effect of aspirin on the growth of C6 rat glioma and on time of development of ENU-induced tumors of the nervous system.
Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model.
Parecoxib exhibits anti-inflammatory and neuroprotective effects in a rat model of transient global cerebral ischemia.
Parecoxib reduced ventilation induced lung injury in acute respiratory distress syndrome.
Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-?B/COX-2 pathway.
Participation of macrophages in the mechanism mediating the enhancement of metastasis formation after tumour resection.
Particulate Matter-Induced Inflammation/Oxidative Stress in Macrophages: Fucosterol from Padina boryana as a Potent Protector, Activated via NF-?B/MAPK Pathways and Nrf2/HO-1 Involvement.
Passive cigarette smoke exposure inhibits ultraviolet light B-induced skin tumors in SKH-1 hairless mice by blocking the nuclear factor kappa B signalling pathway.
Pathogenesis of Helicobacter pylori Infection.
Pathological changes of frozen shoulder in rat model and the therapeutic effect of PPAR-? agonist.
Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract.
Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1.
Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: Correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2.
Pattern of expression of immune-relevant genes in the gonad of a teleost, the gilthead seabream (Sparus aurata L.).
Patterns and localization of gene expression during intramembranous bone regeneration in the rat femoral marrow ablation model.
Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo.
PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo.
PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells.
PC-SPES: a potent inhibitor of nuclear factor-kappa B rescues mice from lipopolysaccharide-induced septic shock.
PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2.
Pectin does not inhibit intestinal carcinogenesis in APC-deficient Min/+ mice.
Pediococcus pentosaceus-Fermented Cordyceps militaris Inhibits Inflammatory Reactions and Alleviates Contact Dermatitis.
Peiminine inhibits the IL-1? induced inflammatory response in mouse articular chondrocytes and ameliorates murine osteoarthritis.
Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways.
PEP27-2, a Potent Antimicrobial Cell-Penetrating Peptide, Reduces Skin Abscess Formation during Staphylococcus aureus Infections in Mouse When Used in Combination with Antibiotics.
Perfluorocarbon@Porphyrin Nanoparticles for Tumor Hypoxia Relief to Enhance Photodynamic Therapy against Liver Metastasis of Colon Cancer.
Perineural expression of high-mobility group box-1 contributes to long-lasting mechanical hypersensitivity via matrix metalloproteinase-9 upregulation in mice with painful peripheral neuropathy.
Periodontal inflammation and alveolar bone loss induced by Aggregatibacter actinomycetemcomitans is attenuated in sphingosine kinase 1-deficient mice.
Perioperative biobehavioral interventions to prevent cancer recurrence through combined inhibition of ?-adrenergic and cyclooxygenase 2 signaling.
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
Perioperative moxifloxacin treatment in rats subjected to deep hypothermic circulatory arrest: Reduction in cerebral inflammation but without improvement in cognitive performance.
Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis.
Peritumoral adipose tissue as a source of inflammatory and angiogenic factors in colorectal cancer.
Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth.
Peroxisome Proliferator-Activated Receptors (PPAR)? Agonists as Master Modulators of Tumor Tissue.
Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells.
Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis.
Persistent Inactivation of Macrophage Cyclooxygenase-2 in Mycobacterial Pulmonary Inflammation.
Perspiration promotes the effect of sulphite on the shielding response of rodent skin.
PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model.
PET radiotracer [¹?F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation.
Peucedani Japonici Radix ameliorates lipopolysaccharide-induced neuroinflammation by regulating microglial responses.
Peucedanum japonicum extract attenuates allergic airway inflammation by inhibiting Th2 cell activation and production of pro-inflammatory mediators.
PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells.
PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer.
PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells.
PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer.
PGE2 Inhibits IL-10 Production via EP2-Mediated ?-Arrestin Signaling in Neuroinflammatory Condition.
PGE2 production in oral cancer cell lines is COX-2-dependent.
PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.
PGE2 released by primary sensory neurons modulates Toll-like receptor 4 activities through an EP4 receptor-dependent process.
PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system.
PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors.
pH and redox dual-responsive nanoparticles based on disulfide-containing poly(?-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
pH-Dependent Behavior of Novel Gellan Beads Loaded with Naproxen.
pH-Responsive nanoparticles based on ibuprofen prodrug as drug carriers for inhibition of primary tumor growth and metastasis.
Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer.
Pharmacological and dietary factors in prevention of colorectal cancer.
Pharmacological and Pharmacokinetic Studies with Agaricoglycerides, Extracted from Grifola frondosa, in Animal Models of Pain and Inflammation.
Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets.
Pharmacological characterization of liquiritigenin, a chiral flavonoid in licorice.
Pharmacological characterization of Solanum cernuum Vell.: 31-norcycloartanones with analgesic and anti-inflammatory properties.
Pharmacological evaluation of continentalic acid for antidiabetic potential.
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells.
Pharmacological inhibition of TLR4/NF-?B with TLR4-IN-C34 attenuated microcystin-leucine arginine toxicity in bovine Sertoli cells.
Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer.
Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer.
Pharmacology of Cannabinoid Receptor Agonists and a Cyclooxygenase-2 Inhibitor in Rat Bone Tumor Pain.
Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors.
Pharmacophore modelling, atom-based 3D-QSAR generation and virtual screening of molecules projected for mPGES-1 inhibitory activity.
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.
Phase II study of celecoxib in metastatic differentiated thyroid carcinoma.
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers.
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Phaseolin Attenuates Lipopolysaccharide-Induced Inflammation in RAW 264.7 Cells and Zebrafish.
Phellodendron amurense and Its Major Alkaloid Compound, Berberine Ameliorates Scopolamine-Induced Neuronal Impairment and Memory Dysfunction in Rats.
Phenethyl isothiocyanate inhibits 12-o-tetradecanoylphorbol-13-acetate-induced inflammatory responses in mouse skin.
Phenolcarboxylic acids from medicinal herbs exert anticancer effects through disruption of COX-2 activity.
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors.
Phenotypic characterization of a human synovial sarcoma cell line, SW982, and its response to dexamethasone.
PHGPx overexpression induces an increase in COX-2 activity in colon carcinoma cells.
Phloretin Inhibits Phorbol Ester-Induced Tumor Promotion and Expression of Cyclooxygenase-2 in Mouse Skin: Extracellular Signal-Regulated Kinase and Nuclear Factor-?B as Potential Targets.
Phlorofucofuroeckol B suppresses inflammatory responses by down-regulating nuclear factor ?B activation via Akt, ERK, and JNK in LPS-stimulated microglial cells.
Phosphodiesterase 4B plays a role in benzophenone-3-induced phototoxicity in normal human keratinocytes.
Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo.
Phospholipase A2-activating protein--an important regulatory molecule in modulating cyclooxygenase-2 and tumor necrosis factor production during inflammation.
Phospholipid Incorporation of Non-Methylene-Interrupted Fatty Acids (NMIFA) in Murine Microglial BV-2 Cells Reduces Pro-Inflammatory Mediator Production.
Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.
Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib.
Photo-protective activity of pogostone against UV-induced skin premature aging in mice.
Photodynamic Therapeutic Role of Indocyanine Green in Tumor-Associated Inflammation in Skin Cancer.
Photodynamic therapy: combined modality approaches targeting the tumor microenvironment.
Photoprotective effects of sulindac against ultraviolet B-induced phototoxicity in the skin of SKH-1 hairless mice.
Physalis angulata Calyces Modulate Macrophage Polarization and Alleviate Chemically Induced Intestinal Inflammation in Mice.
Physical Activity, Tumor PTGS2 Expression, and Colorectal Cancer Survival: A Molecular Pathological Epidemiology (MPE) Approach.
Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.
Physiologic and innate immunity responses to bacterial lipopolysaccharide administration in beef heifers supplemented with OmniGen-AF.
Physiological COX-2 Expression in Breast Epithelium Associates with COX-2 Levels in Ductal Carcinoma in Situ and Invasive Breast Cancer in Young Women.
Phytochemical Profile and Anti-Inflammatory Activity of the Fraction from Artemisia lavandulaefolia.
Phytochemical profile, antioxidative and anti-inflammatory potentials of Gynura bicolor DC.
Phytochemicals and cancer.
Phytosterols Suppress Phagocytosis and Inhibit Inflammatory Mediators via ERK Pathway on LPS-Triggered Inflammatory Responses in RAW264.7 Macrophages and the Correlation with Their Structure.
PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac.
Piceatannol Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by Modulation of Nrf2/HO-1/NF?B Axis.
Piceatannol inhibits phorbol ester-induced NF-kappa B activation and COX-2 expression in cultured human mammary epithelial cells.
Piceatannol inhibits the IL-1?-induced inflammatory response in human osteoarthritic chondrocytes and ameliorates osteoarthritis in mice by activating Nrf2.
Piceatannol protects against cisplatin nephrotoxicity via activation of Nrf2/HO-1 pathway and hindering NF-?B inflammatory cascade.
Picrorhizones A-H, Polyprenylated Benzoylphloroglucinols from the Stem Bark of Garcinia picrorhiza.
Pierisformoside B exhibits neuroprotective and anti-inflammatory effects in murine hippocampal and microglial cells via the HO-1/Nrf2-mediated pathway.
Pifithrin-?, an inhibitor of p53 transactivation, up-regulates COX-2 expression through an MAPK-dependent pathway.
Pinocembrin Reduces Arthritic Symptoms in Mouse Model via Targeting Sox4 Signaling Molecules.
Pinocembrin, a novel histidine decarboxylase inhibitor with anti-allergic potential in in vitro.
Pinolenic acid inhibits human breast cancer MDA-MB-231 cell metastasis in vitro.
Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids.
Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis.
Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat.
Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat.
Pioglitazone, a Specific Ligand of the Peroxisome Proliferator-Activated Receptor Gamma Reduces Gastric Mucosal Injury Induced by Ischaemia/Reperfusion in Rat.
Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells.
Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/?-catenin signaling pathway.
Piperine inhibits LPS induced expression of inflammatory mediators in RAW 264.7 cells.
Piperine, a functional food alkaloid, exhibits inhibitory potential against TNBS-induced colitis via the inhibition of I?B-?/NF-?B and induces tight junction protein (claudin-1, occludin, and ZO-1) signaling pathway in experimental mice.
Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer.
Piperlongumine inhibits neuroinflammation via regulating NF-?B signaling pathways in lipopolysaccharide-stimulated BV2 microglia cells.
Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention.
Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus.
Pistacia chinensis Inhibits NO Production and Upregulates HO-1 Induction via PI-3K/Akt Pathway in LPS Stimulated Macrophage Cells.
Pitfalls in the use of arachidonic acid oxidation products to assign lipoxygenase activity in cancer cells.
Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage.
Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-?-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice.
Plant-derived anticancer agents - curcumin in cancer prevention and treatment.
Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies.
Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer.
Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms.
Platelet activation by cells isolated from human tumor tissues: effect of cyclooxygenase blockade.
Platelet and shear rate promote tumor cell adhesion to human endothelial extracellular matrix--absence of a role for platelet cyclooxygenase.
Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy.
Platycodon grandiflorum Saponins Ameliorate Cisplatin-Induced Acute Nephrotoxicity through the NF-?B-Mediated Inflammation and PI3K/Akt/Apoptosis Signaling Pathways.
PLC?1: a potential target of RNA interference therapy for gastric cancer.
Pleurotus ostreatus inhibits colitis-related colon carcinogenesis in mice.
Plumericin prevents intestinal inflammation and oxidative stress in vitro and in vivo.
Pluripotency and immunomodulatory signatures of canine induced pluripotent stem cell-derived mesenchymal stromal cells are similar to harvested mesenchymal stromal cells.
PMK-S005 Alleviates Age-Related Gastric Acid Secretion, Inflammation, and Oxidative Status in the Rat Stomach.
Polydatin has anti-inflammatory and antioxidant effects in LPS-induced macrophages and improves DSS-induced mice colitis.
Polydatin inhibits the IL-1?-induced inflammatory response in human osteoarthritic chondrocytes by activating the Nrf2 signaling pathway and ameliorates murine osteoarthritis.
Polydeoxyribonucleotide Exerts Therapeutic Effect by Increasing VEGF and Inhibiting Inflammatory Cytokines in Ischemic Colitis Rats.
Polygalactan from bivalve Crassostrea madrasensis attenuates nuclear factor-?B activation and cytokine production in lipopolysaccharide-activated macrophage.
Polygoni Rhizoma Inhibits Inflammatory Response through Inactivation of Nuclear Factor-kappaB and Mitogen Activated Protein Kinase Signaling Pathways in RAW264.7 Mouse Macrophage Cells.
Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.
Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study.
Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer.
Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort.
Polymorphisms in cyclooxygenase-2 gene in endometrial cancer patients.
Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features.
Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study.
Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study.
Polymorphisms within inflammatory genes and colorectal cancer.
Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells.
Polypeptide growth factors and angiogenesis.
Polyphenol-rich extract of Ocimum gratissimum leaves ameliorates colitis via attenuating colonic mucosa injury and regulating pro-inflammatory cytokines production and oxidative stress.
Polyphenol-rich grape powder extract (GPE) attenuates inflammation in human macrophages and in human adipocytes exposed to macrophage-conditioned media.
Polyphenolic fraction of Lonicera caerulea L. fruits reduces oxidative stress and inflammatory markers induced by lipopolysaccharide in gingival fibroblasts.
Polyphenols from blossoms of Citrus aurantium L. var. amara Engl. show significant anti-complement and anti-inflammatory effects.
Polyphenols from Tamarix nilotica: LC?ESI-MSn Profiling and In Vivo Antifibrotic Activity.
Polyphenols from Toona sinensiss Seeds Alleviate Neuroinflammation Induced by 6-Hydroxydopamine Through Suppressing p38 MAPK Signaling Pathway in a Rat Model of Parkinson's Disease.
Polypodium Leucotomos Extract Decreases UV-Induced Cox-2 Expression and Inflammation, Enhances DNA Repairs, and Decreases Mutagenesis in Hairless Mice.
Polysaccharide of Hericium erinaceus attenuates colitis in C57BL/6 mice via regulation of oxidative stress, inflammation-related signaling pathways and modulating the composition of the gut microbiota.
Polysulfide and Hydrogen Sulfide Ameliorate Cisplatin-Induced Nephrotoxicity and Renal Inflammation through Persulfidating STAT3 and IKK?.
Polyunsaturated Fatty Acid Diet and Upregulation of Lipoxin A4 Reduce the Inflammatory Response of Preeclampsia.
Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies.
Pomegranate By-Products in Colorectal Cancer Chemoprevention: Effects in Apc-Mutated Pirc Rats and Mechanistic Studies In Vitro and Ex Vivo.
Poor prognosis of colorectal cancer in patients over 80 years old is associated with down-regulation of tumor suppressor genes.
Porcine spermatozoa inhibit post-breeding cytokine induction in uterine epithelial cells in vivo.
Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Positive acceleration adaptive training attenuates gastric ischemia-reperfusion injury through COX-2 and PGE2 expression.
Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer.
Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas.
Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.
Possible link between NO concentrations and COX-2 expression in systems treated with soy-isoflavones.
Possible participation of intracellular platelet-activating factor in tumor necrosis factor-alpha production by rat peritoneal macrophages.
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice.
Post-insult ibuprofen treatment attenuates damage to the serotonergic system after hypoxia-ischemia in the immature rat brain.
Post-Intake of S-Ethyl Cysteine and S-Methyl Cysteine Improved LPS-Induced Acute Lung Injury in Mice.
Post-Treatment of Synthetic Polyphenolic 1,3,4 Oxadiazole Compound A3, Attenuated Ischemic Stroke-Induced Neuroinflammation and Neurodegeneration.
Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Postoperative efficacy of low-temperature plasma radiofrequency ablation in elderly patients with laryngeal carcinoma and its influences on tumor markers and COX-2 and VEGF expressions in laryngeal carcinoma tissues.
Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival.
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.
Posttranscriptional and posttranslational determinants of cyclooxygenase expression.
Posttranscriptional Regulation of Cyclooxygenase 2 Expression in Colorectal Cancer.
Potent anti-cancer effect of 3'-hydroxypterostilbene in human colon xenograft tumors.
Potent anti-cancer effects of citrus peel flavonoids in human prostate xenograft tumors.
Potent antitumor activity in experimental hepatocellular carcinoma by adenovirus-mediated coexpression of TRAIL and shRNA against COX-2.
Potent chemopreventive agents against pancreatic cancer.
Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid.
Potent suppression of both spontaneous and carcinogen-induced colitis-associated colorectal cancer in mice by dietary celastrol supplementation.
Potential Anti-Inflammatory and Anti-Cancer Properties of Farnesol.
Potential Anti-Skin Aging Effect of (-)-Catechin Isolated from the Root Bark of Ulmus davidiana var. japonica in Tumor Necrosis Factor-?-Stimulated Normal Human Dermal Fibroblasts.
Potential anticancer properties of grape antioxidants.
Potential antitumor activity of nonsteroidal anti-inflammatory drugs against Ehrlich ascites carcinoma in experimental animals.
Potential clinical application of interleukin-27 as an antitumor agent.
Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis.
Potential for a localized immune response by the ruminal epithelium in nonpregnant heifers following a short-term subacute ruminal acidosis challenge.
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer.
Potential misidentification of cyclooxygenase-2 by Western blot analysis and prevention through the inclusion of appropriate controls.
Potential new therapeutics for Waldenstrom's macroglobulinemia.
Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Potential relevance of cyclooxygenase-2 expression in keratocystic odontogenic tumours - an immunohistochemical study.
Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers.
Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis.
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
Potential role of selective COX-2 inhibitors in cancer management.
Potential therapeutic effect of thymoquinone and/or bee pollen on fluvastatin-induced hepatitis in rats.
Potential therapeutic effects of Ulva lactuca water fraction on monosodium glutamate-induced testicular and prostatic tissue damage in rats.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening.
Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy.
Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis.
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
Potentiation of tumor formation by topical administration of 15-deoxy-delta12,14-prostaglandin J2 in a model of skin carcinogenesis.
Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors.
PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation.
PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice.
PPAR? delivered by Ch-GNPs onto titanium surfaces inhibits implant-induced inflammation and induces bone mineralization of MC-3T3E1 osteoblast-like cells.
PPAR? ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.
PPAR? regulates inflammatory reaction by inhibiting the MAPK/NF-?B pathway in C2C12 skeletal muscle cells.
PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells.
PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.
pRb2/p130 protein in relation to clinicopathological and biological variables in rectal cancers with a clinical trial of preoperative radiotherapy.
Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases.
Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia.
Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model.
Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma.
Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs.
Preclinical Studies of a Specific PPAR? Modulator in the Control of Skin Inflammation.
Preclinical Studies Suggest Complex Nutraceutical Strategies May Have Potential for Preventing and Managing Sepsis.
Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry.
Predicting factors for locoregional failure of high-dose-rate brachytherapy for early-stage oral cancer.
Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions.
Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies.
Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling.
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients.
Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue.
Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.
Predictive value of cyclooxygenase 2 and Bcl-2 for cervical lymph node metastasis in mucoepidermoid carcinoma.
Predictive value of Cyclooxygenase-2 over expression for identifying prostate cancer from benign prostatic hyperplasia in prostate biopsy specimens.
Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.
Preferential expression of cyclooxygenase-2 in colonic-phenotype of gastric intestinal metaplasia: association with helicobacter pylori and gastric carcinoma.
Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
Prefrontal Cortex and Hippocampus Inflammation in Mice Fed High-Carbohydrate or High-Fat Diets.
Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice.
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer.
Preliminary proteomic analysis of indomethacin's effect on tumor transplanted with colorectal cancer cell in nude mice.
Premna odorata extract as a protective agent on neurotoxic effect of aluminum: neurochemical, molecular, and histopathological alterations.
Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies.
Preoperative intravenous flurbiprofen reduces postoperative pain and inflammatory cytokines in elderly patients after hip arthroplasty.
Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours.
Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.
Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
Presence of pyrroloquinazoline alkaloid in Adhatoda vasica attenuates inflammatory response through the downregulation of pro-inflammatory mediators in LPS stimulated RAW 264.7 macrophages.
Present medical management of Barrett's oesophagus.
Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
Pretreatment with Lactobacillus reuteri F-9-35 attenuates ethanol-induced gastric injury in rats.
Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
Prevalence of 5-Lipoxygenase Expression in Canine Osteosarcoma and the Effects of a Dual 5-Lipoxygenase/Cyclooxygenase Inhibitor on Osteosarcoma Cells In Vitro and In Vivo.
Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1.
Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma.
Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids.
Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo.
Prevention of colitis-associated colorectal cancer with 8-hydroxydeoxyguanosine.
Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea.
Prevention of collagen-induced arthritis in mice by Cervus korean TEMMINCK var. mantchuricus Swinhoe.
Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Prevention of colorectal cancer: tumor progression, chemoprevention, and COX-2 inhibition.
Prevention of oral carcinogenesis in rats by Dracaena cinnabari resin extracts.
Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice.
Prevention of the toxic action of tumor necrosis factor by cyclooxygenase inhibitor and leukopenia.
Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in survivin.
Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.
Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor.
Prevention strategies with aromatase inhibitors.
Preventive and therapeutic effects of Lactobacillus paracasei B21060-based synbiotic treatment on gut inflammation and barrier integrity in colitic mice.
Preventive and therapeutic effects of oleuropein against carbon tetrachloride-induced liver damage in mice.
Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model.
Preventive effect of polysaccharides from the large yellow croaker swim bladder on HCl/ethanol induced gastric injury in mice.
Preventive effect of silymarin in cerebral ischemia-reperfusion-induced brain injury in rats possibly through impairing NF-?B and STAT-1 activation.
Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db obese mice.
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
Preventive inositol hexaphosphate extracted from rice bran inhibits colorectal cancer through involvement of Wnt/?-catenin and COX-2 pathways.
Preventive potential of wheat bran fractions against experimental colon carcinogenesis: implications for human colon cancer prevention.
Previous physical exercise alters the hepatic profile of oxidative-inflammatory status and limits the secondary brain damage induced by severe traumatic brain injury in rats.
Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages.
Primary and secondary prevention of colorectal cancer.
Primary sensory neurons regulate Toll-like receptor-4-dependent activity of glial cells in dorsal root ganglia.
Pro- and anti-inflammatory cytokine expression levels in macrophages; An approach to develop indazolpyridin-methanones as novel inflammation medication.
Pro-apoptotic and anti-neoplastic impact of luteolin on solid Ehrlich carcinoma.bearing mice exposed to gamma radiation.
Pro-Inflammatory Effects of Indoxyl Sulfate in Mice: Impairment of Intestinal Homeostasis and Immune Response.
Pro-labour myometrial gene expression: are preterm labour and term labour the same?
Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2.
Pro/antioxidant status in murine skin following topical exposure to cumene hydroperoxide throughout the ontogeny of skin cancer.
Proanthocyanidins improves lead-induced cognitive impairments by blocking endoplasmic reticulum stress and nuclear factor-?B-mediated inflammatory pathways in rats.
Proanthocyanidins inhibit in vitro and in vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin E(2) and prostaglandin E(2) receptors.
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats.
Proceedings of the RTOG (Radiation Therapy Oncology Group) Symposium: COX-2 Inhibitors and Cancer Therapeutics. June 2001.
Production of prostaglandinE2 via bile acid is enhanced by trypsin and acid in normal human esophageal epithelial cells.
Products of arachidonic acid metabolism and the effects of cyclooxygenase inhibition on ongoing cutaneous allergic reactions in human beings.
Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility.
Progastrin and cyclooxygenase-2 in colorectal cancer.
Progesterone protects blood-brain barrier function and improves neurological outcome following traumatic brain injury in rats.
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions.
Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis.
Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy.
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Prognostic evaluation of COX-2 expression in renal cell carcinoma.
Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma.
Prognostic factors in Hungarian breast cancer patients.
Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients.
Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.
Prognostic impact of cyclooxygenase-2 in breast cancer.
Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression.
Prognostic implications of tumor volume response and COX-2 expression change during radiotherapy in cervical cancer patients.
Prognostic importance of COX-2 expression in patients with colorectal cancer.
Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer.
Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma.
Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: A meta-analysis of observational studies.
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma.
Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer.
Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer.
Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens.
Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma.
Prognostic Significance of COX-2 Immunohistochemical Expression in Colorectal Cancer: A Meta-Analysis of the Literature.
Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma.
Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer.
Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus.
Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma.
Prognostic Significance of Cyclooxygenase-2 and Response to Chemotherapy in Invasive Ductal Breast Carcinoma Patients by Real Time Surface Plasmon Resonance Analysis.
Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis.
Prognostic significance of cyclooxygenase-2 in cervical cancer: A meta-analysis.
Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma.
Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma.
Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis.
Prognostic significance of cyclooxygenase-2 overexpression in glottic cancer.
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer.
Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population.
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours.
Prognostic Significance of Prostaglandin-Endoperoxide Synthase-2 Expressions in Human Breast Carcinoma: A Multiomic Approach.
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy.
Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer.
Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.
Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer.
Prognostic value of COX-2, P53, and EZH-2 evaluated by quantitative image analysis in premalignant and malignant breast lesions.
Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Progress in COX-2 inhibitors: a journey so far.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Progressive loss of nigrostriatal dopaminergic neurons induced by inflammatory responses to fipronil.
Proinflammatory CD4+ CD45RB(hi) lymphocytes promote mammary and intestinal carcinogenesis in Apc(Min/+) mice.
Proinflammatory Cytokine Expression in Cyclooxygenase-2-deficient Primary Osteoblasts.
Proinflammatory cytokines enhance COX-1 gene expression in cultured rat glomerular mesangial cells.
Proinflammatory cytokines induce cyclooxygenase-2 mRNA and protein expression in human pulp cell cultures.
Proinflammatory effects of photoactivated methylene blue on rat model of Walker 256 carcinosarcoma.
Proinflammatory mediators related to orthodontically induced periapical root resorption in rat mandibular molars.
Prokaryotic expression, purification and characterization of human cyclooxygenase-2.
Prolactin alters the mRNA expression of osteoblast-derived osteoclastogenic factors in osteoblast-like UMR106 cells.
Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?
Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma.
Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells.
Promoter methylation regulates cyclooxygenase expression in breast cancer.
Promoter methylation status of the tumor suppressor genes p16 and cadherin 1 in cervical intraepithelial neoplasia.
Promotion of cell differentiation, and suppression of cell growth and cyclooxygenase-2 expression by differentiation-inducing agents in human oral squamous carcinoma SCC25 cells.
Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction.
Prophylactic effect of Biochanin A in lipopolysaccharide-stimulated BV2 microglial cells.
Prophylactic Effect of Opuntia ficus indica Fruit Peel Extract against Irradiation-Induced Colon Injury in Rats.
Propofol Suppresses LPS-Induced Inflammation in Amnion Cells via Inhibition of NF-?B Activation.
Prospects of controlling breast cancer metastasis by immune intervention.
Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome.
Prostacyclin production is not controlled by prostacyclin synthase but by cyclooxygenase-2 in a human follicular dendritic cell line, HK.
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.
Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy.
Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth.
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
Prostaglandin catabolic enzymes as tumor suppressors.
Prostaglandin concentrations and prostaglandin synthetase activity in N-nitrosomethylurea-induced rat mammary adenocarcinoma.
Prostaglandin D2 Attenuates Bleomycin-Induced Lung Inflammation and Pulmonary Fibrosis.
Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis.
Prostaglandin E(2) Drives Cyclooxygenase-2 Expression via Cyclic AMP Response Element Activation in Human Pancreatic Cancer Cells.
Prostaglandin E(2) pathway in head and neck squamous cell carcinoma.
Prostaglandin E(2) receptor EP(1) transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Prostaglandin E(2) regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors.
Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells.
Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.
Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2.
Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?
Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2.
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.
Prostaglandin E2 Pathway Is Dysregulated in Gastric Adenocarcinoma in a Caucasian Population.
Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo.
Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer.
Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis.
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth.
Prostaglandin E2 receptors EP2 and EP4 are down-regulated in human mononuclear cells after injury.
Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer.
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.
PROSTAGLANDIN E2 stimulates cancer-related phenotypes in prostate cancer PC3 cells through cyclooxygenase-2.
Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.
Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer.
Prostaglandin E2 stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells.
Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells.
Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells.
Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?
Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells.
Prostaglandin F(2alpha) stimulation of cyclooxygenase-2 promoter activity by the FP(B) prostanoid receptor.
Prostaglandin Gbetagamma signaling stimulates gastrulation movements by limiting cell adhesion through Snai1a stabilization.
Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect.
Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia.
Prostaglandin inhibitors and the chemoprevention of noncolonic malignancy.
Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.
Prostaglandin synthases influence thyroid follicular cell proliferation but not carcinogenesis in rats initiated with N-bis(2-hydroxypropyl)nitrosamine.
Prostaglandin synthetase and prostaglandin E2 levels in human breast carcinoma.
Prostaglandin synthetase inhibitors as immunoadjuvants in the treatment of cancer.
Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China.
Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin.
Prostaglandins and cancer.
Prostaglandins and the regulation of tumor growth.
Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.
Prostaglandins in cancer cell adhesion, migration, and invasion.
Prostaglandins in carcinomas of the head and neck.
Prostaglandins in human brain tumors.
Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors.
Prostaglandins: critical roles in pregnancy and colon cancer.
Prostanoid receptor EP1 expression in breast cancer.
Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2.
Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation.
Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition.
Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes.
Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases and nuclear factor kappa B.
Proteases and their receptors as mediators of inflammation-associated colon cancer.
Protection against Fas-induced liver apoptosis in transgenic mice expressing cyclooxygenase 2 in hepatocytes.
Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor: role of antioxidant enzymes and effect of cyclooxygenase inhibitors.
Protection by Huang-Lian-Jie-Du decoction and its constituent herbs of lipopolysaccharide-induced acute kidney injury.
Protection by indomethacin against acute radiation esophagitis.
Protection from inflammatory bowel disease and colitis-associated carcinogenesis with 4-vinyl-2,6-dimethoxyphenol (canolol) involve suppression of oxidative stress and inflammatory cytokines.
Protective effect of (+)-catechin against lipopolysaccharide-induced inflammatory response in RAW 264.7 cells through downregulation of NF-?B and p38 MAPK.
Protective effect of a mixture of Aloe vera and Silybum marianum against carbon tetrachloride-induced acute hepatotoxicity and liver fibrosis.
Protective effect of Alpha-Linolenic acid on Lipopolysaccharide-Induced Orchitis in mice.
Protective Effect of Areca catechu Leaf Ethanol Extract Against Ethanol-Induced Gastric Ulcers in ICR Mice.
Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
Protective effect of cannabidiol against cadmium hepatotoxicity in rats.
Protective effect of Chrysanthemum indicum Linne against 1-methyl-4-phenylpridinium ion and lipopolysaccharide-induced cytotoxicity in cellular model of Parkinson's disease.
Protective Effect of Cicer arietinum L. (Chickpea) Ethanol Extract in the Dextran Sulfate Sodium-Induced Mouse Model of Ulcerative Colitis.
Protective effect of Codium fragile against UVB-induced pro-inflammatory and oxidative damages in HaCaT cells and BALB/c mice.
Protective effect of Cordyceps sinensis extract on lipopolysaccharide-induced acute lung injury in mice.
Protective Effect of Ethanol Extracts of the Chinese Caterpillar Mushroom, Ophiocordyceps sinensis (Ascomycetes), on the Experimental Middle Cerebral Artery Occlusion/Reperfusion (MCAO/R) Model.
Protective effect of gentiopicroside against dextran sodium sulfate induced colitis in mice.
Protective effect of Ginkgo biloba leaves extract, EGb761, on endotoxin-induced acute lung injury via a JNK- and Akt-dependent NF?B pathway.
Protective Effect of Ginkgolic Acid in Attenuating LDL Induced Inflammation Human Peripheral Blood Mononuclear Cells via Altering the NF-?B Signaling Pathway.
Protective effect of ginsenosides Rg1 and Re on lipopolysaccharide-induced sepsis by competitive binding to Toll-like receptor 4.
Protective effect of marine mangrove Rhizophora apiculata on acetic acid induced experimental colitis by regulating anti-oxidant enzymes, inflammatory mediators and nuclear factor-kappa B subunits.
Protective effect of melatonin against hippocampal injury of rats with intermittent hypoxia.
Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype.
Protective effect of phlorotannins from Eisenia bicyclis against lipopolysaccharide-stimulated inflammation in HepG2 cells.
Protective effect of proanthocyanidins against doxorubicin-induced nephrotoxicity in rats.
Protective Effect of Processed Panax ginseng, Sun Ginseng on UVB-irradiated Human Skin Keratinocyte and Human Dermal Fibroblast.
Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells.
Protective effect of rutin on mercuric chloride-induced reproductive damage in male rats.
Protective effect of sesamin in lipopolysaccharide-induced mouse model of acute kidney injury via attenuation of oxidative stress, inflammation, and apoptosis.
Protective effect of short-term genistein supplementation on the early stage in diabetes-induced renal damage.
Protective effect of telmisartan treatment against arsenic-induced testicular toxicity in rats.
Protective effect of wild ginseng cambial meristematic cells on d-galactosamine-induced hepatotoxicity in rats.
Protective Effects Induced by Two Polyphenolic Liquid Complexes from Olive (Olea europaea, mainly Cultivar Coratina) Pressing Juice in Rat Isolated Tissues Challenged with LPS.
Protective effects of asiaticoside on septic lung injury in mice.
Protective Effects of Chlorogenic Acid against Experimental Reflux Esophagitis in Rats.
Protective effects of chlorogenic acid against ischemia/reperfusion injury in rat liver: molecular evidence of its antioxidant and anti-inflammatory properties.
Protective Effects of Chrysin Against Oxidative Stress and Inflammation Induced by Lead Acetate in Rat Kidneys: a Biochemical and Histopathological Approach.
Protective Effects of Cinnamaldehyde against Mesenteric Ischemia-Reperfusion-Induced Lung and Liver Injuries in Rats.
Protective effects of cyclooxygenase-2 inhibitors on narrow-band ultraviolet B-irradiated epidermal Ia+ Langerhans cells and Thy-1+ dendritic epidermal T cells in mice.
Protective effects of Danshensu on liver injury induced by omethoate in rats.
Protective effects of diallyl disulfide against acetaminophen-induced nephrotoxicity: A possible role of CYP2E1 and NF-?B.
Protective effects of fermented ginseng on streptozotocin-induced pancreatic beta-cell damage through inhibition of NF-kappaB.
Protective effects of HV-P411 complex against D-galactosamine-induced hepatotoxicity in rats.
Protective Effects of Hyperoside against Carbon Tetrachloride-Induced Liver Damage in Mice.
Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats.
Protective effects of maslinic acid against alcohol-induced acute liver injury in mice.
Protective effects of orange (Citrus sinensis L.) peel aqueous extract and hesperidin on oxidative stress and peptic ulcer induced by alcohol in rat.
Protective effects of polydatin from Polygonum cuspidatum against carbon tetrachloride-induced liver injury in mice.
Protective Effects of Polydatin on Septic Lung Injury in Mice via Upregulation of HO-1.
Protective effects of Polygonum multiflorum on ischemic stroke rat model analysed by 1H NMR metabolic profiling.
Protective effects of silymarin against photocarcinogenesis in a mouse skin model.
Protective Effects of Taurine Chloramine on Experimentally Induced Colitis: NF?B, STAT3, and Nrf2 as Potential Targets.
Protective Effects of Timosaponin AIII against UVB-Radiation Induced Inflammation and DNA Injury in Human Epidermal Keratinocytes.
Protective effects of Weilikang decoction on gastric ulcers and possible mechanisms.
Protective effects of zingerone on cisplatin-induced nephrotoxicity in female rats.
Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice.
Protective Mechanisms of Thymoquinone on Methotrexate-induced Intestinal Toxicity in Rats.
Protective potential of the methanol extract of Macrothelypteris oligophlebia rhizomes for chronic non-bacterial prostatitis in rats.
Protective role of ?-carotene against oxidative stress and neuroinflammation in a rat model of spinal cord injury.
Protective Role of Corilagin on A?25-35-Induced Neurotoxicity: Suppression of NF-?B Signaling Pathway.
Protective role of selenium against over-expression of cancer-related apoptotic genes induced by o-cresol in rats.
Protective Roles of Selenium on Nitric Oxide and the Gene Expression of Inflammatory Cytokines Induced by Cadmium in Chicken Splenic Lymphocytes.
Protective vascular effects of quercitrin in acute TNBS-colitis in rats: the role of nitric oxide.
Protein Arginine Methyltransferase 1 (PRMT1) Selective Inhibitor, TC-E 5003, Has Anti-Inflammatory Properties in TLR4 Signaling.
Protein expression profiles in the epidermis of cyclooxygenase-2 transgenic mice by 2-dimensional gel electrophoresis and mass spectrometry.
Protein fraction of Calotropis procera latex protects against 5-fluorouracil-induced oral mucositis associated with downregulation of pivotal pro-inflammatory mediators.
Protein kinase A antagonist inhibits ?-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in ApcMin/+ mice.
Protein kinase C delta overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2.
Protein kinase CK2 promotes cancer cell viability via up-regulation of cyclooxygenase-2 expression and enhanced prostaglandin E2 production.
Protein kinase D mediates synergistic expression of COX-2 induced by TNF-{alpha} and bradykinin in human colonic myofibroblasts.
Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein.
Protium javanicum Burm. Methanol Extract Attenuates LPS-Induced Inflammatory Activities in Macrophage-Like RAW264.7 Cells.
Protocatechuic acid improves functional recovery after spinal cord injury by attenuating blood-spinal cord barrier disruption and hemorrhage in rats.
Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate activated NFkappaB, AP-1, COX-2, and iNOS in mouse epidermis.
PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
PTGS2 (COX-2) -765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma.
PTGS2 (Cyclooxygenase-2) Expression and Survival among Colorectal Cancer Patients: A Systematic Review.
PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).
PTGS2 Over-Expression: A Colorectal Carcinoma Initiator not an Invasive Factor.
Pulchinenoside B4 exerts the protective effects against cisplatin-induced nephrotoxicity through NF-?B and MAPK mediated apoptosis signaling pathways in mice.
Pulmonary delivery of tea tree oil-?-cyclodextrin inclusion complexes for the treatment of fungal and bacterial pneumonia.
Pulmonary toxicity in mice following exposure to cerium chloride.
Pulmotoxicological effects caused by long-term titanium dioxide nanoparticles exposure in mice.
Pulsed Electromagnetic Field Modulates Tendon Cells Response in IL-1?-Conditioned Environment.
Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts.
Purification and function of two analgesic and anti-inflammatory peptides from coelomic fluid of the earthworm, Eisenia foetida.
Pyrethroid bifenthrin induces oxidative stress, neuroinflammation, and neuronal damage, associated with cognitive and memory impairment in murine hippocampus.
Pyrimidine-based fluorescent COX-2 inhibitors: synthesis and biological evaluation.
Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule.
Pyruvate Kinase M2 Promotes Prostate Cancer Metastasis Through Regulating ERK1/2-COX-2 Signaling.
QSAR Classification-Based Virtual Screening Followed by Molecular Docking Identification of Potential COX-2 Inhibitors in a Natural Product Library.
QSAR, docking and in vivo studies for immunomodulatory activity of isolated triterpenoids from Eucalyptus tereticornis and Gentiana kurroo.
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer.
Quantitative Analysis and In vitro Anti-inflammatory Effects of Gallic Acid, Ellagic Acid, and Quercetin from Radix Sanguisorbae.
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer.
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
Quantitative analysis of COX-2 promoter methylation in gastric carcinoma.
Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells.
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media.
Quercetin Attenuates Manganese-Induced Neuroinflammation by Alleviating Oxidative Stress through Regulation of Apoptosis, iNOS/NF-?B and HO-1/Nrf2 Pathways.
Quercetin Suppresses Cyclooxygenase-2 Expression and Angiogenesis through Inactivation of P300 Signaling.
Quercetin Suppresses the Migration and Invasion in Human Colon Cancer Caco-2 Cells Through Regulating Toll-like Receptor 4/Nuclear Factor-kappa B Pathway.
Quinolines: a new hope against inflammation.
Rac1 and Cdc42 are required for phagocytosis, but not NF-kappaB-dependent gene expression, in macrophages challenged with Pseudomonas aeruginosa.
Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications.
Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2.
Radiation therapy generates platelet-activating factor agonists.
Radiation treatment of acute inflammation in mice.
Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor.
Radiation-induced c-Jun activation depends on MEK1-ERK1/2 signaling pathway in microglial cells.
Radiation-induced neuroinflammation and radiation somnolence syndrome.
Radical-scavenging and Anti-inflammatory Activity of Quercetin and Related Compounds and Their Combinations Against RAW264.7 Cells Stimulated with Porphyromonas gingivalis Fimbriae. Relationships between Anti-inflammatory Activity and Quantum Chemical Parameters.
Radical-scavenging and Pro-/anti-inflammatory Activity of Tetracycline and Related Phenolic Compounds With or Without Visible Light Irradiation.
Radioiodinated indomethacin amide for molecular imaging of cyclooxygenase-2 expressing tumors.
Radioiodination and in vivo assessment of the potential of newly synthesized pyrrolizine-5-carboxamides derivative in tumor model.
Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity--a critical update.
Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Radiosynthesis and Biological Evaluation of [18F]Triacoxib: A New Radiotracer for PET Imaging of COX-2.
Radiosynthesis and evaluation of [18F]FMTP, a COX-2 PET ligand.
Radiosynthesis and Preclinical Evaluation of 11C-VA426, a Cyclooxygenase-2 Selective Ligand.
Radiosynthesis of a ¹?F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo.
Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme.
RAGE-Specific Inhibitor FPS-ZM1 Attenuates AGEs-Induced Neuroinflammation and Oxidative Stress in Rat Primary Microglia.
Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival.
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Rapid induction of colon carcinogenesis in CYP1A-humanized mice by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate.
Rapid method for identification of chemopreventive compounds using multiplex RT-PCR for cyclooxygenase mRNA expression.
Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors.
Ras up-regulation of cyclooxygenase-2.
Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels.
Re: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.
Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11: cyclopentenone prostaglandins and 4-hydroxy-2-nonenal covalently modify and inhibit the AMP-kinase kinase that modulates cellular energy homeostasis and protein translation.
Reactive nitrogen species in colon carcinogenesis.
Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin.
Rebamipide reduces amyloid-? 1-42 (A?42) production and ameliorates A?43-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells.
Recent advances in chemoprevention of cancer.
Recent advances in inducible cyclooxygenase (COX-2) inhibition.
Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick.
Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.
Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.
Recombinant glucocorticoid induced tumour necrosis factor receptor (rGITR) induced COX-2 activity in murine macrophage Raw 264.7 cells.
Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis.
Red Bean Extract Inhibits Lipopolysaccharide-Induced Inflammation and H?O?-Induced Oxidative Stress in RAW 264.7 Macrophages.
Red clover extract: a source for substances that activate peroxisome proliferator-activated receptor alpha and ameliorate the cytokine secretion profile of lipopolysaccharide-stimulated macrophages.
Red ginseng represses hypoxia-induced cyclooxygenase-2 through sirtuin1 activation.
Red wine and black tea polyphenols modulate the expression of cycloxygenase-2, inducible nitric oxide synthase and glutathione-related enzymes in azoxymethane-induced f344 rat colon tumors.
Red-Osier Dogwood Extracts Prevent Inflammatory Responses in Caco-2 Cells and a Caco-2 BBe1/EA.hy926 Cell Co-Culture Model.
Redox Factor-1 Inhibits Cyclooxygenase-2 Expression via Inhibiting of p38 MAPK in the A549 Cells.
Reduced Choroidal Neovascular Membrane Formation in Cyclooxygenase-2 Null Mice.
Reduced COX-2 protein in colorectal cancer with defective mismatch repair.
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer.
Reduced tumour progression and angiogenesis in 1,2-dimethylhydrazine mice treated with NS-398 is associated with down-regulation of cyclooxygenase-2 and decreased beta-catenin nuclear localisation.
Reducing prostaglandin E2 production to raise cancer immunogenicity.
Reducing the risk of colorectal cancer by intervening in the process of carcinogenesis: a status report.
Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.
Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma.
Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma.
Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive.
Reduction of intracellular pH inhibits constitutive expression of cyclooxygenase-2 in human colon cancer cells.
Reduction of scar formation in full-thickness wounds with topical celecoxib treatment.
Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs.
Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition.
Reflections about Osteoarthritis and Curcuma longa.
Regular Aspirin Use Associates with Lower Risk of Colorectal Cancers With Low Numbers of Tumor-infiltrating Lymphocytes.
Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis.
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Regulation of aquaporin 4 expression by lipoxin A4 in astrocytes stimulated by lipopolysaccharide.
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment.
Regulation of Colonic Epithelial Repair in Mice by Toll-like Receptors and Hyaluronic Acid.
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.
Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1? is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
Regulation of COX-2 expression by miR-146a in lung cancer cells.
Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation.
Regulation of COX-2 expression in human cancers.
Regulation of COX-2 gene expression in rat uterus in vivo and in vitro.
Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway.
Regulation of cyclooxygenase isoforms in the renal thick ascending limb: effects of extracellular calcium.
Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1.
Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol.
Regulation of cyclooxygenases by protein kinase C. Evidence against the importance of direct enzyme phosphorylation.
Regulation of cytosolic phospholipase A2, cyclooxygenase-1 and -2 expression by PMA, TNFalpha, LPS and M-CSF in human monocytes and macrophages.
Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A.
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2.
Regulation of inflammation and COX-2 gene expression in benzo (a) pyrene induced lung carcinogenesis in mice by all trans retinoic acid (ATRA).
Regulation of inflammation in cancer by eicosanoids.
Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation.
Regulation of Innate Immune Function in Bovine Oviduct Epithelial Cells in Culture: The Homeostatic Role of Epithelial Cells in Balancing Th1/Th2 Response.
Regulation of JAK2/STAT3 and NF-?B signal transduction pathways; Veronica polita alleviates dextran sulfate sodium-induced murine colitis.
Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2.
Regulation of ovulatory genes in bovine granulosa cells: lessons from siRNA silencing of PTGS2.
Regulation of p53, nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin.
Regulation of polyisoprenylated methylated protein methyl esterase by polyunsaturated fatty acids and prostaglandins.
Regulation of Proinflammatory Mediators via NF-?B and p38 MAPK-Dependent Mechanisms in RAW 264.7 Macrophages by Polyphenol Components Isolated from Korea Lonicera japonica THUNB.
Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase.
Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2.
Regulation of prostaglandin endoperoxide H synthase-2 expression by 2,3,7,8,-tetrachlorodibenzo-p-dioxin.
Regulation of prostaglandin endoperoxide H synthase-2 induction by dioxin in rat hepatocytes: possible c-Src-mediated pathway.
Regulation of prostaglandin H synthase 2 expression in human monocytes by the marine natural products manoalide and scalaradial. Novel effects independent of inhibition of lipid mediator production.
Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis.
Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer.
Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells.
Regulation of the plasminogen activator inhibitor-2 (PAI-2) gene in murine macrophages. Demonstration of a novel pattern of responsiveness to bacterial endotoxin.
Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice.
Regulation of transforming growth factor-{beta}-dependent cyclooxygenase-2 expression in fibroblasts.
Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?
Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor.
Regulatory pathways in photodynamic therapy induced apoptosis.
Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis.
Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells.
Regulatory T cells in cancer: an overview and perspectives on cyclooxygenase-2 and Foxp3 DNA methylation.
Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner.
Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder.
Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.
Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
Relationship between COX-2 expression and clinicopathological features of colorectal cancers.
Relationship between cyclooxygenase-2 (COX-2) content and prognosis in nasopharyngeal carcinoma before and after radiochemotherapy.
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.
Relationship between lipoxygenase and human testicular cancer.
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance.
Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer.
Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice.
Relationship of CD95 and COX-2 in renal cell carcinomas with survival and other prognostic parameters: A tissue microarray study.
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
Relationship of endothelial area with VEGF-A, COX-2, maspin, c-KIT, and DOG-1 immunoreactivity in liposarcomas versus non-lipomatous soft tissue tumors.
Relationship of the suppression of macrophage mediated tumor cytotoxicity in conjunction with secretion of prostaglandin from the macrophages of breast cancer patients.
Relationships of pain in pancreatic cancer patients with pathological stage and expressions of NF-?B and COX-2.
Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis.
Relative Expression of Vitamin D Hydroxylases, CYP27B1 and CYP24A1, and of Cyclooxygenase-2 and Heterogeneity of Human Colorectal Cancer in Relation to Age, Gender, Tumor Location, and Malignancy: Results from Factor and Cluster Analysis.
Relative inhibition of lipid peroxidation, cyclooxygenase enzymes, and human tumor cell proliferation by natural food colors.
Renal COX-2, cytokines and 20-HETE: tubular and vascular mechanisms.
Renal histology and immunohistochemistry after acute hemorrhage in rats under sevoflurane and ketoprofen effect.
Renal interstitial cell tumor in a dog: clinicopathologic, imaging, and histologic features.
Renoprotective mechanisms of chlorogenic acid in cisplatin-induced kidney injury.
Repeated low-dose ultraviolet (UV) B exposures of humans induce limited photoprotection against the immune effects of erythemal UVB radiation.
Repetitive, noninvasive imaging of cyclooxygenase-2 gene expression in living mice.
Replication-competent adenoviruses with the type 35-derived fiber-knob region achieve reactive oxygen species-dependent cytotoxicity and produce greater toxicity than those with the type 5-derived region in pancreatic carcinoma.
Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma.
Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.
Repurposing [11C]PS13 for PET imaging of cyclooxygenase-1 (COX-1) in ovarian cancer xenograft mouse models.
Resampling-based multiple hypothesis testing procedures for genetic case-control association studies.
Research Article Flavocoxid Protects Against Cadmium-Induced Disruption of the Blood-Testis Barrier and Improves Testicular Damage and Germ Cell Impairment in Mice.
Research progress of ursolic acid's anti-tumor actions.
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Resistance of cholangiocarcinoma cells to parthenolide-induced apoptosis by the excretory-secretory products of Clonorchis sinensis.
Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against ?? T cell cytotoxicity.
Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Resistance to ursolic acid-induced apoptosis through involvement of melanogenesis and COX-2/PGE2 pathways in human M4Beu melanoma cancer cells.
Resokaempferol-mediated anti-inflammatory effects on activated macrophages via the inhibition of JAK2/STAT3, NF-?B and JNK/p38 MAPK signaling pathways.
Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.
Response gene to complement 32 expression in macrophages augments paracrine stimulation-mediated colon cancer progression.
Response of Walker 256 carcinosarcoma cells to 12-O-tetradecanoylphorbol 13-acetate: possible regulation by endogenous cyclooxygenase metabolites.
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
RESPONSE: re: enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme
Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.
Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.
Resveratrol and apoptosis.
Resveratrol attenuates brain damage in permanent focal cerebral ischemia via activation of PI3K/Akt signaling pathway in rats.
Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice.
Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells.
Resveratrol directly targets COX-2 to inhibit carcinogenesis.
Resveratrol downregulates the TLR4 signaling pathway to reduce brain damage in a rat model of focal cerebral ischemia.
Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats.
Resveratrol induces sumoylated COX-2-dependent anti-proliferation in human prostate cancer LNCaP cells.
Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells.
Resveratrol inhibits obesity-associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin-low breast cancer.
Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity.
Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets.
Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells.
Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2.
Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.
Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer.
Reversibility of Aberrant Global DNA and Estrogen Receptor-alpha Gene Methylation Distinguishes Colorectal Precancer from Cancer.
Review article: COX-2, prostanoids and colon cancer.
Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.
Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies.
Rg3-enriched Korean Red Ginseng extract inhibits blood-brain barrier disruption in an animal model of multiple sclerosis by modulating expression of NADPH oxidase 2 and 4.
RGS10 Regulates the Expression of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha through a G Protein-Independent Mechanism.
Rheological, sensorial, and chemopreventive properties of milk fermented with exopolysaccharide-producing lactic cultures.
Rheumatoid arthritis: current clinical and research directions.
Rho protein inhibition blocks cyclooxygenase-2 expression by proinflammatory mediators in endothelial cells.
RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility.
Rhododendrin ameliorates skin inflammation through inhibition of NF-?B, MAPK, and PI3K/Akt signaling.
RhoGDI deficiency induces constitutive activation of Rho GTPases and COX-2 pathways in association with breast cancer progression.
Rice Protein Exerts Anti-Inflammatory Effect in Growing and Adult Rats via Suppressing NF-?B Pathway.
Rifampicin ameliorates lipopolysaccharide-induced cognitive and motor impairments via inhibition of the TLR4/MyD88/NF-?B signaling pathway in mice.
Rifampicin ameliorates lithium-pilocarpine-induced seizures, consequent hippocampal damage and memory deficit in rats: Impact on oxidative, inflammatory and apoptotic machineries.
Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation.
RIP140 and LCoR expression in gastrointestinal cancers.
Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy.
Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation.
RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells.
RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells.
RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor.
RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer.
RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells.
RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.
ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences.
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Rofecoxib Attenuates the Pathogenesis of Amyotrophic Lateral Sclerosis by Alleviating Cyclooxygenase-2-Mediated Mechanisms.
Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer.
Rofecoxib has different effects on chemokine production in colorectal cancer cells and tumor immune splenocytes.
Rofecoxib prevents ctdsDNA against damage induced by copper sulfate and ultraviolet B radiation in vitro study.
Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes.
Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
Roflumilast prevents lymphotoxin ? (TNF-?)-induced inflammation activation and degradation of type 2 collagen in chondrocytes.
Role of ALDH1 in the prognosis of esophageal cancer and its relationship with tumor microenvironment.
Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs.
Role of chemopreventive agents in cancer therapy.
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.
Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis.
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.
Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell Line.
Role of COX-2 inhibitors in cancer therapy.
Role of COX-2 selective inhibitors for prevention and treatment of cancer.
Role of COX-2 specific inhibitors in oncogenesis.
Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth.
Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Role of curcumin in protection of gastric mucosa against stress-induced gastric mucosal damage. Involvement of hypoacidity, vasoactive mediators and sensory neuropeptides.
Role of cyclic AMP responsive element in the UVB induction of cyclooxygenase-2 transcription in human keratinocytes.
Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer.
Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer.
Role of cyclooxygenase-2 in breast cancer.
Role of cyclooxygenase-2 in colorectal cancer.
Role of cyclooxygenase-2 in gastric cancer development and progression.
Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.
Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma.
Role of cyclooxygenase-2 in pathogenesis and prevention of colorectal cancer.
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.
Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma.
Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer.
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer.
Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study.
Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea.
Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.
Role of cyclooxygenases COX-1 and COX-2 in modulating adipogenesis in 3T3-L1 cells.
Role of cyclooxygenases in angiogenesis.
Role of cytokines and Jak3/Stat3 signaling in the 1,2-dimethylhydrazine dihydrochloride-induced rat model of colon carcinogenesis: early target in the anticancer strategy.
Role of eicosanoids in prostate cancer progression.
Role of immunohistochemical cyclo-oxygenase-2 (COX-2) and osteocalcin in differentiating between osteoblastomas and osteosarcomas.
Role of inflammation and inflammatory mediators in colorectal cancer.
Role of Interleukin-1? in Radiation-Enhancement of MDA-MB-231 Breast Cancer Cell Invasion.
Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice.
Role of Kupffer cells in alcoholic hepatitis.
Role of Kupffer cells in the progression of CRC liver metastases after the first stage of ALPPS.
Role of leukotriene B(4) in celecoxib-mediated anticancer effect.
Role of lipid-derived mediators in tumor necrosis factor-induced endothelin-1 release in vivo.
Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer.
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.
Role of macrophage colony-stimulating factor (M-CSF)-dependent macrophages in gastric ulcer healing in mice.
Role of melittin-like region within phospholipase A(2)-activating protein in biological function.
Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice.
Role of Modulator of Inflammation Cyclooxygenase-2 in Gammaherpesvirus Mediated Tumorigenesis.
Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2.
Role of NF-kappaB in TNF-alpha-induced COX-2 expression in synovial fibroblasts from human TMJ.
Role of nitric oxide in the regulation of fibrogenic factors in experimental liver fibrosis in mice.
Role of non-neuronal cholinergic system in breast cancer progression.
Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors.
Role of Nrf2 in Suppressing LPS-Induced Inflammation in Mouse Peritoneal Macrophages by Polyunsaturated Fatty Acids Docosahexaenoic Acid and Eicosapentaenoic Acid.
Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma.
Role of p21CIP1 as a determinant of SC-560 response in human HCT116 colon carcinoma cells.
Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
Role of Peroxiredoxin 2 in the Protection Against Ferrous Sulfate-Induced Oxidative and Inflammatory Injury in PC12 Cells.
Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.
Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis.
Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.
Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.
Role of prostaglandins in tumor microenvironment.
Role of proteinase-activated receptor-2 on cyclooxygenase-2 expression in H. pylori-infected gastric epithelial cells.
Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries.
Role of the Cyclooxygenase Pathway in the Association of Obstructive Sleep Apnea and Cancer.
Role of the tumor necrosis factor-alpha, cyclooxygenase-2, prostaglandin E2, and effect of low-intensity pulsed ultrasound in an in vitro herniated disc resorption model.
Role of TLR-4 in liver macrophage and endothelial cell responsiveness during acute endotoxemia.
Role of TLR4 in olfactory-based spatial learning activity of neonatal mice after developmental exposure to diesel exhaust origin secondary organic aerosol.
Role of Toll-like receptors in gastrointestinal malignancies.
Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach.
Role of vitamin and mineral supplementation and aspirin use in cancer survivors.
Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes.
Roles of ERK and p38 mitogen-activated protein kinases in phorbol ester-induced NF-kappaB activation and COX-2 expression in human breast epithelial cells.
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis.
Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer.
Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention.
ROS induced by spring viraemia of carp virus activate the inflammatory response via the MAPK/AP-1 and PI3K signaling pathways.
Rosmarinic acid ameliorates acute liver damage and fibrogenesis in carbon tetrachloride-intoxicated mice.
Rosmarinic Acid antagonizes activator protein-1-dependent activation of cyclooxygenase-2 expression in human cancer and nonmalignant cell lines.
Rosmarinic acid inhibits DMH-induced cell proliferation in experimental rats.
Rottlerin enhances IL-1?-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cells.
Rotula aquatica Lour attenuates secretion of proinflammatory mediators and cytokines in lipopolysaccharide-induced inflammatory responses in murine RAW 264.7 macrophages.
Rotundic acid reduces LPS-induced acute lung injury in vitro and in vivo through regulating TLR4 dimer.
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.
Ruscogenin reduces cerebral ischemic injury via NF-?B-mediated inflammatory pathway in the mouse model of experimental stroke.
Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines.
Rutin, a quercetin glycoside, alleviates acute endotoxemic kidney injury in C57BL/6 mice via suppression of inflammation and up-regulation of antioxidants and SIRT1.
S-allyl cysteine protects against lipopolysaccharide-induced acute kidney injury in the C57BL/6 mouse strain: Involvement of oxidative stress and inflammation.
S-allyl cysteine, an active ingredient of garlic, attenuates acute liver dysfunction induced by lipopolysaccharide/ d-galactosamine in mouse: Underlying mechanisms.
S-allylmercaptocysteine ameliorates lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammation and oxidative stress via nuclear factor kappa B and Keap1/Nrf2 pathways.
S-layer protein mediates the stimulatory effect of Lactobacillus helveticus MIMLh5 on innate immunity.
S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF-kappaB pathway in rats.
S1P/S1P2 signaling induces cyclooxygenase-2 expression in Wilms tumor.
S632A3, a new glutarimide antibiotic, suppresses lipopolysaccharide-induced pro-inflammatory responses via inhibiting the activation of glycogen synthase kinase 3?
Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa).
Safflower polysaccharide inhibits the development of tongue squamous cell carcinoma.
Saffron: A potential candidate for a novel anticancer drug against hepatocellular carcinoma.
Saikosaponin A mediates the inflammatory response by inhibiting the MAPK and NF-?B pathways in LPS-stimulated RAW 264.7 cells.
Saikosaponin B2 Suppresses Inflammatory Responses Through IKK/I?B?/NF-?B Signaling Inactivation in LPS-Induced RAW 264.7 Macrophages.
Salidroside attenuates LPS-stimulated activation of THP-1 cell-derived macrophages through down-regulation of MAPK/NF-kB signaling pathways.
Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo.
Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.
Salivary Inflammatory Molecules as Biomarkers of Sleep Alterations: A Scoping Review.
Salix tetrasperma Roxb. Extract Alleviates Neuropathic Pain in Rats via Modulation of the NF-?B/TNF-?/NOX/iNOS Pathway.
Salvianolic Acid A Has Anti-Osteoarthritis Effect In Vitro and In Vivo.
Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways.
Saponins from
Sarcoid-Like Granulomatous Disease: Pathologic Case Series in World Trade Center Dust Exposed Rescue and Recovery Workers.
Sargassum fulvellum Protects HaCaT Cells and BALB/c Mice from UVB-Induced Proinflammatory Responses.
Sasa quelpaertensis leaf extract suppresses dextran sulfate sodium-induced colitis in mice by inhibiting the proinflammatory mediators and mitogen-activated protein kinase phosphorylation.
Schisandrin B Ameliorates ICV-Infused Amyloid ? Induced Oxidative Stress and Neuronal Dysfunction through Inhibiting RAGE/NF-?B/MAPK and Up-Regulating HSP/Beclin Expression.
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the ?-carrageenan-induced paw edema model.
Screening and isolation of cyclooxygenase-2 inhibitors from the stem bark of Phellodendron amurense Ruprecht by ultrafiltration with liquid chromatography and tandem mass spectrometry, and complex chromatography.
Screening and isolation of cyclooxygenase-2 inhibitors from Trifolium pratense L. via ultrafiltration, enzyme-immobilized magnetic beads, semi-preparative high-performance liquid chromatography and high-speed counter-current chromatography.
Screening for colon cancer and evaluation of chemoprevention with coxibs.
Scutellarin Attenuates the IL-1?-Induced Inflammation in Mouse Chondrocytes and Prevents Osteoarthritic Progression.
Selected pro-inflammatory factor transcripts in bovine endometrial epithelial cells are regulated during the oestrous cycle and elevated in case of subclinical or clinical endometritis.
Selection of metastatic breast cancer cells based on adaptability of their metabolic state.
Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered.
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Selective COX-2 inhibitor, NS-398, inhibits the replicative senescence of cultured dermal fibroblasts.
Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018).
Selective COX-2 inhibitors as chemopreventive and therapeutic agents.
Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships.
Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer.
Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway.
Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer.
Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice.
Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.
Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma.
Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.
Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer.
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.
Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.
Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.
Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia.
Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer.
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest.
Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma.
Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog.
Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin.
Selective inhibition of cyclooxygenase-2 protects porcine aortic endothelial cells from human antibody-mediated complement-dependent cytotoxicity.
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo.
Selective inhibition of prostacyclin synthase activity by rofecoxib.
Selective jejunal manipulation causes postoperative pan-enteric inflammation and dysmotility.
Selective PGE2 Suppression Inhibits Colon Carcinogenesis and Modifies Local Mucosal Immunity.
Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts.
Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.
Selenium alleviates cadmium-induced inflammation and meat quality degradation via antioxidant and anti-inflammation in chicken breast muscles.
Selenium attenuates pro-inflammatory gene expression in macrophages.
Selenium deficiency sensitizes the skin for UVB-induced oxidative damage and inflammation which involved the activation of p38 MAPK signaling.
Selenium Inhibits LPS-Induced Pro-inflammatory Gene Expression by Modulating MAPK and NF-?B Signaling Pathways in Mouse Mammary Epithelial Cells in Primary Culture.
Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells.
Selenium relieves oxidative stress, inflammation, and apoptosis within spleen of chicken exposed to mercuric chloride.
Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.
Selenomethionine relieves inflammation in the chicken trachea caused by LPS though inhibiting the NF-?B pathway.
Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression.
SeMet mediates anti-inflammation in LPS-induced U937 cells targeting NF-?B signaling pathway.
Seminal plasma modulates the immune-cytokine network in the porcine uterine tissue and pre-ovulatory follicles.
Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism.
Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism.
Sensitization of colon cancer cell lines to butyrate-mediated proliferation inhibition by combined application of indomethacin and nordihydroguaiaretic acid.
Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells.
Sequential expression of inducible nitric oxide synthase and cyclooxygenase-2 during DMBA-induced hamster buccal pouch carcinogenesis.
Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy.
Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesis.
SerpinB3 upregulates the Cyclooxygenase-2 / ?-Catenin positive loop in colorectal cancer.
Serum adipocyte fatty acid-binding protein in the critically ill.
Serum lipid profiles in patients receiving endocrine treatment for breast cancer-the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial.
Serum metabolites from walnut-fed aged rats attenuate stress-induced neurotoxicity in BV-2 microglial cells.
Serum proteomic profiles suggest celecoxib-modulated targets and response predictors.
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase.
Sesamol Ameliorates Cyclophosphamide-Induced Hepatotoxicity by Modulating Oxidative Stress and Inflammatory Mediators.
Sesamol suppresses cyclooxygenase-2 transcriptional activity in colon cancer cells and modifies intestinal polyp development in Apc (Min/+) mice.
Sesquiterpene Coumarins from Ferula sinkiangensis Act as Neuroinflammation Inhibitors.
Sesquiterpene dimer (DSF-52) from Artemisia argyi inhibits microglia-mediated neuroinflammation via suppression of NF-?B, JNK/p38 MAPKs and Jak2/Stat3 signaling pathways.
Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation.
Severity of gastritis determines glandular stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.
Sex Differences in the Central and Peripheral Manifestations of Ischemia-induced Heart Failure in Rats.
Sex-Mediated Differences in LPS Induced Alterations of TNF?, IL-10 Expression, and Prostaglandin Synthesis in Primary Astrocytes.
Shikonin Isolated from Lithospermum erythrorhizon Downregulates Proinflammatory Mediators in Lipopolysaccharide-Stimulated BV2 Microglial Cells by Suppressing Crosstalk between Reactive Oxygen Species and NF-?B.
Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications.
Shizukaol B, an active sesquiterpene from Chloranthus henryi, attenuates LPS-induced inflammatory responses in BV2 microglial cells.
Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer.
shRNA-targeted Cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells.
Signal transduction network leading to COX-2 induction: a road map in search of cancer chemopreventives.
Signal transduction pathways for epidermal growth factor stimulated cyclooxygenase-2 induction in astrocytes.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2.
Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells.
Signet-ring cell carcinoma of colorectum-current perspectives and molecular biology.
Significance of COX-2 expression in human esophageal squamous cell carcinoma.
Significance of COX-2 expression in human renal cell carcinoma cell lines.
Significance of COX-2 expression in human renal cell carcinoma.
Significance of Cox-2 expression in rectal cancers with or without preoperative radiotherapy.
Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers.
Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus.
Significance of immunohistochemical overexpression of cyclooxygenase-2 in overall and disease-free survival of oral squamous cell carcinoma patients.
Significance of Serum Markers and Urinary Microalbumin in the Diagnosis of Early Renal Damage in Patients with Gout.
Significance of uroplakin III expression in recurrence of solitary muscle non-invasive bladder cancer.
Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126.
Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion.
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells.
Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.
Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice.
Silibinin inhibits tumor promotional triggers and tumorigenesis against chemically induced two-stage skin carcinogenesis in Swiss albino mice: possible role of oxidative stress and inflammation.
Silibinin modulates TNF-? and IFN-? mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells.
Silica-based nanoparticle uptake and cellular response by primary microglia.
Similar antineoplastic effects of nimesulide, a selective COX-2 inhibitor, and prostaglandin E1 on B16-F10 murine melanoma cells.
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice.
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells.
Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2.
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice.
Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.
Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.
Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX-2 pathway in rats.
Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products.
Simvastatin treatment ameliorates injury of rat testes induced by cadmium toxicity.
Sinapic Acid Inhibits IL-1?-Induced Apoptosis and Catabolism in Nucleus Pulposus Cells and Ameliorates Intervertebral Disk Degeneration.
Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.
Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats.
Sinomenine contributes to the inhibition of the inflammatory response and the improvement of osteoarthritis in mouse-cartilage cells by acting on the Nrf2/HO-1 and NF-?B signaling pathways.
Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo.
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Sitagliptin attenuates in?ammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-?B pathway inhibition.
Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas.
Size-dependent effect of zinc oxide on toxicity and inflammatory potential of human monocytes.
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas.
Skin tumor promotion by argemone oil/alkaloid in mice: Evidence for enhanced cell proliferation, ornithine decarboxylase, cyclooxygenase-2 and activation of MAPK/NF-kappaB pathway.
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Smallanthus sonchifolius leaf attenuates neuroinflammation.
Smoking and Colorectal Cancer Risk by Tumor Genetic and Epigenetic Subtypes: A Molecular Pathological Epidemiology (MPE) Study.
Smoking and COX-2 Functional Polymorphisms Interact to Increase the Risk of Gastric Cardia Adenocarcinoma in Chinese Population.
Smoking-induced changes in cancer-related factors in patients with upper tract urothelial cancer.
Snail and Cox-2 expressions are associated with WHO tumor grade and survival rate of patients with gliomas.
Snail up-regulates proinflammatory mediators and inhibits differentiation in oral keratinocytes.
SNS-032 prevents hypoxia-mediated glioblastoma cell invasion by inhibiting hypoxia inducible factor-1alpha expression.
Sodium butyrate inhibits angiogenesis of human intestinal microvascular endothelial cells through COX-2 inhibition.
Sodium Hydrosulfide Attenuates Beta-Amyloid-Induced Cognitive Deficits and Neuroinflammation via Modulation of MAPK/NF-?B Pathway in Rats.
Solid lipid nanoparticles-mediated enhanced antidepressant activity of duloxetine in lipopolysaccharide-induced depressive model.
Solid variant of aneurysmal bone cyst in the tibia treated with simple curettage without bone graft: a case report.
Solid-State and Solution Characterization of Myricetin.
Soluble EP2 neutralizes prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth.
Some studies on spontaneous Hymenolepis diminuta infection in laboratory rats.
Sonchus asper extract inhibits LPS-induced oxidative stress and pro-inflammatory cytokine production in RAW264.7 macrophages.
Sonic hedgehog inhibitors prevent colitis-associated cancer via orchestrated mechanisms of IL-6/gp130 inhibition, 15-PGDH induction, Bcl-2 abrogation, and tumorsphere inhibition.
Sonicated Protein Fractions of Mycoplasma hyopneumoniae Induce Inflammatory Responses and Differential Gene Expression in a Murine Alveolar Macrophage Cell Line.
Sophoraflavanone G prevents Streptococcus mutans surface antigen I/II-induced production of NO and PGE2 by inhibiting MAPK-mediated pathways in RAW 264.7 macrophages.
Soy isoflavone genistein attenuates lipopolysaccharide-induced cognitive impairments in the rat via exerting anti-oxidative and anti-inflammatory effects.
Soyasaponins reduce inflammation by downregulating MyD88 expression and suppressing the recruitments of TLR4 and MyD88 into lipid rafts.
Soybean isoflavone ameliorates cognitive impairment, neuroinflammation, and amyloid ? accumulation in a rat model of Alzheimer's disease.
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.
Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production.
Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats.
Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells.
Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: Regulation of synovial proliferation and inflammatory gene expression.
Sphingosine Kinase 1 expression in peritoneal macrophages is required for colon carcinogenesis.
Sphingosine kinase 1 is up-regulated in colon carcinogenesis.
Sphingosine-1-phosphate enhances IL-1{beta}-induced COX-2 expression in mouse intestinal subepithelial myofibroblasts.
Spinal cord long-term potentiation (LTP) is associated with increased dorsal horn gene expression of IL-1beta, GDNF and iNOS.
Spinal nuclear factor-kappa B (NF-?B) p65 activation contributes to peripheral inflammation and hyperalgesia in rat adjuvant-induced arthritis.
Spirodela polyrhiza (L.) Sch. ethanolic extract inhibits LPS-induced inflammation in RAW264.7 cells.
Spiroindolone analogues bearing benzofuran moiety as a selective cyclooxygenase COX-1 with TNF-? and IL-6 inhibitors.
Spirulina and C-phycocyanin reduce cytotoxicity and inflammation-related genes expression of microglial cells.
Src Is a Prime Target Inhibited by Celtis choseniana Methanol Extract in Its Anti-Inflammatory Action.
Src kinase is a direct target of apigenin against UVB-induced skin inflammation.
Src/Syk/IRAK1-targeted anti-inflammatory action of Torreya nucifera butanol fraction in lipopolysaccharide-activated RAW264.7 cells.
Standardized Fraction of Turbinaria ornata Alleviates Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice via Upregulation of FOXP3+ Regulatory T Cells.
Standardized ginger (Zingiber officinale) extract reduces bacterial load and suppresses acute and chronic inflammation in Mongolian gerbils infected with cagAHelicobacter pylori.
Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.
Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.
Stauntoside B inhibits macrophage activation by inhibiting NF-?B and ERK MAPK signalling.
Staurosporine synergistically potentiates the deoxycholate-mediated induction of COX-2 expression.
Stemodin-derived analogues with lipid peroxidation, cyclooxygenase enzymes and human tumour cell proliferation inhibitory activities.
Stephania delavayi Diels. inhibits breast carcinoma proliferation through the p38 MAPK/NF-?B/COX-2 pathway.
Steppogenin Isolated from Cudrania tricuspidata Shows Antineuroinflammatory Effects via NF-?B and MAPK Pathways in LPS-Stimulated BV2 and Primary Rat Microglial Cells.
Stercurensin inhibits nuclear factor-?B-dependent inflammatory signals through attenuation of TAK1-TAB1 complex formation.
Steroidal alkaloid solanine A from Solanum nigrum Linn. exhibits anti-inflammatory activity in lipopolysaccharide/interferon ?-activated murine macrophages and animal models of inflammation.
Steroidal alkaloids from the bulbs of Fritillaria pallidiflora Schrenk and their anti-inflammatory activity.
Sterols and triterpenoids as potential anti-inflammatories: Molecular docking studies for binding to some enzymes involved in inflammatory pathways.
Stevia residue extract alone and combination with allopurinol attenuate hyperuricemia in fructose-PO-induced hyperuricemic mice.
Stilbenes and Anthocyanins Reduce Stress Signaling in BV-2 Mouse Microglia.
Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Strategy for prevention of cancers of the esophagus.
Stress-Related Regulation Is Abnormal in the Psoriatic Uninvolved Skin.
Stressors Due to Handling Impair Gut Immunity in Meagre (Argyrosomus regius): The Compensatory Role of Dietary L-Tryptophan.
Stromal COX-2 signaling activated by deoxycholic acid mediates proliferation and invasiveness of colorectal epithelial cancer cells.
Stromal TRIM28-associated signaling pathway modulation within the colorectal cancer microenvironment.
Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma.
Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients.
Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer.
Structural Change in Microbiota by a Probiotic Cocktail Enhances the Gut Barrier and Reduces Cancer via TLR2 Signaling in a Rat Model of Colon Cancer.
Structural characteristics and biological effects of exopolysaccharide produced by cyanobacterium Nostoc sp.
Structural characterization, molecular modification and hepatoprotective effect of melanin from Lachnum YM226 on acute alcohol-induced liver injury in mice.
Structural modeling and simulation studies of human cyclooxygenase (COX) isozymes with selected terpenes: implications in drug designing and development.
Structure activity relationship of antiproliferative agents using multiple linear regression.
Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. identification of novel chemotherapeutic drug resistance modulators.
Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).
Studies into the Anticancer Effects of Selenomethionine against Human Colon Cancer.
Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody.
Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.
Studies on the Contribution of Cox-2 Expression in the Progression of Oral Squamous Cell Carcinoma and H-Ras Activation.
Studies on the role of platelet eicosanoid metabolism and integrin alpha IIb beta 3 in tumor-cell-induced platelet aggregation.
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Study of cyclooxygenase-2 in renal cell carcinoma.
Study of the polymorphisms of cyclooxygenase-2 (-765G>C) and 5-lipoxygenase (1708G>A) in patients with colorectal cancer.
Study on the Anti-Tumor Mechanism and Target of Triptolide based on Network Pharmacology and Molecular Docking.
Stylopine from Chelidonium majus inhibits LPS-induced inflammatory mediators in RAW 264.7 cells.
Subacute arsenic exposure through drinking water reduces the pharmacodynamic effects of ketoprofen in male rats.
Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation.
Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Substance P Induces HO-1 Expression in RAW 264.7 Cells Promoting Switch towards M2-Like Macrophages.
Successful preoperative treatment of pediatric bladder inflammatory myofibroblastic tumor with anti-inflammatory therapy.
Successful treatment of a recurrent chest wall desmoid tumor with cyclooxygenase-2 inhibitors.
Successful treatment of an unresectable inflammatory myofibroblastic tumor of the frontal bone using a cyclooxygenase-2 inhibitor and methotrexate.
Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib.
Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study.
Sulforaphane Ameliorates 3-Nitropropionic Acid-Induced Striatal Toxicity by Activating the Keap1-Nrf2-ARE Pathway and Inhibiting the MAPKs and NF-?B Pathways.
Sulforaphane controls the release of paracrine factors by keratinocytes and thus mitigates particulate matter-induced premature skin aging by suppressing melanogenesis and maintaining collagen homeostasis.
Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells.
Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model.
Sulforaphane exerts neuroprotective effects via suppression of the inflammatory response in a rat model of focal cerebral ischemia.
Sulforaphane inhibits phorbol ester-stimulated IKK-NF-?B signaling and COX-2 expression in human mammary epithelial cells by targeting NF-?B activating kinase and ERK.
Sulforaphane inhibits prostaglandin E2 synthesis by suppressing microsomal prostaglandin E synthase 1.
Sulfosuccinimidyl oleate sodium is neuroprotective and alleviates stroke-induced neuroinflammation.
Sulfur and nitrogen-containing compounds from the whole bodies of Blaps japanensis.
Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms.
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib.
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.
Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction.
Supplementation of American ginseng berry extract mitigated cisplatin-evoked nephrotoxicity by suppressing ROS-mediated activation of MAPK and NF-?B signaling pathways.
Suppressed Helicobacter pylori-associated gastric tumorigenesis in Fat-1 transgenic mice producing endogenous ?-3 polyunsaturated fatty acids.
Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2.
Suppression by citrus auraptene of phorbol ester-and endotoxin-induced inflammatory responses: role of attenuation of leukocyte activation.
Suppression of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation in mice by transduced Tat-Annexin protein.
Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
Suppression of Alzheimer's disease-related phenotypes by the heat shock protein 70 inducer, geranylgeranylacetone, in APP/PS1 transgenic mice via the ERK/p38 MAPK signaling pathway.
Suppression of carbonyl reductase expression enhances malignant behaviour in uterine cervical squamous cell carcinoma: Carbonyl reductase predicts prognosis and lymph node metastasis.
Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by conjugated linoleic acid in murine macrophages.
Suppression of cyclooxygenase-2 expression of skin fibroblasts by wogonin, a plant flavone from Scutellaria radix.
Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid.
Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells.
Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure.
Suppression of endotoxin-induced proinflammatory responses by citrus pectin through blocking LPS signaling pathways.
Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Suppression of LPS-induced inflammatory and NF-?B responses by anomalin in RAW 264.7 macrophages.
Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor.
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol.
Suppression of nuclear factor-kappaB activity in macrophages by chylomicron remnants: modulation by the fatty acid composition of the particles.
Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.
Suppression of polyclonal, tumor cell and alloantigen-induced proliferation: identification of cyclooxygenase pathway dependent and independent mechanisms.
Suppression of Proinflammatory Cytokines and Mediators in LPS-Induced RAW 264.7 Macrophages by Stem Extract of Alternanthera sessilis via the Inhibition of the NF-?B Pathway.
Suppression of Prostaglandin E2 by Malaria Parasite Products and Antipyretics Promotes Overproduction of Tumor Necrosis Factor- alpha : Association with the Pathogenesis of Childhood Malarial Anemia.
Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth.
Suppression of Src and Syk in the NF-?B signaling pathway by Olea europaea methanol extract is leading to its anti-inflammatory effects.
Suppression of STAT3 Phosphorylation and RelA/p65 Acetylation Mediated by MicroRNA134 Plays a Pivotal Role in the Apoptotic Effect of Lambertianic Acid.
Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways.
Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1.
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Suppression of tumor promoter-induced chemiluminescence in mouse epidermal cells by several inhibitors of arachidonic acid metabolism.
Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats.
Suppressive Effect of Flavonoids from Korean Citrus aurantium L. on the Expression of Inflammatory Mediators in L6 Skeletal Muscle Cells.
Suppressive effect of natural sesquiterpenoids on inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) activity in mouse macrophage cells.
Suppressive effect of non-anaphylactogenic anti-IgE antibody on the development of dextran sulfate sodium-induced colitis.
Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
Surface modified multifaceted nanocarriers for oral non-conventional cancer therapy; synthesis and evaluation.
Surfactin C inhibits Mycoplasma hyopneumoniae-induced transcription of proinflammatory cytokines and nitric oxide production in murine RAW 264.7 cells.
Surgery as a double-edged sword: a clinically feasible approach to overcome the metastasis-promoting effects of surgery by blunting stress and prostaglandin responses.
Surgical infections: blocking the mediator cascade responsible for sepsis and septic shock.
Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process.
Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition.
Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray.
Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2.
Survivin and Cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes.
Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.
Synbiotics suppress colitis-induced tumorigenesis in a colon-specific cancer mouse model.
Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein.
Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord.
Synergistic anti-inflammatory effects of quercetin and catechin via inhibiting activation of TLR4-MyD88-mediated NF-?B and MAPK signaling pathways.
Synergistic anti-tumor effects of melatonin and PUFAs from walnuts in a murine mammary adenocarcinoma model.
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.
Synergistic COX2 Induction by IFN? and TNF? Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.
Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.
Synergistic effect of ascorbic acid and taurine in the treatment of a spinal cord injury-induced model in rats.
Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients.
Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation.
Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3.
Synergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female rats.
Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells.
Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.
Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells.
Synergistic Inhibition Effect of Tumor Growth by Using Celecoxib in Combination With Oxaliplatin.
Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines.
Synergistic regulation of COX-2 expression by bombesin and transforming growth factor-beta.
Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Synergy of Physico-chemical and Biological Experiments for Developing a Cyclooxygenase-2 Inhibitor.
Synovial tissue inflammation in early and late osteoarthritis.
Synthesis and anti-inflammatory activity of novel steroidal chalcones with 3?-pregnenolone ester derivatives in RAW 264.7 cells in vitro.
Synthesis and anti-inflammatory effects of novel emodin derivatives bearing azole moieties.
Synthesis and biological evaluation of new heteroaryl carboxylic acid derivatives as anti-inflammatory-analgesic agents.
Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.
Synthesis and biological evaluation of phenyl-1H-1,2,3-triazole derivatives as anti-inflammatory agents.
Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [99mTc] via N4(GGAG) for ?V?3 integrin-targeted drug delivery.
Synthesis and biological evaluation of some novel resveratrol amide derivatives as potential anti-tumor agents.
Synthesis and characterization of boron fenbufen and its F-18 labeled homolog for boron neutron capture therapy of COX-2 overexpressed cholangiocarcinoma.
Synthesis and Cyclooxygenase Inhibition of Sulfonamide-Substituted (Dihydro)Pyrrolo[3,2,1-hi]indoles and Their Potential Prodrugs.
Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted with Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells.
Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor.
Synthesis and evaluation of novel D-ring substituted steroidal pyrazolines as potential anti-inflammatory agents.
Synthesis and evaluation of ortho-[18F] fluorocelecoxib for COX-2 cholangiocarcinoma imaging.
Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression.
Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer.
Synthesis of dihydropyrazole sulphonamide derivatives that act as anti-cancer agents through COX-2 inhibition.
Synthesis of eicosanoids by gamma-interferon-differentiated U937 cells.
Synthesis of hyaluronan in oesophageal cancer cells is uncoupled from the prostaglandin-cAMP pathway.
Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.
Synthesis of Resveratrol Derivatives and In Vitro Screening for Potential Cancer Chemopreventive Activities.
Synthesis of three 18F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold.
Synthesis, 3D-QSAR, and Molecular Modeling Studies of Triazole Bearing Compounds as a Promising Scaffold for Cyclooxygenase-2 Inhibition.
Synthesis, characterisation and biological evaluation of copper and silver complexes based on acetylsalicylic acid.
Synthesis, characterization, and cellular investigations of porphyrin- and chlorin-indomethacin conjugates for photodynamic therapy of cancer.
Synthesis, Inhibitory Activity, and In Silico Modeling of Selective COX-1 Inhibitors with a Quinazoline Core.
Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors.
Synthesis, structural characterization, molecular docking study, biological activity of carbon monoxide release molecules as potent antitumor agents.
Synthetic Fluororutaecarpine Inhibits Inflammatory Stimuli and Activates Endothelial Transient Receptor Potential Vanilloid-Type 1.
Synthetic pathways of gallbladder mucosal prostanoids: the role of cyclooxygenase-1 and 2.
Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor.
Systemic bone loss and induction of coronary vessel disease in a rat model of chronic inflammation.
Systemic Inflammation as a Driver of Brain Injury: the Astrocyte as an Emerging Player.
Systemic treatment of hepatocellular carcinoma.
T-Cell Activation-Inhibitory Assay to Screen Caloric Restriction Mimetics Drugs for Drug Repositioning.
Tagitinin F has anti-inflammatory, anti-nociceptive and anti-matrix metalloproteinase properties: An in silico, in vitro and in vivo study.
Taiwanin C elicits apoptosis in arecoline and 4-nitroquinoline-1-oxide-induced oral squamous cell carcinoma cells and hinders proliferation via epidermal growth factor receptor/PI3K suppression.
Tamarind Seed (Tamarindus indica) Extract Ameliorates Adjuvant-Induced Arthritis via Regulating the Mediators of Cartilage/Bone Degeneration, Inflammation and Oxidative Stress.
Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
Tangeretin Improves Glucose Uptake in a Coculture of Hypertrophic Adipocytes and Macrophages by Attenuating Inflammatory Changes.
Tangeretin, a citrus pentamethoxyflavone, exerts cytostatic effect via p53/p21 up-regulation and suppresses metastasis in 7,12-dimethylbenz(?)anthracene-induced rat mammary carcinoma.
Tannic acid modulates NF?B signaling pathway and skin inflammation in NC/Nga mice through PPAR? expression.
Tanshinol ameliorates CCl4-induced liver fibrosis in rats through the regulation of Nrf2/HO-1 and NF-?B/I?B? signaling pathway.
Tanshinone II--a inhibits angiogenesis through down regulation of COX-2 in human colorectal cancer.
Tanshinone?IIA attenuates the deleterious effects of oxidative stress in osteoporosis through the NF??B signaling pathway.
Taraxerol inhibits LPS-induced inflammatory responses through suppression of TAK1 and Akt activation.
Targeted CFTR gene disruption with zinc-finger nucleases in human intestinal epithelial cells induces oxidative stress and inflammation.
Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice.
Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer.
Targeted imaging of cancer by fluorocoxib C, a near-infrared cyclooxygenase-2 probe.
Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.
Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy.
Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer.
Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: synthesis, pharmacokinetics, and tumor growth inhibition.
Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice.
Targeted quantitative analysis of eicosanoid lipids in biological samples using liquid chromatography-tandem mass spectrometry.
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
Targeted therapies in bladder cancer: an overview of in vivo research.
Targeted therapies in metastatic esophageal cancer: Advances over the past decade.
Targeting apoptosis pathways by Celecoxib in cancer.
Targeting arachidonic acid pathway by natural products for cancer prevention and therapy.
Targeting cell signaling pathways for drug discovery: an old lock needs a new key.
Targeting COX-2 abrogates mammary tumorigenesis: Breaking cancer-associated suppression of immunosurveillance.
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
Targeting COX-2 expression by natural compounds: A promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy.
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
Targeting cyclooxygenase-2 for cancer prevention and treatment.
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background.
Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E(2) cooperation.
Targeting Inflammatory Processes Mediated by TRPVI and TNF-? for Treating Noise-Induced Hearing Loss.
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
Targeting Lipid Peroxidation for Cancer Treatment.
Targeting NOX, INOS and COX-2 in inflammatory cells: Chemoprevention using food phytochemicals.
Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.
Targeting of COX-2 expression by recombinant adenovirus shRNA attenuates the malignant biological behavior of breast cancer cells.
Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression.
Targeting prostaglandin E EP receptors to inhibit metastasis.
Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment.
Targeting signal transduction pathways by chemopreventive agents.
Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population.
Targeting the D Series Resolvin Receptor System for the Treatment of Osteoarthritis Pain.
Targeting the eicosanoid pathway in non-small-cell lung cancer.
Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor.
Tart cherry anthocyanins inhibit tumor development in Apc(Min) mice and reduce proliferation of human colon cancer cells.
Tart Cherry Extracts Reduce Inflammatory and Oxidative Stress Signaling in Microglial Cells.
Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line.
Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis.
Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice.
Tea polyphenols inhibit cyclooxygenase-2 expression and block activation of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss mice.
Telmisartan treatment attenuates arsenic-induced hepatotoxicity in mice.
Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects.
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Temporal and spatial patterns of ovarian gene transcription following an ovulatory dose of gonadotropin in the rat.
Tenacissoside H exerts an anti-inflammatory effect by regulating the nf-?b and p38 pathways in zebrafish.
Tepoxalin a dual 5-LOX-COX inhibitor and erlotinib an EGFR inhibitor halts progression of gastric cancer in tumor xenograft mice.
Terminalia bellirica (Gaertn.) Roxb fruit exerts anti-inflammatory effect via regulating arachidonic acid pathway and pro-inflammatory cytokines in lipopolysaccharide-induced RAW 264.7 macrophages.
Terrein reduces age-related inflammation induced by oxidative stress through Nrf2/ERK1/2/HO-1 signalling in aged HDF cells.
Tert-butylhydroquinone protects PC12 cells against ferrous sulfate-induced oxidative and inflammatory injury via the Nrf2/ARE pathway.
Tetrachlorobenzoquinone exhibits neurotoxicity by inducing inflammatory responses through ROS-mediated IKK/I?B/NF-?B signaling.
Tetramethoxy hydroxyflavone p7F downregulates inflammatory mediators via the inhibition of nuclear factor kappaB.
Tetramethylpyrazine (TMP) protects against sodium arsenite-induced nephrotoxicity by suppressing ROS production, mitochondrial dysfunction, pro-inflammatory signaling pathways and programed cell death.
TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway.
TGF-? acts as a dual regulator of COX-2/PGE2 tumor promotion depending of its cross-interaction with H-Ras and Wnt/?-catenin pathways in colorectal cancer cells.
TGF-? Effects on Prostate Cancer Cell Migration and Invasion Are Mediated by PGE2 through Activation of PI3K/AKT/mTOR Pathway.
TGF-?1 protection against A?1-42-induced hippocampal neuronal inflammation and apoptosis by T?R-I.
TGF-beta and colorectal carcinogenesis.
Thalidomide as a multi-template for development of biologically active compounds.
Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.
The -765C allele of the cyclooxygenase-2 gene as a potential risk factor of colorectal cancer: a meta-analysis.
The -765G>C polymorphism in the cyclooxygenase-2 gene and digestive system cancer: a meta-analysis.
The 21-aminosteroid 16-desmethyl tirilazad mesylate prevents necroinflammatory changes in experimental alcoholic liver disease.
The activation of BDNF reduced inflammation in a spinal cord injury model by TrkB/p38 MAPK signaling.
The activation of gilthead seabream professional phagocytes by different PAMPs underlines the behavioural diversity of the main innate immune cells of bony fish.
The Activation of Heat-Shock Protein After Copper(II) and/or Arsenic(III)-Induced Imbalance of Homeostasis, Inflammatory Response in Chicken Rectum.
The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid.
The Adjuvant Effect of Squalene, an Active Ingredient of Functional Foods, on Doxorubicin-Treated Allograft Mice.
The Algal Meroterpene 11-Hydroxy-1'-O-Methylamentadione Ameloriates Dextran Sulfate Sodium-Induced Colitis in Mice.
The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade.
The Antagonistic Effect of Selenium on Cadmium-Induced Damage and mRNA Levels of Selenoprotein Genes and Inflammatory Factors in Chicken Kidney Tissue.
The Antagonistic Effect of Selenium on Lead-Induced Inflammatory Factors and Heat Shock Protein mRNA Level in Chicken Cartilage Tissue.
The Antagonistic Effect of Selenium on Lead-Induced Inflammatory Factors and Heat Shock Proteins mRNA Expression in Chicken Livers.
The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling.
The Anti-Cancer Effects of a Zotarolimus and 5-Fluorouracil Combination Treatment on A549 Cell-Derived Tumors in BALB/c Nude Mice.
The anti-inflammatory activity of oligomeric proanthocyanidins via inhibition of NF-?B and MAPK in LPS-stimulated MAC-T cells.
The anti-inflammatory and anti-glycative effects of rosmarinic acid in the livers of type 1 diabetic mice.
The anti-inflammatory and antinociceptive effects of NF-kappaB inhibitory guanidine derivative ME10092.
The anti-inflammatory effect of tussilagone, from Tussilago farfara, is mediated by the induction of heme oxygenase-1 in murine macrophages.
The Anti-inflammatory Effect of Z-Ligustilide in Experimental Ovariectomized Osteopenic Rats.
The anti-inflammatory effects of an ethanolic extract of the rhizome of Atractylodes lancea, involves Akt/NF-?B signaling pathway inhibition.
The anti-inflammatory effects of ethyl acetate on Lipopolysaccharide/D-galactosamine challenged mice and Lipopolysaccharide activated RAW264.7 cells.
The Anti-inflammatory Effects of Lignan Glycosides from Cistanche tubulosa stems on LPS/IFN-?-induced RAW264.7 Macrophage Cells via PI3K/ AKT Pathway.
The anti-inflammatory influence of Cinnamomum burmannii against multi-walled carbon nanotube-induced liver injury in rats.
The Anti-Inflammatory Properties of Citrus wilsonii Tanaka Extract in LPS-Induced RAW 264.7 and Primary Mouse Bone Marrow-Derived Dendritic Cells.
The anti-inflammatory prostaglandin 15d-PGJ2 decreases oxidative/nitrosative mediators in brain after acute stress in rats.
The Anti-Oxidative and Anti-Neuroinflammatory Effects of Sargassum horneri by Heme Oxygenase-1 Induction in BV2 and HT22 Cells.
The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2.
The antidepressant- and anxiolytic-like effects of fluoxetine and clozapine in chronically isolated rats involve inhibition of hippocampal TNF-?.
The Antinociceptive Effect of Light-Emitting Diode Irradiation on Incised Wounds Is Correlated with Changes in Cyclooxygenase 2 Activity, Prostaglandin E2, and Proinflammatory Cytokines.
The Antioxidant and Anti-Inflammatory Activities of 8-Hydroxydaidzein (8-HD) in Activated Macrophage-Like RAW264.7 Cells.
The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts.
The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines.
The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
The association between cyclooxygenase-2 1195 G/A polymorphism and hepatocellular carcinoma: evidence from a meta-analysis.
The ATRA-induced differentiation of medulloblastoma cells is enhanced with LOX/COX inhibitors: an analysis of gene expression.
The basis for the chemopreventive action of resveratrol.
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa.
The beneficial effect of cold atmospheric plasma on parameters of molecules and cell function involved in wound healing in human osteoblast-like cells in vitro.
The Bitter Barricading of Prostaglandin Biosynthesis Pathway: Understanding the Molecular Mechanism of Selective Cyclooxygenase-2 Inhibition by Amarogentin, a Secoiridoid Glycoside from Swertia chirayita.
The Calcium-Sensing Receptor Is Involved in Follicle-Stimulating Hormone-Induced Cumulus Expansion in in vitro Cultured Porcine Cumulus-Oocyte Complexes.
The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.
The CC-genotype of the cyclooxygenase-2 gene associates with decreased risk of nasopharyngeal carcinoma in a Tunisian population.
The clinical potential of cyclooxygenase-2-specific inhibitors.
The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma.
The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.
The co-induced effects of molybdenum and cadmium on the mRNA expression of inflammatory cytokines and trace element contents in duck kidneys.
The combination of curcumin and 5-fluorouracil in cancer therapy.
The Combined Blockade of ?-Adrenoceptor and COX-2 During the Perioperative Period to Improve Long-term Cancer Outcomes.
The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.
The connection between lymphangiogenic signalling and prostglandin biology: A missing link in the metastatsic pathway.
The contributions of cyclooxygenase-2 to tumor angiogenesis.
The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis.
The Cox-2 -1195 G > A polymorphism and cancer risk: a meta-analysis of 25 case-control studies.
The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function.
The COX-2 inhibitor NS398 selectively sensitizes hypoxic HeLa cells to ionising radiation by mechanisms both dependent and independent of COX-2.
The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers.
The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway.
The COX-2-1195AA Genotype Is Associated with Diffuse-Type Gastric Cancer in Korea.
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.
The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis.
The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.
The Cyclooxigenase-2 Inhibitor Parecoxib Prevents Epidermal Dysplasia in HPV16-Transgenic Mice: Efficacy and Safety Observations.
The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines.
The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK.
The Cyclooxygenase-2 (PTGS2) 8473T>C Polymorphism is Associated with Breast Cancer Risk.
The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells.
The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model.
The Cyclooxygenase-2 Inhibitor Nimesulide, a Nonsteroidal Analgesic, Decreases the Effect of Radiation Therapy in Head-and-Neck Cancer Cells.
The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway.
The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial.
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer.
The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis.
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
The cyclooxygenase-2/prostaglandin E2 pathway and its role in the pathogenesis of human and dog hematological malignancies.
The direct inhibition of prostaglandin synthetase of human breast cancer tumor tissue by tamoxifen.
The Dynamic Changes of Gut Microbiota in Muc2 Deficient Mice.
The Effect of 7-Hydroxycoumarin on Dextran Sulfate Sodium-induced Ulcerative Colitis.
The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers.
The effect of celecoxib on the development of diethylnitrosamine-induced liver tumors in rats.
The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture.
The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma.
The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer.
The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent.
The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines.
The Effect of Human Adipose Tissue-Derived Mesenchymal Stem Cells in Rat's Subglottic Stenosis Model.
The effect of hydroxy safflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-?.
The effect of lipopolysaccharide on enhanced inflammatory process with age: Modulation of NF-?B.
The effect of meloxicam, a selective COX-2 inhibitor, on the microvasculature of small metastatic liver tumors in rats.
The Effect of miR-146a on the Gene Expression of Immunoregulatory Cytokines in Human Mesenchymal Stromal Cells.
The effect of nimesulide, a selective cyclooxygenase-2 inhibitor, on Ets-1 and Ets-2 expression in head and neck cancer cell lines.
The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines.
The effect of perioperative analgesic drugs omnopon and dexketoprofen on the functional activity of immune cells in murine model of tumor surgery.
The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease.
The Effect of Rice Bran Extract on Arterial Blood Pressure, Hepatic Steatosis, and Inflammation in Mice Fed with a High-Fat Diet.
The effect of rutin on ovarian ischemia-reperfusion injury in a rat model.
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study.
The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.
The effect of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta and IL-6 on chorioamnion secretion of prostaglandins (PG)F 2 alpha and E2 in pigs.
The effect of tumor necrosis factor-alpha (TNF-alpha, interleukin (IL)-1beta and IL-6 on prostaglandins (PG)F2alpha and E2 secretion from maternal placenta in pigs.
The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer.
The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo.
The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production.
The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats.
The effects of Chamaecyparis obtusa essential oil on pain-related behavior and expression of pro-inflammatory cytokines in carrageenan-induced arthritis in rats.
The effects of curcumin on depressive-like behavior in mice after lipopolysaccharide administration.
The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.
The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer cells.
The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
The Effects of G2013 (?-L-guluronic Acid) in a Pentylenetetrazole-induced Kindling Animal Model of Epilepsy.
The effects of konjac oligosaccharide on TNBS-induced colitis in rats.
The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis.
The effects of Lepeophtheirus salmonis infections on the stress response and immunological status of Atlantic salmon (Salmo salar).
The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors.
The effects of piroxicam and deracoxib on canine mammary tumour cell line.
The effects of pre-B-cell colony-enhancing factor on the human fetal membranes by microarray analysis.
The Effects of Selenium in Acrylamide-Induced Nephrotoxicity in Rats: Roles of Oxidative Stress, Inflammation, Apoptosis, and DNA Damage.
The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells.
The effects of two new antagonists of secretory PLA2 on TNF, iNOS, and COX-2 expression in activated macrophages.
The ehrlich tumor induces pain-like behavior in mice: a novel model of cancer pain for pathophysiological studies and pharmacological screening.
The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model.
The emerging role of COX-2, 15-LOX, and PPAR? in metabolic diseases and cancer: An introduction to novel multi-target directed ligands (MTDLs).
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2.
The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors.
The EP4 antagonist, L-161,982, induces apoptosis, cell cycle arrest and inhibits prostaglandin E2 induced proliferation in oral squamous carcinoma Tca8113 cells.
The epidermal growth factor receptor increases cytokine production and cutaneous inflammation in response to ultraviolet irradiation.
The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidoacrylate, and methyl-2-acetamidoacrylate, exhibit anti-inflammatory properties in vivo and/or in vitro.
The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment.
The expression of cyclooxygenase in transitional cell carcinoma cell lines: its correlation with tumor differentiation, invasiveness and prostanoids production.
The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma.
The expression of cyclooxygenase-2 in cervical cancers and Hela cells was regulated by estrogen/progestogen.
The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
The expression of immune-regulatory genes in rainbow trout, Oncorhynchus mykiss, during a natural outbreak of proliferative kidney disease (PKD).
The expression of immune-regulatory genes in rainbow trout, Oncorhynchus mykiss, during amoebic gill disease (AGD).
The expression profile and bioinformatics analysis of microRNAs in human bronchial epithelial cells treated by beryllium sulfate.
The extracellular role of Ref-1 as anti-inflammatory function in lipopolysaccharide-induced septic mice.
The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation.
The flavonoid-enriched extract from the root of Smilax china L. inhibits inflammatory responses via the TLR-4-mediated signaling pathway.
The flavonoid-rich fraction from rhizomes of Smilax glabra Roxb. ameliorates renal oxidative stress and inflammation in uric acid nephropathy rats through promoting uric acid excretion.
The flavouring phytochemical 2-pentanone reduces prostaglandin production and COX-2 expression in colon cancer cells.
The function of the selective inhibitors of cyclooxygenase 2.
The functional -765G?C polymorphism of the COX-2 gene may reduce the risk of developing crohn's disease.
The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.
The G protein-coupled oestrogen receptor, GPER1, mediates direct anti-inflammatory effects of oestrogens in human cholinergic neurones from the nucleus basalis of Meynert.
The GPR55 antagonist CID16020046 protects against intestinal inflammation.
The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1.
The guggul for chronic diseases: ancient medicine, modern targets.
The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression.
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.
The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2.
The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
The Immunomodulatory Activities of Picria Fel-Terrae Lour Herbs towards RAW 264.7 Cells.
The impact of COX-2 on invasion of osteosarcoma cell and its mechanism of regulation.
The impact of cyclooxygenase-2 and vascular endothelial growth factor C immunoexpression on the prognosis of penile carcinoma.
The impact of damage-associated molecules released from canine tumor cells on gene expression in macrophages.
The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR-? Agonist.
The in vitro development of cytotoxicity in response to granulocyte/macrophage-colony-stimulating factor or interferon gamma in the peripheral blood monocytes of patients with solid tumors: modulation by arachidonic acid metabolic inhibitors.
The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli.
The induction of ornithine decarboxylase caused by 12-O-tetradecanoylphorbol-13-acetate in isolated epidermal cells is inhibited by lipoxygenase inhibitors but not by cyclooxygenase inhibitors.
The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models.
The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition.
The influence of arachidonic acid metabolites on cell division in the intestinal epithelium and in colonic tumors.
The influence of Cox-2 and bioactive lipids on hematological cancers.
The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines.
The influence of transforming growth factor-?, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer.
The inhibitory effect of Gleditsia sinensis on cyclooxygenase-2 expression in human esophageal squamous cell carcinoma.
The inhibitory effect of vitamin E on pulmonary polyamine biosynthesis, cell proliferation and carcinogenesis in mice.
The interaction between the Wnt/?-catenin signaling cascade and PKG activation in cancer.
The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer.
The investigation of the protective effects of nimesulide on experimental testicular ischemia-reperfusion injury in rats.
The invisible arm of immunity in common cancer chemoprevention agents.
The involvement of nuclear factor-kappa B in cyclooxygenase-2 overexpression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene.
The liver X receptor agonist TO901317 protects mice against cisplatin-induced kidney injury.
The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro.
The malignant phenotype of breast cancer cells is reduced by COX-2 silencing.
The medicinal chemistry implications of the anticancer effects of aspirin and other NSAIDs.
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
The Mixture of Anemarrhena asphodeloides and Coptis chinensis Attenuates High-Fat Diet-Induced Colitis in Mice.
The Modulating Effect of Ursodeoxycholic Acid on Liver Tissue Cyclooxygenase-2 Expression Following Extended Hepatectomy.
The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.
The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.
The mRNA overexpression of inflammatory enzymes, phospholipase A2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone.
The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2.
The Neoflavonoid Latifolin Isolated from MeOH Extract of Dalbergia odorifera Attenuates Inflammatory Responses by Inhibiting NF-?B Activation via Nrf2-Mediated Heme Oxygenase-1 Expression.
The Neuroprotective Effect of Astaxanthin on Pilocarpine-Induced Status Epilepticus in Rats.
The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-?B pathway.
The nonsteroidal anti-inflammatory drug indomethacin activates the eIF2alpha kinase PKR, causing a translational block in human colorectal cancer cells.
The novel IGF-IR/Akt-dependent anticancer activities of glucosamine.
The novel N-methyl-d-aspartate receptor antagonist MN-08 ameliorates lipopolysaccharide-induced acute lung injury in mice.
The Novel Nutraceutical KJS018A Prevents Hepatocarcinogenesis Promoted by Inflammation.
The overexpression of cyclo-oxygenase-2 in chronic periodontitis.
The p38 MAPK inhibitor JLU1124 inhibits the inflammatory response induced by lipopolysaccharide through the MAPK-NF-?B pathway in RAW264.7 macrophages.
The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid.
The possible ameliorative effect of simvastatin versus sulfasalazine on acetic acid induced ulcerative colitis in adult rats.
The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A.
The potential and rationale for COX-2 inhibitors in lung cancer.
The potential curative effect of rebamipide in hepatic ischemia/reperfusion injury.
The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
The potential role of COX-2 in cancer stem cell mediated canine mammary tumor initiation: an immunohistochemical study.
The potential role of COX-2 in cancer stem cell-mediated canine mammary tumor initiation: an immunohistochemical study.
The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?
The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients.
The preventive effect of ellagic acid on brain damage in rats via regulating of Nrf-2, NF-kB and apoptotic pathway.
The preventive effect of linalool on acute and chronic UVB-mediated skin carcinogenesis in Swiss albino mice.
The preventive effects of aspirin on preeclampsia based on network pharmacology and bioinformatics.
The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy.
The preventive role of breadfruit against inflammation-associated epithelial carcinogenesis in mice.
The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: Convergence with the anti-apoptotic effect of thyroid hormone.
The probiotic mixture IRT5 ameliorates age-dependent colitis in rats.
The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer.
The prognostic roles of cyclooxygenase-2 for patients with basal cell carcinoma.
The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer.
The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma.
The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers.
The prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/ COX2) rs5277 polymorphism does not influence risk of colorectal cancer in an Iranian population.
The protective effect of Ellagic acid (EA) in osteoarthritis: An in vitro and in vivo study.
The protective effect of hesperetin in osteoarthritis: an in vitro and in vivo study.
The Protective Effect of Magnolol in Osteoarthritis: In vitro and in vivo Studies.
The Protective Effect of Polygonum cuspidatum (PCE) Aqueous Extract in a Dry Eye Model.
The protective effects of Aquilariae Lignum Resinatum extract on 5-Fuorouracil-induced intestinal mucositis in mice.
The Protective Role of Carbon Monoxide (CO) Produced by Heme Oxygenases and Derived from the CO-Releasing Molecule CORM-2 in the Pathogenesis of Stress-Induced Gastric Lesions: Evidence for Non-Involvement of Nitric Oxide (NO).
The protective role of etoricoxib against diethylnitrosamine/2-acetylaminofluorene-induced hepatocarcinogenesis in Wistar rats: The impact of NF-?B/COX-2/PGE2 signaling.
The protective role of selenium against cadmium-induced hepatotoxicity in laying hens: Expression of Hsps and inflammation-related genes and modulation of elements homeostasis.
The Protective Roles of Butein on Indomethacin Induced Gastric Ulcer in Mice.
The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells.
The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer.
The relationship between cyclooxygenase-2 expression and colorectal cancer.
The relationship between HPV16 and expression of cyclooxygenase-2, P53 and their prognostic roles in esophageal squamous cell carcinoma.
The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer.
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder.
The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors.
The renal medullary thick ascending limb as a model for understanding lipid mediators in sepsis.
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
The rigid steroid 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) is a dissociated glucocorticoid receptor modulator potentially useful as a novel coadjuvant in breast cancer chemotherapy.
The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review.
The role of adiponectin in endothelial dysfunction and hypertension.
The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer.
The role of aspirin in colorectal cancer chemoprevention.
The role of bile acids in cellular invasiveness of gastric cancer.
The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.
The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
The role of COX-2 in intestinal cancer.
The role of COX-2 in intestinal inflammation and colorectal cancer.
The role of COX-2 in mediating the effect of PTEN on BMP9 induced osteogenic differentiation in mouse embryonic fibroblasts.
The role of COX-2 in rectal cancer treated with preoperative radiotherapy.
The role of COX-2 inhibition in breast cancer treatment and prevention.
The role of COX-2 inhibitors in lung cancer.
The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer.
The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease.
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
The role of cyclooxygenase and lipoxygenase in cancer chemoprevention.
The role of cyclooxygenase inhibitors in cancer prevention.
The role of cyclooxygenase products in lung injury induced by tumor necrosis factor in sheep.
The role of cyclooxygenase-2 and inflammatory cytokines in pain induction of herniated lumbar intervertebral disc.
The role of cyclooxygenase-2 and prostaglandins in colon cancer.
The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
The role of cyclooxygenase-2 in prostate cancer.
The role of cyclooxygenases in inflammation, cancer, and development.
The Role of Eicosanoids in Gynecological Malignancies.
The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma.
The role of immunohistochemistry expression of COX-2 in differentiating pigmented benign and malignant skin neoplasms.
The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
The role of inflammation in bladder cancer.
The role of inflammation in colon cancer.
The role of NSAIDs in colon cancer prevention.
The role of nutrition and chemoprevention in colorectal cancer: from observations to expectations.
The role of nutritional lipids and antioxidants in UV-induced skin cancer.
The role of PGE2-associated inflammatory responses in gastric cancer development.
The role of platelet cyclooxygenase and lipoxygenase pathways in tumor cell induced platelet aggregation.
The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer.
The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy.
The role of prostaglandins and other eicosanoids in the gastrointestinal tract.
The Role of Prostaglandins in Different Types of Cancer.
The role of selective COX-2 inhibitors in reactive oxygen species formation in osteosarcoma cells after X-ray irradiation.
The role of Syk/I?B-?/NF-?B pathway activation in the reversal effect of BAY 61-3606, a selective Syk inhibitor, on hypotension and inflammation in a rat model of zymosan-induced non-septic shock.
The role of the EP receptors for prostaglandin E2 in skin and skin cancer.
The Role of the Mediators of Inflammation in Cancer Development.
The role of thiamine in cancer: possible genetic and cellular signaling mechanisms.
The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide.
The selective 5-LOX inhibitor 11-keto-?-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades.
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis.
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.
The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.
The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxcil™) exerts anti-tumour effects in-vitro independent of cyclooxygenase-2 expression levels.
The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2.
The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma.
The Simultaneous Expression of Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 May Enhance Angiogenesis and Tumor Venous Invasion in Tissues of Colorectal Cancers.
The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.
The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha.
The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself.
The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
The study of endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms.
The suppressive effects of metformin on inflammatory response of otitis media model in human middle ear epithelial cells.
The synergetic effect of edaravone and borneol in the rat model of ischemic stroke.
The Targets of Curcumin.
The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas.
The therapeutic activity of curcumin through its anti-cancer potential on oral squamous cell carcinoma: A study on Sprague Dawley rat.
The therapeutic effects of Periploca forrestii Schltr. Stem extracts on collagen-induced arthritis by inhibiting the activation of Src/NF-?B signaling pathway in rats.
The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.
The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.
The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.
The Tpl2 Kinase Regulates the COX-2/Prostaglandin E2 Axis in Adipocytes in Inflammatory Conditions.
The transcription factor c-Fos coordinates with histone lysine-specific demethylase 2A to activate the expression of cyclooxygenase-2.
The transcription factor C/EBPbeta is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts.
The transcription factor Snail expressed in cutaneous squamous cell carcinoma induces epithelial-mesenchymal transition and down-regulates COX-2.
The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.
The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs.
The Underlying Molecular Mechanisms Involved in Traditional Chinese Medicine Smilax china L. for the Treatment of Pelvic Inflammatory Disease.
The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma.
The use of Cox-2 and PPAR? signaling in anti-cancer therapies.
The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers.
The use of diclofenac sodium in urological practice: A structural and neurochemical based review.
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
The use of nimesulide and its analogues in cancer chemoprevention.
The value of MG7-Ag and COX-2 for predicting malignancy in gastric precancerous lesions.
Therapeutic effect of berberine on chronic atrophic gastritis based on plasma and urine metabolisms.
Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice.
Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis.
Therapeutic Effects of
Therapeutic effects of Qian-Yu decoction and its three extracts on carrageenan-induced chronic prostatitis/chronic pelvic pain syndrome in rats.
Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis.
Therapeutic efficacy of zingerone against vancomycin-induced oxidative stress, inflammation, apoptosis and aquaporin 1 permeability in rat kidney.
Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism.
Therapeutic perspective of thiosemicarbazones derivatives in inflammatory pathologies: A summary of in vitro/in vivo studies.
Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma.
Therapeutic potential of monoacylglycerol lipase inhibitors.
Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.
Therapeutic role of telmisartan against acetaminophen hepatotoxicity in mice.
Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation.
Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma.
Therapeutical effects of vaccine from Trypanosoma cruzi amastigote surface protein 2 by simultaneous inoculation with live parasites.
Therapy with interleukin-22 alleviates hepatic injury and hemostasis dysregulation in rat model of acute liver failure.
Thioredoxin-interacting protein-derived peptide (TN13) inhibits LPS-induced inflammation by inhibiting p38 MAPK signaling.
Three Novel Alkaloids from Portulaca oleracea L. and Their Anti-inflammatory Effects.
Three-dimensional structure of human cyclooxygenase (hCOX)-1.
Threshold dose of liver tumor promoting effect of ?-naphthoflavone in rats.
Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways.
Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo.
Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment.
Thrombomodulin Influences the Survival of Patients with Non-Metastatic Colorectal Cancer through Epithelial-To-Mesenchymal Transition (EMT).
Thromboxane Inhibitors Attenuate Inflammatory and Fibrotic Changes in Rat Liver Despite Continued Ethanol Administrations.
Thromboxane production by platelets during tumor cell-induced platelet activation.
Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation.
Thymoquinone therapy abrogates toxic effect of cadmium on rat testes.
Thymoquinone: An IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities.
Thyroid Cancer and Nonsteroidal Anti-Inflammatory Drug Use: A Pooled Analysis of Patients Older Than 40 Years of Age.
Thyroid hormone-induced expression of inflammatory cytokines interfere with resveratrol-induced anti-proliferation of oral cancer cells.
TI-I-174, a Synthetic Chalcone Derivative, Suppresses Nitric Oxide Production in Murine Macrophages via Heme Oxygenase-1 Induction and Inhibition of AP-1.
Tilapia hepcidin 2-3 peptide modulates lipopolysaccharide-induced cytokines and inhibits tumor necrosis factor-alpha through cyclooxygenase-2 and phosphodiesterase 4D.
Time dependent neuroprotection of dexamethasone in experimental focal cerebral ischemia: the involvement of NF-?B pathways.
Time-dependent mRNA expression of selected pro-inflammatory factors in the endometrium of primiparous cows postpartum.
Timosaponin AIII inhibits melanoma cell migration by suppressing COX-2 and in vivo tumor metastasis.
Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Tissue biomarkers as prognostic variables of cervical cancer.
Tissue inhibitor of metalloproteinases in oral squamous cell carcinomas - a therapeutic target?
Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?
Tissue microarray study for classification of breast tumors.
Tissue tumor marker expression in smokers, including serum cotinine concentrations, in women with cervical intraepithelial neoplasia or normal squamous cervical epithelium.
TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells.
TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer.
TNF superfamily gene polymorphism as prognostic factor in early breast cancer.
TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE(2) production in cells of the myeloid lineage.
TNF-{alpha} potentiates lysophosphatidic acid-induced COX-2 expression via PKD in human colonic myofibroblasts.
TNF? up-regulates COX-2 in chronic progressive nephropathy through nuclear accumulation of RelB and NF-?B2.
TNF?-activated stromal COX-2 signalling promotes proliferative and invasive potential of colon cancer epithelial cells.
tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS).
To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor.
Tocotrienol Inhibits Secretion of Angiogenic Factors from Human Colorectal Adenocarcinoma Cells by Suppressing Hypoxia-Inducible Factor-1{alpha}
Tocotrienols: inflammation and cancer.
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression.
Toll-like receptor 2 mediates ischemia-reperfusion injury of the small intestine in adult mice.
Toll-like receptor 4 is involved in neuroprotection afforded by ischemic preconditioning.
Toll-like receptor 4 regulates gastric pit cell responses to Helicobacter pylori infection.
Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells.
Toll-like receptor-9 (TLR-9) deficiency alleviates optic nerve injury (ONI) by inhibiting inflammatory response in vivo and in vitro.
Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.
TOP1 and 2, polysaccharides from Taraxacum officinale, attenuate CCl(4)-induced hepatic damage through the modulation of NF-kappaB and its regulatory mediators.
Topical (+)-catechin emulsified gel prevents DMBA/TPA-induced squamous cell carcinoma of the skin by modulating antioxidants and inflammatory biomarkers in BALB/c mice.
Topical anti-inflammatory effects of isorhamnetin glycosides isolated from Opuntia ficus-indica.
Topical application of a bioadhesive black raspberry gel modulates gene expression and reduces cyclooxygenase 2 protein in human premalignant oral lesions.
Topical application of glycolic acid suppresses the UVB induced IL-6, IL-8, MCP-1 and COX-2 inflammation by modulating NF-?B signaling pathway in keratinocytes and mice skin.
Topical application with conjugated linoleic acid ameliorates 2, 4-dinitrofluorobenzene-induced atopic dermatitis-like lesions in BALB/c mice.
Total C-21 steroidal glycosides, isolated from the root tuber of Cynanchum auriculatum Royle ex Wight, attenuate hydrogen peroxide-induced oxidative injury and inflammation in L02 cells.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Towards aspirin-inspired self-immolating molecules which target the cyclooxygenases.
Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors.
Toxicological Effect of Manganese on NF-?B/iNOS-COX-2 Signaling Pathway in Chicken Testes.
Toxicological effects of thimerosal on rat kidney: a histological and biochemical study.
Tpl-2/cot and cox-2 in breast cancer.
Tpl2 is a key mediator of arsenite-induced signal transduction.
Trace amounts of antibiotic exacerbated diarrhea and systemic inflammation of weaned pigs infected with a pathogenic Escherichia coli.
TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.
TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin.
TRAMP prostate tumor growth is slowed by walnut diets through altered IGF-1 levels, energy pathways, and cholesterol metabolism.
Trans-4,4'-dihydroxystilbene ameliorates cigarette smoke-induced progression of chronic obstructive pulmonary disease via inhibiting oxidative stress and inflammatory response.
Trans-chalcone added in topical formulation inhibits skin inflammation and oxidative stress in a model of ultraviolet B radiation skin damage in hairless mice.
Transcorneal Electrical Stimulation Inhibits Retinal Microglial Activation and Enhances Retinal Ganglion Cell Survival After Acute Ocular Hypertensive Injury.
Transcription, translation and secretion of interleukin 1 and tumor necrosis factor: effects of tebufelone, a dual cyclooxygenase/5-lipoxygenase inhibitor.
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response element-binding protein.
Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs.
Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues.
Transcriptional regulation of fatty acid cyclooxygenases-1 and -2.
Transcriptional regulation of mPGES1 in Cancer: an alternative approach to drug discovery?
Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells.
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2.
Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNFalpha- and IL-6-stimulated activation are not antagonized.
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.
Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression.
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.
Transgenic Panax ginseng inhibits the production of TNF-alpha, IL-6, and IL-8 as well as COX-2 expression in human mast cells.
Transitional Cell Carcinoma in Fishing Cats (Prionailurus viverrinus): Pathology and Expression of Cyclooxygenase-1, -2, and p53.
Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.
Transketolase-like protein 1 expression in recurrent oral squamous cell carcinoma after curative resection: a case report.
Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer.
Traumatic injury induces differential expression of cell death genes in organotypic brain slice cultures determined by complementary DNA array hybridization.
Treatment of actinic keratosis through inhibition of cyclooxygenase-2: Potential mechanism of action of diclofenac sodium 3% in hyaluronic acid 2.5.
Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007)*.
Treatment of gastric ulcers and diarrhea with the Amazonian herbal medicine sangre de grado.
Treatment of inflammatory bowel disease via green tea polyphenols: possible application and protective approaches.
Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.
Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.
Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.
Treatment with NADPH oxidase inhibitor apocynin alleviates diabetic neuropathic pain in rats.
TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer.
Triclosan reduces microsomal prostaglandin E synthase-1 expression in human gingival fibroblasts.
Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts.
Triggering of suicidal erythrocyte death by celecoxib.
Trigonelline protects hippocampus against intracerebral A?(1-40) as a model of Alzheimer's disease in the rat: insights into underlying mechanisms.
Trimethyltin-activated cyclooxygenase stimulates tumor necrosis factor-alpha release from glial cells through reactive oxygen species.
Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-?-treated A549 cells.
Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors.
Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts.
Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site.
Tristetraprolin binds to the COX-2 mRNA 3' untranslated region in cancer cells.
Triterpene glycosides from red ginseng marc and their anti-inflammatory activities.
Triticum aestivum Sprouts Extract Inhibits Azoymethane (AOM)/Dextran Sodium Sulfate (DSS)-Induced Colon Carcinogenesis in Mice.
Troxerutin suppresses the inflammatory response in advanced glycation end-product-administered chondrocytes and attenuates mouse osteoarthritis development.
Tryptanthrin exerts anti-breast cancer effects both in vitro and in vivo through modulating the inflammatory tumor microenvironment.
Tryptophan free diet delays healing of chronic gastric ulcers in rat.
Tualang Honey Reduced Neuroinflammation and Caspase-3 Activity in Rat Brain after Kainic Acid-Induced Status Epilepticus.
Tumor Acidosis and Hypoxia Differently Modulate the Inflammatory Program: Measurements In Vitro and In Vivo.
Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors.
Tumor Cell Invasion Induced by Radiation in Balb/C Mouse is Prevented by the Cox-2 Inhibitor NS-398.
Tumor cell proliferation and cyclooxygenase enzyme inhibitory compounds in Amaranthus tricolor.
Tumor cell proliferation and cyclooxygenase inhibitory constituents in horseradish (Armoracia rusticana) and Wasabi (Wasabia japonica).
Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1.
Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).
Tumor cells induce COX-2 and mPGES-1 expression in microvascular endothelial cells mainly by means of IL-1 receptor activation.
Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function.
Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma.
Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study.
Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression.
Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase.
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Tumor growth reduction is regulated at the gene level in Walker 256 tumor-bearing rats supplemented with fish oil rich in EPA and DHA.
Tumor Immune Microenvironment and Chemosensitivity Signature for Predicting Response to Chemotherapy in Gastric Cancer.
Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: mechanisms of enhancement using prostaglandin synthetase inhibitors.
Tumor initiation inhibition through inhibition COX-1 activity of a traditional Korean herbal prescription, Geiji-Bokryung-Hwan, in human hepatocarcinoma cells.
Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of "tumor-phlegm microenvironment".
Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.
Tumor markers in ovarian carcinoma.
Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts.
Tumor necrosis factor alpha and interleukin-1beta stimulate the expression of cyclooxygenase II but do not alter prostaglandin E2 receptor mRNA levels in cultured dorsal root ganglia cells.
Tumor necrosis factor alpha stimulates amnion prostaglandin biosynthesis primarily via an action on fatty acid cyclooxygenase.
Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages.
Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells.
Tumor necrosis factor-alpha induces renal cyclooxygenase-2 expression in response to hypercalcemia.
Tumor necrosis factor-alpha inversely regulates prostaglandin D2 and prostaglandin E2 production in murine macrophages. Synergistic action of cyclic AMP on cyclooxygenase-2 expression and prostaglandin E2 synthesis.
Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs.
Tumor necrosis factor-alpha upregulates the prostaglandin E2 EP1 receptor subtype and the cyclooxygenase-2 isoform in cultured amnion WISH cells.
Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in human tracheal smooth muscle cells: involvement of p42/p44 and p38 mitogen-activated protein kinases and nuclear factor-kappaB.
Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells.
Tumor necrosis factor-alpha-induced cyclooxygenase-2 overexpression in eutopic endometrium of women with endometriosis by stromal cell culture through nuclear factor-kappaB activation.
Tumor necrosis factor-induced mortality is reversed with cyclooxygenase inhibition.
Tumor promotion as a target of cancer prevention.
Tumor resistance mechanisms and their consequences on ?? T cell activation.
Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer.
Tumor-Associated Macrophage-Induced Invasion and Angiogenesis of Human Basal Cell Carcinoma Cells by Cyclooxygenase-2 Induction.
Tumor-Associated Macrophages in the Development of 4-Nitroquinoline-1-Oxide-Induced Tongue Squamous Cell Carcinoma in a Mouse Model.
Tumor-associated macrophages induce invasion and poor prognosis in human gastric cancer in a cyclooxygenase-2/MMP9-dependent manner.
Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation.
Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins.
Tumor-suppressive effect of retinoid receptor-induced gene-1 (RRIG1) in esophageal cancer.
Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression.
Tumour angiogenesis in Epstein-Barr virus-associated post-transplant smooth muscle tumours.
Tumour necrosis factor alpha mediates transient receptor potential vanilloid 1-dependent bilateral thermal hyperalgesia with distinct peripheral roles of interleukin-1beta, protein kinase C and cyclooxygenase-2 signalling.
Tumour necrosis factor-alpha regulation of prostaglandin H synthase-2 transcription is not through nuclear factor-kappaB in amnion-derived AV-3 cells.
Tumour necrosis factor-alpha stimulates increased expression of prostaglandin endoperoxide H synthase Type 2 mRNA in amnion-derived WISH cells.
Tumour necrosis factor-alpha-dependent regulation of prostaglandin endoperoxide synthase-2.
Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha.
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
Tunicamycin inhibits Toll-like receptor-activated inflammation in RAW264.7 cells by suppression of NF-?B and c-Jun activity via a mechanism that is independent of ER-stress and N-glycosylation.
Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-?B and FHC pathways.
Two new farnesyl phenolic compounds with anti-inflammatory activities from Ganoderma duripora.
Two novel anti-inflammatory 21-nordammarane saponins from tetraploid Jiaogulan ( Gynostemma pentaphyllum ).
Two Novel Compounds with Tri-aryl Structures as Effective Anti-Breast Cancer Candidates In-vivo.
Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways.
Tyrosine phosphatase-dependent/tyrosine kinase-independent induction of nuclear factor-kappa B by tumor necrosis factor-alpha: effects on prostaglandin endoperoxide synthase-2 mRNA accumulation.
Ultrasound Stimulation Suppresses LPS-Induced Proinflammatory Responses by Regulating NF-?B and CREB Activation in Microglial Cells.
Ultraviolet B(UVB)-induced cox-2 expression in murine skin: an immunohistochemical study.
Ultraviolet radiation-induced inflammation activates ?-catenin signaling in mouse skin and skin tumors.
Understanding the Interplay between COX-2 and hTERT in Colorectal Cancer Using a Multi-Omics Analysis.
Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer.
Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran.
Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells.
Up-regulation of cyclooxygenase-2 by cobalt chloride-induced hypoxia is mediated by phospholipase D isozymes in human astroglioma cells.
Up-regulation of cyclooxygenase-2 by interleukin-1beta in colon carcinoma cells.
Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase.
Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus.
Up-regulation of cyclooxygenase-2-derived prostaglandin E(2) in colon cancer cells resistant to 5-fluorouracil.
Up-regulation of HB-EGF by the COX-2/PGE2 signaling associates with the cisplatin resistance and tumor recurrence of advanced HNSCC.
Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation.
Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor.
Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
UP446, analgesic and anti-inflammatory botanical composition.
Update on COX-2 selective inhibitors: chemical classification, side effects and their use in cancers and neuronal diseases.
Update on nonsteriodal anti-inflammatory drugs.
Upregulation of COX-2 and PGE2 Induced by TNF-? Mediated Through TNFR1/MitoROS/PKC?/P38 MAPK, JNK1/2/FoxO1 Cascade in Human Cardiac Fibroblasts.
Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy.
Upregulation of cyclooxygenase-2 and thromboxane A2 production mediate the action of tumor necrosis factor-alpha in isolated rat myenteric ganglia.
Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells.
Upregulation of cyclooxygenase-2 is associated with activation of the alternative nuclear factor kappa B signaling pathway in colonic adenocarcinoma.
Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.
Upregulation of intrinsic apoptotic pathway in NSAIDs mediated chemoprevention of experimental lung carcinogenesis.
Upregulation of Mobility in Pancreatic Cancer Cells by Secreted S100A11 Through Activation of Surrounding Fibroblasts.
Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha.
Upregulation of the EP1 receptor for prostaglandin E(2) promotes skin tumor progression.
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2.
Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
Urban air pollution produces up-regulation of myocardial inflammatory genes and dark chocolate provides cardioprotection.
Ureteral Access Sheath Influence on the Ureteral Wall Evaluated by Cyclooxygenase-2 and Tumor Necrosis Factor-? in a Porcine Model.
Urolithin A targets the PI3K/Akt/NF-?B pathways and prevents IL-1?-induced inflammatory response in human osteoarthritis: in vitro and in vivo studies.
Uroprotective mechanism of quercetin against cyclophosphamide-induced urotoxicity: Effect on oxidative stress and inflammatory markers.
Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis.
Ursodeoxycholic acid and chemoprevention of colorectal cancer.
Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin.
Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer.
Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition.
Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.
Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice.
Ursolic acid ameliorates carbon tetrachloride-induced oxidative DNA damage and inflammation in mouse kidney by inhibiting the STAT3 and NF-?B activities.
Ursolic Acid Attenuates D-Galactose-Induced Inflammatory Response in Mouse Prefrontal Cortex through Inhibiting AGEs/RAGE/NF-{kappa}B Pathway Activation.
Ursolic acid enhances cyclooxygenases and tumor necrosis factor-alpha expression in mouse skin.
Ursolic acid inhibits the initiation, progression of prostate cancer and prolongs the survival of TRAMP mice by modulating pro-inflammatory pathways.
Ursolic acid isolated from the seed of Cornus officinalis ameliorates colitis in mice by inhibiting the binding of lipopolysaccharide to Toll-like receptor 4 on macrophages.
Ursolic acid protects chondrocytes, exhibits anti-inflammatory properties via regulation of the NF-?B/NLRP3 inflammasome pathway and ameliorates osteoarthritis.
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.
Use of quantitative real-time PCR to determine the local inflammatory response in the intestinal mucosa and muscularis of horses undergoing small intestinal resection.
Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Using chemopreventive agents to enhance the efficacy of cancer therapy.
Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.
USP8 protects against lipopolysaccharide-induced cognitive and motor deficits by modulating microglia phenotypes through TLR4/MyD88/NF-?B signaling pathway in mice.
Uterine involution and endometrial function in postpartum pony mares.
Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling.
Utility of Apc-mutant rats with a colitis-associated colon carcinogenesis model for chemoprevention studies.
Utilization of endoscopic inoculation in a mouse model of intrauterine infection-induced preterm birth: role of interleukin 1beta.
UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression.
UVB-induced interleukin-18 production is downregulated by tannic acids in human HaCaT keratinocytes.
Vaccinium bracteatum Thunb. Exerts Anti-Inflammatory Activity by Inhibiting NF-?B Activation in BV-2 Microglial Cells.
Validating potent anti-inflammatory and anti-rheumatoid properties of Drynaria quercifolia rhizome methanolic extract through in vitro, in vivo, in silico and GC-MS-based profiling.
Validation of a Multiplexed Gene Signature Assay for Diagnosis of Canine Cancers from Formalin-Fixed Paraffin-Embedded Tissues.
Validation of cyclooxygenase-2 as a direct anti-inflammatory target of 4-O-methylhonokiol in zymosan-induced animal models.
Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer.
Vanillic Acid, a Bioactive Phenolic Compound, Counteracts LPS-Induced Neurotoxicity by Regulating c-Jun N-Terminal Kinase in Mouse Brain.
Vanillin protects the blood-milk barrier and inhibits the inflammatory response in LPS-induced mastitis in mice.
Variances in the level of of COX-2 and iNOS in different grades of endometrial cancer.
Variation in cyclooxygenase expression levels within the colorectum.
Variation in Essential Oil and Bioactive Compounds of Curcuma kwangsiensis Collected from Natural Habitats.
Various In Vitro Bioactivities of Secondary Metabolites Isolated from the Sponge Hyrtios aff. Erectus from the Red Sea Coast of Egypt.
Vascular endothelial function is improved by oral glycine treatment in aged rats.
Vascular Endothelial Growth Factor and not Cyclooxygenase 2 Promotes Endothelial Cell Viability in the Pancreatic Tumor Microenvironment.
Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2.
Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.
Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells.
Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2.
Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma.
Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
VEGF-C and COX-2 expression in papillary thyroid cancer.
VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro.
Venestatin from parasitic helminths interferes with receptor for advanced glycation end products (RAGE)-mediated immune responses to promote larval migration.
Veronicastrum axillare Alleviates Lipopolysaccharide-Induced Acute Lung Injury via Suppression of Proinflammatory Mediators and Downregulation of the NF-?B Signaling Pathway.
Versican expression level in cumulus cells is associated with human oocyte developmental competence.
Vestibular Schwannoma Growth With Aspirin and Other Nonsteroidal Anti-inflammatory Drugs.
Viburnum pichinchense methanol extract exerts anti-inflammatory effects via targeting the NF-?B and caspase-11 non-canonical inflammasome pathways in macrophages.
Vinorelbine's anti-tumor actions may depend on the mitotic apoptosis, autophagy and inflammation: hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas.
Virtual Dual inhibition of COX-2 / 5-LOX enzymes based on binding properties of alpha-amyrins, the anti-inflammatory compound as a promising anti-cancer drug.
Virtual Screening for Finding Novel COX-2 Inhibitors as Antitumor Agents.
Vitamin C suppresses proliferation of the human melanoma cell SK-MEL-2 through the inhibition of cyclooxygenase-2 (COX-2) expression and the modulation of insulin-like growth factor II (IGF-II) production.
Vitamin D mitigates the adverse effects of obesity on breast cancer in mice.
Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of Mechanistic Studies and Future Directions for Epidemiological Studies.
Vitamin D, linoleic acid, arachidonic acid and COX-2 in colorectal cancer patients in relation to disease stage, tumour localisation and disease progression.
Vitamin E and breast cancer.
Vitamin E metabolite 13'-carboxychromanols inhibit pro-inflammatory enzymes, induce apoptosis and autophagy in human cancer cells by modulating sphingolipids and suppress colon tumor development in mice.
Vitex doniana Leaves Extract Ameliorates Alterations Associated with 7, 12-Dimethyl Benz[a]Anthracene-Induced Mammary Damage in Female Wistar Rats.
Vitex negundo and its medicinal value.
Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).
Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation.
Water extract of processed Hydrangea macrophylla (Thunb.) Ser. leaf attenuates the expression of pro-inflammatory mediators by suppressing Akt-mediated NF-?B activation.
Water Soluble Antioxidative Crude Polysaccharide From Russula senecis Elicits TLR Modulated NF-?B Signaling Pathway and Pro-inflammatory Response in Murine Macrophages.
Water-separated part of Chloranthus serratus alleviates lipopolysaccharide- induced RAW264.7 cell injury mainly by regulating the MAPK and Nrf2/HO-1 inflammatory pathways.
Water-Soluble Arginyl-Diosgenin Analog Attenuates Hippocampal Neurogenesis Impairment Through Blocking Microglial Activation Underlying NF-?B and JNK MAPK Signaling in Adult Mice Challenged by LPS.
Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01).
What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?
What's New in the Field of Prostate Cancer Chemoprevention?
What's new in the field of prostate cancer chemoprevention?
Wheat Bran Extract Regulates Mast Cell-Mediated Allergic Responses In Vitro and In Vivo.
Wheatgrass inhibits the lipopolysaccharide-stimulated inflammatory effect in RAW 264.7 macrophages.
Why cyclooxygenase-2 inhibition plus chemotherapy?
Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS.
Wild Bitter Melon Leaf Extract Inhibits Porphyromonas gingivalis-Induced Inflammation: Identification of Active Compounds through Bioassay-Guided Isolation.
Wine polyphenols exert antineoplasic effect on androgen resistant PC-3 cell line through the inhibition of the transcriptional activity of COX-2 promoter mediated by NF-k?.
Withaferin A Inhibits Nuclear Factor-?B-Dependent Pro-Inflammatory and Stress Response Pathways in the Astrocytes.
Withaferin A Protects Against High-Fat Diet-Induced Obesity Via Attenuation of Oxidative Stress, Inflammation, and Insulin Resistance.
Withanolide sulfoxide from Aswagandha roots inhibits nuclear transcription factor-kappa-B, cyclooxygenase and tumor cell proliferation.
Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression.
Wogonin Inhibits LPS-Induced Inflammatory Responses in Rat Dorsal Root Ganglion Neurons Via Inhibiting TLR4-MyD88-TAK1-Mediated NF-?B and MAPK Signaling Pathway.
Wogonin, a bioactive flavonoid in herbal tea, inhibits inflammatory cyclooxygenase-2 gene expression in human lung epithelial cancer cells.
Wogonoside inhibits inflammatory cytokine production in lipopolysaccharide-stimulated macrophage by suppressing the activation of the JNK/c-Jun signaling pathway.
Wound healing activity of neferine in experimental diabetic rats through the inhibition of inflammatory cytokines and nrf-2 pathway.
Xanthohumol suppresses inflammation in chondrocytes and ameliorates osteoarthritis in mice.
Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor-kappa B.
Xanthorrhizol, a natural sesquiterpenoid, induces apoptosis and growth arrest in HCT116 human colon cancer cells.
Xanthotoxol exerts neuroprotective effects via suppression of the inflammatory response in a rat model of focal cerebral ischemia.
Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde.
XIST accelerates neuropathic pain progression through regulation of miR-150 and ZEB1 in CCI rat models.
XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers.
YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis.
YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer.
Yin Yang 1 enhances cyclooxygenase-2 gene expression in macrophages.
Young Yum pill inhibits inflammatory mediators and nuclear factor-kappa B signaling in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Zafirlukast in combination with pseudohypericin attenuates spinal cord injury and motor function in experimental mice.
Zaltoprofen prevents carbon tetrachloride-induced reduction of body weight in rats.
Zeaxanthin exerts protective effects on acetic acid-induced colitis in rats via modulation of pro-inflammatory cytokines and oxidative stress.
Zerumbone Protects against Carbon Tetrachloride (CCl4)-Induced Acute Liver Injury in Mice via Inhibiting Oxidative Stress and the Inflammatory Response: Involving the TLR4/NF-?B/COX-2 Pathway.
Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha,beta-unsaturated carbonyl group is a prerequisite.
Zinc and iron complexes of oleanolic acid, (OA) attenuate allergic airway inflammation in rats.
Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression.
Zinc inhibited LPS-induced inflammatory responses by upregulating A20 expression in microglia BV2 cells.
Zinc supplementation suppresses 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis.
Zingerone attenuates vancomycin-induced hepatotoxicity in rats through regulation of oxidative stress, inflammation and apoptosis.
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.
ZPDC glycoprotein inhibits inflammation-related cytokine and protein via nuclear factor-kappa B in dextran sulfate sodium-stimulated ICR mouse.
Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression.
[(123)I]Iodooctyl fenbufen amide as a SPECT tracer for imaging tumors that over-express COX enzymes.
[6]-Gingerol impedes 7,12-dimethylbenz(a)anthracene-induced inflammation and cell proliferation-associated hamster buccal pouch carcinogenesis through modulating Nrf2 signaling events.
[6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol ester-stimulated mouse skin.
[A Case of Complete Regression of Hepatocellular Carcinoma during Administration of COX-2 Inhibitor.]
[A case of desmoid tumor and advanced sigmoid colon cancer with liver metastasis in familial adenomatous polyposis (FAP)].
[A case of favorable response after combination treatment with interferon-? and cyclooxygenase-2 inhibitor against metastatic renal cell carcinoma].
[A Case of Pelvic Desmoid-Type Fibromatosis Treated by Radiation and Medication Therapies].
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]
[A new drug approach approved in the USA. Cox-2 inhibitor in intestinal cancer]
[A relationship between cyclooxygenase-2 expression and tumor angiogenesis in experimental rat liver carcinogenesis.]
[Advance in studies on anti-cancer activity and mechanism of flavonoids].
[Aldo-keto reductase 1 member B1 (AKR1B1) inhibits retinal ganglion cell activity via activating NF-?B pathway and inducing mouse BV-2 microglia activation].
[Amentoflavone inhibits inflammation of mouse BV-2 microglia cells induced by lipopolysaccharide].
[Analysis of HIF-1? and COX-2 expression in tumor stroma and correlation with the degree of neoplasm invasiveness in laryngeal cancer--preliminary study].
[Angiopoietin-2 regulates vessels encapsulated by tumor clusters positive hepatocellular carcinoma nest-type metastasis via integrin ?5?1].
[Anti-cancer treatment with prostaglandin synthetase inhibitor in animal models]
[Antisense inhibition of cyclooxygenase-2 reduces malignant phenotype of gastric cancer cells]
[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
[Arachidonic acid and prostaglandins, inflammation and oncology]
[Barrett's esophageal adenocarcinoma]
[Bioinformatic analysis of direct protein targets of aspirin against human breast cancer proliferation].
[Biological effect of endostatin on transplanted human lung adenocarcinoma Calu-6 tumor in nude mice]
[Biological functions of cyclooxygenase 2: control of its expression and activity]
[Case of villous tumor of the rectum presenting with severe diarrhea and electrolyte depletion syndrome]
[Chemo-preventive effect of Angelica sinensis' supercritical extracts on AOM/DSS-induced mouse colorectal carcinoma associated with inflammation].
[Chemoprevention of familial cancer]
[Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats]
[Clinicopathologic significance of cyclooxygenase-2 mRNA expression in human breast carcinoma]
[Compound K suppresses myeloid-derived suppressor cells in a mouse model bearing CT26 colorectal cancer xenograft].
[Correlation between Stat3 signal transduction pathway and expression of cyclooxygenase-2 in colorectal cancer cells]
[Correlation of cyclooxygenase 2 expression with microlymphatic density and its clinical significance]
[Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma]
[Correlation of time-density curve of CT enhancement with angiogenesis in lung cancer.]
[COX and study of cancer therapy]
[COX inhibitor, suppression of polyposis, and chemoprevention]
[COX- 2 expression in gastric cancer and its relationship with lymphangiogenesis and lymph node metastasis]
[Cox-2 and CD105 expression in breast cancer and disease-free survival.]
[COX-2 as an early diagnostic marker of virus-associated human malignant neoplasms].
[COX-2 expression and ovarian cancer]
[COX-2 inhibitor and colon cancer]
[COX-2 inhibitors in cancer prevention]
[COX-2 inhibitors in inflammatory bowel disease: friends or foes?]
[Coxibs for postoperative analgesia].
[Crystal-induced activation of the inflammasome: gout and pseudogout.]
[Current topics in the regulation of prostanoids--2. The interaction with cytokines and nitric oxide]
[Cyclo-oxygenase-2 and p53 immunoreactivity in superficial early colorectal carcinoma]
[Cyclooxygenase 2 and colorectal cancer: therapeutic implications]
[Cyclooxygenase 2 inhibitors and cancer chemoprevention]
[Cyclooxygenase 2 inhibitors and colorectal cancer]
[Cyclooxygenase 2 inhibitors and urologic and gynaecologic cancers]
[Cyclooxygenase inhibitors in chemoprevention and treatment of esophageal squamous cell carcinoma]
[Cyclooxygenase inhibitors]
[Cyclooxygenase-2 (COX-2) in digestive cancer. Therapeutic implications]
[Cyclooxygenase-2 expression as a prognostic factor in sporadic colorectal cancer]
[Cyclooxygenase-2 expression in female pulmonary adenocarcinoma.]
[Cyclooxygenase-2 inhibitors and cancer prevention]
[Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications]
[Cyclooxygenases in the skin]
[Cyclooxygenases]
[Detection of EGFR and COX-2 expression by immunohistochemical method on a tissue microarray section in lung cancer and biological significance]
[Detection of expression of p53, p16, and cyclooxygenase 2 in pancreatic cancer by tissue microarray and correlation among these three genes]
[Dual role of daphnetin in suppressing HMGB1 release and HMGB1-induced inflammation in murine macrophage RAW264.7 cells and human monocytic THP-1 cells in vitro].
[Ease-2 and inducible nitric oxide synthase in tongue hyperplasia and tongue squamous cell carcinoma]
[Effect of anti-HPV16 E6-ribozyme on cell proliferation and invasiveness of cervical carcinoma cell line CaSKi.]
[Effect of As(2)O(3) on Expressions of COX-2 and Matrix Metalloproteinases in SGC7901 and K562 Cells.]
[Effect of cyclooxygenase-2,and matrix metalloproteinase-2 expression on prognosis of lung cancer]
[Effect of lysine clonixinate and indomethacin on lipoxygenase and cyclooxygenase activity in colon isolated from cancer patients]
[Effect of nonsteroidal antiinflammatory drugs on colonic lipoxygenase and cyclooxygenase activities from patients with colonic neoplasia]
[Effect of selective cyclooxygenase-2 inhibitor celebrex on expression of vascular endothelial growth factor (VEGF) in pancreatic carcinoma]
[Effects of apple polyphenols on monocrotaline-induced pulmonary vascular remodeling in rats and its mechanism].
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellar carcinoma].
[Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis]
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]
[Effects of inhibition of cyclooxygenase-2 by RNA interference on proliferation and apoptosis of human gastric cancer cells: an experimental study with human gastric cancer cells and mice]
[Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]
[Effects of propyl gallate on serum inflammatory factors and protein expression of COX-2 and ICAM-1 in ischemic myocardium of rats with acute myocardial infarction]
[Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors]
[Expression and clinical significance of Cox-2 and XIAP in malignant tumors of the salivary gland].
[Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma]
[Expression and clinical significance of cyclooxygenase-2 in medulloblastoma]
[Expression and clinical significance of cyclooxygenase-2 in nasal and paranasal sinus carcinoma]
[Expression and clinical significance of hypoxia-inducible factor-1alpha and cyclooxygenase-2 in laryngeal squamous cell carcinoma]
[Expression and function of E prostanoid receptors in urological cancer].
[Expression and implication of cyclooxygenase-2 mRNA in prostate cancer]
[Expression and prognostic significance of cyclooxygenase-2 in supraglottic laryngeal squamous cell carcinomas]
[Expression and prognostic value of COX- 2, p16(INK4A) and p53 in patients with classical Hodgkin lymphoma].
[Expression and significance of cyclooxygenase-2 in human pancreatic carcinomas]
[Expression of CD44v6 and COX-2 in pleomorphic adenomas and carcinomas of parotid gland].
[Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance]
[Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]
[Expression of COX-2 and VEGF-C in squamous cell carcinoma of the tongue and its correlation to lymph node metastasis]
[Expression of COX-2 protein in colorectal carcinoma and the clinical implication]
[Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors]
[Expression of cyclooxygenase in bladder transitional cell carcinoma]
[Expression of cyclooxygenase-2 and vascular endothelial growth factor in human prostate cancer and its significance]
[Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof]
[Expression of cyclooxygenase-2 in esophageal squamous cell carcinogenesis]
[Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas]
[Expression of hypoxia-inducible factor 1? in osteosarcoma and its value in predicting chemosensitivity].
[Expression of p53, p21, PCNA and COX-2 and its relationship with recurrence in the early-stage laryngeal cancer with negative surgical margin].
[Expression of the cyclooxygenase-2 gene in human breast carcinoma]
[Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance.]
[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]
[Expressions of cyclooxygenase-2 and basic fibroblast growth factor in nasopharyngeal carcinoma and their association with radiotherapy sensitivity].
[Expressions of cyclooxygenase-2 and cholecystokinin-B receptor mRNA in human colorectal cancer and their significances]
[Expressions of cyclooxygenase-2 and vascular endothelial growth factor in human lung cancer tissue.]
[Expressions of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma and their correlation]
[Flow cytometric quantitative analysis of multiple tumor suppressor gene 1 (MTS1) and cyclooxygenase-2 (COX-2) gene expressions in invasive breast cancers and their clinical significance]
[Formula: see text], a Rare Protopanaxatriol-Type Ginsenoside Fraction from Black Ginseng, Suppresses Inflammatory Gene iNOS via the Iinhibition of p-STAT-1 and NF-[Formula: see text]B.
[Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing].
[Gastric carcinoma and chronic gastritis: epigenetic regulation of CDH1 (E-Cadherin), CDKN2A (p16INK4A), PTGS2 (COX-2) and EGFR genes through methylation]
[Genetic abnormalities of digestive tract adenocarcinomas and correlation with the histologic sequence of their development]
[Growth inhibition of NS-398 combined with cisplatin on human lung adenocarcinoma cells and its mechanism.]
[Histone H3 acetylation of tumor necrosis factor-alpha and cyclooxygenase-2 in patients with type 2 diabetes].
[Hormones and auto-paracrine tumor growth regulators in osteogenic sarcoma]
[Hormones, autocrine and paracrine regulators of tumor growth in osteosarcoma]
[In vitro investigation on the mechanism of cyclooxygenase-2 upregulation induced by spleen tyrosine kinase-nuclear factor ?B signaling in cancer pain caused by oral cancer-associated macrophage].
[Influence of selective cyclooxygenase-2 inhibitor on proliferation of human gastric cancer cells]
[Inhibiting cerebral glioma growth with continuous low-dose chemotherapy and cyclooxygenase-2 inhibitor in nude mice]
[Inhibition of demethylation of protein phosphatase 2A catalytic subunit (PP2Ac) promotes M1 polarization of macrophages].
[Inhibition of the growth of a murine transplantable tumor, colon 26, by the prostaglandin synthetase inhibitor, indomethacin]
[Inhibitory effect of nimesulide and oxaliplatin on tumor growth and lymphatic metastasis of transplanted human lung cancer in nude mice].
[Inhibitory effect of NS398 on the proliferation of human ovarian cancer cell lines CAOV3 and OVCAR3 in vitro]
[Inhibitory effects of Aspisol on growth of transplanted breast cancer in C3H mice]
[Inhibitory effects of celecoxib combined with octreotide on growth of multidrug resistant human gastric cancer cell line SGC7901/ADR.]
[Inhibitory Effects of Cyclooxygenase-2 Inhibitor Celecoxib on Growth and Angiogenesis of Human Liver Cancer HepG2 Cell Xenografts in Small Nude Mice.]
[Is there a future for COX-2 inhibitors?]
[Markers for non-invasive molecular genetic diagnosis of oncourological diseases].
[Mechanism of Danggui Sini Decoction in treatment of primary dysmenorrhea based on network pharmacology and molecular docking].
[MiR-26b inhibits proliferation, invasion, and migration of glioma by targeting cyclooxygenase-2].
[Neoadiuvant teleradiotherapy decreases cancer tissue and serum concentration of prostaglandin E2 and cyclooxygenase-2 expression in patients with rectal cancer].
[NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]
[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]
[Non-steroidal anti-inflammatory drugs and chemoprevention of digestive cancer]
[Non-steroidal anti-inflammatory drugs and intestinal side effects]
[NS398 induced apoptosis in pancreatic carcinoma cell strain BxPC-3 through a COX-2-in dependent pathway]
[NSAIDs caused gastric mucosal injury: with a special reference to COX-2]
[Osteosarcoma: biochemical and endocrinological studies as a basis for its pathogenetic treatments]
[Overexpression of COX-2 and its clinical significance in non-small cell lung cancer]
[p53, p16 E COX-2 expression in esophageal squamous cell carcinoma and histopathological association]
[PPARgamma-gene therapy using an adenovirus vector for inflammatory bowel disease]
[Preventive effects of berberine on experimental colon cancer and relationship with cyclooxygenase-2 expression].
[Prognostic and Predictive Factors for Pancreatic Adenocarcinoma].
[Prognostic significance of cyclooxygenase (COX-1 and COX-2) expression in endometrial carcinoma (clinical and immunohistochemical study)]
[Prostaglandin E2 synthases]
[Prostate carcinoma: higher COX-2 contents in advanced tumors]
[Protective effects of curcumin on neonatal rats with necrotizing enterocolitis]
[Protein expression and clinical significance of cyclooxygenase 2 and nuclear factor kappa B in gastric mucosa-associated lymphoid tissue lymphoma.]
[Relation between COX-2 protein expression and biologic behavior of ovarian carcinoma]
[Relationship between cyclooxygenase (COX)-2 and malignant tumors]
[Relationship between cyclooxygenase- 2 expression and angiogenesis in patients with gastric cancer]
[Relationship between cyclooxygenase-2 protein expression, prostaglandins levels and biologic behavior in ovarian carcinoma tissue]
[Relationship between the expression of cyclooxygenase-2 and microvessel density in oral squamnous cell carcinoma]
[Relationship between the gene polymorphisms of oxidative metabolism enzyme of exogenous chemicals and the susceptibility to neoplasms].
[Relationship of cyclooxygenase-2 and multidrug resistance associated factors to chemosensitivities in gastrointestinal carcinomas]
[Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities]
[Role and mechanism of cAMP/Ca 2+ signal pathway in differentiation of bone marrow mesenchymal stem cells into neuronal cells induced by salidroside].
[Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases]
[Role of immunohistochemical study of extracellular matrix components in the estimation of the malignant potential of adrenal pheochromocytomas]
[Selective cyclooxygenase-2 inhibitors and the digestive tract]
[Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior]
[Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma]
[Study of COX-2 expression and angiogenesis in non-small cell lung cancer.]
[Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction].
[Study on the effect of COX-2's selective inhibitor on human colorectal adenoma cells proliferation]
[Suppression of COX-2 protein to cell apoptosis in non-small cell lung cancer.]
[Survivin and COX-2 expressions in giant cell tumor of bone and their relation to the prognosis]
[Synergistic lethal effect of mDRA-6 and nimesulide on human hepatocellular cancer cell line SMMC-7721]
[Synthesis of arachidonic acid cascade eicosanoids in tumors of various histogenesis in mice]
[Targeted drugs in radiation therapy]
[The antimicrobial effects of chitosans on oral pathogenic microbes in vitro.]
[The clinical significance of expression of cyclooxygenase-2 gene in breast cancer]
[The connection of miR-21 and miR-155 with regulation of 15-HPGDH mRNA in human breast cancer cells].
[The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer]
[The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]
[The effects of celecoxib on mammary tumorigenesis and aging in HER2/neu transgenic mice]
[The Effects of Interfering COX-2 Gene Expression on Malignant Proliferation of Human Lung Adenocarcinoma A2 Cell in vitro.]
[The Expression and Clinical Significance of HIF-1?, COX-2 and E-cadherin in Patients with Lung Adenocarcinoma.]
[The expression and significance of HIF-1alpha and COX-2 in laryngeal squamous cell carcinoma]
[The expressiong of cyclooxygenase-2 in laryngeal squamous cell carcinoma and its relationship with MVD]
[The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer]
[The IL-6 and COX-2 expression related to sensitivity of chemoradiotherapy and prognosis in esophageal carcinoma]
[The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results]
[The potential role of Id1 in COX-2 mediated angiogenesis in gastric cancer]
[The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer]
[The role of cyclooxygenase-2 and vascular endothelial growth factor-C in lymphatic metastasis of gastric cancer]
[The role of stromal mast cells in the modification of CD4+CD25+Foxp³ regulatory T cells, Th17 lymphocytes and cytotoxic lymphocytes Tc1 in the development and progression of tumor].
[The role of TLR4 receptor in development of inflammation and carcinogenesis in ulcerative colitis and pharmacotherapy of this disorder].
[The significance of the expression of cyclooxygenase-2 in bladder transitional cell carcinoma tissues]
{gamma}-Tocotrienol Inhibits Pancreatic Tumors and Sensitizes Them to Gemcitabine Treatment by Modulating the Inflammatory Microenvironment.
Neoplasms, Basal Cell
Beyond the scalpel: targeting hedgehog in skin cancer prevention.
Neoplasms, Glandular and Epithelial
Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Immunohistochemical expression of cyclooxygenase-2 in canine ovarian carcinomas.
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Ultraviolet B(UVB)-induced cox-2 expression in murine skin: an immunohistochemical study.
Neoplasms, Neuroepithelial
A study on the biological behavior of human brain tumors. Part I. Arachidonic acid metabolism and DNA content.
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
Neoplasms, Radiation-Induced
Tumor Cell Invasion Induced by Radiation in Balb/C Mouse is Prevented by the Cox-2 Inhibitor NS-398.
Neoplasms, Squamous Cell
COX-2 expression in dysplasia of the head and neck: correlation with elF4E.
Cox-2 in non-small cell lung cancer: A meta-analysis.
Cyclooxygenase-1 deletion enhances apoptosis but does not protect against ultraviolet light-induced tumors.
Cyclooxygenase-2 in cervical neoplasia: a review.
Epithelial to mesenchymal transition in cutaneous squamous cell carcinoma is correlated with COX-2 expression but not with the presence of stromal macrophages or CD10-expressing cells.
Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey.
MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.
Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis.
Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.
Neoplastic Cells, Circulating
Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer.
Clinical significance of circulating tumor cells and their expression of cyclooxygenase-2 in patients with nasopharyngeal carcinoma.
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.
The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
Neoplastic Processes
CXCR-4 and COX-2 Expression in Basal Cell Carcinomas and Well-Differentiated Squamous Cell Carcinomas of the Skin; Their Relationship with Tumor Invasiveness and Histological Subtype.
Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications.
Cyclooxygenase-2 expression in dermatofibroma and dermatofibrosarcoma protuberans.
Cyclooxygenase-2 expression in the normal human eye and its expression pattern in selected eye tumours.
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.
Nephritis
Anti-inflammatory action of dietary fish oil and calorie restriction.
COX-2 inhibition and prostaglandin receptors in experimental nephritis.
Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis.
Glomerular eicosanoid production in acute serum sickness nephritis.
Hyaluronan-induced cyclooxygenase-2 expression promotes thromboxane A2 production by renal cells.
Mechanisms underlying the anti-inflammatory effects of essential fatty acid deficiency in experimental glomerulonephritis. Inhibited release of a monocyte chemoattractant by glomeruli.
Overexpression of cyclooxygenase-2 predisposes to podocyte injury.
Roles of lipid mediators in kidney injury.
Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis.
[Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib]
Nephritis, Interstitial
Acute interstitial nephritis and COX-2 inhibition.
Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid.
Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib.
Celecoxib-induced acute interstitial nephritis.
COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature.
Cyclooxygenase-2 inhibitor-associated minimal-change disease.
Cyclooxygenase-2 inhibitor-induced acute interstitial nephritis.
Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib.
[Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib]
Nephrocalcinosis
A novel compound heterozygous ROMK mutation presenting as late onset Bartter syndrome associated with nephrocalcinosis and elevated 1,25(OH)(2) vitamin D levels.
Inhibition of experimental nephrocalcinosis with a prostaglandin synthetase inhibitor.
Nephrolithiasis
[Experimental evidence of magnesium salts for treatment of calcium oxalate nephrolithiasis in an animal model based on sodium oxalate and a cyclooxygenase 2 selective inhibitor].
[The effectiveness of certain magnesium salts in nephrolithiasis caused by the use of sodium oxalate and celecoxib].
Nephrosclerosis
Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R.
Nephrosis, Lipoid
Cyclooxygenase-2 inhibitor-associated minimal-change disease.
Nephrotic Syndrome
Cyclooxygenase-2 inhibitor-associated minimal-change disease.
Nephrotic syndrome and interstitial nephritis associated with celecoxib.
Pharmacological and Genetic Inhibition of Downstream Targets of p38 MAPK in Experimental Nephrotic Syndrome.
Profound urinary protein loss and acute renal failure caused by cyclooxygenase-2 inhibitor.
Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users.
Nerve Compression Syndromes
Clinical Vignette. Sciatic nerve entrapment secondary to heterotopic ossification: imaging findings and potential effect of selective cox-2 inhibitors.
Nervous System Diseases
A novel gliotic P2 receptor mediating cyclooxygenase-2 induction in rat and human astrocytes.
Amyloid-? Induces Cyclooxygenase-2 and PGE2 Release in Human Astrocytes in NF-? B Dependent Manner.
Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone.
Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms.
Cyclooxygenase-2 in synaptic signaling.
Docking Studies and Molecular Dynamics Simulation of Ipomoea batatas L. Leaves Compounds as Lipoxygenase (LOX) Inhibitor.
Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation.
In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons.
Mechanism of age-associated up-regulation in macrophage PGE2 synthesis.
[COX-2 regulation of prostaglandins in synaptic signaling].
Neuralgia
(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2.
?-Spinasterol: a cyclooxygenase inhibitor and a TRPV1 antagonist presents an antinociceptive effect in clinically relevant models of pain in mice.
A stable prostacyclin analog enhances ectopic activity in rat sensory neurons following neuropathic injury.
Ameliorative effect of combined administration of inducible nitric oxide synthase inhibitor with cyclooxygenase-2 inhibitors in neuropathic pain in rats.
Biphasic effects of chronic intrathecal gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats.
Bradykinin receptor antagonists and cyclooxygenase inhibitors in vincristine- and streptozotocin-induced hyperalgesia.
Capnellene, a natural marine compound derived from soft coral, attenuates chronic constriction injury-induced neuropathic pain in rats.
Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1/2 signaling.
Celecoxib reverts oxaliplatin-induced neuropathic pain through inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion.
Cellular sources of cyclooxygenase-1 and -2 up-regulation in the spinal dorsal horn after spinal nerve ligation.
Changes in expression of cyclooxygenase-2 in the spinal dorsal horn after intrathecal p38MAPK inhibitor SB203580 on neuropathic pain in rats.
Curcumin Alleviates Neuropathic Pain by Inhibiting p300/CBP Histone Acetyltransferase Activity-Regulated Expression of BDNF and Cox-2 in a Rat Model.
Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain.
Cyclooxygenase-1 in the spinal cord is altered after peripheral nerve injury.
Cyclooxygenase-2 expression in Schwann cells and macrophages in the sciatic nerve after single spinal nerve injury in rats.
Demonstration of antiallodynic effects of the cyclooxygenase-2 inhibitor meloxicam on established diabetic neuropathic pain in mice.
Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats.
Effect of etodolac, a COX-2 inhibitor, on neuropathic pain in a rat model.
Effects of electroacupuncture intervention on expression of cyclooxygenase 2 and microglia in spinal cord in rat model of neuropathic pain.
Electroacupuncture inhibits cyclooxygenase-2 up-regulation in rat spinal cord after spinal nerve ligation.
Electroacupuncture versus celecoxib for neuropathic pain in rat SNL model.
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.
Etodolac Blocks the Allyl Isothiocyanate-Induced Response in Mouse Sensory Neurons by Selective TRPA1 Activation.
GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
High-throughput proteomics and protein biomarker discovery in an experimental model of inflammatory hyperalgesia: effects of nimesulide.
Inhibition of COX-2 alleviates lumbar spinal stenosis-induced chronic mechanical allodynia in rats.
Interventions in chronic pain management. 4. Medications in pain management.
Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats.
MicroRNA?143?3p contributes to the regulation of pain responses in collagen?induced arthritis.
MiR-150 alleviates neuropathic pain via inhibiting toll-like receptor 5.
miR-194 relieve neuropathic pain and prevent neuroinflammation via targeting FOXA1.
MiR-28-5p relieves neuropathic pain by targeting Zeb1 in CCI rat models.
miR-384-5p ameliorates neuropathic pain by targeting SCN3A in a rat model of chronic constriction injury.
NCX 2057, a novel NO-releasing derivative of ferulic acid, suppresses inflammatory and nociceptive responses in in vitro and in vivo models.
Parecoxib and its metabolite valdecoxib directly interact with cannabinoid binding sites in CB1-expressing HEK 293 cells and rat brain tissue.
Peri-sciatic administration of indomethacin early after nerve injury can attenuate the development of tactile allodynia in a rat model of L5 single spinal nerve injury.
Progesterone reduces the expression of spinal cyclooxygenase-2 and inducible nitric oxide synthase and prevents allodynia in a rat model of central neuropathic pain.
Role for cyclooxygenase 2 in the development and maintenance of neuropathic pain and spinal glial activation.
Role of prostaglandin E2 in the synthesis of the pro-inflammatory cytokine interleukin-6 in primary sensory neurons: an in vivo and in vitro study.
Spinal cyclooxygenase-2 is involved in development of allodynia after nerve injury in rats.
Systemic meloxicam reduces tactile allodynia development after L5 single spinal nerve injury in rats.
The Attenuation of Pain Behavior and Serum COX-2 Concentration by Curcumin in a Rat Model of Neuropathic Pain.
The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization.
The impact of pain management on quality of life.
The rat intervertebral disk degeneration pain model: relationships between biological and structural alterations and pain.
The Role of Organic Small Molecules in Pain Management.
Thymus algeriensis and Thymus fontanesii exert neuroprotective effect against chronic constriction injury-induced neuropathic pain in rats.
Upregulation of miR-183 represses neuropathic pain through inhibiton of MAP3K4 in CCI rat models.
[Changes in expression of cyclooxygenase-2 in the spinal dorsal horn after intrathecal p38MAPK inhibitor SB203580 on neuropathic pain in rats].
Neuralgia, Postherpetic
A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective COX-2 Inhibitor, GW406381, in Patients With Postherpetic Neuralgia.
Neurilemmoma
COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake.
Expression of HIF-1, galectin-3, cox-2 and Wilms tumor-1 protein in multiple schwannomas of the conus medullaris.
Expression of prostaglandin H synthase-2 in human brain tumors.
Neuritis
Involvement of cyclooxygenase-1 and -2 in the sciatic nerve of rats with experimental autoimmune neuritis.
New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis.
The action mechanism of cyclooxygenase-2 inhibitor for treatment of experimental allergic neuritis.
The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis.
[Immunopathology of inflammatory neuropathies]
Neuritis, Autoimmune, Experimental
Involvement of cyclooxygenase-1 and -2 in the sciatic nerve of rats with experimental autoimmune neuritis.
New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis.
The action mechanism of cyclooxygenase-2 inhibitor for treatment of experimental allergic neuritis.
The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis.
[Immunopathology of inflammatory neuropathies]
Neuroblastoma
A Coral-Derived Compound Improves Functional Recovery after Spinal Cord Injury through Its Antiapoptotic and Anti-Inflammatory Effects.
Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1? and A? between glial and neuron cells.
All-trans retinoic acid induces COX-2 and prostaglandin E2 synthesis in SH-SY5Y human neuroblastoma cells: involvement of retinoic acid receptors and extracellular-regulated kinase 1/2.
Antioxidant effect of acetyl-l-carnitine against cisplatin-induced cardiotoxicity.
Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.
Caspase-1 inhibitors abolish deleterious enhancement of COX-2 expression induced by HIV-1 gp120 in human neuroblastoma cells.
Celecoxib Exerts Neuroprotective Effects in ?-Amyloid-Treated SH-SY5Y Cells Through the Regulation of Heme Oxygenase-1: Novel Insights for an Old Drug.
Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Conversion of arachidonic acid to cyclooxygenase and lipoxygenase products, and incorporation into phospholipids in the mouse neuroblastoma clone, Neuro-2A.
Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro.
Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma.
Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.
Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.
Cyclooxygenase-2 is a neuronal target gene of NF-kappaB.
Cyclooxygenase-2 is Essential for Mediating the Effects of Calcium Ions on Stimulating Phosphorylation of Tau at the Sites of Ser 396 and Ser 404.
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.
Cyclooxygenase-2 stimulates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG108-15 cells.
Death of cultured human neuroblastoma cells induced by HIV-1 gp120 is prevented by NMDA receptor antagonists and inhibitors of nitric oxide and cyclooxygenase.
Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
Enterovirus 71 modulates a COX-2/PGE2/cAMP-dependent viral replication in human neuroblastoma cells: Role of the c-Src/EGFR/p42/p44 MAPK/CREB signaling pathway.
Enterovirus 71 modulates a COX-2/PGE2/cAMP-dependent viral replication in human neuroblastoma cells: role of the c-Src/EGFR/p42/p44 MAPK/CREB signaling pathway.
Human immunodeficiency virus type 1 envelope glycoprotein 120 induces cyclooxygenase-2 expression in neuroblastoma cells through a nuclear factor-kappaB and activating protein-1 mediated mechanism.
Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease.
Inhibition of human malignant neuroblastoma cell DNA synthesis by lipoxygenase metabolites of arachidonic acid.
Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor.
Inhibition of human neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor nimesulide.
Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease.
Interleukin-1beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB.
Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.
JNK and p38 MAPK regulate oxidative stress and the inflammatory response in chlorpyrifos-induced apoptosis.
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Methamphetamine toxicity-induced calcineurin activation, nuclear translocation of nuclear factor of activated T-cells and elevation of cyclooxygenase 2 levels are averted by calpastatin overexpression in neuroblastoma SH-SY5Y cells.
Mild Hypothermia Prevents NO-Induced Cytotoxicity in Human Neuroblastoma Cells Via Induction of COX-2.
Neuroblastoma SH-SY5Y cytotoxicity, anti-amyloidogenic activity and cyclooxygenase inhibition of Lasianthus trichophlebus (Rubiaceae).
Neuroprotective and Anti-Inflammatory Activities of Allyl Isothiocyanate through Attenuation of JNK/NF-?B/TNF-? Signaling.
Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein.
NSAIDs in neuroblastoma therapy.
Paraquat induces cyclooxygenase-2 (COX-2) implicated toxicity in human neuroblastoma SH-SY5Y cells.
Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Prostaglandin E2 promotes MYCN non-amplified neuroblastoma cell survival via ?-catenin stabilization.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Regulation of the cyclooxygenase-2 system by interleukin-1beta through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells.
Resveratrol inhibits prostaglandin formation in IL-1beta-stimulated SK-N-SH neuronal cells.
Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex.
The oral administration of retinoic acid enhances nociceptive withdrawal reflexes in rats with soft-tissue inflammation.
The Sarin-like Organophosphorus Agent bis (isopropyl methyl)phosphonate Induces Apoptotic Cell Death and COX-2 Expression in SK-N-SH Cells.
The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.
Up-regulation of cyclooxygenase-1 in neuroblastoma cell lines by retinoic acid and corticosteroids.
Upregulation of DSCR1 (RCAN1 or Adapt78) in the peri-infarct cortex after experimental stroke.
Zinc Oxide Nanoparticles Exhibit Both Cyclooxygenase- and Lipoxygenase-Mediated Apoptosis in Human Bone Marrow-Derived Mesenchymal Stem Cells.
Neurodegenerative Diseases
(-)-Nyasol, isolated from Anemarrhena asphodeloides suppresses neuroinflammatory response through the inhibition of I-?B? degradation in LPS-stimulated BV-2 microglial cells.
A novel gliotic P2 receptor mediating cyclooxygenase-2 induction in rat and human astrocytes.
Adult human microglia secrete cytokines when exposed to neurotoxic prion protein peptide: no intermediary role for prostaglandin E2.
An Activity-Based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells.
Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages.
Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches.
Celecoxib delays cognitive decline in an animal model of neurodegeneration.
Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans.
Characterization of novel furan compounds on the basis of their radical scavenging activity and cytoprotective effects against glutamate- and lipopolysaccharide-induced insults.
Co-nanoencapsulated meloxicam and curcumin improves cognitive impairment induced by amyloid-beta through modulation of cyclooxygenase-2 in mice.
Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression.
Curcumin: from food spice to cancer prevention.
Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli.
Cyclooxygenase-1 is involved in the inhibition of hippocampal neurogenesis after lipopolysaccharide-induced neuroinflammation.
Cyclooxygenase-2 in epilepsy.
Cyclooxygenase-2 in synaptic signaling.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease.
Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: Real-time monitoring of RGC survival using Thy-1-EGFP transgenic mice.
Cyclooxygenase-2/PGE(2) pathway facilitates pentylenetetrazol-induced seizures.
Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders.
Detection of Cyclooxygenase-1 in Activated Microglia During Amyloid Plaque Progression: PET Studies in Alzheimer's Disease Model Mice.
Detection of Overexpressed COX-2 in Precancerous Lesions of Hamster Pancreas and Lungs by Molecular Imaging: Implications for Early Diagnosis and Prevention.
Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats.
Divergent effects of prostaglandin receptor signaling on neuronal survival.
Effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, on various biochemical parameters of brain associated with pentylenetetrazol-induced chemical kindling in mice.
Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease.
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO.
Exogenous ATP modulates PGE2 release in macrophages through sustained phosphorylation of CDK9 and p38 MAPK.
Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat.
In situ click chemistry generation of cyclooxygenase-2 inhibitors.
In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl ester.
Induction of COX-2 and reactive gliosis by P2Y receptors in rat cortical astrocytes is dependent on ERK1/2 but independent of calcium signalling.
Inflammation in central nervous system injury.
Interactive involvement of hippocampal cAMP/PKA and cyclooxygenase-2 signaling pathways in spatial learning in the Morris water maze.
Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease.
Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease.
Mechanism of age-associated up-regulation in macrophage PGE2 synthesis.
Misoprostol reverse hippocampal neuron cyclooxygenase-2 downstream signaling imbalance in aluminum-overload rats.
Modulation of cyclooxygenase-2 and brain reactive astrogliosis by purinergic P2 receptors.
Monoacylglycerol lipase inhibitor protects primary cultured neurons against homocysteine-induced impairments in rat caudate nucleus through COX-2 signaling.
Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation.
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Parecoxib alleviates the motor behavioral decline of aged rats by ameliorating mitochondrial dysfunction in the substantia nigra via COX-2/PGE2 pathway inhibition.
Prostanoid Receptor EP2 as a Therapeutic Target.
Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity.
Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice.
Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats.
Radiosynthesis and Preclinical Evaluation of 11C-VA426, a Cyclooxygenase-2 Selective Ligand.
Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme.
Role of COX-2 in inflammatory and degenerative brain diseases.
Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex.
Synergy of Physico-chemical and Biological Experiments for Developing a Cyclooxygenase-2 Inhibitor.
Synthesis, 3D-QSAR, and Molecular Modeling Studies of Triazole Bearing Compounds as a Promising Scaffold for Cyclooxygenase-2 Inhibition.
The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.
Therapeutic potential of monoacylglycerol lipase inhibitors.
Three-dimensional structure of human cyclooxygenase (hCOX)-1.
Transgenic mouse for conditional, tissue-specific Cox-2 overexpression.
Zingansikpoongtang modulates beta-amyloid and IL-1beta-induced cytokine production and cyclooxygenase-2 expression in human astrocytoma cells U373MG.
[COX-2 regulation of prostaglandins in synaptic signaling].
Neuroectodermal Tumors, Primitive
Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism.
Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib.
Neuroendocrine Tumors
Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors.
Cox-2 promotes chromogranin A expression and bioactivity: evidence for a prostaglandin E2-dependent mechanism and the involvement of a proximal cyclic adenosine 5'-monophosphate-responsive element.
Cyclooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors.
Neurofibromatoses
COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake.
Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas.
Neurofibromatosis 2
COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake.
Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas.
Neurofibrosarcoma
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.
Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells.
Neurogenic Inflammation
Bradykinin and interleukin-1? synergistically increase the expression of cyclooxygenase-2 through the RNA-binding protein HuR in rat dorsal root ganglion cells.
Cyclooxygenase inhibitors acetylsalicylic acid and indomethacin do not affect capsaicin-induced neurogenic inflammation in human skin.
Effects of Parecoxib on Plasma Protein Extravasation and c-Fos Expression in the Rat.
Efficacy of active compounds of Chanqin granules on airway neurogenic inflammation induced by PM2.5 in vivo.
Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine.
Neuroinflammatory Diseases
(+)-Sesamin attenuates chronic unpredictable mild stress-induced depressive-like behaviors and memory deficits via suppression of neuroinflammation.
3-Substituted 1,5-Diaryl-1 H-1,2,4-triazoles as Prospective PET Radioligands for Imaging Brain COX-1 in Monkey. Part 1: Synthesis and Pharmacology.
3-Substituted 1,5-Diaryl-1 H-1,2,4-triazoles as Prospective PET Radioligands for Imaging Brain COX-1 in Monkey. Part 2: Selection and Evaluation of [11C]PS13 for Quantitative Imaging.
6-O-angeloylplenolin exerts neuroprotection against lipopolysaccharide-induced neuroinflammation in vitro and in vivo.
A Combination of Resveratrol and Curcumin is Effective Against Aluminum Chloride-Induced Neuroinflammation in Rats.
A role for cyclooxygenase-1 in beta-amyloid-induced neuroinflammation.
A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation.
Acetate reduces PGE2 release and modulates phospholipase and cyclooxygenase levels in neuroglia stimulated with lipopolysaccharide.
Acute neuroinflammation and neurogenesis: a role for microglial COX-1.
Altered brain lipid composition in cyclooxygenase-2 knockout mouse.
Amelioration of Diabetes-induced Cognitive Deficits by GSK-3? Inhibition is Attributed to Modulation of Neurotransmitters and Neuroinflammation.
Amyloidogenic, neuroinflammatory and memory dysfunction effects of HIV-1 gp120.
An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders.
Angiotensin II Receptor Blockers Attenuate Lipopolysaccharide-Induced Memory Impairment by Modulation of NF-?B-Mediated BDNF/CREB Expression and Apoptosis in Spontaneously Hypertensive Rats.
Anti-Amnesic Effect of Walnut via the Regulation of BBB Function and Neuro-Inflammation in A?1-42-Induced Mice.
Anti-inflammatory Activity of 8-Hydroxydaidzein in LPS-Stimulated BV2 Microglial Cells via Activation of Nrf2-Antioxidant and Attenuation of Akt/NF-?B-Inflammatory Signaling Pathways, as Well As Inhibition of COX-2 Activity.
Anti-Inflammatory Effect of Lycopene on Experimental Spinal Cord Ischemia Injury via Cyclooxygenase-2 Suppression.
Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation.
Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside.
Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: Possible involvement of NF-?B and p38 MAPK inhibition.
Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats.
Attenuated SIV causes persisting neuroinflammation in the absence of a chronic viral load and neurotoxic ART.
Benzimidazole Containing Acetamide Derivatives Attenuate Neuroinflammation and Oxidative Stress in Ethanol-Induced Neurodegeneration.
Brain-targeted Angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation.
Budesonide epimer R, LAU-8080 and phenyl butyl nitrone synergistically repress cyclooxygenase-2 induction in [IL-1beta+Abeta42]-stressed human neural cells.
Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain.
CCAAT/Enhancer binding protein ? regulates prostaglandin E synthase expression and prostaglandin E2 production in activated microglial cells.
Celecoxib Prevents Cognitive Impairment and Neuroinflammation in Soluble Amyloid ?-treated Rats.
Centrally Synthesized Estradiol is a Potent Anti-Inflammatory in the Injured Zebra Finch Brain.
Circ_0005075 targeting miR-151a-3p promotes neuropathic pain in CCI rats via inducing NOTCH2 expression.
Cognitive effects of NSAIDs in cerebral ischemia: A hypothesis exploring mechanical action mediated pharmacotherapy.
Cognitive-enhancing effects of Rhus verniciflua bark extract and its active flavonoids with neuroprotective and anti-inflammatory activities.
COX-1 and COX-2 polymorphisms in susceptibility to cerebral palsy in very preterm infants.
COX-1 Inhibitors: Beyond Structure Toward Therapy.
COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity.
Cox-2 Plays a Vital Role in the Impaired Anxiety Like Behavior in Colchicine Induced Rat Model of Alzheimer Disease.
COX-2-PGE2 signaling pathway contributes to hippocampal neuronal injury and cognitive impairment in PTZ-kindled epilepsy mice.
Curcumin alleviates lumbar radiculopathy by reducing neuroinflammation, oxidative stress and nociceptive factors.
Cyclooxygenase (COX)-1 Activity Precedes the COX-2 Induction in Abeta-Induced Neuroinflammation.
Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.
Cyclooxygenase-1 is involved in the inhibition of hippocampal neurogenesis after lipopolysaccharide-induced neuroinflammation.
Cyclooxygenase-1 mediates neuroinflammation and neurotoxicity in a mouse model of retinitis pigmentosa.
Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid.
Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2'-Des-methyl-sulindac Sulfide Scaffold.
Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management.
Cyclooxygenase-2 in synaptic signaling.
Cyclooxygenase-2 inhibitor blocks the production of West Nile virus-induced neuroinflammatory markers in astrocytes.
Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain.
Deoxyelephantopin ameliorates lipopolysaccharides (LPS)-induced memory impairments in rats: Evidence for its anti-neuroinflammatory properties.
Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer's disease.
Detection of Cyclooxygenase-1 in Activated Microglia During Amyloid Plaque Progression: PET Studies in Alzheimer's Disease Model Mice.
Different Activation of IL-10 in the Hippocampus and Prefrontal Cortex During Neurodegeneration Caused by Trimethyltin Chloride.
Dual Role of Vitamin C on the Neuroinflammation Mediated Neurodegeneration and Memory Impairments in Colchicine Induced Rat Model of Alzheimer Disease.
Dysregulation in myelination mediated by persistent neuroinflammation: Possible mechanisms in chemotherapy-related cognitive impairment.
Early increased density of cyclooxygenase-2 (COX-2) immunoreactive neurons in Down syndrome.
Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures.
Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier.
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO.
Endogenous 2-Arachidonoylglycerol Alleviates Cyclooxygenases-2 Elevation-Mediated Neuronal Injury From SO2 Inhalation via PPAR? Pathway.
Erythropoietin attenuates motor neuron programmed cell death in a burn animal model.
Ethanol extract of Scutellaria baicalensis Georgi prevents oxidative damage and neuroinflammation and memorial impairments in artificial senescense mice.
Expression of cyclooxygenase-2 and microsomal prostaglandin-E synthase in amoeboid microglial cells in the developing brain and effects of cyclooxygenase-2 neutralization on BV-2 microglial cells.
Expression of mGlu Receptor Genes in the Hippocampus After Intoxication with Trimethyltin.
First-in-human evaluation of [11C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain.
FLZ attenuates learning and memory deficits via suppressing neuroinflammation induced by LPS in mice.
Gadolinium-Based Neuroprognostic Magnetic Resonance Imaging Agents Suppress COX-2 for Prevention of Reperfusion Injury after Stroke.
Genetic and Histological Alterations Reveal Key Role of Prostaglandin Synthase and Cyclooxygenase 1 and 2 in Traumatic Brain Injury-Induced Neuroinflammation in the Cerebral Cortex of Rats Exposed to Moderate Fluid Percussion Injury.
Glycine inhibits ethanol-induced oxidative stress, neuroinflammation and apoptotic neurodegeneration in postnatal rat brain.
Haplotypes of coping behavior associated QTL regions reveal distinct transcript profiles in amygdala and hippocampus.
Hazelnut and neuroprotection: Improved memory and hindered anxiety in response to intra-hippocampal A? injection.
Highly Selective Cyclooxygenase-1 Inhibitors P6 and Mofezolac Counteract Inflammatory State both In Vitro and In Vivo Models of Neuroinflammation.
Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: Protection by angiotensin converting enzyme inhibition.
Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.
Identification of highly connected hub genes in the protective response program of human macrophages and microglia activated by alpha B-crystallin.
Impact of structural alterations on the radiopharmacological profile of 18F-labeled pyrimidines as cyclooxygenase-2 (COX-2) imaging agents.
Impaired lipid metabolism markers to assess the risk of neuroinflammation in autism spectrum disorder.
In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl ester.
Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products.
Inhibition of NK1R attenuates LPS-induced microglial inflammation and consequent death of PC12 cells.
inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice.
Integrated communications between cyclooxygenase-2 and Alzheimer's disease.
Interactive involvement of hippocampal cAMP/PKA and cyclooxygenase-2 signaling pathways in spatial learning in the Morris water maze.
Is cyclooxygenase-1 involved in neuroinflammation?
Juglanin ameliorates LPS-induced neuroinflammation in animal models of Parkinson's disease and cell culture via inactivating TLR4/NF-?B pathway.
Krüppel-like factor 4 regulates amyloid-? (A?)-induced neuroinflammation in Alzheimer's disease.
Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit.
Lipoteichoic acid induces prostaglandin E(2) release and cyclooxygenase-2 synthesis in rat cortical neuronal cells: involvement of PKCepsilon and ERK activation.
Long non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation while Stimulates Neurite Outgrowth and its Correlation with MiR-125b Mediated PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease.
Luteolin alleviates cognitive impairment in Alzheimer's disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation.
Luteoloside attenuates neuroinflammation in focal cerebral ischemia in rats via regulation of the PPAR?/Nrf2/NF-?B signaling pathway.
Matcha Improves Metabolic Imbalance-Induced Cognitive Dysfunction.
Metabolic syndrome exacerbates amyloid pathology in a comorbid Alzheimer's mouse model.
miR-194 relieve neuropathic pain and prevent neuroinflammation via targeting FOXA1.
Modulation of LOX and COX pathways via inhibition of amyloidogenesis contributes to mitoprotection against ?-amyloid oligomer-induced toxicity in an animal model of Alzheimer's disease in rats.
Molecular Mechanisms of Curcumin in Neuroinflammatory Disorders: A Mini Review of Current Evidences.
Monoacylglycerol lipase blockade impairs fine motor coordination and triggers cerebellar neuroinflammation through cyclooxygenase-2.
Neonatal Inhibition of Connexin 36 Ameliorates Fetal Brain Injury Induced by Maternal Noninfectious Fever in Mice.
Neuroinflammation in Alzheimer's Disease: Are NSAIDs and Selective COX-2 Inhibitors the Next Line of Therapy?
Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?
Neuroinflammation induced by lipopolysaccharide leads to memory impairment and alterations in hippocampal leptin signaling.
Neuroinflammation, COX-2, and ALS--a dual role?
Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation.
Neuroprotective effect of curcumin on okadaic acid induced memory impairment in mice.
Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson's disease models.
NIR Laser Photobiomodulation Induces Neuroprotection in an In Vitro Model of Cerebral Hypoxia/Ischemia.
Noninfectious Fever in the Near-Term Pregnant Rat Induces Fetal Brain Inflammation: A Model for the Consequences of Epidural-Associated Maternal Fever.
Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide.
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Nuclear imaging of inflammation in neurologic and psychiatric disorders.
Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain.
Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence.
Peony seed oil ameliorates neuroinflammation-mediated cognitive deficits by suppressing microglial activation through inhibition of NF-?B pathway in presenilin 1/2 conditional double knockout mice.
PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study.
Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction.
Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets.
Protective effects of protocatechuic acid against cognitive impairment in an amyloid beta-induced Alzheimer's disease mouse model.
Quercetin Attenuates Manganese-Induced Neuroinflammation by Alleviating Oxidative Stress through Regulation of Apoptosis, iNOS/NF-?B and HO-1/Nrf2 Pathways.
Radiation-induced edema is dependent on cyclooxygenase 2 activity in mouse brain.
Radiosynthesis and evaluation of [18F]FMTP, a COX-2 PET ligand.
Rapid and simultaneous quantitation of prostanoids by UPLC-MS/MS in rat brain.
Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional neuronal deletion of cyclooxygenase-2 gene.
Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2.
Regulation of prostaglandin E2 synthesis after brain irradiation.
Regulatory Effects of Neuroinflammatory Responses Through Brain-Derived Neurotrophic Factor Signaling in Microglial Cells.
Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?
Repurposing [11C]PS13 for PET imaging of cyclooxygenase-1 (COX-1) in ovarian cancer xenograft mouse models.
Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent.
Rethinking the role of cyclooxygenase-1 in neuroinflammation: more than homeostasis.
RGS10 Regulates the Expression of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha through a G Protein-Independent Mechanism.
Rifampicin ameliorates lithium-pilocarpine-induced seizures, consequent hippocampal damage and memory deficit in rats: Impact on oxidative, inflammatory and apoptotic machineries.
Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease.
Roles of prostaglandin synthesis in excitotoxic brain diseases.
Simultaneous inhibition of COX-2 and activation of PPAR-? resulted in the same level and pattern of neuroprotection as they were targeted separately.
Sodium P-aminosalicylic acid inhibits sub-chronic manganese-induced neuroinflammation in rats by modulating MAPK and COX-2.
Sodium thiosulphate attenuates brain inflammation induced by systemic lipopolysaccharide administration in C57BL/6J mice.
Splenic Immune Cells In Experimental Neonatal Hypoxia-Ischemia.
Stress-Induced Alterations of Immune Profile in Animals Suffering by Tau Protein-Driven Neurodegeneration.
Sub-chronic celecoxib prevents soluble beta amyloid-induced depressive-like behaviour in rats.
Suppression of MALAT1 ameliorates chronic constriction injury-induced neuropathic pain in rats via modulating miR-206 and ZEB2.
Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection.
Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation.
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression.
Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.
The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease.
The Cox-2 Inhibitor Meloxicam Ameliorates Neuroinflammation and Depressive Behavior in Adult Mice after Splenectomy.
The COX-2/prostanoid signaling cascades in seizure disorders.
The cyclooxygenase-2 inhibitor parecoxib inhibits surgery-induced proinflammatory cytokine expression in the hippocampus in aged rats.
The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition.
The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.
The Role of Brain Cyclooxygenase-2 (Cox-2) Beyond Neuroinflammation: Neuronal Homeostasis in Memory and Anxiety.
Trans-Cinnamaldehyde, An Essential Oil in Cinnamon Powder, Ameliorates Cerebral Ischemia-Induced Brain Injury via Inhibition of Neuroinflammation Through Attenuation of iNOS, COX-2 Expression and NF?-B Signaling Pathway.
Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in Mice.
Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes.
Update on SAR Studies Toward New COX-1 Selective Inhibitors.
Valproic acid potentiates curcumin-mediated neuroprotection in lipopolysaccharide induced rats.
Virgin Coconut Oil-Induced Neuroprotection in Lipopolysaccharide-Challenged Rats is Mediated, in Part, Through Cholinergic, Anti-Oxidative and Anti-Inflammatory Pathways.
XIST accelerates neuropathic pain progression through regulation of miR-150 and ZEB1 in CCI rat models.
[(11)C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?
[COX-2 regulation of prostaglandins in synaptic signaling].
[Screening of key genes and pathways of ischemic stroke and prediction of traditional Chinese medicines based on bioinformatics].
Neurologic Manifestations
Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia.
Neuroma
Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study.
Neuroma, Acoustic
COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake.
Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas.
Neutropenia
C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes.
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.
Endotoxin pretreatment enhances neutrophil FMLP-receptor binding and activity in guinea pigs.
Nevi and Melanomas
Immunohistochemical expression of cyclooxygenase-2 (COX-2) in oral nevi and melanoma.
Nevus
Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression.
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Evaluation of Cyclooxygenase-2 Expression in Association with Clinical-Pathological Factors in Malignant Melanoma.
Expression of cyclooxygenase 2 in human malignant melanoma.
Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression.
Immunohistochemical detectability of cyclooxygenase-2 expression in cells of human melanocytic skin lesions: A methodological review.
Immunohistochemical expression of cyclooxygenase-2 (COX-2) in oral nevi and melanoma.
[Evaluation of COX-2 protein expression in melanocytic nevi in children].
Nevus, Pigmented
Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
[Evaluation of COX-2 protein expression in melanocytic nevi in children].
Newcastle Disease
Cyclooxygenase-2 Facilitates Newcastle Disease Virus Proliferation and Is as a Target for Canthin-6-One Antiviral Activity.
Nocturnal Enuresis
[Nocturnal enuresis as a manifestation of autocoidosis]
Non-alcoholic Fatty Liver Disease
A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice.
Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease.
COX-2 in liver fibrosis.
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study .
Cyclooxygenase-2 Promotes Hepatocellular Apoptosis by Interacting with TNF-? and IL-6 in the Pathogenesis of Nonalcoholic Steatohepatitis in Rats.
Enhanced expression of pro-inflammatory mediators and liver X receptor-regulated lipogenic genes in nonalcoholic fatty liver disease and hepatitits C.
Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A2 Pathway.
Green Tea Lowers Hepatic COX-2 and Prostaglandin E2 in Rats with Dietary Fat-Induced Nonalcoholic Steatohepatitis.
LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
LSEC Fenestrae Are Preserved Despite Pro-inflammatory Phenotype of Liver Sinusoidal Endothelial Cells in Mice on High Fat Diet.
Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor ?.
Suppressing Cyclooxygenase-2 Prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt/p53 signal pathway.
The preventive effect of phenolic-rich extracts from Chinese sumac fruits against nonalcoholic fatty liver disease in rats induced by a high-fat diet.
Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).
[An experimental study on the expression and pathogenic effects of cyclooxygenase-2 in nonalcoholic fatty liver disease]
[Effect of total flavones of hawthorn leafonon expression of COX-2/Nrf2 in liver of rats with nonalcoholic steatohepatitis].
[Pathogenesis and treatment of non-alcoholic fatty liver disease.]
[Relationship between single nucleotide polymorphisms in the promoter of COX-2 gene and hereditariness to NAFLD].
Nose Diseases
Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps.
Obesity
Adipose mTORC1 Suppresses Prostaglandin Signaling and Beige Adipogenesis via the CRTC2-COX-2 Pathway.
Altered cyclooxygenase-1 and enhanced thromboxane receptor activities underlie attenuated endothelial dilatory capacity of omental arteries in obesity.
Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity.
Augmented oxidative stress and preserved vasoconstriction induced by hydrogen peroxide in coronary arteries in obesity: role of COX-2.
Biological stereoselectivity of atropisomeric natural products and drugs.
Comment on Francés et al. Hepatic Cyclooxygenase-2 Expression Protects Against Diet-Induced Steatosis, Obesity, and Insulin Resistance. Diabetes 2015;64:1522-1531.
Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats.
COX-2 inhibition does not reverse the increased sympathetic modulation in MSG obese rats.
Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians.
Cyclooxygenase inhibition improves endothelial vasomotor dysfunction of visceral adipose arterioles in human obesity.
Cyclooxygenase-2 and the inflammogenesis of breast cancer.
Cyclooxygenase-2 Controls Energy Homeostasis in Mice by de Novo Recruitment of Brown Adipocytes.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
CYP450, COX-2 and Obesity Related Renal Damage.
Dietary trans-10, cis-12 conjugated linoleic acid reduces early glomerular enlargement and elevated renal cyclooxygenase-2 levels in young obese fa/fa zucker rats.
Effect of a selective cyclooxygenase type 2 inhibitor celecoxib on depression associated with obesity in mice: an approach using behavioral tests.
Effects of high-fat diet on plasma profiles of eicosanoid metabolites in mice.
Enhanced cyclooxygenase 2-mediated vasorelaxation in coronary arteries from insulin-resistant obese Zucker rats.
Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking.
Evidence of changes in alpha-1/AT1 receptor function generated by diet-induced obesity.
Hematopoietic cyclooxygenase-2 deficiency increases adipose tissue inflammation and adiposity in obesity.
Hepatic cyclooxygenase-2 expression protects against diet-induced steatosis, obesity and insulin resistance.
High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice.
Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic disorders in mice.
Increased central and peripheral inflammation and inflammatory hyperalgesia in Zucker rat model of leptin receptor deficiency and genetic obesity.
Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice.
Interleukin-1? and prostaglandin-synthesizing enzymes as modulators of human omental and subcutaneous adipose tissue function.
Involvement of prostacyclin synthase in high-fat-diet-induced obesity.
Ketoprofen alleviates diet-induced obesity and promotes white fat browning in mice via the activation of COX-2 through mTORC1-p38 signaling pathway.
Leptin deficiency-induced obesity exacerbates ultraviolet B radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet B-irradiated mouse skin.
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
Leptin-mediated inflammatory signaling crucially links visceral fat inflammation to obesity-associated ?-cell dysfunction.
Lipidomic profiling of high-fat diet-induced obesity in mice: Importance of cytochrome P450-derived fatty acid epoxides.
Maternal obesity alters the expression of embryonic regulatory transcripts in the preimplantation ovine conceptus.
Neuronal maturation in the hippocampal dentate gyrus via chronic oral administration of Artemisa annua extract is independent of COX-2 signaling pathway in the diet-induced obesity (DIO) mice model.
Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor ?.
NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.
Obesity is induced in mice heterozygous for cyclooxygenase-2.
Prostaglandin Endoperoxide H Synthase-2 (PGHS-2) Variants and Risk of Obesity and Microvascular Dysfunction Among Tunisians: Relevance of rs5277 (306G/C) and rs5275 (8473T/C) Genetic Markers.
Psoriasis and hypertension: a case-control study.
Response to Comment on Francés et al. Hepatic Cyclooxygenase-2 Expression Protects Against Diet-Induced Steatosis, Obesity, and Insulin Resistance. Diabetes 2015;64:1522-1531.
Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity.
Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase.
Silibinin Differentially Decreases the Aggressive Cancer Phenotype in an In Vitro Model of Obesity and Prostate Cancer.
Tea polyphenols attenuate liver inflammation by modulating obesity-related genes and down-regulating COX-2 and iNOS expression in high fat-fed dogs.
The Dualistic Effect of COX-2-Mediated Signaling in Obesity and Insulin Resistance.
The impact of ethnicity and cardiovascular risk on the pharmacologic management of osteoarthritis: a US perspective.
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer.
The Tpl2 Kinase Regulates the COX-2/Prostaglandin E2 Axis in Adipocytes in Inflammatory Conditions.
Understanding the molecular aspects of oriental obesity pattern differentiation using DNA microarray.
Weighted gene co-expression network analysis of expression data of monozygotic twins identifies specific modules and hub genes related to BMI.
[?ptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity].
Obesity, Abdominal
Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity.
Obesity, Maternal
Maternal obesity alters the expression of embryonic regulatory transcripts in the preimplantation ovine conceptus.
Obesity, Morbid
The Dualistic Effect of COX-2-Mediated Signaling in Obesity and Insulin Resistance.
Obstetric Labor, Premature
15-hydroxyprostaglandin dehydrogenase and cyclooxygenase 2 messenger ribonucleic acid expression and immunohistochemical localization in human cervical tissue during term and preterm labor.
5-Hydroxyeicosatetraenoic acid and human parturition.
Activities of Andrographis paniculata (AS201-01) Tablet on Cox-2 and Prostaglandin Expression of Placental of Plasmodium berghei Infected Mice.
Anti-inflammatory drugs and their mechanism of action.
Antiprostaglandin drugs.
Are Periodontal Bacterial Profiles and Placental Inflammatory Infiltrate in Pregnancy Related to Birth Outcomes?
Bacterially-induced preterm labor and regulation of prostaglandin-metabolizing enzyme expression in mice: the role of toll-like receptor 4.
Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus.
Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo.
Differential expression and regulation of microsomal prostaglandin E(2) synthase in human fetal membranes and placenta with infection and in cultured trophoblast cells.
Dose-dependent effects of meloxicam administration on cyclooxygenase-1 and cyclooxygenase-2 protein expression in intrauterine tissues and fetal tissues of a sheep model of preterm labor.
Effect of acupuncture treatment on uterine motility and cyclooxygenase-2 expression in pregnant rats.
Effect of calcium ionophore A23187 on prostaglandin synthase type 2 and 15-hydroxy-prostaglandin dehydrogenase expression in human chorion trophoblast cells.
Effect of indometacin pretreatment on protamine sulfate-mediated relaxation of the isolated rat uterus: the role of the antioxidative defense system.
Effect of lipopolysaccharide on uterine contractions and prostaglandin production in pregnant rats.
Effect of maternal administration of selective cyclooxygenase (COX)-2 inhibitors on renal size, growth factors, proteinases, and COX-2 secretion in the fetal rabbit.
Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix.
Evidence for a spatial and temporal regulation of prostaglandin-endoperoxide synthase 2 expression in human amnion in term and preterm parturition.
Evidence for interleukin-10-mediated inhibition of cyclo- oxygenase-2 expression and prostaglandin production in preterm human placenta.
IFN-gamma-mediated inhibition of COX-2 expression in the placenta from term and preterm labor pregnancies.
Increase in prostaglandin H synthase 2, but not prostaglandin F2alpha synthase mRNA in intrauterine tissues during betamethasone-induced premature labor and spontaneous term labor in sheep.
Inhibition of cyclooxygenase-2 prevents inflammation-mediated preterm labor in the mouse.
Inhibition of epoxy-eicosanoid degradation improves the tocolytic effects of indomethacin in the uterus from pregnant women.
Mechanism of action of antiinflammatory drugs.
Mechanism of action of aspirin-like drugs.
Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells.
Nonsteroidal antiinflammatory agents.
Novel Targeting of Cyclooxygenase-2 (COX-2) Pre-mRNA Using Antisense Morpholino Oligonucleotides Directed to the 3' Acceptor and 5' Donor Splice Sites of Exon 4: Suppression of COX-2 Activity in Human Amnion-Derived WISH and Myometrial Cells.
Progesterone and prostaglandin H synthase-2 involvement in alcohol-induced preterm birth in mice.
Prostaglandin endoperoxide H synthase (PGHS) activity and PGHS-1 and -2 messenger ribonucleic acid abundance in human chorion throughout gestation and with preterm labor.
Prostaglandin endoperoxide synthase kinetics in human amnion before and after labor at term and following preterm labor.
Resveratrol protects from lipopolysaccharide-induced inflammation in the uterus and prevents experimental preterm birth.
Safety of Ibuprofen tocolysis.
The expression of cytosolic phospholipase A2 and prostaglandin endoperoxide synthase in ovine maternal uterine and fetal tissues during late gestation and labor.
The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4.
The microRNA (miR)-199a/214 Cluster Mediates Opposing Effects of Progesterone and Estrogen on Uterine Contractility during Pregnancy and Labor.
The mitogen-activated protein kinase dependent expression of prostaglandin H synthase-2 and interleukin-8 messenger ribonucleic acid by myometrial cells: the differential effect of stretch and interleukin-1{beta}.
The promise of prostaglandins: have they fulfilled their potential as therapeutic targets for the delay of preterm birth?
Treatment of premature labor by prostaglandin synthetase inhibitors.
Treatment of symptomatic polyhydramnios with indomethacin.
Tumor necrosis factor-alpha upregulates the prostaglandin E2 EP1 receptor subtype and the cyclooxygenase-2 isoform in cultured amnion WISH cells.
Update on tocolytic therapy.
[Adverse effects of ketoprofen after intrauterine exposure. Value of plasma determination]
[Expression of cyclooxygenase-2 and 15-prostaglandin dehydrogenase of placenta and fetal membranes in patients of preterm labor]
[Expression of cyclooxygenase-2 in fetal membranes of premature delivery]
[Nifedipine in gynecology and obstetrics]
Ocular Hypertension
2-(1-Hexyn-1-yl)adenosine-induced intraocular hypertension is mediated via K+ channel opening through adenosine A2A receptor in rabbits.
Comparison of topically applied flurbiprofen or bromfenac ophthalmic solution on post-operative ocular hypertension in canine patients following cataract surgery.
Odontogenic Cyst, Calcifying
Calcifying odontogenic cyst: A 26-year retrospective clinicopathological analysis and immunohistochemical study.
Odontogenic Cysts
Cyclooxygenase-2 protein expression modulates cell proliferation and apoptosis in solid ameloblastoma and odontogenic keratocyst. An immunohistochemical study.
Investigation of clinicopathological parameters and expression of COX-2, bcl-2, PCNA, and p53 in primary and recurrent sporadic odontogenic keratocysts.
Odontogenic epithelial proliferation is correlated with COX-2 expression in dentigerous cyst and ameloblastoma.
Signaling pathways regulating IL-1alpha-induced COX-2 expression.
Odontogenic Tumors
A comparative immunohistochemical analysis of COX-2, p53, and Ki-67 expression in keratocystic odontogenic tumors.
An overview on the expression of cyclooxygenase-2 in tumors of the head and neck.
Cyclooxygenase-2 expression in keratocystic odontogenic tumour decreased following decompression.
Expression of Human Papillomavirus is Correlated with Ki-67 and COX-2 Expressions in Keratocystic Odontogenic Tumor.
Immunohistochemical analysis of COX-2 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma: A comparative study.
Potential relevance of cyclooxygenase-2 expression in keratocystic odontogenic tumours - an immunohistochemical study.
Protein 53, B-Cell Lymphoma-2, Cyclooxygenase-2, and CD105 Reactivity in Keratocystic Odontogenic Tumors: An Immunohistochemical Analysis.
TGF-? in jaw tumor fluids induces RANKL expression in stromal fibroblasts.
Oligodendroglioma
Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells.
Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression.
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.
Cyclooxygenase-2 in oligodendroglial neoplasms.
Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance.
Expression of prostaglandin H synthase-2 in human brain tumors.
Microwave-assisted antigen retrieval and incubation with cox-2 antibody of archival paraffin-embedded human oligodendroglioma and astrocytomas.
mRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas.
Oligohydramnios
Oligohydramnios and fetal renal sonographic appearances related to prostaglandin synthetase inhibitors. A case report.
Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors.
Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour.
Severe oligohydramnios induced by cyclooxygenase-2 inhibitor nimesulide.
The effect of low-dose aspirin on fetal urine output and amniotic fluid volume.
The promise of prostaglandins: have they fulfilled their potential as therapeutic targets for the delay of preterm birth?
Oligospermia
Cyclooxygenase-2 in testes of infertile men: evidence for the induction of prostaglandin synthesis by interleukin-1beta.
Oliguria
Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery increase the risk of renal failure?
Opioid-Induced Constipation
An opioid receptor-independent mechanism underlies motility dysfunction and visceral hyperalgesia in opioid-induced bowel dysfunction.
Opisthorchiasis
Increased expression of TLR-2, COX-2, and SOD-2 genes in the peripheral blood leukocytes of opisthorchiasis patients induced by Opisthorchis viverrini antigen.
Opportunistic Infections
Accelerated hematopoietic recovery and protective effect of the cyclooxygenase inhibitor indomethacin in bacterial infection of neutropenic mice.
Optic Nerve Diseases
Cyclooxygenase-1 and cyclooxygenase-2 in the human optic nerve head.
Optic Nerve Injuries
Activation of the epidermal growth factor receptor in optic nerve astrocytes leads to early and transient induction of cyclooxygenase-2.
Signal transduction pathways for epidermal growth factor stimulated cyclooxygenase-2 induction in astrocytes.
Oral Submucous Fibrosis
Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes.
Expression of cyclooxygenase 2 in oral submucous fibrosis: An immunohistochemical pilot study.
The up-regulation of cyclooxygenase-2 expression in human buccal mucosal fibroblasts by arecoline: a possible role in the pathogenesis of oral submucous fibrosis.
Translational approach utilizing COX-2, p53, and MDM2 expressions in malignant transformation of oral submucous fibrosis.
Oral Ulcer
Discovery of the possible mechanisms in kouyanqing granule for treatment of oral ulcers based on network pharmacology.
Orbital Diseases
Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients.
Osteoarthritis
4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).
5-Lipoxygenase Metabolic Contributions to NSAID-Induced Organ Toxicity.
A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
A case-control study and meta-analysis reveal the association between COX-2 G-765C polymorphism and primary end-stage hip and knee osteoarthritis.
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury.
A hybrid platform featuring nanomagnetic ligand fishing for discovering COX-2 selective inhibitors from aerial part of Saussurea laniceps Hand.-Mazz.
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.Rofecoxib Osteoarthritis Endoscopy Study Group.
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA.
A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model.
A rapid and sensitive high-performance liquid chromatography assay for rofecoxib in human serum.
A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
A review of the clinical pharmacokinetics of meloxicam.
Adiponectin receptor 1 mediates the difference in adiponectin- induced prostaglandin E2 production in rheumatoid arthritis and osteoarthritis synovial fibroblasts.
An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model.
Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs.
Anticonvulsive Effects of Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase.
Antiosteoarthritic effect of Punica granatum L. peel extract on collagenase induced osteoarthritis rat by modulation of COL-2, MMP-3, and COX-2 expression.
Application of inflammation-responsive promoter for an in vitro arthritis model.
Are COX-2 selective inhibitors safer than NSAIDs for patients with osteoarthritis and rheumatoid arthritis?
Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts.
Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects.
Blood Glutathione Peroxidase Activity in Patients with Osteoarthritis Treated with Oxicams.
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib.
Celastrol, an inhibitor of heat shock protein 90? potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes.
Celecoxib for the treatment of musculoskeletal arthritis.
Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage.
Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.
Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons.
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Celecoxib: a novel treatment for lung cancer.
Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Changing the outcome of osteoarthritis: still a challenge for cyclooxygenase 2 inhibitors.
Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase.
Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review.
Chondroprotective Effects of Genistein against Osteoarthritis Induced Joint Inflammation.
Cirsium japonicum var. maackii and apigenin block Hif-2?-induced osteoarthritic cartilage destruction.
Clinical implications of selective cyclooxygenase-2 inhibition.
Clinical pharmacology of etoricoxib.
Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Clinical pharmacology of selective COX-2 inhibitors.
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Colchicine mesoporous silica nanoparticles/hydrogel composite loaded cotton patches as a new encapsulator system for transdermal osteoarthritis management.
Combatting joint pain and inflammation by dual inhibition of monoacylglycerol lipase and cyclooxygenase-2 in a rat model of osteoarthritis.
Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study.
Comparative efficacy and safety of Verbascox® - a proprietary herbal extract capable of inhibiting human cyclooxygenase-2 - and celecoxib for knee osteoarthritis.
Comparative efficacy and tolerability of nimesulide and piroxicam in osteoarthritis with specific reference to chondroprotection: a double blind randomised study.
Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study).
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip.
Contribution of synovial macrophages to rat advanced osteoarthritis pain resistant to cyclooxygenase inhibitors.
Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors.
COX-1 and -2 activity of rose hip.
COX-2 and colon cancer: Potential targets for chemoprevention.
COX-2 and colon cancer: potential targets for chemoprevention.
COX-2 drug may help treat osteoarthritis.
Cox-2 gene variants in migraine.
COX-2 inhibition and pain management: a review summary.
COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy: reports from a symposium held in conjunction with the Radiation Therapy Oncology Group June 2001 Meeting.
Cox-2 inhibitors and the risk of cardiovascular thrombotic events.
COX-2 inhibitors.
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
COX-2 selective inhibitors in the treatment of osteoarthritis.
COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study.
COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.
COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?
Cross talk between COX-2 inhibitor and hyaluronic acid in osteoarthritic chondrocytes.
Cross-Coupling Effects of Silencing of Cyclooxygenase-2 (COX-2)/Aggrecanase-1 and Over-Expressed Insulin-Like Growth Factor 1 (IGF-1) in an Osteoarthritis Animal Model.
Current considerations for the management of musculoskeletal pain in Asian countries: a special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs.
Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants.
Cyclooxygenase activity in chondrocytes from osteoarthritic and healthy cartilage.
Cyclooxygenase inhibition lowers prostaglandin E2 release from articular cartilage and reduces apoptosis but not proteoglycan degradation following an impact load in vitro.
Cyclooxygenase inhibitors--current status and future prospects.
Cyclooxygenase-2 in human pathological disease.
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Cyclooxygenase-2 inhibitor rofecoxib prevents chondrocytes against hypertrophy via Wnt/?-catenin pathway.
Cyclooxygenase-2 inhibitor treatment of older osteoarthritis patients.
Cyclooxygenase-2 regulates PTHrP transcription in human articular chondrocytes and is involved in the pathophysiology of osteoarthritis in rats.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Cyclooxygenase-2, Asymmetric Dimethylarginine and the Cardiovascular Hazard from NSAIDs.
Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
Defining COX-2 inhibitors.
Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes.
Differential expression of COX-2 in osteoarthritis and rheumatoid arthritis.
Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review.
Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
DNA Sequence Variants in the Five Prime Untranslated Region of the Cyclooxygenase-2 Gene Are Commonly Found in Healthy Dogs and Gray Wolves.
Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis.
Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis.
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
Echinocystic Acid Inhibits IL-1?-Induced COX-2 and iNOS Expression in Human Osteoarthritis Chondrocytes.
Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.
Effect of an academic detailing intervention on the utilization rate of cyclooxygenase-2 inhibitors in the elderly.
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells.
Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study.
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.
Effects of Naproxcinod on Blood Pressure in Patients with Osteoarthritis.
Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.
Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial.
Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.
Efficacy and safety of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee- a subset analysis.
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan.
Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.
Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
Efficacy of lumiracoxib in osteoarthritis: a review of nine studies.
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion.
Epigallocatechin-3-O-gallate up-regulates microRNA-199a-3p expression by down-regulating the expression of cyclooxygenase-2 in stimulated human osteoarthritis chondrocytes.
Etodolac: An overview of a selective COX-2 inhibitor.
Etoricoxib decreases subchondral bone mass and attenuates biomechanical properties at the early stage of osteoarthritis in a mouse model.
Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial.
Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].
Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital.
Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study.
Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.
Expression and activity of COX-1 and 2 and 5-LOX in joint tissues from dogs with naturally occurring coxofemoral joint osteoarthritis.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Expression of cyclooxygenase-1 and -2 in rheumatoid arthritis synovium.
Expression of VEGF-A Signaling Pathway in Cartilage of ACLT-induced Osteoarthritis Mouse Model.
Fluid shear stress-induced osteoarthritis: roles of cyclooxygenase-2 and its metabolic products in inducing the expression of proinflammatory cytokines and matrix metalloproteinases.
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Genetic influences on hand osteoarthritis in finnish women--a replication study of candidate genes.
Global safety of coxibs and NSAIDs.
Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults.
Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes.
H3K4 methylation by Set1A contributes to IL-1-induced COX-2 and iNOS expression in human OA chondrocytes.
How to mechanistically explain the CONDOR study data.
Human bone mesenchymal stem cells-derived exosomes overexpressing microRNA-26a-5p alleviate osteoarthritis via down-regulation of PTGS2.
I have coronary artery disease and osteoarthritis. What can you tell me about COX-2 inhibitors and their possible effects on my heart?
Immunohistochemical localization of cyclooxygenase-1 and -2 in synovial tissues from patients with internal derangement or osteoarthritis of the temporomandibular joint.
Impact of a general practitioner educational intervention on osteoarthritis treatment in an elderly population.
Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution.
Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.
In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.
In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.
In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis.
In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis.
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
Increased gene expression and production of spinal cyclooxygenase 1 and 2 during experimental osteoarthritis pain.
Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.
Influence of polymers on the bioavailability of microencapsulated celecoxib.
Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis.
Inhibition of cyclooxygenase-2 activity in subchondral bone modifies a subtype of osteoarthritis.
Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: implications for therapeutic intervention in osteoarthritis.
Intra-articular injection of the cyclooxygenase-2 inhibitor parecoxib attenuates osteoarthritis progression in anterior cruciate ligament-transected knee in rats: role of excitatory amino acids.
Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats.
Ischemic colitis associated with rofecoxib.
Isolation and structural characterization of the photolysis products of etoricoxib.
Isolation of linoleic and alpha-linolenic acids as COX-1 and -2 inhibitors in rose hip.
Lack of a chondroprotective effect of cyclooxygenase 2 inhibition in a surgically induced model of osteoarthritis in mice.
Lactoferrin from Camelus dromedarius Inhibits Nuclear Transcription Factor-kappa B Activation, Cyclooxygenase-2 Expression and Prostaglandin E2 Production in Stimulated Human Chondrocytes.
Licofelone (Merckle).
Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.
Licofelone inhibits interleukin-18-induced pro-inflammatory cytokine release and cellular proliferation in human mesangial cells.
Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity.
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics.
Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac.
Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months.
Lumiracoxib (Novartis).
Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Lumiracoxib.
Managing the adverse effects of nonsteroidal anti-inflammatory drugs.
Mechanism of action of aspirin-like drugs.
Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques.
Meeting the therapeutic challenge of the patient with osteoarthritis.
Meloxicam ameliorates the cartilage and subchondral bone deterioration in monoiodoacetate-induced rat osteoarthritis.
Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium.
Meloxicam in the management of post-operative pain: Narrative review.
Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
MicroRNA-199a* regulates the expression of cyclooxygenase-2 in human chondrocytes.
MicroRNA-558 regulates the expression of cyclooxygenase-2 and IL-1?-induced catabolic effects in human articular chondrocytes.
Microsomal prostaglandin E2 synthase 1 expression in basic calcium phosphate crystal-stimulated fibroblasts: role of prostaglandin E2 and the EP4 receptor.
Modulation of Inflammatory Mediators by Polymeric Nanoparticles Loaded with Anti-Inflammatory Drugs.
Molecular Imaging of Inflammation in Osteoarthritis Using a Water-Soluble Fluorocoxib.
Molecular targets of dietary polyphenols with anti-inflammatory properties.
Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
NF-kappaBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes.
Nimesulide aggravates redox imbalance and calcium dependent mitochondrial permeability transition leading to dysfunction in vitro.
Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.
Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Novel insights and therapeutical applications in the field of inhibitors of COX-2.
Novel insights into the mechanism of decreased expression of type X collagen in human mesenchymal stem cells from patients with osteoarthritis cultured on nitrogen-rich plasma polymers: Implication of cyclooxygenase-1.
NSAID induction of interleukin 1/catabolin inhibitor production by osteoarthritic synovial tissue.
Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation.
Optimization of a nonviral transfection system to evaluate Cox-2 controlled interleukin-4 expression for osteoarthritis gene therapy in vitro.
Osteoarthritis and rheumatoid arthritis: will new data clarify the risk:benefit ratio of cyclooxygenase-2 inhibitors?
Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors.
Osteoarthritis therapy--are there still unmet needs?
Osthole ameliorates cartilage degradation by downregulation of NF-?B and HIF-2? pathways in an osteoarthritis murine model.
Outcome measures in osteoarthritis: randomized controlled trials.
Pain management in osteoarthritis: the role of COX-2 inhibitors.
Participation of cyclooxygenase-1 in prostaglandin E2 release from synovitis tissue in primary osteoarthritis in vitro.
Pathophysiology and first-line treatment of osteoarthritis.
Pedobarography: a novel approach to test the efficacy of treatments for lameness; an experience with mavacoxib in dogs with elbow osteoarthritis.
Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market.
Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
Pharmacoeconomics of coxib therapy.
Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.
PHARMACOKINETICS OF ORAL MAVACOXIB IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER).
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans.
Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors.
Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice.
Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
Population pharmacokinetics of mavacoxib in osteoarthritic dogs.
Population-based case-control study: chemoprotection of colorectal cancer with non-aspirin nonsteroidal anti-inflammatory drugs and other drugs for pain control.
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.
Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy.
Prescriptions for cyclooxygenase-2 inhibitors and other nonsteroidal anti-inflammatory agents in a medicaid managed care population: African Americans versus Caucasians.
Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha.
Prostaglandin EP2 receptor signalling inhibits the expression of matrix metalloproteinase 13 in human osteoarthritic chondrocytes.
Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients.
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Rofecoxib improves quality of life in patients with hip or knee osteoarthritis.
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
Role and regulation of cyclooxygenase-2 during inflammation.
Role of cyclooxygenase-1 and -2 in health and disease.
Role of eicosanoids in structural degradation in osteoarthritis.
S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs.
Safety assessment of vitacoxib: 180-day chronic oral toxicity studies.
Safety of anti-inflammatory treatment--new ways of thinking.
Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte.
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors.
Shikonin inhibits inflammation and chondrocyte apoptosis by regulation of the PI3K/Akt signaling pathway in a rat model of osteoarthritis.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Single dose oral celecoxib for postoperative pain.
Stichopus chloronotus aqueous extract as a chondroprotective agent for human chondrocytes isolated from osteoarthitis articular cartilage in vitro.
Study of osteoarthritis treatment with anti-inflammatory drugs: cyclooxygenase-2 inhibitor and steroids.
Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
Synthesis of stable isotope-labelled firocoxib.
The (-765 G->C) promoter variant of the COX-2/PTGS2 gene is associated with a lower risk for end-stage hip and knee osteoarthritis.
The association between cyclooxygenase-2 (COX-2/PTGS2) gene polymorphism and osteoarthritis.
The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment.
The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia.
The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF-?1 and NGF expressions in chondrocytes.
The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors.
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
The efficacy and toleration of celecoxib (Celebrex) in the treatment of osteoarthritis in Nigeria: a multicentre study.
The Evaluation of the Effect of Herbal Extract on Osteoarthritis: In Vitro and In Vivo Study.
The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.
The impact of drug coverage on COX-2 inhibitor use in Medicare.
The impact of ethnicity and cardiovascular risk on the pharmacologic management of osteoarthritis: a US perspective.
The impact of pain management on quality of life.
The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2.
The influence of probiotic diet and chondroitin sulfate administration on Ptgs2, Tgfb1 and Col2a1 expression in rat knee cartilage during monoiodoacetate-induced osteoarthritis.
The mechanism of action of aspirin.
The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials.
The possibilities of pharmacological treatment of cartilage damage in degenerative joint disease.
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
The prospective use of COX-2 inhibitors for the treatment of temporomandibular joint inflammatory disorders.
The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway.
The role of COX-2 inhibitors in rheumatoid and osteoarthritis.
The role of COX-2 produced by cartilage in arthritis.
The role of tramadol in current treatment strategies for musculoskeletal pain.
The roles of prostaglandin F2 in regulating the expression of matrix metalloproteinase-12 via an insulin growth factor-2-dependent mechanism in sheared chondrocytes.
The therapeutic approaches of community based primary care practitioners to osteoarthritis of the hip in an elderly patient.
Therapeutic Trajectory Following Intra-Articular Hyaluronic acid Injection in Knee Osteoarthritis - Meta-Analysis.
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Trial of tramadol/acetaminophen tablets for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug.
Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways.
Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.
Valdecoxib for the management of chronic and acute pain.
Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.
Value of cyclooxygenase-2 specific inhibitors in the management of osteoarthritis.
Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.
Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
What influences seniors' choice of medications for osteoarthritis? Qualitative inquiry.
When are NSAIDs appropriate in osteoarthritis?
When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis?
When to consider a COX-2 inhibitor for osteoarthritis of the knee.
[?ptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity].
[A Case of Complete Regression of Hepatocellular Carcinoma during Administration of COX-2 Inhibitor.]
[A critical evaluation of side effect data on COX-2 inhibitors]
[Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]
[Changes of six serum biomarkers of rabbits with experimental osteoarthritis].
[Comparison of the pharmacologic effect of diacerein and a selective COX-2 inhibitor in the mouse induced-granuloma model]
[Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis]
[COX-2 inhibitor in arthrosis. Discontinuation before operations not necessary]
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy]
[EFFICACY OF SEQUENTIAL TREATMENT WITH ADDUCTOR CANAL NERVE BLOCK AND CYCLOOXYGENASE 2 SELECTIVE INHIBITOR AFTER TOTAL KNEE ARTHROPLASTY].
[Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition]
[New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results]
[Osteoarthritis and COX-2 inhibitors]
[Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology]
[SECOT consensus on medial femorotibial osteoarthritis].
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]
[Selective cyclooxygenase-2 inhibitors and the digestive tract]
[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review.]
[Side effects of COX-2 selective inhibitors. Critic related with its administration in patients with rheumatoid arthritis and osteoarthritis]
[Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances]
[The role of nonsteroidal anti-inflammatory drugs, oral preparations, and viscosupplementation in conservative treatment of cartilage lesions].
[Treatment of osteoarthritis with COX-2 inhibitors: good for the stomach, but bad for the patient?]
Osteoarthritis, Hip
Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis.
COX-2 inhibitors.
Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
Rofecoxib improves quality of life in patients with hip or knee osteoarthritis.
[From PICO to search terms on the Internet: how to find relevant information? New coxibs: do they have a better gastrointestinal safety?]
Osteoarthritis, Knee
A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.
Blood Glutathione Peroxidase Activity in Patients with Osteoarthritis Treated with Oxicams.
Comparative efficacy and safety of Verbascox® - a proprietary herbal extract capable of inhibiting human cyclooxygenase-2 - and celecoxib for knee osteoarthritis.
Comparative efficacy and tolerability of nimesulide and piroxicam in osteoarthritis with specific reference to chondroprotection: a double blind randomised study.
Contribution of synovial macrophages to rat advanced osteoarthritis pain resistant to cyclooxygenase inhibitors.
COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study.
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
Effect of Systematic Exercise Rehabilitation on Patients With Knee Osteoarthritis: A Randomized Controlled Trial.
Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis.
Increased expression of cyclooxygenase-2 in synovium tissues and synovial fluid from patients with knee osteoarthritis is associated with downregulated microRNA-758-3p expression.
Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.
Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first Multi-Centre Clinical Trial using quantitative MRI.
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis.
The efficacy of Curcuma Longa L. extract as an adjuvant therapy in primary knee osteoarthritis: a randomized control trial.
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
When to consider a COX-2 inhibitor for osteoarthritis of the knee.
[EXPERIMENTAL STUDY ON LENTIVIRUS-MEDIATED MULTI-GENES CO-TRANSFECTION IN BONE MARROW MESENCHYMAL STEM CELLS FOR TREATMENT OF KNEE OSTEOARTHRITIS IN CYNOMOLGUS MONKEY].
Osteoarthropathy, Primary Hypertrophic
Safety and efficacy of cyclooxygenase-2 inhibition for treatment of primary hypertrophic osteoarthropathy: A single-arm intervention trial.
Osteoblastoma
Intraarticular osteoid osteoma associated with synovitis: a possible role of cyclooxygenase-2 expression by osteoblasts in the nidus.
Osteochondrodysplasias
Protective effect of Astragaloside IV to inhibit thiram-induced tibial dyschondroplasia.
Osteochondroma
Cyclooxygenase-2 expression correlates with development, progression, metastasis, and prognosis of osteosarcoma: a meta-analysis and trial sequential analysis.
Osteolysis
Calcium metabolism in breast cancer.
Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis.
Failure of indomethacin to reduce hypercalcemia in patients with breast cancer.
Investigations using clinically relevant particles. Reference: Im et al., The effect of COX-2 inhibitors on periprosthetic osteolysis, Biomaterials 25, 269-275 (2004).
Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
Protective effects of COX-2 inhibitor on titanium-particle-induced inflammatory osteolysis via the down-regulation of RANK/RANKL.
The effect of COX-2 inhibitors on periprosthetic osteolysis.
Osteoma, Osteoid
COX-1 and COX-2 expression in osteoid osteomas.
Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma.
Effect of rofecoxib on pain caused by osteoid osteoma.
Intraarticular osteoid osteoma associated with synovitis: a possible role of cyclooxygenase-2 expression by osteoblasts in the nidus.
Mechanism of intramedullary high intensity area on T2-weighted magnetic resonance imaging in osteoid osteoma: a possible role of COX-2 expression.
Osteomyelitis
Cyclooxygenase-2 (COX-2) polymorphism rs689466 may contribute to the increased susceptibility to post-traumatic osteomyelitis in Chinese population.
Genetic Determinants for Bacterial Osteomyelitis: A Focused Systematic Review of Published Literature.
Local osteogenic expression of cyclooxygenase-2 and systemic response in porcine models of osteomyelitis.
Osteophyte
Cyclooxygenase-2 in human pathological disease.
Protective effects of hydroxytyrosol-supplemented refined olive oil in animal models of acute inflammation and rheumatoid arthritis.
Osteoporosis
Chitooligosaccharides prevent osteopenia by promoting bone formation and suppressing bone resorption in ovariectomised rats: possible involvement of COX-2.
Feedback Control of the Arachidonate Cascade in Osteoblastic Cells by 15-deoxy-Delta-Prostaglandin J(2).
MYLK and PTGS1 Genetic Variations Associated with Osteoporosis and Benign Breast Tumors in Korean Women.
New drugs and new targets.
The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study.
Osteoporosis, Postmenopausal
Inhibition of osteoclastogenesis by mechanically stimulated osteoblasts is attenuated during estrogen deficiency.
[Effect of cyclooxygenase-2 on bone loss in ovariectomized rats].
Osteosarcoma
15-Deoxy-?12,14-prostaglandin J2 induces Cox-2 expression in human osteosarcoma cells through MAPK and EGFR activation involving reactive oxygen species.
A combination of selective COX-2 inhibitors and hydrogen peroxide increase the reactive oxygen species formation in osteosarcoma cells after X-ray irradiation.
A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation.
Aberrant Expression of PAFAH1B3 Affects Proliferation and Apoptosis in Osteosarcoma.
Analysis of gene expression in cyclooxygenase-2-overexpressed human osteosarcoma cell lines.
Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells.
Catechins-Modified Selenium-Doped Hydroxyapatite Nanomaterials for Improved Osteosarcoma Therapy Through Generation of Reactive Oxygen Species.
Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway.
Celecoxib Inhibits ?-Catenin-dependent Survival of the Human Osteosarcoma MG-63 Cell Line.
Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line.
Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells.
Correlation between the changes of serum COX 2, APE1, VEGF, TGF-? and TSGF levels and prognosis in patients with osteosarcoma before and after treatment.
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
Cyclooxygeanse-2 promotes metastasis in osteosarcoma.
Cyclooxygenase-2 expression correlates with development, progression, metastasis, and prognosis of osteosarcoma: a meta-analysis and trial sequential analysis.
Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.
Cyclooxygenase-2 Expression in Animal Cancers.
Cyclooxygenase-2 expression in canine appendicular osteosarcomas.
Cyclooxygenase-2 expression in pediatric sarcomas.
Cyclooxygenase-2 expression in uterine leiomyosarcomas.
Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma.
Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway.
Cyclooxygenase-2 Overexpression Predicts Poor Survival in Patients with High-grade Extremity Osteosarcoma: A Pilot Study.
Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells.
Differential effects of nonsteroidal anti-inflammatory drugs on constitutive and inducible prostaglandin G/H synthase in cultured bone cells.
Differentiation of human osteosarcoma cells by isolated phlorotannins is subtly linked to COX-2, iNOS, MMPs, and MAPK signaling: implication for chronic articular disease.
Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor.
Effects of dexamethasone and celecoxib on calcium homeostasis and expression of cyclooxygenase-2 mRNA in MG-63 human osteosarcoma cells.
Elucidating the mechanisms of action of parecoxib in the MG-63 osteosarcoma cell line.
Enhanced expression of cyclooxygenase-2 related multi-drug resistance gene in melanoma and osteosarcoma cell lines by TSG-6 secreted from canine adipose-derived mesenchymal stem/stromal cells.
Euxanthone Impairs the Metastatic Potential of Osteosarcoma by Reducing COX-2 Expression.
Exposure of Wistar rats to 24-h psycho-social stress alters gene expression in the inferior colliculus.
Expression and clinical significance of cyclooxygenase-2 and microRNA-143 in osteosarcoma.
Expression of cyclooxygenase-2 in osteosarcoma of bone.
Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.
Expression of the aryl hydrocarbon receptor pathway and cyclooxygenase-2 in dog tumors.
FosB transcription factor regulates COX-2 expression in colorectal cancer cells without affecting PGE2 expression.
Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation.
Immunohistochemical Expression of COX-2, mPGES and EP2 Receptor in Normal and Reactive Canine Bone and in Canine Osteosarcoma.
In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells.
Integrin-mediated expression of bone formation-related genes in osteoblast-like cells in response to fluid shear stress: roles of extracellular matrix, Shc, and mitogen-activated protein kinase.
Letter regarding the article of Jiao G. J. et al. entitled "Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis".
Limited inhibitory effects of non-steroidal antiinflammatory drugs on in vitro osteogenic differentiation in canine cells.
Lipopolysaccharide stimulates the production of prostaglandin E2 and the receptor Ep4 in osteoblasts.
lncRNA-PACER upregulates COX-2 and PGE2 through the NF-?B pathway to promote the proliferation and invasion of colorectal-cancer cells.
Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves ?v?5 integrin, ILK and AP-1-dependent pathways.
Osteosarcoma Stem Cell Potent Gallium(III)-Polypyridyl Complexes Bearing Diflunisal.
Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis.
P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene.
Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry.
Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis.
Quantitative assessment of the association of COX-2 (Cyclooxygenase-2) immunoexpression with prognosis in human osteosarcoma: a meta-analysis.
Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells.
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
T-cell activation and early gene response in dogs.
The anti-apoptotic property of NS-398 at high dose can be mediated in part through NF-kappaB activation, hsp70 induction and a decrease in caspase-3 activity in human osteosarcoma cells.
The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway.
The impact of COX-2 on invasion of osteosarcoma cell and its mechanism of regulation.
The pregnant myometrium is epigenetically activated at contractility-driving gene loci prior to the onset of labor in mice.
The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.
The role of selective COX-2 inhibitors in reactive oxygen species formation in osteosarcoma cells after X-ray irradiation.
Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
[Expression of hypoxia-inducible factor 1? in osteosarcoma and its value in predicting chemosensitivity].
[Hormones and auto-paracrine tumor growth regulators in osteogenic sarcoma]
[Osteosarcoma: biochemical and endocrinological studies as a basis for its pathogenetic treatments]
Otitis
A Glycosaminoglycan-Rich Fraction from Sea Cucumber Isostichopus badionotus Has Potent Anti-Inflammatory Properties In Vitro and In Vivo.
Otitis Media
Cyclooxygenase 2 expression in otitis media with effusion.
Expressions of cyclooxygenase 1 and 2 in endotoxin-induced otitis media with effusion in the rat.
Otitis Media with Effusion
Cyclooxygenase 2 expression in otitis media with effusion.
Experimental otitis media with effusion induced by platelet activating factor.
Expressions of cyclooxygenase 1 and 2 in endotoxin-induced otitis media with effusion in the rat.
Otorhinolaryngologic Diseases
[Nimesulide (Aulin)--the selective COX-2 inhibitor in the treatment of ENT diseases]
[Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology]
Otosclerosis
Bone resorption in experimental otosclerosis in rats.
Ototoxicity
Assessment of the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 inhibitor, in rats.
Effect of leukotriene inhibitor on otoacoustic emissions in salicylate ototoxicity.
Ototoxicity of salicylate, nonsteroidal antiinflammatory drugs, and quinine.
Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome.
Ovarian Cysts
Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters.
Formation of ovarian follicular cysts and corpora lutea after treatment with antihistamine or indomethacin in prepubertal gilts.
Ovarian Hyperstimulation Syndrome
Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome?
Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
Ovarian Neoplasms
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.
Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.
Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells.
Blueberries inhibit cyclooxygenase-1 and cyclooxygenase-2 activity in human epithelial ovarian cancer.
Ceramide induces COX-2-dependent induction of apoptosis in human ovarian cancer OVCAR-3 cells by mechanisms that partially overlap with actions of resveratrol.
Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression.
Clinical evaluations of a new ovarian cancer marker, COX-1.
Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer.
COX-1 Inhibitors: Beyond Structure Toward Therapy.
COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
COX-2 expression in ovarian cancer: an updated meta-analysis.
COX-2 expression pattern is related to ovarian cancer differentiation and prognosis, but is not consistent with new model of pathogenesis.
COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.
COX-2-PGE2-EPs in gynecological cancers.
COX2 and PGE2 mediate EGF-induced E-cadherin-independent human ovarian cancer cell invasion.
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.
Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer.
Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-?B Pathway.
Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells.
Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium.
Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer.
Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Cyclooxygenase-2 and its role in ovulation: a 2004 account.
Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms.
Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis.
Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells.
Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition.
Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus).
Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.
Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.
Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs.
Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells.
Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.
Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer.
Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.
Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor.
Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice.
Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.
Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts.
Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice.
Effects of cyclooxygenase-2 gene silencing on the biological behavior of SKOV3 ovarian cancer cells.
Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.
Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.
Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor.
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.
Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
Expression of cyclooxygenase-2 in ovarian cancer cell lines.
Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome.
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH(2))D(3)) and prostaglandin E(2) (PGE(2)) serum level in ovarian cancer patients.
Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.
Flaxseed enriched diet-mediated reduction in ovarian cancer severity is correlated to the reduction of prostaglandin E2 in laying hen ovaries.
Gonadotropins Induce Tumor Cell Migration and Invasion by Increasing Cyclooxygenases Expression and Prostaglandin E2 Production in Human Ovarian Cancer Cells.
Gonadotropins promote human ovarian cancer cell migration and invasion via a cyclooxygenase 2-dependent pathway.
High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time.
Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy.
Immunohistochemical visualization of pro-inflammatory cytokines and enzymes in ovarian tumors.
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.
Inducible COX-2-dependent apoptosis in human ovarian cancer cells.
Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells.
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells.
Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
Ovarian cancer G protein-coupled receptor 1-dependent and -independent vascular actions to acidic pH in human aortic smooth muscle cells.
Ovarian cancers arising from endometriosis: A microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2.
Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation.
PET radiotracer [¹?F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation.
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.
Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk.
Preventative effect of celecoxib in dimethylbenz[a]anthracene-induced ovarian cancer in rats.
Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: A meta-analysis of observational studies.
Promotion of osteoclast differentiation and activation in spite of impeded osteoblast-lineage differentiation under acidosis: Effects of acidosis on bone metabolism.
Prostaglandin E2 production in ovarian cancer cell lines is regulated by cyclooxygenase-1, not cyclooxygenase-2.
Repurposing [11C]PS13 for PET imaging of cyclooxygenase-1 (COX-1) in ovarian cancer xenograft mouse models.
RGS10 Regulates the Expression of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha through a G Protein-Independent Mechanism.
Roles of E-cadherin and cyclooxygenase enzymes in predicting different survival patterns of optimally cytoreduced serous ovarian cancer patients.
Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.
Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression.
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism.
Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers.
Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer.
Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody.
Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.
Synergistic COX2 Induction by IFN? and TNF? Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.
Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3.
Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.
Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer.
Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection.
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors.
The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.
The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer.
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
The prognostic significance of COX-2 and survivin expression in ovarian cancer.
Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells.
Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.
Urinary PGE-M levels and risk of ovarian cancer.
Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer.
Vitamin d inhibits ovarian cancer cell line proliferation in combination with celecoxib and suppresses cyclooxygenase-2 expression.
[Classical and novel molecular prognostic factors in ovarian cancers]
[COX-2 expression and ovarian cancer]
[Inhibitory effect of NS398 on the proliferation of human ovarian cancer cell lines CAOV3 and OVCAR3 in vitro]
[NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]
[Small interfering RNA-mediated COX-2 gene silencing inhibits the proliferation and migration of human ovarian cancer cell line CAOV-3.]
Overweight
Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects.
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.
Neutrophil Infiltration and Systemic Vascular Inflammation in Obese Women.
NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.
The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers.
Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities.
Paget Disease, Extramammary
Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Paget's Disease, Mammary
Expression of Cox-2 and Bcl-2 in Paget's Disease of the Breast.
Pancreatic Cyst
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Pancreatic Diseases
[Cyclooxygenase-2 gene expression in pancreatic disease]
Pancreatic Neoplasms
5-Lipoxygenase and Cyclooxygenase inhibitory Dammarane triterpenoid 1 from Borassus flabellifer seed coat, inhibits Tumor Necrosis Factor-? secretion in LPS induced THP-1 human monocytes and induces apoptosis in MIA PaCa-2 Pancreatic cancer cells.
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor.
Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer.
Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells.
Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-?B signaling by 6-shogaol.
Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer.
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma.
Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell lines.
Bioinformatic mining and validation of the effects of ferroptosis regulators on the prognosis and progression of pancreatic adenocarcinoma.
Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells.
Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
Cell Intrinsic Role of Cox-2 in Pancreatic Cancer Development.
Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry.
Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma.
Combined treatment with PPAR-? agonists in pancreatic cancer: a glimmer of hope for cancer therapy?
Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.
Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures.
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Correlation between Spiral CT Preoperative Staging of Pancreatic Cancer and PTEN and COX-2 Expression.
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines.
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells.
Cyclooxygenase-2 -1195G>A (rs689466) polymorphism and cancer susceptibility: an updated meta-analysis involving 50,672 subjects.
Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells.
Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer.
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.
Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.
Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E2.
Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.
Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer.
Cyclooxygenase-2 is overexpressed in chronic pancreatitis.
Cyclooxygenase-2 Polymorphisms and Pancreatic Cancer Susceptibility.
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.
Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer.
Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor.
Direct Sequencing of Cyclooxygenase-2 (COX-2) Revealed an Intronic Variant rs201231411 in Iranian Patients with Pancreatic Cancer.
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer.
Emerging drugs in pancreatic cancer.
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
EpCAM-Targeted 3WJ RNA Nanoparticle Harboring Delta-5-Desaturase siRNA Inhibited Lung Tumor Formation via DGLA Peroxidation.
Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease.
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers.
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.
Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?
Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray.
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts.
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer.
Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.
Inflammation and the development of pancreatic cancer.
Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.
Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma.
Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin.
Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer.
Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents.
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ?-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.
Knockdown of hTERT by SiRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2.
Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer.
Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer.
Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma.
miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells.
Molecular targeting therapy for pancreatic cancer.
Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2.
Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.
Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN.
Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
Novel therapeutic targets for pancreatic cancer.
Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth.
Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model.
Pancreatic cancer and thromboembolic disease, 150 years after Trousseau.
Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs.
PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells.
PGE2 Released by Pancreatic Cancer Cells Undergoing ER Stress Transfers the Stress to DCs Impairing Their Immune Function.
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer.
Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis.
Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk.
Prostaglandin E(2) Drives Cyclooxygenase-2 Expression via Cyclic AMP Response Element Activation in Human Pancreatic Cancer Cells.
Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumor--a single institution series.
Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2.
Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells.
Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.
Regulatory role of G protein-coupled receptors in pancreatic cancer development and progression.
Relationships of pain in pancreatic cancer patients with pathological stage and expressions of NF-?B and COX-2.
Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against ?? T cell cytotoxicity.
Retraction: "Concurrent inhibition of NF-?B, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer" by Ali et al.
Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer.
Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis.
Role of inflammation in pancreatic carcinogenesis and the implications for future therapy.
Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer.
Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo.
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.
The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2.
The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK.
The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer cells.
The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer.
The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2.
Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF.
Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.
Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer.
Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy.
Vascular Endothelial Growth Factor and not Cyclooxygenase 2 Promotes Endothelial Cell Viability in the Pancreatic Tumor Microenvironment.
Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
[Association between single nucleotide polymorphisms in the promoter of cyclooxygenase COX-2 gene and hereditary susceptibility to pancreatic cancer]
[Detection of expression of p53, p16, and cyclooxygenase 2 in pancreatic cancer by tissue microarray and correlation among these three genes]
[Effects of rofecoxib on angiogenesis of pancreatic cancer xenograft in nude mice]
[Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment]
Pancreaticobiliary Maljunction
Bile from a patient with anomalous pancreaticobiliary ductal union promotes the proliferation of human cholangiocarcinoma cells via COX-2 pathway.
Different expression of cyclooxygenase-2 in biliary epithelia of bile duct cancer with or without pancreaticobiliary maljunction.
Immunohistochemical analysis of cyclooxygenase-2 and vascular endothelial growth factor in pancreaticobiliary maljunction.
Metachronous Carcinomas of the Biliary Tract in a Patient Treated Three Times with Curative Surgery.
Pancreatitis
A possible case of saw palmetto-induced pancreatitis.
Celecoxib Oral Administration for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Randomized Prospective Trial.
COX-2 inhibition results in alterations in nuclear factor (NF)-kappaB activation but not cytokine production in acute pancreatitis.
COX-2 is not required for the development of murine chronic pancreatitis.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclooxygenase-2 gene disruption attenuates the severity of acute pancreatitis and pancreatitis-associated lung injury.
Cyclooxygenase-2 is overexpressed in chronic pancreatitis.
Cyclooxygenase-2 plays a central role in the genesis of pancreatitis and associated lung injury.
Cyclooxygenase-2 transcription is stimulated and amylase secretion is inhibited in pancreatic acinar cells after induction of acute pancreatitis.
Effect of inducible cyclooxygenase expression on local microvessel blood flow in acute interstitial pancreatitis.
Effects of dual inhibitor of cyclooxygenase and 5-lipoxygenase on acute necrotizing pancreatitis in rats.
Effects of prostaglandin and indomethacin on diet-induced acute pancreatitis in mice.
Ethyl pyruvate ameliorates liver injury secondary to severe acute pancreatitis.
Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.
IFN-gamma protects cerulein-induced acute pancreatitis by repressing NF-kappa B activation.
Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury.
Inhibition of cyclooxygenase-2 in experimental severe acute pancreatitis.
Inhibition of cyclooxygenase-2 reduces the protective effect of hepatocyte growth factor in experimental pancreatitis.
Intestinal barrier dysfunction and increased COX-2 gene expression in the gut of elderly rats with acute pancreatitis.
Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents.
Ischemic preconditioning inhibits development of edematous cerulein-induced pancreatitis: Involvement of cyclooxygenases and heat shock protein 70.
Nonsteroidal anti-inflammatory drugs alleviate severity of post-endoscopic retrograde cholangiopancreatography pancreatitis by inhibiting inflammation and reducing apoptosis.
Prevention of Severe Acute Pancreatitis With Cyclooxygenase-2 Inhibitors: A Randomized Controlled Clinical Trial.
Role of COX-2 in microcirculatory disturbance in experimental pancreatitis.
Selective cyclooxygenase-2 inhibitor ameliorates cholecystokinin-octapeptide-induced acute pancreatitis in rats.
Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis.
Smad4 loss synergizes with TGF? overexpression in promoting pancreatic metaplasia, PanIN development, and fibrosis.
The Effect of Genetic Polymorphisms of Cyclooxygenase 2 on Acute Pancreatitis in Turkey.
Toward routine use of nonsteroidal anti-inflammatory drugs for patients undergoing endoscopic retrograde cholangiopancreatography.
[Acute pancreatitis after treatment by celecoxib.]
[Role of cyclooxygenase-2 in pulmonary microcirculation disorder in rats with acute pancreatitis]
Pancreatitis, Acute Hemorrhagic
Cyclooxygenase and lipoxygenase metabolism in sodium taurocholate induced acute hemorrhagic pancreatitis in rats.
Pancreatitis, Acute Necrotizing
Effects of dual inhibitor of cyclooxygenase and 5-lipoxygenase on acute necrotizing pancreatitis in rats.
Pancreatitis, Chronic
A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis.
COX-2 is not required for the development of murine chronic pancreatitis.
Cyclooxygenase 2 expression in chronic pancreatitis: correlation with stage of the disease and diabetes mellitus.
Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer.
Cyclooxygenase-2 is overexpressed in chronic pancreatitis.
Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines.
Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas.
Prostaglandin E2 modulates TNF-alpha-induced MCP-1 synthesis in pancreatic acinar cells in a PKA-dependent manner.
Transgenic expression of cyclooxygenase-2 in pancreatic acinar cells induces chronic pancreatitis.
Papilloma
3,3'-diindolylmethane suppresses 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and tumor promotion in mouse skin via the downregulation of inflammatory mediators.
Altered prostanoid signaling contributes to increased skin tumorigenesis in tpl2 knockout mice.
Are FDA-Approved Sunscreen Components Effective in Preventing Solar UV-Induced Skin Cancer?
Avian Papilloma and Squamous Cell Carcinoma: a Histopathological, Immunohistochemical and Virological study.
Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors.
Cell-type-specific roles for COX-2 in UVB-induced skin cancer.
Characterization of cyclooxygenase in laryngeal papilloma by molecular techniques.
Constitutive Overexpression of the Oncogene Rac1 in the Airway of Recurrent Respiratory Papillomatosis Patients is a Targetable Host-Susceptibility Factor.
Cox-2 gene expression in chemically induced skin papillomas cannot predict subsequent tumor fate.
COX-2 Overexpression in Schneiderian Papillomas.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.
Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis.
Elevated prostaglandin E2 level via cPLA2--COX-2--mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats.
Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Expression of COX-1, COX-2 and mPGES-1 in penile and preputial papillomas and squamous cell carcinomas in the horse.
Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation.
Immunohistochemical assessment of p16, COX-2 and EGFR in HPV-positive cervical squamous intraepithelial lesions.
Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.
Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Inhibition of Phorbol Ester-induced Mouse Skin Tumor Promotion and COX-2 Expression by Celecoxib: C/EBP as a Potential Molecular Target.
Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets.
Inhibitory effects of the standardized extract (DA-9601) of Artemisia asiatica Nakai on phorbol ester-induced ornithine decarboxylase activity, papilloma formation, cyclooxygenase-2 expression, inducible nitric oxide synthase expression and nuclear transcription factor kappa B activation in mouse skin.
Is cyclooxygenase-2 important in skin carcinogenesis?
Juvenile recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: Initial report.
Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2.
Molecular carcinogenesis in equine penile cancer: A potential animal model for human penile cancer.
Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression.
Recurrent respiratory papillomatosis: update 2008.
Reduction of p38 mitogen-activated protein kinase and cyclooxygenase-2 signaling by isoflurane inhibits proliferation and apoptosis evasion in human papillomavirus-infected laryngeal papillomas.
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels.
The expression of epidermal growth factor receptor, vascular endothelial growth factor, matrix metalloproteinase-2, and cyclooxygenase-2 in relation to human papilloma viral load and persistence of human papillomavirus after conization with negative margins.
The expression pattern of prostaglandin E synthase and EP receptor isoforms in normal mouse skin and preinvasive skin neoplasms.
Tissue biomarkers as prognostic variables of cervical cancer.
Ultraviolet B(UVB)-induced cox-2 expression in murine skin: an immunohistochemical study.
Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas.
Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor-kappa B.
[The expressions of PPAR-gamma, COX-2 in the lesions of patients with condyloma acuminatum and bowenoid papulosis]
Papilloma, Intraductal
Expression of cyclooxygenase-2 in malignant and benign breast tumors.
Papilloma, Inverted
COX-2 overexpression in sinonasal inverted papilloma.
Inflammation and apoptosis in malignant transformation of sinonasal inverted papilloma: the role of the bridge molecules, cyclooxygenase-2, and nuclear factor ?B.
Pattern of expression of cyclooxygenase-2 in malignant transformation of sinonasal inverted papilloma.
[Significances of COX-2, p21, Ki-67 expression and HPV infection in nasal inverted papilloma].
Papillomavirus Infections
Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma.
Constitutive Overexpression of the Oncogene Rac1 in the Airway of Recurrent Respiratory Papillomatosis Patients is a Targetable Host-Susceptibility Factor.
Deregulated cyclooxygenase-2 expression in oral premalignant tissues.
Expression of Human Papillomavirus is Correlated with Ki-67 and COX-2 Expressions in Keratocystic Odontogenic Tumor.
Immunohistochemical assessment of p16, COX-2 and EGFR in HPV-positive cervical squamous intraepithelial lesions.
Immunohistochemical evaluation of COX-2 expression in HPV-positive cervical squamous intraepithelial lesions.
Increased detection of clue cells in smears from cervical intraepithelial lesions with reduced expression of COX-2.
[Significances of COX-2, p21, Ki-67 expression and HPV infection in nasal inverted papilloma].
Paraganglioma
HuR in pheochromocytomas and paragangliomas - overexpression in verified malignant tumors.
Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background.
Paramyxoviridae Infections
Original research article Parainfluenza virus infection enhances NSAIDs-induced inhibition of PGE2 generation and COX-2 expression in human airway epithelial cells.
Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection.
Paraplegia
A potential protective effect of alpha-tocopherol on vascular complication in spinal cord reperfusion injury in rats.
Parasitemia
Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency.
Aspirin treatment of mice infected with Trypanosoma cruzi and implications for the pathogenesis of Chagas disease.
Effects of eicosanoid biosynthesis inhibitors on the prophenoloxidase-activating system and microaggregation reactions in the hemolymph of Rhodnius prolixus infected with Trypanosoma rangeli.
Lymphocyte muscarinic cholinergic activity and PGE2 involvement in experimental Trypanosoma cruzi infection.
Suppression of Prostaglandin E2 by Malaria Parasite Products and Antipyretics Promotes Overproduction of Tumor Necrosis Factor- alpha : Association with the Pathogenesis of Childhood Malarial Anemia.
Parasitic Diseases
Entamoeba histolytica: induction of cyclooxygenase-2 expression during amoebic liver abscess formation in hamsters (Mesocricetus auratus).
IL-4 up-regulates cyclooxygenase-1 expression in macrophages.
Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome?
Paratuberculosis
Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.
Parkinson Disease
Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease.
COX-2 and neurodegeneration in Parkinson's disease.
COX-2 in the neurodegenerative process of Parkinson's disease.
COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice.
Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson's disease.
Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration.
Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells.
Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.
Cyclooxygenase-2 polymorphisms in Parkinson's disease.
Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity.
Drp1-dependent mitochondrial fission regulates p62-mediated autophagy in LPS-induced activated microglial cells.
Effect of preferential cyclooxygenase-2 (COX-2) inhibitor against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced striatal lesions in rats: behavioral, biochemical and histological evidences.
Enzymatic oxidation of dopamine: the role of prostaglandin H synthase.
Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development.
Function of COX-2 and prostaglandins in neurological disease.
Genetic association of cyclooxygenase-2 gene polymorphisms with Parkinson's disease susceptibility in Chinese Han population.
Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation.
Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease.
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.
Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease.
Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease.
Mechanism of age-associated up-regulation in macrophage PGE2 synthesis.
Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration.
Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease.
Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells.
Paraquat induces cyclooxygenase-2 (COX-2) implicated toxicity in human neuroblastoma SH-SY5Y cells.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity.
Progress in COX-2 inhibitors: a journey so far.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets.
Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.
Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats.
Role of cyclooxygenase-2 in tetrahydrobiopterin-induced dopamine oxidation.
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease.
The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats.
The Effect of Docosahexaenoic Acid on Visual Evoked Potentials in a Mouse Model of Parkinson's Disease: The Role of Cyclooxygenase-2 and Nuclear Factor Kappa-B.
The effect of guggulipid and nimesulide on MPTP-induced mediators of neuroinflammation in rat astrocytoma cells, C6.
The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease.
The effects of piroxicam in the attenuation of MPP+/MPTP toxicity in vitro and in vivo.
The role of ?-adrenergic blockers in Parkinson's disease: possible genetic and cell-signaling mechanisms.
The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission.
[Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease]
[Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway.]
[P38MAPK pathway regulates COX-2 and caspase-3 expression in a mouse model of Parkinson disease.]
[The effect of cyclooxygenase-2 on dopaminergic neurons in substantia nigra of Parkinson's disease mice induced by MPTP].
Parkinsonian Disorders
Cyclooxygenase-2 Directs Microglial Activation-Mediated Inflammation and Oxidative Stress Leading to Intrinsic Apoptosis in Zn-Induced Parkinsonism.
Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells.
Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats.
Paroxysmal Hemicrania
Hemicrania continua changed to chronic paroxysmal hemicrania after treatment with cyclooxygenase-2 inhibitor.
Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors.
Pelvic Inflammatory Disease
Study on the Bioassay of Anti-Inflammatory Effects of Fuke Qianjin Capsule Based on COX-2 Inhibiting Activity.
Penile Neoplasms
[Value of targeted therapy for penile cancer.]
Peptic Ulcer
"Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.
A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients.
A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries.
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Aspirin-induced peptic ulcer and genetic polymorphisms.
Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan.
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Clinical manifestations of gout and their management.
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
COX-2 Gene Promoter Methylation in Patients Infected with Helicobacter Pylori.
COX-2 inhibition versus gastroprotection with dual COX inhibitors: an evidence-based approach.
COX-2 inhibitors in rheumatoid arthritis.
Cyclooxygenase-2 inhibitors in patients with high gastrointestinal risk: are we there yet?
Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea.
Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?
Effect of a specific cyclooxygenase-gene polymorphism (A-842G/C50T) on the occurrence of peptic ulcer hemorrhage.
Epidemiology of acute upper gastrointestinal bleeding.
Evaluation of extemporaneously manufactured topical gels containing aceclofenac on inflammation and hyperalgesia in rats.
Future expectations in the prophylaxis of intestinal bleeding.
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Gastroduodenal safety of cyclooxygenase-2 inhibitors.
Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs.
Gastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indometacin and other non-steroidal anti-inflammatory drugs to pigs: a model for human gastrointestinal disease.
Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time.
Helicobacter pylori and non-malignant diseases.
Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors.
Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin.
Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
Inhibition of cyclooxygenase: a novel approach to cancer prevention.
Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism.
Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations.
Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention.
Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer.
NSAID-induced gastrointestinal and cardiovascular injury.
Pharmacology and efficacy of cyclooxygenase (COX) inhibitors.
Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: A study from northern India.
Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Risk factors associated with refractory peptic ulcers.
Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study.
Supportive care of elderly patients with cancer.
The IL-1B Genetic Polymorphism Is Associated with Aspirin-Induced Peptic Ulcers in a Korean Ethnic Group.
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
The therapeutic approaches of community based primary care practitioners to osteoarthritis of the hip in an elderly patient.
Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans.
When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations.
[A genetic background of ulcer diseases induced by NSAID/aspirin].
[Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions]
[Are COX-2 inhibitors truly able to prevent NSAIDs-associated ulcer?]
[From PICO to search terms on the Internet: how to find relevant information? New coxibs: do they have a better gastrointestinal safety?]
[Guidelines of prevention and treatment for NSAID-related peptic ulcers]
[Low-dose aspirin (LDA)/nonsteroidal anti-inflammatory drugs(NSAIDs)-induced gastrointestinal injury in Japan].
[Treatment of peptic ulcer related to rheumatic diseases]
Peptic Ulcer Perforation
30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study.
Induction of cyclooxygenase-2 in mesothelial cells in peritonitis caused by perforated ulcers--an immunohistochemical study in humans.
Peri-Implantitis
Histological evaluation of peri-implant mucosal and gingival tissues in peri-implantitis, peri-implant mucositis and periodontitis patients: a cross-sectional clinical study.
Long non-coding RNA and mRNA expression profiles in peri-implantitis vs periodontitis.
PPAR-?, RXR, VDR, and COX-2 Expressions in gingival tissue samples of healthy individuals, periodontitis and peri-implantitis patients.
Periapical Granuloma
Immunohistochemical Analysis of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha in Periapical Lesions.
[Expression of cyclooxygenase 2 mRNA in apical periodontitis.]
Periapical Periodontitis
Celecoxib treatment dampens LPS-induced periapical bone resorption in a mouse model.
Periapical bone response to bacterial lipopolysaccharide is shifted upon cyclooxygenase blockage.
[Expression of cyclooxygenase 2 mRNA in apical periodontitis.]
Periarthritis
Oxaprozin: kinetic and dynamic profile in the treatment of pain.
Perinatal Death
Opposing actions of prostaglandins and oxytocin determine the onset of murine labor.
Periodontal Diseases
?-Glucans (Saccharomyces cereviseae) Reduce Glucose Levels and Attenuate Alveolar Bone Loss in Diabetic Rats with Periodontal Disease.
Assessment of Alloxan-Induced Diabetic Rats as a Periodontal Disease Model Using a Selective Cyclooxygenase (COX)-2 Inhibitor.
Comparative evaluation of the efficacy of the cyclooxygenase pathway inhibitor and nitric oxide synthase inhibitor in the reduction of alveolar bone loss in ligature induced periodontitis in rats: An experimental study.
Cox-2 Expression in Gingival Biopsies From Periodontal Patients is Correlated With Connective Tissue Loss.
COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats.
Cyclooxygenase-2 and matrix metalloproteinase-9 expressions correlate with tissue inflammation degree in periodontal disease.
Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.
Effect of meloxicam on gingival crevicular fluid IL-1beta and IL1 receptor antagonist levels in subjects with chronic periodontitis, and its effects on clinical parameters.
Effects of Selective Versus Non-Selective COX-2 Inhibition on Experimental Periodontitis.
Endotoxins potentiate COX-2 and RANKL expression in compressed PDL cells.
Enhancement of lipopolysaccharide-stimulated cyclooxygenase-2 mRNA expression and prostaglandin E2 production in gingival fibroblasts from individuals with Down syndrome.
Evaluation of DNA methylation of inflammatory genes following treatment of chronic periodontitis: A pilot case-control study.
Flurbiprofen: a potent inhibitor of alveolar bone resorption in beagles.
Induction of COX-2 expression by mechanical tension force in human periodontal ligament cells.
Induction of cyclooxygenase-2 mRNA and protein expression in human gingival fibroblasts stimulated with nicotine.
Involvement of cyclooxygenase-2 in interleukin-1alpha-induced prostaglandin production by human periodontal ligament cells.
Involvement of cyclooxygenase-2 in serum-induced prostaglandin production by human oral gingival epithelial cells.
Involvement of the P2X7 purinergic receptor and c-Jun N-terminal and extracellular signal-regulated kinases in cyclooxygenase-2 and prostaglandin E2 induction by LL-37.
Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease.
Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis.
Porphyromonas gingivalis Fimbria-Induced Expression of Inflammatory Cytokines and Cyclooxygenase-2 in Mouse Macrophages and Its Inhibition by the Bioactive Compounds Fibronectin and Melatonin.
Preventive effects of a Kampo medicine, Shosaikoto, on inflammatory responses in LPS-treated human gingival fibroblasts.
Prostaglandin production via induction of cyclooxygenase-2 by human gingival fibroblasts stimulated with lipopolysaccharides.
Regulation of nicotine-induced cyclooxygenase-2 protein expression in human gingival fibroblasts.
Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.
Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats.
Short-term effect of COX-2 selective inhibitor as an adjunct for the treatment of periodontal disease: a clinical double-blind study in humans.
The effects of a topically-active non-steroidal anti-inflammatory drug on ligature-induced periodontal disease in the squirrel monkey.
The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease.
Topical Application of Hangeshashinto (TJ-14) in the Treatment of Chemotherapy-Induced Oral Mucositis.
Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP).
[The role of COX-2 in dentistry. Past or future?]
Periodontitis
Anti-inflammatory effect of ATB-352, a H2S -releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats.
Assessment of microRNA-144-5p and its putative targets in inflamed gingiva from chronic periodontitis patients.
Association between cyclooxygenase-2 gene polymorphisms and risk of periodontitis: a meta-analysis involving 5653 individuals.
Association of matrix metalloproteinase (MMP)-1, 3, 9, interleukin (IL)-2, 8 and cyclooxygenase (COX)-2 gene polymorphisms with chronic periodontitis in a Chinese population.
Association of matrix metalloproteinase (MMP-1, MMP-3 and MMP-9) and cyclooxygenase-2 gene polymorphisms and their proteins with chronic periodontitis.
Autophagy upregulates inflammatory cytokines in gingival tissue of patients with periodontitis and lipopolysaccharide-stimulated human gingival fibroblasts.
Azilsartan increases levels of IL-10, down-regulates MMP-2, MMP-9, RANKL/RANK, Cathepsin K and up-regulates OPG in an experimental periodontitis model.
Carvedilol decrease IL-1? and TNF-?, inhibits MMP-2, MMP-9, COX-2, and RANKL expression, and up-regulates OPG in a rat model of periodontitis.
Celecoxib suppresses lipopolysaccharide-stimulated oral squamous cell carcinoma proliferation in vitro and in vivo.
Changes in cyclooxygenase metabolites in experimental periodontitis in Macaca mulatta.
Cinnamic acid decreases periodontal inflammation and alveolar bone loss in experimental periodontitis.
Comparative evaluation of the efficacy of the cyclooxygenase pathway inhibitor and nitric oxide synthase inhibitor in the reduction of alveolar bone loss in ligature induced periodontitis in rats: An experimental study.
Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats.
COX-2 gene polymorphisms and risk of chronic periodontitis: a case-control study and meta-analysis.
COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats.
COX-2 is associated with periodontitis in Europeans.
Curcumin attenuates cyclooxygenase-2 expression via inhibition of the NF-?B pathway in lipopolysaccharide-stimulated human gingival fibroblasts.
Cyclooxygenase 2 gene polymorphisms and chronic periodontitis in a North Indian population: a pilot study.
Cyclooxygenase-2 and matrix metalloproteinase-9 expressions correlate with tissue inflammation degree in periodontal disease.
Cyclooxygenase-2 Gene-765 single nucleotide polymorphism as a protective factor against periodontitis in Taiwanese.
Cyclooxygenase-2 Inhibitors Decrease Interleukin-1?-Stimulated Prostaglandin E
Cyclooxygenase-2 inhibitors decrease interleukin-1beta-stimulated prostaglandin E2 and IL-6 production by human gingival fibroblasts.
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats.
Effect of telmisartan on levels of IL-1, TNF-?, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model.
Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss.
Effects of Selective Cyclooxygenase-2 Inhibitor and Omega-3 Fatty Acid on Serum Interleukin-1?, Osteocalcin, and C-Reactive Protein Levels in Rats.
Effects of Selective Cyclooxygenase-2 Inhibitor and Omega-3 Fatty Acid on Serum Interleukin-1beta, Osteocalcin, and C-Reactive Protein Levels in Rats.
Effects of Selective Versus Non-Selective COX-2 Inhibition on Experimental Periodontitis.
Endothelial dysfunction in rats with ligature-induced periodontitis: Participation of nitric oxide and cycloxygenase-2-derived products.
Enhancement of carbachol-induced amylase secretion in parotid glands from rats with experimental periodontitis.
Epigenetic change in E-Cardherin and COX-2 to predict chronic periodontitis.
Epigenetic regulation of inflammation in periodontitis: cellular mechanisms and therapeutic potential.
Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis.
Genes related to inflammation and bone loss process in periodontitis suggested by bioinformatics methods.
Genetic Factors and the Risk of Periodontitis Development: Findings from a Systematic Review Composed of 13 Studies of Meta-Analysis with 71,531 Participants.
Histological evaluation of peri-implant mucosal and gingival tissues in peri-implantitis, peri-implant mucositis and periodontitis patients: a cross-sectional clinical study.
Host modulation therapy with anti-inflammatory agents.
Impact of an anti-inflammatory therapy and its withdrawal on the progression of experimental periodontitis in rats.
Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats.
Influence of experimental periodontitis on cholinergic stimulation of K+ release in rat parotid glands.
Interleukin-1beta-induced prostaglandin E2 production by human gingival fibroblasts is upregulated by glycine.
Local administration of Tiludronic Acid downregulates important mediators involved in periodontal tissue destruction in experimental periodontitis in rats.
Long non-coding RNA and mRNA expression profiles in peri-implantitis vs periodontitis.
Moving into a new era of periodontal genetic studies: relevance of large case-control samples using severe phenotypes for genome-wide association studies.
Olmesartan decreases IL-1? and TNF-? levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis.
Periodontitis Deteriorates Cognitive Function and Impairs Neurons and Glia in a Mouse Model of Alzheimer's Disease.
Periodontitis increases vascular cyclooxygenase-2: potential effect on vascular tone.
Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis.
Porphyromonas gingivalis induces RANKL in bone marrow stromal cells: involvement of the p38 MAPK.
PPAR-?, RXR, VDR, and COX-2 Expressions in gingival tissue samples of healthy individuals, periodontitis and peri-implantitis patients.
Preterm birth and/or low birth weight are associated with periodontal disease and the increased placental immunohistochemical expression of inflammatory markers.
Prostaglandin H synthase isoenzyme distribution in the gingival tissue of patients with periodontitis: Pronounced expression adjacent to gram-positive bacteria.
Protective effects of baicalin on ligature-induced periodontitis in rats.
Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats.
Proteinase-activated receptor-2 (PAR2) agonist causes periodontitis in rats.
Reduction of orthodontic tooth movement by experimentally induced periodontal inflammation in mice.
Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats.
Selective cyclooxygenase-2 inhibition prevents bone resorption.
Sex-specific up-regulation of p50-associated COX-2 extragenic RNA (PACER) lncRNA in periodontitis.
Short-term effect of COX-2 selective inhibitor as an adjunct for the treatment of periodontal disease: a clinical double-blind study in humans.
The Effects of Selective COX-2 Inhibitor/Celecoxib and Omega-3 Fatty Acid on Matrix Metalloproteinases, TIMP-1, and Laminin-5gamma2-Chain Immunolocalization in Experimental Periodontitis.
The overexpression of cyclo-oxygenase-2 in chronic periodontitis.
The Role of DNA Methylation and Histone Modification in Periodontal Disease: A Systematic Review.
Tocoyena sellowiana extract decreases bone loss in an experimental model of periodontitis in rats: Putative role for cyclooxygenase-2 and IL-1? inhibition.
Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP).
Peripheral Arterial Disease
Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability.
Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.
Inhibition of cyclooxygenase attenuates the blood pressure response to plantar flexion exercise in peripheral arterial disease.
Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication.
Peripheral Nerve Injuries
COX-1-dependent prostaglandin D2 in microglia contributes to neuropathic pain via DP2 receptor in spinal neurons.
Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury.
Cyclooxygenase-1 in the spinal cord is altered after peripheral nerve injury.
Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats.
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.
GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
Increased levels of cyclooxygenase-2 mRNA in the rat spinal cord after peripheral inflammation: an in situ hybridization study.
Preemptive effects of intrathecal cyclooxygenase inhibitor or nitric oxide synthase inhibitor on thermal hypersensitivity following peripheral nerve injury.
Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury.
Peripheral Nervous System Diseases
Cyclooxygenase-2 pathway as a potential therapeutic target in diabetic peripheral neuropathy.
Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.
Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes.
Peripheral Vascular Diseases
Plasma factor and platelet sensitivity to prostacyclin in patients with peripheral vascular disease before and after treatment with a combination of a cyclooxygenase and a phosphodiesterase inhibitor.
The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction.
[Defects in the prostaglandin system. VII. (Generalized, inherited [?]) cyclooxygenase defect]
Peritoneal Fibrosis
A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells.
Stimulation of Cyclooxygenase 2 Expression in Rat Peritoneal Mesothelial Cells.
Peritoneal Neoplasms
Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Peritonitis
Alterations in spontaneous contractions of rat ileum and jejunum after peritonitis.
Alterations in spontaneous contractions of rat proximal and distal colon after peritonitis.
Anti-inflammatory and antinociceptive effects of racemic goniothalamin, a styryl lactone.
Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA.
Dermal Fibroblasts Promote Alternative Macrophage Activation Improving Impaired Wound Healing.
Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes.
Effect of indomethacin on peritoneal protein loss in a rabbit model of peritonitis.
Effects of intraperitoneal cyclooxygenase inhibition on inflammatory mediators in dialysate and peritoneal membrane characteristics during peritonitis in continuous ambulatory peritoneal dialysis.
Free-radical and cyclooxygenase-catalyzed lipid peroxidation in membranes of blood cells under UV irradiation.
Gentamicin and indomethacin in the treatment of septic shock: effects on prostacyclin and thromboxane A2 production.
Induction of cyclooxygenase-2 in mesothelial cells in peritonitis caused by perforated ulcers--an immunohistochemical study in humans.
Inhibition of Cyclooxygenase-2 Suppresses Lymph Node Metastasis via Reduction of Lymphangiogenesis.
Longitudinal Changes of NF-?B Downstream Mediators and Peritoneal Transport Characteristics in Incident Peritoneal Dialysis Patients.
Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis.
Lycopene rich extract from red guava (Psidium guajava L.) displays anti-inflammatory and antioxidant profile by reducing suggestive hallmarks of acute inflammatory response in mice.
Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings.
Preclinical pharmacokinetic and pharmacodynamic evaluation of thiazolidinone PG15: an anti-inflammatory candidate.
Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.
Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis.
Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality.
Peroxisomal Disorders
Cyclooxygenase pathway in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin.
Persistent Fetal Circulation Syndrome
[The effect of indomethacin on placental permeability and the fetal lung circulation]
Persistent Infection
Chronic infection during placental malaria is associated with up-regulation of cycloxygenase-2.
Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression.
Role of cytosolic and calcium independent phospholipases A2 in insulin secretion impairment of INS-1E cells infected by S. aureus.
Peutz-Jeghers Syndrome
Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome.
Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis.
N-methylnitrosourea aggravates gastrointestinal polyposis in Lkb1+/- mice.
Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers syndrome.
Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.
Pharyngitis
Effect of sodium azulene sulfonate on capsaicin-induced pharyngitis in rats.
Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac.
Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors.
The Acidic Fraction of Isatidis Radix Regulates Inflammatory Response in LPS-Stimulated RAW264.7 Macrophages through MAPKs and NF-?B Pathway.
Utility and sensitivity of the sore throat pain model: results of a randomized controlled trial on the COX-2 selective inhibitor valdecoxib.
Yan-Hou-Qing formula attenuates ammonia-induced acute pharyngitis in rats via inhibition of NF-?B and COX-2.
Phenylketonurias
Coupled Genome-Wide DNA Methylation and Transcription Analysis Identified Rich Biomarkers and Drug Targets in Triple-Negative Breast Cancer.
Pheochromocytoma
Apo J/clusterin expression and secretion: Evidence for 15-deoxy-?(12,14)-PGJ(2)-dependent mechanism.
Benzo[a]pyrene diol epoxide up-regulates COX-2 expression through NF-kappaB in rat astrocytes.
Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway.
Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells.
Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma.
Gi-coupled prostanoid receptors are the likely targets for COX-1-generated prostanoids in rat pheochromocytoma (PC12) cells.
Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.
HuR in pheochromocytomas and paragangliomas - overexpression in verified malignant tumors.
Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
Nitric oxide induces apoptosis via AP-1-driven upregulation of COX-2 in rat pheochromocytoma cells.
Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients.
Simultaneous inhibition of COX-2 and activation of PPAR-? resulted in the same level and pattern of neuroprotection as they were targeted separately.
Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background.
[Role of immunohistochemical study of extracellular matrix components in the estimation of the malignant potential of adrenal pheochromocytomas]
Photosensitivity Disorders
Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Protective effect of a topical sunscreen formulation fortified with melatonin against UV-induced photodermatitis: an immunomodulatory effect via NF-?B suppression.
Pigmentation Disorders
Antioxidant, Antimicrobial, and Bioactive Potential of Two New Haloarchaeal Strains Isolated from Odiel Salterns (Southwest Spain).
Pituitary ACTH Hypersecretion
Cyclooxygenase enzyme and PGE2 expression in patients with functional and non-functional pituitary adenomas.
Pituitary Neoplasms
Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.
Analysis of COX-2, PD-L1 and ARG1 expression in human pituitary adenoma.
Biomarkers of pituitary neoplasms: a review (Part II).
Cyclooxygenase enzyme and PGE2 expression in patients with functional and non-functional pituitary adenomas.
Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.
Cyclooxygenase-2 expression in human pituitary tumors.
Expression of cyclooxygenase-2 (COX-2) in pituitary tumours.
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Placenta, Retained
Outcomes from Experimental Testing of Nonsteroidal Anti-Inflammatory Drug (NSAID) Administration during the Transition Period of Dairy Cows.
Plasmacytoma
PVT1 (rs13281615) and miR-146a (rs2910164) polymorphisms affect the prognosis of colon cancer by regulating COX2 expression and cell apoptosis.
Platelet Storage Pool Deficiency
Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.
Pleural Effusion
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Quantitation of arachidonic acid lipoxygenase products in malignant and nonmalignant effusions.
Pleurisy
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Are the anti-inflammatory effects of dexamethasone responsible for inhibition of the induction of enzymes involved in prostanoid formation in rat carrageenin-induced pleurisy?
COX-2 expression in stromal fibroblasts self-limits their numbers in lymph node inflammatory responses.
Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy.
Cyclooxygenase enzymes and their products in the carrageenan-induced pleurisy in rats.
Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation.
Effect of combination of nitric oxide synthase and cyclooxygenase inhibitors on carrageenan-induced pleurisy in rats.
Effect of methylguanidine in carrageenan-induced acute inflammation in the rats.
Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, on carrageenan-induced pleurisy and stress-induced gastric lesions in rats.
Effects of TZI-41127, a novel selective 5-lipoxygenase inhibitor, on A23187-induced pleurisy in rats.
Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Expression and function of cyclooxygenase-2 in mesothelial cells during late phase of rat carrageenin-induced pleurisy.
Increased migration of neutrophils to granulocyte-colony stimulating factor in rat carrageenin-induced pleurisy: roles of complement, bradykinin, and inducible cyclooxygenase-2.
Indicaxanthin from cactus pear fruit exerts anti-inflammatory effects in carrageenin-induced rat pleurisy.
Induction of prostaglandin H synthase-2 in rat carrageenin-induced pleurisy and effect of a selective COX-2 inhibitor.
Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation.
Involvement of leukotriene B4 in zymosan-induced rat pleurisy: inhibition of leukocyte infiltration by the 5-lipoxygenase inhibitor T-0757.
Leukotriene B4 production and pharmacologic regulation of reverse passive Arthus pleurisy: importance of antigen dose.
Local and systemic expression of inducible nitric oxide synthase in comparison with that of cyclooxygenase-2 in rat carrageenin-induced pleurisy.
Local anti-inflammatory activities of tixocortol 21-pivalate, inhibition of prostaglandins and leukotrienes synthesis, in carrageenin-induced pleurisy. Reversion of effects by RU 486.
Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Paracetamol-inhibitable COX-2.
Pharmacological studies on zymosan inflammation in rats and mice. 2: Zymosan-induced pleurisy in rats.
Prostaglandin F(2alpha) produced by inducible cyclooxygenase may contribute to the resolution of inflammation.
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
Role of prostaglandin H synthase-2 in prostaglandin E2 formation in rat carrageenin-induced pleurisy.
Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2).
[Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors]
Pleuropneumonia
5-Lipoxygenase and cyclooxygenase-2 in the lungs of pigs naturally affected by enzootic pneumonia and porcine pleuropneumonia.
Expression of cyclooxygenase-2 in swine naturally infected with Actinobacillus pleuropneumoniae.
Immunohistochemical detection of cyclooxygenase-2 in lungs of pigs naturally infected with Actinobacillus pleuropneumoniae.
In vitro effects of Actinobacillus pleuropneumoniae on inducible nitric oxide synthase and cyclooxygenase-2 in porcine alveolar macrophages.
Pneumococcal Infections
Streptococcus pneumoniae induced regulation of cyclooxygenase-2 in human lung tissue.
Pneumoconiosis
Polymorphisms in cyclooxygenase-2 gene and risk of developing coal workers' pneumoconiosis: a case-control study.
Rare pneumoconiosis induced by long-term amorphous silica exposure: the histological characteristics and expression of cyclooxygenase-2 as an antifibrogenic mediator in macrophages.
Pneumonia
5-Lipoxygenase and cyclooxygenase-2 in the lungs of pigs naturally affected by enzootic pneumonia and porcine pleuropneumonia.
A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen.
AdipoR-increased intracellular ROS promotes cPLA2 and COX-2 expressions via activation of PKC and p300 in adiponectin-stimulated human alveolar type II cells.
Airway hyperresponsiveness induced by intermittent hypoxia in rats.
Allergic lung responses are increased in prostaglandin H synthase-deficient mice.
ATP mediates NADPH oxidase/ROS generation and COX-2/PGE2 expression in A549 cells: role of P2 receptor-dependent STAT3 activation.
Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor.
Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2.
Cigarette smoke extract-induced COX-2 expression via a PKC{alpha}/c-Src/EGFR, PDGFR/PI3K/Akt/NF-{kappa}B pathway and p300 in tracheal smooth muscle cells.
Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer.
Concomitant activation of extracellular signal-regulated kinase and induction of COX-2 stimulates maximum prostaglandin E2 synthesis in human airway epithelial cells.
Conditional regulation of cyclooxygenase-2 in tracheobronchial epithelial cells modulates pulmonary immunity.
Contribution of alveolar type II cell-derived cyclooxygenase-2 to basal airway function, lung inflammation, and lung fibrosis.
COX-2 expression and inflammatory effects by diesel exhaust particles in vitro and in vivo.
COX-2 Inhibits Th9 Differentiation During Allergic Lung Inflammation Via Downregulation of IL-17RB.
Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication.
Cyclooxygenase inhibitor use is associated with increased COVID-19 severity.
Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs.
Cyclooxygenase-1 overexpression decreases Basal airway responsiveness but not allergic inflammation.
Cyclooxygenase-2 (COX-2) Regulates Th17 Cell Differentiation During Allergic Lung Inflammation.
Cyclooxygenase-2 expression in inflammatory lung lesions of nonhuman primates.
Cyclooxygenase-2 expression in pigs infected experimentally with Mycoplasma hyopneumoniae.
Cycloxygenase Inhibition Enhances the Effects of Surfactant Therapy in Endotoxin-Induced Rat Model of ARDS.
Cytochrome P450 metabolites of arachidonic acid but not cyclooxygenase-2 metabolites contribute to the pulmonary vascular hyporeactivity in rats with acute Pseudomonas pneumonia.
Dimethyl Sulfoxide Attenuates Acute Lung Injury Induced by Hemorrhagic Shock/Resuscitation in Rats.
Effect of cyclooxygenase blockade on gas exchange and hemodynamics in Pseudomonas pneumonia.
Effect of methylprednisolone and of ibuprofen, a nonsteroidal antiinflammatory agent, on bronchoalveolar inflammation following endotoxemia.
Eriobotrya japonica leaf and its triterpenes inhibited lipopolysaccharide-induced cytokines and inducible enzyme production via the nuclear factor-kappaB signaling pathway in lung epithelial cells.
Formaldehyde induces lung inflammation by an oxidant and antioxidant enzymes mediated mechanism in the lung tissue.
Fractions of Boswellia serrata suppress LTA4, LTC4, Cyclooxygenase-2 activities and mRNA in HL-60 Cells and reduce lung inflammation in BALB/c mice.
HIGH-TIDAL VOLUME VENTILATION AGGRAVATES SEPSIS-INDUCED MULTIORGAN DYSFUNCTION IN A DEXAMETHASONE-INHIBITABLE MANNER.
Immunohistochemical Labelling of Cyclooxygenase-2 in Lung Lesions of Calves Infected with Mycoplasma bovis.
Induction of COX-2 in human airway cells by manganese: role of PI3K/PKB, p38 MAPK, PKCs, Src, and glutathione depletion.
Inflammatory signalings involved in airway and pulmonary diseases.
Inhalation therapy with the synthetic TIP-like peptide AP318 attenuates pulmonary inflammation in a porcine sepsis model.
Inhibition of COX-2 Aggravates Neutrophil Migration and Pneumocyte Apoptosis in Surfactant-Depleted Rat Lungs.
Lectin-detectable effects of localized pneumonia on airway mucous cell populations: role of cyclooxygenase metabolites.
Lung inflammation caused by adenosine-5'-triphosphate is mediated via Ca2+/PKCs-dependent COX-2/PGE2 induction.
Meconium aspiration stimulates cyclooxygenase-2 and nitric oxide synthase-2 expression in rat lungs.
miR-155 Modulates Cockroach Allergen- and Oxidative Stress-Induced Cyclooxygenase-2 in Asthma.
Mitigation and Treatment of Radiation-Induced Thoracic Injury With a Cyclooxygenase-2 Inhibitor, Celecoxib.
Modulative effect of a new hydrazide derivative on wheat-induced pulmonary inflammation in rats.
Myeloid-Derived Suppressor Cells Dampen Airway Inflammation Through Prostaglandin E2 Receptor 4.
Nontypeable Haemophilus influenzae induces COX-2 and PGE2 expression in lung epithelial cells via activation of p38 MAPK and NF-kappa B.
Participation of NADPH Oxidase-Related Reactive Oxygen Species in Leptin-Promoted Pulmonary Inflammation: Regulation of cPLA2? and COX-2 Expression.
Persistent Inactivation of Macrophage Cyclooxygenase-2 in Mycobacterial Pulmonary Inflammation.
Prostaglandins mediate the fetal pulmonary response to intrauterine inflammation.
Protection by indomethacin against acute radiation esophagitis.
Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.
Pulmonary artery contractility in pneumonia: role of cyclooxygenase products and nitric oxide.
Pulmonary oxygen toxicity in the guinea pig. Effect of indomethacin.
Resolvin D1 Improves the Resolution of Inflammation via Activating NF-?B p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome.
Role of PPAR? in COX-2 Activation in Mycobacterial Pulmonary Inflammation.
Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis.
SIGNALING PATHWAYS AND MEDIATORS IN LPS-INDUCED LUNG INFLAMMATION IN DIABETIC RATS: ROLE OF INSULIN.
Streptococcus pneumoniae induced regulation of cyclooxygenase-2 in human lung tissue.
Temporal profile of serum mitochondrial DNA (mtDNA) in patients with aneurysmal subarachnoid hemorrhage (aSAH).
The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia.
The role of cyclooxygenase-2 in mechanical ventilation-induced lung injury.
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
Pneumonia, Pneumococcal
Streptococcus pneumoniae induced p38 MAPK- and NF-kappaB-dependent COX-2 expression in human lung epithelium.
Pneumoperitoneum
Spontaneous Intestinal Perforation: The Long-Term Outcome.
Pneumothorax
Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis.
Polycystic Kidney Diseases
Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2WS25/- mouse model of autosomal dominant polycystic kidney disease.
Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease.
Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.
Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.
Renal cyclooxygenase and lipoxygenase products are altered in polycystic kidneys and by dietary soy protein and fish oil treatment in the Han:SPRD-Cy rat.
Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease.
Polycystic Kidney, Autosomal Dominant
Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.
Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2WS25/- mouse model of autosomal dominant polycystic kidney disease.
Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.
Polycystic Ovary Syndrome
Effect of bee venom on IL-6, COX-2 and VEGF levels in polycystic ovarian syndrome induced in Wistar rats by estradiol valerate.
Expression of the genes for peroxisome proliferator-activated receptor-?, cyclooxygenase-2, and proinflammatory cytokines in granulosa cells from women with polycystic ovary syndrome.
The effects of 6-Gingerol on reproductive improvement, liver functioning and Cyclooxygenase-2 gene expression in estradiol valerate - Induced polycystic ovary syndrome in Wistar rats.
Polyhydramnios
Enhancement of amniotic cyclooxygenase type 2 activity in women with preterm delivery associated with twins or polyhydramnios.
Treatment of polyhydramnios with prostaglandin synthetase inhibitor (indomethacin).
Treatment of symptomatic polyhydramnios with indomethacin.
Polymyositis
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis.
The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis.
Polyneuropathies
New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis.
Up-regulation of cyclooxygenase-2 in inflammatory demyelinating neuropathy.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve.
Polyuria
COX-2 activity transiently contributes to increased water and NaCl excretion in the polyuric phase after release of ureteral obstruction.
Cyclooxygenase-2 inhibitor preserves medullary aquaporin-2 expression and prevents polyuria after ureteral obstruction.
Indomethacin in streptozocin-induced nephrogenic diabetes insipidus.
Lithium induces microcysts and polyuria in adolescent rat kidney independent of cyclooxygenase-2.
Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria.
Mice Lacking mPGES-1 Are Resistant to Lithium-Induced Polyuria.
Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2.
Urinary tract obstruction induces transient accumulation of COX-2-derived prostanoids in kidney tissue.
Porcine Reproductive and Respiratory Syndrome
Highly pathogenic porcine reproductive and respiratory syndrome virus induces prostaglandin E2 production through cyclooxygenase 1, which is dependent on the ERK1/2-p-C/EBP-? pathway.
Porokeratosis
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Post-Exercise Hypotension
Postexercise hypotension is not explained by a prostaglandin-dependent peripheral vasodilation.
Pouchitis
Increase in cyclooxygenase-2 and nitric oxide-synthase-2 mRNAs in pouchitis without modification of inducible isoenzyme heme-oxygenase-1.
RISK OF CANCER IN PATIENTS WITH CHRONIC POUCHITIS AFTER RESTORATIVE PROCTOCOLECTOMY FOR ULCERATIVE COLITIS.
Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis.
Pre-Eclampsia
-765 G?C and -1195 A?G Promoter Variants of the Cyclooxygenase-2 Gene Decrease the Risk for Preeclampsia.
Activation of NF-kappaB and expression of COX-2 in association with neutrophil infiltration in systemic vascular tissue of women with preeclampsia.
Activities of phospholipase A2, cyclooxygenase, and PGI2 synthase of umbilical venous endothelial cells in preeclamptic women.
Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition?
Aspirin induces increased expression of both prostaglandin H synthase-1 and prostaglandin H synthase-2 in cultured human placental trophoblast.
Chronic infection during placental malaria is associated with up-regulation of cycloxygenase-2.
Control of prostacyclin synthesis in pregnancy-induced hypertension.
Curcumin's Effect on COX-2 and IL-10 Serum in Preeclampsia's Patient Undergo Sectio Caesarea with Spinal Anesthesia.
Cyclooxygenase gene expression in human endometrium and decidua.
Cyclooxygenase-1 and -2 in human placenta and placental bed after normal and pre-eclamptic pregnancies.
Deficient glutathione peroxidase activity in preeclampsia is associated with increased placental production of thromboxane and lipid peroxides.
Differentiation and growth on a fibrin matrix modulate the cyclooxygenase expression and thromboxane production by cultured human placental trophoblasts.
Eicosanoids in preeclampsia.
Increased Expression of Thioredoxin-1 Binding Protein-2 in Placentas in Preeclampsia.
Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.
Maternal vitamin D deficiency influences long-chain polyunsaturated fatty acids and pregnancy outcome in association with alterations in one-carbon metabolism.
Mechanisms of vascular dysfunction in the interleukin-10-deficient murine model of preeclampsia indicate nitric oxide dysregulation.
Microparticles from preeclamptic women induce vascular hyporeactivity in vessels from pregnant mice through an overproduction of NO.
Neutrophil expression of cyclooxygenase 2 in preeclampsia.
Placental tissue cyclo-oxygenase 1 and 2 in pre-eclamptic and normal pregnancy.
Plasma from preeclamptic women increases human endothelial cell prostacyclin production without changes in cellular enzyme activity or mass.
TGF-?1 inhibits human trophoblast cell invasion by upregulating cyclooxygenase-2.
The effect of indomethacin and prostacyclin agonists on blood pressure in a rat model of preeclampsia.
The expression and activity of prostaglandin H synthase-2 is enhanced in trophoblast from women with preeclampsia.
The expression of cyclooxygenase-2 in human umbilical vein endothelial cell culture from preeclampsia.
The induction of cyclooxygenase-2 (COX-2) in cultured endothelial cells treated with serum from preeclampsia is mediated by interleukin-6.
The preventive effects of aspirin on preeclampsia based on network pharmacology and bioinformatics.
The role of arachidonic acid metabolites in preeclampsia.
The Study of Cyclooxygenase 2 in Human Decidua of Preeclampsia.
Thromboxane A(2) limits differentiation and enhances apoptosis of cultured human trophoblasts.
Vitamin D stimulates miR-26b-5p to inhibit placental COX-2 expression in preeclampsia.
[Association study between -765G > C and -1195G > A functional polymorphisms in the cyclooxygenase 2 gene and risk of preeclampsia].
[The changes of LCHAD in preeclampsia with different clinical features and the correlation with NADPH P47-phox, p38MAPK-?, COX-2 and serum FFA and TG].
Precancerous Conditions
Cyclooxygenase-2 expression in early gastric cancer, intestinal metaplasia and Helicobacter pylori infection.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
?-lactam structured,4-(4-(Methylsulfonyl)phenyl)-1-pentyl-3-phenoxyazetidin-2-one: Selectively targets cancerous B lymphocyte Mitochondria.
Association study of cyclooxygenase 2 single nucleotide polymorphisms and childhood acute lymphoblastic leukemia in Taiwan.
Evaluation of Cytotoxic Potentials of Novel Cyclooxygenase-2 Inhibitor against ALL Lymphocytes and Normal Lymphocytes and Its Anticancer Effect through Mitochondrial Pathway.
Inhibitory effect of berberine on interleukin-2 secretion from PHA-treated lymphocytic Jurkat cells.
Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model.
Pregnancy, Prolonged
Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix.
Loss of cannabinoid receptor CB1 induces preterm birth.
Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors.
[Developmental toxicity of the over-the-counter analgetics and antypiretics].
Premature Birth
Cyclo-oxygenase inhibitors for treating preterm labour: what is the molecular evidence?
De novo Synthesis of SAA1 in the Placenta Participates in Parturition.
Efficacy and specificity of non-steroidal anti-inflammatory drugs for the inhibition of cytokine-stimulated prostaglandin E(2) secretion by amnion-derived WISH cells.
Fetal fibronectin signaling induces matrix metalloproteases and cyclooxygenase-2 (COX-2) in amnion cells and preterm birth in mice.
In utero exposure to phthalates and fetal development.
Inhibition of cyclooxygenase isoforms in late- but not midgestation decreases contractility of the ductus arteriosus and prevents postnatal closure in mice.
IRF5 is increased in labouring myometrium and regulates pro-labour mediators.
Mono-ethylhexyl phthalate stimulates prostaglandin secretion in human placental macrophages and THP-1 cells.
N-acetylcysteine prevents preterm birth by attenuating the LPS-induced expression of contractile associated proteins in an animal model.
NODAL in the Uterus Is Necessary for Proper Placental Development and Maintenance of Pregnancy.
Preterm birth and/or low birth weight are associated with periodontal disease and the increased placental immunohistochemical expression of inflammatory markers.
Progesterone and prostaglandin H synthase-2 involvement in alcohol-induced preterm birth in mice.
Resveratrol Protects Against Pathological Preterm Birth by Suppression of Macrophage-Mediated Inflammation.
Risk of preterm birth following late pregnancy exposure to NSAIDs or COX-2 inhibitors.
The effect of progesterone on genes involved in preterm labor.
The Preventive Effects of Quercetin on Preterm Birth Based on Network Pharmacology and Bioinformatics.
The promise of prostaglandins: have they fulfilled their potential as therapeutic targets for the delay of preterm birth?
The role of n-3 fatty acids in gestation and parturition.
Pressure Ulcer
Selective inhibition of COX-2 improves cutaneous wound healing of pressure ulcers in mice through reduction of iNOS expression.
Primary Ovarian Insufficiency
An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.
Prion Diseases
Adult human microglia secrete cytokines when exposed to neurotoxic prion protein peptide: no intermediary role for prostaglandin E2.
Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease.
Cyclooxygenase-2, prostaglandin E2, and microglial activation in prion diseases.
Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C.
Prognathism
Genetic Factors Involved in Mandibular Prognathism.
Prolactinoma
Cyclooxygenase enzyme and PGE2 expression in patients with functional and non-functional pituitary adenomas.
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
prostaglandin-e synthase deficiency
Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile.
prostaglandin-endoperoxide synthase deficiency
A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors.
A protective role for cyclooxygenase-2 in drug-induced liver injury in mice.
A quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer.
A vasoconstrictor role for cyclooxygenase-1-mediated prostacyclin synthesis in mouse renal arteries.
Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice.
Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice.
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease.
Augmentation of allergic inflammation in the airways of cyclooxygenase-2-deficient mice.
Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.
Bleeding disorder due to platelet prostaglandin H synthase-1 (PGHS-1) deficiency.
Characterization of a partial prostaglandin endoperoxide H synthase-1 deficiency in a patient with a bleeding disorder.
Concomitant activation of functionally opposing prostacyclin and thromboxane prostanoid receptors by cyclo-oxygenase-1-mediated prostacyclin synthesis in mouse arteries.
Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection.
COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.
COX-2 inhibition affects growth rate of Chlamydia muridarum within epithelial cells.
Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis.
Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice.
Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice.
Cyclooxygenase-2 deficiency causes delayed ossification of lumbar vertebral endplates.
Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury.
Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis.
Cyclooxygenase-2 deficiency impairs muscle-derived stem cell-mediated bone regeneration via cellular autonomous and non-autonomous mechanisms.
Cyclooxygenase-2 deficiency in macrophages leads to defective p110? PI3K signaling and impairs cell adhesion and migration.
Cyclooxygenase-2 deficiency increases epidermal apoptosis and impairs recovery following acute UVB exposure.
Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis.
Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice.
Cyclooxygenase-2 deficiency protects livers from ischemia/reperfusion injury.
Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.
Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.
Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair.
Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain.
DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects.
Deficiency in either COX-1 or COX-2 genes does not affect amyloid beta protein burden in amyloid precursor protein transgenic mice.
Effect of celecoxib on cyclooxygenase-1-mediated prostacyclin synthesis and endothelium-dependent contraction in mouse arteries.
Effects of Cyclooxygenase-1 and -2 Gene Disruption on Helicobacter pylori-Induced Gastric Inflammation.
Epinephrine potentiation of arachidonate-induced aggregation of cyclooxygenase-deficient platelets.
Further studies on a specific platelet antibody found in Bernard-Soulier syndrome and its effects on normal platelet function.
Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation.
Hematopoietic cyclooxygenase-2 deficiency increases adipose tissue inflammation and adiposity in obesity.
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic disorders in mice.
Impaired post-irradiation survival of cyclooxygenase-2-deficient mice.
Inactivation of inducible nitric oxide synthase protects intestinal pacemaker cells from postoperative damage.
Inducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling.
Induction of COX-2 Enzyme and Down-regulation of COX-1 Expression by Lipopolysaccharide (LPS) Control Prostaglandin E2 Production in Astrocytes.
Inflammation with the participation of arachidonic (AA) and linoleic acid (LA) derivatives (HETEs and HODEs) is necessary in the course of a normal reproductive cycle and pregnancy.
Is COX-2 inhibition a panacea for cancer prevention?
Late Postoperative Hemorrhage in a Patient With Undiagnosed COX-1 Deficiency After Third Molar Extractions.
Multiple female reproductive failures in cyclooxygenase 2-deficient mice.
Opposing actions of prostaglandins and oxytocin determine the onset of murine labor.
Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice.
Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.
PTGS-2-PTGER2/4 signaling pathway partially protects from diabetogenic toxicity of streptozotocin in mice.
Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice.
Reduced sulfur mustard-induced skin toxicity in cyclooxygenase-2 knockout and celecoxib-treated mice.
Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy.
Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.
Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension.
Role of cyclooxygenase-2 in deoxynivalenol-induced immunoglobulin a nephropathy.
Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice.
The role of the EP receptors for prostaglandin E2 in skin and skin cancer.
Vasoconstrictor role of cyclooxygenase-1-mediated prostacyclin synthesis in non-insulin-dependent diabetic mice induced by high-fat diet and streptozotocin.
Vasomotor Reaction to Cyclooxygenase-1-Mediated Prostacyclin Synthesis in Carotid Arteries from Two-Kidney-One-Clip Hypertensive Mice.
[Defects in the prostaglandin system. VII. (Generalized, inherited [?]) cyclooxygenase defect]
[Platelet cyclooxygenase deficiency]
Prostatic Hyperplasia
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer?
Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate.
Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
Insilico and In Vitro Study: COX-2 Inhibition by Ethanol Extract of Dayak Onion Bulb (Eleutherine americana Merr) as Treatment Innovation of Benign Prostatic Hyperplasia (BPH).
Predictive value of Cyclooxygenase-2 over expression for identifying prostate cancer from benign prostatic hyperplasia in prostate biopsy specimens.
Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions.
Studies on antibacterial, anti-inflammatory and antioxidant activity of herbal remedies used in the treatment of benign prostatic hyperplasia and prostatitis.
The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A.
The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer.
The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling.
[Correlation of IPSS with IL-8 and COX-2 levels in patients with benign prostatic hyperplasia and prostatitis].
[Expression of COX-2 in prostatic cancer and benign prostatic hyperplasia]
[Expression of cyclooxygenase-2 and vascular endothelial growth factor in human prostate cancer and its significance]
Prostatic Intraepithelial Neoplasia
Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer.
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer.
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies.
Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.
The role of cyclooxygenase-2 in prostate cancer.
Prostatic Neoplasms
A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.
A local paracrine and endocrine network involving TGF?, Cox-2, ROS, and estrogen receptor ? influences reactive stromal cell regulation of prostate cancer cell motility.
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Aerobic Training and Green Tea Extract Protect against N-methyl-N-nitrosourea-induced Prostate Cancer.
Aerobic Training and Green Tea Extract Protect against NMU-induced Prostate Cancer.
American Urological Association--94th annual meeting. 1-6 May 1999, Dallas, USA.
An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer.
Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
Annexin A5 suppresses cyclooxygenase-2 expression by downregulating the protein kinase C-?-nuclear factor-?B signaling pathway in prostate cancer cells.
Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-kappaB and crosstalk between the extrinsic and intrinsic apoptotic pathways.
Anticancer effects of licofelone (ML-3000) in prostate cancer cells.
Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo.
Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells.
Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells.
Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe?
Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis.
Association between the 8473T>C polymorphism of PTGS2 and prostate cancer risk: a metaanalysis including 24,716 subjects.
Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in taiwan.
Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism.
Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk.
BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib.
Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.
Biochemical control of the combination of cyclooxygenase-2 inhibitor and 125 I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial.
Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.
Breast cancer--new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?
Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease.
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials.
Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.
Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study.
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
COX-2 gene promoter haplotypes and prostate cancer risk.
COX-2 inhibition and cancer: experimental findings and clinical correlates.
COX-2 inhibition: a possible role in the management of prostate cancer?
COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer.
COX-2 inhibitors and other NSAIDs in bladder and prostate cancer.
COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins.
COX-2 inhibitors in prostate cancer treatment--hold your horses?
COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67.
COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer.
COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men.
COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells.
COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
Cyanidin attenuates PGE2 production and cyclooxygenase-2 expression in LNCaP human prostate cancer cells.
Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians.
Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men.
Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity.
Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.
Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo.
Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer.
Cyclooxygenase-2 and Angiogenesis in Prostate Cancer.
Cyclooxygenase-2 and prostate carcinogenesis.
Cyclooxygenase-2 as a marker for prostate cancer.
Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer.
Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer.
Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.
Cyclooxygenase-2 inhibitors and prostate cancer.
Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study.
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.
Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer?
Cyclooxygenase-2 promotes prostate cancer progression.
Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line.
Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Cyclooxygenase-2: a therapeutic target for prostate cancer.
Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment.
Decrease in expression or activity of cytosolic phospholipase A(2)alpha increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells.
Determination of cyclooxygenase and arachidonic acid metabolites in invasive human prostate cancer cells.
Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk.
Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model.
Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells.
Differential gene methylation patterns in cancerous and non?cancerous cells.
Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells.
Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
DNA oxidation induced by cyclooxygenase-2.
Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells.
Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2.
Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer.
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.
Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation.
Effect of endothelin-1 on cyclooxygenase-2 expression in human hormone refractory prostate cancer cells.
Effect of low-fat diet on plasma levels of NF-{kappa}B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer.
Effects of Obesity on the Regulation of Macrophage Population in the Prostate Tumor Microenvironment.
Enforced Expression of miR-101 inhibits prostate cancer cell growth by modulating cyclooxygenase-2 pathway in vivo.
EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer.
Estrogen-dependent induction of cyclooxygenase-2 in the canine prostate in vivo.
Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways.
Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis.
Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence.
Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.
Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
Expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.
Genetic Polymorphisms in Inflammation Pathway Genes and Prostate Cancer Risk.
Genetic variation in the COX-2 gene and the association with prostate cancer risk.
Genetic Variations in Inflammatory Response Genes and Their Association with the Risk of Prostate Cancer.
Glucose-regulated protein 78 mediates hormone-independent prostate cancer progression and metastasis through maspin and COX-2 expression.
Growth Inhibitory and Pro-Apoptotic Effects of Ornamental Pomegranate Extracts in Du145 Human Prostate Cancer Cells.
Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer.
Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.
Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression.
Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer.
Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines.
Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma.
Inflammation and prostate cancer: a future target for prevention and therapy?
Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance.
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.
Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.
Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
Interleukin-1? promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer.
Lack of association between the cyclooxygenase 2 -765G>C polymorphism and prostate cancer risk: a meta-analysis.
LLW-3-6 and celecoxib impacts growth in prostate cancer cells and subcellular localization of COX-2.
Management of prostate cancer. Part 1: chemoprevention.
Mechanisms of the anti-proliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast(®)) on colon adenocarcinoma (HT29) cells in vitro.
Meta-analysis of epidemiological studies demonstrates significant association of PTGS2 polymorphism rs689470 and no significant association of rs20417 with prostate cancer.
Methylated genes as potential biomarkers in prostate cancer.
Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b+Gr1+MDSCs from bone marrow.
Modeling of cyclooxygenase-2 and 5-lipooxygenase inhibitory activity of apoptosis-inducing agents potentially useful in prostate cancer chemotherapy: Derivatives of diarylpyrazole.
Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer.
Molecular characterization of canine prostaglandin G/H synthase-2 and regulation in prostatic adenocarcinoma cells in vitro.
Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398.
Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation.
New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.
New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (COX) blockers in erectile dysfunction.
Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort.
Non-steroidal anti-inflammatory drugs in the treatment of genitourinary malignancies: focus on clinical data.
Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study.
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.
Novel antineoplastic isochalcones inhibit the expression of cyclooxygenase 1,2 and EGF in human prostate cancer cell line LNCaP.
Novel insights and therapeutical applications in the field of inhibitors of COX-2.
NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells.
NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.
Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer.
omega-3 Fatty Acids, Genetic Variants in COX-2 and Prostate Cancer.
Oncogenic action of phospholipase A2 in prostate cancer.
Oncogenic action of secreted phospholipase A2 in prostate cancer.
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies.
Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
p53 and Cyclooxygenase-2 Expression are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-Naïve Prostate Cancer.
Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells.
Pharmacological Approaches to Reducing the Risk of Prostate Cancer.
Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy.
Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers.
Pitfalls in the use of arachidonic acid oxidation products to assign lipoxygenase activity in cancer cells.
Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.
Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort.
Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk.
Predictive value of Cyclooxygenase-2 over expression for identifying prostate cancer from benign prostatic hyperplasia in prostate biopsy specimens.
Proapoptotic anti-inflammatory drugs.
Production, structural and biochemical characterization relevant to antitumor property of acidic exopolysaccharide produced from Bacillus sp. NRC5.
Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer.
Prognostic Value of Prostaglandin-endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical Prostatectomy.
Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?
Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.
Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.
Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells.
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.
PROSTAGLANDIN E2 stimulates cancer-related phenotypes in prostate cancer PC3 cells through cyclooxygenase-2.
Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis.
Prostate cancer chemoprevention: an overview of United States trials.
Prostate cancer: A COX-2 far?
Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes.
PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).
Pyruvate Kinase M2 Promotes Prostate Cancer Metastasis Through Regulating ERK1/2-COX-2 Signaling.
Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells.
Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo.
Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells.
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.
Renal effects of high-dose celecoxib in elderly men with Stage D2 prostate carcinoma.
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion.
Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Resveratrol induces sumoylated COX-2-dependent anti-proliferation in human prostate cancer LNCaP cells.
Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin.
Retraction: Suppression of N-Methyl-N-nitrosourea/Testosterone-Induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s).
Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.
RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor.
Role of eicosanoids in prostate cancer progression.
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells.
Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53.
SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells.
Statin induces apoptosis and cell growth arrest in prostate cancer cells.
Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.
Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells.
Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro.
Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer.
TGF-? Effects on Prostate Cancer Cell Migration and Invasion Are Mediated by PGE2 through Activation of PI3K/AKT/mTOR Pathway.
TGF-beta1 Reverses Inhibition of COX-2 With NS398 and Increases Invasion in Prostate Cancer Cells.
The arachidonic Acid pathway and its role in prostate cancer development and progression.
The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.
The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.
The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.
The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs.
The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.
The multiple effects of aspirin in prostate cancer patients.
The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer.
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review.
The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.
The role of cyclooxygenase-2 in prostate cancer.
The Role of Genetic Variants in the Association between Dietary Acrylamide and Advanced Prostate Cancer in the Netherlands Cohort Study on Diet and Cancer.
The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.
Tissue Biomarkers for Prognosis of prostate cancer: A Systematic Review and Meta-analysis.
Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells.
Up-regulation of cyclooxygenase-2 by product-prostaglandin E2.
Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level.
Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.
Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
VIP induces NF-?B1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
What's New in the Field of Prostate Cancer Chemoprevention?
What's new in the field of prostate cancer chemoprevention?
Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression.
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.
Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression.
[Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer]
[Effects of a selective cyclooxygenase 2 inhibitor celecoxib on the proliferation and apoptosis of human prostate cancer cell line PC-3]
[ETIOLOGY OF PROSTATE CANCER].
[Expression and implication of cyclooxygenase-2 mRNA in prostate cancer]
[Expression of COX-2 in different human prostate cancer cell lines and its significance].
[Expression of COX-2 in prostatic cancer and benign prostatic hyperplasia]
[Expression of cyclooxygenase-2 and vascular endothelial growth factor in human prostate cancer and its significance]
[Expressions of CD4+ CD25(high) regulatory T cells, TGF-beta 1 and COX-2 in the peripheral blood of prostate cancer patients].
[Molecular-targeted therapy for hormone-refractory prostate cancer]
[Nutrition and pharmacological treatment for prevention of prostate cancer]
[Relationship between cyclooxygenase (COX)-2 and malignant tumors]
Prostatitis
Chronic Pelvic Pain Syndrome (CPPS) and Semen Quality of Korean Men in Their 4th Decade.
Correlation study of chronic nonbacterial prostatitis with the levels of COX-2 and PGE2 in prostatic secretion.
COX-1 and -2 expressions in sex-related organs of neonatally estrogen-treated rats and in activated and nonactivated macrophage RAW264.7 cells with phytoestrogen.
Extracorporeal shock wave therapy decreases COX-2 by inhibiting TLR4-NF?B pathway in a prostatitis rat model.
Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat.
Overexpression of lncRNA GAS5 suppresses prostatic epithelial cell proliferation by regulating COX-2 in chronic non-bacterial prostatitis.
Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions.
Prostatic protective nature of the flavonoid-rich fraction from Cyclosorus acuminatus on carrageenan-induced non-bacterial prostatitis in rat.
Studies on antibacterial, anti-inflammatory and antioxidant activity of herbal remedies used in the treatment of benign prostatic hyperplasia and prostatitis.
The alteration of inflammatory markers and apoptosis on chronic prostatitis induced by estrogen and androgen.
[Correlation of IPSS with IL-8 and COX-2 levels in patients with benign prostatic hyperplasia and prostatitis].
[Xiaojin Wan inhibits the expression of COX-2 in prostate tissues of prostatitis pain rats]
Protein-Energy Malnutrition
Aquagenic wrinkling of the palms in patients with cystic fibrosis homozygous for the delta F508 CFTR mutation.
protein-tyrosine-phosphatase deficiency
Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice.
Proteinuria
A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
A role for thromboxane in complement-mediated glomerular injury.
A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells.
Albumin-induced podocyte injury and protection are associated with regulation of COX-2.
Chondroitin sulfate degradation and eicosanoid metabolism pathways are impaired in focal segmental glomerulosclerosis: Experimental confirmation of an in silico prediction.
Chronic inhibition of NOS-2 ameliorates renal injury, as well as COX-2 and TGF-beta 1 overexpression in 5/6 nephrectomized rats.
COX-2 but not mPGES-1 contributes to renal PGE2 induction and diabetic proteinuria in mice with type-1 diabetes.
COX-2-derived prostaglandins as mediators of the deleterious effects of nicotine in chronic kidney disease.
Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension.
Effect of aspirin and sulindac in rabbit nephrotoxic nephritis.
Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis.
Effects of celecoxib and nordihydroguaiaretic acid on puromycin aminonucleoside-induced nephrosis in the rat.
Effects of Dietary Salt on Intrarenal Angiotensin System, NAD(P)H Oxidase, COX-2, MCP-1 and PAI-1 Expressions and NF-kappaB Activity in Salt-Sensitive and -Resistant Rat Kidneys.
Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats.
Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum.
Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats.
Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
NIACIN AMELIORATES OXIDATIVE STRESS, INFLAMMATION, PROTEINURIA, AND HYPERTENSION IN RATS WITH CHRONIC RENAL FAILURE.
Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney.
PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism.
Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.
Predominant functional roles for thromboxane A2 and prostaglandin E2 during late nephrotoxic serum glomerulonephritis in the rat.
Puromycin Induces Reversible Proteinuric Injury in Transgenic Mice Expressing Cyclooxygenase-2 in Podocytes.
Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.
Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.
Selective Cyclooxygenase-2 Inhibitor Suppresses Renal Thromboxane Production but Not Proliferative Lesions in the MRL/lpr Murine Model of Lupus Nephritis.
Small bowel cyclooxygenase 2 (COX-2) expression in patients with IgA nephropathy.
[Renal protective effects of specific cyclooxygenase-2 inhibitor in rats with subtotal renal ablation]
protoporphyrin ferrochelatase deficiency
Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia.
Pruritus
Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching.
Mast cell disease.
Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review.
[Effect of preoperative cyclooxygenase-2 inhibitor for postoperative pain in patients after total knee arthroplasty: a meta-analysis].
Pseudomyxoma Peritonei
COX-2 expression in pseudomyxoma peritonei.
Pseudorabies
Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus.
Psoriasis
Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis Via COX-1.
Antiproliferative effect of two novel COX-2 inhibitors on human keratinocytes.
Apigenin, a nonmutagenic dietary flavonoid suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells.
Co-localization of COX-2, CYP4F8, and mPGES-1 in epidermis with prominent expression of CYP4F8 mRNA in psoriatic lesions.
Effect of chunghyuldan in chronic oxazolone-induced mouse dermatitis.
Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis.
Expression of pro-angiogenic genes in mesenchymal stem cells derived from dermis of patients with psoriasis.
Human fibroblasts support the expansion of IL-17-producing T cells via up-regulation of IL-23 production by dendritic cells.
Inflammasome Signaling and Impaired Vascular Health in Psoriasis.
Modulation of Cox-1, 5-, 12- and 15-Lox by popular herbal remedies used in southern Italy against psoriasis and other skin diseases.
Non steroidal anti-inflammatory and anti-allergy agents.
Perioperative management of medications for psoriasis and psoriatic arthritis: a review for the dermasurgeon.
Preclinical study of methotrexate-based hydrogels versus surfactant based liquid crystal systems on psoriasis treatment.
Psoriasis and hypertension: a case-control study.
Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.
Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis.
The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis.
Pterygium
Chemokine CXCR-4 and cyclooxygenase-2 in the pathogenesis of pterygium
Comment on Cyclooxygenase-2 expression in primary and recurrent pterygium and Authors' response.
Comment on papper: Cyclooxygenase-2 expression in primary and recurrent pterygium.
Corrigendum: Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium.
Cyclooxygenase 2 expression in pterygium.
Cyclooxygenase-2 expression in primary and recurrent pterygium.
Cyclooxygenase-2-expressing macrophages in human pterygium co-express vascular endothelial growth factor.
Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium.
Relationship between expression of cyclooxygenase 2 and neovascularization in human pterygia.
Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium.
The Influence of Chemokine CXCR4 and Cyclooxygenase-2 in the Recurrence of Pterygium.
[Blood vessel multiply and significance of expression of Cox-2, VEGF in pterygium]
[Expression of cyclooxygenase-2 in pterygium and effects of selective cyclooxygenase-2 inhibitor on human pterygium fibroblasts]
Pulmonary Arterial Hypertension
A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels.
Cyclooxygenase-2 expression in lung in patients with congenital heart malformations and pulmonary arterial hypertension.
H2S inhibition of chemical hypoxia-induced proliferation of HPASMCs is mediated by the upregulation of COX-2/PGI2.
Indomethacin and LY171883 modify porcine cardiopulmonary responses to leukotrienes.
Post-ischemic rupture of the anterior papillary muscle of the right ventricle associated with persistent pulmonary hypertension of the newborn: a case report.
Prostacyclin therapy for pulmonary arterial hypertension.
Pulmonary Atelectasis
Improved oxygenation with prostaglandin F2alpha with and without inhaled nitric oxide in dogs.
Lipoxygenase and cyclooxygenase blockade by BW 755C enhances pulmonary hypoxic vasoconstriction.
Pulmonary Disease, Chronic Obstructive
Active ingredients targeting Nrf2 in the Mongolian medicine Qiwei Putao powder: Systematic pharmacological prediction and validation for chronic obstructive pulmonary disease treatment.
Anti-inflammatory action of herbal medicine comprised of Scutellaria baicalensis and Chrysanthemum morifolium.
Associations of the NRF2/KEAP1 pathway and antioxidant defense gene polymorphisms with chronic obstructive pulmonary disease.
Bradykinin increases IL-8 generation in airway epithelial cells via COX-2-derived prostanoids.
Chronic bronchitis: reflex on the pulmonary circulation.
Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products.
Curcumin Attenuates Airway Inflammation and Airway Remolding by Inhibiting NF-?B Signaling and COX-2 in Cigarette Smoke-Induced COPD Mice.
Cyclooxigenase-2 Levels are Increased in the Lung Tissue and Bronchial Tumors of Patients with Chronic Obstructive Pulmonary Disease.
Cyclooxygenase 2 1195G > A polymorphism is associated with chronic obstructive pulmonary disease in Japanese and Chinese patients.
Cyclooxygenase-2 -765G>C polymorphism is associated with C-reactive protein levels in resistant smokers but not in chronic obstructive pulmonary disease patients.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis.
Decreased expression of the NF-?B family member RelB in lung fibroblasts from Smokers with and without COPD potentiates cigarette smoke-induced COX-2 expression.
Determining Pharmacological Mechanisms of Chinese Incompatible Herbs Fuzi and Banxia in Chronic Obstructive Pulmonary Disease: A Systems Pharmacology-Based Study.
Dietary ?-6 polyunsaturated fatty acid arachidonic acid increases inflammation, but inhibits ECM protein expression in COPD.
Effect of a single nucleotide polymorphism in miR-146a on COX-2 protein expression and lung function in smokers with chronic obstructive pulmonary disease.
Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD.
Endothelin-1 increases expression of cyclooxygenase-2 and production of interlukin-8 in hunan pulmonary epithelial cells.
Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD.
Functional polymorphism of cyclooxygenase-2 gene (G-765C) in chronic obstructive pulmonary disease patients.
Identification of differentially expressed genes and signaling pathways in chronic obstructive pulmonary disease via bioinformatic analysis.
Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD.
Low levels of the AhR in chronic obstructive pulmonary disease (COPD)-derived lung cells increases COX-2 protein by altering mRNA stability.
Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways.
Molecular Mechanism of Xixin-Ganjiang Herb Pair Treating Chronic Obstructive Pulmonary Disease-Integrated Network Pharmacology and Molecular Docking.
Overexpression of farnesoid X receptor in small airways contributes to epithelial to mesenchymal transition and COX-2 expression in chronic obstructive pulmonary disease.
Polymorphisms rs2745557 in PTGS2 and rs2075797 in PTGER2 are associated with the risk of chronic obstructive pulmonary disease development in a Tunisian cohort.
Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke.
Prostaglandin E2 possesses different potencies in inducing Vascular Endothelial Growth Factor and Interleukin-8 production in COPD human lung fibroblasts.
Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease.
Pulmonary surfactant-associated protein B regulates prostaglandin-endoperoxide synthase-2 and inflammation in chronic obstructive pulmonary disease.
Reduced miR-146a increases prostaglandin E? in chronic obstructive pulmonary disease fibroblasts.
The Clinical Efficiency and the Mechanism of Sanzi Yangqin Decoction for Chronic Obstructive Pulmonary Disease.
The cyclooxygenase-2-765C promoter polymorphism protects against the development of chronic obstructive pulmonary disease.
The cyclooxygenase-2-prostaglandin e2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts.
The NF-?B family member RelB regulates microRNA miR-146a to suppress cigarette smoke-induced COX-2 protein expression in lung fibroblasts.
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
The role of cyclooxygenase-2 in the protection against apoptosis in vascular endothelial cells induced by cigarette smoking.
VEGF synthesis is induced by prostacyclin and TGF-? in distal lung fibroblasts from COPD patients and control subjects: Implications for pulmonary vascular remodelling.
[Expressions of cyclooxygenase-2 and matrix metalloproteinase-2 and airflow obstruction in patients with chronic obstructive pulmonary disease]
Pulmonary Edema
Alpha-thrombin-induced pulmonary vasoconstriction.
BW-755C diminishes smoke-induced pulmonary edema.
Cyclooxygenase and lipoxygenase inhibition by BW-755C reduces acrolein smoke-induced acute lung injury.
Edema from cyclooxygenase products of endogenous arachidonic acid in isolated lung.
Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome.
Ethyl pyruvate protects rats from phosgene-induced pulmonary edema by inhibiting cyclooxygenase2 and inducible nitric oxide synthase expression.
Histamine receptor and prostaglandin synthetase blockers in ethchlorvynol-induced pulmonary edema in canines.
Indomethacin blunts ethchlorvynol-induced pulmonary hypertension but not pulmonary edema.
Inhibition of cyclooxygenase production does not prevent arachidonate from increasing extravascular lung water and albumin in an isolated dog lung.
PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide.
Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors.
[Late effects of acute inhibition of cyclooxygenase on tissue gas exchange in experimental pulmonary edema lesions]
Pulmonary Embolism
Contribution of pulmonary vasoconstriction to haemodynamic instability after acute pulmonary embolism. Implications for treatment?
Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary embolism.
Influence of L-arginine on the expression of eNOS and COX2 in experimental pulmonary thromboembolism.
Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat.
[Antithrombotic action of benzydamine]
Pulmonary Fibrosis
Citrus alkaline extracts prevent fibroblast senescence to ameliorate pulmonary fibrosis via activation of COX-2.
Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis.
Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.
Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis.
Evaluation of cyclooxygenase-2 fluctuation via a near-infrared fluorescent probe in idiopathic pulmonary fibrosis cell and mice models.
Expression of cyclooxygenase-2 in human lung carcinoma.
Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.
MELATONIN ALLEVIATES BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN MICE.
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.
Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production.
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis.
Pulpitis
An immunohistological study on cyclooxygenase-2 in human dental pulp.
Differential regulation of interleukin-6 and inducible cyclooxygenase gene expression by cytokines through prostaglandin-dependent and -independent mechanisms in human dental pulp fibroblasts.
Effect of non-steroidal anti-inflammatory drugs on pulpal and periapical inflammation induced by lipopolysaccharide.
Purpura, Thrombocytopenic, Idiopathic
Flow cytometric analysis of platelet cyclooxygenase-1 and -2 and surface glycoproteins in patients with immune thrombocytopenia and healthy individuals.
Pyelonephritis
COX-2 inhibitor induced anuric renal failure in a previously healthy young woman.
Effect of a Selective Cyclooxygenase-2 Inhibitor on Renal Scarring.
Renal tissue damage after experimental pyelonephritis: role of antioxidants and selective cyclooxygenase-2 inhibitors.
Role of suppressor cells in experimental pyelonephritis.
Pyometra
Cystic endometrial hyperplasia-pyometra syndrome in bitches: identification of hemodynamic, inflammatory, and cell proliferation changes.
Identifying diagnostic endocrine markers and changes in endometrial gene expressions during pyometra in cats.
Positive correlation between patency and mRNA levels for cyclooxygenase-2 and prostaglandin E synthase in the uterine cervix of bitches with pyometra.
Prostaglandin synthesis genes are differentially transcripted in normal and pyometra endometria of bitches.
Radiation Fibrosis Syndrome
Celecoxib and radiation therapy in non-small-cell lung cancer.
Radiation Pneumonitis
Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis.
Radicular Cyst
Immunohistochemical Analysis of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha in Periapical Lesions.
Immunohistochemical localization of cyclooxygenase-2 in radicular cysts.
The fibroblast of radicular cyst facilitate osteoclastogenesis via the autocrine of Fibronectin containing extra domain A.
[Expression of cyclooxygenase 2 mRNA in apical periodontitis.]
Radiculopathy
Cyclooxygenase-2 inhibitor SC-236 attenuates mechanical allodynia following nerve root injury in rats.
Effect of mechanical compression on the lumbar nerve root: localization and changes of intraradicular inflammatory cytokines, nitric oxide, and cyclooxygenase.
Epidural injection of cyclooxygenase-2 inhibitor attenuates pain-related behavior following application of nucleus pulposus to the nerve root in the rat.
Pre-treatment with Meloxicam Prevents the Spinal Inflammation and Oxidative Stress in DRG Neurons that Accompany Painful Cervical Radiculopathy.
The role of cyclooxygenase-2 and inflammatory cytokines in pain induction of herniated lumbar intervertebral disc.
Rectal Neoplasms
A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer.
A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial.
A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line.
Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy.
Clinical significance of VEGFR-2 and (18)F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.
COX-2 verexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy.
Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy.
Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer.
Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer.
Differential expression of cyclooxygenase 2 in human colorectal cancer.
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
Expression of Cyclooxygenase-2 and Tumor Microvessel Density in Colorectal Cancer.
Expressions of miR-302a, miR-105, and miR-888 Play Critical Roles in Pathogenesis, Radiotherapy, and Prognosis on Rectal Cancer Patients: A Study From Rectal Cancer Patients in a Swedish Rectal Cancer Trial of Preoperative Radiotherapy to Big Database Analyses.
High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Metabolic and molecular relative percentage coreduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer.
POLYMORPHISM OF THE COX-2 GENE AND SUSCEPTIBILITY TO COLON AND RECTAL CANCER.
Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer.
Pretreatment CD133 and Cyclooxygenase-2 Expression as the Predictive Markers of the Pathological Effect of Chemoradiotherapy in Rectal Cancer Patients.
Pretreatment Expression of 13 Molecular Markers as a Predictor of Tumor Responses After Neoadjuvant Chemoradiation in Rectal Cancer.
Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy.
PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer.
Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp.
Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study.
Significance of Cox-2 expression in rectal cancers with or without preoperative radiotherapy.
The role of COX-2 and Ki-67 over-expression in the prediction of pathologic response of rectal cancer to neoadjuvant chemoradiation therapy.
The role of COX-2 in rectal cancer treated with preoperative radiotherapy.
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Tissue microarrays in chinese human rectal cancer: study of expressions of the tumor-associated genes.
[Neoadiuvant teleradiotherapy decreases cancer tissue and serum concentration of prostaglandin E2 and cyclooxygenase-2 expression in patients with rectal cancer].
[Perioperative immunomodulatory therapy does not decrease postoperative recurrence rate of rectal cancer].
Renal Artery Obstruction
Acute upregulation of COX-2 by renal artery stenosis.
Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP.
Epithelial COX-2 expression is not regulated by nitric oxide in rodent renal cortex.
General inhibition of renocortical cyclooxygenase-2 expression by the renin-angiotensin system.
Renal Insufficiency
Acute effects of clometacin on renal prostaglandin biosynthesis in healthy subjects.
Acute intrinsic renal failure induced by indomethacin: role of prostaglandin synthetase inhibition.
Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors.
Acute, anuric renal failure associated with two doses of a cyclooxygenase-2 inhibitor.
Angiotensin II stimulates cyclooxygenase-2 mRNA expression in renal tissue from rats with kidney failure.
Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia.
COX-2 inhibitor induced anuric renal failure in a previously healthy young woman.
COX-2 inhibitors and renal failure: the triple whammy revisited.
COX-2: friend or foe?
Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase.
Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
Cyclooxygenase-2 and kidney failure.
Cyclooxygenase-2/sclerostin mediates TGF-?1-induced calcification in vascular smooth muscle cells and rats undergoing renal failure.
Defective expression of Tamm-Horsfall protein/uromodulin in COX-2-deficient mice increases their susceptibility to urinary tract infections.
Design and optimization of PLGA-based diclofenac loaded nanoparticles.
Do cyclooxygenase-2 knockout mice have primary hyperparathyroidism?
Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials.
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
Effects of No.2 Renal Failure Recipe on expressions of cyclooxygenase-2 and -1 mRNAs in rats with chronic renal failure.
Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with furosemide on renal functions and renal Cox-2 expression in rats.
Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet.
Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice.
Involvement of endogenous prostaglandin E2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions.
Nephrotoxicity of selective COX-2 inhibitors.
Pharmacokinetics of etoricoxib in patients with renal impairment.
Potassium channel-mediated vasorelaxation is impaired in experimental renal failure.
Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Renal pathology resulting from PGHS-2 gene ablation in DBA/B6 mice.
Rokumi-jio-gan-Containing Prescriptions Attenuate Oxidative Stress, Inflammation, and Apoptosis in the Remnant Kidney.
Salt supplementation ameliorates developmental kidney defects in COX-2-/- mice.
Subtotal nephrectomy stimulates cyclooxygenase 2 expression and prostacyclin synthesis in the rat remnant kidney.
The renin-angiotensin system in kidney development: role of COX-2 and adrenal steroids.
[Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?]
[Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]
[Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects]
[Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors]
[Specific cyclooxygenase-2 inhibitor analgesics: therapeutic advances.]
[Treatment of rheumatic disease with renal insufficiency].
Renal Insufficiency, Chronic
A comparative study of chronic kidney disease in dogs and cats: Induction of cyclooxygenases.
A maladaptive role for EP4 receptors in podocytes.
Celecoxib modifies glomerular basement membrane, mesangium and podocytes in OVE26 mice, but ibuprofen is more detrimental.
COX-2 inhibitors and the kidney.
Influence of creatinine versus glomerular filtration rate on non-steroidal anti-inflammatory drug prescriptions in chronic kidney disease.
Low expression of cyclooxygenase-2 in chronic kidney disease in young dogs.
NSAID use and progression of chronic kidney disease.
Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study.
Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease.
Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study.
The effect of prostaglandin synthetase inhibitors on renal function: studies in normal rats during sodium or water diuresis and in rats with chronic renal insufficiency.
The protective effect of prostacyclin on adriamycin-induced apoptosis in rat renal tubular cells.
The renal effects of NSAIDs in dogs.
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
Thromboxane mediates glomerular haemodynamics in a model of chronic glomerular disease.
Thromboxane Prostanoid Receptors Enhance Contractions, Endothelin-1 and Oxidative Stress in Microvessels From Mice With Chronic Kidney Disease.
Reperfusion Injury
A potential protective effect of alpha-tocopherol on vascular complication in spinal cord reperfusion injury in rats.
Blockade of fibronectin-alpha4beta1 adhesive interactions down-regulates cyclooxygenase-2 inducible nitric oxide synthase and prolongs recipient survival in a 24-hour model of cold hepatic ischemia-reperfusion injury.
Cardiovascular Properties of a Nitric Oxide Releasing Rofecoxib Analogue: Beneficial Anti-hypertensive Activity and Enhanced Recovery in an Ischemic Reperfusion Injury Model.
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.
Constitutive COX-2 activity in cardiomyocytes confers permanent cardioprotection Constitutive COX-2 expression and cardioprotection.
Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury.
Cyclooxygenase inhibition aggravates ischemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes.
Cyclooxygenase inhibition prior to ventricular fibrillation induced ischemia reperfusion injury impairs survival and outcomes.
Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes.
Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: Real-time monitoring of RGC survival using Thy-1-EGFP transgenic mice.
Down-regulation of cyclooxygenase-2 is involved in ischemic postconditioning protection against renal ischemia reperfusion injury in rats.
Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury.
Effects of the COX-2 inhibitor FK3311 on ischemia - reperfusion injury in the rat lung.
Gadolinium-Based Neuroprognostic Magnetic Resonance Imaging Agents Suppress COX-2 for Prevention of Reperfusion Injury after Stroke.
Hepatic ischemia and reperfusion injury in the absence of myeloid cell-derived COX-2 in mice.
Inhibition of cyclooxygenase metabolite production attenuates ischemia-reperfusion lung injury.
Inhibition of cyclooxygenase-2 improves cardiac function following long-term preservation.
Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury?
Ischemia reperfusion injury in the isolated hemoperfused bovine uterus--a model for the investigation of anti-inflammatory substances?
Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2.
LncRNA MALAT1 aggravates inflammation response through regulating PTGS2 by targeting miR-26b in myocardial ischemia-reperfusion injury.
LncRNA-Malat1 down-regulates miR-211-5p expression to promote neuronal damage from cerebral ischemia reperfusion injury.
Modulation of the neurological and vascular complications by grape seed extract in a rat model of spinal cord ischemia-reperfusion injury by downregulation of both osteopontin and cyclooxygenase-2.
Novel Combination of COX-2 Inhibitor and Antioxidant Therapy for Modulating Oxidative Stress Associated with Intestinal Ischemic Reperfusion Injury and Endotoxemia.
Perillyl alcohol improves functional and histological outcomes against ischemia-reperfusion injury by attenuation of oxidative stress and repression of COX-2, NOS-2 and NF-?B in middle cerebral artery occlusion rats.
Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2.
Positive acceleration adaptive training attenuates gastric ischemia-reperfusion injury through COX-2 and PGE2 expression.
Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2.
Protective effect of indomethacin in renal ischemia-reperfusion injury in mice.
Protective role of hepatocyte cyclooxygenase-2 expression against liver ischemia-reperfusion injury in mice.
Pyrrolidine dithiocarbamate attenuate shock wave induced MDCK cells injury via inhibiting nuclear factor-kappa B activation.
Role of cyclooxygenase-2 in myocardial infarction and ischaemia.
Selective cyclooxygenase-2 inhibitor ameliorates warm ischemia-reperfusion injury of the canine liver.
Study of cyclooxygenase-2 in renal ischemia-reperfusion injury.
Temporal determination of lung NO system and COX-2 upregulation following ischemia-reperfusion injury.
The effect of a selective cyclooxygenase-2 inhibitor in extended liver resection with ischemia in dogs.
The effect of cyclooxygenase 2 inhibitor (FK3311) on ischemia-reperfusion injury with hepatectomy in dogs.
The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model.
The effects of a cyclooxygenase-2 inhibitor, FK3311, on total hepatic ischemia-reperfusion injury of the rat.
The effects of a selective cyclooxygenase-2 inhibitor on small bowel ischemia-reperfusion injury.
The effects of cyclooxygenase (COX)-2 inhibition on ischemia-reperfusion injury in liver transplantation.
Thromboxane A2 in postischemic acute compartmental syndrome.
[Effect of scalp acupuncture on the expression of NF-kappaB mRNA, COX-2 mRNA and their proteins in rats with acute cerebral ischemia-reperfusion injury]
[Effects of scalp acupuncture on acute cerebral ischemia-reperfusion injury in rats.]
[Mechanism of Musk and Borneol on Inflammatory of Cerebral Ischemia and Reperfusion Injury at Different Time Points of Acute Phase in Rats].
Respiratory Distress Syndrome
Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome.
Meta-analysis: Methods, strengths, weaknesses, and political uses.
Parecoxib reduced ventilation induced lung injury in acute respiratory distress syndrome.
Resolvin D1 Improves the Resolution of Inflammation via Activating NF-?B p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome.
Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?
Therapeutic intervention in a rat model of adult respiratory distress syndrome: III. Cyclooxygenase pathway inhibition.
Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism.
[Pharmacologic treatment of hypoxemia in adult respiratory distress syndrome]
Respiratory Hypersensitivity
Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease.
Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells.
Respiratory Insufficiency
Dexamethasone and indomethacin modify endotoxin-induced respiratory failure in pigs.
Effects of neuroactive substances on the morphine-induced respiratory depression; an in vitro study.
Ibuprofen plus prostaglandin E1 in a septic porcine model of adult respiratory distress syndrome.
Rat pulmonary cyclooxygenase-2 expression in response to endotoxin challenge: differential regulation in the various types of cells in the lung.
[The effect of cyclooxygenase and thromboxane synthetase inhibition on oxygen metabolism in canine acute respiratory failure]
Respiratory Tract Infections
Cyclooxygenase inhibitor use is associated with increased COVID-19 severity.
Retinal Degeneration
Effect of antioxidants, anti-inflammatory drugs, and histamine antagonists on sparfloxacin-induced phototoxicity in mice.
Inhibition of cyclooxygenase-2 expression by zinc-chelator in retinal ischemia.
Specific roles for Group V secretory PLA? in retinal iron-induced oxidative stress. Implications for age-related macular degeneration.
Retinal Diseases
Dynamics of Cyclooxygenase-1 Positive Microglia/Macrophage in the Retina of Pathological Model Mice as a Biomarker of the Retinal Inflammatory Diseases.
Retinal Dystrophies
[The effect of cyclooxygenase inhibitors on the course of hereditary retinal dystrophy in RCS rats]
Retinal Neovascularization
Cytochrome P450 2C8 ?3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization--brief report.
Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice.
Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression.
Retinitis
Human cytomegalovirus induced cyclooxygenase-2 in human retinal pigment epithelial cells augments viral replication through a prostaglandin pathway.
Retinitis Pigmentosa
Cyclooxygenase-1 mediates neuroinflammation and neurotoxicity in a mouse model of retinitis pigmentosa.
Retinoblastoma
Cox-2 expression in retinoblastoma.
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Cyclooxygenase-2 expression in retinoblastoma: an immunohistochemical analysis.
Cyclooxygenase-2 expression in the normal human eye and its expression pattern in selected eye tumours.
Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma.
Increased serum progesterone and estradiol correlate to increased COX-2 tissue expression in cervical intraepithelial neoplasia.
Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose.
Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease.
Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex.
Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).
The effect of a selective cyclooxygenase-2 (COX-2) inhibitor on the proliferation rate of retinoblastoma cell lines.
The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment.
Retinopathy of Prematurity
COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity.
Peroxide-cyclooxygenase interactions in postasphyxial changes in retinal and choroidal hemodynamics.
Rett Syndrome
Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome.
Neuropathology of Rett syndrome.
Rhabdoid Tumor
Establishment and characterization of a new cell line, FRTK-1, derived from human malignant rhabdoid tumor of the kidney, with overexpression of epidermal growth factor receptor and cyclooxygenase-2.
Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1).
Rhabdomyosarcoma
Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.
Cyclooxygenase-2 expression in pediatric sarcomas.
Cyclooxygenase-2 expression in uterine leiomyosarcomas.
Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma.
Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma.
Rhabdomyosarcoma, Alveolar
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rheumatic Diseases
Analgesics are not always the culprits: isolated gastric fundal varices as the cause of recurrent upper GI bleed in a patient with SLE, rheumatoid arthritis and polymyositis overlap syndrome.
Anti-inflammatory pharmacotherapy during pregnancy.
Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity.
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.
Clinical implications of selective cyclooxygenase-2 inhibition.
COX-2: separating myth from reality.
Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy.
Dipyrone & 2,5-dimethylcelecoxib suppress Th2-related chemokine production in monocyte.
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis.
Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.
Intelligent use of NSAIDs--where do we stand?
Safety of meloxicam: a global analysis of clinical trials.
The fight against rheumatism: from willow bark to COX-1 sparing drugs.
The management of chronic pain in important patient subgroups.
[COX-2 inhibitors: a new treatment in rheumatic diseases]
[Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors]
[Management of antirheumatic drugs in kidney failure].
[Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition]
[Nonsteroidal anti-inflammatory agents in the management of rheumatic disorders]
[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
[Rheumatism therapy, from the economic viewpoint. COX-2 inhibitor as cost saving drug]
[Tolerable pain therapy in rheumatism saves long-term costs. Despite this most COX-2 candidates receive conventional NSAID therapy.]
[Treatment of peptic ulcer related to rheumatic diseases]
Rhinitis
Aspirin sensitivity and desensitization for asthma and sinusitis.
Aspirin sensitivity: implications for patients with coronary artery disease.
Aspirin-induced rhinitis and asthma.
Clinical and pathologic perspectives on aspirin sensitivity and asthma.
Cyclooxygenase and lipoxygenase metabolite generation in nasal polyps.
Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis.
Effects of a specific cysteinyl leukotriene antagonist, pranlukast, on antigen-induced cysteinyl leukotriene-mediated rhinitis in guinea pigs.
Expression of cyclo-oxygenase 1 and 2 proteins in upper respiratory mucosa.
Expression of cyclooxygenase-2 in canine epithelial nasal tumors.
Role of cyclooxygenase 1 and 2 in asthma and rhinitis.
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
Validation of guinea pig model of allergic rhinitis by oral and topical drugs.
Rhinitis, Allergic
A novel concept of immunological and allergy interactions in autism spectrum disorders: Molecular, anti-inflammatory effect of osthole.
Decreased serum IgE level, decreased IFN-gamma and IL-5 but increased IL-10 production, and suppressed cyclooxygenase 2 mRNA expression in patients with perennial allergic rhinitis after treatment with a new mixed formula of Chinese herbs.
Effect of flurbiprofen, a cyclooxygenase inhibiting drug, on induced allergic rhinitis.
Effects of a specific cysteinyl leukotriene antagonist, pranlukast, on antigen-induced cysteinyl leukotriene-mediated rhinitis in guinea pigs.
Expression of cyclo-oxygenase 1 and 2 proteins in upper respiratory mucosa.
New evidence of H1-receptor independent COX-2 inhibition by fexofenadine HCl in vitro.
Polymorphisms in chronic rhinosinusitis with nasal polyps - a systematic review.
The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy.
The DP receptor, allergic inflammation and asthma.
Rhinitis, Allergic, Seasonal
Combination treatment using the COX-2 inhibitor meloxicam and an anti-allergic in pollinosis.
Hay fever treatment with combined antihistamine and cyclooxygenase-inhibiting drugs.
Riboflavin Deficiency
Effects of riboflavin deficiency upon prostaglandin biosynthesis in rat kidney.
Rickettsia Infections
Infection of human endothelial cells with spotted Fever group rickettsiae stimulates cyclooxygenase 2 expression and release of vasoactive prostaglandins.
Potential roles for regulatory oxygenases in rickettsial pathogenesis.
Regulation of inducible heme oxygenase and cyclooxygenase isozymes in a mouse model of spotted fever group rickettsiosis.
Rocky Mountain Spotted Fever
Rickettsia rickettsii infection of human macrovascular and microvascular endothelial cells reveals activation of both common and cell type-specific host response mechanisms.
Rickettsia rickettsii infection of human pulmonary microvascular endothelial cells: modulation of cyclooxygenase-2 expression.
Root Resorption
Celebrex offers a small protection from root resorption associated with orthodontic movement.
Effects of Photobiomodulation and Ultrasound Applications on Orthodontically Induced Inflammatory Root Resorption; Transcriptional Alterations in OPG, RANKL, Cox-2: An Experimental Study in Rats.
Histological analysis of orthodontic root resorption in rats treated with the cyclooxygenase-2 (COX-2) inhibitor celecoxib.
Primary teeth show less protecting factors against root resorption.
Proinflammatory mediators related to orthodontically induced periapical root resorption in rat mandibular molars.
Rotavirus Infections
Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step.
PPAR? Agonists as an Anti-Inflammatory Treatment Inhibiting Rotavirus Infection of Small Intestinal Villi.
Salmonella Infections
Cyclooxygenase-2 Inhibition Enhances Activation of T Helper Type 1 Responses During Salmonella Infection.
Salmonella infection induces a hypersecretory phenotype in human intestinal xenografts by inducing cyclooxygenase 2.
Salter-Harris Fractures
Roles of COX-2 and iNOS in the bony repair of the injured growth plate cartilage.
Sarcoidosis
Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications.
Association of the 3050G>C polymorphism in the cyclooxygenase 2 gene with systemic sarcoidosis.
Cyclooxygenase-2 polymorphisms confer susceptibility to sarcoidosis but are not related to prognosis.
Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis.
Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis.
Prostaglandin synthetase inhibition in hypercalcaemia with sarcoidosis.
Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis.
[Cyclooxygenase-2 polymorphisms and bronchoalveolar lavage cellularity of sarcoidosis].
Sarcoidosis, Pulmonary
Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications.
Interleukin 1 production by alveolar macrophages is decreased in smokers.
Production of cyclooxygenase products by alveolar macrophages in pulmonary sarcoidosis.
Prostaglandins and thromboxanes in the bronchoalveolar lavage fluid: possible immunoregulation in sarcoidosis.
Sarcoma
A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line.
Advances that are changing the diagnosis and treatment of malignant bone tumors.
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor.
Association between Degree of Anaplasia and Degree of Inflammation with the Expression of COX-2 in Feline Injection Site Sarcomas.
COX-2 expression in striated muscle under physiological conditions.
Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.
Cyclooxygenase-2 expression in chondrosarcoma.
Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentation.
Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
Cyclooxygenase-2 expression in pediatric sarcomas.
Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma.
Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.
Cyclooxygenase-2 Is an Independent Predictor of Poor Prognosis in Uterine Leiomyosarcomas.
Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.
Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2.
Expression of HuR and Cyclooxygenase-2 in Nodular Fasciitis and Low-Grade Sarcoma: An Immunohistochemical Study.
In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations.
Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.
Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells.
Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model.
Prevention of drug-induced upset to energy production in the S180 sarcoma by inhibition of prostaglandin synthetase [proceedings]
Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-?B and matrix metalloproteinase-2/-9 signaling pathways.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2.
The pharmacologic inhibition of the xc- antioxidant system improves the antitumor efficacy of COX inhibitors in the in vivo model of 3-MCA tumorigenesis.
The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer.
Sarcoma 180
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger.
Sarcoma, Avian
Drug inhibition and cellular regulation of prostaglandin G/H synthase isoenzyme 2.
Molecularly targeted therapy for gastrointestinal cancer.
Simulated lung transfection by nebulization of liposome cDNA complexes using a cascade impactor seeded with 2-CFSME0-cells.
Sarcoma, Endometrial Stromal
Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
Cyclooxygenase-2 Is an Independent Predictor of Poor Prognosis in Uterine Leiomyosarcomas.
Sarcoma, Ewing
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma.
Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.
Cyclooxygenase-2 expression in pediatric sarcomas.
Expression of embryonic lethal abnormal vision (ELAV)-like protein HuR and cyclooxygenase-2 (COX-2) in Ewing sarcoma.
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Sarcoma, Kaposi
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Evidence of COX-1 and COX-2 expression in Kaposi's sarcoma tissues.
Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion.
Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells.
KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi's sarcoma.
NFAT AND CREB REGULATE KAPOSI'S SARCOMA ASSOCIATED HERPES VIRUS (KSHV) INDUCED CYCLOOXYGENASE-2 (COX-2).
[Let-7 miRNA silencing promotes Kaposi's sarcoma-associated herpesvirus lytic replication via activating mitogen-activated protein kinase kinase kinase kinase 4 and its downstream factors].
Sarcoma, Synovial
Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentation.
Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma.
Epithelium-specific Ets transcription factor-1 acts as a negative regulator of cyclooxygenase-2 in human rheumatoid arthritis synovial fibroblasts.
Sarcopenia
Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults.
Prostaglandin E2 induces transcription of skeletal muscle mass regulators interleukin-6 and muscle RING finger-1 in humans.
Schistosomiasis
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.
[Relationship between multi-gene proteins in colorectal carcinoma complicated with chronic schistosomiasis: an immunohistochemical study by using tis- sue microarray techniques].
[Relationship between multi-gene proteins in colorectal carcinoma complicated with chronic schistosomiasis: an immunohistochemical study by using tissue microarray techniques].
Scleritis
Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis.
Flurbiprofen: A Nonselective Cyclooxygenase (COX) Inhibitor for Treatment of Noninfectious, Non-necrotizing Anterior Scleritis.
Scleroderma, Systemic
Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis.
Immunohistochemical and morphometric evaluation of COX 1 and COX-2 in the remodeled lung in idiopathic pulmonary fibrosis and systemic sclerosis.
Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.
Scoliosis
Low expression of microRNA-143 is related to degenerative scoliosis possibly by regulation of cyclooxygenase-2 expression.
Scrapie
Increased expression and localization of cyclooxygenase-2 in astrocytes of scrapie-infected mice.
Seizures
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus.
Acute effects of aceclofenac, COX-2 inhibitor, on penicillin-induced epileptiform activity.
Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice.
Anticonvulsant action of celecoxib (alone and in combination with sub-threshold dose of phenytoin) in electroshock induced convulsion.
Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazole-kindled rats is associated with memory impairment.
Anticonvulsive effects of endogenous prostaglandins formed in brain of spontaneously convulsing gerbils.
Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats.
Assessment of the effects of the cyclooxygenase-2 inhibitor rofecoxib on visuospatial learning and hippocampal cell death following kainate-induced seizures in the rat.
Behavioral changes and expression of heat shock protein hsp-70 mRNA, brain-derived neurotrophic factor mRNA, and cyclooxygenase-2 mRNA in rat brain following seizures induced by systemic administration of kainic acid.
Carvacrol mitigates proconvulsive effects of lipopolysaccharide, possibly through the hippocampal cyclooxygenase-2 inhibition.
Cerebral superoxide anion generation during seizures in newborn pigs.
Characterization of seizure-induced cysteinyl-leukotriene formation in brain tissue of convulsion-prone gerbils.
Co-administration of subtherapeutic diazepam enhances neuroprotective effect of COX-2 inhibitor, NS-398, after lithium pilocarpine-induced status epilepticus.
Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy.
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.
COX-2/PGE2 axis regulates hippocampal BDNF/TrkB signaling via EP2 receptor after prolonged seizures.
Cyclooxygenase-1 as a Potential Therapeutic Target for Seizure Suppression: Evidences from Zebrafish Pentylenetetrazole-Seizure Model.
Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management.
Cyclooxygenase-2 expression and effect of celecoxib in flurothyl-induced neonatal seizure.
Cyclooxygenase-2 expression in the hippocampus of genetically epilepsy susceptible El mice was increased after seizure.
Cyclooxygenase-2 expression is induced in rat brain after kainate-induced seizures and promotes neuronal death in CA3 hippocampus.
Cyclooxygenase-2 in epilepsy.
Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus.
Cyclooxygenase-2 inhibitors differentially attenuate pentylenetetrazol-induced seizures and increase of pro- and anti-inflammatory cytokine levels in the cerebral cortex and hippocampus of mice.
Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus.
Cyclooxygenase-2/PGE(2) pathway facilitates pentylenetetrazol-induced seizures.
Differential effect of cyclooxygenase-2 preferring [correction of prefering] inhibitors on electrically- and chemically-induced seizures in mice.
Differential effect of prostaglandin synthetase inhibitor pretreatment on pentylenetetrazol-induced seizures in rat.
Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
Effect of cyclooxygenase inhibitors on pentylenetetrazol (PTZ)-induced convulsions: Possible mechanism of action.
Effect of cyclooxygenase-2 (COX-2) inhibitors in various animal models (bicuculline, picrotoxin, maximal electroshock-induced convulsions) of epilepsy with possible mechanism of action.
Effect of indomethacin on cerebral blood flow and development of oxygen convulsions.
Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.
Effects of manganese complexes of curcumin and diacetylcurcumin on kainic acid-induced neurotoxic responses in the rat hippocampus.
Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy.
Emodin plays an interventional role in epileptic rats via multidrug resistance gene 1 (MDR1).
Enhanced cyclooxygenase-2 expression in olfactory-limbic forebrain following kainate-induced seizures.
Evidence for increased activity of mouse brain fatty acid cyclooxygenase following drug-induced convulsions.
Expression of cyclo-oxygenase 2 in rat brain following kainate treatment.
Formation and functions of prostaglandins in the central nervous system in rodents.
Gamma-Decanolactone Alters the Expression of GluN2B, A1 Receptors, and COX-2 and Reduces DNA Damage in the PTZ-Induced Seizure Model After Subchronic Treatment in Mice.
Immunomodulatory effect of Celecoxib on HMGB1/TLR4 pathway in a recurrent seizures model in immature rats.
In vivo activation of N-methyl-D-aspartate receptors in the rat hippocampus increases prostaglandin E(2) extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms.
In vivo assessment of mechanisms underlying the neurovascular basis of postictal amnesia.
Indomethacin treatment prior to pentylenetetrazole-induced seizures downregulates the expression of il1b and cox2 and decreases seizure-like behavior in zebrafish larvae.
Inducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling.
Inferior collicular seizure generalization produces site-selective cortical induction of cyclooxygenase 2 (COX-2).
Inflammation and reactive oxygen species as disease modifiers in epilepsy.
Influence of etoricoxib on anticonvulsant activity of phenytoin and diazepam in experimental seizure models in mice.
Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.
Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors.
Involvement of prostaglandins in an animal model of Shigella-related seizures.
Involvement of the arachidonic acid cascade in the hypersusceptibility to pentylenetetrazole-induced seizure during diazepam withdrawal.
Lesioning of deep prepiriform cortex protects against ischemic neuronal necrosis by attenuating extracellular glutamate concentrations.
Lipoxygenase products of polyunsaturated fatty acid metabolism in the central nervous system: biosynthesis and putative functions.
Long-term electrical stimulation at ear and electro-acupuncture at ST36-ST37 attenuated COX-2 in the CA1 of hippocampus in kainic acid-induced epileptic seizure rats.
Maintenance of the Innate Seizure Threshold by Cyclooxygenase-2 is Not Influenced by the Translational Silencer, T-cell Intracellular Antigen-1.
Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease.
Mechanisms of asphyxial brain damage, and possible pharmacologic interventions, in the fetus.
Neuroendocrine involvements of the prostaglandin autacoids.
Neuromodulatory role of endogenous interleukin-1? in acute seizures: Possible contribution of cyclooxygenase-2.
Nimesulide aggravates kainic acid-induced seizures in the rat.
NMDA-induced seizure intensity is enhanced in COX-2 deficient mice.
Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy.
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition.
Profiling of eicosanoid production in the rat hippocampus during kainic acid-induced seizure: dual phase regulation and differential involvement of COX-1 and COX-2.
Prophylactic, prandial rofecoxib treatment lacks efficacy against acute PTZ-induced seizure generation and kindling acquisition.
Prostaglandin E(2) potentiates methylmalonate-induced seizures.
Prostaglandin E(2) produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region.
Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice.
Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling.
Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism.
Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor potentiates the anticonvulsant activity of tiagabine against pentylenetetrazol-induced convulsions in mice.
Role of COX-2 in inflammatory and degenerative brain diseases.
Roles of prostaglandin synthesis in excitotoxic brain diseases.
Seizure following the Use of the COX-2 Inhibitor Etoricoxib.
Seizure susceptibility in immature brain due to lack of COX-2-induced PGF2?
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling.
Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy?
Soman increases neuronal COX-2 levels: Possible link between seizures and protracted neuronal damage.
Stage- and region-specific cyclooxygenase expression and effects of a selective COX-1 inhibitor in the mouse amygdala kindling model.
Staged anticonvulsant screening for chronic epilepsy.
Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist.
Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice.
Temporal profile of serum mitochondrial DNA (mtDNA) in patients with aneurysmal subarachnoid hemorrhage (aSAH).
The bacterial endotoxin lipopolysaccharide enhances seizure susceptibility in mice: involvement of proinflammatory factors: nitric oxide and prostaglandins.
The cyclooxygenase and lipoxygenase inhibitor BW755C protects rats against kainic acid-induced seizures and neurotoxicity.
The long-term high-frequency repetitive transcranial magnetic stimulation does not induce mRNA expression of inflammatory mediators in the rat central nervous system.
The neuronal excitability time-dependently changes after lipopolysaccharide administration in mice: Possible role of cyclooxygenase-2 induction.
The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus.
Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
Treatment-resistant bipolar depression: concepts and challenges for novel interventions.
[Time course of COX-2 expression in hippocampus of the seizure rats].
Sepsis
3-[(4-chlorophenyl)selanyl]-1-methyl-1H-indole ameliorates long-lasting depression- and anxiogenic-like behaviors and cognitive impairment in post-septic mice: Involvement of neuroimmune and oxidative hallmarks.
?-glutamylcysteine exhibits anti-inflammatory effects by increasing cellular glutathione level.
A Systematic Study of the Mechanism of Acacetin Against Sepsis Based on Network Pharmacology and Experimental Validation.
Anti-inflammatory Effects of Deuterium-Depleted Water Plus Rosa Damascena Mill. Essential Oil Via Cyclooxygenase-2 Pathway in Rats.
Assessing the effect of Mentha longifolia essential oils on COX-2 expression in animal model of sepsis induced by caecal ligation and puncture.
Blockade of prostaglandin products augments macrophage and neutrophil tumor necrosis factor synthesis in burn injury.
Bone Marrow Mesenchymal Stromal Cells on Silk Fibroin Scaffolds to Attenuate Polymicrobial Sepsis Induced by Cecal Ligation and Puncture.
Bupivacaine inhibits COX-2 expression, PGE2, and cytokine production in endotoxin-activated macrophages.
Canine platelets express functional Toll-like receptor-4: lipopolysaccharide-triggered platelet activation is dependent on adenosine diphosphate and thromboxane A2 in dogs.
Cardiopulmonary effects of tumor necrosis factor-alpha in the piglet: influence of cyclooxygenase inhibition.
Cecal ligation and puncture is associated with pulmonary injury in the rat: role of cyclooxygenase pathway products.
Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats.
Celecoxib Enhances the Efficacy of Low-Dose Antibiotic Treatment against Polymicrobial Sepsis in Mice and Clinical Isolates of ESKAPE Pathogens.
Characterization of changes in plasma and tissue oxylipin levels in LPS and CLP induced murine sepsis.
Combination of aspirin with essential fatty acids is superior to aspirin alone to prevent or ameliorate sepsis or ARDS.
Comparison of thromboxane inhibitors to cyclooxygenase inhibitors on survival in a newborn rat model for group B streptococcal sepsis.
Cyclooxygenase inhibition and vascular reactivity in a rat model of hyperdynamic sepsis.
Cyclooxygenase inhibition in sepsis: is there life after death?
Cyclooxygenase inhibitors attenuate bradykinin-induced vasoconstriction in septic isolated rat lungs.
Cyclooxygenase-2 and nuclear factor-kappaB in myocardium of end stage human heart failure.
Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis.
Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection.
Cyclooxygenase-2-mediated regulation of Kupffer cell interleukin-6 production following trauma-hemorrhage and subsequent sepsis.
Differential microvascular response to cyclooxygenase blockade in the rat small intestine during acute bacteremia.
Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat.
Disordered enterocyte signaling and intestinal barrier dysfunction in the pathogenesis of necrotizing enterocolitis.
Effect of cyclooxygenase and lipoxygenase products on pulmonary function in group B streptococcal sepsis.
Effect of methylprednisolone, indomethacin, and diethylcarbamazine on survival rate following trauma and sepsis in rats.
Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis.
Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages.
Evidence for tumor necrosis factor alpha as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis.
Failure of therapy with 2,3-dihydroxybenzoic acid to modify the course of sepsis-induced lung injury.
Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis.
Foenumoside B isolated from Lysimachia foenum-graecum extract suppresses LPS-induced inflammatory response via NF-?B/AP-1 inactivation in murine macrophages and in endotoxin-induced shock model.
Group B streptococcal (GBSS) newborn septic shock model: the role of prostaglandins.
Hydrogen sulfide upregulates cyclooxygenase-2 and prostaglandin E metabolite in sepsis-evoked acute lung injury via transient receptor potential vanilloid type 1 channel activation.
Imaging cyclooxygenase-2 (Cox-2) gene expression in living animals with a luciferase knock-in reporter gene.
Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.
Influence of cyclooxygenase inhibitors on gut immune cell distribution and apoptosis rate in experimental sepsis.
Influence of prostaglandin D2 on hemodynamic effects of group B streptococcus in neonatal lambs.
Inhibition of cyclooxygenase-2 by NS-398 following hemorrhage and subsequent sepsis: no beneficial effects in either gender.
Inhibition of eicosanoid production by BW755C does not attenuate sepsis-induced alterations in glucose kinetics.
Isoprostanes and PGE2 production in human isolated pulmonary artery smooth muscle cells: concomitant and differential release.
Ketamine attenuates liver injury attributed to endotoxemia: role of cyclooxygenase-2.
Kupffer cell ablation attenuates cyclooxygenase-2 expression after trauma and sepsis.
Methylprednisolone plus ibuprofen increases mortality in septic rats.
mRNA and protein stability regulate the differential expression of pro- and anti-inflammatory genes in endotoxin-tolerant THP-1 cells.
Parecoxib does not suppress thromboxane synthesis in newborn piglets with group B streptococcal sepsis.
Pentoxyphilline as a cyclooxygenase (cox-2) inhibitor in experimental sepsis.
Pharmacologic reduction in tumor necrosis factor activity of pulmonary alveolar macrophages.
Phospholipids and their inhibitors: a critical evaluation of their role in the treatment of sepsis.
Preclinical Studies Suggest Complex Nutraceutical Strategies May Have Potential for Preventing and Managing Sepsis.
Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition.
Protective effect of acacetin on sepsis-induced acute lung injury via its anti-inflammatory and antioxidative activity.
Regional blood flow distribution in endotoxin-treated dogs: modification by ibuprofen.
Role of prostaglandins in determining the increased cardiac sympathetic nerve activity in ovine sepsis.
Role of tumor necrosis factor in sepsis and acute lung injury.
Sepsis induces an increase in thick ascending limb Cox-2 that is TLR4 dependent.
Serum adipocyte fatty acid-binding protein in the critically ill.
The effects of a prostaglandin synthetase inhibitor, ibuprofen, on the cardiopulmonary response to endotoxin in sheep.
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
The Nephroprotective Effect of MS-275 on Lipopolysaccharide (LPS)-Induced Acute Kidney Injury by Inhibiting Reactive Oxygen Species (ROS)-Oxidative Stress and Endoplasmic Reticulum Stress.
Thromboxane synthetase inhibitors in septic shock.
Transcriptional regulation of the cyclooxygenase-2 gene in macrophages by PU.1.
Tumor necrosis factor-induced mortality is reversed with cyclooxygenase inhibition.
[Effects of polydatin on ALT, AST, TNF-alpha, and COX-2 in sepsis model mice].
[Screening and identification of potential targets of carthamin against sepsis].
Sepsis-Associated Encephalopathy
Experimental sepsis-associated encephalopathy is accompanied by altered cerebral blood perfusion and water diffusion and related to changes in cyclooxygenase-2 expression and glial cell morphology but not to blood-brain barrier breakdown.
Sertoli Cell-Only Syndrome
Cyclooxygenase-2 in testes of infertile men: evidence for the induction of prostaglandin synthesis by interleukin-1beta.
Serum Sickness
Glomerular eicosanoid production in acute serum sickness nephritis.
Severe Combined Immunodeficiency
A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice.
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF).
Sexually Transmitted Diseases
Rectal stricture associated with the long-term use of ibuprofen suppositories.
Shock, Septic
?-Solanine Isolated from Solanum tuberosum L. cv Jayoung Abrogates LPS-Induced Inflammatory Responses via NF-?B Inactivation in RAW 264.7 Macrophages and Endotoxin-Induced Shock Model in Mice.
A glycoprotein from Porphyra yezoensis produces anti-inflammatory effects in liposaccharide-stimulated macrophages via the TLR4 signaling pathway.
Activation of the PGI(2)/IP system contributes to the development of circulatory failure in a rat model of endotoxic shock.
Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages.
c-di-GMP Induces COX-2 Expression in Macrophages in a STING-Independent Manner.
Caffeic acid phenethyl ester protects mice from lethal endotoxin shock and inhibits lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW 264.7 macrophages via the p38/ERK and NF-kappaB pathways.
Circulatory responses to endothelin-1 and nitric oxide with special reference to endotoxin shock and nitric oxide inhalation.
Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Cyclooxygenase 2 pathway and its therapeutic inhibition in superantigen-induced toxic shock.
Effect of methylprednisolone, indomethacin, and diethylcarbamazine on survival rate following trauma and sepsis in rats.
Effects of two different inhibitors of the arachidonic acid metabolism on platelet sequestration in endotoxic shock.
Eugenosedin-A amelioration of lipopolysaccharide-induced up-regulation of p38 MAPK, inducible nitric oxide synthase and cyclooxygenase-2.
Exogenous heat shock cognate protein 70 pretreatment attenuates cardiac and hepatic dysfunction with associated anti-inflammatory responses in experimental septic shock.
Gentamicin and indomethacin in the treatment of septic shock: effects on prostacyclin and thromboxane A2 production.
Human septic myopathy: induction of cyclooxygenase, heme oxygenase and activation of the ubiquitin proteolytic pathway.
Ibuprofen in canine endotoxin shock.
Ibuprofen intervention in canine septic shock: reduction of pathophysiology without decreased cytokines.
Indomethacin and thromboxane A2/prostaglandin H2 antagonist SQ29,548 impair in vitro contractions of aortic rings of ex vivo-treated lipopolysaccharide rats.
Inducible cardiac-specific overexpression of cyclooxygenase-2 (COX-2) confers resistance to ischemia/reperfusion injury.
Induction of cytosolic phospholipase A2 and prostaglandin H2 synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes.
Induction of nitric oxide synthase and dual effects of nitric oxide and cyclooxygenase products in regulation of arterial contraction in human septic shock.
Inhibition of lipoxygenase (LOX) or of cyclooxygenase (COX) improves survival of rats in endotoxin shock.
Inhibition of vasoactive substances in experimental endotoxin shock.
Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
L-alpha-phosphatidylcholine-induced stimulation of PGI2 production in canine gallbladders following hypovolemic shock and Escherichia coli sepsis.
Modulation of cyclooxygenase-2 expression by phosphatidylcholine specific phospholipase C and D in macrophages stimulated with lipopolysaccharide.
Myocardial Redox Hormesis Protects the Heart of Female Mice in Sepsis.
Neoagarooligosaccharides prevent septic shock by modulating A20-and cyclooxygenase-2-mediated interleukin-10 secretion in a septic-shock mouse model.
Nodakenin Suppresses Lipopolysaccharide-Induced Inflammatory Responses in Macrophage Cells by Inhibiting Tumor Necrosis Factor Receptor-Associated Factor 6 and Nuclear Factor-?B Pathways and Protects Mice from Lethal Endotoxin Shock.
Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway.
Prostaglandin synthetase inhibitors in endotoxin or septic shock--a review.
Protection of myocardial function during endotoxin shock by ibuprofen.
Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.
Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo.
The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock.
TNF-alpha and cyclooxygenase metabolites do not modulate C. albicans septic shock with disseminated candidiasis.
Treatment of experimental canine endotoxin shock with ibuprofen, a cyclooxygenase inhibitor.
Vitamin E in relation to lipid peroxidation in experimental septic shock.
Shoulder Dislocation
Increased nerve growth factor expression in the synovial tissues of patients with rotator cuff tears.
Shoulder Impingement Syndrome
[In vitro effects of diclofenac and selective cyclooxygenase-2 inhibitors on prostaglandin release from inflamed bursa subacromialis tissue in patients with subacromial syndrome]
Shoulder Pain
Expression of interleukin-1beta, cyclooxygenase-2, and prostaglandin E2 in a rotator cuff tear in rabbits.
Sialadenitis
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Silicosis
Crystalline and amorphous silica differentially regulate the cyclooxygenase-prostaglandin pathway in pulmonary fibroblasts: implications for pulmonary fibrosis.
Enhanced release of prostaglandin E2 from macrophages of rats with silicosis.
Sinusitis
Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.
Asthma in children and ASA intolerance.
Expression of cyclo-oxygenase 1 and 2 proteins in upper respiratory mucosa.
Mechanisms of aspirin desensitization.
Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.
New immunohistologic findings on the differential role of cyclooxygenase 1 and cyclooxygenase 2 in nasal polyposis.
Skin Diseases
1-methylnicotinamide effects on the selected markers of endothelial function, inflammation and haemostasis in diabetic rats.
Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching.
Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Cyclooxygenases in the skin: pharmacological and toxicological implications.
Effects of 1-methylnicotinamide and its metabolite N-methyl-2-pyridone-5-carboxamide on streptozotocin-induced toxicity in murine insulinoma MIN6 cell line.
Immunohistochemical Detection of COX-2 in Feline and Canine Actinic Keratoses and Cutaneous Squamous Cell Carcinoma.
Modulation of Cox-1, 5-, 12- and 15-Lox by popular herbal remedies used in southern Italy against psoriasis and other skin diseases.
[The expressions of PPAR-gamma, COX-2 in the lesions of patients with condyloma acuminatum and bowenoid papulosis]
Skin Neoplasms
A comparative study: the prospective influence of nanovectors in leveraging the chemopreventive potential of COX-2 inhibitors against skin cancer.
A new wrinkle on topical vitamin E and photo-inflammation: Mechanistic studies of a hydrophilic gamma-tocopherol derivative compared with alpha-tocopherol.
A role for cyclooxygenase-2 in ultraviolet light-induced skin carcinogenesis.
Activation of p38 MAP kinase and JNK pathways by UVA irradiation.
Adaptor protein p62 promotes skin tumor growth and metastasis and is induced by UVA radiation.
Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: Role of cyclooxygenase-2 and novel J-series prostamides.
Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation.
Benzo[a]pyrene diol-epoxide (B[a]PDE) upregulates COX-2 expression through MAPKs/AP-1 and IKKbeta/NF-kappaB in mouse epidermal Cl41 cells.
Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines.
Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model.
Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats.
Cell-type-specific roles for COX-2 in UVB-induced skin cancer.
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.
COX-2 expression correlates with microvessel density in non-melanoma skin cancer from renal transplant recipients and immunocompetent individuals.
COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer.
Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases.
Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1.
Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis.
Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis.
Cyclooxygenase inhibitors for skin cancer prevention: are they beneficial enough?
Cyclooxygenase-2 deficiency increases epidermal apoptosis and impairs recovery following acute UVB exposure.
Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases.
Cyclooxygenase-2 expression and association with skin cancer: A meta-analysis based on Chinese patients.
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Cyclooxygenases: Mediators of UV-Induced Skin Cancer and Potential Targets for Prevention.
Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer.
Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial.
Enhanced expression of cylooxygenase-2 by UV in aged human skin in vivo.
Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha.
Genetically determined susceptibility to COX-2 inhibitors: a report of exaggerated responders to diclofenac 3% gel in the treatment of actinic keratoses.
Genetics and nonmelanoma skin cancer in kidney transplant recipients.
Immunohistochemical Analysis of Cyclooxygenase-2 in Non-Melanocytic Skin Cancer: Correlation With Morphological Subtype and Histologic Grade.
Immunohistochemical expression of cyclooxygenase-2 in skin cancers.
Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development.
In vitro growth inhibition by indomethacin on human oral squamous cell carcinoma lines synergistically suppressed by all-trans retinoic acid correlating to apoptosis.
Influence of Cyclooxygenase-2 (COX-2) Gene Promoter Polymorphism at Position -765 on Skin Cancer after Renal Transplantation.
Inhibition of bcl-2 and cox-2 Protein Expression after Local Application of a New Carmustine-Loaded Clinoptilolite-Based Delivery System in a Chemically Induced Skin Cancer Model in Mice.
Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells.
Is cyclooxygenase-2 important in skin carcinogenesis?
Ketoconazole suppresses prostaglandin E(2)-induced cyclooxygenase-2 expression in human epidermoid carcinoma A-431 cells.
LONG-TERM USE OF A NEW TOPICAL FORMULATION CONTAINING PIROXICAM 0.8% AND SUNSCREEN: EFFICACY AND TOLERABILITY ON ACTINIC KERATOSIS. A PROOF OF CONCEPT STUDY.
Molecular pathology of cyclooxygenase-2 in neoplasia.
Negative feedback regulation of phosphatidylinositol 3-kinase/Akt pathway by over-expressed cyclooxygenase-2 in human epidermal cancer cells.
NSAIDs in dermatologic therapy: review and preview.
p38 MAP kinase plays a functional role in UVB-Induced mouse skin carcinogenesis.
Photochemoprevention of ultraviolet B signaling and photocarcinogenesis.
Photodynamic Therapeutic Role of Indocyanine Green in Tumor-Associated Inflammation in Skin Cancer.
Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin.
Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.
Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes.
siRNA-mediated knock-down of COX-2 in melanocytes suppresses melanogenesis.
SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer.
Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer.
TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis.
The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors.
The role of cyclooxygenase-2 in the pathogenesis of skin cancer.
The role of immunohistochemistry expression of COX-2 in differentiating pigmented benign and malignant skin neoplasms.
The role of p38 in UVA-induced cyclooxygenase-2 expression in the human keratinocyte cell line, HaCaT.
The role of the EP receptors for prostaglandin E2 in skin and skin cancer.
The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention.
Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases.
Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.
Ultraviolet B(UVB)-induced cox-2 expression in murine skin: an immunohistochemical study.
UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression.
Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation.
[Cyclooxygenases in the skin]
Sleep Apnea Syndromes
Excessive daytime sleepiness is associated with changes in salivary inflammatory genes transcripts.
Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea.
Sleep Apnea, Obstructive
Liver X Receptor Gene Expression is Enhanced in Children with Obstructive Sleep Apnea-Hyperpnoea Syndrome and Cyclooxygenase-2 (COX-2) is Correlated with Severity of Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS).
Role of the Cyclooxygenase Pathway in the Association of Obstructive Sleep Apnea and Cancer.
[Cyclooxygenase-2 overexpression and vascular endothelial growth factor expression in pharyngeal tissue of patients with OSAHS correlates with angiogenesis].
Sleep Deprivation
Influence of sleep deprivation and morphine on the expression of inducible nitric oxide synthase and cyclooxygenase-2 in skin of hairless mice.
Sleep Wake Disorders
Indomethacin reverts sleep disorders produced by ozone exposure in rats.
Small Cell Lung Carcinoma
Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines.
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation.
Expression of cyclooxygenase-2 in human lung carcinoma.
Hierarchical clustering of lung cancer cell lines using DNA methylation markers.
Identification of key genes involved in nasopharyngeal carcinoma.
Meloxicam inhibits the growth of non-small cell lung cancer.
Nicotine, lung and cancer.
Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2.
Smooth Muscle Tumor
Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
Soft Tissue Injuries
A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
The effect of nonsteroidal anti-inflammatory drugs on tissue healing.
Solitary Kidney
Cyclooxygenase-2, prostaglandin E2, and prostanoid receptor EP2 in fluid flow shear stress-mediated injury in the solitary kidney.
Spasm
Antioxidant is a useful supportive agent for the treatment of coronary vasospasm with endothelial dysfunction in pig.
Dietary L-arginine restores aspirin-induced endothelial dysfunction in rat aorta.
Molsidomine: alternative approaches to treat myocardial ischemia.
NS-398 (a Selective Cyclooxygenase-2 Inhibitor) Decreases Agonist-Induced Contraction of the Human Ureter via Calcium Channel Inhibition.
Spermatic Cord Torsion
Inflammation and Oxidative Stress in Testicular Torsion: Do They Deserve Intensive Treatment to Save Both Guilty and Innocent Testes?
Sphincter of Oddi Dysfunction
Toward routine use of nonsteroidal anti-inflammatory drugs for patients undergoing endoscopic retrograde cholangiopancreatography.
Spinal Cord Diseases
Quantitative analysis of cyclooxygenase 2 in the posterior longitudinal ligament of cervical spondylotic myelopathy.
Spinal Cord Injuries
A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury.
An anti-CD11d integrin antibody reduces cyclooxygenase-2 expression and protein and DNA oxidation after spinal cord injury in rats.
Analysis of interaction between etoricoxib and tramadol against mechanical hyperalgesia of spinal cord injury in rats.
CD11d integrin blockade reduces the systemic inflammatory response syndrome after spinal cord injury.
Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone.
Cyclooxygenase-2 induction in rat spinal cord injury mediated by proinflammatory tumor necrosis factor-alpha and interleukin-1.
Downregulating lncRNA PVT1 Relieves Astrocyte Overactivation Induced Neuropathic Pain Through Targeting miR-186-5p/CXCL13/CXCR5 Axis.
Effects of COX-2 and iNOS inhibitors alone or in combination with olfactory ensheathing cell grafts after spinal cord injury.
High mobility group box 1 mediates inflammatory response of astrocytes via cyclooxygenase 2/prostaglandin E2 signaling following spinal cord injury.
Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice.
Localization of cyclooxygenase-2 induced following traumatic spinal cord injury.
Neuroprotective effect of novel celecoxib derivatives against spinal cord injury via attenuation of COX-2, oxidative stress, apoptosisand inflammation.
Persistent accumulation of cyclooxygenase-1 (COX-1) expressing microglia/macrophages and upregulation by endothelium following spinal cord injury.
Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats.
Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib).
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
Reduction of pathological and behavioral deficits following spinal cord contusion injury with the selective cyclooxygenase-2 inhibitor NS-398.
Role of cyclooxygenase 2 in acute spinal cord injury.
Sevoflurane preconditioning ameliorates traumatic spinal cord injury through caveolin-3-dependent cyclooxygenase-2 inhibition.
Tempol reduces injury area in rat model of spinal cord contusion injury through suppression of iNOS and COX-2 expression.
The Investigation of the Cox-2 Selective Inhibitor Parecoxib Effects in Spinal Cord Injury in Rat.
Traumatic spinal cord injury in rats causes increases in tissue thromboxane but not peptidoleukotrienes.
Spinal Cord Ischemia
Anti-Inflammatory Effect of Lycopene on Experimental Spinal Cord Ischemia Injury via Cyclooxygenase-2 Suppression.
Biomarkers of free radical injury during spinal cord ischemia.
Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia.
Spinal Diseases
Cyclooxygenase-2 deficiency causes delayed ossification of lumbar vertebral endplates.
Spondylarthropathies
Autoantibodies to the HLA-B27 sequence cross-react with the hypothetical peptide from the arthritis-associated Shigella plasmid.
Spondylitis
Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.
Spondylitis, Ankylosing
Association of renal papillary necrosis and ankylosing spondylitis.
Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.
Connection of COX-2 variants to ankylosing spondylitis susceptibility.
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.
Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells.
Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
Evaluation of the oral administration of ?-l-guluronic acid on COX-1 and COX-2 gene expression profile in ankylosing spondylitis patients.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Influence of CYP2C9 and COX-2 Genetic Polymorphisms on Clinical Efficacy of Non-Steroidal Anti-Inflammatory Drugs in Treatment of Ankylosing Spondylitis.
Meloxicam in the management of post-operative pain: Narrative review.
Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
Update on nonsteriodal anti-inflammatory drugs.
Spondylolisthesis
High-grade slippage of the lumbar spine in a rat model of spondylolisthesis: effects of cyclooxygenase-2 inhibitor on its deformity.
Spotted Fever Group Rickettsiosis
Infection of human endothelial cells with spotted Fever group rickettsiae stimulates cyclooxygenase 2 expression and release of vasoactive prostaglandins.
Regulation of inducible heme oxygenase and cyclooxygenase isozymes in a mouse model of spotted fever group rickettsiosis.
Squamous Cell Carcinoma of Head and Neck
5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats.
7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma.
A replication-selective adenoviral vector for head and neck cancers.
A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation.
A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells.
A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas.
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.
Amphiregulin as a tumor promoter for oral squamous cell carcinoma: involvement of cyclooxygenase 2.
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.
Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk.
Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.
c-Jun N-terminal kinase negatively regulates epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines.
CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma.
CD44high/ESAlow squamous cell carcinoma cell-derived prostaglandin E2 confers resistance to 5-fluorouracil-induced apoptosis in CD44high/ESAhigh cells.
Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.
Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study.
Chemopreventive activity of Tualang honey against oral squamous cell carcinoma-in vivo.
Clinicopathological significance of cyclooxygenase-2 expression in hypopharyngeal squamous cell carcinoma.
Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma.
Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Comparison of COX2 expression between oral squamous cell carcinoma, leukoplakia and normal mucosa.
Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma.
Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas.
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.
Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma.
COX-1 and COX-2 Expression in Feline Oral Squamous Cell Carcinoma.
COX-2 Docking Structural Analysis with Phytochemical Extracts of Rosemary: A Possible Cytotoxicity on Head and Neck Squamous Cell Carcinoma Cell Line (HEp-2).
COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma.
COX-2 expression in dysplasia of the head and neck: correlation with elF4E.
COX-2 expression in oral lichen planus.
COX-2 Gene increases tongue cancer cell proliferation and invasion through VEGF-C pathway.
COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data.
COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma.
Cyclo-oxygenase-2 expression in oral squamous cell carcinoma.
Cyclooxygenase 2 promoter-based replication-selective adenoviral vector for hypopharyngeal cancer.
Cyclooxygenase and CD147 expression in oral squamous cell carcinoma patient samples and cell lines.
Cyclooxygenase-2 expression and clinical parameters in laryngeal squamous cell carcinoma, vocal fold nodule, and laryngeal atypical hyperplasia.
Cyclooxygenase-2 expression in oral squamous cell carcinoma.
Cyclooxygenase-2 expression in oral tongue squamous cell carcinoma.
Cyclooxygenase-2 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma.
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.
Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma.
Cyclooxygenase-2-1195G>A Polymorphism and Head and Neck Squamous Cell Carcinoma Susceptibility: A Meta-Analysis of 1564 Cases and 2346 Controls.
Cyclooxygenase-2-765G>C functional promoter polymorphism and its association with oral squamous cell carcinoma.
Cytoplasmic HuR over-expression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas.
Decreased gene expression of human beta-defensin-1 in the development of squamous cell carcinoma of the oral cavity.
Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines.
Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.
Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma.
Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers.
DNA polymorphisms and tissue cyclooxygenase-2 expression in oral lichen planus: a case-control study.
Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma.
Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.
Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.
Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib.
Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for COX-2 induction by areca quid ingredients in oral keratinocytes.
Elevated Levels of Urinary Prostaglandin E Metabolite Indicate a Poor Prognosis in Ever Smoker Head and Neck Squamous Cell Carcinoma Patients.
Endoplasmic Reticulum Stress Response as a Possible Mechanism of Cyclooxygenase-2-independent Anticancer Effect of Celecoxib.
Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4.
Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation.
Epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines is mediated through extracellular signal-regulated kinase 1/2 and p38 but is Src and nuclear factor-kappa B independent.
Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Evaluation of HPV and EBV in OSCC and the expression of p53, p16, E-cadherin, COX-2, MYC, and MLH1.
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Expression and clinical implication of cyclooxygenase-2 and e-cadherin in oral squamous cell carcinomas.
Expression of COX-2, CD44v6 and CD147 and Relationship with Invasion and Lymph Node Metastasis in Hypopharyngeal Squamous Cell Carcinoma.
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.
Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma.
Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-?B in oral squamous cell carcinoma.
Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in Oral Squamous Cell Carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation.
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance.
Functional variants of COX-2 and risk of tobacco-related oral squamous cell carcinoma in high-risk Asian Indians.
Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-{kappa}B and STAT3 pathways in head and neck cancer cells.
Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression.
High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma.
Histologic correlation of VEGF and COX-2 expression with tumor size in squamous cell carcinoma of the larynx and hypopharynx.
Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma.
Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective.
Immunohistochemical detection of Ki-67 is not associated with tumor-infiltrating macrophages and cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical expression of cyclooxygenase-2 in oral squamous cell carcinoma.
Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor.
Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1.
Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis.
Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer.
Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44.
Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation.
Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2.
Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma.
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.
Nimesulide and indomethacin induce apoptosis in head and neck cancer cells.
NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-induced expression of COX-2.
Nuclear factor ?B and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma.
Overexpression of COX-2 in oral squamous cell carcinoma patients undergoing chemoradiotherapy.
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma.
Overexpression of lipocalins and pro-inflammatory chemokines and altered methylation of PTGS2 and APC2 in oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide.
PGE2 production in oral cancer cell lines is COX-2-dependent.
Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro.
Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population.
Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma.
Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma.
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.
Promotion of cell differentiation, and suppression of cell growth and cyclooxygenase-2 expression by differentiation-inducing agents in human oral squamous carcinoma SCC25 cells.
Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy.
Prostaglandin E(2) pathway in head and neck squamous cell carcinoma.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Relation between proinflammatory mediators and epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma.
Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.
Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells.
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways.
Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma.
Significance of immunohistochemical overexpression of cyclooxygenase-2 in overall and disease-free survival of oral squamous cell carcinoma patients.
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma.
Studies on the Contribution of Cox-2 Expression in the Progression of Oral Squamous Cell Carcinoma and H-Ras Activation.
Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment.
Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model.
The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor.
The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.
The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines.
The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells.
The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines.
The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma.
The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.
The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
The therapeutic activity of curcumin through its anti-cancer potential on oral squamous cell carcinoma: A study on Sprague Dawley rat.
Translational approach utilizing COX-2, p53, and MDM2 expressions in malignant transformation of oral submucous fibrosis.
Up-regulation of HB-EGF by the COX-2/PGE2 signaling associates with the cisplatin resistance and tumor recurrence of advanced HNSCC.
Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2 -1195G>a polymorphism reveal risk of oral cancer.
[Expression and clinical significance of hypoxia-inducible factor-1alpha and cyclooxygenase-2 in laryngeal squamous cell carcinoma]
[Expression and prognostic significance of cyclooxygenase-2 in supraglottic laryngeal squamous cell carcinomas]
[Nuclear factor kappaB/p65 and cyclooxygenase-2 expression and clinic significance in human laryngeal squamous cell carcinoma]
[Relationship between the expression of cyclooxygenase-2 and microvessel density in oral squamnous cell carcinoma]
[The expression and significance of HIF-1alpha and COX-2 in laryngeal squamous cell carcinoma]
[The expression of COX-2 mRNA and protein in human laryngeal squamous cell carcinoma]
[The expressiong of cyclooxygenase-2 in laryngeal squamous cell carcinoma and its relationship with MVD]
[The expressions of cyclooxygenase-2 (Cox-2),VEGF in oral squamous cell carcinoma and precancerous lesions and their significances]
[The influence of COX-2 depressant in angiogenesis of oral squamous cell carcinoma].
ST Elevation Myocardial Infarction
Do Not Use Cycloxigenase-2 Inhibitors in STEMI.
Starvation
Autophagy is deficient and inversely correlated with COX-2 expression in nasal polyps: a novel insight into the inflammation mechanism.
Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells.
Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines.
Cyclooxygenase-2 Induction by Amino Acid Deprivation Requires p38 Mitogen-Activated Protein Kinase in Human Glioma Cells.
Enhancement of prostaglandin D(2) production through cyclooxygenase-2 and lipocalin-type prostaglandin D synthase by upstream stimulatory factor 1 in human brain-derived TE671 cells under serum starvation.
n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
p38 mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E2 biosynthesis stimulated by interleukin-1beta.
Status Epilepticus
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus.
Age-dependent cyclooxygenase-2 induction and neuronal damage after status epilepticus in the postnatal rat hippocampus.
Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats.
Co-administration of subtherapeutic diazepam enhances neuroprotective effect of COX-2 inhibitor, NS-398, after lithium pilocarpine-induced status epilepticus.
Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy.
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.
CRE-mediated transcription and COX-2 expression in the pilocarpine model of status epilepticus.
Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats.
Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus.
Enhanced cyclooxygenase-2 expression in olfactory-limbic forebrain following kainate-induced seizures.
Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.
Involvement of nitrergic system in anticonvulsant effect of zolpidem in lithium-pilocarpine induced status epilepticus: Evaluation of iNOS and COX-2 genes expression.
Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy.
Sesamin ameliorates oxidative stress and mortality in kainic acid-induced status epilepticus by inhibition of MAPK and COX-2 activation.
Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.
Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy.
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy.
The cyclooxygenase and lipoxygenase inhibitor BW755C protects rats against kainic acid-induced seizures and neurotoxicity.
Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
[Effects of cyclooxygenase-2 selective inhibitor celecoxib on the expression of major vault protein in rats with status epilepticus].
Stevens-Johnson Syndrome
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
Stillbirth
[Developmental toxicity of the over-the-counter analgetics and antypiretics].
Stomach Diseases
Beta-carotene inhibits Helicobacter pylori-induced expression of inducible nitric oxide synthase and cyclooxygenase-2 in human gastric epithelial AGS cells.
COX-2 Gene Promoter Methylation in Patients Infected with Helicobacter Pylori.
Interaction of Cyclooxygenase-2 with Helicobacter pylori Induces Gastric Chronic Nonresolving Inflammation and the Formation of Syndrome of Internal Block of Static Blood in Helicobacter pylori-Related Gastric Diseases.
Quantitative analysis of COX-2 promoter methylation in gastric carcinoma.
Sex differences in mucosal response to Helicobacter pylori infection in the stomach and variations in interleukin-8, COX-2 and trefoil factor family 1 gene expression.
Stomach Neoplasms
-765 g>c polymorphism of the cox-2 gene and gastric cancer risk in Brazilian population.
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer.
15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer.
?-tocotrienol inhibits the invasion and migration of human gastric cancer cells through downregulation of cyclooxygenase-2 expression.
A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.
A Genetic Variant in 3'-Untranslated Region of Cyclooxygenases-2 Gene Is Associated with Risk of Gastric Cancer in a Chinese Population.
A mechanistic study of cigarette smoke and cyclooxygenase-2 on proliferation of gastric cancer cells.
A new cyclo-oxygenase-2 gene variant in the Han Chinese population is associated with an increased risk of gastric carcinoma.
A polymorphism in the 3'-utr of cyclooxygenase-2 and the risk of gastric cancer.
A positive feedback loop between STAT3 and cyclooxygenase-2 gene may contribute to Helicobacter pylori-associated human gastric tumorigenesis.
A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer.
Acetyl-11-keto-?-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/ cyclooxygenase-2 signaling pathway.
Alterations of cyclooxygenase-2 methylation levels before and after intervention trial to prevent gastric cancer in a Chinese population.
Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.
Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells.
Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.
Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway.
Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2.
Assessment of COX-2 expression presence and severity by immunohistochemical method in patients with chronic active gastritis and intestinal metaplasia.
Association between color doppler vascularity index, angiogenesis-related molecules, and clinical outcomes in gastric cancer.
Association between COX-2 -1195G>A polymorphism and gastrointestinal cancer risk: A meta-analysis.
Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer.
Association between rs20417 polymorphism in cyclooxygenase-2 and gastric cancer susceptibility: Evidence from15 case-control studies.
Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer.
Bile acid induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells.
Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro.
Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer.
Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway.
Celecoxib induces apoptosis through Akt inhibition in 5-fluorouracil-resistant gastric cancer cells.
Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils.
Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils.
Celecoxib Inhibits Helicobacter pylori-induced Invasion of Gastric Cancer Cells Through an Adenine Nucleotide Translocator-Dependent Mechanism.
Chemoprevention of gastric cancer by celecoxib in rats.
Chemoprevention of gastric cancer.
Chemoprevention of gastric cancer: role of COX-2 inhibitors and other agents.
Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible?
Chemopreventive effect of celecoxib in gastric cancer.
Chemopreventive effects of rofecoxib and folic acid on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats.
Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer.
Clinical and prognosis relevance of COX-2 expression in Tunisian patients with primary gastric adenocarcinoma.
Clinical significance of prostaglandin E synthase expression in gastric cancer tissue.
Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma.
Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo.
Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer.
Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome.
Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma.
Correlation between cyclooxygenase-2, proliferative activity, and mucin phenotype in human advanced gastric cancer.
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis.
COX-2 and angiogenesis in gastric cancer.
COX-2 and gastric cancer: More on inflammation and neoplasia.
COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray.
COX-2 inhibition and the prevention of gastric cancer.
COX-2 Inhibitors and Gastric Cancer.
COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer.
COX-2 overexpression in canine tumors: potential therapeutic targets in oncology.
COX-2 promotes metastasis and predicts prognosis on gastric cancer via regulating mTOR.
COX-2 regulates E-cadherin expression through the NF-?B/Snail signaling pathway in gastric cancer.
COX-2 regulates Snail expression in gastric cancer via the Notch1 signaling pathway.
COX-2, TFF1, and Src define better prognosis in young patients with gastric cancer.
Curcumin Enhances the Anticancer Effect Of 5-fluorouracil against Gastric Cancer through Down-Regulation of COX-2 and NF- ?B Signaling Pathways.
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.
Cyclooxygenase-2 -1195G>A (rs689466) polymorphism and cancer susceptibility: an updated meta-analysis involving 50,672 subjects.
Cyclooxygenase-2 and gastric cancer.
Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma.
Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue.
Cyclooxygenase-2 expression in early gastric cancer, intestinal metaplasia and Helicobacter pylori infection.
Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis.
Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients.
Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis.
Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia.
Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.
Cyclooxygenase-2 inhibition and gastric cancer.
Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line.
Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts.
Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice.
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR.
Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines.
Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma.
Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.
Cyclooxygenase-2 polymorphisms and the risk of gastric cancer in various degrees of relationship in the Chinese Han population.
Cyclooxygenase-2 polymorphisms were associated with the risk of gastric cancer: evidence from a meta-analysis based on case-control studies.
Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
Cycloxygenase-2 is Essential for the Survival and Proliferation of Gastric Cancer Cells.
Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway.
Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2).
Detection and Clinical Significance of COX-2 Gene SNPs in Gastric Cancer.
Diet folate, DNA methylation and polymorphisms in methylenetetrahydrofolate reductase in association with the susceptibility to gastric cancer.
Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability.
DNA repair Ku proteins in gastric cancer cells and pancreatic acinar cells.
Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth.
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers.
EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer.
Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer.
Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer.
Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention.
Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer.
Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis.
Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells.
Effect of pertussis toxin and herbimycin A on proteinase-activated receptor 2-mediated cyclooxygenase 2 expression in Helicobacter pylori-infected gastric epithelial AGS cells.
Effects of combined octreotide and aspirin on the growth of gastric cancer.
Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor.
Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial.
Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development.
Elevated cyclooxygenase-2 expression in patients with early gastric cancer in the gastric pylorus.
Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer.
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer.
Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile.
Ethanol extracts of Allium sp. regulate cyclooxygenase-2 and E-cadherin expression in gastric cancer MKN74 cell line and enhance doxorubicin toxicity.
Evaluation of specific biochemical indicators of Helicobacter pylori-associated gastric cancer in Egypt.
Expression of 15-PGDH is downregulated by COX-2 in gastric cancer.
Expression of COX-2 in stomach cancers and its relation to their biological features.
Expression of COX-2 in Stomach Carcinogenesis.
Expression of COX-2 proteins in gastric mucosal lesions.
Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis.
Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma.
Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis.
Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer.
Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma.
Expression of cyclooxygenase-2 in gastric cancer and its relation to liver metastasis and long-term prognosis.
Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.
Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression.
Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells.
Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells.
Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines.
Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer.
Expression of peroxisome proliferator-activated receptor delta in human gastric cancer and its response to specific COX-2 inhibitor.
Expression profiles of Annexin A1, formylated peptide receptors and cyclooxigenase-2 in gastroesophageal inflammations and neoplasias.
Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications.
Expressions of Ras Homolog Gene Family, Member A (RhoA) and Cyclooxygenase-2 (COX-2) Proteins in Early Gastric Cancer and Their Role in the Development of Gastric Cancer.
Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells.
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells.
Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility.
Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population.
Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.
Genetic Variations in Prostaglandin E2 Pathway Identified as Susceptibility Biomarkers for Gastric Cancer in an Intermediate Risk European Country.
Ghrelin Regulates Cyclooxygenase-2 Expression and Promotes Gastric Cancer Cell Progression.
Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells.
Harmine combined with paclitaxel inhibits tumor proliferation and induces apoptosis through down-regulation of cyclooxygenase-2 expression in gastric cancer.
Harmine induces apoptosis and inhibits tumor cell proliferation, migration and invasion through down-regulation of cyclooxygenase-2 expression in gastric cancer.
Helicobacter pylori and EBV in gastric carcinomas: methylation status and microsatellite instability.
Helicobacter pylori enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signaling pathway in MKN45 cells.
Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis.
Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway.
Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.
Helicobacter pylori promotes apoptosis, activates cyclooxygenase (COX)-2 and inhibits heat shock protein HSP70 in gastric cancer epithelial cells.
Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors.
Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer.
Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation.
Heterogeneity of COX-2 and multidrug resistance between primary tumors and regional lymph node metastases of gastric cancer.
Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients.
Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.
Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival.
Inactivation of COX-2, HMLH1 and CDKN2A Gene by Promoter Methylation in Gastric Cancer: Relationship with Histological Subtype, Tumor Location and Helicobacter pylori Genotype.
Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer.
Increased expression of cyclooxygenase-2 in first-degree relatives of gastric cancer patients.
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Increased expression of interleukin-1alpha and cyclooxygenase-2 in human gastric cancer: a possible role in tumor progression.
Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines.
Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways.
Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.
Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells.
Influences of Helicobacter pylori on cyclooxygenase-2 expression and prostaglandinE2 synthesis in rat gastric epithelial cells in vitro.
Infrequent COX-2 expression due to promoter hypermethylation in gastric cancers in Dalian, China.
Inhibition of Akt/PKB by a COX-2 inhibitor induces apoptosis in gastric cancer cells.
Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.
Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants.
Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells.
Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.
Interaction between cyclooxygenase-2 and inducible nitric oxide synthase in gastric cancer.
Interaction between cyclooxygenase-2, Snail, and E-cadherin in gastric cancer cells.
Interaction of Cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer.
Interleukin-1beta induces cyclo-oxygenase-2 expression in gastric cancer cells by the p38 and p44/42 mitogen-activated protein kinase signaling pathways.
Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis.
Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer.
Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice.
Involvement of nuclear factor ?B (NF-?B) in the downregulation of cyclooxygenase-2 (COX-2) by genistein in gastric cancer cells.
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
KITENIN is associated with tumor progression in human gastric cancer.
Lactobacillus acidophilus 74-2 and butyrate induce cyclooxygenase (COX)-1 expression in gastric cancer cells.
Long noncoding RNA NEAT1 promotes tumorigenesis in H. pylori gastric cancer by sponging miR-30a to regulate COX-2/BCL9 pathway.
Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells.
MAPK (ERK2) kinase--a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth.
MBP-1 Suppresses Growth and Metastasis of Gastric Cancer Cells through COX-2.
Mechanism and clinical significance of cyclooxygenase-2 expression in gastric cancer.
Melatonin set out to ER stress signaling thwarts epithelial mesenchymal transition and peritoneal dissemination via calpain-mediated C/EBP? and NF?B cleavage.
Methylation status of COX-2 in blood leukocyte DNA and risk of gastric cancer in a high-risk Chinese population.
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion.
MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2.
MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2.
Microvessel density is a prognostic marker of human gastric cancer.
miR-21 inhibits the effects of cyclooxygenase-2 inhibitor NS398 on apoptosis and invasion in gastric cancer cells.
miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models.
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.
Molecular basis of therapeutic approaches to gastric cancer.
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches.
Monocyte chemoattractant protein 1 and CD40 ligation have a synergistic effect on vascular endothelial growth factor production through cyclooxygenase 2 upregulation in gastric cancer.
Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.
Myrrh induces the apoptosis and inhibits the proliferation and migration of gastric cancer cells through down-regulating cyclooxygenase-2 expression.
NF-?B targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors.
Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways.
Nicotine and gastric cancer.
Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2.
Non-steroidal anti-inflammatory drugs in prevention of gastric cancer.
Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression.
Nonsteroidal anti-inflammatory drugs prevent gastric cancer associated with the use of proton pump inhibitors after Helicobacter pylori eradication.
Notch2-induced COX-2 expression enhancing gastric cancer progression.
Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway.
Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells.
Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer.
Overexpression of cyclooxygenase-2 in gastric cancer correlates with the high abundance of vascular endothelial growth factor-C and lymphatic metastasis.
Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability.
Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells.
Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression.
PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system.
Phthalate plasticizer di(2-ethyl-hexyl) phthalate induces cyclooxygenase-2 expression in gastric adenocarcinoma cells.
PLC?1: a potential target of RNA interference therapy for gastric cancer.
Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study.
Population, Epidemiological, and Functional Genetics of Gastric Cancer Candidate Genes in Peruvians with Predominant Amerindian Ancestry.
Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.
Preferential expression of cyclooxygenase-2 in colonic-phenotype of gastric intestinal metaplasia: association with helicobacter pylori and gastric carcinoma.
Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide.
Preparation of novel anthraquinone-based aspirin derivatives with anti-cancer activity.
Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer.
Prognostic significance of expression of cysteine-rich 61 and cyclooxygenase-2 in gastric cancer.
Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.
Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells.
Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer.
Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model.
Prostaglandin E2 stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells.
Protease-activated receptor-2 induces expression of vascular endothelial growth factor and cyclooxygenase-2 via the mitogen-activated protein kinase pathway in gastric cancer cells.
Pseudolaric acid B circumvents multidrug resistance phenotype in human gastric cancer SGC7901/ADR cells by downregulating Cox-2 and P-gp expression.
R-flurbiprofen reverses multidrug resistance, proliferation and metastasis in gastric cancer cells by p75(NTR) induction.
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Relation of cyclooxygenase-2 expression with premalignant gastric lesions.
Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.
Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
Role of cyclooxygenase-2 in gastric cancer development and progression.
Roles of Cyclooxygenase-2 gene -765G?>?C (rs20417) and -1195G?>?A (rs689466) polymorphisms in gastric cancer: A systematic review and meta-analysis.
Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis.
Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma.
Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
Sex differences in mucosal response to Helicobacter pylori infection in the stomach and variations in interleukin-8, COX-2 and trefoil factor family 1 gene expression.
Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products.
Sinomenine inhibits proliferation of SGC-7901 gastric adenocarcinoma cells via suppression of cyclooxygenase-2 expression.
Statins Were Associated with a Reduced Gastric Cancer Risk in Patients with Eradicated Helicobacter Pylori Infection: A Territory-Wide Propensity Score Matched Study.
Study on the association of COX-2 genetic polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu province in China.
Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer.
Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.
The 765G>C polymorphism in the cyclooxygenase-2 gene and gastric cancer risk: an update by meta-analysis.
The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2.
The anti-cancer effect of COX-2 inhibitors on gastric cancer cells.
The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers.
The COX-2-1195AA Genotype Is Associated with Diffuse-Type Gastric Cancer in Korea.
The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines.
The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
The effects of radix curcumae extract on expressions of VEGF, COX-2 and PCNA in gastric mucosa of rats fed with MNNG.
The function and mechanism of COX-2 in angiogenesis of gastric cancer cells.
The immunogenetics and pathogenesis of gastric cancer. Highlights of the First Sino-European Workshop on the Immunogenetics and Pathogenesis of Gastric Cancer.
The influence of transforming growth factor-?, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer.
The mechanism of COX-2 regulating HERG channel in gastric cancer cells.
The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer.
The role of bile acids in cellular invasiveness of gastric cancer.
The role of propranolol as a radiosensitizer in gastric cancer treatment.
the selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.
The value of MG7-Ag and COX-2 for predicting malignancy in gastric precancerous lesions.
Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2.
Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice.
Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of "tumor-phlegm microenvironment".
WIN 55,212-2 Inhibits the Epithelial Mesenchymal Transition of Gastric Cancer Cells via COX-2 Signals.
Wnt/?-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells.
[Antisense inhibition of cyclooxygenase-2 reduces malignant phenotype of gastric cancer cells]
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]
[Association between Helicobacter pylori cagA strain infection and expression of cyclooxygenase 2 in gastric carcinoma]
[Celecoxib induces apoptosis and inhibites angiogenesis in gastric cancer]
[Chinese herbal medicine Jianpi Jiedu Formula down-regulates the expression of vascular endothelial growth factor in human gastric cell line MKN45 induced by Helicobacter pylori by inhibiting cyclooxygenase-2.]
[Correlation of Helicobacter pylori infection with the expression of COX-2 and EGFR and VEGF in human gastric carcinoma]
[COX and study of cancer therapy]
[COX- 2 expression in gastric cancer and its relationship with lymphangiogenesis and lymph node metastasis]
[COX-2 expression in gastric cancers]
[COX-2 expression in the H. pylori infected gastric mucosal epithelia and its significance]
[Delayed rectifier K(+) channel regulated by cyclooxygenase-2 in human gastric cancer cell]
[Effect of a selective COX-2 inhibitor on cell proliferation and apoptosis in human gastric cancer cell line BGC-823]
[Effect of jianpi jiedu recipe on microvessel density and cyclooxygenm-2 expression in Heliobacter pylori induced gastric cancer].
[Effect of jianpi tongluo jiedu recipe on expression levels of COX-2, NF-kappaBp65, and Bcl-2 in gastric mucosa of patients with precancerous lesions of gastric cancer].
[Effect of polyunsaturated fatty acids ?-3 and ?-6 on angiogenesis formation in human gastric cancer].
[Effects of gastrin receptor antagonist and cyclooxygenase-2 inhibitor on proliferation and apoptosis of gastric cancer cell]
[Effects of inhibition of cyclooxygenase-2 by RNA interference on proliferation and apoptosis of human gastric cancer cells: an experimental study with human gastric cancer cells and mice]
[Expression of cyclooxygenase-2 and urokinase plasminogen activator in gastric carcinoma and the clinical significance thereof]
[Expression of peroxisome proliferators-activated receptor-gamma and cyclooxygenase-2 in Helicobacter pylori infection-associated diseases and significance thereof]
[Expression of tissue microarray p53, p16 and cyclooxygenase-2 in gastric cancer]
[Expressions of COX-2, PKC-? and miR-101 in gastric cancer and their correlations].
[Genetic polymorphisms in the promoter region of cyclooxygenase-2 and their association with risk of gastric cancer]
[Helicobacter pylori, cyclooxygenase-2 and gastric cancer]
[Influence of selective cyclooxygenase-2 inhibitor on proliferation of human gastric cancer cells]
[Inhibition of gastric cancer cells growth in vitro by sulindac]
[Inhibitory effects of celecoxib combined with octreotide on growth of multidrug resistant human gastric cancer cell line SGC7901/ADR.]
[Jianpi jiedu recipe inhibited Helicobacter pylori-induced the expression of cyclooxygenase-2 via p38MAPK/ATF-2 signal transduction pathway in human gastric cancer cells].
[Mechanism of apoptosis induced by specific COX-2 inhibitor SC236 in gastric cancer cells]
[Mechanisms of Inhibiting Proliferation and Inducing Apoptosis of Human Gastric Cancer Cell Line SGC7901 by Ursolic Acid.]
[Nimesulide, a selective cyclooxygenase-2 inhibitor inhibits telomerase activity by blocking activation of PKB in gastric cancer cell line]
[Relationship between cyclooxygenase- 2 expression and angiogenesis in patients with gastric cancer]
[Research on relationships of gastric cancer with serum trace elements, Helicobacter pylori and COX-2 in gastric tissue]
[Role of cyclooxygenase-2 (COX-2) and peroxisome proliferator-activated receptor (PPAR) in gastric cancer]
[Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior]
[The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]
[The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma]
[The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo]
[The potential role of Id1 in COX-2 mediated angiogenesis in gastric cancer]
[The role of cyclooxygenase-2 and vascular endothelial growth factor-C in lymphatic metastasis of gastric cancer]
Stomach Ulcer
Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor.
Anti-Inflammatory Effects of Licania macrocarpa Cuatrec Methanol Extract Target Src- and TAK1-Mediated Pathways.
Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats.
Artesunate affords protection against aspirin-induced gastric injury by targeting oxidative stress and proinflammatory signaling.
Aspirin and ulcers.
Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan.
Attenuation of ischemia-reperfusion-induced gastric ulcer by low-dose vanadium in male Wistar rats.
Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors.
Chrysin Modulates Genes Related to Inflammation, Tissue Remodeling, and Cell Proliferation in the Gastric Ulcer Healing.
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Comparison of nitric oxide-releasing NSAID and vitamin C with classic NSAID in healing of chronic gastric ulcers; involvement of reactive oxygen species.
COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions.
COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications.
Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing.
Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives.
Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers.
Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
Cyclooxygenase-2 specificity and its clinical implications.
Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts.
Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile.
Differential effects of selective and non-selective inhibition of nitric oxide synthase on the expression and activity of cyclooxygenase-2 during gastric ulcer healing.
Differential role of platelet-activating factor in gastric mucosal ulcer healing.
Discovery of a COX-2 selective inhibitor hit with anti-inflammatory activity and gastric ulcer protective effect.
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance.
Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2.
Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor.
Effect of the oral absorption of benzenesulfonanilide-type cyclooxygenase-1 inhibitors on analgesic action and gastric ulcer formation.
Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats.
Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats.
Effects of Rumex patientia root extract on indomethacine and ethanol induced gastric damage in rats.
Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation.
Experimental production of peptic ulcer, gastric damage and cancer models and their use in pathophysiological studies and pharmacological treatment - Polish achievements.
Expression and activities of three inducible enzymes in the healing of gastric ulcers in rats.
Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells.
Expression of cyclooxygenase isoforms in ulcerated tissues of the nonglandular portion of the stomach in horses.
Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine.
Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats.
Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs.
Gastroprotective Effects of Fermented Lotus Root against Ethanol/HCl-Induced Gastric Mucosal Acute Toxicity in Rats.
Gaultherin, a natural salicylate derivative from Gaultheria yunnanensis: towards a better non-steroidal anti-inflammatory drug.
Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor.
Heregulin-alpha and heregulin-beta expression is linked to a COX-2-PGE2 pathway in human gastric fibroblasts.
Impaired gastric ulcer healing in diabetic rats: role of heat shock protein, growth factors, prostaglandins and proinflammatory cytokines.
Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration.
In vivo gastroprotective effect along with pharmacokinetics, tissue distribution and metabolism of isoliquiritigenin in mice.
Induction of COX-1, suppression of COX-2 and pro-inflammatory cytokines gene expression by moringa leaves and its aqueous extract in aspirin-induced gastric ulcer rats.
Induction of cyclo-oxygenase-2 expression in naturally occurring gastric ulcers.
Influence of COX-2 and local cytokine expressions in gastric ulcer mucosa by H. pylori and NSAID.
Interaction of hepatocyte growth factor and non-steroidal anti-inflammatory drugs during gastric epithelial wound healing.
Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor.
Involvement of cyclooxygenase-1 and cyclooxygenase-2 activity in the therapeutic effect of ghrelin in the course of ethanol-induced gastric ulcers in rats.
Is COX-2 inhibition a panacea for cancer prevention?
Lack of gastric toxicity of nitric oxide-releasing indomethacin, NCX-530, in experimental animals.
Levels of cyclooxygenase-1 and -2 mRNA expression at various stages of acute gastric injury induced by ischemia-reperfusion in rats.
Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans.
Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats.
Mechanism of action of celecoxib on normal and acid-challenged gastric mucosa.
Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers.
Methanolic Extract of Distemonanthus benthamianus (Caesalpiniaceae) Stem Bark Suppresses Ethanol/Indomethacin-Induced Chronic Gastric Injury in Rats.
Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue.
Mucosal expression of cyclooxygenase isoforms 1 and 2 is increased with worsening damage to the gastric mucosa.
Mucosal repair and COX-2 inhibition.
Multipathway Integrated Adjustment Mechanism of Glycyrrhiza Triterpenes Curing Gastric Ulcer in Rats.
Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing.
Novel roles of local insulin-like growth factor-1 activation in gastric ulcer healing: promotes actin polymerization, cell proliferation, re-epithelialization, and induces cyclooxygenase-2 in a phosphatidylinositol 3-kinase-dependent manner.
NSAIDs inhibit the activation of egr-1 gene in microvascular endothelial cells. A key to inhibition of angiogenesis?
Oxyresveratrol ameliorates ethanol-induced gastric ulcer via downregulation of IL-6, TNF-?, NF-?B, and COX-2 levels, and upregulation of TFF-2 levels.
Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat.
Polysaccharide of Black cumin (Nigella sativa) modulates molecular signaling cascade of gastric ulcer pathogenesis.
Protective role of ?-patchoulene from Pogostemon cablin against indomethacin-induced gastric ulcer in rats: Involvement of anti-inflammation and angiogenesis.
Rebamipide induces the gastric mucosal protective factor, cyclooxygenase-2, via activation of 5'-AMP-activated protein kinase.
Recombinant Human Epidermal Growth Factor Alleviates Gastric Antral Ulcer Induced by Naproxen: A Non-steroidal Anti Inflammatory Drug.
Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.
Regulation by endogenous interleukin-1 of mRNA expression of healing-related factors in gastric ulcers in rats.
Role of COX-2 inhibition on the formation and healing of gastric ulcers induced by indomethacin in the rat.
Role of cyclooxygenase isoforms in gastric mucosal defence.
Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing.
Role of cyclooxygenase-2 in gastric mucosal defense.
Role of cyclooxygenase-2 in modulating gastric acid secretion in the normal and inflamed rat stomach.
Role of cyclooxygenase-2 in the healing of gastric ulcers in rats.
Role of microsomal prostaglandin E synthase-1 in the facilitation of angiogenesis and the healing of gastric ulcers.
Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice.
Roles of Cyclooxygenase, Prostaglandin E2 and EP Receptors in Mucosal Protection and Ulcer Healing in the Gastrointestinal Tract.
Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation.
Spirulina ameliorates aspirin-induced gastric ulcer in albino mice by alleviating oxidative stress and inflammation.
The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts.
The EP4 antagonist, L-161,982, induces apoptosis, cell cycle arrest and inhibits prostaglandin E2 induced proliferation in oral squamous carcinoma Tca8113 cells.
The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer.
The role of cyclooxygenase in gastric mucosal protection.
The Role of Cyclooxygenase-2 in Inflammation.
Tryptophan free diet delays healing of chronic gastric ulcers in rat.
Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer.
[Effects of cyclooxygenase-2 on formation and healing of acetic acid-induced gastric ulcer in rats]
[Expression and activity of cyclooxygenases-1 and -2 in acetic acid induced gastric ulcer in rats]
[Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors]
[Non-steroidal anti-inflammatory agents (NSAID's) with lesser side effects by selective inhibition of cyclo-oxygenase-2]
[Selective COX-2 inhibitor delays experimental gastric ulcer healing by stimulating gastric acid secretion in rats]
[The choice of selective COX-2 inhibitors]
[The role of mucoprotective drugs in a treatment and prevention for NSAID-induced gastric ulcer]
Stomatitis
Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols.
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis.
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes.
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study.
Spatio-temporal localization of HIF-1alpha and COX-2 during irradiation-induced oral mucositis in a rat model system.
The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis.
Stroke
1alpha,25-Dihydroxyvitamin D(3) treatment does not alter neuronal cyclooxygenase-2 expression in the cerebral cortex after stroke.
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.
Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
Animal models of cerebral ischemia for evaluation of drugs.
Anti-inflammatory drugs in the 21st century.
Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke.
Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack.
Aspirin resistance: A fact or a myth?
Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking.
Association of COX-2 rs20417 with aspirin resistance.
Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?
Cardiovascular hazard and non-steroidal anti-inflammatory drugs.
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Cardiovascular risk, hypertension, and NSAIDs.
Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use.
Chronic inhibition of cyclooxygenase-2 induces dendritic hypertrophy and limited functional improvement following motor cortex stroke.
Clinical pharmacology of etoricoxib.
Clinico-pathological correlations in fatal ischemic stroke. An immunohistochemical study of human brain penumbra.
Colonic bacterial translocation as a possible factor in stress-worsening experimental stroke outcome.
Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice.
Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
COX-2 inhibitors and metabolism of essential fatty acids.
COX-2 inhibitors--IBC conference. 12-13 April 1999, Coronado, CA, USA.
COX-2 rs20417 Polymorphism Is Associated with Stroke and White Matter Disease.
COX-2-derived prostacyclin modulates vascular remodeling.
Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.
Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke.
Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction.
Cyclooxygenase-1 gene knockout does not alter middle cerebral artery occlusion in a mouse stroke model.
Cyclooxygenase-2 and stroke: the long and short of it.
Cyclooxygenase-2 genetic polymorphism and stroke subtypes in chinese.
Cyclooxygenase-2 Inhibition Provides Lasting Protection Following Germinal Matrix Hemorrhage in Premature Infant Rats.
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.
Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders.
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function.
Dehydroascorbic acid normalizes several markers of oxidative stress and inflammation in acute hyperglycemic focal cerebral ischemia in the rat.
Discovery of Herbal Pairs Containing Gastrodia elata Based on Data Mining and the Delphi Expert Questionnaire and Their Potential Effects on Stroke through Network Pharmacology.
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat.
Efficacy and safety of short-term use of COX-2 inhibitors in patients after an acute stroke with musculoskeletal pain.
Emotion recollected in tranquility: lessons learned from the COX-2 saga.
Enhanced in vivo platelet activation in subtypes of ischemic stroke.
Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat.
Estrogen stimulation of COX-2-derived PGI2 confers atheroprotection.
Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study.
Experience-dependent brain plasticity after stroke: effect of ibuprofen and poststroke delay.
Function of COX-2 and prostaglandins in neurological disease.
Gadolinium-Based Neuroprognostic Magnetic Resonance Imaging Agents Suppress COX-2 for Prevention of Reperfusion Injury after Stroke.
Genetic Deletion or Pharmacological Inhibition of Cyclooxygenase-2 Reduces Blood-Brain Barrier Damage in Experimental Ischemic Stroke.
Glibenclamide Enhances the Therapeutic Benefits of Early Hypothermia after Severe Stroke in Rats.
GPCR antagonists as an alternative to COX-2 inhibitors: a case for the PGE(2) EP(1) receptor.
Hepatic ischemia and reperfusion injury in the absence of myeloid cell-derived COX-2 in mice.
How to get from antiplatelet to antithrombotic treatment.
Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding.
Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin.
In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons.
Increased neuronal injury in transgenic mice with neuronal overexpression of human cyclooxygenase-2 is reversed by hypothermia and rofecoxib treatment.
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study.
Increased risk of stroke in patients with osteoarthritis: a population-based cohort study.
Indomethacin preconditioning induces ischemic tolerance by modifying zinc availability in the brain.
Induction of cyclooxygenase-2 mRNA in gerbil hippocampal neurons after transient forebrain ischemia.
Influence of Cyclooxygenase-1 Genotype on ex vivo Aspirin Response in Patients at Risk for Stroke.
Inhibition of cyclooxygenase-1 does not reduce mortality in post-ischemic stroke rats.
Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients.
Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients.
Interactions among Variants in Eicosanoid Genes Increase Risk of Atherothrombotic Stroke in Chinese Populations.
Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial.
Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C.
Microglia and cyclooxygenase-2: Possible therapeutic targets of progesterone for stroke.
Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity.
Microsomal Prostaglandin E Synthase-1-Derived PGE2 Inhibits Vascular Smooth Muscle Cell Calcification.
Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction.
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke.
Neuroprotection mediated by the EP? receptor avoids the detrimental side effects of COX-2 inhibitors following ischaemic injury.
Neuroprotective effect of 2-hydroxy arachidonic acid in a rat model of transient middle cerebral artery occlusion.
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia.
Neuroprotective properties of prostaglandin I2 IP receptor in focal cerebral ischemia.
Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke.
Nonsteroidal anti-inflammatory drugs exposure and the central nervous system.
Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders.
Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression.
PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
PGE(2) EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease.
PGF(2alpha) FP Receptor Contributes to Brain Damage Following Transient Focal Brain Ischemia.
Platelet activation and lipid peroxidation in patients with acute ischemic stroke.
Platelet Response to Aspirin in Chinese Stroke Patients is Independent of Genetic Polymorphisms of COX-1 C50T and COX-2 G765C.
Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats.
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity.
Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity.
Protective effect of Etoricoxib against middle cerebral artery occlusion induced transient focal cerebral ischemia in rats.
Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice.
Protective effects of D-Limonene against transient cerebral ischemia in stroke-prone spontaneously hypertensive rats.
Rat paw oedema modeling and NSAIDs: Timing of effects.
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.
Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
Signaling via the prostaglandin E? receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia.
Spreading Depressions and Periinfarct Spreading Depolarizations in the Context of Cortical Plasticity.
Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review.
Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection.
Targeting apoptosis pathways by Celecoxib in cancer.
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
The Cardiovascular Pharmacology of COX-2 Inhibition.
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
The role of prostaglandin e2 in stroke-reperfusion injury.
The translational therapeutics of prostaglandin inhibition in atherothrombosis.
Tim-3 cell signaling and iNOS are involved in the protective effects of ischemic postconditioning against focal ischemia in rats.
Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke.
Upregulated expression of Toll-like receptor 4 in peripheral blood of ischaemic stroke patients correlates with cyclooxygenase 2 expression.
Vioxx(R): What should we tell our patients?
[Antiplatelet therapy: update in secondary stroke prevention].
[Guideline for prophylaxis and treatment of NSAID-associated gastric ulcerations]
[Nonsteroidal anti-inflammatory agents--choice between disturbances of gastrointestinal tract and cardiovascular toxicity]
[Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects]
Stroke, Lacunar
Cyclooxygenase 2 genetic polymorphism may increase the risk of developing leukoaraiosis in chinese.
Stupor
The role of prostaglandin synthetase in the rate depressant effects and narcosis caused by ethanol.
Subarachnoid Hemorrhage
Effects of oxyhemoglobin in vitro in cerebral arteries from normal animals and animals subject to subarachnoid hemorrhage or indomethacin treatment.
Inducible cyclooxygenase expression in canine basilar artery after experimental subarachnoid hemorrhage.
Overexpression of cyclooxygenase-2 in rabbit basilar artery endothelial cells after subarachnoid hemorrhage.
Prostaglandin metabolism and prostacyclin in cerebral vasospasm.
Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit.
The neuroprotective effects of cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid hemorrhage.
Use of indomethacin in brain-injured patients with cerebral perfusion pressure impairment: preliminary report.
Sudden Unexpected Death in Epilepsy
A possible role of cyclooxygenase-2 in the relationship between sleep and sudden unexpected death in epilepsy.
Sunburn
Cyclooxygenase-2 deficiency increases epidermal apoptosis and impairs recovery following acute UVB exposure.
Effect of Artocarpus communis Extract on UVB Irradiation-Induced Oxidative Stress and Inflammation in Hairless Mice.
Photoprotection by honeybush extracts, hesperidin and mangiferin against UVB-induced skin damage in SKH-1 mice.
Protective effects of silymarin against photocarcinogenesis in a mouse skin model.
Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation.
Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.
Sweet Syndrome
Sweet's syndrome associated with the intake of a selective cyclooxygenase-2 (COX-2) inhibitor.
Synovitis
Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog.
Bone marrow lesions, subchondral bone cysts and subchondral bone attrition are associated with histological synovitis in patients with end-stage knee osteoarthritis: a cross-sectional study.
Comparative efficacy of oral meloxicam and phenylbutazone in 2 experimental pain models in the horse.
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
Contribution of synovial macrophages to rat advanced osteoarthritis pain resistant to cyclooxygenase inhibitors.
Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs.
Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs.
Expression of cyclooxygenase-1 and -2 in IL-1beta-induced synovitis of the temporomandibular joint.
Expression of cyclooxygenase-2 in chondroblastoma: immunohistochemical analysis with special emphasis on local inflammatory reaction.
Immunohistochemical localization of cyclooxygenase-1 and -2 in synovial tissues from patients with internal derangement or osteoarthritis of the temporomandibular joint.
In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor.
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis.
Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-1beta.
Intraarticular osteoid osteoma associated with synovitis: a possible role of cyclooxygenase-2 expression by osteoblasts in the nidus.
Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs.
Novel protagonists in autoinflammatory arthritis of familial mediterranean Fever.
Participation of cyclooxygenase-1 in prostaglandin E2 release from synovitis tissue in primary osteoarthritis in vitro.
Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis.
Pro-Apoptotic Effects of Tepoxalin, a Cyclooxygenase/Lipoxygenase Dual Inhibitor, on Canine Synovial Fibroblasts.
Sulforaphane Inhibits IL-1?-Induced Proliferation of Rheumatoid Arthritis Synovial Fibroblasts and the Production of MMPs, COX-2, and PGE2.
Variations in gene expression levels with severity of synovitis in dogs with naturally occurring stifle osteoarthritis.
Syphilis
Rectal stricture associated with the long-term use of ibuprofen suppositories.
Rectal stricture associated with the long-term use of|| ibuprofen suppositories.
Tachycardia
Cardiac dysfunction caused by purified human C3a anaphylatoxin.
Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.
Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Prostaglandins and the antiarrhythmic effect of preconditioning in the isolated rat heart.
Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement.
Role of prostaglandins in marihuana-induced bronchodilation.
[Effect of cyclooxygenase inhibition on the adaptation of coronary blood flow to tachycardia]
Tachypnea
Mediator mechanisms involved in TRPV1 and P2X receptor-mediated, ROS-evoked bradypneic reflex in anesthetized rats.
Takotsubo Cardiomyopathy
A case of takotsubo cardiomyopathy precipitated by lumiracoxib, a selective COX-2 inhibitor.
Tauopathies
Neuroprotection and improvement of the histopathological and behavioral impairments in a murine Alzheimer's model treated with Zephyranthes carinata alkaloids.
Temporomandibular Joint Disorders
[The role of hypoxia on expression of cyclooxygenase-2 in synovial fibroblasts derived from human temporomandular joint]
Tendinopathy
Cyclic mechanical stretching of human tendon fibroblasts increases the production of prostaglandin E2 and levels of cyclooxygenase expression: a novel in vitro model study.
Effects of celecoxib on migration, proliferation and collagen expression of tendon cells.
Increased expression of transforming growth factor-beta1 in patellar tendinosis.
Infrared (810 nm) low-level laser therapy in rat achilles tendinitis: a consistent alternative to drugs.
Low-level laser therapy (LLLT; 780 nm) acts differently on mRNA expression of anti- and pro-inflammatory mediators in an experimental model of collagenase-induced tendinitis in rat.
Tension-Type Headache
Lumiracoxib.
Teratocarcinoma
Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid.
Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice.
Teratoma
COX-2 expression in nonepithelial ovarian malignancies.
Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation.
Testicular Neoplasms
Arachidonic acid pathway: A molecular target in human testicular cancer (Review).
CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer.
Cyclooxygenase-1 and -2 in human testicular tumours.
Tetanus
Increased cyclooxygenase-2 and nuclear factor-?B/p65 expression in mouse hippocampi after systemic administration of tetanus toxin.
Thiamine Deficiency
Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide.
Thrombasthenia
A quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer.
DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects.
Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.
Thrombocythemia, Essential
Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway.
In silico modeling of the antiplatelet pharmacodynamics of low-dose aspirin in health and disease.
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.
Thrombocytopenia
Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis.
Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.
Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants.
Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis.
Haemodynamic and haematologic effects of Acanthaster planci venom in dogs.
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
Thromboembolism
Approaches to rheumatoid arthritis in 2000.
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.
Free radical scavenging mechanisms during pulmonary thromboembolism in rats.
PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
Thrombophilia
COX-2 inhibitors and hypercoagulability.
Revealing the mechanisms and the material basis of Rubia cordifolia L. on abnormal uterine bleeding with uniting simultaneous determination of four components and systematic pharmacology approach-experimental validation.
Thrombosis
1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.
12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics.
A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
A Review on the risk of myocardial infarction associated with the NSAID diclofenac.
A seven-step plan for becoming a moderately rich and famous biochemist.
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Adverse effects of COX-2 inhibitors.
Anti-platelet properties of Pim kinase inhibition is mediated through disruption of thromboxane A2 receptor signalling.
Antiplatelet activity of L-sulforaphane by regulation of platelet activation factors, glycoprotein IIb/IIIa and thromboxane A2.
Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug.
Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022.
Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs.
Arterial Thrombosis Is Accompanied by Elevated Mitogen-Activated Protein Kinase (MAPK) and Cyclooxygenase-2 (COX-2) Expression via Toll-Like Receptor 4 (TLR-4) Activation by S100A8/A9.
Balancing prostanoid activity in the human vascular system.
Cardiovascular Consequences of Prostanoid I Receptor Deletion in Microsomal Prostaglandin E Synthase-1-Deficient Hyperlipidemic Mice.
Cardiovascular effects of common analgesics.
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Carrageenin-induced thrombosis in the rat and mouse as a test model of substances influencing thrombosis.
Characterization of the human prostaglandin H synthase 1 gene (PTGS1): exclusion by genetic linkage analysis as a second modifier gene in familial thrombosis.
COX-2 inhibition and thrombotic tendency: a need for surveillance.
COX-2 protects against thrombosis of the retinal vasculature in a mouse model of proliferative retinopathy.
Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1.
Cyclooxygenase 2 inhibition and thrombosis: comment on the article by Crofford et al.
Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary embolism.
Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis.
Cyclooxygenase, lipoxygenase and tumor angiogenesis.
Cyclooxygenase-2 and atherosclerosis.
Cyclooxygenase-2 and inflammation in atherosclerosis.
Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis.
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis.
Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs.
Differences and similarities in ibrutinib and acalabrutinib effects on platelet functions.
Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
Effect of Mediterranean diet on the expression of pro-atherogenic genes in a population at high cardiovascular risk.
Effect of platelet inhibition on experimental venous thrombosis in the rabbit.
Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis.
Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.
Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients.
Endothelial progenitor cells bind and inhibit platelet function and thrombus formation.
Exchange of cyclooxygenase dependent metabolites between vessel wall and platelets in arterial thrombosis.
Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
Galpha12 specifically regulates COX-2 induction by sphingosine 1-phosphate. Role for JNK-dependent ubiquitination and degradation of IkappaBalpha.
Gastroduodenal mucosal defense: role of endogenous mediators.
Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
Impact of Aspirin Eugenol Ester on Cyclooxygenase-1, Cyclooxygenase-2, C-Reactive Protein, Prothrombin and Arachidonate 5-Lipoxygenase in Healthy Rats.
Inducible cyclooxygenase-2 expression after experimental intracerebral hemorrhage.
Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy.
Inhibitory effects of ASP6537, a selective cyclooxygenase-1 inhibitor, on thrombosis and neointima formation in rats.
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Intracellular Erythrocyte PAF Acetylhydrolase 1 Inactivates Aspirin in Blood.
Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2.
Involvement of nitric oxide and cyclooxygenase products in photoactivation-induced microvascular occlusion.
Local gene transduction of cyclooxygenase-1 increases blood flow in injured atherosclerotic rabbit arteries.
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
NCX-4016 (NicOx SA).
NSAIDs and heart failure: A dangerous relationship.
On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1.
Paradoxical Thrombotic Effects of Aspirin: Experimental Study on 1000 Animals.
Platelet adhesivity to subendothelium is influenced by polymorphonuclear leukocytes: studies with aspirin and salicylate.
Platelet kainate receptor signaling promotes thrombosis by stimulating cyclooxygenase activation.
Polyunsaturated fatty acid biosynthesis pathway and genetics. implications for interindividual variability in prothrombotic, inflammatory conditions such as COVID-19?,??,?,??.
Potential cardiovascular effects of COX-2 selective nonsteroidal antiinflammatory drugs.
Preparation and characterization of a novel aspirin derivative with anti-thrombotic and gastric mucosal protection properties.
Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene.
Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.
Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin.
Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis.
Prostaglandin-endoperoxide synthase-2 deletion affects the natural trafficking of Annexin A2 in monocytes and favours venous thrombosis in mice.
Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.
Reflectance spectroscopy of clotting blood: a description of the time-dependent behavior.
Regulation of cerebral microvascular endothelial cell cyclooxygenase-2 message and activity by blood derived vasoactive agents.
Relationship between cyclooxygenase-2 inhibition and thrombogenesis.
Relative risk of cardiovascular events in patients with rheumatoid arthritis.
Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition?
Role of eicosanoids in the kappa-carrageenin rat tail thrombosis.
Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.
Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).
Tetrahydrocurcumin Downregulates MAPKs/cPLA2 Signaling and Attenuates Platelet Thromboxane A2 Generation, Granule Secretion, and Thrombus Growth.
The effect of inhibition of endothelial cell cyclooxygenase on arterial thrombosis.
The effect of ketorolac on microvascular thrombosis in an experimental rabbit model.
The potential of selective COX-2 inhibitors in inflammatory and other diseases.
The role of prostaglandins in platelet-vessel wall interaction.
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse.
Thromboxane-B(2) levels in serum of rabbits receiving a single intravenous dose of aqueous extract of garlic and onion.
Tissue-specific modulation of cyclooxygenase-2 (Cox-2) expression in the uterus and the v. cava by estrogens and phytoestrogens.
Vascular COX-2 modulates blood pressure and thrombosis in mice.
Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma.
[A new medical treatment for thrombosis by genetic engineering]
[Prevention of thrombosis and vascular inflammation: importance of combined cyclooxygenase and 5-lipoxygenase inhibitors]
[Role of cyclooxygenase-2 in pulmonary microcirculation disorder in rats with acute pancreatitis]
[Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology]
[Specific cyclooxygenase-2 inhibitor analgesics: therapeutic advances.]
Thrombotic Stroke
Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations.
Thymoma
a-Tocopherol modifies the expression of genes related to oxidative stress and apoptosis during invitro maturation and enhances the developmental competence of rabbit oocytes.
COX-2 upregulation in thymomas and thymic carcinomas.
Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
Incorporation of 5,8,11,14-eicosatetraynoic acid (ETYA) into cell lipids: competition with arachidonic acid for esterification.
Thyroid Cancer, Papillary
Assessment of cyclooxygenase-1 and 2 gene expression levels in chronic autoimmune thyroiditis, papillary thyroid carcinoma and nontoxic nodular goitre.
Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma.
COX-2 expression in papillary thyroid carcinoma (PTC) in cytological material obtained by fine needle aspiration biopsy (FNAB).
Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
Expression of COX-2 is increased with age in papillary thyroid cancer.
Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions.
High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma.
Immunohistochemical Demonstration of Membrane-bound Prostaglandin E(2) Synthase-1 in Papillary Thyroid Carcinoma.
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma.
Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth.
VEGF-C and COX-2 expression in papillary thyroid cancer.
[Expression of COX-2 and VEGF-C in papillary thyroid carcinoma and their relationship to cervical lymph metastases]
Thyroid Carcinoma, Anaplastic
Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation.
Thyroid Diseases
Cyclooxygenase-2 expression in human thyroid disease.
Thyroid Neoplasms
15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Antitumor activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in medullary thyroid carcinoma.
Assessment of cyclooxygenase-1 and 2 gene expression levels in chronic autoimmune thyroiditis, papillary thyroid carcinoma and nontoxic nodular goitre.
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line.
COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study.
COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?
Cyclooxygenase 1 and 2 expressions in the human thyroid gland.
Cyclooxygenase-2 (COX-2) gene polymorphism in patients with differentiated thyroid carcinomas in the Turkish population
Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.
Cyclooxygenase-2 expression and its association with thyroid lesions.
Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis.
Cyclooxygenase-2 expression in medullary thyroid carcinoma.
Cyclooxygenase-2 expression in thyroid neoplasms.
Cyclooxygenase-2 expression in thyroid nodules.
Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland.
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism.
Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression.
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma.
Histopathological and Immunohistochemical Characteristics of Thyroid Carcinoma in the Dog.
Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas.
Phase II study of celecoxib in metastatic differentiated thyroid carcinoma.
Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation.
Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism.
TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway.
Thyroid Cancer and Nonsteroidal Anti-Inflammatory Drug Use: A Pooled Analysis of Patients Older Than 40 Years of Age.
Thyroid Nodule
Cyclooxygenase-2 expression in thyroid nodules.
Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours.
Immunohistochemical expression of COX-2 in thyroid nodules.
Phase II study of celecoxib in metastatic differentiated thyroid carcinoma.
Thyroiditis
CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.
Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis.
Cyclooxygenase-2 expression in human thyroid disease.
Immunohistochemical expression of COX-2 in thyroid nodules.
Thyroiditis, Autoimmune
Assessment of cyclooxygenase-1 and 2 gene expression levels in chronic autoimmune thyroiditis, papillary thyroid carcinoma and nontoxic nodular goitre.
High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma.
Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase.
Tinnitus
Assessment of the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 inhibitor, in rats.
Cochlear NMDA receptor blockade prevents salicylate-induced tinnitus.
Effects of C-phycocyanin and Spirulina on Salicylate-Induced Tinnitus, Expression of NMDA Receptor and Inflammatory Genes.
Enhancement of Endocannabinoid-dependent Depolarization-induced Suppression of Excitation in Glycinergic Neurons by Prolonged Exposure to High Doses of Salicylate.
Expression of COX-2 and NMDA receptor genes at the cochlea and midbrain in salicylate-induced tinnitus.
Inhibitors of oxidative and hydrolytic endocannabinoid degradation do not enhance depolarization-induced suppression of excitation on dorsal cochlear nucleus glycinergic neurons.
Salicylate enables cochlear arachidonic-acid-sensitive NMDA receptor responses.
Salicylate induces tinnitus through activation of cochlear NMDA receptors.
Tongue Neoplasms
COX-2 Gene increases tongue cancer cell proliferation and invasion through VEGF-C pathway.
Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-c and lymph node metastasis in human oral tongue cancer.
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.
Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats.
Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression.
Tonsillitis
Expression of cyclooxygenase-1 and 2 in chronic tonsillitis.
The Acidic Fraction of Isatidis Radix Regulates Inflammatory Response in LPS-Stimulated RAW264.7 Macrophages through MAPKs and NF-?B Pathway.
[Enzyme histochemical characteristics of prostaglandin synthetase, adenylate cyclase and cAMP in a focus of inflammation in chronic tonsillitis]
Toothache
Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors.
[Pain management after third molar extraction. Observations of the use of mefenamic acid and rofecoxib in the treatment of postoperative pain in the dental office]
Tourette Syndrome
Anti-inflammatory therapy with a COX-2 inhibitor in Tourette's syndrome.
Toxoplasmosis
Cyclooxygenase (COX)-2 Inhibitors Reduce Toxoplasma gondii Infection and Upregulate the Pro-inflammatory Immune Response in Calomys callosus Rodents and Human Monocyte Cell Line.
Cyclooxygenase (COX)-2 modulates Toxoplasma gondii infection, immune response and lipid droplets formation in human trophoblast cells and villous explants.
Tremor
Progress in COX-2 inhibitors: a journey so far.
Triple Negative Breast Neoplasms
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.
Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts.
Centromere protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2.
Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells.
Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients.
Cyclooxygenase-2 regulates TGF?-induced cancer stemness in triple-negative breast cancer.
Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients.
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.
Expression of cyclooxygenase-2 and Bcl-2 in breast cancer and their relationship with triple-negative disease.
Future Aspects for Cannabinoids in Breast Cancer Therapy.
Gancochlearols E - I, meroterpenoids from Ganoderma cochlear against COX-2 and triple negative breast cancer cells and the absolute configuration assignment of ganomycin K.
Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells.
Understanding the tumour microenvironment communication network from a NOS2/COX2 perspective.
Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.
Trismus
Corticosteroids or cyclooxygenase 2-selective inhibitor medication for the management of pain and swelling after third-molar surgery.
The selective and non-selective cyclooxygenase inhibitors valdecoxib and piroxicam induce the same postoperative analgesia and control of trismus and swelling after lower third molar removal.
Tuberculosis
Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model.
Cholera toxin induces a shift from inactive to active cyclooxygenase 2 in alveolar macrophages activated by Mycobacterium bovis BCG.
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice.
In search of cyclooxygenase inhibitors, anti-Mycobacterium tuberculosis and anti-malarial drugs from Thai flora and microbes.
Inhibition of TNF-alpha-induced cyclooxygenase-2 expression by Mycobacterium bovis BCG in human alveolar epithelial A549 cells.
Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors.
Mycobacterial 3-hydroxyacyl-l-thioester dehydratase Y derived from Mycobacterium tuberculosis induces COX-2 expression in mouse macrophages through MAPK-NF-?B pathway.
Nonpeptidal compounds from the insect Polyphaga plancyi and their biological evaluation.
Novel Function of Cyclooxygenase-2: Suppressing Mycobacteria by Promoting Autophagy via the Protein Kinase B/Mammalian Target of Rapamycin Pathway.
Phenolic derivatives from Blaps japanensis and their biological evaluation.
Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.
Reaction of haem containing proteins and enzymes with hydroperoxides: the radical view.
The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection.
The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat.
The landscape of different molecular modules in an immune microenvironment during tuberculosis infection.
Tuberculosis, Multidrug-Resistant
Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPK-dependent, p-aminosalicylic acid-sensitive signaling cascade.
Tuberculosis, Pulmonary
A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.
Tuberous Sclerosis
IL-4 up-regulates cyclooxygenase-1 expression in macrophages.
miR147b: A novel key regulator of interleukin 1 beta-mediated inflammation in human astrocytes.
Typhlitis
Prevention of cecitis in hamsters by certain prostaglandins.
Typhoid Fever
Pyrogenic renal hyperemia: the role of prostaglandins.
Uremia
Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition.
Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.
Prostaglandin synthetase inhibitors are not beneficial in the hypercatabolic state of acute uremia in rats.
Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect.
[The level of thromboxane A2 and prostacyclin in patients with chronic kidney failure undergoing hemodialysis]
Ureteral Obstruction
Alteration of renal cyclooxygenase expression due to partial unilateral ureteral obstruction in neonatal.
Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice.
Circadian CLOCK Mediates Activation of Transforming Growth Factor-? Signaling and Renal Fibrosis through Cyclooxygenase 2.
COX-2 activity transiently contributes to increased water and NaCl excretion in the polyuric phase after release of ureteral obstruction.
COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction.
Cyclooxygenase 2 inhibition exacerbates AQP2 and pAQP2 downregulation independently of V2 receptor abundance in the postobstructed kidney.
Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction.
Cyclooxygenase-2 expression is up-regulated in obstructed human ureter.
Cyclooxygenase-2 inhibitor decreases extracellular matrix synthesis in stretched renal fibroblasts.
Cyclooxygenase-2 inhibitor preserves medullary aquaporin-2 expression and prevents polyuria after ureteral obstruction.
Disruption of cyclooxygenase type 2 exacerbates apoptosis and renal damage during obstructive nephropathy.
Disruption of cyclooxygenase-2 prevents down-regulation of cortical AQP2 and AQP3 in response to bilateral ureteral obstruction in the mouse.
Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction?
Effects of dietary protein on glomerular eicosanoid production in rats with bilateral ureteral obstruction.
Evaluation of urothelial stretch-induced cyclooxygenase-2 expression in a mouse ureteral obstruction model.
Evaluation of urothelial stretch-induced cyclooxygenase-2 expression in novel human cell culture and porcine in vivo ureteral obstruction models.
Increase in enzyme activities of prostaglandin biosynthesis and catabolism by acute ureteral ligation in rat kidney.
Increased cyclooxygenase-2 expression and prostaglandin E2 production in pressurized renal medullary interstitial cells.
Increased renal tubular synthesis of prostaglandins in the rabbit kidney in response to ureteral obstruction.
Increases in glomerular eicosanoid production in rats with bilateral ureteral obstruction are mediated by enhanced enzyme activities of both the cyclooxygenase and 5-lipoxygenase pathways.
NS-398 (a Selective Cyclooxygenase-2 Inhibitor) Decreases Agonist-Induced Contraction of the Human Ureter via Calcium Channel Inhibition.
PI3K mediates stretch-induced COX-2 expression during urinary tract obstruction.
Prediction of the mechanisms of action of shenkang in chronic kidney disease: A network pharmacology study and experimental validation.
Quercetin attenuates cyclooxygenase-2 expression in response to acute ureteral obstruction.
Regional expression of cyclooxygenase isoforms in the rat kidney in complete unilateral ureteral obstruction.
Role of COX-2 in Unilateral Ureteral Obstruction: What Is New?
Role of cyclooxygenase-2 in the development of interstitial fibrosis in kidneys following unilateral ureteral obstruction in mice.
ROS dependence of cyclooxygenase-2 induction in rats subjected to unilateral ureteral obstruction.
Suppression of 15-hydroxyprostaglandin dehydrogenase messenger RNA concentration, protein expression, and enzymatic activity during human ureteral obstruction.
The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice.
Ureteral obstruction reverses glomerular proliferation in immune complex glomerulonephritis.
Urinary tract obstruction induces transient accumulation of COX-2-derived prostanoids in kidney tissue.
[The renal protective effect of selective cyclooxygenase-2 inhibitor on obstructive nephropathy]
Urethral Stricture
Use of cyclooxygenase-2 inhibitor for prevention of urethral strictures secondary to transurethral resection of the prostate.
Urinary Bladder Neck Obstruction
Cyclooxygenase-2 is expressed in bladder during fetal development and stimulated by outlet obstruction.
The influence of piroxicam, a non-selective cyclooxygenase inhibitor, on autonomic nervous system activity in experimental cyclophosphamide-induced hemorrhagic cystitis and bladder outlet obstruction in rats.
The restorative effect of a selective cyclooxygenase-2 inhibitor on urothelial cell-cell interactions after partial bladder outlet obstruction in rats.
Ultrastructural and immunohistochemical analysis of rat uroepithelial cell junctions after partial bladder outlet obstruction and selective COX-2 inhibitor treatment.
Urinary Bladder Neoplasms
A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
A modified reduced-temperature antigen retrieval protocol effective for use with a polyclonal antibody to cyclooxygenase-2 (PG 27).
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.
American Urological Association--94th annual meeting. 1-6 May 1999, Dallas, USA.
An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis.
Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression.
Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase.
Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.
Association of cyclooxygenase-2 expression with prognosis of state T1 grade 3 bladder cancer.
Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer.
Associations of cyclooxygenase 2 polymorphic genotypes with bladder cancer risk in Taiwan.
Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression.
Bladder cancer prevention. Part I: what do I tell my patients about lifestyle changes and dietary supplements?
Boxing bladder cancer with COX-2-specific inhibition.
Brucea javanica oil induces apoptosis in T24 bladder cancer cells via upregulation of caspase-3, caspase-9, and inhibition of NF-kappaB and COX-2 expressions.
Can intravesical application of paracetamol benefit the chemotherapy treatment of bladder cancer?
Canine invasive transitional cell carcinoma cell lines: In vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study.
Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Chalcone derivatives inhibit human platelet aggregation and inhibit growth in human bladder cancer cells.
Chemoprevention of superficial bladder cancer.
Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
Controls of Nuclear Factor-Kappa B Signaling Activity by 5'-AMP-Activated Protein Kinase Activation With Examples in Human Bladder Cancer Cells.
Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Cox-2 and Her2/neu co-expression in invasive bladder cancer.
COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells.
Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.
Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue.
Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2? contributes to human bladder cancer cell survival.
Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects.
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.
Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis.
Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy.
Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder.
Cyclooxygenase-2 Expression Is Up-regulated by 2-Aminobiphenyl in a ROS and MAPK-Dependent Signaling Pathway in a Bladder Cancer Cell Line.
Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.
Cyclooxygenase-2 polymorphisms and bladder cancer risk: a meta-analysis based on case-control studies.
Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence.
Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer.
Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1.
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.
Detection of carcinogen-induced bladder cancer by fluorocoxib A.
Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A.
Diet and cancer prevention studies in p53-deficient mice.
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial.
Effects of Short-term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary Bladder.
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway.
Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas.
Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination.
Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522.
Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells.
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Expression of cyclooxygenase-2 in patients with bladder carcinoma.
Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells.
Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India.
Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder.
High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives.
Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2.
In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines.
Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells.
Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer.
Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells.
Inhibition of TPL2 by interferon-? suppresses bladder cancer through activation of PDE4D.
Interferon induction and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer.
Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro.
Metabolic activation of carcinogenic aromatic amines by dog bladder and kidney prostaglandin H synthase.
Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis.
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.
Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer.
p38 MAPK plays a distinct role in sulforaphane-induced up-regulation of ARE-dependent enzymes and down-regulation of COX-2 in human bladder cancer cells.
Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1.
Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: Correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2.
Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report.
Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer.
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor.
Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model.
Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro.
Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer.
Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.
Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer.
Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.
Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder.
Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.
Significance of uroplakin III expression in recurrence of solitary muscle non-invasive bladder cancer.
Sodium arsenite induces cyclooxygenase-2 expression in human uroepithelial cells through MAPK pathway activation and reactive oxygen species induction.
Study of Arachidonic Acid Pathway in Human Bladder Tumor.
Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells.
Suppressive Effect of Matrine on Tumor Invasion in N-Butyl-N-(4-Hydroxybutyl)Nitrosamine-Induced Urinary Bladder Carcinogenesis.
Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.
Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro.
The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator.
The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients.
The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells.
The role of inflammation in bladder cancer.
Transactivation of PTGS2 by PAX5 signaling potentiates cisplatin resistance in muscle-invasive bladder cancer cells.
Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.
Urothelial overexpression of insulin-like growth factor-1 increases susceptibility to p-cresidine-induced bladder carcinogenesis in transgenic mice.
[Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications]
[Effects of selective cyclooxygenase-2 inhibitor on proliferation and apoptosis of human bladder cancer cell line T24]
[Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas]
[Mechanisms for effect of osthole on inhibiting the growth and invasion of bladder cancer cells].
[Relationship between cyclooxygenase (COX)-2 and malignant tumors]
[The significance of the expression of cyclooxygenase-2 in bladder transitional cell carcinoma tissues]
Urinary Bladder, Overactive
Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder.
Urinary Calculi
Prostaglandin synthetase inhibition with indomethacin rectal suppositories in the treatment of acute and chronic urinary calculus obstruction.
Urinary Incontinence
Expression of cyclooxygenase-2 in the canine lower urinary tract with regard to the effects of gonadal status and gender.
Urinary Retention
Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors.
[TYPICAL TYPE CYSTITIS GLANDULARIS PRESENTING URINARY RETENTION IN A YOUNG MAN: ADJUVANT THERAPY USING ORAL CYCLOOXYGENASE-2 INHIBITOR: A CASE REPORT].
Urinary Tract Infections
Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer.
Urogenital Abnormalities
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Urogenital Neoplasms
COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer.
Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer.
Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro.
Urolithiasis
An animal model of calcium oxalate urolithiasis based on a cyclooxygenase 2 selective inhibitor.
Urologic Neoplasms
Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review.
Cyclooxygenase-2: a therapeutic target for prostate cancer.
The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
Urticaria
Analgesics, allergy and asthma.
Analgesics.
Aspirin and NSAID sensitivity.
Asthma in children and ASA intolerance.
Cetirizine premedication prevents acute urticaria induced by weak COX-1 inhibitors in multiple NSAID reactors.
Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years.
Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update.
COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs.
Drug-induced urticaria.
H1-Antihistamine Premedication in NSAID-Associated Urticaria.
Idiosyncrasy to pyrazolone drugs.
Management of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactions.
Mechanism of chronic urticaria exacerbation by aspirin.
NSAID-induced urticaria and angioedema: a reappraisal of its clinical management.
Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
Restoration of aspirin tolerance following omalizumab treatment in a patient with chronic spontaneous urticaria.
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema.
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.
The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria.
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.
Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Urticaria and angioedema induced by COX-2 inhibitors.
Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Uterine Cervical Neoplasms
Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene.
Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer.
Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase.
Association between overexpression of cyclooxygenase-2 and suppression of apoptosis in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion.
Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients With Cervical Cancer.
Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).
Celecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cells.
Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target.
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Celecoxib, a COX-2 Selective Inhibitor, Induces Cell Cycle Arrest at the G2/M Phase in HeLa Cervical Cancer Cells.
Clinical evaluations of a new ovarian cancer marker, COX-1.
Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer.
Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility.
Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells.
COX-1 is coupled with mPGES-1 and ABCC4 in human cervix cancer cells.
COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128.
COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
Cox-2, EGFR, and ERBB-2 Expression in Cervical Intraepithelial Neoplasia and Cervical Cancer Using an Automated Imaging System.
COX-2-PGE2-EPs in gynecological cancers.
Crocetin downregulates the proinflammatory cytokines in methylcholanthrene-induced rodent tumor model and inhibits COX-2 expression in cervical cancer cells.
Crosstalk between possible cytostatic and antiinflammatory potential of ketoprofen in the treatment of culture of colon and cervix cancer cell lines.
Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer.
Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.
Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery.
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Cyclooxygenase-2 expression as a predictor of para-aortic lymph node recurrence in uterine cervical cancer.
Cyclooxygenase-2 expression in cervical cancer.
Cyclooxygenase-2 Expression in Cervical Squamous Cell Carcinoma: the Significance of Expression in Neoplastic Cells within the Lymphovascular Space.
Cyclooxygenase-2 expression in lymph node metastasis of cervical and vulvar cancer.
Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis.
Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure.
Cyclooxygenase-2 gene polymorphisms and risk of cervical cancer in a North Indian population.
Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis.
Cyclooxygenase-2 in cervical neoplasia: a review.
Cyclooxygenase-2 is overexpressed in human cervical cancer.
Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
Downregulation of HOTAIR Expression Mediated Anti-Metastatic Effect of Artesunate on Cervical Cancer by Inhibiting COX-2 Expression.
Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer.
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma.
Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels.
Evaluation of expression of apoptosis-related proteins and their correlation with HPV, telomerase activity, and apoptotic index in cervical cancer.
Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.
Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.
Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications.
Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion.
Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.
Expression of cyclooxygenase-2 related to angiogenesis in uterine cervical cancers.
Expression of metastases-associated genes in cervical cancers resected in the proliferative and secretory phases of the menstrual cycle.
Expressions of survivin, P16(INK4a), COX-2, and Ki-67 in cervical cancer progression reveal the potential clinical application.
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Downregulates the Expression of Protumor Factors Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in a GM-CSF Receptor-Independent Manner in Cervical Cancer Cells.
High cyclooxygenase-2 expression in cervical adenocarcinomas.
High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion.
High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy.
Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells.
Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells.
Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer.
Immunohistochemical evaluation of COX-2 expression in HPV-positive cervical squamous intraepithelial lesions.
In regard to Ishikawa et al.: Cyclooxygenase-2 impairs treatment effect of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis (Int J Radiat Oncol Biol Phys 2006;66:1347-1355).
Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.
Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy.
Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention.
Influences of cyclooxygenase-1 and -2 expression on the radiosensitivities of human cervical cancer cell lines.
Inhibition of COX2 enhances the chemosensitivity of dichloroacetate in cervical cancer cells.
Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population.
MUC16 facilitates cervical cancer progression via JAK2/STAT3 phosphorylation-mediated cyclooxygenase-2 expression.
Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy.
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
Prediction of lymphovascular space invasion using a combination of tenascin-C, cox-2, and PET/CT radiomics in patients with early-stage cervical squamous cell carcinoma.
Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.
Prognostic implications of tumor volume response and COX-2 expression change during radiotherapy in cervical cancer patients.
Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer.
Prognostic significance of cyclooxygenase-2 in cervical cancer: A meta-analysis.
Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer.
R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway.
Roles of MiR-101 and its target gene Cox-2 in early diagnosis of cervical cancer in Uygur women.
Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival.
The close correlation between heparanase and COX-2 expression in lymphangiogenesis of cervical cancer.
The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer.
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels.
The expression of cyclooxygenase-2 in cervical cancers and Hela cells was regulated by estrogen/progestogen.
The role of COX-2 in breast and cervical cancer.
The Role of Eicosanoids in Gynecological Malignancies.
Transcriptome changes induced by RUNX3 in cervical cancer cells in vitro.
Understanding the Interplay between COX-2 and hTERT in Colorectal Cancer Using a Multi-Omics Analysis.
Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease.
Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women.
VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro.
[Retracted] Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels.
Uterine Cervicitis
Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer.
Uterine Hemorrhage
Action of a prostaglandin synthetase inhibitor on IUD associated uterine bleeding.
Cyclooxygenase-2 regulated by the nuclear factor-?B pathway plays an important role in endometrial breakdown in a female mouse menstrual-like model.
Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users.
Mifepristone-induced vaginal bleeding is associated with increased immunostaining for cyclooxygenase-2 and decrease in prostaglandin dehydrogenase in luteal phase endometrium.
Non-contraceptive health benefits of oral contraceptives.
The effect of a prostaglandin synthetase inhibitor, indomethacin, on excessive uterine bleeding.
Uterine Neoplasms
Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts.
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells.
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.
Uterine Prolapse
Does Uterine Prolapse Alter Endometrial Cyclooxygenase 2 Expression and Promote the Development of Premalignant Lesions?
Uveitis
Anti-inflammatory effects of betamethasone phosphate, dexamethasone phosphate and indomethacin on rabbit ocular inflammation induced by bovine serum albumin.
Cyclooxygenase-2 expression in the eyes of cats with and without uveitis.
Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation.
Inhibition of endotoxin-induced uveitis and potentiation of cyclooxygenase-2 protein expression by alpha-melanocyte-stimulating hormone.
Mediators of the ocular inflammatory response to interleukin-1 beta plus tumor necrosis factor-alpha.
Modulation of immune responses by cyclo-oxygenase inhibitors during intraocular inflammation.
Role of interleukin 6 in the inflammatory response after cataract surgery. An experimental and clinical study.
Steroidal and nonsteroidal drugs in endotoxin-induced uveitis.
The role of arachidonate metabolites in ocular inflammation.
Topical diclofenac sodium, dexamethasone and placebo compared in a model of immunogenic uveitis in rabbits.
Uveitis, Anterior
Anti-inflammatory effects of specific cyclooxygenase 2,5-lipoxygenase, and inducible nitric oxide synthase inhibitors on experimental autoimmune anterior uveitis (EAAU).
Mediators of the ocular inflammatory response to interleukin-1 beta plus tumor necrosis factor-alpha.
Vaccinia
Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection.
Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis.
Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid.
Poxvirus-induced alteration of arachidonate metabolism.
Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.
Vaginal Neoplasms
The Role of Eicosanoids in Gynecological Malignancies.
Vaginosis, Bacterial
Lactobacillus johnsonii HY7042 ameliorates Gardnerella vaginalis-induced vaginosis by killing Gardnerella vaginalis and inhibiting NF-?B activation.
Varicocele
Expression of cyclooxygenase-1 (COX-1) and COX-2 in human male gametes from normal patients, and those with varicocele and diabetes: a potential molecular marker for diagnosing male infertility disorders.
Seminal cyclooxygenase relationship with oxidative stress in infertile oligoasthenoteratozoospermic men with varicocele.
Varicose Ulcer
Expression of cyclooxygenase isoforms in normal human skin and chronic venous ulcers.
Matrix metalloproteinase (MMP)-1 and MMP-2, but not COX-2 serve as additional predictors for chronic venous ulcer healing.
Varicose Veins
Cyclic nucleotides and production of prostanoids in human varicose veins.
Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: linkage with varicosis.
Vascular Calcification
Cyclooxygenase-2/sclerostin mediates TGF-?1-induced calcification in vascular smooth muscle cells and rats undergoing renal failure.
Microsomal Prostaglandin E Synthase-1-Derived PGE2 Inhibits Vascular Smooth Muscle Cell Calcification.
Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model.
Vascular Diseases
15-Hydroxy-5,8,11,13-eicosatetraenoic acid inhibits human vascular cyclooxygenase. Potential role in diabetic vascular disease.
A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans.
A role for uric acid in the progression of renal disease.
Angiotensin II increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells.
ATP stimulates PGE2/cyclin D1-dependent VSMCs proliferation via STAT3 activation: Role of PKCs-dependent NADPH oxidase/ROS generation.
COX-1 and COX-2 inhibitors.
COX-1 and vascular disease.
Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty.
Cyclooxygenase-2 induction by bradykinin in human pulmonary artery smooth muscle cells is mediated by the cyclic AMP response element through a novel autocrine loop involving endogenous prostaglandin E2, E-prostanoid 2 (EP2), and EP4 receptors.
Cyclooxygenase-2 inhibition and coagulation.
Cyclooxygenase-dependent vasoconstrictor alters vascular function in the vitamin E-deprived rat.
Functional coupling expression of COX-2 and cPLA2 induced by ATP in rat vascular smooth muscle cells: role of ERK1/2, p38 MAPK, and NF-kappaB.
Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli.
Inhibition of platelet function in thrombosis.
Management of peptic ulcer disease not related to Helicobacter.
Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: A potentially protective mechanism in atherosclerotic vascular disease and cancer.
PKC-delta/c-Src-mediated EGF receptor transactivation regulates thrombin-induced COX-2 expression and PGE(2) production in rat vascular smooth muscle cells.
Platelet-derived growth factor-induced stabilization of cyclooxygenase 2 mRNA in rat smooth muscle cells requires the c-Src family of protein-tyrosine kinases.
Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation.
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
Prostacyclin protects against elevated blood pressure and cardiac fibrosis.
Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease.
Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity.
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Vascular Ring
Comparative effects of nitroglycerin and nitroprusside on prostacyclin generation in adult human vessel wall.
Disruption of COX-2 and eNOS does not confer protection from cardiovascular failure in lipopolysaccharide-treated conscious mice and isolated vascular rings.
Omega-3 polyunsaturated fatty acids augment endothelium-dependent vasorelaxation by enhanced release of EDRF and vasodilator prostaglandins.
Superoxide radical-mediated endothelial injury and vasoconstriction of rat thoracic aortic rings.
The Lignan (-)-Cubebin Inhibits Vascular Contraction and Induces Relaxation Via Nitric Oxide Activation in Isolated Rat Aorta.
Vascular System Injuries
25-hydroxycholesterol increases eicosanoids and alters morphology in cultured pulmonary artery smooth muscle and endothelial cells.
Abnormal Pressure Stress Reduces Interleukin-1?-Induced Cyclooxygenase-2 Expression in Cultured Rat Vascular Smooth Muscle Cells.
Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits.
Analysis of Vascular Cell Response to Hypertension Induced by Pressure Loading and Its Application as a Tool for Exploring Pharmacological Modes of Action.
Cadmium exposure induces vascular injury due to endothelial oxidative stress: the role of local angiotensin II and COX-2.
Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27).
Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats.
Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty.
Effects of low-dose Beraprost sodium, a stable prostaglandin I2 analogue, on reperfusion injury to rabbit lungs.
Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo.
Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury.
Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells.
[Role of cyclooxygenase metabolites in the increase in pulmonary vascular permeability caused by mechanically activated white blood cells]
Vasculitis
COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
Vasospasm, Intracranial
Cerebral vasospasm: effects of prostaglandin synthetase inhibitors in vitro.
Contractions induced by NO synthase inhibition in isolated rat basilar artery: role of the endothelium and endogenous vasoconstrictors.
Prostaglandin metabolism and prostacyclin in cerebral vasospasm.
Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit.
Venous Thromboembolism
Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use.
Venous Thrombosis
Analgesic Efficacy and Hematologic Effects of Robenacoxib in Mice.
Prostaglandin-endoperoxide synthase-2 deletion affects the natural trafficking of Annexin A2 in monocytes and favours venous thrombosis in mice.
Ventilator-Induced Lung Injury
Cyclooxygenase Inhibition in Ventilator-Induced Lung Injury.
Cyclooxygenase-2 Activity Regulates Recruitment of VEGF-Secreting Ly6Chigh Monocytes in Ventilator-Induced Lung Injury.
Effects of COX-2 inhibitor on ventilator-induced lung injury in rats.
Hydrogen Sulfide Confers Lung Protection During Mechanical Ventilation via Cyclooxygenase 2, 15-deoxy ?12,14-Prostaglandin J2, and Peroxisome Proliferator-Activated Receptor Gamma.
Ventricular Fibrillation
Cyclooxygenase inhibition prior to ventricular fibrillation induced ischemia reperfusion injury impairs survival and outcomes.
Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat.
Non-selective cyclooxygenase inhibition before periodic acceleration (pGz) cardiopulmonary resuscitation (CPR) in a porcine model of ventricular fibrillation.
Vesicular Stomatitis
NSAID treatment suppresses VSV propagation in mouse CNS.
Reversible restriction of vesicular stomatitis virus in permissive cells treated with inhibitors of prostaglandin biosynthesis.
Virus Diseases
Acetylsalicylic acid reduces viral shedding induced by thermal stress.
Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection.
Amino acids 1 to 422 of the spike protein of SARS associated coronavirus are required for induction of cyclooxygenase-2.
Aspirin-induced asthma: new insights into pathogenesis and clinical presentation of drug intolerance.
Beneficial effect of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with asthma during viral infection.
CCR5-Dependent Activation of mTORC1 Regulates Translation of Inducible NO Synthase and COX-2 during Encephalomyocarditis Virus Infection.
Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection.
Comparison of expression profiles induced by dust mite in airway epithelia reveals a common pathway.
Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection.
Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents.
Cyclooxygenase-2 Facilitates Newcastle Disease Virus Proliferation and Is as a Target for Canthin-6-One Antiviral Activity.
Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression.
Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies.
Differential effects of triptolide and tetrandrine on activation of COX-2, NF-kappaB, and AP-1 and virus production in dengue virus-infected human lung cells.
Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice.
EICOSANOIDS MEDIATE CELLULAR IMMUNE RESPONSE AND PHENOLOXIDASE REACTION TO VIRAL INFECTION IN ADULT Pimpla turionellae.
Eicosanoids mediate Galleria mellonella cellular immune response to viral infection.
Epigenetic changes mediated by microRNA miR29 activate cyclooxygenase 2 and lambda-1 interferon production during viral infection.
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
High-throughput screen of protein expression levels induced by cyclooxygenase-2 during influenza a virus infection.
Hypothesis: decreased use of pediatric aspirin has contributed to the increasing prevalence of childhood asthma.
Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins.
New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin.
NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways.
Original research article Parainfluenza virus infection enhances NSAIDs-induced inhibition of PGE2 generation and COX-2 expression in human airway epithelial cells.
Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice.
Phosphatidylinositol 3-kinase regulates macrophage responses to double-stranded RNA and encephalomyocarditis virus.
Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.
Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection.
Regulation of cyclooxygenase-2 expression by macrophages in response to double-stranded RNA and viral infection.
Reversal of virus-induced alveolar macrophage bactericidal dysfunction by cyclooxygenase inhibition in vitro.
Role of cyclooxygenase-2 in H5N1 viral pathogenesis and the potential use of its inhibitors.
Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis.
Role of MAPK in the regulation of double-stranded RNA- and encephalomyocarditis virus-induced cyclooxygenase-2 expression by macrophages.
Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells.
Soluble interleukin-6 receptor-mediated innate immune response to DNA and RNA viruses.
Src family kinases participate in the regulation of encephalomyocarditis virus-induced cyclooxygenase-2 expression by macrophages.
The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections.
The role and regulation of COX-2 during viral infection.
The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE(2) release in murine brain-derived endothelial cells following Theiler's virus infection.
The viral protein A238L inhibits cyclooxygenase-2 expression through a nuclear factor of activated T cell-dependent transactivation pathway.
Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10.
Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung.
Vitamin E Deficiency
A reexamination of the role of oxygen in retrolental fibroplasia.
In vitro and in vivo effects of vitamin E on arachidonic acid metabolism in rat platelets.
The effects of vitamin E depletion and repletion on prostaglandin synthesis in semitendinosus muscle of young rabbits.
Vitiligo
Expression of IL-17 and COX2 Gene in Peripheral Blood Leukocytes of Vitiligo Patients.
Study of the relation between two common cyclooxygenase 2 gene polymorphisms with risk of developing and subtypes of vitiligo in Egyptian patients.
Vitiligo: a possible model of degenerative diseases.
Vitreoretinopathy, Proliferative
Fibroblast growth-promoting activity in proliferative vitreoretinopathy: antagonism by acetylsalicylic acid.
von Willebrand Diseases
A quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer.
Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.
Vulvar Lichen Sclerosus
The role of angiogenesis and COX-2 expression in the evolution of vulvar lichen sclerosus to squamous cell carcinoma of the vulva.
Vulvar Neoplasms
Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
Combined COX-2/PPAR? Expression as Independent Negative Prognosticator for Vulvar Cancer Patients.
Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer.
Cyclooxygenase-2 expression in lymph node metastasis of cervical and vulvar cancer.
Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial lesions.
Identification of potential prognostic markers for vulvar cancer using immunohistochemical staining of tissue microarrays.
Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer.
The Role of Eicosanoids in Gynecological Malignancies.
Vulvar Vestibulitis
The expression of cyclooxygenase 2 and inducible nitric oxide synthase indicates no active inflammation in vulvar vestibulitis.
Vulvitis
Vulvar fixed drug eruption. A report of 13 cases.
Warts
[VEGF, COX-2 and MVD in lesions of patients with condyloma acuminatum]
Wasting Syndrome
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Water Intoxication
COX-2 and the kidneys.
Wernicke Encephalopathy
Immunohistochemical expression of proinflammatory cytokines IL-1?, IL-6, TNF-? and involvement of COX-2, quantitatively confirmed by Western blot analysis, in Wernicke's encephalopathy.
Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide.
West Nile Fever
Cyclooxygenase-2 inhibitor blocks the production of West Nile virus-induced neuroinflammatory markers in astrocytes.
Whooping Cough
Astrocytes are target cells for endothelins and sarafotoxin.
Bordetella pertussis adenylate cyclase toxin (ACT) induces cyclooxygenase-2 (COX-2) in murine macrophages and is facilitated by ACT interaction with CD11b/CD18 (Mac-1).
CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration.
Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.
Contrary effects of sphingosine-1-phosphate on expression of ?-smooth muscle actin in transforming growth factor ?1-stimulated lung fibroblasts.
Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinase production by human monocytes.
Effect of pertussis toxin and herbimycin A on proteinase-activated receptor 2-mediated cyclooxygenase 2 expression in Helicobacter pylori-infected gastric epithelial AGS cells.
Effects of sphingosine-1-phosphate and ceramide-1-phosphate on rat intestinal smooth muscle cells: implications for postoperative ileus.
Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation.
Endogenous cannabinoid anandamide directly inhibits voltage-dependent Ca(2+) fluxes in rabbit T-tubule membranes.
Endothelin-1 stimulates the release of arachidonic acid and prostaglandins in cultured human ciliary muscle cells: activation of phospholipase A2.
EP2 receptor activates dual G protein signaling pathways that mediate contrasting proinflammatory and relaxatory responses in term pregnant human myometrium.
Generation of inositol phosphates, cytosolic Ca2+, and ionic fluxes in PC12 cells treated with bradykinin.
Ghrelin signaling in human mesenteric arteries.
Glucose transport stimulation by bradykinin in Swiss 3T3 fibroblasts: a pertussis toxin-sensitive mechanism operates without involvement of arachidonic acid and cyclic AMP.
Histidine regulation of cyclic AMP metabolism in cultured renal epithelial LLC-PK1 cells.
Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery.
Involvement of Rho and p38 MAPK in endothelin-1-induced expression of PGHS-2 mRNA in osteoblast-like cells.
Mastoparan elicits prostaglandin E2 generation and inhibits inositol phosphate accumulation via different mechanisms in rabbit astrocytes.
Mechanical stimulation of skeletal muscle increases prostaglandin F2 alpha production, cyclooxygenase activity, and cell growth by a pertussis toxin sensitive mechanism.
Moderate hypothermia attenuates ?(1)-adrenoceptor-mediated contraction in isolated rat aorta: the role of the endothelium.
Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenesis in mammalian cells: II. A pathway involving arachidonic acid release, prostaglandin synthesis, and cyclic AMP accumulation.
Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.
Pertussis toxin and H-7 distinguish mechanisms involved in eicosanoid release from lipopolysaccharide-primed macrophages. Eicosanoid release from lipopolysaccharide-primed macrophages.
Pertussis toxin attenuates platelet-activating factor-induced pulmonary hemodynamic alterations in pigs.
R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism.
Regulation of lysophosphatidic acid-induced COX-2 expression by ERK1/2 activation in cultured feline esophageal epithelial cells.
Role of endothelin-1 in regulating proliferation of cultured rabbit airway smooth muscle cells.
Role of Rac and Cdc42 in lysophosphatidic acid-mediated cyclo-oxygenase-2 gene expression.
Signal transduction by tumor necrosis factor alpha is mediated through a guanine nucleotide-binding protein in osteoblast-like cell line, MC3T3-E1.
Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL.
Sphingosine 1-phosphate induces cyclooxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells.
Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells.
The bradykinin receptor--a putative receptor-operated channel in PC12 cells: studies of neurotransmitter release and inositol phosphate accumulation.
The effect of adrenomedullin on the L-type calcium current in myocytes from septic shock rats: signaling pathway.
Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta.
Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA.
Wilms Tumor
Analysis of Cox-2 expression in Wilms' tumor.
Expression of cyclooxygenase-2 in Wilms tumor: immunohistochemical study using tissue microarray methodology.
Importance of COX-2 expression in Wilms' tumour: A preliminary study.
Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN, Eljuga L, Shawber CJ, Feirt N, Mansukhani M, Stempak D, Baruchel S, Bender JG, Kandel JJ, Yamashiro DJ, Department of Pediatrics, College of Physicians and Surgeons of Columbia University, New York, NY.
Inhibition of Cyclooxygenase-2 Disrupts Tumor Vascular Mural Cell Recruitment and Survival Signaling.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves ?v?5 integrin, ILK and AP-1-dependent pathways.
Nephroblastoma overexpressed gene (NOV) enhances RCC cell motility through upregulation of ICAM-1 and COX-2 expression via Akt pathway.
Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.
S1P/S1P2 signaling induces cyclooxygenase-2 expression in Wilms tumor.
Wiskott-Aldrich Syndrome
A novel arachidonic acid metabolite with stimulatory effect on PHA-induced mitogenesis of lymphocytes.
Differentially up-regulated genes in proliferating porcine neonatal pancreas cells caused by epidermal growth factor.
Wound Infection
A Novel Virulence Strategy for Pseudomonas aeruginosa Mediated by an Autotransporter with Arginine-Specific Aminopeptidase Activity.
Burn injury with infection alters prostaglandin E2 synthesis and metabolism.
Xanthomatosis
Impact of Cyclooxygenase-2 1195 G-Carrier Genotype Associated with Intestinal Metaplasia and Endoscopic Findings Based on Kyoto Classification.
Xeroderma Pigmentosum
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
The Role of Genetic Variants in the Association between Dietary Acrylamide and Advanced Prostate Cancer in the Netherlands Cohort Study on Diet and Cancer.
Xerostomia
Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice.
Zellweger Syndrome
Cyclooxygenase pathway in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin.